PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Short, AD; Taylor, CW				Short, AD; Taylor, CW			Parathyroid hormone controls the size of the intracellular Ca2+ stores available to receptors linked to inositol trisphosphate formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PTH/PTHRP RECEPTOR; KIDNEY-CELL LINE; 1,4,5-TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; SIGNALING PROPERTIES; OSTEOSARCOMA CELLS; PEPTIDE RECEPTOR; CALCIUM-RELEASE; CLONING	In HEK 293 cells stably expressing type 1 parathyroid (PTH) receptors, PTH stimulated release of intracellular Ca2+ stores in only 27% of cells, whereas 96% of cells responded to carbachol, However, in almost all cells PTH potentiated the response to carbachol by about 3-fold. Responses to carbachol did not desensitize, but only the first challenge in Ca2+-free medium caused an increase in [Ca2+](i), indicating that the carbachol-sensitive Ca2+ stores had been emptied. Subsequent addition of PTH also failed to increase [Ca2+](i), but when it was followed by carbachol there was a substantial increase in [Ca2+](i), A similar potentiation was observed between ATP and PTH but not between carbachol and ATP. Intracellular heparin inhibited responses to carbachol and PTH, and pretreatment with ATP and carbachol abolished responses to PTH, suggesting that the effects of PTH involve inositol trisphosphate (IP3) receptors, PTH neither stimulated detectable IP3 formation nor affected the amount formed in response to ATP or carbachol, PTH stimulated cyclic AMP formation, but this was not the means whereby PTH potentiated Ca2+ signals. We suggest that PTH may regulate Ca2+ mobilization by facilitating translocation of Ca2+ between discrete intracellular stores and that it thereby regulates the size of the Ca2+ pool available to receptors linked to IP3 formation.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Taylor, CW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.	cwt1000@cam.ac.uk	Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BABICH M, 1991, ENDOCRINOLOGY, V129, P1463, DOI 10.1210/endo-129-3-1463; Behar V, 1996, ENDOCRINOLOGY, V137, P2748, DOI 10.1210/en.137.7.2748; BIRD GS, 1993, J BIOL CHEM, V268, P17917; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; DAWSON AP, 1989, CELL CALCIUM, V10, P343, DOI 10.1016/0143-4160(89)90060-2; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; FUJIMORI A, 1991, ENDOCRINOLOGY, V128, P3032, DOI 10.1210/endo-128-6-3032; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; Hansen LH, 1998, AM J PHYSIOL-CELL PH, V274, pC1552, DOI 10.1152/ajpcell.1998.274.6.C1552; HARGREAVES AC, 1994, MOL PHARMACOL, V46, P1120; HARVEY S, 1993, J ENDOCRINOL, V139, P353, DOI 10.1677/joe.0.1390353; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; Jobert AS, 1997, ENDOCRINOLOGY, V138, P5282, DOI 10.1210/en.138.12.5282; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Loomis-Husselbee JW, 1998, BIOCHEM J, V331, P947, DOI 10.1042/bj3310947; Marchant JS, 1997, CURR BIOL, V7, P510, DOI 10.1016/S0960-9822(06)00222-3; MASSRY SG, 1995, MINER ELECTROL METAB, V21, P13; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Pines M, 1996, BONE, V18, P381, DOI 10.1016/8756-3282(96)00008-7; PINES M, 1994, ENDOCRINOLOGY, V135, P1713, DOI 10.1210/en.135.4.1713; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; SCHNEIDER H, 1993, EUR J PHARM-MOLEC PH, V246, P149, DOI 10.1016/0922-4106(93)90092-N; SEUWEN K, 1995, BRIT J PHARMACOL, V114, P1613, DOI 10.1111/j.1476-5381.1995.tb14947.x; Tong YH, 1996, J BIOL CHEM, V271, P8183, DOI 10.1074/jbc.271.14.8183; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	37	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1807	1813		10.1074/jbc.275.3.1807	http://dx.doi.org/10.1074/jbc.275.3.1807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636879	hybrid			2022-12-25	WOS:000084940000042
J	Sun, HY; Squier, TC				Sun, HY; Squier, TC			Ordered and cooperative binding of opposing globular domains of calmodulin to the plasma membrane Ca-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; OXIDE SYNTHASE ACTIVITIES; PEPTIDE COMPLEX; TARGET PROTEINS; ACTIVATION; RECOGNITION; METHIONINE; FRAGMENTS; PHOSPHORYLATION; RESOLUTION	We have investigated the mechanisms of activation of the plasma membrane (PM) Ca-ATPase by calmodulin (CaM), which result in enhanced calcium transport rates and the maintenance of low intracellular calcium levels. We have isolated the amino- or carboxyl-terminal domains of CaM (i.e. CaMN or CaMC), permitting an identification of their relative specificity for binding to sites on either the PM Ca-ATPase or a peptide (C28W) corresponding to the CaM-binding sequence. We find that either CaMN or CaMC alone is capable of productive interactions with the PM Ca-ATPase that induces enzyme activation. There are, however, large differences in the affinity and specificity of binding between CaMN and CaMC and either C28W or the PM Ca-ATPase, The initial binding interaction between CaMC and the PM Ca-ATPase is highly specific, having approximately 10,000-fold greater affinity in comparison with CaMN, However, following the initial association of either CaMC or CaMN, there is a 300-fold enhancement in the affinity of CaMN for the secondary binding site. Thus, while CaMC binds with a high affinity to the two CaM-binding sites within the PM Ca-ATPase in a sequential manner, CaMN binds cooperatively with a lower affinity to both binding sites. These large differences in the binding affinities and specificities of the amino- and carboxyl-terminal domains ensure that CaM binding to the PM Ca-ATPase normally involves the formation of a specific complex in which the initial high affinity association of the carboxyl-terminal domain promotes the association of the amino-terminal domain necessary for enzyme activation.	Univ Kansas, Dept Mol Biosci, Biochem & Biophys Sect, Lawrence, KS 66045 USA	University of Kansas	Squier, TC (corresponding author), Univ Kansas, Dept Mol Biosci, Biochem & Biophys Sect, Lawrence, KS 66045 USA.	TSQUIER@UKANS.EDU			NIA NIH HHS [AG 12993] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG012993] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; Barth A, 1998, J BIOL CHEM, V273, P2174, DOI 10.1074/jbc.273.4.2174; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; CHAPMAN ER, 1992, BIOCHEMISTRY-US, V31, P12819, DOI 10.1021/bi00166a016; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chin D, 1997, J BIOL CHEM, V272, P5510, DOI 10.1074/jbc.272.9.5510; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Edwards RA, 1998, BIOCHEM J, V331, P149, DOI 10.1042/bj3310149; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Gao J, 1998, BIOPHYS J, V74, P1115, DOI 10.1016/S0006-3495(98)77830-0; Gao J, 1998, BIOCHEMISTRY-US, V37, P9536, DOI 10.1021/bi9803877; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUERINI D, 1984, J BIOL CHEM, V259, P5172; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P17810, DOI 10.1021/bi981656w; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NEWTON D, 1985, BIOCHIM BIOPHYS ACTA, V845, P533, DOI 10.1016/0167-4889(85)90222-8; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; Peersen OB, 1997, PROTEIN SCI, V6, P794; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; PERSECHINI A, 1993, BIOCHIM BIOPHYS ACTA, V1163, P309, DOI 10.1016/0167-4838(93)90167-P; Quadroni M, 1998, BIOCHEMISTRY-US, V37, P6523, DOI 10.1021/bi972930+; Sun HY, 1999, BIOCHEMISTRY-US, V38, P12266, DOI 10.1021/bi9818671; Tjandra N, 1999, CALCIUM AS A CELLULAR REGULATOR, P152; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; Yao YH, 1996, BIOCHEMISTRY-US, V35, P6815, DOI 10.1021/bi960229k; Yao YH, 1996, BIOCHEMISTRY-US, V35, P12015, DOI 10.1021/bi960834n; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Yuan T, 1999, PROTEIN SCI, V8, P113; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546; [No title captured]	42	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1731	1738		10.1074/jbc.275.3.1731	http://dx.doi.org/10.1074/jbc.275.3.1731			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636869	hybrid			2022-12-25	WOS:000084940000032
J	Floyd, H; Ni, J; Cornish, AL; Zeng, ZZ; Liu, D; Carter, KC; Steel, J; Crocker, PR				Floyd, H; Ni, J; Cornish, AL; Zeng, ZZ; Liu, D; Carter, KC; Steel, J; Crocker, PR			Siglec-8 - A novel eosinophil-specific member of the immunoglobulin superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-SITE; MYELIN-ASSOCIATED GLYCOPROTEIN; MOLECULAR-CLONING; CD22; SIALOADHESIN; ANTIGEN; CD33; EXPRESSION; RECEPTOR; LOCALIZATION	We describe the characterization of siglec-8, a novel sialic acid-binding immunoglobulin-like lectin that is expressed specifically by eosinophils. A full-length cDNA encoding siglec-8 was isolated from a human eosinophil cDNA library. Siglec-8 is predicted to contain three extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail of 47 amino acids. The siglec-8 gene mapped on chromosome 19q13.33-41, closely linked to genes encoding CD33 (siglec-3), siglec-5, siglec-6, and siglec-7. When siglec-8 was expressed on COS cells or as a recombinant protein fused to the Fc region of human IgG(1), it was able to mediate sialic acid-dependent binding to human erythrocytes and to soluble sialoglycoconjugates. Using specific monoclonal antibodies, siglec-8 could be detected only on eosinophils and hence appears to be the first example of an eosinophil-specific transmembrane receptor.	Univ Dundee, Dept Biochem, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Human Genome Sci Inc, Rockville, MD 20852 USA; Imperial Canc Res Fund, London WC1, England	University of Dundee; GlaxoSmithKline; Human Genome Sciences Inc	Crocker, PR (corresponding author), Univ Dundee, Dept Biochem, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	p.r.crocker@dundee.ac.uk		Crocker, Paul/0000-0001-6230-0293				Boyce JA, 1997, ALLERGY ASTHMA PROC, V18, P293, DOI 10.2500/108854197778590489; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker P R, 1998, Glycobiology, V8, pv; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; CROCKER PR, 1986, J EXP MED, V164, P1862, DOI 10.1084/jem.164.6.1862; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; DORKEN B, 1986, J IMMUNOL, V136, P4470; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Gergely J, 1999, IMMUNOL LETT, V68, P3, DOI 10.1016/S0165-2478(99)00024-3; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HASLETT C, 1997, WEIRS HDB EXPT IMMUN, V4; KANTOR AB, 1997, WEIRS HDB EXPT IMMUN, V2; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Nitschke L, 1999, J EXP MED, V189, P1513, DOI 10.1084/jem.189.9.1513; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PEIPER SC, 1988, BLOOD, V72, P314; PEIPER SC, 1989, LEUCOCYTE TYPING 4 W, P814; SGROI D, 1993, J BIOL CHEM, V268, P7011; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; Takei Y, 1997, CYTOGENET CELL GENET, V78, P295, DOI 10.1159/000134676; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273	28	160	171	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					861	866		10.1074/jbc.275.2.861	http://dx.doi.org/10.1074/jbc.275.2.861			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625619	hybrid			2022-12-25	WOS:000084836600023
J	Hughes, WE; Woscholski, R; Cooke, FT; Patrick, RS; Dove, SK; McDonald, NQ; Parker, PJ				Hughes, WE; Woscholski, R; Cooke, FT; Patrick, RS; Dove, SK; McDonald, NQ; Parker, PJ			SAC1 encodes a regulated lipid phosphoinositide phosphatase, defects in which can be suppressed by the homologous Inp52p and Inp53p phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PROTEIN TRANSLOCATION; INOSITOL; 5-KINASE; CELLS; PHOSPHOLIPIDS; CYTOSKELETON	The yeast protein Sac1p is involved in a range of cellular functions, including inositol metabolism, actin cytoskeletal organization, endoplasmic reticulum ATP transport, phosphatidylinositol-phosphatidylcholine transfer protein function, and multiple-drug sensitivity. The activity of Sac1p and its relationship to these phenotypes are unresolved. We show here that the regulation of lipid phosphoinositides in sac1 mutants is defective, resulting in altered levels of all lipid phosphoinositides, particularly phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. We have identified two proteins with homology to Sac1p that can suppress drug sensitivity and also restore the levels of the phosphoinositides in sac1 mutants. Overexpression of truncated forms of these suppressor genes confirmed that suppression was due to phosphoinositide phosphatase activity within these proteins. We have now demonstrated this activity for Sac1p and have characterized its specificity. The in vitro phosphatase activity and specificity of Sac1p were not altered by some mutations. Indeed, in vivo mutant Sac1p phosphatase activity also appeared unchanged under conditions in which cells were drug-resistant. However, under different growth conditions, both drug sensitivity and the phosphatase defect were manifest. It is concluded that SAC1 encodes a novel lipid phosphoinositide phosphatase in which specific mutations can cause the sac1 phenotypes by altering the in vivo regulation of the protein rather than by destroying phosphatase activity.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Struct Biol Lab, London WC2A 3PX, England; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England	Cancer Research UK; Cancer Research UK; Imperial College London; University of Birmingham; University of London; Birkbeck University London	Hughes, WE (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Hughes, William/0000-0002-7149-3987				BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; FOLCH J, 1949, J BIOL CHEM, V177, P497; Guilherme A, 1998, BIOSCIENCE REP, V18, P79, DOI 10.1023/A:1020184210183; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Hsuan JJ, 1998, ADV CANCER RES, V74, P167, DOI 10.1016/S0065-230X(08)60767-8; Hughes WE, 1999, YEAST, V15, P1111, DOI 10.1002/(SICI)1097-0061(199908)15:11<1111::AID-YEA440>3.0.CO;2-H; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kochendorfer KU, 1999, EMBO J, V18, P1506, DOI 10.1093/emboj/18.6.1506; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MEMON AR, 1989, BIOCHEM BIOPH RES CO, V162, P1295, DOI 10.1016/0006-291X(89)90814-0; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; NOVICK P, 1989, GENETICS, V121, P659; PETITOU M, 1978, ANAL BIOCHEM, V91, P350, DOI 10.1016/0003-2697(78)90849-7; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rivas MP, 1999, MOL BIOL CELL, V10, P2235, DOI 10.1091/mbc.10.7.2235; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; THIYAGARAJAH P, 1984, BIOCHEM INT, V9, P625; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416	42	94	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					801	808		10.1074/jbc.275.2.801	http://dx.doi.org/10.1074/jbc.275.2.801			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625610	hybrid			2022-12-25	WOS:000084836600014
J	Lee, SY; Wang, RG; Soderhall, K				Lee, SY; Wang, RG; Soderhall, K			A lipopolysaccharide- and beta-1,3-glucan-binding protein from hemocytes of the freshwater crayfish Pacifastacus leniusculus - Purification, characterization, and cDNA cloning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDOGLYCAN RECOGNITION PROTEIN; BINDING-PROTEIN; MOLECULAR-CLONING; INNATE IMMUNITY; SERINE-PROTEASE; BOMBYX-MORI; PERIPLANETA-AMERICANA; GLUCAN-BINDING; BLOOD-CELLS; CRAB	A lipopolysaccharide- and beta-1,3-glucan-binding protein (LGBP) was isolated and characterized from blood cells (hemocytes) of the freshwater crayfish Pacifastacus leniusculus. The LGBP was purified by chromatography on Blue-Sepharose and phenyl-Sepharose, followed by Sephacryl S-200. The LGBP has a molecular mass of 36 kDa and 40 kDa on 10% SDS-polyacrylamide gel electrophoresis under reducing and nonreducing conditions, respectively. The calculated mass of LGBP is 39,492 Da, which corresponds to the native size of LGBP; the estimated pi of the mature LGBP is 5.80. LGBP has binding activity to lipopolysaccharides as well as to beta-1,3-glucans such as laminarin and curdlan, but peptidoglycan could not bind to LGBP. Cloning and sequencing of LGBP showed significant homology with several putative Gram-negative bacteria-binding proteins and beta-1,3-glucanases. Interestingly, LGBP also has a structure and functions similar to those of the coelomic cytolytic factor-1, a lipopolysaccharide- and glucan-binding protein from the earthworm Eisenia foetida. To evaluate the involvement of LGBP in the prophenoloxidase (proPO) activating system, a polyclonal antibody against LGBP was made and used for the inhibition of phenoloxidase (PO) activity triggered by the beta-1,3-glucan laminarin in the hemocyte lysate of crayfish. The PO activity was blocked completely by the anti-LGBP antibody. Moreover, the PO activity could be recovered by the addition of purified LGBP. These results suggest that the 36-kDa LGBP plays a role in the activation of the proPO activating system in crayfish and thus seems to play an important role in the innate immune system of crayfish.	Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, S-75236 Uppsala, Sweden	Uppsala University	Soderhall, K (corresponding author), Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, Norbyvagen 18A, S-75236 Uppsala, Sweden.			Lee, So Young/0000-0003-3130-785X				Asgari S, 1998, P NATL ACAD SCI USA, V95, P3690, DOI 10.1073/pnas.95.7.3690; ASPAN A, 1991, INSECT BIOCHEM, V21, P363, DOI 10.1016/0020-1790(91)90002-V; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; Bachman ES, 1996, P NATL ACAD SCI USA, V93, P6808, DOI 10.1073/pnas.93.13.6808; BARRACCO MA, 1991, CELL TISSUE RES, V266, P491, DOI 10.1007/BF00318590; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; CERENIUS L, 1994, J BIOL CHEM, V269, P29462; Cho MY, 1999, EUR J BIOCHEM, V262, P737, DOI 10.1046/j.1432-1327.1999.00416.x; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; DUVIC B, 1992, EUR J BIOCHEM, V207, P223, DOI 10.1111/j.1432-1033.1992.tb17041.x; DUVIC B, 1990, J BIOL CHEM, V265, P9327; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Foukas LC, 1998, J BIOL CHEM, V273, P14813, DOI 10.1074/jbc.273.24.14813; Hall M, 1999, P NATL ACAD SCI USA, V96, P1965, DOI 10.1073/pnas.96.5.1965; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Inamori K, 1999, J BIOL CHEM, V274, P3272, DOI 10.1074/jbc.274.6.3272; Iwanaga S, 1998, J BIOCHEM, V123, P1; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Johansson MW, 1999, J CELL SCI, V112, P917; JOMORI T, 1992, FEBS LETT, V296, P283, DOI 10.1016/0014-5793(92)80305-Z; JOMORI T, 1991, J BIOL CHEM, V266, P13318; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kawabata S, 1999, DEV COMP IMMUNOL, V23, P391, DOI 10.1016/S0145-305X(99)00019-1; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KOBAYASHI M, 1990, CELL TISSUE RES, V260, P13, DOI 10.1007/BF00297485; Koizumi N, 1999, FEBS LETT, V443, P139, DOI 10.1016/S0014-5793(98)01701-3; Koizumi N, 1997, EUR J BIOCHEM, V248, P217, DOI 10.1111/j.1432-1033.1997.t01-1-00217.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIFOOK J, 1966, J INSECT PHYSIOL, V12, P195, DOI 10.1016/0022-1910(66)90136-3; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LEONARD C, 1985, INSECT BIOCHEM, V15, P803, DOI 10.1016/0020-1790(85)90109-X; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mendoza HL, 1999, DEV COMP IMMUNOL, V23, P359, DOI 10.1016/S0145-305X(99)00017-8; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Parrillo J E, 1993, N Engl J Med, V328, P1471; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Schnapp D, 1996, EUR J BIOCHEM, V240, P532, DOI 10.1111/j.1432-1033.1996.0532h.x; SEKI N, 1994, J BIOL CHEM, V269, P1370; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; SMITH VJ, 1986, IMMUNE MECH INVERTEB, P59; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; SUGUMARAN M, 1991, FEBS LETT, V295, P233, DOI 10.1016/0014-5793(91)81431-7; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; Vasta GR, 1999, DEV COMP IMMUNOL, V23, P401, DOI 10.1016/S0145-305X(99)00020-8; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	58	250	267	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1337	1343		10.1074/jbc.275.2.1337	http://dx.doi.org/10.1074/jbc.275.2.1337			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625682	hybrid, Green Submitted			2022-12-25	WOS:000084836600086
J	Sakash, JB; Chan, RS; Tsuruta, H; Kantrowitz, ER				Sakash, JB; Chan, RS; Tsuruta, H; Kantrowitz, ER			Three of the six possible intersubunit stabilizing interactions involving Glu-239 are sufficient for restoration of the homotropic and heterotropic properties of Escherichia coli aspartate transcarbamoylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; REGULATORY CHAIN; CATALYTIC CHAIN; CARBAMOYLTRANSFERASE; MODEL; COOPERATIVITY; PURIFICATION; REPLACEMENT; RESOLUTION; PROTEINS	A hybrid version of Escherichia coli aspartate transcarbamoylase was investigated in which one catalytic subunit has the wild-type sequence, and the other catalytic subunit has Glu-239 replaced by Gln, Since Glu-239 is involved in intersubunit interactions, this hybrid could be used to evaluate the extent to which T state stabilization is required for homotropic cooperativity and for heterotropic effects. Reconstitution of the hybrid holoenzyme (two different catalytic subunits with three wild-type regulatory subunits) was followed by separation of the mixture by anion-exchange chromatography. To make possible the resolution of the three holoenzyme species formed by the reconstitution, the charge of one of the catalytic subunits was altered by the addition of six aspartic acid residues to the C terminus of each of the catalytic chains (AT-C catalytic subunit). Control experiments indicated that the AT-C catalytic subunit as well as the holoenzyme formed with AT-C and wild-type regulatory subunits had essentially the same homotropic and heterotropic properties as the native catalytic subunit and holoenzyme, indicating that the addition of the aspartate tail did not influence the function of either enzyme. The control reconstituted holoenzyme, in which both catalytic subunits have Glu-239 replaced by Gln, exhibited no cooperativity, an enhanced affinity for aspartate, and essentially no heterotropic response identical to the enzyme isolated without reconstitution. The hybrid containing one normal and one mutant catalytic subunit exhibited homotropic cooperativity with a Hill coefficient of 1.4 and responded to the nucleotide effecters at about 50% of the level of the wild-type enzyme. Small angle x-ray scattering experiments with the hybrid enzyme indicated that in the absence of ligands it was structurally similar, but not identical, to the T state of the wild-type enzyme. In contrast to the wild-type enzyme, addition of carbamoyl phosphate induced a significant alteration in the scattering pattern, whereas the bisubstrate analog N-phosphonoacetyl-L-aspartate induced a significant change in the scattering pattern indicating the transition to the R-structural state. These data indicate that in the hybrid enzyme only three of the usual six interchain interactions involving Glu-239 are sufficient to stabilize the enzyme in a low affinity, low activity state and allow an allosteric transition to occur.	Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER; NCRR NIH HHS [P41RR01209] Funding Source: Medline; NIGMS NIH HHS [GM26237] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANGEUX JP, 1968, BIOCHEMISTRY-US, V7, P531, DOI 10.1021/bi00842a007; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; DEMBOWSKI NJ, 1993, PROTEIN ENG, V6, P123, DOI 10.1093/protein/6.1.123; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GERHART JC, 1963, COLD SPRING HARB SYM, V28, P491, DOI 10.1101/SQB.1963.028.01.065; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; GOUAUX JE, 1989, BIOCHEMISTRY-US, V28, P1798, DOI 10.1021/bi00430a056; HONZATKO RB, 1982, P NATL ACAD SCI-BIOL, V79, P7171, DOI 10.1073/pnas.79.23.7171; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1985, J MOL BIOL, V186, P715, DOI 10.1016/0022-2836(85)90391-2; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ONUFFER JJ, 1994, PROTEIN ENG, V7, P413, DOI 10.1093/protein/7.3.413; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sakash JB, 1998, BIOCHEMISTRY-US, V37, P281, DOI 10.1021/bi972102g; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEBBINS JW, 1989, J BIOL CHEM, V264, P14860; Svergun DI, 1997, PROTEINS, V27, P110; TAUC P, 1990, J MOL BIOL, V214, P327, DOI 10.1016/0022-2836(90)90164-H; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; Tsuruta H, 1998, J APPL CRYSTALLOGR, V31, P672, DOI 10.1107/S0021889898002702; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46; XU W, 1988, BIOCHEMISTRY-US, V27, P5507, DOI 10.1021/bi00415a018	36	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					752	758		10.1074/jbc.275.2.752	http://dx.doi.org/10.1074/jbc.275.2.752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625604	hybrid			2022-12-25	WOS:000084836600008
J	Hirata, T; Nakamura, N; Omote, H; Wade, Y; Futai, M				Hirata, T; Nakamura, N; Omote, H; Wade, Y; Futai, M			Regulation and reversibility of vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; YEAST SACCHAROMYCES-CEREVISIAE; MEMBRANE-VESICLES; INORGANIC PYROPHOSPHATASE; HETEROLOGOUS EXPRESSION; TONOPLAST VESICLES; PROTON TRANSPORT; SUBUNIT; PROTEIN; ACIDIFICATION	Arabidopsis thaliana vacuolar H+-translocating pyrophosphatase (V-PPase) was expressed functionally in yeast vacuoles with endogenous vacuolar H+-ATPase (V-ATPase), and the regulation and reversibility of V-ATPase were studied using these vacuoles. Analysis of electrochemical proton gradient (Delta mu H) formation with ATP and pyrophosphate indicated that the proton transport by V-ATPase or V-PPase is not regulated strictly by the proton chemical gradient (Delta pH). On the other hand, vacuolar membranes may have a regulatory mechanism for maintaining a constant membrane potential (Delta Psi). Chimeric vacuolar membranes showed ATP synthesis coupled with Delta mu H established by V-PPase. The ATP synthesis was sensitive to bafilomycin A(1) and exhibited two apparent K-m values for ADP. These results indicate that V-ATPase is a reversible enzyme. The ATP synthesis was not observed in the presence of nigericin, which dissipates Delta pH but not Delta Psi, suggesting that Delta pH is essential for ATP synthesis.	Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka Univ, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan	Japan Science & Technology Agency (JST); Osaka University	Futai, M (corresponding author), Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka Univ, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp	OMOTE, Hiroshi/B-1635-2011					ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DUPAIX A, 1989, FEBS LETT, V249, P13, DOI 10.1016/0014-5793(89)80005-5; Facanha AR, 1998, PLANT PHYSIOL, V116, P1487, DOI 10.1104/pp.116.4.1487; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; Futai M, 1998, J BIOCHEM-TOKYO, V124, P259, DOI 10.1093/oxfordjournals.jbchem.a022105; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; IHARA K, 1991, ARCH BIOCHEM BIOPHYS, V286, P111, DOI 10.1016/0003-9861(91)90015-B; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; Inoue K, 1997, PLANT CELL PHYSIOL, V38, P366, DOI 10.1093/oxfordjournals.pcp.a029176; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; Nakamura N, 1997, J BIOL CHEM, V272, P11344; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; ROISIN MP, 1980, FEBS LETT, V115, P143, DOI 10.1016/0014-5793(80)80745-9; ROS R, 1995, J BIOL CHEM, V270, P4368, DOI 10.1074/jbc.270.9.4368; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SCHMIDT AL, 1993, ARCH BIOCHEM BIOPHYS, V306, P407, DOI 10.1006/abbi.1993.1530; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; UCHIDA E, 1988, J BIOL CHEM, V263, P45; WADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1101, P296, DOI 10.1016/0005-2728(92)90085-G; WADA Y, 1994, J BIOENERG BIOMEMBR, V26, P631, DOI 10.1007/BF00831538; WADA Y, 1987, J BIOL CHEM, V262, P17260; Wada Y, 1997, J CELL SCI, V110, P1299; WANG YZ, 1986, PLANT PHYSIOL, V81, P497, DOI 10.1104/pp.81.2.497; Yokoyama K, 1998, J BIOL CHEM, V273, P20504, DOI 10.1074/jbc.273.32.20504; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	39	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					386	389		10.1074/jbc.275.1.386	http://dx.doi.org/10.1074/jbc.275.1.386			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617629	hybrid			2022-12-25	WOS:000085951600053
J	Wilkinson, BM; Tyson, JR; Reid, PJ; Stirling, CJ				Wilkinson, BM; Tyson, JR; Reid, PJ; Stirling, CJ			Distinct domains within yeast Sec61p involved in post-translational translocation and protein dislocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE RECOGNITION; SACCHAROMYCES-CEREVISIAE; SECRETORY PROTEIN; ER DEGRADATION; COMPLEX; TRANSPORT; PROTEASOME; GENE; COMPONENTS	The translocation of secretory polypeptides into and across the membrane of the endoplasmic reticulum (ER) occurs at the translocon, a pore-forming structure that orchestrates the transport and maturation of polypeptides at the ER membrane. Recent data also suggest that misfolded or unassembled polypeptides exit the ER via the translocon for degradation by the cytosolic ubiquitin/proteasome pathway. Sec61p is a highly conserved multispanning membrane protein that constitutes a core component of the translocon, We have found that the essential function of the Saccharomyces cerevisiae Sec61p is retained upon deletion of either of two internal regions that include transmembrane domains 2 and 3, respectively, However, a deletion mutation encompassing both of these domains was found to be nonfunctional, Characterization of yeast mutants expressing the viable deletion alleles of Sec61p has revealed defects in post-translational translocation. In addition, the transmembrane domain 3 deletion mutant is induced for the unfolded protein response and is defective in the dislocation of a misfolded ER protein. These data demonstrate that the various activities of Sec61p can be functionally dissected, In particular, the transmembrane domain 2 region plays a role in post-translational translocation that is required neither for cotranslational translocation nor for protein dislocation.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Stirling, CJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-2-5 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.							Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Broughton J, 1997, J CELL SCI, V110, P2715; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HAMMAN BD, 1997, CELL, V89, P534; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; Sambrook J., 2002, MOL CLONING LAB MANU; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STIRLING CJ, 1993, NATO ASI SERIES H, V71, P293; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilkinson BM, 1997, J MEMBRANE BIOL, V155, P189, DOI 10.1007/s002329900171; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549	50	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					521	529		10.1074/jbc.275.1.521	http://dx.doi.org/10.1074/jbc.275.1.521			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617647	hybrid			2022-12-25	WOS:000085951600071
J	Yu, B; Gu, LJ; Simon, MI				Yu, B; Gu, LJ; Simon, MI			Inhibition of subsets of G protein-coupled receptors by empty mutants of G protein alpha subunits in G(0), G(11), and G(16)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; CELLS; NUCLEOTIDES; ACTIVATION; SIGNALS; FAMILY	We previously reported that the xanthine nucleotide binding G(o)alpha mutant, G(o)alpha X, inhibited the activation of G(i)-coupled receptors. We constructed similar mutations in G(11)alpha and G(16)alpha and characterized their nucleotide binding and receptor interaction. First, we found that G(11)alpha X and G(16)alpha X expressed in COS-7 cells bound xanthine 5'-O-(thiotriphosphate) instead of guanosine 5'-O-(thiotriphosphate). Second, we found that G(11)alpha X and G(16)alpha X interacted with beta gamma subunits in the presence of xanthine diphosphate. These experiments demonstrated that G(11)alpha X and G(16)alpha X were xanthine nucleotide-binding proteins, similar to G(o)alpha X. Third, in COS-7 cells, both G(11)alpha X and G(16)alpha X inhibited the activation of G(q)-coupled receptors, whereas only G(16)alpha X inhibited the activation of G(i)-coupled receptors. Therefore, when in the nucleotide-free state, empty G(11)alpha X and G(16)alpha X appeared to retain the same receptor binding specificity as their wild-type counterparts. Finally, we found that G(o)alpha X, G(11)alpha X, and G(16)alpha X all inhibited the endogenous thrombin receptors and lysophosphatidic acid receptors in NIH3T3 cells, whereas G(11)alpha X and G(16)alpha X, but not G(o)alpha X, inhibited the activation of transfected m1 muscarinic receptor in these cells. We conclude that these empty G protein mutants of G(o)alpha, G(11)alpha, and G(16)alpha can act as dominant negative inhibitors against specific subsets of G protein-coupled receptors.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Yu, B (corresponding author), CALTECH, Div Biol, 147-75, Pasadena, CA 91125 USA.							ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GRAND RJA, 1996, BIOCHEM J, V313, P356; HENDERSON JF, 1973, NUCLEOTIDE METABOLIS, P97; HILL CS, 1995, CELL, V81, P1156; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PARKER EM, 1991, J BIOL CHEM, V266, P519; QUICK MW, 1994, J BIOL CHEM, V269, P30164; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; Yu B, 1998, J BIOL CHEM, V273, P30183, DOI 10.1074/jbc.273.46.30183	19	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					71	76		10.1074/jbc.275.1.71	http://dx.doi.org/10.1074/jbc.275.1.71			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617587	Green Accepted, hybrid			2022-12-25	WOS:000085951600011
J	Wehling, M; Cai, BY; Tidball, JG				Wehling, M; Cai, BY; Tidball, JG			Modulation of myostatin expression during modified muscle use	FASEB JOURNAL			English	Article						atrophy; myotendinous junction; plantaris muscle; rat; unloading	GROWTH-FACTOR-BETA; RAT SOLEUS MUSCLE; HINDLIMB SUSPENSION; EXTRACELLULAR-MATRIX; FACTOR-BETA-1; ACTIVATION; CATTLE; GENE; RNA; MECHANISMS	Previous findings have provided strong evidence that myostatin functions as a negative regulator of muscle mass during development and growth. In the present study , we test the hypothesis that myostatin may serve a similar function in fully differentiated muscle experiencing modified loading. Our findings show that the myostatin expression can be modulated in fully differentiated, non-pathologicalskeletal muscle in a manner that is inversely related to changes in muscle mass. Atrophy of rat hind limb muscles induce by 10 days of unloading resulted in in a 165 decrease in plantaris mass, a 110% increase in myostatin mRNA, and a 37% increase in myostatin protein. Immunohistochemical observations showed that a detectable increase in myostatin concentration at myotendinous junctions during muscle unloading. The concentration of myostatin mRNA and protein returned to values not significantly different from ambulatory controls after 4 days of reloading, during which time plantaris mass also returned to control values. However the results also show that of 30min of daily muscle loading during the unloading period were sufficient to prevent significant losses of muscle mass caused by muscle unloading, although muscle mass loos during unloading is accompanied by increases in myostatin.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tidball, JG (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Young Dr S, Los Angeles, CA 90095 USA.	jtidball@physci.ucla.edu	Tidball, James/H-7970-2012	Tidball, James/0000-0003-1202-8038	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040343] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40343] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; CASTILLODEMARUENDA E, 1978, TISSUE CELL, V10, P749, DOI 10.1016/0040-8166(78)90061-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARR KC, 1989, J APPL PHYSIOL, V67, P1827, DOI 10.1152/jappl.1989.67.5.1827; DAUNNO DS, 1992, J APPL PHYSIOL, V72, P428, DOI 10.1152/jappl.1992.72.2.428; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; GIBSON MC, 1982, ANAT REC, V202, P329, DOI 10.1002/ar.1092020305; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; HAUSCHKA EO, 1988, J APPL PHYSIOL, V65, P1231, DOI 10.1152/jappl.1988.65.3.1231; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; KERR LD, 1988, J BIOL CHEM, V263, P16999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; MOREYHOLTON E, 1981, PHYSIOLOGIST S, V24, pS45; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Nakashima M, 1999, MECH DEVELOP, V80, P185, DOI 10.1016/S0925-4773(98)00205-6; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; SHAW SR, 1987, J BIOMECH, V20, P225, DOI 10.1016/0021-9290(87)90289-2; Spencer MJ, 1997, J CELL BIOCHEM, V64, P55, DOI 10.1002/(SICI)1097-4644(199701)64:1<55::AID-JCB9>3.0.CO;2-Z; STPIERRE BA, 1994, J APPL PHYSIOL, V77, P290, DOI 10.1152/jappl.1994.77.1.290; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TIDBALL JG, 1991, J BIOMECH, V24, P43, DOI 10.1016/0021-9290(91)90376-X; TISCHLER ME, 1990, METABOLISM, V39, P756, DOI 10.1016/0026-0495(90)90113-Q	33	171	191	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					103	110		10.1096/fasebj.14.1.103	http://dx.doi.org/10.1096/fasebj.14.1.103			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627285				2022-12-25	WOS:000084784700013
J	Wijesuriya, SD; Zhang, GR; Dardis, A; Miller, WL				Wijesuriya, SD; Zhang, GR; Dardis, A; Miller, WL			Transcriptional regulatory elements of the human gene for cytochrome P450c21 (steroid 21-hydroxylase) lie within intron 35 of the linked C4B gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL ADRENAL-HYPERPLASIA; TENASCIN-X; FACTOR-I; MURINE 21-HYDROXYLASE; NUCLEOTIDE-SEQUENCE; NUCLEAR PROTEINS; PROMOTER ELEMENT; RECEPTOR GENE; TUMOR-CELLS; BOVINE GENE	The CYP21 gene, which encodes P450c21, the adrenal steroid SI-hydroxylase needed for glucocorticoid synthesis, lies in the major histocompatibility locus only 2.3 kilobase pairs (kb) downstream from the C4 gene. A 300-base pair (bp) proximal promoter and two upstream regions within C4 are needed for expression of mouse CYP21; the human gene also has a proximal promoter, but upstream elements have not been studied. To search for upstream regulatory elements in human CYP21B, we examined up to 9 kb of 5'-flanking DNA by transient transfection into human adrenal NCI-H295A cells. The 300-bp proximal promoter had substantial activity, but constructs retaining the DNA between -4.6 and -5.6 kb had increased activity, indicating the presence of distal elements. This region does not correspond to the mouse upstream regions, lying further upstream within intron 35 of C4B, which encompasses the previously described "Z promoter," DNase I footprinting located two elements, F1 and F2, lying -186 to -195 bp and -142 to -151 bp upstream from the Z cap site (-4862 to -4871 and -4818 to -4827 bp upstream of the CYP21B cap site). Each element formed a specific DNA-protein complex and conferred orientation-independent expression to a heterologous promoter. Mutations abolished formation of the DNA-protein complexes but only partially decreased expression. We identified a third site, F3, lying at -33 to -42 bp from Z. Competitive gel mobility supershift assays and co-transfection studies with SF-1 produced in vitro indicate F2 and F3 bind SF-1; BLAST searches and Southwestern blotting suggest that NF-W2 may bind F1. These results indicate that the Z promoter is a component of the CYP21 promoter needed to drive its adrenal-specific expression and that CYP21 transcription elements within C4 have kept these two genes linked during evolution.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Bldg MR-4,Rm 209, San Francisco, CA 94143 USA.		Miller, Walter L/J-3696-2012		NIDDK NIH HHS [DK4254, DK37922] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BRISTOW J, 1993, J BIOL CHEM, V268, P12919; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; Burch GH, 1997, NAT GENET, V17, P104, DOI 10.1038/ng0997-104; BURCH GH, 1995, DEV DYNAM, V203, P491, DOI 10.1002/aja.1002030411; CARROLL MC, 1985, P NATL ACAD SCI USA, V82, P521, DOI 10.1073/pnas.82.2.521; CHANG SF, 1995, MOL ENDOCRINOL, V9, P1330, DOI 10.1210/me.9.10.1330; CHAPLIN DD, 1986, P NATL ACAD SCI USA, V83, P9601, DOI 10.1073/pnas.83.24.9601; CHUNG BC, 1985, DNA-J MOLEC CELL BIO, V4, P211, DOI 10.1089/dna.1985.4.211; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DORN A, 1989, MOL CELL BIOL, V9, P312, DOI 10.1128/MCB.9.1.312; Endoh A, 1998, MOL CELL ENDOCRINOL, V137, P13, DOI 10.1016/S0303-7207(97)00224-4; GAZDAR AF, 1990, CANCER RES, V50, P5488; GITELMAN SE, 1992, MOL CELL BIOL, V12, P2124, DOI 10.1128/MCB.12.5.2124; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; HANDLER JD, 1988, J BIOL CHEM, V263, P13068; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; HUM DW, 1995, DNA CELL BIOL, V14, P451, DOI 10.1089/dna.1995.14.451; JOHN ME, 1986, BIOCHEMISTRY-US, V25, P2846, DOI 10.1021/bi00358a016; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; KOHLER PO, 1971, J CLIN ENDOCR METAB, V65, P122; KOMINAMI S, 1980, J BIOL CHEM, V255, P3386; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Marchal R, 1998, BIOCHEM BIOPH RES CO, V247, P28, DOI 10.1006/bbrc.1998.8733; MARTIN H, 1989, MACROPHAGE DERIVED C, P155; MATTESON KJ, 1987, P NATL ACAD SCI USA, V84, P5858, DOI 10.1073/pnas.84.16.5858; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MELLON SH, 1989, J CLIN INVEST, V84, P1497, DOI 10.1172/JCI114325; MILLER WL, 1987, J PEDIATR-US, V111, P1, DOI 10.1016/S0022-3476(87)80334-7; MILSTONE DS, 1992, J BIOL CHEM, V267, P21924; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; Morel Y, 1991, Adv Hum Genet, V20, P1; Morohashi K, 1999, TRENDS ENDOCRIN MET, V10, P169, DOI 10.1016/S1043-2760(98)00142-8; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; PARISSENTI AM, 1993, MOL ENDOCRINOL, V7, P283, DOI 10.1210/me.7.2.283; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PARKER KL, 1986, J BIOL CHEM, V261, P5353; PARKER KL, 1985, P NATL ACAD SCI USA, V82, P7860, DOI 10.1073/pnas.82.23.7860; RICE DA, 1990, J BIOL CHEM, V265, P8052; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; RODRIGUES NR, 1987, EMBO J, V6, P1653, DOI 10.1002/j.1460-2075.1987.tb02414.x; Rodriguez H, 1997, J CLIN ENDOCR METAB, V82, P365, DOI 10.1210/jc.82.2.365; SKOW LC, 1988, DNA-J MOLEC CELL BIO, V7, P143, DOI 10.1089/dna.1988.7.143; Speek M, 1996, HUM MOL GENET, V5, P1749, DOI 10.1093/hmg/5.11.1749; SPEEK M, 1995, MOL ENDOCRINOL, V9, P1655, DOI 10.1210/me.9.12.1655; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; TEE MK, 1995, HUM MOL GENET, V4, P2109, DOI 10.1093/hmg/4.11.2109; TEE MK, 1995, GENOMICS, V28, P171, DOI 10.1006/geno.1995.1128; Therrell BL, 1998, PEDIATRICS, V101, P583, DOI 10.1542/peds.101.4.583; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WHITE PC, 1985, P NATL ACAD SCI USA, V82, P1089, DOI 10.1073/pnas.82.4.1089; WHITE PC, 1994, HUM MUTAT, V3, P373, DOI 10.1002/humu.1380030408; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; WHITE PC, 1984, NATURE, V312, P465, DOI 10.1038/312465a0; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; YASAMURA Y, 1966, CANCER RES, V26, P529; YU CY, 1991, J IMMUNOL, V146, P1057; Zhang PL, 1997, MOL ENDOCRINOL, V11, P891, DOI 10.1210/me.11.7.891; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	64	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38097	38106		10.1074/jbc.274.53.38097	http://dx.doi.org/10.1074/jbc.274.53.38097			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608879	hybrid			2022-12-25	WOS:000084528000079
J	Yang, Y; Wu, JA; Watson, JT				Yang, Y; Wu, JA; Watson, JT			Probing the folding pathways of long R-3 insulin-like growth factor-I (LR(3)IGF-I) and IGF-I via capture and identification of disulfide intermediates by cyanylation methodology and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC RIBONUCLEASE-A; TRYPSIN-INHIBITOR; BIOLOGICAL PROPERTIES; KINETIC ROLE; REGENERATION; DEPENDENCE; PROTEINS; PRODUCTS; STATE; VITRO	This report describes an integrated investigation of the refolding and reductive unfolding of insulin-like growth factor (IGF-I) and its variant, long R-3 IGF-I (LR(3)IGF-I), which has a Glu(3) to Arg(3) substitution and a hydrophobic 13-amino acid N-terminal extension. The refolding performed in glutathione redox buffer was quenched at different time points by adjusting the pH to 2.0-3.0 with a 1 N HCl solution of 1-cyano-4-dimethylaminopyridinium tetrafluoroborate, which trapped intermediates via cyanylation of free sulfhydryl groups. The disulfide structure of the intermediates was determined by chemical cleavage followed by mass mapping with mass spectrometry. Six refolding intermediates of IGF-I and three refolding intermediates of LR(3)IGF-I were isolated and characterized. Folding pathways of IGF-I and LR(3)IGF-I are proposed based on the time-dependent distribution and disulfide structure of the corresponding trapped intermediates. Similarities and differences in the refolding behavior of IGF-I and LR(3)IGF-I are discussed.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Watson, JT (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.							CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CREIGHTON TE, 1994, BIOCHEMISTRY-US, V33, P1534, DOI 10.1021/bi00172a033; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1992, BIOESSAYS, V14, P195, DOI 10.1002/bies.950140310; CREIGHTON TE, 1974, J MOL BIOL, V87, P563, DOI 10.1016/0022-2836(74)90104-1; DARBY NJ, 1995, J MOL BIOL, V249, P463, DOI 10.1006/jmbi.1995.0309; FROESCH ER, 1963, J CLIN INVEST, V42, P1816, DOI 10.1172/JCI104866; GLOCKER O, 1994, P NATL ACAD SCI USA, V91, P5868; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; Hober S, 1997, BIOCHEMISTRY-US, V36, P4616, DOI 10.1021/bi9611265; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LI YJ, 1995, NAT STRUCT BIOL, V2, P489, DOI 10.1038/nsb0695-489; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; MILNER SJ, 1995, BIOCHEM J, V308, P865, DOI 10.1042/bj3080865; PAIN RH, 1994, MECHANISMS PROTEIN F, P112; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; RINDERKNECHT E, 1976, P NATL ACAD SCI USA, V73, P2365, DOI 10.1073/pnas.73.7.2365; Rosenfeld RD, 1997, ARCH BIOCHEM BIOPHYS, V342, P298, DOI 10.1006/abbi.1997.9996; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2690, DOI 10.1021/bi00061a029; ROTHWARF DM, 1991, J AM CHEM SOC, V113, P6293, DOI 10.1021/ja00016a068; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2680, DOI 10.1021/bi00061a028; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2698, DOI 10.1021/bi00061a030; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; TOMAS FM, 1993, J ENDOCRINOL, V137, P413, DOI 10.1677/joe.0.1370413; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wu J, 1998, PROTEIN SCI, V7, P1017; Wu J, 1997, PROTEIN SCI, V6, P391; Xu XB, 1996, BIOCHEMISTRY-US, V35, P6406, DOI 10.1021/bi960090d; Yang Y, 1998, J AM CHEM SOC, V120, P5834, DOI 10.1021/ja9736018	35	35	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37598	37604		10.1074/jbc.274.53.37598	http://dx.doi.org/10.1074/jbc.274.53.37598			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608814	hybrid			2022-12-25	WOS:000084528000014
J	Chatterjee, S; Han, H; Rollins, S; Cleveland, T				Chatterjee, S; Han, H; Rollins, S; Cleveland, T			Molecular cloning, characterization, and expression of a novel human neutral sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; APOPTOSIS; TNF	Neutral sphingomyelinase (N-SMase) has emerged as an important cell membrane-associated enzyme that participates in several signal transduction and cell regulatory phenomena. Using expression cloning, we have identified a 3.7-kilobase pair cDNA transcript for N-SMase whose open reading frame predicts a 397-amino acid polypeptide. Transfection of COS-7 cells with cDNA for N-SMase resulted in a marked increase in N-SMase activity. Recombinant N-SMase (r-N-SMase) had the following physical-chemical properties. Mg2+ activated and Cu2+ and glutathione inhibited the activity of r-N-SMase, In contrast, dithiothreitol did not alter the activity of the enzyme, Of several phospholipids examined, sphingomyelin was the preferred substrate for r-N-SMase, The apparent molecular mass of r-N-SMase derived from COS-7 cells was similar to 90 kDa, similar to the native neutral sphingomyelinase prepared from human urine. However, upon expression in Escherichia coli, the apparent molecular mass of the recombinant enzyme was similar to 45 kDa, We speculate that this apparent difference in recombinant enzymes derived from COS-7 and E. coli cells may be due to extensive post-transcriptional changes. r-N-SMase has numerous post-transcriptional modification sites such as phosphorylation sites via protein kinase C, casein kinase II, tyrosine kinase, and cAMP- and cGMP-dependent protein kinases as well as sites for glycosylation and myristoylation, Amino acid sequence alignment studies revealed that r-N-SMase has some similarity to acid sphingomyelinase and significant homology to the death domains of tumor necrosis factor-alpha receptor-1 and Fas/Apo-I. We believe that the molecular cloning and characterization of N-SMase cDNA will accelerate the process to define its role as a key regulator in apoptosis, lipid and lipoprotein metabolism, and other cell regulatory pathways.	Johns Hopkins Hosp, Dept Pediat, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Chatterjee, S (corresponding author), Johns Hopkins Hosp, Dept Pediat, 600 N Wolfe St,CMSC 6-124, Baltimore, MD 21287 USA.				NHLBI NIH HHS [1-P50-HL47212] Funding Source: Medline; NIDDK NIH HHS [R01-DK31722] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Chatterjee S, 1999, CHEM PHYS LIPIDS, V102, P79, DOI 10.1016/S0009-3084(99)00077-8; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; CHIMUA SJ, 1996, CANCER RES, V56, P2711; Ghosh N, 1998, MOL CELL BIOCHEM, V189, P161, DOI 10.1023/A:1006910200656; Hofmann K, 1999, TRENDS BIOCHEM SCI, V24, P227, DOI 10.1016/S0968-0004(99)01410-3; ITOH N, 1993, J BIOL CHEM, V268, P10932; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; LUI B, 1997, CELL DEV BIOL, V8, P311; LUI B, 1997, J BIOL CHEM, V272, P16281; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SPENCE MW, 1993, ADV LIPID RES, V26, P3; TAKI T, 1995, ANAL BIOCHEM, V224, P490, DOI 10.1006/abio.1995.1077; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	22	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37407	37412		10.1074/jbc.274.52.37407	http://dx.doi.org/10.1074/jbc.274.52.37407			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601312	hybrid			2022-12-25	WOS:000084382700083
J	Yao, XY; Grade, S; Wriggers, W; Rubenstein, PA				Yao, XY; Grade, S; Wriggers, W; Rubenstein, PA			His(73), often methylated, is an important structural determinant for actin - A mutagenic analysis of His(73) of yeast actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; PROTEOLYTIC DIGESTION; SUBDOMAIN 3/4-LOOP; ATP-ACTIN; DYNAMICS; FILAMENT; MUTATION; METHYLHISTIDINE; POLYMERIZATION; PHALLOIDIN	His(73), has been proposed to regulate the release of P-i from the interior of actin following polymerization-dependent hydrolysis of bound ATP, Although it is a 3-methylhistidine in the vast majority of actins, His(73) is unmethylated in S. cerevisiae actin, We mutated His(73) in yeast actin to Arg, Lys, Ala, Gln, and Glu and detected no altered phenotypes associated with the mutations in vivo, However, they significantly affect actin function in vitro. Substitution of the more basic residues resulted in enhanced thermal stability, decreased rate of nucleotide exchange, and decreased susceptibility to controlled proteolysis relative to wild-type actin, The opposite effects are observed with the neutral and anionic substitutions. All mutations reduced the rate of polymerization, Molecular dynamics simulations predict a new conformation for the His(73) imidazole in the absence of a methyl group. It also predicts that Arg(73) tightens and stabilizes the actin and that Glu(73) causes a rearrangement of the bottom of actin's interdomain cleft leading possibly to our observed destabilization of actin, Considering the exterior location of His(73), this work indicates a surprisingly important role for the residue as a major Structural determinant of actin and provides a clue to the impact caused by methylation of His(73).	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of Iowa; University of California System; University of California San Diego	Rubenstein, PA (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.			Wriggers, Willy/0000-0001-5326-3152; Rubenstein, Peter/0000-0003-1225-4414	NIGMS NIH HHS [GM33689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; CARLIER MF, 1984, J BIOL CHEM, V259, P7349; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; CHEN X, 1995, J BIOL CHEM, V270, P11406, DOI 10.1074/jbc.270.19.11406; COOK RK, 1992, PRACTICAL APPROACHES, P99; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P13; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kalhor HR, 1999, ARCH BIOCHEM BIOPHYS, V370, P105, DOI 10.1006/abbi.1999.1370; Kuang B, 1997, J BIOL CHEM, V272, P1237, DOI 10.1074/jbc.272.2.1237; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Orlova A, 1997, J MOL BIOL, V265, P469, DOI 10.1006/jmbi.1996.0761; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; ORLOVA A, 1993, J MOL BIOL, V232, P334, DOI 10.1006/jmbi.1993.1393; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; RICH SA, 1976, J MOL BIOL, V104, P777, DOI 10.1016/0022-2836(76)90181-9; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SOLOMON LR, 1987, J BIOL CHEM, V262, P11382; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; SUSSMAN DJ, 1984, J BIOL CHEM, V259, P7349; Wriggers W, 1999, PROTEINS, V35, P262, DOI 10.1002/(SICI)1097-0134(19990501)35:2<262::AID-PROT11>3.0.CO;2-N; Wriggers W, 1997, BIOPHYS J, V73, P624, DOI 10.1016/S0006-3495(97)78098-6; Wriggers W, 1998, BIOPHYS J, V75, P646, DOI 10.1016/S0006-3495(98)77555-1	32	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37443	37449		10.1074/jbc.274.52.37443	http://dx.doi.org/10.1074/jbc.274.52.37443			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601317	hybrid			2022-12-25	WOS:000084382700088
J	Zhu, KC; Wang, J; Zhu, JH; Jiang, JY; Shou, J; Chen, XB				Zhu, KC; Wang, J; Zhu, JH; Jiang, JY; Shou, J; Chen, XB			p53 induces TAP1 and enhances the transport of MHC class I peptides	ONCOGENE			English	Article						p53; TAP1; MHC class I; interferon gamma; tumor surveillance	MAJOR HISTOCOMPATIBILITY COMPLEX; HUMAN CANCERS; ANTIGEN PRESENTATION; GENE-EXPRESSION; DOWN-REGULATION; BREAST-CANCER; CELLS; APOPTOSIS; PROTEIN; IDENTIFICATION	The transporter associated with antigen processing (TAP) I is required for the major histocompatibility complex (MHC) class I antigen presentation pathway, which plays a key role in host tumor surveillance. Since more than 50% of tumors have a dysfunctional p53, evasion of tumor surveillance by tumor cells may be linked to loss of p53 function. Here we found that TAP1 is strongly induced by p53 and DNA-damaging agents through a p53-responsive element. We also found that p73, which is homologous to p53, is capable of inducing TAP1 and cooperates with p53 to activate TAP1. Furthermore, me found that by inducing TAP1, p53 enhances the transport of MHC class I peptides and expression of surface MHC-peptide complexes, and cooperates with interferon gamma to activate the MHC class I pathway. These results suggest that tumor surveillance may be a mechanism by which p53 and/or p73 function as tumor suppressors.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.			Zhu, Kuichun/0000-0002-3594-5616	NCI NIH HHS [CA81237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; Alpan RS, 1996, CANCER RES, V56, P4358; Amiot L, 1998, BRIT J HAEMATOL, V100, P655, DOI 10.1046/j.1365-2141.1998.00631.x; BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN XB, 1995, CANCER RES, V55, P4257; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gobin SJP, 1997, IMMUNITY, V6, P601, DOI 10.1016/S1074-7613(00)80348-9; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Johnsen A, 1998, CANCER RES, V58, P3660; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAKLAMANIS L, 1995, CANCER RES, V55, P5191; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Khanna R, 1998, CANCER RES, V58, P310; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ma WL, 1997, J BIOL CHEM, V272, P16585, DOI 10.1074/jbc.272.26.16585; Martin BK, 1997, IMMUNITY, V6, P591, DOI 10.1016/S1074-7613(00)80347-7; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MUNGER K, 1989, J VIROL, V63, P4417; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; RESTIFO NP, 1993, J IMMUNOTHER, V14, P182, DOI 10.1097/00002371-199310000-00004; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Vitale M, 1998, CANCER RES, V58, P737; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang ZG, 1998, CANCER RES, V58, P2149; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061	47	72	72	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7740	7747		10.1038/sj.onc.1203235	http://dx.doi.org/10.1038/sj.onc.1203235			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618714				2022-12-25	WOS:000084256900003
J	Loging, WT; Reisman, D				Loging, WT; Reisman, D			Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53	ONCOGENE			English	Article						mutant p53; gene expression; TIMP-3; tumor suppressor	MOUSE-TISSUE INHIBITOR; TATA-BINDING PROTEIN; CELL-CYCLE ARREST; TRANSCRIPTIONAL REPRESSION; MATRIX METALLOPROTEINASES; GROWTH-FACTOR; FUNCTION MUTATIONS; MOLECULAR-CLONING; CARCINOMA-CELLS; DNA-ELEMENTS	The p53 gene is a tumor suppressor that regulates the expression of genes required for cell cycle arrest or apoptosis. Mutations in p53 have been observed in over 60% of all human cancers. Certain classes of mutant p53 proteins maintain some of their activities or acquire novel activities and thus may contribute to the transformed phenotype. By carrying out an analysis of differential gene expression using cDNA expression arrays, we compared the expression patterns of cells expressing no p53 to isogenic lines expressing the codon 248 Arg to Trp mutant p53 allele (R248W). In this report, we show that the R248W and D281G p53 mutants, two of the more commonly occurring mutations, as well as wild type p53, repress transcription of the tissue inhibitor of metalloproteinases type 3 (TIMP3) gene by greater than tenfold. TIMP3 expression has been observed to be repressed in many tumors and its reduced expression is thought to contribute to tumor metastasis and invasiveness by allowing increased activity of metalloproteinases in the extracellular matrix. Since mutant forms of p53 tend to be expressed at greatly elevated levels in many human tumors, the retention of their ability to repress TIMP3 illustrate one mechanism by which mutant forms of the p53 gene may contribute to tumorigenesis.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Reisman, D (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ahonen M, 1998, CANCER RES, V58, P2310; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Balint E, 1996, CANCER RES, V56, P1648; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P2433; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Bian JH, 1996, CARCINOGENESIS, V17, P2559, DOI 10.1093/carcin/17.12.2559; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chan EC, 1998, BBA-MOL BASIS DIS, V1407, P200, DOI 10.1016/S0925-4439(98)00041-6; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Foley J, 1996, CANCER RES, V56, P4056; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIAO M, 1994, AM J PATHOL, V145, P702; HSIAO M, 1995, MOL CARCINOGEN, V13, P112, DOI 10.1002/mc.2940130208; Hussain SP, 1998, CANCER RES, V58, P4023; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim HT, 1997, BIOCHEM J, V324, P547, DOI 10.1042/bj3240547; Kinzler KW, 1998, COLORECTAL TUMORS GE, P565; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LILL J, 1995, ONCOGENE, V10, P2387; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIYASHITA T, 1995, CELL, V80, P293; Muller BF, 1996, ONCOGENE, V12, P1941; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHOHAT O, 1987, ONCOGENE, V1, P277; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1994, CANCER RES, V54, P1139; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Ueno H, 1997, CANCER RES, V57, P2055; VAN MEIR EG, 1994, CANCER RES, V54, P649; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XIAO H, 1994, MOL CELL BIOL, V14, P7103; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35	90	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7608	7615		10.1038/sj.onc.1203135	http://dx.doi.org/10.1038/sj.onc.1203135			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602522				2022-12-25	WOS:000084119600024
J	Yin, ZN; Spitz, MR; Babaian, RJ; Strom, SS; Troncoso, P; Kagan, J				Yin, ZN; Spitz, MR; Babaian, RJ; Strom, SS; Troncoso, P; Kagan, J			Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3	ONCOGENE			English	Article						chromosome 13; prostate cancer; loss of heterozygosity; tumor suppressor gene	ALLELIC LOSS; RETINOBLASTOMA GENE; FREQUENT LOSS; P53 PROTEIN; LOCI; CARCINOMA; HETEROZYGOSITY; DELETION; BRCA2; 13Q	We studied loss of heterozygosity (LOH) on human chromosome 13q in prostate cancer specimens to determine the location of a putative tumor suppressor gene (TSG) and to correlate these losses with the clinicopathological stage of the disease. Overall 13 (21%) of 61 specimens analysed had an allele loss on the long arm of chromosome 13, The most frequent (37%) LOH among the informative cases with allele losses was detected at the D13S284 locus on chromosome 13q14.3. A portion of the DNA segment that spans this locus and is flanked by the microsatellite loci D13S153 and D13S163 was lost in 85% of the specimens with allele losses and was designated as a LOH cluster region (LCR). The LCR spans more than 6 Mbp of DNA, The results suggest that a TSG relevant for the development of prostate cancer is located telomeric to the RE locus. There was a significant correlation (P=0.0024) between chromosome 13q LOH and advanced metastatic disease, suggesting that loss of 13q14.3 region is associated with prostate cancer progression, However, further research must be conducted to establish the identity and function of this putative TSG.	Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Sect Expt Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kagan, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Sect Expt Lab Med, Box 054,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA68758-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, AJCC CANC STAGING MA; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOVA GS, 1993, CANCER RES, V53, P3869; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; Brooks JD, 1996, CANCER RES, V56, P3814; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; Cairns P, 1997, CANCER RES, V57, P4997; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Cooney KA, 1996, CANCER RES, V56, P1142; Cunningham JM, 1996, CANCER RES, V56, P4475; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; KAGAN J, 1995, ONCOGENE, V11, P2121; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P291, DOI 10.1002/gcc.2870130410; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LATIL A, 1995, B CANCER, V82, P589; Li CD, 1998, ONCOGENE, V16, P481, DOI 10.1038/sj.onc.1201554; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu Y, 1997, ONCOGENE, V15, P2463, DOI 10.1038/sj.onc.1201643; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1995, CANCER RES, V55, P5390; MASTERO R, 1996, CANCER RES, V56, P1146; Melamed J, 1997, CLIN CANCER RES, V3, P1867; Mottaz AE, 1997, PROSTATE, V31, P209; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Pearce SHS, 1996, CLIN ENDOCRINOL, V45, P195, DOI 10.1046/j.1365-2265.1996.d01-1561.x; PEI L, 1995, CANCER RES, V55, P1613; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; Salem CE, 1997, J UROLOGY, V158, P510, DOI 10.1016/S0022-5347(01)64520-8; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Sigurdsson S, 1997, J MOL MED-JMM, V75, P758, DOI 10.1007/s001090050162; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; Suzuki H, 1998, CANCER RES, V58, P204; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1997, CANCER RES, V57, P5221; TRAPMAN J, 1994, CANCER RES, V54, P6061; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; VISAKORPI T, 1995, CANCER RES, V55, P342; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Weinstein IB, 1996, J CELL BIOCHEM, P23; YOO GH, 1994, CANCER RES, V54, P4603; ZAR JH, 1991, BIOSTATISTICAL ANAL; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	49	52	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7576	7583		10.1038/sj.onc.1203203	http://dx.doi.org/10.1038/sj.onc.1203203			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602517				2022-12-25	WOS:000084119600019
J	Foray, N; Randrianarison, V; Marot, D; Perricaudet, M; Lenoir, G; Feunteun, J				Foray, N; Randrianarison, V; Marot, D; Perricaudet, M; Lenoir, G; Feunteun, J			Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2	ONCOGENE			English	Article						BRCA1; BRCA2; DNA repair; radiation	DOUBLE-STRAND BREAKS; SUSCEPTIBILITY GENE BRCA2; ATAXIA-TELANGIECTASIA; CANCER-CELLS; REPAIR DEFICIENCY; CHROMOSOME-DAMAGE; CYCLE ARREST; DNA-REPAIR; P53; RADIATION	There is now evidence to suggest that BRCA1 and BRCA2 are involved in the response of cells to DNA damage and cell cycle checkpoint control. This report examines the death pathways of human cells with various BRCA1 and BRCA2 genotypes after exposure to gamma-rays, A lack of functional BRCA1 and BRCA2 led to defective repair of DNA double-strand breaks in irradiated cells. This impairment resulted in a relaxation of cell cycle checkpoints, production of micronuclei, and a loss of proliferative capacity, Heterozygous BRCA1 and BRCA2 mutations also led to enhanced radiosensitivity, with an impaired proliferative capacity after irradiation. The existence of a phenotype related to radiosensitivity in BRCA1(+/-) and BRCA2(+/-) cells raises the question of the response of heterozygous women to radiation.	Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS UMR 1582, Lab Vectorol & Transfert Genes, F-94805 Villejuif, France; Univ Lyon 1, CNRS UMR 5641, Lab Genet & Canc, F-69365 Lyon, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Feunteun, J (corresponding author), Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, Rue Camille Desmoulins, F-94805 Villejuif, France.		Foray, Nicolas/I-4755-2018; Foray, Nicolas/Q-2363-2019; Feunteun, Jean/AAZ-1267-2020	Foray, Nicolas/0000-0002-1282-1303; Foray, Nicolas/0000-0002-1282-1303; Feunteun, Jean/0000-0003-1212-9189				Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; BADIE C, 1995, CANCER RES, V55, P1232; BADIE C, 1995, RADIAT RES, V144, P26, DOI 10.2307/3579232; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Chong J P, 1996, Prog Cell Cycle Res, V2, P83; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; DAMICO AV, 1994, RADIOTHER ONCOL, V33, P3, DOI 10.1016/0167-8140(94)90079-5; Davies MA, 1998, CANCER RES, V58, P5285; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; EVANS HH, 1993, RADIAT RES, V134, P307, DOI 10.2307/3578190; Fajac A, 1996, INT J CANCER, V68, P67, DOI 10.1002/(SICI)1097-0215(19960927)68:1<67::AID-IJC13>3.0.CO;2-3; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Foray N, 1996, RADIAT RES, V146, P53, DOI 10.2307/3579395; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Johnston PJ, 1997, MUTAT RES-DNA REPAIR, V385, P1, DOI 10.1016/S0921-8777(97)00034-7; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI CY, 1995, ONCOGENE, V11, P1885; LIN JY, 1995, ONCOGENE, V10, P2387; LIU N, 1993, MUTAGENESIS, V8, P503, DOI 10.1093/mutage/8.6.503; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Otto AM, 1996, J CANCER RES CLIN, V122, P603, DOI 10.1007/BF01221192; Paglin S, 1997, BIOCHEM BIOPH RES CO, V237, P678, DOI 10.1006/bbrc.1997.7117; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; SCOTT D, 1994, LANCET, V344, P1444, DOI 10.1016/S0140-6736(94)90615-7; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shiloh Yosef, 1998, Biochimica et Biophysica Acta, V1378, pR11, DOI 10.1016/S0304-419X(98)00020-1; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	40	134	135	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7334	7342		10.1038/sj.onc.1203165	http://dx.doi.org/10.1038/sj.onc.1203165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602489				2022-12-25	WOS:000084119400019
J	Umemori, H; Hayashi, T; Inoue, T; Nakanishi, S; Mikoshiba, K; Yamamoto, T				Umemori, H; Hayashi, T; Inoue, T; Nakanishi, S; Mikoshiba, K; Yamamoto, T			Involvement of protein tyrosine phosphatases in activation of the trimeric G protein G(q/11)	ONCOGENE			English	Article						tyrosine phosphorylation; tyrosine phosphatase; metabotropic glutamate receptor; G protein; G alpha(q/11); IP3	METABOTROPIC GLUTAMATE RECEPTORS; HETEROTRIMERIC G-PROTEINS; SIGNAL TRANSDUCTION; PHENYLARSINE OXIDE; RAT-1 FIBROBLASTS; ALPHA-SUBUNIT; PHOSPHORYLATION; KINASES; TRANSFORMATION; CELLS	A variety of receptors coupled to the heterotrimeric guanine nucleotide-binding protein G(q/11) stimulate intracellular Ca2+ release through inositol (1,4,5)-trisphosphate (IP3) formation. We previously reported that tyrosine phosphorylation of the alpha subunit of the G(q/11) protein by protein tyrosine kinases (PTKs) regulates the activation of G(q/11) protein. Here we show that protein tyrosine phosphatases (PTPs) are also essential for G(q/11) protein activation. We find that G(q/11) protein-coupled receptor-mediated formation of IP3 is blocked by PTP inhibitors as well as PTK inhibitors. These inhibitors act prior to G(q/11) protein activation. Tyrosine phosphorylation of the alpha subunit of G(q/11) appears to inhibit its interaction with receptors. Thus, PTP is required for controlling the level of tyrosine phosphorylation of the alpha subunit of G(q/11) to promote its interaction with receptors. Therefore, we conclude that PTKs and PTPs co-operate to proceed activation cycle of the G(q/11) protein through tyrosine phosphorylation and de-phosphorylation of the alpha subunit of G(q/11).	Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo 1088639, Japan; Kyoto Univ, Fac Med, Dept Sci Biol, Kyoto 6068501, Japan	University of Tokyo; University of Tokyo; Kyoto University	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan.		Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015	Inoue, Takafumi/0000-0002-2728-0060; Umemori, Hisashi/0000-0001-7198-2062; Hayashi, Takashi/0000-0003-3591-2109				ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLUML K, 1994, J BIOL CHEM, V269, P18870; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; Fusaki N, 1996, J IMMUNOL, V156, P1369; GREENWALT DE, 1994, BRIT J HAEMATOL, V88, P830, DOI 10.1111/j.1365-2141.1994.tb05124.x; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Helgadottir A, 1997, ARTERIOSCL THROM VAS, V17, P287, DOI 10.1161/01.ATV.17.2.287; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; MATTINGLY RR, 1992, J BIOL CHEM, V267, P7470; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; YANAGA F, 1995, FEBS LETT, V368, P377, DOI 10.1016/0014-5793(95)00670-5; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	25	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7399	7402		10.1038/sj.onc.1203152	http://dx.doi.org/10.1038/sj.onc.1203152			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602498				2022-12-25	WOS:000084119400028
J	Keularts, IMLW; van Gorp, RMA; Feijge, MAH; Vuist, WMJ; Heemskerk, JWM				Keularts, IMLW; van Gorp, RMA; Feijge, MAH; Vuist, WMJ; Heemskerk, JWM			alpha(2A)-adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHOLIPASE-C; CYCLIC-AMP; ADENYLATE-CYCLASE; ALPHA-2-ADRENERGIC RECEPTOR; TYROSINE PHOSPHORYLATION; NA+/H+ EXCHANGE; INTACT-CELLS; EPINEPHRINE; ACTIVATION	alpha(2A)-Adrenergic receptor-mediated Ca2+ signaling and integrin alpha(IIb)beta(3) exposure were investigated in human platelets under conditions where indirect, thromboxane- or ADP-mediated effects were absent. The alpha(2)-adrenergic receptor agonists, UK14304 and epinephrine (EPI), were unable to raise cytosolic levels of inositol 1,4,5-trisphosphate (InsP(3)) or Ca2+ but potentiated the [Ca2+](i) rises evoked by other agonists that act through stimulation of phospholipase C (thrombin or platelet-activating factor) or stimulation of Ca2+-induced Ca2+ release (CICR) in the absence of InsP(3) generation (thimerosal or thapsigargin), In addition, alpha(2)-adrenergic stimulation resulted in a 20% lowering in the cytosolic cAMP level. In platelets treated with G(s alpha)-stimulating prostaglandin E-1, EPI increased the Ca2+ signal evoked by either phospholipase C- or CICR-stimulating agonists mainly through modulation of the cAMP level. The stimulating effects of UK14304 and EPI on platelet Ca2+ responses, and also on integrin alpha(IIb)beta(3) exposure and platelet aggregation, were abolished by pharmacological stimulation of cAMP-dependent protein kinase, and these effects were mimicked by inhibition of this activity. In permeabilized platelets, UK14304 and EPI potentiated InsP(3)-induced, CICR-mediated mobilization of Ca2+ from internal stores in a similar way as did inhibition of cAMP-dependent protein kinase, In summary, a G(i alpha)-mediated decrease in cAMP level appears to play a major role in the platelet-activating effects of alpha(2A)-adrenergic receptor stimulation. Thus, in platelets, unlike other cell types, occupation of the G(i alpha)-coupled alpha(2A)-adrenergic receptors does not result in phospholipase C activation but rather in modulation of the Ca2+ response by relieving cAMP-mediated suppression of InsP(3)-dependent CICR.	Univ Limburg, Dept Human Biol, NL-6200 MD Maastricht, Netherlands; Univ Limburg, Dept Biochem, NL-6200 MD Maastricht, Netherlands	Hasselt University; Maastricht University; Hasselt University; Maastricht University	Heemskerk, JWM (corresponding author), Univ Limburg, Dept Human Biol, POB 616, NL-6200 MD Maastricht, Netherlands.		Heemskerk, Johan/AAM-8323-2021	Heemskerk, Johan/0000-0002-2848-5121				AKTORIES K, 1981, FEBS LETT, V130, P235, DOI 10.1016/0014-5793(81)81128-3; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; Banno Y, 1998, THROMB HAEMOSTASIS, V79, P1008; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; CHABRE O, 1994, J BIOL CHEM, V269, P5730; COBB CE, 1987, J BIOL CHEM, V262, P16566; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dorn GW, 1997, BIOCHEMISTRY-US, V36, P6415, DOI 10.1021/bi970080s; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; GALITZKY J, 1990, BRIT J PHARMACOL, V100, P862, DOI 10.1111/j.1476-5381.1990.tb14105.x; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; HALBRUGGE M, 1993, PROTEIN KINASES BLOO, P245; HARRIS DN, 1979, J CYCLIC NUCL PROT, V5, P125; Haslam R J, 1978, Adv Cyclic Nucleotide Res, V9, P533; HASLAM RJ, 1971, BIOCHEM J, V125, P377, DOI 10.1042/bj1250377; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; HEEMSKERK JWM, 1993, J BIOL CHEM, V268, P356; Heemskerk JWM, 1997, EUR J BIOCHEM, V249, P547, DOI 10.1111/j.1432-1033.1997.00547.x; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P19, DOI 10.1016/0005-2736(92)90158-I; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; MARTI KB, 1992, P NATL ACAD SCI USA, V89, P2784, DOI 10.1073/pnas.89.7.2784; MICHEL MC, 1989, J BIOL CHEM, V264, P4986; NIEUWLAND R, 1993, BIOCHIM BIOPHYS ACTA, V1148, P185, DOI 10.1016/0005-2736(93)90128-M; Paul BZS, 1998, BRIT J HAEMATOL, V102, P1204; PEERSCHKE EI, 1982, BLOOD, V60, P71; REGAN JW, 1986, J BIOL CHEM, V261, P3894; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Ryningen A, 1998, BBA-LIPID LIPID MET, V1394, P235, DOI 10.1016/S0005-2760(98)00106-4; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1989, BLOOD, V73, P150; SIESS W, 1984, J BIOL CHEM, V259, P8286; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; STEEN VM, 1988, BIOCHEM J, V253, P581, DOI 10.1042/bj2530581; SWEATT JD, 1986, J BIOL CHEM, V261, P8660; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; THOMAS DP, 1967, NATURE, V215, P298, DOI 10.1038/215298a0; THOMPSON NT, 1986, EUR J BIOCHEM, V161, P399, DOI 10.1111/j.1432-1033.1986.tb10459.x; VUIST WMJ, 1994, BLOOD, V83, P899; WARE JA, 1986, J CLIN INVEST, V77, P878, DOI 10.1172/JCI112385; ZAVOICO GB, 1984, BIOCHEM BIOPH RES CO, V120, P579, DOI 10.1016/0006-291X(84)91294-4	47	73	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1763	1772		10.1074/jbc.275.3.1763	http://dx.doi.org/10.1074/jbc.275.3.1763			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636873	hybrid			2022-12-25	WOS:000084940000036
J	Flugel, RS; Hwangbo, Y; Lambalot, RH; Cronan, JE; Walsh, CT				Flugel, RS; Hwangbo, Y; Lambalot, RH; Cronan, JE; Walsh, CT			Holo-(acyl carrier protein) synthase and phosphopantetheinyl transfer in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; ACID BIOSYNTHESIS; PDXJ OPERON; COENZYME-A; CLONING; STREPTOMYCES; POLYKETIDE; EXPRESSION	Holo-(acyl carrier protein) synthase (AcpS) posttranslationally modifies apoacyl carrier protein (apoACP) via transfer of 4'-phosphopantetheine from coenzyme A (CoA) to the conserved serine 36 gamma-OH of apoACP, The resulting holo-acyl carrier protein (holoACP) is then active as the central coenzyme of fatty acid biosynthesis, The acpS gene has previously been identified and shown to be essential for Escherichia coli growth, Earlier mutagenic studies isolated the E, coli MP4 strain, whose elevated growth requirement for CoA was ascribed to a deficiency in holoACP synthesis. Sequencing of the acpS gene from the E. coli MP4 strain (denoted acpS1) showed that the AcpS1 protein contains a G4D mutation. AcpS1 exhibited a similar to 5-fold reduction in its catalytic efficiency when compared with wild type AcpS, accounting for the E. coli MP4 strain phenotype, It is shown that a conditional acpS mutant accumulates apoACP in vivo under nonpermissive conditions in a manner similar to the E, coli MP4 strain. In addition, it is demonstrated that the gene product, YhhU, of a previously identified E. coli open reading frame can completely suppress the acpS conditional, lethal phenotype upon overexpression of the protein, suggesting that YhhU may be involved in an alternative pathway for phosphopantetheinyl transfer and holoACP synthesis in E. coli.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	Harvard University; Harvard Medical School; Harvard University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Walsh, CT (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	walsh@walsh.med.harvard.edu	Cronan, John/V-6626-2019	Hwangbo, Yon/0000-0001-8380-0641	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020011, R37GM020011, T32GM008313] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline; NIGMS NIH HHS [GM20011, 5T32-GM08313-07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cleland W. W, 1970, ENZYMES, V2, P1; Cronan Jr. J.E., 1987, ESCHERICHIA COLI SAL, P474; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; Debabov DV, 1996, J BACTERIOL, V178, P3869, DOI 10.1128/jb.178.13.3869-3876.1996; Earhart C.F., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1075; ELOVSON J, 1968, J BIOL CHEM, V243, P3603; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Gehring AM, 1997, BIOCHEMISTRY-US, V36, P8495, DOI 10.1021/bi970453p; Ghose R, 1996, FEBS LETT, V388, P66, DOI 10.1016/0014-5793(96)00512-1; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HILL RB, 1995, PROTEIN EXPRES PURIF, V6, P394, DOI 10.1006/prep.1995.1052; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P6135, DOI 10.1021/bi00416a046; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; Keating DH, 1996, J BACTERIOL, V178, P2662, DOI 10.1128/jb.178.9.2662-2667.1996; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; LAM HM, 1992, J BACTERIOL, V174, P1554, DOI 10.1128/jb.174.5.1554-1567.1992; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J.H., 1992, SHORT COURSE BACTERI, P150; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULZ H, 1969, J BIOL CHEM, V244, P6577; SCHULZ H, 1975, J BIOL CHEM, V250, P2299; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1	29	105	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					959	968		10.1074/jbc.275.2.959	http://dx.doi.org/10.1074/jbc.275.2.959			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625633	hybrid			2022-12-25	WOS:000084836600037
J	Kishi, H; Mikawa, T; Seto, M; Sasaki, Y; Kanayasu-Toyoda, T; Yamaguchi, T; Imamura, M; Ito, M; Karaki, H; Bao, JJ; Nakamura, A; Ishikawa, R; Kohama, K				Kishi, H; Mikawa, T; Seto, M; Sasaki, Y; Kanayasu-Toyoda, T; Yamaguchi, T; Imamura, M; Ito, M; Karaki, H; Bao, JJ; Nakamura, A; Ishikawa, R; Kohama, K			Stable transfectants of smooth muscle cell line lacking the expression of myosin light chain kinase and their characterization with respect to the actomyosin system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT INTERACTION; ACTIN-BINDING DOMAIN; GROWTH-FACTOR; CULTURED-CELLS; PROTEIN; PHOSPHORYLATION; LOCALIZATION; RECEPTOR; ACTIVATION; MIGRATION	We constructed a plasmid vector having a 1.4-kilobase pair insert of myosin light chain kinase (MLCK) cDNA in an antisense direction to express antisense mRNA The construct was then transfected to SM3, a cell line from vascular smooth muscle cells, producing a few stable transfectants. The down-regulation of MLCK expression in the transfectants was confirmed by both Northern and Western blots. The control SM3 showed chemotaxic motility to platelet-derived growth factor-BB, which was supported by lamellipodia. However, the transfectants showed neither chemotaxic motility nor developed lamellipodia, indicating the essential role of MLCK in the motility. The specificity for the targeting was assessed by a few tests including the rescue experiment. Despite this importance of MLCK, platelet-derived growth factor-BB failed to induce MLC20 phosphorylation in not only the transfectants but also in SM3. The mode in which MLCK was involved in the development of membrane ruffling is discussed with special reference to the novel property of MLCK that stimulates the ATPase activity of smooth muscle myosin without phosphorylating its light chain.	Gunma Univ, Sch Med, Dept Pharmacol, Maebashi, Gumma 3718511, Japan; Gunma Univ, Sch Med, Dept Internal Med 1, Maebashi, Gumma 3718511, Japan; Cornell Univ, Coll Med, Dept Cell Biol, New York, NY 10021 USA; Asahi Chem Ind Co Ltd, Shizuoka 4160934, Japan; Natl Inst Hlth Sci, Tokyo 1588501, Japan; Natl Ctr Neurol & Psychiat, Tokyo 1878551, Japan; Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pharmacol, Bunkyo Ku, Tokyo 1138657, Japan	Gunma University; Gunma University; Cornell University; National Institute of Health Sciences - Japan; National Center for Neurology & Psychiatry - Japan; Mie University; University of Tokyo	Kohama, K (corresponding author), Gunma Univ, Sch Med, Dept Pharmacol, Maebashi, Gumma 3718511, Japan.		Kishi, Hiroko/AAR-9148-2021	Kishi, Hiroko/0000-0003-2896-7355	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056987, R01HL054128, R01HL062175] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62175, HL54128, HL56987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKASU T, 1993, NEURON, V11, P1133, DOI 10.1016/0896-6273(93)90226-H; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMAN A, 1990, J CELL SCI, V97, P399; DABROWSKA R, 1982, BIOCHEM BIOPH RES CO, V107, P1524, DOI 10.1016/S0006-291X(82)80172-1; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GALLAGHER PJ, 1995, J BIOL CHEM, V270, P29090, DOI 10.1074/jbc.270.49.29090; Gallagher PJ, 1997, MOL CELL BIOCHEM, V173, P51, DOI 10.1023/A:1006876318155; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRIERO V, 1981, CELL, V27, P449, DOI 10.1016/0092-8674(81)90386-X; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; Hayakawa K, 1999, BBA-MOL CELL RES, V1450, P12, DOI 10.1016/S0167-4889(99)00034-8; HAYAKAWA K, 1994, BIOCHEM BIOPH RES CO, V199, P786, DOI 10.1006/bbrc.1994.1298; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KOHAMA K, 1992, BIOCHEM BIOPH RES CO, V184, P1204, DOI 10.1016/S0006-291X(05)80010-5; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; MARSTON S, 1995, INT J BIOCHEM CELL B, V27, P97, DOI 10.1016/1357-2725(94)00080-U; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MIKAWA T, 1992, DEV DYNAM, V193, P11, DOI 10.1002/aja.1001930104; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakurada K, 1998, AM J PHYSIOL-CELL PH, V274, pC1563, DOI 10.1152/ajpcell.1998.274.6.C1563; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SASAKI Y, 1989, J BIOCHEM-TOKYO, V106, P1009, DOI 10.1093/oxfordjournals.jbchem.a122956; SATO M, 1995, J BIOCHEM, V118, P1; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Seto M, 1996, PFLUG ARCH EUR J PHY, V432, P7, DOI 10.1007/s004240050099; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SHRINSKY VP, 1993, J BIOL CHEM, V268, P16578; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WILSON AK, 1991, J CELL BIOL, V114, P277, DOI 10.1083/jcb.114.2.277; YE LH, 1994, J BIOCHEM, V116, P1377, DOI 10.1093/oxfordjournals.jbchem.a124690; Ye LH, 1997, J BIOL CHEM, V272, P32182, DOI 10.1074/jbc.272.51.32182; Ye LH, 1999, P NATL ACAD SCI USA, V96, P6666, DOI 10.1073/pnas.96.12.6666	43	35	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1414	1420		10.1074/jbc.275.2.1414	http://dx.doi.org/10.1074/jbc.275.2.1414			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625693	hybrid			2022-12-25	WOS:000084836600097
J	Rauer, H; Lanigan, MD; Pennington, MW; Aiyar, J; Ghanshani, S; Cahalan, MD; Norton, RS; Chandy, KG				Rauer, H; Lanigan, MD; Pennington, MW; Aiyar, J; Ghanshani, S; Cahalan, MD; Norton, RS; Chandy, KG			Structure-guided transformation of charybdotoxin yields an analog that selectively targets Ca2+-activated over voltage-gated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; HUMAN T-LYMPHOCYTES; MUTANT CYCLES; IN-VIVO; CLOTRIMAZOLE; BLOCKADE; MEMBER; KV1.3; CONSERVATION; EXPRESSION	We have used a structure-based design strategy to transform the polypeptide toxin charybdotoxin, which blocks several voltage-gated and Ca2+-activated KC channels, into a selective inhibitor. As a model system, we chose two channels in T-lymphocytes, the voltage-gated channel Kv1.3 and the Ca2+-activated channel IKCa1, Homology models of both channels were generated based on the crystal structure of the bacterial channel KcsA. Initial docking of charybdotoxin was undertaken with both models, and the accuracy of these docking configurations was tested by mutant cycle analyses, establishing that charybdotoxin has a similar docking configuration in the external vestibules of IKCa1 and Kv1.3. Comparison of the refined models revealed a unique cluster of negatively charged residues in the turret of Kv1.3, not present in IKCa1, To exploit this difference, three novel charybdotoxin analogs were designed by introducing negatively charged residues in place of charybdotoxin Lys(32), which lies in close proximity to this cluster. These analogs block IKCa1 with similar to 20-fold higher affinity than Kv1.3, The other charybdotoxin-sensitive Kv channels, Kv1.2 and Rv1.6, contain the negative cluster and are predictably insensitive to the charybdotoxin position 32 analogs, whereas the maxi-K-Ca, channel, hSlo, lacking the cluster, is sensitive to the analogs. This provides strong evidence for topological similarity of the external vestibules of diverse K+ channels and demonstrates the feasibility of using structure-based strategies to design selective inhibitors for mammalian K+ channels. The availability of potent and selective inhibitors of IKCa1 will help to elucidate the role of this channel in T-lymphocytes during the immune response as well as in erythrocytes and colonic epithelia.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Biomol Res Inst, Parkville, Vic 3052, Australia; Bachem Biosci Inc, King Of Prussia, PA 19406 USA; AstraZeneca Pharmaceut, Target Discovery Dept, Wilmington, DE 19850 USA	University of California System; University of California Irvine; AstraZeneca	Chandy, KG (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Rm 291,Joan Irvine Smith Hall, Irvine, CA 92697 USA.			Norton, Raymond/0000-0001-8893-0584; pennington, michael/0000-0001-5446-3447	NIGMS NIH HHS [GM54221] Funding Source: Medline; NIMH NIH HHS [MH59222] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS014609, R56NS014609, R01NS014609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; BRUGNARA C, 1995, J PHARMACOL EXP THER, V273, P266; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; Brugnara C, 1995, Curr Opin Hematol, V2, P132; Brugnara C, 1995, Ann N Y Acad Sci, V763, P262, DOI 10.1111/j.1749-6632.1995.tb32411.x; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; GARCIA ML, 1995, AM J PHYSIOL-CELL PH, V269, pC1, DOI 10.1152/ajpcell.1995.269.1.C1; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GODLSTEIN SA, 1994, NEURON, V12, P1377; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; Hanson DC, 1999, BRIT J PHARMACOL, V126, P1707, DOI 10.1038/sj.bjp.0702480; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; KIRSCH GE, 1991, FEBS LETT, V278, P55, DOI 10.1016/0014-5793(91)80082-E; Koo GC, 1997, J IMMUNOL, V158, P5120; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MUNUJOS P, 1995, BIOCHEMISTRY-US, V34, P10771, DOI 10.1021/bi00034a009; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rauer H, 1999, BRIT J PHARMACOL, V127, P1065, DOI 10.1038/sj.bjp.0702599; Rauer H, 1996, MOL PHARMACOL, V50, P1625; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542	39	96	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1201	1208		10.1074/jbc.275.2.1201	http://dx.doi.org/10.1074/jbc.275.2.1201			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625664	hybrid			2022-12-25	WOS:000084836600068
J	Gary-Gouy, H; Bruhns, P; Schmitt, C; Dalloul, A; Daeron, M; Bismuth, G				Gary-Gouy, H; Bruhns, P; Schmitt, C; Dalloul, A; Daeron, M; Bismuth, G			The pseudo-immunoreceptor tyrosine-based activation motif of CD5 mediates its inhibitory action on B-cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CBL PROTOONCOGENE; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATASE 1C; NEGATIVE REGULATION; CYTOPLASMIC DOMAIN; IN-VIVO; TRANSDUCTION MOLECULE; FC-RECEPTORS; ZETA-CHAIN	Genetic studies revealed that CD5 could be a negative regulator of the B-cell antigen receptor (BCR). We explore here the effect of human CD5 on BCR-triggered responses. B cells were obtained expressing a chimera composed of extracellular and transmembrane domains of Fc gamma type IIB receptor fused to CD5 cytoplasmic domain (CD5cyt). Coligation of the chimera with the BCR induces CD5cyt tyrosine phosphorylation. A rapid inhibition of BCR-induced calcium response is observed, as well as a partial but delayed inhibition of phospholipase C gamma-1 phosphorylation. Activation of extracellular regulated kinase-2 is also severely impaired. Moreover, at the functional level, interleukin-2 production is abolished. Src homology 2 domain-bearing tyrosine phosphatase SHP-1 and Src homology 2 domain-bearing inositol 5'-phosphatase SHIP usually participate in negative regulation of the BCR. We show that they do not associate with the phosphorylated CD5 chimera. We finally demonstrate that the pseudo-immunoreceptor tyrosine based activation motif present in CD5cyt is involved because its deletion eliminates the inhibitory effect of the chimera, both at biochemical and functional levels. These results demonstrate the inhibitory role of CD5 pseudo-immunoreceptor tyrosine based activation motif tyrosine phosphorylation on BCR signaling. They further support the idea that CD5 uses mechanisms different from those already described to negatively regulate the BCR pathway.	Ctr Hosp Pitie Salpetriere, CERVI, CNRS,UMR 7627, Lab Immunol Cellulaire, F-75013 Paris, France; Inst Curie, INSERM, U255, Lab Immunol Cellulaire & Clin, F-75005 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Bismuth, G (corresponding author), Ctr Hosp Pitie Salpetriere, CERVI, CNRS,UMR 7627, Lab Immunol Cellulaire, 83 Blvd Hop, F-75013 Paris, France.	gbismuth@ccr.jussieu.fr	Bruhns, Pierre/F-5567-2013	Bruhns, Pierre/0000-0002-4709-8936; GARY, HELENE/0000-0002-9555-5484				ALBEROLAILA J, 1993, J IMMUNOL, V151, P4423; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Bauch A, 1998, EUR J IMMUNOL, V28, P2167, DOI 10.1002/(SICI)1521-4141(199807)28:07<2167::AID-IMMU2167>3.0.CO;2-L; Biancone L, 1996, J EXP MED, V184, P811, DOI 10.1084/jem.184.3.811; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Bruhns P, 1999, J IMMUNOL, V162, P3168; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; Calvo J, 1998, J IMMUNOL, V161, P6022; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Cerutti A, 1996, J IMMUNOL, V157, P1854; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; Dennehy KM, 1998, EUR J IMMUNOL, V28, P1617, DOI 10.1002/(SICI)1521-4141(199805)28:05<1617::AID-IMMU1617>3.0.CO;2-7; Dennehy KM, 1997, EUR J IMMUNOL, V27, P679, DOI 10.1002/eji.1830270316; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GaryGouy H, 1997, J IMMUNOL, V159, P3739; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Gringhuis SI, 1997, J BIOL CHEM, V272, P31809, DOI 10.1074/jbc.272.50.31809; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; GUTHMANN MD, 1995, P NATL ACAD SCI USA, V92, P9397, DOI 10.1073/pnas.92.20.9397; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; HAYAKAWA K, 1983, J EXP MED, V157, P202, DOI 10.1084/jem.157.1.202; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Jamin C, 1996, EUR J IMMUNOL, V26, P57, DOI 10.1002/eji.1830260109; JONES B, 1986, J IMMUNOL, V136, P348; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P812, DOI 10.1002/eji.1830240406; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Malbec O, 1998, J IMMUNOL, V160, P1647; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; OSMAN N, 1992, EUR J IMMUNOL, V22, P2995, DOI 10.1002/eji.1830221135; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Perez-Villar JJ, 1999, MOL CELL BIOL, V19, P2903; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Pospisil R, 1996, J EXP MED, V184, P1279, DOI 10.1084/jem.184.4.1279; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; Raab M, 1996, BIOCHEM BIOPH RES CO, V222, P50, DOI 10.1006/bbrc.1996.0696; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Simarro M, 1997, J IMMUNOL, V159, P4307; Simarro M, 1999, J IMMUNOL, V162, P5149; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tarakhovsky A, 1997, J EXP MED, V185, P981, DOI 10.1084/jem.185.6.981; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; Tridandapani S, 1999, J IMMUNOL, V162, P1408; Tridandapani S, 1997, J IMMUNOL, V158, P1125; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VAN DE VELDE H, 1991, NATURE, V351, P662; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; WEISS A, 1987, J IMMUNOL, V139, P3245	76	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					548	556		10.1074/jbc.275.1.548	http://dx.doi.org/10.1074/jbc.275.1.548			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617650	hybrid			2022-12-25	WOS:000085951600074
J	Kwon, T; Kwon, DY; Chun, J; Kim, JH; Kang, SS				Kwon, T; Kwon, DY; Chun, J; Kim, JH; Kang, SS			Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CDC42 GTPASES; REGULATED EXPRESSION; INDEPENDENT PATHWAYS; LIPID PRODUCTS; P115 RHOGEF; S6 KINASE; ACTIVATION; ONCOGENE; FAMILY	A putative Akt kinase phosphorylation site ((64)ydRIR-plSYp(73)) was found in Rac1/CDC42 and Rho family proteins (RhoA, RhoB, RhoC, and RhoG). Phosphorylation of Rac1 by Akt kinase was assayed with recombinant Rac1 protein and the fluorescein-labeled Rac1 peptide. It was shown that the Rac1 peptide and the recombinant protein were phosphorylated by the activated recombinant Akt kinase and the lysate of SK-MEL28 cells, a human melanoma cell line. The phosphorylation of Rac1 inhibited its GTP-binding activity without any significant change in GTPase activity, Both the GTP-binding and GTPase activities of Rac1 S71A protein (with the serine residue to be phosphorylated replaced with alanine) were abolished regardless of the treatment of Akt kinase. Akt kinase activity and Rac1 peptide phosphorylation were down-regulated by the treatment of SK-MEL28 cells with wortmannin or LY294002 (a phosphoinositide 3-kinase inhibitor), but JNK/SAPK kinase activity was up-regulated. Thus, the results suggest that Akt kinase of the phosphoinositide 3-kinase signal transduction pathway phosphorylates serine 71 of Rac1 as one of its authentic substrates and modulates the Rac1 signal transduction pathway through phosphorylation.	Chongbuk Natl Univ, Dept Sci Educ, Div Sci Educ, Chongju 361763, South Korea; Samsung Biomed Res Inst, Clin Res Ctr, Seoul 135230, South Korea; Seoul Natl Univ Hosp, Seoul 110530, South Korea; Univ Wisconsin, Dept Entomol, Madison, WI 53705 USA; Kwangju Inst Sci & Technol, Dept Life Biol, Kwangju 500712, South Korea	Jeonbuk National University; Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National University (SNU); Seoul National University Hospital; University of Wisconsin System; University of Wisconsin Madison; Gwangju Institute of Science & Technology (GIST)	Kang, SS (corresponding author), Chongbuk Natl Univ, Dept Sci Educ, Div Sci Educ, Chongju 361763, South Korea.	95324JIN@mail.hitel.net	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208; Kwon, Taegun/0000-0002-0205-8535				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; delPeso L, 1997, SCIENCE, V278, P687; DISDSBURRY J, 1989, J BIOL CHEM, V264, P16378; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; FAGAN KP, 1994, EXP EYE RES, V59, P235, DOI 10.1006/exer.1994.1102; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Gringhuis SI, 1998, MOL CELL BIOL, V18, P1725, DOI 10.1128/MCB.18.3.1725; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jones GE, 1998, CELL ADHES COMMUN, V6, P237, DOI 10.3109/15419069809004479; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MARTIN GA, 1995, EMBO J, V14, P4385, DOI 10.1002/j.1460-2075.1995.tb00113.x; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; MOLL J, 1991, ONCOGENE, V6, P863; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roberts ML, 1998, BIOCHEM BIOPH RES CO, V251, P166, DOI 10.1006/bbrc.1998.9434; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Seo HS, 1997, EUR J BIOCHEM, V249, P293, DOI 10.1111/j.1432-1033.1997.00293.x; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	53	180	186	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					423	428		10.1074/jbc.275.1.423	http://dx.doi.org/10.1074/jbc.275.1.423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617634	hybrid			2022-12-25	WOS:000085951600058
J	O'Keeffe, B; Fong, Y; Chen, D; Zhou, S; Zhou, Q				O'Keeffe, B; Fong, Y; Chen, D; Zhou, S; Zhou, Q			Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; CELL-FREE SYSTEM; PROTEIN-KINASE; IN-VIVO; ELONGATION-FACTOR; GLUCOCORTICOID RECEPTOR; CATALYTIC SUBUNIT; HSP90; TRANSACTIVATION	Tat activation of HIV-1 transcription is mediated by human transcription elongation factor P-TEFb, which interacts with Tat and phosphorylates the C-terminal domain of RNA polymerase II. The catalytic subunit of the P-TEFb complex, Cdk9, has been shown to interact with cyclin T and several other proteins of unknown identity, Consequently, the exact subunit composition of active P-TEFb has not been determined. Here we report the affinity purification and identification of the Cdk9 associated proteins. In addition to forming a heterodimer with cyclin T1, Cdk9 interacted with the molecular chaperone Hsp76 or a kinase-specific chaperone complex, Hsp90/Cdc37, to form two separate chaperone-Cdk9 complexes, Although the Cdk9/cyclin T1 dimer was exceptionally stable and produced slowly in the cell, free and unprotected Cdk9 appeared to be degraded rapidly, Several lines of evidence indicate the heterodimer of Cdk9/cyclin T1 to be the mature, active form of P-TEFb responsible for phosphorylation of the C-terminal domain of RNA polymerase II interaction with the Tat activation domain, and mediation of Tat activation of HIV-1 transcription. Pharmacological inactivation of Hsp90/Cdc37 function by geldanamycin revealed an essential role for the chaperone-Cdk9 complexes in generation of Cdk9/cyclin TI, Our data suggest a previously unrecognized chaperone-dependent pathway involving the sequential actions of Hsp70 and Hsp90/Cdc37 in the stabilization/folding of Cdk9 as well as the assembly of an active Cdk9/cyclin T1 complex responsible for P-TEFb-mediated Tat transactivation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Zhou, Q (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 206 Stanley Hall,3206, Berkeley, CA 94720 USA.	qzhou@uclink4.berkeley.edu			NIAID NIH HHS [AI-41757] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041757] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chen D, 1999, MOL CELL BIOL, V19, P2863; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Kim JB, 1999, MOL CELL BIOL, V19, P5960; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Li XY, 1998, GENE DEV, V12, P2992, DOI 10.1101/gad.12.19.2992; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Parada CA, 1999, EMBO J, V18, P3688, DOI 10.1093/emboj/18.13.3688; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	46	121	123	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					279	287		10.1074/jbc.275.1.279	http://dx.doi.org/10.1074/jbc.275.1.279			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617616	hybrid			2022-12-25	WOS:000085951600040
J	Alldridge, LC; Harris, HJ; Plevin, R; Hannon, R; Bryant, CE				Alldridge, LC; Harris, HJ; Plevin, R; Hannon, R; Bryant, CE			The annexin protein lipocortin 1 regulates the MAPK/ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HUMAN RECOMBINANT LIPOCORTIN-1; ADENOCARCINOMA CELL-LINE; TUMOR-NECROSIS-FACTOR; MAP KINASE KINASE; FACTOR-KAPPA-B; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; CYCLE ARREST	Lipocortin 1 (annexin 1) is a calcium- and phospholipid-binding protein that modulates anti-inflammatory responses including those induced by lipopolysaccharide. To investigate the precise role of lipocortin 1 in regulating the lipopolysaccharide-induced signal transduction pathways, we generated stable RAW 264.7 macrophage cell lines expressing decreased and increased lipocortin 1 protein. Several RAW 264.7 clones with increased lipocortin 1 protein levels showed constitutive activation of the mitogen-activated protein kinase extracellular signal-regulated kinase, which was down-regulated following lipopolysaccharide treatment. Conversely, clones with decreased lipocortin 1 protein expression showed prolonged extracellular signal-regulated kinase activity, following lipopolysaccharide activation. Lipocortin 1 specifically regulates the components of the extracellular signal-regulated kinase pathway, since changes in lipocortin 1 protein expression had no affect on the related mitogen-activated protein kinases p38 and c-Jun N-terminal kinase. Lipocortin 1 modulated upstream components of the extracellular signal-regulated kinase pathway and associated with the adaptor protein growth factor binding protein. The downstream consequences of altered extracellular signal-regulated kinase activity were independent of the proinflammatory transcription factor nuclear factor kappa B. These data indicate that Lipocortin 1 specifically regulates proximal signaling components of the extracellular signal-regulated kinase signal transduction pathway, resulting in the modulation of biochemical functions in RAW macrophages.	Univ Cambridge, Dept Clin Vet Med, Cambridge CB3 0ES, England; Univ Strathclyde, Dept Physiol & Pharmacol, Glasgow, Lanark, Scotland; Queen Mary Univ London, St Bartholomews & Royal London Sch Med & Dent, Dept Biochem Pharmacol, London EC1M 6BQ, England	University of Cambridge; University of Strathclyde; University of London; Queen Mary University London	Bryant, CE (corresponding author), Univ Cambridge, Dept Clin Vet Med, Madingley Rd, Cambridge CB3 0ES, England.	ceb27@cus.cam.ac.uk		Plevin, Robin/0000-0002-7849-1220				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Briant L, 1998, J IMMUNOL, V160, P1875; Bryant CE, 1998, BIOCHEM PHARMACOL, V55, P279, DOI 10.1016/S0006-2952(97)00462-0; Chu J, 1998, BLOOD, V92, P1697, DOI 10.1182/blood.V92.5.1697.417a06_1697_1706; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CROXTALL JD, 1992, P NATL ACAD SCI USA, V89, P3571, DOI 10.1073/pnas.89.8.3571; Croxtall JD, 1998, BRIT J PHARMACOL, V123, P975, DOI 10.1038/sj.bjp.0701679; Curto M, 1998, BIOCHEM BIOPH RES CO, V243, P555, DOI 10.1006/bbrc.1997.7982; DAVIDSON J, 1991, BRIT J PHARMACOL, V102, P7, DOI 10.1111/j.1476-5381.1991.tb12122.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diakonova M, 1997, J CELL SCI, V110, P1199; DINARELLO CA, 1992, BACTERIAL ENDOTOXIC, P105; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; GENG Y, 1993, J IMMUNOL, V151, P6692; GEPPERT TD, 1994, MOL MED, V1, P93; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; KIEHEN TL, 1995, IMMUNOPHARMACOLOGY, V29, P187; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCALLUM RE, 1992, BACTERIAL ENDOTOXIC, P145; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mollenhauer J, 1997, CELL MOL LIFE SCI, V53, P506, DOI 10.1007/s000180050063; MORGAN RO, 1995, MOL BIOL EVOL, V12, P967; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; MOSS SE, 1995, NATURE, V378, P446, DOI 10.1038/378446a0; PERRETTI M, 1993, J IMMUNOL, V150, P992; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Pouliot M, 1997, J IMMUNOL, V158, P4930; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rose DM, 1997, J IMMUNOL, V158, P3433; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Tombes RM, 1998, BIOCHEM J, V330, P1451; Traverso V, 1998, J CELL SCI, V111, P1405; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Ward AC, 1998, BBA-MOL CELL RES, V1448, P70, DOI 10.1016/S0167-4889(98)00120-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	52	121	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37620	37628		10.1074/jbc.274.53.37620	http://dx.doi.org/10.1074/jbc.274.53.37620			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608817	hybrid			2022-12-25	WOS:000084528000017
J	Delmotte, MH; Tahayato, A; Formstecher, P; Lefebvre, P				Delmotte, MH; Tahayato, A; Formstecher, P; Lefebvre, P			Serine 157, a retinoic acid receptor alpha residue phosphorylated by protein kinase C in vitro, is involved in RXR center dot RAR alpha heterodimerization and transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; DNA-BINDING; TERATOCARCINOMA DIFFERENTIATION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; CARCINOMA CELLS; ACTIVATION; EXPRESSION; PATHWAY; TRANSLOCATION	Retinoic acid (RA) regulation of cellular proliferation and differentiation is mediated, at least in part, through two related nuclear receptors, RAR and RXR. RA-induced modulation of gene expression leads generally to cellular differentiation, whereas stimulation of the protein kinase C (PHC) signaling pathway is associated with cellular proliferation. Pursuant to our discovery that prolonged activation of PKCs induced a strong decrease in RA responsiveness of a retinoid-inducible reporter gene, we have further investigated the connections between these two signaling pathways. We demonstrate that PKC isoforms alpha and gamma are able to phosphorylate human RAR alpha (hRAR alpha) in vitro on a single serine residue located in the extended DNA binding domain (T box). The introduction of a negative charge at this position (serine 157) strongly decreased hRAR alpha transcriptional activity, whereas a similar mutation at other PKC consensus phosphorylation sites had no effect. The effect on transcriptional activation was correlated with a decrease in the capacity of hRAR alpha to heterodimerize with hRXR alpha. Thus hRAR alpha is a direct target for PKC alpha and gamma, which may control retinoid receptor transcriptional activities during cellular proliferation and differentiation.	Fac Med Henri Warembourg, INSERM, U459, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Lefebvre, P (corresponding author), Fac Med Henri Warembourg, INSERM, U459, 1 Pl Verdun, F-59045 Lille, France.		Lefebvre, Philippe/F-2685-2010	Lefebvre, Philippe/0000-0002-9366-5129				BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; Berry DM, 1996, J BIOL CHEM, V271, P16090, DOI 10.1074/jbc.271.27.16090; Blobe GC, 1996, CANCER SURV, V27, P213; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Cho YH, 1997, J CELL PHYSIOL, V172, P306, DOI 10.1002/(SICI)1097-4652(199709)172:3<306::AID-JCP4>3.0.CO;2-S; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HSIEH JC, 1993, J BIOL CHEM, V268, P15118; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Khuri FR, 1996, CELL GROWTH DIFFER, V7, P595; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KRISHNAN AV, 1991, MOL ENDOCRINOL, V5, P605, DOI 10.1210/mend-5-4-605; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; KURIE JM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P203, DOI 10.1016/0167-4889(93)90142-C; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lefebvre B, 1998, BIOCHEMISTRY-US, V37, P9240, DOI 10.1021/bi9804840; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; LISSOOS TW, 1993, J BIOL CHEM, V268, P25132; Marino M, 1998, BIOCHEM BIOPH RES CO, V245, P254, DOI 10.1006/bbrc.1998.8413; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mouchon A, 1999, MOL CELL BIOL, V19, P3073; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; POLLOK KE, 1991, CELL SIGNAL, V3, P435, DOI 10.1016/0898-6568(91)90074-5; Quack M, 1998, NUCLEIC ACIDS RES, V26, P5372, DOI 10.1093/nar/26.23.5372; Rachez C, 1996, J BIOL CHEM, V271, P17996, DOI 10.1074/jbc.271.30.17996; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rosewicz S, 1996, ENDOCRINOLOGY, V137, P3340, DOI 10.1210/en.137.8.3340; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SIMBOLICAMPBELL M, 1994, J BIOL CHEM, V269, P3257; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; TAHAYATO A, 1997, RETINOID PROTOCOLS, P277; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; YANG YL, 1994, MOL ENDOCRINOL, V8, P1370, DOI 10.1210/me.8.10.1370; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311	46	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38225	38231		10.1074/jbc.274.53.38225	http://dx.doi.org/10.1074/jbc.274.53.38225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608897	hybrid			2022-12-25	WOS:000084528000097
J	Kim, ST; Lim, DS; Canman, CE; Kastan, MB				Kim, ST; Lim, DS; Canman, CE; Kastan, MB			Substrate specificities and identification of putative substrates of ATM kinase family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; CYCLE CHECKPOINT PATHWAY; TELANGIECTASIA GENE ATM; ATAXIA-TELANGIECTASIA; CELL-CYCLE; PROTEIN-KINASE; DNA-DAMAGE; P53; PRODUCT; BREAST	Ataxia telangiectasia mutated (ATM) phosphorylates p53 protein in response to ionizing radiation, but the complex phenotype of AT cells suggests that it must have other cellular substrates as well. To identify substrates for ATM and the related kinases ATR and DNA-PK, we optimized in vitro kinase assays and developed a rapid peptide screening method to determine general phosphorylation consensus sequences. ATM and ATR require Mn2+, but not DNA ends or Ku proteins, for optimal in vitro activity while DNA-PKCs requires Mg2+, DNA ends, and Bh proteins. From p53 peptide mutagenesis analysis, me found that the sequence S/TQ is a minimal essential requirement for all three kinases. In addition, hydrophobic amino acids and negatively charged amino acids immediately NH2-terminal to serine or threonine are positive determinants and positively charged amino acids in the region are negative determinants for substrate phosphorylation. We determined a general phosphorylation consensus sequence for ATM and identified putative in vitro targets by using glutathione S-transferase peptides as substrates. Putative ATM in vitro targets include p95/nibrin, Mre11, Brca1, Rad17, PTS, WRN, and ATM (S440) itself. Brca2, phosphatidylinositol 3-kinase, and DNA-5B peptides were phosphorylated specifically by ATR, and DNA Ligase IV is a specific in vitro substrate of DNA-PK.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Kastan, MB (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Lim, Dae-Sik/C-1599-2011; Kim, Seong-Tae/A-9917-2013	Lim, Dae-Sik/0000-0003-2356-7555; , Christine/0000-0001-8892-7430	NCI NIH HHS [CA71387, CA21765] Funding Source: Medline; NIEHS NIH HHS [ES0577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071387, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 1998, CELL GROWTH DIFFER, V9, P961; Bluyssen HAR, 1999, GENOMICS, V55, P219, DOI 10.1006/geno.1998.5642; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1995, ONCOGENE, V11, P609; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin M, 1998, BRIT MED J, V317, P486; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li L, 1999, ONCOGENE, V18, P1689, DOI 10.1038/sj.onc.1202469; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; SCHROTER H, 1985, EMBO J, V4, P3867, DOI 10.1002/j.1460-2075.1985.tb04159.x; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Swift M, 1999, BRIT MED J, V318, P400, DOI 10.1136/bmj.318.7180.400; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Westphal CH, 1998, CANCER RES, V58, P5637; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	44	619	672	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37538	37543		10.1074/jbc.274.53.37538	http://dx.doi.org/10.1074/jbc.274.53.37538			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608806	hybrid			2022-12-25	WOS:000084528000006
J	Vinion-Dubiel, AD; McClain, MS; Czajkowsky, DM; Iwamoto, H; Ye, D; Cao, P; Schraw, W; Szabo, G; Blanke, SR; Shao, ZF; Cover, TL				Vinion-Dubiel, AD; McClain, MS; Czajkowsky, DM; Iwamoto, H; Ye, D; Cao, P; Schraw, W; Szabo, G; Blanke, SR; Shao, ZF; Cover, TL			A dominant negative mutant of Helicobacter pylori vacuolating toxin (VacA) inhibits VacA-induced cell vacuolation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIN; PROTEIN; BINDING; MEMBRANE; ACID; CYTOSOL; GENE	Most Helicobacter pylori strains secrete a toxin (VacA) that causes structural and functional alterations in epithelial cells and is thought to play an important role in the pathogenesis of H. pylori-associated gastroduodenal diseases, The amino acid sequence, ultrastructural morphology, and cellular effects of VacA are unrelated to those of any other known bacterial protein toxin, and the VacA mechanism of action remains poorly understood. To analyze the functional role of a unique strongly hydrophobic region near the VacA amino terminus, we constructed an H pylori strain that produced a mutant VacA protein (VacA-(Delta 6-27)) in which this hydrophobic segment was deleted. VacA-(Delta 6-27) was secreted by H. pylori, oligomerized properly, and formed two-dimensional lipid-bound crystals with structural features that were indistinguishable from those of wild-type VacA However, VacA-(Delta 6-27) formed ion-conductive channels in planar Lipid bilayers significantly more slowly than did wild-type VacA and the mutant channels were less anion-selective. Mixtures of wild-type VacA and VacA-(Delta 6-27) formed membrane channels with properties intermediate between those formed by either isolated species, VacA-(Delta 6-27) did not exhibit any detectable defects in binding or uptake by HeLa cells, but this mutant toxin failed to induce cell. vacuolation, Moreover, when an equimolar mixture of purified VacA(Delta 6-27) and purified wild-type VacA were added simultaneously to HeLa cells, the mutant toxin exhibited a dominant negative effect, completely inhibiting the vacuolating activity of wild-type VacA A dominant negative effect also was observed when HeLa cells were cotransfected with plasmids encoding wild-type and mutant toxins. me propose a model in which the dominant negative effects of VacA-(Delta 6-27) result from protein-protein interactions between the mutant and wild-type VacA proteins, thereby resulting in the formation of mixed oligomers with defective functional activity.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Biophys Program, Charlottesville, VA 22908 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Houston System; University of Houston; University of Virginia; University of Virginia	Cover, TL (corresponding author), Vanderbilt Univ, Sch Med, Div Infect Dis, A3310 Med Ctr N, Nashville, TN 37232 USA.		Shao, Zhifeng/B-6075-2013; Cover, Timothy/I-3814-2015; McClain, Mark S/A-6942-2009	Cover, Timothy/0000-0001-8503-002X; McClain, Mark S/0000-0002-9857-4883	NCRR NIH HHS [RR07720] Funding Source: Medline; NIAID NIH HHS [AI39657] Funding Source: Medline; NIDDK NIH HHS [DK53623] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053623] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Burroni D, 1998, INFECT IMMUN, V66, P5547, DOI 10.1128/IAI.66.11.5547-5550.1998; Copass M, 1997, INFECT IMMUN, V65, P1949, DOI 10.1128/IAI.65.5.1949-1952.1997; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1993, INFECT IMMUN, V61, P5008, DOI 10.1128/IAI.61.12.5008-5012.1993; Cover TL, 1996, MOL MICROBIOL, V20, P241, DOI 10.1111/j.1365-2958.1996.tb02612.x; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; Czajkowsky DM, 1998, FEBS LETT, V430, P51, DOI 10.1016/S0014-5793(98)00461-X; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; Engel A, 1999, CURR BIOL, V9, pR133, DOI 10.1016/S0960-9822(99)80081-5; ENGLEMAN DM, 1996, SCIENCE, V274, P1850; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Iwamoto H, 1999, FEBS LETT, V450, P101, DOI 10.1016/S0014-5793(99)00474-3; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; Massari P, 1998, INFECT IMMUN, V66, P3981, DOI 10.1128/IAI.66.8.3981-3984.1998; Miles E W, 1977, Methods Enzymol, V47, P431; Molinari M, 1998, BIOCHEM BIOPH RES CO, V248, P334, DOI 10.1006/bbrc.1998.8808; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Montecucco C, 1998, CURR OPIN CELL BIOL, V10, P530, DOI 10.1016/S0955-0674(98)80069-0; Papini E, 1998, J CLIN INVEST, V102, P813, DOI 10.1172/JCI2764; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; Reyrat JM, 1999, J MOL BIOL, V290, P459, DOI 10.1006/jmbi.1999.2877; Satin B, 1997, J BIOL CHEM, V272, P25022, DOI 10.1074/jbc.272.40.25022; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Seto K, 1998, FEBS LETT, V431, P347, DOI 10.1016/S0014-5793(98)00788-1; STENMARK H, 1988, J BIOL CHEM, V263, P13449; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277; 1994, IARC MONOGR EVAL CAR, V61, P177	43	112	116	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37736	37742		10.1074/jbc.274.53.37736	http://dx.doi.org/10.1074/jbc.274.53.37736			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608833	hybrid			2022-12-25	WOS:000084528000033
J	Vollmer, JY; Alix, P; Chollet, A; Takeda, K; Galzi, JL				Vollmer, JY; Alix, P; Chollet, A; Takeda, K; Galzi, JL			Subcellular compartmentalization of activation and desensitization of responses mediated by NK2 neurokinin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN-FLUORESCENT PROTEIN; P NK-1 RECEPTOR; SUBSTANCE-P; LIGAND-BINDING; KINASE-C; ACETYLCHOLINE-RECEPTOR; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; CAVEOLAE; CELLS	A functional fluorescent neurokinin NK2 receptor was constructed by joining enhanced green fluorescent protein to the amino-terminal end of the rat NK2 receptor and was expressed in human embryonic kidney cells. On cell suspensions, the binding of fluorescent Bodipy-labeled neurokinin A results in a saturatable and reversible decrease of NK2 receptor fluorescence via fluorescence resonance energy transfer. This can be quantified for nM to mu M agonist concentrations and monitored in parallel with intracellular calcium responses. On single cells, receptor site occupancy and local agonist concentration can be determined in real time from the decrease in receptor fluorescence. Simultaneous measurement of intracellular calcium responses and agonist binding reveals that partial receptor site occupancy is sufficient to desensitize cellular response to a second agonist application to the same membrane area. Subsequent stimulation of a distal membrane area leads to a second response to agonist, provided that it had not been exposed to agonist during the first application. Together with persistent translocation of fluorescent protein kinase C to the membrane area exposed to agonist, the present data support that not only homologous desensitization but also heterologous desensitization of NK2 receptors is compartmentalized to discrete membrane domains.	Ecole Super Biotechnol Strasbourg, Dept Recepteurs & Prot Membranaires, CNRS, F-67400 Illkirch Graffenstaden, France; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Univ Strasbourg 1, Fac Pharm, CNRS, UMR 7034, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Galzi, JL (corresponding author), Ecole Super Biotechnol Strasbourg, Dept Recepteurs & Prot Membranaires, CNRS, UPR 9050,Blvd Sebastien Brant, F-67400 Illkirch Graffenstaden, France.	galzi@esbs.u-strasbg.fr						ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Alblas J, 1996, EMBO J, V15, P3351, DOI 10.1002/j.1460-2075.1996.tb00700.x; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; DIMARZO V, 1993, J NEUROSCI, V13, P4846; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; EMONDSALT X, 1992, LIFE SCI, V50, pPL101, DOI 10.1016/0024-3205(92)90352-P; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; Feron O, 1999, LIFE SCI, V64, P471, DOI 10.1016/S0024-3205(98)00590-6; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HUANG RRC, 1995, BIOCHEMISTRY-US, V34, P10048, DOI 10.1021/bi00031a029; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; Lefkowitz RJ, 1996, NAT BIOTECHNOL, V14, P283, DOI 10.1038/nbt0396-283; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; NAKANISHI S, 1993, REGUL PEPTIDES, V46, P37, DOI 10.1016/0167-0115(93)90009-W; NEMETH K, 1995, J BIOL CHEM, V270, P27601, DOI 10.1074/jbc.270.46.27601; NEUBIG RR, 1993, MOL PHARMACOL, V43, P734; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Periasamy A, 1997, P SOC PHOTO-OPT INS, V2983, P58, DOI 10.1117/12.274324; POSNER RG, 1994, MOL PHARMACOL, V45, P65; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SASAI Y, 1989, BIOCHEM BIOPH RES CO, V165, P695, DOI 10.1016/S0006-291X(89)80022-1; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; THASTRUP O, 1996, Patent No. 23898; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VARRAULT A, 1992, N-S ARCH PHARMACOL, V346, P367; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; Weill C, 1999, J RECEPT SIGNAL TR R, V19, P423, DOI 10.3109/10799899909036662; Weill C, 1999, J NEUROCHEM, V73, P791, DOI 10.1046/j.1471-4159.1999.0730791.x; WERGE TM, 1994, J BIOL CHEM, V269, P22054; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	61	43	45	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37915	37922		10.1074/jbc.274.53.37915	http://dx.doi.org/10.1074/jbc.274.53.37915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608858	Green Published, hybrid			2022-12-25	WOS:000084528000058
J	Zhen, YJ; Hoganson, CW; Babcock, GT; Ferguson-Miller, S				Zhen, YJ; Hoganson, CW; Babcock, GT; Ferguson-Miller, S			Definition of the interaction domain for cytochrome c on cytochrome c oxidase - I. Biochemical, spectral, and kinetic characterization of surface mutants in subunit II of Rhodobacter sphaeroides cytochrome aa(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; PARACOCCUS-DENITRIFICANS; ELECTRON-TRANSFER; CHEMICAL MODIFICATION; BINDING DOMAINS; RHODOPSEUDOMONAS-SPHAEROIDES; HIGH-AFFINITY; 2.8 ANGSTROM; SITE; PURIFICATION	To determine the interaction site for cytochrome c (Cc) on cytochrome c oxidase (CcO), a number of conserved carboxyl residues in subunit TI of Rhodobacter sphaeroides CcO were mutated to neutral forms. A highly conserved tryptophan, Trp(143), was also mutated to phenylalanine and alanine. Spectroscopic and metal analyses of the surface carboxyl mutants revealed no overall structural changes. The double mutants D188Q/E189N and D151Q/E152N exhibit similar steady-state kinetic behavior as wild-type oxidase with horse Cc and R sphaeroides Cc(2), showing that these residues are not involved in Cc binding. The single mutants E148Q, E157Q, D195N, and D214N have decreased activities and increased K-m values, indicating they contribute to the Cc:CcO interface. However, their reactions with horse and R. sphaeroides Cc are different, as expected from the different distribution of surface lysines on these cytochromes a. Mutations at Trp(143) severely inhibit activity without changing the K-m for Cc or disturbing the adjacent Cu-A center. From these data, we identify a Cc binding area on CcO with Trp(143) and Asp(214) close to the site of electron transfer and Glu(148), Glu(157) and Asp(195) providing electrostatic guidance. The results are completely consistent with time-resolved kinetic measurements (Wang, K, Zhen, Y., Sadoski, R,, Grinnell, S., Geren, L., Ferguson-Miller, S., Durham, B., and Millett, F.(1999) J. Biol Chem. 274, 38042-38050) and computational docking analysis (Roberts, V. A, and Pique, M. E. (1999) J. Biol. Chem. 274, 38051-38060).	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Ferguson-Miller, S (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	fergus20@pilot.msu.edu		Zhen, Eugene/0000-0002-0162-5665	NIGMS NIH HHS [GM26916, GM57323, GM25480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026916, R01GM025480, P01GM057323, R37GM026916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY EA, 1985, J BIOL CHEM, V260, P2458; BISSON R, 1982, FEBS LETT, V144, P359, DOI 10.1016/0014-5793(82)80672-8; BLAIR DF, 1983, CHEM SCRIPTA, V21, P43; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BRAUTIGAN DL, 1978, J BIOL CHEM, V253, P130; CAO JL, 1991, GENE, V101, P133, DOI 10.1016/0378-1119(91)90235-4; COOPER CE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P187, DOI 10.1016/0005-2728(90)90184-6; ERREDE B, 1978, BIOCHEMISTRY-US, V17, P1015, DOI 10.1021/bi00599a012; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; GARBER EAE, 1990, BIOCHIM BIOPHYS ACTA, V1015, P279, DOI 10.1016/0005-2728(90)90032-Y; GENNIS RB, 1982, EUR J BIOCHEM, V125, P189, DOI 10.1111/j.1432-1033.1982.tb06667.x; GREENWOOD C, 1983, BIOCHEM J, V215, P303, DOI 10.1042/bj2150303; HILL BC, 1991, J BIOL CHEM, V266, P2219; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KANG CH, 1978, J BIOL CHEM, V253, P6502; KITUCHI G, 1965, BIOCHIM BIOPHYS ACTA, V94, P1; LAPPALAINEN P, 1995, BIOCHEMISTRY-US, V34, P5824, DOI 10.1021/bi00017a014; Malatesta F, 1998, FEBS LETT, V434, P322, DOI 10.1016/S0014-5793(98)01006-0; MARGOLIASH E, 1996, CYTOCHROME C MULTIDI; Margoliash E., 1979, PORPHYRINS, V7, P149; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V807, P308, DOI 10.1016/0005-2728(85)90263-4; Miller MA, 1996, BIOCHEMISTRY-US, V35, P667, DOI 10.1021/bi952557a; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MILLETT F, 1982, BIOCHEMISTRY-US, V21, P3857, DOI 10.1021/bi00259a021; MYERS D, 1988, ANN NY ACAD SCI, V550, P85, DOI 10.1111/j.1749-6632.1988.tb35325.x; Myllykallio H, 1999, P NATL ACAD SCI USA, V96, P4348, DOI 10.1073/pnas.96.8.4348; OSHEROFF N, 1979, CYTOCHROME OXIDASE, P281; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PAN LP, 1993, BIOCHEMISTRY-US, V32, P8492, DOI 10.1021/bi00084a014; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; RIEDER R, 1980, J BIOL CHEM, V255, P4732; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SINJORGO KMC, 1984, BIOCHIM BIOPHYS ACTA, V767, P48, DOI 10.1016/0005-2728(84)90078-1; SMITH HT, 1977, BIOCHEMISTRY-US, V16, P4971, DOI 10.1021/bi00642a005; SPECK SH, 1984, J BIOL CHEM, V259, P1064; STEFFENS GJ, 1979, CYTOCHROME OXIDASE, P79; TAHA TSM, 1992, BIOCHEMISTRY-US, V31, P9090, DOI 10.1021/bi00152a053; TIEDE DM, 1993, BIOCHEMISTRY-US, V32, P4515, DOI 10.1021/bi00068a006; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TURBA A, 1995, EUR J BIOCHEM, V231, P259, DOI 10.1111/j.1432-1033.1995.0259f.x; Wang KF, 1999, J BIOL CHEM, V274, P38042, DOI 10.1074/jbc.274.53.38042; Wang KF, 1996, BIOCHEMISTRY-US, V35, P15107, DOI 10.1021/bi9611117; Witt H, 1997, FEBS LETT, V409, P128, DOI 10.1016/S0014-5793(97)00485-7; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; WITT H, 1995, BBA-BIOENERGETICS, V1230, P74, DOI 10.1016/0005-2728(95)00050-S; Witt H, 1998, EUR J BIOCHEM, V251, P367, DOI 10.1046/j.1432-1327.1998.2510367.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zhen Y, 1998, PROTEIN EXPRES PURIF, V13, P326, DOI 10.1006/prep.1998.0903; ZHEN Y, 1998, THESIS MICHIGAN STAT; ZUMFT WG, 1992, EUR J BIOCHEM, V208, P31, DOI 10.1111/j.1432-1033.1992.tb17156.x; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	57	90	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38032	38041		10.1074/jbc.274.53.38032	http://dx.doi.org/10.1074/jbc.274.53.38032			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608872	hybrid			2022-12-25	WOS:000084528000072
J	David-Pfeuty, T				David-Pfeuty, T			Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells	ONCOGENE			English	Article						cyclin-dependent kinase; protein-kinase inhibitor; wt p53; apoptosis; anti-tumor agent	PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN FIBROBLASTS; CHEMICAL INHIBITORS; PHASE-TRANSITION; DNA-REPLICATION; PURINE ANALOGS; CDC28 MUTATION; RIBOSOMAL-RNA; CANCER-CELLS	The cdk2 gene has been identified as a human cdc2/CDC28-related gene that encodes a protein kinase essential for the G1/S transition in mammalian cells, but not for the G2/M transition, which requires Cdk1, another p34(cdc2/CDC28) homolog, Novel potential functions of Cdk2 have been uncovered by using two potent and specific inhibitors of its kinase activity, roscovitine and olomoucine, on human wt p53-expresser untransformed and tumor-derived cells. At concentrations equal or superior to respectively 30- and 20-fold their in vitro IC50 values for cyclin B/Cdk1, cyclin A/Cdk2 and cyclin E/Cdk2, the Cdk inhibitors precipitately induce a dramatic nuclear accumulation of wt p53 and a delocalization of nucleolin from the nucleolus In all interphase cells, whatever their cell cycle status, acting in this way like the DNA-damaging drug, mitomycin C (7 mu g/ml). These early events are soon followed by a nucleolar fragmentation in both normal and tumor cells in the presence of the Cdk inhibitors but not in the presence of the DNA-damaging drug. Yet, treatment with either type of compounds eventually triggers rapidly the death of the tumor cells and, much more slowly, that of the normal cells. The Cdk inhibitors, however, stimulate cell death from any stage of the cell cycle, whereas the DNA-damaging drug kills more efficaciously S phase cells. These observations provide a hint that the Cdk2 kinase might be involved in controlling the nuclear le,els of the tumor suppressor wt p53 protein and in maintaining the nucleolar integrity and function, linking in this way the cell division cycle machinery to survival functions and overall cell metabolism via the control of nucleocytoplasmic transport and of ribosome production.	Ctr Univ Orsay, Inst Curie Rech, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	David-Pfeuty, T (corresponding author), Ctr Univ Orsay, Inst Curie Rech, CNRS, UMR 146, Batiment 110, F-91405 Orsay, France.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; An B, 1997, ONCOL REP, V4, P1129; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BATES S, 1994, ONCOGENE, V9, P71; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DavidPfeuty T, 1997, CANCER RES, V57, P4482; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DavidPfeuty T, 1996, ONCOGENE, V13, P1447; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAUTIER T, 1992, J CELL SCI, V102, P729; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; JIANG W, 1993, ONCOGENE, V8, P3447; KARN J, 1989, ONCOGENE, V4, P773; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; Meijer L., 1995, PROGR CELL CYCLE RES, V1; MEIJER L, 1997, PROGR CELL CYCLE RES, V3; Meijer L., 1996, PROGR CELL CYCLE RES, V2; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHIELI P, 1994, CANCER RES, V54, P3391; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ONGKEKO W, 1995, J CELL SCI, V108, P2897; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; SEDLACEK HH, 1996, ANN ONCOL         S1, V7, P77; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; WIMMEL A, 1994, ONCOGENE, V9, P995; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016/0006-2952(93)90590-S; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU Z, 1994, TRENDS CELL BIOL, V4, P414; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; [No title captured]	79	81	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7409	7422		10.1038/sj.onc.1203103	http://dx.doi.org/10.1038/sj.onc.1203103			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602500				2022-12-25	WOS:000084119600002
J	Pim, D; Banks, L				Pim, D; Banks, L			HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6	ONCOGENE			English	Article						HPV E6; p531 E6*; apoptosis	HUMAN PAPILLOMAVIRUS TYPE-16; OPEN READING FRAME; MESSENGER-RNA; CELL-LINE; EARLY GENES; TRANSCRIPTION; ONCOPROTEIN; PATTERNS; DNA; IDENTIFICATION	We have previously demonstrated that ectopic expression of the HPV-18 E6*I protein has an antiproliferative effect in cells derived from HPV-containing cervical tumours. This effect correlated with the ability of E6*I to inhibit the E6-mediated degradation of p53 both in vitro and in vivo and with an increase in p53 transcriptional trans-activation. The observation that the E6*I protein can interact with both full-length HPV-18 E6 and E6-AP proteins in vitro indicated the mechanism by which this activity was mediated. In this study we describe a mutational strategy to attempt to differentiate between the E6-AP and full-length HPV-18 E6 interactions, with respect to the biological function of E6. We identify regions of the E6*I protein essential for its interaction with full-length E6 and important for its interaction with E6-AP. We show that a mutant of E6*I which is unable to bind to full-length HPV-18 E6 protein is unable to inhibit the E6-directed degradation of p53 and is also unable to inhibit the proliferation of a cervical tumour-derived cell line. Finally, we show that inhibition of transformed cell growth by E6*I protein correlates with its ability to induce apoptosis in a p53-dependent manner. These results raise the intriguing possibility of using E6*I as a basis for therapeutic intervention in HPV-associated tumours.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Pim, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.							BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; BUTZ K, 1995, ONCOGENE, V10, P927; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; LOWE SW, 1993, CELL, V74, P847; Mantovani F, 1999, ONCOGENE, V18, P3309, DOI 10.1038/sj.onc.1202688; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHERMAN L, 1992, VIROLOGY, V191, P953, DOI 10.1016/0042-6822(92)90271-P; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1995, J VIROL, V69, P7023, DOI 10.1128/JVI.69.11.7023-7031.1995; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	25	72	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7403	7408		10.1038/sj.onc.1203134	http://dx.doi.org/10.1038/sj.onc.1203134			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602499				2022-12-25	WOS:000084119600001
J	Ricol, D; Cappellen, D; El Marjou, A; Gil-Diez-de-Medina, S; Girault, JM; Yoshida, T; Ferry, G; Tucker, G; Poupon, MF; Chopin, D; Thiery, JP; Radvanyi, F				Ricol, D; Cappellen, D; El Marjou, A; Gil-Diez-de-Medina, S; Girault, JM; Yoshida, T; Ferry, G; Tucker, G; Poupon, MF; Chopin, D; Thiery, JP; Radvanyi, F			Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer	ONCOGENE			English	Article						bladder; fibroblast growth factor receptor; human; urothelial cell carcinoma; tumour suppressor gene	LIGAND-BINDING SPECIFICITY; PROSTATE EPITHELIAL-CELLS; HUMAN PANCREATIC-CANCER; K-SAM; DIFFERENTIAL EXPRESSION; TRANSGENIC MICE; GASTRIC-CANCER; GENE; ACTIVATION; BFGF	FGFRs (fibroblast growth factor receptors) are encoded by four genes (FGFR1-4). Alternative splicing results in various receptor isoforms, The FGFR2-IIIb variant is present in a wide variety of epithelia, including the bladder epithelium. Recently, we have shown that FGFR2-IIIb is downregulated in a subset of transitional cell carcinomas of the bladder, and that this downregulation is associated with a poor prognosis. We investigated possible tumour suppressive properties of FGFR2-IIIb by transfecting two human bladder tumour cell lines, J82 and T24, which have no endogenous FGFR2-IIIb expression, with FGFR2-IIIb cDNA, No stable clones expressing FGFR2-IIIb were isolated with the J82 cell line, For the T24 cell line, stable transfectants expressing FGFR2-IIIb had reduced growth in vitro and formed fewer tumours in nude mice which, in addition, grew more slowly. The potential mechanisms leading to decreased FGFR2-IIIb mRNA levels mere also investigated, The 5' region of the human FGFR2 gene was isolated and found to contain a CpG island which was partially methylated in more than half the cell lines and tumours which do not express FGFR2-IIIb, No homozygous deletion was identified in any of the tumours or cell lines with reduced levels of FGFR2-IIIb, Mutational analysis of the entire coding region of FGFR2-IIIb at the transcript level was performed in 33 bladder tumours, In addition to normal FGFR2-IIIb mRNA, abnormal transcripts were detected in two tumour samples, These abnormal mRNAs resulted from exon skipping which affected the region encoding the kinase domain. Altogether, these results show that FGFR2-IIIb has tumour growth suppressive properties in bladder carcinomas and suggest possible mechanisms of FGFR2 gene inactivation.	Inst Curie, CNRS, UMR 144, Sect Rech, Paris 05, France; CHU Henri Mondor, Grp Etude Tumeurs Urol, F-94010 Creteil, France; CHU Henri Mondor, Serv Urol, F-94010 Creteil, France; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan; Inst Rech Servier, Div Cancerol Expt, F-92150 Suresnes, France; Inst Curie, CNRS, UMR 147, Sect Rech, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; National Cancer Center - Japan; Servier; Institut de Recherches Internationales Servier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Radvanyi, F (corresponding author), Inst Curie, CNRS, UMR 144, Sect Rech, 26 Rue Ulm, Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424	NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; AVIVI A, 1992, ONCOGENE, V7, P1957; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DELL KR, 1992, J BIOL CHEM, V267, P21225; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; DEMEDINA SGD, 1999, IN PRESS ONCOGENE; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Feng SJ, 1997, CANCER RES, V57, P5369; Fenig E, 1997, CLIN CANCER RES, V3, P135; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GIROLDI LA, 1994, INVAS METAST, V14, P71; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1988, ONCOGENE RES, V3, P177; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; ITOH H, 1994, CANCER RES, V54, P3237; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KISHI T, 1994, BIOCHEM BIOPH RES CO, V202, P1387, DOI 10.1006/bbrc.1994.2084; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Lamm DL, 1996, CA-CANCER J CLIN, V46, P93, DOI 10.3322/canjclin.46.2.93; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; Matsubara A, 1998, CANCER RES, V58, P1509; MATTEI MG, 1991, HUM GENET, V87, P84, DOI 10.1007/BF01213098; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; REED JA, 1994, AM J PATHOL, V144, P329; Rubin J. S., 1995, V74, P191; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SCHWEIGERER L, 1987, J CLIN INVEST, V80, P1516, DOI 10.1172/JCI113236; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159	56	104	115	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7234	7243		10.1038/sj.onc.1203186	http://dx.doi.org/10.1038/sj.onc.1203186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602477				2022-12-25	WOS:000084119400007
J	Smart, P; Lane, EB; Lane, DP; Midgley, C; Vojtesek, B; Lain, S				Smart, P; Lane, EB; Lane, DP; Midgley, C; Vojtesek, B; Lain, S			Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B	ONCOGENE			English	Article						leptomycin B; senescence; p53 response; normal fibroblasts; neuroblastoma	CYTOPLASMIC SEQUESTRATION; ANTICANCER ACTIVITY; DNA-DAMAGE; IN-VIVO; PROTEIN; CYCLE; EXPRESSION; IRRADIATION; ANTIBODIES; SENESCENCE	p53 tumour suppressor protein levels and p53-dependent transcriptional activity have been recently shown to increase in cells treated with leptomycin B (LMB), an inhibitor of nuclear export. Experiments presented here show that LMB treatment leads to growth arrest and a senescence-like phenotype in human normal fibroblast cultures. This effect is reversible after removal of the drug and further passage by trypsinization. Instead, LMB has a strong cytotoxic effect on human neuroblastoma cell lines even at nanomolar concentrations. In both these cell types the effects of LMB are attenuated when the activity of the endogenous wild type p53 protein is abrogated by overexpression of a dominant negative p53 mutant. We conclude that the induction of the p53 response by LMB plays an important role in the effects of this drug on cultured cells.	Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, Dundee DD1 5EH, Scotland; Univ Dundee, Dept Anat & Physiol, CRC, Cell Struct Res Grp, Dundee DD1 5EH, Scotland; Masaryk Mem Canc Inst, Dept Cellular & Mol Oncol, Brno 65653, Czech Republic	University of Dundee; University of Dundee; Masaryk Memorial Cancer Institute	Lain, S (corresponding author), Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, MSI-WTB Complex, Dundee DD1 5EH, Scotland.		Lane, David P/C-4920-2008; Lain, Sonia/B-6980-2014	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; deLaat A, 1996, PHOTOCHEM PHOTOBIOL, V63, P492; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; JENNEY M, 1994, LANCET, V344, P210, DOI 10.1016/S0140-6736(94)92991-2; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Kuhnt M, 1998, APPL ENVIRON MICROB, V64, P714; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; LAIN S, IN PRESS EXP CELL RE; LEOPOLD WR, 1984, CANCER RES, V44, P1928; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Melino G, 1997, APOPTOSIS AND CANCER, P222; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Newlands ES, 1996, BRIT J CANCER, V74, P648, DOI 10.1038/bjc.1996.415; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Renzing J, 1996, J CELL SCI, V109, P1105; ROBERTS BJ, 1986, CANCER CHEMOTH PHARM, V16, P95; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SHAULIAN E, 1995, ONCOGENE, V10, P671; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TUNAC JB, 1985, J ANTIBIOT, V38, P460, DOI 10.7164/antibiotics.38.460; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Wynford-Thomas D, 1999, J PATHOL, V187, P100; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	40	71	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7378	7386		10.1038/sj.onc.1203260	http://dx.doi.org/10.1038/sj.onc.1203260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602494				2022-12-25	WOS:000084119400024
J	Franzini-Armstrong, C				Franzini-Armstrong, C			The sarcoplasmic reticulum and the control of muscle contraction	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		DIHYDROPYRIDINE RECEPTOR CDNA; DYSGENIC SKELETAL-MUSCLE; RYANODINE RECEPTOR; ALPHA SUBUNITS; PROTEIN; CALSEQUESTRIN; LOCALIZATION; RESTORATION; CONNECTION; VESICLES		Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Franzini-Armstrong, C (corresponding author), Univ Penn, Dept Cell & Dev Biol, B1 Anat Chem Bldg, Philadelphia, PA 19104 USA.							Andersson-Cedergren E., 1959, J ULTRASTRUCT RES  S, V1, P5, DOI [10.1016/S0889-1605(59)80002-1, DOI 10.1016/S0889-1605(59)80002-1]; BENNETT HS, 1953, AM J ANAT, V195, P61; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; ENDO M, 1966, J PHYSIOL-LONDON, V185, P224, DOI 10.1113/jphysiol.1966.sp007983; FLUCHER BE, 1991, J CELL BIOL, V115, P1345, DOI 10.1083/jcb.115.5.1345; FLUCHER BE, 1996, Proc Natl Acad Sci USA, V93, P265; FRANZINIARMSTRO.C, 1964, J CELL BIOL, V22, P675, DOI 10.1083/jcb.22.3.675; FRANZINIARMSTRO.C, 1988, TRENDS CELL BIOL, V8, P251; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; HUXLEY AF, 1971, P ROY SOC LOND B BIO, V1, P27; HUXLEY HE, 1964, NATURE, V202, P10676; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; Ouyang Y, 1997, BRAIN RES, V775, P52, DOI 10.1016/S0006-8993(97)00840-8; PAGE S, 1964, J PHYSIOL-LONDON, V175, pP10; PAGE SG, 1965, J CELL BIOL, V26, P477, DOI 10.1083/jcb.26.2.477; PEACHEY LD, 1965, J CELL BIOL, V25, P209, DOI 10.1083/jcb.25.3.209; PEACHEY LD, 1959, SCIENCE, V129, P721, DOI 10.1126/science.129.3350.721; PORTER KEITH R., 1956, JOUR BIOPHYS AND BIOCHEM CYTOL, V2, P163, DOI 10.1083/jcb.2.4.163; PORTER KR, 1957, J BIOPHYS BIOCHEM CY, V3, P269, DOI 10.1083/jcb.3.2.269; Powell JA, 1996, J CELL BIOL, V134, P375, DOI 10.1083/jcb.134.2.375; Protasi F, 1997, J CELL BIOL, V137, P859, DOI 10.1083/jcb.137.4.859; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; Protasi F, 1996, DEV BIOL, V173, P265, DOI 10.1006/dbio.1996.0022; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROBERTSON JD, 1956, J BIOPHYS BIOCHEM CY, V2, P369, DOI 10.1083/jcb.2.4.369; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SUN XH, 1995, J CELL BIOL, V129, P659, DOI 10.1083/jcb.129.3.659; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKEI K, 1992, J NEUROSCI, V12, P489; TAKEKURA H, 1994, BIOPHYS J, V67, P793, DOI 10.1016/S0006-3495(94)80539-9; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; VILLA A, 1993, EXP CELL RES, V209, P140, DOI 10.1006/excr.1993.1294; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; WEBER A, 1959, J BIOL CHEM, V234, P2764	42	65	73	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S266	S270		10.1096/fasebj.13.9002.S266	http://dx.doi.org/10.1096/fasebj.13.9002.S266			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619141				2022-12-25	WOS:000084390200019
J	Doliana, R; Canton, A; Bucciotti, F; Mongiat, M; Bonaldo, P; Colombatti, A				Doliana, R; Canton, A; Bucciotti, F; Mongiat, M; Bonaldo, P; Colombatti, A			Structure, chromosomal localization, and promoter analysis of the human elastin microfibril interfase located protein (EMILIN) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-BINDING-PROTEIN; 5'-FLANKING REGION; MOLECULAR-CLONING; FUNCTIONAL PROMOTER; CONNECTIVE-TISSUE; MARFAN-SYNDROME; GLYCOPROTEIN; FIBRILLIN; KETOHEXOKINASE; SEQUENCE	Elastin microfibril interfase-located protein (EMILIN) is an extracellular matrix glycoprotein abundantly expressed in elastin-rich tissues such as the blood vessels, skin, heart, and lung. It occurs with elastic fibers at the interface between amorphous elastin and microfibrils. In vitro experiments suggested a role for EMILIN in the process of elastin deposition. This multimodular protein consists of 995 amino acids; the domain organization includes a C1q-like globular domain at the C terminus, a short collagenous stalk, a region containing two leucine zippers, and at least four heptad repeats with a high potential for forming coiled-coil alpha-helices and, at the N terminus, a cysteine-rich sequence characterized by a partial epidermal growth factor-like motif and homologous to a region of multimerin. Here we report the complete characterization of the human and murine EMILIN gene, their chromosomal assignment, and preliminary functional data of the human promoter, A cDNA probe corresponding to the C terminus of EMILIN was used to isolate two genomic clones from a human BAC library. Sequencing of several derived subclones allowed the characterization of the whole gene that was found to be about 8 kilobases in size and to contain 8 exons and 7 introns, The internal exons range in size from 17 base pairs to 1929 base pairs. All internal intron/exon junctions are defined by canonical splice donor and acceptor sites, and the different domains potentially involved in the formation of a coiled-coil structure are clustered in the largest exon, The 3'-end of the EMILIN gene overlaps with the 5'-end of the promoter region of the ketohexokinase gene, whose chromosomal position is between markers D2S305 and D2S165 on chromosome 2. A 1600-base pair-long sequence upstream of the translation starting point was evaluated for its promoter activity; five deletion constructs were assayed after transfection in primary chicken fibroblasts and in a human rhabdomyosarcoma cell line. This analysis indicates the existence of two contiguous regions able to modulate luciferase expression in both cell types used, one with a strong activatory function, ranging from positions -204 to -503, and the other, ranging from positions -504 to -683, with a strong inhibitory function.	Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy; Univ Padua, Ist Istol & Embriol, I-35100 Padua, Italy; Univ Udine, Dept Sci & Tecnol Biomed, I-33100 Udine, Italy	IRCCS Aviano (CRO); University of Padua; University of Udine	Colombatti, A (corresponding author), Ctr Riferimento Oncol, Div Oncol Sperimentale 2, I-33081 Aviano, Italy.		Doliana, Roberto/AAA-1479-2019; Bucciotti, Francesco/AAZ-1255-2020; Mongiat, Maurizio/H-8297-2018	Doliana, Roberto/0000-0002-8324-7564; Bucciotti, Francesco/0000-0002-4253-855X; Mongiat, Maurizio/0000-0001-6509-0068; colombatti, alfonso/0000-0002-3676-2379; Bonaldo, Paolo/0000-0002-9571-8140	Telethon [E.0704] Funding Source: Medline	Telethon(Fondazione Telethon)		ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BASHIR MM, 1994, BIOCHEMISTRY-US, V33, P593, DOI 10.1021/bi00168a026; Biery NJ, 1999, GENOMICS, V56, P70, DOI 10.1006/geno.1998.5697; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; BRESSAN GM, 1983, J BIOL CHEM, V258, P3262; CHEN YP, 1993, J BIOL CHEM, V268, P27381; COLOMBATTI A, 1985, COLLAGEN REL RES, V5, P181; COLOMBATTI A, 1988, J BIOL CHEM, V263, P17534; COLOMBATTI A, 1985, J CELL BIOL, V100, P18, DOI 10.1083/jcb.100.1.18; COLOMBATTI A, 1987, COLLAGEN REL RES, V7, P259; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Doliana R, 1999, J BIOL CHEM, V274, P16773, DOI 10.1074/jbc.274.24.16773; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GLESBY MJ, 1989, JAMA-J AM MED ASSOC, V262, P523, DOI 10.1001/jama.262.4.523; Hatzinikolas G, 1998, J BIOL CHEM, V273, P29309, DOI 10.1074/jbc.273.45.29309; Hayward BE, 1996, MAMM GENOME, V7, P454, DOI 10.1007/s003359900132; Hayward BE, 1998, EUR J BIOCHEM, V257, P85, DOI 10.1046/j.1432-1327.1998.2570085.x; Hayward BE, 1997, BIOCHEM SOC T, V25, P140, DOI 10.1042/bst0250140; HAYWARD CPM, 1995, J BIOL CHEM, V270, P18246, DOI 10.1074/jbc.270.31.18246; Henderson M, 1996, J HISTOCHEM CYTOCHEM, V44, P1389, DOI 10.1177/44.12.8985131; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Li DY, 1997, HUM MOL GENET, V6, P1021, DOI 10.1093/hmg/6.7.1021; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pollner R, 1997, FEBS LETT, V405, P31, DOI 10.1016/S0014-5793(97)00152-X; PUTNAM EA, 1995, NAT GENET, V11, P456, DOI 10.1038/ng1295-456; Raghunath M, 1999, J INVEST DERMATOL, V112, P97, DOI 10.1046/j.1523-1747.1999.00483.x; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; ROAK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401; SAADAT M, 1994, JPN J GENET, V69, P697, DOI 10.1266/jjg.69.697; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Speek M, 1996, HUM MOL GENET, V5, P1749, DOI 10.1093/hmg/5.11.1749; Wightman PJ, 1997, MAMM GENOME, V8, P700, DOI 10.1007/s003359900544; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	44	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					785	792		10.1074/jbc.275.2.785	http://dx.doi.org/10.1074/jbc.275.2.785			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625608	hybrid			2022-12-25	WOS:000084836600012
J	Evanko, DS; Thiyagarajan, MM; Wedegaertner, PB				Evanko, DS; Thiyagarajan, MM; Wedegaertner, PB			Interaction with G beta gamma is required for membrane targeting and palmitoylation of G alpha(s), and G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ALPHA-SUBUNIT; GTP-BINDING PROTEIN; PLASMA-MEMBRANE; ADENYLYL-CYCLASE; CRYSTAL-STRUCTURE; HORMONE RECEPTOR; PHOSPHOLIPASE-C; FATTY ACYLATION; AMINO-TERMINUS; RAS PROTEINS	Peripheral membrane proteins utilize a variety of mechanisms to attach tightly, and often reversibly, to cellular membranes. The covalent lipid modifications, myristoylation and palmitoylation, are critical for plasma membrane localization of heterotrimeric G protein alpha subunits, For alpha(s) and alpha(q), two subunits that are palmitoylated but not myristoylated, we examined the importance of interacting with the G protein beta gamma dimer for their proper plasma membrane localization and palmitoylation. Conserved alpha subunit N-terminal amino acids predicted to mediate binding to beta gamma were mutated to create a series of beta gamma binding region mutants expressed in HEK293 cells. These alpha(s) and alpha(q) mutants were found in soluble rather than particulate fractions, and they no longer localized to plasma membranes as demonstrated by immunofluorescence microscopy, The mutations also inhibited incorporation of radiolabeled palmitate into the proteins and abrogated their signaling ability. Additional alpha(q) mutants, which contain these mutations but are modified by both myristate and palmitate, retained their localization to plasma membranes and ability to undergo palmitoylation, These findings identify binding to beta gamma as a critical membrane attachment signal for alpha(s) and alpha(q) and as a prerequisite for their palmitoylation, while myristoylation can restore membrane localization and palmitoylation of beta gamma binding-deficient alpha(s) subunits.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th St,839 BLSB, Philadelphia, PA 19107 USA.	p_wedegaertner@lac.jci.tju.edu			NIGMS NIH HHS [GM56444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056444, R56GM056444, R01GM056444] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Busconi L, 1997, BIOCHEM J, V328, P23, DOI 10.1042/bj3280023; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DENKER BM, 1992, J BIOL CHEM, V267, P6272; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; Gillen KM, 1998, J CELL SCI, V111, P3235; GRAF R, 1992, J BIOL CHEM, V267, P24307; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; HALLAK H, 1994, J BIOL CHEM, V269, P4571; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Jones TLZ, 1998, BIOCHEMISTRY-US, V37, P3196, DOI 10.1021/bi972253j; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KOEGEL M, 1994, BIOCHEM J, V303, P349; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Schroeder H, 1996, J CELL BIOL, V134, P647, DOI 10.1083/jcb.134.3.647; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; Stanislaus D, 1998, BIOL REPROD, V59, P579, DOI 10.1095/biolreprod59.3.579; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WEDEGAERTNER PB, 1999, CRC METH SIG TRANS, P153; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Wise A, 1997, FEBS LETT, V407, P257, DOI 10.1016/S0014-5793(97)00300-1; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Zlatkine P, 1997, J CELL SCI, V110, P673	65	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1327	1336		10.1074/jbc.275.2.1327	http://dx.doi.org/10.1074/jbc.275.2.1327			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625681	hybrid			2022-12-25	WOS:000084836600085
J	Nathanson, L; Gromet-Elhanan, Z				Nathanson, L; Gromet-Elhanan, Z			Mutations in the beta-subunit Thr(159) and Glu(184) of the Rhodospirillum rubrum F0F1 ATP synthase reveal differences in ligands for the coupled Mg2+- and decoupled Ca2+-dependent F0F1 activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CORE COMPLEX; F1-ATPASE; BINDING; PROTEIN; MUTANTS; PURIFICATION; RESOLUTION; EXTRACTION	In the crystal structure of the mitochondrial F(1)ATPase, the beta-Thr(163) residue was identified as a ligand to Mg2+ and the beta-Glu(188) as directly involved in catalysis. We replaced the equivalent beta-Thr(159) Of the chromatophore F0F1 ATP synthase of Rhodospirillum rubrum with Ser, Ala, or Val and the Glu(184) with Gin or Lys. The mutant beta subunits were isolated and tested for their capacity to assemble into a beta-less chromatophore F0F1 and restore its lost activities. All of them were found to bind into the beta-less enzyme with the same efficiency as the wild type beta subunit, but only the beta-Thr(159) --> Ser mutant restored the activity of the assembled enzyme. These results indicate that both Thr(159) and Glu(184) not required for assembly and that Glu(184) is indeed essential for all the membrane-bound chromatophore F0F1 activities. A detailed comparison between the wild type and the beta-Thr(159), Ser mutant revealed a rather surprising difference. Although this mutant restored the wild type levels and all specific properties of this F0F1 proton-coupled ATP synthesis as well as Mg- and Mn-dependent ATP hydrolysis, it did not restore at all the proton-decoupled CaATPase activity. This clear difference between the ligands for Mg2+ and Mn2+, where threonine can be replaced by serine, and Ca2+, where only threonine is active, suggests that the beta-subunit catalytic site has different conformational states when occupied by Ca2+ as compared with Mg2+ These different states might result in different interactions between the beta and gamma subunits, which are involved in linking F-1 catalysis with F-0 proton-translocation and can thus explain the complete absence of Ca-dependent proton-coupled F0F1 catalytic activity.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Gromet-Elhanan, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Nathanson, Lubov/ABC-2642-2021	Nathanson, Lubov/0000-0003-1038-9083				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AMANO T, 1994, FEBS LETT, V348, P93, DOI 10.1016/0014-5793(94)00588-5; ANDVALOJC PJ, 1993, BIOCHIM BIOPHYS ACTA, V1143, P51; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVNI A, 1991, J BIOL CHEM, V266, P7317; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Clayton R. K., 1963, BACTERIAL PHOTOSYNTH, P495; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; Du ZY, 1999, EUR J BIOCHEM, V263, P430, DOI 10.1046/j.1432-1327.1999.00512.x; Du ZY, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P27; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; Gromet-Elhanan Z., 1995, ANOXYGENIC PHOTOSYNT, P807; GROMETELHANAN Z, 1989, BIOCHEMISTRY-US, V28, P3645, DOI 10.1021/bi00435a004; GrometElhanan Z, 1995, PHOTOSYNTH RES, V46, P79, DOI 10.1007/BF00020418; GROMETELHANAN Z, 1986, METHOD ENZYMOL, V126, P528; GROMETELHANAN Z, 1984, BIOCHEMISTRY-US, V23, P1022, DOI 10.1021/bi00300a034; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCHMAN Y, 1976, FEBS LETT, V178, P10; Hu DL, 1998, FEBS LETT, V421, P65, DOI 10.1016/S0014-5793(97)01531-7; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; JENSEN PR, 1992, J BACTERIOL, V174, P7635, DOI 10.1128/JB.174.23.7635-7641.1992; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTY RE, 1996, OXYGENIC PHOTOSYNTHE, P439; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; Nathanson L, 1998, J BIOL CHEM, V273, P10933, DOI 10.1074/jbc.273.18.10933; Nathanson L, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P51; OMOTE H, 1992, J BIOL CHEM, V267, P20571; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; OREN R, 1979, BIOCHIM BIOPHYS ACTA, V548, P106, DOI 10.1016/0005-2728(79)90191-9; PARK MY, 1994, J BIOCHEM-TOKYO, V116, P1139, DOI 10.1093/oxfordjournals.jbchem.a124640; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PHILOSOPH S, 1977, J BIOL CHEM, V252, P8747; RICHTER ML, 1996, OXYGENIC PHOTOSYNTHE, P453; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sokolov M, 1996, BIOCHEMISTRY-US, V35, P1242, DOI 10.1021/bi9511189; Sokolov M, 1999, J BIOL CHEM, V274, P13824, DOI 10.1074/jbc.274.20.13824; Strotmann H., 1998, MOL BIOL CHLOROPLAST, P477; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; Tucker WC, 2000, J BIOL CHEM, V275, P906, DOI 10.1074/jbc.275.2.906; VIK SB, 1994, J BIOL CHEM, V269, P30364; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBSTER GD, 1977, FEBS LETT, V76, P29, DOI 10.1016/0014-5793(77)80114-2	50	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					901	905		10.1074/jbc.275.2.901	http://dx.doi.org/10.1074/jbc.275.2.901			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625625	hybrid			2022-12-25	WOS:000084836600029
J	Ozoline, ON; Fujita, N; Ishihama, A				Ozoline, ON; Fujita, N; Ishihama, A			Transcription activation mediated by the carboxyl-terminal domain of the RNA polymerase alpha-subunit - Multipoint monitoring using a fluorescent probe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; FUNCTIONAL MAP; PROMOTER DNA; CONTACT SITE; BINDING; ELEMENT; CRP; IDENTIFICATION; MUTATIONS	Conformational changes within the carboxyl-terminal domain of the Escherichia coli RNA polymerase alpha-subunit (alpha-CTD) upon interaction with the DNA UP element or the transcription factor cAMP receptor protein (CRP) were studied by monitoring the spectral parameters of a fluorescent dye, fluorescein mercuric acetate, conjugated to various positions of alpha-CTD. When fluorescein mercuric acetate was conjugated to Cys located on helix I and the loop between helices III and TV, the spectral changes typical for DNA interaction were observed for the RNA polymerase-promoter binary complex with UP element-dependent rrnBP1 and the ternary complex with the CRP-dependent uxuAB promoter in the presence of cAMP/CRP. Likewise, the chemical nuclease iron-(p-bromoacetamidobenzyl)-EDTA conjugated to Cys-269 or Cys-272 introduced CRP-dependent cleavage of the uxuAB promoter, as in the case of rrnBP1 (Murakami, K., Owens, J. T., Belyaeva, T, A, Meares, C. F., Busby, S. J. W., and Ishihama, A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11274-11278), indicating that CRP rearranges the topology of the DNA contact surface in alpha-CTD. Conformational changes in alpha-CTD were also observed upon formation of a binary complex with the uxuAB (in the absence of CRP) and factor-independent T7D promoters. The spectral changes suggested that helix TV of alpha-CTD approaches the negatively charged phosphate moiety of DNA, In agreement with this prediction, iron-(p-bromoacetamidobenzyl)-EDTA conjugated to Cys-309 induced extensive DNA cleavage upstream from the uxuAB promoter -35 element, We propose that helix IV of alpha-CTD is involved in direct interaction with some promoters.	Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan; Russian Acad Sci, Inst Cell Biophys, Pushchino 142292, Moscow Region, Russia	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Cell Biophysics RAS	Ishihama, A (corresponding author), Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan.							AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; BUSBY S, 1995, REGULATION GENE EXPR, P255; Caslake LF, 1997, J BACTERIOL, V179, P1787, DOI 10.1128/jb.179.5.1787-1795.1997; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Colland F, 1999, EMBO J, V18, P4049, DOI 10.1093/emboj/18.14.4049; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Fujita N, 1996, METHOD ENZYMOL, V273, P121; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; Greiner DP, 1997, BIOCONJUGATE CHEM, V8, P44, DOI 10.1021/bc9600731; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HEYDUK E, 1993, CELL MOL BIOL RES, V39, P401; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Ishihama A., 1997, NUCL ACIDS MOL BIOL, V11, P53; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P671, DOI 10.1093/nar/11.3.671; Masulis I. S., 1998, Molekulyarnaya Biologiya (Moscow), V32, P598; Murakami K, 1997, P NATL ACAD SCI USA, V94, P11274, DOI 10.1073/pnas.94.21.11274; Murakami K, 1997, P NATL ACAD SCI USA, V94, P1709, DOI 10.1073/pnas.94.5.1709; Murakami K, 1996, EMBO J, V15, P4358, DOI 10.1002/j.1460-2075.1996.tb00809.x; Owens JT, 1998, BIOCHEMISTRY-US, V37, P7670, DOI 10.1021/bi980188n; Ozoline ON, 1999, J BIOMOL STRUCT DYN, V16, P825, DOI 10.1080/07391102.1999.10508295; Ozoline ON, 1998, EUR J BIOCHEM, V253, P371, DOI 10.1046/j.1432-1327.1998.2530371.x; Ozoline ON, 1997, NUCLEIC ACIDS RES, V25, P4703, DOI 10.1093/nar/25.23.4703; Ozoline ON, 1998, PROTEINS, V30, P183; OZOLINE ON, 1991, BIOCHIM BIOPHYS ACTA, V1076, P387, DOI 10.1016/0167-4838(91)90481-E; OZOLINE ON, 1993, BIOCHIM BIOPHYS ACTA, V1172, P251, DOI 10.1016/0167-4781(93)90211-U; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; Williams SM, 1997, NUCLEIC ACIDS RES, V25, P4028, DOI 10.1093/nar/25.20.4028; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	37	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1119	1127		10.1074/jbc.275.2.1119	http://dx.doi.org/10.1074/jbc.275.2.1119			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625654	hybrid			2022-12-25	WOS:000084836600058
J	Ray, R; Chen, G; Vande Velde, C; Cizeau, J; Park, JH; Reed, JC; Gietz, RD; Greenberg, AH				Ray, R; Chen, G; Vande Velde, C; Cizeau, J; Park, JH; Reed, JC; Gietz, RD; Greenberg, AH			BNIP3 heterodimerizes with Bcl-2/Bcl-X-L and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL-PROMOTING PROTEINS; YEAST 2-HYBRID SYSTEM; ENDOPLASMIC-RETICULUM; C-ELEGANS; CAENORHABDITIS-ELEGANS; ACTIVATES APOPTOSIS; FAMILY PROTEINS; CYTOCHROME-C; X-L; INTERACTING PROTEIN	BNIP3 (formerly NIP3) is a pro-apoptotic, mitochondrial protein classified in the Bcl-2 family based on limited sequence homology to the Bcl-2 homology 3 (BH3) domain and COOH-terminal transmembrane (TM) domain. BNIP3 expressed in yeast and mammalian cells interacts with survival promoting proteins Bcl-2, Bcl-X-L, and CED-9. Typically, the BH3 domain of pro-apoptotic Bcl-2 homologues mediates Bcl-2/Bcl-X-L heterodimerization and confers pro-apoptotic activity. Deletion mapping of BNIP3 excluded its BH3-like domain and identified the NH, terminus (residues 1-49) and TM domain as critical for Bcl-2 heterodimerization, and either region was sufficient for Bcl-X-L interaction. Additionally, the removal of the BH3-like domain in BNIP3 did not diminish its killing activity. The TM domain of BNIP3 is critical for homodimerization, pro-apoptotic function, and mitochondrial targeting. Several TM domain mutants were found to disrupt SDS-resistant BNIP3 homodimerization but did not interfere with its killing activity or mitochondrial localization. Substitution of the BNIP3 TM domain with that of cytochrome b(5) directed protein expression to nonmitochondrial sites and still promoted apoptosis and heterodimerization with Bcl-2 and Bcl-X-L. We propose that BNIP3 represents a subfamily of Bcl-2-related proteins that functions without a typical BH3 domain to regulate apoptosis from both mitochondrial and nonmitochondrial sites by selective Bcl-2/Bcl-X-L interactions.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Kyung Hee Univ, Coll Med, Dept Pathol, Seoul 130701, South Korea; Burnham Inst, La Jolla, CA 92037 USA; Univ Manitoba, Fac Med, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; Kyung Hee University; Sanford Burnham Prebys Medical Discovery Institute; University of Manitoba	Greenberg, AH (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 100 Olivia St, Winnipeg, MB R3E 0V9, Canada.		Vande Velde, Christine/F-2721-2016; Velde, Christine Vande/AAB-8828-2020	Vande Velde, Christine/0000-0001-5926-1529; 				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DIEFFENBACH CW, 1995, PCR PRIMER LAB MANUA, P603; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Gibson L, 1996, ONCOGENE, V13, P665; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Ng FWH, 1998, J BIOL CHEM, V273, P3140, DOI 10.1074/jbc.273.6.3140; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ohi N, 1999, CELL DEATH DIFFER, V6, P314, DOI 10.1038/sj.cdd.4400493; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; SOLTYS BJ, 1992, BIOCHEM CELL BIOL, V70, P1174, DOI 10.1139/o92-163; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	89	275	306	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1439	1448		10.1074/jbc.275.2.1439	http://dx.doi.org/10.1074/jbc.275.2.1439			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625696	hybrid			2022-12-25	WOS:000084836600100
J	Shen, Y; Lyons, P; Cooley, M; Davidson, D; Veillette, A; Salgia, R; Griffin, JD; Schaller, MD				Shen, Y; Lyons, P; Cooley, M; Davidson, D; Veillette, A; Salgia, R; Griffin, JD; Schaller, MD			The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CELL-MIGRATION; PTP-PEST; LIM DOMAIN; SH3 DOMAIN; IDENTIFICATION; INHIBITION; P130(CAS); BINDING; SRC	The noncatalytic domain of protein-tyrosine phosphatase (PTP)-PEST contains a binding site for the focal adhesion-associated protein paxillin. This binding site has been narrowed to a 52-residue sequence that is composed of two nonoverlapping, weak paxillin binding sites. The PTP-PEST binding site on paxillin has been mapped to the two carboxyl-terminal LIM (lin11, isl-1, and mec-3) domains, Transient expression of PTP-PEST reduced tyrosine phosphorylation of p130(cas), as anticipated. A PTP-PEST mutant defective for binding p130(cas) does not cause a reduction in its tyrosine phosphorylation in vivo, Expression of PTP-PEST also caused a reduction of phosphotyrosine on paxillin. Expression of mutants of PTP-PEST with deletions in the paxillin-binding site did not associate with paxillin in vivo and failed to cause a reduction in the phosphotyrosine content of paxillin, These results demonstrate that paxillin can serve as a PTP-PEST substrate in vivo and support the model that a noncatalytic domain interaction recruits paxillin to PTP-PEST to facilitate its dephosphorylation.	Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; McGill University; Harvard University; Dana-Farber Cancer Institute	Schaller, MD (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, Taylor Hall CB 7090, Chapel Hill, NC 27599 USA.			Cooley, Marion A./0000-0002-4286-745X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057943, R29GM053666] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57943, GM53666] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUTHRIE C, 1991, GUIDE YEAST GENETICS, P186; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Nishiya N, 1999, J BIOL CHEM, V274, P9847, DOI 10.1074/jbc.274.14.9847; Oh ES, 1999, MOL CELL BIOL, V19, P3205; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; Thomas SM, 1999, J CELL SCI, V112, P181; TURNER CE, 1994, J CELL SCI, V107, P1583; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	40	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1405	1413		10.1074/jbc.275.2.1405	http://dx.doi.org/10.1074/jbc.275.2.1405			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625692	hybrid, Green Published			2022-12-25	WOS:000084836600096
J	Feliciello, A; Gallo, A; Mele, E; Porcellini, A; Troncone, G; Garbi, C; Gottesman, ME; Avvedimento, EV				Feliciello, A; Gallo, A; Mele, E; Porcellini, A; Troncone, G; Garbi, C; Gottesman, ME; Avvedimento, EV			The localization and activity of cAMP-dependent protein kinase affect cell cycle progression in thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; MOLECULAR-CLONING; II-BETA; EPITHELIAL-CELLS; CDNA STRUCTURE; GOLGI-COMPLEX; AMP; EXPRESSION; TRANSCRIPTION; ACTIVATION	cAMP signals are received and transmitted by multiple isoforms of cAMP-dependent protein kinases (PKAs), typically determined by their specific regulatory subunits. We describe changes in the cAMP signal transduction pathway during cell cycle progression in synchronized rat thyroid cells. Both PKA type II (PKAII) localization and nuclear cAMP signaling are significantly modified during G(0) and G(1)-S transitions. G(1) is characterized by PKA activation and amplified cAMP signal transduction. This is associated with a decrease in the concentration of RI and RII regulatory subunits and enhanced anchoring of PKAII to the Golgi-centrosome region. Just prior to S, the cAMP pathway is depressed. Up-regulation of the pathway by exogenous cAMP in G(1) inhibited the subsequent decay of the Cdk inhibitor p27 and delayed the onset of S phase. Forced translocation of endogenous PKAII to the cytosol downregulated cAMP signaling, advancing the timing of p27 decay and inducing premature exit from G(1). These data indicate that membrane-bound PKA amplifies the transduction of cAMP signals in G(1) and that the length of G(1) is influenced by cAMP-PKA.	Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol & Cellulare, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Sci Biomorfol & Funzionali, I-80131 Naples, Italy; Univ Catanzaro, Fac Med, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Columbia Univ, Inst Canc Res, New York, NY 10032 USA	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; Magna Graecia University of Catanzaro; Columbia University	Avvedimento, EV (corresponding author), II Policlin, Fac Med, Dipartimento Biol & Patol Mol & Cellulare, Via S Pansini 5, I-80131 Naples, Italy.		Porcellini, Antonio/E-1900-2011; Porcellini, Antonio/AAC-6097-2019	Porcellini, Antonio/0000-0001-6882-9518; Feliciello, Antonio/0000-0002-7932-2170				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ARMSTRONG R, 1995, MOL CELL BIOL, V15, P1826; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BATTAGLIA C, 1993, CELL GROWTH DIFFER, V4, P185; Cassano S, 1996, J BIOL CHEM, V271, P29870, DOI 10.1074/jbc.271.47.29870; Chain DG, 1999, NEURON, V22, P147, DOI 10.1016/S0896-6273(00)80686-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLETTA G, 1986, SCIENCE, V233, P458, DOI 10.1126/science.3726540; Depoortere F, 1998, J CELL BIOL, V140, P1427, DOI 10.1083/jcb.140.6.1427; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Feliciello A, 1998, J BIOL CHEM, V273, P23361, DOI 10.1074/jbc.273.36.23361; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Hennig D, 1998, J BIOL CHEM, V273, P19602, DOI 10.1074/jbc.273.31.19602; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KUNO T, 1987, BIOCHEM BIOPH RES CO, V146, P878, DOI 10.1016/0006-291X(87)90612-7; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OYEN O, 1988, MOL ENDOCRINOL, V2, P1070, DOI 10.1210/mend-2-11-1070; Paolillo M, 1999, J BIOL CHEM, V274, P6546, DOI 10.1074/jbc.274.10.6546; Porcellini A, 1997, ONCOGENE, V15, P781, DOI 10.1038/sj.onc.1201240; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SMETS LA, 1987, J CELL PHYSIOL, V133, P395, DOI 10.1002/jcp.1041330227; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Zheng JY, 1998, J CELL SCI, V111, P1061	40	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					303	311		10.1074/jbc.275.1.303	http://dx.doi.org/10.1074/jbc.275.1.303			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617619	hybrid			2022-12-25	WOS:000085951600043
J	Hach, A; Hon, T; Zhang, L				Hach, A; Hon, T; Zhang, L			The coiled coil dimerization element of the yeast transcriptional activator Hap1, a Gal4 family member, is dispensable for DNA binding but differentially affects transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN(2)CYS(6) BINUCLEAR CLUSTER; SACCHAROMYCES-CEREVISIAE; POSITIVE CONTROL; CRYSTAL-STRUCTURE; OXIDATIVE STRESS; GENE-EXPRESSION; ZINC FINGER; PROTEIN; COMPLEX; MECHANISM	The heme activator protein Hap1 is a member of the yeast Gal4 family, which consists of transcription factors with a conserved Zn(2)Cys(6) cluster that recognizes a CGG triplet. Many members of the Gal4 family contain a coiled coil dimerization element and bind symmetrically to DNA as homodimers. However, Hap1 possesses two unique properties. First, Hap1 binds asymmetrically to a direct repeat of two CGG triplets. Second, Hap1 binds to two classes of DNA elements, UAS1/CYC1 and UAS/CYC7, and permits differential transcriptional activation at these sites. Here we determined the residues of the Hap1 dimerization domain critical for DNA binding and differential transcriptional activation. We found that the Hap1 dimerization domain is composed of functionally redundant elements that can substitute each other in DNA binding and transcriptional activation. Remarkably, deletion of the coiled coil dimerization element did not severely diminish DNA binding and transcriptional activation at UAS1/CYC1 but completely abolished transcriptional activation at UAS/CYC7. Furthermore, Ala substitutions in the dimerization element selectively diminished transcriptional activation at UAS/CYC7. These results strongly suggest that the coiled coil dimerization element is responsible for differential transcriptional activation at UAS1/CYC1 and UAS/CYC7 and for making contacts with a putative coactivator or part of the transcription machinery.	NYU, Sch Med, Dept Biochem, New York, NY 10016 USA	New York University	Zhang, L (corresponding author), NYU, Sch Med, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.	zhang102@mcrcr0.med.nyu.edu	Zhang, Li/L-5206-2013	Zhang, Li/0000-0001-9242-0763	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053453] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; Buisson N, 1998, J BIOL CHEM, V273, P9527, DOI 10.1074/jbc.273.16.9527; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; GARDNER KH, 1995, NAT STRUCT BIOL, V2, P898, DOI 10.1038/nsb1095-898; Gosink KK, 1996, J BACTERIOL, V178, P5182, DOI 10.1128/jb.178.17.5182-5187.1996; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; Hach A, 1999, MOL CELL BIOL, V19, P4324; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KIM KS, 1990, P NATL ACAD SCI USA, V87, P4524, DOI 10.1073/pnas.87.12.4524; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; King DA, 1999, NAT STRUCT BIOL, V6, P22; King DA, 1999, NAT STRUCT BIOL, V6, P64; LODI T, 1991, MOL CELL BIOL, V11, P3762, DOI 10.1128/MCB.11.7.3762; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; PREZANT T, 1987, MOL CELL BIOL, V7, P3252, DOI 10.1128/MCB.7.9.3252; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; SIDDIQUI AH, 1989, MOL CELL BIOL, V9, P4706, DOI 10.1128/MCB.9.11.4706; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WINKLER H, 1988, EMBO J, V7, P1799, DOI 10.1002/j.1460-2075.1988.tb03011.x; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHANG L, 1994, GENETICS, V136, P813; ZHANG L, 1993, P NATL ACAD SCI USA, V90, P2851, DOI 10.1073/pnas.90.7.2851; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110; Zhang L, 1998, MOL CELL BIOL, V18, P3819, DOI 10.1128/MCB.18.7.3819; Zhao XJ, 1996, J BIOL CHEM, V271, P25131, DOI 10.1074/jbc.271.41.25131; Zitomer RS, 1997, KIDNEY INT, V51, P507, DOI 10.1038/ki.1997.71	39	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					248	254		10.1074/jbc.275.1.248	http://dx.doi.org/10.1074/jbc.275.1.248			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617612	hybrid			2022-12-25	WOS:000085951600036
J	Kharbanda, S; Saxena, S; Yoshida, K; Pandey, P; Kaneki, M; Wang, QZ; Cheng, K; Chen, YN; Campbell, A; Sudha, T; Yuan, ZM; Narula, J; Weichselbaum, R; Nalin, C; Kufe, D				Kharbanda, S; Saxena, S; Yoshida, K; Pandey, P; Kaneki, M; Wang, QZ; Cheng, K; Chen, YN; Campbell, A; Sudha, T; Yuan, ZM; Narula, J; Weichselbaum, R; Nalin, C; Kufe, D			Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; RADIATION-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; ABL TYROSINE KINASE; CYTOCHROME-C; SIGNAL-TRANSDUCTION; IONIZING-RADIATION; GAMMA-RADIATION; BCL-2	Activation of the stress-activated protein kinase (SAPK/JNK) by genotoxic agents is necessary for induction of apoptosis, We report here that ionizing radiation ionizing radiation exposure induces translocation of SAPK to mitochondria and association of SAPK with the anti-apoptotic Bcl-x(L) protein. SAPK phosphorylates Bcl-x(L) on threonine 47 (Thr-47) and threonine 115 (Thr-115) in vitro and in vivo. In contrast to wild-type Bcl-x(L), a mutant Bcl-x(L) with the two threonines substituted by alanines (Ala-47, Ala-115) is a more potent inhibitor of ionizing radiation-induced apoptosis, These findings indicate that translocation of SAPK to mitochondria is functionally important for interactions with Bcl-x(L) in the apoptotic response to genotoxic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol,Div Canc Pharmacol, Boston, MA 02115 USA; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Novartis Pharmaceut, Preclin Res, Oncol Res Program, E Hanover, NJ 07936 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Manitoba; Novartis; University of Chicago	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol,Div Canc Pharmacol, 44 Binney St, Boston, MA 02115 USA.	surender_kharbanda@dfci.harvard.edu			NCI NIH HHS [CA 55421, CA 75216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075216, R44CA055421, R43CA055421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P128; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; SALEEM A, 1995, J IMMUNOL, V154, P4150; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Woodgett JR, 1996, CANCER SURV, V27, P127; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	54	376	394	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					322	327		10.1074/jbc.275.1.322	http://dx.doi.org/10.1074/jbc.275.1.322			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617621	hybrid			2022-12-25	WOS:000085951600045
J	Lill, NL; Douillard, P; Awwad, RA; Ota, S; Lupher, ML; Miyake, S; Meissner-Lula, N; Hsu, VW; Band, H				Lill, NL; Douillard, P; Awwad, RA; Ota, S; Lupher, ML; Miyake, S; Meissner-Lula, N; Hsu, VW; Band, H			The evolutionarily conserved n-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; PHOSPHOTYROSINE-BINDING DOMAIN; TYROSINE KINASE-ACTIVITY; PROTOONCOGENE C-CBL; FACTOR EGF RECEPTOR; ACTIVATED T-CELLS; V-CBL; INDUCED ENDOCYTOSIS; POSTENDOCYTIC TRAFFICKING; PHOSPHORYLATION SITES	The mammalian proto-oncoprotein Cbl and its homologues in Caenorhabditis elegans and Drosophila are evolutionarily conserved negative regulators of the epidermal growth factor receptor (EGF-R), Overexpression of wild-type Cbl enhances down-regulation of activated EGF-R from the cell surface. We report that the Cbl tyrosine kinase-binding (TKB) domain is essential for this activity. Whereas wild-type Cbl enhanced ligand-dependent EGF-R ubiquitination, down-regulation from the cell surface, accumulation in intracellular vesicles, and degradation, a Cbl TKB domain-inactivated mutant (G306E) did not. Furthermore, the transforming truncation mutant Cbl-N (residues 1-357), comprising only the Cbl TKB domain, functioned as a dominant negative protein. It colocalized with EGF-R in intracellular vesicular structures, yet it suppressed down-regulation of EGF-R from the surface of cells expressing endogenous wild-type Cbl. Therefore, Chi-mediated down-regulation of EGF-R requires the integrity of both the N-terminal TKB domain and additional C-terminal sequences. A Cbl truncation mutant comprising amino acids 1-440 functioned like wild-type Cbl in down-regulation assays. This mutant includes the evolutionarily conserved TKB and RING finger domains but lacks the less conserved C-terminal sequences, We conclude that the evolutionarily conserved N terminus of Cbl is sufficient to effect enhancement of EGF-R ubiquitination and down-regulation from the cell surface.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Lymphocyte Biol Sect, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Band, H (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Lymphocyte Biol Sect, Dept Med,Div Rheumatol Immunol & Allergy, Smith Bldg,Rm 538C,1 Jimmy Fund Way, Boston, MA 02115 USA.	hband@rics.bwh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA076118, R01CA075075] Funding Source: NIH RePORTER; NCI NIH HHS [CA75075, CA76118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn SJ, 1998, BIOCHEM BIOPH RES CO, V244, P62, DOI 10.1006/bbrc.1998.8220; Andoniou CE, 1996, ONCOGENE, V12, P1981; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Baulida J, 1996, J BIOL CHEM, V271, P5251; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; CANTLEY LC, 1994, J CELL SCI, P121; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAHANA JA, 1996, CURRENT PROTOCOLS MO; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE JH, 1994, GENE DEV, V8, P60, DOI 10.1101/gad.8.1.60; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Maki CG, 1996, CANCER RES, V56, P2649; Marengere LEM, 1997, J IMMUNOL, V159, P70; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Sato J D, 1983, Mol Biol Med, V1, P511; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA Y, 1988, J IMMUNOL, V140, P4348; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	95	119	121	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					367	377		10.1074/jbc.275.1.367	http://dx.doi.org/10.1074/jbc.275.1.367			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617627	hybrid			2022-12-25	WOS:000085951600051
J	Lombard, M; Fontecave, M; Touati, D; Niviere, V				Lombard, M; Fontecave, M; Touati, D; Niviere, V			Reaction of the desulfoferrodoxin from Desulfoarculus baarsii with superoxide anion - Evidence for a superoxide reductase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS ATCC-27774; SULFATE-REDUCING BACTERIA; RBO GENE-PRODUCT; ESCHERICHIA-COLI; NITRIC-OXIDE; IRON; DISMUTASE; PROTEINS; OVERPRODUCTION; PEROXYNITRITE	Desulfoferrodoxin is a small protein found in sulfate-reducing bacteria that contains two independent mononuclear iron centers, one ferric and one ferrous. Expression of desulfoferrodoxin from Desulfoarculus baarsii has been reported to functionally complement a superoxide dismutase deficient Escherichia coli strain. To elucidate by which mechanism desulfoferrodoxin could substitute for superoxide dismutase in E. coli, we have purified the recombinant protein and studied its reactivity toward O-2(radical anion). Desulfoferrodoxin exhibited only a weak, superoxide dismutase activity (20 units mg(-1)) that could hardly account for its antioxidant properties. UV-visible and electron paramagnetic resonance spectroscopy studies revealed that the ferrous center of desulfoferrodoxin could specifically and efficiently reduce O-2(radical anion), with a rate constant of 6-7 x 10(8) M-1 s(-1). In addition, we showed that membrane and cytoplasmic E. coli protein extracts, using NADH and NADPH as electron donors, could reduce the O-2(radical anion) oxidized form of desulfoferrodoxin. Taken together, these results strongly suggest that desulfoferrodoxin behaves as a superoxide reductase enzyme and thus provide new insights into the biological mechanisms designed for protection from oxidative stresses.	Univ Grenoble 1, CNRS, CEA, DBMS,Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble 9, France; Univ Paris 06, CNRS, Inst Jacques Monod, F-75251 Paris, France; Univ Paris 07, CNRS, Inst Jacques Monod, F-75251 Paris 05, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Niviere, V (corresponding author), Univ Grenoble 1, CNRS, CEA, DBMS,Lab Chim & Biochim,Ctr Redox Biol, 17 Ave Martyrs, F-38054 Grenoble 9, France.		Lombard, Murielle/E-4974-2019	Lombard, Murielle/0000-0002-4775-3494; Niviere, Vincent/0000-0002-5132-457X				BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL C, 1985, J AM CHEM SOC, V107, P3295, DOI 10.1021/ja00297a040; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; CYPIONKA H, 1985, FEMS MICROBIOL ECOL, V31, P39, DOI 10.1016/0378-1097(85)90045-X; Devreese B, 1996, FEBS LETT, V385, P138, DOI 10.1016/0014-5793(96)00364-X; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; HALLIWELL B, 1989, FREE RADICAL BIO MED, P71; HANSEN TA, 1994, ANTON LEEUW INT J G, V66, P165, DOI 10.1007/BF00871638; HARDY JA, 1981, CURR MICROBIOL, V6, P259, DOI 10.1007/BF01566873; HATCHIKIAN EC, 1977, BIOCHIMIE, V59, P153, DOI 10.1016/S0300-9084(77)80286-1; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; KLUG D, 1972, J BIOL CHEM, V247, P4839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOURA I, 1990, J BIOL CHEM, V265, P21596; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; Romao CV, 1999, EUR J BIOCHEM, V261, P438, DOI 10.1046/j.1432-1327.1999.00278.x; TAVARES P, 1994, J BIOL CHEM, V269, P10504; VERHAGEN MFJM, 1993, FEBS LETT, V336, P13, DOI 10.1016/0014-5793(93)81599-U; Voordouw JK, 1998, APPL ENVIRON MICROB, V64, P2882	25	135	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					115	121		10.1074/jbc.275.1.115	http://dx.doi.org/10.1074/jbc.275.1.115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617593	Green Submitted, hybrid			2022-12-25	WOS:000085951600017
J	Day, JM; Murdoch, AD; Hardingham, TE				Day, JM; Murdoch, AD; Hardingham, TE			The folded protein modules of the C-terminal G3 domain of aggrecan can each facilitate the translocation and secretion of the extended chondroitin sulfate attachment sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE PROTEOGLYCAN; CORE PROTEIN; GENE; BIOSYNTHESIS; CHONDROCYTES; EXPRESSION; LECTIN; CHONDRODYSTROPHY; NANOMELIA; PRECURSOR	Aggrecan is a multidomain proteoglycan containing both extended and folded protein modules. The C-terminal G3 domain contains a lectin-like, complement regulatory protein-like, and two alternatively spliced epidermal growth factor-like modules. It has been proposed that the lectin module alone has a necessary role in the intracellular translocation and secretion of proteins expressed containing G3. Constructs containing human aggrecan G3 together with 1155 bases of the adjacent chondroitin sulfate attachment region (CS-2) were prepared with different combinations and deletions of the protein modules and transfected into mammalian cells of monkey or hamster origin. The results showed that the products containing only the unfolded protein sequences (CS-2 with or without the C-terminal tail sequence) were translated and accumulated intracellularly but were not secreted. In contrast the constructs containing any of the folded protein modules and the extended CS-2 region were translated and secreted from the cells. The results show that the lectin module was not unique in facilitating the intracellular translocation and secretion of the G3 domain. The conservation of G3-like domains within the aggrecan family of proteoglycans may therefore result from their participation in other extracellular functions.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Hardingham, TE (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Hardingham, Timothy/0000-0001-8271-6763				Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; Brissett NC, 1998, BIOCHEM J, V329, P415; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; CIZDZIEL PE, 1991, MOL CARCINOGEN, V4, P14, DOI 10.1002/mc.2940040105; COUCHMAN JR, 1984, NATURE, V307, P650, DOI 10.1038/307650a0; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Dudhia J, 1996, BIOCHEM J, V313, P933, DOI 10.1042/bj3130933; FULOP C, 1993, J BIOL CHEM, V268, P17377; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1993, J BIOL CHEM, V268, P23504; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; MCLACHLAN JA, 1982, CANCER RES, V42, P3040; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; RATCLIFFE A, 1985, J CELL BIOL, V101, P2355, DOI 10.1083/jcb.101.6.2355; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; SALEQUE S, 1993, GLYCOBIOLOGY, V3, P185, DOI 10.1093/glycob/3.2.185; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535; VERTEL BM, 1994, BIOCHEM J, V301, P211, DOI 10.1042/bj3010211; VERTEL BM, 1993, J CELL SCI, V104, P939; VERTEL BM, 1995, TRENDS CELL BIOL, V5, P458, DOI 10.1016/S0962-8924(00)89115-1; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999	29	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38107	38111		10.1074/jbc.274.53.38107	http://dx.doi.org/10.1074/jbc.274.53.38107			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608880	hybrid			2022-12-25	WOS:000084528000080
J	Lee, BI; Wilson, DM				Lee, BI; Wilson, DM			The RAD2 domain of human exonuclease 1 exhibits 5 ' to 3 ' exonuclease and flap structure-specific endonuclease activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE EXO1; EUKARYOTIC DNA-REPLICATION; DOUBLE-STRAND BREAKS; ESCHERICHIA-COLI; MUTATION AVOIDANCE; MISMATCH REPAIR; SCHIZOSACCHAROMYCES-POMBE; CONDITIONAL LETHALITY; POLYMERASE-I	The RAD2 family of nucleases includes human XPG (Class I), FEN1 (Class II), and HEX1/hEXO1 (Class In) products gene. These proteins exhibit a blend of substrate specific exo- and endonuclease activities and contribute to repair, recombination, and/or replication. To date, the substrate preferences of the EXO1-liIre Glass III proteins have not been thoroughly defined, We report here that the RAD2 domain of human exonuclease 1 (HEX1-N2) exhibits both a robust 5' to 3' exonuclease activity on single- and double-stranded DNA substrates as well as a flap structure-specific endonuclease activity but does not show specific endonuclease activity at 10-base pair bubble-like structures, G:T mismatches, or uracil residues. Both the 5' to 3' exonuclease and flap endonuclease activities require a divalent metal cofactor, with Mg2+ being the preferred metal ion. HEX1-N2 is similar to 3-fold less active in Mn2+-containing buffers and exhibits <5% activity in the presence of Co2+, Zn2+, or Ca2+, The optimal pH range for the nuclease activities: of HEX1-N2 is 7.2-8.2, The specific activity of its 5' to 3' exonuclease function is 2.5-7-fold higher on blunt end and 5'-recessed double-stranded DNA substrates compared with duplex 5'-overhang or single-stranded DNAs, The Bap endonuclease activity of HEX1-N2 is similar to that of human flap endonuclease-1, both in terms of turnover efficiency (k(cat)) and site of incision, and is as efficient (k(cat)/K-m) as its exonuclease function. The nuclease activities of HEX1-N2 described here indicate functions for the EXO1-like proteins in replication, repair, and/or recombination that may overlap with human flap endonuclease-1.	Univ Calif Lawrence Livermore Natl Lab, Mol & Struct Biol Div, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Wilson, DM (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Mol & Struct Biol Div, L-452, Livermore, CA 94551 USA.		Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395	NATIONAL CANCER INSTITUTE [R01CA079056] Funding Source: NIH RePORTER; NCI NIH HHS [CA79056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; Ceska TA, 1998, TRENDS BIOCHEM SCI, V23, P331, DOI 10.1016/S0968-0004(98)01259-6; DELUCIA P, 1969, NATURE, V224, P1164, DOI 10.1038/2241164a0; Digilio FA, 1996, DEV BIOL, V178, P90, DOI 10.1006/dbio.1996.0200; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Johnson RE, 1998, CURR GENET, V34, P21, DOI 10.1007/s002940050362; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KONRAD EB, 1977, J BACTERIOL, V130, P167, DOI 10.1128/JB.130.1.167-172.1977; Kornberg A., 1980, DNA REPLICATION; Lee BI, 1999, NUCLEIC ACIDS RES, V27, P4114, DOI 10.1093/nar/27.20.4114; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; MONK M, 1972, J BACTERIOL, V109, P971, DOI 10.1128/JB.109.3.971-978.1972; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Nickoloff JA, 1998, DNA DAMAGE REPAIR, V2; NICKOLOFF JA, 1998, DNA DAMAGE REPAIR, V1; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Qiu JZ, 1999, J BIOL CHEM, V274, P17893, DOI 10.1074/jbc.274.25.17893; Qiu JZ, 1998, NUCLEIC ACIDS RES, V26, P3077, DOI 10.1093/nar/26.13.3077; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Sayers JR, 1998, NAT STRUCT BIOL, V5, P668, DOI 10.1038/1358; Schmutte C, 1998, CANCER RES, V58, P4537; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Symington LS, 1998, NUCLEIC ACIDS RES, V26, P5589, DOI 10.1093/nar/26.24.5589; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X; WAGA S, 1994, J BIOL CHEM, V269, P10923; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Yonemasu R, 1997, NUCLEIC ACIDS RES, V25, P1553, DOI 10.1093/nar/25.8.1553; Yu Z, 1999, ENVIRON MOL MUTAGEN, V33, P3, DOI 10.1002/(SICI)1098-2280(1999)33:1<3::AID-EM2>3.0.CO;2-L	55	152	157	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37763	37769		10.1074/jbc.274.53.37763	http://dx.doi.org/10.1074/jbc.274.53.37763			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608837	hybrid			2022-12-25	WOS:000084528000037
J	Outten, CE; Outten, FW; O'Halloran, TV				Outten, CE; Outten, FW; O'Halloran, TV			DNA distortion mechanism for transcriptional activation by ZntR, a Zn(II)-responsive MerR homologue in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; SOXR PROTEIN; METALLOREGULATORY PROTEIN; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; BINDING; PROMOTER; COMPLEX; ZINC	MerR-like DNA distortion mechanisms have been proposed for a variety of stress-responsive transcription factors. The Escherichia coli ZntR protein, a homologue of MerR, has recently been shown to mediate Zn(II)responsive regulation of zntA, a gene involved in Zn(II) detoxification. To determine whether the MerR DNA distortion mechanism is conserved among MerR family members, we have purified ZntR to homogeneity and shown that it is a zinc receptor that is necessary and sufficient to stimulate Zn-responsive transcription at the zntA promoter. Biochemical, DNA footprinting, and in vitro transcription assays indicate that apo-ZntR binds in the atypical 20-base pair spacer region of the promoter and distorts the DNA in a manner that is similar to apo-MerR. The addition of Zn(II) to ZntR converts it to a transcriptional activator protein that introduces changes in the DNA conformation. These changes apparently make the promoter a better substrate for RNA polymerase. We propose that this zinc-sensing homologue of MerR restructures the target promoter in a manner similar to that of other stress-responsive transcription factors. The ZntR metalloregulatory protein is a direct Zn(II) sensor that catalyzes transcriptional activation of a zinc efflux gene, thus preventing intracellular Zn(II) from exceeding an optimal but as yet unknown concentration.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-ohalloran@nwu.edu	O'Halloran, Thomas/ABE-6125-2021; Outten, Caryn E./I-9433-2019	O'Halloran, Thomas/0000-0001-8732-5059; Outten, Caryn E./0000-0003-0335-6531; Outten, Franklin/0000-0002-9095-0194	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061, T32GM008382, R01GM038784] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM08382, R01 GM038784, T32 GM08061, R01 GM38784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED M, 1995, J BACTERIOL, V177, P3904, DOI 10.1128/jb.177.14.3904-3910.1995; AHMED M, 1994, J BIOL CHEM, V269, P28506; AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; ANSARI AZ, 1995, NATURE, V374, P371; ANSARI AZ, 1994, TRANSCRIPTION MECHAN, P369; Baranova NN, 1999, MOL MICROBIOL, V31, P1549, DOI 10.1046/j.1365-2958.1999.01301.x; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Brocklehurst KR, 1999, MOL MICROBIOL, V31, P893, DOI 10.1046/j.1365-2958.1999.01229.x; BROWN NL, 1986, MOL GEN GENET, V202, P143, DOI 10.1007/BF00330531; BROWN NL, 1991, J CELL BIOCHEM, V46, P106; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; Chiu ML, 1999, J BIOL CHEM, V274, P20578, DOI 10.1074/jbc.274.29.20578; COMESS KM, 1994, BIOCHEMISTRY-US, V33, P4175, DOI 10.1021/bi00180a010; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; Coulombre B, 1999, MICROBIOL MOL BIOL R, V63, P457, DOI 10.1128/MMBR.63.2.457-478.1999; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; Dai X, 1999, CURR OPIN MICROBIOL, V2, P126, DOI 10.1016/S1369-5274(99)80022-8; Dalet K, 1999, FEMS MICROBIOL LETT, V174, P111, DOI 10.1016/S0378-1097(99)00128-7; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; GASTON K, 1992, NUCLEIC ACIDS RES, V20, P3391, DOI 10.1093/nar/20.13.3391; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOLMES DJ, 1993, EMBO J, V12, P3183, DOI 10.1002/j.1460-2075.1993.tb05987.x; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; Kuroda M, 1999, MICROBIOL IMMUNOL, V43, P115, DOI 10.1111/j.1348-0421.1999.tb02382.x; LAHM A, 1991, NUCLEIC ACIDS MOL BI, V5, P171; Loh J, 1999, J BACTERIOL, V181, P1544, DOI 10.1128/JB.181.5.1544-1554.1999; LUND P, 1989, NUCLEIC ACIDS RES, V17, P5517, DOI 10.1093/nar/17.14.5517; Maniatis T., 1989, MOL CLONING LAB MANU; MARTELL AE, 1998, 46 NIST; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; Muller HP, 1995, SOMAT CELL MOLEC GEN, V21, P289, DOI 10.1007/BF02257464; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; RALSTON DM, 1990, P NATL ACAD SCI USA, V87, P3846, DOI 10.1073/pnas.87.10.3846; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; Rivetti C, 1999, EMBO J, V18, P4464, DOI 10.1093/emboj/18.16.4464; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; ROUCH DA, 1995, J IND MICROBIOL, V14, P249; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; Singh VK, 1999, MOL MICROBIOL, V33, P200, DOI 10.1046/j.1365-2958.1999.01466.x; SPASSKY A, 1988, EMBO J, V7, P1871, DOI 10.1002/j.1460-2075.1988.tb03020.x; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; THEDERAHN T, 1990, BIOCHEM BIOPH RES CO, V168, P756, DOI 10.1016/0006-291X(90)92386-E; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; WATTON SP, 1990, J AM CHEM SOC, V112, P2824, DOI 10.1021/ja00163a067; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713	64	153	158	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37517	37524		10.1074/jbc.274.53.37517	http://dx.doi.org/10.1074/jbc.274.53.37517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608803	hybrid, Green Published			2022-12-25	WOS:000084528000003
J	Qin, JZ; Chaturvedi, V; Denning, MF; Choubey, D; Diaz, MO; Nickoloff, BJ				Qin, JZ; Chaturvedi, V; Denning, MF; Choubey, D; Diaz, MO; Nickoloff, BJ			Role of NF-kappa B in the apoptotic-resistant phenotype of keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CELL-DEATH; BCL-X; ACTIVATION; KINASE; SKIN; ALPHA; PATHOGENESIS; EXPRESSION; INDUCTION	Several studies point to a role for NF-kappa B in modulating epidermal thickness and apoptotic susceptibility of keratinocytes. When phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA) are topically applied, prominent epidermal thickening occurs, and exposure to interferon (IFN)-gamma promotes increased epidermal thickness producing psoriatic lesions, While keratinocytes derived from psoriatic plaque resist apoptosis, and combination of TPA and IFN-gamma activates NF-kappa B, the molecular mechanism linking NE-kappa B activation and keratinocyte apoptosis resistance was unknown. Therefore, we examined the ability of IFN-gamma plus TPA to influence NF-kappa B activity, gene expression, and response to UV light-induced apoptosis, These responses in normal keratinocytes were compared with immortalized keratinocytes (HaCaT cells). Exposure of normal keratinocytes to IFN-gamma plus TPA produced a synergistic activation: of NF-kappa B, compared with when each reagent was used individually. Normal keratinocytes when exposed to IFN-gamma plus TPA acquired a resistance to UV light-induced apoptosis, which was dependent on NF-kappa B because expression of a dominant negative form of I kappa B alpha overcame the resistance. Compared with normal keratinocytes, HaCaT cells have a dysfunctional constitutive NF-kappa B signaling pathway not induced by IFN-gamma and TPA, rendering HaCaT cells highly susceptible to W-induced apoptosis, Thus, immortalized HaCaT cells have an abnormal constitutive and dysfunctional NF-kappa B signaling system. These results provide evidence that activation and proper regulation of NF-kappa B is essential for acquisition of an apoptotic-resistant phenotype for epidermal-derived keratinocytes.	Loyola Univ, Med Ctr, Dept Pathol, Skin Canc Res Labs,Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Radiat Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Med, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Nickoloff, BJ (corresponding author), Loyola Univ, Med Ctr, Dept Pathol, Skin Canc Res Labs,Cardinal Bernardin Canc Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA.	Bnickol@luc.edu	Choubey, Divaker/A-4771-2008					BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Foo SY, 1999, TRENDS GENET, V15, P229; GERBER HP, 1992, NUCLEIC ACIDS RES, V20, P5855, DOI 10.1093/nar/20.21.5855; GRIFFITHS CEM, 1990, BRIT J DERMATOL, V122, P333, DOI 10.1111/j.1365-2133.1990.tb08281.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Pena JC, 1998, CANCER RES, V58, P2111; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; RASMUSSEN HH, 1993, J INVEST DERMATOL, V101, P560, DOI 10.1111/1523-1747.ep12365986; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1999, APMIS, V107, P73, DOI 10.1111/j.1699-0463.1999.tb01528.x; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; WroneSmith T, 1997, AM J PATHOL, V151, P1321; YUSPA SH, 1994, CANCER RES, V54, P1178; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	39	106	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37957	37964		10.1074/jbc.274.53.37957	http://dx.doi.org/10.1074/jbc.274.53.37957			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608863	hybrid			2022-12-25	WOS:000084528000063
J	Rao, S; He, LF; Chakravarty, S; Ojima, I; Orr, GA; Horwitz, SB				Rao, S; He, LF; Chakravarty, S; Ojima, I; Orr, GA; Horwitz, SB			Characterization of the taxol binding site on the microtubule - Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACLITAXEL TAXOL; MITOTIC BLOCK; AMINO-ACIDS; INVITRO; CELLS; POLYMERIZATION; PHOTOLABELS	Photoaffinity labeling methods have allowed a definition of the sites of interaction between Taxol and its cellular target, the microtubule, specifically beta-tubulin. Our previous studies have indicated that [H-3]3'-(p-azidobenzamido)Taxol photolabels the N-terminal 31 amino acids of beta-tubulin (Rao, S., Krauss, N. E., Heerding, J. M., Swindell, C. S., Ringel, I., Orr, G. A, and Horwitz, S. B. (1994) J. Biol. Chem. 269, 3132-3134) and [H-3]2-(m-azidobenzoyl)Taxol photolabels a peptide containing amino acid residues 217-233 of beta-tubulin (Rao, S., Orr, G. A, Chaudhary, A G., Kingston, D. G. I., and Horwitz, S. B. (1995) J. Biol Chem. 270, 20235-20238). The site of photoincorporation of a third photoaffinity analogue of Taxol, [H-3]7-(benzoyldihydrocinnamoyl) Taxol, has been determined. This analogue stabilizes microtubules polymerized in the presence of GTP, but in contrast to Taxol, does not by itself enhance the polymerization of tubulin to its polymer form. CNBr digestion of [H-3]7-(benzoyldihydrocinnamoyl)Taxol-labeled tubulin, with further arginine-specific cleavage by clostripain resulted in the isolation of a peptide containing amino acid residues 277-293. Amino acid sequence analysis indicated that the photoaffinity analogue crosslinks to Arg(282) in beta-tubulin. Advances made by electron crystallography in understanding the structure of the tubulin dimer have allowed us to visualize the three sites of photoincorporation by molecular modeling. There is good agreement between the binding site of Taxol in beta-tubulin as determined by photoaffinity labeling and electron crystallography.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Horwitz, SB (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Kingston, David G. I./B-4272-2009	Kingston, David G. I./0000-0001-8944-246X; Ojima, Iwao/0000-0002-3628-1161	NATIONAL CANCER INSTITUTE [R01CA083185, R01CA077263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042798] Funding Source: NIH RePORTER; NCI NIH HHS [CA77263, CA83185] Funding Source: Medline; NIGMS NIH HHS [GM42798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; GEORG GI, 1992, BIOORG MED CHEM LETT, V2, P735, DOI 10.1016/S0960-894X(00)80402-3; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; GILLES AM, 1979, J BIOL CHEM, V254, P1462; Gonzalez-Garay ML, 1999, J BIOL CHEM, V274, P23875, DOI 10.1074/jbc.274.34.23875; GROVER S, 1995, BIOCHEMISTRY-US, V34, P3927, DOI 10.1021/bi00012a009; GUERITTEVOEGELEIN F, 1990, ACTA CRYSTALLOGR C, V46, P781, DOI 10.1107/S0108270189009376; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KINGSTON DGI, 1995, ACS SYM SER, V583, P203; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MASTROPAOLO D, 1995, P NATL ACAD SCI USA, V92, P6920, DOI 10.1073/pnas.92.15.6920; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Ojima I, 1997, J AM CHEM SOC, V119, P5519, DOI 10.1021/ja9633777; Ojima I, 1999, BIOORG MED CHEM LETT, V9, P1189, DOI 10.1016/S0960-894X(99)00161-4; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; Wu Q, 1998, BIOCHEMISTRY-US, V37, P11272, DOI 10.1021/bi980598b	32	162	168	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37990	37994		10.1074/jbc.274.53.37990	http://dx.doi.org/10.1074/jbc.274.53.37990			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608867	hybrid			2022-12-25	WOS:000084528000067
J	Saenko, EL; Yakhyaev, AV; Mikhailenko, I; Strickland, DK; Sarafanov, AG				Saenko, EL; Yakhyaev, AV; Mikhailenko, I; Strickland, DK; Sarafanov, AG			Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; CELL-SURFACE PROTEOGLYCANS; ACTIVATOR INHIBITOR TYPE-1; FACTOR PATHWAY INHIBITOR; RECOMBINANT FACTOR-VIII; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; VONWILLEBRAND-FACTOR; PROTEIN/ALPHA(2)-MACROGLOBULIN RECEPTOR; LIVER-TRANSPLANTATION	In the present study, we found that catabolism of coagulation factor VIII (fVIII) is mediated by the low density lipoprotein receptor-related protein (LPR), a liver multiligand endocytic receptor. In a solid phase assay, fVIII was shown to bind to LRP (K-d 116 nM). The specificity was confirmed by a complete inhibition of fVII/LRP binding by 39-kDa receptor-associated protein (RAP), an antagonist of all LRP ligands. The region of fVIII involved in its binding to LRP was localized within the A2 domain residues 484-509, based on the ability of the isolated A2 domain and the synthetic A2 domain peptide 484-509 to prevent fVIII interaction with LRP, Since vWf did not inhibit fVIII binding to LRP, we proposed that LRP receptor may internalize fVIII from its complex with vWf, Consistent with this hypothesis, mouse embryonic fibroblasts that express LRP, but not fibroblasts genetically deficient in LRP, were able to catabolize I-125-fVIII complexed with vWf, which was not internalized by the cells. These processes could be inhibited by RAP and A2 subunit of fVIII, indicating that cellular internalization and degradation were mediated by interaction of the A2 domain of fVIII with LRP. In vivo studies of I-125-fVIII vWf complex clearance in mice demonstrated that RAP completely inhibited the fast phase of the biphasic I-125-fVIII clearance that is responsible for removal of 60% of fVIII from circulation. Inhibition of the RAP-sensitive phase prolonged the half-life of I-125-fVIII in circulation by 3.3-fold, indicating that LRP receptor plays an important role in fVIII clearance.	Amer Red Cross, Holland Lab, Rockville, MD 20855 USA	American Red Cross	Saenko, EL (corresponding author), Amer Red Cross, Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.			Sarafanov, Andrey/0000-0001-6124-9713	NHLBI NIH HHS [HL50784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BONTEMPO FA, 1987, BLOOD, V69, P1721; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CONNELLY S, 1995, HUM GENE THER, V6, P185, DOI 10.1089/hum.1995.6.2-185; Connelly S, 1996, BLOOD, V87, P4671, DOI 10.1182/blood.V87.11.4671.bloodjournal87114671; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FAY PJ, 1986, THROMB RES, V37, P425; Fijnvandraat K, 1997, THROMB HAEMOSTASIS, V77, P298; FULCHER CA, 1985, J CLIN INVEST, V76, P117, DOI 10.1172/JCI111933; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Ho GY, 1996, J BIOL CHEM, V271, P9497, DOI 10.1074/jbc.271.16.9497; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; HOYER LW, 1980, BLOOD, V55, P1056; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; KOPPELMAN SJ, 1994, J LAB CLIN MED, V123, P585; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; LETHAGEN S, 1992, ANN HEMATOL, V65, P253, DOI 10.1007/BF01836069; LEWIS JH, 1985, NEW ENGL J MED, V312, P1189; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; MACGREGOR IR, 1995, VOX SANG, V69, P319, DOI 10.1111/j.1423-0410.1995.tb00367.x; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; Mordenti J, 1996, TOXICOL APPL PHARM, V136, P75, DOI 10.1006/taap.1996.0008; MORFINI M, 1992, THROMB HAEMOSTASIS, V68, P433; MORFINI M, 1993, THROMB HAEMOSTASIS, V70, P270; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Narita M, 1998, BLOOD, V91, P555, DOI 10.1182/blood.V91.2.555.555_555_560; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OVER J, 1978, J CLIN INVEST, V62, P223, DOI 10.1172/JCI109120; Rodenburg KW, 1998, BIOCHEM J, V329, P55; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VLOT AJ, 1995, BLOOD, V85, P3150, DOI 10.1182/blood.V85.11.3150.bloodjournal85113150; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; WISE RJ, 1991, J BIOL CHEM, V266, P21948	57	182	205	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37685	37692		10.1074/jbc.274.53.37685	http://dx.doi.org/10.1074/jbc.274.53.37685			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608826	hybrid			2022-12-25	WOS:000084528000026
J	Hertig, CM; Kubalak, SW; Wang, YB; Chien, KR				Hertig, CM; Kubalak, SW; Wang, YB; Chien, KR			Synergistic roles of neuregulin-1 and insulin-like growth factor-I in activation of the phosphatidylinositol 3-kinase pathway and cardiac chamber morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TYROSINE KINASES; EMBRYONIC HEART; MICE LACKING; IGF-I; RECEPTOR; CELLS; MOUSE; ERBB2; ACETYLCHOLINESTERASE	Cardiac chamber morphogenesis requires the coordinated growth of both cardiac muscle and endocardial cell lineages. Paracrine growth factors may modulate the coordinated cellular specification and differentiation during cardiac chamber morphogenesis, as suggested by the essential role of endothelial-derived growth factors, neuregulin-1, and insulin-like growth factor-I. Using the whole mouse embryo culture system for delivery of diffusible factors into the cardiac chamber, neuregulin-1 was shown to promote trabeculation of the ventricular wall. Another factor, insulin-like growth factor-I, had no apparent effect by itself. Combined treatment with neuregulin-1 and insulin-like growth factor-I strongly induced DNA synthesis of cardiomyocytes and expansion of both the ventricular compact zone and the atrioventricular cushions leading to chamber growth and maturation. In cultured cardiomyocytes, combined neuregulin-1 and insulin-like growth factor-I also had a synergistic effect to promote DNA synthesis and cellular growth, which were prevented by wortmannin, an inhibitor of phosphatidylinositol 3-kinase, Adenoviral delivery of dominant negative Rad, which acts downstream of phosphatidylinositol S-kinase, blocked the effect of combined neuregulin-1/insulin-like growth factor-I treatment. These studies support the concept that the interaction of neuregulin-1 and insulin-like growth factor-I pathways plays an important role in coordinating cardiac chamber morphogenesis and may occur through convergent activation of phosphatidylinositol 3-kinase.	Univ Calif San Diego, Dept Med, Salk Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA; Univ Maryland, Dept Physiol, Washington, DC 20212 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Medical University of South Carolina	Chien, KR (corresponding author), Univ Calif San Diego, Dept Med, Salk Program Mol Med, 0613-C,9500 Gilman Dr, La Jolla, CA 92093 USA.			Wang, Yibin/0000-0003-0852-0767				Arkell R, 1997, DEVELOPMENT, V124, P1; Bonassar LJ, 1997, EXP CELL RES, V234, P1, DOI 10.1006/excr.1997.3574; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; Burgaud JL, 1996, EXP CELL RES, V223, P412, DOI 10.1006/excr.1996.0096; Chen J, 1998, DEVELOPMENT, V125, P1943; CohenGould L, 1996, DEV BIOL, V177, P265, DOI 10.1006/dbio.1996.0161; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; COPP AJ, 1990, POST IMPLANTATION MA, P31; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DERCOLE AJ, 1996, HORM RES, V1, P5; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; Gruber PJ, 1998, DEVELOPMENT, V125, P4427; Hertig CM, 1996, J CELL SCI, V109, P11; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P375; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; LAMERS WH, 1987, ANAT REC, V217, P361, DOI 10.1002/ar.1092170407; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; Luo ZD, 1996, J NEUROCHEM, V67, P111; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; NAKAMURA T, 1994, ANAT EMBRYOL, V190, P367; Okajima Y, 1998, J BIOL CHEM, V273, P22877, DOI 10.1074/jbc.273.36.22877; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Parrizas M, 1997, J BIOL CHEM, V272, P154; PEXIEDER T, 1986, TERATOLOGY, V33, P91; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; POWELLBRAXTON L, 1993, ANN NY ACAD SCI, V692, P300; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Ramsdell AF, 1997, DEV BIOL, V188, P64, DOI 10.1006/dbio.1997.8637; Reiss K, 1996, P NATL ACAD SCI USA, V93, P8630, DOI 10.1073/pnas.93.16.8630; Ruiz-Lozano P, 1998, DEVELOPMENT, V125, P533; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STURM K, 1993, METHOD ENZYMOL, V225, P164; Sugi Y, 1996, DEV BIOL, V175, P66, DOI 10.1006/dbio.1996.0096; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; Tessarollo L, 1998, TRENDS CARDIOVAS MED, V8, P34, DOI 10.1016/S1050-1738(97)00119-9; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VUILLEMIN M, 1989, AM J ANAT, V184, P114, DOI 10.1002/aja.1001840203; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261	57	73	76	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37362	37369		10.1074/jbc.274.52.37362	http://dx.doi.org/10.1074/jbc.274.52.37362			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601306	hybrid			2022-12-25	WOS:000084382700077
J	Zhang, JH; Wang, XS; Bove, KE; Xu, M				Zhang, JH; Wang, XS; Bove, KE; Xu, M			DNA fragmentation factor 45-deficient cells are more resistant to apoptosis and exhibit different dying morphology than wild-type control cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 GENE FAMILY; CYTOCHROME-C; CHROMATIN CONDENSATION; MEDIATED APOPTOSIS; DEATH RECEPTORS; ELEGANS; PROTEIN; ACTIVATION; SURVIVAL; ENCODES	The DNA fragmentation factor 45 (DFF45) is a subunit of a heterodimeric DNase complex critical for the induction of DNA fragmentation in vitro, To understand the in vivo role of DFF45 in programmed cell death, we measured the expression of DFF45 during mouse development and compared DNA fragmentation and viability of DFF45-deficient cells with wild-type control cells after activation of apoptosis, We found that DFF45 is ubiquitously expressed throughout mouse development, Moreover, DFF45-deficient thymocytes are resistant to DNA fragmentation with in vivo dexamethasone treatment, Furthermore, primary thymocytes from DFF45 mutant mice are also more resistant to apoptosis than wild-type control cells on exposure to several apoptotic stimuli. Dying DFF45-deficient thymocytes exhibit different morphology than wild-type control cells in that they show reduced degree of chromatin condensation, absent nuclear fragmentation, intranuclear cytoplasmic invagination, and striking nuclear chromatin conglutination after release from disintegrating cells. These results indicate that DFF45 is essential during normal apoptosis.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Div Pathol, Cincinnati, OH 45229 USA	University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Xu, M (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA.		zhang, jianhua/D-3404-2009	Zhang, Jianhua/0000-0002-2128-9574	NIDA NIH HHS [DA11005, DA11284] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA011284, R29DA011005] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; Cory S, 1998, P NATL ACAD SCI USA, V95, P12077, DOI 10.1073/pnas.95.21.12077; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Sambrook J., 2002, MOL CLONING LAB MANU; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	54	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37450	37454		10.1074/jbc.274.52.37450	http://dx.doi.org/10.1074/jbc.274.52.37450			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601318	hybrid			2022-12-25	WOS:000084382700089
J	Macho, A; Calzado, MA; Jimenez-Reina, L; Ceballos, E; Leon, J; Munoz, E				Macho, A; Calzado, MA; Jimenez-Reina, L; Ceballos, E; Leon, J; Munoz, E			Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms	ONCOGENE			English	Article						Tat; apoptosis; Bcr-abl; CPP32; mitochondria	MITOCHONDRIAL-PERMEABILITY-TRANSITION; HIV-INFECTED PERSONS; CERAMIDE-INDUCED APOPTOSIS; NF-KAPPA-B; T-CELLS; CYTOCHROME-C; TAT PROTEIN; PROGRAMMED DEATH; LYMPH-NODES; ACTIVATION	The effects of HIV-1 Tat protein on mitochondria membrane permeability and apoptosis were analysed in lymphoid cells. In this report we show that stable-transfected HIV-Tat cells are primed to undergo apoptosis upon serum withdrawal. This effect was observed in both the Jhan T cell line and the K562 cells, the latter expressing the bcr-abl chimeric gene, which confers resistance to apoptosis induced by different stimuli. Using a cytofluorimetric approach we have determined that serum withdrawal induces a disruption of the transmembrane mitochondrial potential (Delta psi(m)) followed bq an increase of reactive oxygen species (ROS) and the subsequent DNA nuclear loss in K562-Tat cells but not in the K562-pcDNA cell line. These pre-apoptotic events were associated with the cleavage of the caspase-3, while the expression of Bcl-2, Bcl-X-L and Bas proteins was not affected by the presence of Tat, Regardless of the steady state of the Bar protein, we found that in both K562 and K562-Tat cells, this protein is located in the nucleus, but after serum withdrawal its localization was mainly in the cytoplasm, The activity of caspase-3 detected in K562-Tat cells after serum withdrawal paralleled with the mitochondria permeability transition. Nevertheless, in Jhan-Tat cells the inhibition of this caspase with the specific inhibitor, z-DEVD-cmk, did not affect the disruption of the mitochondria potential induced by serum withdrawal. Interestingly, ae found that HIV-Tat protein accumulates at the mitochondria in the K562-Tat cells cultured under low serum conditions, and this mitochondrial localization correlated with the Delta psi(m) disruption detected in these cells. In addition, HIV-Tat protein synergies with protoporphyrin IX (PPIX), a ligand of the mitochondrial benzodiazepine receptor, in the induction of apoptosis in both Jhan and K562 cells. Thus, HIV-1 Tat protein may induce apoptosis by a mechanism that involves mitochondrial PT and may contribute to the lymphocyte depletion seen in AIDS patients.	Univ Cordoba, Fac Med, Dept Fisiol & Inmunol, E-14071 Cordoba, Spain	Universidad de Cordoba	Munoz, E (corresponding author), Univ Cordoba, Fac Med, Dept Fisiol & Inmunol, Avda Menendez Pidal S-N, E-14071 Cordoba, Spain.		Munoz, Eduardo/I-5225-2012; Quirós, Antonio Macho/H-1403-2012; Calzado, Marco A./S-2295-2019; Leon, Javier/K-4615-2014; Calzado, Marco/E-9046-2016	Munoz, Eduardo/0000-0001-8478-5842; Quirós, Antonio Macho/0000-0002-9294-8709; Calzado, Marco A./0000-0002-5338-535X; Calzado, Marco/0000-0002-5338-535X; Jimenez Reina, Luis/0000-0003-4434-7308; Leon, Javier/0000-0001-5803-0112				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gougeon ML, 1996, J IMMUNOL, V156, P3509; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Herbein G, 1998, J VIROL, V72, P660, DOI 10.1128/JVI.72.1.660-670.1998; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kim CN, 1997, CANCER RES, V57, P3115; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; LEWIS DE, 1994, J IMMUNOL, V153, P412; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Macho A, 1998, CELL GROWTH DIFFER, V9, P277; MACHO A, 1995, BLOOD, V86, P2481; Macho A, 1997, J IMMUNOL, V158, P4612; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCloskey TW, 1997, J IMMUNOL, V158, P1014; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MEYAARD L, 1994, J CLIN INVEST, V93, P982, DOI 10.1172/JCI117105; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Munoz E, 1997, BIOCHEM J, V325, P23, DOI 10.1042/bj3250023; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Nishita M, 1998, EXP CELL RES, V244, P357, DOI 10.1006/excr.1998.4203; Patki AH, 1996, CELL IMMUNOL, V169, P40, DOI 10.1006/cimm.1996.0088; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; ROTHWELL NJ, 1983, BIOSCIENCE REP, V3, P217, DOI 10.1007/BF01122453; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Sastry KJ, 1996, ONCOGENE, V13, P487; Slater AFG, 1996, CELL DEATH DIFFER, V3, P57; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tuosto L, 1995, EUR J IMMUNOL, V25, P2907, DOI 10.1002/eji.1830251030; Wadia JS, 1998, J NEUROSCI, V18, P932; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zauli G, 1996, J IMMUNOL, V157, P2216; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	66	57	57	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7543	7551		10.1038/sj.onc.1203095	http://dx.doi.org/10.1038/sj.onc.1203095			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602513				2022-12-25	WOS:000084119600015
J	Kaji, T; Yamada, A; Miyajima, S; Yamamoto, C; Fujiwara, Y; Wight, TN; Kinsella, MG				Kaji, T; Yamada, A; Miyajima, S; Yamamoto, C; Fujiwara, Y; Wight, TN; Kinsella, MG			Cell density-dependent regulation of proteoglycan synthesis by transforming growth factor-beta(1) in cultured bovine aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; SMALL INTERSTITIAL PROTEOGLYCANS; FACTOR-BETA; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ARTERIAL PROTEOGLYCANS; MOLECULAR-WEIGHT; CORE PROTEINS; DNA-SYNTHESIS	The regulation of vascular endothelial cell behavior during angiogenesis and in disease by transforming growth factor-beta(1) (TGF-beta(1)) is complex, but it clearly involves growth factor-induced changes in extracellular matrix synthesis. Proteoglycans (PGs) synthesized by endothelial cells contribute to the formation of the vascular extracellular matrix and also influence cellular proliferation and migration. Since the effects of TGF-beta(1) on vascular smooth muscle cell growth are dependent on cell density, it is possible that TGF-beta(1) also directs different patterns of PG synthesis in endothelial cells at different cell densities. In the present study, dense and sparse cultures of bovine aortic endothelial cells were metabolically labeled with [H-3]glucosamine, [S-35]sulfate, or S-35-labeled amino acids in the presence of TGF-beta(1). The labeled PGs were characterized by DEAE-Sephacel ion exchange chromatography and Sepharose CL-4B molecular sieve chromatography, The glycosaminoglycan M-r and composition were analyzed by Sepharose CL-6B chromatography, and the core protein M-r was analyzed by SDS-polyacrylamide gel electrophoresis, before and after digestion with papain, heparitinase, or chondroitin ABC lyase. These experiments indicate that the effect of TGF-beta(1) on vascular endothelial cell PG synthesis is dependent on cell density. Specifically, TGF-beta(1) induced an accumulation of small chondroitin/dermatan sulfate PGs (CS/DSPGs) with core proteins of similar to 50 kDa in the medium of both dense and sparse cultures, but a cell layer-associated heparan sulfate PG with a core protein size of similar to 400 kDa accumulated only in dense cultures. Moreover, only in the dense cell cultures did TGF-beta(1) cause CS/DSPG hydrodynamic size to increase, which was due to the synthesis of CS/DSPGs with longer glycosaminoglycan chains. The heparan sulfate PG and CS/DSPG core proteins were identified as perlecan and biglycan, respectively, by Western blot analysis. The present data suggest that TGF-beta(1) promotes the synthesis of both perlecan and biglycan when endothelial cell density is high, whereas only biglycan synthesis is stimulated when the cell density is low. Furthermore, glycosaminoglycan chains are elongated only in biglycan synthesized by the cells at a high cell density.	Hokuriku Univ, Fac Pharmaceut Sci, Dept Environm Hlth, Kanazawa, Ishikawa 9201181, Japan; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	Hokuriku University; University of Washington; University of Washington Seattle	Kaji, T (corresponding author), Hokuriku Univ, Fac Pharmaceut Sci, Dept Environm Hlth, Ho 3 Kanagawa Machi, Kanazawa, Ishikawa 9201181, Japan.		Fujiwara, Yasuyuki/AAB-8775-2020	Fujiwara, Yasuyuki/0000-0003-0028-0658				ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; ASUNDI V, 1990, EUR J CELL BIOL, V52, P98; AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BERENSON GS, 1984, EXP MOL PATHOL, V41, P267, DOI 10.1016/0014-4800(84)90043-1; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; CAMEJO G, 1980, ATHEROSCLEROSIS, V36, P55, DOI 10.1016/0021-9150(80)90198-7; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287, DOI 10.1073/pnas.84.15.5287; CHEN JK, 1991, IN VITRO CELL DEV B, V27, P6; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DODGE GR, 1990, J BIOL CHEM, V265, P18023; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; GILL PJ, 1981, BIOCHEM J, V194, P299, DOI 10.1042/bj1940299; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GUITERREZ P, 1997, CARDIOVASC PATHOL, V6, P271; HEIMER R, 1995, J MOL CELL CARDIOL, V27, P2191, DOI 10.1016/S0022-2828(95)91479-X; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KAPOOR R, 1981, BIOCHEM J, V197, P259, DOI 10.1042/bj1970259; KINSELLA MG, 1986, J CELL BIOL, V102, P679, DOI 10.1083/jcb.102.3.679; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KISSANE JM, 1958, J BIOL CHEM, V233, P184; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MORITA H, 1990, BIOCHEM J, V265, P61, DOI 10.1042/bj2650061; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; REGISTER TC, 1990, CONNECT TISSUE RES, V25, P35, DOI 10.3109/03008209009009811; ROBERTS AB, 1989, AM REV RESPIR DIS, V140, P1126, DOI 10.1164/ajrccm/140.4.1126; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; ROWE HA, 1985, ARTERIOSCLEROSIS, V5, P101, DOI 10.1161/01.ATV.5.1.101; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAKU T, 1989, J BIOL CHEM, V264, P3514; SALISBURY BGJ, 1985, AM J PATHOL, V120, P6; SALISBURY BGJ, 1981, J BIOL CHEM, V256, P8050; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Saxena Uday, 1994, Current Opinion in Lipidology, V5, P316, DOI 10.1097/00041433-199410000-00002; SCHMIDT A, 1982, EUR J BIOCHEM, V125, P95, DOI 10.1111/j.1432-1033.1982.tb06655.x; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; SILVERSTEIN JJ, 1987, SEMIN THROMB HEMOST, V13, P504; WAGNER WD, 1983, J BIOL CHEM, V258, P1136; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WASTESON A, 1973, BIOCHEM J, V136, P1069, DOI 10.1042/bj1361069; Weiser MCM, 1997, MOL BIOL CELL, V8, P999, DOI 10.1091/mbc.8.6.999; Weiser MCM, 1996, MATRIX BIOL, V15, P331, DOI 10.1016/S0945-053X(96)90136-5; Wight T N, 1980, Prog Hemost Thromb, V5, P1; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YLAHERTTUALA S, 1986, LAB INVEST, V54, P402	63	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1463	1470		10.1074/jbc.275.2.1463	http://dx.doi.org/10.1074/jbc.275.2.1463			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625699	hybrid			2022-12-25	WOS:000084836600103
J	Pei, L				Pei, L			Phosphorylation modulates the function of the vasoactive intestinal polypeptide receptor transcriptional repressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; REPLICATION FACTOR-C; THYROID-HORMONE RECEPTOR; BINDING-PROTEIN; RESPONSIVE ELEMENT; SOMATOSTATIN GENE; MOLECULAR-CLONING; DNA-LIGASE; T-ANTIGEN; EXPRESSION	The transcriptional repressor for rat vasoactive intestinal polypeptide receptor 1 (VIPR-RP) is a recently isolated transcription factor. In this study, we have characterized the functional domains of VIPR-RP and the importance of phosphorylation on VIPR-RP function. Using various regions of VIPR-RP in gel mobility shift assays, we show that the amino acid sequences between positions 367 and 475 play an essential role for VIPR-RP DNA binding. Transient transfection of fusion constructs containing GAL4 DNA binding domain and different parts of VTPR-RP indicated that there are two separate transcriptional repression domains in VIPR-RP, located between amino acids 50 and 101 and between 469 and 527. We demonstrated that VIPR-RP is phosphorylated in vitro by casein kinase II on Ser-69/71 and Thr-110, and by cAMP-dependent kinase on Ser-245/361. Furthermore, by site-directed mutagenesis, we show that phosphorylation of the casein kinase II sites potentiates VIPR-RP transcriptional repression activity by enhancing its nuclear translocation, and that phosphorylation by cAMP-dependent kinase inhibits VIPR-RP transcriptional repression function without affecting its subcellular localization. These observations suggest that phosphorylation plays an important role in regulating VIPR-RP function.	Univ Calif Los Angeles, Cedars Sinai Res Inst, Sch Med, Div Endocrinol & Metab, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Cedars Sinai Med Ctr, Div Endocrinol & Metab, 8700 Beverly Blvd,D3066, Los Angeles, CA 90048 USA.				NIDDK NIH HHS [DK-02346] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HIGG EA, 1985, EMBO J, V4, P2801; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JIN WD, 1994, MOL ENDOCRINOL, V8, P1377, DOI 10.1210/me.8.10.1377; KALDERON D, 1984, NATURE, V311, P109; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; LAUER G, 1991, J BACTERIOL, V173, P5047, DOI 10.1128/jb.173.16.5047-5053.1991; LU Y, 1993, BIOCHEM BIOPH RES CO, V193, P779, DOI 10.1006/bbrc.1993.1693; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MCGEHEE RE, 1995, MOL ENDOCRINOL, V9, P487, DOI 10.1210/me.9.4.487; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Pei L, 1997, REGUL PEPTIDES, V71, P153, DOI 10.1016/S0167-0115(97)01012-4; PEI L, 1995, BIOCHEM J, V308, P719, DOI 10.1042/bj3080719; Pei L, 1998, J BIOL CHEM, V273, P19902, DOI 10.1074/jbc.273.31.19902; Pei L, 1996, J BIOL CHEM, V271, P20879; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SHARK KB, 1992, FEMS MICROBIOL LETT, V96, P19, DOI 10.1111/j.1574-6968.1992.tb05387.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; TONE Y, 1994, J BIOL CHEM, V269, P31157; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662	41	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1176	1182		10.1074/jbc.275.2.1176	http://dx.doi.org/10.1074/jbc.275.2.1176			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625661	hybrid			2022-12-25	WOS:000084836600065
J	Borgens, RB; Shi, R				Borgens, RB; Shi, R			Immediate recovery from spinal cord injury through molecular repair of nerve membranes with polyethylene glycol	FASEB JOURNAL			English	Article						nerve fusion; nerve repair; neurotrauma	APPLIED ELECTRIC-FIELDS; FUNCTIONAL RECOVERY; GUINEA-PIGS; FUSION; HEMISECTION; MECHANISM; MODEL	A brief application of the hydrophilic polymer polyethylene glycol (PEG) swiftly repairs nerve membrane damage associated with severe spinal cord injury in adult guinea pigs. A 2 min application of PEG to a standardized compression injury to the cord immediately reversed the loss of nerve impulse conduction through the injury in all treated animals while nerve impulse conduction remained absent in all sham-treated guinea pigs. Physiological recovery was associated with a significant recovery of a quantifiable spinal cord dependent behavior in only PEG-treated animals. The application of PEG could be delayed for similar to 8 h without adversely affecting physiological and behavioral recovery which continued to improve for up to 1 month after PEG treatment.-Borgens, R. B., Shi, R. Immediate recovery from spinal cord injury through molecular repair of nerve membranes with polyethylene glycol.	Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Borgens, RB (corresponding author), Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, W Lafayette, IN 47907 USA.							AHKONG QF, 1987, J CELL SCI, V88, P389; ALDEWINCKEL TL, 1982, BIOCHIM BIOPHYS ACTA, V689, P548; ASANO T, 1995, J NEUROTRAUM, V12, P993; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BLIGHT AR, 1990, J COMP NEUOL, V60, P446; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; FEHLINGS M, 1995, EXP NEUROL, V132, P123; Griffin John W., 1995, P375; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; Honmou Osamu, 1995, P480; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; MASSENBURG D, 1993, BIOCHEMISTRY-US, V32, P9172, DOI 10.1021/bi00086a024; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; PONTECORVO G, 1975, SOMAT CELL GENET, V1, P397, DOI 10.1007/BF01538671; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; SHI R, 1997, SOC NEUR ABSTR, V108, P16; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; THIERAULT E, 1988, J NEUROPHYSIOL, V60, P446; Tilcock C PS, 1979, BIOCHEMISTRY-US, V688, P645; YAWO H, 1985, J NEUROSCI, V5, P1626; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	39	94	99	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					27	35		10.1096/fasebj.14.1.27	http://dx.doi.org/10.1096/fasebj.14.1.27			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627277				2022-12-25	WOS:000084784700005
J	Li, ZG; Kim, SH; Higgins, JMG; Brenner, MB; Sacks, DB				Li, ZG; Kim, SH; Higgins, JMG; Brenner, MB; Sacks, DB			IQGAP1 and calmodulin modulate E-cadherin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; CGS 9343B; PROTEIN; ACTIN; CDC42; BINDING; COMPLEX; ALPHA(E)BETA(7); IDENTIFICATION; CYTOKINESIS	Ca2+-dependent cell-cell adhesion is mediated by the cadherin family of transmembrane proteins. Adhesion is achieved by homophilic interaction of the extracellular domains of cadherins on adjacent cells, with the cytoplasmic regions serving to couple the complex to the cytoskeleton. IQGAP1, a novel RasGAP-related protein that interacts with the cytoskeleton, binds to actin, members of the Rho family, and E-cadherin, Calmodulin binds to IQGAP1 and regulates its association with Cdc42 and actin. Here we demonstrate competition between calmodulin and E-cadherin for binding to IQGAP1 both in vitro and in a normal cellular milieu. Immunocytochemical analysis in MCF-7 (E-cadherin positive) and MDA-MB-231 (E-cadherin negative) epithelial cells revealed that E-cadherin is required for accumulation of IQGAP1 at cell-cell junctions. The cell-permeable calmodulin antagonist CGS9343B significantly increased IQGAP1 at areas of MCF-7 cell-cell contact, with a concomitant decrease in the amount of E-cadherin at cell-cell junctions. Analysis of E-cadherin function revealed that CGS9343B significantly decreased homophilic E-cadherin adhesion, On the basis of these data, we propose that disruption of the binding of calmodulin to IQGAP1 enhances the association of IQGAP1 with components of the cadherin-catenin complex at cell-cell junctions, resulting in impaired E-cadherin function.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Tthorn 530,75 Francis St, Boston, MA 02115 USA.			Sacks, David/0000-0003-3100-0735; Higgins, Jonathan/0000-0001-6622-8268	NCI NIH HHS [CA 75205] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA075205, R01CA075205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APODACA G, 1994, J BIOL CHEM, V269, P19005; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Cohen P, 1988, CALMODULIN; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; GEHM BD, 1991, BIOCHEMISTRY-US, V30, P11302, DOI 10.1021/bi00111a016; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; MOTOHASHI N, 1991, ANTICANCER RES, V11, P1125; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; Osawa M, 1998, J MOL BIOL, V276, P165, DOI 10.1006/jmbi.1997.1524; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; REDDY GPV, 1992, BIOCHEMISTRY-US, V31, P10426, DOI 10.1021/bi00158a002; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V200, P1754, DOI 10.1006/bbrc.1994.1656; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHASHKIN P, 1995, J BIOL CHEM, V270, P25613, DOI 10.1074/jbc.270.43.25613; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA T, 1982, MOL PHARMACOL, V22, P403; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Tolosa E, 1996, J IMMUNOL METHODS, V192, P165, DOI 10.1016/0022-1759(96)00042-7; VANDONSELAAR M, 1994, NAT STRUCT BIOL, V1, P795, DOI 10.1038/nsb1194-795; Weiss B, 1980, Ann N Y Acad Sci, V356, P319, DOI 10.1111/j.1749-6632.1980.tb29621.x; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517	34	119	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37885	37892		10.1074/jbc.274.53.37885	http://dx.doi.org/10.1074/jbc.274.53.37885			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608854	hybrid			2022-12-25	WOS:000084528000054
J	Saavedra, HI; Fukasawa, K; Conn, CW; Stambrook, PJ				Saavedra, HI; Fukasawa, K; Conn, CW; Stambrook, PJ			MAPK mediates RAS-induced chromosome instability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; SPINDLE ASSEMBLY CHECKPOINT; XENOPUS-OOCYTE MATURATION; GTP-BINDING PROTEINS; WILD-TYPE P53; HA-RAS; GENOMIC INSTABILITY; GENE AMPLIFICATION; SIGNALING PATHWAY	The generation of micronuclei is a reflection of DNA damage, defective mitosis, and loss of genetic material, The involvement of the MAPK pathway in mediating v-ras-induced micronuclei in NIH 3T3 cells was examined by inhibiting MAPK activation, Conversely, the MAPK pathway was constitutively activated by infecting cells with a v-mos retrovirus, Micronucleus formation was inhibited by the MAPK kinase inhibitors PD98059 and U0126, but not by wortmannin, an inhibitor of the Ras/phosphatidylinositol 3-kinase pathway. Transduction of cells with v-mos resulted in an increase in micronucleus formation, also consistent with the involvement of the MAPK pathway. Staining with the anti-centromeric CREST antibody revealed that instability induced by constitutive activation of MAPK is due predominantly to aberrant mitotic segregation, since most of the micronuclei were CREST-positive, reflective of lost chromosomes. A significant fraction of the micronuclei were CREST-negative, reflective of lost acentric chromosome fragments. Some of the instability observed was due to mitotic events, consistent with the increased formation of bi-nucleated cells, which result from perturbations of the mitotic spindle and failure to undergo cytokinesis, This chromosome instability, therefore, is a consequence of mitotic aberrations, mediated by the MAPK pathway, including centrosome amplification and formation of mitotic chromosome bridges.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Stambrook, PJ (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA.				NATIONAL CANCER INSTITUTE [R01CA065769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER; NCI NIH HHS [CA65769] Funding Source: Medline; NIEHS NIH HHS [ES07250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARZYNKIEWICZ Z, 1997, CURRENT PROTOCOLS CY, V1; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; DEGRASSI F, 1988, MUTAT RES, V203, P339, DOI 10.1016/0165-1161(88)90030-1; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; FENECH M, 1989, MUTAGENESIS, V4, P98, DOI 10.1093/mutage/4.2.98; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; FUKASAWA K, 1995, P NATL ACAD SCI USA, V92, P3430, DOI 10.1073/pnas.92.8.3430; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; GUDI R, 1990, MUTAT RES, V234, P263, DOI 10.1016/0165-1161(90)90038-P; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAGAG N, 1990, ONCOGENE, V5, P1481; Harlow E., 1988, ANTIBODIES LAB MANUA; HENNIG UGG, 1988, MUTAT RES, V203, P405, DOI 10.1016/0165-1161(88)90013-1; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ICHIKAWA T, 1990, CANCER RES, V50, P6349; ICHIKAWA T, 1991, PROSTATE, V18, P163, DOI 10.1002/pros.2990180209; JESSUS C, 1991, DEVELOPMENT, V111, P813; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOONG AC, 1994, CANCER RES, V54, P5273; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LARIN Z, 1994, HUM MOL GENET, V3, P689, DOI 10.1093/hmg/3.5.689; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu HS, 1998, BRIT J CANCER, V77, P1777, DOI 10.1038/bjc.1998.296; LIU HS, 1992, CANCER RES, V52, P983; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILLER BM, 1993, MUTAGENESIS, V8, P35, DOI 10.1093/mutage/8.1.35; MILLER BM, 1991, MUTAGENESIS, V6, P297, DOI 10.1093/mutage/6.4.297; MILLER BM, 1990, MUTAGENESIS, V5, P411, DOI 10.1093/mutage/5.4.411; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1997, BIOCHIM BIOPHYS ACTA, V1333, pF86; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NUSSE M, 1994, METHOD CELL BIOL, V42, P149; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUSSO CA, 1995, CANCER RES, V55, P1122; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; SCHRIEVERSCHWEMMER G, 1994, MUTAGENESIS, V9, P333, DOI 10.1093/mutage/9.4.333; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; THOMSON EJ, 1988, MUTAGENESIS, V3, P415, DOI 10.1093/mutage/3.5.415; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; VANDENBERG S, 1991, MOL CARCINOGEN, V4, P460, DOI 10.1002/mc.2940040609; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; WANI MA, 1994, CANCER RES, V54, P2504; Wani MA, 1997, SOMAT CELL MOLEC GEN, V23, P123, DOI 10.1007/BF02679971; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WOESSNER RD, 1990, CANCER RES, V50, P2901; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	87	83	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38083	38090		10.1074/jbc.274.53.38083	http://dx.doi.org/10.1074/jbc.274.53.38083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608877	hybrid			2022-12-25	WOS:000084528000077
J	Hishikawa, K; Oemar, BS; Tanner, FC; Nakaki, T; Luscher, TF; Fujii, T				Hishikawa, K; Oemar, BS; Tanner, FC; Nakaki, T; Luscher, TF; Fujii, T			Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; IMMEDIATE EARLY GENE; ALPHA ANTAGONIST; IN-VIVO; EXPRESSION; INHIBITION; FAMILY; TUMORS; DEATH; BCL-2	Connective tissue growth factor (CTGF) is a member of an emerging CCN gene family that is implicated in various diseases associated with fibro-proliferative disorder including scleroderma and atherosclerosis. The function of CTGF in human cancer is largely unknown. We now show that CTGF induces apoptosis in the human breast cancer cell line MCF-7. CTGF mRNA was completely absent in MCF-7 but strongly induced by treatment with transforming growth factor beta (TGF-beta). TGF-beta by itself induced apoptosis in MCF-7, and this effect was reversed by co-treatment with CTGF antisense oligonucleotide. Overexpression of CTGF gene in transiently transfected MCF-7 cells significantly augmented apoptosis. Moreover, recombinant CTGF protein significantly enhanced apoptosis in MCF-7 cells as evaluated by DNA fragmentation, Tdt-mediated dUTP biotin nick end-labeling staining, flow cytometry analysis, and nuclear staining using Hoechst 33258. Finally, recombinant CTGF showed no effect on Bar protein expression but significantly reduced Bcl2 protein expression. Taken together, these results suggest that CTGF is a major inducer of apoptosis in the human breast cancer cell line MCF-7 and that TGF-beta-induced apoptosis in MCF-7 cells is mediated, in part, by CTGF.	Teikyo Univ, Sch Med, Dept Pharmacol, Itabashi Ku, Tokyo 1738605, Japan; Univ Zurich, Inst Physiol, Zurich, Switzerland; Univ Zurich Hosp, Dept Cardiol, CH-8091 Zurich, Switzerland	Teikyo University; University of Zurich; University of Zurich; University Zurich Hospital	Hishikawa, K (corresponding author), Teikyo Univ, Sch Med, Dept Pharmacol, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.		Hishikawa, Keiichi/A-8661-2011; Nakaki, Toshio/C-4832-2009	Oemar, Barry/0000-0003-1996-5817				Antoshina Elena, 1997, In Vitro Cellular and Developmental Biology Animal, V33, P212; Babic AM, 1999, MOL CELL BIOL, V19, P2958; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CHEN H, 1996, J CELL BIOCHEM, V61, P19; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; Eck KM, 1998, BRIT J CANCER, V77, P2129, DOI 10.1038/bjc.1998.357; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; HISHIKAWA K, 1995, FEBS LETT, V360, P291, DOI 10.1016/0014-5793(95)00124-R; Hishikawa K, 1997, CIRCULATION, V96, P3610; Hu SM, 1998, J BIOL CHEM, V273, P29648, DOI 10.1074/jbc.273.45.29648; Igarashi A, 1998, J CUTAN PATHOL, V25, P143, DOI 10.1111/j.1600-0560.1998.tb01706.x; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KHOSLA S, 1994, ENDOCRINOLOGY, V135, P1887, DOI 10.1210/en.135.5.1887; Kubo M, 1998, BRIT J DERMATOL, V139, P192; Kurokawa H, 1999, ONCOL REP, V6, P33; KYPRIANOU N, 1991, CANCER RES, V51, P162; NAUMOVSKI L, 1994, BLOOD, V83, P2261; Nishida T, 1998, BIOCHEM BIOPH RES CO, V247, P905, DOI 10.1006/bbrc.1998.8895; Noviello C, 1996, CLIN CANCER RES, V2, P1601; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Oemar BS, 1997, CIRCULATION, V95, P831; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PERRY RR, 1995, BRIT J CANCER, V72, P1441, DOI 10.1038/bjc.1995.527; PIETENPOL JA, 1994, CANCER RES, V54, P3714; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Sathyamoorthy N, 1998, ANTICANCER RES, V18, P2449; Scholz G, 1996, MOL CELL BIOL, V16, P481; Shimo T, 1998, J BIOCHEM-TOKYO, V124, P130, DOI 10.1093/oxfordjournals.jbchem.a022071; Tamatani T, 1998, BIOCHEM BIOPH RES CO, V251, P748, DOI 10.1006/bbrc.1998.9543; Tatsuta M, 1998, BRIT J CANCER, V78, P857, DOI 10.1038/bjc.1998.593; Theile M, 1996, ONCOGENE, V13, P677; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; TSUKADA T, 1995, BIOCHEM BIOPH RES CO, V210, P1076, DOI 10.1006/bbrc.1995.1766; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	47	138	162	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37461	37466		10.1074/jbc.274.52.37461	http://dx.doi.org/10.1074/jbc.274.52.37461			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601320	hybrid			2022-12-25	WOS:000084382700091
J	Wang, YR; Windh, RT; Chen, CA; Manning, DR				Wang, YR; Windh, RT; Chen, CA; Manning, DR			N-myristoylation and beta gamma play roles beyond Anchorage in the palmitoylation of the G protein alpha(o) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACHMENT; LIPID MODIFICATIONS; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; ADP-RIBOSYLATION; HORMONE RECEPTOR; PERTUSSIS TOXIN; FUSION PROTEIN	Many of the alpha subunits of heterotrimeric GTP-binding regulatory proteins (G proteins) are palmitoylated, a modification proposed to play a key role in the stable anchorage of the subunits to the plasma membrane. Palmitoylation of alpha subunits from the G(i) family is preceded by N-myristoylation, which alone or together with beta gamma probably supports a reversible interaction of the alpha subunit with membrane as a prerequisite to the eventual incorporation of palmitate, Previous studies have not addressed, however, the question of whether membrane association alone, carried out through N-myristoylation, interaction with beta gamma, or other events, is sufficient for palmitoylation, We report here for alpha(o) that it is not. We found that N-myristoylation is required for palmitoylation at least in part because it supports events subsequent to membrane attachment. Mutants of alpha(o) designed to target the subunit to membrane without an N-myristoyl group are unable to be palmitoylated as evaluated by incorporation of [H-3]palmitate. Mutants of alpha(o) unable to interact normally with beta gamma yet still attach to membrane demonstrate that beta gamma, in contrast, is not required for palmitoylation. beta gamma becomes necessary, however, when the N-myristoyl group is absent. Our results suggest that N-myristoylation and beta gamma, while almost certainly relevant to the reversible interaction of alpha(o) with membrane, also play at least partly overlapping, post-anchorage roles in palmitoylation.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Manning, DR (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	manning@pharm.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53156] Funding Source: Medline; NIMH NIH HHS [MH14654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CARTY DJ, 1994, METHOD ENZYMOL, V237, P63; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN CA, 1999, CRC METH SIG TRANS, P99; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DENKER BM, 1992, J BIOL CHEM, V267, P6272; Drmota T, 1998, J BIOL CHEM, V273, P24000, DOI 10.1074/jbc.273.37.24000; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; Galbiati F, 1996, BIOCHEM J, V313, P717, DOI 10.1042/bj3130717; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; HALLAK H, 1994, J BIOL CHEM, V269, P4571; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; LEE E, 1992, J BIOL CHEM, V267, P1212; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; NEER EJ, 1984, J BIOL CHEM, V259, P4222; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Song KS, 1997, CELL MOL BIOL, V43, P293; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TSAI SC, 1984, J BIOL CHEM, V259, P5320; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351	62	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37435	37442		10.1074/jbc.274.52.37435	http://dx.doi.org/10.1074/jbc.274.52.37435			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601316	hybrid			2022-12-25	WOS:000084382700087
J	Liu, QQ; Choe, WC; Campbell, JL				Liu, QQ; Choe, WC; Campbell, JL			Identification of the Xenopus laevis homolog of Saccharomyces cerevisiae DNA2 and its role in DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE REGULATION; CDC6 PROTEIN; YEAST; HELICASE; EXONUCLEASE; ENCODES; GENE; ENDONUCLEASE; BINDING	The DNA2 gene of Saccharomyces cerevisiae is essential for growth and appears to be required for a late stage of chromosomal DNA replication. S. cerevisiae Dna2p (ScDna2p) is a DNA helicase and also a nuclease. We have cloned and sequenced the homologous gene from Xenopus (Xenopus Dnaa), Xenopus Dna2p (XDna2p) is 32% identical to ScDna2p, and the similarity extends over the entire length, including but not limited to the five conserved helicase motifs, XDna2p is even more closely related (60% identical) to a partial human cDNA. The Xenopus Dnaa (XDna2) gene was able to complement an S, cerevisiae dna2-1 mutant strain for growth at the nonpermissive temperature, suggesting that XDna2p is a functional as well as a structural homolog of the yeast protein. Recombinant XDna2p was expressed in insect cells and purified. Like the ScDna2p purified from yeast, it is a single-stranded DNA endonuclease and a DNA-dependent ATPase, suggesting that both of these activities are part of the essential function of Dna2p. However, unlike ScDna2p from yeast, recombinant XDna2p showed no DNA helicase activity. When XDna2 was immunodepleted from interphase egg extracts, chromosomal DNA replication was almost completely inhibited. From the size of the residually synthesized DNA from the XDna2-depleted egg extracts, it seems that initiation of DNA replication may be impaired, This interpretation is also supported by the normal DNA replication of M13 single-stranded DNA in the XDna2-depleted egg extracts.	CALTECH, Braun Lab, Pasadena, CA 91125 USA	California Institute of Technology	Campbell, JL (corresponding author), CALTECH, Braun Lab, Pasadena, CA 91125 USA.				NIGMS NIH HHS [GM25508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Braguglia D, 1998, J MOL BIOL, V281, P631, DOI 10.1006/jmbi.1998.1973; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1995, METHOD ENZYMOL, V262, P108; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; Formosa T, 1999, GENETICS, V151, P1459; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Gould KL, 1998, GENETICS, V149, P1221; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kornberg A., 1992, DNA REPLICATION; KUO CL, 1983, P NATL ACAD SCI-BIOL, V80, P6465, DOI 10.1073/pnas.80.21.6465; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; MILES J, 1992, P NATL ACAD SCI USA, V89, P1276, DOI 10.1073/pnas.89.4.1276; MILES J, 1992, MOL CELL BIOL, V12, P5274; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263	46	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1615	1624		10.1074/jbc.275.3.1615	http://dx.doi.org/10.1074/jbc.275.3.1615			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636853	hybrid			2022-12-25	WOS:000084940000016
J	Xia, Y; McMillin, JB; Lewis, A; Moore, M; Zhu, WG; Williams, RS; Kellems, RE				Xia, Y; McMillin, JB; Lewis, A; Moore, M; Zhu, WG; Williams, RS; Kellems, RE			Electrical stimulation of neonatal cardiac myocytes activates the NFAT3 and GATA4 pathways and up-regulates the adenylosuccinate synthetase 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; DEPENDENT TRANSCRIPTIONAL PATHWAY; SPONTANEOUSLY HYPERTENSIVE RATS; MYOCARDIAL-CELL HYPERTROPHY; THYROID-HORMONE; MESSENGER-RNA; ALPHA-ACTIN; VENTRICULAR MYOCYTES; MOLECULAR-CLONING; C-JUN	Electrically stimulated pacing of cultured cardiomyocytes serves as an experimentally convenient and physiologically relevant in vitro model of cardiac hypertrophy, Electrical pacing triggers a signaling cascade that results in the activation of the muscle-specific Adss1 gene and the repression of the nonmuscle Adss2 isoform. Activation of the Adss1 gene involves the calcineurin-mediated dephosphorylation of NFAT3, allowing its translocation to the nucleus, where it can directly participate in Adss1 gene activation. Mutational studies show that an NFAT binding site located in the Adss1 5'-flanking region is essential for this activation. Electrical pacing also results in the increased synthesis of GATA4, another critical cardiac transcription factor required for Adss1 gene expression. MEF2C also produces transactivation of the Adss1 gene reporter in control and paced cardiac myocytes. Using the Adss1 gene as a model, these studies are the first to demonstrate that electrical pacing activates the calcineurin/NFAT3 and GATA4 pathways as a means of regulating cardiac gene expression.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol Oncol, Dallas, TX 75235 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; Baylor College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kellems, RE (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin, Houston, TX 77030 USA.	rkellems@bmb.med.uth.tmc.edu			NHLBI NIH HHS [HL38863] Funding Source: Medline; NIAMS NIH HHS [AR40849] Funding Source: Medline; NICHD NIH HHS [HD34130] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034130] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R56HD034130] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR040849, R01AR040849] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARAI H, 1988, CIRC RES, V62, P926, DOI 10.1161/01.RES.62.5.926; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; BREVET A, 1976, SCIENCE, V193, P1152, DOI 10.1126/science.959833; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DUBUS I, 1990, CIRC RES, V66, P867, DOI 10.1161/01.RES.66.3.867; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FabreSuver C, 1996, J BIOL CHEM, V271, P4646, DOI 10.1074/jbc.271.9.4646; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; GUSTAFSON TA, 1986, CIRC RES, V59, P194, DOI 10.1161/01.RES.59.2.194; GUTKOWSKA J, 1986, HYPERTENSION, V8, P137; Hogan PG, 1999, NATURE, V398, P200, DOI 10.1038/18327; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LEE HR, 1988, J BIOL CHEM, V263, P7352; Lewis AL, 1996, J BIOL CHEM, V271, P22647, DOI 10.1074/jbc.271.37.22647; Lewis AL, 1999, J BIOL CHEM, V274, P14188, DOI 10.1074/jbc.274.20.14188; Luo ZY, 1998, NAT MED, V4, P1092, DOI 10.1038/2578; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NEYSES L, 1991, BIOCHEM BIOPH RES CO, V181, P22, DOI 10.1016/S0006-291X(05)81376-2; Olson EN, 1999, CIRC RES, V84, P623, DOI 10.1161/01.RES.84.6.623; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Qin WN, 1997, J BIOL CHEM, V272, P25210, DOI 10.1074/jbc.272.40.25210; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; WAN B, 1995, J BIOL CHEM, V270, P26433, DOI 10.1074/jbc.270.44.26433; WINEGRAD S, 1990, P NATL ACAD SCI USA, V87, P2456, DOI 10.1073/pnas.87.7.2456; Xia Y, 1998, J BIOL CHEM, V273, P12593, DOI 10.1074/jbc.273.20.12593; Xia Y, 1996, J BIOL CHEM, V271, P12082, DOI 10.1074/jbc.271.20.12082; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232	46	91	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1855	1863		10.1074/jbc.275.3.1855	http://dx.doi.org/10.1074/jbc.275.3.1855			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636885	hybrid			2022-12-25	WOS:000084940000048
J	Boguslawski, G; Hale, LV; Yu, XP; Miles, RR; Onyia, JE; Santerre, RF; Chandrasekhar, S				Boguslawski, G; Hale, LV; Yu, XP; Miles, RR; Onyia, JE; Santerre, RF; Chandrasekhar, S			Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; OSTEOBLAST-LIKE CELLS; GROWTH-FACTOR-I; PARATHYROID-HORMONE; GENE-EXPRESSION; CALPHOSTIN-C; BONE; RECEPTOR; PROMOTER; MOUSE	Osteocalcin is a major noncollagenous protein component of bone extracellular matrix, synthesized and secreted exclusively by osteoblastic cells in the late stage of maturation, and is considered indicator of osteoblast differentiation. Osteocalcin expression is modulated by parathyroid hormone (PTH) and a variety of other factors. The cAMP-dependent protein kinase pathway has been shown previously to have an essential role in PTH signaling and regulation of osteocalcin expression. To determine the extent to which other pathways may also participate in osteocalcin expression, we used rat and human osteoblast-like cell lines to generate stably transfected clones in which the osteocalcin promoter was fused to a luciferase reporter gene. These clones were examined for their responsiveness to agents known to activate or interfere with protein kinase A (PKA)- and protein kinase C (PKC)-dependent pathways. We have found that forskolin, cAMP, and PTH, as well as insulin-like growth factor I (IGF-I) and basic fibroblast growth factor, all were effective in activating the osteocalcin promoter. Phorbol 12-myristate 13-acetate (PIMA) was also a strong inducer of the promoter, indicating that PKC plays a role in expression of osteocalcin. In combination with PTH or forskolin, the effect of PMA was additive to synergistic. Calphostin C, a selective inhibitor of PRC, decreased the PMA-, PTH-, and IGF-I-induced luciferase activity in a dose-dependent manner; a PKA inhibitor, H-89, also blocked the induction by PTH and IGF-I but not by PMA. We conclude that regulation of osteocalcin transcription is mediated by both PKA-dependent and PKC-dependent mechanisms and that the respective kinases reside on a linear or convergent pathway.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res,Div Endocrine, Indianapolis, IN 46285 USA	Eli Lilly	Chandrasekhar, S (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res,Div Endocrine, Indianapolis, IN 46285 USA.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chorev Michael, 1996, P305; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy Patricia, 1996, P183; Finkelstein Joel S., 1996, P993; Fitzpatrick Lorraine A., 1996, P339; GUO J, 1995, ENDOCRINOLOGY, V136, P3884, DOI 10.1210/en.136.9.3884; HEINRICHS AAJ, 1993, J CELL BIOCHEM, V53, P240, DOI 10.1002/jcb.240530309; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Jobert AS, 1997, ENDOCRINOLOGY, V138, P5282, DOI 10.1210/en.138.12.5282; Jobert AS, 1998, J CLIN INVEST, V102, P34, DOI 10.1172/JCI2918; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kudo Y, 1998, EUR J ENDOCRINOL, V138, P443, DOI 10.1530/eje.0.1380443; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; McCarthy TL, 1997, J BIOL CHEM, V272, P18132, DOI 10.1074/jbc.272.29.18132; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; NODA M, 1988, J BIOL CHEM, V263, P18574; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; Pines M, 1996, BONE, V18, P381, DOI 10.1016/8756-3282(96)00008-7; PRICE PA, 1981, J BIOL CHEM, V256, P2754; Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756-3282(97)00276-7; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; Schwartz Z, 1997, BONE, V21, P249, DOI 10.1016/S8756-3282(97)00123-3; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; STEIN GS, 1998, FRONT BIOSCI, V3, P849; SUNUHARA RK, 1996, ANN REV PHARM TOXICO, V36, P461; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; vanLeeuwen JPTM, 1996, BBA-MOL CELL RES, V1312, P55, DOI 10.1016/0167-4889(96)00016-X; Yang RJ, 1996, J BIOL CHEM, V271, P29839, DOI 10.1074/jbc.271.47.29839; YOON K, 1988, BIOCHEMISTRY-US, V27, P8521, DOI 10.1021/bi00423a003; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	37	79	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					999	1006		10.1074/jbc.275.2.999	http://dx.doi.org/10.1074/jbc.275.2.999			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625638	hybrid			2022-12-25	WOS:000084836600042
J	Casano, LM; Zapata, JM; Martin, M; Sabater, B				Casano, LM; Zapata, JM; Martin, M; Sabater, B			Chlororespiration and poising of cyclic electron transport - Plastoquinone as electron transporter between thylakoid NADH dehydrogenase and peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASTID NDH GENES; COMPLEX-I; SUPEROXIDE-DISMUTASE; CHLOROPLAST GENOME; RESPIRATORY-CHAIN; FLOWERING PLANT; BARLEY; IDENTIFICATION; EXPRESSION; TOBACCO	Polypeptides encoded by plastid ndh genes form a complex (Ndh) which could reduce plastoquinone with NADH, Through a terminal oxidase, reduced plastoquinone would be oxidized in chlororespiration, However, isolated Ndh complex has low activity with plastoquinone and no terminal oxidase has been found in chloroplasts, thus the function of Ndh complex is unknown. Alternatively, thylakoid hydroquinone peroxidase could oxidize reduced plastoquinone with H2O2, By immunoaffinity chromatography, we have purified the plastid Ndh complex of barley (Hordeum vulgare L,) to investigate the electron donor and acceptor specificity. A detergent-containing system was reconstructed with thylakoid Ndh complex and peroxidase which oxidized NADH with H2O2 in a plastoquinone-dependent process. This system and the increases of thylakoid Ndh complex and peroxidase activities under photooxidative stress suggest that the chlororespiratory process consists of the sequence of reactions catalyzed by Ndh complex, peroxidase (acting on reduced plastoquinone), superoxide dismutase, and the non-enzymic one-electron transfer from reduced iron-sulfur protein (FeSP) to O-2, When FeSP is a component of cytochrome b(6).f complex or of the same Ndh complex, O-2 may be reduced with NADH, without requirement of light. Chlororespiration consumes reactive species of oxygen and, eventually, may decrease their production by lowering O-2 concentration in chloroplasts, The common plastoquinone pool with photosynthetic electron transport suggests that chlororespiratory reactions may poise reduced and oxidized forms of the intermediates of cyclic electron transport under highly fluctuating light intensities.	Univ Alcala de Henares, Dept Biol Vegetal, Madrid 28871, Spain	Universidad de Alcala	Sabater, B (corresponding author), Univ Alcala de Henares, Dept Biol Vegetal, Madrid 28871, Spain.	bvsabater@alcala.es	Sabater, Bartolome/B-6039-2008; Casano, Leonardo M. M/H-1036-2015	Sabater, Bartolome/0000-0002-8586-1226; Casano, Leonardo M. M/0000-0002-2304-7317				Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAKER NR, 1984, CHLOROPLAST BIOGENES, P207; BENNOUN P, 1982, P NATL ACAD SCI-BIOL, V79, P4352, DOI 10.1073/pnas.79.14.4352; BENNOUN P, 1994, BBA-BIOENERGETICS, V1186, P59, DOI 10.1016/0005-2728(94)90135-X; BERGER S, 1993, PLANTA, V190, P25, DOI 10.1007/BF00195671; Biehler K, 1996, PLANT PHYSIOL, V112, P265, DOI 10.1104/pp.112.1.265; BOWLER C, 1992, ANNU REV PLANT PHYS, V43, P83, DOI 10.1146/annurev.pp.43.060192.000503; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burrows PA, 1998, EMBO J, V17, P868, DOI 10.1093/emboj/17.4.868; CASANO LM, 1994, PLANT PHYSIOL, V106, P1033, DOI 10.1104/pp.106.3.1033; Catala R, 1997, PLANT CELL PHYSIOL, V38, P1382, DOI 10.1093/oxfordjournals.pcp.a029133; COHEN AS, 1979, PLANT PHYSIOL, V64, P717, DOI 10.1104/pp.64.5.717; CUELLO J, 1995, PLANT CELL PHYSIOL, V36, P265, DOI 10.1093/oxfordjournals.pcp.a078758; DEPAMPHILIS CW, 1990, NATURE, V348, P337, DOI 10.1038/348337a0; Feild TS, 1998, PLANT PHYSIOL, V116, P1209, DOI 10.1104/pp.116.4.1209; Freyer R, 1995, PLANT MOL BIOL, V29, P679, DOI 10.1007/BF00041158; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GARAB G, 1989, PLANTA, V179, P349, DOI 10.1007/BF00391080; HABERHAUSEN G, 1994, PLANT MOL BIOL, V24, P217, DOI 10.1007/BF00040588; HEBER U, 1992, PLANT PHYSIOL, V100, P1621, DOI 10.1104/pp.100.4.1621; Kofer W, 1998, MOL GEN GENET, V258, P166, DOI 10.1007/s004380050719; Kubicki A, 1996, PLANTA, V199, P276, DOI 10.1007/BF00196569; KUONEN DR, 1986, ANAL BIOCHEM, V153, P221, DOI 10.1016/0003-2697(86)90084-9; Laloue H, 1997, PLANT PHYSIOL BIOCH, V35, P341; Martin M, 1996, PLANT CELL PHYSIOL, V37, P293, DOI 10.1093/oxfordjournals.pcp.a028945; NEWCOMB EH, 1971, PHOTOSYNTHESIS PHOTO, P173; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; Pearcy RW, 1994, PHOTOINHIBITION PHOT, P255; Quiles MJ, 1996, PLANT CELL PHYSIOL, V37, P1134, DOI 10.1093/oxfordjournals.pcp.a029064; Sazanov LA, 1996, BIOCHEM SOC T, V24, P739, DOI 10.1042/bst0240739; Sazanov LA, 1998, P NATL ACAD SCI USA, V95, P1319, DOI 10.1073/pnas.95.3.1319; Shikanai T, 1998, P NATL ACAD SCI USA, V95, P9705, DOI 10.1073/pnas.95.16.9705; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; UNO T, 1987, J BIOL CHEM, V262, P4549; WAKASUGI T, 1994, P NATL ACAD SCI USA, V91, P9794, DOI 10.1073/pnas.91.21.9794; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; Zapata JM, 1998, PHYTOCHEMISTRY, V48, P1119, DOI 10.1016/S0031-9422(98)00133-2	37	118	129	0	30	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					942	948		10.1074/jbc.275.2.942	http://dx.doi.org/10.1074/jbc.275.2.942			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625631	hybrid			2022-12-25	WOS:000084836600035
J	Gerbaud, V; Pignol, D; Loret, E; Bertrand, JA; Berland, Y; Fontecilla-Camps, JC; Canselier, JP; Gabas, N; Verdier, JM				Gerbaud, V; Pignol, D; Loret, E; Bertrand, JA; Berland, Y; Fontecilla-Camps, JC; Canselier, JP; Gabas, N; Verdier, JM			Mechanism of calcite crystal growth inhibition by the N-terminal undecapeptide of lithostathine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC STONE PROTEIN; HUMAN-SERUM-ALBUMIN; ACIDIC MACROMOLECULES; MOLECULAR-DYNAMICS; BIOMINERALIZATION; STEREOCHEMISTRY; CRYSTALLIZATION; SIMULATIONS; NUCLEATION; REFINEMENT	Pancreatic juice is supersaturated with calcium carbonate. Calcite crystals therefore may occur, obstruct pancreatic ducts, and finally cause a lithiasis. Human lithostathine, a protein synthesized by the pancreas, inhibits the growth of calcite crystals by inducing a habit modification: the rhombohedral {10 (1) over bar 4} usual habit is transformed into a needle-like habit through the {11 (2) over bar 0} crystal form. A similar observation was made with the N-terminal undecapeptide (pE(1)R(11)) of lithostathine. We therefore aimed at discovering how peptides inhibit calcium salt crystal growth. We solved the complete x-ray structure of lithostathine, including the flexible N-terminal domain, at 1.3 Angstrom. Docking studies of PE1R11 With the (10 (1) over bar 4) and (11 (2) over bar 0) faces through molecular dynamics simulation resulted in three successive steps. First, the undecapeptide progressively unfolded as it approached the calcite surface. Second, mobile lateral chains of amino acids made hydrogen bonds with the calcite surface. Last, electrostatic bonds between calcium ions and peptide bonds stabilized and anchored pE(1)R(11) on the crystal surface, pE(1)R(11)-calcite interaction was stronger with the (11 (2) over bar 0) face than with the (10 (1) over bar 4) face, confirming earlier experimental observations. Energy contributions showed that the peptide backbone governed the binding more than did the lateral chains. The ability of peptides to inhibit crystal growth is therefore essentially based on backbone flexibility.	Fac Pharm Marseille, UPRESA CNRS 6032, Unite Propre Rech & Enseignement Super, F-13385 Marseille 05, France; Univ Toulouse 3, Inst Natl Polytech Toulouse, Ecole Natl Super Genie Chim, UMR CNRS 5503,Lab Genie Chim, F-31078 Toulouse, France; CEA, CNRS, Inst Biol Struct, Lab Cristallog & Cristallogenese Prot, F-38027 Grenoble, France; UPR CNRS 9027, Lab Ingn Syst Macromol, F-13009 Marseille, France; Hop St Marguerite, Serv Nephrol, F-13385 Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National Polytechnique de Toulouse; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Verdier, JM (corresponding author), Fac Pharm Marseille, UPRESA CNRS 6032, Unite Propre Rech & Enseignement Super, 27 Bd Jean Moulin, F-13385 Marseille 05, France.		GERBAUD, Vincent/Q-6864-2019; Gerbaud, Vincent/J-7676-2013	GERBAUD, Vincent/0000-0003-2738-7922; Gerbaud, Vincent/0000-0003-2738-7922; VERDIER, Jean-Michel/0000-0002-7252-1556; PIGNOL, David/0000-0002-8070-0319				ADDADI L, 1986, MOL CRYST LIQ CRYST, V134, P305, DOI 10.1080/00268948608079592; ADDADI L, 1987, P NATL ACAD SCI USA, V84, P2732, DOI 10.1073/pnas.84.9.2732; ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; Benson SW, 1996, J AM CHEM SOC, V118, P10645, DOI 10.1021/ja962101w; BERNARD JP, 1992, GASTROENTEROLOGY, V103, P1277, DOI 10.1016/0016-5085(92)91516-7; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Bimmler D, 1997, J BIOL CHEM, V272, P3073, DOI 10.1074/jbc.272.5.3073; BOEK ES, 1992, J CHEM PHYS, V96, P7010, DOI 10.1063/1.462560; Boistelle R, 1986, Adv Nephrol Necker Hosp, V15, P173; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; CATTI M, 1993, PHYS CHEM MINER, V20, P104; Cerini C, 1999, J BIOL CHEM, V274, P22266, DOI 10.1074/jbc.274.32.22266; Cerini C, 1999, KIDNEY INT, V55, P1776, DOI 10.1046/j.1523-1755.1999.00426.x; De Reggi M, 1998, J BIOL CHEM, V273, P4967, DOI 10.1074/jbc.273.9.4967; DECARO AM, 1989, BIOCHIM BIOPHYS ACTA, V994, P281, DOI 10.1016/0167-4838(89)90305-1; DeOliveira DB, 1997, J AM CHEM SOC, V119, P10627, DOI 10.1021/ja972270w; DEREGGI M, 1995, EUR J BIOCHEM, V230, P503; EFFENBERGER H, 1981, Z KRISTALLOGR, V156, P233, DOI 10.1524/zkri.1981.156.3-4.233; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRANKS F, 1983, WATER, P15; GEFFROY C, 1997, THESIS U FRANCHECOMT; Geider S, 1996, J BIOL CHEM, V271, P26302, DOI 10.1074/jbc.271.42.26302; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; JENKINS HDB, 1976, J INORG NUCL CHEM, V38, P371, DOI 10.1016/0022-1902(76)80265-5; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; KNIGHT CA, 1993, BIOPHYS J, V64, P252, DOI 10.1016/S0006-3495(93)81361-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lin CH, 1998, J CRYST GROWTH, V191, P791, DOI 10.1016/S0022-0248(98)00130-4; MANN S, 1988, NATURE, V332, P119, DOI 10.1038/332119a0; MANN S, 1990, J CHEM SOC FARADAY T, V86, P1873, DOI 10.1039/ft9908601873; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; OHTAKI H, 1993, CHEM REV, V93, P1157, DOI 10.1021/cr00019a014; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pignol D, 1995, PROTEINS, V23, P604, DOI 10.1002/prot.340230418; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; SCHEELE G, 1984, PANCREATITIS CONCEPT, P119; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; Tsai FTF, 1997, PROTEINS, V28, P41; VEIS A, 1967, BIOCHEMISTRY-US, V6, P2409, DOI 10.1021/bi00860a017; VERDIER JM, 1993, SCANNING MICROSCOPY, V7, P1017; WEINER S, 1991, TRENDS BIOCHEM SCI, V16, P252, DOI 10.1016/0968-0004(91)90098-G; WEISSBUCH I, 1995, ACTA CRYSTALLOGR B, V51, P115, DOI 10.1107/S0108768194012061; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; Yamashita K, 1996, CHEM MATER, V8, P2697, DOI 10.1021/cm9602858	50	61	62	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1057	1064		10.1074/jbc.275.2.1057	http://dx.doi.org/10.1074/jbc.275.2.1057			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625646	hybrid			2022-12-25	WOS:000084836600050
J	Loussouarn, G; Makhina, EN; Rose, T; Nichols, CG				Loussouarn, G; Makhina, EN; Rose, T; Nichols, CG			Structure and dynamics of the pore of inwardly rectifying K-ATP channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNEL; SULFONYLUREA RECEPTOR; SCANNING MUTAGENESIS; SUBUNIT; STOICHIOMETRY; SELECTIVITY; CONDUCTION; MECHANISM; RECTIFICATION; SENSITIVITY	Inwardly rectifying K+ currents are generated by a complex of four Kir (Kir1-6) subunits. Pore properties are conferred by the second transmembrane domain (M2) of each subunit. Using cadmium ions as a cysteine-interacting probe, we examined the accessibility of substituted cysteines in M2 of the Kir6.2 subunit of inwardly rectifying K-ATP channels. The ability of Cd2+ ions to inhibit channels was used as the estimate of accessibility. The distribution of Cd2+ accessibility is consistent with an alpha-helical structure of M2. The apparent surface of reactivity is broad, and the most reactive residues correspond to the solvent-accessible residues in the bacterial KcsA channel crystal structure. In several mutants, single channel measurements indicated that inhibition occurred by a single transition from the open state to a zero-conductance state. Analysis of currents expressed from mixtures of control and L164C mutant subunits indicated that at least three cysteines are required for coordination of the Cd2+ ion. Application of phosphatidylinositol 4,Ei-diphosphate to inside-out membrane patches stabilized the open state of all mutants and also reduced cadmium sensitivity, Moreover, the Cd2+ sensitivity of several mutants was greatly reduced in the presence of inhibitory ATP concentrations. Taken together, these results are consistent with state-dependent accessibility of single Cd2+ ions to coordination sites within a relatively narrow inner vestibule.	Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Physiol & Cell Biol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Loussouarn, Gildas/D-3590-2015; Loussouarn, Gildas/ABH-6043-2020; Nichols, Colin/D-6336-2012	Loussouarn, Gildas/0000-0001-8007-5931; Loussouarn, Gildas/0000-0001-8007-5931; ROSE, Thierry/0000-0001-8863-0207	NHLBI NIH HHS [HL54171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIYAR J, 1994, BIOPHYS J, V67, P2261, DOI 10.1016/S0006-3495(94)80710-6; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Choe S, 1995, P NATL ACAD SCI USA, V92, P12046, DOI 10.1073/pnas.92.26.12046; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Collins A, 1997, P NATL ACAD SCI USA, V94, P5456, DOI 10.1073/pnas.94.10.5456; DEUTSCH N, 1994, J GEN PHYSIOL, V104, P773, DOI 10.1085/jgp.104.4.773; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; Lu T, 1999, NEURON, V22, P571, DOI 10.1016/S0896-6273(00)80711-4; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; Trapp S, 1998, J GEN PHYSIOL, V112, P325, DOI 10.1085/jgp.112.3.325; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	41	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1137	1144		10.1074/jbc.275.2.1137	http://dx.doi.org/10.1074/jbc.275.2.1137			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625656	hybrid			2022-12-25	WOS:000084836600060
J	Nemir, M; Bhattacharyya, D; Li, XM; Singh, K; Mukherjee, AB; Mukherjee, BB				Nemir, M; Bhattacharyya, D; Li, XM; Singh, K; Mukherjee, AB; Mukherjee, BB			Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; GENE-EXPRESSION; CELL-ADHESION; BASEMENT-MEMBRANE; GROWTH-FACTOR; IN-VITRO; C-SRC; PROTEIN; INTEGRIN; PROMOTER	Osteopontin (OPN) is a sialic acid-rich, adhesive, extracellular matrix (ECM) protein with Arg-Gly-Asp cell-binding sequence that interacts with several integrins, including alpha(v)beta(3), Since the ECM is a key regulator of mammary gland morphogenesis, and mammary epithelial cells express OPN at elevated levels, we sought to determine whether this protein plays a role in the postnatal mammary gland development. By generating transgenic mice that express OPN antisense-RNA (AS-OPN mice) in the mammary epithelia we achieved suppression of OPN production in this organ. The pregnant AS-OPN mice displayed a lack of mammary alveolar structures, a drastic reduction in the synthesis of beta-casein, whey acidic milk protein, and lactation deficiency. In agreement with these findings, we uncovered that a mammary cell line, NMuMG, which undergoes both structural and functional differentiation on ECM-coated plates, when transfected with an antisense OPN-cDNA construct, failed to undergo such differentiation. Furthermore, the results of gel-invasion assays demonstrated that these cells manifest elevated matrix metalloproteinase (MMP) activity when OPN expression is significantly reduced. The identity of this proteinase as MMP-2 is confirmed by Western blotting, zymography, and inhibition of its activity by a specific inhibitor, TIMP-2. Taken together, our results demonstrate, for the first time, an essential role of OPN in mammary gland differentiation and that the molecular mechanism(s) of its action, at least in part, involves downregulation of MMP-2.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; NICHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mukherjee, BB (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.	baridm@bio1.lan.mcgill.ca	Bhattacharyya, Dibyendu/GRS-5261-2022; Bhattacharyya, Dibyendu/AAE-9208-2022	Bhattacharyya, Dibyendu/0000-0003-3252-7440; Bhattacharyya, Dibyendu/0000-0003-3252-7440	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000910] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000910] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEHREND EI, 1993, J BIOL CHEM, V268, P11172; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; BUTLER WT, 1995, ANN NY ACAD SCI, V760, P6, DOI 10.1111/j.1749-6632.1995.tb44615.x; Chackalaparampil I, 1996, ONCOGENE, V12, P1457; Chellaiah M, 1996, ENDOCRINOLOGY, V137, P2432, DOI 10.1210/en.137.6.2432; CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FET V, 1989, GENOMICS, V5, P375, DOI 10.1016/0888-7543(89)90074-8; GRONER B, 1992, J CELL BIOCHEM, V49, P182; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HWANG S, 1994, J BIOL CHEM, V269, P711; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; LAMPE MA, 1991, J IMMUNOL, V147, P2902; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; Liaw L, 1998, J CLIN INVEST, V101, P1468; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NECKERS L, 1993, AM J PHYSIOL, V265, pL1, DOI 10.1152/ajplung.1993.265.1.L1; NEMIR M, 1989, J BIOL CHEM, V264, P18202; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; Rollo EE, 1996, J LEUKOCYTE BIOL, V60, P397, DOI 10.1002/jlb.60.3.397; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SINGH K, 1992, J BIOL CHEM, V267, P23847; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SU LC, 1995, ONCOGENE, V10, P2163; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tezuka KI, 1996, J BIOL CHEM, V271, P22713, DOI 10.1074/jbc.271.37.22713; Uede T, 1997, MICROBIOL IMMUNOL, V41, P641, DOI 10.1111/j.1348-0421.1997.tb01906.x; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weintraub AS, 1996, AM J PATHOL, V149, P259; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; ZIMOLO Z, 1994, AM J PHYSIOL, V266, P376	47	91	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					969	976		10.1074/jbc.275.2.969	http://dx.doi.org/10.1074/jbc.275.2.969			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625634	hybrid			2022-12-25	WOS:000084836600038
J	Takao, N; Mori, R; Kato, H; Shinohara, A; Yamamoto, K				Takao, N; Mori, R; Kato, H; Shinohara, A; Yamamoto, K			c-abl tyrosine kinase is not essential for ataxia telangiectasia mutated functions in chromosomal maintenance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; VERTEBRATE CELLS; NUCLEAR FOCI; IONIZING-RADIATION; PROTEIN; REPAIR; GENE; ATM	c-Abl is activated by DNA damage in an ataxia telangiectasia mutated (ATM)-dependent manner and plays important roles in growth arrest and apoptosis induced by DNA damage. c-Abl also interacts physically and functionally with Rad51, a key molecule in homologous recombinational (HR) DNA repair. To study further the roles of c-Abl in HR DNA repair, we generated c-Abl(-/-) and ATM(-/-)/c-Abl(-/-) mutant cell lines from a chicken B lymphocyte DT40 cell line, comparing the phenotypes of these mutants to those of ATM(-/-) DT40 cells that we had created previously. We found that the time course of radiation-induced Rad51 focus formation is abnormal in ATM(-/-) DT40 cells, consistent with the observation that ATM(-/-) DT40 cells display hypersensitivity to ionizing radiation and highly elevated frequencies of both spontaneous and radiation-induced chromosomal aberrations. In contrast, c-Abl(-/-) cells did not show these ATM-related defects in their cellular response to radiation, nor did the disruption of c-Abl in ATM(-/-) DT40 cells exacerbate these ATM-related defects. However, c-Abl(-/-) DT40 cells, but not ATM(-/-) DT40 cells, were resistant to radiation-induced apoptosis, indicating an important role for c-Abl in this cellular response to ionizing radiation. These results therefore indicate that, although ATM plays an important role in genome maintenance, c-Abl is not essential for this ATM function. These findings suggest that c-Abl and ATM play important roles in the maintenance of the cell homeostasis in response to DNA damage that are, at least in part, independent.	Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Dept Surg 1, Kanazawa, Ishikawa 9200934, Japan; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Kanazawa University; Kanazawa University; University of Chicago	Yamamoto, K (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.			Mori, Ryoichi/0000-0002-7596-9620				ABELSON HT, 1970, CANCER RES, V30, P2213; Agami R, 1999, NATURE, V399, P809; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Gong JG, 1999, NATURE, V399, P806; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEHMANN AR, 1995, TRENDS GENET, V11, P375, DOI 10.1016/S0168-9525(00)89112-X; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; TAKAO N, 1999, IN PRESS ONCOGENE; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tashiro S, 1996, ONCOGENE, V12, P2165; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	29	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					725	728		10.1074/jbc.275.2.725	http://dx.doi.org/10.1074/jbc.275.2.725			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625600	hybrid			2022-12-25	WOS:000084836600004
J	Uh, ST; Van Linden, A; Riches, DWH				Uh, ST; Van Linden, A; Riches, DWH			Phosphorylation of 130-and 95-kDa substrates associated with tumor necrosis factor-alpha receptor CD120a (p55)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERLEUKIN-1 SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TNF RECEPTOR; DEATH DOMAIN; CELL-DEATH; INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; MOUSE MACROPHAGES; EARLY EVENTS	Cross-linking of CD120a (p55), a receptor for tumor necrosis factor (alpha (TNF alpha), initiates downstream events, including the activation of protein Ser/Thr kinases. In this report, we have characterized two protein Ser/Thr kinase substrates that are intrinsically associated with CD120a (p55) in mouse macrophages, and we have investigated the mechanism involved in their phosphorylation, pp130 and pp95 were detected by co-immunoprecipitation with CD120a (p55) from lysates of mouse bone marrow-derived macrophages and were phosphorylated on Ser and Thr residues during in vitro kinase assays in the presence of [gamma-P-32]ATP. The level of phosphorylation of pp130 and pp95 was rapidly and transiently increased in response to TNF alpha in [P-32]orthophosphate-labeled macrophages, although the level of pp130 protein associated with CD120a (p55) remained unchanged as detected by [S-35]methionine labeling. In contrast, pp130 and pp95 were efficiently phosphorylated in in vitro kinase assays of CD120a (p55) immunoprecipitates from unstimulated cells, and the level of phosphorylation was rapidly and transiently reduced in response to TNF alpha. Both pp130 and pp95 were sensitive to dephosphorylation with purified protein phosphatase 2A, and okadaic acid, a PP1/PP2A inhibitor, mimicked the ability of TNF alpha to stimulate the phosphorylation of pp130 and pp95 in intact P-32-labeled macrophages. Collectively, these findings suggest that pp130 and pp95 are constitutively associated with CD120a (p55) and become inducibly phosphorylated in macrophages in response to TNF alpha. We propose that the underlying mechanism of their phosphorylation may involve the inactivation of a cytoplasmic pp130/pp95 Ser/Thr phosphatase.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Dept Med,Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Riches, DWH (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Neustadt Rm D405,1400 Jackson St, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056556, R01HL055549] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55549, HL56556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Dunbar JD, 1997, J IMMUNOL, V158, P4252; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HIGUCHI M, 1993, J BIOL CHEM, V268, P5624; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; PACE JL, 1985, J IMMUNOL, V134, P977; RICHES DWH, 1991, J BIOL CHEM, V266, P24785; Riches DWH, 1996, MOL CELLULAR BIOL WO, P95; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VANDERGEER P, 1993, PROTEIN PHOSPHORYLAT, P38; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WINSTON BW, 1995, J IMMUNOL, V155, P1525; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391; Wu MY, 1997, J BIOL CHEM, V272, P17154, DOI 10.1074/jbc.272.27.17154; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	39	3	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					793	800		10.1074/jbc.275.2.793	http://dx.doi.org/10.1074/jbc.275.2.793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625609	hybrid			2022-12-25	WOS:000084836600013
J	Bieberich, E; Kawaguchi, T; Yu, RK				Bieberich, E; Kawaguchi, T; Yu, RK			N-acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; GLUCOCEREBROSIDE SYNTHETASE; SIGNAL-TRANSDUCTION; DEATH; INHIBITOR; STRESS; PURIFICATION; BIOSYNTHESIS; SUPPRESSION	A novel structural analog of ceramide was synthesized by N-acylation of serinol (2-amino-1,3-propanediol) and studied for its effects on glycolipid biosynthesis and cell differentiation of neuroblastoma cells. Incubation with N-palmitoylated serinol (C16-serinol) increased the concentration of endogenous ceramide by 50-80% and caused apoptosis in rapidly dividing low density cells but not in confluent cells. Cell death was not suppressed by simultaneous incubation with phorbol ester, known to antagonize ceramide-induced apoptosis by activation of protein kinase C (PKC). Purification of potential target proteins of C16-serinol was achieved by affinity chromatography of a protein preparation from rat brain on immobilized C16-serinol. A gel activity assay revealed that the eluate from C16-serinol-Sepharose contained three serine/threonine-specific protein kinases with molecular masses of 50, 70, and 95 kDa. The 70-kDa protein was immunostained on a Western blot using a PKC zeta-specific antibody. The purified PKC zeta could be activated directly by C16-serinol in an in vitro phosphorylation assay. Induction of apoptosis in neuroblastoma cells was suppressed by inhibition of PKC zeta with Go 6983. Our overall results indicate that apoptosis in neuroblastoma cells induced by C16-serinol was at least partially mediated by activation of PKC zeta on condition of ongoing cell division. N-Acylated serinols may thus be useful for induction of apoptosis in mitotic cells and may be of therapeutic potential for treatment of cancer in the nervous system.	Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Med Coll Virginia Campus, Richmond, VA 23298 USA	Virginia Commonwealth University	Bieberich, E (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Med Coll Virginia Campus, 1101 E Marshall St,POB 980614, Richmond, VA 23298 USA.				NINDS NIH HHS [NS 11853] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011853] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE A, 1995, J LIPID RES, V36, P611; Ariga T, 1998, J LIPID RES, V39, P1; ARORA RC, 1972, J LIPID RES, V13, P86; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Bieberich E, 1999, J NEUROCHEM, V72, P1040, DOI 10.1046/j.1471-4159.1999.0721040.x; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; FEWSTER ME, 1969, J CHROMATOGR, V43, P120, DOI 10.1016/S0021-9673(00)99173-8; Freischutz B, 1997, J NEUROCHEM, V68, P2070; Galadari S, 1998, BIOCHEMISTRY-US, V37, P11232, DOI 10.1021/bi980911+; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; INOKUCHI JI, 1987, J LIPID RES, V28, P565; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kapitonov D, 1997, BIOCHEM BIOPH RES CO, V232, P449, DOI 10.1006/bbrc.1997.6240; KRUEGER BK, 1995, J NEUROSCI, V15, P3366; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1994, J BIOL CHEM, V269, P3047; MACALA LJ, 1983, J LIPID RES, V24, P1243; Mangoura D, 1998, J NEUROCHEM, V70, P130; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MILLIGAN CE, 1997, BR MED B, V52, P570; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PLATT FM, 1994, J BIOL CHEM, V269, P8362; RYU EK, 1979, J LIPID RES, V20, P561; Schwab M, 1999, NATURWISSENSCHAFTEN, V86, P71, DOI 10.1007/s001140050574; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WEISNER DA, 1996, GLYCOCONJ J, V13, P327; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YU RK, 1994, PROG BRAIN RES, V101, P31	43	78	88	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					177	181		10.1074/jbc.275.1.177	http://dx.doi.org/10.1074/jbc.275.1.177			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617602	hybrid			2022-12-25	WOS:000085951600026
J	Chang, CH; Frey, PA				Chang, CH; Frey, PA			Cloning, sequencing, heterologous expression, purification, and characterization of adenosylcobalamin-dependent D-lysine 5,6-aminomutase from Clostridium sticklandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE; 2,3-AMINOMUTASE; MUTASE; PROTEIN	D-Lysine 5,6-aminomutase from Clostridium sticklandii catalyzes the 1,2-shift of the epsilon-amino group of D-lysine and reverse migration of C5(H). The two genes encoding 5,6-aminomutase have been cloned, sequenced, and expressed in Escherchia coli. They are adjacent on the Clostridial chromosome and encode polypeptides of 57.3 and 29.2 kilodaltons. The predicted amino acid sequence includes a conserved base-off 5'-deoxyadenosylcobalamin binding motif and a 3-cysteine cluster in the small subunit, as well as a P-loop sequence in the large subunit, Activity of the recombinant enzyme exceeds that of the 5,6-aminomutase purified from C. sticklandii by 6-fold, presumably due to the absence of bound, inactive corrinoids in the recombinant enzyme. The K-m values for adenosylcobalamin and pyridoxal 5'-phosphate are 6.6 and 1.0 mu M, respectively. ATP does not have a regulatory effect on the recombinant protein. The rapid turnover associated inactivation reported for the enzyme purified from Clostridium is also seen with the recombinant form. Aminomutase activity does not depend on structural or catalytic metal ions. Electron paramagnetic resonance experiments with [N-15-dimethylbenz-imidazole]adenosylcobalamin demonstrate base-off binding, consistent with other B-12-dependent enzymes that break unactivated C-H bonds.	Univ Wisconsin, Grad Sch, Inst Enzyme Res, Madison, WI 53705 USA; Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Frey, PA (corresponding author), Univ Wisconsin, Grad Sch, Inst Enzyme Res, Madison, WI 53705 USA.	frey@enzyme.wisc.edu	Chang, Christopher H/A-1404-2012	Chang, Christopher H/0000-0003-3800-6021	NIDDK NIH HHS [DK28607] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028607, R37DK028607] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abend A, 1999, ARCH BIOCHEM BIOPHYS, V370, P138, DOI 10.1006/abbi.1999.1382; BAKER JJ, 1973, BIOCHEMISTRY-US, V12, P1054, DOI 10.1021/bi00730a006; BAKER JJ, 1984, B12, V2, P203; BARANIAK J, 1989, J BIOL CHEM, V264, P1357; Chen HP, 1997, BIOCHEMISTRY-US, V36, P14939, DOI 10.1021/bi971374g; CHIRPICH TP, 1970, J BIOL CHEM, V245, P1778; *GEN COMP GROUP, 1991, 70 ED; JUDD RC, 1990, METHOD ENZYMOL, V182, P613; Lawrence CC, 1999, J BIOL CHEM, V274, P7039, DOI 10.1074/jbc.274.11.7039; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU WP, 1993, J BIOL CHEM, V268, P5605; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MORLEY C G D, 1972, Biochemistry, V11, P600, DOI 10.1021/bi00754a019; MORLEY CGD, 1970, BIOCHEMISTRY-US, V9, P4890, DOI 10.1021/bi00827a010; MORLEY CGD, 1971, BIOCHEMISTRY-US, V10, P2325; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; RIORDAN JF, 1988, METHOD ENZYMOL, V158, P3, DOI 10.1016/0076-6879(88)58041-2; RUZICKA FJ, 2000, IN PRESS J BACTERIOL; Sambrook J, 1989, MOL CLONING LAB MANU, V3; STADTMAN TC, 1973, ADV ENZYMOL RAMB, V38, P413; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Toraya T, 1999, J BIOL CHEM, V274, P3372, DOI 10.1074/jbc.274.6.3372; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Yamanishi M, 1998, BIOCHEMISTRY-US, V37, P4799, DOI 10.1021/bi972572a	24	70	73	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					106	114		10.1074/jbc.275.1.106	http://dx.doi.org/10.1074/jbc.275.1.106			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617592	hybrid			2022-12-25	WOS:000085951600016
J	Hindson, VJ; Moody, PCE; Rowe, AJ; Shaw, WV				Hindson, VJ; Moody, PCE; Rowe, AJ; Shaw, WV			Serine acetyltransferase from Escherichia coli is a dimer of trimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; RHIZOBIUM; NODL; GENE	Equilibrium sedimentation studies show that the serine acetyltransferase (SAT) of Escherichia coli is a hexamer. The results of velocity sedimentation and quasielastic light scattering experiments suggest that the identical subunits are loosely packed and/or arranged in an ellipsoidal fashion. Chemical cross-linking studies indicate that the fundamental unit of quaternary structure is a trimer. The likelihood, therefore, is that in solution SAT exists as an open arrangement of paired trimers. Crystals of SAT have 32 symmetry, consistent with such an arrangement, and the cell density function is that expected for a hexamer, Electron microscopy with negative staining provides further evidence that SAT has an ellipsoidal subunit organization, the dimensions of the particles consistent with the proposed paired trimeric subunit arrangement. A bead model analysis supports the view that SAT has a low packing density and, furthermore, indicates that the monomers may have an ellipsoidal shape. Such a view is in keeping with the ellipsoidal subunit shape of trimeric LpxA, an acyltransferase with which SAT shares contiguous repeats of a hexapeptide motif.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Nottingham, Sch Biol Sci, Natl Ctr Mol Hydrodynam Business Ctr, Loughborough LE12 5RD, Leics, England	University of Leicester; University of Nottingham	Hindson, VJ (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	vhindson@picr.man.ac.uk	Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238				BAECKER PA, 1980, ANAL BIOCHEM, V102, P16, DOI 10.1016/0003-2697(80)90310-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P6689, DOI 10.1021/bi980106v; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK PF, 1978, J BIOL CHEM, V253, P7874; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; DENK D, 1987, J GEN MICROBIOL, V133, P515; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; Dunn SM, 1996, PROTEIN SCI, V5, P538; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; HARDING SE, 1992, LASER LIGHT SCATTERI, P7; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE AGW, 1990, J MOL BIOL, V213, P167, DOI 10.1016/S0022-2836(05)80129-9; LEU LS, 1994, BIOCHEMISTRY-US, V33, P2667, DOI 10.1021/bi00175a040; LEWENDON A, 1995, J BIOL CHEM, V270, P26326, DOI 10.1074/jbc.270.44.26326; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; Murray IA, 1997, ANTIMICROB AGENTS CH, V41, P1; NAKAMURA K, 1987, PLANT CELL PHYSIOL, V28, P885, DOI 10.1093/oxfordjournals.pcp.a077370; OTWINOWSKI Z, 1993, OSCILLATION DATA RED, P56; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROWE AJ, 1984, TECHNIQUES DETERMINI; SMITH IK, 1969, BIOCHEM BIOPH RES CO, V36, P111; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; WEBER G, 1975, ADV PROTEIN CHEM, V29, P314; WIEBERS JL, 1967, J BIOL CHEM, V242, P12; WIGLEY DB, 1990, FEBS LETT, V277, P267, DOI 10.1016/0014-5793(90)80862-D	29	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					461	466		10.1074/jbc.275.1.461	http://dx.doi.org/10.1074/jbc.275.1.461			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617639	hybrid			2022-12-25	WOS:000085951600063
J	Miyahara, M; Nakanishi, H; Takahashi, K; Satoh-Horikawa, K; Tachibana, K; Takai, Y				Miyahara, M; Nakanishi, H; Takahashi, K; Satoh-Horikawa, K; Tachibana, K; Takai, Y			Interaction of nectin with afadin is necessary for its clustering at cell-cell contact sites but not for its cis dimerization or trans interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLIOVIRUS RECEPTOR GENE; E-CADHERIN; CYTOPLASMIC DOMAIN; ALPHA-CATENIN; ADHESION MOLECULES; COMPLEX-FORMATION; STRUCTURAL BASIS; EXPRESSION; PROTEIN; REGION	We have recently found a novel functional unit of cell-cell adhesion at cadherin-based adherens junctions, consisting of at least nectin, a hemophilic cell adhesion molecule, and afadin, an actin filament-binding protein, which connects nectin to the actin cytoskeleton. Here we studied a mechanism of cell-cell adhesion of the nectin-afadin system by use of a cadherin-deficient L cell line stably expressing the intact form of mouse nectin-2 alpha, a truncated form of nectin-2 alpha incapable of interacting with afadin (nectin-2 alpha-Delta C), or a point-mutated form of nectin-2 alpha capable of interacting with afadin and a cadherin-expressing EL cell. line, which transiently expressed the point-mutated form of nectin-2 alpha, We found that the interaction of nectin-2 alpha with afadin was necessary for their clustering at cell-cell contact sites. However, nectin-2 alpha-Delta C showed cis dimerization and trans interaction, both of which did not require the interaction of nectin-2 alpha with afadin. We have previously shown in EL cells that the interaction of nectin-1 with afadin is necessary for its recruitment to adherens junctions. We found that the trans interaction of nectin-2 alpha was furthermore necessary for this recruitment. On the basis of these observations, we propose a model for the mechanism of cell-cell adhesion of nectin and roles of afadin in this mechanism.	Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, Osaka 5650871, Japan.			Nakanishi, Hiroyuki/0000-0002-9765-0266				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck C A, 1992, Semin Cell Biol, V3, P179; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leahy DJ, 1997, ANNU REV CELL DEV BI, V13, P363, DOI 10.1146/annurev.cellbio.13.1.363; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; PRASAD R, 1993, CANCER RES, V53, P5624; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SIEBER F, 1981, J CELL BIOL, V90, P55, DOI 10.1083/jcb.90.1.55; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Tucker KL, 1997, NUCLEIC ACIDS RES, V25, P3745, DOI 10.1093/nar/25.18.3745; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	49	125	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					613	618		10.1074/jbc.275.1.613	http://dx.doi.org/10.1074/jbc.275.1.613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617658	hybrid			2022-12-25	WOS:000085951600082
J	Vasilyeva, E; Liu, Q; MacLeod, KJ; Baleja, JD; Forgac, M				Vasilyeva, E; Liu, Q; MacLeod, KJ; Baleja, JD; Forgac, M			Cysteine scanning mutagenesis of the noncatalytic nucleotide binding site of the yeast V-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; CLATHRIN-COATED VESICLES; ADENOSINE-TRIPHOSPHATASE; DIRECTED MUTAGENESIS; B-SUBUNIT; MUTATIONAL ANALYSIS; STRUCTURAL-CHANGES; CATALYTIC SUBUNIT; CDNA SEQUENCE	To investigate residues involved in the formation of the noncatalytic nucleotide binding sites of the vacuolar proton-translocating adenosine triphosphatase (V-ATPase), cysteine scanning mutagenesis of the VMA2 gene that encodes the B subunit in yeast was performed. Replacement of the single endogenous cysteine residue at position 188 gave rise to a Cys-less form of the B subunit (Vma2p) which had near wild-type levels of activity and which was used in the construction of 16 single cysteine-containing mutants. The ability of adenine nucleotides to prevent reaction of the introduced cysteine residues with the sulfhydryl reagent 3-(N-maleimidopropionyl)biocytin (biotin-maleimide) was evaluated by Western blot. Biotin-maleimide labeling of the purified V-ATPase from the wild-type and the mutants S152C, L178C, N181C, A184C, and T279C was reduced after reaction with the nucleotide analog 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate (BzATP). These results suggest the proximity of these residues to the nucleotide binding site on the B subunit, In addition, we have examined the level of endogenous nucleotide bound to the wild-type V-ATPase and to a mutant (the A subunit mutant R483Q) which is postulated to be altered at the noncatalytic site and which displays a marked nonlinearity in ATP hydrolysis (MacLeod, K. J., Vasilyeva, E., Baleja, J. D., and Forgac, M. (1998) J. Biol. Chem. 273, 150-156), The R483Q mutant contained 2.6 mol of ATP/mol of V-ATPase compared with the wild-type enzyme, which contained 0.8 mol of ATP/mol of V-ATPase, These results suggest that binding of additional ATP to the noncatalytic sites may modulate the catalytic activity of the enzyme.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University; Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	mforgac@opal.tufts.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM034478, R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BRUNGER AT, 1987, XPLOR SYSTEM XRAY CR; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; FENG Y, 1992, J BIOL CHEM, V267, P5817; Fillingame RH, 1997, J EXP BIOL, V200, P217; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; HIRATA R, 1990, J BIOL CHEM, V265, P6726; JOUNOUCHI M, 1993, J BIOCHEM-TOKYO, V114, P171, DOI 10.1093/oxfordjournals.jbchem.a124150; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIMGRUBER RM, 1976, J BIOL CHEM, V251, P7103; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PENG SB, 1995, J BIOL CHEM, V270, P16926; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; STEVENS TH, 1991, METHOD ENZYMOL, V194, P644; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; Vasilyeva E, 1996, J BIOL CHEM, V271, P12775, DOI 10.1074/jbc.271.22.12775; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1993, J BIOL CHEM, V268, P6241; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; Yokoyama K, 1998, J BIOL CHEM, V273, P20504, DOI 10.1074/jbc.273.32.20504; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	55	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					255	260		10.1074/jbc.275.1.255	http://dx.doi.org/10.1074/jbc.275.1.255			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617613	hybrid			2022-12-25	WOS:000085951600037
J	Gsell, S; Eschenhagen, T; Kaspareit, G; Nose, M; Scholz, H; Behrens, O; Wieland, T				Gsell, S; Eschenhagen, T; Kaspareit, G; Nose, M; Scholz, H; Behrens, O; Wieland, T			Apparent up-regulation of stimulatory G-protein alpha subunits in the pregnant human myometrium is mimicked by elevated smoothelin expression	FASEB JOURNAL			English	Article						epitope sharing; smooth muscle; G alpha(s); mRNA expression; adenylyl cyclase	BETA-ADRENERGIC-RECEPTOR; MESSENGER-RIBONUCLEIC-ACID; ADENYLATE-CYCLASE; RAT MYOMETRIUM; DOWN-REGULATION; PRETERM LABOR; GENE-EXPRESSION; GUINEA-PIG; IDENTIFICATION; ISOFORMS	Sensitization of adenylyl cyclase (AC) by increased expression of large isoforms of the stimulatory G-protein G alpha(s) has been suggested as a mechanism that governs uterine quiescence during pregnancy. We quantified several components of the AC pathway in pregnant (P, n=21) and nonpregnant human myometria (NP, n=10). AC activity was similar to sevenfold higher in P than in NP under basal and stimulated conditions (MnCl2/GTP/GTP + isoproterenol). in addition, relative stimulation (% of basal) by 5'-guanosine-beta gamma-iminotriphosphate and forskolin was twofold higher in P. beta-Adrenoceptor density was low and unaltered in P. G alpha(s) mRNA splice variants did not differ in P. Using antisera against different epitopes of G alpha(s) (carboxyl-/more aminoterminal), we found unchanged expression of G alpha(s) short and long (45, 47 kDa) in P. Two additional proteins in P (51, 59 kDa) were detectable only by the carboxyl-terminal antiserum and lacked GTP binding properties. The 59 kDa protein could be identified as a recently discovered cytoskeletal protein, smoothelin, which was 10-fold increased in P. These data indicate that the apparent up-regulation of large G alpha(s) species in P is mimicked by elevated smoothelin. Therefore, the increase in AC cannot be attributed to changes in G alpha(s)- or beta-adrenoreceptors. Epitope sharing between G alpha(s), and smoothelin should be considered in experiments on smooth muscle tissues.-Gsell, S., Eschenhagen, T., Kaspareit, G., Nose, M., Scholz, H., Behrens, O., Wieland, T. Apparent up-regulation of stimulatory G-protein alpha subunits in the pregnant human myometrium is mimicked by elevated smoothelin expression.	Univ Hamburg, Krankenhaus Eppendorf, Abt Pharmakol, Inst Expt, D-20246 Hamburg, Germany; Univ Hamburg, Krankenhaus Eppendorf, Abt Pharmakol, Klin Pharmakol & Toxikol, D-20246 Hamburg, Germany; Kreiskrankenhaus Rendsburg, Cynakol Abt, D-24768 Rendsburg, Germany	University of Hamburg; University of Hamburg	Eschenhagen, T (corresponding author), Univ Erlangen Nurnberg, Dept Clin Pharmacol, Inst Expt & Clin Pharmacol, Fahrstr 17, D-91054 Erlangen, Germany.	thomas.eschenhagen@pharmakologie.uni-erlangen.de	Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				AbiGerges N, 1997, MOL PHARMACOL, V52, P482, DOI 10.1124/mol.52.3.482; ARKINSTALL SJ, 1990, J ENDOCRINOL, V127, P15, DOI 10.1677/joe.0.1270015; BERNAL AL, 1995, TRENDS PHARMACOL SCI, V16, P129, DOI 10.1016/S0165-6147(00)89000-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BREUILLER M, 1990, J CLIN ENDOCR METAB, V70, P1299, DOI 10.1210/jcem-70-5-1299; BREUILLER M, 1987, GYNECOL OBSTET INVES, V24, P28, DOI 10.1159/000298771; CAVAILLE F, 1986, EUR J BIOCHEM, V160, P507, DOI 10.1111/j.1432-1033.1986.tb10068.x; COHEN-TANNOUDJI J, 1991, J MOL ENDOCRINOL, V6, P137, DOI 10.1677/jme.0.0060137; ELWARDYMEREZAK J, 1994, J MOL ENDOCRINOL, V13, P23, DOI 10.1677/jme.0.0130023; Engelhardt S, 1997, J CLIN ENDOCR METAB, V82, P1235, DOI 10.1210/jc.82.4.1235; ESCHENHAGEN T, 1995, J MOL CELL CARDIOL, V27, P357, DOI 10.1016/S0022-2828(08)80033-8; EUROPEFINNER GN, 1993, ENDOCRINOLOGY, V132, P2484, DOI 10.1210/en.132.6.2484; EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835; EuropeFinner GN, 1996, J CLIN ENDOCR METAB, V81, P1069, DOI 10.1210/jc.81.3.1069; FEINSTEIN DL, 1992, GLIA, V5, P139, DOI 10.1002/glia.440050208; GRANNEMAN JG, 1989, ENDOCRINOLOGY, V125, P2328, DOI 10.1210/endo-125-5-2328; HATJIS CG, 1985, AM J OBSTET GYNECOL, V151, P943, DOI 10.1016/0002-9378(85)90673-8; JAKOBS KH, 1985, ADV CYCLIC NUCLEOTID, V19, P25; KEHLENBACH RH, 1994, NATURE, V372, P804; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LEONI P, 1990, BIOCHEM J, V269, P31, DOI 10.1042/bj2690031; LEVENO KJ, 1992, NEW ENGL J MED, V327, P349, DOI 10.1056/NEJM199207303270510; MATTERA R, 1986, FEBS LETT, V206, P36, DOI 10.1016/0014-5793(86)81336-9; MHAOUTY S, 1995, J BIOL CHEM, V270, P11012, DOI 10.1074/jbc.270.18.11012; Mhaouty-Kodja S, 1997, J BIOL CHEM, V272, P31100, DOI 10.1074/jbc.272.49.31100; Mittmann C, 1998, J MOL MED, V76, P133, DOI 10.1007/s001090050201; MOLNAR M, 1990, J CLIN ENDOCR METAB, V71, P1243, DOI 10.1210/jcem-71-5-1243; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perkins J P, 1973, Adv Cyclic Nucleotide Res, V3, P1; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; RIEMER RK, 1988, MOL PHARMACOL, V33, P389; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SCARPACE PJ, 1990, MECH AGEING DEV, V52, P169, DOI 10.1016/0047-6374(90)90122-V; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; TANFIN Z, 1991, FEBS LETT, V278, P4, DOI 10.1016/0014-5793(91)80070-J; vanderLoop FTL, 1996, J CELL BIOL, V134, P401, DOI 10.1083/jcb.134.2.401; WARSOP H, 1993, J DEV PHYSIOL, V19, P91; Wehrens XHT, 1997, FEBS LETT, V405, P315, DOI 10.1016/S0014-5793(97)00207-X; WIELAND T, 1993, J BIOL CHEM, V268, P18111; ZUMBIHL R, 1994, EUR J PHARM-MOLEC PH, V288, P9, DOI 10.1016/0922-4106(94)90004-3	44	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					17	26		10.1096/fasebj.14.1.17	http://dx.doi.org/10.1096/fasebj.14.1.17			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627276				2022-12-25	WOS:000084784700004
J	Dajani, R; Cleasby, A; Neu, M; Wonacott, AJ; Jhoti, H; Hood, AM; Modi, S; Hersey, A; Taskinen, J; Cooke, RM; Manchee, GR; Coughtrie, MWH				Dajani, R; Cleasby, A; Neu, M; Wonacott, AJ; Jhoti, H; Hood, AM; Modi, S; Hersey, A; Taskinen, J; Cooke, RM; Manchee, GR; Coughtrie, MWH			X-ray crystal structure of human dopamine sulfotransferase, SULT1A3 - Molecular modeling and quantitative structure-activity relationship analysis demonstrate a molecular basis for sulfotransferase substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL SULFOTRANSFERASE; ESTROGEN SULFOTRANSFERASE; SULFURYL TRANSFER; SULFATION; SALBUTAMOL; MECHANISM; BIOLOGY; PLASMA	Humans are one of the few species that produce large amounts of catecholamine sulfates, and they have evolved a specific sulfotransferase, SULT1A3 (M-PST), to catalyze the formation of these conjugates. An orthologous protein has yet to be found in other species. To further our understanding of the molecular basis for the unique substrate selectivity of this enzyme, we have solved the crystal structure of human SULT1A3, complexed with 3'-phosphoadenosine 5'-phosphate (PAP), at 2.5 Angstrom resolution and carried out quantitative structure-activity relationship (QSAR) analysis with a series of phenols and catechols. SULT1A3 adopts a similar fold to mouse estrogen sulfotransferase, with a central five-stranded beta-sheet surrounded by alpha-helices. SULT1A3 is a dimer in solution but crystallized with a monomer in the asymmetric unit of the cell, although dimer interfaces were formed by interaction across crystallographic 2-fold axes. QSAR analysis revealed that the enzyme is highly selective for catechols, and catecholamines in particular, and that hydrogen bonding groups and lipophilicity (cLogD) strongly influenced K-m. We also investigated further the role of Glu(146) in SULT1A3 using site-directed mutagenesis and showed that it plays a key role not only in defining selectivity for dopamine but also in preventing many phenolic xenobiotics fi om binding to the enzyme.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Glaxo Wellcome Med Res Ctr, Prot Sci Unit, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev, Res Biomet, Ware SG12 0DP, Herts, England; Univ Helsinki, Viikki Bioctr, Dept Pharm, FIN-00014 Helsinki, Finland	University of Dundee; GlaxoSmithKline; GlaxoSmithKline; University of Helsinki	Coughtrie, MWH (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Coughtrie, Michael/C-3855-2009	Coughtrie, Michael/0000-0003-1989-1416; Hersey, Anne/0000-0003-4679-6211				Brix LA, 1999, BIOCHEM J, V337, P337, DOI 10.1042/0264-6021:3370337; BRONAUGH RL, 1975, J PHARMACOL EXP THER, V195, P441; CAMPBELL NRC, 1987, MOL PHARMACOL, V32, P813; Coughtrie MWH, 1996, HUM EXP TOXICOL, V15, P547, DOI 10.1177/096032719601500701; Coughtrie MWH, 1998, CHEM-BIOL INTERACT, V109, P3, DOI 10.1016/S0009-2797(97)00117-8; Dajani R, 1998, MOL PHARMACOL, V54, P942, DOI 10.1124/mol.54.6.942; Dajani R, 1999, PROTEIN EXPRES PURIF, V16, P11, DOI 10.1006/prep.1999.1030; DOUSA MK, 1988, P SOC EXP BIOL MED, V188, P427; Duffel MW, 1997, COMPREHENSIVE TOXICO, V3, P365; Eaton EA, 1996, BRIT J CLIN PHARMACO, V41, P201, DOI 10.1111/j.1365-2125.1996.tb00183.x; FOLDES A, 1973, BIOCHIM BIOPHYS ACTA, V327, P365, DOI 10.1016/0005-2744(73)90419-1; Glatt H, 1997, FASEB J, V11, P314, DOI 10.1096/fasebj.11.5.9141497; HOCHHAUS G, 1992, INT J CLIN PHARM TH, V30, P342; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Klaassen CD, 1997, FASEB J, V11, P404, DOI 10.1096/fasebj.11.6.9194521; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REITER C, 1983, N-S ARCH PHARMACOL, V324, P140, DOI 10.1007/BF00497020; Rubin GL, 1996, XENOBIOTICA, V26, P1113, DOI 10.3109/00498259609050256; SCOTT MC, 1987, J CHROMATOGR-BIOMED, V413, P17, DOI 10.1016/0378-4347(87)80209-8; STROBEL G, 1990, BIOCHEM INT, V20, P343; Suiko M, 1998, J BIOCHEM-TOKYO, V124, P707, DOI 10.1093/oxfordjournals.jbchem.a022170; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Zhang HP, 1998, J BIOL CHEM, V273, P10888, DOI 10.1074/jbc.273.18.10888	26	126	127	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37862	37868		10.1074/jbc.274.53.37862	http://dx.doi.org/10.1074/jbc.274.53.37862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608851	hybrid			2022-12-25	WOS:000084528000051
J	Fujii, Y; Shimokawa, H; Sekiguchi, M; Nakabeppu, Y				Fujii, Y; Shimokawa, H; Sekiguchi, M; Nakabeppu, Y			Functional significance of the conserved residues for the 23-residue module among MTH1 and MutT family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTT; NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; DNA-SYNTHESIS; ENCODING 8-OXO-DGTPASE; MUTAGENIC SUBSTRATE; NUDIX HYDROLASES; ADP-RIBOSE; ENZYME; GENE; MECHANISM	Human MTH1 and Escherichia coli MutT proteins hydrolyze 7,8-dihydro-8-oxo-dGTP (8-oxo-dGTP) to monophosphate, thus avoiding the incorporation of 8-oxo-7,8-dihydroguanine into nascent DNA. Although only 30 amino acid residues (23%) are identical between MTH1 and MutT, there is a highly conserved region consisting of 23 residues (MTH1, Gly(36)-Gly(58)) With 14 identical residues. A chimeric protein MTH1-Ec, in which the 23-residue sequence of MTH1 was replaced with that of MutT, retains its capability to hydrolyze 8-oxo-dGTP, thereby indicating that the 23-residue sequences of MTH1 and MutT are functionally and structurally equivalent and constitute functional modules. By saturation mutagenesis of the module in MTH1, 14 of the 23 residues proved to be essential to exert 8-oxo-dGTPase activity. For the other 9 residues (40, 42, 44, 46, 47, 40, 50, 54, and 58), positive mutants were obtained, and Arg(50) can be replaced with hydrophobic residues (Val, Leu, or Re), with a greater stability and higher specific activity of the enzyme. Indispensabilities of Val(39), Ile(45), and Leu(53) indicate that an amphipathic property of alpha-helix I consisting of 14 residues of the module (Thr(44)-Gly(58)) is essential to maintain the stable catalytic surface:for 8-oxo-dGTPase.	Kyushu Univ, Med Inst Bioregulat, Dept Biochem, Higashi Ku, Fukuoka 8128582, Japan; Fukuoka Dent Coll, Dept Biol, Fukuoka 8140175, Japan; Fukuoka Dent Coll, Frontier Res Ctr, Fukuoka 8140175, Japan; Japan Sci & Technol Corp, CREST, Osaka, Japan	Kyushu University; Fukuoka Dental College (FDC); Fukuoka Dental College (FDC); Japan Science & Technology Agency (JST)	Nakabeppu, Y (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Biochem, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; Cai JP, 1997, NUCLEIC ACIDS RES, V25, P1170, DOI 10.1093/nar/25.6.1170; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CHENG KC, 1992, J BIOL CHEM, V267, P166; FRICK DN, 1995, BIOCHEMISTRY-US, V34, P5577, DOI 10.1021/bi00016a032; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; Hayakawa H, 1999, BIOCHEMISTRY-US, V38, P3610, DOI 10.1021/bi982361l; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; Luria SE, 1943, GENETICS, V28, P491; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; Miyazawa S, 1996, J MOL BIOL, V256, P623, DOI 10.1006/jmbi.1996.0114; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; Oda H, 1997, J BIOL CHEM, V272, P17843, DOI 10.1074/jbc.272.28.17843; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Rost B, 1996, METHOD ENZYMOL, V266, P525; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sekiguchi M, 1996, GENES CELLS, V1, P139, DOI 10.1046/j.1365-2443.1996.d01-232.x; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Yakushiji H, 1997, MUTAT RES-DNA REPAIR, V384, P181, DOI 10.1016/S0921-8777(97)00025-6; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	37	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38251	38259		10.1074/jbc.274.53.38251	http://dx.doi.org/10.1074/jbc.274.53.38251			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608900	hybrid			2022-12-25	WOS:000084528000100
J	Lee, W; Ryu, JW; Souto, RP; Pilch, PF; Jung, CY				Lee, W; Ryu, JW; Souto, RP; Pilch, PF; Jung, CY			Separation and partial characterization of three distinct intracellular GLUT4 compartments in rat adipocytes - Subcellular fractionation without homogenization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; INSULIN-STIMULATED TRANSLOCATION; 3T3-L1 ADIPOCYTES; GLUT4-CONTAINING VESICLES; PLASMA-MEMBRANE; STORAGE-VESICLES; ADIPOSE-TISSUE; MAJOR PROTEIN; CELL-SURFACE; ENDOCYTOSIS	Insulin recruits GLUT4 from an intracellular location to the plasma membrane in rat adipocytes. The process involves multiple intracellular compartments and multiple protein functions, details of which are largely unknown partly due to our inability to separate individual GLUT4 compartments. Here, by hypotonic lysis, differential centrifugation, and glycerol density gradient sedimentation, we separated intracellular GLUT4 compartments in rat adipocytes into three fractions: plasma membrane-containing fraction T and plasma mem brane-free fractions H and L, The GLUT4 contents in fractions T, H, and L were similar to 25, 56, and 18% of total GLUT4, respectively, in basal adipocytes and 55, 42, and 3-4% in insulin-stimulated adipocytes, The plasma membrane GLUT4 contents estimated separately further revealed that intracellular GLUT4 in fraction T amounts to similar to 20% in both basal and insulin-stimulated adipocytes, Organelle-specific marker and membrane traffic related protein distribution data suggested that intracellular GLUT4 in fraction T represents sorting endosomes, whereas GLUT4 in fractions H and L represents storage endosomes and exocytic vesicles, respectively. The subcellular fractionation without homogenization described here should be useful in identifying the role of the individual GLUT4 compartments and the associated proteins in insulin-induced GLUT4 recruitment in rat adipocytes.	Vet Adm Med Ctr, Biophys Lab, Buffalo, NY 14215 USA; SUNY Buffalo, Sch Med, Dept Physiol & Biophys, Buffalo, NY 14215 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Boston University	Jung, CY (corresponding author), Vet Adm Med Ctr, Biophys Lab, 3495 Bailey Ave, Buffalo, NY 14215 USA.		Souto, Ricardo/F-7828-2012; Lee, Wan/B-6252-2013	Souto, Ricardo/0000-0002-6281-5956; Lee, Wan/0000-0002-5181-2135; Pilch, Paul/0000-0003-1997-0499; Ryu, Jiwon/0000-0003-0251-7858	NIDDK NIH HHS [R01 DK13376, R01 DK30425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425, R01DK013376] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIN CC, 1992, J BIOL CHEM, V267, P11681; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; Charron MJ, 1999, J BIOL CHEM, V274, P3253, DOI 10.1074/jbc.274.6.3253; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1987, J BIOL CHEM, V262, P11817; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JHUN BH, 1991, J BIOL CHEM, V266, P22260; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; Lee W, 1997, BIOCHEM BIOPH RES CO, V240, P409, DOI 10.1006/bbrc.1997.7671; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MARTZ A, 1986, J BIOL CHEM, V261, P3606; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; RODBELL M, 1967, J BIOL CHEM, V242, P5751; RODBELL M, 1964, J BIOL CHEM, V239, P375; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; Sleeman MW, 1998, J BIOL CHEM, V273, P3132, DOI 10.1074/jbc.273.6.3132; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; YANG J, 1993, J BIOL CHEM, V268, P4600	55	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37755	37762		10.1074/jbc.274.53.37755	http://dx.doi.org/10.1074/jbc.274.53.37755			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608836	hybrid			2022-12-25	WOS:000084528000036
J	Prigent-Tessier, A; Tessier, C; Hirosawa-Takamori, M; Boyer, C; Ferguson-Gottschall, S; Gibori, G				Prigent-Tessier, A; Tessier, C; Hirosawa-Takamori, M; Boyer, C; Ferguson-Gottschall, S; Gibori, G			Rat decidual prolactin - Identification, molecular cloning, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL GENE-EXPRESSION; HETEROLOGOUS EXPRESSION; LUTEINIZING-HORMONE; LUTEOTROPHIC ACTION; CORPUS-LUTEUM; PROTEIN-B; TISSUE; PREGNANCY; RECEPTORS; CELLS	Establishment and maintenance of pregnancy require the activity of a highly specialized maternal tissue, the decidua. It is well established that the human decidua synthesizes and releases prolactin. However, in the rat, no study has been able to demonstrate the production of prolactin by the decidua. In this report, we established for the first time using Northern blot analysis and reverse transcription-polymerase chain reaction, Western blot analysis, immunocytochemistry, and enzyme-linked immunosorbent assay, that a defined cell population located in the rat antimesometrial decidua ex presses prolactin mRNA, as well as synthesizes and secretes this hormone. By reverse transcription-polymerase chain reaction and rapid amplification of cDNA ends, we cloned a fall-length cDNA for rat decidua prolactin, whose sequence was identical to that of pituitary prolactin. Our results also showed that pituitary prolactin appeared to down-regulate decidual prolactin levels. Under these circumstances, inhibition of pituitary prolactin secretion led to a rise in both decidual prolactin mRNA and protein expression. Moreover, addition of exogenous prolactin to primary decidual cells in culture also caused a marked decrease in decidual prolactin mRNA expression. Finally, treatment of primary decidual cells with steroid hormones or 8-bromo-cAMP revealed a differential regulation of decidual prolactin expression from that of pituitary suggesting a tissue-specific regulation of prolactin gene expression, possibly through the use of an alternative promoter in rat decidua.	Univ Illinois, Coll Med, Dept Physiol & Biophys MC 901, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gibori, G (corresponding author), Univ Illinois, Coll Med, Dept Physiol & Biophys MC 901, 835 S Wolcott Ave, Chicago, IL 60612 USA.	ggibori@uic.edu		tessier, anne/0000-0001-6655-5074	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012356] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-12356] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAHAMSOHN PA, 1993, J EXP ZOOL, V266, P603, DOI 10.1002/jez.1402660610; Akcali KC, 1996, ENDOCRINOLOGY, V137, P3123, DOI 10.1210/en.137.7.3123; ALBARRACIN CT, 1994, J BIOL CHEM, V269, P7772; ALBARRACIN CT, 1991, ENDOCRINOLOGY, V129, P1821, DOI 10.1210/endo-129-4-1821; BASURAY R, 1980, BIOL REPROD, V23, P507, DOI 10.1095/biolreprod23.3.507; BASURAY R, 1983, BIOL REPROD, V28, P551, DOI 10.1095/biolreprod28.3.551; BELL SC, 1983, OXFORD REV REPRODUCT, V5, P220; CHAN YL, 1987, J BIOL CHEM, V262, P1111; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENTS J, 1983, ENDOCRINOLOGY, V112, P1133, DOI 10.1210/endo-112-3-1133; Cohick CB, 1997, J ENDOCRINOL, V152, P291, DOI 10.1677/joe.0.1520291; COOKE NE, 1982, NATURE, V297, P603, DOI 10.1038/297603a0; CROZE F, 1990, ENDOCRINOLOGY, V127, P2665, DOI 10.1210/endo-127-6-2665; DAVIS JRE, 1990, J ENDOCRINOL, V125, P171, DOI 10.1677/joe.0.1250171; DEFEO VJ, 1967, CELLULAR BIOL UTERUS, P191; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; DUCKWORTH ML, 1988, MOL ENDOCRINOL, V2, P912, DOI 10.1210/mend-2-10-912; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GELLERSEN B, 1989, MOL CELL ENDOCRINOL, V64, P127, DOI 10.1016/0303-7207(89)90073-7; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; GIBORI G, 1981, ENDOCRINOLOGY, V108, P2060, DOI 10.1210/endo-108-6-2060; GIBORI G, 1985, ENDOCRINOLOGY, V116, P1784, DOI 10.1210/endo-116-5-1784; GIBORI G, 1994, REPROD BIOL, P217; GIBORI G, 1984, ENDOCRINOLOGY, V115, P1157, DOI 10.1210/endo-115-3-1157; GIBORI G, 1974, ENDOCRINOLOGY, V95, P1113, DOI 10.1210/endo-95-4-1113; GIBORI G, 1987, REGULATION OVARIAN T, P379; GIBORI G, 1995, MOL CELLULAR ASPECTS, P67; GLASSER SR, 1990, TROPOBLAST INVASION, P377; GOLANDER A, 1978, SCIENCE, V202, P311, DOI 10.1126/science.694535; GU Y, 1994, ENDOCRINOLOGY, V135, P1272, DOI 10.1210/en.135.3.1272; GU Y, 1995, ENDOCRINOLOGY, V136, P2451, DOI 10.1210/en.136.6.2451; GU Y, 1992, ENDOCRINOLOGY, V131, P1321, DOI 10.1210/en.131.3.1321; Gu Y, 1996, ENDOCRINOLOGY, V137, P4878, DOI 10.1210/en.137.11.4878; GU Y, 1994, ENDOCRINOLOGY, V135, P1422, DOI 10.1210/en.135.4.1422; HERZ Z, 1986, ENDOCRINOLOGY, V118, P2203, DOI 10.1210/endo-118-6-2203; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JAYATILAK PG, 1984, BIOL REPROD, V31, P556, DOI 10.1095/biolreprod31.3.556; JAYATILAK PG, 1989, ENDOCRINOLOGY, V125, P659, DOI 10.1210/endo-125-2-659; JAYATILAK PG, 1985, P NATL ACAD SCI USA, V82, P217, DOI 10.1073/pnas.82.1.217; JAYATILAK PG, 1986, J ENDOCRINOL, V110, P115, DOI 10.1677/joe.0.1100115; KALISON B, 1985, J ENDOCRINOL, V104, P241, DOI 10.1677/joe.0.1040241; LABRIE F, 1980, J STEROID BIOCHEM, V12, P323, DOI 10.1016/0022-4731(80)90287-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lockwood CJ, 1996, J SOC GYNECOL INVEST, V3, P159, DOI 10.1016/1071-5576(96)00005-6; MACMANUS JP, 1989, BIOCHEM BIOPH RES CO, V159, P278, DOI 10.1016/0006-291X(89)92434-0; MARTEL D, 1984, ENDOCRINOLOGY, V114, P1627, DOI 10.1210/endo-114-5-1627; Orwig KE, 1997, ENDOCRINOLOGY, V138, P2491, DOI 10.1210/en.138.6.2491; Parr MB., 1989, BIOL UTERUS, P233; Rasmussen CA, 1996, ENDOCRINOLOGY, V137, P5558, DOI 10.1210/en.137.12.5558; Rasmussen CA, 1997, BIOL REPROD, V56, P647, DOI 10.1095/biolreprod56.3.647; RIDDICK DH, 1978, LIFE SCI, V23, P1913, DOI 10.1016/0024-3205(78)90557-X; ROBY KF, 1993, J BIOL CHEM, V268, P3136; ROTHCHILD I, 1975, ENDOCRINOLOGY, V97, P838, DOI 10.1210/endo-97-4-838; SMITH MS, 1976, ENDOCRINOLOGY, V98, P696, DOI 10.1210/endo-98-3-696; Soares MJ, 1998, BIOL REPROD, V58, P273, DOI 10.1095/biolreprod58.2.273; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; SORTINO MA, 1989, ENDOCRINOLOGY, V124, P2013, DOI 10.1210/endo-124-4-2013; TANG BQ, 1993, ENDOCRINOLOGY, V133, P2197, DOI 10.1210/en.133.5.2197; Telgmann R, 1998, HUM REPROD UPDATE, V4, P472, DOI 10.1093/humupd/4.5.472; Zhong L, 1997, BIOCHEM BIOPH RES CO, V235, P587, DOI 10.1006/bbrc.1997.6833	61	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37982	37989		10.1074/jbc.274.53.37982	http://dx.doi.org/10.1074/jbc.274.53.37982			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608866	hybrid			2022-12-25	WOS:000084528000066
J	Ide, N; Hata, Y; Nishioka, H; Hirao, K; Yao, I; Deguchi, M; Mizoguchi, A; Nishimori, H; Tokino, T; Nakamura, Y; Takai, Y				Ide, N; Hata, Y; Nishioka, H; Hirao, K; Yao, I; Deguchi, M; Mizoguchi, A; Nishimori, H; Tokino, T; Nakamura, Y; Takai, Y			Localization of membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 at tight junctions of epithelial cells	ONCOGENE			English	Article						MAGI-1/BAP1; SAP97/hDLG; E-cadherin; ZO-1; tight junction	TUMOR-SUPPRESSOR PROTEIN; POSTSYNAPTIC DENSITY; SIGNALING PATHWAYS; HUMAN HOMOLOG; DOMAIN; FAMILY; APC; INTERACTS; BINDING; PSD-95	Membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 and Synapse-associated protein (SAP) 97/human Discs-large tumor suppressor gene (hDLG) are ubiquitous isoforms of synaptic scaffolding molecule (S-SCAM) and Postsynaptic density(PSD)-95/SAP90, both of which are implicated in the structures of synapses, respectively. SAP97/hDLG is localized at epithelial junctions and may function as a scaffolding protein, but the subcellular localization or the function of MAGI-1/BAP1 has not been clarified. In intestinal epithelial cells, MAGI-1/BAP1 was localized at tight junctions, whereas SAP97/hDLG was localized diffusely at cell-cell junctions. In Madine Darby canine kidney (MDCK) cells, MAGI-1/BAP1 was colocalized with ZO-1, whereas SAP97/hDLG was colocalized with E-cadherin. In MDCK cells, dominant active and negative mutants of Rad small G protein changed the amounts of SAP97/hDLG at cell-cell junctions, but not that of MAGI-1/BAP1. When MDCK cells were switched to a low Ca2+ medium, E-cadherin disappeared from the plasma membrane, and cells were dissociated. The phorbol 12-myristate 13-acetate-treatment after the low Ca2+ switch induced a tight junction-like structure. MAGI-1/BAP1 was recruited with ZO-1 to this structure, but SAP97/hDLG or E-cadherin was not. These findings suggest that MAGI-1/BAP1 is a component of tight junctions of epithelial cells, and that its role is different from that of SAP97/hDLG.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, ERATO, Takai Biotimer Project, JCR Pharmaceut Co Ltd, Kobe, Hyogo 6512241, Japan; Kyoto Univ, Grad Sch, Dept Anat & Neurobiol, Kyoto 6068315, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	Osaka University; Japan Science & Technology Agency (JST); Kyoto University; University of Tokyo	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Tokino, Takashi/AAI-9887-2021					Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Reuver SM, 1998, J CELL SCI, V111, P1071; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889	31	102	102	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7810	7815		10.1038/sj.onc.1203153	http://dx.doi.org/10.1038/sj.onc.1203153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618722				2022-12-25	WOS:000084256900011
J	Karsunky, H; Geisen, C; Schmidt, T; Haas, K; Zevnik, B; Gau, E; Moroy, T				Karsunky, H; Geisen, C; Schmidt, T; Haas, K; Zevnik, B; Gau, E; Moroy, T			Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc	ONCOGENE			English	Article						cyclin E; Ki-ras; p27(KIP1); MNU; lymphoma; oncogene cooperation	BREAST-CANCER CELLS; CDK INHIBITORS; RETINOBLASTOMA PROTEIN; RESTRICTION POINT; DEPENDENT KINASES; THYMIC LYMPHOMAS; NUCLEAR-PROTEIN; EXPRESSION; PROLIFERATION; P27(KIP1)	To study the oncogenic activity of cyclin E in an in vivo system we generated transgenic mice expressing high levels of cyclin Ii: in T-lymphocytes by using a construct containing the CD2 locus control region. These animals were neither predisposed to develop any tumors spontaneously nor showed an increased incidence when crossbred with E mu L-myc transgenic mice but developed hyperplasia in peripheral lymphoid organs at later age with an incidence of 27%. When treated with the DNA methylating carcinogen N-methylnitrosourea (MNU) that provokes the development of T-cell lymphomas, CD2-cyclin E transgenic animals came down with T-cell neoplasia showing a significant higher incidence (54%) than normal non transgenic controls (31%). In one of eight tumors that arose in normal MNU treated mice me could find an expected activating point mutation in the Ki-ras gene (12.5%). In contrast, the same mutation occurred in five of 16 tumors from CD2-cyclin E transgenic mice (31.2%). Whereas cyclin E overexpression alone did not lead to an increased CDK2 activity we observed in ail tumors that emerged from either MNU treated normal mice or treated CD2-cyclin E transgenics a downregulation of p27(KIP1) and a higher histone HI kinase activity: in CDK2 immunoprecipitates compared to normal tissue. These findings demonstrate that high level expression of cyclin E can predispose T-cells for hyperplasia and malignant transformation. However, the results also suggest that this activity of cyclin E is manifest only when other cooperating oncogenes in particular I as genes are present and activated. This would be consistent with our previous finding that cyclin E and Ha-Ras cooperate in focus formation assays in rat embryo fibroblasts.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011; Zevnik, Branko/AAB-7853-2020	Zevnik, Branko/0000-0001-7845-9522				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Erlanson M, 1998, BLOOD, V92, P770; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL M, 1995, ONCOGENE, V11, P1581; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hogan B, 1994, MANIPULATING MOUSE E; JOSHI VV, 1970, J NATL CANCER I, V44, P185; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LIU LL, 1994, CANCER RES, V54, P4648; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; NEWCOMB EW, 1995, MOL CARCINOGEN, V13, P89, DOI 10.1002/mc.2940130205; NEWCOMB EW, 1989, ANTICANCER RES, V9, P1407; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; SEWING A, 1993, J CELL SCI, V104, P545; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WOLOWIEC D, 1995, LEUKEMIA, V9, P1382; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	45	37	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7816	7824		10.1038/sj.onc.1203205	http://dx.doi.org/10.1038/sj.onc.1203205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618723				2022-12-25	WOS:000084256900012
J	Nur-E-Kamal, MSA; Kamal, JM; Qureshi, MM; Maruta, H				Nur-E-Kamal, MSA; Kamal, JM; Qureshi, MM; Maruta, H			The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation	ONCOGENE			English	Article						CDC42; ACK; NGF; neurite outgrowth; Ras transformation; tumor suppressor	PROTEIN; BRADYKININ; GTPASE; GAP; ACTIVATION; DOMAIN; GROWTH	Based on the previous experiments with the N17 mutant of CDC42, it has been speculated, but not proved as yet, that CDC42 is required for Ras-induced malignant transformation of fibroblasts. However, since this inhibitor could sequester many GDP-dissociation stimulators (GDSs), such as DBL, OST and Tiam-1 which activate not only CDC42, but also Rho or Rac, in fact it is not a specific inhibitor that inactivates only CDC42, Thus, we have taken the minimum CDC42-binding domain (residues 504-545, called ACK42) of the Tyr-kinase ACK-1 that binds only CDC42 in the GTP-bound form, and thereby blocking the interactions of CDC42-GTP with its downstream effecters such as ACKs, PAKs and N-WASP, First of all, using the ACK42-GST fusion protein as a specific ligand for the GTP-CDC42 complex, we have revealed that CDC42 is activated by oncogenic Ras mutants such as v-Ha-Ras in NIH3T3 fibroblasts, and similarly in PC12 cells by both NGF (Nerve Growth Factor) and EGF (Epidermal Growth Factor) which activate the endogenous normal Ras, providing the first direct evidence that CDC42 acts downstream of Ras and NGF/EGF. Furthermore, over-expression of ACK42 completely reversed Ras-induced malignant phenotypes such as focus formation and anchorage/serum-independent growth of the fibroblasts, and a cell-permeable derivative of ACK42 called WR-ACK42 strongly inhibited the growth of Ras transformants, with little effect on the parental normal cell growth, and also abolished Ras-induced filopodium/microspike formation of the fibroblasts which is CDC42-dependent. These observations unambiguously proved for the first time that the RAS-induced activation of CDC42 is indeed essential for Ras to transform the fibroblasts, and furthermore suggest that ACK42 or its peptidomimetics are potentially useful for genotherapy or chemotherapy of Ras-associated cancer.	Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Univ Med & Dent New Jersey, RW Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; UAE Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain 17666, U Arab Emirates	Ludwig Institute for Cancer Research; Rutgers State University New Brunswick; Rutgers State University Medical Center; United Arab Emirates University	Maruta, H (corresponding author), Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia.							Aramori I, 1997, MOL PHARMACOL, V51, P171, DOI 10.1124/mol.51.2.171; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MARUTA H, 1998, MOL B INT U, V3, P151; MARUTA H, 1996, REGULATION RAS SIGNA, P139; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Wang DZM, 1997, CANCER RES, V57, P2478; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819	27	47	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7787	7793						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618719				2022-12-25	WOS:000084256900008
J	Nass, SJ; Ferguson, AT; El-Ashry, D; Nelson, WG; Davidson, NE				Nass, SJ; Ferguson, AT; El-Ashry, D; Nelson, WG; Davidson, NE			Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells	ONCOGENE			English	Article						breast cancer; estrogen receptor; DNA methylation; S phase; p21	RECEPTOR GENE-EXPRESSION; ESTROGEN-RECEPTOR; SIGNALING PATHWAY; METHYLTRANSFERASE; GROWTH; CARCINOGENESIS; PROGRESSION; ISLANDS; TARGET	Estrogen receptor (ER)-negative breast cancer cells display extensive methylation of the ER gene CpG island and elevated DNA methyltransferase (DMT) expression compared to ER-positive cells. The present study demonstrates that DMT protein levels tightly correlate with S phase fraction in ER-positive cells, whereas ER-negative cells express DMT throughout the cell cycle. In addition, levels of p21(CIP1), which disrupts DMT binding to PCNA, are inversely correlated with DMT levels, Therefore increased DMT expression in ER-negative cells is not simply due to elevated S-phase fraction, but rather to more complex changes that allow cells to escape normal cell cycle-dependent controls on DMT expression. Because ER-negative breast tumors often have activated growth factor pathways, the impact of these pathways on DMT expression was examined in ER-positive cells. Stable transfection with fibroblast growth factors (FGFs) 1 and 4 led to increased DMT expression that could not be accounted for by a shift in S phase fraction. Elevated DMT protein expression in FGF-transfectants was accompanied by a significant decrease in p21, again suggesting a reciprocal relationship between these two proteins. However, acquisition of an estrogen-independent phenotype, even in conjunction with elevated DMT levels, was not sufficient to promote ER gene silencing via methylation, These results indicate that multiple steps are required for de novo methylation of the ER CpG island.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20007 USA	Johns Hopkins University; Johns Hopkins Medicine; Georgetown University	Davidson, NE (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, 422 N Bond St, Baltimore, MD 21231 USA.			Nass, Sharyl/0000-0001-5874-5337				Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clarke M, 1998, LANCET, V351, P1451; CLARKE R, 1994, BREAST CANCER RES TR, V31, P237, DOI 10.1007/BF00666157; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; FERGUSON AT, 1995, CANCER RES, V55, P2279; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lapidus RG, 1998, CANCER RES, V58, P2515; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MIYOSHI E, 1993, CARCINOGENESIS, V14, P603, DOI 10.1093/carcin/14.4.603; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SAMAAN NA, 1981, CANCER, V47, P554, DOI 10.1002/1097-0142(19810201)47:3<554::AID-CNCR2820470322>3.0.CO;2-W; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; VICKER PJ, 1988, MOL ENDOCRINOL, V2, P866; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891	34	32	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7453	7461		10.1038/sj.onc.1203138	http://dx.doi.org/10.1038/sj.onc.1203138			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602504				2022-12-25	WOS:000084119600006
J	Liao, GJ; Kreitzer, G; Cook, TA; Gundersen, GG				Liao, GJ; Kreitzer, G; Cook, TA; Gundersen, GG			A signal transduction pathway involved in microtubule-mediated cell polarization	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		VIMENTIN INTERMEDIATE FILAMENTS; DETYROSINATED MICROTUBULES; SELECTIVE STABILIZATION; ORGANELLE TRANSPORT; ALPHA-TUBULIN; KINESIN; MITOCHONDRIA; FIBROBLASTS; TYROSINE; CHAIN		Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Gundersen, GG (corresponding author), Columbia Univ, Dept Anat & Cell Biol, 630 W 168th St, New York, NY 10032 USA.							ARGARANA CE, 1978, MOL CELL BIOCHEM, V19, P17; BALL EH, 1982, P NATL ACAD SCI-BIOL, V79, P123, DOI 10.1073/pnas.79.1.123; BLOSE SH, 1976, J CELL BIOL, V70, P459, DOI 10.1083/jcb.70.2.459; BULINSKI JC, 1991, BIOESSAYS, V13, P285, DOI 10.1002/bies.950130605; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; GUNDERSEN GG, 1987, J CELL BIOL, V105, P251, DOI 10.1083/jcb.105.1.251; GUNDERSEN GG, 1994, J CELL SCI, V107, P645; GUNDERSEN GG, 1988, P NATL ACAD SCI USA, V85, P5946, DOI 10.1073/pnas.85.16.5946; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; GURLAND G, 1995, J CELL BIOL, V131, P1275, DOI 10.1083/jcb.131.5.1275; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; HALLAK ME, 1977, FEBS LETT, V73, P147, DOI 10.1016/0014-5793(77)80968-X; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Khodjakov A, 1998, MOL BIOL CELL, V9, P333, DOI 10.1091/mbc.9.2.333; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kreitzer G, 1999, MOL BIOL CELL, V10, P1105, DOI 10.1091/mbc.10.4.1105; Liao GJ, 1998, J BIOL CHEM, V273, P9797, DOI 10.1074/jbc.273.16.9797; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; Martys JL, 1999, MOL BIOL CELL, V10, P1289, DOI 10.1091/mbc.10.5.1289; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; NAGASAKI T, 1992, CELL MOTIL CYTOSKEL, V23, P45, DOI 10.1002/cm.970230106; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; RAYBIN D, 1977, BIOCHEMISTRY-US, V16, P2189, DOI 10.1021/bi00629a023; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; VALE RD, 1988, J CELL BIOL, V107, P2233, DOI 10.1083/jcb.107.6.2233; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387	32	13	13	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S257	S260		10.1096/fasebj.13.9002.S257	http://dx.doi.org/10.1096/fasebj.13.9002.S257			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619139				2022-12-25	WOS:000084390200017
J	Liu, CL; Tsai, CC; Lin, SC; Wang, LI; Hsu, CI; Hwang, MJ; Lin, JY				Liu, CL; Tsai, CC; Lin, SC; Wang, LI; Hsu, CI; Hwang, MJ; Lin, JY			Primary structure and function analysis of the Abrus precatorius agglutinin A chain by site-directed mutagenesis - Pro(199) of amphiphilic alpha-helix H impairs protein synthesis inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; RIBOSOME-INACTIVATING PROTEINS; AMINO-ACID-RESIDUES; X-RAY-ANALYSIS; ABRIN-A; B-CHAIN; EUKARYOTIC RIBOSOMES; NUCLEOTIDE-SEQUENCE; COMMUNIS AGGLUTININ; ESCHERICHIA-COLI	Abrus agglutinin (AAG), a low-toxicity protein from the plant Abrus precatorius, is less lethal than abrina (ABRa) in mice (LD50 = 5 mg/kg versus 20 mu g/kg of body weight). Nucleotide sequence analysis of a cDNA clone encoding full-length AAG showed an open reading frame with 1641 base pairs, corresponding to a 547-amino acid residue preproprotein containing a signal peptide and a linker region (two amino acid residues) between the AAG-A and AAG-B subunits, AAG had high homology to ABRa (77.8%). The 13 amino acid residues involved in catalytic function, which are highly conserved among abrins and ricins, were also conserved within AAG-A, The protein synthesis inhibitory activity of AAG-A (IC50 = 3.5 nM) was weaker than that of ABRa-A (0.05 nM), Molecular modeling followed by site-directed mutagenesis showed that Pro(199) of AAG-A, located in amphiphilic helix H and corresponding to Asn(200) of ABRa-A, can induce bending of helix H. This bending would presumably affect the binding of AAG-A to its target sequence, GpApGpAp, in the tetraloop structure of the 28 S rRNA subunit and could be one of the major factors contributing to the relatively weak protein synthesis inhibitory activity and toxicity of AAG.	Natl Taiwan Univ, Coll Med, Inst Biochem, Taipei 100, Taiwan; Natl Def Med Ctr, Inst Life Sci, Taipei, Taiwan; Acad Sinica, Inst Biomed, Taipei 115, Taiwan	National Taiwan University; National Defense Medical Center; Academia Sinica - Taiwan	Lin, JY (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem, 9F,1 Sect,1 JenAi Rd, Taipei 100, Taiwan.		Lin, Su-Chang/F-2899-2016; Lin, Jung-Yaw/AGW-9336-2022	Lin, Su-Chang/0000-0003-0687-3139; Lin, Jung-Yaw/0000-0002-6341-1160				BARBIERI L, 1982, CANCER SURV, V1, P489; BOULTER D, 1984, PHILOS T ROY SOC B, V304, P323, DOI 10.1098/rstb.1984.0027; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; Chen JK, 1997, PROTEIN ENG, V10, P827, DOI 10.1093/protein/10.7.827; CHEN YL, 1992, FEBS LETT, V309, P115, DOI 10.1016/0014-5793(92)81076-X; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; ENDO Y, 1991, J MOL BIOL, V221, P193, DOI 10.1016/0022-2836(91)90814-M; FUNATSU G, 1991, BIOCHIMIE, V73, P1157, DOI 10.1016/0300-9084(91)90160-3; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HUANG QC, 1995, BIOCHEM J, V309, P285, DOI 10.1042/bj3090285; HUNG CH, 1994, EUR J BIOCHEM, V219, P83, DOI 10.1111/j.1432-1033.1994.tb19917.x; HUNG CH, 1992, BIOCHEM BIOPH RES CO, V184, P1524, DOI 10.1016/S0006-291X(05)80056-7; HUNG CH, 1993, J MOL BIOL, V229, P263, DOI 10.1006/jmbi.1993.1029; Kaku H, 1996, J BIOL CHEM, V271, P1480, DOI 10.1074/jbc.271.3.1480; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; Kitaoka Y, 1998, EUR J BIOCHEM, V257, P255, DOI 10.1046/j.1432-1327.1998.2570255.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LIN JY, 1981, J NATL CANCER I, V66, P523; LIN JY, 1981, TOXICON, V19, P41; Lin SH, 1996, EUR J BIOCHEM, V240, P564, DOI 10.1111/j.1432-1033.1996.0564h.x; MA XG, 1987, SCI CHINA SER B, V30, P692; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICOLSON GL, 1972, BIOCHIM BIOPHYS ACTA, V266, P543, DOI 10.1016/0005-2736(72)90109-5; NICOLSON GL, 1972, CANCER RES, V35, P144; NIELSEN NC, 1984, PHILOS T ROY SOC B, V304, P287, DOI 10.1098/rstb.1984.0024; OELTMANN TN, 1991, FASEB J, V5, P2334, DOI 10.1096/fasebj.5.10.1676688; OLSNES S, 1982, RECEPTORS RECOGNITIO, V31, P131; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; ROBERTS LM, 1985, J BIOL CHEM, V260, P5682; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRIPE F, 1992, BIOTECHNOLOGY, V10, P405; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	44	36	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1897	1901		10.1074/jbc.275.3.1897	http://dx.doi.org/10.1074/jbc.275.3.1897			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636890	hybrid			2022-12-25	WOS:000084940000053
J	Nguyen, BD; Xia, ZC; Cutruzzola, F; Allocatelli, CT; Brunori, R; La Mar, GN				Nguyen, BD; Xia, ZC; Cutruzzola, F; Allocatelli, CT; Brunori, R; La Mar, GN			Solution H-1 NMR study of the influence of distal hydrogen bonding and N terminus acetylation on the active site electronic and molecular structure of Aplysia limacina cyanomet myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; AMINO-ACID-SEQUENCES; HEME CAVITY; PARAMAGNETIC PROTEIN; ASCARIS HEMOGLOBIN; 2-DIMENSIONAL NMR; CYANIDE COMPLEXES; CRYSTAL-STRUCTURE; MET MYOGLOBIN; AXIAL LIGANDS	The sea hare Aplysia limacina possesses a myoglobin in which a distal H-bond is provided by Arg E10 rather than the common His E7. Solution H-1 NMR studies of the cyanomet complexes of true wild-type (WT), recombinant wild-type (rWT), and the V(E7)H/R(E10)T and V(E7)H mutants of Aplysia Mb designed to mimic the mammalian Rib heme pocket reveal that the distal His in the mutants is rotated out of the heme pocket and is unable to provide a stabilizing H-bond to bound ligand and that WT and rWT differ both in the thermodynamics of heme orientational disorder and in heme contact shift pattern. The mean of the four heme methyl shifts is shown to serve as a sensitive indicator of variations in distal H-bonding among a set of mutant cyanomet globins. The heme pocket perturbations in rWT relative to WT were traced to the absence of the N-terminal acetyl group ill rWT that participates in an H-bond to the EF corner in WT. Analysis of dipolar contacts between heme and axial His and between heme and the protein matrix reveal a small similar to 2 degrees rotation of the axial His in rWT relative to true WT and a similar to 3 degrees rotation of the heme in the double mutant relative to rWT Mb. It is demonstrated that both the direction and magnitude of the rotation of the axial His relative to the heme can be determined from the change in the pattern of the contact-dominated heme methyl shift and from the dipolar-dominated heme meso-H shift. However, only NOE data can determine whether it is the His or heme that actually rotates in the protein matrix.	Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; Univ Roma La Sapienza, Dipartimento Sci Biochim, I-00185 Rome, Italy	University of California System; University of California Davis; Sapienza University Rome	La Mar, GN (corresponding author), Univ Calif Davis, Dept Chem, Davis, CA 95616 USA.	lamar@indigo.ucdavis.edu	Cutruzzola', Francesca/G-4052-2011	Cutruzzola', Francesca/0000-0002-4621-2135; Brunori, Maurizio/0000-0002-7795-1635	NHLBI NIH HHS [HL 16087] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016087, R01HL016087] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BAX A, 1982, 2 DIMENSIONAL NUCLEA, P50; BERTINI I, 1993, CHEM REV, V93, P2833, DOI 10.1021/cr00024a009; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CROSS KJ, 1985, J MAGN RESON, V64, P220, DOI 10.1016/0022-2364(85)90346-4; Cutruzzola F, 1996, BIOCHEM J, V314, P83, DOI 10.1042/bj3140083; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P65; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; INUBUSHI T, 1983, J MAGN RESON, V51, P128, DOI 10.1016/0022-2364(83)90109-9; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; Krzywda S, 1998, BIOCHEMISTRY-US, V37, P15896, DOI 10.1021/bi9812470; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; La Mar G.N., 2000, PORPHYRIN HDB, V5, P185; LAMAR GN, 1977, BIOCHIM BIOPHYS ACTA, V498, P422, DOI 10.1016/0304-4165(77)90280-X; LECOMTE JTJ, 1987, J AM CHEM SOC, V109, P7219, DOI 10.1021/ja00257a068; Nguyen BD, 1999, J AM CHEM SOC, V121, P208, DOI 10.1021/ja982555o; Nguyen BD, 1998, J BIOL CHEM, V273, P9517, DOI 10.1074/jbc.273.16.9517; PANDE U, 1986, BIOCHEMISTRY-US, V25, P5638, DOI 10.1021/bi00367a044; PEYTON DH, 1989, BIOCHEMISTRY-US, V28, P4880, DOI 10.1021/bi00437a053; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; QIN J, 1993, BIOPHYS J, V65, P2178, DOI 10.1016/S0006-3495(93)81270-0; QIN J, 1992, J BIOMOL NMR, V2, P597, DOI 10.1007/BF02192849; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; QIN J, 1993, J MOL BIOL, V231, P1009, DOI 10.1006/jmbi.1993.1348; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P5493, DOI 10.1021/bi00184a018; RAJARATHNAM K, 1993, BIOCHEMISTRY-US, V32, P5670, DOI 10.1021/bi00072a024; Shokhirev NV, 1998, J BIOL INORG CHEM, V3, P581, DOI 10.1007/s007750050271; Shokhirev NV, 1998, J AM CHEM SOC, V120, P981, DOI 10.1021/ja972265s; SHULMAN RG, 1971, J MOL BIOL, V57, P93, DOI 10.1016/0022-2836(71)90121-5; SMERDON SJ, 1995, BIOCHEMISTRY-US, V34, P8715, DOI 10.1021/bi00027a022; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; SUZUKI T, 1986, J BIOL CHEM, V261, P3692; TENTORI L, 1973, INT J PEPT PROT RES, V5, P187; TRAVAGLINI ALLOCATELLI C, 1994, FEBS LETT, V352, P63, DOI 10.1016/0014-5793(94)00918-X; TRAYLOR TG, 1980, J AM CHEM SOC, V102, P2844, DOI 10.1021/ja00528a058; TURNER DL, 1995, EUR J BIOCHEM, V227, P829, DOI 10.1111/j.1432-1033.1995.tb20208.x; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wu YY, 1998, BIOCHEMISTRY-US, V37, P6979, DOI 10.1021/bi9728295; Wu YY, 1996, BBA-PROTEIN STRUCT M, V1298, P261, DOI 10.1016/S0167-4838(96)00137-9; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P131; Yamamoto Y, 1998, ANNU REP NMR SPECTRO, V36, P1, DOI 10.1016/S0066-4103(08)60005-8; YAMAMOTO Y, 1990, FEBS LETT, V264, P113; Yamamoto Y, 1998, BBA-PROTEIN STRUCT M, V1388, P349, DOI 10.1016/S0167-4838(98)00193-9; YAMAMOTO Y, 1992, J MOL BIOL, V228, P343, DOI 10.1016/0022-2836(92)90823-3; Zhang W, 1997, BIOPHYS J, V73, P1019, DOI 10.1016/S0006-3495(97)78135-9; Zhang W, 1996, EUR J BIOCHEM, V237, P841, DOI 10.1111/j.1432-1033.1996.0841p.x; ZHAO XF, 1995, J BIOL CHEM, V270, P20763, DOI 10.1074/jbc.270.35.20763	55	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					742	751		10.1074/jbc.275.2.742	http://dx.doi.org/10.1074/jbc.275.2.742			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625603	hybrid			2022-12-25	WOS:000084836600007
J	Oda, Y; Tu, CL; Chang, WH; Crumrine, D; Komuves, L; Mauro, T; Elias, PM; Bikle, DD				Oda, Y; Tu, CL; Chang, WH; Crumrine, D; Komuves, L; Mauro, T; Elias, PM; Bikle, DD			The calcium sensing receptor and its alternatively spliced form in murine epidermal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED ENVELOPE; KERATINOCYTE DIFFERENTIATION; EXTRACELLULAR CALCIUM; CA2+-SENSING RECEPTOR; FUNCTIONAL EXPRESSION; CLONING; CELLS; HYPERPARATHYROIDISM; TRANSGLUTAMINASE; HYPERCALCEMIA	We have recently reported that human keratinocytes express both the full-length calcium sensing receptor (CaR) and an alternatively spliced form lacking exon 5, which were suggested to be involved in calcium induced keratinocyte differentiation. To understand further the role of these CaRs, we analyzed the structure of mouse CaRs, and investigated their role using a mouse model in which only the full-length CaR was disrupted. Our results show that both the full-length and the alternatively spliced variant lacking exon 5 encoding 77 amino acids of the extracellular domain were expressed in mouse epidermis. The deletion of the full-length CaR increased the production of the alternatively spliced form of CaR in mutant mice. The keratinocytes derived from these mutant mice did not respond to extracellular calcium, suggesting that the full-length CaR is required to mediate calcium signaling in the keratinocytes. The loss of the full-length CaR altered the morphologic appearance of the epidermis and resulted in a reduction of the mRNA and protein levels of the keratinocyte differentiation marker, loricrin. These results indicate that CaR is important in epidermal differentiation, and that the alternatively spliced form does not fully compensate for loss of the full-length CaR.	Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med & Dermatol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Endocrinol, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Oda, Y (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med & Dermatol, 4150 Clement St, San Francisco, CA 94121 USA.	y2073@itsa.ucsf.edu		Tu, Chia-Ling/0000-0002-7323-7733	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448, R01AR038386] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR39448, R01-AR38386] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bikle DD, 1996, J CLIN INVEST, V97, P1085, DOI 10.1172/JCI118501; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Chattopadhyay N, 1996, ENDOCR REV, V17, P289, DOI 10.1210/er.17.4.289; Elias PM, 1998, J INVEST DERMATOL, V110, P399, DOI 10.1046/j.1523-1747.1998.00151.x; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gibson DFC, 1996, J INVEST DERMATOL, V106, P154, DOI 10.1111/1523-1747.ep12329856; HEBERT SC, 1995, CURR OPIN CELL BIOL, V7, P484, DOI 10.1016/0955-0674(95)80004-2; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; Komuves LG, 1998, J INVEST DERMATOL, V111, P429, DOI 10.1046/j.1523-1747.1998.00296.x; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Naito T, 1998, P NATL ACAD SCI USA, V95, P5178, DOI 10.1073/pnas.95.9.5178; Nakamura K, 1999, FASEB J, V13, pA1563; Oda Y, 1998, J BIOL CHEM, V273, P23344, DOI 10.1074/jbc.273.36.23344; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; Quarles LD, 1997, J BONE MINER RES, V12, P393, DOI 10.1359/jbmr.1997.12.3.393; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203	23	94	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1183	1190		10.1074/jbc.275.2.1183	http://dx.doi.org/10.1074/jbc.275.2.1183			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625662	hybrid			2022-12-25	WOS:000084836600066
J	Celie, PHN; Lenting, PJ; Mertens, K				Celie, PHN; Lenting, PJ; Mertens, K			Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor IX contributes to enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA THROMBOPLASTIN ANTECEDENT; HUMAN FACTOR-VIII; X-RAY STRUCTURE; HEMOPHILIA-B; LIGHT-CHAIN; CHRISTMAS FACTOR; CA2+ BINDING; EGF DOMAIN; IN-VITRO; ACTIVATION	The three-dimensional structure of activated factor IX comprises multiple contacts between the two epidermal growth factor (EGF)-like domains. One of these is a salt bridge between Glu(78) and Arg(94), which is essential for binding of factor Ma to its cofactor factor VIII and for factor VIII-dependent factor X activation (Christophe, O. D., Lenting, P. J., Kolkman, J. A. Brownlee, G. G., and Mertens, K. (1998) J. Biol. Chem. 273, 222-227). We now addressed the putative hydrophobic contact at the interface between the EGF-like domains, Recombinant factor IX chimeras were constructed in which hydrophobic regions Phe(75)-Phe(77) and Lys(106)-Val(108) were replaced by the corresponding sites of factor X and factor VII, Activated factor IX/factor X chimeras were indistinguishable from normal factor Ma with respect to factor Ma enzymatic activity. In contrast, factor IXa(75-77)/factor VII displayed similar to 2-fold increased factor X activation in the presence of factor VIII, suggesting that residues 75-77 contribute to cofactor-dependent factor X activation. Activation of factor X by factor IX106-108/factor VII was strongly decreased, both in the absence and presence of factor VIII. Activity could be restored by simultaneous substitution of the hydrophobic sites in both EGF-like domains for factor VII residues. These data suggest that factor Ma enzymatic activity requires hydrophobic contact between the two EGF-like domains.	CLB, Dept Plasma Prot Technol, NL-1066 CX Amsterdam, Netherlands; Univ Utrecht, UIPS, Dept Pharmaceut, NL-3584 CA Utrecht, Netherlands	Utrecht University	Mertens, K (corresponding author), CLB, Dept Plasma Prot Technol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.		Lenting, Peter/AAH-5663-2019; Lenting, Peter/F-8269-2013; Celie, Patrick/AAY-9559-2021	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; 				AHMAD SS, 1992, J BIOL CHEM, V267, P8571; AJAJ SP, 1999, THROMB HAEMOSTASIS, V82, P218; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Celie PHN, 1999, BRIT J HAEMATOL, V106, P792, DOI 10.1046/j.1365-2141.1999.01590.x; Chang JY, 1997, J CLIN INVEST, V100, P886, DOI 10.1172/JCI119604; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Fay PJ, 1999, THROMB HAEMOSTASIS, V82, P193; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LENTING PJ, 1995, J BIOL CHEM, V270, P14884, DOI 10.1074/jbc.270.25.14884; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; MANN KG, 1990, BLOOD, V76, P1; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MERTENS K, 1993, BRIT J HAEMATOL, V85, P133, DOI 10.1111/j.1365-2141.1993.tb08656.x; NISHIMURA H, 1993, J BIOL CHEM, V268, P24041; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; STENFLO J, 1991, BLOOD, V78, P1637; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; TAO BY, 1994, PCR TECHNOLOGY CURRE, P71; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433	40	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					229	234		10.1074/jbc.275.1.229	http://dx.doi.org/10.1074/jbc.275.1.229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617609	hybrid			2022-12-25	WOS:000085951600033
J	Dong, JY; Wiley, HS				Dong, JY; Wiley, HS			Trafficking and proteolytic release of epidermal growth factor receptor ligands are modulated by their membrane-anchoring domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; MAMMARY EPITHELIAL-CELLS; CANINE KIDNEY-CELLS; PHORBOL-ESTER; TGF-ALPHA; EGF PRECURSOR; METALLOPROTEASE INHIBITOR; ECTODOMAIN CLEAVAGE; SIGNAL-TRANSDUCTION	Ligands that bind to the epidermal growth factor (EGF) receptor are initially synthesized as integral membrane proteins that are released from the cell surface by regulated proteolysis. To study the role of the membrane-anchoring domain in ligand release, we made two artificial ligands. The first possessed the membrane-anchoring domain from EGF whereas the second had the corresponding domain from heparin binding EGF-like growth factor (HB-EGF). Both ligands lacked amino-terminal extensions, and were epitope-tagged at the carboxyl terminus, Following stable expression in human mammary epithelial cells, their cellular localization and rate of proteolytic release were examined. We found that constructs with the membrane-anchoring domain from EGF were found primarily at the cell surface and displayed a relatively high rate of constitutive release. Constructs with the HB-EGF membrane-anchoring domain displayed a higher internalized fraction and a very low rate of constitutive release, The two ligand constructs also displayed different patterns of stimulated release. Proteolysis of the chimera with the HB-EGF membrane-anchoring domain was stimulated by activation of protein kinase C, but release of EGF from constructs with the EGF membrane-anchoring domain was insensitive to this. Calcium ionophores, calmodulin antagonists, and tyrosine phosphatase inhibitors stimulated the release of both ligands, Furthermore, the release of the two constructs showed different sensitivity to metalloprotease inhibitors. Despite a large fold-increase in ligand proteolysis following cell stimulation, only a small fraction of total cell-associated ligand was released per hour. Our results show that the membrane-anchoring domain of EGF-like ligands can specify both their localization and proteolytic processing. The structures of the membrane-anchoring region of this class of ligands can thus regulate their activity.	Univ Utah, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Wiley, HS (corresponding author), Univ Utah, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA.			Wiley, Steven/0000-0003-0232-6867	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD028528] Funding Source: NIH RePORTER; NICHD NIH HHS [P01-HD28528] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMOND BD, 1994, J BIOL CHEM, V269, P26635; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Burke PM, 1999, J CELL PHYSIOL, V180, P448, DOI 10.1002/(SICI)1097-4652(199909)180:3<448::AID-JCP16>3.0.CO;2-8; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; EMING SA, 1995, J INVEST DERMATOL, V105, P756, DOI 10.1111/1523-1747.ep12325550; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Hansen LA, 1997, AM J PATHOL, V150, P1959; HARANO T, 1994, J BIOL CHEM, V269, P20305; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; LAKSHMANAN J, 1992, AM J PHYSIOL, V263, pE142, DOI 10.1152/ajpendo.1992.263.1.E142; LANZREIN M, 1995, BIOCHEM J, V310, P285, DOI 10.1042/bj3100285; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MROCZKOWSKI B, 1993, ENDOCRINOLOGY, V132, P417, DOI 10.1210/en.132.1.417; Nakagawa T, 1996, J BIOL CHEM, V271, P30858, DOI 10.1074/jbc.271.48.30858; Niikura H, 1997, INT J GYNECOL PATHOL, V16, P60, DOI 10.1097/00004347-199701000-00010; NISHIKAWA K, 1987, METHOD ENZYMOL, V146, P11; ONO M, 1994, J BIOL CHEM, V269, P31315; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tada H, 1999, J CELL BIOCHEM, V72, P423, DOI 10.1002/(SICI)1097-4644(19990301)72:3<423::AID-JCB11>3.3.CO;2-G; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tsao MS, 1996, EXP CELL RES, V223, P268, DOI 10.1006/excr.1996.0081; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Wiley HS, 1998, J CELL BIOL, V143, P1317, DOI 10.1083/jcb.143.5.1317; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	59	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					557	564		10.1074/jbc.275.1.557	http://dx.doi.org/10.1074/jbc.275.1.557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617651	hybrid			2022-12-25	WOS:000085951600075
J	Genini, D; Budihardjo, I; Plunkett, W; Wang, XD; Carrera, CJ; Cottam, HB; Carson, DA; Leoni, LM				Genini, D; Budihardjo, I; Plunkett, W; Wang, XD; Carrera, CJ; Cottam, HB; Carson, DA; Leoni, LM			Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; CELL-FREE-EXTRACTS; CYTOCHROME-C; DNA-POLYMERASES; IN-VITRO; INDUCTION; 2-CHLORODEOXYADENOSINE; DEATH; EXPRESSION; THERAPY	Adenine deoxynucleosides, such as 2-chloradeoxyadenosine (2CdA) and fludarabine, induce apoptosis in quiescent lymphocytes, and are thus useful drugs for the treatment of indolent lymphoproliferative diseases, We previously demonstrated that that the 5'-triphosphate metabolite of 2CdA (2CdATP), similar to dATP, can co-operate with cytochrome c and apoptosis protein-activating factor-1 (APAF-1) to trigger a caspase pathway in a HeLa cell-free system. We used a fluorometry-based assay of caspase activation to extend the analysis to several other clinically relevant adenine deoxynucleotides in B-chronic lymphocytic leukemia extracts. The nucleotide-induced caspase activation displayed typical Michaelis-Menten kinetics. As estimated by the V-max/K-m ratios, the relative efficiencies of different nucleotides were Ara-ATP > 9-fluoro-9-beta-D-arabinofuranosyladenine 5'-triphosphate > dATP > SCdATP > 9-beta-D-arabinofuranosylguanine 5'-triphosphate > dADP > ATP. In contrast to dADP, both ADP and its nonhydrolyzable alpha,beta-methylphosphonate analog were strong inhibitors of APAF-1-dependent caspase activation. The hierarchy of nucleotide activation was confirmed in a fully reconstituted system using recombinant APAF-1 and recombinant procaspase-9. These results suggest that the potency of adenine deoxynucleotides as co-factors for APAF-1-dependent caspase activation is due bath to stimulation by the 5'-triphosphates and lack of inhibition by the 5'-diphosphates, The capacity of adenine deoxynucleoside metabolites to activate the apoptosome pathway may be an additional biochemical mechanism that plays a role in the chemotherapy of indolent lymphoproliferative diseases.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Univ Texas, SW Med Ctr, Dept Biochem, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center	Leoni, LM (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [P01CA081534, P20CA081534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023200] Funding Source: NIH RePORTER; NCI NIH HHS [CA81534] Funding Source: Medline; NIGMS NIH HHS [GM23200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJAJ S, 1983, BLOOD, V62, P75; Carlucci F, 1997, BBA-MOL BASIS DIS, V1360, P203, DOI 10.1016/S0925-4439(96)00077-4; CARSON DA, 1992, P NATL ACAD SCI USA, V89, P2970, DOI 10.1073/pnas.89.7.2970; CARSON DA, 1983, BLOOD, V62, P737; Eguchi Y, 1997, CANCER RES, V57, P1835; Fenaux P, 1996, LANCET, V347, P1432; GANDHI V, 1993, LEUKEMIA LYMPHOMA, V10, P49, DOI 10.3109/10428199309147356; GOTTLIEB RA, 1995, P NATL ACAD SCI USA, V92, P5965, DOI 10.1073/pnas.92.13.5965; HANADA M, 1993, BLOOD, V82, P1820; HENTOSH P, 1990, J BIOL CHEM, V265, P4033; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Juliusson G, 1996, J CLIN ONCOL, V14, P2160, DOI 10.1200/JCO.1996.14.7.2160; Juliusson G, 1996, ANN ONCOL, V7, P373; KAWASAKI H, 1993, BLOOD, V81, P597; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUSE R, 1985, BLUT, V50, P243, DOI 10.1007/BF00320301; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; LIEBES LF, 1983, CANCER RES, V43, P5608; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marton A, 1997, EUR J BIOCHEM, V250, P467, DOI 10.1111/j.1432-1033.1997.0467a.x; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; MOFFATT JG, 1964, CAN J CHEM, V42, P599, DOI 10.1139/v64-087; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBRIEN S, 1995, BLOOD, V85, P307; PARKER WB, 1988, MOL PHARMACOL, V34, P485; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Robertson LE, 1996, LEUKEMIA, V10, P456; ROBERTSON LE, 1993, BLOOD, V81, P143; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; SHEWACH DS, 1989, CANCER RES, V49, P6498; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang XN, 1997, EXP CELL RES, V235, P210, DOI 10.1006/excr.1997.3667; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	137	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					29	34		10.1074/jbc.275.1.29	http://dx.doi.org/10.1074/jbc.275.1.29			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617581	hybrid			2022-12-25	WOS:000085951600005
J	Poukka, H; Aarnisalo, P; Santti, H; Janne, OA; Palvimo, JJ				Poukka, H; Aarnisalo, P; Santti, H; Janne, OA; Palvimo, JJ			Coregulator small nuclear RING finger protein (SNURF) enhances Sp1-and steroid receptor-mediated transcription by different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANDROGEN RECEPTOR; DNA-BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTORS; ESTROGEN-RECEPTOR; FUNCTIONAL SYNERGY; THYROID-HORMONE; BREAST-CANCER; SP1; COACTIVATOR	The small nuclear RING finger protein SNURF is not only a coactivator in steroid receptor-dependent transcription but also activates transcription from steroid-independent promoters. In this work, we show that SNURF, via the RING finger domain, enhances protein binding to Sp1 elements/GC boxes and interacts and cooperates with Sp1 in transcriptional activation. The activation of androgen receptor (AR) function requires regions other than the RING finger of SNURF, and SNURF does not influence binding of AR to cognate DNA elements. The zinc finger region (ZFR) together with the hinge region of AR are sufficient for contacting SNURF. The nuclear localization signal in the boundary between ZFR and the hinge region participates in the association of AR with SNURF, and a receptor mutant lacking the C-terminal part of the bipartite nuclear localization signal shows attenuated response to coexpressed SNURF. Some AR ZFR point mutations observed in patients with partial androgen insensitivity syndrome or male breast cancer impair the interaction of AR with SNURF and also render AR refractory to the transcription-activating effect of SNURF. Collectively, SNURF modulates the transcriptional activities of androgen receptor and Sp1 via different domains, and it may act as a functional link between steroid- and Sp1-regulated transcription.	Univ Helsinki, Inst Biomed, Dept Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Palvimo, JJ (corresponding author), Univ Helsinki, Inst Biomed, Dept Physiol, POB 9,Siltavuorenpenger 20 J, FIN-00014 Helsinki, Finland.	jorma.palvimo@helsinki.fi		Palvimo, Jorma/0000-0003-2373-0578				Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; ALLERA A, 1995, J CLIN ENDOCR METAB, P2697; ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; Copps K, 1998, EMBO J, V17, P5409, DOI 10.1093/emboj/17.18.5409; Ding H, 1999, J BIOL CHEM, V274, P19573, DOI 10.1074/jbc.274.28.19573; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Gottlieb B, 1998, NUCLEIC ACIDS RES, V26, P234, DOI 10.1093/nar/26.1.234; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hiort O, 1996, AM J MED GENET, V63, P218, DOI 10.1002/(SICI)1096-8628(19960503)63:1<218::AID-AJMG38>3.0.CO;2-P; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Moilanen A, 1997, FEBS LETT, V412, P355, DOI 10.1016/S0014-5793(97)00791-6; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Palvimo JJ, 1996, BIOCHEM J, V316, P993, DOI 10.1042/bj3160993; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Poujol N, 1997, MOL CELL ENDOCRINOL, V130, P43, DOI 10.1016/S0303-7207(97)00072-5; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Weidemann W, 1998, J CLIN ENDOCR METAB, V83, P1173, DOI 10.1210/jc.83.4.1173; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	63	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					571	579		10.1074/jbc.275.1.571	http://dx.doi.org/10.1074/jbc.275.1.571			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617653	hybrid			2022-12-25	WOS:000085951600077
J	Webb, Y; Hermida-Matsumoto, L; Resh, MD				Webb, Y; Hermida-Matsumoto, L; Resh, MD			Inhibition of protein palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE MEMBRANE DOMAINS; ALPHA-SUBUNITS; TYROSINE KINASE; FISH-OIL; BIOCHEMICAL-CHARACTERIZATION; MYRISTOYLATED PROTEINS; N-MYRISTOYLTRANSFERASE; CYSTEINE RESIDUES; S-ACYLATION; ACTIVATION	The ability of the Src family kinases Fyn and Lck to participate in signaling through the T cell receptor is critically dependent on their dual fatty acylation with myristate and palmitate. Here we identify a palmitate analog, 2-bromopalmitate, that effectively blocks Fyn fatty acylation in general and palmitoylation in particular. Treatment of COS-1 cells with 2-bromopalmitate blocked myristoylation and palmitoylation of Fyn and inhibited membrane binding and localization of Fyn to detergent-resistant membranes (DRMs), In Jurkat T cells, 2-bromopalmitate blocked localization of the endogenous palmitoylated proteins Fyn, Lck, and LAT to DRMs. This resulted in impaired signaling through the T cell receptor as evidenced by reductions in tyrosine phosphorylation, calcium release, and activation of mitogen-activated protein kinase. We also examined the ability of long chain polyunsaturated fatty acids (PUFAs) to inhibit protein fatty acylation, PUFAs have been reported to inhibit T cell signaling by excluding Src family kinases from DRMs. Here we show that the PUFAs arachidonic acid and eicosapentaenoic acid inhibit Fyn palmitoylation and consequently block Fyn localization to DRMs, We propose that inhibition of protein palmitoylation represents a novel mechanism by which PUFAs exert their immunosuppressive effects.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.			Resh, Marilyn/0000-0001-6118-9466	NATIONAL CANCER INSTITUTE [P01CA029502, P30CA029502, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057966] Funding Source: NIH RePORTER; NCI NIH HHS [CA29502, P30-CA08748] Funding Source: Medline; NIGMS NIH HHS [GM57966] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Bano MC, 1998, BIOCHEM J, V330, P723, DOI 10.1042/bj3300723; Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; CAMP LA, 1994, J BIOL CHEM, V269, P23212; Cappelli P, 1997, J NEPHROL, V10, P157; CLELAND LG, 1988, J RHEUMATOL, V15, P1171; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; Das AK, 1997, J BIOL CHEM, V272, P11021; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; PAIGE LA, 1989, J MED CHEM, V32, P1665, DOI 10.1021/jm00128a001; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; RESH MD, 1994, CELL, V76, P422; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Towers TL, 1999, MOL CELL BIOL, V19, P4191; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; VanCott EM, 1997, PROSTAG LEUKOTR ESS, V57, P33, DOI 10.1016/S0952-3278(97)90490-7; VANDERHEIDE JJH, 1993, NEW ENGL J MED, V329, P769, DOI 10.1056/NEJM199309093291105; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZURIER RB, 1993, PROSTAG LEUKOTR ESS, V48, P57, DOI 10.1016/0952-3278(93)90010-T	52	357	369	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					261	270		10.1074/jbc.275.1.261	http://dx.doi.org/10.1074/jbc.275.1.261			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617614	hybrid			2022-12-25	WOS:000085951600038
J	Liu, JA; Shriver, Z; Blaiklock, P; Yoshida, K; Sasisekharan, R; Rosenberg, RD				Liu, JA; Shriver, Z; Blaiklock, P; Yoshida, K; Sasisekharan, R; Rosenberg, RD			Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3A sulfates N-unsubstituted glucosamine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; L-SELECTIN; DEACETYLASE/N-SULFOTRANSFERASE; UNSATURATED DISACCHARIDES; FLAVOBACTERIUM-HEPARINUM; MONOCLONAL-ANTIBODY; ANTITHROMBIN-III; CDNA CLONING; AMINO-GROUPS; EXPRESSION	3-O-Sulfation of glucosamine by heparan sulfate D-glucosaminyl 3-O-sulfotransferase (3-OST-1) is the key modification in anticoagulant heparan sulfate synthesis. However, the heparan sulfates modified by 3-OST-2 and 3-OST-3A, isoforms of 3-OST-1, do not have anticoagulant activity, although these isoforms transfer sulfate to the 3-OH position of glucosamine residues. In this study, we characterize the substrate specificity of purified 3-OST-3A at the tetrasaccharide level. The 3-OST-3A enzyme was purified from Sf9 cells infected with recombinant baculovirus containing 3-OST-3A cDNA. Two S-OST-3A-modified tetrasaccharides were purified from the 3-O-S-35-sulfated heparan sulfate that was digested by heparin lyases. These tetrasaccharides were analyzed using nitrous acid and enzymatic degradation combined with matrix-assisted laser desorption/ionization-mass spectrometry. Two novel tetrasaccharides were discovered with proposed structures of Delta UA2S-G-1cNS-IdoUA2S-[S-35]GlcNH(2)3S and Delta UA2S-GlcNS-IdoUA-2S-[3-S-35]GlcNH(2)3S6S. The results demonstrate that 3-OST-3A sulfates N-unsubstituted glucosamine residues, and the 3-OST-3A modification sites are probably located in defined oligosaccharide sequences. Our study suggests that oligosaccharides with N-unsubstituted glucosamine are precursors for sulfation by 3-OST-3A. The intriguing linkage between N-unsubstituted glucosamine and the 3-O-sulfation by 3-OST-3A may provide a clue to the potential biological functions of 3-OST-3A-modified heparan sulfate.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth Sci, Cambridge, MA 02139 USA; Beth Israel Hosp, Mol Med Unit, Boston, MA 02215 USA; Seikagaku Corp, Tokyo Res Inst, Higashiyamato, Tokyo 207, Japan	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Seikagaku Corporation	Rosenberg, RD (corresponding author), MIT, Dept Biol, 68-480,31 Ames St, Cambridge, MA 02139 USA.				NHLBI NIH HHS [5.POL.HL41484] Funding Source: Medline; NIGMS NIH HHS [R01.GM57073] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Hom LG, 1998, BIOTECHNIQUES, V25, P18, DOI 10.2144/98251bm01; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; JUHASZ P, 1995, CARBOHYD RES, V270, P131, DOI 10.1016/0008-6215(94)00012-5; KARIYA Y, 1992, COMP BIOCHEM PHYS B, V103, P473, DOI 10.1016/0305-0491(92)90323-J; KATO M, 1994, J BIOL CHEM, V269, P18881; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Toma L, 1998, J BIOL CHEM, V273, P22458, DOI 10.1074/jbc.273.35.22458; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	45	87	101	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38155	38162		10.1074/jbc.274.53.38155	http://dx.doi.org/10.1074/jbc.274.53.38155			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608887	hybrid			2022-12-25	WOS:000084528000087
J	Castro, DS; Arvidsson, M; Bolin, MB; Perlmann, T				Castro, DS; Arvidsson, M; Bolin, MB; Perlmann, T			Activity of the Nur1 carboxy-terminal domain depends on cell type and integrity of the activation function 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; LIGAND-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; NUCLEAR RECEPTORS; ACID RECEPTOR; NGFI-B; TRANSCRIPTIONAL ACTIVATION; THYROID-HORMONE; RESPONSE PATHWAYS; CONSERVED REGION	Nurr1, a member of the nuclear hormone receptor superfamily, was recently demonstrated to be of critical importance in the developing central nervous system, where it is required for the generation of midbrain dopamine cells. Nuclear receptors encompass a transcriptional activation function (activation function 2; AF2) within their carboxyl-terminal domains important for ligand-induced transcriptional activation. Since a Nurr1 ligand remains to be identified, the role of the Nurr1 AF2 region in transcriptional activation is unclear. However, here we show that the Nurr1 AF2 contributes to constitutive activation independent of exogenously added ligands in human embryo kidney 293 cells and in neural cell lines. Extensive mutagenesis indicated a crucial role of the AF2 core region for transactivation but also identified unique features differing from previously characterized receptors, In addition, Nurr1 did not appear to interact with, and was not stimulated by, several previously identified coactivators such as the steroid receptor coactivator 1. In contrast, adenovirus protein E1A, stably expressed in 293 cells, was shown to contribute to AF2-dependent activation. Finally, while the AF2 core of RXR is required for ligand-induced transcriptional activation by Nurr1-RXR heterodimers, the functional integrity of Nurr1 AF2 core is not critical. These results establish that the ligand binding domain of Nurr1 has intrinsic capacity for transcriptional activation depending on cell type and mode of DNA binding. Furthermore, these results are consistent with the possibility that gene expression in the central nervous system can be modulated by an as yet unidentified ligand interacting with the ligand binding domain of Nurr1.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research; Karolinska Institutet	Perlmann, T (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.		Bondesson, Maria/H-3027-2012; Castro, Diogo S/I-6217-2016	Bondesson, Maria/0000-0001-6358-5788; Castro, Diogo S/0000-0001-8178-9565				BARRETTINO D, 1994, EMBO J, V13, P3039; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; Botling J, 1997, J BIOL CHEM, V272, P9443; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FOLKERS GE, 1995, MOL CELL BIOL, V15, P5868; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Gong WR, 1997, MOL ENDOCRINOL, V11, P1476, DOI 10.1210/me.11.10.1476; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jurutka PW, 1997, J BIOL CHEM, V272, P14592, DOI 10.1074/jbc.272.23.14592; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Maruyama K, 1998, INT J ONCOL, V12, P1237; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Montminy M, 1997, NATURE, V387, P654, DOI 10.1038/42594; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; ONATE SA, 1995, SCIENCE, V270, P1354; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TONE Y, 1994, J BIOL CHEM, V269, P31157; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Wahlstrom GM, 1999, MOL ENDOCRINOL, V13, P1119, DOI 10.1210/me.13.7.1119; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1991, SCIENCE, V252, P1297; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YUA C, 1998, P NATL ACAD SCI USA, V95, P7939; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	61	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37483	37490		10.1074/jbc.274.52.37483	http://dx.doi.org/10.1074/jbc.274.52.37483			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601324	hybrid			2022-12-25	WOS:000084382700095
J	Engel, ME; McDonnell, MA; Law, BK; Moses, HL				Engel, ME; McDonnell, MA; Law, BK; Moses, HL			Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; BINDING PROTEIN; RECEPTOR; GENE; IDENTIFICATION; PATHWAY; DPC4; TRANSDUCTION; SAPK/JNK; PROMOTER	SMAD and JNK cascades are essential components of the transforming growth factor-beta (TGF-beta) signaling machinery and are implicated in common transcriptional responses. However, the relationship of these pathways to one another downstream of the TGF-beta receptor complex is unknown. We show that JNK is rapidly activated by TGF-beta in a SMAD-independent manner and phosphorylates Smad3 outside its -SSXS motif. Smad3 phosphorylation by JNK facilitates both its activation by the TGF-beta receptor complex and its nuclear accumulation. JNK regulates SMAD- and TGF-beta-mediated transcriptional responses, yet JNK activators only partially stimulate transcriptional responses characteristic of TGF-beta without coincident SMAD pathway activation. These results suggest an interdependent relationship between the JNK and SMAD pathways in TGF-beta-mediated transcription.	Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Moses, HL (corresponding author), Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, 649 Med Res Bldg 11, Nashville, TN 37232 USA.	hal.moses@mcmail.vanderbilt.edu	Law, Brian/L-6043-2019		NCI NIH HHS [CA48799, CA42572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048799, R35CA042572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Engel ME, 1998, J CELL BIOCHEM, P111; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schutte M, 1996, CANCER RES, V56, P2527; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	34	431	455	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37413	37420		10.1074/jbc.274.52.37413	http://dx.doi.org/10.1074/jbc.274.52.37413			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601313	hybrid			2022-12-25	WOS:000084382700084
J	Inoue, S				Inoue, S			Windows to dynamic fine structures, then and now	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		MICROTUBULE; MICROSCOPE	How can we learn about dynamic fine structures that are far too small to be resolved with the light microscope without destroying the active living cell? Examples spanning the last half century show how polarized light microscopy can-and should-continue to provide an attractive window for such studies. Long before microtubules were found with electron microscopy, or their assembly properties were biochemically characterized in isolated cell-free systems, the dynamic fine structure of the mitotic spindle and assembly properties of its: microtubules were revealed in living cells by polarized light microscopy, More recently, the polarizing microscope was improved, by invention of the new Pol-Scope, so that quantitative measurements of birefringence retardation and axes could be made rapidly for all image pixels independent of their birefringence axis: orientation. In addition, the centrifuge polarizing microscope, just developed, allows us to follow the dynamic ordering of fine structures in living cells as they become stratified or restructured by centrifugal acceleration of up to ten thousand times gravity. The significance of these technological advances is discussed.	Marine Biol Lab, Woods Hole, MA 02543 USA	Marine Biological Laboratory - Woods Hole	Inoue, S (corresponding author), Marine Biol Lab, 7 MBL St, Woods Hole, MA 02543 USA.							[Anonymous], 1952, EXP CELL RES       S, V2, P305, DOI DOI 10.1142/9789812790866_0011; CHAMBERS R, 1951, BIOL BULL, V101, P206; EDGERTON H, 1987, STOPPING TIME PHOTOG, P126; Goda M, 1998, BIOL BULL, V195, P212, DOI 10.2307/1542845; HARVEY EB, 1941, BIOL BULL, V114, P118; HARVEY EB, 1940, BIOL BULL, V166, P187; HIRAMOTO Y, 1995, INT REV CYTOL, V157, P99, DOI 10.1016/S0074-7696(08)62157-9; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; INOUE S, 1967, J GEN PHYSIOL, V50, P259, DOI 10.1085/jgp.50.6.259; INOUE S, 1953, CHROMOSOMA, V5, P487, DOI 10.1007/BF01271498; Inoue S., 1981, Journal of Cell Biology, V91, P131; Inoue S, 1998, MOL BIOL CELL, V9, P1603, DOI 10.1091/mbc.9.7.1603; Inoue S., 1998, Microscopy and Microanalysis, V4, P36, DOI 10.1017/S1431927600020304; Inoue S., 1964, PRIMITIVE MOTILE SYS, P549; Inoue S., 1997, VIDEO MICROSCOPY FUN; Inoue S, 1986, VIDEO MICROSCOPY; Inoue Shinya, 1993, P100; Katoh K, 1997, BIOL BULL, V193, P219, DOI 10.1086/BBLv193n2p219; Oldenbourg R, 1996, NATURE, V381, P811, DOI 10.1038/381811a0; OLDENBOURG R, 1999, METHODS CELL BIOL ST; OLMSTED JB, 1973, BIOCHEMISTRY-US, V12, P4282, DOI 10.1021/bi00745a037; Porter K.R., 1966, CIBA FDN S PRINC BIO, P308; SANGER JM, 1990, CELL MOTIL CYTOSKEL, V17, P356; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104	24	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S185	S190		10.1096/fasebj.13.9002.S185	http://dx.doi.org/10.1096/fasebj.13.9002.S185			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619125	Bronze			2022-12-25	WOS:000084390200003
J	Chen, NH; Ferrer, JV; Javitch, JA; Justice, JB				Chen, NH; Ferrer, JV; Javitch, JA; Justice, JB			Transport-dependent accessibility of a cytoplasmic loop cysteine in the human dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NOREPINEPHRINE TRANSPORTER; ETHYLMALEIMIDE-INDUCED REDUCTION; N-ETHYLMALEIMIDE; NEURONAL CARRIER; BINDING DOMAINS; <H-3>WIN-35,428 BINDING; SEROTONIN TRANSPORTER; UPTAKE INHIBITORS; H-3 MAZINDOL; COCAINE	The effect of covalent sulfhydryl modification on dopamine uptake by the human dopamine transporter was determined by rotating disc electrode voltammetry. A transporter construct, X5C, with five mutated cysteines (C90A, C135A, C306A, C319F, and C342A) and the constructs into which the wild-type cysteines were substituted back into X5C, one at a time, all showed nearly normal binding affinity for [H-3]CFT and for cocaine, but they displayed significant reductions in K-m and V-max for DA uptake. Reaction of Cys-90 or Cys-306 with impermeant methanethiosulfonate derivatives enhanced dopamine uptake to a similar extent as the previously observed enhancement of [H-3]CFT binding caused by the same reaction, suggesting that cocaine may bind preferentially to a conformation in the transport cycle. m-Tyramine increased the rate of reaction of (2-amino-ethyl)methanethiosulfonate (MTSEA) with X-A342C, the construct with a cytoplasmic loop residue Cys-342 restored. This m-tyramine-induced increase in reactivity appeared to require the inward transport rather than the outward transport or external binding of m-tyramine, and it was prevented by cocaine. Thus, inward translocation of substrates may involve structural rearrangement of hDAT, which likely exposes Cys-342 to reaction with MTSEA, and Cys-342 may be located on a part of the transporter associated with cytoplasmic gating.	Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Columbia Univ, Coll Mol Recognit, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA	Emory University; Columbia University; Columbia University; Columbia University	Chen, NH (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, POB 1649, Peoria, IL 61656 USA.			Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON DRUG ABUSE [R03DA010896] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00179, DA10896, DA1176] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BONNET JJ, 1990, J PHARMACOL EXP THER, V253, P1206; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Burgess KSD, 1999, J NEUROCHEM, V73, P656, DOI 10.1046/j.1471-4159.1999.0730656.x; Burnette WB, 1996, ANAL CHEM, V68, P2932, DOI 10.1021/ac960022x; CAO CJ, 1989, MEMBRANE BIOCHEM, V8, P207, DOI 10.3109/09687688909026815; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen NH, 1999, J PHARMACOL EXP THER, V290, P940; Chen NH, 1998, J NEUROSCI, V18, P10257; Chen NH, 1998, J NEUROCHEM, V71, P653; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1992, MOL PHARMACOL, V42, P383; HERON C, 1994, EUR J PHARMACOL, V264, P391, DOI 10.1016/0014-2999(94)00502-8; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; JOHNSON KM, 1992, EUR J PHARM-MOLEC PH, V227, P411, DOI 10.1016/0922-4106(92)90159-S; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; MEIERGERD SM, 1994, J NEUROCHEM, V62, P998; Pifl C, 1997, BRIT J PHARMACOL, V121, P205, DOI 10.1038/sj.bjp.0701137; Reith MEA, 1996, BIOCHEM PHARMACOL, V52, P1435, DOI 10.1016/S0006-2952(96)00508-4; REITH MEA, 1992, N-S ARCH PHARMACOL, V345, P309; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SAADOUNI S, 1994, EUR J PHARM-MOLEC PH, V268, P187, DOI 10.1016/0922-4106(94)90188-0; SCHWERI MM, 1990, NEUROPHARMACOLOGY, V29, P901, DOI 10.1016/0028-3908(90)90140-M; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Sonders MS, 1997, J NEUROSCI, V17, P960; Sur C, 1997, BIOCHEM BIOPH RES CO, V241, P68, DOI 10.1006/bbrc.1997.7771; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8; WANG JB, 1995, J NEUROCHEM, V64, P1416; Xu C, 1997, N-S ARCH PHARMACOL, V355, P64; ZACZEK R, 1991, J PHARMACOL EXP THER, V257, P830	34	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1608	1614		10.1074/jbc.275.3.1608	http://dx.doi.org/10.1074/jbc.275.3.1608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636852	hybrid			2022-12-25	WOS:000084940000015
J	Bova, MP; Mchaourab, HS; Han, Y; Fung, BKK				Bova, MP; Mchaourab, HS; Han, Y; Fung, BKK			Subunit exchange of small heat shock proteins - Analysis of oligomer formation of alpha A-crystallin and Hsp27 by fluorescence resonance energy transfer and site-directed truncations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; SMALL STRESS PROTEINS; HUMAN GLIOMA-CELLS; B-CRYSTALLIN; QUATERNARY STRUCTURE; MOLECULAR CHAPERONE; CELLULAR THERMORESISTANCE; ACTIN POLYMERIZATION; CONSERVED DOMAIN; GENE-EXPRESSION	alpha A-Crystallin, a member of the small heat shock protein (sHsp) family, is a large multimeric protein composed of 30-40 identical subunits. Its quaternary structure is highly dynamic, with subunits capable of freely and rapidly exchanging between oligomers. We report here the development of a fluorescence resonance energy transfer method for measuring structural compatibility between alpha A-crystallin and other proteins. We found that Hsp27 and alpha B-crystallin readily exchanged with fluorescence-labeled alpha A-crystallin, but not with other proteins structurally unrelated to sHsps. Truncation of 19 residues from the N terminus or 10 residues from the C terminus of alpha A-crystallin did not significantly change its subunit organization or exchange rate constant. In contrast, removal of the first 56 or more residues converts alpha A-crystallin into a predominantly small multimeric form consisting of three or four subunits, with a concomitant loss of exchange activity. These findings suggest residues 20-56 are essential for the formation of large oligomers and the exchange of subunits. Similar results were obtained with truncated Hsp27 lacking the first 87 residues. We further showed that the exchange rate is independent of alpha A-crystallin concentration, suggesting subunit dissociation may be the rate-limiting step in the exchange reaction. Our findings reveal a quarternary structure of alpha A-crystallin, consisting of small multimers of alpha A-crystallin subunits in a dynamic equilibrium with the oligomeric complex.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Fung, BKK (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.				NATIONAL EYE INSTITUTE [R01EY005895, R29EY012018, R01EY012018, T32EY007026] Funding Source: NIH RePORTER; NEI NIH HHS [EY05895, EY12018, EY07026] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; AUGUSTEYN RC, 1989, BIOCHIM BIOPHYS ACTA, V999, P293, DOI 10.1016/0167-4838(89)90012-5; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; CLAUWAERT J, 1989, CURR EYE RES, V8, P397, DOI 10.3109/02713688908996387; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; England P, 1997, BIOCHEMISTRY-US, V36, P164, DOI 10.1021/bi961419y; GERNOLD M, 1993, DEV GENET, V14, P103, DOI 10.1002/dvg.1020140204; Guay J, 1997, J CELL SCI, V110, P357; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HEAD MW, 1993, AM J PATHOL, V143, P1743; HEIKKILA JJ, 1993, DEV GENET, V14, P87, DOI 10.1002/dvg.1020140202; Hitotsumatsu T, 1996, CANCER, V77, P352, DOI 10.1002/(SICI)1097-0142(19960115)77:2<352::AID-CNCR19>3.0.CO;2-0; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; JAFFE NS, 1991, LENS CATARACT; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; Jansson M, 1997, BIOCHEMISTRY-US, V36, P4108, DOI 10.1021/bi961553i; JEDZINIAK JA, 1972, INVEST OPHTH VISUAL, V11, P905; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO K, 1992, J BIOL CHEM, V267, P7718; KATO S, 1992, ACTA NEUROPATHOL, V84, P443; KATO S, 1993, NEUROPATH APPL NEURO, V19, P436, DOI 10.1111/j.1365-2990.1993.tb00466.x; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Kokke BPA, 1998, FEBS LETT, V433, P228, DOI 10.1016/S0014-5793(98)00917-X; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lutsch G, 1997, CIRCULATION, V96, P3466; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P14627, DOI 10.1021/bi971700s; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; NENE V, 1986, MOL BIOCHEM PARASIT, V21, P179, DOI 10.1016/0166-6851(86)90021-6; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; PERSSON E, 1995, BIOCHEMISTRY-US, V34, P12775, DOI 10.1021/bi00039a038; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P511; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V749, P227, DOI 10.1016/0167-4838(83)90229-7; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; WANG KY, 1994, J BIOL CHEM, V269, P13601; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZANTEMA A, 1989, J VIROL, V63, P3368, DOI 10.1128/JVI.63.8.3368-3375.1989	90	216	219	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1035	1042		10.1074/jbc.275.2.1035	http://dx.doi.org/10.1074/jbc.275.2.1035			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625643	hybrid			2022-12-25	WOS:000084836600047
J	Dell'Angelica, EC; Aguilar, RC; Wolins, N; Hazelwood, S; Gahl, WA; Bonifacino, JS				Dell'Angelica, EC; Aguilar, RC; Wolins, N; Hazelwood, S; Gahl, WA; Bonifacino, JS			Molecular characterization of the protein encoded by the Hermansky-Pudlak syndrome type 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AP-3 ADAPTER COMPLEX; PALE EAR EP; VESICLE FORMATION; LOCUS HETEROGENEITY; HPS GENE; CLATHRIN; ENDOCYTOSIS; MUTATION; TRANSPORT; DOMAIN	Hermansky-Pudlak syndrome (HPS) comprises a group of genetic disorders characterized by defective lysosome-related organelles. The most common form of HPS (HPS type 1) is caused by mutations in a gene encoding a protein with no homology to any other known protein. Here we report the identification and biochemical characterization of this gene product, termed HPS1p, Endogenous HPS1p was detected in a wide variety of human cell lines and exhibited an electrophoretic mobility corresponding to a protein of similar to 80 kDa, In contrast to previous theoretical analysis predicting that HPS1p is an integral membrane protein, we found that this protein was predominantly cytosolic, with a small amount being peripherally associated with membranes, The sedimentation coefficient of the soluble form of HPS1p was similar to 6 S as inferred from ultracentrifugation on sucrose gradients. HPS1p-deficient cells derived from patients with HPS type 1 displayed normal distribution and trafficking of the lysosomal membrane proteins, CD63 and Lamp-1. This was in contrast to cells from HPS type 2 patients, having mutations in the beta 3A subunit of the AP-3 adaptor complex, which exhibited increased routing of these lysosomal proteins through the plasma membrane, Similar analyses performed on fibroblasts from 10 different mouse models of HPS revealed that only the AP-3 mutants pearl and mocha display increased trafficking of Lamp-1 through the plasma membrane. Taken together, these observations suggest that the product of the HPS1 gene is a cytosolic protein capable of associating with membranes and involved in the biogenesis and/or function of lysosome-related organelles by a mechanism distinct from that dependent on the AP-3 complex.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000131, Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Boissy RE, 1998, LAB INVEST, V78, P1037; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Harlow E., 1988, ANTIBODIES LAB MANUA; Hazelwood S, 1997, AM J HUM GENET, V61, P1088, DOI 10.1086/301611; HERMANSKY F, 1959, BLOOD, V14, P162, DOI 10.1182/blood.V14.2.162.162; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MANGINI NJ, 1985, J COMP NEUROL, V241, P191, DOI 10.1002/cne.902410207; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Oh J, 1998, AM J HUM GENET, V62, P593, DOI 10.1086/301757; Ooi CE, 1998, J CELL BIOL, V142, P391, DOI 10.1083/jcb.142.2.391; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shotelersuk V, 1998, MOL GENET METAB, V65, P85, DOI 10.1006/mgme.1998.2729; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Spritz RA, 1999, CLIN GENET, V55, P309, DOI 10.1034/j.1399-0004.1999.550503.x; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Wildenberg SC, 1998, J INVEST DERMATOL, V110, P777, DOI 10.1046/j.1523-1747.1998.00183.x; Witkop C J, 1990, Bol Asoc Med P R, V82, P333; Zhen LJ, 1999, BLOOD, V94, P146, DOI 10.1182/blood.V94.1.146.413k39_146_155	40	84	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1300	1306		10.1074/jbc.275.2.1300	http://dx.doi.org/10.1074/jbc.275.2.1300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625677	hybrid			2022-12-25	WOS:000084836600081
J	Athenstaedt, K; Daum, G				Athenstaedt, K; Daum, G			1-acyldihydroxyacetone-phosphate reductase (Ayr1p) of the yeast Saccharomyces cerevisiae encoded by the open reading frame YIL124w is a major component of lipid particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXYACETONE PHOSPHATE ACYLTRANSFERASE; ENDOPLASMIC-RETICULUM; GENE DISRUPTIONS; BIOSYNTHESIS; PROTEINS; PCR; CHROMATOGRAPHY; MEMBRANES; STEROLS	Biosynthesis of phosphatidic acid through the dihydroxyacetone phosphate pathway requires NADPH-dependent reduction of the intermediate 1-acyldihydroxyacetone phosphate before the second step of acylation. Studies with isolated subcellular fractions of the yeast Saccharomyces cerevisiae revealed that lipid particles and the endoplasmic reticulum harbor 1-acyldihydroxyacetone-phosphate reductase (ADR) activity, Deletion of the open reading frame YIL124w (in the following named AYR1) abolished reduction of 1-acyldihydroxyacetone phosphate in lipid particles, whereas ADR activity in microsomes of the deletion strain was decreased approximately 3-fold as compared with the wild-type level, This result indicates that (i) both lipid particles and microsomes harbor Ayr1p, which was confirmed by immunological detection of the protein in these two cellular compartments, and (ii) microsomes contain at least one additional ADR activity. As a consequence of this redundancy, deletion of AYR1 neither results in an obvious growth phenotype nor affects the lipid composition of a haploid deletion strain. When a heterozygous AYR1(+)/layr1(-) diploid strain was subjected to sporulation; however, spores bearing the ary1 defect failed to germinate, suggesting that Ayr1p plays an essential role at this stage. Overexpression of Ayr1p at a 5- to 10-fold level of wild type caused growth arrest. Heterologous expression of Ayr1p in Escherichia coli resulted in gain of ADR activity in the prokaryote, confirming that YIL124w is the structural gene of the enzyme and does not encode a regulatory or auxiliary component required for reduction of 1-acyldihydroxyacetone phosphate. Taken together, these results identified Ayr1p of the yeast as the first ADR from any organism at the molecular level.	Graz Univ Technol, Inst Biochem & Lebensmittelchem, A-8010 Graz, Austria; Biomembrane Res Ctr, Spezialforsch Bereich, A-8010 Graz, Austria	Graz University of Technology	Daum, G (corresponding author), Graz Univ Technol, Inst Biochem & Lebensmittelchem, Petersgasse 12-2, A-8010 Graz, Austria.	f548daum@mbox.tu-graz.ac.at		Athenstaedt, Karin/0000-0001-7198-3989				Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; Bell R. M., 1983, ENZYMES; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; Broekhuyse R. M., 1968, BIOCHIM BIOPHYS ACTA, V260, P449; CHRISTIANSEN K, 1978, BIOCHIM BIOPHYS ACTA, V530, P78, DOI 10.1016/0005-2760(78)90128-5; DATTA SC, 1990, J BIOL CHEM, V265, P8268; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hajra AK, 1997, BBA-LIPID LIPID MET, V1348, P27, DOI 10.1016/S0005-2760(97)00120-3; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; JIMENEZ A, 1980, NATURE, V287, P869, DOI 10.1038/287869a0; JOHNSTON JM, 1970, BIOCHIM BIOPHYS ACTA, V218, P124, DOI 10.1016/0005-2760(70)90099-8; JONES CL, 1980, J BIOL CHEM, V255, P8289; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; LEWIS TA, 1987, BIOCHIM BIOPHYS ACTA, V921, P205, DOI 10.1016/0005-2760(87)90020-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; Martonosi, 1985, ENZYMES BIOL MEMBR, V2, P1; MORRISON WR, 1964, J LIPID RES, V5, P600; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; PATTERSON GW, 1971, ANAL CHEM, V43, P1165, DOI 10.1021/ac60304a015; RACENIS PV, 1992, J BACTERIOL, V174, P5702, DOI 10.1128/JB.174.17.5702-5710.1992; SCHLOSSMAN DM, 1978, J BACTERIOL, V133, P1368, DOI 10.1128/JB.133.3.1368-1376.1978; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; VANDENBOSCH H, 1974, ANNU REV BIOCHEM, V43, P243; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; XU SH, 1988, J CHROMATOGR, V452, P377, DOI 10.1016/S0021-9673(01)81462-X; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; [No title captured]	43	66	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					235	240		10.1074/jbc.275.1.235	http://dx.doi.org/10.1074/jbc.275.1.235			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617610	hybrid			2022-12-25	WOS:000085951600034
J	Tjoelker, LW; Gosting, L; Frey, S; Hunter, CL; Le Trong, H; Steiner, B; Brammer, H; Gray, PM				Tjoelker, LW; Gosting, L; Frey, S; Hunter, CL; Le Trong, H; Steiner, B; Brammer, H; Gray, PM			Structural and functional definition of the human chitinase chitin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST-CELL WALL; SACCHAROMYCES-CEREVISIAE; PROTEIN FAMILY; CHITOTRIOSIDASE; IDENTIFICATION; SEQUENCE; MEMBER; GENE; MACROPHAGES; BACTERIUM	Mammalian chitinase, a chitinolytic enzyme expressed by macrophages, has been detected in atherosclerotic plaques and is elevated in blood and tissues of guinea pigs infected with Aspergillus, Its normal physiological function is unknown, To understand how the enzyme interacts with its substrate, we have characterized the chitin-binding domain, The C-terminal 49 amino acids make up the minimal sequence required for chitin binding activity, The absence of this domain does not affect the ability of the enzyme to hydrolyze the soluble substrate, triacetylchitotriose, but abolishes hydrolysis of insoluble chitin, Within the minimal chitin-binding domain are six cysteines; mutation of any one of these to serine results in complete loss of chitin binding activity. Analysis of purified recombinant chitin-binding domain revealed the presence of three disulfide linkages. The recombinant domain binds specifically to chitin but does not bind chitosan, cellulose, xylan, beta-1,3-glucan, beta-1,3-1,4-glucan, or mannan, Fluorescently tagged chitin-binding domain was used to demonstrate chitin-specific binding to Saccharomyces cerevisiae, Candida albicans, Mucor rouxii, and Neurospora crassa, These experiments define structural features of the minimal domain of human chitinase required for both specifically binding to and hydrolyzing insoluble chitin and demonstrate relevant binding within the context of the fungal cell wall.	ICOS Corp, Bothell, WA 98021 USA; Gryphon Sci, S San Francisco, CA 94080 USA	Icos Corporation	Tjoelker, LW (corresponding author), ICOS Corp, 22021 20th Ave SE, Bothell, WA 98021 USA.							BARTNICKIGARCIA S, 1962, BIOCHIM BIOPHYS ACTA, V58, P102, DOI 10.1016/0006-3002(62)90822-3; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; BROEKAERT WF, 1989, SCIENCE, V245, P1100, DOI 10.1126/science.245.4922.1100; Cabib E, 1997, BIOCHEM SOC T, V25, P200, DOI 10.1042/bst0250200; Chantry D, 1998, J LEUKOCYTE BIOL, V64, P49, DOI 10.1002/jlb.64.1.49; DENTANDT WR, 1988, INT J BIOCHEM, V20, P7413; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Garcia-Casado G, 1998, GLYCOBIOLOGY, V8, P1021, DOI 10.1093/glycob/8.10.1021; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; KITAMURA K, 1982, AGR BIOL CHEM TOKYO, V46, P2093, DOI 10.1080/00021369.1982.10865384; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; MALETTE B, 1995, MOL REPROD DEV, V41, P384, DOI 10.1002/mrd.1080410315; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; MORRISON BW, 1994, ONCOGENE, V9, P3417; OVERDIJK B, 1994, GLYCOBIOLOGY, V4, P797, DOI 10.1093/glycob/4.6.797; Overdijk B, 1996, GLYCOBIOLOGY, V6, P627, DOI 10.1093/glycob/6.6.627; Overdijk B, 1999, MICROBIOL-UK, V145, P259, DOI 10.1099/13500872-145-1-259; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; SCHNELLMANN J, 1994, MOL MICROBIOL, V13, P807, DOI 10.1111/j.1365-2958.1994.tb00473.x; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SELITRENNIKOFF CP, 1999, EMERGING THERAPEUTIC, V3, P53; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Shen ZC, 1999, J MOL EVOL, V48, P341, DOI 10.1007/PL00006478; SLEEP D, 1991, BIO-TECHNOL, V9, P183, DOI 10.1038/nbt0291-183; SVENSSON B, 1989, BIOCHEM J, V264, P309, DOI 10.1042/bj2640309; Tsujibo H, 1998, APPL ENVIRON MICROB, V64, P472; VazquezTorres A, 1997, MICROBIOL MOL BIOL R, V61, P170; VRSANSKA M, 1977, Z ALLG MIKROBIOL, V17, P465, DOI 10.1002/jobm.3630170608; Yamagami T, 1996, BIOSCI BIOTECH BIOCH, V60, P1081, DOI 10.1271/bbb.60.1081	39	103	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					514	520		10.1074/jbc.275.1.514	http://dx.doi.org/10.1074/jbc.275.1.514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617646	hybrid			2022-12-25	WOS:000085951600070
J	Yanai, K; Saito, T; Kakinuma, Y; Kon, Y; Hirota, K; Taniguchi-Yanai, K; Nishijo, N; Shigematsu, Y; Horiguchi, H; Kasuya, Y; Sugiyama, F; Yagami, K; Murakami, K; Fukamizu, A				Yanai, K; Saito, T; Kakinuma, Y; Kon, Y; Hirota, K; Taniguchi-Yanai, K; Nishijo, N; Shigematsu, Y; Horiguchi, H; Kasuya, Y; Sugiyama, F; Yagami, K; Murakami, K; Fukamizu, A			Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN SYSTEM; MACULA DENSA; PRESSURE; GENE	Renin plays a key role in controlling blood pressure through its specific cleavage of angiotensinogen to generate angiotensin I (AI), Although possible existence of the other angiotensin forming enzymes has been discussed to date, its in vivo function remains to be elucidated. To address the contribution of renin, we generated renin knockout mice. Homozygous mutant mice show neither detectable levels of plasma renin activity nor plasma AI, lowered blood pressure 20-30 mm Hg less than normal, increased urine and drinking volume, and altered renal morphology as those observed in angiotensinogen-deficient mice. We recently found the decreased density in granular layer cells of hippocampus and the impaired blood-brain barrier function in angiotensinogen-deficient mice. Surprisingly, however, such brain phenotypes were not observed in renin-deficient mice. Our results demonstrate an indispensable role for renin in the circulating angiotensin generation and in the maintenance of blood pressure, but suggest a dispensable role for renin in the blood-brain barrier function.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Lab Anim Res Ctr, Tsukuba, Ibaraki 3058577, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Expt Anim Sci, Sapporo, Hokkaido 0600818, Japan; Ibaraki Prefectural Univ Hlth Sci, Mol Pathol Ctr, Ibaraki, Osaka 3000331, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; Hokkaido University	Fukamizu, A (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.		Kon, Yasuhiro/F-8525-2012; fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; Kasuya, Yoshitoshi/0000-0003-0614-5836; Kakinuma, Yoshihiko/0000-0001-5470-9128				BOUCHER R, 1977, CIRC RES, V41, P26, DOI 10.1161/01.RES.41.4.26; BUNNEMANN B, 1993, REGUL PEPTIDES, V46, P487, DOI 10.1016/0167-0115(93)90251-3; Clark AF, 1997, J BIOL CHEM, V272, P18185, DOI 10.1074/jbc.272.29.18185; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FUKAMIZU A, 1995, TRENDS ENDOCRIN MET, V6, P279, DOI 10.1016/1043-2760(95)00156-5; HACKENTHAL E, 1978, BIOCHIM BIOPHYS ACTA, V522, P574, DOI 10.1016/0005-2744(78)90089-X; INAGAMI T, 1985, ASPARTIC PROTEINASES, P319; Kakinuma Y, 1998, NAT MED, V4, P1078, DOI 10.1038/2070; Kakinuma Y, 1997, NEUROSCI LETT, V232, P167, DOI 10.1016/S0304-3940(97)00605-8; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; MOFFETT RB, 1987, LIFE SCI, V41, P1867; Nagata M, 1996, LAB INVEST, V75, P745; NIIMURA F, 1995, J CLIN INVEST, V96, P2945; PHILLIPS MI, 1993, REGUL PEPTIDES, V43, P1; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Sharp MGF, 1996, HYPERTENSION, V28, P1126, DOI 10.1161/01.HYP.28.6.1126; SKOTT O, 1987, SCIENCE, V237, P1618, DOI 10.1126/science.3306925; Taniguchi K, 1998, INT J MOL MED, V1, P583; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; TONNESEN MG, 1982, J CLIN INVEST, V69, P25, DOI 10.1172/JCI110437; WRIGHT JW, 1992, BRAIN RES REV, V17, P227, DOI 10.1016/0165-0173(92)90018-H; Wrobel KH, 1997, ACTA ANAT, V160, P1; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458	24	114	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					5	8		10.1074/jbc.275.1.5	http://dx.doi.org/10.1074/jbc.275.1.5			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617578	hybrid			2022-12-25	WOS:000085951600002
J	Chang, Z; Meyer, K; Rapraeger, AC; Friedl, A				Chang, Z; Meyer, K; Rapraeger, AC; Friedl, A			Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ	FASEB JOURNAL			English	Article						skin; basement membrane; FGF; cell signaling	CELL-SURFACE; BASEMENT-MEMBRANE; SELF-ASSOCIATION; BASIC FGF; BINDING; EXPRESSION; IDENTIFICATION; MITOGENESIS; SYNDECAN-1; ACTIVATION	Fibroblast growth factors (FGFs) require heparan sulphate proteoglycans (HSPGs) as cofactors for signaling. The heparan sulphate chains (HS) mediate stable high affinity binding of FGFs to their receptor tyrosine kinase (FR) and may specifically regulate FGF activity. A novel in situ binding assay was developed to examine the ability of HSPGs to promote FGF/FR binding using a soluble FR fusion construct (FR1-AP). this fusion protein probe forms a dimer in solution, simulating the dimerization or oligomerization that is thought to occur at the cell surface physiologically. In frozen sections of human skin, FGF-2 binds to keratinocytes and basement membranes of epidermis and dermal blood vessels. In contrast, in skin preincubation with FGF-2, FR1-AP binds avidly to FGF-2 immobilized on keratinocyte cell surface, but fails to bind to basement membranes at the dermo-epidermal junction or dermal microvessels despite the fact that these structures bind large amounts of FGF-2. Apparently, basement membrane and cell surface HSPGs differ in their ability to mediate the assembly of a FGF/FR signaling complex presumably due to structural differences of the heparan sulfate chains.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 6153 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.							AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Carey DJ, 1997, BIOCHEM J, V327, P1; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Friedl A, 1997, AM J PATHOL, V150, P1443; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; Hoylaerts MF, 1997, J BIOL CHEM, V272, P22781, DOI 10.1074/jbc.272.36.22781; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Krufka A, 1996, BIOCHEMISTRY-US, V35, P11131, DOI 10.1021/bi960125+; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Risau W, 1996, CANCER METAST REV, V15, P149, DOI 10.1007/BF00437466; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Safaiyan F, 1998, EUR J BIOCHEM, V252, P576, DOI 10.1046/j.1432-1327.1998.2520576.x; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	45	94	94	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					137	144		10.1096/fasebj.14.1.137	http://dx.doi.org/10.1096/fasebj.14.1.137			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627288				2022-12-25	WOS:000084784700016
J	Chow, CW; Khurana, S; Woodside, M; Grinstein, S; Orlowski, J				Chow, CW; Khurana, S; Woodside, M; Grinstein, S; Orlowski, J			The epithelial Na+/H+ exchanger, NHE3, is internalized through a clathrin-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLECTING DUCT CELLS; THICK ASCENDING LIMB; COATED PIT FORMATION; RAT NA/H EXCHANGER; PLASMA-MEMBRANE; BRUSH-BORDER; EPSILON-COP; RECYCLING ENDOSOMES; TRANSPORT VESICLES; MAMMALIAN-CELLS	Trafficking of the Na+/H+ exchanger isoform 3 (NHE3) between sub-apical vesicles and apical membrane of epithelial cells is a suggested mechanism of regulation of NHE3 activity. When epitope-tagged NHE3 was stably expressed in NHE-deficient Chinese hamster ovary cells, a sizable fraction was found in recycling endosomes. This system was used to analyze the mechanism of endocytosis of NHE3. Immunofluorescence and radiolabeling experiments showed that inhibition of clathrin-mediated endocytosis using hypertonicity, acid treatment, or K+ depletion inhibited internalization of NHE3. Moreover, transient transfection of an inhibitory mutant of dynamin (DynS45N) blocked the clathrin-mediated uptake of transferrin, as well as the endocytosis of NHE3. In ileal villus cells, endogenous NHE3 was also found to co-purify with isolated clathrin-coated vesicles, thereby confirming their association in native tissues. The role of COP-I subunits in the intracellular traffic of NHE3 was evaluated using ldlF cells, which bear a temperature-sensitive mutation in the epsilon-COP subunit. At the permissive temperature, NHE3 distributed normally, whereas at the restrictive temperature, which induces rapid degradation of epsilon-COP, NHE3 was still internalized, but its subcellular distribution was altered. These results indicate that endocytosis of NHE3 occurs primarily via clathrin-coated pits and vesicles and that normal intracellular trafficking of NHE3 involves an epsilon-COP-dependent step.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Hosp Sick Children, Res Inst, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Baltimore, MD 21205 USA; Univ Toronto, Dept Med, Div Resp Med, Toronto, ON M5S 1A8, Canada; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Baltimore, MD 21205 USA; Hosp Sick Children, Res Inst, Div Cell Biol, Toronto, ON M5G 1X8, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Johns Hopkins University; University of Toronto; Johns Hopkins University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, McIntyre Med Sci Bldg,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	orlowski@med.mcgill.ca	Chow, Chung-Wai/AAP-5533-2020	Chow, Chung-Wai/0000-0001-9344-8522; Khurana, Seema/0000-0002-6884-810X; Orlowski, John/0000-0001-7371-175X				Ambuhl PM, 1996, AM J PHYSIOL-RENAL, V271, pF917, DOI 10.1152/ajprenal.1996.271.4.F917; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; AMEMIYA M, 1995, AM J PHYSIOL-CELL PH, V269, pC126, DOI 10.1152/ajpcell.1995.269.1.C126; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BLOCH DR, 1993, CONTRIB NEPHROL, V101, P19; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BRANT SR, 1995, AM J PHYSIOL-CELL PH, V269, pC198, DOI 10.1152/ajpcell.1995.269.1.C198; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; Chow CW, 1997, J GEN PHYSIOL, V110, P185, DOI 10.1085/jgp.110.2.185; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; DAVOUST J, 1987, EMBO J, V6, P3601, DOI 10.1002/j.1460-2075.1987.tb02691.x; Dunbar LA, 1998, ACTA PHYSIOL SCAND, V163, P289; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; Guerra L, 1998, KIDNEY INT, V53, P1269, DOI 10.1046/j.1523-1755.1998.00897.x; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HILDEN SA, 1990, AM J PHYSIOL, V258, pF1311; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Khurana S, 1996, BIOCHEM J, V313, P509, DOI 10.1042/bj3130509; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Kurzchalia TV, 1996, FEBS LETT, V389, P52, DOI 10.1016/0014-5793(96)00585-6; Laghmani K, 1997, J CLIN INVEST, V99, P24, DOI 10.1172/JCI119128; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LINDNER R, 1994, CELL BIOL LAB HDB, P525; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Noel J, 1996, J CELL SCI, V109, P929; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PEARSE BMF, 1989, METHOD CELL BIOL, V31, P229; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SABOLIC I, 1990, AM J PHYSIOL, V258, pF1245, DOI 10.1152/ajprenal.1990.258.5.F1245; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943, DOI 10.1152/ajpcell.1995.269.4.C943; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WHITNEY JA, 1995, CELL, V83, P703; Wormmeester L, 1998, AM J PHYSIOL-CELL PH, V274, pC1261, DOI 10.1152/ajpcell.1998.274.5.C1261; Yoshioka S, 1997, J BIOCHEM-TOKYO, V122, P641; Zacchi P, 1998, J CELL BIOL, V140, P1039, DOI 10.1083/jcb.140.5.1039; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004; Zhang YB, 1999, AM J PHYSIOL-RENAL, V276, pF711, DOI 10.1152/ajprenal.1999.276.5.F711	67	90	90	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37551	37558		10.1074/jbc.274.53.37551	http://dx.doi.org/10.1074/jbc.274.53.37551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608808	hybrid			2022-12-25	WOS:000084528000008
J	Balendran, A; Currie, R; Armstrong, CG; Avruch, J; Alessi, DR				Balendran, A; Currie, R; Armstrong, CG; Avruch, J; Alessi, DR			Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 56 kinase in vivo at Thr-412 as well as Thr-252	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; MAPKAP KINASE-1; B-ALPHA; IN-VIVO; ACTIVATION; MECHANISM; P70(S6K); INSULIN; PDK1	Protein kinase B and p70 S6 kinase are members of the cyclic AMP-dependent/cyclic GMP-dependent/protein kinase C subfamily of protein kinases and are activated by a phosphatidylinositol 3-kinase-dependent pathway when cells are stimulated with insulin or growth factors. Both of these kinases are activated in cells by phosphorylation of a conserved residue in the kinase domain (Thr-308 of protein kinase B (PKB) and Thr-252 of p70 S6 kinase) and another conserved residue located C-terminal to the kinase domain (Ser-473 of PKB and Thr-412 of p70 S6 kinase). Thr-308 of PKB alpha and Thr-252 of p70 S6 kinase are phosphorylated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) in vitro. Recent work has shown that PDK1 interacts with a region of protein kinase C-related kinase-2, termed the PDK1 interacting fragment (PIF). Interaction with PIF converts PDK1 from a form that phosphorylates PKB at Thr-308 alone to a species capable of phosphorylating Ser-473 as well as Thr-308. This suggests that PDK1 may be the enzyme that phosphorylates both residues in vivo. Here we demonstrate that PDK1 is capable of phosphorylating p70 S6 kinase at Thr-412 in vitro. We study the effect of PIF on the ability of PDK1 to phosphorylate p70 S6 kinase. Surprisingly, we find that PDK1 bound to PIF is no longer able to interact with or phosphorylate p70 S6 kinase in vitro at either Thr-252 or Thr-412, The expression of PIF in cells prevents insulin-like growth factor 1 from inducing the activation of the p70 S6 kinase and its phosphorylation at Thr-412, Overexpression of PDK1 in cells induces the phosphorylation of p70 S6 kinase at Thr-412 in unstimulated cells, and a catalytically inactive mutant of PDK1 prevents the phosphorylation of p70 S6K at Thr-412 in insulin-like growth factor 1-stimulated cells. These observations indicate that PDK1 regulates the activation of p70 S6 kinase and provides evidence that PDK1 mediates the phosphorylation of p70 S6 kinase at Thr-412.	Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Dundee, Dept Biochem, Div Signal Transduct Therapy Unit, Dundee DD1 5EH, Scotland; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Diabet Unit, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Med Serv, Boston, MA 02129 USA	University of Dundee; University of Dundee; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Alessi, DR (corresponding author), Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland.		Currie, Richard/N-6074-2017	Currie, Richard/0000-0002-6528-3326; Alessi, Dario/0000-0002-2140-9185				AKIMOTO K, 1998, BIOCHEM J, V273, P16621; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Hara K, 1998, J BIOL CHEM, V273, P22160; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; PEARSON RB, 1995, EMBO J, V14, P5278; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	37	116	116	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37400	37406		10.1074/jbc.274.52.37400	http://dx.doi.org/10.1074/jbc.274.52.37400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601311	hybrid			2022-12-25	WOS:000084382700082
J	Kannabiran, C; Morris, GF; Mathews, MB				Kannabiran, C; Morris, GF; Mathews, MB			Dual action of the adenovirus E1A 243R oncoprotein on the human proliferating cell nuclear antigen promoter: repression of transcriptional activation by p53	ONCOGENE			English	Article						PCNA; transcription; p53; E1A	CYCLIN-DEPENDENT KINASES; DNA POLYMERASE-DELTA; 19-KILODALTON PROTEIN; FUNCTIONAL DOMAINS; AUXILIARY PROTEIN; COACTIVATOR P300; TUMOR SUPPRESSOR; HOST-CELL; GENE; TRANSFORMATION	The promoter of the human proliferating cell nuclear antigen (PCNA) gene is activated by the adenovirus oncoprotein E1A 243R in HeLa cells. To understand the effect of this oncoprotein on PCNA expression in cells that are sensitive to oncogenic transformation by adenovirus, we studied the effect of E1A 243R on PCNA promoter-directed reporter gene expression in cloned rat embryo fibroblast (CREF) and primary baby rat kidney cells. In contrast to the results obtained in HeLa cells, EIA repressed the PCNA promoter in both cell-types. Promoter analysis identified a p53-responsive element that mediates E1A-induced repression. Repression required the intact N-terminus of EIA 243R, as shown by the ability of mutant EIA proteins to repress the promoter, and correlated with the p300-binding region of EIA. The adenovirus E1B 19K protein relieved repression by EIA 243R. These results reveal dual pathways for induction of this essential DNA replication factor and suggest a mechanism for oncogenic cooperativity between the EIA and E1B oncoproteins.	Cold Spring Harbor Lab, New York, NY 11724 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Cold Spring Harbor Laboratory; Rutgers State University New Brunswick; Rutgers State University Medical Center	Mathews, MB (corresponding author), LV Prasad Eye Inst, Rd 2,Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.		Kannabiran, Chitra/S-9361-2019	Kannabiran, Chitra/0000-0001-8435-0320	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HARPER JW, 1993, CELL, V75, P805; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HERRMANN CH, 1987, ONCOGENE, V2, P25; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRIS GF, 1994, MOL CELL BIOL, V14, P543, DOI 10.1128/MCB.14.1.543; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NEVINS JR, 1992, SCIENCE, V258, P424; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	69	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7825	7833		10.1038/sj.onc.1203294	http://dx.doi.org/10.1038/sj.onc.1203294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618724				2022-12-25	WOS:000084256900013
J	Turpin, E; Dalle, B; de Roquancourt, A; Plassa, LF; Marty, M; Janin, A; Beuzard, Y; de The, H				Turpin, E; Dalle, B; de Roquancourt, A; Plassa, LF; Marty, M; Janin, A; Beuzard, Y; de The, H			Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers	ONCOGENE			English	Article						TSG101; p53; stress , tumor grading; splicing; breast cancer	SUSCEPTIBILITY GENE TSG101; POOR-PROGNOSIS; TRANSCRIPTS; MUTATIONS; HETEROZYGOSITY; REARRANGEMENTS; METASTASIS; HYPOXIA; RNA	The TSG101 gene, identified through insertional mutagenesis, is localized in a region that exhibits LOH in human cancers, suggesting that TSG101 might be a tumor suppressor gene. Numerous studies have then shown the presence of abnormal transcripts in various tumors which appear to result from aberrant splicing of the gene, rather than from intragenic deletions. Moreover, many studies demonstrated that these aberrantly spliced transcripts mere not found in matched normal tissues, We have analysed TSG101 transcripts in 85 breast cancer samples and found that abnormal splicing of the gene is tightly correlated with tumor grade and p53 mutation. In addition, stress induced the appearance of these abnormal transcripts in primary lymphocytes. Hence, TSG101 splicing defects, while unrelated to the oncogenic process per se, could reflect the cellular environment of the tumor cells. The proposed role of stress and hypoxia to select p53 mutant cells could account for the tight association with p53 status.	Hop St Louis, Lab Biochim B, F-75475 Paris 10, France; Hop St Louis, Anat Pathol Lab, F-75475 Paris, France; Hop St Louis, Serv Oncol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Turpin, E (corresponding author), Hop St Louis, Lab Biochim B, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.							BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Carney ME, 1998, J SOC GYNECOL INVEST, V5, P281, DOI 10.1016/s1071-5576(98)00018-5; Chang JG, 1999, BRIT J CANCER, V79, P445, DOI 10.1038/sj.bjc.6690069; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES C, 1992, CANCER RES, V52, P5291; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; KNOWLES MA, 1994, CANCER RES, V54, P531; LAMOND AI, 1995, CURR BIOL, V5, P862, DOI 10.1016/S0960-9822(95)00174-6; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lin PM, 1998, BRIT J HAEMATOL, V102, P753, DOI 10.1046/j.1365-2141.1998.00815.x; Lin SY, 1998, J GASTROEN HEPATOL, V13, P1111, DOI 10.1111/j.1440-1746.1998.tb00585.x; LISUKA M, 1995, GENES CHROM CANC, V13, P40; Oh Y, 1998, ONCOGENE, V17, P1141, DOI 10.1038/sj.onc.1202029; SAITOH S, 1994, ONCOGENE, V9, P2869; Sato T, 1997, CANCER LETT, V115, P47, DOI 10.1016/S0304-3835(97)04705-8; Silvestrini R, 1996, CLIN CANCER RES, V2, P2007; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Valgardsdottir R, 1997, APMIS, V105, P121, DOI 10.1111/j.1699-0463.1997.tb00550.x; Wagner KU, 1998, ONCOGENE, V17, P2761, DOI 10.1038/sj.onc.1202529; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Willeke F, 1998, MOL CARCINOGEN, V23, P195; WINQVIST R, 1995, CANCER RES, V55, P2660	32	28	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7834	7837		10.1038/sj.onc.1203196	http://dx.doi.org/10.1038/sj.onc.1203196			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618725				2022-12-25	WOS:000084256900014
J	Chen, WX; Bowden, GT				Chen, WX; Bowden, GT			Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes	ONCOGENE			English	Article						UVB; p38; ERK; c-fos; AP-1	MAMMALIAN UV RESPONSE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CELLULAR STRESSES; SUBSTRATE-SPECIFICITY; AP-1 ACTIVITY; JUN; PHOSPHORYLATION; TRANSCRIPTION; INHIBITION	The effects of p38 MAP kinase and ERK on UVB induced c-fos gene expression were studied in a human keratinocyte cell line, FL30, UVB significantly increased c-fos gene expression at both the transcriptional and protein le,els. p38 and ERK were also significantly activated after UVB irradiation. Treating the cells with p38 inhibitor SB202190 inhibited p38 activation, but not ERK; treating the cells with MEK-1 inhibitor PD98059 inhibited ERK activation without suppressing p38 activation, The kinase activation was determined by Western blots using phospho-p38 or ERK antibodies, or an in vivo p38 activity assay. Further studies demonstrated that blocking p38 almost completely abrogated UVB induced c-fos gene transcription and c-Fos protein synthesis. Inhibiting ERK partially abrogated UVB induced c-fos transcriptional and protein levels, Suppression of both p38 and ERK not only completely blocked UVB induced c-fos expression, but also decreased c-fos gene basal expression. Our data indicated that p38 may play a more important role than ERK in UVB induced c-fos expression in human keratinocytes, Since c-fos expression may play an important role in UVB induced AP-1 activation, and AP-1 activation is known to play a role in tumor promotion, both p38 and ERK could be potential targets for chemoprevention of skin cancer.	Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [CA27502, CA23074] Funding Source: Medline; NIEHS NIH HHS [P30 ESO6694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barthelman M, 1998, CARCINOGENESIS, V19, P2201, DOI 10.1093/carcin/19.12.2201; Barthelman M, 1998, CANCER RES, V58, P711; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen WX, 1997, NUTR CANCER, V29, P205, DOI 10.1080/01635589709514625; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Huwiler A, 1999, J EXP BIOL, V202, P655; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JANKNECHT R, 1993, EMBO J, V12, P5057; Kaminska B, 1999, MOL CELL NEUROSCI, V13, P405, DOI 10.1006/mcne.1999.0757; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOZANO J, 1994, J BIOL CHEM, V269, P6687; MATSUI MS, 1995, SKIN CANC MECH HUMAN, P21; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; Rosenberger SF, 1996, ONCOGENE, V12, P2301; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; WOODGETT JR, 1995, CLIN EXP PHARMACOL P, V22, P281, DOI 10.1111/j.1440-1681.1995.tb01995.x; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	47	83	90	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7469	7476		10.1038/sj.onc.1203210	http://dx.doi.org/10.1038/sj.onc.1203210			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602506				2022-12-25	WOS:000084119600008
J	Chen, YR; Meyer, CF; Ahmed, B; Yao, ZB; Tan, TH				Chen, YR; Meyer, CF; Ahmed, B; Yao, ZB; Tan, TH			Caspase-mediated cleavage and functional changes of hematopoietic progenitor kinase 1 (HPK1)	ONCOGENE			English	Article						HPK1; JNK; caspase; apoptosis; adaptor	GERMINAL CENTER KINASE; RADIATION-INDUCED APOPTOSIS; JUN NH2-TERMINAL KINASE; PROTEIN-KINASE; CELL-DEATH; PROTEOLYTIC ACTIVATION; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; GAMMA-RADIATION; JNK ACTIVATION	Activation of c-Jun N-terminal kinase (JNK) by Fas ligation is caspase-dependent, suggesting that caspases may regulate activators of the JNK pathway. Here, we report that an upstream activator of JNK, hematopoietic progenitor kinase I (HPK1), was cleaved during apoptosis, Cleavage of HPK1 was blocked by peptide inhibitors for caspases. HPK1 was efficiently processed by recombinant caspase 3 in vitro. A conserved caspase recognition site, DDVD (amino acids 382-385), was found in the HPK1 protein sequence. By testing HPK1 proteins with in vivo and in vitro cleavage assays, we showed that aspartic acid residue 385 is the target for caspases. HPK1 cleavage separated the amino N-terminal kinase domain from the carboxyl C-terminal regulatory domain, and enhanced HPK1 kinase activity. Unlike the full-length HPK1, the N-terminal cleaved product failed to bind adaptor molecules Grb2 (growth factor receptor-bound protein 2) and Crk (CT10 regulator of kinase). The C-terminal fragment, although having three proline-rich domains, bound to Grb2 and Crk less efficiently than the full-length HPK1 protein. Taken together, the cleavage of HPK1 by caspase profoundly changed its biochemical properties.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Hoechst Marion Roussel, CNS Dept, Bridgewater, NJ 08807 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/E-3991-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002	NIAID NIH HHS [R01-AI42532, R01-AI38649] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Ling P, 1999, MOL CELL BIOL, V19, P1359; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shiah SG, 1999, CANCER RES, V59, P391; SONG O, 1996, EMBO J, V15, P3238; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO Z, 1997, J BIOL CHEM, V272, P2118; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	48	62	64	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7370	7377		10.1038/sj.onc.1203116	http://dx.doi.org/10.1038/sj.onc.1203116			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602493				2022-12-25	WOS:000084119400023
J	Muller, K; Mermod, N				Muller, K; Mermod, N			The histone-interacting domain of nuclear factor I activates simian virus 40 DNA replication in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ACCESS; CTF/NF-I; INVITRO; CHROMATIN; PROMOTER; PROTEIN; MINICHROMOSOMES; EXPRESSION; COMPLEX; ORIGIN	Efficient initiation of SV40 DNA replication requires transcription factors that bind auxiliary sequences Banking the minimally required origin. To evaluate the possibility that transcription factors may activate SV40 replication by acting on the chromatin structure of the origin, we used an in vivo replication system in which we targeted GAL4 fusion proteins to the minimally required origin. We found that the proline-rich transcriptional activation domain of nuclear factor I (NF-I), which has been previously shown to interact with histone H3, specifically activates replication. Evaluation of a series of deletion and point mutants of NF-I indicates that the H3-binding domain and the replication activity coincide perfectly. Assays with other transcription factors, such as Spl, confirmed the correlation between the interaction with H3 and the activation of replication. These findings imply that transcription factors such as NF-I can activate SV40 replication via direct interaction with chromatin components, thereby contributing to the relief of nucleosomal repression at the SV40 origin.	Univ Lausanne, Inst Biol Anim, Lab Mol Biotechnol, CH-1015 Lausanne, Switzerland; Univ Lausanne, Ctr Biotechnol, EPFL, UNIL, Lausanne, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne	Mermod, N (corresponding author), Swiss Fed Inst Technol, Ctr Biotechnol, UNIL EPFL, Lab Mol Biotechnol,Dept Chem, CH-1015 Lausanne, Switzerland.							Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; Beato M, 1997, NUCLEIC ACIDS RES, V25, P3559, DOI 10.1093/nar/25.18.3559; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; CREMISI C, 1976, J VIROL, V17, P204, DOI 10.1128/JVI.17.1.204-211.1976; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; LEDNICKY J, 1992, J VIROL, V66, P6379, DOI 10.1128/JVI.66.11.6379-6390.1992; LEECHEN GJ, 1986, MOL CELL BIOL, V6, P3086, DOI 10.1128/MCB.6.9.3086; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAJUMDER S, 1993, EMBO J, V12, P1131, DOI 10.1002/j.1460-2075.1993.tb05754.x; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUL YM, 1992, EMBO J, V11, P751, DOI 10.1002/j.1460-2075.1992.tb05108.x; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1	29	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1645	1650		10.1074/jbc.275.3.1645	http://dx.doi.org/10.1074/jbc.275.3.1645			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636857	hybrid			2022-12-25	WOS:000084940000020
J	Wright, HM; Clish, CB; Mikami, T; Hauser, S; Yanagi, K; Hiramatsu, R; Serhan, CN; Spiegelman, BM				Wright, HM; Clish, CB; Mikami, T; Hauser, S; Yanagi, K; Hiramatsu, R; Serhan, CN; Spiegelman, BM			A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIGLYCIDYL ETHER BADGE; BISPHENOL-A; GENE-EXPRESSION; LIGAND; J(2)	While searching for natural ligands for the peroxisome proliferator-activated receptor (PPAR) gamma, we identified a synthetic compound that binds to this receptor. Bisphenol A diglycidyl ether (BADGE) is a ligand for PPAR gamma with a K-d(app) of 100 mu M. This compound has no apparent ability to activate the transcriptional activity of PPAR gamma; however, BADGE can antagonize the ability of agonist ligands such as rosiglitazone to activate the transcriptional and adipogenic action of this receptor. BADGE also specifically blocks the ability of natural adipogenic cell lines such as 3T3-L1 and 3T3-F442A cells to undergo hormone-mediated cell differentiation. These results provide the first pharmacological evidence that PPAR gamma activity is required for the hormonally induced differentiation of adipogenic cells.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Anesthesia, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Sumitomo Chem Co Ltd, Biotechnol Lab, Takarazuka, Hyogo 6658555, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Sumitomo Chem Co Ltd	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, 1 Jimmy Fund Way,Smith 958, Boston, MA 02115 USA.		Clish, Clary B/ABB-9374-2021; Clish, Clary/AAB-7124-2019	Clish, Clary B/0000-0001-8259-9245; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038765, R01GM038765, R37GM038765] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38765] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Limbird LE, 1998, CELL, V93, P157, DOI 10.1016/S0092-8674(00)81568-8; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; SERHAN CN, 1990, J CLIN INVEST, V85, P772, DOI 10.1172/JCI114503; SHARMAN M, 1995, FOOD ADDIT CONTAM, V12, P779, DOI 10.1080/02652039509374370; Steinmetz R, 1998, ENDOCRINOLOGY, V139, P2741, DOI 10.1210/en.139.6.2741; Summerfield W, 1998, FOOD ADDIT CONTAM A, V15, P818; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X	16	326	339	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1873	1877		10.1074/jbc.275.3.1873	http://dx.doi.org/10.1074/jbc.275.3.1873			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636887	Green Published, hybrid			2022-12-25	WOS:000084940000050
J	Greener, T; Zhao, XH; Nojima, H; Eisenberg, E; Greene, LE				Greener, T; Zhao, XH; Nojima, H; Eisenberg, E; Greene, LE			Role of cyclin G-associated kinase in uncoating clathrin-coated vesicles from non-neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TUMOR-SUPPRESSOR; GOLGI MEMBRANES; MOLECULAR CHAPERONE; AUXILIN; ATPASE; DNAJ; DISSOCIATION; HOMOLOGS; BINDING	Auxilin is a brain-specific DnaJ homolog that is required for Hsc70 to dissociate clathrin from bovine brain clathrin-coated vesicles. However, Hsc70 is also involved in uncoating clathrin-coated vesicles formed at the plasma membrane of non-neuronal cells suggesting that an auxilin homolog may be required for uncoating in these cells. One candidate is cyclin G-associated kinase (GAK), a 150-kDa protein expressed ubiquitously in various tissues. GAK has a C-terminal domain with high sequence similarity to auxilin; like auxilin this C-terminal domain consists of three subdomains, an N-terminal tensin-like domain, a clathrin-binding domain, and a C-terminal J-domain, Western blot analysis shows that GAK is present in rat liver, bovine testes, and bovine brain clathrin-coated vesicles. More importantly, liver clathrin-coated vesicles, which contain GAK but not auxilin, are uncoated by Hsc70, suggesting that GAK acts as an auxilin homolog in non-neuronal cells. In support of this view, the clathrin-binding domain of GAK alone induces clathrin polymerization into baskets and the combined clathrin-binding domain and J-domain of GAK supports uncoating of AP180-clathrin baskets by Hsc70 at pH 7 and induces Hsc70 binding to clathrin baskets at pH 6, Immunolocalization studies suggest that GAK is a cytosolic protein that is concentrated in the perinuclear region; it appears to be highly associated with the trans-Golgi where the budding of clathrin-coated vesicles occurs. We propose that GAK is a required cofactor for the uncoating of clathrin-coated vesicles by Hsc70 in non-neuronal cells.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, Suita, Osaka 5650871, Japan	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Osaka University	Greene, LE (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 3,B1-22, Bethesda, MD 20892 USA.	greenel@helix.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000516, ZIAHL000516] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; Barouch W, 1997, BIOCHEMISTRY-US, V36, P4303, DOI 10.1021/bi962727z; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BUXBAUM E, 1995, J CELL SCI, V108, P1295; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheetham ME, 1996, BIOCHEM J, V319, P103, DOI 10.1042/bj3190103; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Haynie DT, 1996, PROTEIN SCI, V5, P2643, DOI 10.1002/pro.5560051227; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kimura SH, 1997, GENOMICS, V44, P179, DOI 10.1006/geno.1997.4873; King C, 1999, BIOCHEMISTRY-US, V38, P12452, DOI 10.1021/bi9902788; King C, 1997, BIOCHEMISTRY-US, V36, P4067, DOI 10.1021/bi9625307; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lo SH, 1998, MOL BIOL CELL, V9, p412A; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Polishchuk RS, 1999, EUR J CELL BIOL, V78, P170, DOI 10.1016/S0171-9335(99)80096-X; PRASAD K, 1993, J BIOL CHEM, V268, P23758; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHRODER S, 1995, EUR J BIOCHEM, V228, P297, DOI 10.1111/j.1432-1033.1995.tb20263.x; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; Zhu YX, 1998, MOL BIOL CELL, V9, P1323, DOI 10.1091/mbc.9.6.1323	37	125	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1365	1370		10.1074/jbc.275.2.1365	http://dx.doi.org/10.1074/jbc.275.2.1365			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625686	hybrid			2022-12-25	WOS:000084836600090
J	Rock, CO; Calder, RB; Karim, MA; Jackowski, S				Rock, CO; Calder, RB; Karim, MA; Jackowski, S			Pantothenate kinase regulation of the intracellular concentration of coenzyme A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RAT-LIVER; A BIOSYNTHESIS; COA; HEART; PURIFICATION; GENE; PEROXISOMES; EXPRESSION; METABOLISM	Pantothenate kinase (PanK) is the key regulatory enzyme in the CoA biosynthetic pathway in bacteria and is thought to play a similar role in mammalian cells. We examined this hypothesis by identifying and characterizing two murine cDNAs that encoded PanK. The two cDNAs were predicted to arise from alternate splicing of the same gene to yield different mRNAs that encode two isoforms (mPanK1 alpha and mPanK1 beta) with distinct amino termini. The predicted protein sequence of mPanK1 was not related to bacterial PanK but exhibited significant similarity to Aspergillus nidulans PanK. mPanK1 alpha was most highly expressed in heart and kidney, whereas mPanK1 beta mRNA was detected primarily in liver and kidney. Pantothenate was the most abundant pathway component (42.8%) in normal cells providing clear evidence that pantothenate phosphorylation was a rate-controlling step in CoA biosynthesis. Enhanced mPanK1 beta expression eliminated the intracellular pantothenate pool and triggered a 13-fold increase in intracellular CoA content. mPanK1 beta activity in vitro was stimulated by CoA and strongly inhibited by acetyl-CoA illustrating that differential modulation of mPanK1 beta activity by pathway end products also contributed to the management of CoA levels. These data support the concept that the expression and/or activity of PanK is a determining factor in the physiological regulation of the intracellular CoA concentration.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale, Memphis, TN 38105 USA.	suzanne.jackowski@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R01GM045737, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM45737, GM34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abiko Y., 1975, Metabolism of sulphur compounds., P1; ABIKO Y, 1972, BIOCHIM BIOPHYS ACTA, V268, P364, DOI 10.1016/0005-2744(72)90331-2; BHUIYAN AKMJ, 1988, BIOCHEM J, V253, P337, DOI 10.1042/bj2530337; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; Dimroth P, 1997, MOL MICROBIOL, V25, P3, DOI 10.1046/j.1365-2958.1997.4611824.x; DIMROTH P, 1976, EUR J BIOCHEM, V64, P269, DOI 10.1111/j.1432-1033.1976.tb10297.x; FALK KL, 1993, ARCH BIOCHEM BIOPHYS, V301, P424, DOI 10.1006/abbi.1993.1166; FISHER MN, 1985, J BIOL CHEM, V260, P5745; FISHER MN, 1985, FEBS LETT, V190, P293, DOI 10.1016/0014-5793(85)81303-X; FLAMM JA, 1988, GENE, V74, P555, DOI 10.1016/0378-1119(88)90189-8; HALVORSEN O, 1986, SCAND J CLIN LAB INV, V46, P67; HALVORSEN O, 1982, EUR J BIOCHEM, V124, P211, DOI 10.1111/j.1432-1033.1982.tb05927.x; HALVORSEN O, 1983, BIOCHEM PHARMACOL, V32, P1126, DOI 10.1016/0006-2952(83)90638-X; HORIE S, 1986, J BIOCHEM, V99, P1345, DOI 10.1093/oxfordjournals.jbchem.a135602; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; KARASAWA T, 1972, J BIOCHEM-TOKYO, V71, P1065, DOI 10.1093/oxfordjournals.jbchem.a129854; KIRSCHBAUM N, 1990, J NUTR, V120, P1376, DOI 10.1093/jn/120.11.1376; KONDRUP J, 1973, BIOCHEM J, V132, P373, DOI 10.1042/bj1320373; LOPASCHUK GD, 1986, AM J PHYSIOL, V250, pH351, DOI 10.1152/ajpheart.1986.250.3.H351; LUND H, 1986, BIOCHIM BIOPHYS ACTA, V876, P685, DOI 10.1016/0005-2760(86)90058-5; REIBEL DK, 1981, AM J PHYSIOL, V240, pH606, DOI 10.1152/ajpheart.1981.240.4.H606; ROBISHAW JD, 1985, AM J PHYSIOL, V248, pE1, DOI 10.1152/ajpendo.1985.248.1.E1; ROBISHAW JD, 1982, J BIOL CHEM, V257, P967; ROBISHAW JD, 1984, AM J PHYSIOL, V246, pH532, DOI 10.1152/ajpheart.1984.246.4.H532; SAVOLAINEN MJ, 1977, BIOCHEM PHARMACOL, V26, P425, DOI 10.1016/0006-2952(77)90202-7; SIEGMUND KD, 1991, BIOCHIM BIOPHYS ACTA, V1076, P123, DOI 10.1016/0167-4838(91)90228-R; SKREDE S, 1983, EUR J BIOCHEM, V131, P57, DOI 10.1111/j.1432-1033.1983.tb07231.x; SKREDE S, 1979, EUR J BIOCHEM, V98, P223, DOI 10.1111/j.1432-1033.1979.tb13180.x; SKREDE S, 1979, BIOCHEM BIOPH RES CO, V91, P1536, DOI 10.1016/0006-291X(79)91239-7; SMITH CM, 1980, BIOCHEM J, V188, P175, DOI 10.1042/bj1880175; SMITH CM, 1978, J NUTR, V108, P854, DOI 10.1093/jn/108.5.854; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P1705, DOI 10.1128/jb.174.5.1705-1706.1992; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; TAHILIANI AG, 1987, J BIOL CHEM, V262, P11607; TAHILIANI AG, 1991, BIOCHIM BIOPHYS ACTA, V1067, P29, DOI 10.1016/0005-2736(91)90022-Z; TAHILIANI AG, 1989, J BIOL CHEM, V264, P18426; VAGELOS RP, 1971, CURR TOP CELL REGUL, V4, P119; VALLARI DS, 1985, J BACTERIOL, V162, P1156, DOI 10.1128/JB.162.3.1156-1161.1985; VALLARI DS, 1987, J BACTERIOL, V169, P5795, DOI 10.1128/jb.169.12.5795-5800.1987; VALLARI DS, 1985, J BACTERIOL, V164, P136, DOI 10.1128/JB.164.1.136-142.1985; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; VANBROEKHOVEN A, 1981, BIOCHEM BIOPH RES CO, V100, P305, DOI 10.1016/S0006-291X(81)80097-6; VOLTTI H, 1979, BIOCHEM J, V182, P95, DOI 10.1042/bj1820095	48	153	170	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1377	1383		10.1074/jbc.275.2.1377	http://dx.doi.org/10.1074/jbc.275.2.1377			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625688	hybrid			2022-12-25	WOS:000084836600092
J	Dorion, S; Berube, J; Huot, J; Landry, J				Dorion, S; Berube, J; Huot, J; Landry, J			A short lived protein involved in the heat shock sensing mechanism responsible for stress-activated protein kinase 2 (SAPK2/p38) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MAMMALIAN-CELLS; SIGNAL-TRANSDUCTION; CONFERS RESISTANCE; INDUCED APOPTOSIS; HUMAN HSP27; HELA-CELLS; CONSTITUTIVE EXPRESSION; PROTEASOME INHIBITORS; TYROSINE KINASES	The stress-activated protein kinase 2 (SAPK2/p38) is activated by various environmental stresses and also by a vast array of agonists including growth factors and cytokines, This implies the existence of multiple proximal signaling pathways converging to the SAPK2/p38 activation cascade. Here, we show that there is a sensing mechanism highly specific to heat shock for activation of SAPK2/p38, After mild heat shock, cells became refractory to reinduction of the SAPK2/p38 pathway by a second heat shock. This was not the result of a toxic effect because the cells remained fully responsive to reinduction by other stresses, cytokines, or growth factors. Neither the activity of SAPK2/p38 itself nor the accumulation of the heat shock proteins was essential in the desensitization process. The cells were not desensitized to heat shock by other treatments that activated SAPK2/p38, Moreover, inhibiting SAPK2/p38 activity during heat shock did not block desensitization. Also, overexpression of HSP70, HSP27, or HSP90 by gene transfection did not cause desensitization, and inhibiting their synthesis after heat shock did not prevent desensitization. Desensitization rather appeared to be Linked closely to the turnover of a putative upstream activator of SAPK2/p38. Cycloheximide induced a progressive and eventually complete desensitization. The effect was specific to heat shock and minimally affected activation by other stress inducers. Inhibiting protein degradation with MG132 caused the constitutive activation of SAPK2/p38, which was blocked by a pretreatment with either cycloheximide or heat shock. The results thus indicate that there is a sensing pathway highly specific to heat shock upstream of SAPK2/p38 activation. The pathway appears to involve a short Lived protein that is the target of rapid successive up- and downregulation by heat shock.	Univ Laval, Ctr Rech Cancerol, Hotel Dieu Quebec, Quebec City, PQ G1R 2J6, Canada	Laval University	Landry, J (corresponding author), Univ Laval, Ctr Rech Cancerol, Hotel Dieu Quebec, 11 Cote de Palais, Quebec City, PQ G1R 2J6, Canada.	jacques.landry@med.ulaval.ca						ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; Bellmann K, 1996, FEBS LETT, V391, P185, DOI 10.1016/0014-5793(96)00730-2; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; FORNACE AJ, 1989, NUCLEIC ACIDS RES, V17, P1215, DOI 10.1093/nar/17.3.1215; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Garrido C, 1997, CANCER RES, V57, P2661; GERNER EW, 1975, NATURE, V256, P500, DOI 10.1038/256500a0; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Guay J, 1997, J CELL SCI, V110, P357; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HICKEY ED, 1982, BIOCHEMISTRY-US, V21, P1513, DOI 10.1021/bi00536a008; HUOT J, 1991, CANCER RES, V51, P5245; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1996, CANCER RES, V56, P273; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1982, CANCER RES, V42, P2457; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Landry J, 1999, BIOCHEM SOC SYMP, P79; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	73	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37591	37597		10.1074/jbc.274.53.37591	http://dx.doi.org/10.1074/jbc.274.53.37591			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608813	hybrid			2022-12-25	WOS:000084528000013
J	Leber, A; Hemmens, B; Klosch, B; Goessler, W; Raber, G; Mayer, B; Schmidt, K				Leber, A; Hemmens, B; Klosch, B; Goessler, W; Raber, G; Mayer, B; Schmidt, K			Characterization of recombinant human endothelial nitric-oxide synthase purified from the yeast Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYDROBIOPTERIN BINDING-KINETICS; C REDUCTASE-ACTIVITY; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE GENERATION; BRAIN; HEME; EXPRESSION; SUBSTRATE; DOMAIN	Human endothelial nitric-oxide synthase (eNOS) was expressed in the methylotrophic yeast Pichia pastoris, making use of the highly inducible alcohol oxidase promoter. The recombinant protein constituted approximately 3% of total protein and was largely soluble (>75%). About 1 mg of purified eNOS was obtained from 100-ml yeast cell cultures by affinity chromatography of crude cell supernatants. The purified enzyme had a V-max of 192 +/- 18 nmol of L-citrulline x mg(-1) x min(-1), had a K-m for L-arginine of 3.9 +/- 0.2 mu M, and showed an absolute requirement for tetrahydrobiopterin (H(4)biopterin). NADPH oxidase activity was 136 +/- 9 and 342 +/- 24 nmol x mg(-1) x min(-1) in the absence and presence of 0.1 mM L-arginine, respectively, and not affected by H(4)biopterin. The protein contained 0.56 +/- 0.06 equivalents of FAD and 0.79 +/- 0.08 equivalents of FMN. On-line gel filtration/inductively coupled plasma mass spectrometry analysis confirmed that both iron (0.80 +/- 0.09 mol/subunit) and zinc (0.43 +/- 0.03 mol/subunit) were bound to the enzyme. Graphite furnace-atomic absorption spectroscopy yielded a value for bound iron of 0.84 +/- 0.04 mol/subunit. The absorbance of the enzyme at 398 nm implied a heme content of 0.85 +/- 0.09 mol/subunit, and the high pressure liquid chromatography heme assay gave an estimate of 0.71 +/- 0.02 mol heme/subunit. Gel permeation chromatography yielded one single peak with a Stokes radius of 6.62 +/- 0.7 nm, indicating that the native protein is dimeric, Upon low temperature gel electrophoresis the untreated protein appeared mainly as a monomer (88 +/- 3%), but pretreatment with H(4)biopterin and L-arginine led to a pronounced shift toward dimers (77 +/- 4%). Thus,in contrast to bovine eNOS (List,B.M., Klosch, B., Volker, C., Gorren, A C. F., Sessa, W. C., Werner, E. R, Kukovetz, W. R, Schmidt, a, and Mayer, B. (1997) Biochem J; 323, 159-165; Rodriguez-Crespo, L, Gerber, N, C., and Ortiz de Montellano, P.R (1996) J. Biol. Chem 271, 11462-11467), the human eNOS appears to be markedly stabilized by H(4)biopterin.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; Karl Franzens Univ Graz, Inst Analyt Chem, A-8010 Graz, Austria	University of Graz; University of Graz	Schmidt, K (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	kurt.schmidt@kfunigraz.ac.at	Goessler, Walter/A-1084-2016; Mayer, Bernd/B-9391-2008	Goessler, Walter/0000-0002-0142-9373; Raber, Georg/0000-0002-7674-5995; Mayer, Bernd/0000-0002-2921-3494				Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BLACK SM, 1995, DNA CELL BIOL, V14, P789, DOI 10.1089/dna.1995.14.789; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Hellermann GR, 1997, J BIOL CHEM, V272, P12030, DOI 10.1074/jbc.272.18.12030; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jones S, 1996, J BIOTECHNOL, V48, P37, DOI 10.1016/0168-1656(96)01394-6; KLATT P, 1994, J BIOL CHEM, V269, P13861; Klatt P, 1996, METHOD ENZYMOL, V268, P358; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KLATT P, 1992, J BIOL CHEM, V267, P11374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Martasek P, 1999, METHOD ENZYMOL, V301, P70; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; Mayer B, 1996, METHOD ENZYMOL, V268, P420; Mayer B, 1998, N-S ARCH PHARMACOL, V358, P127, DOI 10.1007/PL00005233; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Miller RT, 1999, J BIOL CHEM, V274, P14537, DOI 10.1074/jbc.274.21.14537; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; Narayanasami R, 1997, NITRIC OXIDE-BIOL CH, V1, P39, DOI 10.1006/niox.1996.0103; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Pfeiffer S, 1999, ANGEW CHEM INT EDIT, V38, P1715, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1714::AID-ANIE1714>3.0.CO;2-3; Pieper GM, 1997, J CARDIOVASC PHARM, V29, P8, DOI 10.1097/00005344-199701000-00002; POU S, 1992, J BIOL CHEM, V267, P24173; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Riethmuller C, 1999, J BIOL CHEM, V274, P16047, DOI 10.1074/jbc.274.23.16047; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sari MA, 1996, BIOCHEMISTRY-US, V35, P7204, DOI 10.1021/bi960087u; Schmidt K, 1999, EUR J BIOCHEM, V259, P25, DOI 10.1046/j.1432-1327.1999.00003.x; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770	53	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37658	37664		10.1074/jbc.274.53.37658	http://dx.doi.org/10.1074/jbc.274.53.37658			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608822	hybrid			2022-12-25	WOS:000084528000022
J	Tang, PZ; Tsai-Morris, CH; Dufau, ML				Tang, PZ; Tsai-Morris, CH; Dufau, ML			A novel gonadotropin-regulated testicular RNA helicase - A new member of the DEAD-box family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR GENE; RAT LEYDIG-CELL; MESSENGER-RNA; CHORIONIC-GONADOTROPIN; PROTEIN; TRANSLATION; INITIATION; DESENSITIZATION; STEROIDOGENESIS; TESTIS	A gonadotropin-regulated testicular RNA helicase (GRTH) was identified and characterized GRTH cloned from rat Leydig cell, mouse testis, and human testis cDNA Libraries is a novel member of the DEAD-box protein family. GRTH is transcriptionally up-regulated by chorionic gonadotropin via cyclic AMP-induced androgen formation in the Leydig cell. It has ATPase and RNA helicase activities and increases translation in vitro. This helicase is highly expressed in rat, mouse, and human testes and weakly expressed in the pituitary and hypothalamus. GRTH is produced in both somatic (Leydig. cells) and germinal (meiotic spermatocytes and round haploid spermatids) cells and is developmentally regulated. GRTH predominantly localized in the cytoplasm may function as a translational activator. This novel helicase could be relevant to the control of steroidogenesis and the paracrine regulation of androgen-dependent spermatogenesis in the testis.	NICHHD, Sect Mol Endocrinol, NIH, Bethesda, MD 20892 USA; NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dufau, ML (corresponding author), NICHHD, Sect Mol Endocrinol, NIH, Bldg 49,Rm 6A36,49 Convent Dr MSC 4510, Bethesda, MD 20892 USA.	dufau@helix.nih.gov		Tsai Morris, Chon Hwa/0000-0002-8113-0979				AQUILANO DR, 1985, ENDOCRINOLOGY, V116, P1745, DOI 10.1210/endo-116-5-1745; AQUILANO DR, 1984, ENDOCRINOLOGY, V114, P499, DOI 10.1210/endo-114-2-499; BREMNER WJ, 1994, ENDOCRINOLOGY, V135, P1227, DOI 10.1210/en.135.3.1227; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; CIGORRAGA SB, 1978, J BIOL CHEM, V253, P4297; CLERMONT Y, 1957, AM J ANAT, V100, P241, DOI 10.1002/aja.1001000205; DAN L, 1992, NUCLEIC ACIDS RES, V20, P1967, DOI 10.1093/nar/20.8.1967; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; Dufau ML, 1997, STEROIDS, V62, P128, DOI 10.1016/S0039-128X(96)00171-7; DUFAU ML, 1979, J STEROID BIOCHEM, V11, P193, DOI 10.1016/0022-4731(79)90296-6; DUFAU ML, 1988, ANNU REV PHYSIOL, V50, P483, DOI 10.1146/annurev.ph.50.030188.002411; DUFAU ML, 1978, VITAM HORM, V36, P461; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FOX CH, 1993, CURRENT PROTOCOLS IM; GEE SL, 1994, GENE, V140, P171, DOI 10.1016/0378-1119(94)90541-X; GILMAN M, 1987, CURRENT PROTOCOLS MO; GREENBERG ME, 1990, CURRENT PROTOCOLS MO; GURURAJAN R, 1991, NATURE, V349, P717, DOI 10.1038/349717a0; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Hu ZZ, 1997, J BIOL CHEM, V272, P14263, DOI 10.1074/jbc.272.22.14263; HUHTANIEMI IT, 1982, ENDOCRINOLOGY, V111, P1711, DOI 10.1210/endo-111-5-1711; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; Khanum A, 1997, ENDOCRINOLOGY, V138, P1612, DOI 10.1210/en.138.4.1612; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAEKAWA H, 1994, MOL GEN GENET, V244, P456, DOI 10.1007/BF00583896; Merrick WC, 1997, METHODS, V11, P333, DOI 10.1006/meth.1996.0431; NISHIHARA M, 1988, BIOCHEM BIOPH RES CO, V154, P151, DOI 10.1016/0006-291X(88)90663-8; NOZU K, 1981, J BIOL CHEM, V256, P12; NOZU K, 1981, J BIOL CHEM, V256, P2875; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Tang PZ, 1998, ENDOCRINOLOGY, V139, P4496, DOI 10.1210/en.139.11.4496; Tsai-Morris CH, 1999, ENDOCRINOLOGY, V140, P3534, DOI 10.1210/en.140.8.3534; Tsai-Morris CH, 1998, J CLIN ENDOCR METAB, V83, P288, DOI 10.1210/jc.83.1.288; TSAIMORRIS CH, 1994, J BIOL CHEM, V269, P15868; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651	39	54	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37932	37940		10.1074/jbc.274.53.37932	http://dx.doi.org/10.1074/jbc.274.53.37932			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608860	hybrid			2022-12-25	WOS:000084528000060
J	Kim, HP; Roe, JH; Chock, PB; Yim, MB				Kim, HP; Roe, JH; Chock, PB; Yim, MB			Transcriptional activation of the human manganese superoxide dismutase gene mediated by tetradecanoylphorbol acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; SIGNAL TRANSDUCTION PATHWAYS; PROTEIN-KINASE-C; CYCLIC-AMP; PHORBOL ESTER; MNSOD GENE; SELECTIVE INHIBITOR; OXIDASE ACTIVATION; BINDING-PROTEINS	Transcriptional activation of human manganese superoxide dismutase (MnSOD) mRNA induced by a phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), was examined to identify the responsive transcriptional regulator. The effect of various deletions and mutations within the 5'-flanking region of the human MnSOD gene promoter was evaluated using the luciferase reporter system in A549 human lung carcinoma cells. Deletion of a region between -1292 and -1202 nucleotides upstream of the transcription start site abolished TPA-responsive induction, whereas deletion of the putative binding sequence for NF-kappa B or AP-1 did not. The region between -1292 and -1202 contains a cAMP-responsive element-like sequence, TGACGTCT, which we identified as the manganese Superoxide dismutase TPA-responsive element, MSTRE. Site-specific mutation of the MSTRE abolished the TPA-responsive induction, validating the critical role of this sequence. We detected specific MSTRE activity from nuclear extracts and demonstrated by antibody supershift assay that this activity is closely related to CREB-1/ATF-1. TPA treatment rap idly induced phosphorylation of the CREB-1/ATF-1-like factor via the protein kinase C pathway. These results led us to conclude that the human MnSOD gene having the promoter construct used in this study is induced by TPA via activation of a CREB-1/ATF-1-like factor and not via either NF-kappa B or AP-1, In addition, we found that this induction was blocked by inhibitors of flavoproteins and NADPH oxidases, indicating involvement of enhanced generation of superoxide radical anion as an upstream signal.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Seoul Natl Univ, Coll Nat Sci, Dept Microbiol, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Mol Microbiol, Seoul 151742, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Seoul National University (SNU); Seoul National University (SNU)	Yim, MB (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 3,Rm 202,3 Ctr Dr,MSC-0342, Bethesda, MD 20892 USA.							AEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43; AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; CHURCH SL, 1992, DEV BIOL, V149, P177, DOI 10.1016/0012-1606(92)90274-K; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FUJII J, 1994, BIOCHEM J, V301, P31, DOI 10.1042/bj3010031; FUJII J, 1991, J BIOL CHEM, V266, P23142; GEILEN CC, 1992, FEBS LETT, V309, P381, DOI 10.1016/0014-5793(92)80811-T; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRIS CA, 1991, J IMMUNOL, V147, P149; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; LEE JH, 1990, CANCER RES, V50, P2724; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maniatis T., 1982, MOL CLONING LAB MANU; MEIR B, 1991, BIOCHEM J, V275, P241; MEYRICK B, 1994, AM J RESP CELL MOL, V10, P113, DOI 10.1165/ajrcmb.10.1.8292376; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; OBERLEY LW, 1987, ARCH BIOCHEM BIOPHYS, V254, P69, DOI 10.1016/0003-9861(87)90082-8; OBERLEY LW, 1979, CANCER RES, V39, P1141; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Prestridge DS, 1996, COMPUT APPL BIOSCI, V12, P157; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Yim HS, 1997, J BIOL CHEM, V272, P8861; Zhang N, 1996, BIOCHEM BIOPH RES CO, V220, P171, DOI 10.1006/bbrc.1996.0376	57	82	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37455	37460		10.1074/jbc.274.52.37455	http://dx.doi.org/10.1074/jbc.274.52.37455			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601319	hybrid			2022-12-25	WOS:000084382700090
J	Porter, AC; Fanger, GR; Vaillancourt, RR				Porter, AC; Fanger, GR; Vaillancourt, RR			Signal transduction pathways regulated by arsenate and arsenite	ONCOGENE			English	Article						arsenic; Rac; Rho; PAK; MEKK3; MEKK4	ACTIVATED-PROTEIN-KINASE; HEAT-SHOCK; DIFFERENTIAL ACTIVATION; JUN KINASE; STRESS; CELLS; RAC; RHO; PHOSPHORYLATION; DOMAIN	Arsenate and arsenite activate c-Jun N-terminal kinase (JNK), however, the mechanism by which this occurs is not known, By expressing inhibitory mutant small GTP-binding proteins, p21-activated kinase (PAK) and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinases (MEKKs), we have identified specific proteins that are involved in arsenate-and arsenite-mediated activation of JNK, We observe a distinct difference between arsenate and arsenite signaling, which demonstrates that arsenate and arsenite are capable of activating unique proteins. Both arsenate and arsenite activation of JNK requires Rac and Rho. Neither arsenate nor arsenite signaling was inhibited by a dominant-negative mutant of Cdc42 or Ras. Arsenite stimulation of JNK requires PAK, whereas arsenate-mediated activation of JNK was unaffected by inhibitory mutant PAK. Of the four MEKKs tested, only MEKK3 and MEKK4 are involved in arsenate-mediated activation of JNK. In contrast, arsenite-mediated JNK activation requires MEKK2, MEKK3 and MEKK4. These results better define the mechanisms by which arsenate and arsenite activate JNK and demonstrate differences in the regulation of signal transduction pathways by these inorganic arsenic species.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA	University of Arizona; National Jewish Health	Vaillancourt, RR (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 06694] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMAN RS, 1973, SCIENCE, V182, P1247, DOI 10.1126/science.182.4118.1247; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; JACOBSONKRAM D, 1985, ENVIRON MUTAGEN, V7, P787, DOI 10.1002/em.2860070515; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KENNEY LJ, 1988, J BIOL CHEM, V263, P7954; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE TC, 1985, CARCINOGENESIS, V6, P1421, DOI 10.1093/carcin/6.10.1421; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Mikami K, 1998, PLANT J, V15, P563, DOI 10.1046/j.1365-313X.1998.00227.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; ROSSMAN TG, 1980, ENVIRON MUTAGEN, V2, P371, DOI 10.1002/em.2860020307; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sakurai T, 1998, CHEM RES TOXICOL, V11, P273, DOI 10.1021/tx9701384; Smith AH, 1998, AM J EPIDEMIOL, V147, P660, DOI 10.1093/oxfordjournals.aje.a009507; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIGON S, 1995, J BIOL CHEM, V270, P13091, DOI 10.1074/jbc.270.22.13091; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WHANGER PD, 1977, ENVIRON HEALTH PERSP, V19, P139, DOI 10.2307/3428465; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798; YEH S, 1968, CANCER, V21, P312, DOI 10.1002/1097-0142(196802)21:2<312::AID-CNCR2820210222>3.0.CO;2-K; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907	54	65	67	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7794	7802		10.1038/sj.onc.1203214	http://dx.doi.org/10.1038/sj.onc.1203214			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618720				2022-12-25	WOS:000084256900009
J	Hajra, KM; Ji, XD; Fearon, ER				Hajra, KM; Ji, XD; Fearon, ER			Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements	ONCOGENE			English	Article						E-cadherin; breast cancer; somatic cell hybrid; transcription factor; gene expression; E-box	INVASION-SUPPRESSOR GENE; CELL-LINES; GASTRIC-CANCER; UVOMORULIN; ADHESION; CARCINOMAS; MECHANISMS; MUTATIONS	Inactivation of the E-cadherin cell adhesion molecule is believed critical in the development and behavior of many epithelial cancers, though mutations in the E-cadherin gene account for inactivation in only a fraction of cases, In many breast cancer lines, E-cadherin transcription is extinguished, but the role and significance of alterations in trans-acting transcription factors, promoter hypermethylation, and chromatin changes remain unresolved, To gain further insights into mechanisms underlying E-cadherin in inactivation in breast cancer, we analysed somatic cell hybrids resulting from pairwise fusions between breast cancer lines with intact E-cadherin transcription (E-cad+) and lines lacking E-cadherin transcription (E-cad-), All hybrid lines failed to express E-cadherin transcripts and protein, despite the fact that E-cadherin alleles from E-cad+ lines were present in the hybrids, Elements in the proximal 108 bp of the E-cadherin promoter, when present in reporter gene constructs, mere sufficient to direct strong transcription in E-cad+ breast lines, but displayed weak activity in E-cad- parental lines and hybrids, E-cadherin expression could not be restored in E-cad- lines or hybrids by treatment with a DNA demethylating agent and/or a histone deacetylase inhibitor, Our findings suggest loss of E-cadherin expression in some breast cancers may be due to dominant repression of the trans-acting pathways that regulate E-cadherin transcription.	Univ Michigan, Sch Med, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fearon, ER (corresponding author), Univ Michigan, Med Ctr, Div Med Genet, 1500 W Med Ctr Dr,4301 MSRB3, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R01CA070097, T32CA009676] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA70097, 5 T32 CA09676-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P389; GAMALLO C, 1993, AM J PATHOL, V142, P987; Gayther SA, 1998, CANCER RES, V58, P4086; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Hiraguri S, 1998, CANCER RES, V58, P1972; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; NATT E, 1989, CYTOGENET CELL GENET, V50, P145, DOI 10.1159/000132745; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Poola I, 1998, ANAL BIOCHEM, V258, P209, DOI 10.1006/abio.1998.2629; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	28	98	100	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7274	7279		10.1038/sj.onc.1203336	http://dx.doi.org/10.1038/sj.onc.1203336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602481				2022-12-25	WOS:000084119400011
J	McCormack, MP; Gonda, TJ				McCormack, MP; Gonda, TJ			Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common beta subunit	ONCOGENE			English	Article						cytokine receptor; leukaemia; myeloproliferative disorder; mice	COLONY-STIMULATING FACTOR; HUMAN GM-CSF; ACUTE MYELOBLASTIC-LEUKEMIA; GROWTH SIGNAL-TRANSDUCTION; HEMATOPOIETIC STEM-CELLS; TRANSGENIC MICE; ALPHA-CHAIN; FACTOR GENE; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS	Several constitutively active mutant forms of the common beta subunit of the human IL-3, IL-5 and GMCSF receptors (hpc), which enable it to signal in the absence of ligand, have recently been described. Two of these, V449E and I374N, are amino acid substitutions in the transmembrane and extracellular regions of h beta c, respectively, A third, FI Delta, contains a 37 amino acid duplication in the extracellular domain. We have shown previously that when expressed in primary murine haemopoietic cells, the extracellular mutants confer factor-independence on cells of the neutrophil and monocyte lineages only, whereas V449E does so on all cell types of the myeloid and erythroid compartments. To study the in vivo effects and leukaemic potential of these mutants, we have expressed all three in mice by bone marrow reconstitution using retrovirally infected donor cells, Expression of the extracellular mutants leads to an early onset, chronic myeloproliferative disorder marked by elevations in the neutrophil, monocyte, erythrocyte and platelet lineages, In contrast, expression of V449E leads to an acute leukaemia-like syndrome of anaemia, thrombocytopaenia and blast cell expansion, These data support the possibility that activating mutations in h beta c are involved in haemopoietic disorders in man.	Hanson Ctr Canc Res, Inst Med & Vet Sci, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Gonda, TJ (corresponding author), Hanson Ctr Canc Res, Inst Med & Vet Sci, Frome Rd, Adelaide, SA 5000, Australia.		Gonda, Thomas J/A-3620-2012	McCormack, Matthew/0000-0003-1536-5611				BARRY SC, 1994, J BIOL CHEM, V269, P8488; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; CHANG JM, 1989, J CLIN INVEST, V84, P1488, DOI 10.1172/JCI114324; CHANG JM, 1989, BLOOD, V73, P1487; D'Andrea RJ, 1998, J CLIN INVEST, V102, P1951, DOI 10.1172/JCI3729; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DeJong MO, 1997, STEM CELLS, V15, P275, DOI 10.1002/stem.150275; Doi H, 1997, P NATL ACAD SCI USA, V94, P2513, DOI 10.1073/pnas.94.6.2513; FREEDMAN MH, 1993, BLOOD, V81, P3068; Gonda TJ, 1997, BLOOD, V89, P355, DOI 10.1182/blood.V89.2.355; GUALTIERI RJ, 1989, BLOOD, V74, P2360; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; Jenkins BJ, 1999, J BIOL CHEM, V274, P8669, DOI 10.1074/jbc.274.13.8669; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KAUFMAN DC, 1988, BLOOD, V72, P1329; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1986, BLOOD, V67, P37; METCALF D, 1986, J CELL PHYSIOL, V128, P421, DOI 10.1002/jcp.1041280311; Metcalf D, 1995, HEMOPOIETIC COLONY S; Metcalf D, 1984, CLONAL CULTURE HEMOP; MIYAJIMA A, 1993, BLOOD, V82, P1960; Nishijima I, 1997, BLOOD, V90, P1031, DOI 10.1182/blood.V90.3.1031.1031_1031_1038; OKADA S, 1992, BLOOD, V80, P3044; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; YOUNG DC, 1987, J CLIN INVEST, V79, P100, DOI 10.1172/JCI112769; YOUNG DC, 1986, BLOOD, V68, P1178	35	17	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7190	7199		10.1038/sj.onc.1203226	http://dx.doi.org/10.1038/sj.onc.1203226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602472				2022-12-25	WOS:000084119400002
J	Bruser, T; Selmer, T; Dahl, C				Bruser, T; Selmer, T; Dahl, C			"ADP sulfurylase" from Thiobacillus denitrificans is an adenylylsulfate : phosphate adenylyltransferase and belongs to a new family of nucleotidyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; CHLOROBIUM-VIBRIOFORME; SULFIDE OXIDATION; ATP SULFURYLASE; BINDING-SITE; BACTERIA; YEAST; PURIFICATION; GENERATION	During AMP-dependent sulfite oxidation by some sulfur bacteria, the liberation of sulfate from adenosine-5'-phosphosulfate (APS) is catalyzed by APS:phosphate adenylyltransferase (APAT), Here we report the first biochemical and genetic characterization of APAT, We isolated this enzyme from the chemolithoautotroph Thiobacillus denitrificans and cloned the corresponding gene, The enzyme is homodimeric with 41,387-Da subunits and exhibits a specific activity of 2100 mu mol min(-1) mg(-1). The K-m values are K-m(APS) = 300 mu M and K-m(Pi), = 12 mM. Catalysis occurs by a ping-pong mechanism with a covalently bound AMP as reaction intermediate. The arsenolysis of APS, but not of ADP, CDP, GDP, UDP, or IDP, is also catalyzed, indicating a specific and unidirectional function. The former enzyme name ADP-sulfurylase implies that the reverse reaction is catalyzed; therefore, this name should not be used any longer. Histidine modification of APAT results in complete inactivation that can be suppressed by substrate addition. APAT is highly similar to galactose-1-phosphate uridylyltransferase and also related to Ap(4)A phosphorylase, Active site residues of galactose-1-phosphate uridylyltransferase are conserved in APAT and Ap(4)A phosphorylase, suggesting a histidine as the nucleotide-binding residue in all three enzymes, which together form a new family of nucleotidyltransferases.	Univ Bonn, Inst Mikrobiol & Biotechnol, D-53115 Bonn, Germany; Univ Marburg, Fachbereich Biol Mikrobiol, D-35032 Marburg, Germany	University of Bonn; Philipps University Marburg	Dahl, C (corresponding author), Univ Bonn, Inst Mikrobiol & Biotechnol, Meckenheimer Allee 168, D-53115 Bonn, Germany.		Dahl, Christiane/H-4786-2019	Dahl, Christiane/0000-0001-8288-7546; Bruser, Thomas/0000-0002-5889-8306				ADAMS CA, 1972, BIOCHEM J, V128, P647, DOI 10.1042/bj1280647; ALGUERO M, 1988, Microbiologia (Madrid), V4, P149; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BIAS U, 1987, ARCH MICROBIOL, V147, P406, DOI 10.1007/BF00406141; BOWEN TJ, 1966, BIOCHIM BIOPHYS ACTA, V118, P566, DOI 10.1016/S0926-6593(66)80098-X; Brune DC, 1995, ANOXYGENIC PHOTOSYNT, P847, DOI 10.1007/0-306-47954-0_39; CALIGAN JE, 1995, CURRENT PROTOCOLS PR; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; COOPER BP, 1979, Z NATURFORSCH C, V34, P346; DAHL C, 1994, METHOD ENZYMOL, V243, P400; DAHL C, 1989, Z NATURFORSCH C, V44, P137; FARLEY JR, 1979, J BIOL CHEM, V254, P3537; GURANOWSKI A, 1986, J BIOL CHEM, V261, P5943; Hagen KD, 1997, APPL ENVIRON MICROB, V63, P3957, DOI 10.1128/AEM.63.10.3957-3964.1997; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOOPER AB, 1985, MICROBIOL REV, V49, P140, DOI 10.1128/MMBR.49.2.140-157.1985; Kelly DP, 1997, ANTON LEEUW INT J G, V71, P95, DOI 10.1023/A:1000135707181; KHANNA S, 1983, J GEN MICROBIOL, V129, P1365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YP, 1994, J BACTERIOL, V176, P44, DOI 10.1128/JB.176.1.44-49.1994; MARCH PE, 1988, ONCOGENE, V2, P539; Marzluf GA, 1997, ANNU REV MICROBIOL, V51, P73, DOI 10.1146/annurev.micro.51.1.73; NICHOLLS RG, 1977, BIOCHEM J, V165, P149, DOI 10.1042/bj1650149; PECK HD, 1960, P NATL ACAD SCI USA, V46, P1053, DOI 10.1073/pnas.46.8.1053; PLATEAU P, 1989, J BACTERIOL, V171, P6437, DOI 10.1128/jb.171.12.6437-6445.1989; Reinartz M, 1998, ARCH MICROBIOL, V170, P59, DOI 10.1007/s002030050615; RENOSTO F, 1991, ARCH BIOCHEM BIOPHYS, V290, P66, DOI 10.1016/0003-9861(91)90592-7; ROBINSON AK, 1991, BIOCHEM J, V279, P135, DOI 10.1042/bj2790135; RUZICKA FJ, 1995, BIOCHEMISTRY-US, V34, P5610, DOI 10.1021/bi00016a036; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEDEL M, 1979, BIOCHIM BIOPHYS ACTA, V568, P454, DOI 10.1016/0005-2744(79)90314-0; SCHEDEL M, 1980, ARCH MICROBIOL, V124, P205, DOI 10.1007/BF00427728; SCHUG A, 1979, THESIS U BONN GERMAN; Schwartz NB, 1998, CHEM-BIOL INTERACT, V109, P143, DOI 10.1016/S0009-2797(97)00129-4; SMITH DW, 1991, VARIATIONS AUTOTROPH, P121; STEINERT PM, 1974, ANAL BIOCHEM, V59, P416, DOI 10.1016/0003-2697(74)90294-2; THIELE HH, 1968, A VAN LEEUW J MICROB, V34, P350, DOI 10.1007/BF02046457; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P1212, DOI 10.1021/bi9626517; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; Woltjer RL, 1997, BIOCHEMISTRY-US, V36, P9911, DOI 10.1021/bi963007v	41	36	40	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1691	1698		10.1074/jbc.275.3.1691	http://dx.doi.org/10.1074/jbc.275.3.1691			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636864	hybrid			2022-12-25	WOS:000084940000027
J	van Kerkhof, P; Grovers, R; dos Santos, CMA; Strous, GJ				van Kerkhof, P; Grovers, R; dos Santos, CMA; Strous, GJ			Endocytosis and degradation of the growth hormone receptor are proteasome-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN CONJUGATION SYSTEM; FACTOR BETA-RECEPTOR; BINDING-PROTEIN; PLASMA-MEMBRANE; MEDIATED INTERNALIZATION; SACCHAROMYCES-CEREVISIAE; PROTEOLYTIC PATHWAY; ER DEGRADATION; GENE-PRODUCT; IM-9 CELLS	The ubiquitin conjugation system is involved in ligand-induced endocytosis of the growth hormone receptor (GHR) via a cytosolic 10-amino acid ubiquitin-dependent endocytosis motif, Herein, we demonstrate that the proteasome is also involved in growth hormone receptor down-regulation. Ligand-induced degradation was blocked in the presence of specific proteasomal inhibitors. In addition, growth hormone (GH) internalization was inhibited, whereas the transferrin receptor cycle remained unaffected. A truncated GHR entered the cells independent of proteasome action. In addition, we show that GH internalization is independent of the presence of lysine residues in the cytosolic domain of the receptor, whereas its internalization can still be inhibited by proteasomal inhibitors, Thus, GHR internalization requires proteasome action in addition to an active ubiquitin conjugation system, but ubiquitination of the GHR itself seems not to be required.	Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University	Strous, GJ (corresponding author), Univ Utrecht, Med Ctr, Dept Cell Biol, Heidelberglaan 100,AZU-G02-525, NL-3584 CX Utrecht, Netherlands.	strous@med.uu.nl	Govers, Roland/O-5782-2016	Govers, Roland/0000-0003-1359-5333; van Kerkhof, Peter/0000-0002-8954-2230				Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BAUMANN G, 1986, J CLIN ENDOCR METAB, V62, P134, DOI 10.1210/jcem-62-1-134; BAXTER RC, 1985, ENDOCRINOLOGY, V117, P650, DOI 10.1210/endo-117-2-650; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Breuer P, 1998, J BIOL CHEM, V273, P33254, DOI 10.1074/jbc.273.50.33254; CAHOREAU C, 1994, FEBS LETT, V350, P230, DOI 10.1016/0014-5793(94)00772-1; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GORIN E, 1985, ENDOCRINOLOGY, V116, P1796, DOI 10.1210/endo-116-5-1796; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Haft CR, 1998, ENDOCRINOLOGY, V139, P1618, DOI 10.1210/en.139.4.1618; HARRISON SM, 1995, ENDOCRINOLOGY, V136, P651, DOI 10.1210/en.136.2.651; Hein C, 1997, MOL MICROBIOL, V24, P607, DOI 10.1046/j.1365-2958.1997.3771735.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Horak J, 1997, J BACTERIOL, V179, P1541, DOI 10.1128/jb.179.5.1541-1549.1997; HOU D, 1994, J BIOL CHEM, V269, P14244; ILONDO MM, 1992, ENDOCRINOLOGY, V130, P2037, DOI 10.1210/en.130.4.2037; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LESNIAK MA, 1976, J BIOL CHEM, V251, P3730; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Miura H, 1996, BIOCHEM BIOPH RES CO, V227, P684, DOI 10.1006/bbrc.1996.1569; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1995, BIOCHEM BIOPH RES CO, V217, P224, DOI 10.1006/bbrc.1995.2767; MURPHY LJ, 1984, ENDOCRINOLOGY, V115, P1625, DOI 10.1210/endo-115-4-1625; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; SU CC, 1998, RECENT PROG HORM RES, V53, P61; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; YAMADA K, 1987, BIOCHEMISTRY-US, V26, P4438, DOI 10.1021/bi00388a037	51	145	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1575	1580		10.1074/jbc.275.3.1575	http://dx.doi.org/10.1074/jbc.275.3.1575			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636847	hybrid			2022-12-25	WOS:000084940000010
J	Kaasch, AJ; Joiner, KA				Kaasch, AJ; Joiner, KA			Targeting and subcellular localization of Toxoplasma gondii catalase - Identification of peroxisomes in an apicomplexan parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; PURIFICATION; SEQUENCE	We sought to identify and characterize peroxisomes in the apicomplexan parasite Toxoplasma gondii, To initiate this process, we first cloned and sequenced the gene for T, gondii catalase (EC 1.11.1.6), a marker enzyme for peroxisomes in eukaryotic cells. The gene predicts a protein of 57.2 kDa and 502 amino acids and has a strong homology to other eukaryotic catalases. A polyclonal antiserum raised against a glutathione S-transferase fusion protein recognized a single band with a molecular mass of 63 kDa by immunoblot, By immunofluorescence T, gondii catalase is present primarily in a punctate staining pattern anterior to the parasite nucleus. This compartment is distinguishable from other parasite organelles, namely micronemes, rhoptries, dense granules, and the apicoplast. Cytochemical visualization of catalase using diaminobenzidine precipitation gives a vesicular staining pattern anterior to the nucleus at the light level and round, vesicular structures with an estimated diameter of 100-300 nm by electron microscopy, T, gondii catalase has a putative C-terminal peroxisomal targeting signal in the last 3 amino acids (-AKM). Expression of T. gondii catalase in mammalian cells results in peroxisomal localization, whereas a construct lacking the targeting signal remains in the cytosol, Furthermore, addition of -AKM to the C terminus of chloramphenicol acetyltransferase is sufficient to target this protein to peroxisomes. These results provide the first evidence for peroxisomes in Apicomplexan parasites.	Yale Univ, Dept Internal Med, Infect Dis Sect, Sch Med, New Haven, CT 06520 USA	Yale University	Joiner, KA (corresponding author), Yale Univ, Dept Internal Med, Infect Dis Sect, Sch Med, 808 LCI,333 Cedar St, New Haven, CT 06520 USA.		Kaasch, Achim J/F-8414-2012; Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X; Kaasch, Achim/0000-0002-6659-6738	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030060] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ajioka JW, 1998, GENOME RES, V8, P18, DOI 10.1101/gr.8.1.18; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; CHANG HR, 1989, MICROB PATHOGENESIS, V7, P37, DOI 10.1016/0882-4010(89)90109-5; DEIMANN W, 1991, HISTOCHEMISTRY, V3, P573; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GOUET P, 1995, J MOL BIOL, V249, P933, DOI 10.1006/jmbi.1995.0350; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Karsten V, 1997, METHODS, V13, P103, DOI 10.1006/meth.1997.0503; Kirkman HN, 1999, J BIOL CHEM, V274, P13908, DOI 10.1074/jbc.274.20.13908; Loewen P, 1996, GENE, V179, P39, DOI 10.1016/S0378-1119(96)00321-6; MURRAY HW, 1979, J EXP MED, V150, P938, DOI 10.1084/jem.150.4.938; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SIBLEY LD, 1986, MOL BIOCHEM PARASIT, V19, P83, DOI 10.1016/0166-6851(86)90069-1; Soldati D, 1999, PARASITOL TODAY, V15, P5, DOI 10.1016/S0169-4758(98)01363-5; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANOSSOWSKI I, 1993, J MOL EVOL, V37, P71; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; ZAMOCKY M, 1995, FEBS LETT, V367, P241, DOI 10.1016/0014-5793(95)00568-T	23	42	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1112	1118		10.1074/jbc.275.2.1112	http://dx.doi.org/10.1074/jbc.275.2.1112			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625653	hybrid			2022-12-25	WOS:000084836600057
J	Paine, MJI; Garner, AP; Powell, D; Sibbald, J; Sales, M; Pratt, N; Smith, T; Tew, DG; Wolf, CR				Paine, MJI; Garner, AP; Powell, D; Sibbald, J; Sales, M; Pratt, N; Smith, T; Tew, DG; Wolf, CR			Cloning and characterization of a novel human dual flavin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450 REDUCTASE; FMN-BINDING DOMAIN; NITRIC-OXIDE; METHIONINE SYNTHASE; DELETION (9)(Q34.3); CHROMOSOME 9Q34; NADPH; LIVER; OXIDOREDUCTASE; ACTIVATION	Flavoprotein reductases play a key role in electron transfer in many physiological processes. We have isolated a cDNA with strong sequence similarities to cytochrome P-450 reductase and nitric-oxide synthase. The cDNA encodes a protein of 597 amino acid residues with a predicted molecular mass of 67 kDa. Northern blot analysis identified a predicted transcript of 3.0 kilobase pairs as well as a larger transcript at 6.0 kilobase pairs, and the gene was mapped to chromosome 9q34.3 by fluorescence in situ hybridization analysis. The amino acid sequence of the protein contained distinct FMN-, FAD-, and NADPH-binding domains, and in order to establish whether the protein contained these cofactors, the coding sequence was expressed in insect cells and purified. Recombinant protein bound FMN, FAD, and NADPH cofactors and exhibited a UV-visible spectrum with absorbance maxima at 380, 460, and 626 nm. The purified enzyme reduced cytochrome c, with apparent K-m and k(cat) values of 21 mu M and 1.3 s(-1), respectively, and metabolized the one-electron accepters doxorubicin, menadione, and potassium ferricyanide. Immunoblot analysis of fractionated MCF7 cells with antibodies to recombinant NR1 showed that the enzyme is cytoplasmic and highly expressed in a panel of human cancer cell lines, thus indicating that this novel reductase may play a role in the metabolic activation of bioreductive anticancer drugs and other chemicals activated by one-electron reduction.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Imperial Canc Res Fund,Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; SmithKline Beecham Res, King Of Prussia, PA 19406 USA; Univ Dundee, Ninewells Hosp & Med Sch, Dept Cytogenet, Dundee DD1 9SY, Scotland	University of Dundee; GlaxoSmithKline; University of Dundee	Wolf, CR (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Imperial Canc Res Fund,Mol Pharmacol Unit, Dundee DD1 9SY, Scotland.	rooney@dundee.ac.uk	Paine, Mark/D-3360-2013; Paine, Mark John Ingraham/O-7450-2019	Paine, Mark/0000-0003-2061-7713; Paine, Mark John Ingraham/0000-0003-2061-7713				Ayyash H, 1997, J MED GENET, V34, P610, DOI 10.1136/jmg.34.7.610; BACHUR NR, 1979, P NATL ACAD SCI USA, V76, P954, DOI 10.1073/pnas.76.2.954; BACKES WL, 1993, CYTOCHROME P450, P35; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; Barsukov I, 1997, J BIOMOL NMR, V10, P63, DOI 10.1023/A:1018313830207; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chance PF, 1998, AM J HUM GENET, V62, P633, DOI 10.1086/301769; Chen ZQ, 1998, J BIOL CHEM, V273, P26248, DOI 10.1074/jbc.273.40.26248; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Cummings J, 1998, BIOCHEM PHARMACOL, V56, P405; DIGNAM JD, 1975, BIOCHEM BIOPH RES CO, V63, P845, DOI 10.1016/0006-291X(75)90644-0; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; Garner AP, 1999, CANCER RES, V59, P1929; Gulati S, 1997, J BIOL CHEM, V272, P19171, DOI 10.1074/jbc.272.31.19171; ILAN Z, 1981, J BIOL CHEM, V256, P66; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KEYES SR, 1984, CANCER RES, V44, P5638; Klatt P, 1996, METHOD ENZYMOL, V268, P358; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Makela-Bengs P, 1998, AM J HUM GENET, V63, P506, DOI 10.1086/301968; MASTERS BSS, 1965, J BIOL CHEM, V240, P4081; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OSTOWSKI J, 1989, J BIOL CHEM, V264, P15796; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; SCHIMMENTI LA, 1994, AM J MED GENET, V51, P140, DOI 10.1002/ajmg.1320510211; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Shen A. L., 1993, CYTOCHROME P450, P35; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; Shen AL, 1999, J BIOL CHEM, V274, P5391, DOI 10.1074/jbc.274.9.5391; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; SPEARMAN ME, 1984, MOL PHARMACOL, V26, P566; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WALTON MI, 1992, BIOCHEM PHARMACOL, V44, P251, DOI 10.1016/0006-2952(92)90007-6; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Weiler T, 1998, AM J HUM GENET, V63, P140, DOI 10.1086/301925; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; Zhao Q, 1999, PROTEIN SCI, V8, P298	49	90	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1471	1478		10.1074/jbc.275.2.1471	http://dx.doi.org/10.1074/jbc.275.2.1471			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625700	hybrid			2022-12-25	WOS:000084836600104
J	Sugiyama, Y; Suzuki, A; Kishikawa, M; Akutsu, R; Hirose, T; Waye, MMY; Tsui, SKW; Yoshida, S; Ohno, S				Sugiyama, Y; Suzuki, A; Kishikawa, M; Akutsu, R; Hirose, T; Waye, MMY; Tsui, SKW; Yoshida, S; Ohno, S			Muscle develops a specific form of small heat shock protein complex composed of MKBP/HSPB2 and HSPB3 during myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; CONFERS RESISTANCE; SKELETAL-MUSCLE; EXPRESSION; GENE; FAMILY; HSP27; KINASE; TISSUE; MEMBER	Previously, we identified a new mammalian sHSP, MKBP, as a myotonic dystrophy protein kinase-binding protein, and suggested its important role in muscle maintenance (Suzuki, A., Sugiyama, Y., Hayashi, Y., Nyu-i, N., Yoshida, M., Nonaka, I., Ishiura, S., Arahata, K., and Ohno, S. (1998) J. Cell Biol. 140, 1113-1124). In this paper, we develop the former work by performing extensive characterization of five of the six sHSPs so far identified, that is, HSP27, alpha B-crystallin, p20, MKBP/HSPB2, and HSPB3, omitting lens-specific alpha A-crystallin. Tissue distribution analysis revealed that although each sHSP shows differential constitutive expression in restricted tissues, tissues that express all five sHSPs are only muscle-related tissues. Especially, the expressions of HSPB3, identified for the first time as a 17-kDa protein in this paper, and MKBP/HSPB2 are distinctly specific to muscles. Moreover, these sHSPs form an oligomeric complex with an apparent molecular mass of 150 kDa that is completely independent of the oligomers formed by HSP27, alpha B-crystallin, and p20. The expressions of MKBP/HSPB2 and HSPB3 are induced during muscle differentiation under the control of MyoD, suggesting that the sHSP oligomer comprising MKBP/HSPB2 and HSPB3 represents an additional system closely related to muscle function. The functional divergence among sHSPs in different oligomers is also demonstrated in several ways: 1) an interaction with myotonic dystrophy protein kinase, which has been suggested to be important for the maintenance of myofibril integrity, was observed only for MKBP/HSPB2; 2) a myotube-specific association with actin bundles was observed for HSP27 and alpha B-crystallin, but not for MKBP/HSPB2; and 3) sHSPs whose mRNAs are induced by heat shock are alpha B-crystallin and HSP27. Taken together, the results suggest that muscle cells develop two kinds of stress response systems composed of diverged sHSP members, and that these systems work independently in muscle maintenance and differentiation.	Yokohama City Univ, Sch Med, Dept Biol Mol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Chinese Univ Hong Kong, Dept Biochem, Shatin, NT, Peoples R China; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan	Yokohama City University; Chinese University of Hong Kong; Kyoto University	Suzuki, A (corresponding author), Yokohama City Univ, Sch Med, Dept Biol Mol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan.	abell@med.yokohama-cu.ac.jp; ohnos@med.yokohama-cu.ac.jp	韋妙宜教授, Mary Miu Yee Waye/A-9674-2008; Sugiyama, Yuki/B-2656-2018; Hirose, Tomonori/F-6015-2010; Ohno, Shigeo/B-1768-2010; Tsui, Stephen Kwok-Wing/E-4385-2015; Hirose, Tomonori/M-8872-2019	韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917; Sugiyama, Yuki/0000-0001-7830-0677; Hirose, Tomonori/0000-0003-2428-0919; Ohno, Shigeo/0000-0002-1294-5269; Tsui, Stephen Kwok-Wing/0000-0003-0686-4259; Hirose, Tomonori/0000-0003-2428-0919; Yoshida, Shosei/0000-0001-8861-1866				ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; ATOMI Y, 1991, J BIOCHEM-TOKYO, V110, P812, DOI 10.1093/oxfordjournals.jbchem.a123665; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; Boelens WC, 1998, BBA-PROTEIN STRUCT M, V1388, P513, DOI 10.1016/S0167-4838(98)00215-5; BROOKE MH, 1969, NEUROLOGY, V19, P221, DOI 10.1212/WNL.19.3.221; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; COKE M, 1990, AM J PHYSIOL, V258, pC723; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Iwaki A, 1997, GENOMICS, V45, P386, DOI 10.1006/geno.1997.4956; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1994, J BIOL CHEM, V269, P15302; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam WY, 1996, BBA-MOL CELL RES, V1314, P120, DOI 10.1016/S0167-4889(96)00121-8; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOCKE M, 1991, AM J PHYSIOL, V261, pC774, DOI 10.1152/ajpcell.1991.261.5.C774; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; Lutsch G, 1997, CIRCULATION, V96, P3466; MEHLEN P, 1995, J IMMUNOL, V154, P363; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Yoshida N, 1998, J CELL SCI, V111, P769; Yoshida S, 1996, J CELL BIOL, V132, P181, DOI 10.1083/jcb.132.1.181	49	245	261	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1095	1104		10.1074/jbc.275.2.1095	http://dx.doi.org/10.1074/jbc.275.2.1095			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625651	hybrid			2022-12-25	WOS:000084836600055
J	Aono, S; Keino, H; Ono, T; Yasuda, Y; Tokita, Y; Matsui, F; Taniguchi, M; Sonta, SI; Oohira, A				Aono, S; Keino, H; Ono, T; Yasuda, Y; Tokita, Y; Matsui, F; Taniguchi, M; Sonta, SI; Oohira, A			Genomic organization and expression pattern of mouse neuroglycan C in the cerebellar development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PROTEIN-TYROSINE-PHOSPHATASE; IN-SITU HYBRIDIZATION; O2A PROGENITOR CELLS; PDGF ALPHA-RECEPTOR; EXTRACELLULAR VARIANT; NG2 PROTEOGLYCAN; RAT-BRAIN; BETA; ASSIGNMENT	Neuroglycan C (NGC) is a membrane-spanning chondroitin sulfate proteoglycan with an epidermal growth factor module that is expressed predominantly in the brain. Cloning studies with mouse NGC cDNA revealed the expression of three distinct isoforms (NGC-I, -II, and -III) in the brain and revealed that the major isoform showed 94.3% homology with the rat counterpart. The NGC gene comprised six exons, was approximately 17 kilobases in size, and was assigned to mouse chromosome band 9F1 by fluorescence in situ hybridization, Western blot analysis demonstrated that, although NGC in the immature cerebellum existed in a proteoglycan form, most NGC in the mature cerebellum did not bear chondroitin sulfate chain(s), indicating that NGC is a typical part-time proteoglycan, Immunohistochemical studies showed that only the Purkinje cells were immunopositive in the cerebellum. In the immature Purkinje cells, NGC, probably the proteoglycan form, was immunolocalized to the soma and thick dendrites on which the climbing fibers formed synapses, not to the thin branches on which the parallel fibers formed synapses, This finding suggests the involvement of NGC in the differential adhesion and synaptogenesis of the climbing and parallel fibers with the Purkinje cell dendrites.	Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Aichi 4800392, Japan; Aichi Human Serv Ctr, Inst Dev Res, Dept Genet, Aichi 4800392, Japan; Aichi Human Serv Ctr, Inst Dev Res, Dept Morphol, Aichi 4800392, Japan		Aono, S (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Aichi 4800392, Japan.		Ono, Takao/C-6065-2017	Ono, Takao/0000-0002-0498-8293				BARNEA G, 1994, J BIOL CHEM, V269, P14349; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DAVISSON MT, 1991, CYTOGENET CELL GENET, V58, P1152, DOI 10.1159/000133726; Ito M., 1984, CEREBELLUM NEURAL CO, P21; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; MATSUI F, 1994, NEUROCHEM INT, V25, P425, DOI 10.1016/0197-0186(94)90018-3; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; NESBITT MN, 1973, CHROMOSOMA, V41, P145, DOI 10.1007/BF00319691; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; ONO T, 1993, JPN J GENET, V68, P617, DOI 10.1266/jjg.68.617; Ono T, 1997, CYTOGENET CELL GENET, V79, P101, DOI 10.1159/000134692; OOHIRA A, 1994, NEUROSCI RES, V20, P195, DOI 10.1016/0168-0102(94)90088-4; OOHIRA A, 1998, CONNECT TISSUE, V30, P49; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; Small DH, 1996, J NEUROCHEM, V67, P889; STALLCUP WB, 1981, DEV BIOL, V83, P154, DOI 10.1016/S0012-1606(81)80018-8; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4	24	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					337	342		10.1074/jbc.275.1.337	http://dx.doi.org/10.1074/jbc.275.1.337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617623	hybrid			2022-12-25	WOS:000085951600047
J	Johnson, RP; Craig, SW				Johnson, RP; Craig, SW			Actin activates a cryptic dimerization potential of the vinculin tail domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ASSOCIATION; ACIDIC PHOSPHOLIPIDS; BINDING-SITE; SIGNAL-TRANSDUCTION; ELECTRON-MICROSCOPY; SELF-ASSOCIATION; PROTEIN VINCULIN; FOCAL ADHESIONS; SMOOTH-MUSCLE; TALIN-BINDING	The tail domain of vinculin (V-t) is an actin binding module containing two regions that interact with F-actin. Although intact V-t purified from a bacterial expression system is a globular monomer, each actin binding region dimerizes when expressed individually, suggesting the presence of cryptic self-association sites whose exposure is regulated. We show that actin modulates V-t self-association by inducing or stabilizing a conformational change in V-t that allows dimerization. Chemical cross-linking studies implicate one of the actin binding regions in mediating dimerization in the presence of actin. Actin induced V-t dimers may play a role in the filament cross-linking activity of this protein. The V-t dimers induced by actin are biochemically distinct from the V-t dimers and higher oligomers induced by acidic phospholipids such as phosphatidylinositol 4,5-bisphosphate, suggesting structural differences in V-t bound to these two ligands that may provide a mechanistic basis for inhibition of F-actin binding by phosphatidylinositol 4,5-bisphosphate. The ability of actin to regulate the dimerization state of an actin binding protein suggests that, rather than serving a passive structural role, actin filaments may directly participate in signal transduction and other cellular events that are known to depend on cytoskeletal integrity.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Craig, SW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM41605] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041605, R56GM041605] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DANOWSKI BA, 1992, J CELL BIOL, V118, P1411, DOI 10.1083/jcb.118.6.1411; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Furukawa R, 1997, INT REV CYTOL, V175, P29, DOI 10.1016/S0074-7696(08)62125-7; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; JOHNSON RA, 1995, ENVIRONMETRICS, V6, P341, DOI 10.1002/env.3170060403; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MILAM LM, 1985, J MOL BIOL, V184, P543, DOI 10.1016/0022-2836(85)90301-8; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sanders MC, 1996, J BIOL CHEM, V271, P2651, DOI 10.1074/jbc.271.5.2651; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; Tilney LG, 1998, J CELL BIOL, V143, P121, DOI 10.1083/jcb.143.1.121; TILNEY LG, 1995, J CELL BIOL, V130, P629, DOI 10.1083/jcb.130.3.629; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; Xu WM, 1998, J CELL SCI, V111, P1535; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3	47	63	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					95	105		10.1074/jbc.275.1.95	http://dx.doi.org/10.1074/jbc.275.1.95			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617591	hybrid			2022-12-25	WOS:000085951600015
J	Lau, D; Kunzler, M; Braunwarth, A; Hellmuth, R; Podtelejnikov, A; Mann, M; Hurt, E				Lau, D; Kunzler, M; Braunwarth, A; Hellmuth, R; Podtelejnikov, A; Mann, M; Hurt, E			Purification of protein A-tagged yeast Ran reveals association with a novel karyopherin beta family member, Pdr6p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSPORT; BINDING-PROTEINS; IMPORT RECEPTOR; RNA; PHOSPHORYLATION; LOCALIZATION; RELEASE; COMPLEX	The small GTPase Ran (encoded by GSP1 and GSP2 in yeast) plays a central role in nucleocytoplasmic transport. GSP1 and GSP2 were tagged with protein A and functionally expressed in a gsp1 null mutant. After affinity purification of protein A-tagged Gsp1p or Gsp2p by IgG-Sepharose chromatography, known karyopherin beta transport receptors (e.g. Kap121p and Kap123p) and a novel member of this protein family, Pdr6p, were found to be associated with yeast Ran. Subsequent tagging of Pdr6p with green fluorescent protein revealed association with the nuclear pore complexes in vivo, Thus, functional tagging of yeast Ran allowed the study of its in vivo distribution and interaction with known and novel Ran-binding proteins.	Zentrum Biochem Heidelberg, D-69120 Heidelberg, Germany; Odense Univ, Ctr Expt Bioinformat, DK-5230 Odense, Denmark	University of Southern Denmark	Hurt, E (corresponding author), Zentrum Biochem Heidelberg, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg5@ix.urz.uni-heidelberg.de	Ed Hurt, Dr./AAE-8874-2019; Mann, Matthias/A-3454-2013; Podtelejnikov, Alexandre/B-6120-2017	Ed Hurt, Dr./0000-0002-4535-8255; Mann, Matthias/0000-0003-1292-4799; Podtelejnikov, Alexandre/0000-0002-8124-6584; Kunzler, Markus/0000-0003-1275-0629				BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Maniatis T., 1982, MOL CLONING LAB MANU; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; Scherf U, 1998, BIOCHEM BIOPH RES CO, V250, P623, DOI 10.1006/bbrc.1998.9367; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416	31	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					467	471		10.1074/jbc.275.1.467	http://dx.doi.org/10.1074/jbc.275.1.467			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617640	hybrid			2022-12-25	WOS:000085951600064
J	Xu, YY; Circolo, A; Jing, H; Wang, Y; Narayana, SVL; Volanakis, JE				Xu, YY; Circolo, A; Jing, H; Wang, Y; Narayana, SVL; Volanakis, JE			Mutational analysis of the primary substrate specificity pocket of complement factor B - Asp(226) is a major structural determinant for P-1-Arg binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-G; CRYSTAL-STRUCTURE; COLLAGENOLYTIC SERINE-PROTEASE-1; DIRECTED MUTAGENESIS; SERINE PROTEASES; PROTEIN-B; TRYPSIN; SITE; CHYMOTRYPSIN; RESOLUTION	Factor B is a serine protease, which despite its trypsin-like specificity has Asn instead of the typical Asp at the bottom of the S-1 pocket (position 189, chymotrypsinogen numbering). Asp residues are present at positions 187 and 226 and either one could conceivably provide the negative charge for binding the P-1-Arg of the substrate. Determination of the crystal structure of the factor B serine protease domain has revealed that the side chain of Asp(226) is within the S-1 pocket, whereas Asp(187) is located outside the pocket. To investigate the possible role of these atypical structural features in substrate binding and catalysis, we constructed a panel of mutants of these residues. Replacement of Asp(187) caused moderate (50-60%) decrease in hemolytic activity, compared with wild type factor B, whereas replacement of Asn(189) resulted in more profound reductions (71-95%). Substitutions at these two positions did not significantly affect assembly of the alternative pathway C3 convertase. In contrast, elimination of the negative charge from Asp(296) completely abrogated hemolytic activity and also affected formation of the C3 convertase. Kinetic analyses of the hydrolysis of a P-1-Arg containing thioester by selected mutants confirmed that residue Asp(226) is a primary structural determinant for P-1-Arg binding and catalysis.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Macromol Crystallog, Birmingham, AL 35294 USA; Harvard Univ, Sch Med, Ctr Blood Res, Cambridge, MA 02138 USA; Biomed Sci Res Ctr A Fleming, Vari 16672, Greece	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Alexander Fleming Biomedical Sciences Research Center	Xu, YY (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, THT,Rm 437,1900 Univ Blvd, Birmingham, AL 35294 USA.				NIAID NIH HHS [AI21067, AI39818] Funding Source: Medline; NIAMS NIH HHS [P60AR20614] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039818, R01AI021067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGRAWAL A, 1992, J BIOL CHEM, V267, P25353; Arlaud GJ, 1998, ADV IMMUNOL, V69, P249, DOI 10.1016/S0065-2776(08)60609-4; CAPORALE LH, 1981, J IMMUNOL, V126, P1963; CIRCOLO A, 1997, COMPLEMENT PRACTICAL, P199; COHEN GH, 1981, J MOL BIOL, V148, P449, DOI 10.1016/0022-2836(81)90186-8; COOPER NR, 1975, BIOCHEMISTRY-US, V14, P4245, DOI 10.1021/bi00690a015; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; Czapinska H, 1999, EUR J BIOCHEM, V260, P571, DOI 10.1046/j.1432-1327.1999.00160.x; EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GRESHAM HD, 1986, ANAL BIOCHEM, V154, P454, DOI 10.1016/0003-2697(86)90014-X; Hof P, 1996, EMBO J, V15, P5481, DOI 10.1002/j.1460-2075.1996.tb00933.x; HORIUCHI T, 1993, MOL IMMUNOL, V30, P1587; Hourcade DE, 1998, J BIOL CHEM, V273, P25996, DOI 10.1074/jbc.273.40.25996; IKARI N, 1983, BIOCHIM BIOPHYS ACTA, V742, P318, DOI 10.1016/0167-4838(83)90317-5; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804; KAM CM, 1987, J BIOL CHEM, V262, P3444; KIM S, 1994, BIOCHEMISTRY-US, V33, P14393, DOI 10.1021/bi00252a004; KULICS J, 1994, IMMUNOLOGY, V82, P509; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; PANGBURN MK, 1986, BIOCHEM J, V235, P723, DOI 10.1042/bj2350723; PERONA JJ, 1993, J MOL BIOL, V230, P934, DOI 10.1006/jmbi.1993.1211; Polanowska J, 1998, BBA-PROTEIN STRUCT M, V1386, P189, DOI 10.1016/S0167-4838(98)00085-5; RAPP HJ, 1970, MOL BASIS COMPLEMENT; SCHELLENBERGER V, 1991, EUR J BIOCHEM, V199, P623, DOI 10.1111/j.1432-1033.1991.tb16163.x; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TSU CA, 1994, J BIOL CHEM, V269, P19565; Tsu CA, 1997, BIOCHEMISTRY-US, V36, P5393, DOI 10.1021/bi961753u; Tuckwell DS, 1997, BIOCHEMISTRY-US, V36, P6605, DOI 10.1021/bi963155l; UEDA A, 1987, J IMMUNOL, V138, P1143; Volanakis J E, 1989, Year Immunol, V4, P218; VOLANAKIS JE, 1987, ANAL BIOCHEM, V163, P242, DOI 10.1016/0003-2697(87)90119-9; Volanakis JE, 1998, HUMAN COMPLEMENT SYS, V20, P9, DOI DOI 10.1201/B14212-3; Xu YY, 1997, J IMMUNOL, V158, P5958; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	40	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					378	385		10.1074/jbc.275.1.378	http://dx.doi.org/10.1074/jbc.275.1.378			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617628	hybrid			2022-12-25	WOS:000085951600052
J	Sell, DR; Kleinman, NR; Monnier, VM				Sell, DR; Kleinman, NR; Monnier, VM			Longitudinal determination of skin collagen glycation and glycoxidation rates predicts early death in C57BL/6NNIA mice	FASEB JOURNAL			English	Article						aging; biomarker; glucose; oxidation; Maillard reaction	AGE-DEPENDENT ACCUMULATION; DIETARY RESTRICTION; CALORIC RESTRICTION; MAILLARD REACTION; CAENORHABDITIS-ELEGANS; ULCERATIVE DERMATITIS; GLYCEMIC CONTROL; RHESUS-MONKEYS; LIFE-SPAN; INSULIN	In 1998, the National Institute on Aging launched a 10-year program aimed at identification of biomarkers of aging. Previous results from our laboratory showed that pentosidine, an advanced glycation product, formed in skin collagen at a rate inversely related to maximum life span across several mammalian species. As part of the Biomarkers Program, we investigated the hypothesis that longitudinal determination of glycation and glycoxidation rates in skin collagen could predict longevities in ad libitum-fed (AL) and caloric restricted (CR) mice. C57BL/6NNia male mice were biopsied at age 20 months and at natural death. Glycation (furosine method) was assessed by gas chromatography/mass spectrometry (GC/MS) and the glycoxidation products carboxymethyllysine (CML) and pentosidine were determined by GC/MS and HPLC, respectively. CR vs AL significantly (P<0.0001) increased both means (34 vs. 27 months) and maximum (47 vs. 31 months) life spans. Skin collagen levels of furosine (pmol/mu mol) lysine) were similar to 2.5-fold greater than CML levels and 100-fold greater than pentosidine. Individual accumulation rates modeled as linear equations were significantly (P<0.001) inhibited by CR vs. AL for all parameters and in all cases varied inversely with longevity (P<0.1 to <0.0001). The incidence of three tissue pathologies (lymphoma, dermatitis, and seminal vesiculitis) was found to be attenuated by CR and the latter pathology correlated significantly with longevities(r=0.54, P=0.002). The finding that markers of skin collagen glycation and glycoxidation rates can predict early deaths in AL and CR C57BL/6NNia mice strongly suggests that an age-related deterioration in glucose tolerance is a life span-determining process.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Anim Resource Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Sell, DR (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.		Monnier, Vincent M/B-1371-2009; YAMAMOTO, MASAHIRO/F-9094-2011	YAMAMOTO, MASAHIRO/0000-0003-3859-0125	NATIONAL INSTITUTE ON AGING [R01AG011080, R01AG005601] Funding Source: NIH RePORTER; NIA NIH HHS [AG-11080, AG-05601] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; ANDREWS AG, 1994, VET PATHOL, V31, P293, DOI 10.1177/030098589403100301; BAKER GT, 1988, EXP GERONTOL, V23, P223, DOI 10.1016/0531-5565(88)90025-3; Barzilai N, 1996, AM J PHYSIOL-ENDOC M, V270, pE930, DOI 10.1152/ajpendo.1996.270.6.E930; Baynes J. W., 1989, MAILLARD REACTION AG, P43; BEISSWENGER PJ, 1993, DIABETES CARE, V16, P689, DOI 10.2337/diacare.16.5.689; BODKIN NL, 1995, J GERONTOL A-BIOL, V50, pB142, DOI 10.1093/gerona/50A.3.B142; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; CEFALU WT, 1995, J GERONTOL A-BIOL, V50, pB337, DOI 10.1093/gerona/50A.6.B337; CERAMI A, 1985, J AM GERIATR SOC, V33, P624; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; FEUERS RJ, 1991, BIOL EFFECTS DIETARY, P198; FINCH CE, 1974, J GERONTOL, V29, P134, DOI 10.1093/geronj/29.2.134; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; FURTH AJ, 1988, ANAL BIOCHEM, V175, P347, DOI 10.1016/0003-2697(88)90558-1; Gerstein HC, 1999, J AM COLL CARDIOL, V33, P612, DOI 10.1016/S0735-1097(98)00637-8; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; HARLAN LC, 1987, AM J EPIDEMIOL, V126, P674, DOI 10.1093/oxfordjournals.aje.a114707; HART RW, 1996, LAB ANIMAL       MAR, P29; KALANT N, 1988, MECH AGEING DEV, V46, P89, DOI 10.1016/0047-6374(88)90117-0; KEMNITZ JW, 1994, AM J PHYSIOL, V266, pE540, DOI 10.1152/ajpendo.1994.266.4.E540; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LAGOPOULOS L, 1991, CARCINOGENESIS, V12, P311, DOI 10.1093/carcin/12.2.311; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; LANE MA, 1995, AM J PHYSIOL-ENDOC M, V268, pE941, DOI 10.1152/ajpendo.1995.268.5.E941; Levi B, 1998, J NUTR, V128, P1442, DOI 10.1093/jn/128.9.1442; LYONS TJ, 1991, J CLIN INVEST, V87, P1910, DOI 10.1172/JCI115216; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASORO EJ, 1992, J GERONTOL, V47, pB202, DOI 10.1093/geronj/47.6.B202; MASORO EJ, 1993, J AM GERIATR SOC, V41, P994, DOI 10.1111/j.1532-5415.1993.tb06767.x; MATTS JP, 1995, J CLIN EPIDEMIOL, V48, P389, DOI 10.1016/0895-4356(94)00145-G; McClearn GE, 1997, EXP GERONTOL, V32, P87, DOI 10.1016/S0531-5565(96)00067-8; Miller RA, 1997, J GERONTOL A-BIOL, V52, pB39, DOI 10.1093/gerona/52A.1.B39; Mlekusch W, 1996, MECH AGEING DEV, V92, P43, DOI 10.1016/S0047-6374(96)01801-5; MONNIER VM, 1983, ACS SYM SER, V215, P431; Monnier VM, 1999, DIABETES, V48, P870, DOI 10.2337/diabetes.48.4.870; MONNIER VM, 1989, MAILLARD REACTION AG, P1; MOORADIAN AD, 1990, J GERONTOL, V45, pB183, DOI 10.1093/geronj/45.6.B183; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MURTAGHMARK CM, 1995, J GERONTOL A-BIOL, V50, pB148, DOI 10.1093/gerona/50A.3.B148; Paolisso G, 1996, AM J PHYSIOL-ENDOC M, V270, pE890, DOI 10.1152/ajpendo.1996.270.5.E890; PARKENING TA, 1988, J GERONTOL, V43, pB79, DOI 10.1093/geronj/43.3.B79; Parr T, 1996, MECH AGEING DEV, V88, P75, DOI 10.1016/0047-6374(96)01723-X; Pearline RV, 1996, HEPATOLOGY, V24, P838; Perkins SN, 1998, J INVEST DERMATOL, V111, P292, DOI 10.1046/j.1523-1747.1998.00270.x; Sell DR, 1997, MECH AGEING DEV, V95, P81, DOI 10.1016/S0047-6374(97)01863-0; Sell DR, 1997, J GERONTOL A-BIOL, V52, pB277, DOI 10.1093/gerona/52A.5.B277; Sell DR, 1996, P NATL ACAD SCI USA, V93, P485, DOI 10.1073/pnas.93.1.485; SELL DR, 1995, PHYSL AGING, P235; Sprott Richard L., 1996, P3; Sprott RL, 1997, EXP GERONTOL, V32, P205, DOI 10.1016/S0531-5565(96)00065-4; TURTURRO A, 1992, EXP GERONTOL, V27, P583, DOI 10.1016/0531-5565(92)90013-P; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599; Witt W. M., 1989, Laboratory Animal Science, V39, P470; WITT WM, 1991, BIOL EFFECTS DIETARY, P73	58	77	77	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					145	156		10.1096/fasebj.14.1.145	http://dx.doi.org/10.1096/fasebj.14.1.145			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627289				2022-12-25	WOS:000084784700017
J	Vadlamudi, R; Adam, L; Talukder, A; Mendelsohn, J; Kumar, R				Vadlamudi, R; Adam, L; Talukder, A; Mendelsohn, J; Kumar, R			Serine phosphorylation of paxillin by heregulin-beta 1: role of p38 mitogen activated protein kinase	ONCOGENE			English	Article						heregulin; signaling; spreading; paxillin; motility	FOCAL ADHESION KINASE; NEU DIFFERENTIATION FACTOR; HEPATOCYTE GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; TYROSINE PHOSPHORYLATION; RECEPTOR INTERACTIONS; CARCINOMA-CELLS; GENE-PRODUCT; HUMAN-BREAST; CANCER	The mechanisms through which heregulin (HRG) regulates the progression of breast cancer cells to a more invasive phenotype are currently unknown, Recently we have shown that HRG treatment of breast cancer cells leads to the formation of lamellipodia/filopodia, and increased cell migration and invasiveness through the phosphatidylinositol 3-kinase (PI-3 kinase). Since the process of cell migration must involve changes in adhesion, we explored the potential HRG regulation of paxillin, a major cytoskeletal phosphoprotein of focal adhesion. We report that HRG stimulation of noninvasive breast cancer cells resulted in stimulation of p38 mitogen-activated protein kinase (p38(MAPK)), extracellular signal-regulated kinases (ERK) and PI-3K, and a concurrent unexpected increase in the level of paxillin phosphorylation on serine residue which was sensitive to protein-phosphatase 2b but not to protein tyrosine phosphatase 1, In addition, HRG triggered a rapid redistribution of paxillin to the perinuclear regions from the tyrosine-phosphorylated focal adhesions, and increased cell scattering. There was no effect of HRG on the state of phosphorylation and localization of focal adhesion kinase, The HRG-induced increase in serine phosphorylation of paxillin and cell scattering were selectively inhibited by a specific inhibitor of p38(MAPK) or a dominant-negative p38(MAPK) mutant, but not by inhibitors of p42/44(MAPK) or PI-3 kinase pathways. For the first time our results have shown that HRG, a potent migratory growth factor stimulates serine phosphorylation of paxillin. These findings suggest a role of p38(MAPK) dependent signal transduction pathway(s) in serine phosphorylation and disassembly of the paxillin from the focal complexes during HRG-induced cell shape alterations and motility.	Univ Texas, MD Anderson Canc Ctr, Cell Growth Regulat Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cell Growth Regulat Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA65746, CA80066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BENZ CC, 1993, BREAST CANCER RES TR, V24, P85; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; KIM HH, 1994, J BIOL CHEM, V269, P24747; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KUMAR R, 1995, J CELL BIOCHEM, V62, P102; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LO L, 1999, IN PRESS MOL CARCINO; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARTE BM, 1995, ONCOGENE, V10, P167; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHLAEPFER DD, 1994, NATURE, V372, P786; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Vadlamudi R, 1999, CANCER RES, V59, P2843; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Yamaguchi R, 1997, ONCOGENE, V15, P1753, DOI 10.1038/sj.onc.1201345; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	47	62	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7253	7264		10.1038/sj.onc.1203163	http://dx.doi.org/10.1038/sj.onc.1203163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602479				2022-12-25	WOS:000084119400009
J	Hoshi, S; Goto, M; Koyama, N; Nomoto, K; Tanaka, H				Hoshi, S; Goto, M; Koyama, N; Nomoto, K; Tanaka, H			Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappa B and its inhibitor, I-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NECROSIS-FACTOR-ALPHA; TISSUE FACTOR EXPRESSION; VEIN ENDOTHELIAL-CELLS; HUMAN MONOCYTIC CELLS; ANTIPLATELET AGENT; MEDIATED TRANSCRIPTION; PLATELET-AGGREGATION; INTIMAL HYPERPLASIA; GROWTH-FACTORS	Proliferation of vascular smooth muscle cells (SMC) is a crucial event in the formation of atherosclerotic tissues and is regulated by nuclear transcriptional factors including nuclear factor-kappa B (NF-kappa B). We constructed a reporter gene assay to measure NF-kappa B-dependent transcriptional activity in SMC. Thrombin receptor-activating peptide (TRAP) and basic fibroblast growth factor (bFGF) stimulated SMC proliferation and rapidly enhanced the NF-kappa B transcriptional activity in a dose-dependent manner. 4-Cyano-5,5-bis-(methoxyphenyl)4-pentenoic acid (E5510) significantly inhibited SMC proliferation and also suppressed NF-kappa B transcription stimulated by TRAP and bFGF. In contrast, although tumor necrosis factor (TNF)-alpha activated NF-kappa B transcription, E5510 had no effect on TNF-alpha-induced activation. NF-kappa B was activated after the stimulation of TRAP, bFGF, and TNF-alpha in electrophoretic mobility shift assay, and E5510 suppressed the NF-kappa B activation induced by TRAP and bFGF but not the activation by TNF-alpha. Western blot analysis of I-kappa B alpha and I-kappa B beta, inhibitors of NF-kappa B, indicated that I-kappa B alpha degradation, rather than I-kappa B beta degradation, was important in NF-kappa B activation after the stimulation of TRAP and bFGF. PD98059, an inhibitor of extracellular signal-regulated kinase (ERK) kinase, suppressed NF-kappa B transcriptional activity and SMC proliferation. The phosphorylation of ERK1/2 was rapidly induced by TRAP and bFGF but not by TNF-alpha. These results indicate that TRAP and bFGF induced I-kappa B degradation and NF-kappa B activation through a distinct pathway from TNF-alpha and that ERK1/2 may play an important role in NF-kappa B activation induced by TRAP and bFGF.	Eisai & Co Ltd, Tsukuba Res Labs, Ibaraki, Osaka 3002635, Japan	Eisai Co Ltd	Hoshi, S (corresponding author), Eisai & Co Ltd, Tsukuba Res Labs, Tokodai 5-1-3, Ibaraki, Osaka 3002635, Japan.			Koyama, Noriyuki/0000-0002-7509-6583				Anrather D, 1997, J IMMUNOL, V159, P5620; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Bretschneider E, 1997, THROMB RES, V87, P493, DOI 10.1016/S0049-3848(97)00164-3; BRINKMAN HJM, 1991, EXP CELL RES, V192, P87, DOI 10.1016/0014-4827(91)90161-M; Cercek B, 1997, ATHEROSCLEROSIS, V131, P59, DOI 10.1016/S0021-9150(96)06767-6; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Chen CC, 1996, J CARDIOVASC PHARM, V28, P240, DOI 10.1097/00005344-199608000-00009; Chen G, 1999, LIFE SCI, V64, P1231, DOI 10.1016/S0024-3205(99)00055-7; CLOWES AW, 1991, J VASC SURG, V13, P885; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Deguchi H, 1997, BLOOD, V90, P2345, DOI 10.1182/blood.V90.6.2345.2345_2345_2356; DEISHER TA, 1993, FEBS LETT, V331, P285, DOI 10.1016/0014-5793(93)80354-W; FLORIO C, 1994, AM J PHYSIOL, V266, pL131, DOI 10.1152/ajplung.1994.266.2.L131; FUJIMORI T, 1991, JPN J PHARMACOL, V55, P81, DOI 10.1254/jjp.55.81; Fujioka K, 1996, J CARDIOVASC PHARM, V27, P824, DOI 10.1097/00005344-199606000-00009; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goto M, 1998, J ANTIBIOT, V51, P539, DOI 10.7164/antibiotics.51.539; Goto M, 1999, CYTOKINE, V11, P16, DOI 10.1006/cyto.1998.0390; Goto M, 1996, MOL PHARMACOL, V49, P860; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Haller H, 1996, ARTERIOSCL THROM VAS, V16, P678, DOI 10.1161/01.ATV.16.5.678; Haller H, 1998, ACTA PHYSIOL SCAND, V164, P599; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Hishikawa K, 1997, CIRC RES, V81, P797; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KOYAMA N, 1994, CIRC RES, V75, P682, DOI 10.1161/01.RES.75.4.682; KOYAMA N, 1993, J BIOL CHEM, V268, P13301; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Landry DB, 1997, AM J PATHOL, V151, P1085; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; Lille S, 1997, J SURG RES, V70, P178, DOI 10.1006/jsre.1997.5114; Mallat A, 1998, J BIOL CHEM, V273, P27300, DOI 10.1074/jbc.273.42.27300; Mattana J, 1997, KIDNEY INT, V52, P1478, DOI 10.1038/ki.1997.478; Mawatari K, 1997, J CARDIOVASC SURG, V38, P359; McGilvray ID, 1997, J BIOL CHEM, V272, P10287; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagakura N, 1996, BIOL PHARM BULL, V19, P828; NAKAJIMA T, 1994, BIOCHEM BIOPH RES CO, V203, P1181, DOI 10.1006/bbrc.1994.2307; NAKAJIMA T, 1994, BIOCHEM BIOPH RES CO, V204, P950, DOI 10.1006/bbrc.1994.2552; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; NOMOTO K, 1993, JPN J PHARMACOL, V61, P7, DOI 10.1254/jjp.61.7; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; Parry GCN, 1997, J IMMUNOL, V159, P5450; Pierce JW, 1996, J IMMUNOL, V156, P3961; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Selzman CH, 1999, CIRC RES, V84, P867; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; TAKAHASHI S, 1992, J CARDIOVASC PHARM, V20, P900, DOI 10.1097/00005344-199212000-00009; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	65	88	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					883	889		10.1074/jbc.275.2.883	http://dx.doi.org/10.1074/jbc.275.2.883			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625622	hybrid			2022-12-25	WOS:000084836600026
J	Kazen-Gillespie, KA; Ragsdale, DS; D'Andrea, MR; Mattei, LN; Rogers, KE; Isom, LL				Kazen-Gillespie, KA; Ragsdale, DS; D'Andrea, MR; Mattei, LN; Rogers, KE; Isom, LL			Cloning, localization, and functional expression of sodium channel beta 1A subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN SKELETAL-MUSCLE; LDL RECEPTOR FAMILY; NA+-CHANNEL; MESSENGER-RNA; RAT-BRAIN; SENSORY NEURONS; MOLECULAR DETERMINANTS; XENOPUS OOCYTES; ALPHA-SUBUNITS	Auxiliary beta 1 subunits of voltage-gated sodium channels have been shown to be cell adhesion molecules of the Ig superfamily, Co-expression of alpha and beta 1 subunits modulates channel gating as well as plasma membrane expression levels. We have cloned, sequenced, and expressed a splice variant of beta 1, termed beta 1A, that results from an apparent intron retention event. beta 1 and beta 1A are structurally homologous proteins with type I membrane topology; however, they contain little to no amino acid homology beyond the shared Ig loop region. beta 1A mRNA expression is developmentally regulated in rat brain such that it is complementary to beta 1. beta 1A mRNA is expressed during embryonic development, and then its expression becomes undetectable after birth, concomitant with the onset of beta 1 expression, In contrast, beta 1A mRNA is expressed in adult adrenal gland and heart. Western blot analysis revealed beta 1A protein expression in heart, skeletal muscle, and adrenal gland but not in adult brain or spinal cord. Immunocytochemical analysis of beta 1A expression revealed selective expression in brain and spinal cord neurons, with high expression in heart and all dorsal root ganglia neurons. Co-expression of alpha IIA and beta 1A subunits in Chinese hamster lung 1610 cells results in a 2.5-fold increase in sodium current density compared with cells expressing alpha IIA alone. This increase in current density reflected two effects of beta 1A: 1) an increase in the proportion of cells expressing detectable sodium currents and 2) an increase in the level of functional sodium channels in expressing cells. [H-3]Saxitoxin binding analysis revealed a 4-fold increase in B-max with no change in K-D in cells coexpressing alpha IIA and beta 1A compared with cells expressing alpha IIA alone. beta 1A-expressing cell lines also revealed subtle differences in sodium channel activation and inactivation. These effects of beta 1A subunits on sodium channel function may be physiologically important events in the development of excitable cells.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA	University of Michigan System; University of Michigan; McGill University; Johnson & Johnson; Johnson & Johnson USA	Isom, LL (corresponding author), Univ Michigan, Dept Pharmacol, 1301 MSRB 3, Ann Arbor, MI 48109 USA.			Isom, Lori/0000-0002-9479-6729	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00042] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; ALTIERI DC, 1994, BIOCHEMISTRY-US, V33, P13848, DOI 10.1021/bi00250a039; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; Chen CF, 1995, PFLUG ARCH EUR J PHY, V431, P186, DOI 10.1007/BF00410190; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; DELAPENA P, 1992, J BIOL CHEM, V267, P25703; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; DibHajj SD, 1995, FEBS LETT, V377, P485, DOI 10.1016/0014-5793(95)01400-4; Gliemann J, 1998, BIOL CHEM, V379, P951; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; Higashikawa K, 1996, INT J CANCER, V66, P11, DOI 10.1002/(SICI)1097-0215(19960328)66:1<11::AID-IJC3>3.3.CO;2-L; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KLUGBAUER N, 1995, EMBO J, V14, P1084, DOI 10.1002/j.1460-2075.1995.tb07091.x; KORENBERG JR, 1994, GENOMICS, V22, P88, DOI 10.1006/geno.1994.1348; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; MAKITA N, 1994, GENOMICS, V23, P628, DOI 10.1006/geno.1994.1551; Makita N, 1996, J NEUROSCI, V16, P7117; MAKITA N, 1994, J BIOL CHEM, V269, P7571; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; MCHUGHSUTKOWSKI E, 1990, J BIOL CHEM, V265, P12393; OH YS, 1994, P NATL ACAD SCI USA, V91, P9985, DOI 10.1073/pnas.91.21.9985; PATTON DE, 1994, J BIOL CHEM, V269, P17649; QU YS, 1995, J BIOL CHEM, V270, P25696, DOI 10.1074/jbc.270.43.25696; SADOT E, 1994, J MOL BIOL, V241, P325, DOI 10.1006/jmbi.1994.1508; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Sangameswaran L, 1996, J BIOL CHEM, V271, P5953, DOI 10.1074/jbc.271.11.5953; Sashihara S, 1995, MOL BRAIN RES, V34, P239, DOI 10.1016/0169-328X(95)00168-R; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P360, DOI 10.1007/BF00374796; Shah R. M., 1996, Society for Neuroscience Abstracts, V22, P63; Smith MR, 1998, J NEUROSCI, V18, P6093; Smith RD, 1998, J NEUROSCI, V18, P811; Tabiti K, 1996, GENE, V175, P7, DOI 10.1016/0378-1119(96)00113-8; TONG JF, 1993, BIOCHEM BIOPH RES CO, V195, P679, DOI 10.1006/bbrc.1993.2099; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; WALLNER M, 1993, FEBS LETT, V336, P535, DOI 10.1016/0014-5793(93)80871-Q; WEIGT C, 1992, J MOL BIOL, V227, P593, DOI 10.1016/0022-2836(92)90915-7; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415	45	120	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1079	1088		10.1074/jbc.275.2.1079	http://dx.doi.org/10.1074/jbc.275.2.1079			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625649	hybrid			2022-12-25	WOS:000084836600053
J	Perez-Juste, G; Garcia-Silva, S; Aranda, A				Perez-Juste, G; Garcia-Silva, S; Aranda, A			An element in the region responsible for premature termination of transcription mediates repression of c-myc gene expression by thyroid hormone in neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HISTONE DEACETYLASE; DOWN-REGULATION; RECEPTOR-ALPHA; NEURO-2A CELLS; PROTEIN; DNA; PROMOTER; CTCF; DIFFERENTIATION	The thyroid hormone (T3) blocks proliferation and induces differentiation of neuroblastoma N2a-beta cells that express the thyroid hormone receptor (TR) beta 1 isoform. c-Myc is required for cell cycle progression, and this study shows that T3-induced neuronal differentiation is preceded by a rapid decrease of c-myc gene expression. A negative T3 responsive element (TRE), arranged as an inverted palindrome spaced by three nucleotides, has been identified within the first exon between nucleotides +237 and +268, The TRE is adjacent to the binding site for the transcriptional repressor CCCTC binding factor and maps precisely within the region of RNA polymerase II pausing and release, suggesting a direct implication of TR on premature termination of transcription. Furthermore, the TRE confers repression by T3 to an heterologous promoter only when inserted downstream of the transcription initiation site. Binding of CCCTC binding factor and TR to their cognate sites in the region of transcriptional attenuation, as well as direct interactions between both factors, could facilitate the formation of a repressor complex and the inhibition of c-myc gene expression. These studies provide insight into mechanisms by which TR mediate transcriptional repression and contribute to the understanding of the important effects bf thyroid hormones on growth and differentiation of neuronal cells.	Inst Invest Biomed, Madrid 28029, Spain; Univ Autonoma Madrid, Madrid 28029, Spain	Autonomous University of Madrid	Aranda, A (corresponding author), Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.		Garcia-Silva, Susana/AAW-8528-2021; Aranda, Ana/ABG-8820-2020	Garcia-Silva, Susana/0000-0003-1065-0245; Aranda, Ana/0000-0002-8338-9589				Arnold R, 1996, NUCLEIC ACIDS RES, V24, P2640, DOI 10.1093/nar/24.14.2640; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Jimenez-Lara AM, 1999, FASEB J, V13, P1073, DOI 10.1096/fasebj.13.9.1073; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOHNE AC, 1993, J MOL BIOL, V232, P747, DOI 10.1006/jmbi.1993.1428; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LAVENU A, 1994, ONCOGENE, V9, P527; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAREU KB, 1992, ANNU REV BIOCHEM, V61, P809; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Perez-Juste G, 1999, J BIOL CHEM, V274, P5026, DOI 10.1074/jbc.274.8.5026; Puymirat J, 1995, J BIOL CHEM, V270, P30651, DOI 10.1074/jbc.270.51.30651; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SKERKA C, 1993, ONCOGENE, V8, P2135; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; ZHANG WG, 1992, J BIOL CHEM, V267, P15056	40	60	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1307	1314		10.1074/jbc.275.2.1307	http://dx.doi.org/10.1074/jbc.275.2.1307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625678	hybrid			2022-12-25	WOS:000084836600082
J	Perera, LP				Perera, LP			The TATA motif specifies the differential activation of minimal promoters by varicella zoster virus immediate-early regulatory protein IE62	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIB; BINDING-PROTEIN; DNA COMPLEX; HUMAN CYTOMEGALOVIRUS; ZTA TRANSACTIVATOR; GENE-EXPRESSION; DOMAIN; ELEMENTS; YEAST; TBP	The immediate-early IE62 protein of varicella tester virus is an acidic transcriptional activator capable of up-regulating many viral and cellular promoters with varying efficiencies. We demonstrate that, in the context of a minimal promoter, a TATA element is both sufficient and essential for IE62-mediated transcriptional activation. Differential levels of activation by IE62 in this context were conferred by a panel of naturally occurring sequence variations within the TATA motif itself. TATA motif-specific, differential induction was not obtained when the IE62 acidic activation domain was targeted as a GALE fusion protein to the same panel. The prototype acidic transactivator, VP16 of herpes simplex virus, failed to discriminate between these different TATA motifs when they were placed into an appropriate responsive promoter context. Nonetheless, a chimeric IE62 polypeptide substituted with the VP16 activation domain retained the ability to differentially modulate minimal promoters with various TATA motifs. Taken together with its binding to TATA box-binding protein (TBP) and transcription factor IIB in vitro, we suggest that IE62 has the unusual ability to achieve differential levels of transcriptional activation through different TATA motifs, which may be accomplished either directly or indirectly by recognizing conformational variations in DNA-bound TBP, TBP-transcription factor IIA/B, or TBP-TATA-associated factor complexes.	NCI, Metab Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Perera, LP (corresponding author), NCI, Metab Branch, Div Clin Sci, NIH, Bldg 10,Rm 4B40,MSC 1374, Bethesda, MD 20892 USA.	lperera@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000687] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 00687] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; ARNDT KM, 1994, MOL CELL BIOL, V14, P3719, DOI 10.1128/MCB.14.6.3719; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; Burley SK, 1998, COLD SPRING HARB SYM, V63, P33, DOI 10.1101/sqb.1998.63.33; Carrozza MJ, 1996, MOL CELL BIOL, V16, P3085; CASWELL R, 1993, J GEN VIROL, V74, P2691, DOI 10.1099/0022-1317-74-12-2691; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COHEN JI, 1993, J VIROL, V67, P4246, DOI 10.1128/JVI.67.7.4246-4251.1993; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; COOK WJ, 1995, MOL CELL BIOL, V15, P4998; DAVISON AJ, 1986, J GEN VIROL, V67, P2279, DOI 10.1099/0022-1317-67-10-2279; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GU BH, 1995, MOL CELL BIOL, V15, P3618; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HUANG DH, 1988, J BIOL CHEM, V263, P12596; INCHAUSPE G, 1989, VIROLOGY, V173, P700, DOI 10.1016/0042-6822(89)90583-7; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARTIN KJ, 1990, GENE DEV, V4, P2376, DOI 10.1101/gad.4.12b.2376; MOFFAT JF, 1995, J VIROL, V69, P5236, DOI 10.1128/JVI.69.9.5236-5242.1995; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PERERA LP, 1992, J VIROL, V66, P5298, DOI 10.1128/JVI.66.9.5298-5304.1992; PERERA LP, 1993, J VIROL, V67, P4474, DOI 10.1128/JVI.67.8.4474-4483.1993; PERERA LP, 1992, VIROLOGY, V191, P346, DOI 10.1016/0042-6822(92)90197-W; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PIZZORNO MC, 1991, J VIROL, V65, P3839, DOI 10.1128/JVI.65.7.3839-3852.1991; PIZZORNO MC, 1988, J VIROL, V62, P1167, DOI 10.1128/JVI.62.4.1167-1179.1988; PUGH BF, 1992, J BIOL CHEM, V267, P679; RUSCONI TM, 1990, J MOL BIOL, V215, P301; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; Shen WC, 1998, COLD SPRING HARB SYM, V63, P219, DOI 10.1101/sqb.1998.63.219; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH CA, 1993, J VIROL, V67, P4676, DOI 10.1128/JVI.67.8.4676-4687.1993; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; STARR DB, 1995, J MOL BIOL, V250, P434; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TYLER JK, 1993, NUCLEIC ACIDS RES, V21, P513, DOI 10.1093/nar/21.3.513; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; Xiao WM, 1997, J VIROL, V71, P1757, DOI 10.1128/JVI.71.3.1757-1765.1997; YOSHIMURA M, 1989, GENE, V78, P267, DOI 10.1016/0378-1119(89)90229-1; Zaman Z, 1998, COLD SPRING HARB SYM, V63, P167, DOI 10.1101/sqb.1998.63.167	68	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					487	496		10.1074/jbc.275.1.487	http://dx.doi.org/10.1074/jbc.275.1.487			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617643	hybrid			2022-12-25	WOS:000085951600067
J	Szczesna, D; Zhang, R; Zhao, JJ; Jones, M; Guzman, G; Potter, JD				Szczesna, D; Zhang, R; Zhao, JJ; Jones, M; Guzman, G; Potter, JD			Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; SKELETAL-MUSCLE; MISSENSE MUTATION; ALPHA-TROPOMYOSIN; PROTEIN-C; MOLECULAR-BASIS; CA2+ REGULATION; THIN FILAMENT; MYOSIN; BINDING	To study the effect of troponin (Tn) T mutations that cause familial hypertrophic cardiomyopathy (FHC) on cardiac muscle contraction, wild-type, and the following recombinant human cardiac TnT mutants were cloned and expressed: I79N, R92Q, F110I, E163K, R278C, and intron 16(G(1) --> A) (In16). These TnT FHC mutants were reconstituted into skinned cardiac muscle preparations and characterized for their effect on maximal steady state force activation, inhibition, and the Ca2+ sensitivity of force development. Troponin complexes containing these mutants were tested for their ability to regulate actin-tropomyosin(Tm)-activated myosin-ATPase activity. TnT(R278C) and TnT(F110I) reconstituted preparations demonstrated dramatically increased Ca2+ sensitivity of force development, while those with TnT(R92Q) and TnT(I79N) showed a moderate increase. The deletion mutant, TnT(In16), significantly decreased both the activation and the inhibition of force, and substantially decreased the activation and the inhibition of actin-Tm-activated myosin-ATPase activity. ATPase activation was also impaired by TnT(F110I), while its inhibition was reduced by TnT(R278C). The TnT(E163K) mutation had the smallest effect on the Ca2+ sensitivity of force; however, it produced an elevated activation of the ATPase activity in reconstituted thin filaments. These observed changes in the Ca2+ regulation of force development caused by these mutations would likely cause altered contractility and contribute to the development of FHC.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA	University of Miami	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.				NHLBI NIH HHS [2 RO1 HL42325-11] Funding Source: Medline; NIAMS NIH HHS [AR 45391-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045391] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anan R, 1998, CIRCULATION, V98, P391, DOI 10.1161/01.CIR.98.5.391; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; AUSUBEL FM, 1995, CURRENT PROTOCOLS MO, pCH8; Barton PJR, 1997, ANN HUM GENET, V61, P519, DOI 10.1017/S0003480097006556; Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; Carrier L, 1997, CIRC RES, V80, P427, DOI 10.1161/01.res.0000435859.24609.b3; Charron P, 1998, EUR HEART J, V19, P139, DOI 10.1053/euhj.1997.0575; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; Epstein ND, 1998, ADV EXP MED BIOL, V453, P105; Farza H, 1998, J MOL CELL CARDIOL, V30, P1247, DOI 10.1006/jmcc.1998.0698; Fiske CH, 1925, J BIOL CHEM, V66, P375; Flavigny J, 1998, J MOL MED-JMM, V76, P208, DOI 10.1007/s001090050210; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Gergely J, 1998, ADV EXP MED BIOL, V453, P169; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; ISHII Y, 1991, J BIOL CHEM, V266, P6894; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Marian AJ, 1997, CIRC RES, V81, P76, DOI 10.1161/01.RES.81.1.76; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; MURAKAMI U, 1976, J BIOCHEM, V80, P611, DOI 10.1093/oxfordjournals.jbchem.a131316; NakajimaTaniguchi C, 1997, J MOL CELL CARDIOL, V29, P839, DOI 10.1006/jmcc.1996.0322; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; PAN BS, 1992, J BIOL CHEM, V267, P23052; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; Reinach FC, 1997, CELL STRUCT FUNCT, V22, P219, DOI 10.1247/csf.22.219; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; STRZELECKAGOLASZEWSKA H, 1975, EUR J BIOCHEM, V55, P221, DOI 10.1111/j.1432-1033.1975.tb02154.x; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; Szczesna D, 1996, J BIOL CHEM, V271, P8381, DOI 10.1074/jbc.271.14.8381; SZCZESNA D, 2000, MOL INTERACTIONS ACT, V2; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806; Yu QT, 1999, P ASSOC AM PHYSICIAN, V111, P45, DOI 10.1046/j.1525-1381.1999.09416.x; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	51	122	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					624	630		10.1074/jbc.275.1.624	http://dx.doi.org/10.1074/jbc.275.1.624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617660	hybrid			2022-12-25	WOS:000085951600084
J	Chen, XM; Van Valkenburgh, C; Fang, H; Green, N				Chen, XM; Van Valkenburgh, C; Fang, H; Green, N			Signal peptides having standard and nonstandard cleavage sites can be processed by Imp1p of the mitochondrial inner membrane protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; POTENTIAL ACTIVE-SITE; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; MATRIX ATP; 2 STEPS; PROTEINS; SEQUENCE; IMPORT	We have performed a site-directed mutagenesis study showing that residues comprising the type I signal peptidase signature in the two catalytic subunits of the yeast inner membrane protease, Imp1p and Imp2p, are functionally important, consistent with the idea that these subunits contain a serine/lysine catalytic dyad, Previous studies have shown that Imp1p cleaves signal peptides having asparagine at the -1 position, which deviates from the typical signal peptide possessing a small uncharged amino acid at this position, To determine whether asparagine is responsible for the nonoverlapping substrate specificities exhibited by the inner membrane protease subunits, we have substituted asparagine with 19 amino acids in the Imp1p substrate i-cytochrome (cyt) b(2). The resulting signal peptides containing alanine, serine, cysteine, leucine, and methionine can be cleaved efficiently by Imp1p, The remaining mutant signal peptides are cleaved inefficiently or not at all. Surprisingly, none of the amino acid changes results in the recognition of i-cyt b(2) by Imp2p, whose natural substrate, i-cyt c(1), has alanine at the -1 position. The data demonstrate that (i) although the -1 residue is important in substrates recognized by Imp1p, signal peptides having standard and nonstandard cleavage sites can be processed by Imp1p, and (ii) a -1 asparagine does not govern the substrate specificity of the inner membrane protease subunits.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Green, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NCI NIH HHS [2 T32 CA09385-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; Luciano P, 1996, EXPERIENTIA, V52, P1077, DOI 10.1007/BF01952105; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; OHASHI A, 1982, J BIOL CHEM, V257, P3042; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; SCHNEIDER A, 1994, J BIOL CHEM, V269, P8635; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; SUNG M, 1992, J BIOL CHEM, V267, P13154; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x	32	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37750	37754		10.1074/jbc.274.53.37750	http://dx.doi.org/10.1074/jbc.274.53.37750			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608835	hybrid			2022-12-25	WOS:000084528000035
J	Gunjan, A; Alexander, BT; Sittman, DB; Brown, DT				Gunjan, A; Alexander, BT; Sittman, DB; Brown, DT			Effects of H1 histone variant overexpression on chromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENE; MICROCOCCAL NUCLEASE; LINKER HISTONES; H-1 HISTONES; NUCLEOSOMES; DNA; TRANSCRIPTION; EXPRESSION; BINDING; CELLS	The importance of histone H1 heterogeneity and total H1 stoichiometry in chromatin has been enigmatic Here we report a detailed characterization of the chromatin structure of cells overexpressing either H1(0) or H1c. Nucleosome spacing was found to change during cell cycle progression, and overexpression of either variant in exponentially growing cells results in a Iii-base pair increase in nucleosome repeat length. H1 histones can also assemble on chromatin and influence nucleosome spacing in the absence of DNA replication. Overexpression of H1(0) and, to a lesser extent, H1c results in a decreased rate of digestion of chromatin by micrococcal nuclease. Using green fluorescent protein-tagged H1 variants, we show that micrococcal nuclease-resistant chromatin is specifically enriched in the H1(0) variant. Overexpression of H1(0) results in the appearance of a unique mononucleosome species of higher mobility on nucleoprotein gels. Domain switch mutagenesis revealed that either the N-terminal tail or the central globular domain of the H1(0) protein could independently give rise to this unique mononucleosome species. These results in part explain the differential effects of H1(0) and H1c in regulating chromatin structure and function.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Physiol, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	Sittman, DB (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.	dsittman@biochem.umsmed.edu	alexander, barbara t/J-3776-2013	Gunjan, Akash/0000-0001-8478-3978				AFFOLTER M, 1987, MOL CELL BIOL, V7, P3663, DOI 10.1128/MCB.7.10.3663; ALBRIGHT SC, 1980, J BIOL CHEM, V255, P3673; ALLAN J, 1980, P NATL ACAD SCI-BIOL, V77, P885, DOI 10.1073/pnas.77.2.885; APPELS R, 1972, J MOL BIOL, V70, P425, DOI 10.1016/0022-2836(72)90550-5; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; Brown DT, 1997, NUCLEIC ACIDS RES, V25, P5003, DOI 10.1093/nar/25.24.5003; BROWN DT, 1993, J BIOL CHEM, V268, P713; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; DELUCIA F, 1994, BIOCHEM BIOPH RES CO, V198, P32, DOI 10.1006/bbrc.1994.1005; Gunjan A, 1999, NUCLEIC ACIDS RES, V27, P3355, DOI 10.1093/nar/27.16.3355; HANNON R, 1984, J MOL BIOL, V180, P131, DOI 10.1016/0022-2836(84)90434-0; Howe L, 1998, BIOCHEMISTRY-US, V37, P7077, DOI 10.1021/bi980410o; HUANG HC, 1984, J BIOL CHEM, V259, P4237; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; LENNOX RW, 1984, DEV BIOL, V103, P80, DOI 10.1016/0012-1606(84)90009-5; LENNOX RW, 1984, J BIOL CHEM, V259, P669; LENNOX RW, 1988, BIOCHEM CELL BIOL, V66, P636, DOI 10.1139/o88-073; LEUBA SH, 1994, J MOL BIOL, V235, P871, DOI 10.1006/jmbi.1994.1045; Lu ZH, 1997, J CELL SCI, V110, P2745; NELSON PP, 1979, J BIOL CHEM, V254, P1751; NEWROCK KM, 1977, COLD SPRING HARB SYM, V42, P421, DOI 10.1101/SQB.1978.042.01.045; Nightingale KP, 1996, J BIOL CHEM, V271, P7090, DOI 10.1074/jbc.271.12.7090; NOLL M, 1977, J MOL BIOL, V109, P393, DOI 10.1016/S0022-2836(77)80019-3; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; PEHRSON J, 1980, NATURE, V285, P43, DOI 10.1038/285043a0; PEHRSON JR, 1981, BIOCHEMISTRY-US, V20, P2298, DOI 10.1021/bi00511a035; POCCIA DL, 1992, TRENDS BIOCHEM SCI, V17, P223, DOI 10.1016/0968-0004(92)90382-J; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; Schulze E, 1995, J MOL EVOL, V41, P833; SEYEDIN SM, 1981, EXP CELL RES, V136, P399, DOI 10.1016/0014-4827(81)90019-7; STEIN GS, 1984, HISTONE GENES STRUCT; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Travers A, 1999, TRENDS BIOCHEM SCI, V24, P4, DOI 10.1016/S0968-0004(98)01339-5; van Holde KE., 1989, SPRINGER SERIES MOL; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; Widom J, 1998, CURR BIOL, V8, pR788, DOI 10.1016/S0960-9822(07)00500-3; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; ZLATANOVA J, 1992, J CELL SCI, V103, P889; Zweidler A., 1980, DEV BIOCHEM, V15, P47	48	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37950	37956		10.1074/jbc.274.53.37950	http://dx.doi.org/10.1074/jbc.274.53.37950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608862	hybrid			2022-12-25	WOS:000084528000062
J	Kessen, U; Schaloske, R; Aichem, A; Mutzel, R				Kessen, U; Schaloske, R; Aichem, A; Mutzel, R			Ca2+/calmodulin-independent activation of calcineurin from Dictyostelium by unsaturated long chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; LIMITED PROTEOLYSIS; BOVINE BRAIN; CALMODULIN; CALCIUM; DISCOIDEUM; BINDING; IDENTIFICATION; PHOSPHOLIPIDS; CHEMOTAXIS	This study describes a novel mode of activation for the Ca2+/calmodulin-dependent protein phosphatase calcineurin, Using purified calcineurin from Dictyostelium discoideum we found a reversible, Ca2+/calmodulin-independent activation by the long chain unsaturated fatty acids arachidonic acid, linoleic acid, and oleic acid, which was of the same magnitude as activation by Ca2+/calmodulin, Half-maximal stimulation of calcineurin occurred at fatty acid concentrations of approximately 10 mu M with either p-nitrophenyl phosphate or RII phosphopeptide as substrates, The methyl ester of arachidonic acid and the saturated fatty acids palmitic acid and arachidic acid did not activate calcineurin, The activation was shown to be independent of the regulatory subunit, calcineurin B. Activation by Ca2+/calmodulin and fatty acids was not additive. In binding assays with immobilized calmodulin, arachidonic acid inhibited binding of calcineurin to calmodulin, Therefore fatty acids appear to mimic Ca2+/calmodulin action by binding to the calmodulin-binding site.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany	University of Konstanz	Mutzel, R (corresponding author), Univ Konstanz, Fak Biol, D-78457 Constance, Germany.							ALJOBORE A, 1981, CAN J BIOCHEM CELL B, V59, P880, DOI 10.1139/o81-123; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BUMANN J, 1984, J CELL BIOL, V98, P173, DOI 10.1083/jcb.98.1.173; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Dammann H, 1996, EUR J BIOCHEM, V238, P391, DOI 10.1111/j.1432-1033.1996.0391z.x; Demant EJF, 1999, ANAL BIOCHEM, V267, P366, DOI 10.1006/abio.1998.3019; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Hellstern S, 1997, RES MICROBIOL, V148, P335, DOI 10.1016/S0923-2508(97)81589-6; HIGUCHI S, 1991, J BIOL CHEM, V266, P18104; Horn F, 1996, DIFFERENTIATION, V60, P269, DOI 10.1046/j.1432-0436.1996.6050269.x; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JARRETT HW, 1986, J BIOL CHEM, V261, P4967; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Klumpp S, 1998, FEBS LETT, V437, P229, DOI 10.1016/S0014-5793(98)01237-X; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALCHOW D, 1982, BIOPHYS STRUCT MECH, V9, P131, DOI 10.1007/BF00539112; Moniakis J, 1999, J CELL SCI, V112, P405; Newell PC, 1995, EXPERIENTIA, V51, P1155, DOI 10.1007/BF01944733; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; PICHARD AL, 1977, J BIOL CHEM, V252, P4872; POLESKY AJM, 1995, MOL BIOL CELL S, V6, P91; POLITINO M, 1990, J BIOL CHEM, V265, P7619; POLITINO M, 1987, J BIOL CHEM, V262, P10109; Schaloske R, 1997, BIOCHEM J, V327, P233, DOI 10.1042/bj3270233; Schaloske R, 1998, BIOCHEM J, V332, P541, DOI 10.1042/bj3320541; SCHLATTERER C, 1994, J CELL SCI, V107, P2107; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; TANAKA T, 1980, J BIOL CHEM, V255, P1078; UNTERWEGER N, 1995, CELL CALCIUM, V17, P97, DOI 10.1016/0143-4160(95)90079-9; WINCKLER T, 1991, RES MICROBIOL, V142, P509, DOI 10.1016/0923-2508(91)90184-C; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004; WOLFF DJ, 1976, ARCH BIOCHEM BIOPHYS, V173, P720, DOI 10.1016/0003-9861(76)90310-6; Yumura S, 1996, J CELL SCI, V109, P2673	42	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37821	37826		10.1074/jbc.274.53.37821	http://dx.doi.org/10.1074/jbc.274.53.37821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608845	hybrid			2022-12-25	WOS:000084528000045
J	Mortensen, K; Skouv, J; Hougaard, DM; Larsson, LI				Mortensen, K; Skouv, J; Hougaard, DM; Larsson, LI			Endogenous endothelial cell nitric-oxide synthase modulates apoptosis in cultured breast cancer cells and is transcriptionally regulated by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; HYDROGEN-PEROXIDE; DNA FRAGMENTATION; LYMPHOMA-CELLS; GROWTH ARREST; TUMOR-CELLS; EXPRESSION; GENE; BCL-2; SUPPRESSOR	Nitric oxide can both stimulate and suppress apoptosis. By reverse transcriptase-polymerase chain reaction and sequencing we show that human breast cancer (MCF-7) cells express endothelial cell nitric-oxide synthase (ecNOS), but not other nitric-oxide synthase isoforms. Inhibition of ecNOS activity in MCF-7 cells increased tumor cell apoptosis, and this effect was also seen following treatment with an NO scavenger. In addition, low concentrations of the NO donor sodium nitroprusside inhibited, whereas high concentrations stimulated MCF-7 cell apoptosis. The ecNOS promoter was found to contain a specific binding site for the apoptosis-regulating protein p53. In co-transfection studies wild-type, but not mutant, p53 down-regulated transcription of an ecNOS promoter-luciferase reporter gene construct. In addition, NO donors up-regulated p53 protein levels in MCF-7 cells. These data point to a previously unrecognized p53-dependent regulation of ecNOS expression that may be important both for regulating apoptosis and for avoiding the generation of genotoxic quantities of NO.	Royal Vet & Agr Univ, Inst Anat & Physiol, Div Cell Biol, DK-1870 Frederiksberg C, Denmark; Exiqon AS, Vedbaek, Denmark; Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen, Denmark	University of Copenhagen; Exiqon; Statens Serum Institut	Larsson, LI (corresponding author), Royal Vet & Agr Univ, Inst Anat & Physiol, Div Cell Biol, Gronnegaardsvej 7, DK-1870 Frederiksberg C, Denmark.		Hougaard, David/AAD-6368-2019					Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANI D, 1995, CANCER RES, V55, P5272; Bonfoco E, 1996, NEUROREPORT, V8, P273, DOI 10.1097/00001756-199612200-00054; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ellis G, 1998, CLIN BIOCHEM, V31, P195, DOI 10.1016/S0009-9120(98)00015-0; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; Filep JG, 1997, BIOCHEM J, V321, P897, DOI 10.1042/bj3210897; FORNARI FA, 1994, CELL GROWTH DIFFER, V5, P723; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Harris SR, 1997, BIOCHEM BIOPH RES CO, V235, P509, DOI 10.1006/bbrc.1997.6820; Ho YS, 1997, MOL CARCINOGEN, V19, P101, DOI 10.1002/(SICI)1098-2744(199707)19:2<101::AID-MC5>3.0.CO;2-I; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Iotsova V, 1996, ONCOGENE, V13, P2331; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kawaguchi H, 1997, CIRCULATION, V95, P2441, DOI 10.1161/01.CIR.95.10.2441; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Leach SD, 1998, CANCER RES, V58, P3231; LEIST M, 1994, BIOCHEMICA, V11, P20; LI LM, 1991, CANCER RES, V51, P2531; Lind DS, 1997, J SURG RES, V69, P283, DOI 10.1006/jsre.1997.5015; Lopez-Farre A, 1997, AM J PHYSIOL-HEART C, V272, pH760, DOI 10.1152/ajpheart.1997.272.2.H760; Loweth AC, 1997, FEBS LETT, V400, P285, DOI 10.1016/S0014-5793(96)01392-0; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Melkova Z, 1997, FEBS LETT, V403, P273, DOI 10.1016/S0014-5793(97)00065-3; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MESSMER UK, 1994, FEBS LETT, V355, P23; MIYAHARA K, 1994, EUR J BIOCHEM, V223, P719, DOI 10.1111/j.1432-1033.1994.tb19045.x; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MONCADA S, 1991, PHARMACOL REV, V43, P109; Mortensen K, 1999, CLIN CANCER RES, V5, P1093; Nicotera P, 1997, TRENDS PHARMACOL SCI, V18, P189, DOI 10.1016/S0165-6147(97)90619-2; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Pacelli R, 1996, LANCET, V347, P900, DOI 10.1016/S0140-6736(96)91378-1; Peunova N, 1996, COLD SPRING HARB SYM, V61, P417; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; Polte T, 1997, FEBS LETT, V409, P46, DOI 10.1016/S0014-5793(97)00480-8; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SANDOVAL M, 1995, MEDIAT INFLAMM, V4, P248, DOI 10.1155/S0962935195000391; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; SUN K, 1995, CANCER RES, V55, P5524; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Umansky V, 1997, INT J ONCOL, V10, P465; WANG TTY, 1995, CANCER RES, V55, P2487; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Zeillinger R, 1996, BREAST CANCER RES TR, V40, P205, DOI 10.1007/BF01806216	59	66	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37679	37684		10.1074/jbc.274.53.37679	http://dx.doi.org/10.1074/jbc.274.53.37679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608825	hybrid			2022-12-25	WOS:000084528000025
J	Ryan, MP; Jack, RW; Josten, M; Sahl, HG; Jung, G; Ross, RP; Hill, C				Ryan, MP; Jack, RW; Josten, M; Sahl, HG; Jung, G; Ross, RP; Hill, C			Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROAD-SPECTRUM BACTERIOCIN; BIOLOGICAL-ACTIVITIES; NISIN; BIOSYNTHESIS; POLYPEPTIDE; SEQUENCE; PEPTIDES	Lacticin 3147 is a two-component bacteriocin produced by Lactococcus lactis subspecies lactis DPC3147. In order to further characterize the biochemical nature of the bacteriocin, both peptides were isolated which together are responsible for the antimicrobial activity. The first, LtnA1, is a 3,322 Da 30-amino acid peptide and the second component, LtnA2, is a 29-amino acid peptide with a mass of 2,847 Da. Conventional amino acid analysis revealed that both peptides contain the thioether amino acid, lanthionine, as well as an excess of alanine to that predicted from the genetic sequence of the peptides. Chiral phase gas chromatography coupled with mass spectrometry of amino acid composition indicated that both LtnA1 and LtnA2 contain D-alanine residues and amino acid sequence analysis of LtnA1 confirmed that the D-alanine results from post-translational modification of a serine residue in the primary translation product. Taken together, these results demonstrate that lacticin 3147 is a novel, two-component, D-alanine containing lantibiotic that undergoes extensive post-translational modification which may account for its potent antimicrobial activity against a wide range of Grampositive bacteria.	TEAGASC, Dairy Prod Res Ctr, Fermoy, Cork, Ireland; Univ Coll, Natl Food Biotechnol Ctr, Cork, Ireland; Univ Coll, Dept Microbiol, Cork, Ireland; ECHAZ Microcollect, D-720700 Tubingen, Germany; Univ Tubingen, Inst Organ Chem, D-720700 Tubingen, Germany; Univ Bonn, Inst Med Microbiol & Immunol, D-53105 Bonn, Germany	Teagasc; University College Cork; University College Cork; Eberhard Karls University of Tubingen; University of Bonn	Ross, RP (corresponding author), TEAGASC, Dairy Prod Res Ctr, Moorepk, Fermoy, Cork, Ireland.	pross@moorepark.teagasc.ie	Hill, Colin/A-5611-2012; Ross, Paul/A-7584-2015	Hill, Colin/0000-0002-8527-1445; Ross, Paul/0000-0003-4876-8839				Bierbaum G, 1996, APPL ENVIRON MICROB, V62, P385, DOI 10.1128/AEM.62.2.385-392.1996; BOOTH MC, 1996, MOL MICROBIOL, V269, P27183; BYCROFT BW, 1969, NATURE, V224, P595, DOI 10.1038/224595a0; DELVESBROUGHTON J, 1990, FOOD TECHNOL-CHICAGO, V44, P100; DeVuyst L, 1994, BACTERIOCINS LACTIC, P151; Dougherty BA, 1998, MOL MICROBIOL, V29, P1029, DOI 10.1046/j.1365-2958.1998.00988.x; Fenelon MA, 1999, J DAIRY SCI, V82, P10, DOI 10.3168/jds.S0022-0302(99)75203-3; Fredenhagen A., 1991, NISIN NOVEL LANTIBIO, P131; GERHARDT J, 1994, PEPTIDES CHEM STRUCT, P241; GROSS E, 1971, J AM CHEM SOC, V93, P4634, DOI 10.1021/ja00747a073; Hurst A., 1981, ADV APPL MICROBIOL, V27, P85, DOI [10.1016/s0065-2164(08)70342-3, DOI 10.1016/S0065-2164(08)70342-3, 10.1016/S0065-2164(08)70342-3]; Jack R.W., 1998, LANTIBIOTICS RELATED; KELLNER R, 1988, EUR J BIOCHEM, V177, P53, DOI 10.1111/j.1432-1033.1988.tb14344.x; Kellner R, 1991, NISIN NOVEL LANTIBIO, P141; KESSLER H, 1988, HELV CHIM ACTA, V71, P1924, DOI 10.1002/hlca.19880710811; McAuliffe O, 1999, J APPL MICROBIOL, V86, P251, DOI 10.1046/j.1365-2672.1999.00663.x; McAuliffe O, 1998, APPL ENVIRON MICROB, V64, P439; MEYER HE, 1994, ANAL BIOCHEM, V223, P185, DOI 10.1006/abio.1994.1571; MOR A, 1992, TRENDS BIOCHEM SCI, V17, P481, DOI 10.1016/0968-0004(92)90333-5; Navaratna MADB, 1998, APPL ENVIRON MICROB, V64, P4803; Navaratna MADB, 1999, INFECT IMMUN, V67, P4268, DOI 10.1128/IAI.67.8.4268-4271.1999; ROSS RP, 1999, FEMS MICRO REV, V76, P337; Ryan MP, 1996, APPL ENVIRON MICROB, V62, P612, DOI 10.1128/AEM.62.2.612-619.1996; Ryan MP, 1998, APPL ENVIRON MICROB, V64, P2287; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; SAHL HG, 1985, ANTIMICROB AGENTS CH, V27, P836, DOI 10.1128/AAC.27.5.836; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; SKAUGEN M, 1994, J BIOL CHEM, V269, P27183; ZIMMERMANN N, 1995, EUR J BIOCHEM, V228, P786, DOI 10.1111/j.1432-1033.1995.tb20324.x	29	106	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37544	37550		10.1074/jbc.274.53.37544	http://dx.doi.org/10.1074/jbc.274.53.37544			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608807	hybrid			2022-12-25	WOS:000084528000007
J	Wang, Z; Gaba, A; Sachs, MS				Wang, Z; Gaba, A; Sachs, MS			A highly conserved mechanism of regulated ribosome stalling mediated by fungal arginine attenuator peptides that appears independent of the charging status of arginyl-tRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID BIOSYNTHESIS; OPEN READING FRAME; TRANSFER-RNA-SYNTHETASE; NEUROSPORA-CRASSA; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL REGULATION; CROSS-PATHWAY; NASCENT-PEPTIDE; LEADER PEPTIDE	The Arg attenuator peptide (AAP) is an evolutionarily conserved peptide involved in Arg-specific negative translational control. It is encoded as an upstream open reading frame (uORF) in fungal mRNAs specifying the small subunit of Arg-specific carbamoyl phosphate synthetase, We examined the functions of the Saccharomyces cerevisiae CPA1 and Neurospora crassa arg-2 AAPs using translation extracts from S. cerevisiae, N. crassa, and wheat germ. Synthetic RNA containing AAP and firefly luciferase (LUC) sequences were used to program translation; analyses of LUC activity indicated that the AAPs conferred Arg-specific negative regulation in each system. The AAPs functioned either as uORFs or fused in-frame at the N terminus of LUG. Mutant AAPs lacking function in vivo did not function in vitro. Therefore, trans-acting factors conferring AAP-mediated regulation are in both fungal and plant systems. Analyses of ribosome stalling in the fungal extracts by primer extension inhibition (toeprint) assays showed that these AAPs acted similarly to stall ribosomes in the region immediately distal to the AAP coding region in response to Arg. The regulatory effect increased as the Arg concentration increased; all of the arginyl-tRNAs examined appeared maximally charged at low Arg concentrations. Therefore, AAP-mediated Arg-specific regulation appeared independent of the charging status of arginyl-tRNA.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Sachs, MS (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, 20000 NW Walker Rd, Beaverton, OR 97006 USA.			Sachs, Matthew/0000-0001-9891-9223	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047498, R01GM047498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47498-S, GM47498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alderete JP, 1999, J VIROL, V73, P8330, DOI 10.1128/JVI.73.10.8330-8337.1999; ALZNERDEWEERD B, 1980, NUCLEIC ACIDS RES, V8, P1023, DOI 10.1093/nar/8.5.1023; Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Baek JM, 1998, FUNGAL GENET BIOL, V23, P34, DOI 10.1006/fgbi.1997.1025; BARCISZEWSKA MZ, 1986, BIOCHIMIE, V68, P319, DOI 10.1016/S0300-9084(86)80029-3; Baum M, 1998, NUCLEIC ACIDS RES, V26, P1390, DOI 10.1093/nar/26.6.1390; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Cao JH, 1998, RNA, V4, P181; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; CIGAN AM, 1986, GENE, V41, P343, DOI 10.1016/0378-1119(86)90118-6; CRABEEL M, 1990, MOL CELL BIOL, V10, P1226, DOI 10.1128/MCB.10.3.1226; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DELBECQ P, 1994, MOL CELL BIOL, V14, P2378, DOI 10.1128/MCB.14.4.2378; EBBOLE DJ, 1991, MOL CELL BIOL, V11, P928, DOI 10.1128/MCB.11.2.928; Freitag M, 1996, GENETICS, V142, P117; GANGLOFF J, 1976, EUR J BIOCHEM, V65, P177, DOI 10.1111/j.1432-1033.1976.tb10403.x; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029; GHOSH HP, 1982, NUCLEIC ACIDS RES, V10, P3241, DOI 10.1093/nar/10.10.3241; GILLUM AM, 1977, NUCLEIC ACIDS RES, V4, P4109, DOI 10.1093/nar/4.12.4109; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; Harigai M, 1996, ONCOGENE, V12, P1369; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; Keenan KA, 1997, FUNGAL GENET BIOL, V22, P177, DOI 10.1006/fgbi.1997.1009; KEITH G, 1980, BIOCHEM BIOPH RES CO, V92, P116, DOI 10.1016/0006-291X(80)91527-2; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; KINNEY DM, 1989, MOL CELL BIOL, V9, P4882, DOI 10.1128/MCB.9.11.4882; KITAMOTO K, 1988, J BACTERIOL, V170, P2683, DOI 10.1128/jb.170.6.2683-2686.1988; Konan KV, 1999, J BACTERIOL, V181, P1530, DOI 10.1128/JB.181.5.1530-1536.1999; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LANDICK R, 1996, ESCHERICHIA COLI SAL, V1, P1263; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; LUO ZG, 1995, MOL CELL BIOL, V15, P5235; Luo ZL, 1996, J BACTERIOL, V178, P2172, DOI 10.1128/jb.178.8.2172-2177.1996; Martinez-Garcia JF, 1998, PLANT J, V13, P489, DOI 10.1046/j.1365-313X.1998.00050.x; McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492, DOI 10.1128/MMBR.62.4.1492-1553.1998; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; Ni JP, 1999, NAT STRUCT BIOL, V6, P427; ORBACH MJ, 1990, J BIOL CHEM, V265, P10981; PALACIAN E, 1979, EUR J BIOCHEM, V101, P469, DOI 10.1111/j.1432-1033.1979.tb19741.x; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; SACHS MS, 1991, DEV BIOL, V148, P117, DOI 10.1016/0012-1606(91)90322-T; SACHS MS, 1996, MYCOTA, V3, P315; Salomons GS, 1998, INT J CANCER, V79, P273, DOI 10.1002/(SICI)1097-0215(19980619)79:3<273::AID-IJC11>3.3.CO;2-J; Sattlegger E, 1998, J BIOL CHEM, V273, P20404, DOI 10.1074/jbc.273.32.20404; Shen WC, 1997, FUNGAL GENET BIOL, V21, P40, DOI 10.1006/fgbi.1997.0958; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THURIAUX P, 1972, J MOL BIOL, V67, P277, DOI 10.1016/0022-2836(72)90241-0; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Vilela C, 1999, EMBO J, V18, P3139, DOI 10.1093/emboj/18.11.3139; Wang Z, 1997, J BIOL CHEM, V272, P255; Wang Z, 1998, MOL CELL BIOL, V18, P7528, DOI 10.1128/MCB.18.12.7528; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; WEISSENBACH J, 1975, EUR J BIOCHEM, V56, P521, DOI 10.1111/j.1432-1033.1975.tb02257.x; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; YARUS M, 1989, BIOCHEMISTRY-US, V28, P980, DOI 10.1021/bi00429a010	62	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37565	37574		10.1074/jbc.274.53.37565	http://dx.doi.org/10.1074/jbc.274.53.37565			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608810	hybrid			2022-12-25	WOS:000084528000010
J	Peters, CA; Maizels, ET; Hunzicker-Dunn, M				Peters, CA; Maizels, ET; Hunzicker-Dunn, M			Activation of PKC delta in the rat corpus luteum during pregnancy - Potential role of prolactin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GRANULOSA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; FAMILY MEMBERS; PRL RECEPTOR; PHOSPHORYLATION; TRANSDUCTION; ISOZYMES; HORMONE	Maintenance of pregnancy in the rat requires the corpus luteum, At a time when rat placental lactogens (rPLs) are required to support progesterone production by the corpus luteum and when relaxin expression is initiated, expression of a specific protein kinase C (PKC) isoform, PRC delta, is dramatically increased. We therefore assessed whether prolactin (PRL) receptor activation promotes activation of PKC delta in a luteinized granulosa cell model. We also assessed the activation status of PKC delta in corpora lutea obtained when the corpus luteum is exposed to chronically high concentrations of rPLs. The activity of PKC delta was assessed by two means: an immune complex (IC) assay and Western blotting with a phospho epitope-specific antibody that detects PKC delta phosphorylated on serine 662. PKC delta activation in the IC kinase assay was determined by the ability of immunoprecipitated PKC delta to phosphorylate the PKC delta-preferential substrate small heat shock protein (HSP-27), Treatment of luteinized rat granulosa cells with phorbol myristate acetate, a known activator of PKC, promoted 7-fold increase in HSP-27 phosphorylation by PKC delta, Similarly, immunoreactivity with the phospho-epitope-specific PKC delta antibody was increased in extracts prepared from luteinized granulosa cells treated with phorbol myristate acetate or following in vitro activation of recombinant PKC delta. Using these assays, we assessed whether PRL receptor agonists were capable of activating PKC delta in luteinized granulosa cells. PRL receptor agonists induced translocation PKC delta from the cytosolic to the Triton-soluble membrane fraction and increased PKC delta activity assessed by both IC kinase assay and Western blotting with phospho-epitope-specific PKC delta antibody. Analysis of PKC delta activity in corpora lutes obtained during pregnancy by both the IC kinase assay and We stern blotting with the phospho-epitope-specific PKC delta antibody revealed that PKC delta activity was increased throughout the second half of pregnancy. These results demonstrate that PRL receptor activation promotes the acute activation of PKC delta in luteinized rat granulosa cells, At a time when the rat is exposed to chronically high concentrations of rPLs, PKC delta is increasingly expressed and active.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	mhd@nwu.edu		Maizels, Evelyn/0000-0001-9072-1095	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007068] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD 07068, P01 HD 21921] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Billiard J, 1997, P NATL ACAD SCI USA, V94, P12192, DOI 10.1073/pnas.94.22.12192; BLEY MA, 1991, BIOL REPROD, V44, P880, DOI 10.1095/biolreprod44.5.880; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; CARR DW, 1993, J BIOL CHEM, V268, P20729; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; CUTLER RE, 1994, ENDOCRINOLOGY, V135, P1669, DOI 10.1210/en.135.4.1669; CUTLER RE, 1993, BIOCHIM BIOPHYS ACTA, V1179, P260, DOI 10.1016/0167-4889(93)90081-Y; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; DEVITO WJ, 1993, J NEUROCHEM, V60, P835, DOI 10.1111/j.1471-4159.1993.tb03227.x; FANJUL LF, 1993, EUR J BIOCHEM, V216, P747, DOI 10.1111/j.1432-1033.1993.tb18194.x; GIBORI G, 1988, RECENT PROG HORM RES, V44, P377; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HATA A, 1993, J BIOL CHEM, V268, P9122; HICKEY GJ, 1990, MOL ENDOCRINOL, V4, P3, DOI 10.1210/mend-4-1-3; KEYES PL, 1987, BIOL REPROD, V37, P699, DOI 10.1095/biolreprod37.3.699; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KILEY SC, 1992, MOL ENDOCRINOL, V6, P120, DOI 10.1210/me.6.1.120; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PASQUALINI C, 1994, J NEUROCHEM, V62, P967; Ratovondrahona D, 1998, BIOCHEM BIOPH RES CO, V243, P127, DOI 10.1006/bbrc.1997.7978; RICHARDS JS, 1986, ENDOCRINOLOGY, V118, P1660, DOI 10.1210/endo-118-4-1660; RILLEMA JA, 1989, P SOC EXP BIOL MED, V192, P140, DOI 10.3181/00379727-192-42968; SAURO MD, 1991, J CELL PHYSIOL, V148, P133, DOI 10.1002/jcp.1041480116; Sherwood O D, 1993, Oxf Rev Reprod Biol, V15, P143; SHIMAMOTO T, 1993, ENDOCRINOLOGY, V133, P2127, DOI 10.1210/en.133.5.2127; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; TAYLOR MJ, 1988, BIOL REPROD, V39, P743, DOI 10.1095/biolreprod39.3.743; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719	45	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37499	37505		10.1074/jbc.274.52.37499	http://dx.doi.org/10.1074/jbc.274.52.37499			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601326	hybrid, Green Submitted			2022-12-25	WOS:000084382700097
J	Dermott, JM; Reddy, MVR; Onesime, D; Reddy, EP; Dhanasekaran, N				Dermott, JM; Reddy, MVR; Onesime, D; Reddy, EP; Dhanasekaran, N			Oncogenic mutant of G alpha(12) stimulates cell proliferation through cycloxygenase-2 signaling pathway	ONCOGENE			English	Article						G protein; G alpha(12); oncogene; transformation; signal transduction; COX-2, celebrex, celecoxib	CYTOSOLIC PHOSPHOLIPASE A(2); G-PROTEINS; COOPERATIVE TRANSFORMATION; NIH3T3 CELLS; 3T3 CELLS; EXPRESSION; KINASE; CYCLOOXYGENASE-2; GENE; FIBROBLASTS	Expression of the GTPase-deficient, activated mutant alpha-subunit of the heterotrimeric G protein G12 (G alpha(12)QL) leads to the neoplastic transformation of fibroblast cell lines. The mitogenic pathway regulated by G alpha(12)QL includes an extensive signaling network involving several small GTPases and various kinases. In addition, G alpha(12)QL has been shown to potentiate the serum-induced phospholipase-A(2) activity in NIH3T3 cells. In the present study, we demonstrate that cycloxygenase-2 (COX-2) pathway is involved in the mitogenic pathway activated by G alpha(12)QL Expression of G alpha(12)QL and not G alpha(13)QL, stimulates the serum-induced release of arachidonic acid in NIH3T3 cells. Furthermore, expression of G alpha(12)QL or the stimulation of wild-type G alpha(12) induces the expression of COX-2. Our results also indicate that the COX-2 inhibitor acutely disrupts the DNA-synthesis stimulated by G alpha(12)QL in NIH3T3 cells. These studies, for the first time, identify the crucial role of COX-2 in Gait-mediated regulation of cell proliferation and suggest a role for prostaglandin-derived autocrine loop in G alpha(12)-mediated signaling pathways.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Dennis M, 1997, CEREBROVASC DIS, V7, P22, DOI 10.1159/000108159; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gebauer G, 1999, J CELL BIOCHEM, V75, P547, DOI 10.1002/(SICI)1097-4644(19991215)75:4<547::AID-JCB1>3.3.CO;2-X; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; JIANG H, 1993, FEBS LETT, V3, P319; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Zhang YH, 1996, ONCOGENE, V12, P2377	30	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7185	7189		10.1038/sj.onc.1203345	http://dx.doi.org/10.1038/sj.onc.1203345			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602471				2022-12-25	WOS:000084119400001
J	Copeland, DE				Copeland, DE			Origins of cell biology in the United States	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB				Tulane Univ, New Orleans, LA 70118 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	Tulane University; Marine Biological Laboratory - Woods Hole	Copeland, DE (corresponding author), 41 Fern Lane, Woods Hole, MA 02543 USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S181	S184						4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619124				2022-12-25	WOS:000084390200002
J	Shu, W; Ji, H; Lu, M				Shu, W; Ji, H; Lu, M			Interactions between HIV-1 gp41 core and detergents and their implications for membrane fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; ENVELOPE GLYCOPROTEIN; TRANSMEMBRANE GLYCOPROTEIN; CIRCULAR-DICHROISM; LIPID INTERACTIONS; ATOMIC-STRUCTURE; CONFORMATION; PEPTIDE; MODEL; PH	The gp41 envelope protein mediates entry of human immunodeficiency virus type 1 (HIV-1) into the cell by promoting membrane fusion, The crystal structure of a gp41 ectodomain core in its fusion-active state is a six-helix bundle in which a N-terminal trimeric coiled coil is surrounded by three C-terminal outer helices in an antiparallel orientation. Here we demonstrate that the N34(L6)C28 model of the gp41 core is stabilized by interaction with the ionic detergent sodium dodecyl sulfate (SDS) or the nonionic detergent n-octyl-beta-D-glucopyranoside (beta OG), The high resolution x-ray structures of N34(L6)C28 crystallized from two different detergent micellar media reveal a six-helix bundle conformation very similar to that of the molecule in water. Moreover, N34(L6)C28 adopts a highly alpha-helical conformation in lipid vesicles. Taken together, these results suggest that the six-helix bundle of the gp41 core displays substantial affinity for lipid bilayers rather than unfolding in the membrane environment. This characteristic may be important for formation of the fusion-active gp41 core structure and close apposition of the viral and cellular membranes for fusion.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Cornell University	Lu, M (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	mlu@mail.med.cornell.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI042382, R01AI042382, R21AI042382] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42382] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARBER J, 1989, NATURE, V340, P601, DOI 10.1038/340601a0; BLUMENTHAL R, 1983, J BIOL CHEM, V258, P3409; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CANTOR C, 1980, BIOPHYSICAL CHEM 3, P1131; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GLAESER RM, 1985, BIOCHEMISTRY-US, V24, P6398, DOI 10.1021/bi00344a012; GORDON LM, 1992, BIOCHIM BIOPHYS ACTA, V1139, P257, DOI 10.1016/0925-4439(92)90099-9; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; Hughson FM, 1997, CURR BIOL, V7, pR565, DOI 10.1016/S0960-9822(06)00283-1; Ji H, 1999, J VIROL, V73, P8578, DOI 10.1128/JVI.73.10.8578-8586.1999; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LI SC, 1994, NAT STRUCT BIOL, V1, P368, DOI 10.1038/nsb0694-368; LI SC, 1993, J BIOL CHEM, V268, P22975; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lu M, 1999, J VIROL, V73, P4433, DOI 10.1128/JVI.73.5.4433-4438.1999; Luciw PA, 1996, FIELD VIROLOGY, P1881; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qiao H, 1998, J CELL BIOL, V141, P1335, DOI 10.1083/jcb.141.6.1335; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390, DOI 10.1021/bi00041a016; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; ROTERING BV, 1976, EUR J BIOCHEM, V740, P601; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; Shu W, 1999, BIOCHEMISTRY-US, V38, P5378, DOI 10.1021/bi990199w; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354; VANDEVEN FJM, 1993, BIOCHEMISTRY-US, V32, P8322, DOI 10.1021/bi00083a036; WALLACE BA, 1984, ANAL BIOCHEM, V142, P317, DOI 10.1016/0003-2697(84)90471-8; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; YU YG, 1994, SCIENCE, V266, P274, DOI 10.1126/science.7939662	55	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1839	1845		10.1074/jbc.275.3.1839	http://dx.doi.org/10.1074/jbc.275.3.1839			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636883	hybrid			2022-12-25	WOS:000084940000046
J	Gorbea, C; Taillandier, D; Rechsteiner, M				Gorbea, C; Taillandier, D; Rechsteiner, M			Mapping subunit contacts in the regulatory complex of the 26 S proteasome - S2 and S5b form a tetramer with ATPase subunits S4 and S7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; RABBIT RETICULOCYTE LYSATE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; MULTICATALYTIC PROTEASE; PROTEOLYTIC COMPLEX; FUNCTIONAL-ANALYSIS; 20S PROTEASOME; COILED COILS; CDNA CLONING	The 19 S regulatory complex (RC) of the 26 S proteasome is composed of at least 18 different subunits, including six ATPases that form specific pairs S4-S7, S6-S8, and S6'-S10b in vitro, One of the largest regulatory complex subunits, S2, was translated in reticulocyte lysate containing [S-35]methionine and used to probe membranes containing SDS-polyacrylamide gel electrophoresis separated RC subunits, S2 bound to two ATPases, S4 and S7. Association of S2 with regulatory complex subunits was also assayed by co-translation and sedimentation. S2 formed an immunoprecipitable heterotrimer upon co-translation with S4 and S7. The non-ATPase S5b also formed a ternary complex with S4 and S7 and the three proteins assembled into a tetramer with S2, Neither S2 nor S5b formed complexes with S6'-S10b dimers or with S6-S8 oligomers, The use of chimeric ATPases demonstrated that S2 binds the NH2-terminal region of S4 and the COOH-terminal two-thirds of S7, Conversely, S5b binds the COOH-terminal two-thirds of S4 and to S7's NH2-terminal region. The demonstrated association of S2 with ATPases in the mammalian 19 S regulatory complex is consistent with and extends the recent finding that the yeast RC is composed of two subcomplexes, the lid and the base. (Glickman, M. H., Rubin, D. M., Coux, O., Wefes, I., Pfeifer, G., Cejka, Z., Baumeister, W., Fried, V. A., and Finley, D. (1998) Cell 94, 615-623).	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Rechsteiner, M (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.	rechsteiner@mailman.med.utah.edu		Taillandier, Daniel/0000-0003-4520-0551	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beninga J, 1998, UBIQUITIN BIOL CELL, P191; CHEN ZJ, 1998, UBIQUITIN BIOL CELL, P303; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ferreira PA, 1998, J BIOL CHEM, V273, P24676, DOI 10.1074/jbc.273.38.24676; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P464; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MA CP, 1994, J BIOL CHEM, V269, P3539; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Penney M, 1998, J BIOL CHEM, V273, P23938, DOI 10.1074/jbc.273.37.23938; PETERS JM, 1994, J BIOL CHEM, V269, P7709; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Richmond C, 1997, J BIOL CHEM, V272, P13403, DOI 10.1074/jbc.272.20.13403; Saito A, 1997, GENE, V203, P241, DOI 10.1016/S0378-1119(97)00524-6; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Tanaka K, 1998, IMMUNOL REV, V163, P161; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsurumi C, 1996, EUR J BIOCHEM, V239, P912, DOI 10.1111/j.1432-1033.1996.0912u.x; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; Wilkinson CRM, 1997, J BIOL CHEM, V272, P25768, DOI 10.1074/jbc.272.41.25768	59	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					875	882		10.1074/jbc.275.2.875	http://dx.doi.org/10.1074/jbc.275.2.875			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625621	Green Published, hybrid			2022-12-25	WOS:000084836600025
J	Bowman, EJ; Kendle, R; Bowman, BJ				Bowman, EJ; Kendle, R; Bowman, BJ			Disruption of vma-1, the gene encoding the catalytic subunit of the vacuolar H+-ATPase, causes severe morphological changes in Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CALCIUM-IONS; GROWTH; INACTIVATION; MUTANTS; TRANSPORT; REVEALS; ROLES; DETOXIFICATION; INHIBITION	By using the process of Repeat-induced Point mutation (Selker, E. U., and Garrett, P. W. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 6870-6874), we inactivated vma-1, the gene encoding subunit A of the V-ATPase of Neurospora crassa. Two vma-1 mutant strains were characterized. One was mutated at multiple sites, did not make a protein product, and produced spores that only rarely germinated. The other had four point mutations, made a protein product, and produced viable spores. Neither strain had detectable V-ATPase activity. The uma-1 mutant strains did not grow in medium buffered to pH 7.0 or above or in medium supplemented with the cation Zn2+. They were completely resistant to inhibition by concanamycin C, supporting our hypothesis that the V-ATPase is the in vivo target of this antibiotic. Inactivation of the vma-1 gene had a pronounced effect on morphology and development of the organism. In the mutants tip growth was inhibited, and multiple branching was induced. The vma-1 mutant strains could not differentiate conidia or perithecia. They could grow slowly as mycelia and could donate nuclei in a sexual cross. A mutation in the plasma membrane ATPase, which suppressed the sensitivity of wild type N. crassa to concanamycin, also proved effective in suppressing the sensitivity of a vma-1 null mutant to basic pH but did not correct the morphological defects.	Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Bowman, EJ (corresponding author), Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA.	rbowman@biology.ucsc.edu						BACHHAWAT AK, 1993, YEAST, V9, P175, DOI 10.1002/yea.320090208; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; Bowman EJ, 1997, J BIOL CHEM, V272, P14776, DOI 10.1074/jbc.272.23.14776; BOWMAN EJ, 1988, METHOD ENZYMOL, V157, P562; Davies SA, 1996, J BIOL CHEM, V271, P30677, DOI 10.1074/jbc.271.48.30677; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DAVIS RH, 1986, MICROBIOL REV, V50, P280, DOI 10.1128/MMBR.50.3.280-313.1986; DICKER JW, 1990, J GEN MICROBIOL, V136, P1413, DOI 10.1099/00221287-136-7-1413; Drose S, 1997, J EXP BIOL, V200, P1; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Ferea TL, 1996, GENETICS, V143, P147; Forster C, 1999, J BIOL CHEM, V274, P9442, DOI 10.1074/jbc.274.14.9442; HARKNESS TAA, 1994, GENETICS, V136, P107; HAROLD FM, 1994, MYCOTA, V1, P89; HEATH IB, 1994, MYCOTA, V1, P43; JACKSON SL, 1993, MICROBIOL REV, V57, P367, DOI 10.1128/MMBR.57.2.367-382.1993; Jones EW., 1997, MOL CELLULAR BIOL YE, VIII, P363; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; MILLER AJ, 1990, P NATL ACAD SCI USA, V87, P9348, DOI 10.1073/pnas.87.23.9348; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; OAKLEY CE, 1987, GENE, V53, P293, DOI 10.1016/0378-1119(87)90019-9; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; PERKINS DD, 1984, NEUROSPORA NEWSL, V31, P41; Prokisch H, 1997, MOL GEN GENET, V256, P104, DOI 10.1007/s004380050551; RAJU NB, 1992, MYCOL RES, V96, P241, DOI 10.1016/S0953-7562(09)80934-9; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; Riquelme M, 1998, FUNGAL GENET BIOL, V24, P101, DOI 10.1006/fgbi.1998.1074; SCHMID J, 1988, J GEN MICROBIOL, V134, P2623; Seiler S, 1997, EMBO J, V16, P3025, DOI 10.1093/emboj/16.11.3025; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; SPRINGER ML, 1989, GENE DEV, V3, P559, DOI 10.1101/gad.3.4.559; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUPEK F, 1994, J BIOL CHEM, V269, P26479; TRINCI APJ, 1994, GROWTH DIFFERENTIATI, P175; Xie YY, 1996, J CELL SCI, V109, P489; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x; ZEREZ CR, 1986, J BIOL CHEM, V261, P8877; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	43	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					167	176		10.1074/jbc.275.1.167	http://dx.doi.org/10.1074/jbc.275.1.167			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617601	hybrid			2022-12-25	WOS:000085951600025
J	Norfleet, AM; Clarke, CH; Gametchu, B; Watson, CS				Norfleet, AM; Clarke, CH; Gametchu, B; Watson, CS			Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors	FASEB JOURNAL			English	Article						nongenomic effects; membrane steroid receptors; immunocytochemistry	GLUCOCORTICOID RECEPTOR; PROGESTERONE; PROLIFERATION; ACTIVATION; PATHWAY; BINDING; CAMP	Antibodies (Abs) raised against the estrogen receptor-alpha (ER alpha) were used to investigate the role of ER alpha proteins located at the plasma membrane in mediating the rapid, estrogen-stimulated secretion of prolactin (PRL) from rat pituitary GH(3)/B6/F10 cells. Exposure of the cells to 1 nM 17 beta-estradiol (E-2) significantly increased PRL release after 3 or 6 min. When ER alpha Abs that bind specifically to ER alpha but are too large to diffuse into cells were tested for activity at the cell membrane, Ab R4, targeted to an ER alpha hinge region sequence, increased PRL release in a time-, and concentration-dependent fashion. Ab H151, directed against a different hinge region epitope, decreased PRL release and blocked the stimulatory action of E-2. Abs raised against the DNA binding domain (H226) or the carboxyl terminus (C542) were not biologically active. When each Ab was examined for recognition of ER alpha on the cell surface by immunocytochemistry, all except H151 generated immunostaining in aldehyde-fixed cells. In live cells, however, Ab H151 but not Ab R4 blocked the membrane binding of fluorescently tagged E-2-BSA. Overall, the data indicate that plasma membrane ER alpha proteins mediate estrogen-stimulated PRL release from GH(3)/B6/F10 cells. These results may also convey information about conformationally sensitive areas of the membrane form of ER alpha involved in rapid, nongenomic responses to estrogens,-Norfleet, A. M., Clarke, C. H., Gametchu, B., Watson, C. S. Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Medical College of Wisconsin	Watson, CS (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.				NICHD NIH HHS [R01 HD032481-04, HD32481] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032481] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; BRINK M, 1992, ENDOCRINOLOGY, V130, P3575, DOI 10.1210/en.130.6.3575; BRUBAKER KD, 1994, BIOCHEM BIOPH RES CO, V200, P899, DOI 10.1006/bbrc.1994.1535; FRIEND KE, 1995, P NATL ACAD SCI USA, V92, P4367, DOI 10.1073/pnas.92.10.4367; GAMETCHU B, 1993, FASEB J, V7, P1283, DOI 10.1096/fasebj.7.13.8405814; GAMETCHU B, 1987, SCIENCE, V236, P456, DOI 10.1126/science.3563523; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; KOIKE S, 1987, NUCLEIC ACIDS RES, V15, P2499, DOI 10.1093/nar/15.6.2499; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; NAKHLA AM, 1994, P NATL ACAD SCI USA, V91, P5402, DOI 10.1073/pnas.91.12.5402; NENCI I, 1980, PERSPECTIVES STEROID, P61; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; PAPPAS TC, 1994, ENDOCRINE, V2, P813; PAPPAS TC, 1995, ENDOCRINE, V3, P743, DOI 10.1007/BF03000207; PIETRAS RJ, 1980, BIOCHEM J, V191, P743, DOI 10.1042/bj1910743; Ramirez VD, 1996, CELL MOL NEUROBIOL, V16, P175, DOI 10.1007/BF02088175; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; Sabeur K, 1996, BIOL REPROD, V54, P993, DOI 10.1095/biolreprod54.5.993; Selye H, 1941, P SOC EXP BIOL MED, V46, P116; Somjen D, 1997, J CELL BIOCHEM, V65, P53, DOI 10.1002/(SICI)1097-4644(199704)65:1<53::AID-JCB6>3.0.CO;2-Y; SZEGO CM, 1994, ENDOCRINE, V2, P1079; TESARIK J, 1992, FEBS LETT, V308, P116, DOI 10.1016/0014-5793(92)81256-L; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VAN OE, 1981, MOL CELL ENDOCRINOL, V22, P277; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; WATSON CS, 1995, ENVIRON HEALTH PERSP, V103, P41, DOI 10.2307/3432507; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Wu WX, 1996, BIOL REPROD, V54, P230, DOI 10.1095/biolreprod54.1.230; ZYZEK E, 1981, BIOCHEM BIOPH RES CO, V102, P1151, DOI 10.1016/S0006-291X(81)80132-5	36	100	100	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					157	165		10.1096/fasebj.14.1.157	http://dx.doi.org/10.1096/fasebj.14.1.157			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627290	Green Accepted			2022-12-25	WOS:000084784700018
J	Bonagura, CA; Bhaskar, B; Sundaramoorthy, M; Poulos, TL				Bonagura, CA; Bhaskar, B; Sundaramoorthy, M; Poulos, TL			Conversion of an engineered potassium-binding site into a calcium-selective site in cytochrome c peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPOUND-I; ASCORBATE PEROXIDASE; MANGANESE PEROXIDASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; IDENTIFICATION; TRYPTOPHAN; CATALYSIS; LIGAND	We have previously shown that the K+ site found in ascorbate peroxidase can be successfully engineered into the closely homologous peroxidase, cytochrome c peroxidase (CCP) (Bonagura, C, A, Sundaramoorthy, M., Pappa, H, S., Patterson, W. R., and Poulos, T, L, (1996) Biochemistry 35, 6107-6115; Bonagura, C, A, Sundaramoorthy, M., Bhaskar, B., and Poulos, T. L, (1999) Biochemistry 38, 5538-5545). All other peroxidases bind Ca2+ rather than K+. Using the K+-binding CCP mutant (CCPK2) as a template protein, together with observations from structural modeling, mutants were designed that should bind Ca2+ selectively, The crystal structure of the first generation mutant, CCPCA1, showed that a smaller cation, perhaps Na+, is bound instead of Ca2+. This is probably because the full eight-ligand coordination sphere did not form owing to a local disordering of one of the essential cation ligands, Eased on these observations, a second mutant, CCPCA2, was designed. The crystal structure showed Ca2+ binding in the CCPCA2 mutant and a well ordered cation-binding loop with the full complement of eight protein to cation ligands, Because cation binding to the engineered loop results in diminished CCP activity and destabilization of the essential Trp(191) radical as measured by EPR spectroscopy, these measurements can be used as sensitive methods for determining cation-binding selectivity. Both activity and EPR titration studies show that CCPCA2 binds Ca2+ more effectively than K+, demonstrating that an iterative protein engineering-based approach is important in switching protein cation selectivity.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.							Bonagura CA, 1996, BIOCHEMISTRY-US, V35, P6107, DOI 10.1021/bi960122x; Bonagura CA, 1999, BIOCHEMISTRY-US, V38, P5538, DOI 10.1021/bi982996k; CHOUDHURY K, 1994, J BIOL CHEM, V269, P20239; DARWISH K, 1991, PROTEIN ENG, V4, P701, DOI 10.1093/protein/4.6.701; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; FITZGERALD MM, 1994, BIOCHEMISTRY-US, V33, P3807, DOI 10.1021/bi00179a004; HAHM S, 1993, J AM CHEM SOC, V115, P3372, DOI 10.1021/ja00061a063; HAHM S, 1994, BIOCHEMISTRY-US, V33, P1463; Jensen GM, 1998, J PHYS CHEM B, V102, P8221, DOI 10.1021/jp9811326; KANG CH, 1977, J BIOL CHEM, V252, P919; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; Menyhard DK, 1999, J PHYS CHEM B, V103, P227, DOI 10.1021/jp981765k; MILLER MA, 1994, P NATL ACAD SCI USA, V91, P11118, DOI 10.1073/pnas.91.23.11118; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pappa HS, 1996, BIOCHEMISTRY-US, V35, P4837, DOI 10.1021/bi952935b; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; POULOS TL, 1993, J BIOL CHEM, V268, P4429; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Wilcox SK, 1998, BIOCHEMISTRY-US, V37, P16853, DOI 10.1021/bi9815039; Yeung BKS, 1997, CHEM BIOL, V4, P215, DOI 10.1016/S1074-5521(97)90291-X; YONETANI T, 1966, BIOCHEM PREP, V11, P14; Yonetani T., 1976, ENZYMES, P345	27	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37827	37833		10.1074/jbc.274.53.37827	http://dx.doi.org/10.1074/jbc.274.53.37827			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608846	hybrid			2022-12-25	WOS:000084528000046
J	Gassel, M; Mollenkamp, T; Puppe, W; Altendorf, K				Gassel, M; Mollenkamp, T; Puppe, W; Altendorf, K			The KdpF subunit is part of the K+-translocating Kdp complex of Escherichia coli and is responsible for stabilization of the complex in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA DECARBOXYLASE; MUSCLE SARCOPLASMIC-RETICULUM; CYTOCHROME-C-OXIDASE; POTASSIUM-TRANSPORT; PARACOCCUS-DENITRIFICANS; VEILLONELLA-PARVULA; STRUCTURAL PROTEINS; REACTIVE PROTEIN; ATPASE; EXPRESSION	The hdpABC operon codes for the high affinity K+-translocating Kdp complex (P-type ATPase) of Escherichia coli, Upon expression of this operon in minicells, a so far unrecognized small hydrophobic polypeptide, KdpF, could be identified on high resolution SDS-polyacrylamide gels in addition to the subunits KdpA, KdpB, and KdpC, Furthermore, it could be demonstrated that KdpF remains associated with the purified complex. As determined by mass spectrometry, this peptide is present in its formylated form and has a molecular mass of 3100 Da, KdpF is not essential for growth on low K+ (0.1 mM) medium, as shown by deletion analysis of KdpF, but proved to be indispensable for a functional enzyme complex in vitro. In the absence of KdpF, the ATPase activity of the membrane-bound Hdp complex was almost indistinguishable from that of the wild type. In contrast, the purified detergent-solubilized enzyme complex showed a dramatic decrease in enzymatic activity. However, addition of purified KdpF to the KdpABC complex restored the activity up to wild type level, It is interesting to note that the addition of high amounts of E. coli lipids had a similar effect. Although KdpF is not essential for the function of the Hdp complex in vivo, it is part of the complex and functions as a stabilizing element in vitro, The corresponding operon should now be referred to as kdpFABC.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany; Christian Albrechts Univ Kiel Klinikum, Klin Allgemeine Padiat Bakteriol Labor, D-24105 Kiel, Germany	University Osnabruck; University of Kiel; Schleswig Holstein University Hospital	Altendorf, K (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.	altendorf@biologie.uni-osnabrueck.de						Altendorf K, 1998, ACTA PHYSIOL SCAND, V163, P137; ALTENDORF K, 1975, FEBS LETT, V59, P268, DOI 10.1016/0014-5793(75)80390-5; ALTENDORF K, 1996, BIOMEMBR, V5, P403; ALTENDORF K, 1979, FUNCTION MOL ASPECTS, P53; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BAKKER EP, 1993, ALKALI CATION TRANSP, P00205; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bott M, 1997, EUR J BIOCHEM, V250, P590, DOI 10.1111/j.1432-1033.1997.0590a.x; BUURMAN ET, 1995, J BIOL CHEM, V270, P6678, DOI 10.1074/jbc.270.12.6678; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; EPSTEIN W, 1985, CURR TOP MEMBR TRANS, V23, P153; FILLINGAME RH, 1976, J BIOL CHEM, V251, P6630; Gassel M, 1998, BBA-BIOMEMBRANES, V1415, P77, DOI 10.1016/S0005-2736(98)00179-5; GRAF T, 1978, FEBS LETT, V94, P218, DOI 10.1016/0014-5793(78)80941-7; GUTTERSON NI, 1983, P NATL ACAD SCI-BIOL, V80, P4894, DOI 10.1073/pnas.80.16.4894; HARDWICKE PMD, 1981, BIOCHEM BIOPH RES CO, V102, P250, DOI 10.1016/0006-291X(81)91514-X; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Hellwig P, 1998, BBA-BIOENERGETICS, V1409, P107, DOI 10.1016/S0005-2728(98)00151-0; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HUDER JB, 1993, J BIOL CHEM, V268, P24564; HUDER JB, 1995, J BACTERIOL, V177, P3623, DOI 10.1128/jb.177.13.3623-3630.1995; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kadambi VJ, 1997, BIOCHEM BIOPH RES CO, V239, P1, DOI 10.1006/bbrc.1997.7340; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1978, P NATL ACAD SCI USA, V75, P3216, DOI 10.1073/pnas.75.7.3216; Maniatis T., 1982, MOL CLONING LAB MANU; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NAVARRE C, 1994, J BIOL CHEM, V269, P21262; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; POLAREK JW, 1988, METHOD ENZYMOL, V157, P655; PUPPE W, 1992, MOL MICROBIOL, V6, P3511, DOI 10.1111/j.1365-2958.1992.tb01786.x; PUPPE W, 1991, THESIS U OSNABRUCK O; REEVE JN, 1984, ADV MOL GENETICS, P212; RHOADS DB, 1976, J GEN PHYSIOL, V67, P325, DOI 10.1085/jgp.67.3.325; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; SIEBERS A, 1989, J BIOL CHEM, V264, P5831; SIEBERS A, 1992, J BIOL CHEM, V267, P12717; SIEBERS A, 1988, METHOD ENZYMOL, V157, P668; SIEBERS A, 1993, ALKALI CATION TRANSP, P225; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SPIERS AJ, 1992, J BACTERIOL, V174, P7533, DOI 10.1128/JB.174.23.7533-7541.1992; STUMPE S, 1996, HDB BIOL PHYS, V2, P473; SUGIURA A, 1993, BIOSCI BIOTECH BIOCH, V57, P356, DOI 10.1271/bbb.57.356; SUGIURA A, 1992, MOL MICROBIOL, V6, P1769, DOI 10.1111/j.1365-2958.1992.tb01349.x; TreunerLange A, 1997, J BACTERIOL, V179, P4501, DOI 10.1128/jb.179.14.4501-4512.1997; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; Witt H, 1997, J BIOL CHEM, V272, P5514, DOI 10.1074/jbc.272.9.5514	61	85	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37901	37907		10.1074/jbc.274.53.37901	http://dx.doi.org/10.1074/jbc.274.53.37901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608856	hybrid			2022-12-25	WOS:000084528000056
J	Lescure, A; Gautheret, D; Carbon, P; Krol, A				Lescure, A; Gautheret, D; Carbon, P; Krol, A			Novel selenoproteins identified in silico and in vivo by using a conserved RNA structural motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; IODOTHYRONINE DEIODINASE; OXIDATIVE STRESS; SELENOCYSTEINE; SEQUENCE; EUKARYOTES; ALIGNMENT; PROTEIN; TISSUES; ELEMENT	Selenocysteine is incorporated into selenoproteins by an in-frame UGA codon whose readthrough requires the selenocysteine insertion sequence (SECIS), a conserved hairpin in the 3'-untranslated region of eukaryotic selenoprotein mRNAs, To identify new selenoproteins, we developed a strategy that obviates the need for prior amino acid sequence information, A computational screen was used to scan nucleotide sequence data bases for sequences presenting a potential SECIS secondary structure, The computer-selected hairpins were then assayed in vivo for their functional capacities, and the cDNAs corresponding to the SECIS winners were identified. Four of them encoded novel selenoproteins as confirmed by in vivo experiments. Among these, SelZf1 and SelZf2 share a common domain with mitochondrial thioredoxin reductase-g. The three proteins, however, possess distinct N-terminal domains, We found that another protein, SelX, displays sequence similarity to a protein involved in bacterial pilus formation. For the first time, four novel selenoproteins were discovered based on a computational screen for the RNA hairpin directing selenocysteine incorporation.	Inst Biol Mol & Cellulaire, CNRS, UPR 9002, F-67084 Strasbourg, France; CNRS, UMR 1889, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS)	Krol, A (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	krol@ihmc.u-strasbg.fr		Gautheret, Daniel/0000-0002-1508-8469				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beck MA, 1998, ANNU REV NUTR, V18, P93, DOI 10.1146/annurev.nutr.18.1.93; Behne D, 1996, BIOL TRACE ELEM RES, V55, P99, DOI 10.1007/BF02784172; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Buettner C, 1998, J BIOL CHEM, V273, P33374, DOI 10.1074/jbc.273.50.33374; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; Dandekar T, 1998, BIOINFORMATICS, V14, P271, DOI 10.1093/bioinformatics/14.3.271; DANDEKAR T, 1995, TRENDS GENET, V11, P45, DOI 10.1016/S0168-9525(00)88996-9; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; GAUTHERET D, 1990, COMPUT APPL BIOSCI, V6, P325; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; HUANG XQ, 1992, GENOMICS, V14, P18, DOI 10.1016/S0888-7543(05)80277-0; Kollmus H, 1996, NUCLEIC ACIDS RES, V24, P1195, DOI 10.1093/nar/24.7.1195; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; LAFERRIERE A, 1994, COMPUT APPL BIOSCI, V10, P211; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Pesole G, 1999, NUCLEIC ACIDS RES, V27, P188, DOI 10.1093/nar/27.1.188; STADTMAN TC, 1991, J BIOL CHEM, V266, P16257; TAHA MK, 1988, EMBO J, V7, P4367, DOI 10.1002/j.1460-2075.1988.tb03335.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walczak R, 1996, RNA, V2, P367; Walczak R, 1998, RNA, V4, P74; Wizemann TM, 1996, P NATL ACAD SCI USA, V93, P7985, DOI 10.1073/pnas.93.15.7985	29	216	234	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38147	38154		10.1074/jbc.274.53.38147	http://dx.doi.org/10.1074/jbc.274.53.38147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608886	hybrid			2022-12-25	WOS:000084528000086
J	Matsumura, T; Sakai, M; Matsuda, K; Furukawa, N; Kaneko, K; Shichiri, M				Matsumura, T; Sakai, M; Matsuda, K; Furukawa, N; Kaneko, K; Shichiri, M			Cis-acting DNA elements of mouse granulocyte/macrophage colony-stimulating factor gene responsive to oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PERITONEAL-MACROPHAGES; PROTEIN-KINASE-C; GM-CSF PROMOTER; FACTOR-KAPPA-B; TRANSCRIPTION FACTOR; SCAVENGER RECEPTOR; MESSENGER-RNA; GROWTH-FACTOR; T-CELLS; LIGAND ACTIVITY	We previously demonstrated that the induction of granulocyte/macrophage colony-stimulating factor (GM-CSF) played an important role in oxidized low density lipoprotein (Ox-LDL)-induced macrophage growth as a growth priming factor. The present study was undertaken to elucidate the transcriptional regulation of the GM-CSF gene using Raw 264.7 cells, a mouse macrophage cell line, Transient transfection into Raw 264.7 cells of several 5'-flanking regions of GM-CSF gene-luciferase fusion plasmids revealed the presence of two positive regulatory sites in regions spanning from -97 to -59 and hom -59 to -37 and one negative regulatory site hom -120 to -97 in unstimulated cells. When cells were stimulated by Ox-LDL, there was one positive responsive site from -225 to -120 and one negative responsive site from -97 to -59, which contained the NF-kappa B binding site. Computer analysis revealed the presence of a putative AP-2 binding site from -169 to -160, Mutagenesis of a putative AP-2 binding site and tandem repeat of this site in plasmid resulted in a complete loss and increased responsiveness to Ox-LDL, respectively. Electrophoretic mobility shift assay showed that Ox-LDL increased the binding of certain nuclear protein(s) to a putative AP-2 binding site but decreased their binding to NF-kappa B binding site. S kappa upershift assay showed that nuclear proteins bound to NF-kappa B binding site contained, at least, p50 and p65 but could not demonstrate nuclear protein(s) bound to a putative AP-2 binding site. Our results suggested that a putative AP-2 binding site from -169 to -160 was a positive responsive element to Ox-LDL and that the NF-kappa B binding site hom -91 to -82 was a negative responsive element in Ox-LDL-induced GM-CSF transcription.	Kumamoto Univ, Sch Med, Dept Metab Med, Kumamoto 8605886, Japan	Kumamoto University	Sakai, M (corresponding author), Kumamoto Univ, Sch Med, Dept Metab Med, 1-1-1 Honjo, Kumamoto 8605886, Japan.							ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ARES MPS, 1995, ARTERIOSCL THROM VAS, V15, P1584, DOI 10.1161/01.ATV.15.10.1584; Biwa T, 1998, J BIOL CHEM, V273, P28305, DOI 10.1074/jbc.273.43.28305; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; BROUDY VC, 1987, J IMMUNOL, V139, P464; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; BURGESS AW, 1980, BLOOD, V56, P947; CHEN BDM, 1986, J IMMUNOL, V137, P563; CHEN BDM, 1988, BLOOD, V71, P997; CHODAKEWITZ JA, 1988, J IMMUNOL, V140, P832; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; HAKAMATA H, 1994, ARTERIOSCLER THROMB, V14, P1860, DOI 10.1161/01.ATV.14.11.1860; Hamilton JA, 1999, ARTERIOSCL THROM VAS, V19, P98, DOI 10.1161/01.ATV.19.1.98; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; KOYANONAKAGAWA N, 1993, INT IMMUNOL, V5, P345, DOI 10.1093/intimm/5.4.345; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; Martens JS, 1999, J BIOL CHEM, V274, P10903, DOI 10.1074/jbc.274.16.10903; Martens JS, 1998, J BIOL CHEM, V273, P4915, DOI 10.1074/jbc.273.9.4915; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; Matsuda K, 1997, DIABETES, V46, P354, DOI 10.2337/diabetes.46.3.354; Matsumura T, 1997, ARTERIOSCL THROM VAS, V17, P3013, DOI 10.1161/01.ATV.17.11.3013; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIYAKE S, 1988, EMBO J, V4, P2561; MIYAZAKI A, 1994, J BIOL CHEM, V269, P5264; MIYAZAKI A, 1991, BIOCHIM BIOPHYS ACTA, V1082, P143; MOSER M, 1995, DEVELOPMENT, V121, P2779; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; OHTA T, 1989, FEBS LETT, V257, P435, DOI 10.1016/0014-5793(89)81590-X; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakai M, 1999, ARTERIOSCL THROM VAS, V19, P1726, DOI 10.1161/01.ATV.19.7.1726; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SAKAI M, 1992, FEBS LETT, V314, P199, DOI 10.1016/0014-5793(92)80974-L; Sakai M, 1996, ARTERIOSCL THROM VAS, V16, P600, DOI 10.1161/01.ATV.16.4.600; Sambrook J., 2002, MOL CLONING LAB MANU; Sato Y, 1996, ATHEROSCLEROSIS, V125, P15, DOI 10.1016/0021-9150(96)05829-7; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; STANLEY ER, 1976, J EXP MED, V143, P631, DOI 10.1084/jem.143.3.631; STEWART CC, 1978, J RETICULOENDOTH SOC, V23, P269; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; TSUBOI A, 1991, INT IMMUNOL, V3, P807, DOI 10.1093/intimm/3.8.807; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WRONG GG, 1985, SCIENCE, V228, P810; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	55	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37665	37672		10.1074/jbc.274.53.37665	http://dx.doi.org/10.1074/jbc.274.53.37665			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608823	hybrid			2022-12-25	WOS:000084528000023
J	DeCristofaro, MF; Betz, BL; Wang, WD; Weissman, BE				DeCristofaro, MF; Betz, BL; Wang, WD; Weissman, BE			Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors	ONCOGENE			English	Article						BAF47; SWI/SNF; rhabdomyosarcomas; rhabdoid; tumor suppressor genes	TRANSCRIPTIONAL ACTIVATION; RETINOBLASTOMA PROTEIN; SWI/SNF COMPLEX; HUMAN HOMOLOG; YEAST; BINDING; SNF5; STIMULATION; SWI2/SNF2; COOPERATE	The organization of genomic DNA into chromatin aids in the regulation of gene expression by limiting the access of transcriptional binding domains. The SWI/SNF family of chromatin-remodeling complexes, which are conserved from yeast to humans, open the chromatin to facilitate the transcriptional machinery to access their targets. The gene encoding the BAF47/hSNF5 subunit of the complex has been found mutated in both rhabdoid cell lines and in primary rhabdoid tumors. Since the pediatric tumors rhabdomyosarcoma (RMS) and Wilms' tumor (WT) share a similar genetic link with rhabdoid tumors, it was hypothesized that they may also show alterations of the BAF47 gene. Using primary tumors, the BAF47 protein was detected in all WT but less than 75% of the RMS tested, In cell lines, the BAF47 protein was missing in all rhabdoid cell lines and one RMS cell Line. Analysis of sample DNA displayed either a mutation or deletion of the BAF47 gene in all samples negative for the protein. Several other subunits of the human SWI/SNF complex, including BRG1 which is the subunit directly interacting with the Rb tumor suppressor gene, were detected in all tumor samples. Alteration of BAF47 may be a genetic marker associated with the poor prognosis seen in all rhabdoid tumors but only some RMS.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; NIA, Gerontol Res Ctr, Genet Lab, NIH, Baltimore, MD 21224 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Weissman, BE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295,Rm 32-062, Chapel Hill, NC 27599 USA.		Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928	NATIONAL CANCER INSTITUTE [R01CA063176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008581] Funding Source: NIH RePORTER; NCI NIH HHS [CA63176] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM08581] Funding Source: Medline; PHS HHS [5-T32-WS07017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIEGEL JA, 1990, CANCER RES, V59, P74; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Charles AK, 1998, AM J PATHOL, V153, P991, DOI 10.1016/S0002-9440(10)65641-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Green Daniel M., 1997, P733; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Parham D, 1996, PEDIAT NEOPLASIA MOR, P87; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Pogacnik A, 1997, ACTA CYTOL, V41, P539, DOI 10.1159/000332553; Rosty C, 1998, GENE CHROMOSOME CANC, V21, P82, DOI 10.1002/(SICI)1098-2264(199802)21:2<82::AID-GCC2>3.0.CO;2-3; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	29	74	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7559	7565		10.1038/sj.onc.1203168	http://dx.doi.org/10.1038/sj.onc.1203168			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602515				2022-12-25	WOS:000084119600017
J	Christophe, T; Rabiet, MJ; Tardif, M; Milcent, MD; Boulay, F				Christophe, T; Rabiet, MJ; Tardif, M; Milcent, MD; Boulay, F			Human complement 5a (C5a) anaphylatoxin receptor (CD88) phosphorylation sites and their specific role in receptor phosphorylation and attenuation of G protein-mediated responses - Desensitization of C5a receptor controls superoxide production but not receptor sequestration in HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA-ARRESTIN; CHEMOATTRACTANT RECEPTORS; KINASE-C; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; INTERNALIZATION; ACTIVATION; DYNAMIN	Upon agonist binding, the anaphylatoxin human complement 5a receptor (C5aR) has previously been found to be phosphorylated on the six serine residues of its carboxyl-terminal tail (Giannini, E., Brouchon, L., and Boulay, F. (1995) J. Biol. Chem. 270, 19166-19172), To evaluate the precise roles that specific phosphorylation sites may play in receptor signaling, a series of mutants were expressed transiently in COS-7 cells and stably in the physiologically relevant myeloid HL-60 cells. Ser(334) was found to be a key residue that controls receptor phosphorylation, Phosphorylation of either of two serine pairs, namely Ser(332) and Ser(334) or Ser(334) and Ser(338), was critical for the phosphorylation of C5aR and its subsequent desensitization. Full phosphorylation and desensitization of C5aR were obtained when these serines were replaced by aspartic acid residues. The mutation S338A had no marked effect on the agonist-mediated phosphorylation of C5aR, but it allowed a sustained C5a-evoked calcium mobilization in HL-60 cells. These findings and the ability of the S314A/S317A/S327A/S532A mutant receptor to undergo desensitization indicate that the phosphorylation of Ser(334) and Ser(338) is critical and sufficient for C5aR desensitization. The lack of phosphorylation was found to result not only in a sustained calcium mobilization and extracellular signal-regulated kinase 2 activity but also in the enhancement of the C5a-mediated respiratory burst in neutrophil-like HL-60 cells. For instance, the nonphosphorylatable S332A/S334A mutant receptor triggered a 1.8-2-fold higher production of superoxide as compared with the wild-type receptor. Interestingly, although the desensitization of this mutant was defective, it was sequestered with the same time course and the same efficiency as the wild-type receptor. Thus, in myeloid HL-60 cells, desensitization and sequestration of C5aR appear to occur through divergent molecular mechanisms.	Commissariat Energy Atom, Grenoble, France; CNRS, Dept Biol Mol & Struct, Lab Biochim & Biophys Syst Integres, Unite Mixte Rech Commissariat Energy Atom 314, F-38054 Grenoble 9, France	CEA; CEA; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Boulay, F (corresponding author), Commissariat Energy Atom, Grenoble, France.		Tardif, Marianne/AAA-5357-2019	Tardif, Marianne/0000-0003-4438-8281				Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; ALI H, 1993, J BIOL CHEM, V268, P24247; Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Babior B M, 1995, Curr Opin Hematol, V2, P55; Bei L, 1998, BBA-MOL CELL RES, V1404, P475, DOI 10.1016/S0167-4889(98)00081-0; Bock D, 1997, EUR J IMMUNOL, V27, P1522, DOI 10.1002/eji.1830270631; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Dorey M, 1999, BBA-BIOMEMBRANES, V1416, P217, DOI 10.1016/S0005-2736(98)00224-7; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; EMBER JA, 1994, AM J PATHOL, V144, P393; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FoyouziYoussefi R, 1997, BIOCHEM J, V322, P709, DOI 10.1042/bj3220709; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; KLOS A, 1994, FEBS LETT, V344, P79, DOI 10.1016/0014-5793(94)00350-5; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MERY L, 1994, J BIOL CHEM, V269, P3457; MONTZ H, 1991, IMMUNOLOGY, V74, P373; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Naik N, 1997, J CELL SCI, V110, P2381; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; SCHOLZ W, 1990, CLIN IMMUNOL IMMUNOP, V57, P297, DOI 10.1016/0090-1229(90)90043-P; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; Tardif M, 1998, J IMMUNOL, V161, P6885; TARDIF M, 1993, J IMMUNOL, V150, P3534; TRAPAIDZE N, 1996, J BIOL CHEM, V271, P29273; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	49	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1656	1664		10.1074/jbc.275.3.1656	http://dx.doi.org/10.1074/jbc.275.3.1656			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636859	hybrid			2022-12-25	WOS:000084940000022
J	Wilson, TM; Chen, AD; Hsieh, TS				Wilson, TM; Chen, AD; Hsieh, TS			Cloning and characterization of Drosophila topoisomerase III beta - Relaxation of hypernegatively supercoiled DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNERS-SYNDROME GENES; ESCHERICHIA-COLI RECQ; SACCHAROMYCES-CEREVISIAE; HYPER-RECOMBINATION; BLOOMS-SYNDROME; HELICASE; YEAST; SGS1; HOMOLOG; TOP3	We cloned cDNA encoding Drosophila DNA topoisomerase III, The top3 cDNA encodes an 875-amino acid protein, which is nearly 60% identical to mammalian topoisomerase III beta enzymes. Similarity between the Drosophila protein and the topoisomerase III beta s is particularly striking in the carboxyl-terminal region, where all contain eight highly conserved CXXC motifs not found in other topoisomerase III enzymes. We therefore propose the Drosophila protein is a member of the beta-subfamily of topoisomerase III enzymes, The top3 beta gene is a single-copy gene located at 5 E-F on the X chromosome, P-element insertion into the 5'-untranslated region of this gene affects topoisomerase III beta protein levels, but not the overall fertility and viability of the fly. We purified topoisomerase III beta to near homogeneity and observed relaxation activity only with a hypernegatively supercoiled substrate, but not with plasmid DNA directly isolated from bacterial cells. Despite this difference in substrate preference, the degree of relaxation of the hypernegatively supercoiled substrate is comparable to relaxation of plasmid DNA by other type I enzymes. Drosophila topoisomerase III beta forms a covalent linkage to 5' DNA phosphoryl groups, and the DNA cleavage reaction prefers single-stranded substrate over double-stranded, suggesting an affinity of this enzyme for DNA with non-double-helical structure.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	hsieh@biochem.duke.edu	Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012		NIGMS NIH HHS [GM29006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bate M., 1993, DEV DROSOPHILA MELAN, V1; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Goulaouic H, 1999, NUCLEIC ACIDS RES, V27, P2443, DOI 10.1093/nar/27.12.2443; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HIASA H, 1994, J BIOL CHEM, V269, P2093; KIM RA, 1992, J BIOL CHEM, V267, P17178; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kusano K, 1999, GENETICS, V151, P1027; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; LEE MP, 1993, P NATL ACAD SCI USA, V90, P6656, DOI 10.1073/pnas.90.14.6656; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; NOLAN JM, 1986, P NATL ACAD SCI USA, V83, P3664, DOI 10.1073/pnas.83.11.3664; NOLAN JM, 1991, DNA TOPOISOMERASES C, P23; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Rorth P, 1998, DEVELOPMENT, V125, P1049; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Rothstein R, 1995, GENOME RES, V5, P421, DOI 10.1101/gr.5.5.421; SCHOFIELD MA, 1992, J BACTERIOL, V174, P5168, DOI 10.1128/JB.174.15.5168-5170.1992; Seki T, 1998, J BIOL CHEM, V273, P28553, DOI 10.1074/jbc.273.44.28553; Seki T, 1998, BBA-GENE STRUCT EXPR, V1396, P127, DOI 10.1016/S0167-4781(97)00192-9; Shaiu WL, 1998, MOL CELL BIOL, V18, P4358, DOI 10.1128/MCB.18.7.4358; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wang H, 1996, P NATL ACAD SCI USA, V93, P9477, DOI 10.1073/pnas.93.18.9477; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	51	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1533	1540		10.1074/jbc.275.3.1533	http://dx.doi.org/10.1074/jbc.275.3.1533			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636841	hybrid			2022-12-25	WOS:000084940000004
J	Glavy, JS; Wu, SM; Wang, PJ; Orr, GA; Wolkoff, AW				Glavy, JS; Wu, SM; Wang, PJ; Orr, GA; Wolkoff, AW			Down-regulation by extracellular ATP of rat hepatocyte organic anion transport is mediated by serine phosphorylation of oatp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC NA+/TAUROCHOLATE COTRANSPORT; XENOPUS-LAEVIS OOCYTES; MDR1B P-GLYCOPROTEIN; CYCLIC-AMP; DIRECTED KINASES; IDENTIFICATION; EXPRESSION; PROTEIN; MEMBRANE; BRAIN	Recent studies implicate a role in hepatocyte organic anion transport of a plasma membrane protein that has been termed oatp1 (organic anion transport protein 1), Little is known regarding mechanisms by which its transport activity is modulated in vivo, In previous studies (Campbell, C. G., Spray, D, C,, and Wolkoff, A W, (1993) J, BioL Chem. 268, 15399-15404), we demonstrated that hepatocyte uptake of sulfobromophthalein was down-regulated by extracellular ATP, We have now found that extracellular ATP reduces the V-max for transport of sulfobromophthalein by rat hepatocytes; K-m remains unaltered. Reduced transport also results from incubation of hepatocytes with the phosphatase inhibitors okadaic acid and calyculin A. Immunoprecipitation of biotinylated cell surface proteins indicates that oatp1 remains on the cell surface after exposure of cells to ATP or phosphatase inhibitor, suggesting that loss of transport activity is not caused by transporter internalization. Exposure of P-32-loaded hepatocytes to extracellular ATP results in serine phosphorylation of oatp1 with the appearance of a single major tryptic phosphopeptide; oatp1 from control cells is not phosphorylated, This phosphopeptide comigrates with one of four phosphopeptides resulting from incubation of cells with okadaic acid. These studies indicate that the phosphorylation state of oatp1 must be an important consideration when assessing alterations of its functional expression in pathobiological states.	Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Wolkoff, AW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 625 Ullmann Bldg,1300 Morris Pk Ave, Bronx, NY 10461 USA.			Glavy, Joseph/0000-0003-3716-3965	NATIONAL CANCER INSTITUTE [R01CA056677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK023026] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56677] Funding Source: Medline; NIDDK NIH HHS [DK-41296, DK-23026] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; ABRAMOVITZ M, 1988, J BIOL CHEM, V263, P17627; ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; ANGELETTI R, 1999, AM J PHYSIOL, V275, pC882; Angeletti RH, 1997, P NATL ACAD SCI USA, V94, P283, DOI 10.1073/pnas.94.1.283; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMPBELL CG, 1993, J BIOL CHEM, V268, P15399; Coutinho-Silva R, 1997, AM J PHYSIOL-CELL PH, V273, pC1793, DOI 10.1152/ajpcell.1997.273.6.C1793; DIXON CJ, 1990, BIOCHEM J, V269, P499, DOI 10.1042/bj2690499; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; Glavy JS, 1997, J BIOL CHEM, V272, P5909, DOI 10.1074/jbc.272.9.5909; Glavy JS, 1998, METHOD ENZYMOL, V292, P342; GRUNE S, 1993, J BIOL CHEM, V268, P17734; Hagenbuch B, 1996, BIOCHEM J, V316, P901, DOI 10.1042/bj3160901; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JACQUEMIN E, 1991, J CLIN INVEST, V88, P2146, DOI 10.1172/JCI115546; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KELADA ASM, 1992, J BIOL CHEM, V267, P7021; King BF, 1998, TRENDS PHARMACOL SCI, V19, P506, DOI 10.1016/S0165-6147(98)01271-1; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Li DL, 1998, AM J PHYSIOL-RENAL, V275, pF863, DOI 10.1152/ajprenal.1998.275.6.F863; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; Lu R, 1996, AM J PHYSIOL-RENAL, V270, pF332, DOI 10.1152/ajprenal.1996.270.2.F332; Masuda S, 1999, MOL PHARMACOL, V55, P743; Masuda S, 1997, FEBS LETT, V407, P127, DOI 10.1016/S0014-5793(97)00314-1; MIN AD, 1991, J CLIN INVEST, V87, P1496, DOI 10.1172/JCI115159; Mukhopadhyay S, 1998, J BIOL CHEM, V273, P30039, DOI 10.1074/jbc.273.45.30039; Mukhopadhyay S, 1998, HEPATOLOGY, V28, P1629, DOI 10.1002/hep.510280624; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Satlin LM, 1997, J BIOL CHEM, V272, P26340, DOI 10.1074/jbc.272.42.26340; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; Simon FR, 1996, AM J PHYSIOL-GASTR L, V271, pG1043, DOI 10.1152/ajpgi.1996.271.6.G1043; Simon FR, 1999, AM J PHYSIOL-GASTR L, V276, pG556, DOI 10.1152/ajpgi.1999.276.2.G556; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Wolkoff AW, 1996, SEMIN LIVER DIS, V16, P121, DOI 10.1055/s-2007-1007225; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946; [No title captured]	42	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1479	1484		10.1074/jbc.275.2.1479	http://dx.doi.org/10.1074/jbc.275.2.1479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625701	hybrid			2022-12-25	WOS:000084836600105
J	Owhashi, M; Arita, H; Hayai, N				Owhashi, M; Arita, H; Hayai, N			Identification of a novel eosinophil chemotactic cytokine (ECF-L) as a chitinase family protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCYSTING ENTAMOEBA-INVADENS; CC-CHEMOKINE RECEPTOR; NH2-TERMINAL RESIDUES; SCHISTOSOMA-JAPONICUM; GRANULOMA-FORMATION; MOLECULAR-CLONING; CELLS; MICE; EXPRESSION; SEQUENCE	A novel eosinophil chemotactic cytokine (ECF-L) was purified from the culture supernatant of splenocytes of mice by a combination of anion-exchange chromatography, Procion red-agarose affinity chromatography, size exclusion high performance liquid chromatography (HPLC), and reverse phase HPLC. The NH2-terminal amino acid sequence was determined by direct protein sequencing. An ECF-L cDNA clone of 1,506 nucleotides was isolated from a cDNA library, and the nucleotide sequence predicted a mature protein of 397 amino acids. A recombinant ECF-L showed a level of eosinophil chemotactic activity comparable with that of natural ECF-L, and the activity was inhibited by a monoclonal antibody to ECF-L. ECF-L also attracted T lymphocytes and bone marrow polymorphonuclear leukocytes in vitro, whereas it caused selective extravasation of eosinophils in vivo. ECF-L mRNA was highly expressed in spleen, bone marrow, lung, and heart. A comprehensive GenBank data base search revealed that ECF-L is a chitinase family protein, ECF-L retains those amino acids highly conserved among chitinase family proteins, but Asp and Glu residues essential for the proton donation in hydrolysis were replaced by Asn and Gin, respectively. Although ECF-L contains a consensus CXC sequence near the NH, terminus akin to chemokine family proteins, the rest of ECF-L shows poor homology with chemokines.	Univ Tokushima, Fac Integrated Arts & Sci, Tokushima 7708502, Japan	Tokushima University	Owhashi, M (corresponding author), Univ Tokushima, Fac Integrated Arts & Sci, Tokushima 7708502, Japan.							ARIAS EB, 1994, BIOL REPROD, V51, P685, DOI 10.1095/biolreprod51.4.685; BASS DA, 1979, J CLIN INVEST, V64, P1415, DOI 10.1172/JCI109599; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOROS DL, 1970, J EXP MED, V132, P488, DOI 10.1084/jem.132.3.488; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; Coffey MJ, 1997, AM J PHYSIOL-LUNG C, V272, pL1025, DOI 10.1152/ajplung.1997.272.5.L1025; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DAS S, 1991, BIOCHEM J, V280, P641, DOI 10.1042/bj2800641; FUHRMAN JA, 1992, P NATL ACAD SCI USA, V89, P1548, DOI 10.1073/pnas.89.5.1548; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HAMANN KJ, 1990, J IMMUNOL, V144, P3166; HART GW, 1979, J BIOL CHEM, V254, P9747; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; IWHASHI M, 1994, CURR TOPICS VET RES, V1, P37; KENIGSBERG RL, 1991, J IMMUNOL METHODS, V136, P247, DOI 10.1016/0022-1759(91)90011-4; KINASHI T, 1986, NATURE, V324, P70, DOI 10.1038/324070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITT M, 1963, AM J PATHOL, V42, P529; MARUYAMA H, 1991, EXP HEMATOL, V19, P77; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; MORRISON BW, 1994, ONCOGENE, V9, P3417; Owhashi M, 1996, INT J PARASITOL, V26, P705, DOI 10.1016/0020-7519(96)00054-9; Owhashi M, 1998, PARASITOL RES, V84, P136, DOI 10.1007/s004360050370; OWHASHI M, 1986, INT ARCH ALLER A IMM, V81, P129, DOI 10.1159/000234121; OWHASHI M, 1987, INT ARCH ALLER A IMM, V83, P290, DOI 10.1159/000234310; OWHASHI M, 1982, J IMMUNOL, V129, P226; PAQUETTE Y, 1995, MOL REPROD DEV, V42, P388, DOI 10.1002/mrd.1080420404; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; RAMALHOPINTO FJ, 1978, J EXP MED, V147, P147, DOI 10.1084/jem.147.1.147; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rotman HL, 1996, EXP PARASITOL, V82, P267, DOI 10.1006/expr.1996.0034; SAMAC DA, 1994, PLANT MOL BIOL, V25, P587, DOI 10.1007/BF00029598; SCHALL TJ, 1992, EUR J IMMUNOL, V22, P1477, DOI 10.1002/eji.1830220621; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; SPINDLER KD, 1990, PARASITOL RES, V76, P283, DOI 10.1007/BF00928180; SPRY CJF, 1971, CELL TISSUE KINET, V4, P351, DOI 10.1111/j.1365-2184.1971.tb01545.x; SPRY CJF, 1971, CELL TISSUE KINET, V4, P365, DOI 10.1111/j.1365-2184.1971.tb01546.x; SUGANE K, 1982, PARASITE IMMUNOL, V4, P307, DOI 10.1111/j.1365-3024.1982.tb00442.x; TODD KS, 1978, LAB ANIM, V12, P51, DOI 10.1258/002367778780953099; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanScheltinga ACT, 1996, J MOL BIOL, V262, P243, DOI 10.1006/jmbi.1996.0510; VILLAGOMEZCASTRO JC, 1992, MOL BIOCHEM PARASIT, V52, P53, DOI 10.1016/0166-6851(92)90035-I; WARREN KS, 1975, AM J PATHOL, V80, P279; WATANABE T, 1993, J BIOL CHEM, V268, P18567	51	109	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1279	1286		10.1074/jbc.275.2.1279	http://dx.doi.org/10.1074/jbc.275.2.1279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625674	hybrid			2022-12-25	WOS:000084836600078
J	Harris, RM; Waring, RH; Kirk, CJ; Hughes, PJ				Harris, RM; Waring, RH; Kirk, CJ; Hughes, PJ			Sulfation of "estrogenic" alkylphenols and 17 beta-estradiol by human platelet phenol sulfotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOSOLIC SULFOTRANSFERASES; TROUT ONCORHYNCHUS-MYKISS; CANCER CELL-LINES; ARYL SULFOTRANSFERASE; BREAST-CANCER; ENVIRONMENTAL ESTROGENS; EPITHELIAL-CELLS; HUMAN LIVER; EXPRESSION; NONYLPHENOL	We have investigated the ability of alkylphenols to act as substrates and/or inhibitors of phenol sulfotransferase enzymes in human platelet cytosolic fractions. Our results indicate: (i) straight chain alkylphenols do not interact with the monoamine-sulfating phenol sulfotransferase (SULT1A3); (ii) short chain 4-n-alkylphenols (C < 8) are substrates for the phenol-sulfating enzymes (SULT1A1/2), which exhibit two activity maxima against substrates with alkyl chain lengths of C1-2 and C4-5; (iii) long chain 4-n-substituted alkylphenols (C greater than or equal to 8) are poor substrates and act as inhibitors of SULT1A1/2; (iv) human platelets contain two activities, of low and high affinity, capable of sulfating 17 beta-estradiol, and 4-n-nonylphenol is a partial mixed inhibitor of the low affinity form of this activity. We conclude that by acting either as substrates or inhibitors of SULT1A1/2, alkylphenols may influence the sulfation, and hence the excretion, of estrogens and other phenol sulfotransferase substrates in humans.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Kirk, CJ (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	C.J.Kirk@bham.ac.uk		Waring, Rosemary/0000-0001-6617-5856				ANDERSON C, 1977, BIOCHEMISTRY-US, V36, P2586; ANDERSON RJ, 1980, CLIN CHIM ACTA, V103, P79, DOI 10.1016/0009-8981(80)90233-8; Ashby J, 1997, REGUL TOXICOL PHARM, V26, P102, DOI 10.1006/rtph.1997.1159; Baldwin WS, 1998, ECOTOX ENVIRON SAFE, V39, P104, DOI 10.1006/eesa.1997.1614; BORTHWICK EB, 1993, BIOCHEM J, V289, P719, DOI 10.1042/bj2890719; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Certa H, 1996, ARCH TOXICOL, V71, P112, DOI 10.1007/s002040050365; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; Coughtrie MWH, 1998, CHEM-BIOL INTERACT, V109, P3, DOI 10.1016/S0009-2797(97)00117-8; CRUICKSHANK D, 1993, EUR J PHARM SCI, V1, P41, DOI 10.1016/0928-0987(93)90016-4; Cunny HC, 1997, REGUL TOXICOL PHARM, V26, P172, DOI 10.1006/rtph.1997.1154; DAJANI A, 1988, MOL PHARM, V54, P942; DAO TL, 1971, NATL CANCER I MONOGR, P205; DUFFEL MW, 1981, J BIOL CHEM, V256, P1123; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; FALANY CN, 1994, J STEROID BIOCHEM, V48, P369, DOI 10.1016/0960-0760(94)90077-9; Falany JL, 1996, CANCER RES, V56, P1551; FALANY JL, 1993, J STEROID BIOCHEM, V46, P481, DOI 10.1016/0960-0760(93)90102-3; FOLDES A, 1983, BIOCHIM BIOPHYS ACTA, V327, P365; FROMM HJ, 1975, INITIAL RATE ENZYME, P145; GANMO A, 1989, ENVIRON POLLUT, V59, P115; Harris RM, 1998, GUT, V42, P272, DOI 10.1136/gut.42.2.272; HERNANDEZ JS, 1992, DRUG METAB DISPOS, V20, P413; Hosea NA, 1998, ARCH BIOCHEM BIOPHYS, V353, P365, DOI 10.1006/abbi.1998.0659; JONES AL, 1992, EARLY HUM DEV, V28, P65, DOI 10.1016/0378-3782(92)90007-4; Kloas W, 1999, SCI TOTAL ENVIRON, V225, P59, DOI 10.1016/S0048-9697(98)00332-5; Le Bail JC, 1998, ANTICANCER RES, V18, P1683; Lee PC, 1998, TOXICOL LETT, V99, P117, DOI 10.1016/S0378-4274(98)00153-2; Lutz I, 1999, SCI TOTAL ENVIRON, V225, P49, DOI 10.1016/S0048-9697(99)80016-3; Majdic G, 1996, ENDOCRINOLOGY, V137, P1063, DOI 10.1210/en.137.3.1063; Meldahl AC, 1996, XENOBIOTICA, V26, P1167, DOI 10.3109/00498259609050261; Miller WR, 1998, ENDOCR-RELAT CANCER, V5, P69, DOI 10.1677/erc.0.0050069; MILLINGTON DS, 1975, J STEROID BIOCHEM, V6, P239, DOI 10.1016/0022-4731(75)90139-9; Muller S, 1998, PURE APPL CHEM, V70, P1847, DOI 10.1351/pac199870091847; Nagel SC, 1999, J STEROID BIOCHEM, V69, P343, DOI 10.1016/S0960-0760(99)00078-3; Odum J, 1999, REGUL TOXICOL PHARM, V29, P184, DOI 10.1006/rtph.1999.1286; OZAWA S, 1995, PHARMACOGENETICS, V5, pS135, DOI 10.1097/00008571-199512001-00015; PASQUALINI JR, 1989, J STEROID BIOCHEM, V34, P155, DOI 10.1016/0022-4731(89)90077-0; Pennie WD, 1998, J ENDOCRINOL, V158, pR11, DOI 10.1677/joe.0.158R011; PURHOIT A, 1999, J STEROID BIOCHEM, V68, P129; Qian YM, 1998, J PHARMACOL EXP THER, V286, P555; Routledge EJ, 1997, J BIOL CHEM, V272, P3280, DOI 10.1074/jbc.272.6.3280; Roy D, 1997, J TOXICOL ENV HEALTH, V50, P1, DOI 10.1080/009841097160573; RUDER HJ, 1972, J CLIN INVEST, V51, P1020, DOI 10.1172/JCI106862; SAGE SO, 1990, J PHYSIOL-LONDON, V420, P31, DOI 10.1113/jphysiol.1990.sp017900; SANTNER SJ, 1984, J CLIN ENDOCR METAB, V59, P29, DOI 10.1210/jcem-59-1-29; Saunders PTK, 1997, ADV EXP MED BIOL, V424, P99; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1333S, DOI 10.1093/ajcn/68.6.1333S; Sharpe RM, 1998, BIOL REPROD, V59, P1084, DOI 10.1095/biolreprod59.5.1084; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Sumpter JP, 1998, TOXICOL LETT, V103, P337, DOI 10.1016/S0378-4274(98)00328-2; Tabira Y, 1999, EUR J BIOCHEM, V262, P240, DOI 10.1046/j.1432-1327.1999.00422.x; Thibaut R, 1998, XENOBIOTICA, V28, P745, DOI 10.1080/004982598239164; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; Tran DQ, 1996, BIOCHEM BIOPH RES CO, V229, P518, DOI 10.1006/bbrc.1996.1836; US Environmental Protection Agency, 1998, END DISR SCREEN TEST; Utsumi T, 1999, CANCER RES, V59, P377; WALLE T, 1995, BIOCHEM PHARMACOL, V50, P731, DOI 10.1016/0006-2952(95)00190-B; Zhang HP, 1998, J BIOL CHEM, V273, P10888, DOI 10.1074/jbc.273.18.10888; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1; Zhu XY, 1996, INT J BIOCHEM CELL B, V28, P565, DOI 10.1016/1357-2725(95)00164-6; Zou EM, 1999, ECOTOX ENVIRON SAFE, V42, P185, DOI 10.1006/eesa.1998.1740	62	55	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					159	166		10.1074/jbc.275.1.159	http://dx.doi.org/10.1074/jbc.275.1.159			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617600	hybrid			2022-12-25	WOS:000085951600024
J	Liao, DF; Jin, ZG; Baas, AS; Daum, G; Gygi, SP; Aebersold, R; Berk, BC				Liao, DF; Jin, ZG; Baas, AS; Daum, G; Gygi, SP; Aebersold, R; Berk, BC			Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ANGIOTENSIN-II; MAP KINASES; PROTEIN; ACTIVATION; PATHWAY; PROLIFERATION; CYCLOPHILIN; APOPTOSIS; STIMULATION	Reactive oxygen species have been implicated in the pathogenesis of atherosclerosis and hypertension, in part by promoting vascular smooth muscle cell (VSMC) growth, We have previously shown that LY83583, a generator of O-2(.-), activated extracellular signal-regulated kinases (ERK1/2) with early (10 min) and late (2 h) peaks and stimulated VSMC growth. To investigate whether secreted oxidative stress-induced factors (termed SOXF) from VSMC were responsible for late ERK1/2 activation in response to LY83583, we purified putative SOXF proteins from conditioned medium (2 h of LY83583 exposure) by sequential chromatography based on activation of ERK1/2. Proteins identified by capillary chromatography, electrospray ionization tandem mass spectrometry, and data base searching included heat shock protein 90-alpha: (HSP90-alpha) and cyclophilin B, Western blot analysis of conditioned medium showed specific secretion of HSP90-alpha but not HSP90-beta, Immunodepletion of HSP90-alpha from conditioned medium significantly inhibited conditioned medium-induced ERK1/2 activation. Human recombinant HSP90-alpha reproduced the effect of conditioned medium on ERK1/2 activation. These results show that brief oxidative stress causes sustained release of protein factors from VSMC that can stimulate ERK1/2. These factors may be important mediators for the effects of reactive oxygen species on vascular function.	Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Rochester; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Berk, BC (corresponding author), Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009027, P01HL018645, R01HL049192] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49192, HL18645, F32 HL09027] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Billich A, 1997, J EXP MED, V185, P975, DOI 10.1084/jem.185.5.975; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARONI P, 1991, J BIOL CHEM, V266, P10739; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Griendling KK, 1998, J LAB CLIN MED, V132, P9, DOI 10.1016/S0022-2143(98)90019-1; Griendling KK, 1997, CIRCULATION, V96, P3264; GYI SP, 1999, MOL CELL BIOL, V19, P1720; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Liu GB, 1997, ARTERIOSCL THROM VAS, V17, P1251, DOI 10.1161/01.ATV.17.7.1251; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; NAKAMURA Y, 1995, BIOCHEM BIOPH RES CO, V215, P483, DOI 10.1006/bbrc.1995.2490; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SUGO S, 1994, BIOCHEM BIOPH RES CO, V203, P719, DOI 10.1006/bbrc.1994.2241; Tsai JC, 1996, J BIOL CHEM, V271, P3667; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223	27	218	236	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					189	196		10.1074/jbc.275.1.189	http://dx.doi.org/10.1074/jbc.275.1.189			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617604	hybrid			2022-12-25	WOS:000085951600028
J	Lyall, F; Barber, A; Myatt, L; Bulmer, JN; Robson, SC				Lyall, F; Barber, A; Myatt, L; Bulmer, JN; Robson, SC			Hemeoxygenase expression in human placenta and placental bed implies a role in regulation of trophoblast invasion and placental function	FASEB JOURNAL			English	Article						pregnancy; spiral artery; HO-1; H0-2; protoporphyrin	NITRIC-OXIDE SYNTHASE; HEME OXYGENASE INHIBITORS; FETAL GROWTH-RETARDATION; HSP32 MESSENGER-RNA; CARBON-MONOXIDE; SPIRAL ARTERIES; BLOOD-FLOW; PREGNANCY; RAT; PROTEIN	The purpose of this study was to examine the expression of hemeoxygenases HO-1 and HO-2, which are responsible for the production of carbon monoxide (CO), in the human placenta and placental bed and to determine the role of inhibitors of HO on placental perfusion pressure. We hypothesized that HO is expressed within the placenta and that invading cytotrophoblast cells (CTB) express HO isoforms. The expression of HO-1 and HO-2 was studied on placenta and placental bed biopsies, obtained using a transcervical sampling technique, from normal human pregnancies between 8 and 19 wk gestation and at term. in the placenta, HO-2 immunostaining was prominent in syncytiotrophoblast in the first trimester and reduced toward term (P<0.0005). HO-2 endothelial immunostaining was weak in the first trimester, but increased by term (P<0.0005). Within the placental bed, HO-2 was expressed by CTB in cell columns, the cytotrophoblast shell, and cell islands. Both intravascular CTB and interstitial CTB expressed HO-2. HO-1 immunostaining was low in the placenta but intense on the CTB within the placental bed. A striking feature was the absence of HO-1 from the proximal layers of cell columns, with strong expression on the more distal CTB layers of the cell columns. in placental perfusion studies, a significant dose-dependent increase in perfusion pressure was observed in the presence of zinc protoporphyrin, an inhibitor of HO. These results suggest a role for CO in placental function, trophoblast invasion, and spiral artery transformation. Hemeoxygenase expression in human placenta and placental bed implies a role in regulation of trophoblast invasion and placental function.	Inst Med Genet, Maternal & Fetal Med Sect, Glasgow G3 8SJ, Lanark, Scotland; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA; Univ Newcastle Upon Tyne, Royal Victoria Infirm, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	University of Glasgow; University System of Ohio; University of Cincinnati; Newcastle University - UK	Lyall, F (corresponding author), Inst Med Genet, Maternal & Fetal Med Sect, Glasgow G3 8SJ, Lanark, Scotland.							Barber A, 1999, AM J PATHOL, V155, P831, DOI 10.1016/S0002-9440(10)65182-6; BLANKENSHIP TN, 1993, CELL TISSUE RES, V274, P135, DOI 10.1007/BF00327994; BOURA ALA, 1994, CLIN EXP PHARMACOL P, V21, P737, DOI 10.1111/j.1440-1681.1994.tb02441.x; BROSENS I, 1967, J PATHOL BACTERIOL, V93, P569, DOI 10.1002/path.1700930218; BROSENS IA, 1977, CLIN OBSTET GYNAECOL, V4, P573; Chakder S, 1996, J PHARMACOL EXP THER, V277, P1376; Conrad KP, 1995, PLACENTA, V16, P691, DOI 10.1016/0143-4004(95)90013-6; CONRAD KP, 1993, FASEB J, V7, P1269, DOI 10.1096/fasebj.7.13.7691671; Craven CM, 1998, PLACENTA, V19, P241, DOI 10.1016/S0143-4004(98)90055-8; CRUSE I, 1988, J BIOL CHEM, V263, P2348; DEWOLF F, 1973, AM J OBSTET GYNECOL, V117, P833, DOI 10.1016/0002-9378(73)90500-0; DEWOLF F, 1980, BRIT J OBSTET GYNAEC, V87, P177; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; GAILLARD DA, 1993, ARCH PATHOL LAB MED, V117, P1022; GLANCE DG, 1984, AM J OBSTET GYNECOL, V149, P450, DOI 10.1016/0002-9378(84)90161-3; GUDE NM, 1990, LANCET, V336, P1589, DOI 10.1016/0140-6736(90)93374-X; HAXTON MJ, 1983, BRIT J OBSTET GYNAEC, V90, P501, DOI 10.1111/j.1471-0528.1983.tb08955.x; HUSTIN J, 1990, PLACENTA, V11, P477, DOI 10.1016/S0143-4004(05)80193-6; JAUNIAUX E, 1994, HUM REPROD, V9, P2432, DOI 10.1093/oxfordjournals.humrep.a138465; JOHNSON RA, 1995, HYPERTENSION, V25, P166, DOI 10.1161/01.HYP.25.2.166; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; KHONG TY, 1987, BRIT J OBSTET GYNAEC, V94, P649, DOI 10.1111/j.1471-0528.1987.tb03169.x; KHONG TY, 1995, FETUS NEONATE, V3; Kingdom J, 1998, PLACENTA, V19, P347, DOI 10.1016/S0143-4004(98)90073-X; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; KUTTY RK, 1989, ARCH BIOCHEM BIOPHYS, V268, P100, DOI 10.1016/0003-9861(89)90569-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERE RD, 1993, AM J HEMATOL, V43, P19, DOI 10.1002/ajh.2830430106; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNELL NO, 1979, GYNECOL OBSTET INVES, V10, P106, DOI 10.1159/000299924; Lyall F, 1999, AM J PATHOL, V154, P1105, DOI 10.1016/S0002-9440(10)65363-1; MAINES MD, 1993, MOL CELL NEUROSCI, V4, P389, DOI 10.1006/mcne.1993.1049; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; MAINES MD, 1988, FASEB J, V2, P2257; Mancuso C, 1997, MOL BRAIN RES, V45, P294, DOI 10.1016/S0169-328X(96)00258-6; MANSOURI A, 1982, THROMB HAEMOSTASIS, V48, P286; MCFADYEN IR, 1986, BRIT J OBSTET GYNAEC, V93, P476, DOI 10.1111/j.1471-0528.1986.tb07933.x; MCFAUL SJ, 1987, TOXICOL APPL PHARM, V87, P464, DOI 10.1016/0041-008X(87)90252-3; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; MICHEL MZ, 1990, BRIT J OBSTET GYNAEC, V97, P984, DOI 10.1111/j.1471-0528.1990.tb02468.x; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; MUHLHAUSER J, 1995, J HISTOCHEM CYTOCHEM, V43, P579, DOI 10.1177/43.6.7539466; MYATT L, 1993, PLACENTA, V14, P487, DOI 10.1016/S0143-4004(05)80202-4; MYATT L, 1992, AM J OBSTET GYNECOL, V166, P224, DOI 10.1016/0002-9378(92)91863-6; MYATT L, 1993, PLACENTA, V14, P373, DOI 10.1016/S0143-4004(05)80459-X; MYATT L, 1991, AM J OBSTET GYNECOL, V164, P687, DOI 10.1016/S0002-9378(11)80047-5; MYATT L, 1992, PLACENTA, V13, P1; Ni X, 1997, J CLIN ENDOCR METAB, V82, P4171, DOI 10.1210/jc.82.12.4171; Odrcich MJ, 1998, PLACENTA, V19, P509, DOI 10.1016/S0143-4004(98)91044-X; PIJNENBORG R, 1991, BRIT J OBSTET GYNAEC, V98, P648, DOI 10.1111/j.1471-0528.1991.tb13450.x; PIJNENBORG R, 1983, PLACENTA, V4, P397, DOI 10.1016/S0143-4004(83)80043-5; PIJNENBORG R, 1980, PLACENTA, V1, P3, DOI 10.1016/S0143-4004(80)80012-9; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; SCHNEIDER H, 1991, PLACENTAL TOXICOLOGY, P1; Serfas L, 1998, ARCH BIOCHEM BIOPHYS, V359, P8, DOI 10.1006/abbi.1998.0887; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; SHEPPARD BL, 1976, BRIT J OBSTET GYNAEC, V83, P948, DOI 10.1111/j.1471-0528.1976.tb00781.x; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; TRAKSHEL GM, 1989, J BIOL CHEM, V264, P1323; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Vreman HJ, 1996, CAN J PHYSIOL PHARM, V74, P278, DOI 10.1139/cjpp-74-3-278; WIECZOREK KM, 1995, AM J OBSTET GYNECOL, V173, P708, DOI 10.1016/0002-9378(95)90327-5; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	64	123	133	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					208	219		10.1096/fasebj.14.1.208	http://dx.doi.org/10.1096/fasebj.14.1.208			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627295				2022-12-25	WOS:000084784700023
J	Bachand, F; Autexier, C				Bachand, F; Autexier, C			Functional reconstitution of human telomerase expressed in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; REVERSE-TRANSCRIPTASE; TETRAHYMENA TELOMERASE; YEAST TELOMERASE; RNA COMPONENT; CANCER; OVEREXPRESSION; TEMPLATE; COMPLEX; PROTEIN	Telomerase is a ribonucleoprotein enzyme complex that adds DNA repeats at the ends of chromosomes. In an effort to establish an in vivo heterologous expression system for active human telomerase, we expressed human telomerase reverse transcriptase (hTERT) in Saccharomyces cerevisiae and affinity-purified the protein as a fusion with glutathione S-transferase (GST). Addition of the GST moiety to the N terminus of hTERT did not interfere with telomerase activity when GST-hTERT was expressed in rabbit reticulocyte lysate (RRL) in the presence of the human telomerase RNA (hTR). Active human telomerase was immunoprecipitated from yeast lysates that co-expressed GST-hTERT and hTR. In addition, telomerase activity could be reconstituted in vitro by the addition of HTR to GST-hTERT that was immunoprecipitated from either RRL or S. cerevisiae lysates. The expression and reconstitution of human telomerase activity in yeast will provide powerful biochemical and genetic tools to study the various components required for the assembly and function of this enzyme.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	Lady Davis Institute; McGill University; McGill University	Autexier, C (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Chemin Cote Ste, Montreal, PQ H3T 1E2, Canada.							Ausubel FM, 1998, CURRENT PROTOCOLS MO; AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Dubois N, 1998, MICROBIOL-SGM, V144, P2299, DOI 10.1099/00221287-144-8-2299; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Henning KA, 1998, P NATL ACAD SCI USA, V95, P5667, DOI 10.1073/pnas.95.10.5667; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Licht JD, 1999, GENE DEV, V13, P1116, DOI 10.1101/gad.13.9.1116; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; O'Reilly Marc, 1999, Current Opinion in Structural Biology, V9, P56, DOI 10.1016/S0959-440X(99)80008-6; Pardue ML, 1999, CHROMOSOMA, V108, P73, DOI 10.1007/s004120050354; Reddel RR, 1998, BIOESSAYS, V20, P977, DOI 10.1002/(SICI)1521-1878(199812)20:12<977::AID-BIES3>3.0.CO;2-E; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498	31	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38027	38031		10.1074/jbc.274.53.38027	http://dx.doi.org/10.1074/jbc.274.53.38027			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608871	hybrid			2022-12-25	WOS:000084528000071
J	Brewer, A; Gove, C; Davies, A; McNulty, C; Barrow, D; Koutsourakis, M; Farzaneh, F; Pizzey, J; Bomford, A; Patient, R				Brewer, A; Gove, C; Davies, A; McNulty, C; Barrow, D; Koutsourakis, M; Farzaneh, F; Pizzey, J; Bomford, A; Patient, R			The human and mouse GATA-6 genes utilize two promoters and two initiation codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; IN-SITU HYBRIDIZATION; TRANSLATION INITIATION; REGULATORY ELEMENTS; EXPRESSION; EMBRYOS; XENOPUS; CELLS; DIFFERENTIATION; BINDING	GATA-6 has been implicated in the regulation of myocardial differentiation during cardiogenesis. To determine how its expression is controlled, we have characterized the human and mouse genes. We have mapped their transcriptional start sites and demonstrate that two alternative promoters and 5' noncoding exons are utilized. Both transcript isoforms are expressed in the same tissue-specific and developmental stage-specific pattern, and their ratio appears similar wherever examined. The more upstream noncoding exon showed a substantial degree of homology between the two mammalian species, suggesting a conserved regulatory function. Moreover, in transfection assays we show that elements within this exon act to promote its transcription. Positive regulatory elements that effect transcription from the more downstream exon were not apparent in this assay, revealing a regulatory distinction between the two promoters. We also demonstrate alternative initiator codon usage in both the human and mouse GATA-6 genes. Both isoforms of the protein are synthesized in vitro regardless of which 5' noncoding exon is present in the RNA, although the larger protein has greater transcriptional activation potential in transfection assays. Thus, GATA-6 function in the cell is controlled by a complex interplay of transcriptional and translational regulation.	GKT, Rayne Inst, Dept Mol Med, London SE5 9NU, England; Kings Coll London, Randall Inst, Dev Biol Res Ctr, London WC2B 5RL, England; GKT, Inst Liver Studies, London SE5 9PJ, England; Erasmus Univ, Ctr Med Genet, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	University of London; King's College London; University of London; King's College London; University of London; King's College London; Erasmus University Rotterdam	Patient, R (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England.	roger.patient@nottingham.ac.uk	Farzaneh, Farzin/B-4902-2009; Bomford, Adrian/A-7462-2011; McNulty, Claire/AAJ-6898-2021	Farzaneh, Farzin/0000-0002-9275-2415; McNulty, Claire/0000-0001-8359-2061				Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BARTH J, 1994, BIOTECHNIQUES, V17, P324; Baskin F, 1997, NEUROSCIENCE, V76, P821; BREWER AC, 1995, EMBO J, V14, P757, DOI 10.1002/j.1460-2075.1995.tb07054.x; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GHERZI R, 1995, FEBS LETT, V369, P335, DOI 10.1016/0014-5793(95)00778-8; GHOSH D, 1983, TRANSCRIPTION FACTOR; Gove C, 1997, EMBO J, V16, P355, DOI 10.1093/emboj/16.2.355; He CZ, 1997, J BIOL CHEM, V272, P28550, DOI 10.1074/jbc.272.45.28550; Hu ZZ, 1998, J BIOL CHEM, V273, P26225, DOI 10.1074/jbc.273.40.26225; Huggon IC, 1997, BBA-GENE STRUCT EXPR, V1353, P98, DOI 10.1016/S0167-4781(97)00049-3; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jiang HL, 1999, J BIOL CHEM, V274, P7893, DOI 10.1074/jbc.274.12.7893; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; Jiang YM, 1998, DEV GENET, V22, P263, DOI 10.1002/(SICI)1520-6408(1998)22:3<263::AID-DVG8>3.0.CO;2-4; Korner I, 1997, FEBS LETT, V406, P31, DOI 10.1016/S0014-5793(97)00229-9; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KURATA H, 1992, FEBS LETT, V312, P10, DOI 10.1016/0014-5793(92)81400-G; LABASTIE MC, 1994, GENOMICS, V21, P1, DOI 10.1006/geno.1994.1217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN WJ, 1993, HUMAN EMBRYOLOGY, P131; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEONARD L, 1995, DEV BIOL, V168, P514, DOI 10.1006/dbio.1995.1099; LEONARD MW, 1993, DEVELOPMENT, V119, P519; Lieuw KH, 1997, DEV BIOL, V188, P1, DOI 10.1006/dbio.1997.8575; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; Maniatis T., 1982, MOL CLONING LAB MANU; McGlynn LK, 1996, MOL CELL BIOL, V16, P1936; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; Mu WT, 1999, MOL BRAIN RES, V67, P137, DOI 10.1016/S0169-328X(99)00049-2; Nony P, 1998, J BIOL CHEM, V273, P32910, DOI 10.1074/jbc.273.49.32910; OKEEFE HP, 1991, METHOD CELL BIOL, V36, P443; Onodera K, 1997, J BIOCHEM, V121, P251; ORKIN SH, 1992, BLOOD, V80, P575; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PISCHEDDA C, 1995, P NATL ACAD SCI USA, V92, P3511, DOI 10.1073/pnas.92.8.3511; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; Read EM, 1998, INT J DEV BIOL, V42, P763; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SAIFUDEEN Z, 1995, FEBS LETT, V381, P269; Sambrook J., 2002, MOL CLONING LAB MANU; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	59	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38004	38016		10.1074/jbc.274.53.38004	http://dx.doi.org/10.1074/jbc.274.53.38004			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608869	hybrid			2022-12-25	WOS:000084528000069
J	Bronnikov, GE; Zhang, SJ; Cannon, B; Nedergaard, J				Bronnikov, GE; Zhang, SJ; Cannon, B; Nedergaard, J			A dual component analysis explains the distinctive kinetics of cAMP accumulation in brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN THERMOGENIN; BETA-GAMMA-SUBUNITS; FAT-CELLS; ADIPOSE-TISSUE; ADENYLYL CYCLASE; GENE-EXPRESSION; STIMULATION; CULTURE; RAT; NOREPINEPHRINE	The mechanism behind the distinctive non-Michaelis-Menten, bell-shaped kinetics of cAMP accumulation in brown adipocytes (which underlies the similar kinetics of UCP1 and beta(1)-adrenoreceptor gene expression) was investigated. A theoretical dual component analysis indicated that the observed dose-response curves could be constructed as the resultant of a stimulatory and an inhibitory component. Experimentally, inhibition of the alpha(1)-component of the norepinephrine response revealed the underlying existence of a much larger stimulatory beta(3)-component which displayed monophasic Michaelis-Menten kinetics. The inhibitory alpha(1)-component (which was also monophasic but had a S-fold higher EC50) was mediated via an increase in [Ca2+](i); the protein kinase C pathway was not involved. The [Ca2+](i) increase which resulted in massive inhibition of cAMP accumulation was very low: <100 nM The [Ca2+](i) signal stimulated a calmodulin-controlled phosphodiesterase, possibly PDE-1. The acquirement of this specific interaction pattern between beta- and alpha(1)-adrenergic stimulation was thus part of the differentiation program of the brown adipocytes. It was concluded that an array of synergistic or inhibitory alpha(1)/beta interactions occur in the adrenergic regulation of this cell type which is unique in its dependence upon adrenergic stimulation for cellular proliferation, differentiation, and metabolic function.	Univ Stockholm, Arrhenius Lab F3, Wenner Gren Inst, S-10691 Stockholm, Sweden	Stockholm University	Nedergaard, J (corresponding author), Univ Stockholm, Arrhenius Lab F3, Wenner Gren Inst, S-10691 Stockholm, Sweden.	jan@metabol.su.se	Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Cannon, Barbara/B-3089-2016	Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				BARGE RM, 1988, AM J PHYSIOL, V254, pE323, DOI 10.1152/ajpendo.1988.254.3.E323; BAZIN R, 1997, KEYSTONE S J, V3, P22; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bengtsson T, 1996, J BIOL CHEM, V271, P33366, DOI 10.1074/jbc.271.52.33366; BENGTSSON T, 1998, BETAADRENERGIC RECEP; BERMAN MI, 1987, ARCH BIOCHEM BIOPHYS, V253, P249, DOI 10.1016/0003-9861(87)90658-8; Bronnikov G, 1999, ENDOCRINOLOGY, V140, P4185, DOI 10.1210/en.140.9.4185; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; CHAUDHRY A, 1994, CELL SIGNAL, V6, P457, DOI 10.1016/0898-6568(94)90093-0; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1892; Degerman E, 1998, METHODS, V14, P43, DOI 10.1006/meth.1997.0564; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; GRANNEMAN JG, 1990, J PHARMACOL EXP THER, V254, P508; Granneman JG, 1997, MOL PHARMACOL, V51, P644, DOI 10.1124/mol.51.4.644; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERRON D, 1990, FEBS LETT, V268, P296, DOI 10.1016/0014-5793(90)81031-I; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KikuchiUtsumi K, 1997, BIOCHEM J, V322, P417, DOI 10.1042/bj3220417; KLAUS S, 1995, MOL CELL ENDOCRINOL, V109, P189, DOI 10.1016/0303-7207(95)03502-X; KOIVISTO A, 1997, THESIS STOCKHOLM U S; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; Kuusela P, 1997, BIOCHEM J, V321, P759, DOI 10.1042/bj3210759; LEE SC, 1993, AM J PHYSIOL, V264, pC217, DOI 10.1152/ajpcell.1993.264.1.C217; Lindquist JM, 1998, J BIOL CHEM, V273, P30147, DOI 10.1074/jbc.273.46.30147; MANGANIELLO V, 1988, METHOD ENZYMOL, V159, P504; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MANGANIELLO VC, 1990, CYCLIC NUCLEOTIDE PH; MASON MJ, 1993, BIOCHEM J, V296, P33, DOI 10.1042/bj2960033; MOHELL N, 1987, AM J PHYSIOL, V253, pC301, DOI 10.1152/ajpcell.1987.253.2.C301; Nagaoka Tadasu, 1998, Cell Biochemistry and Biophysics, V29, P49, DOI 10.1007/BF02737828; NANBERG E, 1986, FEBS LETT, V195, P319, DOI 10.1016/0014-5793(86)80185-5; NANBERG E, 1987, BIOCHIM BIOPHYS ACTA, V930, P438, DOI 10.1016/0167-4889(87)90017-6; NECHAD M, 1983, EXP CELL RES, V149, P105, DOI 10.1016/0014-4827(83)90384-1; NISOLI E, 1995, ARCH INT PHARMACOD T, V329, P436; NORONHA M, 1991, METABOLISM, V40, P1327, DOI 10.1016/0026-0495(91)90038-X; RAASMAJA A, 1985, EUR J PHARMACOL, V106, P489; RASMUSSEN H, 1977, PHYSIOL REV, V57, P421, DOI 10.1152/physrev.1977.57.3.421; RASMUSSEN H, 1992, CIBA F SYMP, V164, P98; REHNMARK S, 1989, EXP CELL RES, V182, P75, DOI 10.1016/0014-4827(89)90280-2; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROVATI GE, 1994, TRENDS PHARMACOL SCI, V15, P140, DOI 10.1016/0165-6147(94)90073-6; Strosberg AD, 1995, OBES RES, V3, pS501, DOI 10.1002/j.1550-8528.1995.tb00219.x; SVOBODA P, 1993, BIOCHEM J, V295, P655, DOI 10.1042/bj2950655; Tanaka E, 1995, JPN J PHYSIOL, V45, P1043, DOI 10.2170/jjphysiol.45.1043; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THONBERG H, 1994, J BIOL CHEM, V269, P33179; UNELIUS L, 1993, AM J PHYSIOL, V265, pC1340, DOI 10.1152/ajpcell.1993.265.5.C1340; WELLS JN, 1988, METHOD ENZYMOL, V159, P489; WILCKE M, 1989, BIOCHEM BIOPH RES CO, V163, P292, DOI 10.1016/0006-291X(89)92134-7; Zhao J, 1997, J BIOL CHEM, V272, P32847, DOI 10.1074/jbc.272.52.32847	53	40	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37770	37780		10.1074/jbc.274.53.37770	http://dx.doi.org/10.1074/jbc.274.53.37770			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608838	hybrid			2022-12-25	WOS:000084528000038
J	Ji, HL; Fuller, CM; Benos, DJ				Ji, HL; Fuller, CM; Benos, DJ			Peptide inhibition of constitutively activated epithelial Na+ channels expressed in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOAD URINARY-BLADDER; CORTICAL COLLECTING TUBULE; SODIUM-CHANNEL; LIDDLE-SYNDROME; BETA-SUBUNIT; HUMAN HYPERTENSION; ACETYLCHOLINE-RECEPTOR; HOMOLOGOUS SUBUNITS; MISSENSE MUTATION; ION SELECTIVITY	The hypothesis that 30-amino acid peptides corresponding to the C-terminal portion of the beta- and/or gamma-rat epithelial sodium channel (rENaC) subunits block constitutively activated ENaC was tested by examining the effects of these peptides on wild-type (wt) rENaC (alpha beta gamma-rENaC), truncated Liddle's mutants (alpha beta(T)gamma-, alpha beta gamma(T)-, and alpha beta(T)gamma(T)-rENaC), and point mutants (alpha beta(Y)gamma-, alpha beta gamma(Y)-rENAC) expressed in Xenopus oocytes, The chord conductances of alpha beta(T)gamma-, alpha beta gamma(T)-, and alpha beta(T)gamma(T)-rENaC were 2- or 3-fold greater than for wt alpha beta gamma-rENaC. Introduction of peptides into oocytes expressing alpha beta(T)gamma-, alpha beta gamma(T)-, and alpha beta(T)gamma(T)-rENaC produced a concentration-dependent inhibition of the amiloride-sensitive Na+ conductances, with apparent dissociation constants (K-d) ranging from 1700 to 160 mu M, depending upon whether individual peptides or their combination was used. Injection of peptides alone or in combination into oocytes expressing wt alpha beta gamma-rENaC or single-point mutants did not affect the amiloride-sensitive whole-cell currents. The single channel conductances of all the mutant ENaCs were the same as that of wild type (alpha beta gamma-). The single channel activities (N.P-o) of the mutants were similar to 2.2-2.6-fold greater than wt alpha beta gamma-rENaC (1.08 +/- 0.24, n = 7) and were reduced to 1.09 +/- 0.17 by 100 mu M peptide mixture (n = 9). The peptides were without effect on the single channel properties of either wt or single-point mutants of rENaC, Our data demonstrate that the C-terminal peptides blocked the Liddle's truncation mutant (alpha beta(T)gamma(T)) expressed in Xenopus oocytes but not the single-point mutants (alpha beta(Y)gamma or alpha beta gamma(T)). Moreover, the blocking effect of both peptides in combination on alpha beta(T)gamma(T)-rENaC was synergistic.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Benos, DJ (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, MCLM 704, Birmingham, AL 35294 USA.	Benos@phybio.bhs.uab.edu	Fuller, Cathy/B-4046-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; Bauer RJ, 1996, J NEUROSCI METH, V68, P101, DOI 10.1016/0165-0270(96)00013-1; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BENOS DJ, 1979, J GEN PHYSIOL, V73, P307, DOI 10.1085/jgp.73.3.307; Bubien JK, 1996, AM J PHYSIOL-CELL PH, V270, pC208, DOI 10.1152/ajpcell.1996.270.1.C208; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANTIELLO HF, 1995, KIDNEY INT, V48, P970, DOI 10.1038/ki.1995.379; Chraibi A, 1998, J GEN PHYSIOL, V111, P127, DOI 10.1085/jgp.111.1.127; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Eaholtz G, 1998, J GEN PHYSIOL, V111, P75, DOI 10.1085/jgp.111.1.75; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; FUCHS W, 1977, J PHYSIOL-LONDON, V267, P137, DOI 10.1113/jphysiol.1977.sp011805; Fuller CM, 1997, BIOPHYS J, V72, P1622, DOI 10.1016/S0006-3495(97)78808-8; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HAMILL OP, 1988, PFLUGERS ARCH, V991, P85; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Inoue T, 1998, EUR J ENDOCRINOL, V138, P691, DOI 10.1530/eje.0.1380691; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ismailov II, 1999, BIOCHEMISTRY-US, V38, P354, DOI 10.1021/bi981979s; Ismailov II, 1996, AM J PHYSIOL-CELL PH, V270, pC214, DOI 10.1152/ajpcell.1996.270.1.C214; ISMAILOV II, 1995, J GEN PHYSIOL, V106, P445, DOI 10.1085/jgp.106.3.445; Jackson SNJ, 1998, J MED GENET, V35, P510, DOI 10.1136/jmg.35.6.510; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Ji HL, 1998, AM J PHYSIOL-CELL PH, V274, pC455, DOI 10.1152/ajpcell.1998.274.2.C455; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; LIFTON RP, 1993, J HYPERTENS, V11, P231, DOI 10.1097/00004872-199303000-00002; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; Palmer LG, 1996, J GEN PHYSIOL, V107, P35, DOI 10.1085/jgp.107.1.35; PALMER LG, 1982, J MEMBRANE BIOL, V67, P91, DOI 10.1007/BF01868651; PALMER LG, 1980, J MEMBRANE BIOL, V57, P59, DOI 10.1007/BF01868986; Palmer LG, 1998, J PHYSIOL-LONDON, V509, P151, DOI 10.1111/j.1469-7793.1998.151bo.x; PALMER LG, 1985, J MEMBRANE BIOL, V83, P57, DOI 10.1007/BF01868738; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SARIBANSOHRABY S, 1988, J BIOL CHEM, V263, P13875; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; Warnock DG, 1998, KIDNEY INT, V53, P18, DOI 10.1046/j.1523-1755.1998.00728.x	53	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37693	37704		10.1074/jbc.274.53.37693	http://dx.doi.org/10.1074/jbc.274.53.37693			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608827	hybrid			2022-12-25	WOS:000084528000027
J	Jovov, B; Tousson, A; Ji, HL; Keeton, D; Shlyonsky, V; Ripoll, PJ; Fuller, CM; Benos, DJ				Jovov, B; Tousson, A; Ji, HL; Keeton, D; Shlyonsky, V; Ripoll, PJ; Fuller, CM; Benos, DJ			Regulation of epithelial Na+ channels by actin in planar lipid bilayers and in the Xenopus oocyte expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; ENDOPLASMIC-RETICULUM; LIDDLES SYNDROME; CALCIUM-RELEASE; CATION CHANNELS; APICAL MEMBRANE; ALPHA-SUBUNIT; BETA-SUBUNIT; WW DOMAINS; ENAC	The hypothesis that actin interactions account for the signature biophysical properties of cloned epithelial Na+ channels (ENaC) (conductance, ion selectivity, and long mean open and closed times) was tested using planar lipid bilayer reconstitution and patch clamp techniques. We found the following. 1) In bilayers, actin produced a more than 2-fold decrease in single channel conductance, a 5-fold increase in Na+ versus K+ perms electivity, and a substantial increase in mean open and closed times of wild-type alpha beta gamma-rENaC but hard no effect on a mutant form of rENaC in which the majority of the C terminus of the alpha subunit was deleted (alpha(R613X)beta gamma-rENaC), 2) When alpha(R613X)beta gamma-rENaC was heterologously expressed in oocytes and single channels examined by patch clamp, 12.5-pS channels of relatively low cation permeability were recorded, These characteristics were identical to those recorded in bilayers for either alpha(R613X)beta gamma-rENaC or wild type alpha beta gamma-rENaC in the absence of actin, Moreover, we show that rENaC subunits tightly associate, forming either homo- or heteromeric complexes when prepared by in vitro translation or when expressed in oocytes. Finally, we show that alpha-rENaC is properly assembled but retained in the endoplasmic reticulum compartment, We conclude that actin subserves an important regulatory function for ENaC and that planar bilayers are an appropriate system in which to study the biophysical and regulatory properties of these cloned channels.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Benos, DJ (corresponding author), Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 704, Birmingham, AL 35294 USA.		Fuller, Cathy/B-4046-2011	Shlyonsky, Vadim/0000-0003-2999-6553	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R56DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; Awayda MS, 1999, AM J PHYSIOL-CELL PH, V277, pC216, DOI 10.1152/ajpcell.1999.277.2.C216; Benos DJ, 1997, NEWS PHYSIOL SCI, V12, P55; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fyfe GK, 1998, SEMIN NEPHROL, V18, P138; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; HAN JK, 1990, J CELL BIOL, V110, P1103, DOI 10.1083/jcb.110.4.1103; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; Ismailov II, 1995, BIOPHYS J, V69, P1789, DOI 10.1016/S0006-3495(95)80049-4; Ismailov II, 1996, J MEMBRANE BIOL, V149, P123, DOI 10.1007/s002329900013; Jaconi M, 1997, CURR BIOL, V7, P599, DOI 10.1016/S0960-9822(06)00259-4; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Jovov B, 1998, AM J PHYSIOL-CELL PH, V275, pC449, DOI 10.1152/ajpcell.1998.275.2.C449; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Kieber-Emmons T, 1999, J BIOL CHEM, V274, P9648, DOI 10.1074/jbc.274.14.9648; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCool DJ, 1999, BIOCHEM J, V341, P593, DOI 10.1042/0264-6021:3410593; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PALMER LG, 1986, FASEB J, V45, P2708; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Rossier BC, 1998, J GEN PHYSIOL, V112, P95, DOI 10.1085/jgp.112.2.95; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SMITH PR, 1995, J MEMBRANE BIOL, V147, P195; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; SORSCHER EJ, 1988, AM J PHYSIOL, V255, pC835, DOI 10.1152/ajpcell.1988.255.6.C835; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1996, STRUCTURE, V4, P495, DOI 10.1016/S0969-2126(96)00054-8; Stockand JD, 1999, J BIOL CHEM, V274, P3842, DOI 10.1074/jbc.274.6.3842; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Vallet V, 1998, KIDNEY INT, V54, pS109, DOI 10.1046/j.1523-1755.1998.06721.x; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	46	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37845	37854		10.1074/jbc.274.53.37845	http://dx.doi.org/10.1074/jbc.274.53.37845			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608849	hybrid			2022-12-25	WOS:000084528000049
J	Koshimizu, T; Koshimizu, M; Stojilkovic, SS				Koshimizu, T; Koshimizu, M; Stojilkovic, SS			Contributions of the C-terminal domain to the control of P2X receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; P-2X RECEPTOR; EXTRACELLULAR ATP; SENSORY NEURONS; BRAIN; EXPRESSION; SEQUENCES; FAMILY	The P2X purinergic receptor channels (P2XRs) differ among themselves with respect to the rates of desensitization during prolonged agonist stimulation. Here we studied the desensitization of recombinant channels by monitoring the changes in intracellular free Ca2+ concentration in cells stimulated with ATP, the native and common agonist for all P2XRs. The focus in our investigations was on the relevance of the P2XR C terminus in controlling receptor desensitization. When expressed in GT1 cells, the P2XRs desensitized with rates characteristic to each receptor subtype: P2X(1)R = P2X(3)R > P2X(2b)R > P2X(4)R > P2X(2a)R > P2X(7)R. A slow desensitizing pattern of P2X(2a)R was mimicked partially by P2X(3)R and fully by P2X(4)R when the six-amino acid sequences of these channels located in the cytoplasmic C terminus were substituted with the corresponding arginine 371 to proline 376 sequence of P2X(2a)R. Changing the total net charge in the six amino acids of P2X(4)R to a more positive direction also slowed the receptor desensitization. On the other hand, substitution of arginine 371-proline 376 sequence of P2X(2a)R with the corresponding sequences of P2X(1)R, P2X(3)R, and P2X(4)R increased the rate of receptor desensitization. Furthermore, heterologous polymerization of wild-type P2X(2a)R and mutant P2X(3)R having the C-terminal six amino acids of P2X(2a)R at its analogous position resulted in a functional channel whose desensitization was significantly delayed. These results suggest that composition of the C-terminal six-amino acid sequence and its electrostatic force influence the rate of receptor desensitization.	NICHD, Sect Cellular Signaling, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHD, Sect Cellular Signaling, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.	stankos@helix.nih.gov	Koshimizu, Taka-aki/G-2740-2015	Koshimizu, Taka-aki/0000-0001-5292-7535	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Collo G, 1996, J NEUROSCI, V16, P2495; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; EVANS RJ, 1997, P2 NUCLEOTIDE RECEPT, P43; GarciaGuzman M, 1996, FEBS LETT, V388, P123, DOI 10.1016/0014-5793(96)00499-1; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Koshimizu T, 1998, MOL ENDOCRINOL, V12, P901, DOI 10.1210/me.12.7.901; Koshimizu T, 1998, J BIOL CHEM, V273, P12853, DOI 10.1074/jbc.273.21.12853; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; North RA, 1996, SEMIN NEUROSCI, V8, P187; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PESSIA M, 1995, NEURON, V14, P1039, DOI 10.1016/0896-6273(95)90342-9; Radford KM, 1997, J NEUROSCI, V17, P6529; Ralevic V, 1998, PHARMACOL REV, V50, P413; Seguela P, 1996, J NEUROSCI, V16, P448; Simon J, 1997, MOL PHARMACOL, V52, P237, DOI 10.1124/mol.52.2.237; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Van Goor F, 1999, MOL ENDOCRINOL, V13, P587, DOI 10.1210/me.13.4.587; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7	30	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37651	37657		10.1074/jbc.274.53.37651	http://dx.doi.org/10.1074/jbc.274.53.37651			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608821	hybrid			2022-12-25	WOS:000084528000021
J	Roberts, VA; Pique, ME				Roberts, VA; Pique, ME			Definition of the interaction domain for cytochrome c on cytochrome c oxidase - III. Prediction of the docked complex by a complete, systematic search	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER SITE; PARACOCCUS-DENITRIFICANS; 2.8 ANGSTROM; DOCKING; KINETICS; PROTEINS; BINDING; RECOGNITION; PEROXIDASE; SURFACES	The electron transfer complex between bovine cytochrome c oxidase and horse cytochrome c has been predicted with the docking program DOT, which performs a complete, systematic search over all six rotational and translational degrees of freedom. Energies for over 36 billion configurations were calculated, providing a free-energy landscape showing guidance of positively charged cytochrome c to the negative region on the cytochrome c oxidase surface formed by subunit II. In a representative configuration, the solvent-exposed cytochrome c heme edge is within 4 Angstrom of the indole ring of subunit II residue Trp(104), indicating a likely electron transfer path. These two groups are surrounded by a small, hydrophobic contact region, which is surrounded by electrostatically complementary hydrophilic interactions. Cytochrome c/cytochrome c oxidase interactions of Lys(13) with Asp(119) and Lys(72) with Gln(103) and Asp(158) are the most critical polar interactions due to their proximity to the hydrophobic region and exclusion from bulk solvent, The predicted complex matches previous mutagenesis, binding, and time-resolved kinetics studies that implicate Trp(104) in electron transfer and show the importance of specific charged residues to protein affinity, Electrostatic forces not only enhance long range protein/protein association; they also predominate in short range alignment, creating the transient interaction needed for rapid turnover.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Roberts, VA (corresponding author), Scripps Res Inst, Dept Mol Biol, MB4,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Bashford D., 1997, Scientific Computing in Object-Oriented Parallel Environments. First International Conference, ISCOPE 97. Proceedings, P233; Beinert H, 1997, EUR J BIOCHEM, V245, P521, DOI 10.1111/j.1432-1033.1997.t01-1-00521.x; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; GEREN LM, 1995, J BIOL CHEM, V270, P2466, DOI 10.1074/jbc.270.6.2466; GILSON MK, 1993, J PHYS CHEM-US, V97, P3591, DOI 10.1021/j100116a025; GILSON MK, 1988, PROTEINS, V3, P32, DOI 10.1002/prot.340030104; HILL BC, 1991, J BIOL CHEM, V266, P2219; Huang CC, 1996, BIOCHEMISTRY-US, V35, P3439, DOI 10.1021/bi9526692; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Janin J, 1995, PROG BIOPHYS MOL BIO, V64, P145, DOI 10.1016/S0079-6107(96)00001-6; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LAPPALAINEN P, 1995, BIOCHEMISTRY-US, V34, P5824, DOI 10.1021/bi00017a014; Malatesta F, 1998, FEBS LETT, V434, P322, DOI 10.1016/S0014-5793(98)01006-0; MILLER MA, 1994, BIOCHEMISTRY-US, V33, P8686, DOI 10.1021/bi00195a009; Miller MA, 1996, BIOCHEMISTRY-US, V35, P667, DOI 10.1021/bi952557a; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; ROBERTS VA, 1991, J BIOL CHEM, V266, P13431; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SHOICHET BK, 1993, PROTEIN ENG, V6, P723, DOI 10.1093/protein/6.7.723; SMITH HT, 1977, BIOCHEMISTRY-US, V16, P4971, DOI 10.1021/bi00642a005; Ten Eyck L.F., 1995, P 1995 ACM IEEE SUP; TIEDE DM, 1993, BIOCHEMISTRY-US, V32, P4515, DOI 10.1021/bi00068a006; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VAKSER IA, 1994, PROTEINS, V20, P320, DOI 10.1002/prot.340200405; Wang KF, 1999, J BIOL CHEM, V274, P38042, DOI 10.1074/jbc.274.53.38042; WARWICKER J, 1989, J MOL BIOL, V206, P381, DOI 10.1016/0022-2836(89)90487-7; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; Witt H, 1998, EUR J BIOCHEM, V251, P367, DOI 10.1046/j.1432-1327.1998.2510367.x; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zhen YJ, 1999, J BIOL CHEM, V274, P38032, DOI 10.1074/jbc.274.53.38032	39	135	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38051	38060		10.1074/jbc.274.53.38051	http://dx.doi.org/10.1074/jbc.274.53.38051			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608874	hybrid			2022-12-25	WOS:000084528000074
J	Tu, YP; Popov, S; Slaughter, C; Ross, EM				Tu, YP; Popov, S; Slaughter, C; Ross, EM			Palmitoylation of a conserved cysteine in the regulator of G protein signaling (RGS) domain modulates the GTPase-activating activity of RGS4 and RGS10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; K+ CHANNELS; RHODOPSIN; ACYLATION; PURIFICATION; HYDROLYSIS; G-ALPHA(Z); PALMITATE; RECEPTOR; STATE	RGS4 and RGS10 expressed in Sf9 cells are palmitoylated at a conserved Cys residue (Cys(95) in RGS4 Cys(66) in RGS10) in the regulator of G protein signaling (RGS) domain that is also autopalmitoylated when the purified proteins are incubated with palmitoyl-CoA. RGS4 also autopalmitoylates at a previously identified cellular palmitoylation site, either Cys(2) or Cys(12). The C2A/C12A mutation essentially eliminates both autopalmitoylation and cellular [H-3]palmitate labeling of Cys(95). Membrane-bound RGS4 is palmitoylated both at Cys(95) and Cys(2/12) but cytosolic RGS4 is not palmitoylated. RGS4 and RGS10 are GTPase-activating proteins (GAPs) for the G(i) and G(q) families of G proteins. Palmitoylation of Cys(95) on RGS4 or Cys(66) On RGS10 inhibits GAP activity 80-100% toward either G alpha(i) or G alpha(z) in a single-turnover, solution-based assay. In contrast, when GAP activity was assayed as acceleration of steady-state GTPase in receptor-a protein proteoliposomes, palmitoylation of RGS10 potentiated GAP activity greater than or equal to 20-fold. Palmitoylation near the N terminus of C95V RGS4 did not alter GAP activity toward soluble G alpha(z) and increased G(z) GAP activity about 2-fold in the vesicle-based assay. Dual palmitoylation of wild-type RGS4 remained inhibitory. RGS protein palmitoylation is thus multi-site, complex in its control, and either inhibitory or stimulatory depending on the RGS protein and its sites of palmitoylation.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ross@utsw.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Bunemann M, 1998, J BIOL CHEM, V273, P31186, DOI 10.1074/jbc.273.47.31186; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Cohen SL, 1997, ANAL BIOCHEM, V247, P257, DOI 10.1006/abio.1997.2072; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5783, DOI 10.1021/bi00185a016; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; PARKER EM, 1991, J BIOL CHEM, V266, P519; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Ross EM, 1999, CRC METH SIG TRANS, P123; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; STJULES RS, 1986, EXP EYE RES, V43, P929, DOI 10.1016/0014-4835(86)90071-0; Stoffel RH, 1998, BIOCHEMISTRY-US, V37, P16053, DOI 10.1021/bi981432d; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Veit M, 1998, BBA-LIPID LIPID MET, V1394, P90, DOI 10.1016/S0005-2760(98)00097-6; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zerangue N, 1998, CURR BIOL, V8, pR313, DOI 10.1016/S0960-9822(98)70196-4	44	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38260	38267		10.1074/jbc.274.53.38260	http://dx.doi.org/10.1074/jbc.274.53.38260			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608901	hybrid			2022-12-25	WOS:000084528000101
J	Massimi, P; Pim, D; Bertoli, C; Bouvard, V; Banks, L				Massimi, P; Pim, D; Bertoli, C; Bouvard, V; Banks, L			Interaction between the HPV-16 E2 transcriptional activator and p53	ONCOGENE			English	Article						HPV; E2; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; ONCOGENIC HUMAN PAPILLOMAVIRUSES; ADENOVIRUS-INFECTED CELLS; DNA-REPLICATION; ESTROGEN-RECEPTOR; VIRAL REPLICATION; PROTEIN; BINDING; TRANSACTIVATION; EXPRESSION	The HPV-16 E2 protein is a major regulator of viral DNA replication and gene expression. Through interactions with the viral origin binding protein, El, it localizes El to the origin of replication and stimulates the initiation of viral DNA replication. However, several recent reports have described a number of diverse activities of E2 relating to the induction of apoptosis through both p53 dependent and independent mechanisms, and to induction of growth arrest in both the G1 and G2M phases of the cell cycle. Recent studies have also shown that p53 can specifically inhibit HPV DNA replication, albeit through an unknown mechanism. Since p53 has been described in the replication centres of Herpes Viruses, Adenovirus and SV40 we decided to investigate whether any of the above activities of E2 may be related to an association with p53. We show, in a series of in vitro assays, specific interaction between p53 and HPV-16 E2 via residues in the carboxy terminal half of the E2 protein. Mutational analysis of p53 indicates that sequences in both the DIVA binding and oligomerization domains are essential for the interaction, and a mutant of p53 which is unable to bind E2 is also unable to inhibit HPV DNA replication. Finally, using an inducible system of p53 expression we also show that E2 will complex with p53 in vivo. These results raise the intriguing possibility that p53 may also be involved in HPV DNA replication centres, and also provides explanations for some of the diverse activities reported for the HPV E2 proteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; CEA, Ctr Etude Nucl, DSV, DRR,UMR 217 CNRS,Lab Cancerogenese Mol, F-92265 Fontenay Aux Roses, France	International Center for Genetic Engineering & Biotechnology (ICGEB); CEA	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; HEDGE RS, 1992, NATURE, V359, P505; Hwang ES, 1996, ONCOGENE, V12, P795; Konig C, 1999, J VIROL, V73, P2253; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Piccini A, 1997, J GEN VIROL, V78, P1963, DOI 10.1099/0022-1317-78-8-1963; PICCINI A, 1995, J GEN VIROL, V61, P1630; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, P69; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; REMM M, 1992, NUCLEIC ACIDS RES, V20, P6015, DOI 10.1093/nar/20.22.6015; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; TARUNINA M, 1993, ONCOGENE, V8, P3165; Thomas M, 1996, ONCOGENE, V13, P471; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhong L, 1997, J VIROL, V71, P3146, DOI 10.1128/JVI.71.4.3146-3160.1997	43	66	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7748	7754		10.1038/sj.onc.1203208	http://dx.doi.org/10.1038/sj.onc.1203208			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618715				2022-12-25	WOS:000084256900004
J	Kriebel, P; Patel, BKR; Nelson, SA; Grusby, MJ; LaRochelle, WJ				Kriebel, P; Patel, BKR; Nelson, SA; Grusby, MJ; LaRochelle, WJ			Consequences of Stat6 deletion on Sis/PDGF- and IL-4-induced proliferation and transcriptional activation in murine fibroblasts	ONCOGENE			English	Article						PDGF; IL-4; Stat-6; transcriptional activation	SIMIAN SARCOMA-VIRUS; HUMAN RECOMBINANT INTERLEUKIN-4; GROWTH-FACTOR RECEPTORS; JAK-3 JANUS KINASE; NF-KAPPA-B; TYROSINE PHOSPHORYLATION; FACTOR-I; HEMATOPOIETIC-CELLS; MYELOID CELLS; GENE	Aberrant communication among growth factors and cytokines that regulate tissue homeostasis often results in malignancy. Among the many cell types that participate in this process, stromal fibroblasts communicate in a paracrine and juxtracrine manner with cells of epithelial, endothelial, and hematopoietic origin. For fibroblasts, platelet-derived growth factor (PDGF) is a major proliferative and differentiation agent, Interleukin-4 (IL-4), however, possesses only modulating functions in this cell type. Here, we investigated the consequences of deleting Stat6 on PDGF and IL-4 signaling, proliferation, and transcriptional activation by establishing and characterizing early passage fibroblasts from wild-type and Stat6 null mice. Both wild-type and Stat6(-/-) fibroblasts showed nearly identical PDGFR and IL-4R activation, gross substrate tyrosine phosphorylation, PI 3-kinase activation, as well as Stat1, 3 and 5 DNA binding activities. Unexpectedly, IL-4's enhancement of PDGF-induced [H-3]thymidine incorporation was greatly diminished in Stat6(-/-), but not wild-type fibroblasts, PDGF-induced [H-3]thymidine uptake was largely unaffected. Strikingly, IL-3, but not PDGF induction of the proinflammatory gene products, IL-6 and MCP-1 was markedly reduced in Stat6(-/-) fibroblasts. Thus, Stat6 is an important and specific mediator of IL-1-enhanced PDGF-induced proliferation as well as IL-4's transcriptional activation of IL-6 and MCP-1.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health	LaRochelle, WJ (corresponding author), NCI, Cellular & Mol Biol Lab, Bldg 37,Room 1E24, Bethesda, MD 20892 USA.		Nelson, Stefanie/GRN-7686-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040171, R01AI040171] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40171] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Betsholtz C, 1997, KIDNEY INT, V51, P1361, DOI 10.1038/ki.1997.186; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; Dirks RPH, 1996, MOL BIOL REP, V22, P1, DOI 10.1007/BF00996300; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; FEGHALI CA, 1992, CLIN IMMUNOL IMMUNOP, V63, P182, DOI 10.1016/0090-1229(92)90011-C; FLEMING TP, 1992, CANCER RES, V52, P4550; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HONDA M, 1992, J IMMUNOL, V148, P2175; HOU J, 1994, SCIENCE, V165, P1701; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAPLAN MH, 1996, IMMUNITY, V4, P1; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LEEK RD, 1994, J LEUKOCYTE BIOL, V56, P423, DOI 10.1002/jlb.56.4.423; NEEDLEMAN BW, 1992, ARTHRITIS RHEUM, V35, P67, DOI 10.1002/art.1780350111; NELSON SA, 1999, SOURCEBOOK ASBESTOS, V19, P291; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; OHARA J, 1988, P NATL ACAD SCI USA, V85, P8221, DOI 10.1073/pnas.85.21.8221; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; OWEN AJ, 1982, P NATL ACAD SCI-BIOL, V79, P3203, DOI 10.1073/pnas.79.10.3203; Paquet P, 1996, INT ARCH ALLERGY IMM, V109, P308, DOI 10.1159/000237257; Patel BKR, 1998, GENOMICS, V52, P192, DOI 10.1006/geno.1998.5436; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Paul WE, 1997, CIBA F SYMP, V204, P208; Peden K, 1987, Prog Clin Biol Res, V253, P101; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROTH M, 1995, P NATL ACAD SCI USA, V92, P1312, DOI 10.1073/pnas.92.5.1312; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takemura H, 1998, J RHEUMATOL, V25, P1534; Trautmann A, 1998, J IMMUNOL, V160, P5053; VANDERMEEREN A, 1993, AM J RESP CELL MOL, V8, P214, DOI 10.1165/ajrcmb/8.2.214; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VIGNAUD JM, 1994, CANCER RES, V54, P5455; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	65	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7294	7302		10.1038/sj.onc.1203148	http://dx.doi.org/10.1038/sj.onc.1203148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602484				2022-12-25	WOS:000084119400014
J	Efimova, T; Eckert, RL				Efimova, T; Eckert, RL			Regulation of human involucrin promoter activity by novel protein kinase C isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; SIGNAL-TRANSDUCTION PATHWAY; SERUM RESPONSE ELEMENT; CROSS-LINKED ENVELOPE; HUMAN EPIDERMAL-CELLS; MESSENGER-RNA LEVELS; DELTA PKC-DELTA; TYROSINE PHOSPHORYLATION; HUMAN-SKIN; KERATINOCYTE DIFFERENTIATION	Human involucrin (hINV) mRNA level and promoter activity increase when keratinocytes are treated with the differentiating agent, 12-O-tetradecanoylphorbol-13-acetate (TPA). This response is mediated via a p38 mitogen-activated protein kinase-dependent pathway that targets activator protein 1 (Efimova, T., LaCelle, P. T., Welter, J. F., and Eckert, R. L. (1998) J. Biol, Chem. 273, 24387-24395), In the present study we examine the role of various PKC isoforms in this regulation. Transfection of expression plasmids encoding the novel PKC isoforms delta, epsilon, and eta increase hINV promoter activity. In contrast, neither conventional PKC isoforms (alpha, beta, and gamma) nor the atypical isoform (zeta) regulate promoter activity. Consistent with these observations, promoter activity is inhibited by the PKC delta-selective inhibitor, rottlerin, but not by Go-6976, an inhibitor of conventional PRC isoforms, and novel PKC isoform-dependent promoter activation is inhibited by dominant-negative PKC delta. This regulation appears to be physiologically important, as transfection of keratinocytes with PKC delta, -epsilon, or -eta increases expression of the endogenous hINV gene. Synergistic promoter activation (greater than or equal to 100-fold) is observed when PKC epsilon- or -eta-transfected cells are treated with TPA. In contrast, the PKC delta-dependent response is more complex as either activation or inhibition is observed, depending upon PKC delta concentration.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.			Efimova, Tatiana/0000-0002-9869-1545	NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal C, 1999, J BIOL CHEM, V274, P6190, DOI 10.1074/jbc.274.10.6190; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Eckert RL, 1996, CELL DEATH DIFFER, V3, P373; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; GHERZI R, 1992, BIOCHEM BIOPH RES CO, V184, P283, DOI 10.1016/0006-291X(92)91190-2; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Kadotani M, 1997, J BIOCHEM-TOKYO, V121, P1047; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; KIM SY, 1994, J BIOL CHEM, V269, P27979; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; REYNOLDS NJ, 1994, J INVEST DERMATOL, V103, P364, DOI 10.1111/1523-1747.ep12394957; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Romanova LY, 1998, BIOCHEMISTRY-US, V37, P5558, DOI 10.1021/bi9731807; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Takahashi H, 1998, J INVEST DERMATOL, V110, P218, DOI 10.1046/j.1523-1747.1998.00110.x; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAAR M, 1993, EXP CELL RES, V206, P235, DOI 10.1006/excr.1993.1143; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203	60	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1601	1607		10.1074/jbc.275.3.1601	http://dx.doi.org/10.1074/jbc.275.3.1601			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636851	hybrid			2022-12-25	WOS:000084940000014
J	Fasken, MB; Saunders, R; Rosenberg, M; Brighty, DW				Fasken, MB; Saunders, R; Rosenberg, M; Brighty, DW			A leptomycin B-sensitive homologue of human CRM1 promotes nuclear export of nuclear export sequence-containing proteins in Drosophila cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REV TRANS-ACTIVATOR; MESSENGER-RNA; IMPORTIN-ALPHA; NUCLEOCYTOPLASMIC TRANSPORT; RESPONSIVE ELEMENT; GENE-EXPRESSION; TARGET SEQUENCE; PATHWAY; BINDING	The Rev protein of human immunodeficiency virus is a nuclear shuttling protein that promotes nuclear export of mRNAs that encode the viral structural proteins Gag, Pol, and Env, Rev binds to a highly structured RNA motif, the Rev-responsive element (RRE), that is present in all Rev-responsive viral transcripts and facilitates their entry into a nuclear export pathway by recruiting cellular export factors. In mammalian and yeast cells, the principal export receptor engaged by Rev has been identified as the importin/transportin family member CRM1/exportin 1. CRM1 binds directly to a leucine-rich nuclear export sequence (NES) present in Rev, and similar motifs have been identified in a variety of cellular nuclear shuttling proteins. We and our colleagues previously demonstrated that, in transfected Drosophila cells, HIV-l Rev is fully functional and promotes expression of the viral envelope glycoprotein. We now demonstrate that the fundamental mechanism of Rev action in insect cells is identical to that observed in the mammalian systems. In particular, we show that Drosophila cells express a leptomycin B-sensitive homologue of human CRM1 that supports Rev-dependent gene expression and is required for nuclear export of NES-containing proteins in insect cells.	Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Dundee, Dept Anat & Physiol, Dundee DD1 9SY, Scotland; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	University of Dundee; University of Dundee; GlaxoSmithKline	Brighty, DW (corresponding author), Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.		Fasken, Milo/K-2177-2019	Fasken, Milo/0000-0003-4317-7909				Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; BRIGHTY DW, 1994, P NATL ACAD SCI USA, V91, P8314, DOI 10.1073/pnas.91.18.8314; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Churchill MJ, 1996, J VIROL, V70, P5786, DOI 10.1128/JVI.70.9.5786-5790.1996; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P219; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P4421, DOI 10.1073/pnas.93.9.4421; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gaits F, 1999, MOL BIOL CELL, V10, P1395, DOI 10.1091/mbc.10.5.1395; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Graves LE, 1999, NATURE, V399, P802, DOI 10.1038/21682; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; HAYNES SR, 1990, MOL CELL BIOL, V10, P316, DOI 10.1128/MCB.10.1.316; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HUANG ZM, 1995, MOL CELL BIOL, V15, P3864; IVEYHOYLE M, 1990, MOL CELL BIOL, V10, P6152, DOI 10.1128/MCB.10.12.6152; Iwasaki T, 1998, FEBS LETT, V428, P259, DOI 10.1016/S0014-5793(98)00540-7; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LIU XD, 1995, GENE DEV, V9, P1766, DOI 10.1101/gad.9.14.1766; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Maniatis T., 1982, MOL CLONING LAB MANU; Matsusaka T, 1998, CURR BIOL, V8, P1031, DOI 10.1016/S0960-9822(07)00425-3; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MICHAEL WM, 1995, CELL, V83, P415; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nicolas FJ, 1997, J CELL SCI, V110, P3019; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; PATERSON T, 1991, NUCLEIC ACIDS RES, V19, P5877, DOI 10.1093/nar/19.21.5877; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	64	21	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1878	1886		10.1074/jbc.275.3.1878	http://dx.doi.org/10.1074/jbc.275.3.1878			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636888	hybrid			2022-12-25	WOS:000084940000051
J	Shanmugavelu, M; Baytan, AR; Chesnut, JD; Bonning, BC				Shanmugavelu, M; Baytan, AR; Chesnut, JD; Bonning, BC			A novel protein that binds juvenile hormone esterase in fat body tissue and pericardial cells of the tobacco hornworm Manduca sexta L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIOTHIS-VIRESCENS; GENE; EXPRESSION; PRODUCTS; DISPLAY; SYSTEM; MIDGUT	Juvenile hormone esterase degrades juvenile hormone, which acts in conjunction with ecdysteroids to control gene expression in insects. Circulating juvenile hormone esterase is removed from insect blood by pericardial cells and degraded in lysosomes, In experiments designed to characterize proteins involved in the degradation of juvenile hormone esterase, a pericardial cell cDNA phage display library derived from the tobacco hornworm moth Manduca sexta L. was constructed and screened for proteins that bind juvenile hormone esterase, A 732-base pair cDNA encoding a novel 29-kDa protein (P29) was isolated. Western and Northern analyses indicated that P29 is present in both pericardial cell and fat body tissues and is expressed in each larval instar, In immunoprecipitation experiments, P29 bound injected recombinant juvenile hormone esterase taken up by pericardial cells and native M. sexta juvenile hormone esterase in fat body tissue, where the enzyme is synthesized. Binding assays showed that P29 bound juvenile hormone esterase more strongly than it did a mutant form of the enzyme with mutations that perturb lysosomal targeting. Based on these data, we propose that P29 functions in pericardial cells to facilitate lysosomal degradation of juvenile hormone esterase.	Iowa State Univ, Dept Entomol, Ames, IA 50011 USA; Iowa State Univ, Genet Program, Ames, IA 50011 USA; Invitrogen, Carlsbad, CA 92008 USA	Iowa State University; Iowa State University; Thermo Fisher Scientific	Bonning, BC (corresponding author), Iowa State Univ, Dept Entomol, 411 Sci 2, Ames, IA 50011 USA.	Bbonning@iastate.edu						ABDELAAL YAI, 1986, SCIENCE, V233, P1073, DOI 10.1126/science.3738525; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bonning BC, 1997, ARCH INSECT BIOCHEM, V34, P275, DOI 10.1002/(SICI)1520-6327(1997)34:3<275::AID-ARCH3>3.3.CO;2-T; Bonning BC, 1997, P NATL ACAD SCI USA, V94, P6007, DOI 10.1073/pnas.94.12.6007; Bonning BC, 1999, J INVERTEBR PATHOL, V73, P234, DOI 10.1006/jipa.1998.4839; BONNING BC, 1992, INSECT BIOCHEM MOLEC, V22, P453, DOI 10.1016/0965-1748(92)90141-Z; BOOTH TF, 1992, TISSUE CELL, V24, P267, DOI 10.1016/0040-8166(92)90100-L; Carcamo J, 1998, P NATL ACAD SCI USA, V95, P11146, DOI 10.1073/pnas.95.19.11146; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; Crossley A.C., 1985, P487; Hammock B.D., 1985, P431; HAMMOCK BD, 1990, NATURE, V344, P458, DOI 10.1038/344458a0; HAMMOCK BD, 1985, METHOD ENZYMOL, V111, P487; HANZLIK TN, 1989, J BIOL CHEM, V264, P12419; Haunerland NH, 1996, INSECT BIOCHEM MOLEC, V26, P755, DOI 10.1016/S0965-1748(96)00035-5; ICHINOSE R, 1992, PESTIC BIOCHEM PHYS, V42, P13, DOI 10.1016/0048-3575(92)90069-C; ICHINOSE R, 1992, INSECT BIOCHEM MOLEC, V22, P893, DOI 10.1016/0965-1748(92)90116-V; Locke M, 1998, MICROSCOPIC ANATOMY OF INVERTEBRATES, VOL 11 A-C, P687; Luo WP, 1997, BIOTECHNIQUES, V23, P630, DOI 10.2144/97234bm16; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SNYDER MJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P13, DOI 10.1006/abbi.1995.1362; SNYDER MJ, 1995, INSECT BIOCHEM MOLEC, V25, P455, DOI 10.1016/0965-1748(94)00083-B; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; WROBLEWSKI VJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P461, DOI 10.1016/0003-9861(90)90285-7	27	36	43	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1802	1806		10.1074/jbc.275.3.1802	http://dx.doi.org/10.1074/jbc.275.3.1802			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636878	hybrid			2022-12-25	WOS:000084940000041
J	Bruno, MD; Korfhagen, TR; Liu, C; Morrisey, EE; Whitsett, JA				Bruno, MD; Korfhagen, TR; Liu, C; Morrisey, EE; Whitsett, JA			GATA-6 activates transcription of surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP-A GENE; FACTOR-I; DEFICIENT MICE; DNA-BINDING; B GENE; EXPRESSION; LUNG; PROMOTER; DIFFERENTIATION; INFECTION	Surfactant protein A (SP-A) is a member of the collectin family of innate host defense molecules expressed primarily in respiratory epithelial cells of the lung. SP-A concentrations are influenced by both cell-specific and ubiquitous nuclear proteins that regulate SP-A gene transcription in a cell-selective and temporally regulated manner. In this work, a consensus GATA-binding site (GBS) was identified at positions -69 to -64 of the mouse SP-A gene. The transcriptional activity of wildtype SP-A reporter constructs in HeLa cells was increased 5-10-fold when cotransfected with a GATA-6 expression plasmid, Deletion of the GBS completely blocked transactivation by GATA-6, Transfection of a construct expressing GATA-6-engrailed fusion protein inhibited basal expression of the SP-A/chloramphenicol acetyltransferase construct in MLE-15 cells. Nuclear extract proteins from MLE-15 cells bound to the GBS in the mouse SP-A gene, and a supershifted band was detected with a GATA-6-specific antibody. Transactivation of the wild-type SP-A constructs by GATA-6 increased transcriptional activity 7-10-fold, whereas thyroid transcription factor-1 (TTF-1) increased the activity of these constructs 12-18-fold. The effects of cotransactivating with both GATA-6 and TTF-1 expression constructs were additive. However, mutation of the TTF-1-binding sites alone or in combination decreased GATA-6 transactivation. Likewise, mutation of the GBS blocked TTF-1 activation of the SP-A promoter. In situ hybridization demonstrated GATA-6 mRNA in the peripheral epithelial cells of fetal mouse lung, consistent with the sites of SP-A expression. GATA-6 is expressed in respiratory epithelial cells and binds to a cis-acting element in the SP-A gene promoter, activating the transcriptional activity of the gene.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Cincinnati Children's Hospital Medical Center; University of Pennsylvania	Whitsett, JA (corresponding author), Childrens Hosp, Med Ctr, Div Neonatol & Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058795, R01HL028623] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58795, HL28623] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Bruno MD, 1999, J BIOL CHEM, V274, P27523, DOI 10.1074/jbc.274.39.27523; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Ikegami M, 1998, AM J PHYSIOL-LUNG C, V275, pL247, DOI 10.1152/ajplung.1998.275.2.L247; Ikegami M, 1997, AM J PHYSIOL-LUNG C, V272, pL479, DOI 10.1152/ajplung.1997.272.3.L479; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; LACAZEMASMONTEIL T, 1992, EUR J BIOCHEM, V206, P613, DOI 10.1111/j.1432-1033.1992.tb16966.x; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 1999, J CLIN INVEST, V103, P1015, DOI 10.1172/JCI5849; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; McCormack FX, 1998, BBA-MOL BASIS DIS, V1408, P109, DOI 10.1016/S0925-4439(98)00062-3; Mendelson CR, 1998, BBA-MOL BASIS DIS, V1408, P132, DOI 10.1016/S0925-4439(98)00063-5; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Young PP, 1996, AM J PHYSIOL-LUNG C, V271, pL287, DOI 10.1152/ajplung.1996.271.2.L287; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	32	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1043	1049		10.1074/jbc.275.2.1043	http://dx.doi.org/10.1074/jbc.275.2.1043			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625644	hybrid			2022-12-25	WOS:000084836600048
J	Grundling, A; Blasi, U; Young, R				Grundling, A; Blasi, U; Young, R			Biochemical and genetic evidence for three transmembrane domains in the class I holin, lambda S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; MEMBRANE-PROTEINS; LYSIS; RESIDUES; TRANSLOCATION; MOTIF	lambda S, the prototype class I holin gene, encodes three potential transmembrane domains in its 107 codons, whereas 21 S, the class II prototype spans only 71 codons and encodes two transmembrane domains. Many holin genes, including lambda S and 21 S, have the "dual-start" regulatory motif at the N terminus, suggesting that class I and II holins have the same topology. The primary structure of 21 S strongly suggests a bitopic "helical-hairpin" topology, with N and C termini on the cytoplasmic side of the membrane. However, lambda S chimeras with an N-terminal signal sequence show Lep-dependent function, indicating that the N-terminal domain of S requires export. Here the signal sequence chimera is shown to be sensitive to the missense change A52V, which blocks normal S function. Moreover, cysteine-modification studies in isolated membranes using a collection of S variants with single-cysteine substitutions show that the positions in the core of the 3 putative transmembrane domains of lambda S are protected. Also, S proteins with single-cysteine substitutions in the predicted cytoplasmic and periplasmic loops are more efficiently labeled in inverted membrane vesicles and whole cells, respectively. These data constitute direct evidence that the holin S-lambda has three transmembrane domains and indicate that class I and class II holins have different topologies, despite regulatory and functional homology.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria	Texas A&M University System; Texas A&M University College Station; University of Vienna; Vienna Biocenter (VBC)	Young, R (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.			Grundling, Angelika/0000-0002-6235-8687; Young, Ry/0000-0001-8001-2914	NIGMS NIH HHS [GM27099, R01 GM027099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027099, R37GM027099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barenboim M, 1999, MOL MICROBIOL, V32, P715, DOI 10.1046/j.1365-2958.1999.01385.x; Blasi U, 1996, MOL MICROBIOL, V21, P675, DOI 10.1046/j.1365-2958.1996.331395.x; Blasi U, 1999, J BACTERIOL, V181, P2922; BLASI U, 1990, EMBO J, V9, P981, DOI 10.1002/j.1460-2075.1990.tb08200.x; BLASI U, 1989, EMBO J, V8, P3501, DOI 10.1002/j.1460-2075.1989.tb08515.x; BONOVICH MT, 1991, J BACTERIOL, V173, P2897, DOI 10.1128/JB.173.9.2897-2905.1991; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CHANG CY, 1993, GENE, V133, P9, DOI 10.1016/0378-1119(93)90218-R; CHANG CY, 1995, J BACTERIOL, V177, P3283, DOI 10.1128/jb.177.11.3283-3294.1995; CHANG CY, 1994, SYNTHESIS FUNCTION R; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; Fu DX, 1998, J BIOL CHEM, V273, P17962, DOI 10.1074/jbc.273.28.17962; Graschopf A, 1999, MOL MICROBIOL, V33, P569, DOI 10.1046/j.1365-2958.1999.01501.x; JOHNSONBOAZ R, 1994, MOL MICROBIOL, V13, P495, DOI 10.1111/j.1365-2958.1994.tb00444.x; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LEE JI, 1992, J BIOL CHEM, V267, P938; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; OSBORN MJ, 1980, ANNU REV MICROBIOL, V34, P369, DOI 10.1146/annurev.mi.34.100180.002101; RAAB R, 1986, J BACTERIOL, V167, P1035, DOI 10.1128/jb.167.3.1035-1042.1986; RAAB R, 1988, J MOL BIOL, V199, P95, DOI 10.1016/0022-2836(88)90381-6; READER RW, 1971, VIROLOGY, V43, P607, DOI 10.1016/0042-6822(71)90286-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNAITMAN CA, 1971, J BACTERIOL, V108, P545, DOI 10.1128/JB.108.1.545-552.1971; Schuenemann TA, 1999, J BIOL CHEM, V274, P6855, DOI 10.1074/jbc.274.11.6855; Smith DL, 1998, GENE EXPRESSION, V7, P39; Smith DL, 1998, J BACTERIOL, V180, P4199, DOI 10.1128/JB.180.16.4199-4211.1998; Smith DL, 1998, J BACTERIOL, V180, P2531, DOI 10.1128/JB.180.9.2531-2540.1998; SMITH DL, 1998, PURIFICATION BIOCH C; STEINER M, 1993, MOL MICROBIOL, V8, P525, DOI 10.1111/j.1365-2958.1993.tb01597.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1990, PROTEIN ENG, V4, P109, DOI 10.1093/protein/4.2.109; WULFING C, 1994, J BIOL CHEM, V269, P2895; YOUNG R, 1995, FEMS MICROBIOL REV, V17, P191, DOI 10.1016/0168-6445(94)00079-4; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992; ZAGOTTA MT, 1990, J BACTERIOL, V172, P912, DOI 10.1128/jb.172.2.912-921.1990	35	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					769	776		10.1074/jbc.275.2.769	http://dx.doi.org/10.1074/jbc.275.2.769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625606	hybrid			2022-12-25	WOS:000084836600010
J	Haeseleer, F; Sokal, I; Verlinde, CLMJ; Erdjument-Bromage, H; Tempst, P; Pronin, AN; Benovic, JL; Fariss, RN; Palczewski, K				Haeseleer, F; Sokal, I; Verlinde, CLMJ; Erdjument-Bromage, H; Tempst, P; Pronin, AN; Benovic, JL; Fariss, RN; Palczewski, K			Five members of a novel Ca2+-binding protein (CABP) subfamily with similarity to calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR KINASES; CALCIUM-BINDING; CONFORMATIONAL-CHANGES; POINT MUTATIONS; SITES; LOCALIZATION; PURIFICATION; RESOLUTION; EXPRESSION; MUTANTS	Five members of a novel Ca2+-binding protein subfamily (CaBP), with 46-58% sequence similarity to calmodulin (CaM), were identified in the vertebrate retina. Important differences between these Ca2+-binding proteins and CaM include alterations within their second EF-hand loop that render these motifs inactive in Ca2+ coordination and the fact that their central alpha-helixes are extended by one alpha-helical turn. CaBP1 and CaBP2 contain a consensus sequence for N-terminal myristoylation, similar to members of the recoverin subfamily and are fatty acid acylated in vitro. The patterns of expression differ for each of the various members. Expression of CaBP5, for example, is restricted to retinal rod and cone bipolar cells. In contrast, CaBP1 has a more widespread pattern of expression. In the brain, CaBP1 is found in the cerebral cortex and hippocampus, and in the retina this protein is found in cone bipolar and amacrine cells. CaBP1 and CaBP2 are expressed as multiple, alternatively spliced variants, and in heterologous expression systems these forms show different patterns of subcellular localization. In reconstitution assays, CaBPs are able to substitute functionally for CaM. These data suggest that these novel CaBPs are an important component of Ca2+-mediated cellular signal transduction in the central nervous system where they may augment or substitute for CaM.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, BioMol Struct Ctr, Seattle, WA 98195 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Immunol, Philadelphia, PA 19107 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center; Jefferson University; Jefferson University	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Fariss, Robert/ABI-1771-2020; VERLINDE, CHRISTOPHE LMJ/J-5796-2013	VERLINDE, CHRISTOPHE LMJ/0000-0002-7790-3203; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987; Fariss, Robert/0000-0003-3227-7170	NATIONAL EYE INSTITUTE [F32EY006935, R01EY008061, R29EY008061] Funding Source: NIH RePORTER; NEI NIH HHS [EY08061, EY06935-01, R01 EY008061, F32 EY006935] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BABU YS, 1988, J MOL BIOL, V204, P91; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; BERCHTOLD MW, 1993, GENOMICS, V16, P461, DOI 10.1006/geno.1993.1211; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burge CB, 1998, MOL CELL, V2, P773, DOI 10.1016/S1097-2765(00)80292-0; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GAO ZH, 1993, J BIOL CHEM, V268, P20096; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; HALE IL, 1993, METHOD CELL BIOL, V38, P289; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; Hughes RE, 1998, PROTEIN SCI, V7, P2675, DOI 10.1002/pro.5560071222; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KIM CM, 1993, RECEPTOR, V3, P39; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LAABI Y, 1994, NUCLEIC ACIDS RES, V22, P1147, DOI 10.1093/nar/22.7.1147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MARTIN SR, 1992, EUR J BIOCHEM, V205, P1107, DOI 10.1111/j.1432-1033.1992.tb16879.x; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; RING CS, 1993, FASEB J, V7, P783, DOI 10.1096/fasebj.7.9.8330685; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; Seidenbecher CI, 1998, J BIOL CHEM, V273, P21324, DOI 10.1074/jbc.273.33.21324; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; STAROVASNIK MA, 1992, PROTEIN SCI, V1, P245; Surguchov A, 1997, GENOMICS, V39, P312, DOI 10.1006/geno.1996.4513; Tabernero L, 1997, STRUCTURE, V5, P613, DOI 10.1016/S0969-2126(97)00217-7; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Wicki R, 1996, CELL CALCIUM, V20, P459, DOI 10.1016/S0143-4160(96)90087-1; Wriggers W, 1998, BIOPHYS J, V74, P1622, DOI 10.1016/S0006-3495(98)77876-2; Yamaguchi K, 1999, J BIOL CHEM, V274, P3610, DOI 10.1074/jbc.274.6.3610; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	50	199	210	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1247	1260		10.1074/jbc.275.2.1247	http://dx.doi.org/10.1074/jbc.275.2.1247			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625670	Green Accepted, hybrid			2022-12-25	WOS:000084836600074
J	Kopriva, S; Koprivova, A; Suss, KH				Kopriva, S; Koprivova, A; Suss, KH			Identification, cloning, and properties of cytosolic D-ribulose-5-phosphate 3-epimerase from higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTOSE-PHOSPHATE PATHWAY; RIBULOSE 5-PHOSPHATE 3-EPIMERASE; CALVIN CYCLE; SPINACH-CHLOROPLASTS; ESCHERICHIA-COLI; OXIDATIVE STRESS; TRANSKETOLASE; ENZYME; PURIFICATION; SEQUENCE	Plant cells contain a complete oxidative pentose phosphate pathway in the chloroplasts, but an incomplete pathway was proposed to be present in the cytosol, with cytosolic (cyt) isoforms of ribulose-5-phosphate 3-epimerase (RPEase) and other non-oxidative branch enzymes being undetectable. Here we present for the first time the identification, cloning, and properties of a cyt-RPEase in rice (Oryza sativa) and presence of its homologues in other plant species. Recombinant cyt-RPEase is a homodimer of 24.3-kDa subunits such as in the case of the animal and yeast enzymes, whereas the chloroplast (chl) RPEase is a hexamer. Cytosolic and chloroplastic RPEases cannot be separated by anion exchange chromatography. Since plant cyt-RPEase is more closely related in its primary structure to homologous enzymes in animal and yeast cells than to the chloroplast RPEase, the plant nuclear genes coding for cytosolic and chloroplast RPEases were most likely derived from eubacteria and cyanobacteria, respectively. Accumulation of cyt-RPEase-mRNA and protein is high in root cells, lacking chl-RPEase, and lower in green tissue. These and other observations support the view that green and non-green plant cells possess a complete oxidative pentose phosphate pathway in the cytosol.	Inst Plant Physiol, CH-3013 Bern, Switzerland; Inst Plant Genet & Crop Plant Res, D-06466 Gatersleben, Germany	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Kopriva, S (corresponding author), Inst Forstbot & Baumphysiol, Am Flughafen 17, D-79085 Freiburg, Germany.	kopriva@uni-freiburg.de	Kopriva, Stanislav/C-7401-2013	Kopriva, Stanislav/0000-0002-7416-6551				Allona I, 1998, P NATL ACAD SCI USA, V95, P9693, DOI 10.1073/pnas.95.16.9693; BERNACCHIA G, 1995, EMBO J, V14, P610, DOI 10.1002/j.1460-2075.1995.tb07037.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOWSHER CG, 1992, PLANT J, V2, P893, DOI 10.1111/j.1365-313X.1992.00893.x; Chen YR, 1998, PLANT PHYSIOL, V118, P199, DOI 10.1104/pp.118.1.199; DENNIS DT, 1990, PLANT PHYSL BIOCH MO; Favery B, 1998, EMBO J, V17, P6799, DOI 10.1093/emboj/17.23.6799; FEIERABEND J, 1983, Z PFLANZENPHYSIOL, V110, P247, DOI 10.1016/S0044-328X(83)80107-X; Felsenstein J., 1985, EVOLUTION 1985, V39, P783; Flechner A, 1996, PLANT MOL BIOL, V32, P475, DOI 10.1007/BF00019099; Juhnke H, 1996, MOL GEN GENET, V252, P456, DOI 10.1007/BF02173011; KARMALI A, 1983, BIOCHEM J, V211, P617, DOI 10.1042/bj2110617; Kopp J, 1999, J MOL BIOL, V287, P761, DOI 10.1006/jmbi.1999.2643; Luttge U, 1994, BOTANIK; LYNGSTADAAS A, 1995, MOL GEN GENET, V247, P546, DOI 10.1007/BF00290345; Martin W, 1997, CURR GENET, V32, P1, DOI 10.1007/s002940050241; MARTIN W, 1993, P NATL ACAD SCI USA, V90, P8692, DOI 10.1073/pnas.90.18.8692; Martin W, 1996, PLANT MOL BIOL, V30, P795, DOI 10.1007/BF00019012; Miosga T, 1996, CURR GENET, V30, P404, DOI 10.1007/s002940050149; Mohr H, 1992, PFLANZENPHYSIOLOGIE; Nowitzki U, 1995, PLANT MOL BIOL, V29, P1279, DOI 10.1007/BF00020468; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNARRENBERGER C, 1995, PLANT PHYSIOL, V108, P609, DOI 10.1104/pp.108.2.609; SCHNARRENBERGER C, 1973, ARCH BIOCHEM BIOPHYS, V154, P438, DOI 10.1016/0003-9861(73)90077-5; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Sterky F, 1998, P NATL ACAD SCI USA, V95, P13330, DOI 10.1073/pnas.95.22.13330; SUSS KH, 1993, P NATL ACAD SCI USA, V90, P5514, DOI 10.1073/pnas.90.12.5514; Suss KH, 1997, BOOKS SOIL PLANT ENV, P305; Teige M, 1995, FEBS LETT, V377, P349, DOI 10.1016/0014-5793(95)01373-3; Teige M, 1998, EUR J BIOCHEM, V252, P237, DOI 10.1046/j.1432-1327.1998.2520237.x; Teige M, 1996, PLANT PHYSIOL, V112, P1735; Thom E, 1998, PLANTA, V204, P226, DOI 10.1007/s004250050251; VANDEPEER Y, 1993, COMPUT APPL BIOSCI, V9, P177; Weier T.E., 1982, BOT INTRO PLANT BIOL; WILLIAMSON WT, 1966, METHOD ENZYMOL, V9, P605	36	18	19	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1294	1299		10.1074/jbc.275.2.1294	http://dx.doi.org/10.1074/jbc.275.2.1294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625676	hybrid			2022-12-25	WOS:000084836600080
J	Spahr, H; Beve, J; Larsson, T; Bergstrom, J; Karlsson, KA; Gustafsson, CM				Spahr, H; Beve, J; Larsson, T; Bergstrom, J; Karlsson, KA; Gustafsson, CM			Purification and characterization of RNA polymerase II holoenzyme from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; HEPTAPEPTIDE REPEAT; YEAST; MEDIATOR; PROTEINS; DOMAIN; COMPLEX; IDENTIFICATION; SIGNAL	We have purified the RNA polymerase II holoenzyme from Schizosaccharomyces pombe to near homogeneity, The Mediator complex is considerably smaller than its counterpart in Saccharomyces cerevisiae, containing only nine polypeptides larger than 19 kDa, Five of these Mediator subunits have been identified as the S, pombe homologs to Rgr1, Srb4, Med7, and Nut2 found in S. cerevisiae and the gene product of a previously uncharacterized open reading frame, PMC2, with no clear homologies to any described protein. The presence of Mediator in a S. pombe RNA polymerase II holoenzyme stimulated phosphorylation of the C-terminal domain by TFIIH purified from S, pombe. This stimulation was species-specific, because S. pombe Mediator could not stimulate TFIIH purified from S. cerevisiae, We suggest that the overall structure and mechanism of the Mediator is evolutionary conserved. The subunit composition, however, has evolved to respond properly to physiological signals.	Gothenburg Univ, Inst Med Biochem, S-40530 Gothenburg, Sweden	University of Gothenburg	Gustafsson, CM (corresponding author), Gothenburg Univ, Inst Med Biochem, POB 440, S-40530 Gothenburg, Sweden.			Gustafsson, Claes/0000-0003-3531-8468				Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Balciunas D, 1999, P NATL ACAD SCI USA, V96, P376, DOI 10.1073/pnas.96.2.376; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Gustafsson CM, 1998, J BIOL CHEM, V273, P30851, DOI 10.1074/jbc.273.47.30851; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NONET ML, 1989, GENETICS, V123, P715; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Tabtiang RK, 1998, MOL CELL BIOL, V18, P4707, DOI 10.1128/MCB.18.8.4707; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; Vaughan-Martini Ann, 1998, P391, DOI 10.1016/B978-044481312-1/50052-6	28	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1351	1356		10.1074/jbc.275.2.1351	http://dx.doi.org/10.1074/jbc.275.2.1351			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625684	hybrid			2022-12-25	WOS:000084836600088
J	Tsuchida, M; Manthei, ER; Alam, T; Knechtle, SJ; Hamawy, MM				Tsuchida, M; Manthei, ER; Alam, T; Knechtle, SJ; Hamawy, MM			Regulation of T cell receptor- and CD28-induced tyrosine phosphorylation of the focal adhesion tyrosine kinases Pyk2 and Fak by protein kinase C - A role for protein tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-DEPENDENT PHOSPHORYLATION; PHORBOL ESTER; SIGNAL-TRANSDUCTION; LYMPHOCYTES-T; TUMOR PROMOTERS; PHOSPHOLIPASE-C; ACTIVATION; STIMULATION; PP125(FAK); RAFTK	The T cell receptor (TCR)-CD3 complex and the costimulatory molecule CD28 are critical for T cell function. Both receptors utilize protein tyrosine kinases (PTKs) for the phosphorylation of various signaling molecules, a process that is critical for the function of both receptors, The PTKs of the focal adhesion family, Pyk2 and Fak, have been implicated in the signaling of TCR and CD28. We show here evidence for the regulation of TCR- and CD28-induced tyrosine phosphorylation of the focal adhesion PTKs by protein kinase C (PKC). Thus, treating Jurkat T cells with the PKC activator phorbol 12-myristate 13-acetate (PMA) rapidly and strongly reversed receptor-induced tyrosine phosphorylation of the focal adhesion PTKs. In contrast, PMA did not affect TCR-induced tyrosine phosphorylation of CD3 zeta or the PTKs Fyn and Zap-70. However, PMA induced a strong and rapid dephosphorylation of the linker molecule for activation of T cells. PMA failed to induce the dephosphorylation of proteins in PKC-depleted cells or in cells pretreated with the PKC inhibitor Ro-31-8220, confirming the role of PKC in mediating the PMA effect on receptor-induced protein tyrosine phosphorylation, The involvement of protein tyrosine phosphatases (PTPases) in mediating the dephosphorylation of the focal adhesion PTKs was confirmed by the failure of PMA to dephosphorylate Pyk2 in cells pretreated with the PTPase inhibitor orthovanadate, These results implicate PKC in the regulation of receptor-induced tyrosine phosphorylation of the focal adhesion PTKs in T cells. The data also suggest a role for PTPases in the PKC action.	Univ Wisconsin, Dept Surg, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Hamawy, MM (corresponding author), Univ Wisconsin, Dept Surg, H4-749600 Highland Ave, Madison, WI 53792 USA.			Knechtle, Stuart/0000-0002-1625-385X				ABRAHAM RT, 1988, MOL CELL BIOL, V8, P5448, DOI 10.1128/MCB.8.12.5448; Astier A, 1997, J BIOL CHEM, V272, P228; AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; CANTRELL DA, 1989, J IMMUNOL, V143, P3653; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Fechner JH, 1997, TRANSPLANTATION, V63, P1339, DOI 10.1097/00007890-199705150-00023; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; Hamawy MM, 1997, J BIOL CHEM, V272, P30498, DOI 10.1074/jbc.272.48.30498; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Hutchcroft JE, 1996, J BIOL CHEM, V271, P13362, DOI 10.1074/jbc.271.23.13362; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; ISAKOV N, 1987, J IMMUNOL, V138, P3100; LEDBETTER JA, 1990, BLOOD, V75, P1531; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; MILLS GB, 1989, J IMMUNOL, V142, P1995; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; PARK DJ, 1992, J BIOL CHEM, V267, P1496; PARRY RV, 1997, BIOCHEM SOC T, V25, P305; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsuchida M, 1999, J BIOL CHEM, V274, P6735, DOI 10.1074/jbc.274.10.6735; Tsuchida M, 1999, EUR J IMMUNOL, V29, P2354, DOI 10.1002/(SICI)1521-4141(199907)29:07<2354::AID-IMMU2354>3.0.CO;2-P; van Seventer GA, 1998, EUR J IMMUNOL, V28, P3867, DOI 10.1002/(SICI)1521-4141(199811)28:11<3867::AID-IMMU3867>3.3.CO;2-B; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WARD SG, 1990, J IMMUNOL, V144, P3523; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	55	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1344	1350		10.1074/jbc.275.2.1344	http://dx.doi.org/10.1074/jbc.275.2.1344			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625683	hybrid			2022-12-25	WOS:000084836600087
J	McLarren, KW; Lo, R; Grbavec, D; Thirunavukkarasu, K; Karsenty, G; Stifani, S				McLarren, KW; Lo, R; Grbavec, D; Thirunavukkarasu, K; Karsenty, G; Stifani, S			The mammalian basic helix loop helix protein HES-1 binds to and modulates the transactivating function of the Runt-related factor Cbfa1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; GENE RUNT; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTIONAL REPRESSORS; DROSOPHILA SEGMENTATION; CLEIDOCRANIAL DYSPLASIA; CELL-DIFFERENTIATION; SEX DETERMINATION; OSTEOCALCIN GENE; EXPRESSION	Drosophila Runt is the founding member of a family of related transcription factors involved in the regulation of a variety of cell-differentiation events in invertebrates and vertebrates. Runt-related proteins act as both transactivators and transcriptional repressors, suggesting that context-dependent mechanisms modulate their transcriptional properties. The aim of this study was to elucidate the molecular mechanisms that contribute to the regulation of the functions of the mammalian Runt-related protein, Cbfa1. Here we provide the first demonstration that Cbfa1 (as well as the related protein, Cbfa2/AML1) physically interacts with the basic helix loop helix transcription factor, HES-1, a mammalian counterpart of the Drosophila Hairy and Enhancer of split proteins. This interaction is mediated by the carboxyl-terminal domains of Cbfa1 and HES-1, but does not require their respective tetrapeptide motifs, WRPY and WRPW. Our studies also show that HES-1 can antagonize the binding of Cbfa1 to mammalian transcriptional corepressors of the Groucho family. Moreover, HES-1 can potentiate Cbfa1-mediated transactivation in transfected cells. Taken together, these findings implicate HES-1 in the transcriptional functions of Cbfa1 and suggest that the concerted activities of Groucho and HES proteins modulate the functions of mammalian Hunt-related proteins.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA	McGill University; Baylor College of Medicine	Stifani, S (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.			Stifani, Stefano/0000-0002-2376-7701	NICHD NIH HHS [HD97006] Funding Source: Medline; NIDCR NIH HHS [DE11290] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; Grbavec D, 1999, BIOCHEM J, V337, P13, DOI 10.1042/0264-6021:3370013; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HIMAI Y, 1998, BIOCHEM BIOPH RES CO, V252, P582; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; ITO Y, 1996, J CANCER RES CLIN, V84, P321; Jen WC, 1999, GENE DEV, V13, P1486, DOI 10.1101/gad.13.11.1486; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; Kramer SG, 1999, DEVELOPMENT, V126, P191; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Matsue M, 1997, BONE, V20, P329, DOI 10.1016/S8756-3282(97)00005-7; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; TSAI CC, 1995, DEVELOPMENT, V121, P453; TSAI CC, 1994, DEVELOPMENT, V120, P1671; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yao J, 1998, DEV GROWTH DIFFER, V40, P133; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5	48	148	158	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					530	538		10.1074/jbc.275.1.530	http://dx.doi.org/10.1074/jbc.275.1.530			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617648	hybrid			2022-12-25	WOS:000085951600072
J	Akhmedov, AT; Gross, B; Jessberger, R				Akhmedov, AT; Gross, B; Jessberger, R			Mammalian SMC3 C-terminal and coiled-coil protein domains specifically bind palindromic DNA, do not block DNA ends, and prevent DNA bending	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; CHROMOSOME CONDENSATION; SACCHAROMYCES-CEREVISIAE; STRUCTURAL MAINTENANCE; MITOTIC CHROMOSOME; COMPLEX; SEGREGATION; FAMILY; RECOMBINATION; CONDENSINS	The C-terminal domains of yeast structural maintenance of chromosomes (SMC) proteins were previously shown to bind double-stranded DNA, which generated the idea of the antiparallel SMC heterodimer, such as the SMC1/3 dimer, bridging two DNA molecules. Analysis of bovine SMC1 and SMC3 protein domains now reveals that not only the C-terminal domains, but also the coiled-coil region, binds DNA, while the N terminus is inactive. Duplex DNA and DNA molecules with secondary structures are highly preferred substrates for both the C-terminal and coiled-coil domains. Contrasting other cruciform DNA-binding proteins hire HMG1, the SMC3 C-terminal and coiled-coil domains do not bend DNA, but rather prevent bending in ring closure assays. Phosphatase, exonuclease, and ligase assays showed that neither domain renders DNA ends inaccessible for other enzymes. These observations allow modifications of models for SMC-DNA interactions.	Basel Inst Immunol, CH-4002 Basel, Switzerland		Jessberger, R (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4002 Basel, Switzerland.							Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; Giese K, 1997, P NATL ACAD SCI USA, V94, P12845, DOI 10.1073/pnas.94.24.12845; Graumann PL, 1998, J BACTERIOL, V180, P5749, DOI 10.1128/JB.180.21.5749-5755.1998; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HAGERMAN PJ, 1988, ANN REV BIOPHYS CHEM, V17, P266; Heck MMS, 1997, CELL, V91, P5, DOI 10.1016/S0092-8674(01)80002-7; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; KOTLARZ D, 1986, EMBO J, V5, P799, DOI 10.1002/j.1460-2075.1986.tb04284.x; Kupfer C, 1996, EUR J BIOCHEM, V238, P77, DOI 10.1111/j.1432-1033.1996.0077q.x; Lieberman E, 1998, OBSTET GYNECOL, V92, P1; Lloyd RS, 1993, NUCLEASES, P263; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; LYUBCHENKO Y, 1991, P NATL ACAD SCI USA, V88, P5331, DOI 10.1073/pnas.88.12.5331; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; Stros M, 1998, J BIOL CHEM, V273, P10355; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Strunnikov AV, 1998, TRENDS CELL BIOL, V8, P454, DOI 10.1016/S0962-8924(98)01370-1; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Stursberg S, 1999, GENE, V228, P1, DOI 10.1016/S0378-1119(99)00021-9; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	40	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38216	38224		10.1074/jbc.274.53.38216	http://dx.doi.org/10.1074/jbc.274.53.38216			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608896	hybrid			2022-12-25	WOS:000084528000096
J	Fuentealba, L; Carey, DJ; Brandan, E				Fuentealba, L; Carey, DJ; Brandan, E			Antisense inhibition of syndecan-3 expression during skeletal muscle differentiation accelerates myogenesis through a basic fibroblast growth factor-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; LIMB CARTILAGE DIFFERENTIATION; MYOBLAST DIFFERENTIATION; FACTOR-BETA; N-SYNDECAN; TERMINAL DIFFERENTIATION; CELL-DIFFERENTIATION; PROLIFERATION; FAMILY; ACTIVATION	Syndecan-3 is a member of a family of transmembrane proteoglycans that posses highly homologous cytoplasmic and transmembrane domains and function as extracellular matrix receptors and low-affinity receptors for signaling molecules such as basic fibroblasts growth factor (FGF-2). Syndecan-3 is transiently expressed in developing limb bud and absent in adult skeletal muscle. In this study we investigated the expression of syndecan-3 and its role on FGF-2-dependent inhibition of myogenesis, Syndecan-3 expression was down-regulated during skeletal muscle differentiation of C2C12 myoblasts, as determined by Northern blot analyses and immunoprecipitation. To probe the function of syndecan-3 during myogenesis, C2C12 myoblasts were stably transfected with a plasmid coding for antisense syndecan-3 mRNA The resulting inhibition of syndecan-3 expression caused accelerated skeletal muscle differentiation, as determined by expression of creatine kinase and myosin and myoblast fusion. Expression of a master transcription factor for muscle differentiation, myogenin, was also accelerated in antisense syndecan-3-transfected myoblasts compared with control transfected and wild type cells. Reduced expression of syndecan-3 resulted in a 13-fold decrease in sensitivity to FGF-S-dependent inhibition of myogenin expression. Addition of heparin partially reversed this effect. These results demonstrate that syndecan-3 expression is down-regulated during differentiation and the level of expression of membrane-bound heparan sulfate on myoblast surface is critical for fine modulation of responsiveness to FGF-2. These findings strongly suggest a role for syndecan-3 in regulation of skeletal muscle terminal differentiation.	Catholic Univ Chile, Fac Biol Sci, Dept Cell & Mol Biol, Santiago, Chile; Penn State Coll Med, Sigfried & janet Weis Ctr Res, Henry Hood MD Res Program, Danville, PA 17822 USA	Pontificia Universidad Catolica de Chile; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Brandan, E (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Casilla 114-D, Santiago, Chile.		Brandan, Enrique/A-7063-2017	Brandan, Enrique/0000-0002-6820-5059	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER; FIC NIH HHS [TW 00093] Funding Source: Medline; NINDS NIH HHS [NS21925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BISCHOFF R, 1986, DEV BIOL, V115, P140, DOI 10.1016/0012-1606(86)90235-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDAN E, 1991, EUR J CELL BIOL, V55, P209; BRANDAN E, 1992, J NEUROSCI RES, V32, P51, DOI 10.1002/jnr.490320107; Brandan E, 1998, BASIC APPL MYOL, V8, P107; Brandan E, 1996, EUR J CELL BIOL, V71, P170; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; CAMPOS A, 1993, EUR J BIOCHEM, V216, P587, DOI 10.1111/j.1432-1033.1993.tb18178.x; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; Carey DJ, 1997, J BIOL CHEM, V272, P2873, DOI 10.1074/jbc.272.5.2873; Carey DJ, 1997, BIOCHEM J, V327, P1; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Dealy CN, 1997, DEV BIOL, V184, P343, DOI 10.1006/dbio.1997.8525; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; GOULD SE, 1995, DEV BIOL, V168, P438, DOI 10.1006/dbio.1995.1093; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HU JS, 1990, J BIOL CHEM, V265, P7914; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Larrain J, 1997, J BIOL CHEM, V272, P18418, DOI 10.1074/jbc.272.29.18418; Larrain J, 1998, J BIOL CHEM, V273, P32288, DOI 10.1074/jbc.273.48.32288; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MEGE RM, 1992, J CELL SCI, V103, P897; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Nakanishi T, 1997, J BIOCHEM-TOKYO, V121, P197; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PACIFICI M, 1980, EXP CELL RES, V126, P143, DOI 10.1016/0014-4827(80)90479-6; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; Seghatoleslami MR, 1996, DEV DYNAM, V207, P114, DOI 10.1002/(SICI)1097-0177(199609)207:1<114::AID-AJA11>3.3.CO;2-7; Shimazu A, 1996, EXP CELL RES, V229, P126, DOI 10.1006/excr.1996.0350; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	44	66	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37876	37884		10.1074/jbc.274.53.37876	http://dx.doi.org/10.1074/jbc.274.53.37876			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608853	hybrid			2022-12-25	WOS:000084528000053
J	Inoue, SB; Qadota, H; Arisawa, M; Watanabe, T; Ohya, Y				Inoue, SB; Qadota, H; Arisawa, M; Watanabe, T; Ohya, Y			Prenylation of Rho1p is required for activation of yeast 1,3-beta-glucan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; RAB GERANYLGERANYL TRANSFERASE; VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; COMPONENT-A; 1,3-BETA-D-GLUCAN SYNTHASE; SCHIZOSACCHAROMYCES-POMBE; METAL REQUIREMENTS; CELL POLARIZATION; ESCORT PROTEIN	One of the essential protein substrates of geranylgeranyl transferase type I in the budding yeast Saccharomyces cerevisiae is a rho-type GTPase, Rho1p, which is a regulatory subunit of 1,3-beta-glucan synthase. Previous studies have indicated that modification of Rho1p is significantly reduced in a mutant of the beta subunit of geranylgeranyl transferase type I called cal1-1. Here we present genetic and biochemical evidence showing that modification of Rho1p is required for activity of 1,3-beta-glucan synthase. The 1,3-beta-glucan synthase activity of the cal1-1 membrane was significantly reduced compared with that of the wild-type membrane. The impaired activity was partly due to the reduced amount of Fks1p, a putative catalytic subunit of 1,3-beta-glucan synthase, but also partly due to reduced affinity between unmodified Rho1p and Fks1p. Glutathione S-transferase (GST)-Rho1 proteins with or without the C-terminal motif required for the modification were purified and used to analyze the interaction. The modified form of GST-Rho1p was specifically able to restore the 1,3-beta-glucan synthase of the rho1-3 membrane. Gel overlay analysis indicated that an unmodified form of GST-Rho1p fails to interact with Fks1p. These results indicated that the geranylgeranylation of Rho1p is a prerequisite to the assembly and activation of 1,3-beta-glucan synthase in vitro. Increased cytoplasmic levels of divalent cations such as Ca2+ restored both Rho1p modification and the 1,3-beta-glucan synthase activity of cal1-1, suggesting that cytoplasmic levels of the divalent cations affect geranylgeranyl transferase type I activity in vivo.	Univ Tokyo, Grad Sch Frontier, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1130033, Japan; Nippon Roche Res Ctr, Dept Mycol, Kanagawa 2478530, Japan; Univ Tokyo, Fac Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, PRESTO, Unit Proc & Combined Circuit, Toyonaka, Osaka 5650082, Japan	University of Tokyo; Roche Holding; University of Tokyo; Japan Science & Technology Agency (JST)	Ohya, Y (corresponding author), Univ Tokyo, Grad Sch Frontier, Dept Integrated Biosci, Bunkyo Ku, Tokyo 1130033, Japan.	ohya@biol.s.u-tokyo.ac.jp						ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; Arellano M, 1996, EMBO J, V15, P4584, DOI 10.1002/j.1460-2075.1996.tb00836.x; Arellano M, 1998, MOL MICROBIOL, V29, P1357, DOI 10.1046/j.1365-2958.1998.01009.x; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; BENITOMORENO RM, 1994, CURR GENET, V27, P23, DOI 10.1007/BF00326574; Cabib E, 1998, ANNU REV BIOCHEM, V67, P307, DOI 10.1146/annurev.biochem.67.1.307; CAPLIN BE, 1994, BBA-PROTEIN STRUCT M, V1205, P39, DOI 10.1016/0167-4838(94)90089-2; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HALACHMI D, 1993, FEBS LETT, V316, P73, DOI 10.1016/0014-5793(93)81739-M; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JIANG Y, 1994, P NATL ACAD SCI USA, V91, P4377, DOI 10.1073/pnas.91.10.4377; JIANG Y, 1993, NATURE, V366, P84, DOI 10.1038/366084a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Kondoh O, 1997, J BACTERIOL, V179, P7734, DOI 10.1128/jb.179.24.7734-7741.1997; MAYER ML, 1992, J BIOL CHEM, V267, P20589; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; Nagahashi S, 1997, MOL GEN GENET, V255, P372, DOI 10.1007/s004380050508; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; OHYA Y, 1984, MOL GEN GENET, V193, P389, DOI 10.1007/BF00382073; OHYA Y, 1986, J GEN MICROBIOL, V132, P979; Ohya Y, 1996, MOL GEN GENET, V252, P1, DOI 10.1007/BF02173199; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OHYA Y, 1986, J BACTERIOL, V165, P28, DOI 10.1128/jb.165.1.28-33.1986; Okano H, 1998, J BIOL CHEM, V273, P26375, DOI 10.1074/jbc.273.41.26375; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055	53	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38119	38124		10.1074/jbc.274.53.38119	http://dx.doi.org/10.1074/jbc.274.53.38119			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608882	hybrid			2022-12-25	WOS:000084528000082
J	Nagai, T; Kawabata, S; Shishikura, F; Sugita, H				Nagai, T; Kawabata, S; Shishikura, F; Sugita, H			Purification, characterization, and amino acid sequence of an embryonic lectin in perivitelline fluid of the horseshoe crab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; CDNA CLONING; SUPERFAMILY; PROTEINS	Hemagglutinating activity in perivitelline fluid of the horseshoe crab embryo dramatically increases during the third and fourth molt of the embryo. A 27-kDa lectin, which we named tachylectin-P (TL-P), was newly identified in perivitelline fluid of the horseshoe crab Tachypleus tridentatus, TL-P preferentially agglutinated human A-type erythrocytes, and the activity was inhibited by N-acetyl group-containing monosaccharides, The amino acid sequence analysis indicated that TL-P is almost structurally the same as a hemocyte-derived lectin with no hemagglutinating activity, tachylectin-1 (TL-1), and that 218 out of 221 amino acid residues in total were conserved between the two lectins. Despite the high sequence similarity, biological and biochemical characteristics of TL-P differed from those of TL-1: (i) unlike TL-1, TL-P agglutinates several animal-derived erythrocytes; (ii) unlike TL-1, TL-P has no significant affinity for bacterial lipopolysaccharides or antibacterial activity; (iii) Based on apparent molecular masses determined by gel filtration, TL-P forms a dimer in solution, while TL-1 is present as a monomer; (iv) and TL-P interacts with endogenous proteins of 13 and 14 kDa present in the perivitelline fluid; however, neither has any affinity for TL-I. We propose that TL-P may have an important role in completing embryonic development by interacting with endogenous glycoproteins or N-acetylhexosamines.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Nihon Univ, Sch Med, Dept Biol, Tokyo 1738610, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan	Kyushu University; Nihon University; University of Tsukuba	Kawabata, S (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan.							Beisel HG, 1999, EMBO J, V18, P2313, DOI 10.1093/emboj/18.9.2313; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HARKEY MA, 1995, DEV BIOL, V168, P549, DOI 10.1006/dbio.1995.1101; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; Huh CG, 1998, J BIOL CHEM, V273, P6565, DOI 10.1074/jbc.273.11.6565; Inamori K, 1999, J BIOL CHEM, V274, P3272, DOI 10.1074/jbc.274.6.3272; Iwanaga S, 1998, J BIOCHEM, V123, P1; Kamata H, 1997, J VOLCANOL GEOTH RES, V78, P51, DOI 10.1016/S0377-0273(97)00011-5; Killian CE, 1996, J BIOL CHEM, V271, P9150, DOI 10.1074/jbc.271.15.9150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1993, ANTIMICROB AGENTS CH, V37, P2534, DOI 10.1128/AAC.37.12.2534; MIURA Y, 1994, J BIOL CHEM, V269, P542; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SEKIGUCHI K, 1973, Science Reports of the Tokyo Kyoiku Daigaku Section B, V15, P153; SEKIGUCHI K, 1988, BIOL HORSESHOE CRABS, P139; SHISHIKURA F, 1984, J BIOCHEM, V96, P629, DOI 10.1093/oxfordjournals.jbchem.a134878; SHISHIKURA F, 1984, J BIOCHEM, V96, P621, DOI 10.1093/oxfordjournals.jbchem.a134877; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SUGITA H, 1979, DEV BIOL, V73, P183, DOI 10.1016/0012-1606(79)90062-9; Sugita H., 1988, BIOL HORSESHOE CRABS, P195; TAKEMOTO H, 1985, ANAL BIOCHEM, V145, P245, DOI 10.1016/0003-2697(85)90357-4; Tateno H, 1998, J BIOL CHEM, V273, P19190, DOI 10.1074/jbc.273.30.19190; TETTAMANTI G, 1968, ARCH BIOCHEM BIOPHYS, V124, P41, DOI 10.1016/0003-9861(68)90301-9	27	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37673	37678		10.1074/jbc.274.53.37673	http://dx.doi.org/10.1074/jbc.274.53.37673			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608824	hybrid			2022-12-25	WOS:000084528000024
J	Rao, VR; Corradetti, MN; Chen, JA; Peng, JR; Yuan, JY; Prestwich, GD; Brugge, JS				Rao, VR; Corradetti, MN; Chen, JA; Peng, JR; Yuan, JY; Prestwich, GD; Brugge, JS			Expression cloning of protein targets for 3-phosphorylated phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; GROWTH-FACTOR; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; 3-OH KINASE; INOSITOL POLYPHOSPHATE; HIGH-AFFINITY; ACTIVATION; BINDING	The phosphatidylinositol 3-kinase (PI 3'-K) family of lipid kinases play a critical role in cell proliferation, survival, vesicle trafficking, motility, cytoskeletal rearrangements, and oncogenesis. To identify downstream effecters of PI 3'-K, we developed a novel screen to isolate proteins that bind to the major products of PI 3'-K: phosphatidylinositol-3,4-bisphosphate (PtdIns-3,4-P-2) and PtdIns-3,4,5-trisphosphate (PtdIns-3,4,S-P-3). This screen uses synthetic biotinylated analogs of these lipids in conjunction with libraries of radiolabeled proteins that are produced by coupled in vitro transcription/translation reactions. The feasibility of the screen was initially demonstrated using avidin-coated beads prebound to biotinylated PtdIns-3,4-P-2 and PtdIns-3,4,5-P-3, to specifically isolate the pleckstrin homology domain of the serine/threonine kinase Akt. We then demonstrated the utility of this technique in isolating novel 3'-phosphorylated phosphatidylinositol (3'-PPI)-binding proteins through the preliminary screening of in. vitro transcribed/translated cDNAs fi om a small pool expression library derived from mouse spleen. Three proteins were isolated that bound specifically to 3'PPIs. Two of these proteins have been previously characterized as PIP3BP/p42(IP4) and the PtdIns-3,4,5-P-3-dependent serine/threonine kinase phosphoinositide-dependent kinase 1. The third protein is a novel protein that contains only a Src homology 2 domain and a pleckstrin homology domain; this protein has a higher specificity for both PtdIns-3,4,5-P-3 and PtdIns-3,4-P-2 than for PtdIns-4,5-bisphosphate. Transcripts of this novel gene are present in every tissue analyzed hut are most prominently expressed in spleen. We have renamed this new protein PRISH for 3'-phosphoinositide-interacting Src homology-containing protein. This report demonstrates the utility of this technique for isolating and characterizing 3'-PPI-binding proteins and has broad applicability for the isolation of binding domains for other Lipid products.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah	Brugge, JS (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.				NCI NIH HHS [CA78773, CA27951] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027951, R01CA078773, R01CA027951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM, 1998, CURRENT PROTOCOLS MO; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Blader IJ, 1999, MOL BIOL CELL, V10, P581, DOI 10.1091/mbc.10.3.581; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen J, 1996, J ORG CHEM, V61, P6305, DOI 10.1021/jo960895r; Chen J, 1998, J ORG CHEM, V63, P6511, DOI 10.1021/jo980501r; Chen J, 1998, J ORG CHEM, V63, P430, DOI 10.1021/jo972046p; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kivens WJ, 1998, MOL CELL BIOL, V18, P5291, DOI 10.1128/MCB.18.9.5291; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rubnitz JE, 1998, J PEDIAT HEMATOL ONC, V20, P1, DOI 10.1097/00043426-199801000-00001; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shirai T, 1998, BBA-MOL CELL RES, V1402, P292, DOI 10.1016/S0167-4889(98)00014-7; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stricker R, 1997, FEBS LETT, V405, P229, DOI 10.1016/S0014-5793(97)00188-9; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; Thum O, 1996, TETRAHEDRON LETT, V37, P9017, DOI 10.1016/S0040-4039(96)02117-X; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Venkateswarlu K, 1999, BIOCHEM J, V340, P359, DOI 10.1042/0264-6021:3400359; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zauli G, 1997, BLOOD, V89, P883, DOI 10.1182/blood.V89.3.883; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	72	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37893	37900		10.1074/jbc.274.53.37893	http://dx.doi.org/10.1074/jbc.274.53.37893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608855	hybrid, Green Published			2022-12-25	WOS:000084528000055
J	Schaaf, SG; Beck, J; Nassal, M				Schaaf, SG; Beck, J; Nassal, M			A small 2 '-OH- and base-dependent recognition element downstream of the initiation site in the RNA encapsidation signal is essential for hepatitis B virus replication initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-LOOP STRUCTURE; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE; DNA-SYNTHESIS; ANGSTROM RESOLUTION; 2'-HYDROXYL GROUP; TYROSINE RESIDUE; PROTEIN; COMPLEX; SEQUENCE	Hepatitis B viruses replicate through reverse transcription of an RNA intermediate. In contrast to retroviral reverse transcriptases, their replication enzyme, P protein, does not use a nucleic acid primer but initiates DNA synthesis de novo from within an RNA stem-loop structure called epsilon. A short DNA oligonucleotide is copied from epsilon and covalently attached to P protein, and then synthesis is arrested. The information for initiation site selection and synthesis arrest must be contained in the structure of the P protein/epsilon complex. Because P protein activity depends on cellular chaperones this complex can as yet only be generated by in vitro translation of duck hepatitis B virus P protein in rabbit reticulocyte lysate; functional interaction with its cognate RNA element DE can be monitored by the covalent labeling of P protein during primer synthesis. Combining this in vitro priming reaction and a set of chimeric RNA-DNA DE analogues, we found that only five ribose residues in the 57-nucleotide stem-loop were sufficient to provide a functional template; these are a single residue in the template region and the two base pairs at the tip of the lower stem. The base identities in the very same region are essential as well. The presence of this 2'-OH- and base-dependent determinant shortly downstream of the initiation site suggests a mechanism that can account for both initiation site selection and programmed primer synthesis arrest.	Univ Hosp Freiburg, Dept Internal Med & Mol Biol 2, D-79106 Freiburg, Germany	University of Freiburg	Nassal, M (corresponding author), Univ Hosp Freiburg, Dept Internal Med & Mol Biol 2, Hugstetter Str 55, D-79106 Freiburg, Germany.	nassal2@ukl.uni-freiburg.de	Nassal, Michael/U-4529-2019	Nassal, Michael/0000-0003-2204-9158; Beck, Jurgen/0000-0001-8794-9320				BAIDYA N, 1995, BIOCHEMISTRY-US, V34, P12363, DOI 10.1021/bi00038a033; BAN C, 1994, J MOL BIOL, V236, P275, DOI 10.1006/jmbi.1994.1134; BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; Beck J, 1996, NUCLEIC ACIDS RES, V24, P4364, DOI 10.1093/nar/24.21.4364; Beck J, 1998, MOL CELL BIOL, V18, P6265, DOI 10.1128/MCB.18.11.6265; Beck J, 1997, J VIROL, V71, P4971, DOI 10.1128/JVI.71.7.4971-4980.1997; Beck J, 1997, VIROLOGY, V227, P500, DOI 10.1006/viro.1996.8329; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Chen B, 1997, J MOL BIOL, V271, P311, DOI 10.1006/jmbi.1997.1185; EGLI M, 1993, BIOCHEMISTRY-US, V32, P3221, DOI 10.1021/bi00064a004; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; KNAUS T, 1993, NUCLEIC ACIDS RES, V21, P3967, DOI 10.1093/nar/21.17.3967; LANFORD RE, 1995, J VIROL, V69, P4431, DOI 10.1128/JVI.69.7.4431-4439.1995; Nassal M, 1996, J VIROL, V70, P2764, DOI 10.1128/JVI.70.5.2764-2773.1996; Nassal M, 1996, J VIRAL HEPATITIS, V3, P217, DOI 10.1111/j.1365-2893.1996.tb00047.x; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; Nassal M, 1999, INTERVIROLOGY, V42, P100, DOI 10.1159/000024970; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; POLLACK JR, 1993, J VIROL, V67, P3254, DOI 10.1128/JVI.67.6.3254-3263.1993; POLLACK JR, 1994, J VIROL, V68, P5579, DOI 10.1128/JVI.68.9.5579-5587.1994; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; RIEGER A, 1995, NUCLEIC ACIDS RES, V23, P3909, DOI 10.1093/nar/23.19.3909; Seeger C, 1997, TRENDS MICROBIOL, V5, P447, DOI 10.1016/S0966-842X(97)01141-4; STEITZ TA, 1993, RNA WORLD, P219; TAVIS JE, 1994, J VIROL, V68, P3536, DOI 10.1128/JVI.68.6.3536-3543.1994; USMAN N, 1992, NUCLEIC ACIDS RES, V20, P6695, DOI 10.1093/nar/20.24.6695; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; van den Worm SHE, 1998, NUCLEIC ACIDS RES, V26, P1345, DOI 10.1093/nar/26.5.1345; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; WANG GH, 1994, J VIROL, V68, P8437, DOI 10.1128/JVI.68.12.8437-8442.1994; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WEBER M, 1994, J VIROL, V68, P2994, DOI 10.1128/JVI.68.5.2994-2999.1994; WITHERELL GW, 1991, PROG NUCLEIC ACID RE, V40, P185; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994	42	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37787	37794		10.1074/jbc.274.53.37787	http://dx.doi.org/10.1074/jbc.274.53.37787			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608840	hybrid			2022-12-25	WOS:000084528000040
J	Shirasaki, F; Makhluf, HA; LeRoy, C; Watson, DK; Trojanowska, M				Shirasaki, F; Makhluf, HA; LeRoy, C; Watson, DK; Trojanowska, M			Ets transcription factors cooperate with Sp1 to activate the human Tenascin-C promoter	ONCOGENE			English	Article						Tenascin-C; transcriptional regulation; Fli1; GABP; Sp1	EXTRACELLULAR-MATRIX PROTEIN; ALPHA-2(I) COLLAGEN GENE; BINDING-SITES; DNA-BINDING; MONOCLONAL-ANTIBODIES; HUMAN FIBROBLASTS; TISSUE INHIBITOR; MOUSE TENASCIN; GROWTH-FACTORS; FAMILY MEMBER	Tenascin-C (TN-C), an extracellular matrix glycoprotein is expressed during embryonic development, but is present only at low levels in normal adult tissues. TN-C is re-expressed during wound healing, fibrotic diseases and in cancer. To better understand the mechanisms that control TN-C gene expression, we examined the regulation of the human TN-C promoter in human fibroblasts. We demonstrate that a short segment of the TN-C promoter between bp -133 and -27 contains three evolutionarily conserved Ets binding sites (EBS). These three EBSs bind in vitro expressed Fli1 protein and mediate transactivation of the TN-C gene by Fli1. Furthermore, two proximal EBSs contribute significantly to basal activity of the TN-C promoter. GABP, which is present in human fibroblast nuclear extracts, interacts with the two proximal EBSs, In addition, several Spl and Sp3 binding sites have been located in close proximity to the EBSs within this promoter region. The studies performed in Drosophila cells demonstrate that either Fli1 or GABP alpha + beta 1 functionally interact with Spl resulting in a synergistic stimulation of the TN-C promoter activity. In conclusion, this study shows for the first time that the TN-C gene is regulated by Ets proteins, which together with Spl act as potent activators of TN-C expression.	Med Univ S Carolina, Hollings Canc Ctr, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Trojanowska, M (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA.			Trojanowska, Maria/0000-0001-9550-7178	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042334] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42334] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; CHIQUETEHRISMANN R, 1995, BIOESSAYS, V17, P873, DOI 10.1002/bies.950171009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPERTINO DW, 1995, P NATL ACAD SCI USA, V92, P2131, DOI 10.1073/pnas.92.6.2131; Copertino DW, 1997, P NATL ACAD SCI USA, V94, P1846, DOI 10.1073/pnas.94.5.1846; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crossin KL, 1996, J CELL BIOCHEM, V61, P592; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FUJIWARA S, 1990, HYBRIDOMA, V9, P559, DOI 10.1089/hyb.1990.9.559; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHERZI R, 1995, FEBS LETT, V369, P335, DOI 10.1016/0014-5793(95)00778-8; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Gherzi R, 1997, DNA CELL BIOL, V16, P559, DOI 10.1089/dna.1997.16.559; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; Hodge DR, 1996, ONCOGENE, V12, P11; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KOIZUMI S, 1990, ONCOGENE, V5, P675; Kusagawa H, 1998, BRIT J CANCER, V77, P98, DOI 10.1038/bjc.1998.15; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Mackie EJ, 1997, INT J BIOCHEM CELL B, V29, P1133, DOI 10.1016/S1357-2725(97)00031-9; Mager AM, 1998, INT J DEV BIOL, V42, P561; Makhluf HA, 1996, J INVEST DERMATOL, V107, P856, DOI 10.1111/1523-1747.ep12331160; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Meyer D, 1995, INT J DEV BIOL, V39, P909; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RAO VN, 1993, ONCOGENE, V8, P2167; RETTIG WJ, 1994, J CELL SCI, V107, P487; SAKAI T, 1993, BRIT J CANCER, V67, P1058, DOI 10.1038/bjc.1993.194; SETH A, 1993, ONCOGENE, V8, P1783; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHOJI T, 1992, VIRCHOWS ARCH A, V421, P53, DOI 10.1007/BF01607139; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; YAMADA S, 1992, LIVER, V12, P10; Yoshida T, 1997, J PATHOL, V182, P421; YOSHIDA T, 1995, CANCER LETT, V90, P65, DOI 10.1016/0304-3835(94)03679-D; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zhang XK, 1995, HYBRIDOMA, V14, P563, DOI 10.1089/hyb.1995.14.563	59	79	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7755	7764		10.1038/sj.onc.1203360	http://dx.doi.org/10.1038/sj.onc.1203360			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618716	Bronze			2022-12-25	WOS:000084256900005
J	Hay, ED				Hay, ED			Biogenesis and organization of extracellular matrix	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		COLLAGEN; CYTOSKELETON; FIBROBLASTS; MIGRATION		Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hay, ED (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 220 Longwood Ave, Boston, MA 02115 USA.				NEI NIH HHS [EY09721] Funding Source: Medline; NICHD NIH HHS [HD00143] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD000143] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009721] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		GODMAN GC, 1960, J BIOPHYS BIOCHEM CY, V8, P719, DOI 10.1083/jcb.8.3.719; Harkin DG, 1996, CELL MOTIL CYTOSKEL, V35, P345, DOI 10.1002/(SICI)1097-0169(1996)35:4<345::AID-CM6>3.0.CO;2-5; Hay E.D., 1983, Modern Cell Biology, V2, P509; Hay E. D., 1991, CELL BIOL EXTRACELLU, P468; HAY ED, 1963, DEV BIOL, V7, P152, DOI 10.1016/0012-1606(63)90114-3; Hay ED, 1995, ACTA ANAT, V154, P8; HYNES RO, 1978, CELL, V15, P875, DOI 10.1016/0092-8674(78)90272-6; NADOL JB, 1969, DEV BIOL, V20, P304, DOI 10.1016/0012-1606(69)90017-7; NIST C, 1975, J CELL BIOL, V65, P75, DOI 10.1083/jcb.65.1.75; PORTER KR, 1959, J BIOPHYS BIOCHEM CY, V5, P153, DOI 10.1083/jcb.5.1.153; PORTER KR, 1949, P SOC EXP BIOL MED, V71, P513; PORTER KR, 1964, BIOPHYS J, V4, P167, DOI 10.1016/S0006-3495(64)86936-8; PORTER KR, 1966, CELLULAR CONCEPTS RH, P6; REVEL JP, 1963, Z ZELLFORSCH MIK ANA, V61, P110, DOI 10.1007/BF00341524; ROSS R, 1965, J CELL BIOL, V27, P83, DOI 10.1083/jcb.27.1.83; ROSS R, 1962, J CELL BIOL, V15, P99, DOI 10.1083/jcb.15.1.99; SEIKEVITZ P, 1960, J BIOPHYS BIOCH CYTO, V7, P619; SUGRUE SP, 1981, J CELL BIOL, V91, P45, DOI 10.1083/jcb.91.1.45; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TOMASEK JJ, 1984, J CELL BIOL, V99, P536, DOI 10.1083/jcb.99.2.536; WEINSTOCK M, 1974, J CELL BIOL, V60, P92, DOI 10.1083/jcb.60.1.92	21	10	12	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S281	S283		10.1096/fasebj.13.9002.S281	http://dx.doi.org/10.1096/fasebj.13.9002.S281			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619144				2022-12-25	WOS:000084390200022
J	Pappas, GD				Pappas, GD			Fine structure of host-graft relationships between transplanted chromaffin cells and CNS	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		RAT PERIAQUEDUCTAL GRAY; CHRONIC PAIN; CANCER PAIN; SURVIVAL; IMPLANTS	Our laboratory studies have shown that transplantation of adrenal medullary tissue or isolated chromaffin cells into central nervous system (CNS) pain modulatory regions (i.e., periaqueductal gay and subarachnoid lumbar spinal cord) can reduce pain sensitivity of rats in both acute and chronic pain. The analgesia produced by these transplants is thought to result from release of both opiate peptides and catecholamines, Morphologically, these animal studies also suggest that there is no development of tolerance over long periods of time, and the transplanted chromaffin cells appear to be robust and well integrated with the host tissue. In our initial clinical studies, where allografts of adrenal medullary tissue were transplanted intrathecally to relieve intractable cancer pain, patients obtained significant and long-lasting pain relief. Increased cerebrospinal fluid (CSF) levels of metenkephalin were correlated with the decreased pain scores. Histology of;autopsy tissue obtained from two patients with 1 year transplants revealed viable transplanted chromaffin cells. Because of the limited availability of human adrenal glands, sources of xenogeneic chromaffin cells will need to be identified if effective transplantation therapy for chronic pain is to be developed further.	Univ Illinois, Inst Psychiat, Dept Psychiat, Chicago, IL 60612 USA; Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pappas, GD (corresponding author), Univ Illinois, Inst Psychiat, Dept Psychiat, 1601 W Taylor St M-C 912, Chicago, IL 60612 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028931] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-28931] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bes JC, 1998, CELL TRANSPLANT, V7, P227, DOI 10.1016/S0963-6897(97)00161-9; Czech KA, 1997, EXP NEUROL, V147, P66, DOI 10.1006/exnr.1997.6589; Lazorthes Y, 1995, ADV STER F, V11, P97; Lazorthes Y, 1991, Adv Tech Stand Neurosurg, V18, P143; Michalewicz P., 1997, Society for Neuroscience Abstracts, V23, P1455; Ortega J D, 1992, Cell Transplant, V1, P33; ORTEGA JD, 1994, J NEURAL TRANSP PLAS, V5, P31, DOI 10.1155/NP.1994.31; ORTEGA JD, 1992, J COMP NEUROL, V323, P13, DOI 10.1002/cne.903230103; Pappas G. D., 1998, ADRENAL CHROMAFFIN C, P343; Pappas GD, 1997, NEUROL RES, V19, P71; PAPPAS GD, 1988, PROG BRAIN RES, V78, P513; SAGEN J, 1990, J NEUROCYTOL, V19, P697, DOI 10.1007/BF01188038; SAGEN J, 1987, ANN NY ACAD SCI, V495, P306, DOI 10.1111/j.1749-6632.1987.tb23683.x; SAGEN J, 1990, PAIN, V42, P69, DOI 10.1016/0304-3959(90)91093-X; Unsicker K, 1996, PROG NEUROBIOL, V48, P307, DOI 10.1016/0301-0082(95)00045-3; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; WASFIE T, 1991, TRANSPLANT P, V23, P378; WILSON SP, 1982, J NEUROSCI, V2, P1150; WINNIE AP, 1993, ANESTHESIOLOGY, V79, P644, DOI 10.1097/00000542-199310000-00004	19	4	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S277	S280		10.1096/fasebj.13.9002.S277	http://dx.doi.org/10.1096/fasebj.13.9002.S277			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619143				2022-12-25	WOS:000084390200021
J	Bertsch, U; Deschermeier, C; Fanick, W; Girkontaite, I; Hillemeier, K; Johnen, H; Weglohner, W; Emmrich, F; Mayr, GW				Bertsch, U; Deschermeier, C; Fanick, W; Girkontaite, I; Hillemeier, K; Johnen, H; Weglohner, W; Emmrich, F; Mayr, GW			The second messenger binding site of inositol 1,4,5-trisphosphate 3-kinase is centered in the catalytic domain and related to the inositol trisphosphate receptor site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MOLECULAR-CLONING; EXPRESSION; PROTEINS; DNA; 5-PHOSPHATASES; IDENTIFICATION; ACTIVATION; CALMODULIN; RESIDUES	A segment of inositol 1,4,5 trisphosphate 3-kinase responsible for inositol 1,4,5-trisphosphate (InsP(3)) binding was characterized and confirmed by three different approaches employing the fully active expressed catalytic domain of the enzyme. Part of this moiety was protected from limited tryptic proteolysis by InsP(3). Sequencing of two fragments of 16 and 21 kDa, generated in the absence or presence of InsP(3), respectively, identified segment Glu-271 to Arg-305 as being protected. 15 monoclonal antibodies, all binding to epitopes within this region, inhibited enzyme activity and interfered with inositol phosphate binding. Detailed enzyme kinetic parameters of 32 site-directed mutants revealed residues Arg-276 and Lys-303 in this segment and Arg-322, located nearby, as directly involved in and five other closely neighbored residues, all located within a segment of 73 amino acids, as also influencing InsP(3) binding. Part of this region is similar in sequence to an InsP(3) binding segment in InsP(3) receptors, Combined with the finding that mutants influencing only ATP binding all lie outside this region, these data indicate that an InsP(3) binding core domain is inserted between two segments acting together in ATP binding and phosphate transfer.	Univ Hamburg, Krankenhaus Eppendorf, Inst Med Biochem & Mol Biol, D-20246 Hamburg, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Brahms Diagnost, D-12099 Berlin, Germany; Univ Klin Leipzig, Inst Klin Immunol & Transfus Med, D-04103 Leipzig, Germany	University of Hamburg; University of Wurzburg; Thermo Fisher Scientific; Brahms AG; Leipzig University	Mayr, GW (corresponding author), Univ Hamburg, Krankenhaus Eppendorf, Inst Med Biochem & Mol Biol, Martinistr 52, D-20246 Hamburg, Germany.		Girkontaite, Irute/K-9017-2013	Girkontaite, Irute/0000-0002-3659-3202				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bertsch U, 1999, GENE, V228, P61, DOI 10.1016/S0378-1119(99)00018-9; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; COMMUNI D, 1993, BIOCHEM J, V291, P811, DOI 10.1042/bj2910811; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FOSTER PS, 1994, EUR J BIOCHEM, V222, P955, DOI 10.1111/j.1432-1033.1994.tb18946.x; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; Kanematsu T, 1996, BIOCHEM J, V313, P319, DOI 10.1042/bj3130319; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; SHIN YS, 1995, MOL CELLS, V5, P348; TAKAZAWA K, 1991, BIOCHEM J, V280, P125, DOI 10.1042/bj2800125; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; TAKAZAWA K, 1991, BIOCHEM BIOPH RES CO, V174, P529, DOI 10.1016/0006-291X(91)91449-M; THOMAS S, 1994, BBA-MOL CELL RES, V1220, P219, DOI 10.1016/0167-4889(94)90139-2; Togashi S, 1997, BIOCHEM J, V326, P221, DOI 10.1042/bj3260221; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	37	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1557	1564		10.1074/jbc.275.3.1557	http://dx.doi.org/10.1074/jbc.275.3.1557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636844	hybrid			2022-12-25	WOS:000084940000007
J	Moore, M; Harrison, MS; Peterson, EC; Henry, R				Moore, M; Harrison, MS; Peterson, EC; Henry, R			Chloroplast Oxa1p homolog albino3 is required for post-translational integration off the light harvesting chlorophyll-binding protein into thylakoid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; N-TERMINI; C-TERMINI; TRANSLOCATION; EXPORT; TRANSPORT; IMPORT; MITOCHONDRIA; INSERTION; PATHWAYS	Multiple sorting pathways operate in chloroplasts to localize proteins to the thylakoid membrane. The signal recognition particle (SRP) pathway in chloroplasts employs the function of a signal recognition particle (cpSRP) to target light harvesting chlorophyll-binding protein (LHCP) to the thylakoid membrane. In assays that reconstitute stroma-dependent LHCP integration in vitro, the stroma is replaceable by the addition of GTP, cpSRP, and an SRP receptor homolog, cpFtsY, Still lacking is an understanding of events that take place at the thylakoid membrane including the identification of membrane proteins that may function at the level of cpFtsY binding or LHCP integration. The identification of Oxalp in mitochondria, an inner membrane translocase component homologous to predicted proteins in bacteria and to the albino3 (ALB3) protein in thylakoids, led us to investigate the potential role of ALB3 in LHGP integration. Antibody raised against a 50-amino acid region of ALB3 (ALB3-50aa) identified a single 45-kDa thylakoid protein. Treatment of thylakoids with antibody to ALB3-50aa inhibited LHCP integration, whereas the same antibody treatment performed in the presence of antigen reversed the inhibition. In contrast, transport by the thylakoid Sec or Delta pH pathways was unaffected. These data support a model whereby a distinct translocase containing ALB3 is used to integrate LHCP into thylakoid membranes.	Univ Arkansas, Dept Biol Sci, SCEN 601, Fayetteville, AR 72701 USA	University of Arkansas System; University of Arkansas Fayetteville	Henry, R (corresponding author), Univ Arkansas, Dept Biol Sci, SCEN 601, Fayetteville, AR 72701 USA.		Peterson, Eric/I-3082-2013					ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1989, J BIOL CHEM, V264, P14225; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; Cristobal S, 1999, J BIOL CHEM, V274, P20068, DOI 10.1074/jbc.274.29.20068; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; HARLOW E, 1988, USING ANTIBODIES LAB, P309; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; HULFORD A, 1994, J BIOL CHEM, V269, P3251; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Kogata N, 1999, FEBS LETT, V447, P329, DOI 10.1016/S0014-5793(99)00305-1; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Nilsson R, 1999, EMBO J, V18, P733, DOI 10.1093/emboj/18.3.733; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schuenemann D, 1999, J BIOL CHEM, V274, P12177, DOI 10.1074/jbc.274.17.12177; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; Zhu YX, 1998, GENE, V208, P1, DOI 10.1016/S0378-1119(97)00613-6	34	186	192	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1529	1532		10.1074/jbc.275.3.1529	http://dx.doi.org/10.1074/jbc.275.3.1529			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636840	hybrid			2022-12-25	WOS:000084940000003
J	Yeh, SR; Couture, M; Ouellet, Y; Guertin, M; Rousseau, DL				Yeh, SR; Couture, M; Ouellet, Y; Guertin, M; Rousseau, DL			A cooperative oxygen finding hemoglobin from Mycobacterium tuberculosis - Stabilization of heme ligands by a distal tyrosine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; ALGA CHLAMYDOMONAS-EUGAMETOS; DIMERIC BACTERIAL HEMOGLOBIN; RESONANCE RAMAN-SCATTERING; SITE-DIRECTED MUTAGENESIS; SPECTROSCOPIC CHARACTERIZATION; ALCALIGENES-EUTROPHUS; ANGSTROM RESOLUTION; INDUCED OXIDATION; PRIMARY SEQUENCE	The homodimeric hemoglobin (HbN) from Mycobacterium tuberculosis displays an extremely high oxygen binding affinity and cooperativity, Sequence alignment with other hemoglobins suggests that the proximal F8 ligand is histidine, the distal E7 residue is leucine, and the B10 position is occupied by tyrosine. To determine how these heme pocket residues regulate the ligand binding affinities and physiological functions of HbN, we have measured the resonance Raman spectra of the O-2, CO, and OH- derivatives of the wild type protein and the B10 Tyr --> Leu and Phe mutants. Taken together these data demonstrate a unique distal environment in which the heme bound ligands strongly interact with the B10 tyrosine residue. The implications of these data on the physiological functions of HbN and another heme-containing protein, cytochrome c oxidase, are considered.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Laval, Fac Sci & Engn, Dept Biochem, Quebec City, PQ G1K 7P4, Canada	Yeshiva University; Albert Einstein College of Medicine; Laval University	Yeh, SR (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.		Couture, Manon/F-8326-2015	Couture, Manon/0000-0001-8296-8055; Yeh, Syun-Ru/0000-0002-9858-386X				ANNI H, 1992, MET IONS BIOL SYST, V28, P219; APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1996, EUR J BIOCHEM, V242, P779, DOI 10.1111/j.1432-1033.1996.0779r.x; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; CRAMM R, 1994, J BIOL CHEM, V269, P7349; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Das TK, 1999, J BIOL CHEM, V274, P2916, DOI 10.1074/jbc.274.5.2916; Das TK, 1998, BIOCHEMISTRY-US, V37, P14471, DOI 10.1021/bi981500w; Das TK, 1999, J BIOL CHEM, V274, P4207, DOI 10.1074/jbc.274.7.4207; DAS TK, 2000, IN PRESS BIOCHEMISTR; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Dikshit KL, 1998, ARCH BIOCHEM BIOPHYS, V349, P161, DOI 10.1006/abbi.1997.0432; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; Herold S, 1998, FEBS LETT, V439, P85, DOI 10.1016/S0014-5793(98)01345-3; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; KITAGAWA T, 1982, NATURE, V298, P869, DOI 10.1038/298869a0; Kushkuley B, 1996, BIOPHYS J, V70, P1214, DOI 10.1016/S0006-3495(96)79680-7; Lee JB, 1998, J AM CHEM SOC, V120, P7493, DOI 10.1021/ja980507y; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; ROUSSEAU DL, 1993, J BIOENERG BIOMEMBR, V25, P165, DOI 10.1007/BF00762858; SASSAROLI M, 1988, BIOCHEMISTRY-US, V27, P2496, DOI 10.1021/bi00407a036; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5486, DOI 10.1021/bi00415a015; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; TSAI PS, 1995, BIOTECHNOL PROGR, V11, P288, DOI 10.1021/bp00033a008; Unno M, 1998, J AM CHEM SOC, V120, P2670, DOI 10.1021/ja973293d; VANWART HE, 1985, J BIOL CHEM, V260, P8372; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; Wang J., 1996, METHODS NITRIC OXIDE, P427; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; YU NT, 1983, BIOCHEMISTRY-US, V22, P4534, DOI 10.1021/bi00288a028; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	50	115	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1679	1684		10.1074/jbc.275.3.1679	http://dx.doi.org/10.1074/jbc.275.3.1679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636862	hybrid			2022-12-25	WOS:000084940000025
J	Tandy, S; Williams, M; Leggett, A; Lopez-Jimenez, M; Dedes, M; Ramesh, B; Srai, SK; Sharp, P				Tandy, S; Williams, M; Leggett, A; Lopez-Jimenez, M; Dedes, M; Ramesh, B; Srai, SK; Sharp, P			Nramp2 expression is associated with pH-dependent iron uptake across the apical membrane of human intestinal Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; BASOLATERAL MEMBRANES; EPITHELIAL-CELLS; ZINC TRANSPORT; LINE CACO-2; MECHANISMS; RAT; ABSORPTION; REDUCTION; MUTATION	The absorption of dietary non-heme iron by intestinal enterocytes is crucial to the maintenance of body iron homeostasis. This process must be tightly regulated since there are no distinct mechanisms for the excretion of excess iron from the body. An insight into the cellular mechanisms has recently been provided by expression cloning of a divalent cation transporter (DCT1) from rat duodenum and positional cloning of its human homologue, Nramp2. Here we demonstrate that Nramp2 is expressed in the apical membrane of the human intestinal epithelial cell line, Caco 2 TC7, and is associated with functional iron transport in these cells with a substrate preference for iron over other divalent cations. Iron transport occurs by a proton-dependent mechanism, exhibiting a concurrent intracellular acidification. Taken together, these data suggest that the expression of the Nramp2 transporter in human enterocytes may play an important role in intestinal iron absorption.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Inst Food Res, Norwich NR4 7UA, Norfolk, England; Royal Free Hosp, Dept Biochem & Mol Biol, London NW3 2PF, England; UCL, Sch Med, London NW3 2PF, England	University of East Anglia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School	Sharp, P (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	p.a.sharp@uea.ac.uk	Srai, Kaila/AAE-7039-2021; Srai, Surjit K/C-5575-2009					Arredondo M, 1997, AM J PHYSIOL-GASTR L, V273, pG275, DOI 10.1152/ajpgi.1997.273.2.G275; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; Carriere V, 1996, AM J PHYSIOL-GASTR L, V270, pG976, DOI 10.1152/ajpgi.1996.270.6.G976; CHANTRET I, 1994, J CELL SCI, V107, P213; COX TM, 1981, BIOCHEM J, V194, P753, DOI 10.1042/bj1940753; COX TM, 1980, Q J MED, V49, P249; FLATMAN R, 1998, J PHYSIOL-LONDON, V511, P26; FLEET JC, 1993, AM J PHYSIOL, V264, pG1037, DOI 10.1152/ajpgi.1993.264.6.G1037; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Glahn RP, 1996, J NUTR, V126, P332, DOI 10.1093/jn/126.1.332; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HALLEUX C, 1991, IN VITRO CELL DEV B, V27, P293; Han O, 1999, J NUTR, V129, P98, DOI 10.1093/jn/129.1.98; HAN O, 1995, J NUTR, V125, P1291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCAS ML, 1978, GUT, V19, P735, DOI 10.1136/gut.19.8.735; MCEWAN GTA, 1988, PROC R SOC SER B-BIO, V234, P219, DOI 10.1098/rspb.1988.0045; Nunez MT, 1996, J NUTR, V126, P2151, DOI 10.1093/jn/126.9.2151; ORiordan DK, 1997, J PHYSIOL-LONDON, V500, P379, DOI 10.1113/jphysiol.1997.sp022028; ORIORDAN DK, 1995, EUR J CLIN INVEST, V25, P722, DOI 10.1111/j.1365-2362.1995.tb01950.x; RAFFANIELLO RD, 1992, J CELL PHYSIOL, V152, P356, DOI 10.1002/jcp.1041520217; RAJA KB, 1992, BIOCHIM BIOPHYS ACTA, V1135, P141, DOI 10.1016/0167-4889(92)90129-Y; SHARP PA, 1994, EXP PHYSIOL, V79, P203, DOI 10.1113/expphysiol.1994.sp003753; SHARP PA, 1998, Z GASTROENTEROL VERH, V36, P342; Su MA, 1998, BLOOD, V92, P2157, DOI 10.1182/blood.V92.6.2157.418k16_2157_2163; TACNET F, 1993, J PHYSIOL-LONDON, V465, P57, DOI 10.1113/jphysiol.1993.sp019666; WILLIAMS MR, 1992, J MEMBRANE BIOL, V129, P179	28	234	237	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1023	1029		10.1074/jbc.275.2.1023	http://dx.doi.org/10.1074/jbc.275.2.1023			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625641	hybrid			2022-12-25	WOS:000084836600045
J	Willoughby, DA; Vilalta, A; Oshima, RG				Willoughby, DA; Vilalta, A; Oshima, RG			An Alu element from the K18 gene confers position-independent expression in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KERATIN-18 GENE; ACID RESPONSE ELEMENT; TRANSCRIPTIONAL INTERFERENCE; PROMOTER ELEMENTS; DOMAIN BOUNDARIES; NUCLEAR MATRIX; GLOBIN GENE; HETEROCHROMATIN; DROSOPHILA; SEQUENCE	We have identified a 323-base pair fragment of the 5'-flanking sequence of the K18 gene, which confers position-independent and copy number-dependent expression on two heterologous transgenes. This fragment is composed primarily of an Alu repetitive element. Its activity in mice is correlated with its RNA polymerase III promoter activity and its orientation-dependent ability to inhibit potential transcriptional interference in a transfection assay. However, the activity of the Alu element is not correlated with its enhancer blocking activity, a characteristic of insulator elements. In addition, this Alu element did not block the suppressive effect of co-injecting mouse or satellite DNA with the transgene. This Alu element is likely responsible for at least part of the protective effects of the sequences flanking the K18. These results suggest that transcriptionally active Alu elements may eliminate transcriptional interference of neighboring genes. This Alu element is one component of the locus control region associated with the K18 gene. Other Alu repetitive elements may also function to define regulatory domains.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Southern California	Oshima, RG (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P30CA030199, R01CA042302, F32CA069823] Funding Source: NIH RePORTER; NCI NIH HHS [CA30199, F32 CA69823, CA42302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; ALSHAWI R, 1990, MOL CELL BIOL, V10, P1192, DOI 10.1128/MCB.10.3.1192; Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; BRITTEN RJ, 1994, P NATL ACAD SCI USA, V91, P6148, DOI 10.1073/pnas.91.13.6148; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; GALANG CK, 1994, ONCOGENE, V9, P2913; Geyer PK, 1997, CURR OPIN GENET DEV, V7, P242, DOI 10.1016/S0959-437X(97)80134-7; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; ICHINOSE Y, 1988, GENE, V70, P85, DOI 10.1016/0378-1119(88)90107-2; JUDD BH, 1955, GENETICS, V40, P739; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; Mihaly J, 1998, CELL MOL LIFE SCI, V54, P60, DOI 10.1007/s000180050125; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Milot E, 1996, TRENDS GENET, V12, P123, DOI 10.1016/0168-9525(96)30019-X; NEZNANOV N, 1993, MOL CELL BIOL, V13, P2214, DOI 10.1128/MCB.13.4.2214; Neznanov N, 1996, MOL BIOL CELL, V7, P541, DOI 10.1091/mbc.7.4.541; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; OCONNOR KL, 1994, BIOTECHNIQUES, V17, P502; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PEREZSTABLE C, 1986, MOL CELL BIOL, V6, P2041, DOI 10.1128/MCB.6.6.2041; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; Rees S, 1996, BIOTECHNIQUES, V20, P102; Rhodes K, 1998, J BIOL CHEM, V273, P26534, DOI 10.1074/jbc.273.41.26534; ROBINSON SI, 1982, CELL, V28, P99, DOI 10.1016/0092-8674(82)90379-8; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; Sambrook J., 2002, MOL CLONING LAB MANU; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WILLOUGHBY DA, 1992, EXP NEUROL, V118, P332, DOI 10.1016/0014-4886(92)90191-R; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zhong XP, 1997, P NATL ACAD SCI USA, V94, P5219, DOI 10.1073/pnas.94.10.5219	50	57	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					759	768		10.1074/jbc.275.2.759	http://dx.doi.org/10.1074/jbc.275.2.759			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625605	hybrid			2022-12-25	WOS:000084836600009
J	Bridges, KG; Hua, QX; Brigham-Burke, MR; Martin, JD; Hensley, P; Dahl, CE; Digard, P; Weiss, MA; Coen, DM				Bridges, KG; Hua, QX; Brigham-Burke, MR; Martin, JD; Hensley, P; Dahl, CE; Digard, P; Weiss, MA; Coen, DM			Secondary structure and structure-activity relationships of peptides corresponding to the subunit interface of herpes simplex virus DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINUS; TRANSACTIVATION DOMAIN; TYPE-1; PROTEIN; UL42; PROCESSIVITY; SPECTROSCOPY; REPLICATION; ASSIGNMENT; COUPLINGS	The interaction of the catalytic subunit of herpes simplex virus DNA polymerase with the processivity subunit, UL42, is essential for viral replication and is thus a potential target for antiviral drug discovery. We have previously reported that a peptide analogous to the C-terminal 36 residues of the catalytic subunit, which are necessary and sufficient for its interaction with UL42, forms a monomeric structure with partial alpha-helical character. This peptide and one analogous to the C-terminal 18 residues specifically inhibit UL42-dependent long chain DNA synthesis. Using multidimensional H-1 nuclear magnetic resonance spectroscopy, we have found that the 36-residue peptide contains partially ordered N- and C-terminal alpha-helices separated by a less ordered region. A series of "alanine scan" peptides derived from the C-terminal 18 residues of the catalytic subunit were tested for their ability to inhibit long-chain DNA synthesis and by circular dichroism for secondary structure. The results identify structural aspects and specific side chains that appear to be crucial for interacting with UL42. These findings may aid in the rational design of new drugs for the treatment of herpesvirus infections.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Chicago, Ctr Mol Oncol, Dept Biochem, Chicago, IL 60639 USA; Univ Chicago, Ctr Mol Oncol, Dept Mol Biol, Chicago, IL 60639 USA; Univ Chicago, Ctr Mol Oncol, Dept Chem, Chicago, IL 60639 USA; SmithKline Beecham Pharmaceut, Dept Biol Struct, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA	Harvard University; Harvard Medical School; University of Chicago; University of Chicago; University of Chicago; GlaxoSmithKline; GlaxoSmithKline	Coen, DM (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.		Digard, Paul/B-7717-2008	Digard, Paul/0000-0002-0872-9440	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI026077, U01AI026077, R21AI126077, R01AI019838, F32AI010111, R01AI026077, R56AI019838] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19838, AI10111, AI26077] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DIGARD P, 1993, J VIROL, V67, P1159, DOI 10.1128/JVI.67.3.1159-1168.1993; DIGARD P, 1995, P NATL ACAD SCI USA, V92, P1456, DOI 10.1073/pnas.92.5.1456; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HAMATAKE RK, 1993, J GEN VIROL, V74, P2181, DOI 10.1099/0022-1317-74-10-2181; Hensley P, 1996, STRUCTURE, V4, P367, DOI 10.1016/S0969-2126(96)00042-1; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; KIM YM, 1989, J MAGN RESON, V84, P9, DOI 10.1016/0022-2364(89)90003-6; Loregian A, 1996, PROTEIN EXPRES PURIF, V8, P381, DOI 10.1006/prep.1996.0114; MARCHETTI ME, 1988, J VIROL, V62, P715, DOI 10.1128/JVI.62.3.715-721.1988; MARCY AI, 1990, NUCLEIC ACIDS RES, V18, P1207, DOI 10.1093/nar/18.5.1207; MARSDEN HS, 1994, J GEN VIROL, V75, P3127, DOI 10.1099/0022-1317-75-11-3127; OSCHKINAT H, 1991, BIOPOLYMERS, V31, P699, DOI 10.1002/bip.360310615; OSHEA EK, 1989, SCIENCE, V243, P238; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; STOW ND, 1993, NUCLEIC ACIDS RES, V21, P87, DOI 10.1093/nar/21.1.87; TENNEY DJ, 1993, J VIROL, V67, P543, DOI 10.1128/JVI.67.1.543-547.1993; Tolman JR, 1996, J MAGN RESON SER B, V112, P245, DOI 10.1006/jmrb.1996.0138; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; Wuthrich K, 1986, NMR PROTEINS NUCL AC	22	23	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					472	478		10.1074/jbc.275.1.472	http://dx.doi.org/10.1074/jbc.275.1.472			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617641	hybrid			2022-12-25	WOS:000085951600065
J	Dwivedi, PP; Omdahl, JL; Kola, I; Hume, DK; May, BK				Dwivedi, PP; Omdahl, JL; Kola, I; Hume, DK; May, BK			Regulation of rat cytochrome P450C24 (CYP24) gene expression - Evidence for functional cooperation of Ras-activated Ets transcription factors with the vitamin D receptor in 1,25-dihydroxyvitamin D-3-mediated induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; D-RESPONSIVE ELEMENTS; GM-CSF PROMOTER; 24-HYDROXYLASE GENE; PHORBOL ESTER; CORE PROMOTER; CELLS; IDENTIFICATION; BINDING; D-3	Transcription of the rat CYP24 gene is induced by 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) through two vitamin D response elements (VDREs), A functional Ras-dependent Ets-binding site (EBS) was located downstream from the proximal VDRE and was critical to 1,25(OH)(2)D-3-mediated induction. Cotransfection of Ets-1 and Ets-2 stimulated induction, which was lost when the EBS was mutated. Multiple nuclear-protein complexes from COS-1 cells bound to the EBS in which three complexes were immunologically related to Ets-1. Transcriptional synergy was observed between the proximal VDRE and adjacent EBS as was the attendant formation of a ternary complex between vitamin D receptor- retinoid X receptor (VDR.RXR) and Ets-1. In the absence of 1,25-(OH)(2)D-3 or in the presence of an inactive proximal VDRE, the EBS failed to respond to exogenous Ets-1. However, Ets-1 increased basal expression when cotransfected with a mutant VDR. The inductive action of 1,25-(OH)(2)D-3 was substantially increased by Ras, which was ablated by mutagenesis of the EBS or by expression of a mutated Ets-1 protein (T38A). EBS contribution to hormone induction was prevented by manumycin A, an inhibitor of Ras farnesylation. A fundamental role was established for transcriptional cooperation between Ras-activated Ets proteins and the VDR.RXR complex in mediating 1,25-(OH)(2)D-3 action on the CYP24 promoter.	Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Monash Univ, Inst Reprod & Dev, Mol Genet & Dev Grp, Melbourne, Vic 3168, Australia; Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia	University of New Mexico; University of Adelaide; Monash University; University of Queensland	Omdahl, JL (corresponding author), Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA.		Kola, Ismail/C-5254-2013	Hume, David/0000-0002-2615-1478				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Berry DM, 1996, J BIOL CHEM, V271, P16090, DOI 10.1074/jbc.271.27.16090; BOYAN BD, 1997, VITAMIN D, P259; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; CHEN ML, 1993, ENDOCRINOLOGY, V132, P1782, DOI 10.1210/en.132.4.1782; Christakos S, 1996, BIOCHEM J, V316, P361, DOI 10.1042/bj3160361; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; Dwivedi PP, 1998, J MOL ENDOCRINOL, V20, P327, DOI 10.1677/jme.0.0200327; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; Graves BJ, 1998, SCIENCE, V279, P1000, DOI 10.1126/science.279.5353.1000; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Haussler M. R., 1997, Vitamin D., P149; Hewison M., 1997, Vitamin D., P447; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; Ishiguro H, 1998, J BIOL CHEM, V273, P21941, DOI 10.1074/jbc.273.34.21941; Issa LL, 1998, INFLAMM RES, V47, P451, DOI 10.1007/s000110050360; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOYAMA H, 1994, J CELL BIOCHEM, V55, P230, DOI 10.1002/jcb.240550210; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; LIU M, 1994, MOL ENDOCRINOL, V8, P1593, DOI 10.1210/me.8.12.1593; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MANDLA S, 1990, ENDOCRINOLOGY, V127, P2639, DOI 10.1210/endo-127-6-2639; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; MITSUNOBU H, 1993, P NATL ACAD SCI USA, V90, P2281; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; Norman A. W., 1997, Vitamin D., P233; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; Omdahl J., 1997, Vitamin D., P69; PETERSON JM, 1996, SCIENCE, V269, P1866; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; SLATER SJ, 1995, J BIOL CHEM, V270, P6639, DOI 10.1074/jbc.270.12.6639; Solomon C, 1998, J BIOL CHEM, V273, P17573, DOI 10.1074/jbc.273.28.17573; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMAS RS, 1995, ONCOGENE, V11, P2135; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	62	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					47	55		10.1074/jbc.275.1.47	http://dx.doi.org/10.1074/jbc.275.1.47			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617584	hybrid			2022-12-25	WOS:000085951600008
J	Ridgeway, AG; Wilton, S; Skerjanc, IS				Ridgeway, AG; Wilton, S; Skerjanc, IS			Myocyte enhancer factor 2C and myogenin up-regulate each other's expression and induce the development of skeletal muscle in P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; MYOSIN HEAVY-CHAIN; TRANSCRIPTION FACTOR MEF2C; HELIX-LOOP-HELIX; DNA-BINDING; GENE-EXPRESSION; MOUSE EMBRYOGENESIS; DIFFERENTIAL TRANSACTIVATION; CARDIAC-MUSCLE; E-BOX	Two families of transcription factors, myogenic regulatory factors (MRFs) and myocyte enhancer factor 2 (MEF2), function synergistically to regulate myogenesis, In addition to activating structural muscle-specific genes, MRFs and MEF2 activate each other's expression. The MRF, myogenin, can activate MEF2 DNA binding activity when transfected into fibroblasts and, in turn, the myogenin promoter contains essential MEF2 DNA binding elements. To determine which MEF2 is involved in this regulation, P19 cells stably expressing MyoD and myogenin were compared for their ability to activate the expression of MEF2 family members. There was very little cross-activation of MyoD expression by myogenin and vice versa, Myogenin expression, and not MyoD, was found to up-regulate MEF2C expression. MEF2A, -B, and -D expression levels were not up regulated by overexpression of either MyoD or myogenin. To examine whether MEF2C can differentially regulate MyoD or myogenin expression, P19 cell lines overexpressing MEF2C were analyzed. MEF2C induced myogenesis in P19 cells and up-regulated the expression of myogenin with 25-fold greater efficiency than that of MyoD. Therefore, myogenin and MEF2C participate in a regulatory loop in differentiating stem cells. This positive regulation does not extend to MyoD or the other MEF2 family members. Consequently, MEF2C appears to play a specific role in early events of myogenesis.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Skerjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.	skerjanc@julian.uwo.ca	Skerjanc, Ilona/AAN-3318-2020					Angello JC, 1997, DEV BIOL, V192, P93, DOI 10.1006/dbio.1997.8722; ARNOLD TE, 1994, EXP CELL RES, V212, P321, DOI 10.1006/excr.1994.1150; ASAKURA A, 1993, MOL CELL BIOL, V13, P7153, DOI 10.1128/MCB.13.11.7153; AURADE F, 1994, DIFFERENTIATION, V55, P185, DOI 10.1046/j.1432-0436.1994.5530185.x; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DENARDI C, 1993, J CELL BIOL, V123, P823, DOI 10.1083/jcb.123.4.823; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FUJISAWASEHARA A, 1992, J BIOL CHEM, V267, P10031; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; Grepin C, 1997, DEVELOPMENT, V124, P2387; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HUGHES SM, 1993, DEVELOPMENT, V118, P1137; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lin MH, 1997, DEV BIOL, V182, P240, DOI 10.1006/dbio.1996.8484; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MERRIFIELD PA, 1989, DEV GENET, V10, P372, DOI 10.1002/dvg.1020100505; MILLER JB, 1993, BIOESSAYS, V15, P191, DOI 10.1002/bies.950150308; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; SKERJANC IS, 1999, IN PRESS TRENDS CARD; Subramanian SV, 1996, MECH DEVELOP, V57, P103, DOI 10.1016/0925-4773(96)00542-4; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VENUTI JM, 1995, J CELL BIOL, V128, P563, DOI 10.1083/jcb.128.4.563; Wilton S, 1999, IN VITRO CELL DEV-AN, V35, P175; Wright WE, 1996, DEV GENET, V19, P131, DOI 10.1002/(SICI)1520-6408(1996)19:2<131::AID-DVG4>3.0.CO;2-A; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhao M, 1999, MOL CELL BIOL, V19, P21	72	65	68	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					41	46		10.1074/jbc.275.1.41	http://dx.doi.org/10.1074/jbc.275.1.41			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617583	hybrid			2022-12-25	WOS:000085951600007
J	Santacruz-Toloza, L; Ottolia, M; Nicoll, DA; Philipson, KD				Santacruz-Toloza, L; Ottolia, M; Nicoll, DA; Philipson, KD			Functional analysis of a disulfide bond in the cardiac Na+-Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; DYNAMIC PROPERTIES; STEADY-STATE; PROTEIN; PURIFICATION; DROSOPHILA; TOPOLOGY; REGION; ATP	The electrophoretic mobility of the cardiac Na+-Ca2+ exchange protein is different under reducing and nonreducing conditions, This mobility shift is eliminated in a cysteine-less exchanger, suggesting that the presence or absence of an intramolecular disulfide bond alters the conformation and mobility of the exchanger. Using cysteine mutagenesis and biochemical analysis, we have identified the cysteine residues involved in the disulfide bond. Cysteine 792 in loop h of the exchanger forms a disulfide bond with either cysteine 14 or 20 near the NH2 terminus. Because the NH2 terminus is extracellular, the data establish that loop h must also be extracellular. A rearrangement of disulfide bonds has previously been implicated in the stimulation of exchange activity by combinations of reducing and oxidizing agents. We have investigated the role of cysteines in the stimulation of the exchanger by the combination of FeSO4 and dithiothreitol (Fe-DTT). Using the giant excised patch technique, we find that stimulation of the wild type exchanger by Fe-DTT is primarily due to the removal of a Na+-dependent inactivation process. Analysis of mutated exchangers, however, indicates that cysteines are not responsible for stimulation of the exchange activity by Fe-DTT, Ca2+ blocks modification of the exchanger by Fe-DTT. Disulfide bonds are not involved in redox stimulation of the exchanger, and the modification reaction is unknown. Modulation of Na+-dependent inactivation may be a general mechanism for regulation of Na+-Ca2+ exchange activity and may have physiological significance.	Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, MRL 3-645, Los Angeles, CA 90095 USA.	Kphilipson@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERS DM, 1991, EXCITATION CONTRACTI; Cook O, 1998, BBA-BIOMEMBRANES, V1371, P40, DOI 10.1016/S0005-2736(97)00272-1; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; Dyck C, 1998, J BIOL CHEM, V273, P12981, DOI 10.1074/jbc.273.21.12981; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; Goldhaber JI, 1996, AM J PHYSIOL-HEART C, V271, pH823, DOI 10.1152/ajpheart.1996.271.3.H823; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; IWATA T, 1995, CELL CALCIUM, V17, P263, DOI 10.1016/0143-4160(95)90072-1; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PHILIPSON KD, 1988, BIOCHIM BIOPHYS ACTA, V945, P298, DOI 10.1016/0005-2736(88)90492-0; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; REEVES JP, 1986, J BIOL CHEM, V261, P4948; Saba RI, 1999, BIOCHEM J, V338, P139, DOI 10.1042/0264-6021:3380139; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249	26	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					182	188		10.1074/jbc.275.1.182	http://dx.doi.org/10.1074/jbc.275.1.182			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617603	hybrid			2022-12-25	WOS:000085951600027
J	Kandror, O; Sherman, M; Goldberg, A				Kandror, O; Sherman, M; Goldberg, A			Rapid degradation of an abnormal protein in Escherichia coli proceeds through repeated cycles of association with GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; MOLECULAR CHAPERONE YDJ1; HEAT-SHOCK PROTEIN; CLP PROTEASE; PROCESSIVE DEGRADATION; SPECIFICITY COMPONENT; TRIGGER FACTOR; IN-VIVO; BINDING; DNAK	Molecular chaperones are necessary for the breakdown of many abnormal proteins, but their functions in this process have remained obscure. The rapid degradation of the abnormal fusion protein CRAG in Escherichia coli requires the molecular chaperones GoEL, GroES, and trigger factor and proceeds through the formation of a CRAG-GroEL-trigger factor complex. Also associated with GroEL are smaller discrete fragments of CRAG. Pulse-chase experiments showed that these fragments were short-lived intermediates in CRAG degradation formed by C-terminal cleavages. Thus, CRAG degradation is not highly processive. In cells lacking the ClpP protease, the generation of these fragments and their subsequent degradation were much slower than in the wild type, Dissociation of CRAG from GroEL was necessary for its digestion by the ClpP protease, because in a groES temperature-sensitive mutant, CRAG was stable and accumulated on GroEL. Furthermore, the expression of a dominant GroEL mutant defective in substrate dissociation slowed degradation of both CRAG and the fragments. Therefore, we suggest that CRAG degradation proceeds through multiple rounds of substrate binding to GroEL, followed by their GroES-dependent dissociation, which allows further digestion by the protease, In this multistep process, GroEL and GroES function repeatedly, apparently to allow further degradation of CRAG and its fragments by the protease.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kandror, O (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; EDMUNDS T, 1986, J CELL BIOCHEM, V32, P187, DOI 10.1002/jcb.240320304; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Hartl F U, 1991, Semin Immunol, V3, P5; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; HUANG HC, 1997, THESIS HARVARD U CAM; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; Kandror O, 1997, J BIOL CHEM, V272, P1730, DOI 10.1074/jbc.272.3.1730; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KANDROR O, 1994, J BIOL CHEM, V269, P23575; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SHERMAN MY, 1992, EMBO J, V11, P71; SHERMAN MYS, 1996, STRESS INDUCIBLE CEL, P57; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Welch WJ, 1991, CURR OPIN CELL BIOL, V3, P1033, DOI 10.1016/0955-0674(91)90125-I; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679	37	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37743	37749		10.1074/jbc.274.53.37743	http://dx.doi.org/10.1074/jbc.274.53.37743			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608834	hybrid			2022-12-25	WOS:000084528000034
J	Wen, X; Lin, HH; Shih, HM; Kung, HJ; Ann, DK				Wen, X; Lin, HH; Shih, HM; Kung, HJ; Ann, DK			Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PLECKSTRIN-HOMOLOGY DOMAIN; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; BINDING DOMAIN; PH DOMAINS; PATHWAY; BMX; PHOSPHORYLATION	Etk/BMX is a non-receptor protein tyrosine kinase that requires a functional phosphatidylinositol 3-kinase via the pleckstrin homology domain to be activated by cytokine. In the present study, a conditionally active form of Etk was constructed by fusing the hormone-binding domain of estrogen receptor (ER) to an amino terminus truncated form of Etk, PH Delta 1-68Etk, to generate Delta Etk:ER. In stably transfected Pa-4 Delta Etk:ER cells, the activity of Delta Etk:ER was stimulated within minutes by the treatment of Delta Etk:ER stimulant, estradiol, and sustained for greater than 24 h. A robust induction in the phosphorylation of signal transducers and activators of transcription (STAT) proteins, including STAT1, STAT3, and STAT5, was accompanied with Delta Etk:ER activation. Moreover, the conditionally activated Etk stimulated STAT1- and STAT5-dependent reporter activities by similar to 160- and similar to 15-fold, respectively, however, elicited only a modest STAT3-mediated reporter activation. Qualitatively comparable results were obtained in lung A549 cells, indicating that Delta Etk:ER inducible system could function in an analogous fashion in different epithelial cells. Furthermore, we demonstrated that Etk activation alone augmented cyclin D1 promoter/enhancer activity via its STAT5 response element in both Pa-4 Delta Etk:ER and A549 cells. Altogether, these findings support the notion that the activation of Etk kinase is sufficient to transactivate STAT-mediated gene expression. Hence, our inducible Delta Etk:ER system represents a novel approach to investigate the biochemical events following Etk activation and to evaluate the contribution by kinase activation of Etk alone or in conjunction with other signaling pathway(s) to the ultimate biological responses.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei, Taiwan; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	University of Southern California; University of Southern California; National Health Research Institutes - Taiwan; University of California System; University of California Davis	Ann, DK (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, PSC-210B,1985 Zonal Ave, Los Angeles, CA 90033 USA.		Shih, Hsiu-Ming/S-7023-2018; Kung, Hsing-Jien/C-7651-2013		NIDCR NIH HHS [R01-DE100742] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baba K, 1999, MOL CELL BIOL, V19, P4405; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Lee CK, 1997, J BIOL CHEM, V272, P21872, DOI 10.1074/jbc.272.35.21872; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Mattsson PT, 1996, BIOESSAYS, V18, P825, DOI 10.1002/bies.950181009; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Saharinen P, 1997, BLOOD, V90, P4341; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SATOH T, 1992, J BIOL CHEM, V267, P25423; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yamaguchi T, 1999, J BIOL CHEM, V274, P15575, DOI 10.1074/jbc.274.22.15575; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770	44	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38204	38210		10.1074/jbc.274.53.38204	http://dx.doi.org/10.1074/jbc.274.53.38204			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608894	hybrid			2022-12-25	WOS:000084528000094
J	Ananthaswamy, HN; Ouhtit, A; Evans, RL; Gorny, A; Khaskina, P; Sands, AT; Conti, CJ				Ananthaswamy, HN; Ouhtit, A; Evans, RL; Gorny, A; Khaskina, P; Sands, AT; Conti, CJ			Persistence of p53 mutations and resistance of keratinocytes to apoptosis are associated with the increased susceptibility of mice lacking the XPC gene to UV carcinogenesis	ONCOGENE			English	Article						sunlight; skin cancer; p53; apoptosis; DNA repair	INDUCED SKIN TUMORS; NUCLEOTIDE EXCISION-REPAIR; SQUAMOUS-CELL CARCINOMAS; GROUP-C FIBROBLASTS; XERODERMA-PIGMENTOSUM; ULTRAVIOLET-B; DNA-DAMAGE; HAIRLESS MICE; MOUSE SKIN; SUPPRESSOR GENE	Like xeroderma pigmentosum (XP) patients, transgenic mice lacking nucleotide excision repair (NER) genes such as XPA and XPC are extremely susceptible to ultraviolet (UV)-induced skin cancer, Because the p53 gene is an important target for UV carcinogenesis and because the p53 protein modulates NER, we investigated the consequences of NER deficiency on UV-induced p53 mutations in XPC-/- mouse skin tumors. Thirty-eight (76%) of 50 UV-induced XPC-/- skin tumor analysed displayed C --> T or CC --> TT transitions at dipyrimidine sites on the untranscribed strand of the p53 gene. A major hot spot for p53 mutation occurred at codon 270, which is also a hot spot in UV-induced skin tumors from NER-proficient C3H and SKH-hr 1 mice. Interestingly, codon 270 mutations were induced in both XPC-/- and +/+ mouse skin after 1 week of UV irradiation, but the mutations persisted only in XPC-/- mouse skin after 3-4 weeks of chronic UV, The persistence of UV-induced p53 mutations in XPC-/- mouse skin was associated with decreased apoptosis and increased proliferation of keratinocytes, suggesting that these events may contribute to the accelerated development of UV-induced skin tumors in XPC-/- mice.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Lexicon Genet, The Woodlands, TX 77381 USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center; Lexicon Pharmaceuticals; University of Texas System; UTMD Anderson Cancer Center	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA046523, P30CA016672, R01CA042157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42157, CA 46523, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Berg RJW, 1997, CANCER RES, V57, P581; Berg RJW, 1998, J INVEST DERMATOL, V110, P405, DOI 10.1111/j.1523-1747.1998.00173.x; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; Cheo DL, 1996, CURR BIOL, V6, P1691, DOI 10.1016/S0960-9822(02)70794-X; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1989, CARCINOGENESIS, V10, P1691, DOI 10.1093/carcin/10.9.1691; de Vries A, 1998, ONCOGENE, V16, P2205, DOI 10.1038/sj.onc.1201744; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; EVANS MK, 1993, CANCER RES, V53, P5377; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FORD JM, 1994, MOL CARCINOGEN, V10, P105, DOI 10.1002/mc.2940100208; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; KANJILAL S, 1993, CANCER RES, V53, P2961; KRESS S, 1992, CANCER RES, V52, P6400; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li G, 1996, AM J PATHOL, V148, P1113; Li G, 1997, AM J PATHOL, V150, P1457; Ljungman M, 1996, ONCOGENE, V13, P823; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nataraj AJ, 1996, P NATL ACAD SCI USA, V93, P7961, DOI 10.1073/pnas.93.15.7961; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; ROBBINS JH, 1988, JAMA-J AM MED ASSOC, V260, P384; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; SETLOW RB, 1969, P NATL ACAD SCI USA, V64, P1035, DOI 10.1073/pnas.64.3.1035; SMITH ML, 1995, ONCOGENE, V10, P1053; Takeuchi S, 1998, CANCER RES, V58, P641; VANKRANEN HJ, 1995, CARCINOGENESIS, V16, P1141; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	39	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7395	7398		10.1038/sj.onc.1203147	http://dx.doi.org/10.1038/sj.onc.1203147			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602497				2022-12-25	WOS:000084119400027
J	Kiermaier, A; Gawn, JM; Desbarats, L; Saffrich, R; Ansorge, W; Farrell, PJ; Eilers, M; Packham, G				Kiermaier, A; Gawn, JM; Desbarats, L; Saffrich, R; Ansorge, W; Farrell, PJ; Eilers, M; Packham, G			DNA binding of USF is required for specific E-box dependent gene activation in vivo	ONCOGENE			English	Article						Myc; Max; USF; prothymosin-alpha; IgH enhancer; EBV	HEAVY-CHAIN ENHANCER; C-MYC; TRANSCRIPTION FACTOR; COOPERATIVE INTERACTION; HISTONE DEACETYLASE; TARGET GENE; CELL-GROWTH; PROTEINS; TRANSFORMATION; RECOGNITION	Although USF-1 and -2 are the major proteins that bind to Myc-regulated E-box (CACGTG) elements in many cells, there is no clear role for USF during Myc-dependent gene regulation. Using dominant negative alleles of USF-1 we now show that DNA binding by USF at a MSc-regulated E-box limits the ability of another E-box binding factor, TFE-3, to activate a target gene of Myc in vivo and to stimulate S phase entry in resting fibroblasts, Similarly, dominant negative alleles of USF-1 relieve the restriction that presents activation of the IgH enhancer by TFE-3 in non B-cells, DNA binding activity of USF complexes is abundant in primary human B-cells and is significantly downregulated during B-cell immortalization, Re-expression of USF-1 in immortalized B-cells retards proliferation. Our data establish an essential role for USF in restricting E-box dependent gene activation in vivo and suggest that this control is relaxed during cellular immortalization.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Microbiol, London W2 1PG, England; EMBL, Biochem Instrumentat Programme, D-69117 Heidelberg, Germany; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ Marburg, Inst Mol Biol & Tumour Res, D-35033 Marburg, Germany	Imperial College London; European Molecular Biology Laboratory (EMBL); Imperial College London; Ludwig Institute for Cancer Research; Philipps University Marburg	Packham, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Microbiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Ansorge, Wilhelm/AAN-8780-2020	Saffrich, Rainer/0000-0002-0547-4550; Eilers, Martin/0000-0002-0376-6533				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Aperlo C, 1996, EUR J BIOCHEM, V241, P249, DOI 10.1111/j.1432-1033.1996.0249t.x; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Berger A, 1998, BBA-LIPID LIPID MET, V1390, P225, DOI 10.1016/S0005-2760(97)00180-X; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; DAMARE ARF, 1994, EMBO J, V13, P180; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Galibert MD, 1997, J IMMUNOL, V159, P6176; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MAEKAWA T, 1991, NUCLEIC ACIDS RES, V19, P4689, DOI 10.1093/nar/19.17.4689; Merrell K, 1997, MOL CELL BIOL, V17, P3335, DOI 10.1128/MCB.17.6.3335; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sinclair Alison J., 1995, V7, P89; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; TOBIAS KE, 1995, ONCOGENE, V11, P1721; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	34	23	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7200	7211		10.1038/sj.onc.1203166	http://dx.doi.org/10.1038/sj.onc.1203166			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602473				2022-12-25	WOS:000084119400003
J	Kogel, D; Bierbaum, H; Preuss, U; Scheidtmann, KH				Kogel, D; Bierbaum, H; Preuss, U; Scheidtmann, KH			C-terminal truncation of Dlk/ZIP kinase leads to abrogation of nuclear transport and high apoptotic activity	ONCOGENE			English	Article						Dlk/ZIP kinase; nuclear transport; PML bodies; actin filaments; apoptosis	PROTEIN-KINASE; CELL-DEATH; SERINE/THREONINE KINASE; SIGNAL-TRANSDUCTION; NASCENT RNA; PATHWAYS; PML; IDENTIFICATION; BODIES	Dlk (also termed ZIP kinase) is a novel serine/threonine kinase with a unique C-terminal domain that is rich in arginine and contains three putative NLS motifs and a functional lecuine zipper. Dlk is indeed localized in the nucleus where it shows a speckled distribution, To elucidate the biological functions of Dlk, we wanted to identify the signals relevant for nuclear transport and further the nuclear structures which Dlk binds to. Expression of various deletion and point mutations of Dlk as GFP fusion proteins revealed that the leucine zipper is required for association with speckles and the most C-terminal NLS is necessary and sufficient for nuclear transport. Interestingly, a C-terminal deletion mutant defective for nuclear transport exhibited a pronounced colocalization with actin filaments and, even more strikingly, was a very potent inducer of apoptosis, This apoptotic activity was abrogated, however, when this mutant was retargeted to the nucleus via a heterologous NLS from large T, indicating that Dlk only exerts an apoptotic activity in the cytoplasm, To identify the speckle like structures to which Dlk binds we performed immunofluorescence analyses with antibodies directed against representative marker proteins of replication, transcription, or splicing centers. None of these marker proteins revealed a colocalization with Dlk. Instead, we found a partial colocalization with PML bodies which seem to play a key role in regulation of apoptosis, Taken together, these data strongly suggest a functional role for Dlk in control of cell survival which is dependent on its subcellular localization.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany	University of Bonn	Scheidtmann, KH (corresponding author), Univ Bonn, Inst Genet, Roemerstr 164, D-53117 Bonn, Germany.			Kogel, Donat/0000-0003-1209-0210				Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HOZAK P, 1994, J CELL SCI, V107, P2191; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STUURMAN N, 1992, J CELL SCI, V101, P773; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	36	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7212	7218		10.1038/sj.onc.1203169	http://dx.doi.org/10.1038/sj.onc.1203169			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602474				2022-12-25	WOS:000084119400004
J	Satir, P				Satir, P			The cilium as a biological nanomachine	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		CILIARY BEAT FREQUENCY; MICROTUBULE TRANSLOCATION; LIGHT-CHAIN; 22S DYNEIN; CYCLIC-AMP; PHOSPHORYLATION; PARAMECIUM; INNER		Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Satir, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; BONINI NM, 1986, CELL MOTIL CYTOSKEL, V6, P256, DOI 10.1002/cm.970060303; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; FAWCETT DW, 1954, J MORPHOL, V94, P221, DOI 10.1002/jmor.1050940202; GIBBONS IR, 1995, CELL MOTIL CYTOSKEL, V32, P136, DOI 10.1002/cm.970320214; Habermacher G, 1997, J CELL BIOL, V136, P167, DOI 10.1083/jcb.136.1.167; Hamasaki T, 1995, BIOPHYS J, V69, P2569, DOI 10.1016/S0006-3495(95)80128-1; HAMASAKI T, 1991, P NATL ACAD SCI USA, V88, P7918, DOI 10.1073/pnas.88.18.7918; HAMASAKI T, 1995, CELL MOTIL CYTOSKEL, V32, P121, DOI 10.1002/cm.970320210; HENNESSEY T, 1985, EUR J CELL BIOL, V36, P153; HOLWILL MEJ, 1994, CELL MOTIL CYTOSKEL, V27, P287, DOI 10.1002/cm.970270402; MANTON I, 1952, SYM SOC EXP BIOL, V6, P306; Porter ME, 1996, CURR OPIN CELL BIOL, V8, P10, DOI 10.1016/S0955-0674(96)80042-1; SATIR P, 1997, HDB PHYSIOL 14, P787; Satir Peter, 1993, Trends in Cell Biology, V3, P409, DOI 10.1016/0962-8924(93)90092-F; SEDAR AW, 1955, J BIOPHYS BIOCHEM CY, V1, P583, DOI 10.1083/jcb.1.6.583; SUGRUE P, 1991, J CELL SCI, V98, P5; Taylor HC, 1999, CELL MOTIL CYTOSKEL, V43, P167, DOI 10.1002/(SICI)1097-0169(1999)43:2<167::AID-CM8>3.3.CO;2-H; [No title captured]	19	13	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S235	S237		10.1096/fasebj.13.9002.S235	http://dx.doi.org/10.1096/fasebj.13.9002.S235			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619134	Bronze			2022-12-25	WOS:000084390200012
J	Baenziger, JE; Morris, ML; Darsaut, TE; Ryan, SE				Baenziger, JE; Morris, ML; Darsaut, TE; Ryan, SE			Effect of membrane lipid composition on the conformational equilibria of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO-CALIFORNICA; AGONIST BINDING; CHOLESTEROL; SPECTROSCOPY; ACTIVATION; BILAYER; NMR	The effects of cholesterol (Chol) and an anionic lipid, dioleoylphosphatidic acid (DOPA) on the conformational equilibria of the nicotinic acetylcholine receptor (nAChR) have been investigated using Fourier transform infrared difference spectroscopy. The difference between spectra recorded in the presence and absence of agonist from the nAChR reconstituted into 3:1:1 egg phosphatidylcholine (EPC)/DOPA/Chol membranes exhibits positive and negative bands that serve as markers of the structural changes associated with the resting to desensitized conformational change. These markers are absent in similar difference spectra recorded from the nAChR reconstituted into EPC membranes lacking both Chol and DOPA, indicating that the nAChR cannot undergo conformational change in response to agonist binding. When low levels of either Chol or DOPA up to 25 mol % of the total lipid are included in the EPC membranes, the markers suggest the predominant stabilization of a conformation that is a structural intermediate between the resting and desensitized states. At higher levels of either Chol or DOPA, the nAChR is stabilized in a conformation that is capable of undergoing agonist-induced desensitization, although DOPA appears to be required for the nAChR to adopt a conformation fully equivalent to that found in native and 3:1:1 EPC/DOPA/Chol membranes. The ability of these two structurally diverse lipids, as well as others (Ryan, S. E., Demers, C. N., Chew, J. P., Baenziger, J. E. (1996) J. Biol. Chem. 271, 24590-24597), to modulate the functional state of the nAChR suggests that lipids act on the nAChR via an indirect effect on some physical property of the lipid bilayer, The data also suggest that anionic lipids are essential to stabilize a fully functional nAChR, We propose that membrane fluidity modulates the relative populations of nAChRs in the resting and desensitized states but that subtle structural changes in the presence of anionic lipids are essential for full activity.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Baenziger, JE (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.			Baenziger, John/0000-0002-2888-5328				Addona GH, 1998, BBA-BIOMEMBRANES, V1370, P299, DOI 10.1016/S0005-2736(97)00280-0; Baenziger JE, 1999, BIOCHEMISTRY-US, V38, P4905, DOI 10.1021/bi990181l; BHUSHAN A, 1993, BIOPHYS J, V64, P716, DOI 10.1016/S0006-3495(93)81431-0; BUTLER DH, 1993, BIOCHIM BIOPHYS ACTA, V1150, P17, DOI 10.1016/0005-2736(93)90116-H; Corbin J, 1998, BBA-BIOMEMBRANES, V1414, P65, DOI 10.1016/S0005-2736(98)00153-9; DAMLE VN, 1978, BIOCHEM BIOPH RES CO, V84, P845, DOI 10.1016/0006-291X(78)91661-3; Dreger M, 1997, BIOCHEMISTRY-US, V36, P839, DOI 10.1021/bi960666z; FERNANDEZBALLESTER G, 1994, BIOCHEMISTRY-US, V33, P4065, DOI 10.1021/bi00179a035; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; MARCELJA S, 1974, BIOCHIM BIOPHYS ACTA, V367, P165, DOI 10.1016/0005-2736(74)90040-6; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; MCNAMEE MG, 1988, ADV MEMBRANE FLUIDIT, V2, P43; METHOT N, 1995, BIOCHEMISTRY-US, V34, P15142, DOI 10.1021/bi00046a021; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; OCHOA ELM, 1983, BIOCHIM BIOPHYS ACTA, V727, P151, DOI 10.1016/0005-2736(83)90379-6; Raines DE, 1998, BBA-BIOMEMBRANES, V1374, P83, DOI 10.1016/S0005-2736(98)00133-3; Rankin SE, 1997, BIOPHYS J, V73, P2446, DOI 10.1016/S0006-3495(97)78273-0; Ryan SE, 1996, J BIOL CHEM, V271, P24590, DOI 10.1074/jbc.271.40.24590; Ryan SE, 1999, MOL PHARMACOL, V55, P348, DOI 10.1124/mol.55.2.348; SALMON A, 1987, J AM CHEM SOC, V109, P2600, DOI 10.1021/ja00243a010; SUNSHINE C, 1994, BBA-BIOMEMBRANES, V1191, P59, DOI 10.1016/0005-2736(94)90233-X; Williamson PTF, 1998, BIOCHEMISTRY-US, V37, P10854, DOI 10.1021/bi980390q; YEAGLE PL, 1988, BIOL CHOLESTEROL, P121	24	119	119	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					777	784		10.1074/jbc.275.2.777	http://dx.doi.org/10.1074/jbc.275.2.777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625607	hybrid			2022-12-25	WOS:000084836600011
J	Han, Q; Campbell, RL; Gangloff, A; Huang, YW; Lin, SX				Han, Q; Campbell, RL; Gangloff, A; Huang, YW; Lin, SX			Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17 beta-hydroxysteroid dehydrogenase - C-18/C-19 steroid discrimination and enzyme-induced strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BREAST-CANCER; PROTEIN; RECEPTOR; NADP(+); BINDING; INHIBITORS; TISSUES; DESIGN; DHEA	Steroid hormones share a very similar structure, but they behave distinctly. We present structures of human estrogenic 17 beta-hydroxysteroid dehydrogenase(17 beta-HSD1) complexes with dehydroepiandrosterone (DHEA) and dihydrotestosterone (DHT), providing the first pictures to date of DHEA and DHT bound to a protein. Comparisons of these structures with that of the enzyme complexed with the most potent estrogen, estradiol, revealed the structural basis and general model for sex hormone recognition and discrimination. Although the binding cavity is almost entirely composed of hydrophobic residues that can make only nonspecific interactions, the arrangement of residues is highly complementary to that of the estrogenic substrate. Relatively small changes in the shape of the steroid hormone can significantly affect the binding affinity and specificity. The K-m of estrone is more than 1000-fold lower than that of DHEA and the K-m of estradiol is about 10 times lower than that of DHT, The structures suggest that Leu-149 is the primary contributor to the discrimination of C-19 steroids and estrogens by 17 beta-HSD1. The critical role of Leu-149 has been well confirmed by site-directed mutagenesis experiments, as the Leu-149 --> Val variant showed a significantly decreased K-m for C-19 steroids while losing discrimination between estrogens and C-19 steroids. The electron density of DHEA also revealed a distortion of its 17-ketone toward a beta-oriented form, which approaches the transition-state conformation for DHEA reduction.	CHU Laval, Res Ctr, MRC, Grp Mol Endocrinol, St Foy, PQ G1V 4G2, Canada; Univ Laval, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Lin, SX (corresponding author), CHU Laval, Res Ctr, MRC, Grp Mol Endocrinol, St Foy, PQ G1V 4G2, Canada.			Lin, Sheng-Xiang/0000-0001-9149-375X; Campbell, Robert/0000-0002-5473-5876				ANDERSSON S, 1995, J ENDOCRINOL, V146, P197, DOI 10.1677/joe.0.1460197; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; Bennett MJ, 1997, STRUCTURE, V5, P799, DOI 10.1016/S0969-2126(97)00234-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON R, 1994, J STEROID BIOCHEM, V50, P275, DOI 10.1016/0960-0760(94)90132-5; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Brunger A.T., 1992, X PLOR VERSION 3 1 M; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAIRA MR, 1995, J CHEM CRYSTALLOGR, V25, P393, DOI 10.1007/BF01665276; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; GHOSH S, 1988, ANAL BIOCHEM, V169, P227, DOI 10.1016/0003-2697(88)90278-3; Griffiths K, 1997, EUR UROL, V32, P24; *INV CORP, 1997, BAC N BLUE TM TRANSF; JARABAK J, 1966, BIOCHEMISTRY-US, V5, P1269, DOI 10.1021/bi00868a021; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LABRIE C, 1992, CANCER RES, V52, P610; LABRIE F, 1994, BAILLIERE CLIN ENDOC, V8, P451, DOI 10.1016/S0950-351X(05)80261-7; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; LIN SX, 1992, J BIOL CHEM, V267, P16182; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; LUU-THE V, 1990, Molecular Endocrinology, V4, P268; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Mazza C, 1998, J BIOL CHEM, V273, P8145, DOI 10.1074/jbc.273.14.8145; MILGROM E, 1990, HORMONES MOL DIS, P405; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nokelainen P, 1998, MOL ENDOCRINOL, V12, P1048, DOI 10.1210/me.12.7.1048; OTWINOWSKI Z, 1996, METHODS ENZYMOLOGY P, V76; Peltoketo H, 1996, J ENDOCRINOL, V150, pS21; Penning TM, 1996, ENDOCR-RELAT CANCER, V3, P41, DOI 10.1677/erc.0.0030041; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; SAWETAWAN C, 1994, MOL CELL ENDOCRINOL, V99, P161, DOI 10.1016/0303-7207(94)90004-3; Shealy CN, 1995, INTEGR PHYS BEH SCI, V30, P308, DOI 10.1007/BF02691603; THOMAS DB, 1984, CANCER-AM CANCER SOC, V53, P595, DOI 10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y	35	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1105	1111		10.1074/jbc.275.2.1105	http://dx.doi.org/10.1074/jbc.275.2.1105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625652	hybrid			2022-12-25	WOS:000084836600056
J	Hjelmsoe, I; Allen, CE; Cohn, MA; Tulchinsky, EM; Wu, LC				Hjelmsoe, I; Allen, CE; Cohn, MA; Tulchinsky, EM; Wu, LC			The kappa B and V(D)J recombination signal sequence binding protein KRC regulates transcription of the mouse metastasis-associated gene S100A4/mts1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MTS1 GENE; TUMOR-CELLS; MOLECULAR-CLONING; CARCINOMA-CELLS; DNA-METHYLATION; ANTISENSE RNA; MESSENGER-RNA; EXPRESSION; P9KA; ELEMENT	A kappa B-like sequence, Sb, is integral to the composite enhancer located in the first intron of the metastasis-associated gene, S100A4/mts1. Oligonucleotides containing this sequence form three specific complexes with nuclear proteins prepared from S100A4/mts1-expressing CSML100 adenocarcinoma cells. Protein studies show the Sb-interacting complexes include NF-kappa B/Rel proteins, p50.p50 and p50.p65 dimers, Additionally, the Sb sequence was bound by an unrelated similar to 200-kDa protein, p200. Site-directed mutagenesis in conjunction with transient transfections indicate that p200, but not the NF-kappa B/Rel proteins, transactivates S100A4/mts1, To identify candidate genes for p200, double-stranded DNA probes containing multiple copies of Sb were used to screen a randomly primed lambda gt11 cDNA expression library made from CSML100 poly(A)(+) RNA. Two clones corresponding to the DNA-binding proteins KRC and Alf1 were identified. KRC encodes a large zinc finger protein that binds to the kappa B motif and to the signal sequences of V(D)J recombination. In vitro DNA binding assays using bacterially expressed KRC fusion proteins, demonstrate specific binding of KRC to the Sb sequence. In addition, introduction of KRC expression vectors into mammalian cells induces expression of S100A4/mts1 and reporter genes driven by S100A4/mts1 gene regulatory sequences. These data indicate that KRC positively regulates transcription of S100A4/mts1.	Ohio State Univ, Dept Internal Med, Davis Med Ctr, Columbus, OH 43210 USA; Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen, Denmark; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol, Columbus, OH 43210 USA; Ohio State Univ, Dept Immunol, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Danish Cancer Society; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Wu, LC (corresponding author), Ohio State Univ, Dept Internal Med, Davis Med Ctr, Rm S2077,480 W 9th Ave, Columbus, OH 43210 USA.		Tulchinsky, Eugene/ABD-7070-2021; Wu, Lai-Chu/E-4328-2011	Wu, Lai-Chu/0000-0002-1348-269X; Cohn, Martin/0000-0002-2988-3009	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048798, R55GM048798] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058] Funding Source: Medline; NIGMS NIH HHS [GM48798] Funding Source: Medline; PHS HHS [T32] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Albertazzi E, 1998, DNA CELL BIOL, V17, P335, DOI 10.1089/dna.1998.17.335; Albertazzi E, 1998, DNA CELL BIOL, V17, P1003, DOI 10.1089/dna.1998.17.1003; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMBARTSUMIAN N, 1995, GENE, V159, P125, DOI 10.1016/0378-1119(94)00778-Q; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Bachmeyer C, 1999, NUCLEIC ACIDS RES, V27, P643, DOI 10.1093/nar/27.2.643; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; Barraclough R, 1998, BBA-MOL CELL RES, V1448, P190, DOI 10.1016/S0167-4889(98)00143-8; BONVEN BJ, 1995, J MOL BIOL, V249, P564, DOI 10.1006/jmbi.1995.0319; BRADY JP, 1995, J BIOL CHEM, V270, P1221, DOI 10.1074/jbc.270.3.1221; Chen DS, 1997, J BIOL CHEM, V272, P20283, DOI 10.1074/jbc.272.32.20283; COLLICK A, 1990, NUCLEIC ACIDS RES, V18, P625, DOI 10.1093/nar/18.3.625; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies MPA, 1996, ONCOGENE, V13, P1631; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dorflinger U, 1999, MOL CELL BIOL, V19, P3736; Dukhanina EA, 1997, FEBS LETT, V410, P403, DOI 10.1016/S0014-5793(97)00576-0; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; Ke YQ, 1997, INT J CANCER, V71, P832, DOI 10.1002/(SICI)1097-0215(19970529)71:5<832::AID-IJC22>3.0.CO;2-8; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Maelandsmo GM, 1996, CANCER RES, V56, P5490; Mak CH, 1998, IMMUNOGENETICS, V48, P32, DOI 10.1007/s002510050397; MAK CH, 1994, NUCLEIC ACIDS RES, V22, P383, DOI 10.1093/nar/22.3.383; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Morgenstern B, 1996, P NATL ACAD SCI USA, V93, P12098, DOI 10.1073/pnas.93.22.12098; Morgenstern B, 1998, BIOINFORMATICS, V14, P290, DOI 10.1093/bioinformatics/14.3.290; Nakamura N, 1998, CLIN EXP METASTAS, V16, P471; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; Prokhortchouk EB, 1998, J MOL BIOL, V280, P227, DOI 10.1006/jmbi.1998.1857; Ridinger K, 1998, BBA-MOL CELL RES, V1448, P254, DOI 10.1016/S0167-4889(98)00137-2; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; SEELER JS, 1994, J VIROL, V68, P1002, DOI 10.1128/JVI.68.2.1002-1009.1994; Sherbet GV, 1998, ANTICANCER RES, V18, P2415; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Tarabykina S, 1996, GENE, V168, P151, DOI 10.1016/0378-1119(95)00742-3; TULCHINSKY E, 1992, P NATL ACAD SCI USA, V89, P9146, DOI 10.1073/pnas.89.19.9146; TULCHINSKY E, 1993, ONCOGENE, V8, P79; TULCHINSKY E, 1995, BBA-GENE STRUCT EXPR, V1261, P243, DOI 10.1016/0167-4781(95)00013-7; Tulchinsky E, 1997, J BIOL CHEM, V272, P4828, DOI 10.1074/jbc.272.8.4828; Tulchinsky EM, 1996, ONCOGENE, V12, P1737; TULCHINSKY EM, 1990, GENE, V87, P219, DOI 10.1016/0378-1119(90)90305-B; Wahls WP, 1998, SOMAT CELL MOLEC GEN, V24, P41, DOI 10.1007/BF02677494; WATANABE Y, 1992, J BIOL CHEM, V267, P17136; WU LC, 1993, NUCLEIC ACIDS RES, V21, P5067, DOI 10.1093/nar/21.22.5067; WU LC, 1996, GENOMICS, V35, P3415	57	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					913	920		10.1074/jbc.275.2.913	http://dx.doi.org/10.1074/jbc.275.2.913			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625627	hybrid			2022-12-25	WOS:000084836600031
J	Mott, JD; Thomas, CL; Rosenbach, MT; Takahara, K; Greenspan, DS; Banda, MJ				Mott, JD; Thomas, CL; Rosenbach, MT; Takahara, K; Greenspan, DS; Banda, MJ			Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE INHIBITOR; BONE MORPHOGENETIC PROTEIN-1; CAPILLARY ENDOTHELIAL-CELLS; ALPHA-1-PROTEINASE INHIBITOR; NEUTROPHIL CHEMOATTRACTANT; MATRIX METALLOPROTEINASES; EXPRESSION; TIMP-1; IDENTIFICATION; GLYCOPROTEIN	Activity of matrix metalloproteinases (MMP) is regulated by a family of proteins called tissue inhibitors of metalloproteinases (TIMP). Four TIMPs have been cloned, and their molecular weights range from 29,000 to 20,000. By reverse zymography, we have observed a metalloproteinase inhibitor with an apparent molecular weight of 16,500 from medium conditioned by human brain tumor cells. Antibodies directed against TIMPs failed to react with the 16,500 molecular weight inhibitor, indicating that it was not a truncated form of a known TIMP. The inhibitor was isolated from conditioned medium using affinity and ion exchange chromatography, N-terminal sequences of the inhibitor matched amino acid sequences within the C-terminal domain of a protein known as procollagen C-terminal proteinase enhancer (PCPE), Thus, the inhibitor was named CT-PCPE. Comparison of the N-terminal domain of TIMP with CT-PCPE revealed that both contained six cysteine residues. As in the case of TIMP, reduction and alkylation abolished the inhibitory activity of CT-PCPE. Purified CT-PCPE inhibited MMP-2 with an IC50 value much greater than that of TIMP-2, This implies that MMPs may not be the physiologic targets for CT-PCPE inhibition. However, these results suggest that CT-PCPE may constitute a new class of metalloproteinase inhibitor.	Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Mott, JD (corresponding author), Lawrence Berkeley Nat Lab, Mail Stop 74-157, Berkeley, CA 94720 USA.			Thomas-Virnig, Christina/0000-0002-8179-7749; Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR43621] Funding Source: Medline; NIEHS NIH HHS [T32-ES07106] Funding Source: Medline; NIGMS NIH HHS [GM46846] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAR R, 1986, COLLAGEN REL RES, V6, P267; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; APODACA G, 1990, CANCER RES, V50, P2322; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; Banyai L, 1999, PROTEIN SCI, V8, P1636, DOI 10.1110/ps.8.8.1636; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Caterina NCM, 1997, J BIOL CHEM, V272, P32141, DOI 10.1074/jbc.272.51.32141; CHANG S, 1994, P NATL ACAD SCI USA, V91, P5695; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERRON GS, 1986, J BIOL CHEM, V261, P2810; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KESSLER E, 1990, BIOCHEM BIOPH RES CO, V173, P81, DOI 10.1016/S0006-291X(05)81024-1; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; LUI YE, 1997, J BIOL CHEM, V272, P20479; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsuzawa K, 1996, J NEUROPATH EXP NEUR, V55, P88, DOI 10.1097/00005072-199601000-00009; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Reddi AH, 1996, SCIENCE, V271, P463, DOI 10.1126/science.271.5248.463; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STOCKER W, 1995, PROTEIN SCI, V4, P823; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	44	94	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1384	1390		10.1074/jbc.275.2.1384	http://dx.doi.org/10.1074/jbc.275.2.1384			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625689	hybrid			2022-12-25	WOS:000084836600093
J	Nakatani, Y; Tanioka, T; Sunaga, S; Murakami, M; Kudo, I				Nakatani, Y; Tanioka, T; Sunaga, S; Murakami, M; Kudo, I			Identification of a cellular protein that functionally interacts with the C2 domain of cytosolic phospholipase A(2)alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIMENTIN INTERMEDIATE FILAMENTS; ARACHIDONIC-ACID RELEASE; HUMAN SW-13 CELLS; MAST-CELLS; CALCIUM IONOPHORE; STEROID-SYNTHESIS; NUCLEAR-ENVELOPE; BINDING DOMAIN; A(2); KINASE	Cytosolic phospholipase A(2) (cPLA(2)) cu plays critical roles in lipid mediator synthesis. We performed far-Western analysis and identified a 60-kDa protein (P60) that interacted with cPLA(2)alpha in a Ca2+-dependent manner. Peptide microsequencing revealed that purified P60 was identical to vimentin, a major component of the intermediate filament. The interaction occurred between the C2 domain of cPLA(2)alpha and the head domain of vimentin. Immunofluorescence microscopic analysis demonstrated that cPLA(2)alpha and vimentin colocalized around the perinuclear area in cPLA(2)alpha-overexpressing human embryonic kidney 293 cells following A23187 stimulation. Forcible expression of vimentin in vimentin-deficient SW13 cells augmented A23187-induced arachidonate release. Moreover, overexpression of the vimentin head domain in rat fibroblastic 3Y1 cells exerted a dominant inhibitory effect on arachidonate metabolism, significantly reducing A23187-induced arachidonate release and attendant prostanoid generation. These results suggest that vimentin is an adaptor for cPLA(2)alpha to function properly during the eicosanoid-biosynthetic process.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.							ABDULLAH K, 1995, BBA-GEN SUBJECTS, V1244, P157, DOI 10.1016/0304-4165(94)00218-M; ALMAHBOBI G, 1992, EXP CELL RES, V200, P361, DOI 10.1016/0014-4827(92)90184-A; AMEGADZIE BY, 1993, GENE, V128, P307, DOI 10.1016/0378-1119(93)90580-V; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; Chou YH, 1997, CURR OPIN CELL BIOL, V9, P49, DOI 10.1016/S0955-0674(97)80151-2; CiesielskiTreska J, 1995, EUR J CELL BIOL, V68, P369; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Czar MJ, 1996, EUR J CELL BIOL, V70, P322; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; FRABKE WW, 1987, CELL, V49, P131; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gillard BK, 1998, EXP CELL RES, V242, P561, DOI 10.1006/excr.1998.4126; Gillard BK, 1998, GLYCOBIOLOGY, V8, P885, DOI 10.1093/glycob/8.9.885; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Hall PF, 1995, J STEROID BIOCHEM, V55, P601, DOI 10.1016/0960-0760(95)00211-1; HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; Inagaki N, 1996, NEUROCHEM RES, V21, P795, DOI 10.1007/BF02532302; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NAKATANI Y, 1994, J IMMUNOL, V153, P796; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Naraba H, 1998, J IMMUNOL, V160, P2974; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SARRIA AJ, 1994, J CELL SCI, V107, P1593; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; TREJOSKALLI AV, 1995, P NATL ACAD SCI USA, V92, P8940, DOI 10.1073/pnas.92.19.8940; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; YAMAKI K, 1992, JPN J PHARMACOL, V58, P299, DOI 10.1254/jjp.58.299	69	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1161	1168		10.1074/jbc.275.2.1161	http://dx.doi.org/10.1074/jbc.275.2.1161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625659	hybrid			2022-12-25	WOS:000084836600063
J	Ryder, JW; Fahlman, R; Wallberg-Henriksson, H; Alessi, DR; Krook, A; Zierath, JR				Ryder, JW; Fahlman, R; Wallberg-Henriksson, H; Alessi, DR; Krook, A; Zierath, JR			Effect of contraction on mitogen-activated protein kinase signal transduction in skeletal muscle - Involvement of the mitogen- and stress-activated protein kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT CAPACITY; MAMMALIAN-CELLS; EXERCISE; PATHWAY; MAP; INHIBITOR; P38; INSULIN; INTERLEUKIN-1; MECHANISM	Growing evidence suggests that activation of mitogen-activated protein kinase (MAPK) signal transduction mediates changes in muscle gene expression in response to exercise. Nevertheless, little is known about upstream or downstream regulation of MAPK in response to muscle contraction. Here we show that ex vivo muscle contraction stimulates extracellular signal-regulated kinase 1 and 2 (ERK1/2), and p38(MAPK) phosphorylation. Phosphorylation of ERK1/2 or p38(MAPK) was unaffected by protein kinase C inhibition (GF109203X), suggesting that protein kinase C is not involved in mediating contraction-induced MAPK signaling. Contraction-stimulated phosphorylation of ERK1/2 and p38(MAPK) was completely inhibited by pretreatment with PD98059 (MAPK kinase inhibitor) and SB203580 (p38(MAPK) inhibitor), respectively. Muscle contraction also activated MAPK downstream targets p90 ribosomal S6 kinase (p90(Rsk)), MAPK-activated protein kinase 2 (MAPKAP-K2), and mitogen- and stress-activated protein kinase 1 (MSK1). Use of PD98059 or SB203580 revealed that stimulation of p90(Rsk) and MAPKAP-K2 most closely reflects ERK and p38MAPK stimulation, respectively. Stimulation of MSK1 in contracting skeletal muscle required the activation of both ERK and p38(MAPK). These data demonstrate that muscle contraction, separate from systemic influence, activates MAPK signaling. Furthermore, we are the first to show that contractile activity stimulates MAPKAP-K2 and MSK1.	Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17176 Stockholm, Sweden; Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; University of Dundee	Zierath, JR (corresponding author), Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden.		Krook, Anna/K-1192-2015	Krook, Anna/0000-0002-0891-0258; Alessi, Dario/0000-0002-2140-9185; Zierath, Juleen/0000-0001-6891-7497				ALESSI DR, 1989, J BIOL CHEM, V270, P274; Armstrong SC, 1999, J MOL CELL CARDIOL, V31, P555, DOI 10.1006/jmcc.1998.0891; Aronson D, 1997, J BIOL CHEM, V272, P25636, DOI 10.1074/jbc.272.41.25636; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; Aronson D, 1998, BIOCHEM BIOPH RES CO, V251, P106, DOI 10.1006/bbrc.1998.9435; BAYAERT R, 1996, EMBO J, V15, P1914; CLELAND PJF, 1989, J BIOL CHEM, V264, P17704; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hjeltnes N, 1998, FASEB J, V12, P1701, DOI 10.1096/fasebj.12.15.1701; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOWERY OH, 1972, FLEXIBLE SYSTEM ENZY, P189; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAY LB, 1988, J BIOL CHEM, V263, P12721; REN JM, 1994, J BIOL CHEM, V269, P14396; RICHTER EA, 1987, FEBS LETT, V217, P232, DOI 10.1016/0014-5793(87)80669-5; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sherwood DJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE870, DOI 10.1152/ajpendo.1999.276.5.E870; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	34	128	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1457	1462		10.1074/jbc.275.2.1457	http://dx.doi.org/10.1074/jbc.275.2.1457			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625698	hybrid			2022-12-25	WOS:000084836600102
J	Collins, BE; Ito, H; Sawada, N; Ishida, H; Kiso, M; Schnaar, RL				Collins, BE; Ito, H; Sawada, N; Ishida, H; Kiso, M; Schnaar, RL			Enhanced binding of the neural siglecs, myelin-associated glycoprotein and Schwann cell myelin protein, to Chol-1 (alpha-series) gangliosides and novel sulfated Chol-1 analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINERGIC-SPECIFIC ANTIGEN; SIALYL-LEWIS-X; IMMUNOGLOBULIN SUPERFAMILY; SELECTIN INHIBITORS; BOVINE BRAIN; ACID; SIALOADHESIN; ADHESION; CD22; RECOGNITION	Extended glycoconjugate binding specificities of three sialic acid-dependent immunoglobulin-like family member lectins (siglecs), myelin-associated glycoprotein (MAG), Schwann cell myelin protein (SMP), and sialoadhesin, were compared by measuring siglec-mediated cell adhesion to immobilized gangliosides, Synthetic gangliosides bearing the oc series determinant (NeuAc alpha 2,6-linked to GalNAc on a gangliotetraose core) were tested, including GD1 alpha (IV(3)NeuAc, III(6)NeuAc-Gg(4)OseCer), GD1 alpha with modified sialic acid residues at the III6-position, and the "Chol-1" gangliosides GT1a alpha (IV(3)NeuAc, III(6)NeuAc, II(3)NeuAc-Gg(4)OseCer) and GQ1b alpha (IV(3)NeuAc, III(6)NeuAc, II3(NeuAc)(2)-Gg(4)OseCer). The a-series gangliosides displayed enhanced potency for MAG- and SMP-mediated cell adhesion (GQ1b alpha > GT1a alpha, GD1 alpha > GT1b, GD1a >> GM1 (nonbinding)), whereas sialoadhesin-mediated adhesion was comparable with cu-series and non-a-series gangliosides, GD1 alpha derivatives with modified sialic acids (7-, 8-, or g-deoxy) or sulfate (instead of sialic acid) at the III6-position supported adhesion comparable with that of GD1 alpha. Notably, a novel GT1a alpha analog with sulfates at two internal sites of sialylation (NeuAc alpha 2,3Gal beta 1,4GalNAc-6-sulfate beta 1, 4Gal3-sulfate beta 1,4Glc beta 1,1'ceramide) was the most potent siglec-binding structure tested to date (10-fold more potent than GT1a alpha in supporting MAG and SMP binding). Together with prior studies, these data indicate that MAG and SMP display an extended structural specificity with a requirement for a terminal alpha 2,3-linked NeuAc and great enhancement by nearby precisely spaced anionic charges.	Johns Hopkins Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Gifu Univ, Dept Appl Bioorgan Chem, Gifu 5011193, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Gifu University	Schnaar, RL (corresponding author), Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	schnaar@jhu.edu	Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484	NIGMS NIH HHS [GM07626] Funding Source: Medline; NINDS NIH HHS [NS37096] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037096, R37NS037096] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; Collins BE, 1997, J BIOL CHEM, V272, P16889, DOI 10.1074/jbc.272.27.16889; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; Crocker P R, 1998, Glycobiology, V8, pv; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; FERRETTI P, 1986, J NEUROCHEM, V46, P1888; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; Galustian C, 1999, J BIOL CHEM, V274, P18213, DOI 10.1074/jbc.274.26.18213; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; HOTTA K, 1995, J CARBOHYD CHEM, V14, P491, DOI 10.1080/07328309508005353; Irie F, 1996, GLYCOCONJUGATE J, V13, P177, DOI 10.1007/BF00731492; Ito H, 1998, CARBOHYD RES, V306, P579; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KELM S, 1993, EUR J BIOCHEM, V255, P663; Kogan TP, 1995, J MED CHEM, V38, P4976, DOI 10.1021/jm00026a004; Li YT, 1999, J BIOL CHEM, V274, P10014, DOI 10.1074/jbc.274.15.10014; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; PRABHANJAN H, 1992, CARBOHYD RES, V233, P87, DOI 10.1016/S0008-6215(00)90922-4; PRABHANJAN H, 1991, CARBOHYD RES, V220, P127, DOI 10.1016/0008-6215(91)80011-B; RAO BNN, 1994, J BIOL CHEM, V269, P19663; RICHARDSON PJ, 1982, J NEUROCHEM, V38, P1605, DOI 10.1111/j.1471-4159.1982.tb06640.x; Sawada N, 1999, CARBOHYD RES, V316, P1, DOI 10.1016/S0008-6215(99)00081-6; SGROI D, 1993, J BIOL CHEM, V268, P7011; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; Strenge K, 1998, EUR J BIOCHEM, V258, P677, DOI 10.1046/j.1432-1327.1998.2580677.x; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; TAKI T, 1986, J BIOL CHEM, V261, P3075; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; Yang LJS, 1996, ANAL BIOCHEM, V236, P161, DOI 10.1006/abio.1996.0145; Yin XH, 1998, J NEUROSCI, V18, P1953, DOI 10.1523/jneurosci.18-06-01953.1998	46	57	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37637	37643		10.1074/jbc.274.53.37637	http://dx.doi.org/10.1074/jbc.274.53.37637			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608819	hybrid			2022-12-25	WOS:000084528000019
J	de la Rosa, DA; Zhang, P; Naray-Fejes-Toth, A; Fejes-Toth, G; Canessa, CM				de la Rosa, DA; Zhang, P; Naray-Fejes-Toth, A; Fejes-Toth, G; Canessa, CM			The serum and glucocorticoid kinase sgk increases the abundance of epithelial sodium channels in the plasma membrane of Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY; EXPRESSION; MEMBER	The serum- and glucocorticoid-induced kinase (sgk) is a serine and threonine kinase that stimulates amiloride-sensitive sodium transport in Xenopus oocytes. Because aldosterone induces phosphorylation on serine/threonine (Ser/Thr) residues in the carboxyl termini of beta and gamma subunits of epithelial sodium channels (ENaCs) and causes an increase in the sgk transcript in mammalian and amphibian renal epithelial cells, it seems likely that sgk mediates the action of aldosterone to stimulate sodium transport. Experiments were performed in Xenopus oocytes to determine the mechanism by which sgk increases sodium conductance by examining its effect on phosphorylation, kinetics, and membrane abundance of ENaC. Our results demonstrate that deletions of the carboxyl termini of the three subunits do not inhibit sgk-induced sodium current, indicating that the effect of sgk is not mediated via phosphorylation within the carboxyl termini of ENaC. They also show no evidence that sgk reduces the removal of ENaC from the plasma membrane because mutations of tyrosine residues in the sequences necessary for endocytosis and degradation did not affect the response to sgk. Further studies performed with the patch-clamp technique indicated that sgk did not increase the open probability or changed the kinetics of ENaC. These studies, however, showed a 3-fold increase in the abundance of ENaC in the plasma membrane in the presence of sgk compared with control. Together, the experiments indicate that sgk stimulates electrogenic sodium transport by increasing the number of ENaCs at the cell surface and suggest that sgk may mediate the early increase in aldosterone-induced sodium current.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Dartmouth Coll, Sch Med, Dept Physiol, Hanover, NH 03755 USA	Yale University; Dartmouth College	Canessa, CM (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06510 USA.		Alvarez de la Rosa, Diego/H-8500-2015	Alvarez de la Rosa, Diego/0000-0002-4324-2793	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054061] Funding Source: NIH RePORTER; NIDDK NIH HHS [5-RO1-DK54061] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISTON TN, 1997, MOL ENDOCRINOL, V11, P934; Asher C, 1996, AM J PHYSIOL-CELL PH, V271, pC605, DOI 10.1152/ajpcell.1996.271.2.C605; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; May A, 1997, J AM SOC NEPHROL, V8, P1813; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; PACHA J, 1993, J GEN PHYSIOL, V102, P25, DOI 10.1085/jgp.102.1.25; ROSSIER BC, 1992, KIDNEY PHYSL PATHOPH, V1, P1373; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031	21	226	228	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37834	37839		10.1074/jbc.274.53.37834	http://dx.doi.org/10.1074/jbc.274.53.37834			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608847	hybrid			2022-12-25	WOS:000084528000047
J	Elmendorf, JS; Boeglin, DJ; Pessin, JE				Elmendorf, JS; Boeglin, DJ; Pessin, JE			Temporal separation of insulin-stimulated GLUT4/IRAP vesicle plasma membrane docking and fusion in 3T3L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; GTP-GAMMA-S; 3T3-L1 ADIPOCYTES; TRANSLOCATION; TRAFFICKING; PROTEIN; AMINOPEPTIDASE; SYNTAXIN-4; MUNC18C; SNARES	Examination of the time and temperature dependence of insulin-stimulated GLUT4/IRAP-containing vesicle trafficking demonstrated an approximate 7-fold increase in the half-time for plasma membrane translocation at 23 degrees C (t(1/2) = similar to 30 min) compared with 37 degrees C (t(1/2) = similar to 4 min) without a significant change in the extent of either GLUT4 or IRAP translocation. Localization of the endogenous GLUT4 and expressed GLUT4-enhanced green fluorescent protein fusion protein in intact 3T3L1 adipocytes demonstrated that at 23 degrees C there was a time-dependent accumulation of discrete GLUT4-containing vesicles adjacent to the inner face of the cell surface membrane but that was not contiguous and/or physically incorporated into the plasma membrane. Together, these data demonstrate that the temperature-dependent decrease in the rate of GLUT4 and IRAP translocation results from a reduction in GLUT4/IRAP-containing vesicle fusion and not trafficking or docking to the plasma membrane.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.				NIDDK NIH HHS [DK25925, DK49781, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R01DK049781, R37DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BABIA T, 1994, EUR J CELL BIOL, V63, P172; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; Blum R, 1999, J CELL SCI, V112, P537; Calakos N, 1996, PHYSIOL REV, V76, P1; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Goda Y, 1997, P NATL ACAD SCI USA, V94, P769, DOI 10.1073/pnas.94.3.769; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin S, 1997, J CELL SCI, V110, P2281; Martin Sally, 1999, Cell Biochemistry and Biophysics, V30, P89, DOI 10.1007/BF02737886; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Oatey PB, 1997, BIOCHEM J, V327, P637; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROBINSON LJ, 1992, AM J PHYSIOL, V263, P383; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; VONGRAFENSTEIN H, 1986, J CELL BIOL, V103, P2343, DOI 10.1083/jcb.103.6.2343; Zorzano A, 1998, INT J MOL MED, V2, P263	29	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37357	37361		10.1074/jbc.274.52.37357	http://dx.doi.org/10.1074/jbc.274.52.37357			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601305	hybrid			2022-12-25	WOS:000084382700076
J	Singh, BB; Patel, HH; Roepman, R; Schick, D; Ferreira, PA				Singh, BB; Patel, HH; Roepman, R; Schick, D; Ferreira, PA			The zinc finger cluster domain of RanBP2 is a specific docking site for the nuclear export factor, exportin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX PROTEIN; ANTI-FUNGAL ANTIBIOTICS; NF-KAPPA-B; LEPTOMYCIN-B; MESSENGER-RNA; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; TRANSPORT FACTOR; FUSION PROTEINS; RAN/TC4 GTPASE	The Ran-binding protein 2 (RanBP2) is a large scaffold cyclophilin-related protein expressed in photoreceptor cells. Red/green opsin, Ran-GTPase, and the 19 S regulatory complex of the proteasome associate with specific RanBP2 structural modules. Some of these play a role in chaperoning the functional expression of opsin. RanBP2 localization at cytoplasmic fibrils emanating from the nuclear pore complex and interaction with the Ran GTPase support also its role in nucleocytoplasmic transport processes. The degenerate nucleoporin repeat motifs FXFG, GLFG, and XXFG have been proposed to mediate the movement of nucleocytoplasmic transport factors, In particular, RanBP2 has been implicated in nuclear import processes, Here, we show the zinc fingers of RanBP2 associate with high specificity to the nuclear export factor, exportin-1 (CRM1). The bovine RanBP2 transcript contained only five of the eight zinc fingers reported in the human counterpart and are sufficient for exportin-1 association with RanBP2. In contrast to Ran interaction with RanBP2-exportin-1 complex, exportin-1 binding to the zinc finger cluster domain of RanBP2 is insensitive to leptomycin B and nucleotide-bound state of Ran-GTPase. Our results indicate that the zinc finger-rich domain of RanBP2 constitutes a docking site for exportin-1 during nuclear export. Thus, RanBP2 emerges as a key component of the nuclear export pathway.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands	Medical College of Wisconsin; Radboud University Nijmegen	Ferreira, PA (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ferreira@post.its.mcw.edu	Ferreira, Paulo A/S-4209-2016; Roepman, Ronald/B-1339-2014; Ferreira, Paulo/A-3893-2008; Patel, Hemal/C-7325-2019	Ferreira, Paulo A/0000-0003-4585-1717; Roepman, Ronald/0000-0002-5178-8163; Patel, Hemal/0000-0001-6722-9625; Singh, Brij/0000-0003-0535-5997	NATIONAL EYE INSTITUTE [R01EY011993] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011993, EY11993] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; ANDEREGG G, 1967, HELV CHIM ACTA, V50, P2330, DOI 10.1002/hlca.19670500817; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; Cheng CL, 1998, J NEUROCHEM, V71, P2401; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; Dasso M, 1998, AM J HUM GENET, V63, P311, DOI 10.1086/301990; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Fekkes P, 1999, BIOCHEMISTRY-US, V38, P5111, DOI 10.1021/bi982818r; FERREIRA PA, 1995, J BIOL CHEM, V270, P23179, DOI 10.1074/jbc.270.39.23179; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Ferreira PA, 1997, P NATL ACAD SCI USA, V94, P1556, DOI 10.1073/pnas.94.4.1556; Ferreira PA, 2000, METHOD ENZYMOL, V315, P455; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1996, ONCOGENE, V13, P1801; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646; HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573; HERKETH TR, 1983, J BIOL CHEM, V258, P4876; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Krebber H, 1997, GENOMICS, V43, P247, DOI 10.1006/geno.1997.4777; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; MANUTIS M, 1997, J CELL BIOL, V135, P1457; MCMORROW I, 1994, BBA-GENE STRUCT EXPR, V1217, P219, DOI 10.1016/0167-4781(94)90040-X; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Neville M, 1999, EMBO J, V18, P3746, DOI 10.1093/emboj/18.13.3746; Nothwang HG, 1998, GENOMICS, V47, P383, DOI 10.1006/geno.1997.5119; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RAYMOND PA, 1993, NEURON, V10, P1161, DOI 10.1016/0896-6273(93)90064-X; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WILKEN N, 1995, EUR J CELL BIOL, V68, P211; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	75	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37370	37378		10.1074/jbc.274.52.37370	http://dx.doi.org/10.1074/jbc.274.52.37370			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601307	Green Published, hybrid			2022-12-25	WOS:000084382700078
J	Stahl, T; Glockmann, C; Soll, J; Heins, L				Stahl, T; Glockmann, C; Soll, J; Heins, L			Tic40, a new "old" subunit of the chloroplast protein import translocon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER ENVELOPE MEMBRANE; PEA-CHLOROPLASTS; MACHINERY; IDENTIFICATION; APPARATUS; COMPONENTS; LOCALIZATION; COMPLEXES	The protein import translocon at the inner envelope of chloroplasts (Tic complex) is a heteroligomeric multisubunit:complex. Here, we describe Tic40 from pea as a new component of this complex. Tic40 from pea is a homologue of a protein described earlier from Brassica napus as Cim/Com44 or the Toc36 subunit of the translocon at the outer envelope of chloroplasts, respectively (Wu, C., Seibert, F. S., and Ko, K. (1994) J. Biol. Chem. 269, 32264-32271; Ko, K., Budd, D., Wu, C., Seibert, F., Kourtz, L., and Ko, Z. W, (1995) J. Biol. Chem, 270, 28601-28608; Pang, P., Meathrel, K., and Ko, K. (1997) J. Biol. Chem. 272, 25623-25627), Tic40 can be covalently connected to Tic110 by the formation of a disulfide bridge under oxidizing conditions, indicating its close physical proximity to an established translocon component. The Tic40 protein is synthesized in the cytosol as a precursor with an N-terminal cleavable chloroplast targeting signal and imported into the organelle via the general import pathway. Immunoblotting and immunogold-labeling studies exclusively confine Tic40 to the chloroplastic inner envelope, in which it is anchored by a single putative transmembrane span.	Univ Kiel, Inst Bot, D-24118 Kiel, Germany	University of Kiel	Soll, J (corresponding author), Univ Kiel, Inst Bot, Bot Garten 1-9, D-24118 Kiel, Germany.							Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; ALEFSEN H, 1994, J PLANT PHYSIOL, V144, P339, DOI 10.1016/S0176-1617(11)81196-X; Bolter B, 1998, FEBS LETT, V441, P59, DOI 10.1016/S0014-5793(98)01525-7; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; GRAY MW, 1993, CURR OPIN GENET DEV, V3, P884, DOI 10.1016/0959-437X(93)90009-E; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HOHFELD J, 1995, CELL, V83, P589; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KO K, 1995, J BIOL CHEM, V270, P28601, DOI 10.1074/jbc.270.48.28601; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Kourtz L, 1997, J BIOL CHEM, V272, P2808, DOI 10.1074/jbc.272.5.2808; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; May T, 1999, FEBS LETT, V452, P52, DOI 10.1016/S0014-5793(99)00527-X; Morin XK, 1997, PLANTA, V201, P119, DOI 10.1007/BF01007696; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; Pang P, 1997, J BIOL CHEM, V272, P25623, DOI 10.1074/jbc.272.41.25623; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SAGHAIMAROOF MA, 1984, P NATL ACAD SCI-BIOL, V81, P8014, DOI 10.1073/pnas.81.24.8014; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; Soll J, 1998, PLANT MOL BIOL, V38, P191, DOI 10.1023/A:1006034020192; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x	38	99	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37467	37472		10.1074/jbc.274.52.37467	http://dx.doi.org/10.1074/jbc.274.52.37467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601321	hybrid			2022-12-25	WOS:000084382700092
J	Oettgen, P; Finger, E; Sun, ZJ; Akbarali, Y; Thamrongsak, U; Boltax, J; Grall, F; Dube, A; Weiss, A; Brown, L; Quinn, G; Kas, K; Endress, G; Kunsch, C; Libermann, TA				Oettgen, P; Finger, E; Sun, ZJ; Akbarali, Y; Thamrongsak, U; Boltax, J; Grall, F; Dube, A; Weiss, A; Brown, L; Quinn, G; Kas, K; Endress, G; Kunsch, C; Libermann, TA			PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC ORGANIZATION; CELLS; PROTEIN; DOMAIN; CANCER; PROMOTER; UPSTREAM; DISEASE; THERAPY; ELEMENT	Prostate cancer, the most frequent solid cancer in older men, is a leading cause of cancer deaths. Although proliferation and differentiation of normal prostate epithelia and the initial growth of prostate cancer cells are androgen-dependent, prostate cancers ultimately become androgen-independent and refractory to hormone therapy. The prostate-specific antigen (PSA) gene has been widely used as a diagnostic indicator for androgen-dependent and -independent prostate cancer. Androgen-induced and prostate epithelium-specific PSA expression is regulated by a proximal promoter and an upstream enhancer via several androgen receptor binding sites. However, little progress has been made in identifying androgen-independent regulatory elements involved in PSA gene regulation. We report the isolation of a novel, prostate epithelium-specific Ets transcription factor, PDEF (prostate-derived Ets factor), that among the Ets family uniquely prefers binding to a GGAT rather than a GGAA core. PDEF acts as an androgen-independent transcriptional activator of the PSA promoter. PDEF also directly interacts with the DNA binding domain of androgen receptor and enhances androgen-mediated activation of the PSA promoter. Our results, as well. as the critical roles of other Ets factors in cellular differentiation and tumorigenesis, strongly suggest that PDEF is an important regulator of prostate gland and/or prostate cancer development.	Beth Israel Deaconess Med Ctr, Dept Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Stanford Univ, Sch Med, Dept Surg & Genet, Stanford, CA 94305 USA; Beth Israel Deaconess Med Ctr, Div Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England; Human Genome Sci Inc, Rockville, MD 20850 USA	Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Harvard Medical School; Stanford University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of York - UK; GlaxoSmithKline; Human Genome Sciences Inc	Libermann, TA (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, New England Baptist Bone & Joint Inst, 4 Blackfan Circle, Boston, MA 02115 USA.	tliberma@caregroup.harvard.edu	Oettgen, Peter/AAF-5026-2021; Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179	NATIONAL CANCER INSTITUTE [K08CA071429] Funding Source: NIH RePORTER; NCI NIH HHS [KO8/CA 71429, R29 CA070297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Ablin RJ, 1997, J CANCER RES CLIN, V123, P583, DOI 10.1007/s004320050110; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen CT, 1998, CANCER RES, V58, P2777; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; Chen Y, 1998, ONCOGENE, V16, P1913, DOI 10.1038/sj.onc.1201719; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG LW, 1997, J CELL BIOCHEM, V6, P174; CHUNG LWK, 1992, J CELL BIOCHEM, P99; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; Culig Z, 1997, DRUG AGING, V10, P50, DOI 10.2165/00002512-199710010-00005; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Koivisto P, 1997, CANCER RES, V57, P314; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Nupponen N, 1999, EUR UROL, V35, P351, DOI 10.1159/000019907; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; PAHL HL, 1993, J BIOL CHEM, V268, P5014; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; Robinson EJ, 1998, PROSTATE, V37, P149, DOI 10.1002/(SICI)1097-0045(19981101)37:3<149::AID-PROS4>3.0.CO;2-E; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Small EJ, 2000, CURR OPIN ONCOL, V12, P265, DOI 10.1097/00001622-200005000-00014; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun ZJ, 1997, NUCLEIC ACIDS RES, V25, P3318, DOI 10.1093/nar/25.16.3318; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang XO, 1999, PROSTATE, V39, P182, DOI 10.1002/(SICI)1097-0045(19990515)39:3<182::AID-PROS6>3.0.CO;2-B; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wei Z, 1999, MOL CELL BIOL, V19, P1271; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197; Zhou J, 1998, ONCOGENE, V17, P2719, DOI 10.1038/sj.onc.1202198; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	50	226	257	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1216	1225		10.1074/jbc.275.2.1216	http://dx.doi.org/10.1074/jbc.275.2.1216			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625666	hybrid			2022-12-25	WOS:000084836600070
J	Diaz, BV; Lenoir, MC; Ladoux, A; Frelin, C; Demarchez, M; Michel, S				Diaz, BV; Lenoir, MC; Ladoux, A; Frelin, C; Demarchez, M; Michel, S			Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED TRANSCRIPTIONAL ACTIVATION; ACID RECEPTOR-GAMMA; AP1 BINDING-SITE; PERMEABILITY FACTOR; HUMAN-SKIN; EPIDERMAL-KERATINOCYTES; CULTURED KERATINOCYTES; NUCLEAR RECEPTORS; GENE-EXPRESSION; TYROSINE KINASE	Vascular endothelial growth factor (VEGF) is overexpressed in hyperproliferative diseases, such as psoriasis and cancers, which are characterized by increased angiogenesis. Experimentally, VEGF overexpression can be induced by the treatment of cell cultures and biological tissues with phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate (TPA). Using normal human keratinocytes in conventional cultures and skin grafted onto nude mice in vivo, we show that retinoids can inhibit TPA-mediated VEGF gene induction at the transcriptional level. Because retinoids are biologically active either by interacting with the nuclear retinoic acid receptors or by interfering with the activator protein 1 (AP1) transcription factor, we studied the effect of the retinoic acid derivative CD 2409, which exhibits strong anti-AP1 activity but does not bind to the known retinoic acid receptors in vitro. The results demonstrate that the inhibition of VEGF expression by retinoids only depends on their anti-AP1 activity and does not require gene transactivation via retinoic acid response elements. Because the VEGF promoter contains four potential AP1 binding sites, we used different promoter constructs to identify the functional site responsible for TPA induction and retinoid inhibition. This site turned out to be localized at position -621 of the 5' flanking region of the VEGF gene.	Galderma R&D, F-06902 Valbonne, France; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Galderma R&D SNC; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Michel, S (corresponding author), Galderma R&D, 635 Route Lucioles,BP67, F-06902 Valbonne, France.		LADOUX, ANNIE/S-2077-2019; LADOUX, ANNIE/O-4267-2016	LADOUX, ANNIE/0000-0003-3857-2621; LADOUX, ANNIE/0000-0003-3857-2621				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ASTROM A, 1991, J BIOL CHEM, V266, P17662; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Brauchle M, 1996, J BIOL CHEM, V271, P21793, DOI 10.1074/jbc.271.36.21793; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CAVEY MT, 1990, ANAL BIOCHEM, V186, P19, DOI 10.1016/0003-2697(90)90565-Q; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claffey KP, 1996, CANCER RES, V56, P172; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DEMARCHEZ M, 1986, DEV BIOL, V113, P90, DOI 10.1016/0012-1606(86)90110-7; Detmar M, 1996, J INVEST DERMATOL, V106, P207, DOI 10.1111/1523-1747.ep12340457; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FARR A, 1987, CANCER CELL, V5, P171; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRITSCH PO, 1992, J AM ACAD DERMATOL, V27, P8; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Lee HY, 1999, MOL CELL BIOL, V19, P1973; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li JJ, 1996, CANCER RES, V56, P483; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OIKAWA T, 1989, CANCER LETT, V48, P157, DOI 10.1016/0304-3835(89)90054-2; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Senger DR, 1996, AM J PATHOL, V149, P293; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Shroot B, 1997, J AM ACAD DERMATOL, V36, pS96, DOI 10.1016/S0190-9622(97)70050-1; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Triozzi PL, 1996, CANCER INVEST, V14, P293, DOI 10.3109/07357909609012154; VEGA B, 1997, Patent No. 82636; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Weninger W, 1998, J INVEST DERMATOL, V111, P907, DOI 10.1046/j.1523-1747.1998.00393.x	62	88	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					642	650		10.1074/jbc.275.1.642	http://dx.doi.org/10.1074/jbc.275.1.642			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617662	hybrid			2022-12-25	WOS:000085951600086
J	Fabunmi, RP; Wigley, WC; Thomas, PJ; DeMartino, GN				Fabunmi, RP; Wigley, WC; Thomas, PJ; DeMartino, GN			Activity and regulation of the centrosome-associated proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MOLECULAR-WEIGHT; ATP-DEPENDENT ACTIVATOR; GAMMA-TUBULIN; PROTEIN-DEGRADATION; 20-S PROTEASOME; MULTICATALYTIC PROTEINASE; SACCHAROMYCES-CEREVISIAE; ANTIGEN PRESENTATION; CELL-CYCLE; PA28	Regulated proteolysis is important for maintaining appropriate cellular levels of many proteins. The bulk of intracellular protein degradation is catalyzed by the proteasome. Recently, the centrosome was identified as a novel site for concentration of the proteasome and associated regulatory proteins (Wigley, W. C., Fabunmi, R. P., Lee, M. G., Marino, C. R., Muallem, S., DeMartino, G. N., and Thomas, P. J. (1999) J. Cell Biol. 145, 481-490). Here we provide evidence that centrosomes contain the active 26 S proteasome that degrades ubiquitinated-protein and proteasome-specific peptide substrates. Moreover, the centrosomes contain an ubiquitin isopeptidase activity. The proteolytic activity is ATP dependent and is inhibited by proteasome inhibitors, Notably, treatment of cells with inhibitors of proteasome activity promotes redistribution of the proteasome and associated regulatory proteins to the centrosome independent of an intact microtubule system. These data provide biochemical evidence for active proteasomal complexes at the centrosome, highlighting a novel function for this organizing structure.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Thomas, PJ (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Thomas, Philip J/F-7115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046181, R01DK049835, R37DK049835, R56DK046181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49835, DK46181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams GM, 1997, J MOL BIOL, V273, P646, DOI 10.1006/jmbi.1997.1334; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; BAILLY E, 1992, J CELL SCI, V101, P529; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Bush KT, 1997, J BIOL CHEM, V272, P9086; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Crepieux P, 1997, MOL CELL BIOL, V17, P7375, DOI 10.1128/MCB.17.12.7375; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GORDON C, 1993, NATURE, V366, P357; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; HEIDEMANN SR, 1980, NATURE, V286, P517, DOI 10.1038/286517a0; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hohfeld J, 1998, BIOL CHEM, V379, P269; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1993, J BIOL CHEM, V268, P22514; MA CP, 1992, J BIOL CHEM, V267, P10515; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P273, DOI 10.1016/0003-9861(88)90189-0; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; Moudjou M, 1996, J CELL SCI, V109, P875; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Wigley WC, 1999, J CELL BIOL, V145, P481; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	50	135	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					409	413		10.1074/jbc.275.1.409	http://dx.doi.org/10.1074/jbc.275.1.409			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617632	hybrid			2022-12-25	WOS:000085951600056
J	Panda, M; Gorovits, BM; Horowitz, PM				Panda, M; Gorovits, BM; Horowitz, PM			Productive and nonproductive intermediates in the folding of denatured rhodanese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIC LIGHT-SCATTERING; ESCHERICHIA-COLI; AGGREGATION; PRESSURE; COMPETITION; TEMPERATURE; KINETICS; COVALENT	The competition between protein aggregation and folding has been investigated using rhodanese (thiosulfate:cyanide sulfurtransferase, EC 2.8.1.1) as a model. During folding from a urea-denatured state, rhodanese rapidly forms associated species or intermediates, some of which are large and/or sticky. The early removal of such particles by filtration results in a decreased refolding yield. With time, a portion of the smaller aggregates can partition back first to intermediates and then to refolded protein, while a fraction of these irreversibly form unproductive higher aggregates. Dynamic light scattering measurements indicate that the average sizes of the aggregates formed during rhodanese folding increase from 225 to 325 nm over 45 min and they become increasingly heterogeneous. Glycerol addition or the application of high hydrostatic pressure improved the final refolding yields by stabilizing smaller particles. Although addition of glycerol into the refolding mixture blocks the formation of unproductive aggregates, it cannot dissociate them back to productive intermediates. The presence of 3.9 M urea keeps the aggregates small, and they can be dissociated to monomers by high hydrostatic pressure even after 1 h of incubation. These studies suggest that early associated intermediates formed during folding can be reversed to give active species.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Horowitz, PM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin RL, 1996, FOLD DES, V1, pR1, DOI 10.1016/S1359-0278(96)00003-X; CHRUNYK BA, 1990, BIOCHEMISTRY-US, V29, P2149, DOI 10.1021/bi00460a027; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; Fink A.L., 1998, MOL CHAPERONES LIFE; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; Gorovits BM, 1998, BIOCHEMISTRY-US, V37, P6132, DOI 10.1021/bi9730137; Gorovits BM, 1998, BBA-PROTEIN STRUCT M, V1382, P120, DOI 10.1016/S0167-4838(97)00158-1; Gorovits BM, 1997, J BIOL CHEM, V272, P26999, DOI 10.1074/jbc.272.43.26999; HAGIHARA Y, 1998, MOL CHAPERONES LIFE, P1; HOROWITZ PM, 1993, J BIOL CHEM, V268, P2500; HOROWITZ PM, 1995, BBA-PROTEIN STRUCT M, V1249, P161, DOI 10.1016/0167-4838(95)00037-U; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; Jaenicke R, 1998, BIOL CHEM, V379, P237; Jaenicke Rainer, 1997, V50, P1; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; King J., 1987, PROTEIN ENG, P109; KLEIN J, 1995, APPL ENVIRON MICROB, V61, P1220, DOI 10.1128/AEM.61.4.1220-1225.1995; Klibanov AM, 1997, TRENDS BIOTECHNOL, V15, P97, DOI 10.1016/S0167-7799(97)01013-5; Markley J. L., 1996, HIGH PRESSURE EFFECT; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MURPHY RM, 1991, BIOPOLYMERS, V31, P1289, DOI 10.1002/bip.360311107; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; Prehoda KE, 1998, BIOCHEMISTRY-US, V37, P5785, DOI 10.1021/bi980384u; Ptitsyn Oleg B., 1992, P243; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1987, J BIOL CHEM, V262, P4486; Timasheff S N, 1995, Methods Mol Biol, V40, P253; Weber G., 1992, PROTEIN INTERACTIONS; Xie YS, 1996, PROTEIN SCI, V5, P517; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	35	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					63	70		10.1074/jbc.275.1.63	http://dx.doi.org/10.1074/jbc.275.1.63			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617586	hybrid			2022-12-25	WOS:000085951600010
J	Prevot, D; Voeltzel, T; Birot, AM; Morel, AP; Rostan, MC; Magaud, JP; Corbo, L				Prevot, D; Voeltzel, T; Birot, AM; Morel, AP; Rostan, MC; Magaud, JP; Corbo, L			The leukemia-associated protein Btg1 and the p53-regulated protein Btg2 interact with the homeoprotein Hoxb9 and enhance its transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; PROGRAMMED CELL-DEATH; NEURONAL PC12 CELLS; HOMEODOMAIN PROTEINS; COOPERATIVE INTERACTIONS; DROSOPHILA EMBRYOS; GENE-PRODUCTS; YPWM MOTIF; IN-VITRO; EXPRESSION	BTG1 and BTG2 belong to a family of functionally related genes involved in the control of the cell cycle. As part of an ongoing attempt to understand their biological functions, we used a yeast two-hybrid screening to look for possible functional partners of Btg1 and Btg2. Here we report the physical and functional association between these proteins and the homeodomain protein Hoxb9. We further show that Btg1 and Btg2 enhance Hoxb9-mediated transcription in transfected cells, and we report the formation of a Hoxb9.Btg2 complex on a Hoxb9-responsive target, and the fact that this interaction facilitates the binding of Hoxb9 to DNA, The transcriptional activity of the Hoxb9.Btg complex is essentially dependent on the activation domain of Hoxb9, located in the N-terminal portion of the protein, Our data indicate that Btg1 and Btg2 act as transcriptional cofactors of the Hoxb9 protein, and suggest that this interaction may mediate their antiproliferative function.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Corbo, L (corresponding author), Ctr Leon Berard, INSERM, U453, 28 Rue Laennec, F-69373 Lyon 08, France.							AOKI J, 1991, J CELL BIOL, V115, P1751, DOI 10.1083/jcb.115.6.1751; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Chan SK, 1996, EMBO J, V15, P2476, DOI 10.1002/j.1460-2075.1996.tb00605.x; Chan SK, 1997, DEVELOPMENT, V124, P2007; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen F, 1997, DEV BIOL, V181, P186, DOI 10.1006/dbio.1996.8440; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; EDELMAN GM, 1995, PHILOS T R SOC B, V349, P305, DOI 10.1098/rstb.1995.0118; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GOOMER RS, 1994, P NATL ACAD SCI USA, V91, P7985, DOI 10.1073/pnas.91.17.7985; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Green NC, 1998, J BIOL CHEM, V273, P13273, DOI 10.1074/jbc.273.21.13273; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; HARPER JW, 1993, CELL, V75, P805; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KRUSHEL LA, 1995, P NATL ACAD SCI USA, V92, P4323, DOI 10.1073/pnas.92.10.4323; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; MALICKI J, 1993, MECH DEVELOP, V42, P139, DOI 10.1016/0925-4773(93)90003-G; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Matsuda S, 1996, ONCOGENE, V12, P705; MESNER PW, 1995, J NEUROSCI, V15, P7357; RIMOKH R, 1991, GENE CHROMOSOME CANC, V3, P24, DOI 10.1002/gcc.2870030106; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Shanmugam K, 1997, J BIOL CHEM, V272, P19081, DOI 10.1074/jbc.272.30.19081; SPORNS O, 1995, P NATL ACAD SCI USA, V92, P542, DOI 10.1073/pnas.92.2.542; Walter J, 1996, P NATL ACAD SCI USA, V93, P2680, DOI 10.1073/pnas.93.7.2680; WALTER J, 1994, GENE DEV, V8, P1678, DOI 10.1101/gad.8.14.1678; Wang SL, 1997, DEV BIOL, V188, P322, DOI 10.1006/dbio.1997.8655; Wang YB, 1996, P NATL ACAD SCI USA, V93, P1892, DOI 10.1073/pnas.93.5.1892	45	121	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					147	153		10.1074/jbc.275.1.147	http://dx.doi.org/10.1074/jbc.275.1.147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617598	hybrid			2022-12-25	WOS:000085951600022
J	Someya, Y; Kimura-Someya, T; Yamaguchi, A				Someya, Y; Kimura-Someya, T; Yamaguchi, A			Role of the charge interaction between Arg(70) and Asp(120) in the Tn10-encoded metal-tetracycline/H+ antiporter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; 2ND-SITE SUPPRESSOR MUTATIONS; LACTOSE PERMEASE; RESISTANCE PROTEIN; TRANSPOSON TN10; MEMBRANE TOPOLOGY; SEQUENCE; RESIDUES; CARRIER; HELICES	We reported that the positive charge of Arg(70) is mandatory for tetracycline transport activity of Tn10-encoded metal-tetracycline/H+ antiporter (TetA(B)) (Someya, Y., and Yamaguchi, A. (1996) Biochemistry 35, 9385-9391). Arg(70) may function through a charge-pairing with a negatively charged residue in close proximity. Therefore, we mutated Asp(66) and Asp(120), which are only two negatively charged residues located close to Arg(70) in putative secondary structure of TetA(B) and highly conserved throughout transporters of the major facilitator superfamily. Site-directed mutagenesis studies revealed that Asp(66) is essential, but Asp(120) is important for TetA(B) function. Surprisingly, when Asp(120) was replaced by a neutral residue, the R70A mutant recovered tetracycline resistance and transport activity. There was no such effect in the Asp66 mutation. The charge-exchanged mutant, R70D/D120R, also showed significant drug resistance and transport activity (about 50% of the wild type), although the R70D mutant had absolutely no activity, and the D120R mutant retained very low activity (about 10% of the wild type). Both the R70C and D120C mutants were inactivated by N-ethylmaleimide. Mercuric ion (Hg2+), which gives a positive charge to a SH group of a Cys residue through mercaptide formation, had an opposite effect on the R70C and D120C mutants. The activity of the R70C mutant was stimulated by Hg2+; however, on the contrary, the D120C mutant was partially inhibited. On the other hand, the R70C/D120C double mutant was almost completely inactivated by Hg2+, probably because the side chains at positions 70 and 120 are bridged with Hg2+. The close proximity of positions 70 and 120 were confirmed by disulfide cross-linking formation of the R70C/D120C double mutant when it was oxidized by copper-(1,10-phenanthroline). These results indicate that the positive charge of Arg(70) requires the negative charge of Asp(120) for neutralization, probably for properly positioning transmembrane segments in the membrane.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 5670047, Japan.		Kimura-Someya, Tomomi/C-4169-2017	Kimura-Someya, Tomomi/0000-0003-2232-1801				ALLARD JD, 1992, J BIOL CHEM, V267, P17809; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; ECKERT B, 1989, J BIOL CHEM, V264, P11663; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; JessenMarshall AE, 1997, J BACTERIOL, V179, P2616, DOI 10.1128/jb.179.8.2616-2622.1997; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KATZ BA, 1986, J BIOL CHEM, V261, P5480; Kimura T, 1998, BIOCHEMISTRY-US, V37, P5475, DOI 10.1021/bi973188g; Kimura T, 1997, J BIOL CHEM, V272, P580; KIMURA T, 1995, FEBS LETT, V362, P47, DOI 10.1016/0014-5793(95)00205-N; Kimura T, 1997, BIOCHEMISTRY-US, V36, P6941, DOI 10.1021/bi9631879; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JI, 1993, J BIOL CHEM, V268, P20007; LEE JI, 1992, J BIOL CHEM, V267, P20758; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; Sato M, 1999, J BIOL CHEM, V274, P24721, DOI 10.1074/jbc.274.35.24721; SEOL W, 1992, BIOCHEMISTRY-US, V31, P3550, DOI 10.1021/bi00128a032; Seyfang A, 1997, J BIOL CHEM, V272, P24210, DOI 10.1074/jbc.272.39.24210; Someya Y, 1996, BIOCHEMISTRY-US, V35, P9385, DOI 10.1021/bi961026z; Someya Y, 1997, BBA-BIOENERGETICS, V1322, P230, DOI 10.1016/S0005-2728(97)00088-1; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAMAGUCHI A, 1993, FEBS LETT, V322, P201, DOI 10.1016/0014-5793(93)81568-K; YAMAGUCHI A, 1995, BIOCHEMISTRY-US, V34, P11800, DOI 10.1021/bi00037a018; YAMAMOTO T, 1981, J BACTERIOL, V172, P6942	42	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					210	214		10.1074/jbc.275.1.210	http://dx.doi.org/10.1074/jbc.275.1.210			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617606	hybrid			2022-12-25	WOS:000085951600030
J	van der Vlag, J; den Blaauwen, JL; Sewalt, RGAB; van Driel, R; Otte, AP				van der Vlag, J; den Blaauwen, JL; Sewalt, RGAB; van Driel, R; Otte, AP			Transcriptional repression mediated by polycomb group proteins and other chromatin-associated repressors is selectively blocked by insulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; DROSOPHILA-MELANOGASTER; CHROMOSOMAL PROTEIN; GENE; DNA; ELEMENT; HETEROCHROMATIN; BOUNDARIES; EXPRESSION; ENHANCER	Polycomb group (PcG) proteins repress gene activity over a considerable distance, possibly by spreading along the chromatin fiber. Insulators or boundary elements, genetic elements within the chromatin, may serve to terminate the repressing action of PcG proteins. We studied the ability of insulators to block the action of chromatin-associated repressors such as PcG proteins, HP1, and MeCP2. We found that the Drosophila special chromatin structure insulator completely blocks transcriptional repression mediated by all of the repressors we tested. The Drosophila gypsy insulator was able to block the repression mediated by the PcG proteins Su(z)2 and RING1, as well as mHP1, but not the repression mediated by MeCP2 and the PcG protein HPC2. The 5'-located DNase I-hypersensitive site in the chicken beta-globin locus displayed a limited ability to block repression, and a matrix or scaffold attachment region element was entirely unable to block repression mediated by any repressor tested. Our results indicate that insulators can block repression mediated by PcG proteins and other chromatin-associated repressors, but with a high level of selectivity. This high degree of specificity may provide a useful assay to define and characterize distinct classes of insulators.	Univ Amsterdam, BioCentrum Amsterdam, EC Slater Inst, NL-1018 TV Amsterdam, Netherlands	University of Amsterdam	Otte, AP (corresponding author), Univ Amsterdam, BioCentrum Amsterdam, EC Slater Inst, Plantage Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.		Van der Vlag, Johan/E-4636-2010	Van der Vlag, Johan/0000-0001-7843-5918				BONIFER C, 1997, NUCL ORG CHROMATIN S, P116; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CORCES VG, 1997, NUCL ORG CHROMATIN S, P83; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; Mallin DR, 1998, GENETICS, V148, P331; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MIYNAROVA L, 1994, PLANT CELL, V6, P417; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Sigrist CJA, 1997, GENETICS, V147, P209; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	36	64	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					697	704		10.1074/jbc.275.1.697	http://dx.doi.org/10.1074/jbc.275.1.697			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617669	Green Published, hybrid			2022-12-25	WOS:000085951600093
J	Susini, S; van Haasteren, G; Li, SL; Prentki, M; Schlegel, W				Susini, S; van Haasteren, G; Li, SL; Prentki, M; Schlegel, W			Essentiality of intron control in the induction of c-fos by glucose and glucoincretin peptides in INS-1 beta-cells	FASEB JOURNAL			English	Article						immediate-early response genes; proto-oncogenes; intragenic response element; glucagon-like peptide 1; intracellular Ca2+	GENE-EXPRESSION; INSULIN-SECRETION; PROINSULIN BIOSYNTHESIS; INTRACELLULAR CA2+; TRANSCRIPTION; CALCIUM; GROWTH; ACTIVATION; APOPTOSIS; PROMOTER	Glucose controls long-term processes in the pancreatic beta-cell such as metabolic enzymes gene expression, cell growth, and apoptosis. Such control is likely mediated via the expression of immediate-early response genes since several of these genes including c-fos are strongly induced by glucose in the beta-cell line INS-1, provided costimulation with cAMP-raising glucoincretin hormones. this study addresses the mechanism of c-fos gene activation by glucose. Glucose in the presence of chlorophenylthio-cAMP generated a low threefold induction of the c-fos/basic luciferase reporter gene, which includes only the c-fos promoter. In contrast, the c-fos/intron construct containing the first intron in addition to promoter elements showed a pronounced 16-fold induction, comparable to the increased c-fos mRNA accumulation. Similar observations were made with glucose in combination with the glucoincretins glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and pituitary adenylyl cyclase-activating peptide 38. Deletion of a 119 bp region in intron 1 that includes a transcriptional arrest site did not affect the inductive process. In contrast, a 534 bp deletion comprising a major part of the intron reduced the induction by 75%. At the promoter level, mutating the cAMP response element reduced by more than 60% the transcriptional activation whereas mutating the serum response element had no effect . Inhibitors of protein kinase A and Ca2+/calmodulin-dependent protein kinase each reduced by 50% the reporter gene activation and together fully prevented the glucose-glucoincretin effect. In conclusion, the strong induction of c-fos by glucose and glucoincretins results from Ca2+ and cAMP signaling pathways addressing both the CRE in the promoter and essential response element(s) in the first intron that are unrelated to the transcription arrest site.	Univ Geneva, Fdn Rech Med, CH-1211 Geneva, Switzerland; Univ Montreal, Ctr Rech LC Simard, Dept Nutr, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Ctr Rech LC Simard, Inst Canc, Montreal, PQ H2L 4M1, Canada	University of Geneva; Universite de Montreal; Universite de Montreal	van Haasteren, G (corresponding author), Univ Geneva, Fdn Rech Med, 64 Ave Roseraie, CH-1211 Geneva, Switzerland.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BLANCHARD JM, 1992, M S-MED SCI, V8, P455, DOI 10.4267/10608/3162; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; BUTEAU J, 1999, IN PRESS DIABETOLOGI; Carrion AM, 1998, MOL CELL BIOL, V18, P6921, DOI 10.1128/MCB.18.12.6921; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; COLLART MA, 1991, MOL CELL BIOL, V11, P2862; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FRODIN M, 1995, J BIOL CHEM, V270, P7885; GOKE R, 1988, J ENDOCRINOL, V116, P357, DOI 10.1677/joe.0.1160357; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Josefsen K, 1999, DIABETOLOGIA, V42, P195, DOI 10.1007/s001250051139; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MARIE S, 1993, J BIOL CHEM, V268, P23881; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; Mollard P, 1996, TRENDS ENDOCRIN MET, V7, P361, DOI 10.1016/S1043-2760(96)00186-5; PHILIKPPE J, 1991, ENDOCR REV, V3, P252; Polakowska RR, 1999, J CELL BIOCHEM, V73, P355; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; Roche E, 1997, J BIOL CHEM, V272, P3091, DOI 10.1074/jbc.272.5.3091; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; THORENS B, 1993, DIABETES, V42, P1219, DOI 10.2337/diabetes.42.9.1219; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREISMAN R, 1990, CANCER BIOL, V1, P47; van Haasteren G, 1999, J RECEPT SIGNAL TR R, V19, P481, DOI 10.3109/10799899909036666; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WERLEN G, 1993, J BIOL CHEM, V268, P16596; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; YADA T, 1994, J BIOL CHEM, V269, P1290; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	45	28	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					128	136		10.1096/fasebj.14.1.128	http://dx.doi.org/10.1096/fasebj.14.1.128			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627287				2022-12-25	WOS:000084784700015
J	Buchberger, A; Gassler, CS; Buttner, M; McMacken, R; Bukau, B				Buchberger, A; Gassler, CS; Buttner, M; McMacken, R; Bukau, B			Functional defects of the DnaK756 mutant chaperone of Escherichia coli indicate distinct roles for amino- and carboxyl-terminal residues in substrate and co-chaperone interaction and interdomain communication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-DNA-REPLICATION; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; BACTERIOPHAGE-LAMBDA; NUCLEOPROTEIN STRUCTURES; NUCLEOTIDE EXCHANGE; CELLULAR DEFECTS; ATPASE FRAGMENT; COGNATE PROTEIN; ACTIVE-SITE	The first discovery of an Hsp70 chaperone gene was the isolation of an Escherichia coli mutant, dnaK756, which rendered the cells resistant to lytic infection with bacteriophage lambda, The DnaK756 mutant protein has since been used to establish many of the cellular roles and biochemical properties of DnaK, DnaK756 has three glycine-to-aspartate substitutions at residues 32, 455, and 468, which were reported to result in defects in intrinsic and GrpE-stimulated ATPase activities, substrate binding, stability of the substrate-binding domain, inrerdomain communication, and, consequently, defects in chaperone activity, To dissect the effects of the different amino acid substitutions in DnaK756, we analyzed two DnaK variants carrying only the amino-terminal (residue 32) or the two carboxyl-terminal (residues 455 and 468) substitutions, The amino-terminal substitution interfered with the GrpE-stimulated ATPase activity. The carboxyl-terminal mutations (i) affected stability and function of the substrate-binding domain, (ii) caused a 10-fold elevated ATP hydrolysis rate, but (iii) did not severely affect domain coupling. Surprisingly, DnaK chaperone activity was more severely compromised by the amino-terminal than by the carboxyl-terminal amino acid substitutions both in vivo and in vitro, In the in vitro refolding of denatured firefly luciferase, the defect of the DnaK variant carrying the amino-terminal substitution results from its inability to release, upon GrpE-mediated nucleotide exchange, bound luciferase in a folding competent state. Our results indicate that the DnaK-DnaJ-GrpE chaperone system can tolerate suboptimal substrate binding, whereas the tight kinetic control of substrate dissociation by GrpE is essential.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	University of Freiburg; Johns Hopkins University	Bukau, B (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	bukau@sun2.ruf.uni-freiburg.de	Buchberger, Alexander/J-4070-2019; Buchberger, Alexander/AAF-4728-2019	Buchberger, Alexander/0000-0002-2836-0820; Buchberger, Alexander/0000-0002-2836-0820; Bukau, Bernd/0000-0003-0521-7199	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036526] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; BANECKI B, 1992, J BIOL CHEM, V267, P25051; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BUKAU B, MOL CHAPERONES FOLDI; BURKHOLDER WF, 1999, MOL CHAPERONES FOLDI, P105; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; DODSON M, 1989, J BIOL CHEM, V264, P10719; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; GEORGOPOULOS C P, 1974, Journal of Supramolecular Structure, V2, P349, DOI 10.1002/jss.400020224; GEORGOPOULOS CP, 1979, MOL GEN GENET, V172, P143, DOI 10.1007/BF00268275; GEORGOPOULOS CP, 1977, MOL GEN GENET, V151, P35, DOI 10.1007/BF00446910; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Herbst R, 1997, J BIOL CHEM, V272, P7099, DOI 10.1074/jbc.272.11.7099; JOHNSON C, 1989, J BACTERIOL, V171, P1590, DOI 10.1128/jb.171.3.1590-1596.1989; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; KONIECZNY I, 1995, J BIOL CHEM, V270, P9792, DOI 10.1074/jbc.270.17.9792; LANZER M, 1988, THESIS U HEIDELBERG; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Laufen T., 1998, MOL CHAPERONES PROTE, P241; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; Miller J.H., 1972, EXPT MOL GENETICS; MIYAZAKI T, 1992, J BACTERIOL, V174, P3715, DOI 10.1128/JB.174.11.3715-3722.1992; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SHERMAN MY, 1992, EMBO J, V11, P71; Stephens KM, 1997, J BIOL CHEM, V272, P28800, DOI 10.1074/jbc.272.45.28800; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STRAUS DB, 1989, GENE DEV, V3, P2003, DOI 10.1101/gad.3.12a.2003; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; YOCHEM J, 1978, MOL GEN GENET, V164, P9, DOI 10.1007/BF00267593; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	67	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38017	38026		10.1074/jbc.274.53.38017	http://dx.doi.org/10.1074/jbc.274.53.38017			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608870	hybrid			2022-12-25	WOS:000084528000070
J	Cotrim, PC; Garrity, LK; Beverley, SM				Cotrim, PC; Garrity, LK; Beverley, SM			Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE-THYMIDYLATE SYNTHASE; MEXICANA-MEXICANA PROMASTIGOTES; DIHYDROFOLATE REDUCTASE; PARASITE LEISHMANIA; DRUG-RESISTANCE; METHOTREXATE RESISTANCE; MULTIDRUG RESISTANCE; H-REGION; AMPLIFICATION; DONOVANI	We tested a general method for the identification of drug resistance loci in the trypanosomatid protozoan parasite Leishmania major. Genomic libraries in a multicopy episomal cosmid vector were transfected into susceptible parasites, and drug selections of these transfectant libraries yielded parasites bearing cosmids mediating resistance. Tests with two antifolates led to the recovery of cosmids encoding DHFR-TS or PTR1, two known resistance genes. Overexpression/selection using the toxic nucleoside tubercidin similarly yielded the TOR (toxic nucleoside resistance) locus, as well as a new locus (TUB2) conferring collateral hypersensitivity to allopurinol. Leishmania synthesize ergosterol rather than cholesterol, making this pathway attractive as a chemotherapeutic target. Overexpression/selection using the sterol synthesis inhibitors terbinafine (TBF, targeting squalene epoxidase) and itraconazole (ITZ, targeting lanosterol C(14)-demethylase) yielded nine new resistance loci. Several conferred resistance to both drugs; several were drug-specific, and two TBF-resistant cosmids induced hypersensitivity to ITZ. One TBF-resistant cosmid encoded squalene synthase (SQS1), which is located upstream of the sites of TBF and ITZ action in the ergosterol biosynthetic pathway. This suggests that resistance to "downstream" inhibitors can be mediated by increased expression of ergosterol biosynthetic intermediates. Our studies establish the feasibility of overexpression/selection in parasites and suggest that many Leishmania drug resistance loci are amenable to identification in this manner.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Sao Paulo, Sch Med, DMIP, Inst Trop Med, BR-05403000 Sao Paulo, Brazil	Washington University (WUSTL); Harvard University; Harvard Medical School; Universidade de Sao Paulo	Beverley, SM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	beverley@borcim.wustl.edu	Cotrim, Paulo/C-7899-2013	Cotrim, Paulo/0000-0003-2607-8837; Beverley, Stephen/0000-0001-5319-0811	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021903, R37AI021903] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21903] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARREBOLA R, 1994, J BIOL CHEM, V269, P10590; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; Barrett-Bee K, 1988, Ann N Y Acad Sci, V544, P231, DOI 10.1111/j.1749-6632.1988.tb40409.x; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; Blackwell JM, 1997, T ROY SOC TROP MED H, V91, P107, DOI 10.1016/S0035-9203(97)90187-5; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; Chance Michael L., 1997, P163; CHOW LMC, 1993, MOL BIOCHEM PARASIT, V60, P195, DOI 10.1016/0166-6851(93)90131-G; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; CRUZ AK, 1993, P NATL ACAD SCI USA, V90, P1599, DOI 10.1073/pnas.90.4.1599; DASILVA R, 1987, INFECT IMMUN, V55, P2802, DOI 10.1128/IAI.55.11.2802-2806.1987; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DESCOTEAUX A, 1994, METH MOL G, V3, P22; Detke S, 1997, MOL BIOCHEM PARASIT, V90, P505, DOI 10.1016/S0166-6851(97)00201-6; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P13501; GOAD LJ, 1984, MOL BIOCHEM PARASIT, V10, P161, DOI 10.1016/0166-6851(84)90004-5; GOAD LJ, 1985, MOL BIOCHEM PARASIT, V15, P257, DOI 10.1016/0166-6851(85)90089-1; GOAD LJ, 1985, BIOCHEM PHARMACOL, V34, P3785, DOI 10.1016/0006-2952(85)90250-3; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; HANSEN BD, 1982, PARASITOLOGY, V85, P271, DOI 10.1017/S0031182000055256; Hardy LW, 1997, EXP PARASITOL, V87, P157, DOI 10.1006/expr.1997.4207; HENDERSON DM, 1992, MOL CELL BIOL, V12, P2855, DOI 10.1128/MCB.12.6.2855; IOVANNISCI DM, 1984, MOL CELL BIOL, V4, P1013, DOI 10.1128/MCB.4.6.1013; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; IOVANNISCI DM, 1984, MOL BIOCHEM PARASIT, V12, P139, DOI 10.1016/0166-6851(84)90131-2; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; Kelly S. L., 1992, New approaches for antifungal drugs., P155; KERBY BR, 1993, MOL BIOCHEM PARASIT, V60, P171, DOI 10.1016/0166-6851(93)90129-L; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; Lemley C, 1999, MOL BIOCHEM PARASIT, V104, P93, DOI 10.1016/S0166-6851(99)00132-2; MERCER EI, 1991, LIPIDS, V26, P584, DOI 10.1007/BF02536422; Nare B, 1997, J BIOL CHEM, V272, P13883, DOI 10.1074/jbc.272.21.13883; OGBUNUDE POJ, 1991, EXP PARASITOL, V73, P369, DOI 10.1016/0014-4894(91)90109-A; Ouellette M, 1998, ADV EXP MED BIOL, V456, P99; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1993, ADV EXP MED BIOL, V338, P559; PETRANYI G, 1984, SCIENCE, V224, P1239, DOI 10.1126/science.6547247; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SEGOVIA M, 1994, ANN TROP MED PARASIT, V88, P123, DOI 10.1080/00034983.1994.11812849; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; URBINA JA, 1997, PARASITOLOGY, V114, P91; Vanden Bossche H, 1994, Trends Microbiol, V2, P393, DOI 10.1016/0966-842X(94)90618-1	57	45	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37723	37730		10.1074/jbc.274.53.37723	http://dx.doi.org/10.1074/jbc.274.53.37723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608831	hybrid			2022-12-25	WOS:000084528000031
J	Yoon, SC; Choi, MH				Yoon, SC; Choi, MH			Local sequence dependence of polyhydroxyalkanoic acid degradation in Hydrogenophaga pseudoflava	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-EUTROPHUS; GRANULES; POLY(3-HYDROXYBUTYRATE); BIOSYNTHESIS; COPOLYESTERS; INCLUSIONS; SURFACE; PROTEIN; NMR	The first order intracellular degradation of various polyhydroxyalkanoic acid (PHA) inclusions in Hydrogenophaga pseudoflava cells was investigated by analyzing the compositional and microstructural changes of the PHA. using gas chromatography, C-13 NMR spectroscopy, and differential scanning calorimetry. Two types of PEA, copolymers and blend-type polymers, were separately accumulated in cells for comparison. The constituent monomers were S-hydroxybutyric acid (3HB), 4-hydroxybutyric acid (4HB), and 3-hydroxyvaleric acid (3HV), It was found that the 3HB-4HB copolymer was degraded only when the polymer contained a minimal level of 3HB units. With the cells containing a 3HB/4HB blend-type polymer, only poly(3HB) was degraded, whereas poly(4HB) was not degraded, indicating the totally inactive nature of the intracellular depolymerase against poly(4HB). On the basis of the magnitude of the first order degradation rate constants, the relative substrate specificity of the depolymerase toward the constituting monomer units was determined to decrease in the order 3HB > 3KV > 4HB, C-13 NMR resonances of the tetrad, triad, and dyad sequences were analyzed for the samples isolated before and after degradation experiments. The results showed that the intracellular degradation depended on the local monomer sequence of the copolymers, The relative substrate specificity of the depolymerase determined from the NMR local sequence analysis agreed well with that obtained from the kinetics analysis. It is suggested that, without isolation and purification of the intracellular PHA depolymerase and "native" PHA substrates, the relative specificity of the enzyme as well as the microstructural heterogeneity of the PHA could be determined by measuring in situ the first order degradation rate constants of the PHA in cells.	Gyeongsang Natl Univ, Div Life Sci, Biomat Sci Lab, Chinju 660701, South Korea	Gyeongsang National University	Yoon, SC (corresponding author), Gyeongsang Natl Univ, Div Life Sci, Biomat Sci Lab, Chinju 660701, South Korea.		Yoon, Sung/L-5836-2019	Yoon, Sung Chul/0000-0002-8556-423X				AMOR SR, 1991, MACROMOLECULES, V24, P4583, DOI 10.1021/ma00016a017; ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; BONTHRONE KM, 1992, FEMS MICROBIOL LETT, V103, P269, DOI 10.1111/j.1574-6968.1992.tb05848.x; CHOI MH, 1995, CAN J MICROBIOL, V41, P60, DOI 10.1139/m95-169; Choi MH, 1999, APPL ENVIRON MICROB, V65, P1570; CHOI MH, 1994, APPL ENVIRON MICROB, V60, P3245, DOI 10.1128/AEM.60.9.3245-3254.1994; CHOI MH, 1999, THESIS GYEONGSANG NA; Curley JM, 1996, INT J BIOL MACROMOL, V19, P29, DOI 10.1016/0141-8130(96)01096-3; DOI Y, 1988, MACROMOLECULES, V21, P2722, DOI 10.1021/ma00187a012; Doi Y., 1990, MICROBIAL POLYESTERS; GERNGROSS TU, 1993, J BACTERIOL, V175, P5289, DOI 10.1128/JB.175.16.5289-5293.1993; Jendrossek D, 1996, APPL MICROBIOL BIOT, V46, P451, DOI 10.1007/s002530050844; KAMIYA N, 1989, MACROMOLECULES, V22, P1676, DOI 10.1021/ma00194a030; KAWAGUCHI Y, 1992, MACROMOLECULES, V25, P2324, DOI 10.1021/ma00035a007; Kichise T, 1999, INT J BIOL MACROMOL, V25, P69, DOI 10.1016/S0141-8130(99)00017-3; Kim BK, 1997, J MICROBIOL BIOTECHN, V7, P391; MARCHESSAULT RH, 1970, MACROMOLECULES, V3, P735, DOI 10.1021/ma60018a005; Olabisi O., 1979, POLYM POLYM MISCIBIL, P31; PIEPERFURST U, 1994, J BACTERIOL, V176, P4328, DOI 10.1128/jb.176.14.4328-4337.1994; SAITO T, 1995, CAN J MICROBIOL, V41, P187, DOI 10.1139/m95-186; Song JJ, 1998, INT J BIOL MACROMOL, V23, P165, DOI 10.1016/S0141-8130(98)00046-4; STEINBUCHEL A, 1995, CAN J MICROBIOL, V41, P94, DOI 10.1139/m95-175; STEINBUCHEL A, 1995, FEMS MICROBIOL LETT, V128, P219, DOI 10.1016/0378-1097(95)00125-O; WIECZOREK R, 1995, J BACTERIOL, V177, P2425, DOI 10.1128/jb.177.9.2425-2435.1995	24	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37800	37808		10.1074/jbc.274.53.37800	http://dx.doi.org/10.1074/jbc.274.53.37800			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608842	hybrid			2022-12-25	WOS:000084528000042
J	Kwong, M; Kan, YW; Chan, JY				Kwong, M; Kan, YW; Chan, JY			The CNC basic leucine zipper factor, Nrf1, is essential for cell survival in response to oxidative stress-inducing agents - Role for Nrf1 in gamma-gcs(L) and g(ss) expression in mouse fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; BZIP TRANSCRIPTION FACTOR; GLOBIN GENE-EXPRESSION; HEAVY SUBUNIT GENE; EMBRYONIC LETHALITY; FREE-RADICALS; ELEMENT; NF-E2; INDUCTION; CLONING	Nrf1 is a member of the CNC-basic leucine zipper (CNC-bZIP) family of transcription factors. CNC bZIP factors, together with small Maf proteins, bind as heterodimers to the NF-E2/AP-1 element. Similarity between the NF-E2/AP-1 element and the antioxidant response element identified in a number of promoters of genes involved in detoxification and antioxidant response raises the possibility that Nrf1 plays a role in mediating the antioxidant response element response. In this study, we exploited the availability of cells from Nrf1 knockout mice to study the role of Nrf1 transcription factor in the regulation of antioxidant gene expression and in cellular antioxidant response. Fibroblast cells derived from Nrf1 null embryos showed lower levels of glutathione and enhanced sensitivity to the toxic effects of oxidant compounds. Our results indicate that Nrf1 plays a role in the regulation of genes involved in glutathione synthesis and suggest a basis for a correspondingly low GSH concentration and reduced stress response.	Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Chan, JY (corresponding author), Univ Calif San Francisco, Dept Lab Med, 533 Parnassus Ave,Rm U442, San Francisco, CA 94143 USA.				NIDDK NIH HHS [KO8-DK02603, P01-DK50267] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050267, K08DK002603] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1995, HUM GENET, V95, P265; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; DENEKE SM, 1989, AM J PHYSIOL, V257, P163; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; Galloway DC, 1998, BIOCHEM J, V336, P535, DOI 10.1042/bj3360535; Galloway DC, 1997, BIOCHEM J, V328, P99; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; GRIFFITH OW, 1997, GLUTATHIONE; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; Hogan B, 1994, MANIPULATING MOUSE E; HUANG CS, 1993, J BIOL CHEM, V268, P19675; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; JACKSON SP, 1993, GENE TRANSCRIPTION, V117, P189; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Johnsen O, 1998, NUCLEIC ACIDS RES, V26, P512, DOI 10.1093/nar/26.2.512; JOSHI MS, 1997, ENCY HUMAN BIOL, V4, P107; Knight JA, 1998, ANN CLIN LAB SCI, V28, P331; KRALL J, 1988, J BIOL CHEM, V263, P1910; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Meister A., 1995, METABOLIC BASIS INHE, P1461; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nakagawa Ippei, 1995, Journal of Toxicological Sciences, V20, P557; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, ARCH BIOCHEM BIOPHYS, V344, P387, DOI 10.1006/abbi.1997.0215; Xie T, 1996, BIOCHEM PHARMACOL, V51, P771, DOI 10.1016/0006-2952(95)02394-1; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	50	142	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37491	37498		10.1074/jbc.274.52.37491	http://dx.doi.org/10.1074/jbc.274.52.37491			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601325	hybrid			2022-12-25	WOS:000084382700096
J	Matsuo, M; Kioka, N; Amachi, T; Ueda, K				Matsuo, M; Kioka, N; Amachi, T; Ueda, K			ATP binding properties of the nucleotide-binding folds of SUR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; RESISTANCE-ASSOCIATED PROTEIN; SENSITIVE K+ CHANNELS; SULFONYLUREA RECEPTOR; MULTIDRUG-RESISTANCE; DISTINCT FUNCTIONS; INSULIN-SECRETION; SUBUNIT; RECONSTITUTION	Pancreatic beta cell ATP-sensitive potassium (K-ATP) channels regulate glucose-induced insulin secretion. The activity of the K-ATP channel, composed of SUR1 and Kir6.2 subunits, is regulated by intracellular ATP and ADP, but the molecular mechanism is not clear. To distinguish the ATP binding properties of the two nucleotide-binding folds (NBFs) of SUR1, we prepared antibodies against NBF1 and NBF2, and the tryptic fragment of SUR1 was immunoprecipitated after photoaffinity labeling with 8-azido-[P-32]ATP. The 35-kDa fragment was strongly labeled with 5 mu M 8-azido-[P-32]ATP even in the absence of Mg2+ and was immunoprecipitated with the antibody against NBF1, The 65-kDa fragment labeled with 100 mu M 8-azido-[alpha-P-32]ATP in the presence of Mg2+ was immunoprecipitated with anti-NBF2 and anti-C terminus antibodies. These results indicate that NBF1 of SUR1 binds 8-azido-ATP strongly in a magnesium-independent manner and that NBF2 binds 8-azido-ATP weakly in a magnesium-dependent manner. Furthermore, the 65-kDa tryptic fragment was not photoaffinity-labeled with 8-azido-[gamma-P-32]ATP at 37 degrees C, whereas the 35-kDa tryptic fragment was, suggesting that NBF2 of SUR1 may have ATPase activity and that NBF1 has none or little.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan	Kyoto University	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Biochem Lab, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp		Ueda, Kazumitsu/0000-0003-2980-6078; Kioka, Noriyuki/0000-0002-2708-537X				Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Muller M, 1996, J BIOL CHEM, V271, P1877; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Proks P, 1999, J BIOL CHEM, V274, P25393, DOI 10.1074/jbc.274.36.25393; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	42	83	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37479	37482		10.1074/jbc.274.52.37479	http://dx.doi.org/10.1074/jbc.274.52.37479			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601323	hybrid			2022-12-25	WOS:000084382700094
J	Garcia-Guzman, M; Dolfi, F; Zeh, K; Vuori, K				Garcia-Guzman, M; Dolfi, F; Zeh, K; Vuori, K			Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation	ONCOGENE			English	Article						kinase; oncogenesis; signal transduction; tyrosine phosphorylation	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NECROSIS-FACTOR-ALPHA; GRB2 BINDING-SITE; INVASIVE-GROWTH; DOCKING PROTEIN; V-CRK; PROLONGED ACTIVATION; CELL-TRANSFORMATION; CARBOXY-TERMINUS	Constitutive activation of the Met tyrosine kinase results in transformation of cells of diverse origin. Recent studies have demonstrated a role for the c-Jun N-terminal kinase (JNK) in Met-induced transformation, but little is known about the molecular mechanisms that connect Met to JNK activation. Our studies show that activated Met associates with, and phosphorylates, the docking protein Gab1, which in turn binds to the src homology 2 (SH2)-domain of the adapter protein Crk and recruits Crk to the Met signaling complex. Formation of the Gab1-Crk complex correlates with Met-induced JNK activation, and mutant forms of Met that fail to induce the complex formation also fail to activate JNK. Importantly, expression of a loss-of-function mutant of Crk severely impairs activation of the JNK pathway by Met. We also show here that Met controls the transcription of the matrix metalloproteinase-l (MMP-1) gene in carcinoma cells and that this transcriptional regulation occurs in a Crk-JNK-dependent manner through an AP-1 element in the MMP-1 promoter. Taken together, our data implicate the Gab1-Crk signaling complex in Met-induced JNK activation and suggest that the Gab1-Crk complex formation may be an important event in regulating the tumorigenic phenotype of Met-transformed cells.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA071560, R01CA076037] Funding Source: NIH RePORTER; NCI NIH HHS [CA71560, CA76037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BARDELLI A, 1994, J BIOTECHNOL, V37, P109, DOI 10.1016/0168-1656(94)90002-7; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FELLER SM, 1995, ONCOGENE, V10, P1465; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keegan K, 1996, ONCOGENE, V12, P1537; Khwaja A, 1996, ONCOGENE, V12, P2491; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LONGATI P, 1994, ONCOGENE, V9, P49; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; PATCH LA, 1995, J CELL SCI, V108, P1371; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; Sorokin A, 1998, BIOCHEM J, V334, P595, DOI 10.1042/bj3340595; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	63	73	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7775	7786		10.1038/sj.onc.1203198	http://dx.doi.org/10.1038/sj.onc.1203198			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618718				2022-12-25	WOS:000084256900007
J	Maul, RS; Chang, DD				Maul, RS; Chang, DD			EPLIN, Epithelial protein lost in neoplasm	ONCOGENE			English	Article						breast; prostate; cancer; EPLIN	CANCER-CELLS; LIM DOMAINS; ADHESION; BINDING	We have identified a novel cytoskeletal protein, EPLIN (Epithelial Protein Lost In Neoplasm), that is preferentially er;pressed in human epithelial cells. Two EPLIN isoforms, a 600 amino acid EPLIN-alpha and a 759 amino acid EPLIN-beta, are detected in primary epithelial cells of oral mucosa, prostate and mammary glands. The expression of EPLIN-alpha is either down-regulated or lost in the majority of oral cancer cell lines (8/8), prostate cancer cell lines (4/4) and xenograft tumors (3/3), and breast cancer cell lines (5/6), The amino acid sequence of EPLIN is characterized by the presence of a single centrally located LIM domain. Both EPLIN isoforms localize to filamentous actin and suppress cell proliferation when overexpressed. These findings indicate that the loss of EPLIN seen in cancer cells may play a role in cancer progression.	Univ Calif Los Angeles, Sch Med, Div Hemeonc,Jonnson Comprehens Canc Ctr, Dept Med & Microbiol Immunol & Mol Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hemeonc,Jonnson Comprehens Canc Ctr, Dept Med & Microbiol Immunol & Mol Mol Genet, Factor 10-240,10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NCI NIH HHS [TF32CA75956] Funding Source: Medline; NIGMS NIH HHS [GM58215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA075956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM058215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BALTZ R, 1992, PLANT J, V2, P713, DOI 10.1046/j.1365-313X.1992.t01-13-00999.x; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	16	71	74	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7838	7841		10.1038/sj.onc.1203206	http://dx.doi.org/10.1038/sj.onc.1203206			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618726				2022-12-25	WOS:000084256900015
J	Chiou, ST; Chen, YW; Chen, SC; Chao, CF; Liu, TY				Chiou, ST; Chen, YW; Chen, SC; Chao, CF; Liu, TY			Isolation and characterization of proteins that bind to galactose, lipopolysaccharide of Escherichia coli, and protein A of Staphylococcus aureus from the hemolymph of Tachypleus tridentatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; NATURAL ANTI-GAL; LIMULUS-POLYPHEMUS; INNATE IMMUNITY; HORSESHOE-CRAB; SPECIFICITY; SYSTEM; LECTIN; IGG; ALPHA-2-MACROGLOBULIN	In this study, we report the isolation and characterization of three novel hemolymph proteins that are believed to be involved in the innate immune response of horseshoe crabs, Tachypleus tridentatus. They include two closely related proteins, one that binds to the protein A of Staphylococcus aureus (PAP) and another that binds to the lipopolysaccharide of Escherichia coli (LBP). PAP binds specifically to staphylococcal protein A (SpA) with a K-D of 3.86 x 10(-5) M, whereas LBP binds to lipopolysaccharide (LPS) with a K-D of 1.03 x 10(-6) M. Both PAP and LBP are glycoproteins with an apparent molecular mass of about 40 kDa, N-terminal sequences of PAP and LBP showed 61.9 and 72.2% identity, respectively, to tachylectin-3, a lectin isolated from the amebocyte of T. tridentatus, previously characterized by its affinity to the O-antigen of LPS and blood group A antigen (Muta, T., and Iwanaga, S. (1996) Curr. Opin. Immunol. 8, 41-47). The third protein, a galactose-binding protein (GBP), was found to bind tightly to Sepharose CL-4B and could only be eluted from the column matrix with chaotropic agents, such as 4 iu urea or 2 nr guanidine hydrochloride. Further analysis indicated that GBP binds to D(+)-galactose with a K-D of 2.47 x 10(-7) M. N-terminal sequence analysis showed that GBP shared a 50% identity with lectin L-6, identified in the granules of amebocyte of T. tridentatus. (Gokudan, S., Muta, T., Tsuda, R., Koori, K., Kawahara, T., Seki, N., Mizunoe, Y., Wai, S. N,, Iwanaga, S., and Kawabata, S. (1999) Proc. Natl. Acad Sci. U.S.A 96, 10086-10091). Lectin-L6 and tachylectin-3 are nonglycosylated intracellular proteins with about half the molecular mass of PAP, LBP, and GBP. GBP also binds to PAP and LBP with K-D values of 1.25 x 10(-7) and 1.43 x 10(-8) M, respectively, and this binding is enhanced about 10-fold upon the addition of SpA and LPS to form the GBP.PAP SpA and GBP.LBP.LPS complexes, respectively.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan	Liu, TY (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.							ARMSTRONG PB, 1993, MOL IMMUNOL, V30, P929, DOI 10.1016/0161-5890(93)90017-6; DAM TK, 1992, MOL CELL BIOCHEM, V117, P1; ENGHILD JJ, 1990, BIOCHEMISTRY-US, V29, P10070, DOI 10.1021/bi00495a009; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; FURGUSON MAJ, 1993, GLYCOBIOLOGY PRACTIC, P349; GALILI U, 1987, J EXP MED, V165, P693, DOI 10.1084/jem.165.3.693; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GARBER N, 1992, BIOCHIM BIOPHYS ACTA, V1116, P331, DOI 10.1016/0304-4165(92)90048-Y; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; Hirabayashi J, 1998, J BIOL CHEM, V273, P14450, DOI 10.1074/jbc.273.23.14450; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Inamori K, 1999, J BIOL CHEM, V274, P3272, DOI 10.1074/jbc.274.6.3272; IWANAGA S, 1998, FRONT BIOSCI, V3, pD873; KAPITANY RA, 1973, ANAL BIOCHEM, V56, P361, DOI 10.1016/0003-2697(73)90202-9; Kawabata S, 1999, DEV COMP IMMUNOL, V23, P391, DOI 10.1016/S0145-305X(99)00019-1; LANGONE JJ, 1982, J IMMUNOL METHODS, V55, P277, DOI 10.1016/0022-1759(82)90088-6; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mendoza HL, 1999, DEV COMP IMMUNOL, V23, P359, DOI 10.1016/S0145-305X(99)00017-8; MURER EH, 1975, J CELL PHYSIOL, V86, P533, DOI 10.1002/jcp.1040860310; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; PUGIN J, 1993, J EXP MED, V178, P2193, DOI 10.1084/jem.178.6.2193; ROBEY FA, 1981, J BIOL CHEM, V256, P969; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SOTTRUPJENSEN L, 1990, COMP BIOCHEM PHYS B, V96, P621, DOI 10.1016/0305-0491(90)90066-3; TANAKA T, 1983, J BIOL CHEM, V258, P3552; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612	29	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1630	1634		10.1074/jbc.275.3.1630	http://dx.doi.org/10.1074/jbc.275.3.1630			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636855	hybrid			2022-12-25	WOS:000084940000018
J	Arcari, P; Masullo, L; Masullo, M; Catanzano, F; Bocchini, V				Arcari, P; Masullo, L; Masullo, M; Catanzano, F; Bocchini, V			A NAD(P)H oxidase isolated from the archaeon Sulfolobus solfataricus is not homologous with another NADH oxidase present in the same microorganism - Biochemical characterization of the enzyme and cloning of the encoding gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL-HYDROPEROXIDE REDUCTASE; FLAVOPROTEIN DISULFIDE OXIDOREDUCTASES; HYDROGEN-PEROXIDE; SALMONELLA-TYPHIMURIUM; THIOREDOXIN REDUCTASE; ESCHERICHIA-COLI; PURIFICATION; SEQUENCE; PROTEINS; BINDING	A NAD(P)H oxidase has been isolated from the archaeon Sulfolobus solfataricus. The enzyme is a homodimer with M-r 38,000 per subunit (SsNOX38) containing 1 FAD molecule/subunit, It oxidizes NADH and, less efficiently, NADPH with the formation of hydrogen peroxide. The enzyme was resistant against chemical and physical denaturating agents, The temperature for its half-denaturation was 93 and 75 degrees C in the absence or presence, respectively, of 8 hr urea, The enzyme did not show any reductase activity. The SsNOX38 encoding gene was cloned and sequenced. It accounted for a product of 36.5 kDa. The translated amino acid sequence was made of 332 residues containing two putative beta alpha beta-fold regions, typical of NAD- and FAD-binding proteins. The primary structure of SsNOX38 did not show any homology with the N-terminal amino acid sequence of a NADH oxidase previously isolated from S. solfataricus (SsNOX35) (Masullo, M,, Raimo, G,, Dello Russo, A, Bocchini, V. and Bannister, J. V. (1996) Biotechnol. Appl. Biochem, 23, 47-54), Conversely, it showed 40% sequence identity with a putative thioredoxin reductase from Bacillus subtilis, but it did not contain cysteines, which are essential for the activity of the reductase.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Ctr Ingn Genet Biotecnol Avanzate, I-80131 Naples, Italy	University of Naples Federico II	Bocchini, V (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy.		Masullo, Mariorosario/H-4884-2016	Masullo, Mariorosario/0000-0003-4485-7383				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 1982, MOL CLONING LAB MANU; Arcari P, 1999, BIOCHEMISTRY-US, V38, P12288, DOI 10.1021/bi990418d; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; COCCO D, 1988, EUR J BIOCHEM, V174, P267, DOI 10.1111/j.1432-1033.1988.tb14093.x; Dello Russo A, 1997, BBA-PROTEIN STRUCT M, V1343, P23, DOI 10.1016/S0167-4838(97)00105-2; DEROSA M, 1984, BIOCHEM J, V224, P407, DOI 10.1042/bj2240407; DeVendittis E, 1996, GENE, V176, P27, DOI 10.1016/0378-1119(96)00203-X; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HIGUCHI M, 1993, J GEN MICROBIOL, V139, P2343, DOI 10.1099/00221287-139-10-2343; KOIKE K, 1985, J BIOCHEM, V97, P1279, DOI 10.1093/oxfordjournals.jbchem.a135179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loprasert S, 1997, J BACTERIOL, V179, P3944, DOI 10.1128/jb.179.12.3944-3949.1997; MAEDA K, 1992, BIOCHEM J, V284, P187; Masullo M, 1996, BIOTECHNOL APPL BIOC, V23, P47; MASULLO M, 1996, THESIS CRANFIELD U C; MATSUILEE IS, 1995, J BIOCHEM-TOKYO, V117, P856; NIIMURA Y, 1993, J BACTERIOL, V175, P7945, DOI 10.1128/JB.175.24.7945-7950.1993; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; NIIMURA Y, 1994, BIOSCI BIOTECH BIOCH, V58, P2310, DOI 10.1271/bbb.58.2310; NIIMURA Y, 1989, FEMS MICROBIOL LETT, V61, P79, DOI 10.1016/S0378-1097(98)00072-X; OHNISHI K, 1995, J BIOL CHEM, V270, P5812, DOI 10.1074/jbc.270.11.5812; OHNISHI K, 1994, J BIOL CHEM, V269, P31418; PARK HJ, 1992, EUR J BIOCHEM, V205, P881, DOI 10.1111/j.1432-1033.1992.tb16853.x; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; SAEKI Y, 1985, J BIOCHEM-TOKYO, V98, P1433, DOI 10.1093/oxfordjournals.jbchem.a135411; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Toomey D, 1998, EUR J BIOCHEM, V251, P935, DOI 10.1046/j.1432-1327.1998.2510935.x; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	37	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					895	900		10.1074/jbc.275.2.895	http://dx.doi.org/10.1074/jbc.275.2.895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625624	hybrid			2022-12-25	WOS:000084836600028
J	Asao, H; Fu, XY				Asao, H; Fu, XY			Interferon-gamma has dual potentials in inhibiting or promoting cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT3 ACTIVATION; GROWTH ARREST; TRANSCRIPTIONAL ACTIVATION; TERMINAL DIFFERENTIATION; CYTOPLASMIC REGION; RECEPTOR; ALPHA; MYC; APOPTOSIS; PROTEIN	Many cytokines have dual functions of promoting or inhibiting cell proliferation; however, the molecular mechanism of the dual functions of cytokines is not well understood. Under normal conditions, interleukin (IL)-3 is required for Ba/FS cell proliferation, whereas interferon (IFN)-gamma inhibits Ba/F3 cell proliferation. It is known that Stat1 play a major role in inhibition of cell growth in response to IFN-gamma, We have examined the possibility of whether IFN-gamma can act as a growth-promoting cytokine if the Stat1 function is selectively blocked. We have established variant Ba/F3 cell lines in which Stat1 function is inhibited by a dominant-negative Stat1 mutant. Intriguingly, once Stat1 function is inhibited, IFN-gamma can replace IL-3 acting as an essential growth factor for cell proliferation. To understand the molecular mechanism of regulation of cell proliferation by the cytokines, the signaling pathways and gene induction by IL-3 and IFN-gamma are further studied. Although IL-3 activates mitogenic-activated protein kinase and Akt kinase, IFN-gamma does not. Interestingly, both IL-3 and IFN-gamma induce expression of the c-Myc gene that is not dependent on the Stat1 activity. Expression of a dominant-negative mutant Myc can block IFN-gamma-mediated Ba/F3 cell proliferation, suggesting that c-Myc gene induction is required for IFN-gamma-mediated cell proliferation. These findings suggest that IFN-gamma intrinsically and simultaneously induces specific and conflicting signaling pathways and transcriptional programs that contribute to the potential dual effects of IFN-gamma in promoting or inhibiting cell proliferation.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Fu, XY (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055590] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34522] Funding Source: Medline; NIGMS NIH HHS [GM55590] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hunter T, 1996, BIOCHEM SOC T, V24, P307, DOI 10.1042/bst0240307; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; SUGAMURA K, 1985, J EXP MED, V161, P1243, DOI 10.1084/jem.161.5.1243; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	53	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					867	874		10.1074/jbc.275.2.867	http://dx.doi.org/10.1074/jbc.275.2.867			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625620	hybrid			2022-12-25	WOS:000084836600024
J	Fensome, AC; Rodrigues-Lima, F; Josephs, M; Paterson, HF; Katan, M				Fensome, AC; Rodrigues-Lima, F; Josephs, M; Paterson, HF; Katan, M			A neutral magnesium-dependent sphingomyelinase isoform associated with intracellular membranes and reversibly inhibited by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN ACID SPHINGOMYELINASE; NIEMANN-PICK DISEASE; INDUCED APOPTOSIS; RAT-LIVER; STIMULATED SPHINGOMYELINASE; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-C; DEFICIENT MICE; DISTINCT POOL	Activation of neutral sphingomyelinase(s) and subsequent generation of ceramide has been implicated in a wide variety of cellular responses. Although this enzyme(s) has not been purified and cloned from higher organisms, one mammalian cDNA has been previously isolated based on its similarity to the bacterial enzyme. To further elucidate the function of this neutral sphingomyelinase, we studied its relationship with enzymes present in mammalian cells and tissues, its subcellular localization, and properties that could be important for the regulation of its activity. Using specific antibodies, it is suggested that the enzyme could represent one of several forms of neutral sphingomyelinases present in the extract from brain particulate fraction. In PC12 cells, the enzyme is localized in the endoplasmic reticulum and is not present in the plasma membrane. The same result has been obtained in several cell lines transfected or microinjected with plasmids encoding this enzyme. The molecular and enzymatic properties of the cloned neutral magnesium-dependent sphingomyelinase, produced using baculovirus or bacterial expression systems, have been analyzed, demonstrating the expected ion dependence and substrate specificity. The enzyme activity also has a strong requirement for reducing agents and is reversibly inhibited by reactive oxygen species and oxidized glutathione. The studies demonstrate that the cellular localization and some properties of this enzyme are distinct from properties previously associated with neutral magnesium-dependent sphingomyelinases in crude or partially purified preparations.	Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	University of London; Institute of Cancer Research - UK	Katan, M (corresponding author), Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, Fulham Rd, London SW3 6JB, England.	matilda@icr.ac.uk						Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Adam-Klages S, 1998, J LEUKOCYTE BIOL, V63, P678, DOI 10.1002/jlb.63.6.678; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ALESSENKO A, 1995, MOL CELL BIOCHEM, V143, P169, DOI 10.1007/BF01816950; Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; BERNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99, DOI 10.1016/0005-2760(81)90095-3; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; Ghosh N, 1998, MOL CELL BIOCHEM, V189, P161, DOI 10.1023/A:1006910200656; Hampton MB, 1998, TOXICOL LETT, V103, P355, DOI 10.1016/S0378-4274(98)00333-6; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HOSTETLER KY, 1979, J LIPID RES, V20, P456; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Kaletta K, 1998, FEBS LETT, V434, P377, DOI 10.1016/S0014-5793(98)01013-8; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; Kreder D, 1999, EMBO J, V18, P2472, DOI 10.1093/emboj/18.9.2472; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; QUINN P, 1992, BIOCHIM BIOPHYS ACTA, V1124, P95, DOI 10.1016/0005-2760(92)90131-E; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; ROSS, 1999, ROSSIG L, V274, P6823; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; SPENCE MW, 1982, BIOCHIM BIOPHYS ACTA, V719, P162, DOI 10.1016/0304-4165(82)90321-X; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Takeda Y, 1999, J BIOL CHEM, V274, P10654, DOI 10.1074/jbc.274.15.10654; TAMIYAKOIZUMI K, 1989, J BIOCHEM, V106, P593, DOI 10.1093/oxfordjournals.jbchem.a122901; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tonnetti L, 1999, J EXP MED, V189, P1581, DOI 10.1084/jem.189.10.1581; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; Ueda S, 1998, J IMMUNOL, V161, P6689; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zhang P, 1997, J BIOL CHEM, V272, P9609	56	34	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1128	1136		10.1074/jbc.275.2.1128	http://dx.doi.org/10.1074/jbc.275.2.1128			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625655	hybrid			2022-12-25	WOS:000084836600059
J	Huang, W; Dolmer, K; Liao, XB; Gettins, PGW				Huang, W; Dolmer, K; Liao, XB; Gettins, PGW			NMR solution structure of the receptor binding domain of human alpha(2)-macroglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; BETA-AMYLOID PEPTIDE; HIGH-AFFINITY BINDING; HUMAN ALPHA-2-MACROGLOBULIN; ALPHA-MACROGLOBULINS; PROTEIN; ENDOCYTOSIS; CALCIUM; COMPLEX	Human alpha(2)-macroglobulin-proteinase complexes bind to their receptor, the low density lipoprotein receptor-related protein (LRP), through a discrete 138-residue C-terminal receptor binding domain (RBD), which also binds to the beta-amyloid peptide. We have used NMR spectroscopy on recombinantly expressed uniformly C-13/N-15-labeled human RED to determine its three-dimensional structure in solution, Human RED is a sandwich of two antiparallel beta-sheets, one four-strand and one five-strand, and also contains one alpha-helix of 2.5 turns and an additional 1-turn. helical region. The principal alpha-helix contains two lysine residues on the outer face that are known to be essential for receptor binding. A calcium binding site (K-d similar to 11 mM) is present in the loop region at one end of the beta-sandwich, Calcium binding principally affects this loop region and does not significantly perturb the stable core structure of the domain. The structure and NMR. assignments will enable us to examine in solution specific binding of RED to domains of the receptor and to beta-amyloid peptide.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA.	pgettins@tigger.uic.edu	Dolmer, Klavs/G-5512-2012	Dolmer, Klavs/0000-0001-7359-360X	NCRR NIH HHS [RR02781, RR02301] Funding Source: Medline; NIGMS NIH HHS [GM54414] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301, S10RR002781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054414] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN GR, 1995, J BIOL CHEM, V270, P25133, DOI 10.1074/jbc.270.42.25133; Birkenmeier G, 1997, FEBS LETT, V416, P193, DOI 10.1016/S0014-5793(97)01201-5; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Cai ML, 1998, PROTEIN SCI, V7, P2669, DOI 10.1002/pro.5560071221; DOLMER K, 1995, FEBS LETT, V372, P93, DOI 10.1016/0014-5793(95)00960-H; Du YS, 1997, J NEUROCHEM, V69, P299; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOLTET TL, 1994, FEBS LETT, V344, P242, DOI 10.1016/0014-5793(94)00349-1; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; Jenner L, 1998, STRUCTURE, V6, P595, DOI 10.1016/S0969-2126(98)00061-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Narita M, 1997, J NEUROCHEM, V69, P1904; Qazi U, 1999, J BIOL CHEM, V274, P8137, DOI 10.1074/jbc.274.12.8137; Rodenburg KW, 1998, BIOCHEM J, V329, P55; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WEBB DJ, 1994, J BIOL CHEM, V269, P30402; WILLIAMS SE, 1994, ANN NY ACAD SCI, V737, P1, DOI 10.1111/j.1749-6632.1994.tb44297.x; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1994, METHOD ENZYMOL, V239, P363	31	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1089	1094		10.1074/jbc.275.2.1089	http://dx.doi.org/10.1074/jbc.275.2.1089			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625650	hybrid			2022-12-25	WOS:000084836600054
J	Lackner, CA; Condit, RC				Lackner, CA; Condit, RC			Vaccinia virus gene A18R DNA helicase is a transcript release factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TEMPERATURE-SENSITIVE MUTANTS; PHENOTYPIC CHARACTERIZATION; VIRAL TRANSCRIPTION; TERMINATION FACTOR; ELONGATION-FACTOR; ESCHERICHIA-COLI; INITIATION-FACTOR; DEPENDENT ATPASE; CELLULAR PROTEIN	Prior phenotypic analysis of a vaccinia virus gene A18R mutant, Cts23, showed the synthesis of longer than wild type (Wt) length viral transcripts during the intermediate stage of infection, indicating that the A18R protein may act as a negative transcription elongation factor. The purpose of the work described here was to determine a biochemical activity for the A18R protein. Pulse-labeled transcription complexes established from intermediate virus promoters on bead-bound DNA templates were assayed for transcript release during an elongation step that contained nucleotides and various proteins. Pulse-labeled transcription complexes elongated in the presence of only nucleotides were unable to release nascent RNA. The addition of Wt extract during the elongation phase resulted in release of the nascent transcript, indicating that additional factors present in the Wt extract are capable of inducing transcript release. Extract from Cts23 or mock-infected cells was unable to induce release. The lack of release upon addition of Cts23 extract suggests that A18R is involved in release of nascent RNA. By itself, purified polyhistidine-tagged A18R protein (His-A18R) was unable to induce release; however, release did occur in the presence of purified His-A18R protein plus extract from either Cts23 or mock-infected cells. These data taken together indicate that A18R is necessary but not sufficient for release of nascent transcripts. We have also demonstrated that the combination of A18R protein and mock extract induces transcript release in an ATP-dependent manner, consistent with the fact that the A18R protein is all ATP-dependent helicase. Further analysis revealed that the release activity is not restricted to a vaccinia intermediate promoter but is observed using pulse-labeled transcription complexes initiated from all three viral gene class promoters. Therefore, we conclude that A18R and an as yet unidentified cellular factor(s) are required for the in vitro release of nascent RNA from a vaccinia virus transcription elongation complex.	Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Condit, RC (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.				NIAID NIH HHS [AI18094] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018094] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BAYLISS CD, 1993, VIROLOGY, V194, P254, DOI 10.1006/viro.1993.1256; BAYLISS CD, 1995, J BIOL CHEM, V270, P1550, DOI 10.1074/jbc.270.4.1550; Beaud G, 1997, J GEN VIROL, V78, P3297, DOI 10.1099/0022-1317-78-12-3297; Black EP, 1996, J VIROL, V70, P47, DOI 10.1128/JVI.70.1.47-54.1996; Black EP, 1998, VIROLOGY, V245, P313, DOI 10.1006/viro.1998.9166; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHRISTEN L, 1992, J GEN VIROL, V73, P3155, DOI 10.1099/0022-1317-73-12-3155; Christen LM, 1998, VIROLOGY, V245, P360, DOI 10.1006/viro.1998.9177; CONDIT RC, 1983, VIROLOGY, V128, P429, DOI 10.1016/0042-6822(83)90268-4; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; Condit RC, 1996, VIROLOGY, V220, P10, DOI 10.1006/viro.1996.0280; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; FATHI Z, 1991, VIROLOGY, V181, P273, DOI 10.1016/0042-6822(91)90492-T; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; Hassett DE, 1997, VIROLOGY, V238, P391, DOI 10.1006/viro.1997.8820; HOODADHINGRA U, 1990, VIROLOGY, V174, P60, DOI 10.1016/0042-6822(90)90054-U; HOODADHINGRA U, 1989, J VIROL, V63, P714, DOI 10.1128/JVI.63.2.714-729.1989; Jansa P, 1998, EMBO J, V17, P2855, DOI 10.1093/emboj/17.10.2855; Kovacs GR, 1996, J VIROL, V70, P6796, DOI 10.1128/JVI.70.10.6796-6802.1996; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; LUO Y, 1991, J BIOL CHEM, V266, P13303; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; Mason SW, 1997, EMBO J, V16, P163, DOI 10.1093/emboj/16.1.163; MOS B, 1996, VIROLOGY, P2637; PACHA RF, 1985, J VIROL, V56, P395, DOI 10.1128/JVI.56.2.395-403.1985; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; ROBERTS JW, 1993, CELL, V72, P653, DOI 10.1016/0092-8674(93)90394-6; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SIMPSON DA, 1995, J VIROL, V69, P6131, DOI 10.1128/JVI.69.10.6131-6139.1995; SIMPSON DA, 1994, J VIROL, V68, P3642, DOI 10.1128/JVI.68.6.3642-3649.1994; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang DG, 1997, J BIOL CHEM, V272, P5989, DOI 10.1074/jbc.272.9.5989; Wright CF, 1998, J VIROL, V72, P1446, DOI 10.1128/JVI.72.2.1446-1451.1998; WRIGHT CF, 1989, J VIROL, V63, P4224, DOI 10.1128/JVI.63.10.4224-4233.1989; Xiang Y, 1998, J VIROL, V72, P7012, DOI 10.1128/JVI.72.9.7012-7023.1998; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417; Zhu M, 1998, J VIROL, V72, P3893, DOI 10.1128/JVI.72.5.3893-3899.1998	51	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1485	1494		10.1074/jbc.275.2.1485	http://dx.doi.org/10.1074/jbc.275.2.1485			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625702	hybrid			2022-12-25	WOS:000084836600106
J	Wang-Gillam, A; Pastuszak, I; Stewart, M; Drake, RR; Elbein, AD				Wang-Gillam, A; Pastuszak, I; Stewart, M; Drake, RR; Elbein, AD			Identification and modification of the uridine-binding site of the UDP-GalNAc (GlcNAc) pyrophosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; GLUCOSE PYROPHOSPHORYLASE; THYMIDINE KINASE; CLONING; COMPLEX	UDP-GaINAc pyrophosphorylase (UDP-GaINAcPP; AGX1) catalyzes the synthesis of UDP-GaINAc from UTP and GaINAc-1-P, The 475-amino acid protein (57 kDa protein) also synthesizes UDP-GIcNAc at about 25% the rate of UDP-GaINAc. The cDNA for this enzyme, termed AGX1, was cloned in Escherichia coli, and expressed as an active enzyme that cross-reacted with antiserum against the original pig liver UDP-HexNAcPP, In the present study, we incubated recombinant AGX1 with N-3-UDP-[P-32]GIcNAc and N-3-UDP-[P-32]GaINAc probes to label the nucleotide-binding site, Proteolytic digestions of the labeled enzyme and analysis of the resulting peptides indicated that both photoprobes cross-linked to one 24-amino acid peptide located between residues Val(216) and GlU(240). Four amino acids in this peptide were found to be highly conserved among closely related enzymes, and each of these was individually modified to alanine, Mutation of Gly(222) to Ala in the peptide almost completely eliminated UDP-GIcNAc and UDP-GaINAc synthesis, while mutation of Gly(224) to Ala, almost completely eliminated UDP-GaINAc synthesis, but UDP-GI-cNAc was only diminished by 50%. Both of these mutations also resulted in almost complete loss of the ability of the mutated proteins to cross-link N-3-UDP-[P-32]GaINAc or N-3-UDP-[P-32]GaINAc. On the other hand, mutations of either pro(220) or Tyr(227) to Ala did not greatly affect enzymatic activity, although there was some reduction in the ability of these proteins to cross-link the photoaffinity probes, We also mutated Gly111 to Ala since this amino acid was reported to be necessary for catalysis (Mio, T., Yabe, T., Arisawa, M., and Yamada-Okabe, H, (1998) J. Biol, Chem. 273, 14392-14397). The Gly(111) to Ala mutant lost all enzymatic activity, but interestingly enough, this mutant protein still cross-linked the radioactive N-3-UDP-GlcNAc although not nearly as well as the wild type. On the other hand, mutation of Arg(115) to Ala had no affect on enzymatic activity although it also reduced the amount of cross-linking of N-3-UDP-[P-32]GIcNAc. These studies help to define essential amino acids at or near the nucleotide-binding site and the catalytic site, as well as peptides involved in binding and catalysis.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Elbein, AD (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Slot 516,4301 W Markham, Little Rock, AR 72205 USA.	elbeinaland@exchange.uams.edu	Stewart, Malcolm/AAY-2789-2020	Stewart, Malcolm/0000-0002-5724-9160	NHLBI NIH HHS [HL-17783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; Di Cera E, 1998, ADV PROTEIN CHEM, V51, P59; DIEKMAN AB, 1994, BIOL REPROD, V50, P1087, DOI 10.1095/biolreprod50.5.1087; Drake RR, 1998, P NATL ACAD SCI USA, V95, P4170, DOI 10.1073/pnas.95.8.4170; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; KONISHI Y, 1993, J BIOCHEM-TOKYO, V114, P61, DOI 10.1093/oxfordjournals.jbchem.a124141; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; PATTABIRAMAN T, 1961, BIOCHIM BIOPHYS ACTA, V50, P129, DOI 10.1016/0006-3002(61)91068-X; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; Rechtin TM, 1996, ANAL BIOCHEM, V237, P135, DOI 10.1006/abio.1996.0211; STROMINGER JL, 1959, J BIOL CHEM, V234, P1822; Sunthankar P, 1998, ANAL BIOCHEM, V258, P195, DOI 10.1006/abio.1998.2600; Szumilo T, 1996, J BIOL CHEM, V271, P13147, DOI 10.1074/jbc.271.22.13147; Wang-Gillam A, 1998, J BIOL CHEM, V273, P27055, DOI 10.1074/jbc.273.42.27055; Wild K, 1997, PROTEIN SCI, V6, P2097	16	27	29	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1433	1438		10.1074/jbc.275.2.1433	http://dx.doi.org/10.1074/jbc.275.2.1433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625695	hybrid			2022-12-25	WOS:000084836600099
J	An, SZ; Zheng, YH; Bleu, T				An, SZ; Zheng, YH; Bleu, T			Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; CALCIUM MOBILIZATION; MEMBRANE-RECEPTOR; 2ND MESSENGER; HIGH-AFFINITY; SPHINGOSINE-1-PHOSPHATE; KINASE; GROWTH; ACTIVATION; PATHWAY	Sphingosine l-phosphate (S1P) regulates cell proliferation, apoptosis, motility, and neurite retraction. Contradictory reports propose that S1P acts as either an intracellular second messenger or an extracellular ligand for cell-surface receptors. Hence, the precise signaling mechanisms mediating the diverse cellular effects of S1P remain to be determined. Here, we investigate whether S1P stimulation of cell. proliferation, survival, and related signaling events can be mediated by the recently cloned Edg family members of G protein-coupled receptors. We observed that S1P treatment significantly increased proliferation of HTC4 hepatoma cells stably transfected with human S1P receptor Edg3 or Edg5, which was attributable to stimulation of cell growth and inhibition of apoptosis caused by serum starvation. Edg3 and Edg5 transduced S1P-evoked signaling events relevant to cell proliferation and survival, including activation of the ERK/MAP kinases, and immediate-early induction of c-Jun and c-Fos. Transcriptional activation of reporter genes for the c-fos promoter and the serum response element by Edg3 and Edg5 transfected in Jurkat cells was inhibited by pertussis toxin and C3 exoenzyme, implicating G(i/o)- and Rho-dependent pathways. Our data also indicated that Edg3 and Edg5 mediated the serum response element activation through transcriptional factors Elk-1 and serum response factor. Thus, specific G protein-coupled receptors Edg3 and Edg5 account for, at least in part, S1P-induced cell proliferation, survival, and related signaling events.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	An, SZ (corresponding author), Univ Calif San Francisco, Dept Med, Box 0711,Rm UB8,533 Parnassus Ave, San Francisco, CA 94143 USA.	songzhu@itsa.ucsf.edu						An SZ, 1998, J CELL BIOCHEM, P147; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1999, MOL PHARMACOL, V55, P787; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Berger A, 1996, MOL PHARMACOL, V50, P451; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Choi OH, 1996, NATURE, V380, P634; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Im DS, 1997, AM J PHYSIOL-GASTR L, V272, pG1091, DOI 10.1152/ajpgi.1997.272.5.G1091; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Noh SJ, 1998, J CELL PHYSIOL, V176, P412, DOI 10.1002/(SICI)1097-4652(199808)176:2<412::AID-JCP20>3.0.CO;2-3; Okajima F, 1996, FEBS LETT, V379, P260, DOI 10.1016/0014-5793(95)01526-4; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; Sato K, 1999, FEBS LETT, V443, P25, DOI 10.1016/S0014-5793(98)01676-7; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SU Y, 1994, J BIOL CHEM, V269, P16512; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yatomi Y, 1997, J BIOCHEM, V121, P969; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830; ZUHERINGDORF DM, 1996, N-S ARCH PHARMACOL, V354, P397	56	173	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					288	296		10.1074/jbc.275.1.288	http://dx.doi.org/10.1074/jbc.275.1.288			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617617	hybrid			2022-12-25	WOS:000085951600041
J	Gerlach, AC; Gangopadhyay, NN; Devor, DC				Gerlach, AC; Gangopadhyay, NN; Devor, DC			Kinase-dependent regulation of the intermediate conductance, calcium-dependent potassium channel, hIK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL LINE; CA2+-ACTIVATED K+ CHANNELS; HUMAN T-LYMPHOCYTES; PROTEIN-KINASE; CHLORIDE SECRETION; CA2+ CHANNELS; T84 CELLS; PHOSPHORYLATION; MODULATION; CARBACHOL	We determined the effect of nucleotides and protein kinase A (PKA) on the Ca2+-dependent gating of the cloned intermediate conductance, Ca2+-dependent K+ channel, hIK1, In Xenopus oocytes, during two-electrode voltage-clamp, forskolin plus isobutylmethylxanthine induced a Ca2+-dependent increase in hIK1 activity. In excised inside-out patches, addition of ATP induced a Ca2+-dependent increase in hIK1 activity (NPo). In contrast, neither nonhydrolyzable (AMP-PNP, AMP-PCP) nor hydrolyzable ATP analogs (GTP, CTP, UTP, and ITP) activated hIK1. The ATP-dependent activation of hIK1 required Mg2+ and was reversed by either exogenous alkaline phosphatase or the PKA inhibitor PKI5-24. The Ca2+ dependence of hIK1 activation was best fit with a stimulatory constant (K-s) of 350 nM and a Hill coefficient (n) of 2.3. ATP increased NPo at [Ca2+] > 100 nM while having no effect on K-s or n. Mutation of the single PKA consensus phosphorylation site at serine 334 to alanine (S334A) had no effect on the PKA-dependent activation during either two-electrode voltage-clamp or in excised inside-out patches, When expressed in HEK293 cells, ATP activated hIK1 in a Mg2+-dependent fashion, being reversed by alkaline phosphatase. Neither PKI5-24 nor CaMKII281-309 or PKC19-31 affected the ATP-dependent activation. Northern blot analysis revealed hIK1 expression in the T84 colonic cell line. Endogenous hIK1 was activated by ATP in a Mg2+- and PKI5-24-dependent fashion and was reversed by alkaline phosphatase, whereas CaMKII281-309 and PKC19-31 had no effect on the ATP-dependent activation. The Ca2+-dependent activation (LC, and n) was unaffected by ATP, In conclusion, hIK1 is activated by a membrane delimited PKA when endogenously expressed. Although the oocyte expression system recapitulates this regulation, expression in HEK293 cells does not, The effect of PKA on hIK1 gating is Ca2+-dependent and occurs via an increase in NPo without an effect on either Ca2+ affinity or apparent cooperativity.	Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Devor, DC (corresponding author), Univ Pittsburgh, Dept Cell Biol & Physiol, S312 Biomed Sci Tower,3500 Terr St, Pittsburgh, PA 15261 USA.				NIDDK NIH HHS [DK54941-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054941] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRUGNARA C, 1995, J MEMBRANE BIOL, V147, P71, DOI 10.1007/BF00235398; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DEPEYER JE, 1982, P NATL ACAD SCI-BIOL, V79, P4207; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC138, DOI 10.1152/ajpcell.1998.274.1.C138; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; DEVOR DC, 1993, AM J PHYSIOL, V265, pC1271, DOI 10.1152/ajpcell.1993.265.5.C1271; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MCCANN JD, 1990, AM J PHYSIOL, V258, pL334, DOI 10.1152/ajplung.1990.258.6.L334; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; Pellegrino R, 1998, PFLUG ARCH EUR J PHY, V436, P749, DOI 10.1007/s004240050698; Rader RK, 1996, J IMMUNOL, V156, P1425; REINHART PH, 1991, J NEUROSCI, V11, P1627; ROCH B, 1995, PFLUEGERS ARCH, V426, P355; Rufo PA, 1996, J CLIN INVEST, V98, P2066, DOI 10.1172/JCI119012; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SINGH AK, 1997, PEDIATR PULM, V14, P234; SYME CA, 1998, PEDIATR PULM, V17, P235; TABCHARANI JA, 1994, J MEMBRANE BIOL, V142, P241; TABCHARANI JA, 1994, J MEMBRANE BIOL, V142, P255; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; WANG J, 1999, J NEUROSCI, V19, P1; Wang ZW, 1996, AM J PHYSIOL-LUNG C, V271, pL100, DOI 10.1152/ajplung.1996.271.1.L100; WELSH MJ, 1985, P NATL ACAD SCI USA, V82, P8823, DOI 10.1073/pnas.82.24.8823; WONG SME, 1989, AM J PHYSIOL, V257, pC976, DOI 10.1152/ajpcell.1989.257.5.C976; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	46	91	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					585	598		10.1074/jbc.275.1.585	http://dx.doi.org/10.1074/jbc.275.1.585			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617655	hybrid			2022-12-25	WOS:000085951600079
J	Gulick, AM; Bauer, CB; Thoden, JB; Pate, E; Yount, RG; Rayment, I				Gulick, AM; Bauer, CB; Thoden, JB; Pate, E; Yount, RG; Rayment, I			X-ray structures of the Dictyostelium discoideum myosin motor domain with six non-nucleotide analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-FIBERS; ADENOSINE-TRIPHOSPHATASE; CRYSTAL-STRUCTURE; ATP ANALOGS; COMPLEX; ACTIN; KINETICS; BINDING; SUBFRAGMENT-1; ACTOMYOSIN	The three-dimensional structures of the truncated myosin head from Dictyostelium discoideum myosin II complexed with dinitrophenylaminoethyl-, dinitrophenylaminopropyl-, o--nitrophenylaminoethyl-, m-nitrophenylaminoethyl-, p-nitrophenylaminoethyl-, and o-nitrophenyl-N-methyl-aminoethyl-diphosphate . beryllium fluoride have been determined to better than 2.3-Angstrom resolution. The structure of the protein and nucleotide binding pocket in these complexes is very similar to that of S1dC . ADP . BeFx (Fisher, A. J., Smith, C. A., Thoden, J., Smith, R,, Sutoh, K., Holden, H. M., and Rayment, I. (1995) Biochemistry 34, 8960-8972). The position of the triphosphate-like moiety is essentially identical in all complexes. Furthermore, the alkyl-amino group plays the same role as the ribose by linking the triphosphate to the adenine binding pocket; however, none of the phenyl groups lie in the same position as adenine in S1dC . MgADP . BeFx, even though several of these nucleotide analogs are functionally equivalent to ATP, Rather the former location of adenine is occupied by water in the nanolog complexes, and the phenyl groups are organized in a manner that attempts to optimize their hydrogen bonding interactions with this constellation of solvent molecules. A comparison of the kinetic and structural properties of the nanologs relative to ATP suggests that the ability of a substrate to sustain tension and to generate movement correlates with a well defined interaction with the active site water structure observed in S1dC . MgADP . BeFx.	Univ Wisconsin, Inst Enzyme Res, Madison, WI 53705 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA; Washington State Univ, Dept Math, Pullman, WA 99164 USA; Washington State Univ, Dept Chem, Pullman, WA 99164 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Washington State University; Washington State University; Washington State University	Rayment, I (corresponding author), Univ Wisconsin, Inst Enzyme Res, 1710 Univ Ave, Madison, WI 53705 USA.	ivan_rayment@biochem.wise.edu	rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835; Gulick, Andrew/0000-0003-4238-7453	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008422, R01AR035186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005195, R01DK005195] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR08422, AR35186] Funding Source: Medline; NIDDK NIH HHS [DK05195] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; CHIARONI A, 1971, ACTA CRYSTALL B-STRU, VB 27, P448, DOI 10.1107/S056774087100236X; CLEGG W, 1994, ACTA CRYSTALLOGR C, V50, P583, DOI 10.1107/S0108270193010972; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; DENNY BJ, 1992, J MED CHEM, V35, P2315, DOI 10.1021/jm00090a023; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Ellena J, 1997, ACTA CRYSTALLOGR C, V53, P1930, DOI 10.1107/S0108270197007403; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FISHER AJ, 1995, BIOPHYS J, V68, pS19; FISHER AJ, 1996, MOLDED; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; GEEVES MA, 1991, BIOCHEM J, V274, P1; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; Giese KC, 1997, BIOCHEMISTRY-US, V36, P8465, DOI 10.1021/bi963141f; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOODY RS, 1977, EUR J BIOCHEM, V78, P317, DOI 10.1111/j.1432-1033.1977.tb11742.x; GREENE LE, 1980, J BIOL CHEM, V255, P543; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HENRY GD, 1993, BIOCHEMISTRY-US, V32, P10451, DOI 10.1021/bi00090a022; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KAIDA S, 1989, ACTA CRYSTALLOGR C, V45, P2025, DOI 10.1107/S0108270189008784; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuhlman PA, 1996, MOL BIOL CELL, V7, P1138; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Moschcovich L, 1998, BIOCHEMISTRY-US, V37, P15137, DOI 10.1021/bi980605w; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; NAVAZA J, 1993, ACTA CRYSTALLOGR D, V49, P588, DOI 10.1107/S0907444993005141; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1986, DENZO; PANUNTO TW, 1987, J AM CHEM SOC, V109, P7786, DOI 10.1021/ja00259a030; PATE E, 1993, J BIOL CHEM, V268, P10046; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; RODGERS DW, 1994, STRUCTURE, V2, P1135, DOI 10.1016/S0969-2126(94)00116-2; Sellers JR, 1996, J MUSCLE RES CELL M, V17, P7, DOI 10.1007/BF00140320; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; WANG D, 1993, J MUSCLE RES CELL M, V14, P484, DOI 10.1007/BF00297211; WHITE HD, 1993, J BIOL CHEM, V268, P10039	54	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					398	408		10.1074/jbc.275.1.398	http://dx.doi.org/10.1074/jbc.275.1.398			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617631	hybrid			2022-12-25	WOS:000085951600055
J	Hiser, L; Di Valentin, M; Hamer, AG; Hosler, JP				Hiser, L; Di Valentin, M; Hamer, AG; Hosler, JP			Cox11p is required for stable formation of the Cu-B and magnesium centers of cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYOE GENE-PRODUCT; RHODOBACTER-SPHAEROIDES; PARACOCCUS-DENITRIFICANS; ESCHERICHIA-COLI; HEME-A; SACCHAROMYCES-CEREVISIAE; 2.8 ANGSTROM; YEAST COX10; PROTEIN; METAL	Assembly of the core subunits of the aa(3)-type cytochrome c oxidase in mitochondria and aerobic bacteria such as Rhodobacter sphaeroides requires the association of three subunits and the formation of five to seven metal centers. Several assembly proteins are required for the late stages of oxidase assembly in eukaryotes; some of these are also present in Rb. sphaeroides, To investigate the role of one of these proteins, Cox11p, the mitochondrial-like oxidase of Rb. sphaeroides was overexpressed and purified from cells that lacked cox11, the gene for Cox11p. The oxidase that assembled in the absence of Cox11p lacked Cu-B at the active site and contained greatly reduced amounts of metal at the magnesium/manganese-binding site between subunits I and II. This inactive oxidase, however, did contain hemes a and a(3), Cu-A, and all three subunits, These results indicate that Cox11p is required at a late, perhaps final, step in the assembly of cytochrome oxidase, most likely the insertion of Cu-B. Oxidase which assembled in a strain with a low copy number of cox11 appeared nearly wild type, suggesting that Cox11p is required in substoichiometric amounts for its role in oxidase assembly.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	University of Mississippi; University of Mississippi Medical Center; Michigan State University	Hosler, JP (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.	hosler@fiona.umsmed.edu		di valentin, marilena/0000-0002-2915-8704	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025480, R01GM056824] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56824, GM25480] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1976, BIOCHIM BIOPHYS ACTA, V422, P260, DOI 10.1016/0005-2744(76)90137-6; CAO J, 1992, J BIOL CHEM, V267, P24273; Cobine P, 1999, FEBS LETT, V445, P27, DOI 10.1016/S0014-5793(99)00091-5; DONOHUE TJ, 1991, METHOD ENZYMOL, V204, P459; ESPE MP, 1995, BIOCHEMISTRY-US, V34, P7593, DOI 10.1021/bi00023a005; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; GEREN LM, 1995, J BIOL CHEM, V270, P2466, DOI 10.1074/jbc.270.6.2466; GLERUM DM, 1994, P NATL ACAD SCI USA, V91, P8452, DOI 10.1073/pnas.91.18.8452; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; HALTIA T, 1988, EUR J BIOCHEM, V172, P543, DOI 10.1111/j.1432-1033.1988.tb13923.x; HILL BC, 1991, J BIOL CHEM, V266, P2219; HILL J, 1992, BIOCHEMISTRY-US, V31, P11435, DOI 10.1021/bi00161a023; HOSLER JP, 1992, J BIOL CHEM, V267, P24264; HOSLER JP, 1995, BIOCHEMISTRY-US, V34, P7586, DOI 10.1021/bi00023a004; HUNDT E, 1980, FEBS LETT, V115, P95, DOI 10.1016/0014-5793(80)80734-4; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; Hunter DJB, 1997, FEBS LETT, V412, P43, DOI 10.1016/S0014-5793(97)00735-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Liao GL, 1996, BBA-BIOENERGETICS, V1274, P109, DOI 10.1016/0005-2728(96)00014-X; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Ostermeier C, 1996, CURR OPIN STRUC BIOL, V6, P460, DOI 10.1016/S0959-440X(96)80110-2; Petruzzella V, 1998, GENOMICS, V54, P494, DOI 10.1006/geno.1998.5580; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; SAIKI K, 1993, J BIOL CHEM, V268, P26041; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; STEFFENS GCM, 1987, EUR J BIOCHEM, V164, P295, DOI 10.1111/j.1432-1033.1987.tb11057.x; THOMPSON DA, 1983, BIOCHEMISTRY-US, V22, P3178, DOI 10.1021/bi00282a022; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; van Niel CB, 1944, BACTERIOL REV, V8, P1; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; Wakabayashi T, 1998, FEBS LETT, V440, P141, DOI 10.1016/S0014-5793(98)01431-8; WIELBURSKI A, 1983, BIOCHEM J, V212, P829, DOI 10.1042/bj2120829; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zhen Y, 1998, PROTEIN EXPRES PURIF, V13, P326, DOI 10.1006/prep.1998.0903; Zhen YJ, 1999, J BIOL CHEM, V274, P38032, DOI 10.1074/jbc.274.53.38032	49	170	174	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					619	623		10.1074/jbc.275.1.619	http://dx.doi.org/10.1074/jbc.275.1.619			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617659	Green Published, hybrid			2022-12-25	WOS:000085951600083
J	Leonardi, A; Ellinger-Ziegelbauer, H; Franzoso, G; Brown, K; Siebenlist, U				Leonardi, A; Ellinger-Ziegelbauer, H; Franzoso, G; Brown, K; Siebenlist, U			Physical and functional interaction of filamin (actin-binding protein-280) and tumor necrosis factor receptor-associated factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TNF RECEPTOR-1; TERMINAL KINASE; JNK/SAPK ACTIVATION; SIGNAL TRANSDUCER; CELL-DEATH; FAMILY; ALPHA; TRAF2; BETA	Tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) is an intracellular protein involved in signal transduction from TNF receptor I and II and related receptors. TRAF2 is required for TNF-induced activation of c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), and TRAF2 can also mediate activation of NF-kappa B. Here we have identified the actin-binding protein Filamin (actin-binding protein-280) as a TRAF2-interacting protein. Filamin binds to the Ring zinc finger domain of TRAF2, Overexpressed Filamin inhibits TRAF2-induced activation of JNI/SAPK and of NF-kappa B. Furthermore, ectopically expressed Filamin inhibits NF-kappa B activation induced via TNF, interleukin-1, Toll receptors, and TRAF6 but not activation induced via overexpression of NIK, a downstream effector in these pathways. Importantly, TNF fails to activate SAPK or NF-kappa B in a human melanoma cell line deficient in Filamin. Reintroduction of Filamin into these cells restores the TNF response. The data imply a role for Filamin in inflammatory signal transduction pathways.	NIAID, Immune Activat Sect, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Siebenlist, U (corresponding author), NIAID, Immune Activat Sect, Immunoregulat Lab, NIH, Bldg 10,Rm 11B16, Bethesda, MD 20892 USA.		Franzoso, Guido/GRR-8628-2022; leonardi, antonio/A-2887-2009	leonardi, antonio/0000-0001-8636-9623; Franzoso, Guido/0000-0002-0778-988X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000722, ZIAAI000722, Z01AI000723] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aizawa S, 1997, J BIOL CHEM, V272, P2042; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Edwards DN, 1997, DEVELOPMENT, V124, P3855; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HARTWIG J, 1995, PROTEIN PROFILE, V2, P739; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; OHTA Y, 1991, CELL, V67, P225; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Shi CS, 1999, J IMMUNOL, V163, P3279; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WERSCHE H, 1997, IMMUNITY, V7, P837; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	70	101	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					271	278		10.1074/jbc.275.1.271	http://dx.doi.org/10.1074/jbc.275.1.271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617615	hybrid			2022-12-25	WOS:000085951600039
J	Park, JS; Boyer, S; Mitchell, K; Gilfor, D; Birrer, M; Darlington, G; El Deiry, W; Firestone, GL; Munger, K; Band, V; Fisher, PB; Dent, P				Park, JS; Boyer, S; Mitchell, K; Gilfor, D; Birrer, M; Darlington, G; El Deiry, W; Firestone, GL; Munger, K; Band, V; Fisher, PB; Dent, P			Expression of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21Cip-1/WAF1/MDA6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED PROTEIN; CYCLIN-DEPENDENT KINASES; ADULT-RAT HEPATOCYTES; CELL-PROLIFERATION; P53 GENE; P53-INDEPENDENT INDUCTION; P21(WAF1/CIP1) EXPRESSION; HUMAN KERATINOCYTES; LIVER-REGENERATION; PRIMARY CULTURES	The impact of human papilloma virus (HPV16) E7 proteins and retinoblastoma (RB) antisense oligonucleotides upon mitogen-activated protein kinase (MAPK)-mediated inhibition of DNA synthesis via p21(Cip-1/WAF1/MDA6) (p21) was determined in primary hepatocytes. Prolonged activation of the MAPK pathway in p21(+/+) or p21(-/-) hepatocytes caused a large decrease and increase, respectively, in DNA synthesis. Either transfection with RE antisense oligonucleotides, expression of wild type E7, or RE binding mutant E7 (C24S) proteins increased p21 levels and reduced DNA synthesis in p21(+/+) hepatocytes. RE antisense oligonucleotides and E7 proteins increased apoptosis in p21(+/+), but not p21(-/-), hepatocytes. Expression of wild type E7 increased DNA synthesis above control levels in p21(-/-) cells, which was additive with prolonged MAPK activation. In contrast, expression of mutant E7 did not alter DNA synthesis above control levels in p21(-/-) cells and was supra-additive with prolonged MAPK activation. Antisense ablation of RE in p21(-/-) hepatocytes had a weak stimulatory effect upon DNA synthesis itself but enhanced the capacity of mutant E7 protein to stimulate DNA synthesis to the same level observed using wild type E7. The ability of prolonged MAPK activation to stimulate DNA synthesis in the presence of mutant E7 and antisense RE was additive. Collectively, the present data demonstrate that loss of RE function together with loss of pal function plays an important role in the E7- and MAPK-dependent modulation of apoptosis and DNA synthesis in primary hepatocytes.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA; Tufts Univ, Sch Med, New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77071 USA; NCI, Med Branch, NIH, Bethesda, MD 20181 USA; Univ Penn, Sch Med, Ctr Canc, Dept Med,Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	Virginia Commonwealth University; Virginia Commonwealth University; Columbia University; Columbia University; Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School; University of California System; University of California Berkeley; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dent, P (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA.	PDENT@HSC.VCU.EDU	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Munger, Karl/0000-0003-3288-9935	NCI NIH HHS [R01CA35675, R01CA74468] Funding Source: Medline; NIDDK NIH HHS [R01DK52825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074468, R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358; Auer KL, 1998, FEBS LETT, V436, P131, DOI 10.1016/S0014-5793(98)01074-6; Auer KL, 1998, BIOCHEM J, V336, P551, DOI 10.1042/bj3360551; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Blagosklonny MV, 1997, CANCER RES, V57, P320; Boyer SN, 1996, CANCER RES, V56, P4620; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57; CHEN TC, 1995, J PATHOL, V176, P243, DOI 10.1002/path.1711760306; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P11548, DOI 10.1073/pnas.90.24.11548; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555; Enzenauer C, 1998, INTERVIROLOGY, V41, P80, DOI 10.1159/000024918; Fan GS, 1996, ONCOGENE, V12, P1909; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fernando GJP, 1999, CLIN EXP IMMUNOL, V115, P397; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gao QS, 1999, MOL CELL BIOL, V19, P733; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Hirai A, 1997, J BIOL CHEM, V272, P13; Imai Y, 1996, JPN J CANCER RES, V87, P1056, DOI 10.1111/j.1349-7006.1996.tb03110.x; Jian YC, 1999, CELL GROWTH DIFFER, V10, P101; Jian YC, 1998, ONCOGENE, V17, P2027, DOI 10.1038/sj.onc.1202142; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lochmuller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mineta H, 1998, ANTICANCER RES, V18, P4765; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Pu H, 1997, ACTA MED OKAYAMA, V51, P313; Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; TERAMOTO T, 1994, CANCER RES, V54, P231; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Tombes RM, 1998, BIOCHEM J, V330, P1451; Vrana JA, 1999, RADIAT RES, V151, P559, DOI 10.2307/3580032; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; Westwick JK, 1996, AM J PHYSIOL-GASTR L, V271, pG780, DOI 10.1152/ajpgi.1996.271.5.G780; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zeng YX, 1996, ONCOGENE, V12, P1557	64	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					18	28		10.1074/jbc.275.1.18	http://dx.doi.org/10.1074/jbc.275.1.18			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617580	hybrid			2022-12-25	WOS:000085951600004
J	Yu, CL; Jin, YJ; Burakoff, SJ				Yu, CL; Jin, YJ; Burakoff, SJ			Cytosolic tyrosine dephosphorylation of STAT5 - Potential role of SHP-2 in STAT5 regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER; NUCLEAR TRANSLOCATION; TRANSCRIPTION FACTORS; PHOSPHATASE SHP-1; GENE-EXPRESSION; DNA-BINDING; ACTIVATION; PROTEIN; INDUCTION; RECEPTOR	STAT5, a member of the signal transducers and activators of transcription (STATs), is important in modulating T cell functions through interleukin-2 (IL-2) receptors, Like other STAT proteins, STAT5 undergoes a rapid activation and inactivation cycle upon cytokine stimulation. Tyrosine phosphorylation and dephosphorylation are critical in regulating STAT5 activity. A number of protein tyrosine kinases have been shown to phosphorylate STAT5; however, the phosphatases responsible for STAT5 dephosphorylation remain unidentified, Using CTLL-20 as a model system, we provide evidence that tyrosine dephosphorylation of STAT5 subsequent to IL-2-induced phosphorylation occurs in the absence of STAT5 nuclear translocation and new protein synthesis. Nevertheless, down-regulation of the upstream Janus kinase activity during the deactivation cycle of IL-2-induced signaling does involve new protein synthesis. These findings point to the constitutive presence of STAT5 tyrosine phosphatase activity in the cytosolic compartment. We further demonstrate that SHP-2, but not SHP-1, directly dephosphorylates STAT5 in an in vitro tyrosine phosphatase assay with purified proteins. Furthermore, tyrosine-phosphorylated STAT5 associates with the substrate-trapping mutant (Cys --> Ser) of SHP-2 but not SHP-1, These results suggest a potential role for cytoplasmic protein-tyrosine phosphatases in directly dephosphorylating STAT proteins and in maintaining a basal steady state level of STAT activity.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Burakoff, SJ (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.		Yu, Chao-Lan/D-1834-2011	Yu, Chao-Lan/0000-0002-9381-6011	NATIONAL CANCER INSTITUTE [F32CA079154, R01CA070758] Funding Source: NIH RePORTER; NCI NIH HHS [1-F32-CA-79154-01, CA-70758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aman MJ, 1999, J BIOL CHEM, V274, P30266, DOI 10.1074/jbc.274.42.30266; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Gadina M, 1998, J IMMUNOL, V160, P4657; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Kim H, 1999, MOL CELL BIOL, V19, P5326; Lee CK, 1997, J BIOL CHEM, V272, P21872, DOI 10.1074/jbc.272.35.21872; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muller H, 1997, MOL CELL BIOL, V17, P5508; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Rayanade RJ, 1998, J IMMUNOL, V161, P325; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Servidei T, 1998, J BIOL CHEM, V273, P6233, DOI 10.1074/jbc.273.11.6233; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SWEITZER SM, 1995, J BIOL CHEM, V270, P16510, DOI 10.1074/jbc.270.28.16510; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Yu CL, 1997, J IMMUNOL, V159, P5206	47	124	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					599	604		10.1074/jbc.275.1.599	http://dx.doi.org/10.1074/jbc.275.1.599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617656	hybrid			2022-12-25	WOS:000085951600080
J	Hall, DM; Oberley, TD; Moseley, PM; Buettner, GR; Oberley, LW; Weindruch, R; Kregel, KC				Hall, DM; Oberley, TD; Moseley, PM; Buettner, GR; Oberley, LW; Weindruch, R; Kregel, KC			Caloric restriction improves thermotolerance and reduces hyperthermia-induced cellular damage in old rats	FASEB JOURNAL			English	Article						free radicals; oxidative stress; stress proteins; HSP70; aging; antioxidant enzymes	SYRIAN-HAMSTER TISSUES; IMMUNOHISTOCHEMICAL LOCALIZATION; SUPEROXIDE-DISMUTASE; ANTIOXIDANT ENZYMES; KIDNEY DEVELOPMENT; FISCHER-344 RATS; OXIDATIVE STRESS; HEAT-SHOCK; LIVER; AGE	Adult-onset, long-term caloric restriction (CR) prolongs maximum life span in laboratory rodents. However, the effect of this intervention on an organism's ability to cope with a physical challenge has not been explored. We investigates the influence of CR and aging on stress tolerance in old rats exposed to an environmental heating protocol on two consecutive days. We hypothesized that CR would increase heat tolerance by reducing cellular stress and subsequent accrual of oxidative injury. All calorically restricted rats survived both heat exposures compared with only 50% of their control-fed counterparts. CR also decreased heat-induced radical generation, stress protein accumulation, and cellular injury in the liver. In addition, heat stress stimulated marked induction of the antioxidant enzymes manganese-containing superoxide dismutase and catalase, along with strong nuclear catalase expression in liver samples from samples from rats subjected to CR. In contrast, stress-related induction of antioxidant enzymes was blunted, and nuclear catalase expression was unchanged from euthermic conditions in the control-fed group. These data suggest that CR reduces cellular injury and improves heat tolerance of old animals by lowering radical production and preserving cellular ability to adapt to stress through antioxidant enzyme induction and translocation of these proteins to the nucleus.	Univ Iowa, Integrat Physiol Lab, Dept Exercise Sci, Iowa City, IA 52242 USA; Univ Iowa, Free Rad Res Inst, Iowa City, IA 52242 USA; Univ Iowa, Radiat Res Lab, Iowa City, IA 52242 USA; Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA; VA Hosp, Pathol & Lab Med Serv, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Dept Pathol, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI 53705 USA; Vet Adm Geriat Res, Educ & Clin Ctr, Madison, WI 53705 USA	University of Iowa; University of Iowa; University of Iowa; University of New Mexico; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center	Kregel, KC (corresponding author), Univ Iowa, Integrat Physiol Lab, Dept Exercise Sci, 532 FH, Iowa City, IA 52242 USA.	kevin-kregel@uiowa.edu		Moseley, Pope/0000-0002-3723-9950; Buettner, Garry/0000-0002-5594-1903	NATIONAL INSTITUTE ON AGING [R29AG012350, R01AG012350, R01AG010536, R01AG014687] Funding Source: NIH RePORTER; NIA NIH HHS [AG10536, AG14687, AG12350] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ASH DE, 1982, J BIOL CHEM, V257, P9261; BAKER JE, 1988, P NATL ACAD SCI USA, V85, P2786, DOI 10.1073/pnas.85.8.2786; BLAKE MJ, 1990, J BIOL CHEM, V265, P15275; Christianson DW, 1997, PROG BIOPHYS MOL BIO, V67, P217, DOI 10.1016/S0079-6107(97)88477-5; Chui C-.J., 1970, ARCH SURG-CHICAGO, V101, P478; ERSHLER WB, 1993, J AM GERIATR SOC, V41, P176, DOI 10.1111/j.1532-5415.1993.tb02054.x; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; HARRIS ED, 1992, FASEB J, V6, P2675, DOI 10.1096/fasebj.6.9.1612291; HASS MA, 1988, J BIOL CHEM, V263, P776; HENSCHEL A, 1969, AM J PUBLIC HEALTH N, V59, P2232, DOI 10.2105/AJPH.59.12.2232; HERZFELD A, 1976, BIOCHEM J, V153, P469, DOI 10.1042/bj1530469; KEW M, 1970, AM J MED, V49, P192, DOI 10.1016/S0002-9343(70)80075-4; Kregel K. C., 1996, J APPL PHYSIOL, V80, P262; KREGEL KC, 1990, J APPL PHYSIOL, V68, P1337, DOI 10.1152/jappl.1990.68.4.1337; KREGEL KC, 1995, J APPL PHYSIOL, V79, P1673, DOI 10.1152/jappl.1995.79.5.1673; KUBES P, 1993, AM J PHYSIOL, V264, pG143, DOI 10.1152/ajpgi.1993.264.1.G143; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; LEVINE JA, 1969, AM J MED, V47, P251, DOI 10.1016/0002-9343(69)90151-X; MATSUO M, 1992, MECH AGEING DEV, V64, P273, DOI 10.1016/0047-6374(92)90084-Q; OBERLEY TD, 1991, AM J PATHOL, V139, P355; OBERLEY TD, 1990, AM J PATHOL, V137, P199; PAPACONSTANTINOU J, 1994, ANN NY ACAD SCI, V719, P195, DOI 10.1111/j.1749-6632.1994.tb56829.x; PRIVALLE CT, 1987, P NATL ACAD SCI USA, V84, P2723, DOI 10.1073/pnas.84.9.2723; RYAN AJ, 1995, MED SCI SPORTS EXERC, V28, P423; SANDERSONJP, 1997, J GERONTOL BIOL SCI, V52, pB20; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; SKIBBA JL, 1991, INT J HYPERTHER, V7, P749, DOI 10.3109/02656739109056444; SLINKER BK, 1988, AM J PHYSIOL, V255, pR353, DOI 10.1152/ajpregu.1988.255.3.R353; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; VANDERKRAAIJ AMM, 1989, BIOCHEM J, V264, P687, DOI 10.1042/bj2640687; Weindruch R., 1988, RETARDATION AGING DI; WEINDRUCH RH, 1980, MECH AGEING DEV, V12, P375, DOI 10.1016/0047-6374(80)90070-6; XIA EN, 1995, J NUTR, V125, P195; YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7; YU BP, 1982, J GERONTOL, V37, P130, DOI 10.1093/geronj/37.2.130	37	80	81	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					78	86		10.1096/fasebj.14.1.78	http://dx.doi.org/10.1096/fasebj.14.1.78			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627282				2022-12-25	WOS:000084784700010
J	Hungerford, JE; Sessa, WC; Segal, SS				Hungerford, JE; Sessa, WC; Segal, SS			Vasomotor control in arterioles of the mouse cremaster muscle	FASEB JOURNAL			English	Article						microcirculation; vasodilation; vasoconstriction; conduction	ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION; HAMSTER STRIATED-MUSCLE; SMOOTH-MUSCLE; K+ CHANNELS; EPOXYEICOSATRIENOIC ACIDS; CONDUCTED VASODILATION; MESENTERIC-ARTERY; CEREBRAL-ARTERIES; NITRIC-OXIDE; BLOOD-FLOW	Recent advances in transgenic mouse technology provide novel models to study cardiovascular physiology and pathophysiology. In light of these developments, there is an increasing need for understanding cardiovascular function and blood flow control in normal mice. To this end we have used intravital microscopy to investigate vasomotor control in arterioles of the superfused cremaster muscle preparation of anesthetized C57B16 mice. Spontaneous resting tone increased with branch order and was enhanced by oxygen. Norepinephrine and acetylcholine (ACh) caused concentration-dependent vasoconstriction and vasodilation, respectively, Microiontophoresis of ACh evoked vasodilation that conducted along arterioles; the local (direct) response was inhibited by N-w-nitro-L-arginine (LNA), and both local and conducted responses were inhibited by 17-octadecynoic acid (17-ODYA), Microejection of KCI evoked a biphasic response: a transient conducted vasoconstriction (inhibited by nifedipine), followed by a conducted vasodilation that was insensitive to LNA, indomethacin, and 17-ODYA, Phenylephrine evoked focal vasoconstriction that did not conduct. Perivascular sympathetic nerve stimulation evoked constriction along arterioles that was inhibited by tetrodotoxin. These findings indicate that for arterioles in the mouse cremaster muscle, nitric oxide and endothelial-derived hyperpolarizing factor (as shown by LNA and 17-ODYA interventions, respectively) mediate vasodilatory responses to ACh but not to KCI, and that vasomotor responses spread along; arterioles by multiple pathways of cell-to-cell communication.	Yale Univ, Sch Med, John B Pierce Lab, New Haven, CT 06519 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06519 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA	Yale University; The John B Pierce Laboratory, Inc; Yale University; Yale University	Segal, SS (corresponding author), Yale Univ, Sch Med, John B Pierce Lab, 290 Congress Ave, New Haven, CT 06519 USA.	sssegal@jbpierce.org	babakinejad, babak/G-2674-2012; Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Segal, Steven/0000-0001-5667-2154	NHLBI NIH HHS [R01 HL57665, R01 HL41026] Funding Source: Medline; PHS HHS [R01 JL56786] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041026, R01HL057665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEZ S, 1973, MICROVASC RES, V5, P384, DOI 10.1016/0026-2862(73)90054-X; Beach JM, 1998, AM J PHYSIOL-HEART C, V275, pH1489, DOI 10.1152/ajpheart.1998.275.4.H1489; BURNSTOCK G, 1994, BRIT J PLAST SURG, V47, P527, DOI 10.1016/0007-1226(94)90136-8; Campbell WB, 1999, CIRC RES, V84, P484, DOI 10.1161/01.RES.84.4.484; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Chen GF, 1996, CIRC RES, V79, P827, DOI 10.1161/01.RES.79.4.827; CHEN GF, 1990, J PHYSIOL-LONDON, V421, P521, DOI 10.1113/jphysiol.1990.sp017959; CHEN GTJ, 1992, J METEOROL SOC JPN, V70, P25, DOI 10.2151/jmsj1965.70.1_25; CHRIST GJ, 1993, J PHARMACOL EXP THER, V266, P1054; Christensen G, 1997, AM J PHYSIOL-HEART C, V272, pH2513, DOI 10.1152/ajpheart.1997.272.6.H2513; Clark SG, 1997, J PHARMACOL EXP THER, V282, P1473; COWEN T, 1985, HISTOCHEMISTRY, V82, P205, DOI 10.1007/BF00501396; Doevendans PA, 1998, CARDIOVASC RES, V39, P34, DOI 10.1016/S0008-6363(98)00073-X; Doyle MP, 1997, AM J PHYSIOL-HEART C, V272, pH1364, DOI 10.1152/ajpheart.1997.272.3.H1364; Edwards G, 1998, NATURE, V396, P269, DOI 10.1038/24388; Faraci FM, 1998, AM J PHYSIOL-HEART C, V274, pH564, DOI 10.1152/ajpheart.1998.274.2.H564; Godecke A, 1998, CIRC RES, V82, P186; Haas TL, 1997, MICROVASC RES, V53, P113, DOI 10.1006/mvre.1996.1999; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; Harder DR, 1996, CIRC RES, V79, P54, DOI 10.1161/01.RES.79.1.54; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; James JF, 1998, CIRC RES, V82, P407, DOI 10.1161/01.RES.82.4.407; Kass DA, 1998, CIRC RES, V82, P519, DOI 10.1161/01.RES.82.4.519; Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318; KURJIAKA DT, 1995, CIRC RES, V76, P885, DOI 10.1161/01.RES.76.5.885; Li PL, 1997, CIRC RES, V80, P877; LINDVALL O, 1974, HISTOCHEMISTRY, V39, P97, DOI 10.1007/BF00492041; LITTLE TL, 1995, CIRC RES, V76, P498, DOI 10.1161/01.RES.76.3.498; Lombard JH, 1999, AM J PHYSIOL-HEART C, V276, pH503, DOI 10.1152/ajpheart.1999.276.2.H503; MCCARRON JG, 1990, AM J PHYSIOL, V259, pH902, DOI 10.1152/ajpheart.1990.259.3.H902; Meng W, 1996, AM J PHYSIOL-HEART C, V271, pH1145, DOI 10.1152/ajpheart.1996.271.3.H1145; OLESEN SP, 1988, CIRC RES, V62, P1059, DOI 10.1161/01.RES.62.6.1059; PROCTOR KG, 1985, AM J PHYSIOL, V249, pH34, DOI 10.1152/ajpheart.1985.249.1.H34; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Randall MD, 1998, TRENDS PHARMACOL SCI, V19, P55, DOI 10.1016/S0165-6147(97)01161-9; RHODIN JAG, 1967, J ULTRA MOL STRUCT R, V18, P181, DOI 10.1016/S0022-5320(67)80239-9; Rosenblum WI, 1998, MICROCIRCULATION, V5, P129; SEGAL SS, 1989, AM J PHYSIOL, V256, pH838, DOI 10.1152/ajpheart.1989.256.3.H838; Segal SS, 1996, J PHYSIOL-LONDON, V496, P229, DOI 10.1113/jphysiol.1996.sp021680; SEGAL SS, 1991, AM J PHYSIOL, V261, pH181, DOI 10.1152/ajpheart.1991.261.1.H181; SEGAL SS, 1989, AM J PHYSIOL, V256, pH832, DOI 10.1152/ajpheart.1989.256.3.H832; SEGAL SS, 1986, SCIENCE, V234, P868, DOI 10.1126/science.3775368; Segal SS, 1999, J PHYSIOL-LONDON, V516, P283, DOI 10.1111/j.1469-7793.1999.283aa.x; Shimokawa H, 1996, J CARDIOVASC PHARM, V28, P703, DOI 10.1097/00005344-199611000-00014; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Vanheel B, 1997, J PHYSIOL-LONDON, V501, P331, DOI 10.1111/j.1469-7793.1997.331bn.x; Welsh DG, 1996, CIRC RES, V79, P551, DOI 10.1161/01.RES.79.3.551; Welsh DG, 1998, AM J PHYSIOL-HEART C, V274, pH178, DOI 10.1152/ajpheart.1998.274.1.H178; Xia J, 1998, AM J PHYSIOL-HEART C, V274, pH323, DOI 10.1152/ajpheart.1998.274.1.H323; Xia J, 1995, AM J PHYSIOL-HEART C, V269, pH2022, DOI 10.1152/ajpheart.1995.269.6.H2022; ZOU AP, 1994, J PHARMACOL EXP THER, V268, P474	51	73	76	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					197	207		10.1096/fasebj.14.1.197	http://dx.doi.org/10.1096/fasebj.14.1.197			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627294				2022-12-25	WOS:000084784700022
J	Li, CG; Hampson, IN; Hampson, L; Kumar, P; Bernabeu, C; Kumar, S				Li, CG; Hampson, IN; Hampson, L; Kumar, P; Bernabeu, C; Kumar, S			CD105 antagonizes the inhibitory signaling of transforming growth factor beta 1 on human vascular endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; TGF beta 1; HUVEC	TGF-BETA; UP-REGULATION; CELLULAR-RESPONSES; BINDING-PROTEIN; IN-VITRO; ENDOGLIN; ANGIOGENESIS; EXPRESSION; TGF-BETA-1; RECEPTORS	CD105 (endoglin), a receptor for transforming growth factor beta (TGF beta), is highly expressed in tissue-cultured, activated endothelial cells in vitro and in tissues undergoing angiogenesis in vivo. The absence of CD105 in knockout mice leads to their death from defective vascular development, but the role of CD105 in the modulation of angiogenesis has not been elucidated. TGF beta 1 is a well-recognized regulator of angiogenesis. Using an antisense approach, we have shown that inhibition of CD105 protein translation in cultured human endothelial cells enhances the ability of TGF beta 1 to suppress growth and migration in these cells. The ability of endothelial cells to form capillary tubes was evaluated by the use of a 3-dimensional collagen matrix system where TGF beta 1 not only reduced the length of capillary-like structures, but also caused massive mortality in CD105-deficient cells compared to control cultures. These results provide direct evidence that CD105 antagonizes the inhibitory effects of TGF beta 1 on human vascular endothelial cells and that normal cellular levels of CD105 are required for the formation of new blood vessels.	Univ Manchester, Sch Med, Dept Pathol Sci, Manchester M13 9PT, Lancs, England; St Marys Hosp, Manchester M13 0JH, Lancs, England; Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England; CSIC, E-28006 Madrid, Spain	University of Manchester; University of Manchester; Paterson Institute for Cancer Research; Consejo Superior de Investigaciones Cientificas (CSIC)	Kumar, S (corresponding author), Univ Manchester, Sch Med, Dept Pathol Sci, Stopford Bldg, Manchester M13 9PT, Lancs, England.	MDDPSCL2@FS1.SCG.MAN.AC.UK	Bernabeu, Carmelo/P-4662-2019; Bernabeu, Carmelo/L-3226-2014	Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Hampson, Lynne/0000-0002-0656-0127				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; BATTEGAY EJ, 1995, J MOL MED, V73, P333; Bodey B, 1998, ANTICANCER RES, V18, P1485; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERNANDEZRUIZ E, 1993, CYTOGENET CELL GENET, V64, P204, DOI 10.1159/000133576; Folkman J, 1997, EXS, V79, P1; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KANZAWA S, 1993, ANN PLAS SURG, V30, P244, DOI 10.1097/00000637-199303000-00008; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLEINSOYER C, 1992, BIOL CELL, V75, P155, DOI 10.1016/0248-4900(92)90136-O; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Kumar P, 1996, J PATHOL, V178, P363, DOI 10.1002/(SICI)1096-9896(199604)178:4<363::AID-PATH491>3.0.CO;2-8; Kumar S, 1999, CANCER RES, V59, P856; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 1999, INT J CANCER, V84, P155, DOI 10.1002/(SICI)1097-0215(19990420)84:2<155::AID-IJC11>3.0.CO;2-S; Li CG, 1997, INFLAMM RES, V46, P348, DOI 10.1007/s000110050200; Li CG, 1998, INT J CANCER, V79, P455, DOI 10.1002/(SICI)1097-0215(19981023)79:5<455::AID-IJC2>3.3.CO;2-K; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; Matsuno F, 1999, CLIN CANCER RES, V5, P371; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Miyazono K, 1997, INT J HEMATOL, V65, P97; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; RULO HFC, 1995, J DERMATOL SCI, V10, P103, DOI 10.1016/0923-1811(95)00397-B; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SUTTON AB, 1991, J CELL SCI, V99, P777; SZEKANECZ Z, 1995, CLIN IMMUNOL IMMUNOP, V76, P187, DOI 10.1006/clin.1995.1114; TADA K, 1994, BBA-GEN SUBJECTS, V1201, P135, DOI 10.1016/0304-4165(94)90033-7; Takashima S, 1996, J BIOL CHEM, V271, P24901, DOI 10.1074/jbc.271.40.24901; WANG JM, 1995, INT J CANCER, V62, P791, DOI 10.1002/ijc.2910620624; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	40	207	231	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					55	64		10.1096/fasebj.14.1.55	http://dx.doi.org/10.1096/fasebj.14.1.55			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627280				2022-12-25	WOS:000084784700008
J	Hasegawa, J; Shimahara, H; Mizutani, M; Uchiyama, S; Arai, H; Ishii, M; Kobayashi, Y; Ferguson, SJ; Sambongi, Y; Igarashi, Y				Hasegawa, J; Shimahara, H; Mizutani, M; Uchiyama, S; Arai, H; Ishii, M; Kobayashi, Y; Ferguson, SJ; Sambongi, Y; Igarashi, Y			Stabilization of Pseudomonas aeruginosa cytochrome c(551) by systematic amino acid substitutions based on the structure of thermophilic Hydrogenobacter thermophilus cytochrome c(552)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROMES; ESCHERICHIA-COLI; PYROCOCCUS-FURIOSUS; YEAST ISO-1-CYTOCHROME-C; OXIDIZING BACTERIUM; PROTEIN STABILITY; THERMAL-STABILITY; NMR-SPECTROSCOPY; THERMOSTABILITY; EXPRESSION	A heterologous overexpression system for mesophilic Pseudomonas aeruginosa holocytochrome c(551) (PA c(551)) was established using Escherichia coli as a host organism. Amino acid residues were systematically substituted in three regions of PA c(551) with the corresponding residues from thermophilic Hydrogenobacter thermophilus cytochrome c(552) (HT c(552)), which has similar main chain folding to PA c(551), but is more stable to heat. Thermodynamic properties of PA c(551) with one of three single mutations (Phe-7 to Ala, Phe-34 to Tyr, or Val-78 to Ile) showed that these mutants had increased thermostability compared with that of the wild-type. Ala-7 and Ile-78 may contribute to the thermostability by tighter hydrophobic packing, which is indicated by the three dimensional structure comparison of PA c(551) with HT c(552). In the Phe-34 to Tyr mutant, the hydroxyl group of the Tyr residue and the guanidyl base of Arg-47 formed a hydrogen bond, which did not exist between the corresponding residues in HT c(552). We also found that stability of mutant proteins to denaturation by guanidine hydrochloride correlated with that against the thermal denaturation. These results and others described here suggest that significant stabilization of PA c(551) can be achieved through a few amino acid substitutions determined by molecular modeling with reference to the structure of HT c(552), The higher stability of HT c(552) may in part be attributed to some of these substitutions.	Daiichi Pharmaceut Co Ltd, Edogawa Ku, Tokyo 1348630, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1130032, Japan; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	Daiichi Sankyo Company Limited; Osaka University; University of Tokyo; University of Oxford	Hasegawa, J (corresponding author), Daiichi Pharmaceut Co Ltd, Edogawa Ku, 1-16-13 Kita Kasai, Tokyo 1348630, Japan.		UCHIYAMA, Susumu/F-9590-2017	UCHIYAMA, Susumu/0000-0002-5181-179X				ANDERSON DE, 1993, PROTEIN SCI, V2, P1285, DOI 10.1002/pro.5560020811; ARAI H, 1995, J FERMENT BIOENG, V79, P489, DOI 10.1016/0922-338X(95)91267-9; ARAI H, 1990, FEBS LETT, V261, P195; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Bogin O, 1998, PROTEIN SCI, V7, P1156, DOI 10.1002/pro.5560070509; BRITTON KL, 1995, EUR J BIOCHEM, V229, P688, DOI 10.1111/j.1432-1033.1995.tb20515.x; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Cutruzzola F, 1997, BIOCHEM J, V322, P35, DOI 10.1042/bj3220035; DARWIN A, 1993, J GEN MICROBIOL, V139, P1829, DOI 10.1099/00221287-139-8-1829; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eidsness MK, 1997, BIOCHEMISTRY-US, V36, P10406, DOI 10.1021/bi970110r; GANTER C, 1990, BIOCHEMISTRY-US, V29, P9395, DOI 10.1021/bi00492a013; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Hayashi NR, 1999, INT J SYST BACTERIOL, V49, P783, DOI 10.1099/00207713-49-2-783; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PALMER AG, 1992, J MAGN RESON, V96, P416, DOI 10.1016/0022-2364(92)90097-Q; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; RUSSELL RJM, 1994, STRUCTURE, V2, P1157, DOI 10.1016/S0969-2126(94)00118-9; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; SAMBONGI Y, 1992, BIOSCI BIOTECH BIOCH, V56, P990, DOI 10.1271/bbb.56.990; Sambongi Y, 1996, FEBS LETT, V398, P265, DOI 10.1016/S0014-5793(96)01256-2; SANBONGI Y, 1989, J BACTERIOL, V171, P65, DOI 10.1128/jb.171.1.65-69.1989; SANBONGI Y, 1989, BIOCHEMISTRY-US, V28, P9574, DOI 10.1021/bi00451a004; SANBONGI Y, 1991, EUR J BIOCHEM, V198, P7, DOI 10.1111/j.1432-1033.1991.tb15979.x; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SHUMANN J, 1993, PROTEIN SCI, V2, P1612; Sinha N, 1998, FEMS MICROBIOL LETT, V161, P1; SPASSOV VZ, 1995, PROTEIN SCI, V4, P1516, DOI 10.1002/pro.5560040809; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; TIMKOVICH R, 1990, BIOCHEMISTRY-US, V29, P7773, DOI 10.1021/bi00485a029; UBBINK M, 1992, J BACTERIOL, V174, P3707, DOI 10.1128/JB.174.11.3707-3714.1992; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	44	78	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37533	37537		10.1074/jbc.274.53.37533	http://dx.doi.org/10.1074/jbc.274.53.37533			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608805	Green Published, hybrid			2022-12-25	WOS:000084528000005
J	Kelm, RJ; Elder, PK; Getz, MJ				Kelm, RJ; Elder, PK; Getz, MJ			The single-stranded DNA-binding proteins, Pur alpha, Pur beta, and MSY1 specifically interact with an exon 3-derived mouse vascular smooth muscle alpha-actin messenger RNA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD SHOCK DOMAIN; T ALTERNATIVE EXON; Y-BOX PROTEINS; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; RIBONUCLEOPROTEIN PARTICLES; STIMULATES TRANSCRIPTION; CELLULAR PROTEIN; CONTROL ELEMENT; GLIAL-CELLS	Amino acids 44-53 of mouse vascular smooth muscle alpha-actin are encoded by a region of exon 3 that bears structural similarity to an essential MCAT enhancer element in the 5' promoter of the gene. The single-stranded DNA-binding proteins, Pur alpha Pur beta, and MSY1, interact with each other and with opposite strands of the enhancer to repress transcription in fibroblasts (Sun, S., Stoflet, E. S., Cogan, J. G., Strauch, A. R., and Getz, M. J. (1995) Mol Cell. Biol. 15, 2429-2436; Kelm, R. J., Jr., Cogan, J. G., Elder, P. K., Strauch, A. R., and Getz, M.J. (1999) J. Biol. Chem 274, 14238-14245). In this study, we employed both recombinant and fibroblast-derived proteins 60 demonstrate that all three proteins specifically interact with the mRNA counterpart of the exon 3 sequence in cell-fi ee binding assays. When placed in the 5'-untranslated region of a reporter mRNA, the exon 3-derived sequence suppressed mRNA translation in transfected fibroblasts. Translational efficiency was restored by mutations that impaired mRNA binding of Pur alpha Pur beta, and MYS1, implying that these proteins can also participate in messenger ribonucleoprotein formation in living cells. Additionally, primary structure determinants required for interaction of Pur beta with single-stranded DNA, mRNA, and protein Ligands were mapped by deletion mutagenesis. These experiments reveal highly specific protein-mRNA interactions that are potentially important in regulating expression of the vascular smooth muscle cu-actin gene in fibroblasts.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Kelm, RJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	kelm.robert@mayo.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54281] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIOK S, 1994, MOL CELL BIOL, V14, P6004, DOI 10.1128/MCB.14.9.6004; BAUREN G, 1994, CELL, V76, P183, DOI 10.1016/0092-8674(94)90182-1; BOUVET P, 1995, J BIOL CHEM, V270, P28297; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; Chepenik LG, 1998, GENE, V210, P37, DOI 10.1016/S0378-1119(98)00033-X; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; Ding Y, 1997, NEUROCHEM INT, V31, P45, DOI 10.1016/S0197-0186(96)00127-1; Du Q, 1998, J BIOL CHEM, V273, P19877, DOI 10.1074/jbc.273.31.19877; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; Gallia GL, 1998, J BIOL CHEM, V273, P32662, DOI 10.1074/jbc.273.49.32662; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HERAULT Y, 1993, CELL MOL BIOL RES, V39, P717; Herault Yann, 1995, Gene Expression, V4, P85; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; LEWIN AS, 1995, MOL CELL BIOL, V15, P6971; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; Safak R, 1999, MOL CELL BIOL, V19, P2712; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; Thatikunta P, 1997, J CELL BIOCHEM, V67, P466, DOI 10.1002/(SICI)1097-4644(19971215)67:4<466::AID-JCB5>3.0.CO;2-Q; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Tretiakova A, 1998, J BIOL CHEM, V273, P22241, DOI 10.1074/jbc.273.35.22241; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	50	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38268	38275		10.1074/jbc.274.53.38268	http://dx.doi.org/10.1074/jbc.274.53.38268			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608902	hybrid			2022-12-25	WOS:000084528000102
J	Schaefer, AW; Kamiguchi, H; Wong, EV; Beach, CM; Landreth, G; Lemmon, V				Schaefer, AW; Kamiguchi, H; Wong, EV; Beach, CM; Landreth, G; Lemmon, V			Activation of the MAPK signal cascade by the neural cell adhesion molecule L1 requires L1 internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; COATED VESICLE FORMATION; ANKYRIN-BINDING-ACTIVITY; X-LINKED HYDROCEPHALUS; NEURITE OUTGROWTH; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; N-CAM	L1-mediated axon growth involves intracellular signaling, but the precise mechanisms involved are not yet clear, We report a role for the mitogen-activated protein kinase (MAPK) cascade in L1 signaling. L1 physically associates with the MAPK cascade components Raf-l, ERK2, and the previously identified p90(rsk) in brain. In vitro, ERK2 can phosphorylate L1 at Ser(1204) and Ser(1248) of the L1 cytoplasmic domain. These two serines are conserved in the L1 family of cell adhesion molecules, also being found in neurofascin and NrCAM, The ability of ERK2 to phosphorylate L1 suggests that L1 signaling could directly regulate L1 function by phosphorylation of the L1 cytoplasmic domain. In L1-expressing 3T3 cells, L1 cross-linking can activate ERK2, Remarkably, the activated ERK localizes with endocytosed vesicular L1 rather than cell surface L1, indicating that L1 internalization and signaling are coupled. Inhibition of L1 internalization with dominant-negative dynamin prevents activation of ERK, These results show that L1-generated signals activate the MAPK cascade in a manner most Likely to be important in regulating L1 intracellular trafficking.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Univ Kentucky, Macromol Struct Anal Facil, Lexington, KY 40536 USA; Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA	Case Western Reserve University; University of Kentucky; Case Western Reserve University	Lemmon, V (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Rm E661,2109 Adelbert Rd, Cleveland, OH 44106 USA.		Lemmon, Vance/A-7410-2010; Lemmon, Vance/A-2565-2008; Kamiguchi, Hiroyuki/N-5409-2015	Lemmon, Vance/0000-0003-3550-7576; Kamiguchi, Hiroyuki/0000-0003-1802-6324	NATIONAL EYE INSTITUTE [R01EY005285] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY005285] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; Bailey CH, 1997, NEURON, V18, P913, DOI 10.1016/S0896-6273(00)80331-1; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BRUMMENDORF T, 1994, PROTEIN PROFILE, V1, P963; BurdenGulley SM, 1996, CELL MOTIL CYTOSKEL, V35, P1, DOI 10.1002/(SICI)1097-0169(1996)35:1<1::AID-CM1>3.0.CO;2-F; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DahlinHuppe K, 1997, MOL CELL NEUROSCI, V9, P144, DOI 10.1006/mcne.1997.0608; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; DOHERTY P, 1993, J CELL BIOL, V122, P181, DOI 10.1083/jcb.122.1.181; FINNEGAN SG, 1993, DEV BIOL, V156, P230, DOI 10.1006/dbio.1993.1072; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; Fransen E, 1998, HUM MOL GENET, V7, P999, DOI 10.1093/hmg/7.6.999; Fukuda T, 1997, J COMP NEUROL, V382, P141; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; Hall SG, 1997, J NEUROBIOL, V32, P325, DOI 10.1002/(SICI)1097-4695(199703)32:3<325::AID-NEU6>3.3.CO;2-N; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hassel B, 1997, J BIOL CHEM, V272, P28742, DOI 10.1074/jbc.272.45.28742; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; ITOH K, 1995, SCIENCE, V270, P1369, DOI 10.1126/science.270.5240.1369; ITOH K, 1995, J NEUROSCI, V15, P2504, DOI 10.1523/JNEUROSCI.15-03-02504.1995; ITOH K, 1992, BRAIN RES, V580, P233, DOI 10.1016/0006-8993(92)90949-A; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; Kamiguchi H, 1998, ANNU REV NEUROSCI, V21, P97, DOI 10.1146/annurev.neuro.21.1.97; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 1998, J NEUROSCI, V18, P3749, DOI 10.1523/jneurosci.18-10-03749.1998; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KLINZ SG, 1995, J NEUROCHEM, V65, P84; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kunz S, 1996, J CELL BIOL, V135, P253, DOI 10.1083/jcb.135.1.253; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LANDGREN E, 1995, ONCOGENE, V10, P2027; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MacFarlane JR, 1997, HUM MUTAT, V9, P512; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Ohta Y, 1996, J BIOL CHEM, V271, P11858, DOI 10.1074/jbc.271.20.11858; Okamoto N, 1997, J MED GENET, V34, P670, DOI 10.1136/jmg.34.8.670; Pancook JD, 1997, J IMMUNOL, V158, P4413; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rose SPR, 1996, J PHYSIOLOGY-PARIS, V90, P387, DOI 10.1016/S0928-4257(97)87926-0; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; SALTON SRJ, 1983, J NEUROSCI, V3, P2420; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; STALLCUP WB, 1985, P NATL ACAD SCI USA, V82, P1276, DOI 10.1073/pnas.82.4.1276; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; Wong EV, 1996, J NEUROCHEM, V66, P779; Wong EV, 1995, NEUROSCI LETT, V200, P155, DOI 10.1016/0304-3940(95)12100-I; Wong EV, 1996, J BIOL CHEM, V271, P18217, DOI 10.1074/jbc.271.30.18217; Xie H, 1998, J CELL SCI, V111, P615; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	83	152	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37965	37973		10.1074/jbc.274.53.37965	http://dx.doi.org/10.1074/jbc.274.53.37965			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608864	hybrid			2022-12-25	WOS:000084528000064
J	Sullivan, R; Price, LS; Koffer, A				Sullivan, R; Price, LS; Koffer, A			Rho controls cortical F-actin disassembly in addition to, but independently of, secretion in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; GUANINE-NUCLEOTIDE; FAMILY GTPASES; RAC; EXOCYTOSIS; KINASE; MYOSIN; DOMAIN; ORGANIZATION; CALMODULIN	Localized disassembly of cortical F-actin has long been considered necessary for facilitation of exocytosis. Exposure of permeabilized mast cells to calcium/ATP induces cortical F-actin disassembly (calmodulin-dependent) and secretion (calmodulin-independent). The delay in the onset of secretion is characteristic for the calcium/ATP response and is abolished by GTP. Here we report that a constitutively active mutant of Rho (V14RhoA) enhanced both secretion and cortical F-actin disassembly. In addition, V14RhoA mimicked GTP by abolishing the delay in secretion. Inhibition of Rho by C3 transferase prevented both secretion (similar to 80%) and F-actin disassembly (similar to 20%). Thus, both Rho GTPase and calcium/calmodulin contribute to the control of cortical F-actin disassembly. Stabilization of actin filaments by high concentrations of phalloidin or by a calmodulin-inhibitory peptide (based on the calmodulin-binding domain of myosin light chain kinase) did not affect the extent of secretion or the secretion-enhancing effects of V14RhoA These results further support the existence of divergent, Rho-dependent, pathways regulating actin and exocytosis. Furthermore, compound Y-27632, a specific inhibitor of Rho-associated protein kinase (p160(ROCK)), attenuated the Rho-induced loss of cortical F-actin without affecting secretion. A model is presented in which Rho regulates secretion and cortical F-actin in a manner dependent on and/or synergistic with calcium.	UCL, Dept Physiol, London WC1E 6JJ, England	University of London; University College London	Koffer, A (corresponding author), UCL, Dept Physiol, Univ St, London WC1E 6JJ, England.	a.koffer@ucl.ac.uk		Sullivan, Richard/0000-0002-6435-1825				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; BOROVIKOV YS, 1995, J CELL SCI, V108, P657; Brill S, 1996, MOL CELL BIOL, V16, P4869; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; BUBB MR, 1994, J BIOL CHEM, V269, P14869; BURGOYNE RD, 1987, BIOSCIENCE REP, V7, P281, DOI 10.1007/BF01121449; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; Freshney NW, 1997, FEBS LETT, V407, P111, DOI 10.1016/S0014-5793(97)00309-8; GUILLEMOT JC, 1997, J CELL SCI, V110, P215; HALL A, 1986, J BIOL CHEM, V261, P963; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOFFER A, 1993, BIOCHIM BIOPHYS ACTA, V1176, P236; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LILLIE THW, 1992, BIOCHEM J, V288, P181, DOI 10.1042/bj2880181; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MARTELL AE, 1974, CRITICAL STABILITY C, pR11; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	36	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38140	38146		10.1074/jbc.274.53.38140	http://dx.doi.org/10.1074/jbc.274.53.38140			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608885	hybrid			2022-12-25	WOS:000084528000085
J	Uemura, N; Griffin, JD				Uemura, N; Griffin, JD			The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PROTOONCOGENE PRODUCT P120(CBL); HUMAN B-CELLS; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; BCR-ABL; C-CBL; SIGNALING PATHWAY; ANTIGEN RECEPTOR; BCR/ABL ONCOGENE	Crkl, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in cells from patients with chronic myelogenous leukemia. Crkl binds to BCR/ABL through its N-terminal SH3 domain and is known to interact with several signaling proteins that have been implicated in integrin signaling, including Cb1, Cas, Hef-1, and paxillin. We have previously shown that overexpression of Crkl enhances adhesion to extracellular matrix proteins through beta(1) integrins. In this study, the effects of Crkl on spontaneous and chemokine-directed migration of the hematopoietic cell line Ba/F3 were examined. Full-length, SH2-, and SH3(N)-domain deletion mutants of Crkl were expressed transiently as fusion proteins with green fluorescent protein. Successfully transfected cells were isolated by fluorescence-activated cell sorting. The ability of these cells to migrate across a fibronectin-coated membrane, either spontaneously or in response to the chemokine stromal-derived factor-1 alpha, was determined. Cells expressing green fluorescent protein alone were mot distinguishable from untransfected or mock transfected Ba/F3 cells. However, Ba/F3 cells overexpressing full-length Crkl were found to have an increase in spontaneous migration of 2.8 +/- 0.6-fold in seven independent assays. The enhancement of migration required both the SH2 domain and the N-terminal SH3 domain. Migration in response to stromal-derived factor-1 alpha was not significantly enhanced by overexpression of Crkl. Overexpression of Crkii also augmented spontaneous migration but to a lesser degree than did Crkl. Because the SH2 domain was required for enhanced migration, we looked for changes in phosphotyrosine containing proteins coprecipitating with Crkl, but not Crkl Delta SH2, after integrin cross-linking. Full-length Crkl, but not Crkl Delta SH2, coprecipitated with a single major tyrosine phosphoprotein with an M-r of approximately 120 kDa, identified as chi. The major Crkl SH3-binding protein in these cells was found to be the guanine nucleotide exchange factor, C3G. Interestingly, overexpression of C3G; also enhanced migration, suggesting that a CbI-Crkl-C3G complex may be involved in migration signaling in Ba/F3 cells. These data suggest that Crkl is involved in signaling pathways that regulate migration, possibly through a complex with Cbl and C3G.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA036167, R37CA036167] Funding Source: NIH RePORTER; NCI NIH HHS [CA36167] Funding Source: Medline; NIDDK NIH HHS [DK560654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Andoniou CE, 1996, ONCOGENE, V12, P1981; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FELLER SM, 1995, ONCOGENE, V10, P1465; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Gotoh A, 1997, CELL GROWTH DIFFER, V8, P721; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Kyono WT, 1998, J IMMUNOL, V161, P5555; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liu YH, 1999, J IMMUNOL, V162, P7095; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; Ota J, 1998, BIOCHEM BIOPH RES CO, V252, P779, DOI 10.1006/bbrc.1998.9445; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Robertson H, 1997, BIOCHEM BIOPH RES CO, V240, P46, DOI 10.1006/bbrc.1997.7608; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; Uemura N, 1999, ONCOGENE, V18, P3343, DOI 10.1038/sj.onc.1202689; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	60	92	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37525	37532		10.1074/jbc.274.53.37525	http://dx.doi.org/10.1074/jbc.274.53.37525			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608804	hybrid			2022-12-25	WOS:000084528000004
J	Urbanowski, JL; Piper, RC				Urbanowski, JL; Piper, RC			The iron transporter fth1p forms a complex with the Fet5 iron oxidase and resides on the vacuolar membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; GENE ENCODES; YEAST; PROTEIN; GOLGI; ENDOCYTOSIS; CHLORIDE	Iron transport across the plasmamembrane appears to be a unidirectional process whereby iron uptake is essentially irreversible. One of the major sequestration sites for iron is the vacuole that stores a variety of metals, either as a mechanism to detoxify the cell or as a reservoir of metal to enable the cell to grow when challenged by a low iron environment. Exactly how the vacuole contributes to the overall iron metabolism of the cell is unclear because mutations that affect vacuolar function also perturb the assembly of the plasma membrane high affinity transport system composed of a copper-containing iron oxidase, Fet3p, and an Fe3+-specific iron transporter, Ftr1p, Here, we characterize the iron transporter homologue Fth1p, which is similar to the high affinity plasma membrane iron transporter Ftr1p. We found that Fth1p was localized to the vacuolar surface and, like other proteins that function on the vacuole, did not undergo Pep4-dependent degradation. Co-immunoprecipitation experiments showed that Fth1p also associates with the Fet3p oxidase homologue, Fet5p; and disruption of the PETS gene results in the accumulation of Fth1p in the endoplasmic reticulum, We also found that loss of this protein complex leads to elevated transcriptional activity of the FET3 gene and compromises the ability of the cell to switch from fermentative metabolism to respiratory metabolism. Because the Fet5 protein is oriented such that the oxidase domain of Fet5p is lumenal, this complex may be responsible for mobilizing intravacuolar stores of iron.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Piper, RC (corresponding author), Univ Iowa, Dept Physiol & Biophys, Rm 5-660,Bowen Sci Bldg, Iowa City, IA 52242 USA.			Piper, Robert/0000-0001-9995-5699	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058202] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295] Funding Source: Medline; NIGMS NIH HHS [R01 GM58202-01, R01 GM058202] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE D, 1992, J BIOL CHEM, V267, P20774; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; ORDORIZZI G, 1998, CELL, V95, P847; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; Radisky DC, 1997, P NATL ACAD SCI USA, V94, P5662, DOI 10.1073/pnas.94.11.5662; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spizzo T, 1997, MOL GEN GENET, V256, P547; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Stefan CJ, 1999, J BIOL CHEM, V274, P1835, DOI 10.1074/jbc.274.3.1835; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; WILCOX CA, 1992, MOL BIOL CELL, V3, P1653; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yu JM, 1998, J BIOL CHEM, V273, P21380, DOI 10.1074/jbc.273.33.21380; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787	38	148	156	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38061	38070		10.1074/jbc.274.53.38061	http://dx.doi.org/10.1074/jbc.274.53.38061			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608875	hybrid			2022-12-25	WOS:000084528000075
J	McCullagh, P; Chaplin, T; Meerabux, J; Grenzelias, D; Lillington, D; Poulsom, R; Gregorini, A; Saha, V; Young, BD				McCullagh, P; Chaplin, T; Meerabux, J; Grenzelias, D; Lillington, D; Poulsom, R; Gregorini, A; Saha, V; Young, BD			The cloning, mapping and expression of a novel gene, BRL, related to the AF10 leukaemia gene	ONCOGENE			English	Article						chromosome translocation; leukaemia; MLL; AF10	HISTONE ACETYLTRANSFERASE ACTIVITY; ACUTE MONOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NUCLEAR-PROTEIN CBP; TRANSCRIPTIONAL ACTIVATION; T(10-11) TRANSLOCATION; BINDING-PROTEIN; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MOLECULAR-CLONING	The MLL gene is reciprocally translocated with one of a number of different partner genes in a proportion of human acute leukaemias. The precise mechanism of oncogenic transformation is unclear since most of the partner genes encode unrelated proteins, However, two partner genes, AF10 and AF17 are related through the presence of a cysteine rich region and a leucine zipper. The identification of other proteins with these structures will aid our understanding of their role in normal and leukaemic cells. We report the cloning of a novel human gene (BRL) which encodes a protein containing a cysteine rich region related to that of AF10 and AF17 and is overall most closely related to the previously known protein BR140, BRL maps to chromosome 22q13 and shows high levels of expression in testis and several cell lines. The deduced protein sequence also contains a bromodomain, four potential LXXLL motifs and four predicted nuclear localization signals. A monoclonal antibody raised to a BRL peptide sequence confirmed its widespread expression as a 120 Kd protein and demonstrated localization to the nucleus within spermatocytes.	St Bartholomews & Royal London Sch Med & Dent, Dept Med Oncol, Imperial Canc Res Fund, London EC1M 6BQ, England; Imperial Canc Res Fund, In Situ Hybridizat Serv, London WC2A 3PX, England	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK	Young, BD (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Med Oncol, Imperial Canc Res Fund, Charterhouse Sq, London EC1M 6BQ, England.			Saha, Vaskar/0000-0002-2916-9649				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BEVERLOO HB, 1995, CANCER RES, V55, P4220; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, MOL CELL BIOL, V16, P593; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gregorini A, 1996, GENE CHROMOSOME CANC, V17, P269; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Harlow E, 1998, ANTIBODIES LAB MANUA; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAI JL, 1992, CANCER GENET CYTOGEN, V60, P180, DOI 10.1016/0165-4608(92)90013-X; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEBEAU MM, 1985, LEUKEMIA RES, V9, P605, DOI 10.1016/0145-2126(85)90140-7; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACCOLLIN M, 1993, GENOMICS, V15, P680, DOI 10.1006/geno.1993.1125; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nicolas RH, 1996, GENE, V175, P233, DOI 10.1016/0378-1119(96)82845-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Rinderle C, 1999, HUM MOL GENET, V8, P277, DOI 10.1093/hmg/8.2.277; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Soenen V, 1996, GENE CHROMOSOME CANC, V15, P191, DOI 10.1002/(SICI)1098-2264(199603)15:3<191::AID-GCC9>3.0.CO;2-Y; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tanabe S, 1996, BLOOD, V88, P3535; THOMPSON KA, 1994, BIOCHEM BIOPH RES CO, V198, P1143, DOI 10.1006/bbrc.1994.1162; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TROFATTER JA, 1995, GENOME RES, V5, P214, DOI 10.1101/gr.5.3.214; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	57	19	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7442	7452		10.1038/sj.onc.1203117	http://dx.doi.org/10.1038/sj.onc.1203117			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602503				2022-12-25	WOS:000084119600005
J	Sabourin, LA; Rudnicki, MA				Sabourin, LA; Rudnicki, MA			Induction of apoptosis by SLK, a Ste20-related kinase	ONCOGENE			English	Article						Ste20 kinase; apoptosis; JNK1	STE20-LIKE PROTEIN-KINASE; SIGNAL-TRANSDUCTION; BINDING PROTEIN; CELL-DEATH; CLONING; DOMAIN; SAPK/JNK; CDC42P; SYSTEM; YEAST	We have cloned and characterized a novel murine Ste20-related kinase designated SLK, SLK displays high homology to the Ste20-related kinase LOK, and is more distantly related to MST1 and 2, both Ste20-like kinases, In addition, SLK displays high homology to microtubule and nuclear associated protein (M-NAP) and AT1-46, both of unknown function. SLK is ubiquitously expressed as multiple mRNAs in tissues and cell lines and is downregulated by mitogen depletion in differentiating myoblasts, Biochemical characterization showed that SLK overexpression activates c-Jun amino-terminal kinase 1 (JNK1), However, in vitro kinase assays indicated that SLK was not activated in response to various growth factors or stress-inducing agents. Immunofluorescence studies revealed that SLK colocalized to distinct cytosolic domains, preferentially at the periphery of the cells. In addition, prolonged overexpression of SLK in cultured fibroblasts resulted in apoptosis as demonstrated by annexin-V and TUNEL staining. Our results suggest that SLK belongs to a new family of protein kinases, mediating activation of the stress response pathway through a novel signaling cascade.	McMaster Univ, MOBIX, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada	McMaster University	Rudnicki, MA (corresponding author), McMaster Univ, MOBIX, Inst Mol Biol & Biotechnol, Life Sci Bldg,Room 437,1280 Main St W, Hamilton, ON L8S 4K1, Canada.							Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUGHES DA, 1995, SEMIN CELL BIOL, V6, P89, DOI 10.1016/1043-4682(95)90005-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Itoh S, 1997, ARCH BIOCHEM BIOPHYS, V340, P201, DOI 10.1006/abbi.1997.9893; KATOH M, 1995, ONCOGENE, V10, P1447; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Sambrook J., 2002, MOL CLONING LAB MANU; Schaar DG, 1996, BRAIN RES, V721, P217, DOI 10.1016/0006-8993(96)00176-X; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	27	66	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7566	7575		10.1038/sj.onc.1203119	http://dx.doi.org/10.1038/sj.onc.1203119			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602516				2022-12-25	WOS:000084119600018
J	Kongkanuntn, R; Bubb, VJ; Sansom, OJ; Wyllie, AH; Harrison, DJ; Clarke, AR				Kongkanuntn, R; Bubb, VJ; Sansom, OJ; Wyllie, AH; Harrison, DJ; Clarke, AR			Dysregulated expression of beta-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice	ONCOGENE			English	Article						beta-catenin; Apc; p53; Msh2; intestine; pancreas	WNT SIGNALING PATHWAY; INTESTINAL ADENOMAS; NEGATIVE REGULATOR; COLORECTAL-CANCER; SOMATIC MUTATIONS; DESMOID TUMORS; GENE; CARCINOMA; COMPLEX; AXIN	We have analysed the pattern of beta-catenin expression by immunohistochemistry in mice singly or multiply mutant for Ape, p53 and Msh2. We observed increased expression of beta-catenin in all intestinal lesions arising on an Apc(Min) +/- background. In all categories of lesion studied mosaic patterns of beta-catenin expression were observed, with the proportion of cells showing enhanced expression decreasing with increasing lesion size. p53 statics did not alter these patterns. We also show that beta-catenin dysregulation marks pancreatic abnormalities occurring in Apc(Min) +/- and (Apc(Min) +/-, p53-/-) mice. In these mice both adenomas and adenocarcinomas of the pancreas arose and were characterized by increased expression of beta-catenin, We have extended these analyses to intestinal lesions arising in mice mutant for the mismatch repair gene Msh2, In these mice, increased expression of beta-catenin was again observed. However, in contrast with Apc(Min) +/- mice, a subset of lesions retained normal expression. Taken together, these findings show that increased expression of beta-catenin is an efficient marker of early neoplastic change in both murine intestine and pancreas in Ape mutant mice. However, we also show that dysregulation of beta-catenin is not an obligate step in the development of intestinal lesions, and therefore that genetic events other than the loss of Ape function may initiate the transition from normal to neoplastic epithelium.	Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Clarke, AR (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010				Alman BA, 1997, AM J PATHOL, V151, P329; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P1; Chen HY, 1997, J CELL SCI, V110, P345; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Going JJ, 1996, J PATHOL, V179, P121; HORII A, 1992, CANCER RES, V52, P6696; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Inomata M, 1996, CANCER RES, V56, P2213; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LUONGO C, 1994, CANCER RES, V54, P5947; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Reitmair AH, 1996, CANCER RES, V56, P2922; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sheng HM, 1998, CARCINOGENESIS, V19, P543, DOI 10.1093/carcin/19.4.543; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shoemaker AR, 1997, BIOCHIM BIOPHYS ACTA, V1332, P25; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takayama T, 1996, AM J PATHOL, V148, P39; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; vanOordt CWV, 1997, CARCINOGENESIS, V18, P2197, DOI 10.1093/carcin/18.11.2197	43	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7219	7225		10.1038/sj.onc.1203181	http://dx.doi.org/10.1038/sj.onc.1203181			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602475				2022-12-25	WOS:000084119400005
J	Gremer, L; Kellner, S; Dobbek, H; Huber, R; Meyer, O				Gremer, L; Kellner, S; Dobbek, H; Huber, R; Meyer, O			Binding of flavin adenine dinucleotide to molybdenum-containing carbon monoxide dehydrogenase from Oligotropha carboxidovorans - Structural and functional analysis of a carbon monoxide dehydrogenase species in which the native flavoprotein has been replaced by its recombinant counterpart produced in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; PSEUDOMONAS-CARBOXYDOVORANS; XANTHINE-OXIDASE; ALDEHYDE OXIDOREDUCTASE; DESULFOVIBRIO-GIGAS; COFACTOR; GENES; QUANTITATION; SPECTROSCOPY; EXPRESSION	The carbon monoxide (CO) dehydrogenase of Oligotropha carboxidovorans is composed of an S-selanylcysteine-containing 88.7-kDa molybdoprotein (L), a 17.8-kDa iron-sulfur protein (S), and a 30.2-kDa flavoprotein (M) in a (LMS)(2) subunit structure. The flavoprotein could be removed from CO dehydrogenase by dissociation with sodium dodecylsulfate, The resulting M(LS)(2)- or (LS)(2)-structured CO dehydrogenase species could be reconstituted with the recombinant apoflavoprotein produced in Escherichia coli, The formation of the heterotrimeric complex composed of the apoflavoprotein, the molybdoprotein, and the iron-sulfur protein involves structural changes that translate into the conversion of the apoflavoprotein from non-FAD binding to FAD binding. Binding of FAD to the reconstituted deflavo (LMS)(2) species occurred with second-order kinetics (k(+1) = 1350 M-1 s(-1)) and high affinity (K-d = 1.0 x 10(-9) M). The structure of the resulting flavo (LMS)(2) species at a 2.8-Angstrom resolution established the same fold and binding of the flavoprotein as in wild-type CO dehydrogenase, whereas the S-selanylcysteine 388 in the active-site loop on the molybdoprotein was disordered. In addition, the structural changes related to heterotrimeric complex formation or FAD binding were transmitted to the iron-sulfur protein and could be monitored by EPR, The type II 2Fe:2S center was identified in the N-terminal domain and the type I center in the C-terminal domain of the iron-sulfur protein.	Univ Bayreuth, Lehrstuhl Mikrobiol, D-95440 Bayreuth, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Bavaria, Germany	University of Bayreuth; Max Planck Society	Meyer, O (corresponding author), Univ Bayreuth, Lehrstuhl Mikrobiol, Univ Str 30, D-95440 Bayreuth, Germany.		Gremer, Lothar/H-9128-2013	Gremer, Lothar/0000-0001-7065-5027				BARATA BAS, 1993, BIOCHEMISTRY-US, V32, P11559, DOI 10.1021/bi00094a012; BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P1648, DOI 10.1021/bi00536a027; BEISENHERZ G, 1953, Z NATURFORSCH B, V8, P555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY RC, 1991, BIOCHEM J, V280, P817, DOI 10.1042/bj2800817; BRAY RC, 1983, BIOCHEM J, V211, P687, DOI 10.1042/bj2110687; CARDENAS J, 1974, ANAL BIOCHEM, V60, P372, DOI 10.1016/0003-2697(74)90244-9; CYPIONKA H, 1983, J BACTERIOL, V156, P1178, DOI 10.1128/JB.156.3.1178-1187.1983; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; Gremer L, 1996, EUR J BIOCHEM, V238, P862, DOI 10.1111/j.1432-1033.1996.0862w.x; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; Hanzelmann P, 1999, FEMS MICROBIOL LETT, V176, P139, DOI 10.1111/j.1574-6968.1999.tb13654.x; Hanzelmann P, 1998, EUR J BIOCHEM, V255, P755, DOI 10.1046/j.1432-1327.1998.2550755.x; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; Jessee J., 1986, FOCUS, V8, P9; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; KANDA M, 1972, J BIOL CHEM, V247, P765; KIESSLING M, 1982, FEMS MICROBIOL LETT, V13, P333, DOI 10.1016/0378-1097(82)90122-7; KOMAI H, 1969, J BIOL CHEM, V244, P1692; KRAUT M, 1989, ARCH MICROBIOL, V152, P335, DOI 10.1007/BF00425170; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE DJ, 1978, BIOCHEM J, V169, P471, DOI 10.1042/bj1690471; LOWE DJ, 1972, BIOCHEM J, V130, P239, DOI 10.1042/bj1300239; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MEYER O, 1993, SYST APPL MICROBIOL, V16, P390, DOI 10.1016/S0723-2020(11)80271-7; MEYER O, 1982, J BIOL CHEM, V257, P1333; Meyer Ortwin, 1993, P433; MOURA JJG, 1994, METHOD ENZYMOL, V243, P24; MULLER F, 1990, CHEM BIOCH FLAVINS, V1, P1; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V1, P261; NISHIKIMI M, 1973, J BIOCHEM, V73, P1233, DOI 10.1093/oxfordjournals.jbchem.a130196; Ribbe M, 1997, J BIOL CHEM, V272, P26627, DOI 10.1074/jbc.272.42.26627; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUBEL U, 1995, J BACTERIOL, V177, P2197, DOI 10.1128/jb.177.8.2197-2203.1995; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; ZANETTI G, 1982, EUR J BIOCHEM, V126, P453, DOI 10.1111/j.1432-1033.1982.tb06801.x	41	44	44	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1864	1872		10.1074/jbc.275.3.1864	http://dx.doi.org/10.1074/jbc.275.3.1864			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636886	hybrid			2022-12-25	WOS:000084940000049
J	Thevenod, F; Friedmann, JM; Katsen, AD; Hauser, IA				Thevenod, F; Friedmann, JM; Katsen, AD; Hauser, IA			Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappa B activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; MAMMALIAN-CELLS; CYCLOSPORINE-A; GENE-PRODUCT; HEAT-SHOCK; MDR1 GENE; EXPRESSION; ALPHA; RATS; INDUCTION	Cadmium-mediated toxicity of cultured proximal tubule (PT) cells is associated with increased production of reactive oxygen species (ROS) and apoptosis, We found that cadmium-dependent apoptosis (Hoechst 33342 and annexin V assays) decreased with prolonged CdCl2 (10 mu M) application (controls: 2.4 +/- 1.6%; 5 h: +5.1 +/- 2.3%, 20 h: +5.7 +/- 2.5%, 48 h: +3.3 +/- 1.0% and 72 h: +2.1 +/- 0.4% above controls), while cell proliferation was not affected. Reduction of apoptosis correlated with a time-dependent up-regulation of the drug efflux pump multidrug resistance P-glycoprotein (mdr1) in cadmium-treated cells ( approximate to 4-fold after 72 h), as determined by immunoblotting with the monoclonal antibody C219 and measurement of intracellular accumulation of the fluorescent probe calcein +/- the mdr1 inhibitor PSC833 (0.5 mu M). When mdr1 inhibitors (PSC833, cyclosporine A, verapamil) were transiently added to cells with mdr1 up-regulation by pretreatment for 72 h with cadmium, cadmium-induced apoptosis increased significantly and to a percentage similar to that obtained in cells with no mdr1 up-regulation (72-h cadmium: 5.2 +/- 0.9% versus 72-h cadmium + 1-h PSC833: 7.2 +/- 1.4%; p less than or equal to 0.001), Cadmium-induced apoptosis and mdr1 up-regulation depended on ROS, since co-incubation with the ROS scavengers N-acetylcysteine (15 mM) or pyrrolidine dithiocarbamate (0.1 mM) abolished both responses. Moreover, cadmium- and ROS-associated mdr1 up-regulation was linked to activation of the transcription factor NF-KB; N-acetylcysteine, pyrrolidine dithiocarbamate, and the I kappa B-alpha kinase inhibitor Bay 11-7082 (20 mu M) prevented both, mdr1 overexpression and degradation of the inhibitory NF-kappa B subunit, I kappa B-alpha, induced by cadmium. The data show that 1) cadmium-mediated apoptosis in PT cells is associated with ROS production, 2) ROS increase mdr1 expression by a process involving NF-kappa B activation, and 3) mdr1 overexpression protects PT cells against cadmium-mediated apoptosis, These data suggest that mdr1 up-regulation, at least in part, provides anti-apoptotic protection for PT cells against cadmium-mediated stress.	Univ Saarlandes, Dept Physiol 2, D-66421 Homburg, Germany; Univ Saarlandes, Dept Expt Surg, D-66421 Homburg, Germany; Univ Frankfurt, Dept Nephrol, Zentrum Innere Med, D-60590 Frankfurt, Germany	Saarland University; Saarland University; Goethe University Frankfurt	Thevenod, F (corresponding author), Univ Saarlandes, Dept Physiol 2, D-66421 Homburg, Germany.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Bauerle PA, 1996, CELL, V87, P13; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; CHIN KV, 1990, J BIOL CHEM, V265, P221; Dally H, 1997, CARCINOGENESIS, V18, P1021, DOI 10.1093/carcin/18.5.1021; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; Endo T, 1999, PHARMACOL TOXICOL, V84, P187, DOI 10.1111/j.1600-0773.1999.tb00898.x; FRIEDMAN PA, 1994, TOXICOL APPL PHARM, V128, P257, DOI 10.1006/taap.1994.1205; Gilbert M, 1997, J CELL PHYSIOL, V171, P299, DOI 10.1002/(SICI)1097-4652(199706)171:3<299::AID-JCP8>3.0.CO;2-J; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hauser IA, 1998, KIDNEY INT, V54, P1139, DOI 10.1046/j.1523-1755.1998.00095.x; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Jakob I, 1998, AM J PHYSIOL-CELL PH, V274, pC182, DOI 10.1152/ajpcell.1998.274.1.C182; Jones G, 1997, BRIT J RHEUMATOL, V36, P95; Katsen AD, 1998, VIRCHOWS ARCH, V433, P75, DOI 10.1007/s004280050219; KIM YK, 1988, PHARMACOL TOXICOL, V63, P342, DOI 10.1111/j.1600-0773.1988.tb00966.x; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; Klaassen CD, 1997, DRUG METAB REV, V29, P79, DOI 10.3109/03602539709037574; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Liu J, 1998, TOXICOL SCI, V46, P197, DOI 10.1093/toxsci/46.1.197; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MATSUOKA M, 1995, KIDNEY INT, V48, P383, DOI 10.1038/ki.1995.306; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; O'Brien P, 1998, ARCH TOXICOL, V72, P690, DOI 10.1007/s002040050562; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; PISCATOR M, 1986, CADMIUM HDB EXPT PHA, V80, P179; Schaub TP, 1997, J AM SOC NEPHROL, V8, P1213; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIMADA H, 1991, J PHARMACOBIO-DYNAM, V14, P555, DOI 10.1248/bpb1978.14.555; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TANIMOTO A, 1993, TOXICOL PATHOL, V21, P341, DOI 10.1177/019262339302100401; Thevenod F, 1999, FASEB J, V13, P1751, DOI 10.1096/fasebj.13.13.1751; Thevenod F., 1997, FASEB Journal, V11, pA460; Thevenod F, 1996, J BIOL CHEM, V271, P3300, DOI 10.1074/jbc.271.6.3300; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TWENTYMAN PR, 1991, EUR J CANCER, V27, P1639, DOI 10.1016/0277-5379(91)90435-G; VANANTWERP DJ, 1996, SCIENCE, V274, P782; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Vernhet L, 1999, FEBS LETT, V443, P321, DOI 10.1016/S0014-5793(98)01716-5; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wigler PW, 1999, BIOCHEM BIOPH RES CO, V257, P410, DOI 10.1006/bbrc.1999.0475; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	55	268	283	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1887	1896		10.1074/jbc.275.3.1887	http://dx.doi.org/10.1074/jbc.275.3.1887			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636889	hybrid			2022-12-25	WOS:000084940000052
J	Callahan, C; Neri-Cortes, D; Deutscher, MP				Callahan, C; Neri-Cortes, D; Deutscher, MP			Purification and characterization of the tRNA-processing enzyme RNase BN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXORIBONUCLEASES; IDENTIFICATION; PRECURSORS	RNase BN, a tRNA-processing enzyme previously shown to be required for the 3'-maturation of certain bacteriophage T4-encoded tRNAs, was overexpressed and purified to near homogeneity from Escherichia coli. The purified enzyme, which is free of nucleic acid, is an alpha(2)-dimer with a molecular mass of similar to 65 kDa. RNase BN displays a number of unusual catalytic properties compared with the other exoribonucleases of E. coli, The enzyme is most active at PH 6.5 in the presence of Co2+ and high concentrations of monovalent salts. It is highly specific for tRNA substrates containing an incorrect residue within the universal 3'-CCA sequence. Thus, tRNA-CU and tRNA-CA are effective substrates, whereas intact tRNA-CCA, elongated tRNA-CCA-Cn, phosphodiesterase-treated tRNA and the closely related tRNA-CC are essentially inactive as substrates, RNA or DNA oligonucleotides also are not substrates, These data indicate that RNase BN has an extremely narrow substrate specificity. However, since tRNA molecules with incorrect residues within the -CCA sequence are not normally produced in E. coli, the role of RNase BN in uninfected cells remains to be determined.	Univ Miami, Dept Biochem & Mol Biol, Sch Med, Miami, FL 33101 USA; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA	University of Miami; University of Connecticut	Deutscher, MP (corresponding author), Univ Miami, Dept Biochem & Mol Biol, Sch Med, Miami, FL 33101 USA.				NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHA PK, 1983, J BACTERIOL, V156, P419, DOI 10.1128/JB.156.1.419-420.1983; ASHA PK, 1983, P NATL ACAD SCI-BIOL, V80, P3301, DOI 10.1073/pnas.80.11.3301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callahan C, 1996, J BACTERIOL, V178, P7329, DOI 10.1128/jb.178.24.7329-7332.1996; DEUTSCHER MP, 1978, NUCLEIC ACIDS RES, V5, P3821, DOI 10.1093/nar/5.10.3821; DEUTSCHER MP, 1974, J BIOL CHEM, V249, P6696; DEUTSCHERMP, 1995, TRNA STRUCTURE BIOSY, P51; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; LI ZW, 1994, J BIOL CHEM, V269, P6064; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; MAISURIAN AN, 1973, MOL GEN GENET, V120, P227, DOI 10.1007/BF00267154; MAISURYAN AN, 1975, GENETIKA+, V11, P114; MCCLAIN WH, 1977, ACCOUNTS CHEM RES, V10, P418, DOI 10.1021/ar50119a006; Miller J. H., 1972, EXPT MOL GENETICS, P431; SEIDMAN JG, 1975, CELL, V5, P389, DOI 10.1016/0092-8674(75)90058-6; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2	17	6	6	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1030	1034		10.1074/jbc.275.2.1030	http://dx.doi.org/10.1074/jbc.275.2.1030			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625642	hybrid			2022-12-25	WOS:000084836600046
J	Hains, PG; Sung, KL; Tseng, A; Broady, KW				Hains, PG; Sung, KL; Tseng, A; Broady, KW			Functional characteristics of a phospholipase A(2) inhibitor from Notechis ater serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; AGKISTRODON-BLOMHOFFII-SINITICUS; CROTALUS-DURISSUS-TERRIFICUS; ARTHRITIC SYNOVIAL-FLUID; BEE-VENOM PHOSPHOLIPASE-A2; OXYURANUS-S-SCUTELLATUS; AUSTRALIAN TIGER SNAKE; BLOOD-PLASMA; TRIMERESURUS-FLAVOVIRIDIS; PRESYNAPTIC NEUROTOXIN	A phospholipase A(2) inhibitor has been purified from the serum of Notechis ater using DEAE-Sephacel chromatography. The inhibitor was found to be composed of two protein subunits (alpha and beta) that form the intact complex of approximately 110 kDa. The alpha-chain is a 30-kDa glycoprotein and the beta-chain a nonglycosylated, 25-kDa protein. N-terminal sequence analysis reveals a high level of homology to other snake phospholipase A(2) inhibitors. The inhibitor was shown to be extremely pH and temperature stable. The inhibitor was tested against a wide variety of phospholipase A(2) enzymes and inhibited the enzymatic activity of all phospholipase A(2) enzymes tested, binding with micromole to nanomole affinity. Furthermore, the inhibitor was compared with the Eli-Lilly compound LY311727 and found to have a higher affinity for human secretory nonpancreatic phospholipase A(2) than this chemical inhibitor. The role of the carbohydrate moiety was investigated and found not to affect the in vitro function of the inhibitor.	Univ Technol, Dept Cell & Mol Biol, Toxin Res Grp, Sydney, NSW 2065, Australia	University of Technology Sydney	Broady, KW (corresponding author), Univ Technol, Dept Cell & Mol Biol, Toxin Res Grp, Westbourne St,Gore Hill, Sydney, NSW 2065, Australia.		Hains, Peter/M-4209-2019; Hains, Peter G/E-6089-2015; Hains, Peter/HIK-2945-2022	Hains, Peter/0000-0002-7276-1760; Hains, Peter G/0000-0002-7276-1760; 				Aitadafoun M, 1996, BIOCHEM PHARMACOL, V51, P737; ANDREWS P, 1965, BIOCHEM J, V96, P595, DOI 10.1042/bj0960595; BARRINGTON PL, 1986, TOXICON, V24, P1107, DOI 10.1016/0041-0101(86)90137-6; Binisti C, 1997, J LIPID MEDIAT CELL, V16, P171, DOI 10.1016/S0929-7855(97)00008-4; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BUHL WJ, 1995, BIOCHEM J, V311, P147, DOI 10.1042/bj3110147; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; Cuellar MJ, 1996, J NAT PROD, V59, P977, DOI 10.1021/np9604339; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; FLEER EAM, 1978, EUR J BIOCHEM, V82, P261, DOI 10.1111/j.1432-1033.1978.tb12019.x; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; FOHLMAN J, 1977, FEBS LETT, V84, P367, DOI 10.1016/0014-5793(77)80726-6; FOHLMAN J, 1976, EUR J BIOCHEM, V68, P457, DOI 10.1111/j.1432-1033.1976.tb10833.x; FORTESDIAS CL, 1991, TOXICON, V29, P997, DOI 10.1016/0041-0101(91)90082-3; FORTESDIAS CL, 1994, J BIOL CHEM, V269, P15646; FUJII S, 1995, BIOCHEM J, V308, P297, DOI 10.1042/bj3080297; GIL B, 1995, LIFE SCI, V57, pPL25, DOI 10.1016/0024-3205(95)00260-D; HALPERT J, 1975, J BIOL CHEM, V250, P6990; HASELBECK A, 1992, TOPICS BIOCH, V10; HASELBECK A, 1988, TOP BIOCH, V8, P1; HYODO S, 1995, TETRAHEDRON, V51, P6717, DOI 10.1016/0040-4020(95)00328-6; Inoue S, 1997, BIOCHEM MOL BIOL INT, V41, P529; INOUE S, 1991, J BIOL CHEM, V266, P1001; JAIN MK, 1995, PHYTOCHEMISTRY, V39, P537, DOI 10.1016/0031-9422(94)00960-2; KARLSSON E, 1972, TOXICON, V10, P405, DOI 10.1016/0041-0101(72)90066-9; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KIHARA H, 1976, J BIOCHEM-TOKYO, V80, P341, DOI 10.1093/oxfordjournals.jbchem.a131282; KOGAKI H, 1989, J BIOCHEM-TOKYO, V106, P966, DOI 10.1093/oxfordjournals.jbchem.a122983; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND P, 1982, EUR J BIOCHEM, V124, P441; Lindahl M, 1997, INFLAMMATION, V21, P347, DOI 10.1023/A:1027306118026; Lizano S, 1997, BIOCHEM J, V326, P853, DOI 10.1042/bj3260853; MATSUMOTO K, 1995, J ANTIBIOT, V48, P106, DOI 10.7164/antibiotics.48.106; MICHAELS RM, 1994, CLIN EXP RHEUMATOL, V12, P643; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Nobuhisa I, 1997, EUR J BIOCHEM, V249, P838, DOI 10.1111/j.1432-1033.1997.00838.x; Ohkura N, 1999, J BIOCHEM-TOKYO, V125, P375, DOI 10.1093/oxfordjournals.jbchem.a022297; OHKURA N, 1993, J BIOCHEM-TOKYO, V113, P413, DOI 10.1093/oxfordjournals.jbchem.a124060; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V200, P784, DOI 10.1006/bbrc.1994.1519; Ohkura N, 1997, BIOCHEM J, V325, P527, DOI 10.1042/bj3250527; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V204, P1212, DOI 10.1006/bbrc.1994.2592; Okumura K, 1998, J BIOL CHEM, V273, P19469, DOI 10.1074/jbc.273.31.19469; ORTIZ AR, 1993, J MED CHEM, V36, P1866, DOI 10.1021/jm00065a010; Parks T P, 1990, Adv Exp Med Biol, V275, P55; PERALES J, 1995, EUR J BIOCHEM, V227, P19, DOI 10.1111/j.1432-1033.1995.tb20355.x; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; PUIJK WC, 1977, BIOCHIM BIOPHYS ACTA, V492, P254, DOI 10.1016/0005-2795(77)90076-9; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; RANDOLPH A, 1982, J BIOL CHEM, V257, P2155; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SEILHAMER JJ, 1989, J BIOCHEM, V106, P38, DOI 10.1093/oxfordjournals.jbchem.a122815; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Settineri C A, 1996, Methods Mol Biol, V61, P255; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; Todhunter J A, 1979, Methods Enzymol, V63, P383; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VADAS P, 1986, LAB INVEST, V55, P391; VERHEIJ HM, 1983, BIOCHIM BIOPHYS ACTA, V747, P93, DOI 10.1016/0167-4838(83)90126-7; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WESTERLUND B, 1992, FEBS LETT, V301, P159, DOI 10.1016/0014-5793(92)81238-H	67	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					983	991		10.1074/jbc.275.2.983	http://dx.doi.org/10.1074/jbc.275.2.983			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625636	hybrid			2022-12-25	WOS:000084836600040
J	Mucha, M; Lisowska, K; Goc, A; Filipski, J				Mucha, M; Lisowska, K; Goc, A; Filipski, J			Nuclease-hypersensitive chromatin formed by a CpG island in human DNA cloned as an artificial chromosome in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; GENOME EVOLUTION; CELLS; SITES; GENE; REPLICATION; PROMOTER; MEIOSIS	CPG islands are mostly unmethylated GC-, and CpG-rich chromosomal segments overlapping promoter sequences in all housekeeping and many tissue-specific genes in vertebrates. Typically, these islands show an open chromatin structure, low in histone H1 and rich in acetylated histones. We have previously found that the island-like CGCG-rich sites in human DNA are hypersensitive to DNase I upon cloning in Saccharomyces cerevisiae. Here we studied, with a higher resolution, the chromatin formed in yeast by one such site, the CpG island accompanying the human glucose-6-phosphate dehydrogenase gene. We have found two strong hypersensitive sites and several positioned nucleosomes flanking the island despite the absence in yeast of such chromatin fiber-shaping factors as histone H1, methyltransferase, and the tissue-specific transcription factors. This finding, together with similar observations from our laboratories and others supports the idea that variations in GC and/or CpG content substantially contribute to the DNA sequence features modulating the structure of the chromatin, The composition-dependent fluctuations in the accessibility of DNA in the chromatin may constitute an, evolutionary advantage and may explain the surprising compositional selection that acts in both the coding and non-coding segments of some genes during mammalian evolution.	Univ Paris 06, Lab Mutagenese, Inst Jacques Monod, F-75251 Paris, France; Univ Paris 07, Lab Mutagenese, Inst Jacques Monod, F-75251 Paris, France; Nicholas Copernicus Univ, Genet Lab, PL-87100 Torun, Poland	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Nicolaus Copernicus University	Filipski, J (corresponding author), Univ Paris 06, Lab Mutagenese, Inst Jacques Monod, 2 Pl Jussieu,Tour 43, F-75251 Paris, France.	filipski@ijm.jussieu.fr	Goc, Anna/F-3423-2013; Lisowska, Katarzyna M/G-8295-2011; Goc, Anna/AAM-9436-2021	Goc, Anna/0000-0003-4271-1954; Lisowska, Katarzyna M/0000-0001-9786-3993; Goc, Anna/0000-0003-4271-1954				BERNARDI G, 1986, J MOL EVOL, V24, P1, DOI 10.1007/BF02099946; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chen EY, 1996, HUM MOL GENET, V5, P659, DOI 10.1093/hmg/5.5.659; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; DESCHAVANNE P, 1995, NUCLEIC ACIDS RES, V23, P1350, DOI 10.1093/nar/23.8.1350; DURSO M, 1990, GENOMICS, V7, P531, DOI 10.1016/0888-7543(90)90196-2; Eyre-Walker A, 1999, GENETICS, V152, P675; EYREWALKER A, 1999, P R SOC LOND B, V252, P237; Fan QQ, 1996, MOL CELL BIOL, V16, P2037; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; FILIPSKI J, 1987, FEBS LETT, V217, P184, DOI 10.1016/0014-5793(87)80660-9; Francino HP, 1999, NATURE, V400, P30, DOI 10.1038/21804; Franze A, 1998, FEBS LETT, V437, P313, DOI 10.1016/S0014-5793(98)01259-9; GROMOVA II, 1995, J BIOL CHEM, V270, P18685, DOI 10.1074/jbc.270.31.18685; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HOLMQUIST GP, 1994, TRENDS ECOL EVOL, V9, P65, DOI 10.1016/0169-5347(94)90277-1; Ira G, 1998, NUCLEIC ACIDS RES, V26, P2415, DOI 10.1093/nar/26.10.2415; Klein S, 1996, NAT GENET, V13, P481, DOI 10.1038/ng0896-481; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; Ohta K, 1999, NUCLEIC ACIDS RES, V27, P2175, DOI 10.1093/nar/27.10.2175; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; Patterton HG, 1998, J BIOL CHEM, V273, P7268, DOI 10.1074/jbc.273.13.7268; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; Shimizu TS, 1997, GENE, V205, P103, DOI 10.1016/S0378-1119(97)00542-8; SIMON B, 1994, FEBS LETT, V351, P340, DOI 10.1016/0014-5793(94)00862-0; Svetlova E, 1998, MOL GEN GENET, V257, P292; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wolffe AP, 1998, PROG NUCLEIC ACID RE, V61, P379, DOI 10.1016/S0079-6603(08)60832-6; WU TC, 1995, GENETICS, V140, P55	35	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1275	1278		10.1074/jbc.275.2.1275	http://dx.doi.org/10.1074/jbc.275.2.1275			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625673	hybrid			2022-12-25	WOS:000084836600077
J	Pereira, CA; Alonso, GD; Paveto, MC; Iribarren, A; Cabanas, ML; Torres, HN; Flawia, MM				Pereira, CA; Alonso, GD; Paveto, MC; Iribarren, A; Cabanas, ML; Torres, HN; Flawia, MM			Trypanosoma cruzi arginine kinase characterization and cloning - A novel energetic pathway in protozoan parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; SITE; BINDING; SCALLOP; MUSCLE; ACTIN	This work contains the first description of a guanidino kinase in a flagellar unicellular parasite. The enzyme phosphorylates L-arginine and was characterized in preparations from Trypanosoma cruzi, the ethiological agent of Chagas' disease. The activity requires ATP and a divalent cation. Under standard assay conditions (1 mM L-arginine), the presence of B-fold higher concentrations of canavanine or histidine produced a greater than 50% enzyme inhibition, The base sequence of this enzyme revealed an open reading frame of 357 amino acids and a molecular weight of 40,201. The amino acid sequence shows all of the characteristic consensus blocks of the ATP:guanidino phosphotransferase family and a putative "actinin-type" actin-binding domain. The highest amino acid identities of the T. cruzi sequence, about 70%, were with arginine kinases from Arthropoda. Southern and chromosome blots revealed that the kinase is encoded by a single-copy gene. Moreover, Northern blot analysis showed an mRNA subpopulation of about 2.0 kilobases, and Western blotting of T. cruzi-soluble polypeptides revealed a 40-kDa band. The finding in the parasite of a phosphagen and its biosynthetic pathway, which are totally different from those in mammalian host tissues, points out this arginine kinase as a possible chemotherapy target for Chagas' disease.	Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Invest Ingn Genet & Biol Mol, Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires	Flawia, MM (corresponding author), INGEBI, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Pereira, Claudio A/F-5382-2012; Alonso, Guillermo Daniel/AAI-6674-2020; Torres, Héctor/GXG-1780-2022	Pereira, Claudio A/0000-0001-7874-1894; Alonso, Guillermo Daniel/0000-0001-9386-9431; 				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMARGO EP, 1978, EXP PARASITOL, V46, P141, DOI 10.1016/0014-4894(78)90125-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENGMAN DM, 1987, MOL BIOCHEM PARASIT, V22, P115, DOI 10.1016/0166-6851(87)90041-7; France RM, 1997, ARCH BIOCHEM BIOPHYS, V345, P73, DOI 10.1006/abbi.1997.0243; Henikoff JG, 1999, NUCLEIC ACIDS RES, V27, P226, DOI 10.1093/nar/27.1.226; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Huennekens F. M., 1960, COMP BIOCHEM, P107; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Morrison J. F., 1973, ENZYMES, V8, P457, DOI 10.1016/S1874-6047; PAVETO C, 1995, J BIOL CHEM, V270, P16576, DOI 10.1074/jbc.270.28.16576; Pereira C, 1997, J EUKARYOT MICROBIOL, V44, P155, DOI 10.1111/j.1550-7408.1997.tb05952.x; Pereira CA, 1999, J EUKARYOT MICROBIOL, V46, P566, DOI 10.1111/j.1550-7408.1999.tb05132.x; REDDY SRR, 1992, EUR J BIOCHEM, V206, P251, DOI 10.1111/j.1432-1033.1992.tb16923.x; REDDY SRR, 1991, COMP BIOCHEM PHYS B, V99, P387, DOI 10.1016/0305-0491(91)90059-M; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; ROSENTHAL GA, 1977, J BIOL CHEM, V252, P3679; Strong SJ, 1996, COMP BIOCHEM PHYS B, V113, P809, DOI 10.1016/0305-0491(95)02104-3; YOSHIDA N, 1978, J BACTERIOL, V136, P1184, DOI 10.1128/JB.136.3.1184-1186.1978; Zhou GF, 1998, P NATL ACAD SCI USA, V95, P8449, DOI 10.1073/pnas.95.15.8449; Zingales B, 1997, PARASITOL TODAY, V13, P16	22	141	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1495	1501		10.1074/jbc.275.2.1495	http://dx.doi.org/10.1074/jbc.275.2.1495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625703	Green Published, hybrid			2022-12-25	WOS:000084836600107
J	Savelsbergh, A; Mohr, D; Wilden, B; Wintermeyer, W; Rodnina, MV				Savelsbergh, A; Mohr, D; Wilden, B; Wintermeyer, W; Rodnina, MV			Stimulation of the GTPase activity of translation elongation factor G by ribosomal protein L7/12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; AMINOACYL-TRANSFER-RNA; FACTOR EF-G; ESCHERICHIA-COLI; FACTOR-TU; ACTIVATING-PROTEIN; CODON RECOGNITION; HYDROLYSIS; MECHANISM; COMPLEX	Elongation factors (EFs) Tu and G are GTPases that have important functions in protein synthesis. The low intrinsic GTPase activity of both factors is strongly stimulated on the ribosome by unknown mechanisms. Here we report that isolated ribosomal protein L7/12 strongly stimulates GTP hydrolysis by EF-G, but not by EF-Tu, indicating a major contribution of L7/12 to GTPase activation of EF-G on the ribosome. The effect is due to the acceleration of the catalytic step because the rate of GDP-GTP exchange on EF-G, as measured by rapid kinetics, is much faster than the steady-state GTPase rate. The unique, highly conserved arginine residue in the C-terminal domain of L7/12 is not essential for the activation, excluding an "arginine finger"-type mechanism. L7/12 appears to function by stabilizing the GTPase transition state of EF-G.	Univ Witten Herdecke, Inst Mol Biol, D-58448 Witten, Germany	Witten Herdecke University	Rodnina, MV (corresponding author), Univ Witten Herdecke, Inst Mol Biol, D-58448 Witten, Germany.		Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Savelsbergh, Andreas/0000-0002-6136-3230				Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Bocharov EV, 1998, FEBS LETT, V423, P347, DOI 10.1016/S0014-5793(98)00121-5; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; DONNER D, 1978, P NATL ACAD SCI USA, V75, P3192, DOI 10.1073/pnas.75.7.3192; GALE EF, 1981, ANTIBIOTIC INHIBITOR, P402; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; GUDKOV AT, 1995, FEBS LETT, V367, P280, DOI 10.1016/0014-5793(95)00564-P; HAMEL E, 1972, J BIOL CHEM, V247, P6810; Hamman BD, 1996, BIOCHEMISTRY-US, V35, P16672, DOI 10.1021/bi9615001; HILGENFELD R, 1995, NAT STRUCT BIOL, V2, P3, DOI 10.1038/nsb0195-3; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jagath JR, 1998, BIOCHEMISTRY-US, V37, P15408, DOI 10.1021/bi981523a; KISCHA K, 1971, NATURE-NEW BIOL, V233, P62, DOI 10.1038/newbio233062a0; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; Neuhard J., 1987, ESCHERICHIA COLI SAL; Noel JP, 1997, NAT STRUCT BIOL, V4, P677, DOI 10.1038/nsb0997-677; OLEINIKOV AV, 1993, J BIOL CHEM, V268, P917; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; Rodnina MV, 1995, BIOCHEM CELL BIOL, V73, P1221, DOI 10.1139/o95-132; Rodnina MV, 1999, P NATL ACAD SCI USA, V96, P9586, DOI 10.1073/pnas.96.17.9586; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; SANDER G, 1980, BIOCHEMISTRY-US, V19, P865, DOI 10.1021/bi00546a006; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14225, DOI 10.1021/bi961118o; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SOMMER A, 1985, J BIOL CHEM, V260, P6522; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SORENSEN MA, 1991, J MOL BIOL, V222, P265, DOI 10.1016/0022-2836(91)90211-N; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1999, IN PRESS CELL; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; ZEIDLER W, 1995, EUR J BIOCHEM, V229, P596, DOI 10.1111/j.1432-1033.1995.tb20503.x	49	76	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					890	894		10.1074/jbc.275.2.890	http://dx.doi.org/10.1074/jbc.275.2.890			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625623	hybrid, Green Published			2022-12-25	WOS:000084836600027
J	Yao, N; Hurwitz, J; O'Donnell, M				Yao, N; Hurwitz, J; O'Donnell, M			Dynamics of beta and proliferating cell nuclear antigen sliding clamps in traversing DNA secondary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; CHROMOSOMAL REPLICATION MACHINE; LAGGING-STRAND REPLICATION; ESCHERICHIA-COLI; ACCESSORY PROTEINS; DELTA HOLOENZYME; MISMATCH REPAIR; PCNA; SUBUNIT; MECHANISM	Chromosomal replicases of cellular organisms utilize a ring shaped protein that encircles DNA as a mobile tether for high processivity in DNA synthesis. These "sliding clamps" have sufficiently large linear diameters to encircle duplex DNA and are perhaps even large enough to slide over certain DNA secondary structural elements. This report examines the Escherichia coli beta and human proliferating cell nuclear antigen clamps for their ability to slide over various DNA secondary structures. The results show that these clamps are capable of traversing a 13-nucleotide ssDNA loop, a 4-base pair stem-loop, a 4-nucleotide 5' tail, and a 15-mer bubble within the duplex. However, upon increasing the size of these structures (20-nucleotide loop, 12-base pair stem-loop, 28-nucleotide 5' tail, and 20-nucleotide bubble) the sliding motion of the beta and proliferating cell nuclear antigen over these elements is halted. Studies of the E. coli replicase, DNA polymerase III holoenzyme, in chain elongation with the beta clamp demonstrate that upon encounter with an oligonucleotide annealed in its path, it traverses the duplex and resumes synthesis on the 3' terminus of the oligonucleotide. This sliding and resumption of synthesis occurs even when the oligonucleotide contains a secondary structure element, provided the beta clamp can traverse the structure. However, upon encounter with a downstream oligonucleotide containing a large internal secondary structure, the holoenzyme clears the obstacle by strand displacing the oligonucleotide from the template. Implications of these protein dynamics to DNA transactions are discussed.	Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Dept Microbiol, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Grad Program Mol Biol, New York, NY 10021 USA	Cornell University; Rockefeller University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Yao, N (corresponding author), Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Dept Microbiol, New York, NY 10021 USA.				PHS HHS [38839] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Canceill D, 1996, P NATL ACAD SCI USA, V93, P6647, DOI 10.1073/pnas.93.13.6647; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIASA H, 1989, GENE, V84, P17, DOI 10.1016/0378-1119(89)90134-0; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1992, DNA REPLICATION, P169; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LAMBERT PF, 1986, J VIROL, V58, P450, DOI 10.1128/JVI.58.2.450-458.1986; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6547; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; O'Donnell M, 1999, CURR BIOL, V9, pR545, DOI 10.1016/S0960-9822(99)80348-0; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PONTKINGDON G, 1993, EMBO J, V12, P23, DOI 10.1002/j.1460-2075.1993.tb05628.x; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Stephens KM, 1997, J BIOL CHEM, V272, P28800, DOI 10.1074/jbc.272.45.28800; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; Turner J, 1995, METHOD ENZYMOL, V262, P442; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHEL K, 1975, J BIOL CHEM, V250, P4684	65	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1421	1432		10.1074/jbc.275.2.1421	http://dx.doi.org/10.1074/jbc.275.2.1421			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625694	hybrid			2022-12-25	WOS:000084836600098
J	Devireddy, LR; Jones, CJ				Devireddy, LR; Jones, CJ			Olf-1, a neuron-specific transcription factor, can activate the herpes simplex virus type 1-infected cell protein 0 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; REGULATORY ELEMENTS; ICPO PROMOTER; DNA-BINDING; JC VIRUS; LATENCY; REACTIVATION; CLONING; MUTANTS	Herpes simplex virus type 1 (HSV-1) establishes a lifelong latent infection in sensory neurons of infected individuals. Infected cell protein 0 (ICP0) is important for productive infection and reactivation from latency. Thus, activation of ICP0 expression in neurons is likely to be important for reactivation from latency, In a mouse neuroblastoma cell line, ICP0 promoter activity is high compared with other strong viral promoters. In contrast, promoter activity is low in non-neuronal cells. DNase I footprinting assays indicated that three distinct motifs in the ICP0 promoter are bound by nuclear factors. One of these motifs contains a binding site for a novel helix-loop-helix olfactory neuron-specific transcription factor (Olf-1). Gel shift assays and supershift assays using an Olf-1-specific antibody demonstrated that mouse neuroblastoma cells express Olf-1, which is bound to the Olf-1-like site in the ICP0 promoter. Deletion of the putative Olf-1 motif reduced ICP0 promoter activity more than 5-fold in mouse neuroblastoma cells and prevented trans-activation by an Olf-1 expression vector. We hypothesize that the Olf-1-binding site activates ICP0 promoter activity in neurons during reactivation from latency.	Univ Nebraska, Dept Vet & Biomed Sci, Ctr Biotechnol, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln	Jones, CJ (corresponding author), Univ Nebraska, Dept Vet & Biomed Sci, Ctr Biotechnol, Fair St & E Campus Loop, Lincoln, NE 68583 USA.	cjones@unlnotes.unl.edu						CAI WZ, 1992, J VIROL, V66, P2904, DOI 10.1128/JVI.66.5.2904-2915.1992; CHODOSH LA, 1988, MOL CELL BIOL, V13, P11; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; Davido DJ, 1996, J GEN VIROL, V77, P1853, DOI 10.1099/0022-1317-77-8-1853; Davido DJ, 1998, J GEN VIROL, V79, P2093, DOI 10.1099/0022-1317-79-9-2093; Davis JA, 1996, J NEUROSCI, V16, P5082; Devireddy LR, 1996, J MED VIROL, V49, P205; Devireddy LR, 1998, J VIROL, V72, P7294, DOI 10.1128/JVI.72.9.7294-7301.1998; EVERETT RD, 1989, J GEN VIROL, V70, P1185, DOI 10.1099/0022-1317-70-5-1185; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; Jones C, 1998, Adv Virus Res, V51, P81, DOI 10.1016/S0065-3527(08)60784-8; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LEIB DA, 1989, J VIROL, V63, P759, DOI 10.1128/JVI.63.2.759-768.1989; LIU X, 1990, BIOTECHNIQUES, V9, P168; Lium EK, 1998, J VIROL, V72, P7785, DOI 10.1128/JVI.72.10.7785-7795.1998; Nakshatri H, 1997, ANAL BIOCHEM, V249, P103, DOI 10.1006/abio.1997.2154; NAKSHATRI H, 1990, VIROLOGY, V177, P784, DOI 10.1016/0042-6822(90)90550-B; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; Reed RR, 1998, SCIENCE, V279, P193, DOI 10.1126/science.279.5348.193; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590; STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571; Tamura TA, 1996, NEUROCHEM INT, V29, P573, DOI 10.1016/S0197-0186(96)00048-4; Tsai RYL, 1997, J NEUROSCI, V17, P4159; VERHAAGEN J, 1990, J NEUROSCI RES, V26, P31, DOI 10.1002/jnr.490260105; Wagner EK, 1997, CLIN MICROBIOL REV, V10, P419, DOI 10.1128/CMR.10.3.419; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang SS, 1997, J NEUROSCI, V17, P4149; ZHU XX, 1990, J VIROL, V64, P4489, DOI 10.1128/JVI.64.9.4489-4498.1990	32	16	17	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					77	81		10.1074/jbc.275.1.77	http://dx.doi.org/10.1074/jbc.275.1.77			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617588	hybrid			2022-12-25	WOS:000085951600012
J	El-Mir, MY; Nogueira, V; Fontaine, E; Averet, N; Rigoulet, M; Leverve, X				El-Mir, MY; Nogueira, V; Fontaine, E; Averet, N; Rigoulet, M; Leverve, X			Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; ANTIDIABETIC DRUG METFORMIN; ISOLATED RAT HEPATOCYTES; NITRIC-OXIDE; PHOSPHOINOSITIDE 3-KINASE; PYRUVATE-KINASE; DIABETIC RATS; MITOCHONDRIAL; GLUTATHIONE; BIGUANIDES	We report here a new mitochondrial regulation occurring only in intact cells. We have investigated the effects of dimethylbiguanide on isolated rat hepatocytes, permeabilized hepatocytes, and isolated liver mitochondria, Addition of dimethylbiguanide decreased oxygen consumption and mitochondrial membrane potential only in intact cells but not in permeabilized hepatocytes or isolated mitochondria. Permeabilized hepatocytes after dimethylbiguanide exposure and mitochondria isolated from dimethylbiguanide pretreated livers or animals were characterized by a significant inhibition of oxygen consumption with complex I substrates (glutamate and malate) but not with complex II (succinate) or complex IV (N,N,N',N'-tetramethyl-1,4-phenylenediamine dihydrochloride (TMPD)/ascorbate) substrates, Studies using functionally isolated complex I obtained from mitochondria isolated from dimethylbiguanide-pretreated livers or rats further confirmed that dimethylbiguanide action was located on the respiratory chain complex I. The dimethylbiguanide effect was temperature-dependent, oxygen consumption decreasing by 50, 20, and 0% at 37, 25, and 15 degrees C, respectively. This effect was not affected by insulin-signaling pathway inhibitors, nitric oxide precursor or inhibitors, oxygen radical scavengers, ceramide synthesis inhibitors, or chelation of intra- or extracellular Ca2+. Because it is established that dimethylbiguanide is not metabolized, these results suggest the existence of a new cell-signaling pathway targeted to the respiratory chain complex I with a persistent effect after cessation of the signaling process.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble 09, France; Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Leverve, X (corresponding author), Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, BP 53X, F-38041 Grenoble 09, France.	xavier.leverve@ujf-grenoble.fr	Fontaine, Eric/ABA-8853-2020	Fontaine, Eric/0000-0002-5204-9477				Almeida A, 1998, BRAIN RES, V790, P209, DOI 10.1016/S0006-8993(98)00064-X; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; BAILEY CJ, 1992, BRIT J PHARMACOL, V105, P1009, DOI 10.1111/j.1476-5381.1992.tb09093.x; Bergmeyer H.U, 1974, METHODS ENZYMATIC AN, V3; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V4; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BOLANOS JP, 1994, J NEUROCHEM, V63, P910; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Dominguez LJ, 1996, ENDOCRINOLOGY, V137, P113, DOI 10.1210/en.137.1.113; ESPIE P, 1995, BBA-BIOENERGETICS, V1230, P139, DOI 10.1016/0005-2728(95)00045-K; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; EWIS SA, 1995, J APPL TOXICOL, V15, P387, DOI 10.1002/jat.2550150508; Ewis SA, 1997, J APPL TOXICOL, V17, P409, DOI 10.1002/(SICI)1099-1263(199711/12)17:6<409::AID-JAT462>3.0.CO;2-B; FONTAINE EM, 1995, BIOCHEM BIOPH RES CO, V213, P138, DOI 10.1006/bbrc.1995.2108; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIGORESCU F, 1991, DIABETES METAB, V17, P146; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; JALLING O, 1984, ACTA PHARMACOL TOX, V54, P327; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kessler A, 1998, BIOCHEM J, V330, P277, DOI 10.1042/bj3300277; KISELEV GV, 1975, UKR BIOKHIM ZH+, V47, P389; KLINGENBERG M, 1959, BIOCHEM Z, V331, P486; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Lee AJ, 1996, PHARMACOTHERAPY, V16, P327; LEVERVE XM, 1994, EUR J BIOCHEM, V224, P967, DOI 10.1111/j.1432-1033.1994.00967.x; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; PENTIKAINEN PJ, 1979, EUR J CLIN PHARMACOL, V16, P195, DOI 10.1007/BF00562061; PISON CM, 1995, AM J PHYSIOL-ENDOC M, V268, pE965, DOI 10.1152/ajpendo.1995.268.5.E965; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; Santos RF, 1997, DIABETES METAB, V23, P143; SCHAFER G, 1969, BIOCHIM BIOPHYS ACTA, V172, P334, DOI 10.1016/0005-2728(69)90077-2; SCHAFER G, 1972, EUR J BIOCHEM, V27, P364, DOI 10.1111/j.1432-1033.1972.tb01846.x; SCHAFER G, 1983, DIABETES METAB, V9, P148; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; SHOUKRY MI, 1980, J BIOCHEM BIOPH METH, V3, P219, DOI 10.1016/0165-022X(80)90060-3; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; STADLER J, 1992, ANN SURG, V216, P539, DOI 10.1097/00000658-199211000-00003; Stith BJ, 1998, BIOCHEM PHARMACOL, V55, P533, DOI 10.1016/S0006-2952(97)00540-6; Stith BJ, 1996, ENDOCRINOLOGY, V137, P2990, DOI 10.1210/en.137.7.2990; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; UBL JJ, 1994, BIOCHEM J, V304, P561, DOI 10.1042/bj3040561; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; WIERNSPERGER N, 1995, DIABETES METAB REV, V11, pS3, DOI 10.1002/dmr.5610110503; WIERNSPERGER NF, 1996, HANDB EXP PHARM, V119, P305; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; Wright AD, 1998, DIABETES CARE, V21, P87; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	54	1011	1044	5	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					223	228		10.1074/jbc.275.1.223	http://dx.doi.org/10.1074/jbc.275.1.223			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617608	hybrid			2022-12-25	WOS:000085951600032
J	Lougheed, B; Ly, HD; Wakarchuk, WW; Withers, SG				Lougheed, B; Ly, HD; Wakarchuk, WW; Withers, SG			Glycosyl fluorides can function as substrates for nucleotide phosphosugar-dependent glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-SPECIFIED GLYCOSYLTRANSFERASES; D-GLUCOPYRANOSYL FLUORIDE; BLOOD-GROUP-A; ACCEPTOR ALPHA-L-FUCP-(1->2)-BETA-D-GALP-OR; OLIGOSACCHARIDE SYNTHESIS; CARBOHYDRATE-RECOGNITION; ENZYMATIC-SYNTHESIS; ORGANIC-SYNTHESIS; GLYCOBIOLOGY; STRATEGIES	alpha-Galactosyl fluoride is shown to function as a substrate, in place of uridine-5'-diphosphogalactose, for the alpha-galactosyltransferase from Neisseria meningitidis. The reaction only occurs in the presence of catalytic quantities of uridine 5'-diphosphate, In the presence of galactosyl accepters, the expected oligosaccharide product is formed in essentially quantitative yields, reaction having been performed on multi-milligram scales, In the absence of a suitable acceptor, the enzyme synthesizes uridine-5'-diphosphogalactose, as demonstrated through a coupled assay in which uridine-5'-diphosphogalactose is converted to uridine-5'-diphosphoglucuronic acid with conversion of NAD to NADH. These glycosyl fluoride substrates therefore offer the potential of an inexpensive alternative donor substrate in the synthesis of oligosaccharides as well a means of generating steady state concentrations of nucleotide diphosphate sugars for in situ use by other enzymes. Further, they should prove valuable as mechanistic probes.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0C6, Canada	University of British Columbia; National Research Council Canada	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.		Wakarchuk, Warren/AAO-2774-2020; Wakarchuk, Warren/Q-9514-2017	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679				BELL JE, 1976, J BIOL CHEM, V251, P3003; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; Boons GJ, 1996, TETRAHEDRON, V52, P1095, DOI 10.1016/0040-4020(95)00897-7; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Danishefsky SJ, 1996, ANGEW CHEM INT EDIT, V35, P1380, DOI 10.1002/anie.199613801; DAVIES G, 1997, COMPREHENSIVE BIOL C, V1, P119; DOUGLAS SP, 1991, J AM CHEM SOC, V113, P5095, DOI 10.1021/ja00013a075; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Edebrink P, 1996, CARBOHYD RES, V295, P127, DOI 10.1016/S0008-6215(96)90132-9; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GOLD AM, 1980, BIOCHEMISTRY-US, V19, P3766, DOI 10.1021/bi00557a018; HAYASHI M, 1984, CHEM LETT, P1747, DOI 10.1246/cl.1984.1747; HEHRE EJ, 1990, CARBOHYD RES, V198, P123, DOI 10.1016/0008-6215(90)84282-Y; ICHIKAWA Y, 1992, J AM CHEM SOC, V114, P9283, DOI 10.1021/ja00050a007; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KOBATA A, 1993, ACCOUNTS CHEM RES, V26, P319, DOI 10.1021/ar00030a004; KOBAYASHI S, 1991, J AM CHEM SOC, V113, P3079, DOI 10.1021/ja00008a042; KONSTANTINIDIS AK, 1993, BIOCHEM J, V291, P833; Leatherbarrow R.J, 1990, GRAFIT VERSION 3 0; LINDHORST TK, 1995, CARBOHYD RES, V268, P93, DOI 10.1016/0008-6215(94)00317-9; LOWARY TL, 1993, CARBOHYD RES, V249, P163, DOI 10.1016/0008-6215(93)84068-H; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; MOREAU V, 1996, J CHEM SOC PERK T, V21, P525; NILSSON KGI, 1988, TRENDS BIOTECHNOL, V6, P256, DOI 10.1016/0167-7799(88)90058-3; PALCIC M M, 1991, Glycobiology, V1, P205, DOI 10.1093/glycob/1.2.205; PLESNER L, 1974, J BIOL CHEM, V249, P1119; Qiao L, 1996, J AM CHEM SOC, V118, P7653, DOI 10.1021/ja960274f; SALSAS E, 1975, J BIOL CHEM, V250, P3471; Sears P, 1996, P NATL ACAD SCI USA, V93, P12086, DOI 10.1073/pnas.93.22.12086; Sierks MR, 1996, BIOCHEMISTRY-US, V35, P1865, DOI 10.1021/bi951738+; Simon PM, 1996, DRUG DISCOV TODAY, V1, P522, DOI 10.1016/S1359-6446(96)10044-1; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; THIEM J, 1995, FEMS MICROBIOL REV, V16, P193; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; WOLFRAM S, 1996, MATH VERSION 3 0; WONG CH, 1995, ANGEW CHEM INT EDIT, V34, P521, DOI 10.1002/anie.199505211; Zemplen G, 1929, BER DTSCH CHEM GES, V62, P1613, DOI 10.1002/cber.19290620640; Zopf D, 1996, LANCET, V347, P1017, DOI 10.1016/S0140-6736(96)90150-6	42	38	46	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37717	37722		10.1074/jbc.274.53.37717	http://dx.doi.org/10.1074/jbc.274.53.37717			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608830	hybrid			2022-12-25	WOS:000084528000030
J	Poderoso, JJ; Lisdero, C; Schopfer, F; Riobo, N; Carreras, MC; Cadenas, E; Boveris, A				Poderoso, JJ; Lisdero, C; Schopfer, F; Riobo, N; Carreras, MC; Cadenas, E; Boveris, A			The regulation of mitochondrial oxygen uptake by redox reactions involving nitric oxide and ubiquinol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; HYDROGEN-PEROXIDE; REVERSIBLE INHIBITION; SUPEROXIDE RADICALS; HEART-MITOCHONDRIA; RESPIRATION; PEROXYNITRITE; GENERATION; METABOLISM; REDUCTION	The reversible inhibitory effects of nitric oxide (. NO) on mitochondrial cytochrome oxidase and O-2 uptake are dependent on intramitochondrial . NO utilization. This study was aimed at establishing the mitochondrial pathways for . NO utilization that regulate O-2(radical anion) generation via reductive and oxidative reactions involving ubiquinol oxidation and peroxynitrite (ONOO-) formation. For this purpose, experimental models consisting of intact mitochondria, ubiquinone-depleted/reconstituted submitochondrial particles, and ONOO--supplemented mitochondrial membranes were used. The results obtained from these experimental approaches strongly suggest the occurrence of independent pathways for . NO utilization in mitochondria, which effectively compete with the binding of . NO to cytochrome oxidase, thereby releasing this inhibition and restoring O-2 uptake. The pathways for . NO utilization are discussed in terms of the steady-state levels of . NO and O-2(radical anion) and estimated as a function of O-2 tension. These calculations indicate that mitochondrial . NO decays primarily by pathways involving ONOO- formation and ubiquinol oxidation and, secondarily, by reversible binding to cytochrome oxidase.	Univ Buenos Aires, Univ Hosp, Sch Med, Lab Oxygen Metab, RA-1120 Buenos Aires, DF, Argentina; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ Buenos Aires, Sch Pharm & Biochem, Lab Free Radical Biol, RA-1120 Buenos Aires, DF, Argentina	University of Buenos Aires; University of Southern California; University of Buenos Aires	Poderoso, JJ (corresponding author), Univ Buenos Aires, Univ Hosp, Sch Med, Lab Oxygen Metab, Cordoba 2351, RA-1120 Buenos Aires, DF, Argentina.	jpoderos@fmed.uba.ar	Schopfer, Francisco Jose/AAE-8125-2020; Galdo, Natalia Riobo-Del/AAP-2938-2020	Schopfer, Francisco Jose/0000-0001-9526-695X; Galdo, Natalia Riobo-Del/0000-0002-8942-7873	NATIONAL INSTITUTE ON AGING [R01AG016718] Funding Source: NIH RePORTER; NIA NIH HHS [1RO1AG16718-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antunes F, 1996, FREE RADICAL BIO MED, V21, P917, DOI 10.1016/S0891-5849(96)00185-2; AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; Boczkowski J, 1999, FASEB J, V13, P1637, DOI 10.1096/fasebj.13.12.1637; Borutaite V, 1996, BIOCHEM J, V315, P295, DOI 10.1042/bj3150295; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Boveris A, 1999, METHOD ENZYMOL, V301, P188; BOVERIS A, 1970, Archives of Biochemistry and Biophysics, V141, P641, DOI 10.1016/0003-9861(70)90184-0; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Boveris A, 1997, OXYGEN GENE EXPRESSI, P1; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brown GC, 1997, MOL CELL BIOCHEM, V174, P189, DOI 10.1023/A:1006800322719; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CADENAS E, 1999, ANTIOXIDANT FOOD SUP, P143; Carreras MC, 1996, METHOD ENZYMOL, V269, P65; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; DIONISI O, 1975, BIOCHIM BIOPHYS ACTA, V403, P292, DOI 10.1016/0005-2744(75)90059-5; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; GIULIVI C, 1995, ARCH BIOCHEM BIOPHYS, V316, P909, DOI 10.1006/abbi.1995.1122; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Koivisto A, 1997, FEBS LETT, V417, P75, DOI 10.1016/S0014-5793(97)01258-1; Koppenol WH, 1996, METHOD ENZYMOL, V268, P7; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Packer MA, 1996, BIOCHEM MOL BIOL INT, V40, P527; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1998, AM J PHYSIOL-CELL PH, V274, pC112, DOI 10.1152/ajpcell.1998.274.1.C112; Poderoso JJ, 1999, FREE RADICAL BIO MED, V26, P925, DOI 10.1016/S0891-5849(98)00277-9; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; Stubauer G, 1998, BIOCHEM BIOPH RES CO, V245, P459, DOI 10.1006/bbrc.1998.8457; TAKEHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V323, P27, DOI 10.1006/abbi.1995.0005; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; ZHAO XJ, 1995, BIOCHEM BIOPH RES CO, V212, P1054, DOI 10.1006/bbrc.1995.2076	51	158	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37709	37716		10.1074/jbc.274.53.37709	http://dx.doi.org/10.1074/jbc.274.53.37709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608829	hybrid			2022-12-25	WOS:000084528000029
J	Choi, HI; Hong, JH; Ha, JO; Kang, JY; Kim, SY				Choi, HI; Hong, JH; Ha, JO; Kang, JY; Kim, SY			ABFs, a family of ABA-responsive element binding factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BZIP TRANSCRIPTION FACTORS; ABSCISIC-ACID; SIGNAL-TRANSDUCTION; LOW-TEMPERATURE; LEUCINE-ZIPPER; SPECIFICATION ELEMENTS; FREEZING TOLERANCE; WATER-STRESS; COLD STRESS; G-BOX	Abscisic acid (ABA) plays an important role in environmental stress responses of higher plants during vegetative growth. One of the ABA-mediated responses is the induced expression of a large number of genes, which is mediated by cis-regulatory elements known as abscisic acid-responsive elements (ABREs). Although a number of ABBE binding transcription factors have been known, they are not specifically from vegetative tissues under induced conditions. Considering the tissue specificity of ABA signaling pathways, factors mediating ABA-dependent stress responses during vegetative growth phase may thus have been unidentified so far. Here, we report a family of ABBE binding factors isolated from young Arabidopsis plants under stress conditions. The factors, isolated by a yeast one-hybrid system using a prototypical ABBE and named as ABFs (ABRE binding factors) belong to a distinct subfamily of bZIP proteins. Binding site selection assay performed with one ABF showed that its preferred binding site is the strong ABBE, CACGTGGC. ABFs can transactivate an ABBE-containing reporter gene in yeast. Expression of ABFs is induced by ABA and various stress treatments, whereas their induction patterns are different from one another, Thus, a new family of ABBE binding factors indeed exists that have the potential to activate a large number of ABA/stress-responsive genes in Arabidopsis.	Kumho Life & Environm Sci Lab, Puk Gu, Kwangju 500712, South Korea		Kim, SY (corresponding author), Kumho Life & Environm Sci Lab, Puk Gu, 1 Oryong Dong, Kwangju 500712, South Korea.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Busk PK, 1997, PLANT J, V11, P1285, DOI 10.1046/j.1365-313X.1997.11061285.x; Busk PK, 1998, PLANT MOL BIOL, V37, P425, DOI 10.1023/A:1006058700720; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; Chung JD, 1996, J MATER PROCESS MANU, V5, P3; deBruxelles GL, 1996, PLANT PHYSIOL, V111, P381, DOI 10.1104/pp.111.2.381; FOSTER R, 1994, FASEB J, V8, P192, DOI 10.1096/fasebj.8.2.8119490; GIULIANO G, 1988, P NATL ACAD SCI USA, V85, P7089, DOI 10.1073/pnas.85.19.7089; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; Hollung K, 1997, PLANT MOL BIOL, V35, P561, DOI 10.1023/A:1005815017718; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; Ishitani M, 1997, PLANT CELL, V9, P1935, DOI 10.1105/tpc.9.11.1935; IZAWA T, 1993, J MOL BIOL, V230, P1131, DOI 10.1006/jmbi.1993.1230; Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kim SY, 1998, J PLANT PHYSIOL, V152, P607, DOI 10.1016/S0176-1617(98)80019-9; Kim SY, 1997, PLANT J, V11, P1237, DOI 10.1046/j.1365-313X.1997.11061237.x; KUSANO T, 1995, MOL GEN GENET, V248, P507, DOI 10.1007/BF02423445; LAM E, 1991, J BIOL CHEM, V266, P17131; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; Liu Q, 1998, PLANT CELL, V10, P1391, DOI 10.1105/tpc.10.8.1391; Lu GH, 1996, PLANT CELL, V8, P847, DOI 10.1105/tpc.8.5.847; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; Meshi T, 1995, PLANT CELL PHYSIOL, V36, P1405; Nakagawa H, 1996, PLANT J, V9, P217, DOI 10.1046/j.1365-313X.1996.09020217.x; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; Ono A, 1996, PLANT PHYSIOL, V112, P483, DOI 10.1104/pp.112.2.483; PLA M, 1993, PLANT MOL BIOL, V21, P259, DOI 10.1007/BF00019942; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; Shinozaki K, 1996, CURR OPIN BIOTECH, V7, P161, DOI 10.1016/S0958-1669(96)80007-3; Thomas T. L., 1997, Signal transduction in plants., P23; Thomashow MF, 1998, PLANT PHYSIOL, V118, P1, DOI 10.1104/pp.118.1.1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	41	791	905	16	149	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1723	1730		10.1074/jbc.275.3.1723	http://dx.doi.org/10.1074/jbc.275.3.1723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636868	hybrid			2022-12-25	WOS:000084940000031
J	Appel, H; Gauthier, L; Pyrdol, J; Wucherpfennig, KW				Appel, H; Gauthier, L; Pyrdol, J; Wucherpfennig, KW			Kinetics of T-cell receptor binding by bivalent HLA-DR center dot peptide complexes that activate antigen-specific human T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; ALPHA-BETA; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE REGION; DENDRITIC CELLS; CD3 COMPLEX; DIMERIZATION; CHAIN; TCR; ASSOCIATION	Monovalent major histocompatibility complex-peptide complexes dissociate within seconds from the T-cell receptor (TCR), indicating that dimerization/multimerization may be important during early stages of T-cell activation. Soluble bivalent HLA-DR2.myelin basic protein (MBP) peptide complexes were expressed by replacing the F(ab) arms of an IgG2a antibody with HLA-DR2.MBP peptide complexes. The binding of bivalent HLA-DR2.peptide complexes to recombinant TCR was examined by surface plasmon resonance, The bivalent nature greatly enhanced TCR binding and slowed dissociation from the TCR, with a t(1/2) of 2.1 to 4.6 min. Soluble bivalent HLA-DR2.MBP peptide complexes activated antigen-specific T-cells in the absence of antigen presenting cells. In contrast, soluble antibodies to the TCR.CD3 complex were ineffective, indicating that they failed to induce an active TCR dimer. TCR/CD3 antibodies induced T-cell proliferation when bound by antigen presenting cells that expressed Fc receptors, In the presence of dendritic cells, bivalent HLA-DR2.MBP peptide complexes induced T-cell activation at >100-fold lower concentrations than TCR/CD3 antibodies and were also superior to peptide or antigen. These results demonstrate that bivalent HLA-DR.peptide complexes represent effective ligands for activation of the TCR, The data support a role for TCR dimerization in early TCR signaling and kinetic proofreading.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Wucherpfennig, KW (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.	wucherpf@mbcrr.harvard.edu						ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; ALCOVER A, 1990, J BIOL CHEM, V265, P4131; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Casares S, 1999, J EXP MED, V190, P543, DOI 10.1084/jem.190.4.543; CHERBAS L, 1994, METHOD CELL BIOL, V44, P161, DOI 10.1016/S0091-679X(08)60912-7; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; Exley M, 1991, Semin Immunol, V3, P283; Fanger NA, 1996, J IMMUNOL, V157, P541; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Gauthier L, 1998, P NATL ACAD SCI USA, V95, P11828, DOI 10.1073/pnas.95.20.11828; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Haks MC, 1998, EMBO J, V17, P1871, DOI 10.1093/emboj/17.7.1871; Hamad ARA, 1998, J EXP MED, V188, P1633, DOI 10.1084/jem.188.9.1633; HANSON DC, 1984, J IMMUNOL, V132, P1386; Huppa JB, 1997, J EXP MED, V186, P393, DOI 10.1084/jem.186.3.393; Kalandadze A, 1996, J BIOL CHEM, V271, P20156, DOI 10.1074/jbc.271.33.20156; Kamarck M E, 1987, Methods Enzymol, V151, P150, DOI 10.1016/S0076-6879(87)51017-5; KEARSE KP, 1995, IMMUNITY, V2, P391; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; OHerrin SM, 1997, J EXP MED, V186, P1333, DOI 10.1084/jem.186.8.1333; OLLO R, 1981, P NATL ACAD SCI-BIOL, V78, P2442, DOI 10.1073/pnas.78.4.2442; RATCLIFFE MJH, 1992, J IMMUNOL, V148, P1643; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; She J, 1999, INT IMMUNOL, V11, P845, DOI 10.1093/intimm/11.5.845; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; Utz U, 1996, J VIROL, V70, P843, DOI 10.1128/JVI.70.2.843-851.1996; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; Wang BP, 1999, J IMMUNOL, V162, P88; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279; WUCHERPFENNIG KW, 1995, P NATL ACAD SCI USA, V92, P11935, DOI 10.1073/pnas.92.25.11935	53	54	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					312	321		10.1074/jbc.275.1.312	http://dx.doi.org/10.1074/jbc.275.1.312			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617620	hybrid			2022-12-25	WOS:000085951600044
J	Klarmann, GJ; Smith, RA; Schinazi, RF; North, TW; Preston, BD				Klarmann, GJ; Smith, RA; Schinazi, RF; North, TW; Preston, BD			Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S - Template interactions influence substrate recognition at the polymerase active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DOUBLE-STRANDED DNA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; NUCLEOTIDE-SEQUENCE; CONFERS RESISTANCE; FELINE; FIDELITY; REPLICATION; 3'-AZIDO-3'-DEOXYTHYMIDINE	Studies of drug-resistant reverse transcriptases (RTs) reveal the roles of specific structural elements and amino acids in polymerase function. To characterize better the effects of RT/template interactions on dNTP substrate recognition, we examined the sensitivity of human immunodeficiency virus type 1 (HIV-1) RT containing a new mutation in a "template grip" residue (P157S) to the 5'-triphosphates of (-)-beta-2',3'-dideoxy-3'-thiacytidine (3TC), (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine (FTC), and 3'-azido-3'-deoxythymidine (AZT). A primer extension assay was used to monitor quantitatively drug monophosphate incorporation opposite each of multiple target sites. Wild-type and P157S RTs had similar catalytic activities and processivities on heteropolymeric RNA and DNA templates. When averaged over multiple template sites, P157S RT was 2-7-fold resistant to the 5'-triphosphates of 3TC, FTC, and AZT, Each drug triphosphate inhibited polymerization more efficiently on the DNA template compared with an RNA template of identical sequence. Moreover, chain termination by 3TC and FTC was strongly influenced by template sequence context. Incorporation of FTC and 3TC monophosphate varied up to 10-fold opposite 7 different G residues in the DNA template, and the P157S mutation altered this site specificity. In summary, these data identify Pro(157) as an important residue affecting nucleoside analog resistance and suggest that interactions between RT and the template strand influence dNTP substrate recognition at the RT active site. Our findings are discussed within the context of the HIV-1 RT structure.	Univ Utah, Dept Biochem, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Radiat Oncol, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Emory Univ, Sch Med, Dept Pediat, Decatur, GA 30033 USA; Emory Univ, Sch Med, Georgia Vet Affairs Res Ctr AIDS & HIV Invect, Decatur, GA 30033 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Emory University; Emory University; University of California System; University of California Davis	Preston, BD (corresponding author), Univ Utah, Dept Biochem, Eccles Inst Human Genet, 15 N 2030 E,Rm 2150, Salt Lake City, UT 84112 USA.	bpreston@hci.utah.edu	Schinazi, Raymond F/B-6777-2017		NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038755, R01AI034834] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA42014] Funding Source: Medline; NIAID NIH HHS [R01 AI38755, R01 AI34834] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Arts EJ, 1996, J VIROL, V70, P712, DOI 10.1128/JVI.70.2.712-720.1996; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Bartholomeusz A., 1998, VIRAL HEPATITIS REV, V4, P167; Bebenek K, 1993, REVERSE TRANSCRIPTAS, P85; BOYER PL, 1995, ANTIMICROB AGENTS CH, V39, P1624, DOI 10.1128/AAC.39.7.1624; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; CARROLL SS, 1994, BIOCHEMISTRY-US, V33, P2113, DOI 10.1021/bi00174a018; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P174; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Elder JH, 1998, AIDS RES HUM RETROV, V14, P797, DOI 10.1089/aid.1998.14.797; Emini E. A., 1997, P637; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; HALL JD, 1985, P NATL ACAD SCI USA, V82, P3889, DOI 10.1073/pnas.82.11.3889; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HOONG LK, 1992, J ORG CHEM, V57, P5563, DOI 10.1021/jo00047a004; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang L, 1999, P NATL ACAD SCI USA, V96, P447, DOI 10.1073/pnas.96.2.447; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER BA, 1993, REVERSE TRANSCRIPTAS, P205; MCCLURE MA, 1993, REVERSE TRANSCRIPTAS, P425; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; NORTH TW, 1990, J BIOL CHEM, V265, P5121; NORTH TW, 1995, NAT MED, V1, P410, DOI 10.1038/nm0595-410; NORTH TW, 1990, ANTIMICROB AGENTS CH, V34, P1505, DOI 10.1128/AAC.34.8.1505; Nossal NG, 1998, GENETICS, V148, P1535; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P8088, DOI 10.1073/pnas.86.20.8088; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; Pichoud C, 1999, HEPATOLOGY, V29, P230, DOI 10.1002/hep.510290119; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; REMINGTON KM, 1991, J VIROL, V65, P308, DOI 10.1128/JVI.65.1.308-312.1991; REMINGTON KM, 1994, J VIROL, V68, P632, DOI 10.1128/JVI.68.2.632-637.1994; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schinazi R. F., 1999, INT ANTIVIRAL NEWS, V7, P46; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P2423, DOI 10.1128/AAC.36.11.2423; Smith RA, 1997, J VIROL, V71, P2357, DOI 10.1128/JVI.71.3.2357-2362.1997; Smith RA, 1998, J VIROL, V72, P2335, DOI 10.1128/JVI.72.3.2335-2340.1998; Smith RA, 1999, ANTIMICROB AGENTS CH, V43, P2077, DOI 10.1128/AAC.43.8.2077; Stahlhut MW, 1996, METHOD ENZYMOL, V275, P122; TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; Telesnitsky A., 1997, P121; Ueno T, 1997, BIOCHEMISTRY-US, V36, P1092, DOI 10.1021/bi962393d; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wilson JE, 1996, J BIOL CHEM, V271, P13656, DOI 10.1074/jbc.271.23.13656	64	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					359	366		10.1074/jbc.275.1.359	http://dx.doi.org/10.1074/jbc.275.1.359			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617626	hybrid			2022-12-25	WOS:000085951600050
J	Lee, DJ; Cox, D; Li, JC; Greenberg, S				Lee, DJ; Cox, D; Li, JC; Greenberg, S			Rad and Cdc42 are required for phagocytosis, but not NF-kappa B-dependent gene expression, in macrophages challenged with Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LISTERIA-MONOCYTOGENES INFECTION; BONE-MARROW MACROPHAGES; HUMAN ENDOTHELIAL-CELLS; TRANSCRIPTION FACTOR; MYCOBACTERIUM-TUBERCULOSIS; STAPHYLOCOCCUS-AUREUS; SIGNAL-TRANSDUCTION; NUCLEAR RESPONSES; HUMAN NEUTROPHILS; HUMAN MONOCYTES	Macrophages respond to Gram-negative bacterial pathogens by phagocytosis and pro-inflammatory gene expression. These responses may require GTPases that have been implicated in cytoskeletal alterations and activation of NF-kappa B. To determine the role of Rad and Cdc42 in signal transduction events triggered by Pseudomonas aeruginosa, we expressed GTP binding-deficient alleles of Rad or Cdc42, or Chim-GAP, a Rac1/Cdc42-specific GTPase-activating protein domain, in a subline of RAW 264.7 cells, and challenged the transfected cells with a laboratory strain of P. aeruginosa, PAO1. Expression of Rad N17, Cdc42 N17, or Chim-GAP led to a marked reduction of phagocytosis. In contrast, nuclear translocation of p65 NF-kappa B was unaffected by expression of the same constructs. Incubation of macrophages with PAO1 led to NF-kappa B-dependent expression of inducible nitric-oxide synthase, COX-2, and tumor necrosis factor-alpha, which was unaffected by inhibition of Rad or Cdc42 function. Isogenic strains of PAO1 that lacked surface adhesins were poorly ingested; however, they induced pro-inflammatory gene expression with an efficiency equal to that of PAO1, These results indicate that the signal transduction events leading to phagocytosis and pro-inflammatory protein expression are distinct. Rad and Cdc42 serve as effecters of phagocytosis, but not NF-kappa B-dependent gene expression, in the macrophage response to P. aeruginosa.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Pediat, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol PH8C, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Greenberg, S (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.			Cox, Dianne/0000-0002-0591-9767	NHLBI NIH HHS [HL54164] Funding Source: Medline; NIAID NIH HHS [AI42848] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Allen WE, 1997, J CELL SCI, V110, P707; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; BUSAM K, 1992, INFECT IMMUN, V60, P2008, DOI 10.1128/IAI.60.5.2008-2015.1992; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DRAKE D, 1988, J GEN MICROBIOL, V134, P43; Fasshauer M, 1998, EUR J CELL BIOL, V77, P188, DOI 10.1016/S0171-9335(98)80106-4; Filler SG, 1996, INFECT IMMUN, V64, P2609, DOI 10.1128/IAI.64.7.2609-2617.1996; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; Fulton SA, 1996, INFECT IMMUN, V64, P2523, DOI 10.1128/IAI.64.7.2523-2531.1996; GOODRUM KJ, 1995, INFECT IMMUN, V63, P3715, DOI 10.1128/IAI.63.9.3715-3717.1995; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; HAUF N, 1994, INFECT IMMUN, V62, P2740, DOI 10.1128/IAI.62.7.2740-2747.1994; Hauf N, 1997, P NATL ACAD SCI USA, V94, P9394, DOI 10.1073/pnas.94.17.9394; Kadurugamuwa JL, 1997, J ANTIMICROB CHEMOTH, V40, P615, DOI 10.1093/jac/40.5.615; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; MAHENTHIRALINGAM E, 1995, INFECT IMMUN, V63, P4519, DOI 10.1128/IAI.63.11.4519-4523.1995; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; McDonald PP, 1997, FEBS LETT, V412, P583, DOI 10.1016/S0014-5793(97)00857-0; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; MUROI M, 1994, J BIOL CHEM, V269, P30561; NOEL RF, 1995, INFECT IMMUN, V63, P4046, DOI 10.1128/IAI.63.10.4046-4053.1995; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWAN WR, 1994, P NATL ACAD SCI USA, V91, P6428, DOI 10.1073/pnas.91.14.6428; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHATTOCK RJ, 1994, J GEN VIROL, V75, P849, DOI 10.1099/0022-1317-75-4-849; SHIBATA Y, 1995, J IMMUNOL, V154, P2878; SPEERT DP, 1988, J CLIN INVEST, V82, P872, DOI 10.1172/JCI113692; Sporn LA, 1997, INFECT IMMUN, V65, P2786, DOI 10.1128/IAI.65.7.2786-2791.1997; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TANG H, 1995, INFECT IMMUN, V63, P1278, DOI 10.1128/IAI.63.4.1278-1285.1995; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; TEBO JM, 1994, J IMMUNOL, V153, P4713; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; TSITSIKOV EN, 1995, INT IMMUNOL, V7, P1665, DOI 10.1093/intimm/7.10.1665; Vollebregt M, 1998, FEBS LETT, V432, P40, DOI 10.1016/S0014-5793(98)00821-7; Wilson R, 1998, THORAX, V53, P213, DOI 10.1136/thx.53.3.213; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; YAO L, 1995, INFECT IMMUN, V63, P1835, DOI 10.1128/IAI.63.5.1835-1839.1995	50	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					141	146		10.1074/jbc.275.1.141	http://dx.doi.org/10.1074/jbc.275.1.141			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617597	hybrid			2022-12-25	WOS:000085951600021
J	Son, YJ; Scranton, TW; Sunderland, WJ; Baek, SJ; Miner, JH; Sanes, JR; Carlson, SS				Son, YJ; Scranton, TW; Sunderland, WJ; Baek, SJ; Miner, JH; Sanes, JR; Carlson, SS			The synaptic vesicle protein SV2 is complexed with an alpha 5-containing laminin on the nerve terminal surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; KERATAN SULFATE; NEUROMUSCULAR-JUNCTION; TRANSMEMBRANE TRANSPORTER; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; ENDOCRINE-CELLS; ELECTRIC ORGAN; COLLAGEN-IV; IDENTIFICATION	Interactions between growing axons and synaptic basal lamina components direct the formation of neuromuscular junctions during nerve regeneration. Isoforms of laminin containing alpha 5 or beta 2 chains are potential basal lamina ligands for these interactions. The nerve terminal receptors are unknown. Here we show that SV2, a synaptic vesicle transmembrane proteoglycan, is complexed with a 900-kDa laminin on synaptosomes from the electric organ synapse that is similar to the neuromuscular junctions. Although two laminins are present on synaptosomes, only the 900-kDa laminin is associated with SV2. Other nerve terminal components are absent from this complex. The 900-kDa laminin contains an a5, a beta 1, and a novel gamma chain. To test whether SV2 directly binds the 900-kDa laminin, we looked for interaction between purified SV2 and laminin-1, a laminin isoform with a similar structure. We find SV2 binds with high affinity to purified laminin-1. Our results suggest that a synaptic vesicle component may act as a laminin receptor on the presynaptic plasma membrane; they also suggest a mechanism for activity-dependent adhesion at the synapse.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; Washington University (WUSTL); Washington University (WUSTL)	Carlson, SS (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.				NINDS NIH HHS [NS22367] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTS B, 1994, MOL BIOL CELL, P1213; BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BAJJALIEH SM, 1993, P NATL ACAD SCI USA, V90, P2150, DOI 10.1073/pnas.90.6.2150; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BINDRA PS, 1993, GENE, V137, P299, DOI 10.1016/0378-1119(93)90024-W; BROWN GM, 1994, BIOCHEMISTRY-US, V33, P4836, DOI 10.1021/bi00182a012; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BUCKLEY KM, 1983, P NATL ACAD SCI-BIOL, V80, P7342, DOI 10.1073/pnas.80.23.7342; Carlson SS, 1996, PERSPECT DEV NEUROBI, V3, P373; CARLSON SS, 1978, BIOCHEMISTRY-US, V17, P1188, DOI 10.1021/bi00600a009; CARLSON SS, 1983, J BIOL CHEM, V258, P1082; COWAN D, 1990, BRAIN RES, V509, P1, DOI 10.1016/0006-8993(90)90301-Q; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; GINGRICH JA, 1992, FEBS LETT, V312, P115, DOI 10.1016/0014-5793(92)80917-6; GLICKSMAN MA, 1983, J NEUROCYTOL, V12, P661, DOI 10.1007/BF01181529; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HALL ZW, 1992, MOL NEUROBIOL, P90; HOCKFIELD S, 1993, MOL PROBES NERVOUS S; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; IWATA M, 1993, J NEUROSCI, V13, P195; IWATA M, 1991, J BIOL CHEM, V266, P323; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Janz R, 1998, J NEUROSCI, V18, P9269; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; KUSHNER PD, 1984, J NEUROCHEM, V43, P775, DOI 10.1111/j.1471-4159.1984.tb12799.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIM WA, 1991, METHOD ENZYMOL, V208, P196; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; MILJANICH GP, 1982, J CELL BIOL, V94, P88, DOI 10.1083/jcb.94.1.88; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; Nguyen QT, 1996, CURR OPIN NEUROBIOL, V6, P104, DOI 10.1016/S0959-4388(96)80015-8; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; Patton BL, 1998, NATURE, V393, P698, DOI 10.1038/31502; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SANES JR, 1983, ANNU REV PHYSIOL, V45, P581, DOI 10.1146/annurev.ph.45.030183.003053; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; SCRANTON TW, 1993, J NEUROCHEM, V61, P29, DOI 10.1111/j.1471-4159.1993.tb03535.x; Snow AD, 1996, EXP NEUROL, V138, P305, DOI 10.1006/exnr.1996.0069; STADLER H, 1982, EMBO J, V1, P1381, DOI 10.1002/j.1460-2075.1982.tb01326.x; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; YEAGER RE, 1987, J NEUROSCI, V7, P2390; [No title captured]	55	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					451	460		10.1074/jbc.275.1.451	http://dx.doi.org/10.1074/jbc.275.1.451			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617638	hybrid			2022-12-25	WOS:000085951600062
J	Francois, PP; Preissner, KT; Herrmann, M; Haugland, RP; Vaudaux, P; Lew, DP; Krause, KH				Francois, PP; Preissner, KT; Herrmann, M; Haugland, RP; Vaudaux, P; Lew, DP; Krause, KH			Vitronectin interaction with glycosaminoglycans - Kinetics, structural determinants, and role in binding to endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; S-PROTEIN VITRONECTIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; COAGULASE-NEGATIVE STAPHYLOCOCCI; MULTIMERIC VITRONECTIN; SELF-ASSOCIATION; AUREUS; IDENTIFICATION; ANTITHROMBIN; ADHESION	Vitronectin (VN) is a high affinity heparin-binding protein. The physiological role of this binding has hitherto received little attention, and its molecular determinants are subject to controversy. In this study, we characterized vitronectin interaction with heparin, heparin analogues, bacterial extracts, and cell surface glycosaminoglycans. As assessed by (i) fluorescence assays, (ii) precipitation with heparin-Sepharose beads, or (iii) Western blotting with antibodies against VN347-361 (the heparin-binding site), we demonstrate an exposure of the VN heparin-binding site in multimeric but not mo nomeric vitronectin. Through its heparin-binding site, vitronectin also bound other glycosaminoglycans and Staphylococcus aureus extracts. The kinetics of heparin binding to vitronectin were complex. After a fast association phase (tau = 0.3 s), a slow conversion of an unstable to a stable heparin-vitronectin complex (tau = 180 s) occurred. Heparin binding kinetics and transition to a stable complex were mimicked by VN347-361 demonstrating that this area is the fully functional heparin-binding site of vitronectin. Multimeric vitronectin bound to endothelial cells. This binding was blocked by soluble heparin and was not observed when endothelial cells were pretreated with glycosaminoglycan-removing enzymes. Glycosaminoglycan-dependent interaction of endothelial cells with multimeric vitronectin might be a relevant mechanism for removal of multimeric vitronectin from plasma. Conversion of an unstable to a stable glycosaminoglycan-vitronectin complex is likely to be relevant for association with endothelial cells under flow conditions.	Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Biol Aging Lab, CH-1211 Geneva, Switzerland; Max Planck Inst, Kerckhoff Klin, Haemostasis Res Unit, D-61231 Bad Nauheim, Germany; Mol Probes Inc, Eugene, OR 97402 USA; Univ Munster, Inst Med Microbiol, D-48129 Munster, Germany	University of Geneva; University of Geneva; Kerckhoff Clinic; Max Planck Society; University of Munster	Francois, PP (corresponding author), Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland.		Herrmann, Mathias/B-6475-2013; francois, patrice/AAL-5583-2020; Krause, Karl-Heinz/E-8030-2011	Herrmann, Mathias/0000-0003-2638-2257; Krause, Karl-Heinz/0000-0002-9033-6768; francois, patrice/0000-0002-0540-750X				BARLOW R, 1989, TRENDS PHARMACOL SCI, V10, P440, DOI 10.1016/S0165-6147(89)80006-9; BERGER W, 1994, BIOCHEMISTRY-US, V33, P11875, DOI 10.1021/bi00205a025; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHHATWAL GS, 1987, INFECT IMMUN, V55, P1878, DOI 10.1128/IAI.55.8.1878-1883.1987; COLLIEC S, 1991, THROMB RES, V64, P143, DOI 10.1016/0049-3848(91)90114-C; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; DEAGOSTINI AI, 1994, J CELL BIOCHEM, V54, P174, DOI 10.1002/jcb.240540206; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; Fay WP, 1999, BLOOD, V93, P1825, DOI 10.1182/blood.V93.6.1825.406k37_1825_1830; Gibson AD, 1999, J BIOL CHEM, V274, P6432, DOI 10.1074/jbc.274.10.6432; HEDMAN KS, 1983, CELL, V28, P663; Heilmann C, 1997, MOL MICROBIOL, V24, P1013, DOI 10.1046/j.1365-2958.1997.4101774.x; HESS S, 1995, THROMB HAEMOSTASIS, V74, P258; HUSSAIN M, 1992, J HOSP INFECT, V20, P173, DOI 10.1016/0195-6701(92)90085-Z; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JOZEFONVICZ J, 1990, Journal of Biomaterials Science Polymer Edition, V1, P147; JOZEFONVICZ J, 1992, PURE APPL CHEM, V64, P1783, DOI 10.1351/pac199264111783; KOST C, 1992, J BIOL CHEM, V267, P12098; LIANG OD, 1995, BBA-PROTEIN STRUCT M, V1250, P110, DOI 10.1016/0167-4838(95)00076-7; LIANG OD, 1994, J BIOCHEM-TOKYO, V116, P457, DOI 10.1093/oxfordjournals.jbchem.a124546; LIANG OD, 1993, BIOCHIM BIOPHYS ACTA, V1225, P57, DOI 10.1016/0925-4439(93)90122-H; Liang OD, 1997, FEBS LETT, V407, P169, DOI 10.1016/S0014-5793(97)00330-X; Lim BL, 1996, J BIOL CHEM, V271, P26739, DOI 10.1074/jbc.271.43.26739; MCGAVIN MH, 1993, INFECT IMMUN, V61, P2479, DOI 10.1128/IAI.61.6.2479-2485.1993; Patel JK., 1976, HDB STAT DISTRIBUTIO; PAULSSON M, 1992, J CLIN MICROBIOL, V30, P2006, DOI 10.1128/JCM.30.8.2006-2012.1992; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1990, NEW TRENDS HAEMOSTAS, P123; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; Schrenzel J, 1995, BIOPHYS J, V69, P2378, DOI 10.1016/S0006-3495(95)80107-4; Seiffert D, 1997, J BIOL CHEM, V272, P9971; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1988, BLOOD, V72, P903; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; Ueda H, 1998, J VET MED SCI, V60, P1169, DOI 10.1292/jvms.60.1169; VAUDAUX P, 1992, J BIOMAT SCI-POLYM E, V4, P89; Wells MJ, 1998, J BIOL CHEM, V273, P23440, DOI 10.1074/jbc.273.36.23440; Wilkins-Port CE, 1998, BBA-MOL CELL RES, V1404, P353, DOI 10.1016/S0167-4889(98)00076-7; Zhuang P, 1997, J BIOL CHEM, V272, P6858, DOI 10.1074/jbc.272.11.6858	43	32	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37611	37619		10.1074/jbc.274.53.37611	http://dx.doi.org/10.1074/jbc.274.53.37611			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608816	hybrid			2022-12-25	WOS:000084528000016
J	Meilinger, M; Gschwentner, C; Burger, I; Haumer, M; Wahrmann, M; Szollar, L; Nimpf, J; Huettinger, M				Meilinger, M; Gschwentner, C; Burger, I; Haumer, M; Wahrmann, M; Szollar, L; Nimpf, J; Huettinger, M			Metabolism of activated complement component C3 is mediated by the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA(2)-MACROGLOBULIN RECEPTOR; PSEUDOMONAS EXOTOXIN-A; ALPHA-2-MACROGLOBULIN RECEPTOR; RAT-LIVER; LACTOFERRIN; BINDING; LIGANDS; FAMILY; COMPLEXES; INHIBITOR	Complement component 3 (C3) and alpha(2)-macroglobulin evolved from a common, evolutionarily old, ancestor gene, Low density lipoprotein-receptor-related protein/alpha(2)-macroglobulin receptor (LRP/alpha(2)MR), a member of the low density lipoprotein receptor family, is responsible for the clearance of alpha(2)-macroglobulin-protease complexes. In this study, we examined whether C3 has conserved affinity for LRP/alpha(2)MR. Ligand blot experiments with human I-125-C3 On endosomal proteins show binding to a 600-kDa protein, indistinguishable from LRP/alpha(2)MR by the following criteria: it is competed by receptor-associated protein (the 39-kDa receptor-associated protein that impairs binding of all ligands to LRP/alpha 2MR) and by lactoferrin and Pseudomonas exotoxin, other well known ligands of the multifunctional receptor. Binding of C3 is sensitive to reduction of the receptor and is Ca2+-dependent. All these features are typical for cysteine-rich binding repeats of the low density lipoprotein receptor family. In LRP/alpha(2)MR, they are found in four cassettes (2, 8, 10, and 11 repeats), Ligand blotting to chicken LR8 demonstrates that a single 8-fold repeat is sufficient for binding. Confocal microscopy visualizes initial surface labeling of human fibroblasts incubated with fluorescent labeled C3, which changes after 5 min to an intracellular vesicular staining pattern that is abolished in the presence of receptor-associated protein, Cell uptake is abolished in mouse fibroblasts deficient in LRP/alpha(2)MR. Native plasma C3 is not internalized. We demonstrate that the capacity to internalize C3 is saturable and exhibits a K-D value of 17 nM. After intravenous injection, rat hepatocytes accumulate C3 in sedimentable vesicles with a density typical for endosomes. In conclusion, our ligand blot and uptake studies demonstrate the competence of the LRP/alpha(2)MR to bind and endocytose C3 and provide evidence for an LRP/alpha(2)MR-mediated system participating in C3 metabolism.	Univ Vienna, Dept Med Chem, A-1090 Vienna, Austria; Semmelweis Univ, Sch Med, Inst Pathophysiol, H-1089 Budapest, Hungary; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria	University of Vienna; Semmelweis University; University of Vienna	Huettinger, M (corresponding author), Univ Vienna, Dept Med Chem, Wahringerstr 10, A-1090 Vienna, Austria.			Wahrmann, Markus/0000-0002-1301-8694; Nimpf, Johannes/0000-0002-9273-3492				ARMSTRONG PB, 1993, MOL IMMUNOL, V30, P929, DOI 10.1016/0161-5890(93)90017-6; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; GETTINS PGW, 1993, FEBS LETT, V332, P211, DOI 10.1016/0014-5793(93)80633-6; GOLDENBERG H, 1991, BIOCHIM BIOPHYS ACTA, V1067, P145, DOI 10.1016/0005-2736(91)90036-8; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; JANATOVA J, 1988, METHOD ENZYMOL, V162, P579; JENSEN LS, 1985, P NATL ACAD SCI USA, V82, P9; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAMBRIS JD, 1994, ANN NY ACAD SCI, V712, P354, DOI 10.1111/j.1749-6632.1994.tb33593.x; Maslowska M, 1997, J LIPID RES, V38, P1; MAVROIDIS M, 1995, J IMMUNOL, V154, P2164; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NIMPF J, 1994, ANN NY ACAD SCI, V737, P145, DOI 10.1111/j.1749-6632.1994.tb44308.x; PANGBURN MK, 1992, J BIOL CHEM, V267, P8584; REID KBM, 1993, METHOD ENZYMOL, V223, P1; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; Sniderman AD, 1998, ARTERIOSCL THROM VAS, V18, P147, DOI 10.1161/01.ATV.18.2.147; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	31	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38091	38096		10.1074/jbc.274.53.38091	http://dx.doi.org/10.1074/jbc.274.53.38091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608878	hybrid			2022-12-25	WOS:000084528000078
J	Oh, S; Song, Y; Yim, J; Kim, TK				Oh, S; Song, Y; Yim, J; Kim, TK			The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; NORMAL HUMAN-CELLS; CELLULAR SENESCENCE; LIFE-SPAN; WT1; CANCER; HUMAN-CHROMOSOME-3; IMMORTALIZATION; MUTATIONS; MECHANISM	Regulation of the human telomerase reverse transcriptase (hTERT) gene is the primary determinant for telomerase enzyme activity, which is found in tumor cells but is largely absent from normal somatic cells. Recent studies have shown that Myc protein can transcriptionally activate the hTERT gene. However, little is known about the repression mechanism of the hTERT gene and telomerase enzyme. Here, we developed an expression cloning strategy to identify cDNAs whose products can repress hTERT promoter activity in telomerase-positive immortal cells. Using this screen, we isolated the Wilms' tumor 1 suppressor gene (WT1), WT1 can repress hTERT promoter activity in 293 kidney cells. The WT1 binding site on the hTERT promoter was identified by deletional analysis. Alteration of the WT1 binding site markedly derepresses transcription from an isolated hTERT promoter by inhibiting interaction of WT1 with DNA. These specific repression effects of WT1 were not observed in HeLa cells, which express no endogenous WT1. Furthermore, we show that WT1 can repress the endogenous hTERT promoter and telomerase enzyme activities. These results suggest that WT1 may be a transcriptional repressor of the hTERT gene, at least in some specific cells.	Seoul Natl Univ, Natl Creat Res Initiat Ctr Genet Reprogramming, Inst Mol Biol & Genet, Seoul 151742, South Korea; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA	Seoul National University (SNU); Harvard University; Harvard Medical School	Kim, TK (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr Genet Reprogramming, Inst Mol Biol & Genet, Seoul 151742, South Korea.	TK_Kim@hms.harvard.edu						Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Guan LS, 1998, J BIOL CHEM, V273, P27047, DOI 10.1074/jbc.273.42.27047; HABER DA, 1992, NEW BIOL, V4, P97; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Horikawa I, 1998, MOL CARCINOGEN, V22, P65, DOI 10.1002/(SICI)1098-2744(199806)22:2<65::AID-MC1>3.0.CO;2-J; Horikawa I, 1999, CANCER RES, V59, P826; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OGATA T, 1995, JPN J CANCER RES, V86, P35, DOI 10.1111/j.1349-7006.1995.tb02985.x; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; Rauscher FJ, 1997, CURR TOP MICROBIOL, V220, P151; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; Takakura M, 1999, CANCER RES, V59, P551; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010	36	121	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37473	37478		10.1074/jbc.274.52.37473	http://dx.doi.org/10.1074/jbc.274.52.37473			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601322	hybrid			2022-12-25	WOS:000084382700093
J	Snouwaert, JN; Gowen, LC; Latour, AM; Mohn, AR; Xiao, A; DiBiase, L; Koller, BH				Snouwaert, JN; Gowen, LC; Latour, AM; Mohn, AR; Xiao, A; DiBiase, L; Koller, BH			BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a Brca1 transgene	ONCOGENE			English	Article						BRCA1 proteins; homologous recombination; ES cells; DNA repair; non-homologous recombination	DOUBLE-STRAND BREAK; MURINE BRCA1; TRANSCRIPTIONAL ACTIVATION; NUCLEAR PHOSPHOPROTEIN; OVARIAN-CANCER; MEIOTIC CELLS; DNA-DAMAGE; GENE BRCA1; MOUSE; REPAIR	BRCA1 is a nuclear phosphoprotein that has been classified as a tumor suppressor based on the fact that women carrying a mutated copy of the BRCA1 gene are at increased risk of developing breast and ovarian cancer. The association of BRCA1 with RAD51 has led to the hypothesis that BRCA1 is involved in DNA repair. We describe here the generation and analysis of murine embryonic stem (ES) cell lines in which both copies of the murine homologue of the human BRCA1 gene have been disrupted by gene targeting. We show that exogenous DNA introduced into these BRCA1 deficient cells by electroporation is randomly integrated into the genome at a significantly higher rate than in wild type ES cells. In contrast, integration of exogenous DNA by homologous recombination occurs in BRCA1 deficient cells at a significantly lower rate than in wild type controls. When BRCA1 expression is re-established at 5-10% of normal levels by introduction of a Brca1 transgene into BRCA1 deficient ES cells, the frequency of random integration is reduced to wild type levels, although the frequency of homologous recombination is not significantly improved. These results suggest that BRCA1 plays a role in determining the response of cells to double stranded DNA breaks.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Koller, BH (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.			Morton, Lori/0000-0002-5214-5784; Ramsey, Amy/0000-0002-2717-5279	NCI NIH HHS [CA82423] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082423] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; EASTON DF, 1993, AM J HUM GENET, V52, P678; Game J., 1983, YEAST GENETICS FUNDA, P109; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Larson JS, 1997, CANCER RES, V57, P3351; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOHN A, 1995, DNA CLONING, V4, P143; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Snouwaert JN, 1998, CURRENT TOPICS ON BRCA1, P33, DOI 10.3233/BD-1998-101-206; Templeton NS, 1997, GENE THER, V4, P700, DOI 10.1038/sj.gt.3300457; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zabludoff SD, 1996, ONCOGENE, V13, P649; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	49	164	165	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7900	7907		10.1038/sj.onc.1203334	http://dx.doi.org/10.1038/sj.onc.1203334			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630642				2022-12-25	WOS:000084405900006
J	Lo, PK; Chen, JY; Lo, WC; Chen, BF; Hsin, JP; Tang, PP; Wang, FF				Lo, PK; Chen, JY; Lo, WC; Chen, BF; Hsin, JP; Tang, PP; Wang, FF			Identification of a novel mouse p53 target gene DDA3	ONCOGENE			English	Article						p53; growth suppression; DDA3	WILD-TYPE P53; DNA-DAMAGE; P53-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAIN; PROTEIN; INHIBITOR; GROWTH; CELLS; CHECKPOINT	We have identified a novel p53 regulated gene designated DDA3 through differential mRNA display on IW32 erythroleukemia cells containing a temperature sensitive p53 allele, tsp53val-135. DDA3 mRNA induction could be observed in all sublines expressing tsp53val-135 cultured at permissive temperature as well as in NIH3T3 cells undergoing DNA damage. Upregulation of DDA3 could be detected within 2 h after down-shifting the temperature to 32.5 degrees C; upon shifting back to 38.5 degrees C, DDA3 mRNA rapidly degraded with a half-life of less than 2 h. Actinomycin D, but not cycloheximide, inhibited the p53 dependent DDA3 induction, suggesting that the activation is through transcriptional regulation and does not require de novo protein synthesis. DDA3 was expressed in multiple mouse tissues including brain, spleen, lung, kidney and testis. Full-length DDA3 cDNA was cloned and it contained an open reading frame predicted to encode a proline rich protein of 329 amino acids. Overexpression of DDA3 in H1299 lung carcinoma cells suppressed colony formation. These results suggest that DDA3 is a p53-regulated gene that might participate in the p53-mediated growth suppression.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Mackay Mem Hosp, Dept Pathol, Taipei 104, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Mackay Memorial Hospital	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.		Chen, Joanne Jeou-Yuan/S-7022-2018					Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHOPPIN J, 1984, BLOOD, V64, P341; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISRAELI D, 1997, EMBO J, V16, P4382; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405	48	37	41	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7765	7774		10.1038/sj.onc.1203167	http://dx.doi.org/10.1038/sj.onc.1203167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618717				2022-12-25	WOS:000084256900006
J	Budunova, IV; Perez, P; Vaden, VR; Spiegelman, VS; Slaga, TJ; Jorcano, JL				Budunova, IV; Perez, P; Vaden, VR; Spiegelman, VS; Slaga, TJ; Jorcano, JL			Increased expression of p50-NF-kappa B and constitutive activation of NF-kappa B transcription factors during mouse skin carcinogenesis	ONCOGENE			English	Article						NF-kappa B factors; I kappa B proteins; skin carcinogenesis	DNA-BINDING; ONCOPROTEIN BCL-3; P50 HOMODIMERS; PRECURSOR P105; REL-FAMILY; NUCLEAR-LOCALIZATION; P65 SUBUNIT; PROTEINS; CELLS; ALPHA	To elucidate the possible role of NF-kappa B in mouse skin carcinogenesis we studied the expression of p50 (NF-kappa B1), p52 (NF-kappa B2), p65 (ReIA) and I kappa B-alpha inhibitor as well as kappa B-binding activity in adult SENCAR mouse skin, skin papillomas, and squamous cell carcinomas (SCC) generated by a two-stage carcinogenesis protocol. We found that in normal epidermis all of the above proteins were mostly expressed in the cytoplasm of basal cells. Western blot analysis revealed a dramatic increase of p50 and p52 expression in mouse skin tumors starting from the middle stage of promotion. We also found that the level of I kappa B-alpha protein in many late papillomas and see was lower than in normal epidermis, Results of EMSA showed an increase in kappa B-binding activity in mouse skin tumors and suggested that p50 is the major component of constitutive kappa B-binding complexes in normal epidermis and in tumors. It has been shown that nuclear I kappa B protein Bcl-3 is able to increase p50/p50 homodimer binding to the different kappa B sites in mouse thymocytes. Our finding on Bcl-3 overexpression in late papillomas and SCC could explain the selective increase of p50-related kappa B-binding in mouse skin tumors, Thus, our results strongly suggest the important role of p50 in skin carcinogenesis.	AMC Canc Res Ctr, Denver, CO 80214 USA; CIEMAT, Dept Mol & Cell Biol, E-28040 Madrid, Spain	AMC Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Budunova, IV (corresponding author), AMC Canc Res Ctr, 1600 Pierce St, Denver, CO 80214 USA.		Perez, Paloma/K-8841-2017	Perez, Paloma/0000-0002-7166-2824; Spiegelman, Vladimir S/0000-0003-4847-155X	NATIONAL CANCER INSTITUTE [R01CA079065] Funding Source: NIH RePORTER; NCI NIH HHS [CA79065-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALMAIN A, 1982, NUCLEIC ACIDS RES, V10, P4259, DOI 10.1093/nar/10.14.4259; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Binder RL, 1998, CANCER RES, V58, P4314; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gilmore TD, 1996, ONCOGENE, V13, P1367; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE J, 1993, ONCOGENE, V8, P2067; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Karin M, 1998, CANCER J SCI AM, V4, pS92; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KOONG AC, 1994, CANCER RES, V54, P5273; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Leveillard Thierry, 1993, Gene Expression, V3, P135; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Slaga T J, 1995, Prog Clin Biol Res, V391, P1; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Tobin D, 1996, ONCOGENE, V12, P785; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WATANABE M, 1993, ONCOGENE, V8, P2949; WEIH F, 1994, ONCOGENE, V9, P3289; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058	53	110	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7423	7431		10.1038/sj.onc.1203104	http://dx.doi.org/10.1038/sj.onc.1203104			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602501				2022-12-25	WOS:000084119600003
J	Gavine, PR; Neil, JC; Crouch, DH				Gavine, PR; Neil, JC; Crouch, DH			Protein stabilization: a common consequence of mutations in independently derived v-Myc alleles	ONCOGENE			English	Article						Myc; viral mutations; stabilization	ALPHA IN-VIVO; C-MYC; TRANSFORMING ACTIVITY; INDUCED DEGRADATION; PROTEASOME PATHWAY; TERMINAL REGION; PHOSPHORYLATION; DOMAIN; MYOD; FOS	Myc is overexpressed in many cancers as a result of gene rearrangement or amplification, but coding sequence changes which cluster in the N-terminal transactivation domain also appear to play a role in tumour progression. The prototypic v-Myc gene of MC29 virus differs from avian c-Myc by a series of mutations, including a change at a regulatory phosphorylation site within the mutational hotspot (thr-61) which is known to potentiate transformation in vitro. We now show that the mutation at thr-61 stabilizes the v-Myc protein (turnover difference) and that this single mutation is both necessary and sufficient for the phenotype. A major involvement of the proteasome in Myc degradation was confirmed, but surprisingly, a dilysine motif adjacent to thr-61 proved not to be the ubiquitin target. Two other v-Myc genes which carry a mutation at thr-61 (avian MH2) or a large deletion encompassing this domain (feline T17) were found to be stabilized to a similar extent as MC29, showing that stabilization is a common feature of independently derived Myc oncogenes, These results suggest a common selective process in the genesis of these three viral oncoproteins and a mechanistic link with Jun, Fos and Myb oncoproteins which are also stabilized relative to their cellular counterparts.	Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland; Univ Glasgow, Sch Vet, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland	University of Dundee; University of Glasgow	Crouch, DH (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland.							Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Chen RH, 1996, ONCOGENE, V12, P1493; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COLL J, 1983, EMBO J, V12, P2189; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; CROUCH DH, 1990, ONCOGENE, V5, P683; CROUCH DH, 1993, ONCOGENE, V8, P1849; CURRAN T, 1984, CELL, V36, P259; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; FULTON R, 1996, J VIROL, V170, P1154; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; Kilbey A, 1996, ONCOGENE, V12, P2409; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PULVERER BJ, 1994, ONCOGENE, V9, P59; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	37	16	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7552	7558		10.1038/sj.onc.1203102	http://dx.doi.org/10.1038/sj.onc.1203102			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602514				2022-12-25	WOS:000084119600016
J	Langford, GM				Langford, GM			ER transport on actin filaments in squid giant axon: implications for signal transduction at synapse	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		BRAIN MYOSIN-V; LOCALIZATION; ORGANELLES; MOVEMENT; MOTILITY	The smooth endoplasmic reticulum (SER) is transported on actin filaments in the giant axon of the squid, The identity of the myosin motors that transport S-ER in the squid giant axon has been determined, Our recent studies have shown that the motor for movement of S-ER vesicles on actin filaments is Myosin-V (1), These findings grew out of a series of studies that began with the initial observation that vesicles in the giant axon of the squid move on both microtubules and actin filaments (2). These initial studies documented the ability of individual vesicles to move from microtubules to actin filaments and led to the development of the dual filament model of vesicle transport (3, 4), The model proposes that long-range movement of vesicles occurs on microtubules and short-range movement: on actin filaments. S-ER vesicles were identified as the major population of vesicles in the axon that use myosin-V for movement on actin filaments. The S-ER is the primary site of calcium storage, and it regulates the local cytosolic calcium concentration. Calcium release from the S-ER iu neurons couples electrical excitation to signal transduction cascades, The signaling cascades triggered by the release of calcium from S-ER in dendritic spines are postulated to initiate the cellular mechanisms that lead to learning and memory.	Dartmouth Coll, Dept Biol Sci, Gilman Lab 6044, Hanover, NH 03755 USA	Dartmouth College	Langford, GM (corresponding author), Dartmouth Coll, Dept Biol Sci, Gilman Lab 6044, Hanover, NH 03755 USA.			Langford, George/0000-0001-9737-2182	PHS HHS [9842948, 9506279] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; DekkerOhno K, 1996, BRAIN RES, V714, P226, DOI 10.1016/0006-8993(95)01560-4; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Finch EA, 1998, NATURE, V396, P753, DOI 10.1038/25541; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; KUZNETSOV SA, 1994, CELL MOTIL CYTOSKEL, V28, P231, DOI 10.1002/cm.970280306; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; Langford GM, 1998, BRAIN RES REV, V28, P1, DOI 10.1016/S0165-0173(98)00020-4; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; Molyneaux BJ, 1997, BIOL BULL, V193, P222, DOI 10.1086/BBLv193n2p222; Svoboda K, 1999, NEURON, V22, P427, DOI 10.1016/S0896-6273(00)80698-4; Tabb JS, 1998, J CELL SCI, V111, P3221; Tabb JS, 1996, BIOL BULL, V191, P274, DOI 10.1086/BBLv191n2p274; Takechi H, 1998, NATURE, V396, P757, DOI 10.1038/25547; WOLENSKI JS, 1995, J CELL SCI, V108, P1489	16	9	10	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S248	S250		10.1096/fasebj.13.9002.S248	http://dx.doi.org/10.1096/fasebj.13.9002.S248			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619137				2022-12-25	WOS:000084390200015
J	Baoutina, A; Dean, RT; Jessup, W				Baoutina, A; Dean, RT; Jessup, W			Macrophages can decrease the level of cholesteryl ester hydroperoxides in low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN-DIPLOID FIBROBLASTS; HORMONE-SENSITIVE LIPASE; ALPHA-TOCOPHEROL; LIPID HYDROPEROXIDES; PHOSPHOLIPID HYDROPEROXIDE; MEDIATED OXIDATION; PEROXIDATION; COPPER; LDL	Murine and human macrophages rapidly decreased the level of cholesteryl ester hydroperoxides in low density lipoprotein (LDL) when cultured in media non-permissive for LDL oxidation. This process was proportional to cell number but could not be attributed to the net lipoprotein uptake. Macrophage-mediated loss of lipid hydroperoxides in LDL appears to be metal ion-independent. Degradation of cholesteryl linoleate hydroperoxides was accompanied by accumulation of the corresponding hydroxide as the major product and cholesteryl keto-octadecadienoate as a minor product, although taken together these products could not completely account for the hydroperoxide consumption. Cell-conditioned medium possessed a similar capacity to remove lipid hydroperoxides as seen with cellular monolayers, suggesting that the activity is not an integral component of the cell but is secreted from it. The activity of cell-conditioned medium to lower the level of LDL lipid hydroperoxides is associated with its high molecular weight fraction and is modulated by the availability of free thiol groups. Cell-mediated loss of LDL cholesteryl ester hydroperoxides is facilitated by the presence of alpha-tocopherol in the lipoprotein. Together with our earlier reports on the ability of macrophages to remove peroxides rapidly from oxidized amino acids, peptides, and proteins as well as to clear selectively cholesterol 7-beta-hydroperoxide, results presented in this paper provide evidence of a potential protective activity of the cell against further LDL oxidation by removing reactive peroxide groups in the lipoprotein.	Heart Res Inst, Cell Biol Grp, Camperdown, NSW 2050, Australia	University of Sydney; Heart Research Institute	Baoutina, A (corresponding author), Heart Res Inst, Cell Biol Grp, 145 Missenden Rd, Camperdown, NSW 2050, Australia.	a.baoutina@hri.org.au		Dean, Roger Thornton/0000-0002-8859-8902				BANNAI S, 1980, J CELL PHYSIOL, V104, P215, DOI 10.1002/jcp.1041040211; BANNAI S, 1982, J CELL PHYSIOL, V112, P265, DOI 10.1002/jcp.1041120216; Bao Y, 1997, REDOX REP, V3, P325, DOI 10.1080/13510002.1997.11747130; Baoutina A, 1998, J LIPID RES, V39, P114; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BROOKS CJW, 1971, ATHEROSCLEROSIS, V13, P223, DOI 10.1016/0021-9150(71)90025-6; CONTRERAS JA, 1994, ARTERIOSCLER THROMB, V14, P443, DOI 10.1161/01.ATV.14.3.443; Creighton Thomas E., 1992, P301; DEGRAY JA, 1995, BIOTHIOLS HLTH DIS, P65; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; Follmann H, 1995, BIOFACTORS, V5, P147; FU SL, 1995, BIOCHEM J, V311, P821, DOI 10.1042/bj3110821; Garner B, 1997, J BIOL CHEM, V272, P6927, DOI 10.1074/jbc.272.11.6927; GARNER B, 1994, BIOCHEM J, V301, P421, DOI 10.1042/bj3010421; Garner B, 1996, REDOX REP, V2, P97, DOI 10.1080/13510002.1996.11747035; GROSCH W, 1976, Z LEBENSM UNTERS FOR, V160, P371, DOI 10.1007/BF01106327; Hazell LJ, 1997, FEBS LETT, V414, P541, DOI 10.1016/S0014-5793(97)01066-1; Hurst R, 1999, BIOCHEM J, V338, P723, DOI 10.1042/0264-6021:3380723; IWATSUKI M, 1995, FEBS LETT, V360, P271, DOI 10.1016/0014-5793(95)00122-P; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; JOKAY I, 1988, IMMUNOL LETT, V17, P217, DOI 10.1016/0165-2478(88)90032-6; KHOO JC, 1993, J LIPID RES, V34, P1969; KNIGHT BL, 1982, BIOCHEM J, V202, P145, DOI 10.1042/bj2020145; KOHAR I, 1995, FREE RADICAL BIO MED, V19, P197, DOI 10.1016/0891-5849(95)00010-U; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; KRITHARIDES L, 1995, ARCH BIOCHEM BIOPHYS, V323, P127, DOI 10.1006/abbi.1995.0018; Li F, 1997, J BIOL CHEM, V272, P28666, DOI 10.1074/jbc.272.45.28666; MAIORINO M, 1995, BIOTHIOLS HLTH DIS, P265; Mashima R, 1999, BIOCHEM BIOPH RES CO, V259, P185, DOI 10.1006/bbrc.1999.0739; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; Niu XW, 1999, ARTERIOSCL THROM VAS, V19, P1708, DOI 10.1161/01.ATV.19.7.1708; NOGUCHI N, 1994, BBA-LIPID LIPID MET, V1213, P176, DOI 10.1016/0005-2760(94)90024-8; OLEARY VJ, 1992, BIOCHEM J, V282, P631, DOI 10.1042/bj2820631; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SATTLER W, 1994, ARCH BIOCHEM BIOPHYS, V309, P214, DOI 10.1006/abbi.1994.1105; SATTLER W, 1995, FREE RADICAL BIO MED, V18, P421, DOI 10.1016/0891-5849(94)00170-O; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Smalley DM, 1997, ARTERIOSCL THROM VAS, V17, P3469, DOI 10.1161/01.ATV.17.12.3469; SPARROW CP, 1993, J LIPID RES, V34, P1219; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; SUZUKAWA M, 1994, ATHEROSCLEROSIS, V110, P77, DOI 10.1016/0021-9150(94)90070-1; THOMAS CE, 1991, J PHARMACOL EXP THER, V256, P1182; THOMAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1045, P252, DOI 10.1016/0005-2760(90)90128-K; van Reyk DM, 1999, ARTERIOSCL THROM VAS, V19, P1119, DOI 10.1161/01.ATV.19.4.1119; VANREYK DM, 1995, FREE RADICAL RES, V23, P533, DOI 10.3109/10715769509065274; Witting PK, 1999, METHOD ENZYMOL, V299, P362; Wollman EE, 1997, BIOCHEM BIOPH RES CO, V230, P602, DOI 10.1006/bbrc.1996.6015; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3	52	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1635	1644		10.1074/jbc.275.3.1635	http://dx.doi.org/10.1074/jbc.275.3.1635			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636856	hybrid			2022-12-25	WOS:000084940000019
J	Bourguignon, LYW; Zhu, HB; Shao, LJ; Chen, YW				Bourguignon, LYW; Zhu, HB; Shao, LJ; Chen, YW			CD44 interaction with Tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; HOMING RECEPTOR CD44; MEMBRANE-CYTOSKELETON INTERACTION; PLECKSTRIN HOMOLOGY DOMAIN; ANKYRIN-BINDING DOMAIN; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; PROTEIN-KINASE-C; GROWTH-FACTOR; EPITHELIAL-CELLS	In this study we have explored the interaction between CD44 (the hyaluronic acid (HA)-binding receptor) and Tiam1 (a guanine nucleotide exchange factor) in metastatic breast tumor cells (SP1 cell line). Immunoprecipitation and immunoblot analyses indicate that both the CD44v3 isoform and the Tiam1 protein are expressed in SP1 cells and that these two proteins are physically associated as a complex in vivo. Using an Escherichia coli-derived calmodulin-binding peptide-tagged Tiam1 fragment (i.e. the NH2-terminal pleckstrin homology (PHn) domain and an adjacent protein interaction domain designated as PHn-CC-Ex, amino acids 393-738 of Tiam1) and an in vitro binding assay, we have detected a specific binding interaction between the Tiam1 PHn-CC-Ex domain and CD44. Scatchard plot analysis indicates that there is a single high affinity CD44 binding site in the PHn-CC-Ex domain of Tiam1 with an apparent dissociation constant (K-d) Of 0.2 nM, which is comparable with CD44 binding (K-d = similar to 0.13 nM) to intact Tiam1, These findings suggest that the PHn-CC-Ex domain is the primary Tiam1-binding region for CD44, Most importantly, the binding of HA to CD44v3 of SP1 cells stimulates Tiam1-catalyzed Rad signaling and cytoskeleton-mediated tumor cell migration. Transfection of SP1 cells with Tiam1cDNA promotes Tiam1 association with CD44v3 and up-regulates Rad signaling as well as HA/CD44v3-mediated breast tumor cell migration. Co-transfection of SP1 cells with PHn-CC-Ex cDNA and Tiam1 cDNA effectively inhibits Tiam1 association with CD44 and efficiently blocks tumor behaviors. Taken together, we believe that the linkage between CD44v3 isoform and the PHn-CC-EX domain of Tiam1 is required for HA stimulated Rad signaling and cytoskeleton-mediated tumor cell migration during breast cancer progression.	Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL 33136 USA	University of Miami	Bourguignon, LYW (corresponding author), Univ Miami, Sch Med, Dept Anat & Cell Biol, 1600 NW 10th Ave, Miami, FL 33136 USA.				NCI NIH HHS [CA66163, CA 78633] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066163, R01CA078633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Bourguignon L. Y. W., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P196; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; Bourguignon LYW, 1995, J NEURO-ONCOL, V26, P201, DOI 10.1007/BF01052623; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408; DICKSON RB, 1995, MOL BASIS CANC, P358; ELLIOTT BE, 1988, CANCER RES, V48, P7237; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1998, FEBS LETT, V429, P229, DOI 10.1016/S0014-5793(98)00566-3; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAO M, 1996, J CELL BIOL, V135, P36; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HORST E, 1990, LEUKEMIA, V4, P595; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; JALKANEN S, 1991, J CLIN INVEST, V87, P1835, DOI 10.1172/JCI115205; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JIANG WG, 1994, BRIT J SURG, V81, P1576, DOI 10.1002/bjs.1800811107; JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609; KALISH ED, 1999, FRONT BIOSCI, V4, P1; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIAO HX, 1995, J IMMUNOL, V155, P3938; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUELLER SC, 1991, J CELL SCI, V99, P213; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZ C, 1995, INT J CANCER, V64, P347, DOI 10.1002/ijc.2910640512; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sinn Hans-Peter, 1995, Breast Cancer Research and Treatment, V36, P307, DOI 10.1007/BF00713402; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; UNDERHILL CB, 1987, J BIOL CHEM, V262, P13142; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; ZHANG Y, 1995, METHOD ENZYMOL, V256, P77; Zhu D, 1996, ONCOGENE, V12, P2309; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	68	244	267	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1829	1838		10.1074/jbc.275.3.1829	http://dx.doi.org/10.1074/jbc.275.3.1829			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636882	hybrid			2022-12-25	WOS:000084940000045
J	Tsuchiya, K; Yoshizumi, M; Houchi, H; Mason, RP				Tsuchiya, K; Yoshizumi, M; Houchi, H; Mason, RP			Nitric oxide-forming reaction between the iron-N-methyl-D-glucamine dithiocarbamate complex and nitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; MICE IN-VIVO; BAND EPR SPECTROSCOPY; SEPTIC-SHOCK MICE; L-ARGININE; RELAXING FACTOR; REPERFUSION INJURY; ANIMAL-TISSUES; RAT; GENERATION	The objective of this study was to elucidate the origin of the nitric oxide-forming reactions from nitrite in the presence of the iron-N-methyl-D-glucamine dithiocarbamate complex ((MGD)(2)Fe2+). The (MGD)(2)Fe2+ complex is commonly used in electron paramagnetic resonance (EPR) spectroscopic detection of NO both in vivo and in vitro. Although it is widely believed that only NO can react with (MGD)(2)Fe2+ complex to form the (MGD)(2)Fe2+. NO complex, a recent article reported that the (MGD)(2)Fe2+ complex can react not only with NO, but also with nitrite to produce the characteristic triplet EPR signal of (MGD)(2)Fe2+. NO (Hiramoto, K., Tomiyama, S., and Kikugawa, K. (1997) Free Radical Res, 27, 505-509). However, no detailed reaction mechanisms were given. Alternatively, nitrite is considered to be a spontaneous NO donor, especially at acidic pH values (Samouilov, A, Kuppusamy, P., and Zweier, J. L. (1998) Arch Biochem, Biophys. 357, 1-7). However, its production of nitric oxide at physiological pH is unclear. In this report, we demonstrate that the (MGD)(2)Fe2+ complex and nitrite reacted to form NO as follows: 1) (MGD)(2)Fe2+. NO complex was produced at pH 7.4; 2) concomitantly, the (MGD)(2)Fe3+ complex, which is the oxidized form of (MGD)Fe-2(2+), was formed; 3) the rate of formation of the (MGD)(2)Fe2+. NO complex was a function of the concentration of [Fe2+](2), [MGD], [H+] and [nitrite].	NIEHS, Free Rad Metabolite Sect, Lab Pharmacol & Chem, Natl Inst Hlth, Res Triangle Pk, NC 27709 USA; Univ Tokushima, Sch Med, Dept Pharmacol, Tokushima 770, Japan; Univ Tokushima, Sch Med, Dept Pharm, Tokushima 770, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Tokushima University; Tokushima University	Tsuchiya, K (corresponding author), NIEHS, Free Rad Metabolite Sect, Lab Pharmacol & Chem, Natl Inst Hlth, FO-02, Res Triangle Pk, NC 27709 USA.	tsuchiya@niehs.nih.gov	Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050141] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; ARROYO CM, 1991, FREE RADICAL RES COM, V14, P145, DOI 10.3109/10715769109094127; BECHTHOLD PS, 1981, OPT COMMUN, V36, P373, DOI 10.1016/0030-4018(81)90245-5; Beckman JS, 1996, METHODS NITRIC OXIDE, P61; Doi K, 1996, CANCER-AM CANCER SOC, V77, P1598, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1598::AID-CNCR3>3.0.CO;2-A; FORMAN D, 1985, NATURE, V313, P620, DOI 10.1038/313620a0; Fujii H, 1998, PHYS MED BIOL, V43, P1949, DOI 10.1088/0031-9155/43/7/016; Fujii H, 1997, MAGN RESON MED, V38, P565, DOI 10.1002/mrm.1910380410; Fujii S, 1998, AM J PHYSIOL-GASTR L, V274, pG857, DOI 10.1152/ajpgi.1998.274.5.G857; GREENBERG SS, 1990, CIRC RES, V67, P1446, DOI 10.1161/01.RES.67.6.1446; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hiramoto K, 1997, FREE RADICAL RES, V27, P505, DOI 10.3109/10715769709065790; HOLTZMAN JL, 1968, BIOCHEM J, V110, P407, DOI 10.1042/bj1100407; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Ishiwata H., 1975, Journal of the Food Hygienic Society of Japan [Shokuhin Eiseigaku Zasshi], V16, P89; James PE, 1998, ADV EXP MED BIOL, V454, P181; Jiang JJ, 1997, MOL PHARMACOL, V52, P1081, DOI 10.1124/mol.52.6.1081; JOSEPH J, 1993, BIOCHEM BIOPH RES CO, V192, P926, DOI 10.1006/bbrc.1993.1504; Kamisaki Y, 1997, BBA-MOL BASIS DIS, V1362, P24, DOI 10.1016/S0925-4439(97)00052-5; KOMAROV A, 1993, BIOCHEM BIOPH RES CO, V195, P1191, DOI 10.1006/bbrc.1993.2170; Komarov AM, 1997, BBA-MOL BASIS DIS, V1361, P229, DOI 10.1016/S0925-4439(97)84636-4; KOMAROV AM, 1995, BBA-MOL BASIS DIS, V1272, P29, DOI 10.1016/0925-4439(95)00061-8; KORTH HG, 1994, J AM CHEM SOC, V116, P2767, DOI 10.1021/ja00086a010; Kotake Y, 1999, NITRIC OXIDE-BIOL CH, V3, P114, DOI 10.1006/niox.1999.0214; KUBRINA LN, 1993, BIOCHIM BIOPHYS ACTA, V1176, P240, DOI 10.1016/0167-4889(93)90050-Y; KUBRINA LN, 1992, BIOCHIM BIOPHYS ACTA, V1099, P233, DOI 10.1016/0304-4173(92)90033-B; KUBRINA LN, 1989, B EXP BIOL MED+, V107, P35, DOI 10.1007/BF00837051; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; Laursen JB, 1996, CIRCULATION, V94, P2241, DOI 10.1161/01.CIR.94.9.2241; Lecour S, 1999, J CARDIOVASC PHARM, V33, P78, DOI 10.1097/00005344-199901000-00012; Mikoyan V. D., 1994, Biokhimiya, V59, P732; Mikoyan VD, 1997, BIOFIZIKA+, V42, P490; MIKOYAN VD, 1994, BIOFIZIKA+, V39, P919; MIKOYAN VD, 1994, BIOCHEM MOL BIOL INT, V32, P1157; MIKOYAN VD, 1995, BBA-MOL CELL RES, V1269, P19, DOI 10.1016/0167-4889(95)00092-7; MIKOYAN VD, 1994, BIOFIZIKA+, V39, P915; Mikoyan VD, 1997, BBA-GEN SUBJECTS, V1336, P225, DOI 10.1016/S0304-4165(97)00032-9; Miyajima T, 1997, FREE RADICAL BIO MED, V22, P463, DOI 10.1016/S0891-5849(96)00391-7; MORDVINTCEV P, 1991, ANAL BIOCHEM, V199, P142, DOI 10.1016/0003-2697(91)90282-X; MULSCH A, 1995, BRIT J PHARMACOL, V116, P2743; MULSCH A, 1995, CIRCULATION, V92, P1876, DOI 10.1161/01.CIR.92.7.1876; OBOLENSKAYA MY, 1994, BIOCHEM BIOPH RES CO, V202, P571, DOI 10.1006/bbrc.1994.1966; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Paschenko SV, 1996, BIOCHEM BIOPH RES CO, V225, P577, DOI 10.1006/bbrc.1996.1214; Pou S, 1999, BBA-GEN SUBJECTS, V1427, P216, DOI 10.1016/S0304-4165(99)00014-8; Reinke LA, 1996, ANAL BIOCHEM, V243, P8, DOI 10.1006/abio.1996.0476; Reszka KJ, 1996, J AM CHEM SOC, V118, P8719, DOI 10.1021/ja960922v; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Sasaki T, 1979, J FOOD HYG SOC JPN, V20, P363; SATO S, 1994, BRAIN RES, V647, P91, DOI 10.1016/0006-8993(94)91402-8; Shen JG, 1998, BBA-MOL BASIS DIS, V1406, P228, DOI 10.1016/S0925-4439(98)00007-6; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; Shutenko Z, 1999, BIOCHEM PHARMACOL, V57, P199, DOI 10.1016/S0006-2952(98)00296-2; Suzuki Y, 1998, FREE RADICAL RES, V28, P293, DOI 10.3109/10715769809069281; TANNENBAUM SR, 1976, FOOD COSMET TOXICOL, V14, P549, DOI 10.1016/S0015-6264(76)80006-5; TOMINAGA T, 1994, J CEREBR BLOOD F MET, V14, P715, DOI 10.1038/jcbfm.1994.92; Tsuchiya K, 1999, FREE RADICAL BIO MED, V27, P347, DOI 10.1016/S0891-5849(99)00062-3; VANIN AF, 1993, BIOCHIM BIOPHYS ACTA, V1177, P37, DOI 10.1016/0167-4889(93)90154-H; VEDERNIKOV YP, 1992, EUR J PHARMACOL, V212, P125, DOI 10.1016/0014-2999(92)90085-I; VOEVODSKAYA NV, 1992, BIOCHEM BIOPH RES CO, V186, P1423, DOI 10.1016/S0006-291X(05)81565-7; Wallis G, 1996, SHOCK, V6, P274, DOI 10.1097/00024382-199610000-00009; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Williams D. L. H., 1988, NITROSATION; WOLDMAN YY, 1994, BIOCHEM BIOPH RES CO, V202, P195, DOI 10.1006/bbrc.1994.1912; YONETANI T, 1972, J BIOL CHEM, V247, P2447; Yoshimura T, 1996, NAT BIOTECHNOL, V14, P992, DOI 10.1038/nbt0896-992; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	68	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1551	1556		10.1074/jbc.275.3.1551	http://dx.doi.org/10.1074/jbc.275.3.1551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636843	hybrid			2022-12-25	WOS:000084940000006
J	Ajouz, B; Berrier, C; Besnard, M; Martinac, B; Ghazi, A				Ajouz, B; Berrier, C; Besnard, M; Martinac, B; Ghazi, A			Contributions of the different extramembranous domains of the mechanosensitive ion channel MscL to its response to membrane tension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PATCH-CLAMP; ACTIVATED CHANNELS; PRESSURE; PROTEIN; CELLS	MscL is a mechanosensitive channel that is gated by tension in the membrane bilayer alone. It is a homooligomer of a protein comprising two transmembrane segments connected by an external loop, with the NH(2) and COOH termini located in the cytoplasm, The contributions of the extramembranous domains of the channel to its activity were investigated by specific proteolysis during patch-clamp experiments. Limited proteolysis of the COOH terminus or the NH(2) terminus increased the mechanosensitivity of the channel without changing its conductance. Strikingly, after cleavage of the external loop of each monomer, the channel was still functional, and its mechanosensitivity was increased dramatically, indicating that the loop acts as a spring that resists the opening of the channel and promotes its closure when it is open. These results indicate that the integrity of most of the extramembranous domains is not essential for mechanosensitivity, They suggest that these domains counteract the movement of the transmembrane helices to which they are connected, thus setting the level of sensitivity of the channel to tension.	Univ Paris 11, UMR CNRS 8619, Lab Biomembranes, F-91405 Orsay, France; Univ Western Australia, Dept Pharmacol, Nedlands, WA 6907, Australia	UDICE-French Research Universities; Universite Paris Saclay; University of Western Australia	Ghazi, A (corresponding author), Univ Paris 11, UMR CNRS 8619, Lab Biomembranes, Batiment 430, F-91405 Orsay, France.	alexandre.ghazi@biomemb.u-psud.fr	Martinac, Boris/A-7178-2018	Martinac, Boris/0000-0001-8422-7082				Ajouz B, 1998, J BIOL CHEM, V273, P26670, DOI 10.1074/jbc.273.41.26670; AJOUZ B, 1998, BIOPHYS J, V74, P238; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Blount P, 1997, J BIOL CHEM, V272, P32150, DOI 10.1074/jbc.272.51.32150; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; GarciaAnoveros J, 1997, ANNU REV NEUROSCI, V20, P567, DOI 10.1146/annurev.neuro.20.1.567; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; Hamill OP, 1997, ANNU REV PHYSIOL, V59, P621, DOI 10.1146/annurev.physiol.59.1.621; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamill OP, 1996, PHARMACOL REV, V48, P231; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; Jackson M.B., 1993, THERMODYNAMICS MEMBR, P327; Le Dain AC, 1998, J BIOL CHEM, V273, P12116, DOI 10.1074/jbc.273.20.12116; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; POPOT JL, 1994, METH PHYS S, P41; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; SACHS F, 1992, SOC GEN PHY, V47, P241; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; Saint N, 1998, J BIOL CHEM, V273, P14667, DOI 10.1074/jbc.273.24.14667; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659	31	82	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1015	1022		10.1074/jbc.275.2.1015	http://dx.doi.org/10.1074/jbc.275.2.1015			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625640	hybrid			2022-12-25	WOS:000084836600044
J	Kamphaus, GD; Colorado, PC; Panka, DJ; Hopfer, H; Ramchandran, R; Torre, A; Maeshima, Y; Mier, JW; Sukhatme, VP; Kalluri, R				Kamphaus, GD; Colorado, PC; Panka, DJ; Hopfer, H; Ramchandran, R; Torre, A; Maeshima, Y; Mier, JW; Sukhatme, VP; Kalluri, R			Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGEN; BASEMENT-MEMBRANE; IDENTIFICATION; ORGANIZATION; MODULATION; ADHESION; THERAPY; DOMAINS; CELLS	We isolated and identified an endogenous 24-kDa human basement membrane-derived inhibitor of angiogenesis and tumor growth, termed canstatin, Canstatin, a fragment of the alpha 2 chain of type TV collagen, was produced as a recombinant molecule in Escherichia coli and 293 embryonic kidneys cells. Canstatin significantly inhibited human endothelial cell migration and murine endothelial cell tube formation. Additionally, canstatin potently inhibited 10% fetal bovine serum-stimulated endothelial cell proliferation and induced apoptosis, with no inhibition of proliferation or apoptosis observed on non-endothelial cells. Inhibition of endothelial proliferation was not concomitant with a change in extracellular signal-regulated kinase activation. We demonstrate that apoptosis induced by canstatin was associated with a down-regulation of the anti-apoptotic protein, FLIP. Canstatin also suppressed in vivo growth of large and small size tumors in two human xenograft mouse models with histology revealing decreased CD31-positive vasculature. Collectively, these results suggest that canstatin is a powerful therapeutic molecule for suppressing angiogenesis.	Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Ctr Canc, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, RW 563A,330 Brookline Ave, Boston, MA 02215 USA.		Hopfer, Helmut/T-5954-2019; Sukhatme, Vikas/W-2776-2019; Kalluri, Raghu/E-2677-2015	Hopfer, Helmut/0000-0003-1755-2170; Kalluri, Raghu/0000-0002-2190-547X	NCI NIH HHS [CA-74401] Funding Source: Medline; NIDDK NIH HHS [DK51711, DK55001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Dhanabal M, 1999, CANCER RES, V59, P189; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; GRANT DS, 1994, PATHOL RES PRACT, V190, P854; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HARALABOPOULOS GC, 1994, LAB INVEST, V71, P575; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Madri JA, 1997, TRANSPL IMMUNOL, V5, P179, DOI 10.1016/S0966-3274(97)80035-4; MADRI JA, 1986, J HISTOCHEM CYTOCHEM, V34, P85, DOI 10.1177/34.1.2416801; MARAGOUDAKIS ME, 1993, KIDNEY INT, V43, P147, DOI 10.1038/ki.1993.24; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; OLIVER MH, 1989, J CELL SCI, V92, P513; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Setty S, 1998, J BIOL CHEM, V273, P12244, DOI 10.1074/jbc.273.20.12244; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; ZHANG XM, 1994, DEV BIOL, V164, P10, DOI 10.1006/dbio.1994.1176	28	358	416	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1209	1215		10.1074/jbc.275.2.1209	http://dx.doi.org/10.1074/jbc.275.2.1209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625665	hybrid			2022-12-25	WOS:000084836600069
J	Rellos, P; Sygusch, J; Cox, TM				Rellos, P; Sygusch, J; Cox, TM			Expression, purification, and characterization of natural mutants of human aldolase B - Role of quaternary structure in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY FRUCTOSE INTOLERANCE; MUSCLE ALDOLASE; IDENTIFICATION; GENE; MUTATIONS; VARIANT; REGION	Fructaldolases (EC 4.1.2.13) are ancient enzymes of glycolysis that catalyze the reversible cleavage of phosphofructose esters into cognate triose (phosphates). Three vertebrate isozymes of Class I aldolase have arisen by gene duplication and display distinct activity profiles with fructose 1,6-bisphosphate and with fructose l-phosphate, We describe the biochemical and biophysical characterization of seven natural human aldolase B variants, identified in patients suffering from hereditary fructose intolerance and expressed as recombinant proteins in E, call, from which they were purified to homogeneity. The mutant aldolases were all missense variants and could be classified into two principal groups: catalytic mutants, with retained tetrameric structure but altered kinetic properties (W147R, R303W, and A337V), and structural mutants, in which the homotetramers readily dissociate into subunits with greatly impaired enzymatic activity (A149P, A174D, L256P, and N334K), Investigation of these two classes of mutant enzyme suggests that the integrity of the quaternary structure of aldolase B is critical for maintaining its full catalytic function.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Universite de Montreal	Cox, TM (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Level 5, Cambridge CB2 2QQ, England.			Sygusch, Jurgen/0000-0002-6629-2128				ALI M, 1995, AM J HUM GENET, V56, P1002; ALI M, 1994, HUM MOL GENET, V3, P203; ALI M, 1995, THESIS CAMBRIDGE U C; Beernink PT, 1996, P NATL ACAD SCI USA, V93, P5374, DOI 10.1073/pnas.93.11.5374; BERTHIAUME L, 1993, J BIOL CHEM, V268, P10826; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; BLOM N, 1997, NAT STRUCT BIOL, V4, P38; BOESIGER P, 1994, PEDIATR RES, V36, P436, DOI 10.1203/00006450-199410000-00004; CHAMBERS RA, 1956, LANCET, V2, P340; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; COX TM, 1983, J CLIN INVEST, V72, P201, DOI 10.1172/JCI110958; CROSS NCP, 1990, LANCET, V335, P306, DOI 10.1016/0140-6736(90)90603-3; CROSS NCP, 1990, NUCLEIC ACIDS RES, V18, P1925, DOI 10.1093/nar/18.7.1925; CROSS NCP, 1988, CELL, V53, P881, DOI 10.1016/S0092-8674(88)90349-2; GITZELMANN R, 1995, METABOLIC MOL BASES, P905; GURTLER B, 1971, H-S Z PHYSIOL CHEM, V352, P1455, DOI 10.1515/bchm2.1971.352.2.1455; HEALY MJ, 1973, BIOCHEMISTRY-US, V12, P35, DOI 10.1021/bi00725a006; HERS HG, 1953, BIOCHIM BIOPHYS ACTA, V11, P427, DOI 10.1016/0006-3002(53)90062-6; HEYDUK T, 1991, J BIOL CHEM, V266, P15650; James CL, 1996, J MED GENET, V33, P837, DOI 10.1136/jmg.33.10.837; RACKER E, 1947, J BIOL CHEM, V167, P843; Rellos P, 1999, BIOCHEM J, V340, P321, DOI 10.1042/0264-6021:3400321; ROSE IA, 1965, J BIOL CHEM, V240, P1758; Santamaria R, 1996, J MED GENET, V33, P786, DOI 10.1136/jmg.33.9.786; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sygusch J, 1997, BIOCHEM J, V327, P717, DOI 10.1042/bj3270717; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846	27	28	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1145	1151		10.1074/jbc.275.2.1145	http://dx.doi.org/10.1074/jbc.275.2.1145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625657	hybrid			2022-12-25	WOS:000084836600061
J	Wissink, S; Meijer, O; Pearce, D; van der Burg, B; van der Saag, PT				Wissink, S; Meijer, O; Pearce, D; van der Burg, B; van der Saag, PT			Regulation of the rat serotonin-1A receptor gene by corticosteroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLUCOCORTICOID RECEPTOR; 5-HT1A RECEPTOR; MESSENGER-RNA; MINERALOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; RETINOIC ACID; CROSS-TALK; BRAIN; BINDING	Dysregulation of the serotonergic system and abnormalities of the hypothalamic-pituitary-adrenal axis function have been implicated to be involved in neuropsychiatric disorders, Serotonin-1A receptors have been shown to be suppressed by corticosteroid hormones in a variety of animal studies. This effect may play a central role in the pathophysiology of depression. However, little is known about the molecular mechanism underlying this suppressive effect of corticosteroids, Here, we show by functional analysis of the promoter region of the rat serotonin-1A receptor gene that two NF-KB elements in the promoter contribute to induced transcription of the rat serotonin-1A receptor gene. Furthermore, we show that corticosteroids repress this NF-KB-mediated induction of transcription. Remarkably, we observed that only the glucocorticoid receptor and not the mineralocorticoid receptor was able to mediate this repressive effect of corticosteroids. We argue that negative crosstalk between the glucocorticoid receptor and NF-KB may provide a basis for the molecular mechanism underlying the negative action of corticosteroids on serotonin signaling in the brain.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Med Pharmacol, NL-2300 RA Leiden, Netherlands; Univ Calif San Francisco, Div Nephrol, Dept Med, San Francisco, CA 94143 USA	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Leiden University; Leiden University - Excl LUMC; University of California System; University of California San Francisco	van der Saag, PT (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		meijer, onno c/D-8070-2018	meijer, onno c/0000-0002-8394-6859				ALBERT PR, 1990, J BIOL CHEM, V265, P5825; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Buhot MC, 1997, CURR OPIN NEUROBIOL, V7, P243, DOI 10.1016/S0959-4388(97)80013-X; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CATO ACB, 1996, BIOESSAYS, V18, P317; CHALMERS DT, 1993, J NEUROSCI, V13, P914; CHALMERS DT, 1991, BRAIN RES, V561, P51, DOI 10.1016/0006-8993(91)90748-K; COHN JB, 1985, J CLIN PSYCHIAT, V46, P26; DEKLOET ER, 1991, FRONT NEUROENDOCRIN, V12, P95; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FUXE K, 1985, ENDOCRINOLOGY, V117, P1803, DOI 10.1210/endo-117-5-1803; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HOLSBOER B, 1995, PSYCHOPHARMACOLOGY 4, P957; JULIUS D, 1991, ANNU REV NEUROSCI, V14, P335, DOI 10.1146/annurev.neuro.14.1.335; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; MEIJER OC, 1994, EUR J PHARM-MOLEC PH, V266, P255, DOI 10.1016/0922-4106(94)90134-1; MEIJER OC, 1999, IN PRESS J NEUROENDO; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Parks CL, 1996, J BIOL CHEM, V271, P4417; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; POMPEIANO M, 1992, J NEUROSCI, V12, P440; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; SARRIEAU A, 1984, EUR J PHARMACOL, V98, P151, DOI 10.1016/0014-2999(84)90125-0; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Stokes PE, 1987, PSYCHOPHARMACOLOGY 3, P589; TRABER J, 1987, TRENDS PHARMACOL SCI, V8, P432, DOI 10.1016/0165-6147(87)90231-8; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; vanderBurg B, 1997, TRENDS ENDOCRIN MET, V8, P152, DOI 10.1016/S1043-2760(97)00006-4; Wissink S, 1997, IMMUNOBIOLOGY, V198, P50, DOI 10.1016/S0171-2985(97)80026-5	36	63	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1321	1326		10.1074/jbc.275.2.1321	http://dx.doi.org/10.1074/jbc.275.2.1321			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625680	hybrid			2022-12-25	WOS:000084836600084
J	Chou, TT; Trojanowski, JQ; Lee, VMY				Chou, TT; Trojanowski, JQ; Lee, VMY			A novel apoptotic pathway induced by nerve growth factor-mediated TrkA activation in medulloblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMITIVE NEUROECTODERMAL TUMORS; TYROSINE KINASE-ACTIVITY; CELL-LINES; SIGNAL-TRANSDUCTION; PROTEIN; RAS; NGF; RECEPTORS; PHOSPHORYLATION; EXPRESSION	Nerve growth factor (NGF) induces apoptosis in a human medulloblastoma cell line (MED283) engineered to express TrkA (MED283-TrkA) (Muragaki, Y., Chou, T. T., Haplan, D. R., Trojanowski, J. Q., and Lee, V. M. (1997) J. Neurosci. 17, 530-542), To dissect the molecular signaling pathway that mediates this novel effect, specific receptor mutations in Trk have been employed, We showed that phosphorylation of tyrosine 490 is required for activation of phosphoinositide 3-OH kinase, whereas phosphorylation of tyrosine 785 is required for activation of phospholipase C-gamma, TrkA-mediated apoptosis was abolished when either the ATP-binding site or both tyrosines 490 and 785 were mutated. Because tyrosines 490 and 785 mediate redundant signaling through the Ras-extracellular signal-regulated kinase (Ras-ERK) pathway, we examined the role of Ras-ERK signaling in NGF-induced apoptosis, We found that MED283-TrkA cells expressing a dominant negative Ras inhibitor (N17Ras) failed to undergo ERK activation and apoptosis following NGF treatment, whereas the ERK kinase (mitogen-activated protein kinase kinase) inhibitors PD98059 and U0126 eliminated ERK activation but had no effect on apoptosis, We infer from these data that NGF-induced apoptosis is mediated by a novel Ras and/or Raf signaling pathway.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Lee, VMY (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, 3rd Floor Maloney Bldg,36th & Spruce St, Philadelphia, PA 19104 USA.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERG MM, 1992, J BIOL CHEM, V267, P13; BIGNER SH, 1990, CANCER RES, V50, P2347; Bruggers CS, 1998, J PEDIAT HEMATOL ONC, V20, P18, DOI 10.1097/00043426-199801000-00003; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FRIEDMAN HS, 1985, J NEUROPATH EXP NEUR, V44, P592, DOI 10.1097/00005072-198511000-00005; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kim JYH, 1999, CANCER RES, V59, P711; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; Muragaki Y, 1997, J NEUROSCI, V17, P530; MURAGAKI Y, 1995, J COMP NEUROL, V356, P387, DOI 10.1002/cne.903560306; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Rorke LB, 1997, BRAIN PATHOL, V7, P765, DOI 10.1111/j.1750-3639.1997.tb01063.x; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; YAN GZ, 1995, J NEUROSCI, V15, P6200; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	44	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					565	570		10.1074/jbc.275.1.565	http://dx.doi.org/10.1074/jbc.275.1.565			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617652	hybrid			2022-12-25	WOS:000085951600076
J	Ghoshal, K; Majumder, S; Li, ZL; Dong, XC; Jacob, ST				Ghoshal, K; Majumder, S; Li, ZL; Dong, XC; Jacob, ST			Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-HOMOLOGOUS SEQUENCES; TRANSCRIPTION FACTOR MTF-1; BINDING-PROTEIN MECP2; RNA POLYMERASE-I; CPG METHYLATION; 5-METHYLCYTOSINE CONTENT; HISTONE DEACETYLASE; OXIDATIVE STRESS; ANTICANCER DRUGS; MOUSE	Metallothionein I can be induced in response to a variety of agents that include heavy metals and oxidative stress, On the contrary, its induction was suppressed in some lymphoid-derived cancer cells. The mechanism of this repression has not been elucidated. Here, we show silencing of MT I gene in a solid transplanted rat tumor as a result of promoter methylation at all the 21 CpG dinucleotides that span the region from -225 bp to +1 bp. By contrast, none of these CpG dinucleotides were methylated in the livers from the rats bearing the tumor, which was consistent with the efficient induction of the gene in this tissue by zinc sulfate. Genomic footprinting revealed lack of access of the transcriptional activators to the respective cis-acting elements of the methylated MT-I promoter in the hepatoma. The absence of footprinting was not due to inactivation of the metal regulatory transcription factor MTF-1, because it was highly active in the hepatoma. Treatment of the hepatoma bearing rats with 5-azacytidine, a demethylating agent, induced basal as well as heavy metal-activated MT-I gene expression in the hepatoma, implying that methylation was indeed responsible for silencing the gene. Bisulfite genomic sequencing showed significant (>90%) demethylation of CPG dinucleotides spanning MT-I promoter in the hepatoma following treatment with 5-AzaC, The hypermethylation of MT-I promoter was probably caused by significantly higher (as much as 7-fold) level of DNA methyl transferase activity as well as enhanced expression of its gene in the hepatoma relative to the host liver. These data elucidated for the first time the molecular mechanism for the silencing of a highly inducible gene in a solid tumor transplanted in an animal, as compared with the robust induction in the corresponding parental tissue and have discussed the probable reasons for the suppression of this gene in some tumors.	Ohio State Univ, Coll Med, Dept Med Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Med Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.				NCI NIH HHS [CA 61321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; Aniskovitch LP, 1998, ONCOGENE, V16, P1475, DOI 10.1038/sj.onc.1201659; Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 1998, ADV CANCER RES, V72, P141; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bossard P, 1997, METHODS, V11, P180, DOI 10.1006/meth.1996.0404; CAGATAY G, 1998, EMBO J, V17, P2846; Cai L, 1998, ANTICANCER RES, V18, P4667; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMPERE SJ, 1981, CELL, V25, P233, DOI 10.1016/0092-8674(81)90248-8; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DATTA PK, 1993, CELL MOL BIOL RES, V39, P439; Datta PK, 1997, BIOCHEM BIOPH RES CO, V230, P159, DOI 10.1006/bbrc.1996.5655; DUCEMAN BW, 1981, J BIOL CHEM, V256, P755; Duncan EL, 1999, ONCOGENE, V18, P897, DOI 10.1038/sj.onc.1202370; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fiala ES, 1998, CARCINOGENESIS, V19, P597, DOI 10.1093/carcin/19.4.597; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Hiltunen MO, 1997, BRIT J CANCER, V76, P1124, DOI 10.1038/bjc.1997.522; Jacob ST, 1999, GENE EXPRESSION, V7, P301; Jaenisch R, 1998, CIBA F SYMP, V214, P200; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Kang YJ, 1999, AM J PHYSIOL-HEART C, V276, pH993, DOI 10.1152/ajpheart.1999.276.3.H993; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; Kho MR, 1998, J MOL BIOL, V275, P67, DOI 10.1006/jmbi.1997.1430; KLOTH DM, 1995, BRIT J CANCER, V71, P712, DOI 10.1038/bjc.1995.139; KONDO Y, 1995, CANCER RES, V55, P2021; Kosaki K, 1997, AM J MED GENET, V73, P308; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nan XS, 1998, CIBA F SYMP, V214, P6; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Palmiter R D, 1987, Experientia Suppl, V52, P63; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; Quaife CJ, 1999, TOXICOL APPL PHARM, V155, P107, DOI 10.1006/taap.1998.8609; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Radtke F, 1996, BIOL CHEM H-S, V377, P47, DOI 10.1515/bchm3.1996.377.1.47; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; ROSE KM, 1981, P NATL ACAD SCI-BIOL, V78, P2833, DOI 10.1073/pnas.78.5.2833; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Schroeder M, 1997, BIOCHEM BIOPH RES CO, V235, P403, DOI 10.1006/bbrc.1997.6796; Schwemmle S, 1997, AM J HUM GENET, V60, P1354, DOI 10.1086/515456; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Tajima S, 1998, J BIOCHEM-TOKYO, V123, P993, DOI 10.1093/oxfordjournals.jbchem.a022066; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; Tollefsbol TO, 1997, J MOL BIOL, V269, P494, DOI 10.1006/jmbi.1997.1064; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	78	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					539	547		10.1074/jbc.275.1.539	http://dx.doi.org/10.1074/jbc.275.1.539			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617649	hybrid			2022-12-25	WOS:000085951600073
J	Palacino, JJ; Berechid, BE; Alexander, P; Eckman, C; Younkin, S; Nye, JS; Wolozin, B				Palacino, JJ; Berechid, BE; Alexander, P; Eckman, C; Younkin, S; Nye, JS; Wolozin, B			Regulation of amyloid precursor protein processing by presenilin 1 (PS1) and PS2 in PS1 knockout cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; KINASE-C; IN-VIVO; APOPTOSIS; GENE; MUTATIONS; RELEASE; MICE; EXPRESSION	The presenilin 1 (PS1) and PS2 proteins are thought to play roles in processing of amyloid precursor protein (APP), but the nature of this role is not fully understood. Recent studies have shown that PS1 is necessary for cleavage of APP at the gamma-secretase site. We now show that PS1 and PS2 participate in other aspects of APP processing. Fibroblasts generated from PS1 knockout mice have increased levels of the APP cleavage products, secreted APP (APPs), and APP C-terminal fragments, but lower secretion of APPs and A beta. We have also observed that loss of PS1 prevents protein kinase C or extracellular regulated kinase from increasing production of the APP cleavage products, APPs, and APP C-terminal fragments. Transfection of PS1 -/- cells with PS1 restores the responsiveness of APP processing to protein kinase C and extracellular regulated kinase. This suggests that the changes in APP processing in PS1 -/- cells result strictly from the absence of PS1. Transfection of PS1 -/- cells with PS2 is also able to correct the deficits in APP secretion, which suggests that the PS2 also has the ability to regulate APP processing, Finally, transfection of the truncated PS2 construct, Alg3, into cells lacking PS1 increases APP C-terminal fragments, This suggests that Alg3 can interfere with the processing of APP by PS2, These data point to roles for both PS1 and PS2 in regulating APP processing and suggest that the role of these proteins also includes coupling APP to signal transduction pathways.	Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Neurosci Program, Maywood, IL 60153 USA; Northwestern Univ, Dept Mol Pharmacol, Chicago, IL 60611 USA; Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; Mayo Clin, Dept Pharmacol, Jacksonville, FL 32224 USA	Loyola University Chicago; Loyola University Chicago; Northwestern University; Northwestern University; Mayo Clinic	Wolozin, B (corresponding author), Loyola Univ, Med Ctr, Dept Pharmacol, Bldg 102,Rm 3634,2160 S 1st Ave, Maywood, IL 60153 USA.		Nye, Jeffrey/G-6520-2012	Nye, Jeffrey/0000-0002-6056-281X	NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH012479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013854] Funding Source: NIH RePORTER; NIA NIH HHS [AG13854] Funding Source: Medline; NIMH NIH HHS [1F31MH12479-01] Funding Source: Medline; NINDS NIH HHS [NS35566] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ancolio K, 1997, J NEUROCHEM, V69, P2494, DOI 10.1046/j.1471-4159.1997.69062494.x; Berechid BE, 1999, CURR BIOL, V9, P1493, DOI 10.1016/S0960-9822(00)80121-9; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Buxbaum JD, 1996, ANN NY ACAD SCI, V777, P327, DOI 10.1111/j.1749-6632.1996.tb34441.x; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Guo Q, 1997, J NEUROSCI, V17, P4212; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Mills J, 1997, J NEUROSCI, V17, P9415; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, COLD SPRING HARB SYM, V61, P587; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Slack BE, 1997, BIOCHEM J, V327, P245, DOI 10.1042/bj3270245; SLACK BE, 1993, J BIOL CHEM, V268, P21097; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; White AR, 1998, J NEUROSCI, V18, P6207; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wolozin B, 1998, NEUROBIOL AGING, V19, pS23, DOI 10.1016/S0197-4580(98)00041-4; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	45	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					215	222		10.1074/jbc.275.1.215	http://dx.doi.org/10.1074/jbc.275.1.215			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617607	hybrid			2022-12-25	WOS:000085951600031
J	Nicol, CJ; Zielenski, J; Tsui, LC; Wells, PG				Nicol, CJ; Zielenski, J; Tsui, LC; Wells, PG			An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis	FASEB JOURNAL			English	Article						reactive oxygen species; development; birth defects; phenytoin; human risk	G6PD DEFICIENCY; PHENYTOIN; MALARIA; ENZYME; GLUTATHIONE; METABOLISM; CATALASE; EMBRYOS; DAMAGE; RAT	The primary recognised health risk from common deficiencies in glucose-6-phosphate dehydrogenase (G6PD), a cytoprotective enzyme for oxidative stress, is red blood cell hemolysis. Here we show that litters from untreated pregnant mutant mice with a hereditary G6PD deficiency had increased prenatal death. When treated with the anticonvulsant drug phenytoin, a human teratogen that is commonly used in pregnant women and causes embryonic oxidative stress, G6PD-deficient dams had higher embryonic DNA oxidation and more fetal death and birth defects. The reported G6PD gene mutation was confirmed and used to genotype fetal resorptions, which were primarily G6PD deficient. This is the first evidence that G6PD is a developmentally critical cytoprotective enzyme for both endogenous and xenobiotic-initiated embryopathic oxidative stress and DNA damage. G6PD deficiencies accordingly may have a boarder biological relevance as important determinants of infertility, in utero and postnatal death, and teratogenesis.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.		Tsui, Lap-chee/A-1081-2010					ABUOSBA YK, 1989, J PEDIATR-US, V114, P748, DOI 10.1016/S0022-3476(89)80131-3; AKSU O, 1968, TERATOLOGY, V1, P93, DOI 10.1002/tera.1420010110; ALTMAN PL, 1972, BIOL DATA BOOK, P176; BALAZS L, 1994, NEUROCHEM RES, V19, P1131, DOI 10.1007/BF00965146; Beutler E, 1996, BLOOD CELL MOL DIS, V22, P49, DOI 10.1006/bcmd.1996.0008; BEUTLER E, 1993, AM J HEMATOL, V42, P53, DOI 10.1002/ajh.2830420111; BEUTLER E, 1959, BLOOD, V14, P103, DOI 10.1182/blood.V14.2.103.103; BEUTLER E, 1986, GLUCOSE 6 PHOSPHATE, P3; BURT AM, 1961, DEV BIOL, V3, P84, DOI 10.1016/0012-1606(61)90011-2; CHEN EY, 1991, GENOMICS, V10, P792, DOI 10.1016/0888-7543(91)90465-Q; CLOUGH JR, 1983, J EMBRYOL EXP MORPH, V74, P133; Cooper AJL, 1997, BIOL CHEM, V378, P793; ECKMAN JR, 1979, NATURE, V278, P754, DOI 10.1038/278754a0; EDWARDS RG, 1959, J EXP ZOOL, V141, P299, DOI 10.1002/jez.1401410206; Erel O, 1997, CLIN BIOCHEM, V30, P631, DOI 10.1016/S0009-9120(97)00119-7; FINNELL RH, 1984, AM J MED GENET, V19, P463, DOI 10.1002/ajmg.1320190307; FRIEDMAN MJ, 1979, NATURE, V280, P245, DOI 10.1038/280245a0; Ganshirt D, 1998, FETAL DIAGN THER, V13, P276, DOI 10.1159/000020854; Graf WD, 1995, EUR J PEDIATR SURG, V5, P8, DOI 10.1055/s-2008-1066253; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GUYTON AC, 1987, HUMAN PHYSL MECH DIS, P195; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Jenner P, 1996, PATHOL BIOL, V44, P57; JOLLEY RL, 1958, J BIOL CHEM, V233, P1289; JOLLEY RL, 1959, BIOCHIM BIOPHYS ACTA, V33, P64, DOI 10.1016/0006-3002(59)90498-6; Kim PM, 1996, MOL PHARMACOL, V49, P172; Kirkman HN, 1999, J BIOL CHEM, V274, P13908, DOI 10.1074/jbc.274.20.13908; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; KOSOWER NS, 1970, LANCET, V2, P1343; LAPOSA RR, 1995, TOXICOLOGIST, V15, P161; LAPOSA RR, 1996, FUNDAM APPL TOXIC S1, V30, P195; Lucas AM, 1961, ATLAS AVIAN HEMATOLO, P17; LUZZATTO L, 1995, METABOLIC MOL BASIS, V7, P3367; Martini G, 1996, BIOESSAYS, V18, P631, DOI 10.1002/bies.950180806; MARTINS RN, 1986, J NEUROCHEM, V46, P1042, DOI 10.1111/j.1471-4159.1986.tb00615.x; MAYES PA, 1996, HARPERS BIOCH, P216; MEHTA AB, 1994, POSTGRAD MED J, V70, P871, DOI 10.1136/pgmj.70.830.871; NEWBURGH RW, 1962, ARCH BIOCHEM BIOPHYS, V97, P94, DOI 10.1016/0003-9861(62)90048-6; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PAPACONSTANTINO.J, 1967, BIOCH ANIMAL DEV, V2, P57; Parman T, 1998, J BIOL CHEM, V273, P25079, DOI 10.1074/jbc.273.39.25079; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; PRETSCH W, 1988, BIOCHEM GENET, V26, P89, DOI 10.1007/BF00555491; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; Robkin MA, 1997, INT J DEV BIOL, V41, P283; ROTH EF, 1983, P NATL ACAD SCI-BIOL, V80, P298, DOI 10.1073/pnas.80.1.298; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Sanders S, 1997, MUTAT RES-FUND MOL M, V374, P79, DOI 10.1016/S0027-5107(96)00222-9; SHIGENAGA MK, 1991, FREE RADICAL BIO MED, V10, P211, DOI 10.1016/0891-5849(91)90078-H; SINCLAIR AJ, 1975, P NUTR SOC, V34, P287, DOI 10.1079/PNS19750051; SINGH M, 1989, TERATOLOGY, V40, P453, DOI 10.1002/tera.1420400507; SMITH JE, 1976, ENZYME, V21, P379, DOI 10.1159/000458882; SODEINDE O, 1992, BAILLIERE CLIN HAEM, V5, P367, DOI 10.1016/S0950-3536(11)80024-7; TANIMURA T, 1970, P SOC EXP BIOL MED, V135, P51; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; WASHINGTON EC, 1995, SOUTHERN MED J, V88, P776, DOI 10.1097/00007611-199507000-00019; WEBER GF, 1991, LANCET, V337, P1443, DOI 10.1016/0140-6736(91)93130-2; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; Wells PG, 1997, MUTAT RES-FUND MOL M, V396, P65, DOI 10.1016/S0027-5107(97)00175-9; WELLS PG, 1996, HDB EXPT PHARM DRU 1, V124, P453; WERTH G, 1967, KLIN WOCHENSCHR, V45, P265, DOI 10.1007/BF01747608; WEST JD, 1993, HUM REPROD, V8, P1316, DOI 10.1093/oxfordjournals.humrep.a138249; WILLMORE LJ, 1981, NEUROLOGY, V31, P63, DOI 10.1212/WNL.31.1.63; Winn LM, 1999, FREE RADICAL BIO MED, V26, P266, DOI 10.1016/S0891-5849(98)00193-2; Winn LM, 1995, EUR J NEUROL, V2, P5; WINN LM, 1995, MOL PHARMACOL, V48, P112; YUTHAVONG Y, 1990, BLOOD CELLS, V16, P591; Zollo M, 1993, DNA Seq, V3, P319, DOI 10.3109/10425179309020830	70	142	148	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					111	127		10.1096/fasebj.14.1.111	http://dx.doi.org/10.1096/fasebj.14.1.111			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627286				2022-12-25	WOS:000084784700014
J	Gardsvoll, H; Dano, K; Ploug, M				Gardsvoll, H; Dano, K; Ploug, M			Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT REGULATORY PROTEIN; LINKED-IMMUNOSORBENT-ASSAY; MUTATIONAL ANALYSIS; MONOCLONAL-ANTIBODY; NH2-TERMINAL DOMAIN; KAPPA-BUNGAROTOXIN; CELLULAR RECEPTOR; CRYSTAL-STRUCTURE; DISULFIDE BONDS; HUMAN-TUMOR	The urokinase-type plasminogen activator receptor (uPAR) is a glycolipid anchored multidomain member of the Ly-6/uPAR protein domain superfamily. Studies by site-directed photoaffinity labeling, chemical cross-linking, and ligand-induced protection against chemical modification have highlighted the possible involvement of uPAR domain I and particularly loop 3 thereof in ligand binding (Ploug, RI. (1998) Biochemistry 37, 16494-16505). Guided by these results we have now performed an alanine scanning analysis of this region in uPAR by site-directed mutagenesis and subsequently measured the effects thereof on the kinetics of uPA binding in real-time by surface plasmon resonance. Only four positions in loop 3 of uPAR domain I exhibited significant changes in the contribution to the free energy of uPA binding (Delta Delta G greater than or equal to 1.3 kcal mol(-1)) upon single-site substitutions to alanine (i.e. Arg(53), Leu(55), Tyr(57), and Leu(66)). The energetic impact of these four alanine substitutions was not caused by gross structural perturbations, since all monoclonal antibodies tested having conformation-dependent epitopes on this domain exhibited unaltered binding kinetics, These sites together with a three-dimensional structure for uPAR may provide an appropriate target for rational drug design aimed at developing new receptor binding antagonists with potential application in cancer therapy.	Rigshosp, Finsen Lab, DK-2100 Copenhagen O, Denmark	Rigshospitalet	Ploug, M (corresponding author), Rigshosp, Finsen Lab, Strandboulevarden 49, DK-2100 Copenhagen O, Denmark.			Ploug, Michael/0000-0003-2215-4265				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Bodian DL, 1997, J EXP MED, V185, P507, DOI 10.1084/jem.185.3.507; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; DEWAN JC, 1994, BIOCHEMISTRY-US, V33, P13147, DOI 10.1021/bi00248a026; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Evans CP, 1997, CANCER RES, V57, P3594; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FLETCHER CM, 1994, STRUCTURE, V2, P185, DOI 10.1016/S0969-2126(00)00020-4; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P4847, DOI 10.1021/bi00182a013; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Kussmann M, 1997, J MASS SPECTROM, V32, P593; List K, 1999, J IMMUNOL METHODS, V222, P125, DOI 10.1016/S0022-1759(98)00189-6; Luther T, 1997, AM J PATHOL, V150, P1231; Magdolen V, 1996, EUR J BIOCHEM, V237, P743, DOI 10.1111/j.1432-1033.1996.0743p.x; MASUCCI MT, 1991, J BIOL CHEM, V266, P8655; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Min HY, 1996, CANCER RES, V56, P2428; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; Noel LS, 1998, J BIOL CHEM, V273, P3878, DOI 10.1074/jbc.273.7.3878; NOVOKHATNY V, 1992, J BIOL CHEM, V267, P3878; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V204, P1212, DOI 10.1006/bbrc.1994.2592; OSSOWSKI L, 1991, CANCER RES, V51, P274; Petranka J, 1996, BLOOD CELL MOL DIS, V22, P281, DOI 10.1006/bcmd.1996.0111; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ploug M, 1998, J BIOL CHEM, V273, P13933, DOI 10.1074/jbc.273.22.13933; PLOUG M, 1995, BIOCHEMISTRY-US, V34, P12524, DOI 10.1021/bi00039a006; Ploug M, 1998, BIOCHEMISTRY-US, V37, P16494, DOI 10.1021/bi981203r; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; RONNE E, 1994, J IMMUNOL METHODS, V167, P91, DOI 10.1016/0022-1759(94)90078-7; RONNE E, 1995, BREAST CANCER RES TR, V33, P199, DOI 10.1007/BF00665944; Rosel M, 1998, ONCOGENE, V17, P1989, DOI 10.1038/sj.onc.1202079; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; TESSLER RJ, 1999, APMIS, V107, P168; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	58	73	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37995	38003		10.1074/jbc.274.53.37995	http://dx.doi.org/10.1074/jbc.274.53.37995			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608868	hybrid			2022-12-25	WOS:000084528000068
J	Liao, YH; Kariya, K; Hu, CD; Shibatohge, M; Goshima, M; Okada, T; Watari, Y; Gao, XL; Jin, TG; Yamawaki-Kataoka, Y; Kataoka, T				Liao, YH; Kariya, K; Hu, CD; Shibatohge, M; Goshima, M; Okada, T; Watari, Y; Gao, XL; Jin, TG; Yamawaki-Kataoka, Y; Kataoka, T			RA-GEF, a novel Rap1A guanine nucleotide exchange factor containing a Ras/Rap1A-associating domain, is conserved between nematode and humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE EFFECTOR; BINDING PROTEINS; STRUCTURAL BASIS; MAP KINASE; HA-RAS; ACTIVATION; FAMILY; IDENTIFICATION; CLONING; REGION	A yeast two-hybrid screening for Ras-binding proteins in nematode Caenorhabditis elegans has identified a guanine nucleotide exchange factor (GEF) containing a Ras/Rap1A-associating (RA) domain, termed Ce-RA-GEF. Both Ce-RA-GEF and its human counterpart Hs-RA-GEF possessed a PSD-95/DlgA/ZO-1 (PDZ) domain and a Ras exchanger motif (REM) domain in addition to the RA and GEF domains. They also contained a region homologous to a cyclic nucleotide monophosphate-binding domain, which turned out to be incapable of binding cAMP or cGMP. Although the REM and GEF domains are conserved with other GEFs acting on Ras family small GTP-binding proteins, the RA and PDZ domains are unseen in any of them. Hs-RA-GEF exhibited not only a GTP-dependent binding activity to Rap1A at its RA domain but also an activity to stimulate GDP/GTP exchange of Rap1A both in vitro and in, vivo at the segment containing its REM and GEF domains. However, it did not exhibit any binding or GEF activity toward Ras. On the other hand, Ce-RA-GEF associated with and stimulated GDP/GTP exchange of both Ras and Rap1A These results indicate that Ce-RA-GEF and Hs-RA-G;EF define a novel class of Rap1A GEF molecules, which are conserved through evolution.	Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kataoka, T (corresponding author), Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BRICKMAN E, 1973, J BACTERIOL, V116, P582, DOI 10.1128/JB.116.2.582-587.1973; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GIBBS JB, 1995, METHOD ENZYMOL, V255, P118; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KRAUSE M, 1995, CAENORHABDITIS ELEGA, P513; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; RANNELS SR, 1983, METHOD ENZYMOL, V99, P168; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SHABB JB, 1992, J BIOL CHEM, V267, P5723; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	38	77	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37815	37820		10.1074/jbc.274.53.37815	http://dx.doi.org/10.1074/jbc.274.53.37815			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608844	hybrid			2022-12-25	WOS:000084528000044
J	Sawai, H; Domae, N; Nagan, N; Hannun, YA				Sawai, H; Domae, N; Nagan, N; Hannun, YA			Function of the cloned putative neutral sphingomyelinase as lyso-platelet activating factor-phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN ACID SPHINGOMYELINASE; NIEMANN-PICK DISEASE; CANINE KIDNEY-CELLS; LYSOPHOSPHOLIPASE-D; INDUCED APOPTOSIS; ALKALINE SPHINGOMYELINASE; CELLULAR MEMBRANES; INITIATE APOPTOSIS; GENERATE CERAMIDE	Sphingolipids such as ceramide and sphingosine have been regarded as novel signal mediators in cells. However, the mechanisms of generation of these lipids upon various stimulation remain to be elucidated. Neutral sphingomyelinase (N-SMase) is one of the key enzymes in the generation of ceramide, and recently the cloning of a putative N-SMase was reported. Because the function of the protein was unclear in the previous report, we investigated the role it plays in cells. N-SMase activity in cells overexpressing the protein with hexa-histidine tag was immunoprecipitated with anti-hexa histidine antibody. The metabolism of ceramide and SM was not apparently affected in overexpressing cells. Radiolabeling experiments using [H-3]palmitic acid or [H-3] hexadecanol demonstrated an accumulation of 1-O-alkyl-sn-glycerol and a corresponding decrease of 1-alkyl-2-acyl-sn-glycero-3-phosphocholine in overexpressing cells. In vitro studies showed that both 1-acyl-2-lyso-sn-glycero-3-phosphocholine (lyso-PC) and 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (lyso-platelet activating factor (lyso-PAF)) are good substrates of the protein. In further radiolabeling experiments, 1-acyl-lyso-PC was predominantly and equally metabolized into diacyl-PC in both vector and overexpressing cells. On the other hand, 1-O-alkyl-lyso-PC (lyso-PAF) was metabolized into both diradyl-PC and 1-O-alkyl-glycerol in overexpressing cells but only into diradyl-PC in vector cells. These results suggest that the protein acts as lyso-PAF-PLC rather than lyso-PC-PLC or N-SMase in cells.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Osaka Dent Univ, Dept Med, Hirakata, Osaka 573, Japan; Med Univ S Carolina, Dept Med Lab Sci, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; Arthur G, 1998, BBA-LIPID LIPID MET, V1390, P85, DOI 10.1016/S0005-2760(97)00163-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DAVIS PA, 1981, ARCH BIOCHEM BIOPHYS, V211, P20, DOI 10.1016/0003-9861(81)90424-0; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; Duan RD, 1997, HEPATOLOGY, V26, P823, DOI 10.1053/jhep.1997.v26.pm0009328299; Dziewanowska K, 1996, ARCH BIOCHEM BIOPHYS, V335, P102, DOI 10.1006/abbi.1996.0486; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Goldkorn T, 1998, J CELL SCI, V111, P3209; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KIM MY, 1991, J BIOL CHEM, V266, P484; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; OKAYASU T, 1986, BIOCHIM BIOPHYS ACTA, V876, P58; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; STRUM JC, 1994, J BIOL CHEM, V269, P15493; STRUM JC, 1993, J BIOL CHEM, V268, P25500; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WARNE TR, 1995, J BIOL CHEM, V270, P11147, DOI 10.1074/jbc.270.19.11147; WYKLE RL, 1980, BIOCHIM BIOPHYS ACTA, V619, P58, DOI 10.1016/0005-2760(80)90242-8; WYKLE RL, 1974, J BIOL CHEM, V249, P1742; WYKLE RL, 1977, ARCH BIOCHEM BIOPHYS, V184, P149, DOI 10.1016/0003-9861(77)90336-8	42	86	94	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38131	38139		10.1074/jbc.274.53.38131	http://dx.doi.org/10.1074/jbc.274.53.38131			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608884	hybrid			2022-12-25	WOS:000084528000084
J	Shallom, S; Zhang, K; Jiang, L; Rathod, PK				Shallom, S; Zhang, K; Jiang, L; Rathod, PK			Essential protein-protein interactions between Plasmodium falciparum thymidylate synthase and dihydrofolate reductase domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMALARIAL DRUG-RESISTANCE; ESCHERICHIA-COLI; IN-VITRO; EXPRESSION; MALARIA; PYRIMETHAMINE; GENE; PURIFICATION; COMBINATION; MECHANISM	In Plasmodium falciparum, dihydrofolate reductase and thymidylate synthase activities are conferred by a single 70-kDa bifunctional polypeptide (DHFR-TS, dihydrofolate reductase-thymidylate synthase) which assembles into a functional 140-kDa homodimer, In mammals, the two enzymes are smaller distinct molecules encoded on different genes, A 27-kDa amino domain of malarial DHFR-TS is sufficient to provide DHFR activity, but the structural requirements for TS function have not been established, Although the 3'-end of DHFR-TS has high homology to TS sequences from other species, expression of this protein fragment failed to yield active TS enzyme, and it failed to complement TS- Escherichia coli, Unexpectedly, even partial 5'-deletion of full-length DHFR-TS gene abolished TS function:on the 3'-end, Thus, it was hypothesized that the amino end of the bifunctional parasite protein plays an important role in TS function. When the 27-kDa amino domain (DHFR) was provided in trans, a previously inactive 40-kDa carboxyl domain from malarial DHFR-TS regained its TS function. Physical characterization of the "split enzymes" revealed that the 27- and the 40-kDa fragments of DHFR-TS had reassembled into a 140-kDa hybrid complex, Thus, in malarial DHFR-TS, there are physical interactions between the DHFR domain and the TS domain, and these interactions are necessary:to obtain a catalytically active TS. Interference with these essential protein-protein interactions could lead to new selective strategies to treat malaria resistant to traditional DHFR-TS inhibitors.	Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA	Catholic University of America	Rathod, PK (corresponding author), Catholic Univ Amer, Dept Biol, 620 Michigan Ave NE, Washington, DC 20064 USA.				NIAID NIH HHS [AI26912, AI40956, R01 AI026912] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040956, R01AI026912, R29AI026912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELFORT M, 1984, J BACTERIOL, V160, P371, DOI 10.1128/JB.160.1.371-378.1984; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; BZIK DJ, 1987, P NATL ACAD SCI USA, V84, P8360, DOI 10.1073/pnas.84.23.8360; CANFIELD CJ, 1993, AM J TROP MED HYG, V49, P121, DOI 10.4269/ajtmh.1993.49.121; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; CHEN GX, 1987, MOL PHARMACOL, V32, P723; Elcock AH, 1996, J MOL BIOL, V262, P370, DOI 10.1006/jmbi.1996.0520; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; FOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014; GARRETT CE, 1984, MOL BIOCHEM PARASIT, V11, P257, DOI 10.1016/0166-6851(84)90070-7; HALL SJ, 1991, MOL BIOCHEM PARASIT, V45, P317, DOI 10.1016/0166-6851(91)90100-K; HekmatNejad M, 1996, ANTIMICROB AGENTS CH, V40, P1628, DOI 10.1128/AAC.40.7.1628; HekmatNejad M, 1997, EXP PARASITOL, V87, P222, DOI 10.1006/expr.1997.4228; HekmatNejad M, 1997, EXP PARASITOL, V85, P303, DOI 10.1006/expr.1997.4145; HILLCOAT BL, 1966, J BIOL CHEM, V241, P2995; HITCHINGS GH, 1960, CLIN PHARMACOL THER, V1, P570; HOUGHTON PJ, 1989, P NATL ACAD SCI USA, V86, P1377, DOI 10.1073/pnas.86.4.1377; Huennekens FM, 1996, PROTEIN SCI, V5, P1201; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; LIUZZI M, 1994, NATURE, V372, P695, DOI 10.1038/372695a0; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; Nzila-Mounda A, 1998, ANTIMICROB AGENTS CH, V42, P164, DOI 10.1128/AAC.42.1.164; OAKS SC, 1991, MALARIA; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; RATHOD PK, 1994, ANTIMICROB AGENTS CH, V38, P476, DOI 10.1128/AAC.38.3.476; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSELL PB, 1951, J AM CHEM SOC, V73, P3763, DOI 10.1021/ja01152a060; SANO G, 1994, MOL BIOCHEM PARASIT, V63, P265, DOI 10.1016/0166-6851(94)90062-0; SIRAWARAPORN W, 1993, J BIOL CHEM, V268, P21637; SPINKS A, 1945, ANN TROP MED PARASIT, V39, P220, DOI 10.1080/00034983.1945.11685239; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Trujillo M, 1996, BIOCHEMISTRY-US, V35, P6366, DOI 10.1021/bi952923q; White NJ, 1996, PARASITOL TODAY, V12, P399, DOI 10.1016/0169-4758(96)10055-7; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; WINSTANLEY PA, 1995, ANTIMICROB AGENTS CH, V39, P948, DOI 10.1128/AAC.39.4.948; YOSHIOKA A, 1987, J BIOL CHEM, V262, P8235; Zutshi R, 1998, CURR OPIN CHEM BIOL, V2, P62, DOI 10.1016/S1367-5931(98)80036-7	40	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37781	37786		10.1074/jbc.274.53.37781	http://dx.doi.org/10.1074/jbc.274.53.37781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608839	hybrid, Green Accepted			2022-12-25	WOS:000084528000039
J	Swanton, E; Bishop, N; Woodman, P				Swanton, E; Bishop, N; Woodman, P			Human rabaptin-5 is selectively cleaved by caspase-3 during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCYTIC MEMBRANE-FUSION; INTERLEUKIN-1-BETA CONVERTING-ENZYME; SMALL GTPASE RAB5; CELL-FREE SYSTEM; CYTOCHROME-C; CYSTEINE PROTEASE; GDP/GTP EXCHANGE; SNARE ACTIVATION; ENDOSOME FUSION; HL-60 CELLS	We have previously shown that Xenopus rabaptin-5 is cleaved in apoptotic extracts, with a concomitant reduction in the ability of these extracts to support endosomal membrane fusion (Cosulich, S. C., Horiuchi, H., Zerial, M., Clarke, P. R., and Woodman, P. G. (1997) EMBO J, 16, 6182-6191), In this report we demonstrate that caspase-dependent cleavage is a conserved feature of rabaptin-5. Human rabaptin-5 is cleaved at two sites (HSLD379 and DESD438) in, apoptotic HeLa extracts. Cleavage is: effected by caspase-3, since it is prevented when caspase-3 activity is either inhibited by Ac-DEVD-CHO or removed by immunodepletion. Moreover, an identical pattern of cleavage is observed using recombinant caspase-3, The action of caspase-3 is highly selective; neither caspase-2 nor caspase-7 are able to cleave recombinant or cytosolic rabaptin-5. Caspase-dependent cleavage of rabaptin-5 generates two physically separated coiled coil-forming domains, the C-terminal of which retains the ability to bind the Rab5 exchange factor rabex-5.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Woodman, P (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.			Swanton, Eileithyia/0000-0002-3299-4228				BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Beere HM, 1996, MOL PHARMACOL, V49, P842; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Cosulich SC, 1997, EMBO J, V16, P6182, DOI 10.1093/emboj/16.20.6182; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; HARLOW E, 1988, ANTIBODIES LAB APPRO; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Ohya T, 1998, J BIOL CHEM, V273, P613, DOI 10.1074/jbc.273.1.613; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	48	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37583	37590		10.1074/jbc.274.53.37583	http://dx.doi.org/10.1074/jbc.274.53.37583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608812	hybrid			2022-12-25	WOS:000084528000012
J	Wierzbicka-Patynowski, I; Niewiarowski, S; Marcinkiewicz, C; Calvete, JJ; Marcinkiewicz, MM; McLane, MA				Wierzbicka-Patynowski, I; Niewiarowski, S; Marcinkiewicz, C; Calvete, JJ; Marcinkiewicz, MM; McLane, MA			Structural requirements of echistatin for the recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; GLUTATHIONE-S-TRANSFERASE; III CONNECTING SEGMENT; LIGAND-BINDING; SECONDARY STRUCTURE; VIPER VENOMS; GPIIB-IIIA; ALPHA-V-BETA-3 INTEGRINS; BETA(3) INTEGRIN; ESCHERICHIA-COLI	There are key differences between the amino acid residues of the RGD loops and the C termini of echistatin, a potent antagonist of alpha(IIb)beta(3), alpha(v)beta(3) and alpha(5)beta(1), and eristostatin, a similar disintegrin selectively inhibiting alpha(IIb)beta(3),. In order to identify echistatin motifs required for selective recognition of alpha(v)beta(3) and alpha(5)beta(1) integrins, we expressed recombinant echistatin, eristostatin, and 15 hybrid molecules. We tested them for their ability to inhibit adhesion of different cell lines to fibronectin and von Willebrand factor and to express ligand-induced binding site epitope. The results showed that Asp(27) and Met(28) support recognition of both alpha(v)beta(3) and alpha(5)beta(1). Replacement of Met(28) with Asn completely abolished echistatin's ability to recognize each of the integrins, while replacement of Met(28) with Leu selectively decreased echistatin's ability to recognize alpha(5)beta(1) only. Eristostatin in which C-terminal WNG sequence was substituted with HKGPAT exhibited new activity with alpha(5)beta(1), which was 10-20-fold higher than that of wild type eristostatin, A hypothesis is proposed that the C terminus of echistatin interacts with separate sites on beta(1) and beta(3) integrin molecules.	Univ Delaware, McKinly Lab 057, Dept Med Technol, Newark, DE 19808 USA; Temple Univ, Dept Physiol, Philadelphia, PA 19140 USA; Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; CSIC, Inst Biomed, Valencia 46010, Spain	University of Delaware; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	McLane, MA (corresponding author), Univ Delaware, McKinly Lab 057, Dept Med Technol, Newark, DE 19808 USA.	mclane@udel.edu	Calvete, Juan/P-2555-2019; Calvete, Juan J/K-9619-2014	Calvete, Juan/0000-0001-5026-3122; Calvete, Juan J/0000-0001-5026-3122	NHLBI NIH HHS [HL 0777] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CALVETE JJ, 1994, BIOCHEM BIOPH RES CO, V202, P135, DOI 10.1006/bbrc.1994.1903; COOKE RM, 1991, EUR J BIOCHEM, V202, P323, DOI 10.1111/j.1432-1033.1991.tb16379.x; DALVIT C, 1991, EUR J BIOCHEM, V202, P315, DOI 10.1111/j.1432-1033.1991.tb16378.x; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DU XP, 1993, J BIOL CHEM, V268, P23087; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; Kumar CC, 1998, FEBS LETT, V429, P239; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; MCLANE MA, 1994, BIOCHEM J, V301, P429, DOI 10.1042/bj3010429; McLane MA, 1996, FEBS LETT, V391, P139, DOI 10.1016/0014-5793(96)00716-8; Nakamura Y, 1998, NUCLEIC ACIDS RES, V26, P334, DOI 10.1093/nar/26.1.334; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; PFAFF M, 1994, CELL ADHES COMMUN, V2, P491, DOI 10.3109/15419069409014213; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SAUDEK V, 1991, EUR J BIOCHEM, V202, P329, DOI 10.1111/j.1432-1033.1991.tb16380.x; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINER B, 1993, J BIOL CHEM, V268, P6870; Wierzbicka I, 1997, THROMB RES, V85, P115, DOI 10.1016/S0049-3848(96)00228-9; WILLIAMS J, 1990, BIOCHIM BIOPHYS ACTA, V1039, P81, DOI 10.1016/0167-4838(90)90229-9; Yeh CH, 1998, BLOOD, V92, P3268, DOI 10.1182/blood.V92.9.3268.421k41_3268_3276	40	123	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37809	37814		10.1074/jbc.274.53.37809	http://dx.doi.org/10.1074/jbc.274.53.37809			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608843	hybrid			2022-12-25	WOS:000084528000043
J	Lee, AWM; Nambirajan, S; Moffat, JG				Lee, AWM; Nambirajan, S; Moffat, JG			CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells	ONCOGENE			English	Article						colony-stimulating factor-1 receptor; p31Waf1/Cip1; cyclin D1; MAP kinase; breast cancer; estrogen	COLONY-STIMULATING FACTOR; CYCLIN D1 EXPRESSION; FACTOR-I; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CDK INHIBITORS; INDEPENDENT GROWTH; CARCINOMA CELLS; GENE-EXPRESSION; DNA-DAMAGE	The CSF-1 receptor (CSF-1R) is expressed in >50% of human breast cancers. To investigate the consequence of CSF-1R expression, hormone-dependent human breast cancer cell lines, MCF-7 and T-47D, were transfected with CSF-1R, Unexpectedly, CSF-1 substantially inhibited estradiol (E-2) and insulin-dependent proliferation of MCF-7 transfectants (MCF-7fms) and prevented cyclin E/cdk2 and cyclin A/cdk2 activation, consistent with a G(1) arrest. In contrast, CSF-1 increased DNA synthesis in T-47D transfectants (T-47Dfms) alone and with E-2 or insulin. In response to CSF-1, there was a marked and sustained upregulation of the cyclin-dependent kinase inhibitor, p21(Waf1/Cip1), in MCF-7fms but not T-47Dfms, CSF-1 also markedly upregulated cyclin D1 in MCF-7fms, The coordinate increase in cyclin D1 and p21 had the effect of decreasing the specific but not absolute activity of cyclin D1/cdk4, p53 was not involved since CSF-I induction of p21 was unaffected by dominant-negative p53 expression. ERK activation by CSF-1 was robust and sustained in MCF-7fms and to a much lesser extent in T-47Dfms. Using pharmacological and transient transfection approaches, we showed that ERK activation was necessary and sufficient for p21 induction in MCF-7fms, Moreover, activated MEK inhibited E-2-stimulated cdk2 activity. Our findings indicate that the consequence of CSF-1R-mediated signals in human breast cancer cells is dependent on the genetic background of the particular tumor.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Lee, AWM (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.				NIDDK NIH HHS [R01 DK48929] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048929] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Bacus SS, 1996, ONCOGENE, V12, P2535; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; CASEY G, 1991, ONCOGENE, V6, P1791; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FILDERMAN AE, 1992, CANCER RES, V52, P3661; Flick MB, 1997, ONCOGENE, V14, P2553, DOI 10.1038/sj.onc.1201092; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Iavarone A, 1997, NATURE, V387, P417; JIANG HP, 1994, ONCOGENE, V9, P3397; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; KACINSKI BM, 1991, ONCOGENE, V6, P941; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee AW, 1999, BLOOD, V93, P537, DOI 10.1182/blood.V93.2.537.402k30_537_553; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LEE AWM, 1992, CURR TOP CELL REGUL, V32, P73; LI Y, 1994, ONCOGENE, V9, P2261; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; MUSGROVE EA, 1993, EUR J CANCER, V29A, P2273, DOI 10.1016/0959-8049(93)90221-Z; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Parry D, 1999, MOL CELL BIOL, V19, P1775; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROUSSEL MF, 1994, J CELL SCI, P105; RUDEN TV, 1991, LEUKEMIA, V5, P3; Sapi E, 1998, CANCER RES, V58, P1027; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STANLEY E, 1981, J IMMUNOL METHODS, V264, P1694; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; Tombes RM, 1998, BIOCHEM J, V330, P1451; Wang HS, 1997, CANCER RES, V57, P1750; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAN GZ, 1995, J NEUROSCI, V15, P6200; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	70	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7477	7494		10.1038/sj.onc.1203123	http://dx.doi.org/10.1038/sj.onc.1203123			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602507				2022-12-25	WOS:000084119600009
J	Kim, E; Rohaly, G; Heinrichs, S; Gimnopoulos, D; Meissner, H; Deppert, W				Kim, E; Rohaly, G; Heinrichs, S; Gimnopoulos, D; Meissner, H; Deppert, W			Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53	ONCOGENE			English	Article						p53; mdm2; DNA conformation; non-B-DNA; sequence-specific DNA binding; transcriptional activation	MDM2 GENE; CELL-GROWTH; EXPRESSION; ACTIVATION; PROTEIN; P21; IDENTIFICATION; MODULATION; RADIATION; TERMINUS	Transcriptional activation by the tumor suppressor p53 is regulated at multiple levels, including posttranslational modifications of the p53 protein, interaction of p53 with various regulatory proteins, or at the level of sequence-specific DNA binding to the response elements in p53's target genes. We here propose as an additional regulatory mechanism that the DNA topology of p53-responsive promoters may determine the interaction of p53 with its target genes. We demonstrate that sequence-specific DNA binding (SSDB) and transcriptional activation by p53 of the mdm2 promoter is inhibited when this promoter is present in supercoiled DNA, where it forms a non-B-DNA structure which spans the p53-responsive elements. Relaxation of the supercoiled DNA in vitro resulted in conversion of the non-B-DNA to a B-DNA conformation within the mdm2 promoter, and correlated with an enhanced SSDB of p53 and an elevated expression of a reporter gene. In contrast, sequence specific UNA binding and transcriptional activation of the p21 promoter were not inhibited by DNA supercoiling, We propose that conformational alterations within p53-responsive sites, which either promote or prohibit sequence specific DNA binding of p53, are an important feature in orchestrating the activation of different p53 responsive promoters.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Hamburg, Klinikum Eppendorf, Abt Neurochirurg, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; Di Como CJ, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garcia JF, 1997, HISTOPATHOLOGY, V30, P120, DOI 10.1046/j.1365-2559.1997.d01-577.x; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GELLERT M, 1983, P NATL ACAD SCI-BIOL, V80, P5545, DOI 10.1073/pnas.80.18.5545; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Luna RMD, 1997, NAT GENET, V16, P336; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Shaw P, 1996, ONCOGENE, V12, P921; SINDEN RR, 1983, P NATL ACAD SCI-BIOL, V80, P1797, DOI 10.1073/pnas.80.7.1797; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	31	43	43	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7310	7318		10.1038/sj.onc.1203139	http://dx.doi.org/10.1038/sj.onc.1203139			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602486				2022-12-25	WOS:000084119400016
J	Cho, YS; Han, MK; Choi, YB; Yun, Y; Shin, J; Kim, UH				Cho, YS; Han, MK; Choi, YB; Yun, Y; Shin, J; Kim, UH			Direct interaction of the CD38 cytoplasmic tail and the Lck SH2 domain - CD38 transduces T cell activation signals through associated Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; P56(LCK); RECEPTOR; SURFACE; EXPRESSION; MOLECULE; CHAIN; NAD+	CD38 ligation has been shown to induce activation of intracellular signaling cascade in T lymphocytes through a Lck-dependent pathway. However, it is not clear how Lck initiates the CD38-mediated signaling process. In the present study, we showed that CD38 and Lck were physically associated through the cytoplasmic tail and the Src homology 2 domain, respectively. This was evidenced by coimmunoprecipitation of Lck with CD38 and Lck with isolated CD38 cytoplasmic domain from T cell lysate, cell lysate of COS-7 cells cotransfected with cDNAs of Lck and CD38, or a mixture of in vitro translated CD38 and Lck. Because the CD38 cytoplasmic domain does not contain any tyrosine residue, the interaction should be independent of phosphotyrosine. The interaction was further confirmed by in vitro interaction between a purified Lck Src homology 2 domain and a nonphosphosynthetic peptide corresponding to the membrane proximal region of the CD38 cytoplasmic domain. In addition, CD38 ligation resulted in an elevated tyrosine kinase activity of the CD38 associated Lck and ultimate activation of interleukin-a gene transcription. Furthermore, expression of a kinase-deficient Lck mutant suppressed interleukin-a gene activation in a dose-dependent manner. These results strongly suggested that CD38 ligation indeed tranduced signals for T cell activation using its associated Lck.	Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561182, South Korea; Chonbuk Natl Univ, Inst Med Sci, Chonju 561182, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Samsung Biomed Res Inst, Suwon 440746, South Korea; Sungkyunkwan Univ, Sch Med, Suwon 440746, South Korea	Jeonbuk National University; Jeonbuk National University; Ewha Womans University; Ewha Womans University; Sungkyunkwan University (SKKU)	Kim, UH (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Chonju 561182, South Korea.	uhkim@moak.chonbuk.ac.kr	Choi, Young Bong/J-4317-2019	Choi, Young Bong/0000-0002-2523-1441; Han, Myung-Kwan/0000-0003-1931-8898; /0000-0002-6224-6685; Kim, Uh-Hyun/0000-0003-3304-7190				ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; August A, 1996, J BIOL CHEM, V271, P10054; AUSIELLO CM, 1995, EUR J IMMUNOL, V25, P1477, DOI 10.1002/eji.1830250554; Choi YB, 1999, J IMMUNOL, V163, P5242; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; FUNARO A, 1990, J IMMUNOL, V145, P2390; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GELEZIUNAS R, 1994, FASEB J, V8, P593, DOI 10.1096/fasebj.8.9.8005387; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Hashimoto K, 1996, J EXP MED, V184, P931, DOI 10.1084/jem.184.3.931; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; Inoue S, 1997, J IMMUNOL, V159, P5226; IZQUIERDO PM, 1995, IMMUNOL TODAY, V16, P159; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KIKUCHI Y, 1995, P NATL ACAD SCI USA, V92, P11814, DOI 10.1073/pnas.92.25.11814; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; Kontani K, 1996, J BIOL CHEM, V271, P1534; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; LITVIN DA, 1984, METHOD ENZYMOL, V108, P298; LUND F, 1995, IMMUNOL TODAY, V16, P496; Lund FE, 1998, IMMUNOL REV, V161, P79, DOI 10.1111/j.1600-065X.1998.tb01573.x; Malek SN, 1996, J BIOL CHEM, V271, P6952, DOI 10.1074/jbc.271.12.6952; MALEK SN, 1994, J BIOL CHEM, V269, P33009; Morra M, 1998, FASEB J, V12, P581, DOI 10.1096/fasebj.12.7.581; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; Silvennoinen O, 1996, J IMMUNOL, V156, P100; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; Zubiaur M, 1997, J IMMUNOL, V159, P193	40	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1685	1690		10.1074/jbc.275.3.1685	http://dx.doi.org/10.1074/jbc.275.3.1685			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636863	hybrid			2022-12-25	WOS:000084940000026
J	Guo, N; Faller, DV; Vaziri, C				Guo, N; Faller, DV; Vaziri, C			A novel DNA damage checkpoint involving post-transcriptional regulation of cyclin A expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; ADDUCTS; CANCER; GROWTH; GENE; P53; E2F	The intracellular metabolism of many carcinogenic polycyclic aryl hydrocarbons (PAHs, typified by the ubiquitous pollutant benzo[a]pyrene or B[a]P) generates electrophilic products that react covalently with genomic DNA. Cells that acquire PAM-induced DNA damage undergo growth arrest in a p53-independent manner (Vaziri, C,, and Faller, D. V. (1997) J. Biol. Chem. 272, 2762-2769), In this report we have investigated the molecular basis of PAM-induced cell cycle arrest. Mitogenic signaling events involving cyclins D and E, Rb phosphorylation, and transcriptional activation of E2F-responsive genes (including cyclin E and cyclin A) were unaffected in cells containing PAM-damaged DNA. However, PAM-induced growth arrest was associated with post-transcriptional decreases in cyclin A expression. Mitogen-induced expression of cyclin B, an event that is temporally distal to cyclin A expression, was also inhibited in PAM-treated cells. The PAM-induced cell cycle block was transient, and arrested cells resumed DNA synthesis after a prolonged (similar to 20 h) delay. Resumption of DNA synthesis in PAM-treated cells occurred concomitant with elevated expression of cyclins A and B, PAH-induced cell cycle arrest was overcome by ectopically expressed cyclin A (encoded by a recombinant adenovirus in transiently infected cells). Overall, our results suggest the existence of a DNA damage checkpoint pathway that arrests cell cycle progression via post-transcriptional control of cyclin A expression.	Boston Univ, Sch Med, Ctr Canc Res, Boston, MA 02118 USA	Boston University	Vaziri, C (corresponding author), Boston Univ, Sch Med, Ctr Canc Res, 80 E Concord St, Boston, MA 02118 USA.				NCI NIH HHS [CA50454] Funding Source: Medline; NIEHS NIH HHS [ES09558] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009558, R29ES009558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAUM EJ, 1978, POLYCYCLIC HYDROCARB, P45; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; DIPPLE A, 1995, CARCINOGENESIS, V16, P437, DOI 10.1093/carcin/16.3.437; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; HEMMINKI K, 1993, CARCINOGENESIS, V14, P2007, DOI 10.1093/carcin/14.10.2007; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li DH, 1996, CANCER RES, V56, P287; Mastrangelo G, 1996, ENVIRON HEALTH PERSP, V104, P1166, DOI 10.2307/3432909; Minna John D., 1997, P849; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233; PRUESSSCHWARTZ D, 1988, CARCINOGENESIS, V10, P1863; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	29	33	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1715	1722		10.1074/jbc.275.3.1715	http://dx.doi.org/10.1074/jbc.275.3.1715			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636867	hybrid			2022-12-25	WOS:000084940000030
J	Li, SL; Paulsson, KM; Chen, SW; Sjogren, HO; Wang, P				Li, SL; Paulsson, KM; Chen, SW; Sjogren, HO; Wang, P			Tapasin is required for efficient peptide binding to transporter associated with antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; T-CELL RECEPTOR; TAP; COMPLEX; MOLECULES; SITE; MECHANISMS; ABSENCE	The transporter associated with antigen processing (TAP) binds peptides in its cytosolic part and subsequently translocates the peptides into the lumen of the endoplasmic reticulum (ER), where assembly of major histocompatibility complex (MHC) class I and peptide takes place. Tapasin is a subunit of the TAP complex and binds both to TAP1 and MHC class I. In the absence of tapasin, the assembly of MHC class I in the ER is impaired, and the surface expression is reduced. To clarify the function of tapasin in the processing of antigenic peptides, we studied the interaction of peptide and TAP, peptide transport across the membrane of the ER, and association of peptides with MHC class I molecules in the microsomes derived from tapasin mutant cell line 721.220, its sister cell line 721.221 expressing tapasin, and their HLA-A2 transfectants, The binding of peptides to TAP in tapasin mutant 721.220 cells was significantly diminished in comparison with 721.221 cells. Impaired peptide-TAP interaction resulted in a defective peptide transport in tapasin mutant 721.220 cells. Interestingly, despite the diminished peptide binding to TAP, the transport rate of TAP-associated peptides was not significantly altered in 721.220 cells. After transfection of tapasin cDNA into 721.220 cells, efficient peptide-TAP interaction was restored. Thus, we conclude that tapasin is required for efficient peptide-TAP interaction.	Univ Lund, S-22362 Lund, Sweden	Lund University	Li, SL (corresponding author), Univ Lund, Solvegatan 21, S-22362 Lund, Sweden.			Wang, Ping/0000-0001-8992-1233				ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI U S, V91, P716; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HILL A, 1995, P NATL ACAD SCI USA, V92, P341, DOI 10.1073/pnas.92.2.341; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lewis JW, 1998, EUR J IMMUNOL, V28, P3214, DOI 10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.3.CO;2-3; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; Li SL, 1999, J BIOL CHEM, V274, P8649, DOI 10.1074/jbc.274.13.8649; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PeaceBrewer AL, 1996, IMMUNITY, V4, P505, DOI 10.1016/S1074-7613(00)80416-1; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Suh WK, 1999, J IMMUNOL, V162, P1530; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; Wang P, 1996, J IMMUNOL, V157, P213; Wang P, 1996, J BIOL CHEM, V271, P24830, DOI 10.1074/jbc.271.40.24830	32	56	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1581	1586		10.1074/jbc.275.3.1581	http://dx.doi.org/10.1074/jbc.275.3.1581			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636848	hybrid			2022-12-25	WOS:000084940000011
J	Oberste-Berghaus, C; Zanger, K; Hashimoto, K; Cohen, RN; Hollenberg, AN; Wondisford, FE				Oberste-Berghaus, C; Zanger, K; Hashimoto, K; Cohen, RN; Hollenberg, AN; Wondisford, FE			Thyroid hormone-independent interaction between the thyroid hormone receptor beta 2 amino terminus and coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-RECEPTOR; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; DEOXYRIBONUCLEIC-ACID; RESPONSE ELEMENT; VARIANT ALPHA-2; CO-REPRESSOR; N-COR; BINDING; IDENTIFICATION	Thyroid hormone receptors (TRs) mediate hormone action by binding to DNA response elements (TREs) and either activating or repressing gene expression in the presence of ligand, T-3. Coactivator recruitment to the AF-2 region of TR in the presence of T-3 is central to this process. The different TR isoforms, TR-beta 1, TR-beta 2, and TR-alpha 1, share strong homology in their DNA- and ligand-binding domains but differ in their amino-terminal domains. Because TR-beta 2 exhibits greater T-3-independent activation on TREs than other TR isoforms, we wanted to determine whether coactivators bound to TR-beta 2 in the absence of ligand, Our results show that TR-beta 2, unlike TR-beta 1 or TR-alpha 1, is able to bind certain coactivators (CBP, SRC-1, and pCIP) in the absence of T-3 through a domain which maps to the amino-terminal half of its A/B domain. This interaction is specific for certain coactivators, as TR-beta 2 does not interact with other co-factors (p120 or the CBP-associated factor (pCAF)) in the absence of T-3, The minimal TR-beta 2 domain for coactivator binding is aa 21-50, although aa 1-50 are required for the full functional response. Thus, isoform specific regulation by TRs may involve T-3-independent coactivator recruitment to the transcription complex via the AF-1 domain.	Beth Israel Deaconess Med Ctr, Thyroid Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Wondisford, FE (corresponding author), Beth Israel Deaconess Med Ctr, Thyroid Unit, Res N,Rm 330C,99 Brookline Ave, Boston, MA 02215 USA.	fwondisf@caregroup.harvard.edu		Grasemann, Corinna/0000-0003-1793-4603				ABEL DE, 1999, IN PRESS J CLIN INVE, V104; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7119, DOI 10.1093/nar/11.20.7119; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; DAIMONT BD, 1998, GENE DEV, V12, P3343; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Hadzic E, 1998, J BIOL CHEM, V273, P10270, DOI 10.1074/jbc.273.17.10270; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HOLLENBERG AN, 1998, CURR OPIN ENDOCRINOL, V5, P314; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATZ D, 1993, J BIOL CHEM, V268, P20904; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LECHAN RM, 1994, ENDOCRINOLOGY, V135, P92, DOI 10.1210/en.135.1.92; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; SAKURAI A, 1990, MOL CELL ENDOCRINOL, V71, P83; SAKURAI A, 1989, MOL ENDOCRINOL, V3, P392, DOI 10.1210/mend-3-2-392; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	43	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1787	1792		10.1074/jbc.275.3.1787	http://dx.doi.org/10.1074/jbc.275.3.1787			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636876	hybrid			2022-12-25	WOS:000084940000039
J	Babenko, AP; Gonzalez, G; Bryan, J				Babenko, AP; Gonzalez, G; Bryan, J			Pharmaco-topology of sulfonylurea receptors - Separate domains of the regulatory subunits of K-ATP channel isoforms are required for selective interaction with K+ channel openers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; BINDING; MUSCLE; DEPENDENCE; KIR6.2	The differential responsiveness of (SUR1/K(IR)6.2)(4) pancreatic beta-cell versus (SUR2A/K(IR)6.2)(4) sarcolemmal or (SUR2B/K(IR)6.0)(4) smooth muscle cell K-ATP channels to K+ channel openers (KCOs) is the basis for the selective prevention of hyperinsulinemia, myocardial infarction, nd acute hypertension. KCO-stimulation of K-ATP channels is a unique example of functional coupling between a transport ATPase and a K+ inward rectifier. KCO binding to SUR is Mg-ATP-dependent and antagonizes the inhibition of (K(IR)6.0)(4) pore opening by nucleotides. Patch-clamping of matched chimeric human SUR1-SUR2A/K(IR)6.2 channels was used to identify the SUR regions that specify the selective response of sarcolemmal versus beta-cell channels to cromakalim or pinacidil versus diazoxide. The SUR2 segment containing the 12th through 17th predicted transmembrane domains, TMD12-17, confers sensitivity to the benzopyran, cromakalim, and the pyridine, pinacidil, whereas an SUR1 segment which includes TMD6-11 and the first nucleotide-binding fold, NBF1, controls responsiveness to the benzothiadiazine, diazoxide, These data are incorporated into a functional topology model for the regulatory SUR subunits of K-ATP channels.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Babenko, AP (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.							Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ARENA JP, 1989, AM J PHYSIOL, V257, pH2092; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; BABENKO AP, 1999, FRONTIERS DIABETES, P300; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Dickinson KEJ, 1997, MOL PHARMACOL, V52, P473, DOI 10.1124/mol.52.3.473; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; ESCANDE D, 1988, BIOCHEM BIOPH RES CO, V154, P620, DOI 10.1016/0006-291X(88)90184-2; Hambrock A, 1999, MOL PHARMACOL, V55, P832; Hambrock A, 1998, BRIT J PHARMACOL, V125, P577, DOI 10.1038/sj.bjp.0702109; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Uhde I, 1999, J BIOL CHEM, V274, P28079, DOI 10.1074/jbc.274.40.28079; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	35	102	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					717	720		10.1074/jbc.275.2.717	http://dx.doi.org/10.1074/jbc.275.2.717			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625598	hybrid			2022-12-25	WOS:000084836600002
J	Martin, H; Rodriguez-Pachon, JM; Ruiz, C; Nombela, C; Molina, M				Martin, H; Rodriguez-Pachon, JM; Ruiz, C; Nombela, C; Molina, M			Regulatory mechanisms for modulation of signaling through the cell integrity Slt2-mediated pathway in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; EXCHANGE FACTOR ROM2; MAP KINASE; TYROSINE PHOSPHATASES; TRANSDUCTION PATHWAY; SHUTTLE VECTORS; STRESS-RESPONSE; WALL INTEGRITY; BUD EMERGENCE	Signal transduction mediated by the mitogen-activated protein kinase (MAPK) Slt2 pathway is essential to maintain the cell wall integrity in Saccharomyces cerevisiae. Stimulation of MAPK pathways results in activation by phosphorylation of conserved threonine and tyrosine residues of MAPKs. We have used an antibody that specifically recognizes dually phosphorylated Slt2 to gain insight into the activation and modulation of signaling through the cell integrity pathway. We show that caffeine and vanadate activate this pathway in the absence of osmotic stabilization. The lack of the putative cell surface sensor Mid2 prevents vanadate- but not caffeine-induced Slt2 phosphorylation. Disruption of the Rhol-GTPase-activating protein genes SAC7 and BEM2 leads to constitutive Slt2 activation, indicating their involvement as negative regulators of the pathway. MAPK kinases also seem to participate in signaling regulation, Mkk1 playing a greater role than Mkk2 in signal transmission to Slt2. Additionally, one of the phosphatases involved in Slt2 dephosphorylation is likely to be the dual specificity phosphatase Msg5, since overexpression of MSG5 in a sac7 Delta mutant eliminates the high Slt2 phosphorylation, and disruption of MSG5 in wild type cells results in increased phosphorylation levels, These data present the first evidence for a negative regulation of the cell integrity pathway.	Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain	Complutense University of Madrid	Molina, M (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, Plaza Ramon & Cajal S-N, E-28040 Madrid, Spain.	molmifa@eucmax.sim.ucm.es	Nombela Cano, César/H-2565-2015; Brieva, Humberto Martin/E-9254-2016; Ruiz-Romero, Cristina/B-2937-2009; Ruiz-Romero, Cristina/A-8690-2012; Martín, Humberto/Z-3423-2019; Molina, Maria/ABE-7186-2021	Nombela Cano, César/0000-0003-0757-4034; Brieva, Humberto Martin/0000-0002-6736-3602; Ruiz-Romero, Cristina/0000-0001-7649-9803; Martín, Humberto/0000-0002-6736-3602; Molina, Maria/0000-0003-0074-3309				BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DUNN TM, 1990, MOL CELL BIOL, V10, P2308, DOI 10.1128/MCB.10.5.2308; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; HUANG KN, 1995, GENETICS, V141, P1275; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacoby JJ, 1998, MOL GEN GENET, V258, P148, DOI 10.1007/s004380050717; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KANIKENNULAT C, 1995, GENETICS, V140, P933; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Lussier M, 1997, GENETICS, V147, P435; Mannazzu I, 1998, MICROBIOL-SGM, V144, P2589, DOI 10.1099/00221287-144-9-2589; Martin H, 1996, CURR GENET, V29, P516; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Nakamura T, 1997, MOL GEN GENET, V256, P481, DOI 10.1007/s004380050592; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PARSONS WJ, 1988, MOL PHARMACOL, V34, P37; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Ruiz C, 1999, YEAST, V15, P1001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLER M, 1995, MOL MICROBIOL, V17, P833, DOI 10.1111/j.1365-2958.1995.mmi_17050833.x; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; TAKEUCHI J, 1995, BBA-GENE STRUCT EXPR, V1260, P94, DOI 10.1016/0167-4781(94)00188-9; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690	61	292	296	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1511	1519		10.1074/jbc.275.2.1511	http://dx.doi.org/10.1074/jbc.275.2.1511			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625705	hybrid			2022-12-25	WOS:000084836600109
J	Petiot, A; Ogier-Denis, E; Blommaart, EFC; Meijer, AJ; Codogno, P				Petiot, A; Ogier-Denis, E; Blommaart, EFC; Meijer, AJ; Codogno, P			Distinct classes of phosphatidylinositol 3 '-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; PROTEIN-KINASE-B; PHOSPHOINOSITIDE 3-KINASE ACTIVITY; CONTROLS AUTOPHAGIC SEQUESTRATION; C2 DOMAIN; AKT PROTOONCOGENE; MOUSE FIBROBLASTS; LATE ENDOSOMES; PI 3-KINASE; LINE HT-29	3-Methyladenine which stops macroautophagy at the sequestration step in mammalian cells also inhibits the phosphoinositide 3-kinase (PI3K) activity raising the possibility that PI3K signaling controls the macroautophagic pathway (Blommaart, E. F. C., Krause, U., Schellens, J. P. M., Vreeling-Sindelarova, H., and Meijer, A. J. (1997) fur. J, Biochem. 243, 240-246). The aim of this study was to identify PI3Ks involved in the control of macroautophagic sequestration in human colon cancer HT-29 cells. An increase of class I PISK products (phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-triphosphate) caused by either feeding cells with synthetic lipids (dipalmitoyl phosphatidylinositol 3,4-bisphosphate and dipalmitoyl phosphatidylinositol 3,4,5-triphosphate) or by stimulating the enzymatic activity by interleukin-13 reduced macroautophagy, In contrast, an increase in the class III PISK product (phosphatidylinositol 3-phosphate), either by feeding cells with a synthetic lipid or by overexpressing the p150 adaptor, stimulates macroautophagy. Transfection of a specific class III PISK antisense oligonucleotide greatly inhibited the rate of macroautophagy. In accordance with a role of class III PISK, wortmannin tan inhibitor of PI3Ks) inhibits macroautophagic sequestration and protein degradation in the low nanomolar range (IC50 5-15 nM), Further in vitro enzymatic assay showed that 3-methyladenine inhibits the class III PISK activity. Dipalmitoyl phosphatidylinositol 3-phosphate supplementation or p150 overexpression rescued the macroautophagic pathway in HT-29 cells overexpressing a GTPase-deficient mutant of the G alpha(i3) protein suggesting that both class III PISK and trimeric G(i3) protein signaling are required in the control macroautophagy in HT-29 cells. In conclusion, our results demonstrate that distinct classes of PI3K control the macroautophagic pathway in opposite directions. The roles of PI3Ks in macroautophagy are discussed in the context of membrane recycling.	INSERM, U504, F-94807 Villejuif, France; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Amsterdam; Academic Medical Center Amsterdam	Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	codogno@vjf.inserm.fr	Ogier-Denis, Eric/E-5030-2016; Codogno, Patrice/G-1384-2013	Codogno, Patrice/0000-0002-5492-3180; PETIOT, Anne/0000-0001-8038-470X; Ogier-Denis, Eric/0000-0002-0057-7593				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Berg TO, 1998, J BIOL CHEM, V273, P21883, DOI 10.1074/jbc.273.34.21883; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Codogno P, 1997, CELL SIGNAL, V9, P125, DOI 10.1016/S0898-6568(96)00130-1; Daniele N, 1999, J BIOL CHEM, V274, P3597, DOI 10.1074/jbc.274.6.3597; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Hickinson DM, 1997, CURR BIOL, V7, P987, DOI 10.1016/S0960-9822(06)00418-0; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; MACDOUGLAS LK, 1995, CURR BIOL, V5995, P1404; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; PUNNONEN EL, 1994, EUR J CELL BIOL, V65, P14; Reaves BJ, 1996, J CELL SCI, V109, P749; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Stromhaug PE, 1998, BIOCHEM J, V335, P217, DOI 10.1042/bj3350217; Thyberg J, 1998, EUR J CELL BIOL, V76, P33, DOI 10.1016/S0171-9335(98)80015-0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wright K, 1999, J BIOL CHEM, V274, P17193, DOI 10.1074/jbc.274.24.17193; Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	58	995	1048	1	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					992	998		10.1074/jbc.275.2.992	http://dx.doi.org/10.1074/jbc.275.2.992			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625637	hybrid			2022-12-25	WOS:000084836600041
J	Rubenhagen, R; Ronsch, H; Jung, H; Kramer, R; Morbach, S				Rubenhagen, R; Ronsch, H; Jung, H; Kramer, R; Morbach, S			Osmosensor and osmoregulator properties of the betaine carrier BetP from Corynebacterium glutamicum in proteoliposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCAL-ANESTHETIC TETRACAINE; ESCHERICHIA-COLI; GLYCINE BETAINE; POLYACRYLAMIDE GELS; COMPATIBLE SOLUTES; UPTAKE SYSTEM; CELL-WALL; PROTEINS; STRESS; PHYSIOLOGY	The secondary glycine betaine uptake system BetP of Corynebacterium glutamicum was purified from Escherichia coli membranes in strep-tagged form after heterologous expression of the betP gene and was reconstituted in E, coli lipids. BetP retained its kinetic properties (V-max and K-m for betaine and Na+) as compared with intact cells. The influence of driving forces (Na+ gradient and/or electrical potential) on betaine uptake was quantified in proteoliposomes. BetP was effectively regulated by the external osmolality and was stimulated by the local anesthetic tetracaine. A shift of the optimum of osmotic stimulation to higher osmolalities was linearly correlated with an increasing share of phosphatidyl glycerol, the major lipid of the C. glutamicum plasma membrane in the E. coli lipid proteoliposomes, This finding correlates with results demonstrating an identical shift when betP was expressed in E. coli instead of C. glutamicum. These data indicate that (i) BetP comprises all elements of osmosensing and osmoregulatory mechanisms of betaine uptake, (ii) osmoregulation of BetP is directly related to protein/membrane interactions, (iii) the turgor pressure presumably plays no major role in osmoregulation of BetP, and (iv) the regulatory properties of BetP may be related to the physical state of the surrounding membrane.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany; Univ Osnabruck, Abt Mikrobiol, Fachbereich Biol Chem, D-49069 Osnabruck, Germany	University of Cologne; University Osnabruck	Kramer, R (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-50674 Cologne, Germany.		Jung, Heinrich/K-3790-2014	Jung, Heinrich/0000-0002-5450-3063				AUGER M, 1988, BIOCHEMISTRY-US, V27, P6086, DOI 10.1021/bi00416a038; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGER U, 1999, THESIS U BONN GERMAN; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CREMER J, 1990, MOL GEN GENET, V220, P478, DOI 10.1007/BF00391757; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; Epand RM, 1998, BBA-REV BIOMEMBRANES, V1376, P353, DOI 10.1016/S0304-4157(98)00015-X; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; HOISCHEN C, 1990, J BACTERIOL, V172, P3409, DOI 10.1128/jb.172.6.3409-3416.1990; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; KRAMER R, 1994, FEMS MICROBIOL REV, V13, P75, DOI 10.1111/j.1574-6976.1994.tb00036.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT C, 1995, APPL ENVIRON MICROB, V61, P4334, DOI 10.1128/AEM.61.12.4334-4342.1995; LANDFALD B, 1986, J BACTERIOL, V165, P849, DOI 10.1128/jb.165.3.849-855.1986; Lichtinger T, 1998, BIOCHEMISTRY-US, V37, P15024, DOI 10.1021/bi980961e; LYTEN K, 1995, EMBO J, V14, P1360; MILNER JL, 1988, J BIOL CHEM, V263, P14900; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; Peter H, 1998, J BIOL CHEM, V273, P2567, DOI 10.1074/jbc.273.5.2567; Peter H, 1998, J BACTERIOL, V180, P6005, DOI 10.1128/JB.180.22.6005-6012.1998; Peter H, 1996, J BACTERIOL, V178, P5229, DOI 10.1128/jb.178.17.5229-5234.1996; PRASAD R, 1996, MANUAL MEMBRANE LIPI; Racher KI, 1999, BIOCHEMISTRY-US, V38, P1676, DOI 10.1021/bi981279n; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; SEDDON JM, 1993, PHOSPHOLIPID HDB, P404; SHIMOOKA T, 1992, BIOCHIM BIOPHYS ACTA, V1104, P261, DOI 10.1016/0005-2736(92)90039-O; SKERRA A, 1994, GENE, V151, P131, DOI 10.1016/0378-1119(94)90643-2; Strange K, 1996, NEWS PHYSIOL SCI, V11, P146; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Umaprasad G, 1998, J GENET, V77, P1, DOI 10.1007/BF02933035; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0	39	101	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					735	741		10.1074/jbc.275.2.735	http://dx.doi.org/10.1074/jbc.275.2.735			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625602	hybrid			2022-12-25	WOS:000084836600006
J	Xiao, HY; Hasegawa, T; Isobe, K				Xiao, HY; Hasegawa, T; Isobe, K			p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; BINDING-PROTEIN; ACETYLTRANSFERASE ACTIVITY; TBP COMPLEXES; TRANSCRIPTION; E1A; DIFFERENTIATION; INDUCTION; WAF1/CIP1; DOMAIN	We have reported that histone acetylation induced by trichostatin A (TSA) promotes p21(waf1/cip1) (p21) expression, the GC-box located just upstream of TATA box was responsible for TSA-induced promoter activation, and both Spl and Sp3 were the working activator of this GC-box, To understand the molecular pathway from histone acetylation to this Spl family factors-mediated promoter activation, we investigated the function of p300, one of the histone acetyltransferase, in the present work. The evidence supporting the linkage between p300 and TSA-induced p21 promoter activation were realized from the following findings: 1) cotransfection of p300 elevated pal promoter activity, and this elevation was dependent on TSA-responsive GC-box; 2) TSA-induced promoter activation was blocked by the introduction of p300 dominant-negative mutant into cells; and 3) Sp1- or Sp3-mediated activation was also suppressed by this p300 dominant-negative mutant. Our data also suggested that p300 collaborates with Spl in a way which is different from that when p300 collaborates with p53 in p21 transcription.	Natl INst Longev Sci, Dept Basic Gerontol, Aichi 4748522, Japan; W China Univ Med Sci, Canc Res Inst, Chengdu 610041, Peoples R China	Sichuan University	Isobe, K (corresponding author), Natl INst Longev Sci, Dept Basic Gerontol, 36-3 Gengo Morioka Cho, Aichi 4748522, Japan.		isobe, ken-ichi/A-6685-2011	isobe, ken-ichi/0000-0002-8150-2496				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Billon N, 1996, ONCOGENE, V13, P2047; BOND JA, 1995, CANCER RES, V55, P2404; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HARPER JW, 1993, CELL, V75, P806; JIANG HP, 1994, ONCOGENE, V9, P3397; JONSON M, 1994, MOL CARCINOGEN, V11, P59; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Parks CL, 1996, J BIOL CHEM, V271, P4417; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; Shetty S, 1999, BIOCHEM J, V339, P751, DOI 10.1042/0264-6021:3390751; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	36	154	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1371	1376		10.1074/jbc.275.2.1371	http://dx.doi.org/10.1074/jbc.275.2.1371			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625687	hybrid			2022-12-25	WOS:000084836600091
J	Barroso, S; Richard, F; Nicolas-Etheve, D; Reversat, JL; Bernassau, JM; Kitabgi, P; Labbe-Jullie, C				Barroso, S; Richard, F; Nicolas-Etheve, D; Reversat, JL; Bernassau, JM; Kitabgi, P; Labbe-Jullie, C			Identification of residues involved in neurotensin binding and modeling of the agonist binding site in neurotensin receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PROTEIN-COUPLED RECEPTORS; CONSERVED EXTRACELLULAR CYSTEINES; AMINO-ACID-RESIDUES; NEUROKININ-1 RECEPTOR; NONPEPTIDE ANTAGONIST; DIRECTED MUTAGENESIS; DISULFIDE BOND; NK1 RECEPTOR; DOMAINS	The neurotensin receptor 1 (NTR1) subtype belongs to the family of G protein-coupled receptors and mediates most of the known effects of the neuropeptide including modulation of central dopaminergic transmission. This suggested that nonpeptide agonist mimetics acting at the NTR1 might be helpful in the treatment of Parkinson's disease and schizophrenia. Here, we attempted to define the molecular interactions between neurotensin-(8-13), the pharmacophore of neurotensin, and the rat NTR1, Mutagenesis of the NTR1 identified residues that interact with neurotensin, Structure-activity studies with neurotensin-(8-13) analogs identified the peptide residues that interact with the mutated amino acids in the receptor. By taking these data into account, computer-assisted modeling techniques were used to build a tridimensional model of the neurotensin-(8-13)-binding site in which the N-terminal tetrapeptide of neurotensin(8-13) fits in the third extracellular loop and the C-terminal dipeptide binds to residues at the junction between the extracellular and transmembrane domains of the receptor. Interestingly, the agonist binding site lies on top of the previously described NTR1-binding site for the nonpeptide neurotensin antagonist SR 48692, Our data provide a basis for understanding at the molecular level the agonist and antagonist binding modes and may help design nonpeptide agonist mimetics of the NTR1.	Univ Nice, Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, F-06560 Valbonne, France; Sanofi Rech, Ctr Montpellier, F-3418 Montpellier 04, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Sanofi-Aventis; Sanofi France	Labbe-Jullie, C (corresponding author), Univ Nice, Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.			Labbe-Jullie, Catherine/0000-0001-6398-3807				Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BALDWIN JM, 1997, J MOL BIOL, V213, P899; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; Betancur C, 1997, TRENDS PHARMACOL SCI, V18, P372, DOI 10.1016/S0165-6147(97)01109-7; BHOGAL N, 1994, J BIOL CHEM, V269, P27269; BIDARD JN, 1993, BIOCHEM J, V291, P225, DOI 10.1042/bj2910225; Botto JM, 1997, MOL BRAIN RES, V46, P311, DOI 10.1016/S0169-328X(97)00006-5; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; Dubuc I, 1999, J NEUROSCI, V19, P503, DOI 10.1523/JNEUROSCI.19-01-00503.1999; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; Huang RRC, 1995, BIOCHEMISTRY-US, V34, P16467, DOI 10.1021/bi00050a030; Jagerschmidt A, 1998, MOL PHARMACOL, V53, P878; JI H, 1994, J BIOL CHEM, V269, P16533; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KITABGI P, 1989, NEUROCHEM INT, V14, P111, DOI 10.1016/0197-0186(89)90110-1; Labbe-Jullie C, 1998, J BIOL CHEM, V273, P16351, DOI 10.1074/jbc.273.26.16351; LABBEJULLIE C, 1995, MOL PHARMACOL, V47, P1050; LABBEJULLIE C, 1994, J PHARMACOL EXP THER, V271, P267; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Mazella J, 1996, J NEUROSCI, V16, P5613; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NIETO JL, 1986, INT J PEPT PROT RES, V28, P315; Pang YP, 1996, J BIOL CHEM, V271, P15060, DOI 10.1074/jbc.271.25.15060; PERLMAN JH, 1995, J BIOL CHEM, V270, P24682, DOI 10.1074/jbc.270.42.24682; Perlman JH, 1996, BIOCHEMISTRY-US, V35, P7643, DOI 10.1021/bi952202r; Perlman JH, 1997, BIOCHEMISTRY-US, V36, P15670, DOI 10.1021/bi9713310; Postina R, 1996, J BIOL CHEM, V271, P31593, DOI 10.1074/jbc.271.49.31593; PRESTI ME, 1993, AM J PHYSIOL, V264, pG399, DOI 10.1152/ajpgi.1993.264.3.G399; QUERE L, 1996, J CHEM SOC P1, V2, P2639; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; Turcatti G, 1997, J BIOL CHEM, V272, P21167, DOI 10.1074/jbc.272.34.21167; Valiquette M, 1996, J BIOL CHEM, V271, P18789, DOI 10.1074/jbc.271.31.18789; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; Vita N, 1998, EUR J PHARMACOL, V360, P265, DOI 10.1016/S0014-2999(98)00678-5; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; Webb ML, 1996, BIOCHEMISTRY-US, V35, P2548, DOI 10.1021/bi951836v; XU GY, 1991, INT J PEPT PROT RES, V37, P528; YAMADA M, 1994, MOL PHARMACOL, V46, P470	51	73	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					328	336		10.1074/jbc.275.1.328	http://dx.doi.org/10.1074/jbc.275.1.328			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617622	hybrid			2022-12-25	WOS:000085951600046
J	Chang, T; Kuo, MC; Khoo, KH; Inoue, S; Inoue, Y				Chang, T; Kuo, MC; Khoo, KH; Inoue, S; Inoue, Y			Developmentally regulated expression of a peptide : N-Glycanase during germination of rice seeds (Oryza sativa) and its purification and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-CELL SUSPENSION; I HEAVY-CHAINS; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; ANIMAL-CELLS; GLYCOSYLATION; GLYCOSIDASE; PROTEINS; PNGASE; GLYCOPEPTIDASE	Peptide:N-glycanase (PNGase; EC 3.5.1.52) activity was detected in dormant rice seeds (Oryza sativa) and the imbibed rice grains. Time-course studies revealed that the enzyme activity remained almost constant until about 30 h after imbibition in both of endosperm- and embryo tissue-containing areas, and started to increase only in growing germ part, reached a peak at about 3-day stage, followed by a gradual decrease concomitant with a sharp increase in the coleoptile. The specific activity increased about g-fold at about 3-day stage. PN-Gase was purified to electrophoretic homogeneity from the extracts of germinated rice seeds at 24 h, and the apparent molecular weight of the purified enzyme, estimated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), was about 80,000. The purified enzyme was designated PNGase Os to denote its origin. The N-terminal sequence of the 10 residues was determined to be SYN-VASVAGL, The purified PNGase Os in SDS-PAGE appeared as a rather broad band, consistent with the presence of multiple glycoforms as indicated by chromatographic behavior on a Sephadex G-75 column. PNGase expressed in coleoptile under anoxia condition was also purified, and both of the purified enzymes were found to exhibit very similar, if not identical, electrophoretic mobility in SDS-PAGE. PNGase Os exhibited a broad pH-activity profile with an optimum of 4-5 and, interestingly, was significantly inactivated by K+ and Na+ at near the physiological concentration, 100 mM. These results are discussed in relation to other work.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan	Inoue, Y (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.		Khoo, Kay-Hooi/E-1989-2019; Chen, Tianren/AAS-6018-2021	Khoo, Kay-Hooi/0000-0003-2906-406X; 				Berger S, 1995, BIOCHIMIE, V77, P751, DOI 10.1016/0300-9084(96)88193-4; BRUMMELL DA, 1987, PLANT CELL ENVIRON, V10, P523, DOI 10.1111/1365-3040.ep11603897; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; INOUE S, 1990, TRENDS GLYCOSCI GLYC, V2, P225; ISHIHARA H, 1979, J BIOL CHEM, V254, P715; ISHIZAWA K, 1984, PLANT CELL ENVIRON, V7, P239, DOI 10.1111/j.1365-3040.1984.tb01345.x; KITAJIMA K, 1995, ARCH BIOCHEM BIOPHYS, V319, P393, DOI 10.1006/abbi.1995.1309; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Ku H S, 1970, Planta, V90, P333, DOI 10.1007/BF00386385; LHERNOULD S, 1995, GLYCOCONJUGATE J, V12, P94, DOI 10.1007/BF00731874; LHERNOULD S, 1992, GLYCOCONJUGATE J, V9, P191, DOI 10.1007/BF00731164; NAPIER RM, 1995, NEW PHYTOL, V129, P167, DOI 10.1111/j.1469-8137.1995.tb04291.x; PLUMMER TH, 1987, EUR J BIOCHEM, V163, P167, DOI 10.1111/j.1432-1033.1987.tb10751.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PRIEM B, 1994, BIOCHEM SOC T, V22, P398, DOI 10.1042/bst0220398; PRIEM B, 1992, PLANT PHYSIOL, V98, P399, DOI 10.1104/pp.98.1.399; PRIEM B, 1993, PLANT PHYSIOL, V102, P445, DOI 10.1104/pp.102.2.445; PRIEM B, 1990, GLYCOCONJUGATE J, V7, P121, DOI 10.1007/BF01050375; SEKO A, 1991, J BIOL CHEM, V266, P22110; Seko A, 1999, GLYCOBIOLOGY, V9, P887, DOI 10.1093/glycob/9.9.887; SEKO A, 1991, BIOCHEM BIOPH RES CO, V180, P165; SUGIYAMA K, 1983, BIOCHEM BIOPH RES CO, V112, P155, DOI 10.1016/0006-291X(83)91810-7; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; Suzuki T, 1997, P NATL ACAD SCI USA, V94, P6244, DOI 10.1073/pnas.94.12.6244; Suzuki T, 1998, J BIOL CHEM, V273, P21526, DOI 10.1074/jbc.273.34.21526; SUZUKI T, 1995, GLYCOCONJUGATE J, V12, P183, DOI 10.1007/BF00731318; SUZUKI T, 1994, GLYCOCONJUGATE J, V11, P469, DOI 10.1007/BF00731283; SUZUKI T, 1995, J BIOL CHEM, V270, P15181, DOI 10.1074/jbc.270.25.15181; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P777, DOI 10.1093/glycob/4.6.777; SUZUKI T, 1997, GLYCOSCIENCES STATUS, P122; TAGA EM, 1984, BIOCHEMISTRY-US, V23, P815, DOI 10.1021/bi00300a006; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; YET MG, 1988, J BIOL CHEM, V263, P118; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	40	34	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					129	134		10.1074/jbc.275.1.129	http://dx.doi.org/10.1074/jbc.275.1.129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617595	hybrid			2022-12-25	WOS:000085951600019
J	Segui, B; Bezombes, C; Uro-Coste, E; Medin, JA; Andrieu-Abadie, N; Auge, N; Brouchet, A; Laurent, G; Salvayre, R; Jaffrezou, JP; Levade, T				Segui, B; Bezombes, C; Uro-Coste, E; Medin, JA; Andrieu-Abadie, N; Auge, N; Brouchet, A; Laurent, G; Salvayre, R; Jaffrezou, JP; Levade, T			Stress-induced apoptosis is not mediated by endolysosomal ceramide	FASEB JOURNAL			English	Article						sphingomyelin; sphingomyelinase; Farber disease; ceramidase; lysosome; signal transduction	TUMOR-NECROSIS-FACTOR; NIEMANN-PICK DISEASE; FACTOR-KAPPA-B; ACID SPHINGOMYELINASE; SIGNAL-TRANSDUCTION; LYSOSOMAL SPHINGOMYELINASE; CELL-PROLIFERATION; IONIZING-RADIATION; HUMAN FIBROBLASTS; PHOSPHOLIPASE-C	A major lipid-signaling pathway in mammalian cells implicates the generation of ceramide from the ubiquitous sphingolipid sphingo-mylein (SM). hydrolysis of SM by a sphingomyleinase present in acidic compartments has been reported to mediate, via the production of ceramide, the apoptotic cell death triggered by stress-reducing agents. In the present study, we investigate whether the ceramide formed within or accumulated in lysosomes indeed triggers apoptosis. A series of observations strongly suggests that ceramide involved in stress-induced apoptosis is not endolysosomal: 1) Although short-chain ceramides induced through apoptosis, loading cells with natural ceramide through receptor-mediated endocytosis did not result in cell death. 2) Neither TNF-alpha nor anti-CD95 induced the degradation to ceramide of a natural SM that had been first introduced selectively into acidic compartments. 3) Stimulation of SV40-transformed fibroblasts by TNF-alpha or CD40 ligand resulted in apoptosis equally well in cells derived from control individuals and from patients affected with Farber disease, having a genetic defect of acid ceramidase activity leading to lysosomal accumulation of ceramide. Also, induction of apoptosis using anti-CD95 (Fas) or anti-CD40 antibodies, TNF-alpha, daunorubicin, and ionizing radiation was similar in control and Farber disease lymphoidcells. in all cases, apoptosis was preceeded by a comparable increase of intracellular ceramide levels. 4) Retro-viral-mediated gene transfer and overexpression of acid ceramidase in Farber fibroblasts,which led to complete metabolic correction of the ceramide catabolic defect, did not affect the cell response to TNF-alpha and CD40 ligand.	CHU Rangueil, Inst Louis Bugnard, Lab Biochim Maladies Metabol, INSERM U 466, F-31403 Toulouse 4, France; Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France; Univ Illinois, Hematol Oncol Sect, Chicago, IL USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Levade, T (corresponding author), CHU Rangueil, Inst Louis Bugnard, Lab Biochim Maladies Metabol, INSERM U 466, Bat L3,1 Ave Jean Poulhes, F-31403 Toulouse 4, France.		Bezombes, christine/X-8479-2019; Andrieu-Abadie, Nathalie/N-6793-2013; Bezombes, Christine/G-2743-2017; Bezombes, Christine/AAC-1724-2020; Levade, Thierry/O-8948-2014; Ségui, Bruno/O-8957-2014	Bezombes, christine/0000-0003-4079-4872; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Ségui, Bruno/0000-0002-6119-1889; Auge, Nathalie/0000-0003-2088-7211				Adam D, 1998, BIOCHEM J, V333, P343, DOI 10.1042/bj3330343; Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; Antonarakis S, 1983, PEDIATR RES, V17, p206A; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Bettaieb A, 1999, MOL PHARMACOL, V55, P118, DOI 10.1124/mol.55.1.118; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Chatelut M, 1996, CLIN CHIM ACTA, V245, P61, DOI 10.1016/0009-8981(95)06173-8; Chatelut M, 1997, CLIN CHIM ACTA, V262, P61, DOI 10.1016/S0009-8981(97)06527-3; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DECOCK JGR, 1998, J BIOL CHEM, V273, P7560; DULANEY JT, 1977, PRACTICAL ENZYMOLOGY, P283; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GRABER D, 1994, J NEUROCHEM, V63, P1060; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jaffrezou JP, 1998, LEUKEMIA LYMPHOMA, V29, P453, DOI 10.3109/10428199809050905; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levade T, 1996, J LIPID RES, V37, P2525; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Manthey CL, 1998, CYTOKINE, V10, P654, DOI 10.1006/cyto.1998.0344; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; Medin JA, 1999, HUM GENE THER, V10, P1321, DOI 10.1089/10430349950018003; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MOSER HW, 1995, METABOLIC MOL BASES, P2589; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Skowronski EW, 1996, CELL DEATH DIFFER, V3, P171; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Stoffel B, 1998, EUR J IMMUNOL, V28, P874, DOI 10.1002/(SICI)1521-4141(199803)28:03<874::AID-IMMU874>3.0.CO;2-T; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Woodle ES, 1997, J IMMUNOL, V158, P2156; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	72	47	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					36	47		10.1096/fasebj.14.1.36	http://dx.doi.org/10.1096/fasebj.14.1.36			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627278				2022-12-25	WOS:000084784700006
J	Osickova, A; Osicka, R; Maier, E; Benz, R; Sebo, P				Osickova, A; Osicka, R; Maier, E; Benz, R; Sebo, P			An amphipathic alpha-helix including glutamates 509 and 516 is crucial for membrane translocation of adenylate cyclase toxin and modulates formation and cation selectivity of its membrane channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-INVASIVE ACTIVITY; BORDETELLA-PERTUSSIS; ESCHERICHIA-COLI; MACROPHAGE APOPTOSIS; HEMOLYTIC ACTIVITIES; HYDROPHOBIC MOMENT; PORE FORMATION; IN-VIVO; CALMODULIN; PROTEIN	The Bordetella pertussis adenylate cyclase toxin-hemolysin (ACT or CyaA) is a multifunctional protein. It forms small cation-selective channels in target cell and lipid bilayer membranes and it delivers into cell cytosol the amino-terminal adenylate cyclase (AC) domain, which catalyzes uncontrolled conversion of ATP to cAMP and causes cell intoxication. Here, we demonstrate that membrane translocation of the AC domain into cells is selectively dissociated from ACT membrane insertion and channel formation when a helix-breaking proline residue is substituted for glutamate 509 (Glu-509) within a predicted transmembrane amphipathic alpha-helix. Neutral substitutions of Glu-509 had little effect on toxin activities. In contrast, charge reversal by lysine substitutions of the Glu-509 or of the adjacent Glu-516 residue reduced the capacity of the toxin to translocate the AC domain across membrane and enhanced significantly its specific hemolytic activity and channel forming capacity in lipid bilayer membranes. Combination of the E509K and E516K mutations in a single molecule further exacerbated hemolytic and channel forming activity and ablated translocation of the AC domain into cells. The lysine substitutions strongly decreased the cation selectivity of the channels, indicating that Glu-509 and Glu-516 are located within or close to the membrane channel. These results suggest that the structure including glutamate residues 509 and 516 is critical for AC membrane translocation and channel forming activity of ACT.	Acad Sci Czech Republ, Inst Microbiol, Cellular & Mol Microbiol Div, CZ-14220 Prague 4, Czech Republic; Univ Wurzburg, Theodor Boveri Inst, Biozentrum, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Wurzburg	Sebo, P (corresponding author), Acad Sci Czech Republ, Inst Microbiol, Cellular & Mol Microbiol Div, Videoska 1083, CZ-14220 Prague 4, Czech Republic.	sebo@biomed.cas.cz	SEBO, Peter/F-7423-2011; Osickova, Adriana/H-6841-2014; Osicka, Radim/H-6776-2014; SEBO, Peter/N-2043-2019	SEBO, Peter/0000-0002-9755-7715; Osickova, Adriana/0000-0002-5739-1183; Osicka, Radim/0000-0003-2626-5456; SEBO, Peter/0000-0002-9755-7715; Benz, Roland/0000-0002-9510-9265				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BENZ R, 1994, EUR J BIOCHEM, V220, P339, DOI 10.1111/j.1432-1033.1994.tb18630.x; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GORDON VM, 1989, J BIOL CHEM, V264, P14792; Gray M, 1998, J BIOL CHEM, V273, P18260, DOI 10.1074/jbc.273.29.18260; Gueirard P, 1998, INFECT IMMUN, V66, P1718, DOI 10.1128/IAI.66.4.1718-1725.1998; Guermonprez P, 1999, J IMMUNOL, V162, P1910; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HEWLETT EL, 1983, CLIN RES, V31, pA365; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; Karimova G, 1998, P NATL ACAD SCI USA, V95, P12532, DOI 10.1073/pnas.95.21.12532; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; KRISHTALIK LI, 1995, FEBS LETT, V369, P140, DOI 10.1016/0014-5793(95)00756-Y; LADANT D, 1988, J BIOL CHEM, V263, P2612; OTERO AS, 1995, J BIOL CHEM, V270, P9695, DOI 10.1074/jbc.270.17.9695; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; SEBO P, 1993, MOL MICROBIOL, V9, P999, DOI 10.1111/j.1365-2958.1993.tb01229.x; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SZABO G, 1994, J BIOL CHEM, V269, P22496; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	42	75	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37644	37650						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608820				2022-12-25	WOS:000084528000020
J	Bryckaert, M; Guillonneau, X; Hecquet, C; Courtois, Y; Mascarelli, F				Bryckaert, M; Guillonneau, X; Hecquet, C; Courtois, Y; Mascarelli, F			Both FGF1 and Bcl-x synthesis are necessary for the reduction of apoptosis in retinal pigmented epithelial cells by FGF2: role of the extracellular signal-regulated kinase 2	ONCOGENE			English	Article						FGF; Bcl-x; ERK2; apoptosis; retinal pigmented epithelial cells	FIBROBLAST-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; PEROXYNITRITE-INDUCED APOPTOSIS; FACTOR-I; PHOTORECEPTOR DEGENERATION; NEUROTROPHIC ACTIVITY; PROTOONCOGENE BCL-2; ENDOGENOUS FGF1; PC12 CELLS	Retinal pigmented epithelial (RPE) cells are of central importance in the maintenance of neural retinal function. Changes in the RPE cells associated with repair activities have been described as metaplasia, while RPE cell apoptosis is responsible for the development of a variety of retinal degenerations. We investigated the regulation of the anti-apoptotic properties of the fibroblast growth factors (FGF) 2 in serum-free cultures of RPE cells, In the absence of serum, confluent stationary RPE cells died by apoptosis via a caspase 3-dependent pathway, The addition of FGF2 greatly reduced apoptosis over a 7-day culture period, We demonstrated the involvement of an autocrine loop involving endogenous FGF1 in the mechanisms that govern FGF2-induced resistance to apoptosis by showing: (1) higher levels of apoptosis in cells treated with antisense FGF1 oligonucleotide or after neutralization of excreted FGF1; (2) the long-term activation of FGFR1 and of ERK2, (3) the inhibition of FGFR1 and ERK2 activation and an increase in apoptosis if excreted FGF1 was neutralized, FGF2 also increased the de novo synthesis and the production of Bcl-xl before the onset of apoptosis, Both inhibition of ERK2 activation, which decreased Bcl-xl synthesis, and downregulation of Bcl-x by antisense oligonucleotide treatment inhibited the survival-promoting activity of FGF2, Thus, FGF2-induced cell survival is a progressive adaptive phenomenon involving ERK2 activation by excreted FGF1 and ERK2-dependent Bcl-x production.	Assoc Claude Bernard, CNRS, INSERM, U450, F-75016 Paris, France; IFR Circulat, INSERM, U348, F-75010 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mascarelli, F (corresponding author), Assoc Claude Bernard, CNRS, INSERM, U450, 29 Rue Wilhem, F-75016 Paris, France.		Mascarelli, Frederic/L-8916-2018; Guillonneau, xavier/E-3995-2017; guillonneau, xavier/AAF-9495-2021	Guillonneau, xavier/0000-0001-7379-3935; guillonneau, xavier/0000-0001-7379-3935; Bryckaert, Marijke/0000-0003-3398-0976				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALTERIO J, 1988, FEBS LETT, V242, P41, DOI 10.1016/0014-5793(88)80981-5; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; CLARENC JP, 1993, J BIOL CHEM, V268, P5600; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURLIER F, 1997, J MOL EVOL, V44, P43; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; Desire L, 1998, DEV DYNAM, V212, P63, DOI 10.1002/(SICI)1097-0177(199805)212:1<63::AID-AJA6>3.0.CO;2-0; Enzmann V, 1998, OPHTHALMIC RES, V30, P189, DOI 10.1159/000055473; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; FENNEWALD SM, 1995, J BIOL CHEM, V270, P21718, DOI 10.1074/jbc.270.37.21718; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Funato N, 1997, BIOCHEM BIOPH RES CO, V240, P21, DOI 10.1006/bbrc.1997.7588; Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Garland JM, 1998, BLOOD, V92, P1235, DOI 10.1182/blood.V92.4.1235.416k18_1235_1246; GILLARDON F, 1995, J NEUROSCI RES, V41, P708, DOI 10.1002/jnr.490410517; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542; Guillonneau X, 1998, MOL BIOL CELL, V9, P2785, DOI 10.1091/mbc.9.10.2785; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; GUKOVA M, 1995, J BIOL CHEM, V270, P2620; Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; Levin LA, 1997, INVEST OPHTH VIS SCI, V38, P2545; LEZOUALCH F, 1995, J BIOL CHEM, V270, P12100, DOI 10.1074/jbc.270.20.12100; Lindenboim L, 1998, NEUROSCI LETT, V253, P37, DOI 10.1016/S0304-3940(98)00602-8; Liu JF, 1998, EUR J BIOCHEM, V258, P271, DOI 10.1046/j.1432-1327.1998.2580271.x; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; Mishima K, 1998, MODERN PATHOL, V11, P886; MONTPIED P, 1993, BIOCHEM BIOPH RES CO, V195, P623, DOI 10.1006/bbrc.1993.2091; Myoken Y, 1996, INT J CANCER, V65, P650, DOI 10.1002/(SICI)1097-0215(19960301)65:5<650::AID-IJC15>3.0.CO;2-B; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; Onal MZ, 1997, EUR NEUROL, V38, P141; Papermaster DS, 1997, CELL DEATH DIFFER, V4, P21, DOI 10.1038/sj.cdd.4400210; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SAHL B, 1999, ANTICANCER RES, V19, P731; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shin JT, 1996, ARCH BIOCHEM BIOPHYS, V335, P32, DOI 10.1006/abbi.1996.0479; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Spear N, 1998, ARCH BIOCHEM BIOPHYS, V356, P41, DOI 10.1006/abbi.1998.0741; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; VLODAVSKY I, 1982, EXP CELL RES, V140, P149, DOI 10.1016/0014-4827(82)90166-5; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; YAZOVITSKAYA EM, 1999, MOL CARCINOG, V25, P1; Yokoyama Y, 1997, J NEUROCHEM, V68, P2212	64	48	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7584	7593		10.1038/sj.onc.1203200	http://dx.doi.org/10.1038/sj.onc.1203200			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602518				2022-12-25	WOS:000084119600020
J	Paramio, JM; Navarro, M; Segrelles, C; Gomez-Casero, E; Jorcano, JL				Paramio, JM; Navarro, M; Segrelles, C; Gomez-Casero, E; Jorcano, JL			PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein	ONCOGENE			English	Article						PTEN/MMAC1/TEP1; cell cycle; retinoblastoma protein; signal transduction	PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; GLIOMA-CELLS; KINASE; PHOSPHATASE; INHIBITION; EXPRESSION; G(1); GENE	The tumour suppressor PTEN, also named MMAC1 or TEP1, is associated with a number of malignancies in human populations. This protein has a dual protein phosphatase activity, being also capable to dephosphorylate phosphatidylinositol 3,4,5 triphosphate. We have studied the mechanism of growth suppression attributable to PTEN, We observed that PTEN overexpression inhibits cell growth in a variety of normal and transformed, human and murine cells. Bromodeoxyuridine (BrdU) incorporation and TUNEL labelling experiments in transiently transfected cells demonstrate that this inhibition is due to a cell cycle arrest rather than induction of apoptosis, Given that PTEN is unable to cause cell growth arrest in retinoblastoma (Rb)deficient cell lines, we have explored the possible requirement for pRb in the PTEN-induced inhibition of cell proliferation. We found that the co-expression of SV40 antigen, but not a mutant form (which binds exclusively to p53), and cyclin D1/cdk4 are able to overcome the PTEN-mediated growth suppression. In addition, the reintroduction of a functional pRb, but not its relatives p107 or p130, in Rb-deficient cells restores the sensitivity to PTEN-induced arrest. Finally, the hyperphosphorylation of transfected pRb is inhibited by PTEN co-expression and restored by PI-3K co-expression, Accordingly, PTEN gene is mostly expressed, in parallel to Akt, in mid-late G(1) phase during cell cycle progression prior to pRb hyperphosphorylation. Finally, we have studied the signal transduction pathways modulated by PTEN expression. We found that PTEN-induced growth arrest can be rescued by the co-expression of active PI-3K and downstream effecters such as Akt or PDK1, and also certain small GTPases such as Rad and Cdc42, but not by active Ha-ras, paf or RhoA, Collectively, our data link the tumour suppressor activities of PTEN to the machinery controlling cell cycle through the modulation of signalling molecules whose final target is the functional inactivation of the retinoblastoma gene product.	CIEMAT, Dept Mol & Cell Biol, E-28040 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Paramio, JM (corresponding author), CIEMAT, Dept Mol & Cell Biol, Ave Complutense 22, E-28040 Madrid, Spain.		Paramio, Jesus M/M-8482-2014; Navarro, Manuel/S-1496-2019; Gómez-Casero, Elena/A-7389-2016; Segrelles, Carmen/E-3655-2016; Esteban, Elena Gómez-Casero/AAK-3216-2020	Paramio, Jesus M/0000-0001-7520-3177; Navarro, Manuel/0000-0003-1118-8531; Gómez-Casero, Elena/0000-0002-7040-8832; Segrelles, Carmen/0000-0001-9340-2102; Esteban, Elena Gómez-Casero/0000-0002-7040-8832				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Pearson R B, 1995, Prog Cell Cycle Res, V1, P21; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PRENNAN P, 1997, IMMUNITY, V7, P679; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	104	106	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7462	7468		10.1038/sj.onc.1203151	http://dx.doi.org/10.1038/sj.onc.1203151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602505				2022-12-25	WOS:000084119600007
J	Spencer, JA; Misra, RP				Spencer, JA; Misra, RP			Expression of the SRF gene occurs through a Ras/Sp/SRF-mediated-mechanism in response to serum growth signals	ONCOGENE			English	Article						gene regulation; signal transduction; Sp1; SRF	C-FOS; TRANSCRIPTIONAL ACTIVATION; LYSOPHOSPHATIDIC ACID; BINDING; PROMOTER; ELEMENTS; CALCIUM; SEQUENCES; PATHWAYS; UPSTREAM	Serum Response Factor (SRF) plays a central role in the transcriptional response of mammalian cells to a variety of extracellular signals. It is a key regulator of many cellular early response genes which are believed to be involved in cell growth, differentiation, and development, The mechanism by which SRF activates transcription in response to mitogenic agents has been extensively studied, however, less is known about regulation of the SRF gene itself. Previously, we identified distinct regulatory elements in the SRF promoter that play a role in activation, including an ETS domain binding site, an overlapping Sp1/Egr-1 binding site, and two SRF binding sites, We further showed that serum induces the SRF gene by a mechanism that requires an intact SRF binding site, also termed a CArG box, In the present study we demonstrate that in response to stimulation by cells by lysophosphatidic acid (LPA) or whole serum, the SRF promoter is upregulated by a bipartite pathway that requires both an Spl factor binding site and the CArG motifs for maximal stimulation, The CArG box-dependent component of this pathway is targeted by Rho mediated signals, and the Spl binding site dependent component is targeted by Ras mediated signals.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Misra, RP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NIGMS NIH HHS [R55 GM/OD51856] Funding Source: Medline; NINDS NIH HHS [R29 NS36256] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS036256] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; Chen BK, 1997, BBA-LIPID LIPID MET, V1344, P270, DOI 10.1016/S0005-2760(96)00151-8; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; FUJII M, 1994, J VIROL, V68, P7275, DOI 10.1128/JVI.68.11.7275-7283.1994; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOOLENAAR WH, 1992, COLD SPRING HARB SYM, V57, P163, DOI 10.1101/SQB.1992.057.01.021; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1990, CANCER BIOL, V1, P47; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474	39	38	38	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7319	7327		10.1038/sj.onc.1203121	http://dx.doi.org/10.1038/sj.onc.1203121			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602487				2022-12-25	WOS:000084119400017
J	Ballicora, MA; Frueauf, JB; Fu, YB; Schurmann, P; Preiss, J				Ballicora, MA; Frueauf, JB; Fu, YB; Schurmann, P; Preiss, J			Activation of the potato tuber ADP-glucose pyrophosphorylase by thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXINS; ADPGLUCOSE PYROPHOSPHORYLASE; SMALL-SUBUNIT; CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; PROTEINS; STARCH; MUTAGENESIS; METABOLISM; CELLS; SITE	The potato tuber (Solanum tuberosum L,) ADP-glucose pyrophosphorylase (ADP-GlcPPase) catalyzes the first committed step in starch biosynthesis, The main type of regulation of this enzyme is allosteric, and its activity is controlled by the ratio of activator, 3-phosphoglycerate to inhibitor, P-i. It was reported (Fu, Y,, Ballicora, M, A., Leykam, J, F,, and Preiss, J, (1998) J, Biol, Chem, 273, 25045-25052) that the enzyme was activated by reduction of the Cys(12) disulfide Linkage present in the catalytic subunits, In this study, both reduced thioredoxin f and m from spinach (Spinacia oleracea) leaves reduced and activated the enzyme at low concentrations (10 mu M) of activator (3-phosphoglycerate), Fifty percent activation was at 4.5 and 8.7 mu M for reduced thioredoxin f and m, respectively, and 2 orders of magnitude lower than for dithiothreitol, The activation was reversed by oxidized thioredoxin. Cys(12) is conserved in the ADP-GlcPPases from plant leaves and other tissues except for the monocot endosperm enzymes. We postulate that in photosynthetic tissues, reduction could play a role in the fine regulation of the ADP-GlcPPase mediated by the ferredoxin-thioredoxin system. This is the first time that a covalent mechanism of regulation is postulated in the synthesis of starch.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Univ Neuchatel, Biochim Lab, CH-2007 Neuchatel, Switzerland	Michigan State University; University of Neuchatel	Preiss, J (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.			Ballicora, Miguel/0000-0002-5324-0724				Ballicora MA, 1998, PLANT PHYSIOL, V118, P265, DOI 10.1104/pp.118.1.265; Ballicora MA, 1999, BIOCHEM BIOPH RES CO, V257, P782, DOI 10.1006/bbrc.1999.0469; BALLICORA MA, 1995, PLANT PHYSIOL, V109, P245, DOI 10.1104/pp.109.1.245; Emes MJ, 1997, J EXP BOT, V48, P1995, DOI 10.1093/jexbot/48.317.1995; Fu YB, 1998, PLANT PHYSIOL, V117, P989, DOI 10.1104/pp.117.3.989; Fu YB, 1998, J BIOL CHEM, V273, P25045, DOI 10.1074/jbc.273.39.25045; GHOSH HP, 1966, J BIOL CHEM, V241, P4491; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; IGLESIAS AA, 1991, PLANT PHYSIOL, V97, P1187, DOI 10.1104/pp.97.3.1187; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; KAISER WM, 1979, PLANT PHYSIOL, V63, P105, DOI 10.1104/pp.63.1.105; KIM WT, 1989, PLANT PHYSIOL, V91, P217, DOI 10.1104/pp.91.1.217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mora-Garcia S, 1998, J BIOL CHEM, V273, P16273, DOI 10.1074/jbc.273.26.16273; MoraGarcia S, 1996, FEBS LETT, V380, P123, DOI 10.1016/0014-5793(96)00022-1; MORELL MK, 1987, PLANT PHYSIOL, V85, P182, DOI 10.1104/pp.85.1.182; NAKATA PA, 1994, J BIOL CHEM, V269, P30798; OKITA TW, 1990, PLANT PHYSIOL, V93, P785, DOI 10.1104/pp.93.2.785; Preiss J, 1998, GENET ENG P, V20, P177; PREISS J, 1984, ANNU REV MICROBIOL, V38, P419, DOI 10.1146/annurev.mi.38.100184.002223; PREISS J, 1982, ANNU REV PLANT PHYS, V33, P431, DOI 10.1146/annurev.pp.33.060182.002243; Preiss J., 1997, ENG IMPROVED CARBON, P81; Preiss J., 1988, BIOCH PLANTS, V14., P181; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P272; SIVAK NM, 1998, ADV FOOD NUTR RES, V41, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; SOWOKINOS JR, 1981, PLANT PHYSIOL, V68, P924, DOI 10.1104/pp.68.4.924; Thorbjornsen T, 1996, BIOCHEM J, V313, P149, DOI 10.1042/bj3130149; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	30	128	131	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1315	1320		10.1074/jbc.275.2.1315	http://dx.doi.org/10.1074/jbc.275.2.1315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625679	hybrid, Green Submitted			2022-12-25	WOS:000084836600083
J	Bourot, S; Sire, O; Trautwetter, A; Touze, T; Wu, LF; Blanco, C; Bernard, T				Bourot, S; Sire, O; Trautwetter, A; Touze, T; Wu, LF; Blanco, C; Bernard, T			Glycine betaine-assisted protein folding in a lysA mutant of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSMOTIC-STRESS; CENTRAL CAVITY; GENE; EXPRESSION; GROEL; FLUORESCENCE; SOLUTES; TRANSCRIPTION; ACCUMULATION; INDUCTION	Osmoprotectants exogenously supplied to a hyperosmotic culture medium are efficiently imported and amassed by stressed cells of Escherichia coli, In addition to their evident role in the recovery and maintenance of osmotic balance, these solutes should play an important role on the behavior of cellular macromolecules, for example in the process of protein folding, Using a random chemical mutagenesis approach, a conditional lysine auxotrophic mutant was obtained. The growth of this mutant was restored by addition of either lysine or osmoprotectants including glycine betaine (GB) in the minimal medium. The growth rate increased proportionally with the augmentation of the intracellular GB concentration. The mutation was located in the lysA gene and resulted in the substitution of the Ser at position 384 by Phe of the diaminopimelate decarboxylase (DAPDC), which catalyzes the conversion of meso-diaminopimelate to L-lysine. We purified both the wild type DAPDC and the mutated DAPDC-sf and demonstrated that GB was capable of activating DAPDC-sf in vitro, thus confirming the in vivo results. Most importantly, we showed that the activation was correlated with a conformational change of DAPDC-sf. Taken together, these results show, for the first time, that GB may actively assist in vivo protein folding in a chaperone-like manner.	Univ Rennes 1, Grp Membranes & Osmoregulat, CNRS UPRESA 6026, F-35042 Rennes, France; Univ Bretagne Sud, Lab Biol & Chim Mol, F-56017 Vannes, France; Inst Biol Struct & Microbiol, UPR 9043 CNRS, Lab Chim Bacterienne, F-13402 Marseille, France	Universite de Rennes; UDICE-French Research Universities; Aix-Marseille Universite	Bernard, T (corresponding author), Univ Rennes 1, Grp Membranes & Osmoregulat, CNRS UPRESA 6026, Batiment 14,Campus Beaulieu, F-35042 Rennes, France.	tbernard@univ-rennes1.fr	Touzé, Thierry/GLT-1308-2022; SIRE, Olivier/A-9807-2016	SIRE, Olivier/0000-0003-1126-8646; Touze, Thierry/0000-0002-2176-6537; Bourot, Stephane/0000-0002-9069-5787				ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CAYLEY S, 1992, J BACTERIOL, V174, P1586, DOI 10.1128/jb.174.5.1586-1595.1992; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; ETFINK MR, 1976, J PHYS CHEM-US, V80, P486; FERNANDO T, 1992, BIOCHEMISTRY-US, V31, P3429, DOI 10.1021/bi00128a018; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; HenggeAronis R, 1996, MOL MICROBIOL, V21, P887, DOI 10.1046/j.1365-2958.1996.511405.x; IKUTA S, 1977, J BIOCHEM-TOKYO, V82, P1741, DOI 10.1093/oxfordjournals.jbchem.a131872; JEBBAR M, 1992, J BACTERIOL, V174, P5027, DOI 10.1128/JB.174.15.5027-5035.1992; Kilstrup M, 1997, APPL ENVIRON MICROB, V63, P1826, DOI 10.1128/AEM.63.5.1826-1837.1997; Kojima R, 1996, J BIOL CHEM, V271, P12327, DOI 10.1074/jbc.271.21.12327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER JH, 1972, EXPT MOL GENETICS, P125; MURATA N, 1992, FEBS LETT, V296, P187, DOI 10.1016/0014-5793(92)80376-R; NILSSON B, 1983, NUCLEIC ACIDS RES, V11, P8019, DOI 10.1093/nar/11.22.8019; PALEG LG, 1981, AUST J PLANT PHYSIOL, V8, P107; PETRONINI PG, 1993, BIOCHEM J, V293, P553, DOI 10.1042/bj2930553; Qu YX, 1998, P NATL ACAD SCI USA, V95, P9268, DOI 10.1073/pnas.95.16.9268; Record MT, 1998, ADV PROTEIN CHEM, V51, P281; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMURA Y, 1966, BIOCHIM BIOPHYS ACTA, V118, P396, DOI 10.1016/S0926-6593(66)80048-6; STRAGIER P, 1983, J MOL BIOL, V168, P333, DOI 10.1016/S0022-2836(83)80022-9; STRAGIER P, 1983, J BACTERIOL, V156, P1198, DOI 10.1128/JB.156.3.1198-1203.1983; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; WARR SRC, 1984, J GEN MICROBIOL, V130, P2169; Zargarian L, 1999, BIOCHEMISTRY-US, V38, P1921, DOI 10.1021/bi981199j; Zhang WT, 1996, BIOCHEMISTRY-US, V35, P10506, DOI 10.1021/bi960795f	43	119	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1050	1056		10.1074/jbc.275.2.1050	http://dx.doi.org/10.1074/jbc.275.2.1050			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625645	hybrid			2022-12-25	WOS:000084836600049
J	Leaney, JL; Milligan, G; Tinker, A				Leaney, JL; Milligan, G; Tinker, A			The G protein alpha subunit has a key role in determining the specificity of coupling to, but not the activation of, G protein-gated inwardly rectifying K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CELL-FREE MEMBRANE; I-KACH; POTASSIUM CHANNEL; BINDING-PROTEINS; XENOPUS OOCYTES; MOLECULAR-PROPERTIES; MUSCARINIC RECEPTOR; STRUCTURAL ELEMENTS; ADENYLYL-CYCLASE	In neuronal and atrial tissue, G protein-gated inwardly rectifying K+ channels (Kir3.x family) are responsible for mediating inhibitory postsynaptic potentials and slowing the heart rate, They are activated by G beta gamma dimers released in response to the stimulation of receptors coupled to inhibitory G proteins of the G(i/o) family but not receptors coupled to the stimulatory G protein G(s), We have used biochemical, electrophysiological, and molecular biology techniques to examine this specificity of channel activation. In this study we have succeeded in reconstituting such specificity in an heterologous expression system stably expressing a cloned counterpart of the neuronal channel (Kir3.1 and Kir3.2A heteromultimers), The use of pertussis toxin-resistant G protein alpha subunits and chimeras between G(il) and G(s) indicate a central role for the G protein alpha subunits in determining receptor specificity of coupling to, but not activation of, G protein-gated inwardly rectifying K+ channels.	UCL, Dept Med, Ctr Clin Pharmacol, Rayne Inst, London WC1E 6JJ, England; Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of London; King's College London; University College London; University of Glasgow	Milligan, G (corresponding author), UCL, Dept Med, Ctr Clin Pharmacol, Rayne Inst, 5 Univ St, London WC1E 6JJ, England.	gbca32@udcf.gla.ac.uk; a.tinker@ucl.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Delmas P, 1998, EUR J NEUROSCI, V10, P1654, DOI 10.1046/j.1460-9568.1998.00170.x; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Fong CW, 1998, MOL PHARMACOL, V54, P249, DOI 10.1124/mol.54.2.249; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; HUNT TW, 1994, J BIOL CHEM, V269, P29565; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; Inanobe A, 1999, J NEUROSCI, V19, P1006; Jeong SW, 1999, J NEUROSCI, V19, P4755; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; KLOTZ KN, 1993, N-S ARCH PHARMACOL, V357, P1; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURACHI Y, 1986, AM J PHYSIOL, V251, pH681, DOI 10.1152/ajpheart.1986.251.3.H681; LAURENT E, 1987, MOL CELL ENDOCRINOL, V52, P273, DOI 10.1016/0303-7207(87)90055-4; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; NOMA A, 1978, PFLUG ARCH EUR J PHY, V377, P193, DOI 10.1007/BF00584272; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; Ruiz-Velasco V, 1998, J PHYSIOL-LONDON, V513, P761, DOI 10.1111/j.1469-7793.1998.761ba.x; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; Sorota S, 1999, J PHYSIOL-LONDON, V514, P413, DOI 10.1111/j.1469-7793.1999.413ae.x; SREEDHARAN SP, 1994, BIOCHEM BIOPH RES CO, V203, P141, DOI 10.1006/bbrc.1994.2160; Stevens EB, 1997, J PHYSIOL-LONDON, V503, P547, DOI 10.1111/j.1469-7793.1997.547bg.x; Tsu RC, 1997, MOL PHARMACOL, V52, P38, DOI 10.1124/mol.52.1.38; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Xiao RP, 1999, CIRC RES, V84, P43; Yamada M, 1998, PHARMACOL REV, V50, P723; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3	61	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					921	929		10.1074/jbc.275.2.921	http://dx.doi.org/10.1074/jbc.275.2.921			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625628	hybrid			2022-12-25	WOS:000084836600032
J	Liu, JS; Kuo, SR; McHugh, MM; Beerman, TA; Melendy, T				Liu, JS; Kuo, SR; McHugh, MM; Beerman, TA; Melendy, T			Adozelesin triggers DNA damage response pathways and arrests SV40 DNA replication through replication protein A inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SIMIAN VIRUS-40 DNA; RADIATION-INDUCED PHOSPHORYLATION; S-PHASE CHECKPOINT; SIMIAN-VIRUS-40 DNA; BINDING PROTEIN; P34 SUBUNIT; HUMAN-CELLS; ATAXIA-TELANGIECTASIA; BSC-1 CELLS	The cyclopropylpyrroloindole anti-cancer drug, adozelesin, binds to and alkylates DNA. Treatment of human cells with low levels of adozelesin results in potent inhibition of both cellular and simian virus 40 (SV40) DNA replication. Extracts were prepared from adozelesin-treated cells and shown to be deficient in their ability to support SV40 DNA replication in vitro, This effect on in vitro DNA replication was dependent on both the concentration of adozelesin used and the time of treatment but was not due to the presence of adozelesin in the in vitro assay, Adozelesin treatment of cells was shown to result in the following: induction of p53 protein levels, hyperphosphorylation of replication protein A (RPA), and disruption of the p53-RPA complex (but not disruption of the RPA-cdc2 complex), indicating that adozelesin treatment triggers cellular DNA damage response pathways. Interestingly, in vitro DNA replication could be rescued in extracts from adozelesin-treated cells by the addition of exogenous RPA, Therefore, whereas adozelesin and other anti-cancer therapeutics trigger common DNA damage response markers, adozelesin causes DNA replication arrest through a unique mechanism. The S phase checkpoint response triggered by adozelesin acts by inactivating RPA in some function essential for SV40 DNA replication.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Ctr Microbial Pathogenesis, Buffalo, NY 14214 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute	Melendy, T (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, 138 Farber Hall, Buffalo, NY 14214 USA.	tmelendy@buffalo.edu			NATIONAL CANCER INSTITUTE [P30CA016056, R01CA077491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM056406] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, CA 77491] Funding Source: Medline; NIGMS NIH HHS [GM 56406] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; Brush GS, 1995, METHOD ENZYMOL, V262, P522; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Cheng XB, 1996, RADIOTHER ONCOL, V39, P43, DOI 10.1016/0167-8140(96)01712-4; Cobuzzi RJ, 1996, J BIOL CHEM, V271, P19852, DOI 10.1074/jbc.271.33.19852; Cristofanilli M, 1998, ANTI-CANCER DRUG, V9, P779, DOI 10.1097/00001813-199810000-00006; DOLLARD SC, 1993, J VIROL, V67, P1721, DOI 10.1128/JVI.67.3.1721-1726.1993; EKI T, 1992, J BIOL CHEM, V267, P7284; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; GRAND RJA, 1995, VIROLOGY, V210, P323, DOI 10.1006/viro.1995.1349; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Henricksen LA, 1996, NUCLEIC ACIDS RES, V24, P3107, DOI 10.1093/nar/24.15.3107; HURLEY LH, 1990, J AM CHEM SOC, V112, P4633, DOI 10.1021/ja00168a003; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MAINE IP, 1992, BIOCHEMISTRY-US, V31, P3968, DOI 10.1021/bi00131a012; McHugh MM, 1999, BIOCHEMISTRY-US, V38, P11508, DOI 10.1021/bi990598r; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; Miller SD, 1997, MOL CELL BIOL, V17, P2194, DOI 10.1128/MCB.17.4.2194; MITCHELL MA, 1991, J AM CHEM SOC, V113, P8994, DOI 10.1021/ja00023a085; MIYAMOTO N, 1990, BIOCHEM BIOPH RES CO, V168, P604, DOI 10.1016/0006-291X(90)92363-5; Morgan SE, 1997, CANCER RES, V57, P3386; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; Parry D, 1999, MOL CELL BIOL, V19, P1775; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUN D, 1992, BIOCHEMISTRY-US, V31, P2822, DOI 10.1021/bi00125a025; SUN DY, 1992, J MED CHEM, V35, P1773, DOI 10.1021/jm00088a012; Treuner K, 1999, NUCLEIC ACIDS RES, V27, P1499, DOI 10.1093/nar/27.6.1499; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; Von Hoff DD, 1998, SEMIN ONCOL, V25, P47; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; Wang Y, 1998, RADIAT RES, V149, P284, DOI 10.2307/3579962; Wang Y, 1999, J BIOL CHEM, V274, P22060, DOI 10.1074/jbc.274.31.22060; Wang Y, 1997, CANCER RES, V57, P1654; Wang Y, 1996, RADIAT RES, V145, P408, DOI 10.2307/3579062; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Woynarowski JM, 1999, BBA-GENE STRUCT EXPR, V1444, P201, DOI 10.1016/S0167-4781(99)00002-0; WOYNAROWSKI JM, 1995, BIOCHEMISTRY-US, V34, P13042, DOI 10.1021/bi00040a015; Woynarowski JM, 1997, BBA-GENE STRUCT EXPR, V1353, P50, DOI 10.1016/S0167-4781(97)00046-8; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896	64	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1391	1397		10.1074/jbc.275.2.1391	http://dx.doi.org/10.1074/jbc.275.2.1391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625690	hybrid			2022-12-25	WOS:000084836600094
J	Ajiro, K				Ajiro, K			Histone H2B phosphorylation in mammalian apoptotic cells - An association with DNA fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE CHROMOSOME CONDENSATION; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAYS; CHROMATIN CONDENSATION; H3 PHOSPHORYLATION; PHORBOL ESTERS; OKADAIC ACID; DEATH; THYMOCYTES; ACTIVATION	Histone phosphorylation was investigated in several mammalian cells undergoing apoptosis (human HL-60 and HeLa, mouse FM3A and N18 cells, and rat thymocytes). Among the four nucleosomal core histones (H2A, H2B, H3, and H4), H2B, which is not usually phosphorylated in quiescent or growing cells, was found to be phosphorylated after treatment with various apoptotic inducers. The H2B was phosphorylated around the time when nucleosomal DNA fragmentation was initiated and, like this fragmentation, was completely blocked with Z-Asp-CH2-DCB, an inhibitor of ICE or ICE-like caspase. The involved single phosphopeptide of H2B proved to be phosphorylatable in vitro with a protein kinase C, and the site Ser-32 was tentatively identified. Despite typical apoptotic chromatin condensation, the H3 phosphorylation was at a low level, and the sites where phosphorylation did occur did not include any mitosis-specific phosphopeptides, Phosphorylation of H4 was increased, but the other two histone proteins (H1 and H2A) were not appreciably changed. These observations imply that 1) H2B phosphorylation occurs universally in apoptotic cells and is associated with apoptosis-specific nucleosomal DNA fragmentation, 2) chromatin condensation in apoptosis occurs by a different biochemical mechanism from those operating during mitosis or premature chromosome condensation, and 3) this unique phosphorylation of H2B is a useful biochemical hallmark of apoptotic cells.	Aichi Canc Ctr, Res Inst, Cell Biol Lab, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Ajiro, K (corresponding author), Aichi Canc Ctr, Res Inst, Cell Biol Lab, Nagoya, Aichi 4648681, Japan.							AJIRO K, 1985, J BIOL CHEM, V260, P5379; AJIRO K, 1983, J BIOL CHEM, V258, P4534; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1445, DOI 10.1021/bi00509a007; AJIRO K, 1982, SOMAT CELL GENET, V8, P377, DOI 10.1007/BF01538894; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1454, DOI 10.1021/bi00509a008; Allera C, 1997, J BIOL CHEM, V272, P10817; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BUTLER AP, 1986, J BIOL CHEM, V261, P9421; CARY PD, 1982, EUR J BIOCHEM, V127, P137, DOI 10.1111/j.1432-1033.1982.tb06847.x; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GURLEY LR, 1983, ANAL BIOCHEM, V129, P132, DOI 10.1016/0003-2697(83)90061-1; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HANKS SK, 1983, EXP CELL RES, V148, P293, DOI 10.1016/0014-4827(83)90153-2; HASHIMOTO E, 1976, J BIOL CHEM, V251, P6287; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; HOHMANN P, 1983, MOL CELL BIOCHEM, V57, P81; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; Lavin MF, 1996, EXPERIENTIA, V52, P979, DOI 10.1007/BF01920107; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARUSHIGE Y, 1995, ANTICANCER RES, V15, P267; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; McConkey DJ, 1996, STEM CELLS, V14, P619, DOI 10.1002/stem.140619; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Odaka C, 1996, MICROSC RES TECHNIQ, V34, P267, DOI 10.1002/(SICI)1097-0029(19960615)34:3<267::AID-JEMT9>3.0.CO;2-M; OJEDA F, 1990, CELL IMMUNOL, V125, P535, DOI 10.1016/0008-8749(90)90106-2; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIBATA K, 1993, J BIOL CHEM, V268, P18431; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; SUN XM, 1992, BIOCHEM PHARMACOL, V44, P2131; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; UCKER DS, 1991, NEW BIOL, V3, P103; van Holde K.E., 1988, CHROMATIN; Vodenicharov MD, 1996, CANCER LETT, V106, P51, DOI 10.1016/0304-3835(96)04300-5; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Wolffe A., 1995, CHROMATIN STRUCTURE; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamauchi Y, 1998, EXP CELL RES, V238, P317, DOI 10.1006/excr.1997.3841; Yoshida M, 1997, EXP CELL RES, V232, P225, DOI 10.1006/excr.1997.3538; Zunino SJ, 1996, AM J PATHOL, V149, P653; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	52	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					439	443		10.1074/jbc.275.1.439	http://dx.doi.org/10.1074/jbc.275.1.439			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617636	hybrid			2022-12-25	WOS:000085951600060
J	Sugiura, T; Kondo, S; Kishimoto, S; Miyashita, T; Nakane, S; Kodaka, T; Suhara, Y; Takayama, H; Waku, K				Sugiura, T; Kondo, S; Kishimoto, S; Miyashita, T; Nakane, S; Kodaka, T; Suhara, Y; Takayama, H; Waku, K			Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor - Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MEDIATED IMMUNE MODULATION; ADENYLATE-CYCLASE; RAT-BRAIN; NG108-15 CELLS; SELECTIVE ANTAGONIST; PERIPHERAL-TISSUES; SPLEEN-CELLS; FACTOR-ALPHA; T-CELLS	We examined the effect of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, on the intracellular free Ca2+ concentrations in HL-60 cells that ex press the cannabinoid CB2 receptor. We found that 2-arachidonoylglycerol induces a rapid transient increase in intracellular free Ca2+ concentrations in HL-60 cells. The response was affected by neither cyclooxygenase inhibitors nor lipoxygenase inhibitors, suggesting that arachidonic acid metabolites are not involved. Consistent with this notion, free arachidonic acid was devoid of any agonistic activity. Importantly, the Ca2+ transient induced by 2-arachidonoylglycerol was blocked by pretreatment of the cells with SR144528, CB2 receptor-specific antagonist, but not with SR141716A, a CB1 receptor-specific antagonist, indicating the involvement of the CB2 receptor but not the CB1 receptor in this cellular response. G(i) or G(o) is also assumed to be involved, because pertussis toxin treatment of the cells abolished the response. We further examined the structure-activity relationship. We found that 2-arachidonoylglycerol is the most potent compound among a number of naturally occurring cannabimimetic molecules. Interestingly, anandamide and N-palmitoylethanolamine, other putative endogenous ligands, were found to be a weak partial agonist and an inactive ligand, respectively, These results strongly suggest that the CB2 receptor is originally a 2-arachidonoylglycerol receptor, and 2-arachidonoylglycerol is the intrinsic natural ligand for the CB2 receptor that is abundant in the immune system.	Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan	Teikyo University	Sugiura, T (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan.			Suhara, Yoshitomo/0000-0002-4770-2910				BAYEWITCH M, 1995, FEBS LETT, V375, P143, DOI 10.1016/0014-5793(95)01207-U; Berdyshev EV, 1997, EUR J PHARMACOL, V330, P231, DOI 10.1016/S0014-2999(97)01007-8; Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; BLANCHARD DK, 1986, INT J IMMUNOPHARMACO, V8, P819, DOI 10.1016/0192-0561(86)90020-2; Bouaboula M, 1996, EUR J BIOCHEM, V237, P704, DOI 10.1111/j.1432-1033.1996.0704p.x; Cadas H, 1997, J NEUROSCI, V17, P1226; Carayon P, 1998, BLOOD, V92, P3605, DOI 10.1182/blood.V92.10.3605.422k05_3605_3615; Coffey RG, 1996, BIOCHEM PHARMACOL, V52, P743, DOI 10.1016/0006-2952(96)00356-5; Condie R, 1996, J BIOL CHEM, V271, P13175, DOI 10.1074/jbc.271.22.13175; DEROCQ JM, 1995, FEBS LETT, V369, P177, DOI 10.1016/0014-5793(95)00746-V; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEWEY WL, 1986, PHARMACOL REV, V38, P151; Di Marzo V, 1998, BIOCHEM J, V331, P15; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014-5793(96)00891-5; FISCHERSTENGER K, 1993, J PHARMACOL EXP THER, V267, P1558; FRIDE E, 1995, J PHARMACOL EXP THER, V272, P699; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; HOLLISTER LE, 1992, J PSYCHOACTIVE DRUGS, V24, P159, DOI 10.1080/02791072.1992.10471635; Jbilo O, 1999, FEBS LETT, V448, P273, DOI 10.1016/S0014-5793(99)00380-4; JIN WZ, 1994, J NEUROSCI, V14, P1920; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KAMINSKI NE, 1994, BIOCHEM PHARMACOL, V48, P1899, DOI 10.1016/0006-2952(94)90588-6; Kempe K, 1996, J BIOL CHEM, V271, P17287, DOI 10.1074/jbc.271.29.17287; Kishimoto S, 1996, J IMMUNOL, V157, P4126; KLEIN TW, 1991, J TOXICOL ENV HEALTH, V32, P465, DOI 10.1080/15287399109531496; Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014-5793(98)00581-X; KUSHER DI, 1994, CELL IMMUNOL, V154, P99, DOI 10.1006/cimm.1994.1060; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; LYNN AB, 1994, J PHARMACOL EXP THER, V268, P1612; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; McCoy KL, 1999, J PHARMACOL EXP THER, V289, P1620; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 1998, EUR J PHARMACOL, V362, pR1, DOI 10.1016/S0014-2999(98)00777-8; MECHOULAM R, 1995, CANNABINOID RECEPTOR, P233; Ouyang YL, 1998, MOL PHARMACOL, V53, P676, DOI 10.1124/mol.53.4.676; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Schatz AR, 1997, TOXICOL APPL PHARM, V142, P278, DOI 10.1006/taap.1996.8034; SCHMID PC, 1996, FEBS LETT, V385, P124; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; SPECTER S, 1991, J LEUKOCYTE BIOL, V50, P423, DOI 10.1002/jlb.50.5.423; SPECTER S, 1990, INT J IMMUNOPHARMACO, V12, P261, DOI 10.1016/0192-0561(90)90081-W; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V229, P58, DOI 10.1006/bbrc.1996.1757; Sugiura T, 1997, J BIOCHEM-TOKYO, V122, P890; SUGIURA T, 1994, P JPN C BIOCH LIPIDS, V36, P71; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; ZHENG ZM, 1992, INT J IMMUNOPHARMACO, V14, P1445	57	314	337	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					605	612		10.1074/jbc.275.1.605	http://dx.doi.org/10.1074/jbc.275.1.605			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617657	hybrid			2022-12-25	WOS:000085951600081
J	Zhang, CC; Shapiro, DJ				Zhang, CC; Shapiro, DJ			Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MAP KINASE; TAMOXIFEN; PROLIFERATION; ANTIESTROGENS; TRANSCRIPTION; EXPRESSION; GROWTH; GENE	17 beta-Estradiol (E-2) or the antiestrogen, 4-hydroxytamoxifen (OHT), induce apoptosis in stably transfected estrogen receptor (ER)-positive HeLa-ER5 cells, p38 mitogen-activated protein kinase is implicated in cellular processes involving apoptosis. The p38 kinase inhibitor, SB203580, partially protects HeLa-ER5 cells against apoptosis induced by E-2 or by OHT. E-2 induces the p38 pathway 12-36-fold in ER-positive cell lines, while OHT induces p38 activity 2-5-fold. In an ER-positive cell line selected for resistance to E-2-induced apoptosis, E-2 no longer induced p38, and the ER no longer bound to the estrogen response element, while GIFT induced both p38 and apoptosis. In cells selected for resistance to OHT-induced apoptosis, OHT no longer induced p38, while E-2 induced p38 and apoptosis, and transactivated an estrogen response element-containing reporter gene. In MCF-7 cells, whose growth is stimulated by estrogen, E-2 did not induce p38 or apoptosis, while OHT induced both p38 and apoptosis, and SB203580 protected against OHT-induced apoptosis, This work shows that E-2 and OHT activate the p38 pathway, suggests that they use different pathways for p38 activation, and links activation of the p38 pathway to apoptosis induced by E-2 and by OHT.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, 413 RAL,600 S Mathews Ave, Urbana, IL 61801 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16720] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AITKEN SC, 1985, CANCER RES, V45, P2608; Chen HM, 1996, J CELL BIOCHEM, V61, P9, DOI 10.1002/(SICI)1097-4644(19960401)61:1<9::AID-JCB2>3.3.CO;2-2; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; CORADINI D, 1994, ANTICANCER RES, V14, P1059; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; Fattman CL, 1998, CANCER LETT, V130, P103, DOI 10.1016/S0304-3835(98)00121-9; GUENDA A, 1995, FEBS LETT, V364, P229; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KUSHNER PJ, 1990, MOL ENDOCRINOL, V4, P1465, DOI 10.1210/mend-4-10-1465; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTINEZ JD, 1996, ONCOGENE, V12, P953; MCGAHON AJ, 1995, METHODS CELL BIOL CE, V46, P174; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MINE DM, 1994, J BIOL CHEM, V269, P9253; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PERRY RR, 1995, ANN SURG ONCOL, V2, P238, DOI 10.1007/BF02307030; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zajchowski DA, 1997, J STEROID BIOCHEM, V62, P373, DOI 10.1016/S0960-0760(97)00052-6; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632	35	83	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					479	486		10.1074/jbc.275.1.479	http://dx.doi.org/10.1074/jbc.275.1.479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617642	hybrid			2022-12-25	WOS:000085951600066
J	Lass, A; Sohal, RS				Lass, A; Sohal, RS			Effect of coenzyme Q(10) and alpha-tocopherol content of mitochondria on the production of superoxide anion radicals	FASEB JOURNAL			English	Article						antioxidants; free radicals; oxidative stress; aging	VITAMIN-E; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; MODEL-COMPOUND; UBIQUINONE; GENERATION; LONGEVITY; RESTRICTION; PARTICLES; HOMOLOGS	The effects of coenzyme Q(10) (CoQ(10)) and alpha-tocopherol at the rate of mitochondrial superoxide anion radical (O-2(.-)) geration were examined in skeletal muscle, liver and kidney of 24-day-month mice. Mice were orally administered alpha-tocopherol (200 mg.kg(-1).day(-1)) alone, CoQ(10) (123 mg.kg(-1).day(-1)) alone, or the two together for 13 wk. Administration of alpha-tocopherol resulted in a similar to sevenfold elevation of mitochondrial alpha-tocopherol content. Intake of alpha-tocopherol alone caused an similar to fivefold increase in CoQ content (CoQ(9) and/or CoQ(10)) and alpha-tocopherol of mitochondria. The rate of O-2 generation by sub mitochondrial particles (SMPs) was inversely related to their alpha-tocopherol content but unrelated to CoQ content. Experimental in vitro augmentation of SMPs with varying amounts of alpha-tocopherol caused an up to similar to 50% decrease in the rate of O2T generation. Similar in vitro augmentations of SMPs with CoQ(10) had previously been found to have no effect on O2+ generation The CoQ(10)-induced elevation of alpha-tocopherol in the present study was inferred to be due to a sparing/regeneration by CoQ. results indicate the involvement of alpha-tocopherol in the elimination of mitochondrially generated O2T.-Lass A., Sohal, R. S. Effect of coenzyme Q(10) and alpha-tocopherol content of mitochondria on the production of superoxide anion radicals. .	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Sohal, RS (corresponding author), So Methodist Univ, Dept Biol Sci, 220 Fondren Sci Bldg, Dallas, TX 75275 USA.	rsohal@mail.smu.edu	Lass, Achim/C-3332-2008	Lass, Achim/0000-0002-8190-7151	NIA NIH HHS [R01 AG13563, R01 AG7657] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007657, R01AG013563] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; BOVERIS A, 1980, SUPEROXIDE DISMUTASE, V2, P16; BURLAKOVA EB, 1979, BIOFIZIKA+, V24, P965; CADENAS E, 1989, FEBS LETT, V253, P235, DOI 10.1016/0014-5793(89)80966-4; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; FORSMARK P, 1991, FEBS LETT, V285, P39, DOI 10.1016/0014-5793(91)80720-N; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FUKUZAWA K, 1983, ARCH BIOCHEM BIOPHYS, V226, P242, DOI 10.1016/0003-9861(83)90290-4; GOTOH N, 1992, BIOCHIM BIOPHYS ACTA, V1115, P201, DOI 10.1016/0304-4165(92)90054-X; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LASH LH, 1993, MITOCHONDRIAL DYSFUN, V2, P8; Lass A, 1998, ARCH BIOCHEM BIOPHYS, V352, P229, DOI 10.1006/abbi.1997.0606; Lass A, 1997, J BIOL CHEM, V272, P19199, DOI 10.1074/jbc.272.31.19199; MAGUIRE JJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P47, DOI 10.1016/0003-9861(92)90049-3; NAUMOV V V, 1983, Biophysics (English Translation of Biofizika), V28, P774; OZAWA T, 1978, BIOCHIM BIOPHYS ACTA, V531, P72; OZAWA T, 1985, BIOCHEM BIOPH RES CO, V126, P873, DOI 10.1016/0006-291X(85)90266-9; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1989, MECH AGEING DEV, V49, P129, DOI 10.1016/0047-6374(89)90096-1; SOHAL RS, 1995, FREE RADICAL BIO MED, V19, P499, DOI 10.1016/0891-5849(95)00037-X; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V323, P343, DOI 10.1006/abbi.1995.9955; TAKADA M, 1984, METHOD ENZYMOL, V105, P147; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0	30	102	108	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					87	94		10.1096/fasebj.14.1.87	http://dx.doi.org/10.1096/fasebj.14.1.87			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627283				2022-12-25	WOS:000084784700011
J	Carlotti, F; Chapman, R; Dower, SK; Qwarnstrom, EE				Carlotti, F; Chapman, R; Dower, SK; Qwarnstrom, EE			Activation of nuclear factor kappa B in single living cells - Dependence of nuclear translocation and anti-apoptotic function on EGFPRELA concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; GREEN FLUORESCENT PROTEIN; INTERLEUKIN-1 RECEPTOR COMPLEX; TRANSCRIPTION FACTOR; FACTOR-ALPHA; DNA-BINDING; IN-VITRO; PHOSPHORYLATION; KINASE; SIGNAL	We have studied the dynamics of nuclear translocation during nuclear factor kappa B activation by using a p65(RELA)-enhanced green fluorescent protein (EGFP) fusion construct. Quantitation of expression levels indicates that EGFPRELA can be detected at physiological concentrations of about 60,000 molecules per cell. Stimulation of transfected fibroblasts with interleukin (IL)-1 beta caused nuclear translocation of EGFPRELA, typically resulting in a 30-fold increase in nuclear protein at maximum induction and a concomitant 20% decrease in cytoplasmic levels. The response of individual cells to IL-1 beta was graded, and the kinetics of nuclear translocation were dependent on the dose of IL-1 beta and the level of EGFPRELA expression, The rate of nuclear uptake was saturable, and the time lag for uptake increased at higher EGFPRELA expression levels. Furthermore, nuclear translocation was reduced at less than saturating doses of IL-1 beta suggesting that the pathway is limited by incoming signals. The response to IL-1 beta was biphasic, demonstrating a decline in nuclear import rate at expression levels above three to four times endogenous, This correlated with the anti-apoptotic function of EGFPRELA which was more prominent at low expression levels and demonstrated successively less protection at higher levels, In comparison, transfection of p50 had ho effect on the level of apoptosis and demonstrated some toxicity in combination with EGFPRELA.	Univ Sheffield, Sch Med, Div Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	University of Sheffield; University of Washington; University of Washington Seattle	Qwarnstrom, EE (corresponding author), Univ Sheffield, Sch Med, Div Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England.			dower, steve/0000-0002-4675-4225; Qwarnstrom, Eva/0000-0003-4417-8663				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; DOWER SK, 1986, P NATL ACAD SCI USA, V83, P1060, DOI 10.1073/pnas.83.4.1060; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	50	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37941	37949		10.1074/jbc.274.53.37941	http://dx.doi.org/10.1074/jbc.274.53.37941			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608861	hybrid			2022-12-25	WOS:000084528000061
J	Liu, LA; Engvall, E				Liu, LA; Engvall, E			Sarcoglycan isoforms in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; GIRDLE MUSCULAR-DYSTROPHY; EXTRACELLULAR-MATRIX; EPSILON-SARCOGLYCAN; GAMMA-SARCOGLYCAN; DELTA-SARCOGLYCAN; BETA-SARCOGLYCAN; GENE; CELLS; MOUSE	The heterotetrameric sarcoglycan complex, composed of alpha-, beta-, gamma-, and delta-sarcoglycans, is an important component of the dystrophin-associated glycoprotein assembly in striated muscle, Mutations in any of the four genes encoding sarcoglycans cause a deficiency in all sarcoglycans in the sarcolemma and produce one of four types of limb-girdle muscular dystrophy. A fifth widely expressed sarcoglycan, epsilon-sarcoglycan, has been recently described. epsilon-Sarcoglycan is homologous to alpha-sarcoglycan, but whether it associates with the other sarcoglycans in muscle is not known. In this study, we use wild type and alpha-sarcoglycan-deficient mice to analyze the localization and association of sarcoglycans in skeletal muscle in vivo. The amounts of beta-, gamma-, and delta-sarcoglycans are reduced in alpha-sarcoglycan mutants, whereas the amount of epsilon-sarcoglycan is unchanged, We show here that epsilon-sarcoglycan is complexed with beta-, gamma-, and delta-sarcoglycans in both wild type and alpha-sarcoglycan mutant mice, We also use C2C12 myocytes to study the temporal expression and organization of sarcoglycan complexes during muscle cell differentiation in vitro. In C2C12 cells, alpha- and epsilon-sarcoglycans form separate complexes with beta-, gamma-, and delta-sarcoglycans, Both types of complexes are expressed at the cell surface and presumed to be functional, These results suggest that epsilon-sarcoglycan serves a function similar to that of alpha-sarcoglycan and that residual beta-, gamma-, and delta-sarcoglycan seen in mutant mice and epsilon-sarcoglycan-deficient patients is due to its association with epsilon-sarcoglycan.	Burnham Inst, La Jolla, CA 92037 USA; Stockholm Univ, Wenner Gren Inst, Dept Dev Biol, S-10691 Stockholm, Sweden	Sanford Burnham Prebys Medical Discovery Institute; Stockholm University	Engvall, E (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Araishi K, 1999, HUM MOL GENET, V8, P1589, DOI 10.1093/hmg/8.9.1589; Betto R, 1999, J BIOL CHEM, V274, P7907, DOI 10.1074/jbc.274.12.7907; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Bonnemann CG, 1999, J CHILD NEUROL, V14, P31; Bushby K, 1996, NEUROMUSCULAR DISORD, V6, P439, DOI 10.1016/S0960-8966(96)00392-6; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chan YM, 1998, J CELL BIOL, V143, P2033, DOI 10.1083/jcb.143.7.2033; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 1999, J BIOL CHEM, V274, P26609, DOI 10.1074/jbc.274.37.26609; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Hack AA, 1999, P NATL ACAD SCI USA, V96, P10723, DOI 10.1073/pnas.96.19.10723; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; HOFFMAN EP, 1987, NATURE, V330, P754, DOI 10.1038/330754a0; Holt KH, 1998, J BIOL CHEM, V273, P34667, DOI 10.1074/jbc.273.52.34667; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; Liu L, 1997, BIOCHEM BIOPH RES CO, V235, P227, DOI 10.1006/bbrc.1997.6757; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MCMAHON DK, 1994, AM J PHYSIOL, V266, pC1795, DOI 10.1152/ajpcell.1994.266.6.C1795; McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; Ohno S, 1999, CELL MOL LIFE SCI, V55, P824, DOI 10.1007/s000180050336; OSULLIVAN MJ, 1979, ANAL BIOCHEM, V100, P100, DOI 10.1016/0003-2697(79)90117-9; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583	50	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38171	38176		10.1074/jbc.274.53.38171	http://dx.doi.org/10.1074/jbc.274.53.38171			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608889	hybrid			2022-12-25	WOS:000084528000089
J	Silvera, D; Gamarnik, AV; Andino, R				Silvera, D; Gamarnik, AV; Andino, R			The N-terminal K homology domain of the poly(rC)-binding protein is a major determinant for binding to the poliovirus 5 '-untranslated region and acts as an inhibitor of viral translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; 5'-NONCODING REGION; RNA-BINDING; BINDING-PROTEIN-2; REPLICATION; COMPLEX; VIRUS; END; FORMS; FMR1	The poly(rC)-binding proteins (PCBP1 and PCBP2) are RNA-binding proteins whose RNA recognition motifs are composed of three K homology (IM) domains These proteins are involved in both the stabilization and translational regulation of several cellular and viral RNAs. PCBP1 and PCBP2 specifically interact with both the BI-element known as the cloverleaf structure and the large stem-loop IV RNA of the poliovirus 5'-untranslated region. We have found that the first KH domain of PCBP2 (KH1) specifically interacts with the viral RNAs, and together with viral protein 3CD, KH1 forms a high affinity ternary ribonucleoprotein complex with the cloverleaf RNA, resembling the full-length PCBP protein. Furthermore, KH1 acts as a dominant-negative mutant to inhibit translation from a poliovirus reporter gene in both Xenopus laevis oocytes and HeLa cell in vitro translation extracts.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Andino, R (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.				NIAID NIH HHS [AI40085] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040085, R01AI040085] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andino R, 1999, TRENDS MICROBIOL, V7, P76, DOI 10.1016/S0966-842X(98)01446-2; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BARTON DJ, 1993, J VIROL, V67, P822, DOI 10.1128/JVI.67.2.822-831.1993; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Dejgaard K, 1996, EUR J BIOCHEM, V241, P425, DOI 10.1111/j.1432-1033.1996.00425.x; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; Gamarnik AV, 1997, RNA, V3, P882; Gamarnik AV, 1996, EMBO J, V15, P5988, DOI 10.1002/j.1460-2075.1996.tb00985.x; Graff J, 1998, J VIROL, V72, P9668, DOI 10.1128/JVI.72.12.9668-9675.1998; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; Jan E, 1999, EMBO J, V18, P258, DOI 10.1093/emboj/18.1.258; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; Lewis HA, 1999, STRUCTURE, V7, P191, DOI 10.1016/S0969-2126(99)80025-2; Musco G, 1997, NAT STRUCT BIOL, V4, P712, DOI 10.1038/nsb0997-712; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Parsley TB, 1997, RNA, V3, P1124; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SEKURA CJM, 1987, METHOD ENZYMOL, V152, P284; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193	29	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38163	38170		10.1074/jbc.274.53.38163	http://dx.doi.org/10.1074/jbc.274.53.38163			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608888	hybrid			2022-12-25	WOS:000084528000088
J	Sloan, JS; Dombek, KM; Young, ET				Sloan, JS; Dombek, KM; Young, ET			Post-translational regulation of Adr1 activity is mediated by its DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ADR1; DEPENDENT PROTEIN-KINASE; REPRESSIBLE ALCOHOL-DEHYDROGENASE; GREEN FLUORESCENT PROTEIN; SACCHAROMYCES-CEREVISIAE; ADH2 EXPRESSION; NUCLEAR-LOCALIZATION; GLUCOSE REPRESSION; MULTIPLE MECHANISMS; GENE-EXPRESSION	1ADRI encodes a transcriptional activator that regulates genes involved in carbon source utilization in Saccharomyces cerevisiae. ADR1 is itself repressed by glucose, but the significance of this repression for regulating target genes is not known. To test if the reduction in Adr1 levels contributes to glucose repression of ADH2 expression, we generated yeast strains in which the level of Adr1 produced during growth in glucose-containing medium is similar to that present in wildtype cells grown in the absence of glucose. In these Adr1-overproducing strains, ADH2 expression remained tightly repressed, and UAS1, the element in the ADH2 promoter that binds Adr1, was sufficient to maintain glucose repression. Post-translational modification of Adr1 activity is implicated in repression, since ADH2 derepression occurred in the absence of de novo protein synthesis. The N-terminal 172 amino acids of Adr1, containing the DNA binding and nuclear localization domains, fused to the Herpesvirus VP16-encoded transcription activation domain, conferred regulated expression at UAS1, Nuclear localization of an Adr1-GFP fusion protein was not glucose-regulated, suggesting that the DNA binding domain of Adr1 is sufficient to confer regulated expression on target genes, A Ga14-Adr1 fusion protein was unable to confer glucose repression at GALA-dependent promoters, suggesting that regulation mediated by ADR1 is specific to UAS1.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Young, ET (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	ety@u.washington.edu			NIGMS NIH HHS [GM26079] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026079] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIER DR, 1985, MOL CELL BIOL, V5, P1743, DOI 10.1128/MCB.5.7.1743; BEMIS LT, 1988, MOL CELL BIOL, V8, P2125, DOI 10.1128/MCB.8.5.2125; BLUMBERG H, 1988, MOL CELL BIOL, V8, P1868, DOI 10.1128/MCB.8.5.1868; BLUMBERG H, 1987, NATURE, V328, P443, DOI 10.1038/328443a0; BLUMBERG H, 1987, THESIS U WASHINGTON; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; CIRIACY M, 1979, MOL GEN GENET, V176, P427, DOI 10.1007/BF00333107; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DENIS CL, 1991, MOL GEN GENET, V229, P395, DOI 10.1007/BF00267461; DENIS CL, 1992, MOL CELL BIOL, V12, P1507, DOI 10.1128/MCB.12.4.1507; DENIS CL, 1991, J BIOL CHEM, V266, P17932; DENIS CL, 1987, MOL GEN GENET, V208, P101, DOI 10.1007/BF00330429; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Dombek KM, 1997, MOL CELL BIOL, V17, P1450, DOI 10.1128/MCB.17.3.1450; DOMBEK KM, 1993, MOL CELL BIOL, V13, P4391, DOI 10.1128/MCB.13.7.4391; DONOVIEL MS, 1995, MOL CELL BIOL, V15, P3442; DOWBEK KM, 1999, MOL CELL BIOL, V19, P6029; EISEN A, 1988, MOL CELL BIOL, V8, P4552, DOI 10.1128/MCB.8.10.4552; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IRANI M, 1987, MOL CELL BIOL, V7, P1233, DOI 10.1128/MCB.7.3.1233; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; KARNITZ L, 1992, GENETICS, V132, P351; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; LAMPHIER MS, 1992, P NATL ACAD SCI USA, V89, P5922, DOI 10.1073/pnas.89.13.5922; Legrand-Poels S, 1998, J PHOTOCH PHOTOBIO B, V45, P1, DOI 10.1016/S1011-1344(98)00118-3; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Moser MJ, 1997, J CELL SCI, V110, P1805; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Ostling J, 1996, MOL CELL BIOL, V16, P753; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERO JH, 1991, METHOD ENZYMOL, V194, P749; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; THUKRAL SK, 1989, MOL CELL BIOL, V9, P2360, DOI 10.1128/MCB.9.6.2360; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; VALLARI RC, 1992, MOL CELL BIOL, V12, P1663, DOI 10.1128/MCB.12.4.1663; Verdone L, 1997, J BIOL CHEM, V272, P30828, DOI 10.1074/jbc.272.49.30828; Verdone L, 1996, MOL CELL BIOL, V16, P1978; Young ET, 1998, J BIOL CHEM, V273, P32080, DOI 10.1074/jbc.273.48.32080; YU J, 1989, MOL CELL BIOL, V9, P34, DOI 10.1128/MCB.9.1.34	59	28	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37575	37582		10.1074/jbc.274.53.37575	http://dx.doi.org/10.1074/jbc.274.53.37575			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608811	hybrid			2022-12-25	WOS:000084528000011
J	Feng, JH; Ito, M; Ichikawa, K; Isaka, N; Nishikawa, M; Hartshorne, DJ; Nakano, T				Feng, JH; Ito, M; Ichikawa, K; Isaka, N; Nishikawa, M; Hartshorne, DJ; Nakano, T			Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; BINDING PROTEIN-RHO; MYOTONIC-DYSTROPHY KINASE; ACTIN STRESS FIBERS; REGULATORY SUBUNITS; CA2+ SENSITIZATION; MOLECULAR-CLONING; CATALYTIC SUBUNIT; ARACHIDONIC-ACID; TARGET SUBUNIT-1	It is clear from several studies that myosin phosphatase (MP) can be inhibited via a pathway that involves RhoA. However, the mechanism of inhibition is not established; These studies were carried out to test the hypothesis that Rho-kinase (Rho-associated kinase) via phosphorylation of the myosin phosphatase target subunit 1 (MYPT1) inhibited MP activity and to identify relevant sites of phosphorylation. Phosphorylation by Rho-kinase inhibited MP activity and this reflected a decrease in V-max. Activity of MP with different substrates also was inhibited by phosphorylation, Two major;sites of phosphorylation on MYPT1 were Thr(695) and Thr(850). Various point mutations were designed for these phosphorylation sites. Following thiophosphorylation by Rho kinase and assays of phosphatase activity it was determined that Thr(695) was responsible for inhibition. A site- and phosphorylation-specific antibody was developed for the sequence flanking Thr(695) and this recognized only phosphorylated Thr(695) in both native and recombinant MYPT1. Using this antibody it was shown that stimulation of serum-starved Swiss 3T3 cells by lysophosphatidic acid, thought to activate RhoA pathways, induced an increase in Thr(695) phosphorylation on MYPT1 and this effect was blocked by a Rho-kinase inhibitor, Y-27632. In summary, these results offer strong support for a physiological role of Rho-kinase in regulation of MP activity.	Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan; Mie Univ, Sch Med, Dept Internal Med 2, Tsu, Mie 5148507, Japan; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA	Mie University; Mie University; University of Arizona	Ito, M (corresponding author), Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 5148507, Japan.	m-ito@din.medic.mie-u.ac.jp			NHLBI NIH HHS [HL23615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Beavo J A, 1974, Methods Enzymol, V38, P299; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; Fujioka M, 1998, GENOMICS, V49, P59, DOI 10.1006/geno.1998.5222; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Gailly P, 1997, J PHYSIOL-LONDON, V500, P95, DOI 10.1113/jphysiol.1997.sp022002; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; GONG MC, 1992, J BIOL CHEM, V267, P21492; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V2, P423; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Hirano M, 1999, BIOCHEM BIOPH RES CO, V254, P490, DOI 10.1006/bbrc.1998.9973; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ICHIKAWA K, 1993, BIOCHEM BIOPH RES CO, V193, P827, DOI 10.1006/bbrc.1993.1700; Ichikawa K, 1996, BIOCHEMISTRY-US, V35, P6313, DOI 10.1021/bi960208q; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakai K, 1997, BLOOD, V90, P3936, DOI 10.1182/blood.V90.10.3936; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SELLERS JR, 1985, CURR TOP CELL REGUL, V27, P51; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Suzuki Y, 1999, BLOOD, V93, P3408, DOI 10.1182/blood.V93.10.3408.410k37_3408_3417; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; Takahashi N, 1997, GENOMICS, V44, P150, DOI 10.1006/geno.1997.4859; Tanaka J, 1998, BIOCHEMISTRY-US, V37, P16697, DOI 10.1021/bi980782x; Totsukawa G, 1999, J CELL BIOL, V144, P735, DOI 10.1083/jcb.144.4.735; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; Wissmann A, 1997, GENE DEV, V11, P409, DOI 10.1101/gad.11.4.409; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	57	424	437	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37385	37390		10.1074/jbc.274.52.37385	http://dx.doi.org/10.1074/jbc.274.52.37385			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601309	hybrid			2022-12-25	WOS:000084382700080
J	Jardine, LJ; Milne, DM; Dumaz, N; Meek, DW				Jardine, LJ; Milne, DM; Dumaz, N; Meek, DW			Phosphorylation of murine p53, but not human p53, by MAP kinase in vitro and in cultured cells highlights species-dependent variation in post-translational modification	ONCOGENE			English	Article						p53; ERK; MAP kinase; phosphorylation	ACTIVATED PROTEIN-KINASE; WILD-TYPE P53; IN-VITRO; GENE AMPLIFICATION; FUNCTIONAL DOMAIN; STRESS SIGNALS; GROWTH ARREST; T-ANTIGEN; TRANSACTIVATION; APOPTOSIS	The p53 tumour suppressor protein is tightly regulated by protein-protein association, protein turnover and a variety of post-translational modifications. Multisite phosphorylation plays a major role in activating and in finely tuning p53 function. The proline rich domain of murine p53 is a substrate for phosphorylation, lit vitro and in cultured cells, by the p42(ERK2) and p44(ERK1) mitogen-activated protein (MAP) kinases, However, to date there have been no reports of attempts to determine whether p53 from any other species is a substrate for MAP kinase, In this paper we confirm that murine p53 is targeted by recombinant MAP kinase and by MAP kinases in extracts of both murine and human cells. In contrast, human p53 is not a substrate for recombinant MAP kinase nor are there any detectable levels of protein kinase activity in stimulated human cell extracts which phosphorylate the proline rich domain of human p53 in vitro. Finally, although stimulation of murine fibroblasts with o-tetradecanolylphorbol 13-acetate (TPA), an indirect activator of the MAP kinase pathway, leads to site-specific phosphorylation of murine p53, similar treatment of human fibroblasts and epithelial cells showed no significant changes in the phosphorylation pattern. These data are consistent with accumulating evidence that significant species-dependent differences exist in the post-translational modification of p53.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.		Dumaz, Nicolas/B-5907-2008	Dumaz, Nicolas/0000-0003-3511-2160				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meek DW, 1997, PATHOL BIOL, V45, P804; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MULLER E, 1995, ONCOGENE, V10, P1175; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; Prives C, 1999, J PATHOL, V187, P112; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	36	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7602	7607		10.1038/sj.onc.1203137	http://dx.doi.org/10.1038/sj.onc.1203137			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602521	Bronze			2022-12-25	WOS:000084119600023
J	Gorbsky, GJ; Kallio, M; Daum, JR; Topper, LM				Gorbsky, GJ; Kallio, M; Daum, JR; Topper, LM			Protein dynamics at the kinetochore: cell cycle regulation of the metaphase to anaphase transition	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		CYCLOSOME/ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE; SPINDLE CHECKPOINT; BUDDING YEAST; UNATTACHED KINETOCHORES; MITOTIC FORCES; MAD2; MITOSIS; CDC20; MICROINJECTION	The spindle checkpoint blocks the initiation of anaphase in mitosis and meiosis if chromosomes are not aligned at the metaphase plate, The checkpoint functions by preventing a ubiquitin ligase called the anaphase-promoting complex/cyclosome (APC/C) from ubiquitinylating proteins whose destruction is required for anaphase onset, The spindle checkpoint signal originates at the kinetochores of unaligned chromosomes and is broadcast to the rest of the cell. Although the spindle checkpoint is not understood in detail, several components of the checkpoint-signaling pathway have been identified. Many of these components associate transiently with the kinetochores of unaligned chromosomes, We propose a model in which kinetochores that lack stable attachments to the spindle microtubules serve as catalytic staging areas for the assembly of inhibitor complexes. These inhibitor complexes then leave the kinetochores and block activity of the APC/C throughout the cell. We suggest that microtubule occupancy at kinetochores or physical tension induced by microtubule capture turns off the capability of the kinetochore to produce the APC/C inhibitor. Subsequently, the inhibitor concentration in the cell wanes and anaphase initiates.	Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Gorbsky, GJ (corresponding author), Univ Virginia, Ctr Hlth Sci, Box 439 UVA, Charlottesville, VA 22908 USA.			Gorbsky, Gary/0000-0003-3076-4725; Kallio, Marko/0000-0002-6345-1680				CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CohenFix O, 1997, CURR OPIN CELL BIOL, V9, P800, DOI 10.1016/S0955-0674(97)80080-4; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193	25	17	17	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S231	S234		10.1096/fasebj.13.9002.S231	http://dx.doi.org/10.1096/fasebj.13.9002.S231			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619133	Bronze			2022-12-25	WOS:000084390200011
J	Liu, MTW; Wuebbens, MM; Rajagopalan, KV; Schindelin, H				Liu, MTW; Wuebbens, MM; Rajagopalan, KV; Schindelin, H			Crystal structure of the gephyrin-related molybdenum cofactor biosynthesis protein MogA from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTING FACTOR; MOLYBDOPTERIN BIOSYNTHESIS; REFINEMENT; OXIDOREDUCTASE; REPLACEMENT; DEFICIENCY; TUBULIN; OXIDASE; BINDS; TOOL	Molybdenum cofactor (Moco) biosynthesis is an evolutionarily conserved pathway in archaea, eubacteria, and eukaryotes, including humans. Genetic deficiencies of enzymes involved in this biosynthetic pathway trigger an autosomal recessive disease with severe neurological symptoms, which usually leads to death in early childhood. The MogA protein exhibits affinity for molybdopterin, the organic component of Moco, and has been proposed to act as a molybdochelatase incorporating molybdenum into Moco, MogA is related to the protein gephyrin, which, in addition to its role in Moco biosynthesis, is also responsible for anchoring glycinergic receptors to the cytoskeleton at inhibitory synapses. The high resolution crystal structure of the Escherichia coli MogA protein has been determined, and it reveals a trimeric arrangement in which each monomer contains a central, mostly parallel beta-sheet surrounded by cu-helices on either side. Based on structural and biochemical data, a putative active site was identified, including two residues that are essential for the catalytic mechanism.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Duke University	Schindelin, H (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Schindelin, Hermann/Q-2697-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54835] Funding Source: Medline; NIGMS NIH HHS [GM00091] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1997, METHOD ENZYMOL, V277, P243, DOI 10.1016/S0076-6879(97)77015-0; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CHRISTOPHER JA, 1998, J MOL GRAPHICS, V16, P1998; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; JAMES R, 1993, J DNA SEQUENCING MAP, V3, P327; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joshi MS, 1996, J BACTERIOL, V178, P4310, DOI 10.1128/jb.178.14.4310-4312.1996; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; Reiss J, 1998, NAT GENET, V20, P51, DOI 10.1038/1706; Reiss J, 1998, HUM GENET, V103, P639, DOI 10.1007/s004390050884; Reiss J, 1999, AM J HUM GENET, V64, P706, DOI 10.1086/302296; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	44	74	76	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1814	1822		10.1074/jbc.275.3.1814	http://dx.doi.org/10.1074/jbc.275.3.1814			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636880	hybrid			2022-12-25	WOS:000084940000043
J	Ping, DS; Boekhoudt, G; Zhang, FP; Morris, A; Philipsen, S; Warren, ST; Boss, JM				Ping, DS; Boekhoudt, G; Zhang, FP; Morris, A; Philipsen, S; Warren, ST; Boss, JM			Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; MESSENGER-RNA EXPRESSION; TRANSCRIPTION FACTOR SP1; GROWTH-FACTOR; HIV-1 ENHANCER; ALLERGIC INFLAMMATION; FACTOR-ALPHA; IN-VITRO; CHEMOKINES	The monocyte chemoattractant protein-1 gene (MCP-1) is induced by the inflammatory cytokine tumor necrosis factor through the coordinate assembly of an NF-kappa B-dependent distal regulatory region and a proximal region that has been suggested to bind Spl as well as other factors. To provide a genetic correlation for Spl activity in this system, a cell line homozygous for a targeted truncation of the Spl gene was derived and examined. We found that the lack of Spl binding activity resulted in the inability of both the distal and proximal regions to assemble in vivo even though the binding of NF-kappa B to distal region DNA was unaffected in vitro. We also found that Spl and NF-kappa B were the minimal mammalian transcription factors required for efficient activity when transfected into Drosophila Schneider cells. Additionally, Sp3 was able to compensate for Spl in the Drosophila tissue cell system but not in the Sp1(-/-) cell line suggesting that Spl usage is site-specific and is likely to depend on the context of the binding site. Together, these data provide genetic and biochemical proof for Spl in regulating the MCP-I gene.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Howard Hughes Med Inst, Atlanta, GA 30322 USA; Erasmus Univ, Dept Cell Biol, Ctr Med Genet, Rotterdam, Netherlands	Emory University; Emory University; Emory University; Howard Hughes Medical Institute; Erasmus University Rotterdam	Boss, JM (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.	boss@microbio.emory.edu	Warren, Stephen T/A-2498-2012	Morris, Ann/0000-0003-1489-4431	NCI NIH HHS [CA74271] Funding Source: Medline; NIGMS NIH HHS [T32 GM008490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Brown Z, 1996, J LEUKOCYTE BIOL, V59, P75, DOI 10.1002/jlb.59.1.75; Charron D, 1990, Adv Immunol, V48, P107, DOI 10.1016/S0065-2776(08)60753-1; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DYNAN WS, 1985, P NATL ACAD SCI USA, V82, P4915, DOI 10.1073/pnas.82.15.4915; Faller DV, 1997, J CELL PHYSIOL, V172, P240, DOI 10.1002/(SICI)1097-4652(199708)172:2<240::AID-JCP11>3.3.CO;2-T; FRAZIERJESSEN MR, 1995, J IMMUNOL, V154, P1838; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gibran NS, 1997, J SURG RES, V70, P1, DOI 10.1006/jsre.1997.5017; Glabinski AR, 1996, J IMMUNOL, V156, P4363; GORDON HM, 1992, J IMMUNOL, V148, P4021; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HANAZAWA S, 1994, J BIOL CHEM, V269, P21379; Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; Kronke M, 1992, Immunol Ser, V56, P189; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Lloyd CM, 1997, J LEUKOCYTE BIOL, V62, P676, DOI 10.1002/jlb.62.5.676; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Ping DS, 1999, J IMMUNOL, V162, P727; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Ping DS, 1999, J BIOL CHEM, V274, P31909, DOI 10.1074/jbc.274.45.31909; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SCHWARTZ CJ, 1991, CLIN CARDIOL, V14, P1, DOI 10.1002/clc.4960141302; Shyy JYJ, 1995, J BIOMECH, V28, P1451, DOI 10.1016/0021-9290(95)00093-3; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sozzani S, 1997, J LEUKOCYTE BIOL, V62, P30, DOI 10.1002/jlb.62.1.30; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Weiss L, 1997, J INFECT DIS, V176, P1621, DOI 10.1086/517341; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	56	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1708	1714		10.1074/jbc.275.3.1708	http://dx.doi.org/10.1074/jbc.275.3.1708			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636866	hybrid			2022-12-25	WOS:000084940000029
J	Courtes, C; Lecointe, N; Le Cam, L; Baudoin, F; Sardet, C; Mathieu-Mahul, D				Courtes, C; Lecointe, N; Le Cam, L; Baudoin, F; Sardet, C; Mathieu-Mahul, D			Erythroid-specific inhibition of the tal-1 intragenic promoter is due to binding of a repressor to a novel silencer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEINS; SCL GENE-PRODUCT; PRIMITIVE MYELOID CELLS; EPSILON-GLOBIN GENE; ALPHA-BETA-LINEAGE; CENTROMERIC HETEROCHROMATIN; HEMATOPOIETIC LINEAGES; DISTINCT MECHANISMS	The basic helix-loop-helix tal-l gene plays a key role in hematopoiesis, and its expression is tightly controlled through alternative promoters and complex interactions of cis-acting regulatory elements, tal-1 is not expressed in normal T cells, but its transcription is constitutive in a large proportion of human T cell leukemias. We have previously described a downstream initiation of tal-1 transcription specifically associated with a subset of T cell leukemias that leads to the production of NH2-truncated TAL-1 proteins. In this study, we characterize the human promoter (promoter IV), embedded within a GC-rich region in exon TV, responsible for this transcriptional activity. The restriction of promoter IV usage is assured by a novel silencer element in the 3'-unstranslated region of the human gene that represses its activity in erythroid but not in T cells. The silencer activity is mediated through binding of a tissue-specific nuclear factor to a novel protein recognition motif (designated tal-RE) in the silencer. Mutation of a single residue within the tal-RE abolishes both specific protein binding and silencing activity. Altogether, our results demonstrate that the tal-1 promoter IV is actively repressed in cells of the erythro-megakaryocytic lineage and that this repression is released in leukemic T cells, resulting in the expression of the tal-1 truncated transcript.	Inst Mol Genet, UMR 5535, IFR 24, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Mathieu-Mahul, D (corresponding author), Inst Mol Genet, UMR 5535, IFR 24, 1919 Route Mende, F-34293 Montpellier, France.		Le Cam, Laurent/O-1408-2016; Mathieu, Daniele/G-6092-2012	Baudoin, Florence/0000-0002-2300-1490; LE CAM, Laurent/0000-0003-0325-878X				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; Begley CG, 1999, BLOOD, V93, P2760; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; Bockamp EO, 1997, J BIOL CHEM, V272, P8781, DOI 10.1074/jbc.272.13.8781; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Condorelli GL, 1996, CANCER RES, V56, P5113; Drake CJ, 1997, DEV BIOL, V192, P17, DOI 10.1006/dbio.1997.8751; Ferrier R, 1999, ONCOGENE, V18, P995, DOI 10.1038/sj.onc.1202374; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Gottgens B, 1997, ONCOGENE, V15, P2419, DOI 10.1038/sj.onc.1201426; GREEN AR, 1992, ONCOGENE, V7, P653; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; Hoang T, 1996, BLOOD, V87, P102; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; KALLIANPUR AR, 1994, BLOOD, V83, P1200; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Le Cam L, 1999, BIOTECHNIQUES, V26, P840; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; LECAM A, 1995, EUR J BIOCHEM, V231, P620; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; LEROYVIARD K, 1994, BLOOD, V84, P3819, DOI 10.1182/blood.V84.11.3819.bloodjournal84113819; Li QL, 1997, P NATL ACAD SCI USA, V94, P2444, DOI 10.1073/pnas.94.6.2444; Liao EC, 1998, GENE DEV, V12, P621, DOI 10.1101/gad.12.5.621; MACINTYRE EA, 1992, BLOOD, V80, P1511; MOUTHON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; Ono Y, 1998, MOL CELL BIOL, V18, P6939, DOI 10.1128/MCB.18.12.6939; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; PETERS B, 1993, J BIOL CHEM, V268, P3430; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1997, BIOESSAYS, V19, P607, DOI 10.1002/bies.950190711; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Sinclair AM, 1999, DEV BIOL, V209, P128, DOI 10.1006/dbio.1999.9236; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	71	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					949	958		10.1074/jbc.275.2.949	http://dx.doi.org/10.1074/jbc.275.2.949			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625632	Green Published, hybrid			2022-12-25	WOS:000084836600036
J	Curtis, CL; Hughes, CE; Flannery, CR; Little, CB; Harwood, JL; Caterson, B				Curtis, CL; Hughes, CE; Flannery, CR; Little, CB; Harwood, JL; Caterson, B			n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE-INHIBITION; RHEUMATOID-ARTHRITIS; INTERGLOBULAR DOMAIN; EXPRESSION; CYCLOOXYGENASE-1; SUPPLEMENTATION; INTERLEUKIN-1; CHONDROCYTES; AGGRECANASE; FRAGMENTS	This study describes specific molecular mechanisms by which supplementation, with n-3 fatty acids (i.e. those present in fish oils) can modulate the expression and activity of degradative and inflammatory factors that cause cartilage destruction during arthritis. Our data show that incorporation of n-3 fatty acids (but not other polyunsaturated or saturated fatty acids) into articular cartilage chondrocyte membranes results in a dose-dependent reduction in: (i) the expression and activity of proteoglycan degrading enzymes (aggrecanases) and (ii) the expression of inflammation-inducible cytokines (interleukin (IL)-1 alpha and tumor necrosis factor (TNF)-alpha) and cyclooxygenase (COX-2), but not the constitutively expressed cyclooxygenase COX-1. These findings provide evidence that n-3 fatty acid supplementation can specifically affect regulatory mechanisms involved in chondrocyte gene transcription and thus further advocate a beneficial role for dietary fish oil supplementation in alleviation of several of the physiological parameters that cause and propogate arthritic disease.	Cardiff Univ, Sch Biomed Sci, Connect Tissue Biol Labs, Cardiff CF10 3US, S Glam, Wales	Cardiff University	Caterson, B (corresponding author), Cardiff Univ, Sch Biomed Sci, Connect Tissue Biol Labs, Museum Ave,Biomed Sci Bldg, Cardiff CF10 3US, S Glam, Wales.	caterson@Cardiff.ac.uk	Harwood, John L/A-4308-2010; Little, Christopher B/A-9280-2015	Little, Christopher B/0000-0002-0353-7634; Caterson, Bruce/0000-0001-6016-0661; Harwood, John/0000-0003-2377-2612; Hughes, Clare/0000-0003-4726-5877				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; Ariza-Ariza R, 1998, SEMIN ARTHRITIS RHEU, V27, P366, DOI 10.1016/S0049-0172(98)80016-4; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; AYDELOTTE MB, 1992, CONNECT TISSUE RES, V28, P143, DOI 10.3109/03008209209014233; BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8; Blanco FJ, 1999, J RHEUMATOL, V26, P1366; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Flannery CR, 1999, MATRIX BIOL, V18, P225, DOI 10.1016/S0945-053X(99)00024-4; GARBUS J, 1963, J BIOL CHEM, V238, P59; Griswold DE, 1996, MED RES REV, V16, P181, DOI 10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO;2-X; Gurr MI, 1991, LIPID BIOCH INTRO; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; ILIE MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; Kremer JM, 1996, LIPIDS, V31, pS243, DOI 10.1007/BF02637084; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Okuyama H, 1996, PROG LIPID RES, V35, P409, DOI 10.1016/S0163-7827(96)00012-4; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SICARD B, 1985, THROMB HAEMOSTASIS, V53, P264; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SPERLING RI, 1993, J CLIN INVEST, V91, P651, DOI 10.1172/JCI116245; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TYLER JA, 1985, BIOCHEM J, V227, P869, DOI 10.1042/bj2270869; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Volker D, 1996, J CLIN BIOCHEM NUTR, V20, P83	33	195	204	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					721	724		10.1074/jbc.275.2.721	http://dx.doi.org/10.1074/jbc.275.2.721			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625599	hybrid			2022-12-25	WOS:000084836600003
J	Goto, JJ; Zhu, HN; Sanchez, RJ; Nersissian, A; Gralla, EB; Valentine, JS; Cabelli, DE				Goto, JJ; Zhu, HN; Sanchez, RJ; Nersissian, A; Gralla, EB; Valentine, JS; Cabelli, DE			Loss of in vitro metal ion binding specificity in mutant copper-zinc superoxide dismutases associated with familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULSE-RADIOLYSIS; HYDROGEN-PEROXIDE; TYROSINE NITRATION; K-M; ALS; SITE; CHAPERONE; MECHANISM; PEROXYNITRITE; AGGREGATION	The presence of the copper ion at the active site of human wild type copper-zinc superoxide dismutase (CuZnSOD) is essential to its ability to catalyze the disproportionation of superoxide into dioxygen and hydrogen peroxide, Wild type CuZnSOD and several of the mutants associated with familial amyotrophic lateral sclerosis (FALS) (Ala(4) --> Val, Gly(93) --> Ala, and Leu(38) --> Val) were expressed in Saccharomyces cerevisiae, Purified metal-free (apoproteins) and various remetallated derivatives were analyzed by metal titrations monitored by UV-visible spectroscopy, histidine modification studies using diethylpyrocarbonate, and enzymatic activity measurements using pulse radiolysis. From these studies it was concluded that the FALS mutant CuZnSOD apoproteins, in direct contrast to the human wild type apoprotein, have lost their ability to partition and bind copper and zinc ions in their proper locations in vitro, Similar studies of the wild type and FALS mutant CuZnSOD holoenzymes in the "as isolated" metallation state showed abnormally low copper-to-zinc ratios, although all of the copper acquired was located at the native copper binding sites. Thus, the copper ions are properly directed to their native binding sites in vivo, presumably as a result of the action of the yeast copper chaperone Lys7p (yeast CCS), The loss of metal ion binding specificity of FALS mutant CuZnSODs in vitro may be related to their role in ALS.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA	University of California System; University of California Los Angeles; United States Department of Energy (DOE); Brookhaven National Laboratory	Valentine, JS (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Box 951569, Los Angeles, CA 90095 USA.		Zhu, Haining/A-6076-2008; Valentine, Joan S/B-6665-2008	Zhu, Haining/0000-0001-5498-6694; Valentine, Joan S/0000-0002-7174-925X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28222] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNISTER JV, 1973, FEBS LETT, V32, P303, DOI 10.1016/0014-5793(73)80859-2; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BEEM KM, 1974, J BIOL CHEM, V249, P7298; BEEM KM, 1977, BIOCHEMISTRY-US, V16, P1930, DOI 10.1021/bi00628a027; Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BERTINI I, 1985, J AM CHEM SOC, V107, P4391, DOI 10.1021/ja00301a004; Brown RH, 1998, NAT MED, V4, P1362, DOI 10.1038/3945; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; CABELLI DE, 2000, IN PRESS BIOMIMETIC; CALABRESE L, 1975, FEBS LETT, V59, P29, DOI 10.1016/0014-5793(75)80333-4; CALABRESE L, 1980, CHEM BIOCH ASPECTS S, P265; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Crow JP, 1997, J NEUROCHEM, V69, P1936; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Ellerby LM, 1996, J AM CHEM SOC, V118, P6556, DOI 10.1021/ja953845x; FEE JA, 1975, BIOCHIM BIOPHYS ACTA, V400, P439, DOI 10.1016/0005-2795(75)90200-7; FIELDEN E M, 1973, Biochemical Society Transactions, V1, P52; FIELDEN EM, 1974, BIOCHEM J, V139, P49, DOI 10.1042/bj1390049; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Goto JJ, 1998, J BIOL CHEM, V273, P30104, DOI 10.1074/jbc.273.46.30104; KLUG D, 1972, J BIOL CHEM, V247, P4839; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; LIPPARD SJ, 1977, BIOCHEMISTRY-US, V16, P1136, DOI 10.1021/bi00625a017; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; Lyons TJ, 1999, MET IONS BIOL SYST, V36, P125; MCADAM ME, 1977, BIOCHEM J, V167, P271, DOI 10.1042/bj1670271; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PANTOLIANO MW, 1982, J AM CHEM SOC, V104, P1717, DOI 10.1021/ja00370a045; PARGE HE, 1986, J BIOL CHEM, V261, P6215; RIGO A, 1977, BIOCHEM J, V161, P31, DOI 10.1042/bj1610031; ROE JA, 1990, J AM CHEM SOC, V102, P1538; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; VALENTINE JS, 1979, P NATL ACAD SCI USA, V76, P4245, DOI 10.1073/pnas.76.9.4245; VALENTINE JS, 1980, CHEM BIOCH ASPECTS S, P254; VALENTINE JS, 1981, COPPER PROTEINS, P292; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim HS, 1997, J BIOL CHEM, V272, P8861; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	47	139	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1007	1014		10.1074/jbc.275.2.1007	http://dx.doi.org/10.1074/jbc.275.2.1007			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625639	hybrid			2022-12-25	WOS:000084836600043
J	Hughes, P; Dennis, E; Whitecross, M; Llewellyn, D; Gage, P				Hughes, P; Dennis, E; Whitecross, M; Llewellyn, D; Gage, P			The cytotoxic plant protein, beta-purothionin, forms ion channels in lipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HIPPOCAMPAL-NEURONS; PYRULARIA THIONIN; ALPHA-THIONIN; RESPONSES; CARDIOTOXIN; RESISTANCE; MELITTIN; BARLEY	Thionins are small cysteine-containing, amphipathic plant proteins found in seeds and vegetative tissues of a number of plant genera, Many of them have been shown to be toxic to microorganisms such as fungi, yeast, and bacteria and also to mammalian cells. It has been suggested that thionins are present in seeds to protect them, and the germinating seedling, from attack by phytopathogenic microorganisms, but the mechanism by which they kill cells remains unclear. Using electrophysiological measurements, we have shown that beta-purothionin from wheat flour can form cation-selective ion channels in artificial lipid bilayer membranes and in the plasmalemma of rat hippocampal neurons. We suggest that the generalized toxicity of thionins is due to their ability to generate ion channels in cell membranes, resulting in the dissipation of ion concentration gradients essential for the maintenance of cellular homeostasis.	CSIRO, Plant Ind, Canberra, ACT 2601, Australia; Australian Natl Univ, Div Bot & Zool, Canberra, ACT 0200, Australia; Australian Natl Univ, John Curtin Sch Med Res, Membrane Biol Program, Canberra, ACT 2601, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Australian National University; Australian National University; John Curtin School of Medical Research	Llewellyn, D (corresponding author), CSIRO, Plant Ind, Clunies Ross St, Canberra, ACT 2601, Australia.		Llewellyn, Danny J/D-5230-2009; Dennis, Elizabeth S/A-6074-2008	Llewellyn, Danny J/0000-0001-9535-8707; Dennis, Elizabeth S/0000-0002-7850-591X				ANGERHOFER CK, 1990, TOXICON, V28, P547, DOI 10.1016/0041-0101(90)90299-M; APEL K, 1990, PHYSIOL PLANTARUM, V80, P315, DOI 10.1111/j.1399-3054.1990.tb04413.x; Balls A, 1940, CEREAL CHEM, V17, P243; BOHLMANN H, 1994, CRIT REV PLANT SCI, V13, P1, DOI 10.1080/713608052; BROKAERT W, 1990, FEMS MICROBIOL LETT, V69, P55; Caaveiro JMM, 1998, PROTEIN SCI, V7, P2567, DOI 10.1002/pro.5560071210; CARMONA MJ, 1993, PLANT J, V3, P457, DOI 10.1046/j.1365-313X.1993.t01-24-00999.x; CURMI JP, 1993, J MEMBRANE BIOL, V136, P273; DALEY LS, 1987, J AGR FOOD CHEM, V35, P680, DOI 10.1021/jf00077a011; DECALEYA RF, 1972, APPL MICROBIOL, V23, P998, DOI 10.1128/AEM.23.5.998-1000.1972; Epple P, 1997, PLANT CELL, V9, P509, DOI 10.1105/tpc.9.4.509; FLORACK DEA, 1994, PLANT MOL BIOL, V26, P25, DOI 10.1007/BF00039517; FRACKI WS, 1992, TOXICON, V30, P1427, DOI 10.1016/0041-0101(92)90518-A; GARCIA-OLMEDO F, 1968, Anales Instituto Nacional de Investigaciones Agronomicas (Madrid), V17, P433; Garcia-Olmedo F., 1989, OXFORD SURV PLANT MO, V6, P31; GARCIAOLMEDO F, 1994, PLANT MOL BIOL, V26, P11, DOI 10.1007/BF00039515; Kushmerick C, 1998, FEBS LETT, V440, P302, DOI 10.1016/S0014-5793(98)01480-X; MOLINA A, 1993, PLANT SCI, V92, P168; OHTANI S, 1977, J BIOCHEM-TOKYO, V82, P753; OSORIO E, 1989, TOXICON, V27, P511; PAWLAK M, 1994, PROTEIN SCI, V3, P1788, DOI 10.1002/pro.5560031019; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; Piller SC, 1998, P NATL ACAD SCI USA, V95, P4595, DOI 10.1073/pnas.95.8.4595; PONZ F, 1983, EMBO J, V2, P1035, DOI 10.1002/j.1460-2075.1983.tb01542.x; REDMAN DG, 1969, J SCI FOOD AGR, V20, P427, DOI 10.1002/jsfa.2740200715; TEETER MM, 1990, PROTEINS, V8, P118, DOI 10.1002/prot.340080203; TERRAS FRG, 1992, PLANT PHYSIOL, V100, P1055, DOI 10.1104/pp.100.2.1055; TERWILLIGER TC, 1982, BIOPHYS J, V37, P353, DOI 10.1016/S0006-3495(82)84683-3; Thevissen K, 1996, J BIOL CHEM, V271, P15018, DOI 10.1074/jbc.271.25.15018; VERNON LP, 1992, J TOXICOL-TOXIN REV, V11, P169, DOI 10.3109/15569549209115819; VERNON LP, 1992, TOXICON, V30, P711, DOI 10.1016/0041-0101(92)90005-P; WADA K, 1982, J BIOCHEM-TOKYO, V91, P257, DOI 10.1093/oxfordjournals.jbchem.a133683; WESTERMEIER R, 1997, ELECTROPHORESIS PRAC, P131	33	76	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					823	827		10.1074/jbc.275.2.823	http://dx.doi.org/10.1074/jbc.275.2.823			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625613	hybrid			2022-12-25	WOS:000084836600017
J	Jugloff, DGM; Khanna, R; Schlichter, LC; Jones, OT				Jugloff, DGM; Khanna, R; Schlichter, LC; Jones, OT			Internalization of the Kv1.4 potassium channel is suppressed by clustering interactions with PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; RAT-BRAIN; MEDIATED ENDOCYTOSIS; GUANYLATE KINASES; MOLECULAR-BASIS; MEMBRANE; NEURONS; EXPRESSION; HIPPOCAMPUS; PROTEINS	The contribution of voltage-dependent ion channels to nerve function depends upon their cell-surface distributions. Nevertheless, the mechanisms underlying channel localization are poorly understood. Two phenomena appear particularly important: the clustering of channels by membrane-associated guanylate kinases (MAGUKs), such as PSD-95, and the regional stabilization of cell-surface proteins by differential suppression of endocytosis. Could these phenomena be related? To test this possibility we examined the effect of PSD-95 on the internalization rate of Kv1.4 K+ channels in transfected HEK293 cells using cell-surface biotinylation assays. When expressed alone Kv1.4 was internalized with a half-life of 87 min, but, in the presence of PSD-95, Kv1.4 internalization was completely suppressed. Immunochemistry and electrophysiology showed PSD-95 had little effect on total or cell-surface levels of Kv1.4 or on current amplitude, activation, or inactivation kinetics. Clustering was necessary and sufficient to suppress Kv1.4 internalization since C35S-PSD-95, a mutant reported to bind but not cluster Kv1.4, (confirmed by imaging cells co-expressing a functional, GFP-variant-tagged Kv1.4) restored and, surprisingly, enhanced the rate of Kv1.4 internalization (t(1/2) = 16 min), These data argue PSD-95-mediated clustering suppresses Kv1.4 internalization and suggest a fundamentally new role for PSD-95, and perhaps other MAGUKs, orchestrating the stabilization of channels at the cell-surface.	Univ Toronto, Western Res Inst, Div Cellular & Mol Biol, Hlth Network, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Jones, OT (corresponding author), Univ Toronto, Western Res Inst, Div Cellular & Mol Biol, Hlth Network, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Khanna, Rajesh/0000-0002-9066-2969				Aidley D.J., 1996, ION CHANNELS MOL ACT; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; CASTELLINO RC, 1995, AM J PHYSIOL-HEART C, V269, pH385, DOI 10.1152/ajpheart.1995.269.1.H385; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Cooper EC, 1998, J NEUROSCI, V18, P965; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DARGENT B, 1995, J NEUROCHEM, V65, P407; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Garcia M L, 1997, Adv Pharmacol, V39, P425, DOI 10.1016/S1054-3589(08)60078-2; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Jones OT, 1997, J NEUROSCI, V17, P6152; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KOENIG JA, 1994, J BIOL CHEM, V269, P17174; Kupper J, 1998, EUR J NEUROSCI, V10, P3908; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LIU J, 1994, MOL PHARMACOL, V45, P1198; London B, 1998, J PHYSIOL-LONDON, V509, P171, DOI 10.1111/j.1469-7793.1998.171bo.x; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Negulescu D, 1998, J BIOL CHEM, V273, P20109, DOI 10.1074/jbc.273.32.20109; PARTON RG, 1993, J NEUROSCI RES, V36, P1, DOI 10.1002/jnr.490360102; PARTON RG, 1992, J CELL BIOL, V119, P123, DOI 10.1083/jcb.119.1.123; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Phillips WD, 1997, MOL CELL NEUROSCI, V10, P16, DOI 10.1006/mcne.1997.0634; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; Rasband M, 1998, J NEUROSCI, V18, P36; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Schlichter LC, 1996, GLIA, V17, P225, DOI 10.1002/(SICI)1098-1136(199607)17:3<225::AID-GLIA5>3.0.CO;2-#; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; Wang ZZ, 1999, J NEUROSCI, V19, P1998; Wickenden AD, 1997, J PHYSIOL-LONDON, V504, P271, DOI 10.1111/j.1469-7793.1997.271be.x	52	94	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1357	1364		10.1074/jbc.275.2.1357	http://dx.doi.org/10.1074/jbc.275.2.1357			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625685	hybrid			2022-12-25	WOS:000084836600089
J	Yang, XL; Ji, XH; Shi, XM; Cao, X				Yang, XL; Ji, XH; Shi, XM; Cao, X			Smad1 domains interacting with hoxc-8 induce osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY MEDIATOR SMAD1; GROWTH-FACTOR-BETA; DNA-BINDING; SIGNALING PATHWAYS; HOMEOBOX GENES; CELL-LINE; PROTEIN; TRANSCRIPTION; RECEPTOR; BMP	Bone morphogenetic proteins are potent osteotropic agents that induce osteoblast differentiation and bone formation. The signal transduction of bone morphogenetic proteins has recently been discovered to involve Smad proteins. Smad1 is an essential intracellular component that is specifically phosphorylated by bone morphogenetic protein receptors and translocated into the nucleus upon ligand stimulation. Previously, we have reported that Smad1 activates osteopontin gene expression in response to bone morphogenetic protein simulation through an interaction with a homeodomain transcription factor, Hoxc-8. In the present study, the interaction domains between the two proteins were characterized by deletional analysis in both yeast two-hybrid and gel shift assays. Two regions within the aminoterminal 87 amino acid residues of Smad1 were mapped to interact with Hoxc-8, one of which binds to the homeodomain. Overexpression of recombinant cDNAs encoding the Hoxc-8 interaction domains of Smad1 effectively activated osteopontin gene transcription in transient transfection assays. Furthermore, stable expression of these Smad1 fragments in 2T3 osteoblast precursor cells stimulated osteoblast differentiation-related gene expression and led to mineralized bone matrix formation. Our data suggest that the interaction of amino-terminal Smad1 with Hoxc-8 mimics bone morphogenetic protein signaling and is sufficient to induce osteoblast differentiation and bone cell formation.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Procter & Gamble Co, Pharmaceut, Mason, OH 45040 USA	University of Alabama System; University of Alabama Birmingham; Procter & Gamble	Cao, X (corresponding author), 1670 Univ Blvd,VH G002, Birmingham, AL 35294 USA.				NIDDK NIH HHS [DK53757] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053757] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; BEGLEY CT, 1993, BONE, V14, P661, DOI 10.1016/8756-3282(93)90089-S; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; Cao X, 1996, J BIOL CHEM, V271, P20650, DOI 10.1074/jbc.271.34.20650; CATRON KM, 1995, MOL CELL BIOL, V15, P861; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; KRUMLAUF R, 1992, BIOESSAYS, V14, P245, DOI 10.1002/bies.950140408; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POLLOCK RA, 1995, P NATL ACAD SCI USA, V92, P4492, DOI 10.1073/pnas.92.10.4492; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shimamoto T, 1999, J EXP ZOOL, V283, P186; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; Sreenath TL, 1996, P NATL ACAD SCI USA, V93, P9636, DOI 10.1073/pnas.93.18.9636; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Tiret L, 1998, DEVELOPMENT, V125, P279; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Vigano MA, 1998, MOL CELL BIOL, V18, P6201, DOI 10.1128/MCB.18.11.6201; VIOLETTE SM, 1992, P NATL ACAD SCI USA, V89, P3805, DOI 10.1073/pnas.89.9.3805; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; YAMAGUCHI A, 1995, SEMIN CELL BIOL, V6, P165, DOI 10.1006/scel.1995.0023; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956	50	91	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1065	1072		10.1074/jbc.275.2.1065	http://dx.doi.org/10.1074/jbc.275.2.1065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625647	hybrid			2022-12-25	WOS:000084836600051
J	Lutterbach, B; Westendorf, JJ; Linggi, B; Isaac, S; Seto, E; Hiebert, SW				Lutterbach, B; Westendorf, JJ; Linggi, B; Isaac, S; Seto, E; Hiebert, SW			A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA SEGMENTATION GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; RUNT DOMAIN; AML1 GENE; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; CLEIDOCRANIAL DYSPLASIA; FUNCTIONAL DOMAINS; C/EBP-ALPHA; N-COR	AML1 is one of the most frequently translocated genes in human leukemia. Here we demonstrate that acute myeloid leukemia-1 (AML-1) (Runx-1) represses transcription from a native promoter, p21(Waf1/Cip1). Unexpectedly, this repression did not require interactions with the Groucho co-repressor. To define the mechanism of repression, we asked whether other co-repressors could interact with AML-1. We demonstrate that AML-1 interacts with the mSin3 co-repressors. Moreover, endogenous AML-1 associated with endogenous mSin3A in mammalian cells. A deletion mutant of AML-1 that did not interact with mSin3A failed to repress transcription. The AML-1/mSin3 association suggests a mechanism of repression for the chromosomal translocation fusion proteins that disrupt AML-1.	Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Dept Med, Nashville, TN 37232 USA; Bethel Coll, Dept Biol, N Newton, KS 67117 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	Vanderbilt University; Vanderbilt University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Dept Biochem, Med Res Bldg 2,Rm 512,23rd & Pierce, Nashville, TN 37232 USA.	hiebert@mcmail.vanderbilt.edu	Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [R01CA064140, R01CA077274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013726] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA77274, R01-CA64140] Funding Source: Medline; NIA NIH HHS [R01-AG13726] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; EL DW, 1993, CELL, V75, P817; ERICKSON P, 1992, BLOOD, V80, P1825; Fenrick R, 1998, J CELL BIOCHEM, P194; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GERGEN JP, 1988, GENE DEV, V2, P1179, DOI 10.1101/gad.2.9.1179; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	47	214	220	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					651	656		10.1074/jbc.275.1.651	http://dx.doi.org/10.1074/jbc.275.1.651			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617663	hybrid			2022-12-25	WOS:000085951600087
J	Sasaki, N; Asukagawa, H; Yasuda, R; Hiratsuka, T; Sutoh, K				Sasaki, N; Asukagawa, H; Yasuda, R; Hiratsuka, T; Sutoh, K			Deletion of the myopathy loop of Dictyostelium myosin II and its impact on motor functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; REGULATORY LIGHT-CHAIN; DISCOIDEUM MYOSIN; IN-VIVO; F-ACTIN; DOMAIN; SITE; BINDING; GENE; PHOSPHORYLATION	One of the putative actin-binding sites of Dictyosteliun myosin II is the beta-strand-turn-beta-strand structure (Ile(398)-Leu-Ala-Gly-Arg-Asp(403)-Leu-Val(405)) the "myopathy loop," which is located at the distal end of the upper 50-kDa subdomain and next to the conserved arginine (Arg(397)), whose mutation in human cardiac myosin results in familial hypertrophic cardiomyopathy. The myopathy loop contains the TEDS residue (Asp(403)), which is a target of the heavy-chain kinase in myosin I, Moreover, the loop contains a cluster of hydrophobic residues (Ile(398), Leu(399), Leu(404), and Val(405)), whose side chains are fully exposed to the solvent. In our study, the myopathy loop was deleted from Dictyostelium myosin II to investigate its functional roles. The mutation abolished hydrophobic interactions of actin and myosin in the strong binding state during the ATPase cycle. Association of the mutant myosin and actin was maintained only through ionic interactions under these conditions. Without strong hydrophobic interactions, the mutant myosin still exhibited motor functions, although at low levels. It is likely that the observed defects resulted mainly from a loss of the cluster of hydrophobic residues, since replacement of Asp(403) or Arg(402) with alanine generated a mutant with less severe or no defects compared with those of the deletion mutant.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan; Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan; Asahikawa Med Coll, Dept Chem, Hokkaido 0788510, Japan	University of Tokyo; Keio University; Asahikawa Medical College	Sutoh, K (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan.	sutoh@bio.c.u-tokyo.ac.jp	Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; CHISHOLM RL, 1988, MOL CELL BIOL, V8, P794, DOI 10.1128/MCB.8.2.794; DE LA, 1987, SCIENCE, V236, P1086; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Fujita H, 1997, J CLIN INVEST, V99, P1010, DOI 10.1172/JCI119228; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; JOHARA M, 1993, P NATL ACAD SCI USA, V90, P2127, DOI 10.1073/pnas.90.6.2127; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; Kuhlman PA, 1998, J MUSCLE RES CELL M, V19, P491, DOI 10.1023/A:1005304408812; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; OHALLORAN TJ, 1990, P NATL ACAD SCI USA, V87, P8110, DOI 10.1073/pnas.87.20.8110; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; Suzuki Y, 1997, BIOCHEM BIOPH RES CO, V234, P701, DOI 10.1006/bbrc.1997.6671; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; TAFURI SR, 1989, MOL CELL BIOL, V9, P3073, DOI 10.1128/MCB.9.7.3073; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433	33	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37840	37844		10.1074/jbc.274.53.37840	http://dx.doi.org/10.1074/jbc.274.53.37840			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608848	hybrid			2022-12-25	WOS:000084528000048
J	Sharp, DA; Kratowicz, SA; Sank, MJ; George, DL				Sharp, DA; Kratowicz, SA; Sank, MJ; George, DL			Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; RING FINGER DOMAIN; SOFT-TISSUE SARCOMAS; HUMAN TUMOR-CELLS; P53-ASSOCIATED PROTEIN; ENHANCED TRANSLATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; GENE	The MDM2 oncoprotein has transforming potential that can be activated by overexpression, and it represents a critical regulator of the p53 tumor suppressor protein. To identify other factors with a potential role in influencing the expression and/or function of MDM2, we utilized a yeast two-hybrid screening protocol. Here we report that MDM2 physically interacts with a structurally related protein termed MDMX The results obtained in these studies provide evidence that C-terminal RING finger domains, contained within both of these proteins, play an important role in mediating the association: between MDM2 and MDMX. The interaction of these proteins interferes with MDM2 degradation, leading to an increase in the steady-state levels of MDM2. MDMX also inhibits MDM2-mediated p53 degradation, with subsequent accumulation of p53. Taken together, these data indicate that MDMX has the potential to regulate the expression and function of the MDM2 oncoprotein.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	George, DL (corresponding author), Univ Penn, Sch Med, Dept Genet, 713 Stellar Chance Bldg,422 Curie Blvd, Philadelphia, PA 19104 USA.				NCI NIH HHS [CA-66741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Copps K, 1998, EMBO J, V17, P5409, DOI 10.1093/emboj/17.18.5409; CORDONCARDO C, 1994, CANCER RES, V54, P794; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Freedman DA, 1999, CANCER RES, V59, P1; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Lai ZH, 1998, BIOCHEMISTRY-US, V37, P17005, DOI 10.1021/bi980596r; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	50	242	252	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38189	38196		10.1074/jbc.274.53.38189	http://dx.doi.org/10.1074/jbc.274.53.38189			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608892	hybrid			2022-12-25	WOS:000084528000092
J	Wang, KF; Zhen, YJ; Sadoski, R; Grinnell, S; Geren, L; Ferguson-Miller, S; Durham, B; Millett, F				Wang, KF; Zhen, YJ; Sadoski, R; Grinnell, S; Geren, L; Ferguson-Miller, S; Durham, B; Millett, F			Definition of the interaction domain for cytochrome c on cytochrome c oxidase - II. Rapid kinetic analysis of electron transfer from cytochrome c to Rhodobacter sphaeroides cytochrome oxidase surface mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; IONIC-STRENGTH; PARACOCCUS-DENITRIFICANS; TRANSFER PROTEINS; OXYFERRYL HEME; HIGH-AFFINITY; BINDING-SITE; PEROXIDASE; DERIVATIVES; REDUCTION	The reaction between cytochrome c (Cc) and Rhodobacter sphaeroides cytochrome c oxidase (CcO) was studied using a cytochrome c derivative labeled with ruthenium trisbipyridine at lysine 55 (Ru-55-Cc). Plash photolysis of a 1:1 complex between Ru-55-Cc and CcO at low ionic strength results in electron transfer from photoreduced heme c to Cu-A with an intracomplex rate constant of k(a) = 4 x 10(4) s(-1), followed by electron transfer from Cu-A to heme a with a rate constant of k(b) = 9 x 10(4) s(-1). The effects of CcO surface mutations on the kinetics follow the order D214N > E157Q > E148Q > D195N > D151N/E152Q approximate to D188N/E189Q approximate to wild type, indicating that the acidic residues Asp(214), Glu(157), Glu(148) and Asp(195) On subunit II interact electrostatically with the lysines surrounding the heme crevice of Cc. Mutating the highly conserved tryptophan residue, Trp(143), to Phe or Ala decreased the intracomplex electron transfer rate constant k(a) by 450- and 1200 fold, respectively, without affecting the dissociation constant K-D. It therefore appears that the indole ring of Trp(143) mediates electron transfer from the heme group of Cc to Cu-A These results are consistent with steady-state kinetic results (Zhen, Y., Hoganson, C. W., Babcock, G. T., and Ferguson-Miller, S. (1999) J. Biol Chem 274, 3803238041) and a computational docking analysis (Roberts, V. A, and Pique, M. E. (1999) J. Biol Chem. 274, 38051-38060).	Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	University of Arkansas System; University of Arkansas Fayetteville; Michigan State University	Millett, F (corresponding author), Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA.	millett@comp.uark.edu		Zhen, Eugene/0000-0002-0162-5665	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026916, R01GM026916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26916, GM20488] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERATAN DN, 1992, J PHYS CHEM-US, V96, P2852, DOI 10.1021/j100186a014; BLAIR DF, 1982, BIOCHEMISTRY-US, V21, P6928, DOI 10.1021/bi00269a048; BLAIR DF, 1983, CHEM SCRIPTA, V21, P43; Brzezinski P, 1996, BIOCHEMISTRY-US, V35, P5611, DOI 10.1021/bi960260m; CANN JR, 1970, INTERACTING MOL; COOPER CE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P187, DOI 10.1016/0005-2728(90)90184-6; DURHAM B, 1989, BIOCHEMISTRY-US, V28, P8659, DOI 10.1021/bi00447a057; ELTIS LD, 1991, BIOCHEMISTRY-US, V30, P3663, DOI 10.1021/bi00229a011; FABIAN M, 1987, FEBS LETT, V213, P396, DOI 10.1016/0014-5793(87)81529-6; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; FERGUSONMILLER S, 1988, INTEGRATION MITOCHON, P23; GARBER EAE, 1990, BIOCHIM BIOPHYS ACTA, V1015, P279, DOI 10.1016/0005-2728(90)90032-Y; GEREN L, 1991, BIOCHEMISTRY-US, V30, P9450, DOI 10.1021/bi00103a009; GEREN LM, 1995, J BIOL CHEM, V270, P2466, DOI 10.1074/jbc.270.6.2466; HAHM S, 1994, BIOCHEMISTRY-US, V33, P1473, DOI 10.1021/bi00172a025; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; HAZZARD JT, 1991, BIOCHEMISTRY-US, V30, P213, DOI 10.1021/bi00215a031; HEACOCK DH, 1993, J BIOL CHEM, V268, P27171; HILL BC, 1991, J BIOL CHEM, V266, P2219; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; LAPPALAINEN P, 1995, BIOCHEMISTRY-US, V34, P5824, DOI 10.1021/bi00017a014; LARSSON S, 1995, P NATL ACAD SCI USA, V92, P7167, DOI 10.1073/pnas.92.16.7167; LEMASTERS JJ, 1978, FEBS LETT, V88, P10, DOI 10.1016/0014-5793(78)80595-X; LIU RQ, 1995, BIOCHIMIE, V77, P549, DOI 10.1016/0300-9084(96)88171-5; MARCUS RA, 1956, J CHEM PHYS, V24, P966, DOI 10.1063/1.1742723; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; Mei HK, 1996, BIOCHEMISTRY-US, V35, P15800, DOI 10.1021/bi961487k; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NILSSON T, 1992, P NATL ACAD SCI USA, V89, P6497, DOI 10.1073/pnas.89.14.6497; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; OSHEROFF N, 1980, J BIOL CHEM, V255, P8245; PAN LP, 1993, BIOCHEMISTRY-US, V32, P8492, DOI 10.1021/bi00084a014; RIEDER R, 1980, J BIOL CHEM, V255, P4732; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; SCHROEDL NA, 1977, BIOCHEMISTRY-US, V16, P4961, DOI 10.1021/bi00642a003; SCOTT JR, 1994, J AM CHEM SOC, V116, P7356, DOI 10.1021/ja00095a045; SINJORGO KMC, 1986, BIOCHIM BIOPHYS ACTA, V850, P108, DOI 10.1016/0005-2728(86)90014-9; SMITH HT, 1977, BIOCHEMISTRY-US, V16, P4971, DOI 10.1021/bi00642a005; SMITH HT, 1981, J BIOL CHEM, V256, P4984; SMITH MB, 1980, BIOCHIM BIOPHYS ACTA, V592, P303, DOI 10.1016/0005-2728(80)90191-7; STAUDENMAYER N, 1977, BIOCHEMISTRY-US, V16, P600, DOI 10.1021/bi00623a007; STAUDENMAYER N, 1976, BIOCHEMISTRY-US, V15, P3198, DOI 10.1021/bi00660a007; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Wang KF, 1996, BIOCHEMISTRY-US, V35, P15107, DOI 10.1021/bi9611117; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; WILLIE A, 1992, BIOCHEMISTRY-US, V31, P7237, DOI 10.1021/bi00147a005; WILLIE A, 1993, BIOCHEMISTRY-US, V32, P7519, DOI 10.1021/bi00080a025; WILMS J, 1981, BIOCHIM BIOPHYS ACTA, V635, P13, DOI 10.1016/0005-2728(81)90003-7; WILSON DF, 1976, ARCH BIOCHEM BIOPHYS, V175, P160, DOI 10.1016/0003-9861(76)90495-1; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; WITT H, 1995, BBA-BIOENERGETICS, V1230, P74, DOI 10.1016/0005-2728(95)00050-S; Witt H, 1998, EUR J BIOCHEM, V251, P367, DOI 10.1046/j.1432-1327.1998.2510367.x; WRIGHT JL, 1998, ADV CHEM SER, V254, P99; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; Zaslavsky D, 1998, BIOCHEMISTRY-US, V37, P14910, DOI 10.1021/bi981490z; Zhen YJ, 1999, J BIOL CHEM, V274, P38032, DOI 10.1074/jbc.274.53.38032	62	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38042	38050		10.1074/jbc.274.53.38042	http://dx.doi.org/10.1074/jbc.274.53.38042			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608873	Green Submitted, hybrid			2022-12-25	WOS:000084528000073
J	Elson, A				Elson, A			Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice	ONCOGENE			English	Article						breast cancer; adenocarcinoma; sarcoma	SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; GROWTH-FACTOR; HA-RAS; CARCINOMA CELLS; NEU ONCOGENE; EXPRESSION; BREAST; GENE; TRANSFORMATION	Accurate phosphorylation of tyrosine residues in proteins plays a central role in regulation of cellular function. Although connections between aberrant tyrosine kinase activity and malignancy are well-established, significantly less Is known about the roles of protein tyrosine phosphatases (PTPases) in tumorigenesis. We have previously shown that the transmembranal form of PTPase Epsilon (PTP epsilon) is upregulated in mouse mammary tumors initiated specifically by ras or neu, suggesting that PTP epsilon may play a role in transformation by these two oncogenes, In order to test this notion lit vivo, we created transgenic mice that express elevated le, els of PTP epsilon in their mammary epithelium by use of the MMTV promoter/enhancer, Following several cycles of pregnancy female MMTV-PTP epsilon mice uniformly de, eloped pronounced and persistent mammary hyperplasia which was accompanied by residual milk production. Solitary mammary tumors were often detected secondary to mammary hyperplasia. The sporadic nature of the tumors, the long latency period prior to their development, and low levels of transgene expression in the tumors indicate that PTP epsilon provides a necessary, but insufficient, signal for oncogenesis. The results provide genetic evidence that PTP epsilon plays an accessory role in production of mammary tumors in a manner consistent with its upregulation in mammary tumors induced by ras or neu.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Elson, Ari/0000-0001-9808-9135				Ahmad A, 1998, AM J PATHOL, V152, P721; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Birchmeier C, 1996, ACTA ANAT, V156, P217; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao LG, 1998, J BIOL CHEM, V273, P21077, DOI 10.1074/jbc.273.33.21077; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; FAERMAN A, 1995, J HISTOCHEM CYTOCHEM, V43, P461, DOI 10.1177/43.5.7730585; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; HAO L, 1997, J BIOL CHEM, V272, P29332; Harlow E., 1988, ANTIBODIES LAB MANUA; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; LEDER A, 1992, DEVELOPMENT, V116, P1041; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Quarrie LH, 1996, J CELL PHYSIOL, V168, P559, DOI 10.1002/(SICI)1097-4652(199609)168:3<559::AID-JCP8>3.0.CO;2-O; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TOLEDANOKATCHAL.H, IN PRESS ONCOGENE; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	45	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7535	7542		10.1038/sj.onc.1203098	http://dx.doi.org/10.1038/sj.onc.1203098			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602512				2022-12-25	WOS:000084119600014
J	Ikematsu, N; Yoshida, Y; Kawamura-Tsuzuku, J; Ohsugi, M; Onda, M; Hirai, M; Fujimoto, J; Yamamoto, T				Ikematsu, N; Yoshida, Y; Kawamura-Tsuzuku, J; Ohsugi, M; Onda, M; Hirai, M; Fujimoto, J; Yamamoto, T			Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases	ONCOGENE			English	Article						Tob family; anti-proliferation; CDKs; CCR4 transcription factor; cell cycle	NERVE GROWTH-FACTOR; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MESSENGER-RNA; PROTEIN; IDENTIFICATION; OVEREXPRESSION; PRODUCT; CLONING	Human cDNAs encoding a novel member of Tob/BTG1 anti-proliferative family proteins were cloned. The putative protein product termed Tob2 consisted of 344 amino acids with high similarity to the Tob protein, The tob2 mRNA was 4.1 kb long and was ubiquitously expressed in human adult tissues, as was revealed by Northern blot hybridization, However, further in situ hybridization analysis showed a characteristic expression of the tob2 mRNA in oocytes, suggesting a unique role of Tob2 in oogenesis, Like the Tob protein, Tob2 inhibited cell cycle progression from the G0/G1 to S phases. Intriguingly, the amino-terminal half of Tob2 as well as that of Tob was associated with a human homologue of yeast Caf1, a component of the CCR4 transcription factor complex, Moreover, Caf1 was associated with cyclin dependent kinases, These data suggested that both Tob and Tob2 were involved in cell cycle regulation through their interaction with Caf1, Finally, the tob2 gene was mapped to human chromosome 22q13.1-q13.31.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan.		Ohsugi, Miho/AAY-9339-2020	Ohsugi, Miho/0000-0003-0288-3428				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; HARPER JW, 1993, CELL, V75, P805; Hirai M, 1996, GENOMICS, V34, P263, DOI 10.1006/geno.1996.0283; Iida A, 1998, GENE CHROMOSOME CANC, V21, P108, DOI 10.1002/(SICI)1098-2264(199802)21:2<108::AID-GCC5>3.0.CO;2-4; KIM M, 1999, IN PRESS GENE; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; Matsuda S, 1996, ONCOGENE, V12, P705; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; RABURN DJ, 1995, ENDOCRINOLOGY, V136, P5769, DOI 10.1210/en.136.12.5769; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SCHILD D, 1995, GENETICS, V140, P115; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; Walden PD, 1998, EXP CELL RES, V245, P19, DOI 10.1006/excr.1998.4237; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805	28	122	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7432	7441		10.1038/sj.onc.1203193	http://dx.doi.org/10.1038/sj.onc.1203193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602502				2022-12-25	WOS:000084119600004
J	Palayoor, ST; Youmell, MY; Calderwood, SK; Coleman, CN; Price, BD				Palayoor, ST; Youmell, MY; Calderwood, SK; Coleman, CN; Price, BD			Constitutive activation of I kappa B kinase alpha and NF-kappa B in prostate cancer cells is inhibited by ibuprofen	ONCOGENE			English	Article						NF-kappa B; ibuprofen; prostate; tumor; IKK alpha; androgen	ANDROGEN RECEPTOR GENE; IKK-ALPHA; PHOSPHORYLATION; PROTEIN; BETA; SALICYLATE; EXPRESSION; APOPTOSIS; ASPIRIN; STIMULI	Apoptotic pathways controlled by the Rel/NF-kappa B family of transcription factors may regulate the response of cells to DNA damage. Here, we have examined the NF-kappa B status Of several prostate tumor cell lines. In the androgen-independent prostate tumor cells PC-3 and DU-145, the DNA-binding activity of NF-kappa B was constitutively activated and I kappa B-alpha levels were decreased, In contrast, the androgen-sensitive prostate tumor cell line LNCaP had low levels of NF-kappa B which were upregulated following exposure to cytokines or DNA damage, The activity of the I kappa B-alpha kinase, IKK alpha, which mediates NF-kappa B activation, was also measured. In PC-3 cells, IKK alpha activity was constitutively active, whereas LNCaP cells had minimal IKK alpha activity that was activated by cytokines. The anti-inflammatory agent ibuprofen inhibited the constitutive activation of NF-kappa B and IKK alpha in PC-3 and DU-145 cells, and blocked stimulated activation of NF-kappa B in LNCaP cells. However, ibuprofen did not directly inhibit I kappa B-alpha kinase, The results demonstrate that NF-kappa B is constitutively activated in the hormone-insensitive prostate tumor cell lines PC-3 and DU-145, but not in the hormone responsive LNCaP cell line. The constitutive activation of NF-kappa B in prostate tumor cells may increase expression of anti-apoptotic proteins, thereby decreasing the effectiveness of anti-tumor therapy and contributing to the development of the malignant phenotype.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Joint Ctr Radiat Therapy,Dept Adult Oncol, Boston, MA 02115 USA; NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Joint Ctr Radiat Therapy,Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [CA64585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apakama I, 1996, BRIT J CANCER, V74, P1258, DOI 10.1038/bjc.1996.526; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LASKA EM, 1986, CLIN PHARMACOL THER, V40, P1, DOI 10.1038/clpt.1986.129; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nakajima Y, 1996, PROSTATE, V29, P296; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Palayoor ST, 1998, CLIN CANCER RES, V4, P763; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Soncin F, 1996, BIOCHEM BIOPH RES CO, V229, P479, DOI 10.1006/bbrc.1996.1829; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; TEICHER BA, 1996, RADIAT ONCOL INVEST, V4, P221; TILLEY WD, 1990, CANCER RES, V50, P5382; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	31	276	292	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7389	7394		10.1038/sj.onc.1203160	http://dx.doi.org/10.1038/sj.onc.1203160			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602496				2022-12-25	WOS:000084119400026
J	Takeuchi, S; Cho, SK; Seriu, T; Koike, M; Bartram, CR; Reiter, A; Schrappe, M; Takeuchi, C; Taguchi, H; Koeffler, HP				Takeuchi, S; Cho, SK; Seriu, T; Koike, M; Bartram, CR; Reiter, A; Schrappe, M; Takeuchi, C; Taguchi, H; Koeffler, HP			Identification of three distinct regions of deletion on the long arm of chromosome 11 in childhood acute lymphoblastic leukemia	ONCOGENE			English	Article						LOH; ALL; 11q; MLL; ATM	ATM GENE; SUSCEPTIBILITY; MAP	Cytogenetic analysis of childhood acute lymphoblastic leukemia (ALL) identified deletions of chromosome arm 11q, These observations led us to analyse the loss of heterozygosity (LOH) of chromosome arm 11q in 113 primary childhood ALL samples using 14 microsatellite markers. LOH was found in 18 (16%) patients. Detailed examination identified three distinct regions of deletion. The first region is flanked by D11S901 and D11S1391 at 11q22-23 containing the A TM gene. Mutational analysis suggested that the altered gene in this region is not the ATM gene. The second region is flanked by D11S614 and D11S924 at 11q23 containing the MLL gene, The third region is flanked by D11S1356 and D11S614 at 11q23 containing the MLL gene. All the cases with LOH at MLL locus lacked detectable MLL gene rearrangements. In addition, 20 children have been studied both at initial diagnosis and relapse; none of the individuals who relapsed acquired LOH of 11q, suggesting that 11q deletions were infrequently involved in the progression of childhood ALL. Children with 11q LOH had a good response to induction chemotherapy (P=0.015), These data suggest that alterations of putative tumor suppressor genes on 11q are important events in development of childhood ALL. Our map provides important information toward cloning putative tumor suppressor genes associated with childhood ALL.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany; Hannover Med Sch, Dept Pediat 4, Hannover, Germany; Kochi Med Sch, Dept Med, Kochi 7838505, Japan	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ruprecht Karls University Heidelberg; Hannover Medical School; Kochi University	Takeuchi, S (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA.		Schrappe, Martin/A-8109-2010; Schrappe, Martin/ABA-6144-2020	Cho, Steve Kyungrae/0000-0001-8547-8430				JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; JOHANSSON B, 1993, GENE CHROMOSOME CANC, V8, P205, DOI 10.1002/gcc.2870080402; RAIMONDI SC, 1995, BLOOD, V86, P1881, DOI 10.1182/blood.V86.5.1881.bloodjournal8651881; RAIMONDI SC, 1993, BLOOD, V81, P2237; TAKEUCHI S, 1995, CANCER RES, V55, P5377; Takeuchi S, 1998, BRIT J HAEMATOL, V103, P536, DOI 10.1046/j.1365-2141.1998.00993.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Vorechovsky I, 1996, CANCER RES, V56, P2726; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	9	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7387	7388		10.1038/sj.onc.1203145	http://dx.doi.org/10.1038/sj.onc.1203145			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602495				2022-12-25	WOS:000084119400025
J	Hammarsten, O; DeFazio, LG; Chu, G				Hammarsten, O; DeFazio, LG; Chu, G			Activation of DNA-dependent protein kinase by single-stranded DNA ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; KU PROTEIN; SCID MUTATION; V(D)J RECOMBINATION; BREAK REPAIR; BINDING; TRANSCRIPTION; COMPLEX; LYMPHOCYTES; AUTOANTIGEN	DNA-dependent protein kinase (DNA-PK) is involved in joining DNA double-strand breaks induced by ionizing radiation or V(D)J recombination, The kinase is activated by DNA ends and composed of a DNA binding subunit, Ku, and a catalytic subunit, DNA-PKCS. To define the DNA structure required for kinase activation, we synthesized a series of DNA molecules and tested their interactions with purified DNA-PKCS. The addition of unpaired single strands to blunt DNA ends increased binding and activation of the kinase. When single-stranded loops were added to the DNA ends, binding was preserved, but kinase activation was severely reduced. Obstruction of DNA ends by streptavidin reduced both binding and activation of the kinase, Significantly, short single-stranded oligonucleotides of 3-10 bases were capable of activating DNA-PKCS. Taken together, these data indicate that kinase activation involves a specific interaction with free single-stranded DNA ends. The structure of DNA-PKCS, contains an open channel large enough for double-stranded DNA and an adjacent enclosed cavity with the dimensions of single-stranded DNA. The data presented here support a model in which duplex DNA binds to the open channel, and a single-stranded DNA end is inserted into the enclosed cavity to activate the kinase.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Stanford University	Chu, G (corresponding author), Stanford Univ, Med Ctr, Dept Med Oncol, M211, Stanford, CA 94305 USA.		Hammarsten, Ola/A-2791-2012	Eli, Lisa/0000-0003-3896-0966	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058120] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM58120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FALZON M, 1993, J BIOL CHEM, V268, P10546; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; Smider V, 1998, MOL CELL BIOL, V18, P6853, DOI 10.1128/MCB.18.11.6853; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188	38	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1541	1550		10.1074/jbc.275.3.1541	http://dx.doi.org/10.1074/jbc.275.3.1541			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636842	hybrid			2022-12-25	WOS:000084940000005
J	Jault, JM; Fieulaine, S; Nessler, S; Gonzalo, P; Di Pietro, A; Deutscher, J; Galinier, A				Jault, JM; Fieulaine, S; Nessler, S; Gonzalo, P; Di Pietro, A; Deutscher, J; Galinier, A			The HPr kinase from Bacillus subtilis is a homo-oligomeric enzyme which exhibits strong positive cooperativity for nucleotide and fructose 1,6-bisphosphate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CARBON CATABOLITE REPRESSION; PHOSPHOTRANSFERASE SYSTEM; MITOCHONDRIAL F1-ATPASE; STREPTOCOCCUS-PYOGENES; PHOSPHOCARRIER PROTEIN; PHOSPHORYLATED-HPR; CRYSTAL-STRUCTURE; CATALYTIC SITE; SERYL RESIDUE	Carbon catabolite repression allows bacteria to rapidly alter the expression of catabolic genes in response to the availability of metabolizable carbon sources. In Bacillus subtilis, this phenomenon is controlled by the Hh kinase (HprK) that catalyzes ATP-dependent phosphorylation of either HPr (histidine containing protein) or Crh (catabolite repression HPr) on residue Ser-46. We report here that B, subtilis HprK forms homo-oligomers constituted most likely of eight subunits, Related to this complex structure, the enzyme displays strong positive cooperativity for the binding of its allosteric activator, fructose 1,6-bisphosphate, as evidenced by either kinetics of its phosphorylation activity or the intrinsic fluorescence properties of its unique tryptophan residue, Trp-235, It is further shown that activation of HPr phosphorylation by fructose 1,6-bisphosphate essentially occurs at low ATP and enzyme concentrations. A positive cooperativity was also detected for the binding of natural nucleotides or their 2'(3')-N-methylanthraniloyl derivatives, in either phosphorylation or fluorescence experiments. Most interestingly, quenching of the HprK tryptophan fluorescence by using either iodide or acrylamide revealed a heterogeneity of tryptophan residues within the population of oligomers, suggesting that the enzyme exists in two different conformations. This result suggests a concerted-symmetry model for the catalytic mechanism of positive cooperativity displayed by HprK.	Inst Biol & Chim Prot, UPR 412 CNRS, F-69367 Lyon 07, France; CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; INRA, Lab Genet Microorganismes, F-78850 Thiverval Grignon, France; CNRS ERS 567, F-78850 Thiverval Grignon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Galinier, A (corresponding author), Inst Biol & Chim Prot, UPR 412 CNRS, 7 Passage Vercors, F-69367 Lyon 07, France.		Nessler, Sylvie/R-4296-2016; jault, jean-michel/G-2086-2012	Nessler, Sylvie/0000-0003-4973-9941; jault, jean-michel/0000-0003-1743-2777				Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; Brochu D, 1999, J BACTERIOL, V181, P709, DOI 10.1128/JB.181.3.709-717.1999; CALHOUN DB, 1983, BIOCHEMISTRY-US, V22, P1533, DOI 10.1021/bi00276a003; CAMERON AD, 1994, J MOL BIOL, V238, P615, DOI 10.1006/jmbi.1994.1318; Christensen DP, 1999, APPL ENVIRON MICROB, V65, P2112; Conseil G, 1998, P NATL ACAD SCI USA, V95, P9831, DOI 10.1073/pnas.95.17.9831; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DEUTSCHER J, 1984, FEMS MICROBIOL LETT, V23, P157; DEUTSCHER J, 1985, J BACTERIOL, V163, P1203, DOI 10.1128/JB.163.3.1203-1209.1985; DEUTSCHER J, 1995, MOL MICROBIOL, V15, P1049, DOI 10.1111/j.1365-2958.1995.tb02280.x; DIVITA G, 1991, BIOCHEMISTRY-US, V30, P3256, DOI 10.1021/bi00227a013; DIVITA G, 1993, J BIOL CHEM, V268, P13178; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; FUJITA Y, 1979, J BIOL CHEM, V254, P5340; FUJITA Y, 1995, MOL MICROBIOL, V17, P953, DOI 10.1111/j.1365-2958.1995.mmi_17050953.x; Galinier A, 1998, P NATL ACAD SCI USA, V95, P1823, DOI 10.1073/pnas.95.4.1823; Galinier A, 1999, J MOL BIOL, V286, P307, DOI 10.1006/jmbi.1998.2492; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; GASSNER M, 1977, EUR J BIOCHEM, V75, P287, DOI 10.1111/j.1432-1033.1977.tb11528.x; Gosseringer R, 1997, J MOL BIOL, V266, P665, DOI 10.1006/jmbi.1996.0820; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAULT JM, 1993, J BIOL CHEM, V268, P20762; Jones BE, 1997, J BIOL CHEM, V272, P26530, DOI 10.1074/jbc.272.42.26530; Kanazawa T, 1995, BIOSCIENCE REP, V15, P317, DOI 10.1007/BF01788364; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Kravanja M, 1999, MOL MICROBIOL, V31, P59, DOI 10.1046/j.1365-2958.1999.01146.x; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Martin-Verstraete I, 1999, J BACTERIOL, V181, P2966, DOI 10.1128/JB.181.9.2966-2969.1999; MASON PW, 1981, J BIOL CHEM, V256, P1861; MIMURA CS, 1987, J CELL BIOCHEM, V33, P161, DOI 10.1002/jcb.240330303; MITCHELL WJ, 1993, J BACTERIOL, V175, P2758, DOI 10.1128/JB.175.9.2758-2761.1993; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MURCOTT THL, 1992, EMBO J, V11, P3811, DOI 10.1002/j.1460-2075.1992.tb05472.x; Ormo M, 1998, BIOCHEMISTRY-US, V37, P16565, DOI 10.1021/bi981616s; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; Reizer J, 1998, MOL MICROBIOL, V27, P1157, DOI 10.1046/j.1365-2958.1998.00747.x; RICARD J, 1987, EUR J BIOCHEM, V166, P255, DOI 10.1111/j.1432-1033.1987.tb13510.x; Saier MH, 1996, FEMS MICROBIOL LETT, V138, P97; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THEVENOT T, 1995, J BACTERIOL, V177, P2751, DOI 10.1128/jb.177.10.2751-2759.1995; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; [No title captured]	52	87	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1773	1780		10.1074/jbc.275.3.1773	http://dx.doi.org/10.1074/jbc.275.3.1773			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636874	Green Published, hybrid			2022-12-25	WOS:000084940000037
J	Schwanbeck, R; Manfioletti, G; Wisniewski, JR				Schwanbeck, R; Manfioletti, G; Wisniewski, JR			Architecture of high mobility group protein I-C center dot DNA complex and its perturbation upon phosphorylation by Cdc2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA GENE; FACTOR HMGI-C; CONFORMATIONAL-CHANGES; CHROMOSOMAL-PROTEINS; BINDING PROPERTIES; REGIONS FLANKING; VIRUS INDUCTION; RNA-POLYMERASE; BOX DOMAIN; IDENTIFICATION	The high mobility group I-C (HMGI-C) protein is an abundant component of rapidly proliferating undifferentiated cells. High level expression of this protein is characteristic for early embryonic tissue and diverse tumors. HMGI-C can function as an architectural factor enhancing the activity of transcription factor NF-kappa B on the beta-interferon promoter. The protein has three minor groove DNA-binding domains (AT-hooks), Here, we describe the complex of HMGI-C with a fragment of the beta-interferon promoter, We show that the protein binds to NRDI and PRDII elements of the promoter with its first and second AT-hook, respectively. Phosphorylation by Cdc2 kinase leads to a partial derailing of the AT-hooks from the minor groove, affecting mainly the second binding domain. In contrast, binding to long AT stretches of DNA involves contacts with all three AT-hooks and is marginally sensitive to phosphorylation, Our data stress the importance of conformation of the DNA binding site and protein phosphorylation for its function.	Univ Gottingen, Zool Inst 3, D-37073 Gottingen, Germany; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34127 Trieste, Italy	University of Gottingen; University of Trieste	Wisniewski, JR (corresponding author), Univ Gottingen, Zool Inst 3, Humboldtallee 34A, D-37073 Gottingen, Germany.		Schwanbeck, Ralf/A-2648-2008	Schwanbeck, Ralf/0000-0003-0925-929X; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601				Arlotta P, 1997, J BIOL CHEM, V272, P29904, DOI 10.1074/jbc.272.47.29904; ASHAR HR, 1995, CELL, V82, P57; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; CLAUS P, 1994, J BIOL CHEM, V269, P33042; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; Frank O, 1998, J BIOL CHEM, V273, P20015, DOI 10.1074/jbc.273.32.20015; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; Goodwin G, 1998, INT J BIOCHEM CELL B, V30, P761, DOI 10.1016/S1357-2725(98)00016-8; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MAHONEY WC, 1981, BIOCHEMISTRY-US, V20, P443, DOI 10.1021/bi00505a033; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; Maxam A M, 1980, Methods Enzymol, V65, P499; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; PENDERGRAST PS, 1992, P NATL ACAD SCI USA, V89, P10287, DOI 10.1073/pnas.89.21.10287; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Schwanbeck R, 1997, J BIOL CHEM, V272, P27476, DOI 10.1074/jbc.272.43.27476; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; Wisniewski Jacek R., 1998, Zoologica Poloniae, V43, P5; Wisniewski JR, 1999, BBA-GENE STRUCT EXPR, V1447, P25, DOI 10.1016/S0167-4781(99)00123-2; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	51	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1793	1801		10.1074/jbc.275.3.1793	http://dx.doi.org/10.1074/jbc.275.3.1793			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636877	hybrid			2022-12-25	WOS:000084940000040
J	Caldas, T; Laalami, S; Richarme, G				Caldas, T; Laalami, S; Richarme, G			Chaperone properties of bacterial elongation factor EF-G and initiation factor IF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; BINDING PROTEIN; TRIGGER FACTOR; TRANSFER-RNA; TU; IDENTIFICATION; PURIFICATION; HYDROLYSIS	Elongation factor G(EF-G) and initiation factor 2 (IF2) are involved in the translocation of ribosomes on mRNA and in the binding of initiator tRNA to the 30 S ribosomal subunit, respectively. Here we report that the Escherichia coli EF-G and IF2 interact with unfolded and denatured proteins, as do molecular chaperones that are involved in protein folding and protein renaturation after stress. EF-G and IF2 promote the functional folding of citrate synthase and alpha-glucosidase after urea denaturation. They prevent the aggregation of citrate synthase under heat shock conditions, and they form stable complexes with unfolded proteins such as reduced carboxymethyl alpha-lactalbumin. Furthermore, the EF-G and IF2-dependent renaturations of citrate synthase are stimulated by GTP, and the GTPase activity of EF-G and IF2 is stimulated by the permanently unfolded protein, reduced carboxymethyl alpha-lactalbumin. The concentrations at which these chaperone-like functions occur are lower than the cellular concentrations of EF-G and IF2. These results suggest that EF-G and IF2, in addition to their role in translation, might be implicated in protein folding and protection from stress.	Univ Paris 07, Inst Jacques Monod, F-75005 Paris, France; Univ Poitiers, Inst Biol Mol & Ingn Genet, CNRS, ESA6031, F-86022 Poitiers, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Richarme, G (corresponding author), Univ Paris 07, Inst Jacques Monod, 2 Pl Jussieu, F-75005 Paris, France.	richarme@ccr.jussieu.fr						ARAI N, 1975, J BIOCHEM-TOKYO, V78, P243; BEKTAS M, 1994, FEBS LETT, V356, P89, DOI 10.1016/0014-5793(94)01239-3; BROT N, 1977, MOL MECHANISMS PROTE, P375; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BURKHOLDER WF, 1994, J MOL BIOL, V242, P374; Caldas TD, 1998, PROTEIN EXPRES PURIF, V14, P65, DOI 10.1006/prep.1998.0922; Caldas TD, 1998, J BIOL CHEM, V273, P11478, DOI 10.1074/jbc.273.19.11478; CULL M, 1990, METHOD ENZYMOL, V182, P147; DEVENDITTIS E, 1986, J BIOL CHEM, V261, P4445; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; Grunberg-Manago M., 1996, ESCHERICHIA COLI SAL, V1, P1432; Hardesty Boyd, 1999, Current Opinion in Structural Biology, V9, P111, DOI 10.1016/S0959-440X(99)80014-1; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HERSHEY JWB, 1987, ESCHERICHIA COLI SAL, V1, P613; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Krab IM, 1998, BBA-GENE STRUCT EXPR, V1443, P1, DOI 10.1016/S0167-4781(98)00169-9; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; Kudlicki W, 1997, J BIOL CHEM, V272, P32206, DOI 10.1074/jbc.272.51.32206; Kurland C., 1996, ESCHERICHIA COLI SAL, V240, P979; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LANGER T, 1992, NATURE, V356, P383; LIBEREK K, 1991, P NATL ACAD SCI USA, V22, P14491; Luchin S, 1999, J BIOL CHEM, V274, P6074, DOI 10.1074/jbc.274.10.6074; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MISSIAKAS D, 1993, J BACTERIOL, V175, P2616; RICHARME G, 1993, J BIOL CHEM, V268, P24074; Richarme G, 1998, BIOCHEM BIOPH RES CO, V252, P156, DOI 10.1006/bbrc.1998.9591; Richarme G, 1997, J BIOL CHEM, V272, P15607, DOI 10.1074/jbc.272.25.15607; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; Shibata T, 1996, J BIOL CHEM, V271, P13162, DOI 10.1074/jbc.271.22.13162; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; TRAVERS AA, 1980, BIOCHEMISTRY-US, V19, P1651, DOI 10.1021/bi00549a020; VACHON G, 1993, FEBS LETT, V321, P241, DOI 10.1016/0014-5793(93)80117-D; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5404; WEIJLAND A, 1992, MOL MICROBIOL, V6, P683, DOI 10.1111/j.1365-2958.1992.tb01516.x; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; [No title captured]	45	122	124	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					855	860		10.1074/jbc.275.2.855	http://dx.doi.org/10.1074/jbc.275.2.855			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625618	hybrid			2022-12-25	WOS:000084836600022
J	Smith, DE; Renshaw, BR; Ketchem, RR; Kubin, M; Garka, KE; Sims, JE				Smith, DE; Renshaw, BR; Ketchem, RR; Kubin, M; Garka, KE; Sims, JE			Four new members expand the interleukin-1 superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-INDUCING FACTOR; HUMAN T-CELLS; IL-1 RECEPTOR; MOLECULAR-CLONING; CONVERTING-ENZYME; EXPRESSION; PROTEIN; SEQUENCE; ANTAGONIST; CYTOKINE	We report here the cloning and characterization of four new members of the interleukin-1 (IL-1) family (FIL1 delta, FIL1 epsilon, FIL1 zeta and FLI1 eta, with FIL1 standing for "Family of IL-1"), The novel genes demonstrate significant sequence similarity to IL-1 alpha, IL-1 beta, IL-1ra, and IL-18, and in addition maintain a conserved exon-intron arrangement that is shared with the previously known members of the family. Protein structure modeling also suggests that the FIL1 genes are related to IL-1 beta and IL-1ra. The novel genes form a cluster with the IL-1s on the long arm of human chromosome 2.	Immunex Corp, Seattle, WA 98101 USA	Immunex Corporation	Sims, JE (corresponding author), Immunex Corp, 51 Univ St, Seattle, WA 98101 USA.	sims@immunex.com	Ketchem, Randal R/K-2258-2017; Ketchem, Randal/AAB-4372-2020	Ketchem, Randal R/0000-0002-7821-2682; Ketchem, Randal/0000-0002-7821-2682; Sims, John/0000-0002-5667-9185				Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dinarello CA, 1998, J LEUKOCYTE BIOL, V63, P658, DOI 10.1002/jlb.63.6.658; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Jaroszewski L, 1998, PROTEIN SCI, V7, P1431; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; KUBIN M, 1994, BLOOD, V83, P1847; KUBIN M, 1994, J EXP MED, V180, P211, DOI 10.1084/jem.180.1.211; Kubin MZ, 1999, EUR J IMMUNOL, V29, P3466, DOI 10.1002/(SICI)1521-4141(199911)29:11<3466::AID-IMMU3466>3.0.CO;2-9; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Parnet P, 1996, J BIOL CHEM, V271, P3967; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Thomassen E, 1998, J INTERF CYTOK RES, V18, P1077, DOI 10.1089/jir.1998.18.1077; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Torigoe K, 1997, J BIOL CHEM, V272, P25737, DOI 10.1074/jbc.272.41.25737; Ushio S, 1996, J IMMUNOL, V156, P4274; YOUNG PR, 1998, Patent No. 0879889	41	272	321	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1169	1175		10.1074/jbc.275.2.1169	http://dx.doi.org/10.1074/jbc.275.2.1169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625660	hybrid			2022-12-25	WOS:000084836600064
J	Blaeser, F; Ho, N; Prywes, R; Chatila, TA				Blaeser, F; Ho, N; Prywes, R; Chatila, TA			Ca2+-dependent gene expression mediated by MEF2 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE TYPE-IV/GR; CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; ORPHAN STEROID-RECEPTOR; C-JUN PROMOTER; CYCLOSPORINE-A; T-LYMPHOCYTES; MADS BOX; MYOGENIC LINEAGE; INDUCIBLE MEMBER; THYROID-HORMONE	Ca2+ induction of a subset of cellular and viral immediate-early activation genes in lymphocytes has been previously mapped to response elements recognized by the MEF2 family of transcription factors. Here, we demonstrate that Ca2+ activation of MEF2 response elements in T lymphocytes is mediated in synergy by two Ca2+/calmodulin-dependent enzymes, the phosphatase calcineurin, and the kinase type IV/Gr (CaMKIV/Gr), which promote transcription by the MEF2 family members MEF2A and MEF2D. Calcineurin up-regulates the activity of both factors by an NFAT-dependent mechanism, while CaMKIV/Gr selectively and independently activates MEF2D. These results identify MEF2 proteins as effecters of a pathway of gene induction in T lymphocytes which integrates diverse Ca2+ activation signals and may be broadly operative in several tissues.	Washington Univ, Sch Med, Dept Pediat, Div Immunol Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Columbia University	Chatila, TA (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Immunol Rheumatol, 1 Childrens Pl, St Louis, MO 63110 USA.			Chatila, Talal/0000-0001-7439-2762				Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; Borras AM, 1996, J VIROL, V70, P3894, DOI 10.1128/JVI.70.6.3894-3901.1996; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CALNAN BJ, 1995, IMMUNITY, V3, P273; Chatila T, 1997, J VIROL, V71, P6560, DOI 10.1128/JVI.71.9.6560-6567.1997; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Cron RQ, 1999, J IMMUNOL, V162, P860; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GOLDFELD AE, 1995, VIROLOGY, V209, P225, DOI 10.1006/viro.1995.1247; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3229; Ho N, 1996, J EXP MED, V184, P101, DOI 10.1084/jem.184.1.101; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	56	167	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					197	209		10.1074/jbc.275.1.197	http://dx.doi.org/10.1074/jbc.275.1.197			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617605	hybrid			2022-12-25	WOS:000085951600029
J	Melloni, E; Averna, M; Salamino, F; Sparatore, B; Minafra, R; Pontremoli, S				Melloni, E; Averna, M; Salamino, F; Sparatore, B; Minafra, R; Pontremoli, S			Acyl-CoA-binding protein is a potent m-calpain activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE CALPAIN; CELL-DIFFERENTIATION; SKELETAL-MUSCLE; IDENTIFICATION; MEMBRANE; SYSTEM; RAT; LOCALIZATION; NEUTROPHILS; SENSITIVITY	Acyl-CoA-binding protein, a 20-kDa homodimer that exerts many physiological functions, promotes activation of the classic calpain forms, most markedly that of the m-isozyme, This protein factor was purified from rat skeletal muscle and was also expressed in Escherichia coli. Both native and recombinant acyl-CoA-binding proteins show the same molecular properties and an identical capacity to decrease the [Ca2+] required for m-calpain activity. The binding of long chain acyl-CoAs to acyl-CoA-binding protein does not modify the activating effect on calpains. Acyl-CoA-binding protein seems to be involved in the m-calpain regulation process, whereas the previously identified UK114 activator is a specific modulator of m-calpain. Acyl-CoA-binding protein is proposed as a new component of the Ca2+-dependent proteolytic system. A comparative analysis among levels of classic calpains and their activator proteins is also reported.	Univ Genoa, Biochem Sect, Dept Expt Med, I-16132 Genoa, Italy	University of Genoa	Melloni, E (corresponding author), Univ Genoa, Biochem Sect, Dept Expt Med, Viale Benedetto XV 1, I-16132 Genoa, Italy.	melloni@csita.unige.it	AVERNA, MONICA/R-5719-2019	AVERNA, MONICA/0000-0002-9463-7533				CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Davies EV, 1998, BIOCHEM BIOPH RES CO, V248, P679, DOI 10.1006/bbrc.1998.9031; Dutt P, 1998, FEBS LETT, V436, P367, DOI 10.1016/S0014-5793(98)01167-3; Frolov A, 1998, J BIOL CHEM, V273, P11049, DOI 10.1074/jbc.273.18.11049; Fulceri R, 1997, BIOCHEM J, V325, P423, DOI 10.1042/bj3250423; FYRST H, 1995, BIOCHEM J, V306, P793, DOI 10.1042/bj3060793; GERSUK VH, 1995, GENOMICS, V25, P469, DOI 10.1016/0888-7543(95)80047-P; GLATZ JFC, 1995, PROSTAG LEUKOTR ESS, V52, P121, DOI 10.1016/0952-3278(95)90010-1; Goll DE, 1990, INTRACELLULAR CALCIU, P3; Gossett RE, 1998, ARCH BIOCHEM BIOPHYS, V350, P201, DOI 10.1006/abbi.1997.0521; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; MELLONI E, 1988, P NATL ACAD SCI USA, V85, P3835, DOI 10.1073/pnas.85.11.3835; Melloni E, 1998, BIOCHEM BIOPH RES CO, V249, P583, DOI 10.1006/bbrc.1998.9200; Melloni E, 1998, J BIOL CHEM, V273, P12827, DOI 10.1074/jbc.273.21.12827; Michetti M, 1997, BIOCHEM J, V325, P721, DOI 10.1042/bj3250721; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; MOCCHETTI I, 1986, P NATL ACAD SCI USA, V83, P7221, DOI 10.1073/pnas.83.19.7221; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; OHTA Y, 1976, P NATL ACAD SCI USA, V73, P1232, DOI 10.1073/pnas.73.4.1232; PONTREMOLI S, 1991, ARCH BIOCHEM BIOPHYS, V288, P646, DOI 10.1016/0003-9861(91)90247-G; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1995, EUR J BIOCHEM, V230, P25, DOI 10.1111/j.1432-1033.1995.0025i.x; Sparatore B, 1996, FEBS LETT, V386, P95, DOI 10.1016/0014-5793(96)00418-8; Swinnen JV, 1998, J BIOL CHEM, V273, P19938, DOI 10.1074/jbc.273.32.19938; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	28	57	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					82	86		10.1074/jbc.275.1.82	http://dx.doi.org/10.1074/jbc.275.1.82			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617589	hybrid			2022-12-25	WOS:000085951600013
J	Schiavone, N; Rosini, P; Quattrone, A; Donnini, M; Lapucci, A; Citti, L; Bevilacqua, A; Nicolin, A; Capaccioli, S				Schiavone, N; Rosini, P; Quattrone, A; Donnini, M; Lapucci, A; Citti, L; Bevilacqua, A; Nicolin, A; Capaccioli, S			A conserved AU-rich element in the 3 ' untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis	FASEB JOURNAL			English	Article						bcl-2 regulation; RNA decay; RNA half-life; gene regulation	MESSENGER-RNA DEGRADATION; NECROSIS-FACTOR-ALPHA; HUMAN FOLLICULAR LYMPHOMA; LEUKEMIA-CELL-LINES; PROTEIN-KINASE-C; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; IN-VIVO; B-CELLS; BINDING PROTEINS	The control of mRNA stability is becoming recognized as a crucial point of gene expression regulation. A common element responsible for mRNA decay modulation is the adenine- and uracil-rich element that is found in the 3' untranslated region of numerous mRNAs subjected to fast expression changes in response to various stimuli. Previously we identified a post-transcriptional regulation level for the antiapoptotic bcl-2 gene, which could be involved in t(14;18) lymphoma-associated bcl-2 overexpression. Here we demonstrate that bcl-2 mRNA is endowed with an adenine- and uracil-rich element (ARE) characterized by high evolutionary conservation not only among all chordates examined, but even between chordates and the nematode Caenorhabditis elegans (ced-9 gene). As for other well-established destabilizing AREs, the insertion of the bcl-2 ARE downstream from stable beta-globin mRNA causes an enhanced decay of the beta-globin transcript, which proves its functional role. This possibility is corroborated by the fact that the pathway leading to the modulating activity of bcl-2 ARE is influenced by PKC, since the addition of DAG and TPA markedly attenuated the bcl-2 ARE destabilizing potential. Conversely, it is noteworthy that when C-2-ceramide is added to the culture medium as the apoptotic agent, the beta-globin transcript harboring the bcl-2 ARE undergoes a dramatic increase in decay. This observation clearly indicates that the destabilizing function of bcl-2 ARE is enhanced by apoptotic stimuli and suggests that this element could be involved in a post-transcriptional mechanism of bcl-2 down-regulation during apoptosis. The half-life of the mRNA of bcl-2 in Jurkat cells is prolonged by PKC stimulation and shortened by C-2-ceramide addition, strongly supporting the view that bcl-2 mRNA stability plays a physiological role in modulating bcl-2 expression, particularly in its down-regulation during apoptosis. Thus, this element becomes a new candidate for mediating those bcl-2 gene expression changes-from apoptosis-associated down-regulation to tumor-associated overexpression-observed thus far that profoundly influence single cell fate and tissue homeostasis. Schiavone, N., Rosini, P., Quattrone, A., Donnini, M., Lapucci, A., Citti, L., Bevilacqua, A., Nicolin, A., Capaccioli, S. A conserved AU-rich element in the 3' untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis.	Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; CNR, Ist Mutagenesis & Differentiat, Pisa, Italy; Univ Milan, Dept Pharmacol, Milan, Italy	University of Florence; Consiglio Nazionale delle Ricerche (CNR); University of Milan	Nicolin, A (corresponding author), Univ Florence, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	angelo.nicolin@unimi.it; sergio@cesit1.unifi.it	Lapucci, Andrea/AAA-6645-2019; Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; Schiavone, Nicola/0000-0002-1592-4244; LAPUCCI, Andrea/0000-0001-9613-7164; Quattrone, Alessandro/0000-0003-3333-7630				AGHIB DF, 1990, ONCOGENE, V5, P707; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; Belasco J.G., 2012, CONTROL MESSENGER RN; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; Blagosklonny MV, 1997, CANCER RES, V57, P130; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; Capaccioli S, 1996, ONCOGENE, V13, P105; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN M, 1995, CANCER RES, V55, P991; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GENESTIER L, 1995, INT IMMUNOL, V7, P533, DOI 10.1093/intimm/7.4.533; Haldar S, 1996, CANCER RES, V56, P1253; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Harigai M, 1996, ONCOGENE, V12, P1369; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERNANDEZCASELLES T, 1995, HUM IMMUNOL, V43, P181, DOI 10.1016/0198-8859(94)00168-P; IWAI Y, 1991, J BIOL CHEM, V266, P17959; JEWELL AP, 1994, BRIT J HAEMATOL, V88, P268, DOI 10.1111/j.1365-2141.1994.tb05017.x; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lu QL, 1996, HUM PATHOL, V27, P102, DOI 10.1016/S0046-8177(96)90362-7; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARR F, 1996, J BIOL CHEM, V271, P26074; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Monni O, 1997, BLOOD, V90, P1168, DOI 10.1182/blood.V90.3.1168.1168_1168_1174; Morelli S, 1997, P NATL ACAD SCI USA, V94, P8150, DOI 10.1073/pnas.94.15.8150; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; Ochiai K, 1997, CLIN EXP IMMUNOL, V107, P198, DOI 10.1046/j.1365-2249.1997.d01-884.x; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Quattrone A, 1995, HAEMATOLOGICA, V80, P495; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; Suzuki A, 1996, ONCOGENE, V13, P31; Suzuki A, 1997, CARCINOGENESIS, V18, P883, DOI 10.1093/carcin/18.5.883; Tangye SG, 1997, IMMUNOL CELL BIOL, V75, P127, DOI 10.1038/icb.1997.17; Teague TK, 1997, J IMMUNOL, V158, P5791; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Whitman SP, 1997, J BIOL CHEM, V272, P23481, DOI 10.1074/jbc.272.38.23481; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007; Ziegler A, 1997, JNCI-J NATL CANCER I, V89, P1027, DOI 10.1093/jnci/89.14.1027; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	60	94	98	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					174	184		10.1096/fasebj.14.1.174	http://dx.doi.org/10.1096/fasebj.14.1.174			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627292				2022-12-25	WOS:000084784700020
J	Silakowski, B; Schairer, HU; Ehret, H; Kunze, B; Weinig, S; Nordsiek, G; Brandt, P; Blocker, H; Hofle, G; Beyer, S; Muller, R				Silakowski, B; Schairer, HU; Ehret, H; Kunze, B; Weinig, S; Nordsiek, G; Brandt, P; Blocker, H; Hofle, G; Beyer, S; Muller, R			New lessons of combinatorial biosynthesis from myxobacteria - The myxothiazol biosynthetic gene cluster of Stigmatella aurantiaca DW4/3-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYXOCOCCUS-XANTHUS DEVELOPMENT; POLYKETIDE SYNTHASE GENES; FRUITING BODY FORMATION; BIOLOGICAL PROPERTIES; PEPTIDE SYNTHETASES; GLIDING BACTERIA; MYCOBACTERIUM-TUBERCULOSIS; STREPTOMYCES-AVERMITILIS; MOLECULAR ANALYSIS; BACILLUS-SUBTILIS	The biosynthetic mta gene cluster responsible for myxothiazol formation from the fruiting body forming myxobacterium Stigmatella aurantiaca DW4/3-1 was sequenced and analyzed. Myxothiazol, an inhibitor of the electron transport via the bc(1)-complex of the respiratory chain, is biosynthesized by a unique combination of several polyketide synthases (PKS) and nonribosomal peptide synthetases (NRPS), which are activated by the 4'-phosphopantetheinyl transferase MtaA. Genomic replacement of a fragment of mtaB and insertion of a kanamycin resistance gene into mtaA both impaired myxothiazol synthesis. Genes mtaC and mtaD encode the enzymes for bis-thiazol(ine) formation and chain extension on one pure NRPS (MtaC) and on a unique combination of PKS and NRPS (MtaD), The genes mtaE and mtaF encode PKSs including peptide fragments with homology to methyltransferases, These methyltransferase modules are assumed to be necessary for the formation of the proposed methoxy- and beta-methoxy-acrylate intermediates of myxothiazol biosynthesis. The last gene of the cluster, mtaG, again resembles a NRPS and provides insight into the mechanism of the formation of the terminal amide of myxothiazol, The carbon backbone of an amino acid added to the myxothiazol-acid is assumed to be removed via an unprecedented module with homology to monooxygenases within MtaG.	Gesell Biotechnol Forsch mbH, Abt NBI MX, D-38124 Braunschweig, Germany; Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Inst Pharmazeut Biol, D-38106 Braunschweig, Germany	Gesellschaft fur Biotechnologische Forschung mbH; Ruprecht Karls University Heidelberg; Braunschweig University of Technology	Muller, R (corresponding author), Gesell Biotechnol Forsch mbH, Abt NBI MX, Mascheroder Weg 1, D-38124 Braunschweig, Germany.	rom@gbf.de	Müller, Rolf/B-1559-2008	Müller, Rolf/0000-0002-1042-5665				August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Beyer S, 1999, BBA-GENE STRUCT EXPR, V1445, P185, DOI 10.1016/S0167-4781(99)00041-X; BOLLAG DM, 1995, CANCER RES, V55, P2325; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Cane DE, 1997, CHEM REV, V97, P2463, DOI 10.1021/cr970097g; Chen S, 1999, EUR J BIOCHEM, V261, P98, DOI 10.1046/j.1432-1327.1999.00244.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DENOYA CD, 1995, J BACTERIOL, V177, P3504, DOI 10.1128/jb.177.12.3504-3511.1995; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DOWNARD J, 1993, J BACTERIOL, V175, P7762, DOI 10.1128/JB.175.24.7762-7770.1993; DOWNARD J, 1995, MOL MICROBIOL, V16, P171, DOI 10.1111/j.1365-2958.1995.tb02290.x; Dworkin M, 1996, MICROBIOL REV, V60, P70, DOI 10.1128/MMBR.60.1.70-102.1996; Gaisser S, 1997, MOL GEN GENET, V253, P415, DOI 10.1007/s004380050339; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P11637, DOI 10.1021/bi9812571; Gehring AM, 1998, CHEM BIOL, V5, P573, DOI 10.1016/S1074-5521(98)90115-6; GERTH K, 1983, J ANTIBIOT, V36, P1150, DOI 10.7164/antibiotics.36.1150; Gerth K, 1996, J ANTIBIOT, V49, P560, DOI 10.7164/antibiotics.49.560; GERTH K, 1980, J ANTIBIOT, V33, P1474, DOI 10.7164/antibiotics.33.1474; Gokhale RS, 1999, SCIENCE, V284, P482, DOI 10.1126/science.284.5413.482; HAFNER EW, 1991, J ANTIBIOT, V44, P349, DOI 10.7164/antibiotics.44.349; HAYDOCK SF, 1995, FEBS LETT, V374, P246, DOI 10.1016/0014-5793(95)01119-Y; Hendrickson L, 1999, CHEM BIOL, V6, P429, DOI 10.1016/S1074-5521(99)80061-1; Hofle G., 1995, SEKUNDARMETABOLISMUS, P61; IKEDA H, 1997, POLYKETIDE NONRIBOSO, V7, P2591; Kakavas SJ, 1997, J BACTERIOL, V179, P7515, DOI 10.1128/jb.179.23.7515-7522.1997; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Kennedy J, 1999, SCIENCE, V284, P1368, DOI 10.1126/science.284.5418.1368; Kleinkauf H, 1997, BIOTECHNOLOGY, V7, P277; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; Konz D, 1997, CHEM BIOL, V4, P927, DOI 10.1016/S1074-5521(97)90301-X; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; Kulathila R, 1999, NAT PROD REP, V16, P145, DOI 10.1039/a801346b; KUNZE B, 1984, J ANTIBIOT, V37, P454, DOI 10.7164/antibiotics.37.454; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Marsden AFA, 1998, SCIENCE, V279, P199, DOI 10.1126/science.279.5348.199; Merkler DJ, 1999, J AM CHEM SOC, V121, P4904, DOI 10.1021/ja990517e; MOCEK U, 1993, J AM CHEM SOC, V115, P7557, DOI 10.1021/ja00070a001; Molnar I, 1996, GENE, V169, P1, DOI 10.1016/0378-1119(95)00799-7; Muhlradt PF, 1997, CANCER RES, V57, P3344; NEUMANN B, 1992, TRENDS GENET, V8, P332, DOI 10.1016/0168-9525(92)90269-A; NICOLAOU KC, 1998, ANGEW CHEM, V110, P2120; Paitan Y, 1999, J MOL BIOL, V286, P465, DOI 10.1006/jmbi.1998.2478; POSPIECH A, 1995, MICROBIOL-SGM, V141, P1793, DOI 10.1099/13500872-141-8-1793; Purwantini E, 1998, J BACTERIOL, V180, P2212, DOI 10.1128/JB.180.8.2212-2219.1998; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Quadri LEN, 1998, CHEM BIOL, V5, P631, DOI 10.1016/S1074-5521(98)90291-5; QUALLS GT, 1978, DEV BIOL, V66, P270, DOI 10.1016/0012-1606(78)90291-9; Reichenbach H, 2000, SPR DESKT EDIT CHEM, P149; REICHENBACH H, 1993, MYXOBACTERIA, V2, P347; Reichenbach H, 1993, MYXOBACTERIA, P13; Reichenbach H., 1992, PROKARYOTES, DOI 10.1007/978-1-4757-2191-1_26; Roy RS, 1999, NAT PROD REP, V16, P249, DOI 10.1039/a806930a; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider A, 1998, ARCH MICROBIOL, V169, P404, DOI 10.1007/s002030050590; Schoofs L, 1997, PEPTIDES, V18, P145, DOI 10.1016/S0196-9781(96)00236-7; SCHUPP T, 1995, J BACTERIOL, V177, P3673, DOI 10.1128/jb.177.13.3673-3679.1995; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SHIMKETS LJ, 1993, MYXOBACTERIA, V2, P85; Silakowski B, 1998, J BACTERIOL, V180, P1241, DOI 10.1128/JB.180.5.1241-1247.1998; Silakowski B, 1996, J BACTERIOL, V178, P6706, DOI 10.1128/jb.178.23.6706-6713.1996; SILAKOWSKI B, 1997, THESIS U HEIDELBERG; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TROWITZSCHKIENAST W, 1986, LIEBIGS ANN CHEM, P93; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	68	224	233	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37391	37399		10.1074/jbc.274.52.37391	http://dx.doi.org/10.1074/jbc.274.52.37391			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601310	hybrid			2022-12-25	WOS:000084382700081
J	Verdino, P; Keller, W; Strohmaier, H; Bischof, K; Lindner, H; Koraimann, G				Verdino, P; Keller, W; Strohmaier, H; Bischof, K; Lindner, H; Koraimann, G			The essential transfer protein TraM binds to DNA as a tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; FLUORESCENCE; CONFORMATION; EXPRESSION; PLASMID-R1; REPRESSOR; COMPLEX; DOMAIN	The TraM proteins encoded by F-like plasmids are sequence specific DNA binding proteins that are essential for conjugative DNA transfer. We investigated the quarternary structure and the DNA binding properties of the TraM wild-type protein of the resistance plasmid R1 and two mutant forms thereof. Size-exclusion chromatography and differential scanning calorimetry showed that purified TraM protein (amino acids 2-127) forms stable tetramers in solution. A truncated version of the protein termed TraMM26 (amino acids 2-56) forms dimers, Thus, the dimerization and tetramerization domains can be assigned to the N-terminal and C-terminal domains of TraM, respectively. Further analyses using chemical cross-linking and light scattering corroborated the preferentially tetrameric nature of the protein but also suggest that TraM has a tendency to form higher aggregates. Band-shift and fluorescence spectroscopy investigations of TraM-DNA complexes revealed that the TraM protein is also tetrameric when bound to its minimal DNA binding site, The deduced binding constant in the range of 10(8) M-1 demonstrated a very strong binding of TraM to its preferred DNA sequence. Secondary structure analysis based on CD measurements showed that TraM is mainly cu-helical with a significant increase in alpha-helicity (48 to 58%) upon DNA-binding, indicating an induced fit mechanism.	Karl Franzens Univ Graz, Inst Phys Chem, A-8010 Graz, Austria; Karl Franzens Univ Graz, Inst Mikrobiol, A-8010 Graz, Austria	University of Graz; University of Graz	Keller, W (corresponding author), Karl Franzens Univ Graz, Inst Phys Chem, Heinrichstr 28, A-8010 Graz, Austria.	walter.keller@kfunigraz.ac.at	Keller, Walter/AAW-1501-2021; Koraimann, Günther/H-3835-2019	Keller, Walter/0000-0002-2261-958X; Koraimann, Günther/0000-0002-8937-3027				[Anonymous], 1996, ESCHERICHIA COLI SAL; BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carpenter M L, 1994, Methods Mol Biol, V30, P313; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLEWELL DB, 1993, BACTERIAL CONJUGATIO; DisqueKochem C, 1997, J BACTERIOL, V179, P6133, DOI 10.1128/jb.179.19.6133-6137.1997; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KORONAKIS VE, 1985, GENE AMST, V3, P79; Kupelwieser G, 1998, J MOL BIOL, V275, P81, DOI 10.1006/jmbi.1997.1436; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Leharne SA, 1998, BIOCALORIMETRY, P157; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; Plugariu C, 1998, J PEPT RES, V51, P244; Polzleitner E, 1997, MOL MICROBIOL, V25, P495, DOI 10.1046/j.1365-2958.1997.4831853.x; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHNABLEGGER H, 1991, APPL OPTICS, V30, P4889, DOI 10.1364/AO.30.004889; SCHWAB M, 1991, MOL MICROBIOL, V5, P439, DOI 10.1111/j.1365-2958.1991.tb02127.x; SCHWAB M, 1993, MOL MICROBIOL, V7, P795, DOI 10.1111/j.1365-2958.1993.tb01170.x; Taylor I, 1994, Methods Mol Biol, V30, P327; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WOGER W, 1997, TECHNICAL TIPS ONLIN; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZECHNER EL, 1999, HORIZONTAL GENE POOL, P87	30	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37421	37428		10.1074/jbc.274.52.37421	http://dx.doi.org/10.1074/jbc.274.52.37421			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601314	hybrid			2022-12-25	WOS:000084382700085
J	Bell, MV; Frampton, J				Bell, MV; Frampton, J			v-Myb can transform and regulate the differentiation of melanocyte precursors	ONCOGENE			English	Article						Myb; progenitor; melanocyte; differentiation	MULTIPOTENT HEMATOPOIETIC PROGENITORS; CREST CELL-CULTURES; E26 LEUKEMIA-VIRUS; C-MYB; NEURAL CREST; NEURORETINA CELLS; MONOCLONAL-ANTIBODIES; WAARDENBURG-SYNDROME; MALIGNANT-MELANOMA; LINEAGE COMMITMENT	The activity of the c-Myb transcription factor is essential for the development of definitive multi- and uni-lineage progenitors of the haemopoietic system. Reflecting this requirement, c-Myb has been oncogenically activated by transduction in the E26 avian retrovirus which elicits an acute leukaemia by transforming haemopoietic progenitors, Here, we report the novel finding that Myb in cooperation with EGF receptor signalling can be used to generate clonally expanded populations of transformed cells which have the phenotype of melanocyte precursors. Through the use of a conditional temperature sensitive mutant of Myb, we show that in the transformed cells Myb regulates commitment to melanocyte differentiation and possibly proliferation. These results add to our understanding of the roles of c-Myb beyond the haemopoietic system and to our knowledge and means of investigating the importance of transcription factors in the melanocyte linage.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Frampton, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO T, 1981, J IMMUNOL, V127, P1024; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; Boissy RE, 1997, PIGM CELL RES, V10, P12, DOI 10.1111/j.1600-0749.1997.tb00461.x; BROWN KE, 1992, J BIOL CHEM, V267, P4625; DASGUPTA P, 1989, ONCOGENE, V4, P1201; Eisen TG, 1996, MELANOMA RES, V6, P277, DOI 10.1097/00008390-199608000-00001; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; FRAMPTON J, 1995, EMBO J, V14, P2866, DOI 10.1002/j.1460-2075.1995.tb07286.x; Frampton J, 1997, MOL B INT U, P287; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Gadson PF, 1997, EXP CELL RES, V230, P169, DOI 10.1006/excr.1996.3398; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HORTON MA, 1985, CANCER RES, V45, P5663; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; LAHAV R, 1994, DIFFERENTIATION, V58, P133; Lecoin L, 1998, P NATL ACAD SCI USA, V95, P3024, DOI 10.1073/pnas.95.6.3024; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Li M, 1998, INT J CANCER, V76, P430; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; McNagny KM, 1996, BLOOD, V87, P1343, DOI 10.1182/blood.V87.4.1343.bloodjournal8741343; Miglarese MR, 1997, CELL GROWTH DIFFER, V8, P1199; MOCHII M, 1988, CELL DIFFER DEV, V24, P67, DOI 10.1016/0045-6039(88)90087-5; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NATAF V, 1993, EXP CELL RES, V207, P171, DOI 10.1006/excr.1993.1177; NATAF V, 1995, EXP CELL RES, V218, P394, DOI 10.1006/excr.1995.1171; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TRENT JM, 1989, CANCER RES, V49, P420; Vainio O, 1996, J CELL BIOL, V135, P1655, DOI 10.1083/jcb.135.6.1655; VINCENT M, 1984, DEV BIOL, V103, P468, DOI 10.1016/0012-1606(84)90334-8; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; YASUMOTO K, 1995, J BIOCHEM-TOKYO, V118, P874, DOI 10.1093/jb/118.5.874	52	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7226	7233		10.1038/sj.onc.1203161	http://dx.doi.org/10.1038/sj.onc.1203161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602476				2022-12-25	WOS:000084119400006
J	Reymond, A; Volorio, S; Merla, G; Al-Maghtheh, M; Zuffardi, O; Bulfone, A; Ballabio, A; Zollo, M				Reymond, A; Volorio, S; Merla, G; Al-Maghtheh, M; Zuffardi, O; Bulfone, A; Ballabio, A; Zollo, M			Evidence for interaction between human PRUNE and nm23-H1 NDPKinase	ONCOGENE			English	Article						PRUNE; NDPK; nm 23-H1	NUCLEOSIDE-DIPHOSPHATE KINASE; DROSOPHILA MUTANT-GENES; TUMOR-METASTASIS; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; POINT MUTATION; MESSENGER-RNA; LOCUS RP18; IN-VITRO; PROTEIN	We have isolated a human and murine homologue of the Drosophila prune gene through dbEST searches. The gene is ubiquitously expressed in human adult tissues, while in mouse developing embryos a high level of expression is confined to the nervous system particularly in the dorsal root ganglia, cranial nerves, and neural retina. The gene is composed of eight exons and is located in the 1q21.3 chromosomal region. A pseudogene has been sequenced and mapped to chromosomal region 13q12, PRUNE protein retains the four characteristic domains of DHH phosphoesterases. The synergism between prune and awd(K-pn) in Drosophila has led various authors to propose an interaction between these genes. However, such an interaction has never been supported by biochemical data. By using interaction-mating and in vitro co-immunoprecipitation experiments, we show for the first time the ability of human PRUNE to interact with the human homologue of awd protein (nm23-H1). In contrast, PRUNE is impaired in its interaction with nm23-H1-S120G mutant, a gain-of-function mutation associated with advanced neuroblastoma stages. Consistently, PRUNE and nm23-H1 proteins partially colocalize in the cytoplasm, The data presented are consistent with the view that PRUNE acts as a negative regulator of the nm23-H1 protein. We discuss how PRUNE regulates nm23-H1 protein and postulate possible implications of PRUNE in neuroblastoma progression.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Univ Milan, Osped San Raffaele, Lab Citogenet, I-20127 Milan, Italy; Univ Milan, Osped San Raffaele, Serv Genet Med, I-20127 Milan, Italy; UCL, Inst Ophthalmol, Ophthalmol Dept Mol Genet, London, England	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of London; University College London	Zollo, M (corresponding author), Telethon Inst Genet & Med, San Raffaele Biomed Sci Pk, I-20132 Milan, Italy.		merla, giuseppe/K-4627-2012; BALLABIO, Andrea/AAL-2672-2020	merla, giuseppe/0000-0001-5078-928X; BALLABIO, Andrea/0000-0003-1381-4604; zuffardi, orsetta/0000-0002-1466-4559; Reymond, Alexandre/0000-0003-1030-8327	Telethon [TGM06S01, TGM97000] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; Betke Herbert, 1998, Polish Journal of Pathology, V49, P93; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; Bulfone A, 1998, HUM MOL GENET, V7, P1997, DOI 10.1093/hmg/7.13.1997; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; Chiarelli I, 1998, MOL CELL PROBE, V12, P125, DOI 10.1006/mcpr.1998.0159; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FERRE J, 1986, BIOCH GENET, V7, P545; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Gazzeri S, 1996, LAB INVEST, V74, P158; GILLES AM, 1991, J BIOL CHEM, V266, P8784; Gregory-Evans K, 1998, TRENDS GENET, V14, P103, DOI 10.1016/S0168-9525(98)01402-4; Guo X, 1998, INT J CANCER, V79, P596, DOI 10.1002/(SICI)1097-0215(19981218)79:6<596::AID-IJC7>3.0.CO;2-Y; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hartsough MT, 1998, AM J HUM GENET, V63, P6, DOI 10.1086/301942; Inglehearn CF, 1998, J MED GENET, V35, P788, DOI 10.1136/jmg.35.9.788; Jensen SL, 1996, WORLD J UROL, V14, pS21; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1993, ONCOGENE, V8, P855; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MACDONALD NJ, 1995, EUR J CANCER, V31A, P1096, DOI 10.1016/0959-8049(95)00152-9; MARTINEZ JA, 1995, GUT, V37, P712, DOI 10.1136/gut.37.5.712; MERLO GR, 1989, CANCER RES, V49, P6966; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Mesnildrey S, 1998, J BIOL CHEM, V273, P4436, DOI 10.1074/jbc.273.8.4436; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; Muller W, 1998, CANCER-AM CANCER SOC, V83, P2481, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2481::AID-CNCR11>3.0.CO;2-P; Munier A, 1998, FEBS LETT, V434, P289, DOI 10.1016/S0014-5793(98)00996-X; ODONNELL JM, 1989, DEV GENET, V10, P273, DOI 10.1002/dvg.1020100316; OREVI N, 1975, MUTAT RES, V33, P193, DOI 10.1016/0027-5107(75)90195-5; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; REYMOND A, 1995, ONCOGENE, V11, P1173; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Russell RL, 1998, BRIT J CANCER, V78, P710, DOI 10.1038/bjc.1998.566; Sambrook J., 2002, MOL CLONING LAB MANU; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SASTREGARAU X, 1992, B CANCER, V79, P465; Shimada M, 1998, LIVER, V18, P337; STAHL JA, 1991, CANCER RES, V51, P445; STURTEVANT AH, 1956, GENETICS, V41, P118; Tagashira H, 1998, INT J MOL MED, V2, P65; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; Timmons L, 1996, GENETICS, V144, P1589; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; Volorio S, 1998, DNA SEQUENCE, V9, P307, DOI 10.3109/10425179809008469; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; Xu SY, 1996, HUM MOL GENET, V5, P1193, DOI 10.1093/hmg/5.8.1193; Xu SY, 1998, HUM GENET, V102, P493, DOI 10.1007/s004390050728; Yoshida H, 1998, INT J ONCOL, V13, P1141; Zheng XY, 1998, J EXP CLIN CANC RES, V17, P337	66	71	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7244	7252		10.1038/sj.onc.1203140	http://dx.doi.org/10.1038/sj.onc.1203140			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602478				2022-12-25	WOS:000084119400008
J	Waterman-Storer, CM; Salmon, ED				Waterman-Storer, CM; Salmon, ED			Fluorescent speckle microscopy of microtubules: how low can you go?	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MA	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		PROTEIN; ACTIN; CELLS	Fluorescent speckle microscopy (FSM) is a new technique for visualizing the movement, assembly, and turnover of macromolecular assemblies like the cytoskeleton in living cells. In this method, contrast is created by coassembly of a small fraction of fluorescent subunits in a pool of unlabeled subunits, Random variation in association creates a nonuniform "fluorescent speckle" pattern. Fluorescent speckle movements in time-lapse recordings stand out to the eye and can be measured, Because fluorescent speckles represent fiduciary marks on the polymer lattice, FSM provides the opportunity for the first time to see the 2- land 3-dimensional trajectories of lattice movements within large arrays of polymers as well as identifying sites of assembly and disassembly of individual polymers, The technique works with either microinjection of fluorescently labeled subunits or expression of subunits ligated to green fluorescent protein (GFP). We have found for microtubules assembled in vitro that speckles containing one fluorophore can be detected and recorded using a conventional wide-field epi-fluorescence light microscope and digital imaging with a low noise cooled CCD camera. In living cells, optimal speckle contrast occurs at fractions of labeled tubulin of similar to 0.1-0.5% where the fluorescence of each speckle corresponds to one to seven fluorophores per resolvable unit (similar to 0.27 mu m) in the microscope. This small fraction of labeled subunits significantly reduces out-of-focus fluorescence and greatly improves visibility of fluorescently labeled structures and their dynamics in thick regions of living cells.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute	Salmon, ED (corresponding author), Univ N Carolina, Dept Biol, Biol CB3280, Chapel Hill, NC 27599 USA.	tsalmon@email.unc.edu		Waterman, Clare/0000-0001-6142-6775	NIGMS NIH HHS [GM24364] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024364, R01GM024364] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULINSKI JC, 1994, J CELL SCI, V107, P2839; FAIRE K, 1999, IN PRESS J CELL SCI; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Maddox P, 1999, J CELL BIOL, V144, P977, DOI 10.1083/jcb.144.5.977; PIECE DW, 1998, NATURE, V388, P1933; Salmon ED, 1998, METHOD CELL BIOL, V56, P185, DOI 10.1016/S0091-679X(08)60427-6; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; SASE I, 1995, BIOPHYS J, V69, P323, DOI 10.1016/S0006-3495(95)79937-4; Waterman-Storer C, 1999, METHOD CELL BIOL, V61, P155; Waterman-Storer CM, 1998, CURR BIOL, V8, P1227, DOI 10.1016/S0960-9822(07)00515-5; Waterman-Storer CM, 1998, BIOPHYS J, V75, P2059, DOI 10.1016/S0006-3495(98)77648-9; WatermanStorer CM, 1997, TRENDS CELL BIOL, V7, P503, DOI 10.1016/S0962-8924(97)01171-9; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; WATERMANSTORER CM, 1998, IN BIOL MOL BIOL CEL	14	22	24	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13			2			S225	S230		10.1096/fasebj.13.9002.S225	http://dx.doi.org/10.1096/fasebj.13.9002.S225			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619132				2022-12-25	WOS:000084390200010
J	Ceschini, S; Lupidi, G; Coletta, M; Pon, CL; Fioretti, E; Angeletti, M				Ceschini, S; Lupidi, G; Coletta, M; Pon, CL; Fioretti, E; Angeletti, M			Multimeric self-assembly equilibria involving the histone-like protein H-NS - A thermodynamic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; ESCHERICHIA-COLI; GENE-EXPRESSION; CURVED DNA; REPRESSOR; DIMERIZATION; TOPOLOGY; INVITRO; DOMAIN	The thermodynamic parameters affecting protein-protein multimeric self-assembly equilibria of the histone-like protein H-NS were quantified by "large zone" gel-permeation chromatography. The abundance of the different association states (monomer, dimer, and tetramer) were found to be strictly dependent on the monomeric concentration and affected by physical (temperature) and chemical (cations) parameters. On the basis of the results obtained in this study and the available structural information concerning this protein, a mechanism is proposed to explain the association behavior also in relation to the functional properties of the protein.	Univ Camerino, Post Grad Sch Clin Biochem, Dept Mol Cellular & Anim Biol, I-62032 Camerino, MC, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	University of Camerino; University of Rome Tor Vergata	Angeletti, M (corresponding author), Univ Camerino, Post Grad Sch Clin Biochem, Dept Mol Cellular & Anim Biol, I-62032 Camerino, MC, Italy.		Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022; Angeletti, Mauro/AAC-5597-2019	Angeletti, Mauro/0000-0001-6719-5517; COLETTA, Massimiliano/0000-0002-5489-9467; Lupidi, Giulio/0000-0001-9452-0741				Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BECKETT D, 1991, ANAL BIOCHEM, V196, P69, DOI 10.1016/0003-2697(91)90118-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Collins KD, 1997, BIOPHYS J, V72, P65, DOI 10.1016/S0006-3495(97)78647-8; Creighton T.E., 1993, PROTEINS; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; Falconi M, 1998, EMBO J, V17, P7033, DOI 10.1093/emboj/17.23.7033; Falconi M, 1996, MOL MICROBIOL, V19, P965, DOI 10.1046/j.1365-2958.1996.436961.x; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PON CL, 1988, MOL GEN GENET, V212, P199, DOI 10.1007/BF00334684; PRESS WH, 1986, NUMERICAL RECIPES AR; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROYER CA, 1990, BIOCHEMISTRY-US, V29, P2959; SHINDO H, 1995, FEBS LETT, V360, P125, DOI 10.1016/0014-5793(95)00079-O; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPURIO R, 1992, MOL GEN GENET, V231, P201, DOI 10.1007/BF00279792; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; Terwilliger TC, 1996, BIOCHEMISTRY-US, V35, P16652, DOI 10.1021/bi961050c; TIPPNER D, 1995, J BIOL CHEM, V270, P22243, DOI 10.1074/jbc.270.38.22243; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Ueguchi C, 1997, J MOL BIOL, V274, P145, DOI 10.1006/jmbi.1997.1381; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; USSERY DW, 1994, BIOCHIMIE, V76, P968, DOI 10.1016/0300-9084(94)90022-1; Valdes R Jr, 1979, Methods Enzymol, V61, P125	30	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					729	734		10.1074/jbc.275.2.729	http://dx.doi.org/10.1074/jbc.275.2.729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625601	hybrid			2022-12-25	WOS:000084836600005
J	Han, JH; Hajjar, DP; Tauras, JM; Feng, JW; Gotto, AM; Nicholson, AC				Han, JH; Hajjar, DP; Tauras, JM; Feng, JW; Gotto, AM; Nicholson, AC			Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PPAR-GAMMA; GENE-EXPRESSION; OXIDIZED LDL; FACTOR-BETA; HUMAN ATHEROSCLEROSIS; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN; SR-BI; BINDING	CD36, the macrophage type B scavenger receptor, binds and internalizes oxidized low density lipoprotein, a hey event in the development of macrophage foam cells within atherosclerotic lesions. Expression of CD36 in monocyte/macrophages is dependent on differentiation status and exposure to soluble mediators. In this study, we investigated the effect of transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 2 on the expression of CD36 in macrophages, Treatment of phorbol ester-differentiated THP-1 macrophages with TGF-beta 1 or TGF-beta 2 significantly decreased expression of CD36 mRNA and surface protein. TGF-beta 1/TGF-beta 2 also inhibited CD36 mRNA expression induced by oxidized low density lipoprotein and 15-deoxy Delta(12,14) prostaglandin J(2), a peroxisome proliferator-activated receptor (PPAR)-gamma ligand, suggesting that the TGF-beta 1/TGF-beta 2 down-regulated CD36 expression by inactivating PPAR-gamma-mediated signaling. TGF-beta 1/TGF-beta 2 increased phosphorylation of both mitogen-activated protein (MAP) kinase and PPAR-gamma, whereas NAP kinase inhibitors reversed suppression of CD36 wand inhibited PPAR-gamma phosphorylation induced by TGF-beta 1/TGF-beta 2. Finally, MAP kinase inhibitors alone increased expression of CD36 mRNA and surface protein but had no effect on PPAR-gamma protein levels, Our data demonstrate for the first time that TGF-beta 1 and TGF-beta 2 decrease expression of CD36 by a mechanism involving phosphorylation of MAP kinase, subsequent MAP kinase phosphorylation of PPAR-gamma, and a decrease in CD36 gene transcription by phosphorylated PPAR-gamma.	Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Ctr Vasc Biol, New York, NY 10021 USA	Cornell University; Cornell University	Nicholson, AC (corresponding author), Cornell Univ, Coll Med, Dept Pathol, A-626,1300 York Ave, New York, NY 10021 USA.	nicholso@mail.med.cornell.edu			NHLBI NIH HHS [P50-HL56987] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Engel ME, 1998, J CELL BIOCHEM, P111; FOGELMAN AM, 1988, J CELL SCI, P135; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOWN AM, 1986, AM J PATHOL, V125, P191; GREENWALT DE, 1992, BLOOD, V80, P1105; Han JH, 1999, J LIPID RES, V40, P830; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nakagawa T, 1998, ARTERIOSCL THROM VAS, V18, P1350, DOI 10.1161/01.ATV.18.8.1350; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; STEINBERG D, 1987, CIRCULATION, V76, P508, DOI 10.1161/01.CIR.76.3.508; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Xue JC, 1996, MOL CELL BIOL, V16, P1567; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019	48	154	162	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1241	1246		10.1074/jbc.275.2.1241	http://dx.doi.org/10.1074/jbc.275.2.1241			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625669	hybrid			2022-12-25	WOS:000084836600073
J	LaPointe, CF; Taylor, RK				LaPointe, CF; Taylor, RK			The type 4 prepilin peptidases comprise a novel family of aspartic acid proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR PROTEIN SECRETION; PILIN LEADER PEPTIDASE; GRAM-NEGATIVE BACTERIA; PSEUDOMONAS-AERUGINOSA; N-METHYLTRANSFERASE; ESCHERICHIA-COLI; VIBRIO-CHOLERAE; BIFUNCTIONAL ENZYME; CATALYTIC MECHANISM; TOXIN SECRETION	Type 4 prepilins or prepilin-like-proteins are secreted by a wide range of bacterial species and are required for a variety of functions including type 4 pilus formation, toxin and other enzyme secretion, gene transfer, and biofilm formation. A distinctive feature of these proteins is the presence of a specialized leader peptide that is cleaved off by a cognate membrane-bound type 4 prepilin peptidase (TFPP) during the process of secretion. In this report we show that the TFPPs represent a novel family of bilobed aspartate proteases that is unlike any other protease. The active site pairs of aspartic acids of the two TFPPs in Vibrio cholerae are found at positions 125 and 189 of TcpJ and 147 and 212 of VcpD. Corresponding aspartate residues are completely conserved throughout this extensive peptidase family.	Dartmouth Med Sch, Dept Microbiol, Hanover, NH 03755 USA	Dartmouth College	Taylor, RK (corresponding author), Dartmouth Med Sch, Dept Microbiol, Hanover, NH 03755 USA.	ronald.k.taylor@dartmouth.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023096, F31AI009635] Funding Source: NIH RePORTER; NIAID NIH HHS [R0I AI 23096, AI F31-09635] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bieber D, 1998, SCIENCE, V280, P2114, DOI 10.1126/science.280.5372.2114; Dubnau D, 1997, GENE, V192, P191, DOI 10.1016/S0378-1119(96)00804-9; HOARE DG, 1966, J AM CHEM SOC, V88, P2057, DOI 10.1021/ja00961a045; Hu NT, 1995, MOL MICROBIOL, V18, P769, DOI 10.1111/j.1365-2958.1995.mmi_18040769.x; Inagami T., 1981, BIOCH REGULATION BLO, P39; KAUFMAN MR, 1991, GENE DEV, V5, P1834, DOI 10.1101/gad.5.10.1834; Lory S, 1997, GENE, V192, P117, DOI 10.1016/S0378-1119(96)00830-X; Marsh JW, 1998, MOL MICROBIOL, V29, P1481, DOI 10.1046/j.1365-2958.1998.01031.x; NUNN DN, 1991, P NATL ACAD SCI USA, V88, P3281, DOI 10.1073/pnas.88.8.3281; Oda K, 1998, ADV EXP MED BIOL, V436, P349; Pepe CM, 1996, MOL MICROBIOL, V19, P857, DOI 10.1046/j.1365-2958.1996.431958.x; Pepe JC, 1998, J BIOL CHEM, V273, P19120, DOI 10.1074/jbc.273.30.19120; Pestova EV, 1998, J BACTERIOL, V180, P2701, DOI 10.1128/JB.180.10.2701-2710.1998; Pfau JD, 1998, J BACTERIOL, V180, P4724, DOI 10.1128/JB.180.17.4724-4733.1998; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P365, DOI 10.1111/j.1365-2958.1990.tb00604.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; Rawlings ND, 1999, NUCLEIC ACIDS RES, V27, P325, DOI 10.1093/nar/27.1.325; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P105; REEVES PJ, 1994, MOL MICROBIOL, V12, P445, DOI 10.1111/j.1365-2958.1994.tb01033.x; RUSSEL M, 1984, J BACTERIOL, V159, P1034, DOI 10.1128/JB.159.3.1034-1039.1984; Sandkvist M, 1997, J BACTERIOL, V179, P6994, DOI 10.1128/jb.179.22.6994-7003.1997; SANKARAN K, 1995, METHOD ENZYMOL, V248, P169; SHAW CE, 1990, INFECT IMMUN, V58, P3042, DOI 10.1128/IAI.58.9.3042-3049.1990; STROM MS, 1991, J BACTERIOL, V173, P1175, DOI 10.1128/jb.173.3.1175-1180.1991; STROM MS, 1987, J BACTERIOL, V169, P3181, DOI 10.1128/jb.169.7.3181-3188.1987; STROM MS, 1993, J BIOL CHEM, V268, P15788; STROM MS, 1993, P NATL ACAD SCI USA, V90, P2404, DOI 10.1073/pnas.90.6.2404; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Takahashi K, 1998, ADV EXP MED BIOL, V436, P275; TAKAHASHI K, 1991, ADV EXP MED BIOL, V306, P203; Tonjum T, 1997, GENE, V192, P155, DOI 10.1016/S0378-1119(97)00018-8; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; WU SS, 1995, MOL MICROBIOL, V18, P547, DOI 10.1111/j.1365-2958.1995.mmi_18030547.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	146	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1502	1510		10.1074/jbc.275.2.1502	http://dx.doi.org/10.1074/jbc.275.2.1502			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625704	hybrid			2022-12-25	WOS:000084836600108
J	Pile, LA; Cartwright, IL				Pile, LA; Cartwright, IL			GAGA factor-dependent transcription and establishment of DNase hypersensitivity are independent and unrelated events in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HEAT-SHOCK ELEMENTS; PROMOTER IN-VITRO; PROTEIN INTERACTIONS; HSP70 PROMOTER; DROSOPHILA-MELANOGASTER; (CT)N.(GA)N REPEATS; CHROMATIN STRUCTURE; CELL-CYCLE; GENE	Using a Drosophila transgenic system we investigated the ability of GAGA factor, a putative anti-repressor, to modulate transcription-related events in the absence or presence of a bona fide activator, the Adf-1 transcription factor. In contrast to previous in vitro and in vivo data linking the binding of GAGA factor to the acquisition of DNase hypersensitivity at heat shock promoters, we observed that inserting multiple GAGA binding motifs adjacent to a minimal alcohol dehydrogenase (Adh) promoter led to strongly elevated embryonic transcription without creation of a promoter-associated DNase-hypersensitive (DH) site. Establishment of DNase hypersensitivity required the presence of both GAG;A and Adf-1 binding sites and was accompanied by a further, synergistic increase in transcription. Because Adf-1 is capable neither of establishing a DH site nor of promoting efficient transcription by itself in embryos, it is likely that DH site formation depends on a GAGA factor-mediated binding of Adf-1 to chromatin, perhaps facilitated by a locally remodeled downstream promoter region. More generally we suggest that GAGA factor-binding sequences may operate in a promoter-specific context, with transcriptional activation, polymerase pausing, and/or DH site formation critically dependent on the nature of the sequences (and their binding partners) linked in cis.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Cartwright, IL (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.				NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA59268] Funding Source: Medline; NIEHS NIH HHS [P30-ES06096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agianian B, 1999, J MOL BIOL, V285, P527, DOI 10.1006/jmbi.1998.2355; Benjamin LR, 1998, NUCLEIC ACIDS RES, V26, P1051, DOI 10.1093/nar/26.4.1051; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; Bhat KM, 1996, DEVELOPMENT, V122, P1113; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; CARTWRIGHT IL, 1986, MOL CELL BIOL, V6, P779, DOI 10.1128/MCB.6.3.779; Cartwright IL, 1999, METHOD ENZYMOL, V304, P462; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; Cutler G, 1998, MOL CELL BIOL, V18, P2252, DOI 10.1128/MCB.18.4.2252; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; ENGLAND BP, 1992, P NATL ACAD SCI USA, V89, P683, DOI 10.1073/pnas.89.2.683; ENGLAND BP, 1990, J BIOL CHEM, V265, P5086; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; Gao J, 1998, NUCLEIC ACIDS RES, V26, P5394, DOI 10.1093/nar/26.23.5394; Geyer PK, 1997, CURR OPIN GENET DEV, V7, P242, DOI 10.1016/S0959-437X(97)80134-7; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Han W, 1998, MOL CELL BIOL, V18, P3384, DOI 10.1128/MCB.18.6.3384; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; JACKSON JR, 1992, NUCLEIC ACIDS RES, V20, P5413, DOI 10.1093/nar/20.20.5413; JENUWEIN T, 1993, GENE DEV, V7, P2016, DOI 10.1101/gad.7.10.2016; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; LANEY JD, 1992, GENE DEV, V6, P1531, DOI 10.1101/gad.6.8.1531; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; Li BY, 1996, MOL CELL BIOL, V16, P5433; LU Q, 1992, J MOL BIOL, V225, P985, DOI 10.1016/0022-2836(92)90099-6; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; Mason PB, 1997, J BIOL CHEM, V272, P33227, DOI 10.1074/jbc.272.52.33227; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PEIFER M, 1988, P NATL ACAD SCI USA, V85, P9650, DOI 10.1073/pnas.85.24.9650; Platero JS, 1998, J CELL BIOL, V140, P1297; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 2002, MOL CLONING LAB MANU; SANDALTZOPOULOS R, 1995, NUCLEIC ACIDS RES, V23, P2479, DOI 10.1093/nar/23.13.2479; SHOPLAND LS, 1995, GENE DEV, V9, P2756, DOI 10.1101/gad.9.22.2756; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; Thummel CS, 1992, DROS INF SERV, V71, P150; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Vashee S, 1998, CURR BIOL, V8, P452, DOI 10.1016/S0960-9822(98)70179-4; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Weber JA, 1997, MOL CELL BIOL, V17, P3799, DOI 10.1128/MCB.17.7.3799; Wilkins RC, 1998, NUCLEIC ACIDS RES, V26, P2672, DOI 10.1093/nar/26.11.2672; Wilkins RC, 1999, J MOL BIOL, V285, P515, DOI 10.1006/jmbi.1998.2356; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963	56	12	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1398	1404		10.1074/jbc.275.2.1398	http://dx.doi.org/10.1074/jbc.275.2.1398			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625691	hybrid			2022-12-25	WOS:000084836600095
J	Ritchie, S; Boyd, FM; Wong, J; Bonham, K				Ritchie, S; Boyd, FM; Wong, J; Bonham, K			Transcription of the human c-Src promoter is dependent on Sp1, a novel pyrimidine binding factor SPy, and can be inhibited by triplex-forming oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; PROTOONCOGENE; GENE; EXPRESSION; ACTIVATION; PP60C-SRC; CELLS; ELEMENT	The tyrosine kinase pp60(C-src) has been implicated in the regulation of numerous normal physiological processes as well the development of several human cancers. However, the mechanisms regulating its expression have not been addressed. In the present study, we report the presence of two Sp1/Sp3 binding sites and three polypurine:polypyrimidine (Pu:Py) tracts in the c-Src promoter that are essential for controlling expression. We demonstrate that Sp1, but not Sp3, is capable of activating the c-Src promoter and that Sp3 is also capable of inhibiting Sp1-mediated transactivation. The presence of multiple Pu:Py tracts conferred S1 sensitivity on plasmids in vitro, suggesting they are capable of adopting non B-DNA conformations. These tracts specifically bind a nuclear factor we named SPy (Src pyrimidine binding factor), which demonstrates both novel double- and single-stranded binding specificities. Mutations eliminating SPy binding compromised Src transcriptional activity, especially in concert with additional mutations affecting Sp1 binding, suggesting the two factors may cooperate in regulating c-Src expression. Finally, we demonstrate that tripler-forming oligonucleotides designed to target both Sp1 and Spy binding sites can down-regulate c-Src expression in vitro, suggesting a potential therapeutic approach to controlling c-Src expression in diseases where aberrant expression or activity has been documented.	Univ Saskatchewan, Div Oncol, Canc Agcy, Saskatoon Canc Ctr Res Unit, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 4H4, Canada	University of Saskatchewan; University of Saskatchewan	Bonham, K (corresponding author), Univ Saskatchewan, Div Oncol, Canc Agcy, Saskatoon Canc Ctr Res Unit, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	kbonham@scf.sk.ca						AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; AlunniFabbroni M, 1996, BIOCHEMISTRY-US, V35, P16361, DOI 10.1021/bi961750h; Amaldi F, 1995, BIOCHEM CELL BIOL, V73, P969, DOI 10.1139/o95-104; Babnigg G, 1997, J BIOL CHEM, V272, P29434, DOI 10.1074/jbc.272.47.29434; Bayarsaihan D, 1998, BIOCHEM J, V331, P447, DOI 10.1042/bj3310447; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; BONHAM K, 1993, ONCOGENE, V8, P1973; Brahmachari SK, 1997, GENE, V190, P17, DOI 10.1016/S0378-1119(97)00034-6; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; Dhalla AK, 1998, BIOCHEM J, V336, P373, DOI 10.1042/bj3360373; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; Ko JL, 1998, J BIOL CHEM, V273, P27678, DOI 10.1074/jbc.273.42.27678; Kovacic B, 1998, J BIOL CHEM, V273, P35185; Krasilnikov AS, 1997, NUCLEIC ACIDS RES, V25, P1339, DOI 10.1093/nar/25.7.1339; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; Lavrovsky Y, 1996, EUR J BIOCHEM, V238, P582, DOI 10.1111/j.1432-1033.1996.0582z.x; LEBEAU JM, 1991, J NEUROSCI RES, V28, P299, DOI 10.1002/jnr.490280217; Lou H, 1999, MOL CELL BIOL, V19, P78; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; Muller S, 1999, BIOCHEM BIOPH RES CO, V259, P364, DOI 10.1006/bbrc.1999.0677; Olivas WM, 1996, NUCLEIC ACIDS RES, V24, P1758, DOI 10.1093/nar/24.9.1758; Oosterhuis JH, 1999, J BIOL CHEM, V274, P11708, DOI 10.1074/jbc.274.17.11708; Ritchie S, 1998, ANTISENSE NUCLEIC A, V8, P391, DOI 10.1089/oli.1.1998.8.391; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sakatsume O, 1996, J BIOL CHEM, V271, P31322, DOI 10.1074/jbc.271.49.31322; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; THOMAS TJ, 1995, NUCLEIC ACIDS RES, V23, P3594, DOI 10.1093/nar/23.17.3594; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	52	68	70	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					847	854		10.1074/jbc.275.2.847	http://dx.doi.org/10.1074/jbc.275.2.847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625617	hybrid			2022-12-25	WOS:000084836600021
J	Webb, RJ; Khan, YM; East, JM; Lee, AG				Webb, RJ; Khan, YM; East, JM; Lee, AG			The importance of carboxyl groups on the lumenal side of the membrane for the function of the Ca2+-ATPase of sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; CALCIUM-ATPASE; BINDING-SITES; TRANSPORT; CA2+; (CA2+-MG2+)-ATPASE; CARBODIIMIDE; FLUORESCENCE; MECHANISM; PHOSPHORYLATION	The conventional model for transport of Ca2+ by the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum (SR) involves a pair of binding sites for Ca2+ that change upon phosphorylation of the ATPase from being high affinity and exposed to the cytoplasm to being low affinity and exposed to the lumen. However, a number of recent experiments suggest that in fact transport involves two separate pairs of binding sites for Ca2+, one pair exposed to the cytoplasmic side and the other pair exposed to the lumenal side. Here we show that the carbodiimide 1-ethyl-3-[3-(dimethylamino)-propyl] carbodiimide (EDC) is membrane-impermeable, and we use EDC to distinguish between cytoplasmic and lumenal sites of reaction. Modification of the Ca2+-ATPase in sealed SR vesicles with EDC leads to loss of ATPase activity without modification of the pair of high affinity Ca2+-binding sites. Modification of the purified ATPase in unsealed membrane fragments was faster than modification in SR vesicles, suggesting the presence of more quickly reacting lumenal sites. This was confirmed in experiments measuring EDC modification of the ATPase reconstituted randomly into sealed lipid vesicles. Modification of sites on the lumenal face of the ATPase led to loss of the Ca2+-induced increase in phosphorylation by P-i. It is concluded that carboxyl groups on the lumenal side of the ATPase are involved in Ca2+ binding to the lumenal side of the ATPase and that modification of these sites leads to loss of ATPase activity, The presence of MgATP or MgADP leads to faster inhibition of the ATPase by EDC in unsealed membrane fragments than in sealed vesicles, suggesting that binding of MgATP or MgADP to the ATPase leads to a conformational change on the lumenal side of the membrane.	Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England	University of Southampton	Webb, RJ (corresponding author), Univ Southampton, Sch Biol Sci, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England.							Andersson P, 1998, MATER HIGH TEMP, V15, P243, DOI 10.1080/09603409.1998.11689607; CHIESI M, 1981, ARCH BIOCHEM BIOPHYS, V208, P586, DOI 10.1016/0003-9861(81)90547-6; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COAN C, 1993, FEBS LETT, V335, P33, DOI 10.1016/0014-5793(93)80433-U; Dalton KA, 1999, BIOCHEM J, V342, P431, DOI 10.1042/0264-6021:3420431; Dalton KA, 1998, BIOCHEM J, V329, P637; DEANCOS JG, 1988, BIOCHEMISTRY-US, V27, P1793; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DEMEIS, 1981, LSARCOPLASMIC RETICU; Duggleby RC, 1999, BIOCHEM J, V339, P351, DOI 10.1042/0264-6021:3390351; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FORGE V, 1995, J BIOL CHEM, V270, P18271, DOI 10.1074/jbc.270.31.18271; Gonzalez DA, 1996, BBA-BIOENERGETICS, V1276, P188, DOI 10.1016/0005-2728(96)00076-X; GUILLAIN F, 1980, J BIOL CHEM, V255, P2072; HENDERSON IMJ, 1994, BIOCHEM J, V297, P615, DOI 10.1042/bj2970615; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Khan YM, 1997, BIOCHEM J, V321, P671, DOI 10.1042/bj3210671; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; Lundblad RL., 1995, TECHNIQUES PROTEIN M; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; MUNKONGE F, 1989, BIOCHIM BIOPHYS ACTA, V979, P113, DOI 10.1016/0005-2736(89)90530-0; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; NAKAJIMA N, 1995, BIOCONJUGATE CHEM, V6, P123, DOI 10.1021/bc00031a015; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PICK U, 1985, EUR J BIOCHEM, V152, P83, DOI 10.1111/j.1432-1033.1985.tb09166.x; STARLING AP, 1993, BIOCHEMISTRY-US, V32, P1593, DOI 10.1021/bi00057a025; STEFANOVA HI, 1992, BIOCHEMISTRY-US, V31, P6023, DOI 10.1021/bi00141a010; SUKO J, 1981, EUR J BIOCHEM, V119, P225, DOI 10.1111/j.1432-1033.1981.tb05598.x; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	33	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					977	982		10.1074/jbc.275.2.977	http://dx.doi.org/10.1074/jbc.275.2.977			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625635	hybrid			2022-12-25	WOS:000084836600039
J	Kosova, B; Pante, N; Rollenhagen, C; Podtelejnikov, A; Mann, M; Aebi, U; Hurt, E				Kosova, B; Pante, N; Rollenhagen, C; Podtelejnikov, A; Mann, M; Aebi, U; Hurt, E			Mlp2p, a component of nuclear pore attached intranuclear filaments, associates with Nic96p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; SCANNING ELECTRON-MICROSCOPY; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; NUCLEOCYTOPLASMIC TRANSPORT; MONOCLONAL-ANTIBODIES; MATRIX PROTEIN; BINDING-SITES; COMPLEX; YEAST	A fraction of the yeast nucleoporin Nic96p is localized at the terminal ring of the nuclear basket. When Nic96p was affinity purified from glutaraldehyde-treated spheroplasts, it was found to be associated with Mlp2p. Mlp2p, together with Mlp1p, are the yeast Tpr homologues, which form the nuclear pore attached intranuclear filaments (Strambio-de-Castillia, C., Blobel, G., and Rout, M. P. (1499) J. Cell Biol. 144, 839-855). Double disruption mutants of MLP1 and MLP2 are viable and apparently not impaired in nucleocytoplasmic transport. However, overproduction of MLP1 causes nuclear accumulation of poly(A)(+) RNA in a chromatin-free area of the nucleus.	Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Hurt, E (corresponding author), Biochem Zentrum Heidelberg, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.		Kosova, Buket/AAG-4736-2019; Mann, Matthias/A-3454-2013; Podtelejnikov, Alexandre/B-6120-2017; Ed Hurt, Dr./AAE-8874-2019; Pante, Nelly/GVR-8478-2022	Kosova, Buket/0000-0003-3636-6082; Mann, Matthias/0000-0003-1292-4799; Podtelejnikov, Alexandre/0000-0002-8124-6584; Ed Hurt, Dr./0000-0002-4535-8255; 				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; Arlucea J, 1998, J STRUCT BIOL, V124, P51, DOI 10.1006/jsbi.1998.4054; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; Bangs P, 1998, J CELL BIOL, V143, P1801, DOI 10.1083/jcb.143.7.1801; Belgareh N, 1998, MOL BIOL CELL, V9, P3475, DOI 10.1091/mbc.9.12.3475; BEVEN A, 1991, J CELL SCI, V98, P293; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; Clubb BH, 1998, J CELL BIOCHEM, V70, P240, DOI 10.1002/(SICI)1097-4644(19980801)70:2<240::AID-JCB10>3.0.CO;2-R; CORDES VC, 1993, J CELL BIOL, V123, P1333, DOI 10.1083/jcb.123.6.1333; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Cordes VC, 1998, EXP CELL RES, V245, P43, DOI 10.1006/excr.1998.4246; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FRANKE WW, 1970, J ULTRA MOL STRUCT R, V30, P288, DOI 10.1016/S0022-5320(70)80064-8; FRANKE WW, 1974, CELL NUCLEUS; GEORGATOS SD, 1994, J CELL BIOCHEM, V55, P69, DOI 10.1002/jcb.240550108; GERACE L, 1986, TRENDS BIOCHEM SCI, V11, P443, DOI 10.1016/0968-0004(86)90243-4; GOLDBERG MW, 1992, J CELL BIOL, V119, P1429, DOI 10.1083/jcb.119.6.1429; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; GRANDI P, 1995, EMBO J, V14, P76, DOI 10.1002/j.1460-2075.1995.tb06977.x; Gueth-Hallonet C, 1998, EXP CELL RES, V243, P434, DOI 10.1006/excr.1998.4178; GuethHallonet C, 1997, EXP CELL RES, V233, P21, DOI 10.1006/excr.1997.3557; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; HANER M, 1997, CELL BIOL LAB HDB, V3, P292; HINSHAW JE, 1994, BIOCHEM PHARMACOL, V47, P15, DOI 10.1016/0006-2952(94)90432-4; Hurwitz ME, 1998, P NATL ACAD SCI USA, V95, P11241, DOI 10.1073/pnas.95.19.11241; JACKSON DA, 1988, EMBO J, V7, P3667, DOI 10.1002/j.1460-2075.1988.tb03248.x; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; KALLAJOKI M, 1991, EMBO J, V10, P3351, DOI 10.1002/j.1460-2075.1991.tb04899.x; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KOLLING R, 1993, MOL GEN GENET, V237, P359; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Maniatis T., 1982, MOL CLONING LAB MANU; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; Merdes A, 1998, J CELL SCI, V111, P71; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Pante N, 1995, INT REV CYTOL, V162B, P225; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ris H, 1997, SCANNING, V19, P368, DOI 10.1002/sca.4950190504; RIS H, 1993, J STRUCT BIOL, V111, P148, DOI 10.1006/jsbi.1993.1045; Ris H., 1989, I PHYS C SER, V98, P657; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; SHERMAN F, 1990, METHOD ENZYMOL, V194, P3; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; WILKEN N, 1995, EUR J CELL BIOL, V68, P211; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Zimowska G, 1997, J CELL SCI, V110, P927	64	70	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					343	350		10.1074/jbc.275.1.343	http://dx.doi.org/10.1074/jbc.275.1.343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617624	hybrid, Green Published			2022-12-25	WOS:000085951600048
J	Webster, K; Parish, J; Pandya, M; Stern, PL; Clarke, AR; Gaston, K				Webster, K; Parish, J; Pandya, M; Stern, PL; Clarke, AR; Gaston, K			The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p59-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA CELL-LINES; ONCOGENIC HUMAN PAPILLOMAVIRUSES; TUMOR-SUPPRESSOR PROTEIN; E7 PROTEIN; MEDIATES ASSOCIATION; HUMAN KERATINOCYTES; E6 ONCOPROTEIN; DNA-BINDING; P53; TYPE-16	The human papillomavirus (HPV) E2 protein regulates viral gene expression and is also required for viral replication. HPV-transformed cells often contain chromosomally integrated copies of the HPV genome in which the viral E2 gene is disrupted. We have shown previously that re-expression of the HPV 16 E2 protein in HPV 16-transformed cells results in cell death via apoptosis. Here we show that the HPV 16 E2 protein can induce apoptosis in both HPV-transformed and non-HPV-transformed cell lines. E2-induced apoptosis is abrogated by a trans-dominant negative mutant of p53 or by overexpression of the HPV 16 E6 protein, but is increased by overexpression of wild-type p53. We show that mutations that block the DNA binding activity of E2 do not impair the ability of this protein to induce apoptosis. In contrast, removal of both N-terminal domains from the E2 dimer completely blocks E2-induced cell death. Heterodimers formed between wild-type E2 and N-terminally deleted E2 proteins also fail to induce cell death. Our data suggest that neither the DNA binding activity of E2 nor other HPV proteins are required for the induction of apoptosis by E2 and that E2-induced cell death occurs via a p53-dependent pathway.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Christie Hosp NHS Trust, Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England	University of Bristol; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Gaston, K (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	Kevin.Gaston@Bristol.ac.uk	Parish, Joanna L/L-4820-2015; Gaston, Kevin/K-9237-2019	Parish, Joanna L/0000-0002-7111-4211; Gaston, Kevin/0000-0002-7349-5513				BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BARSOUM J, 1992, J VIROL, V66, P3941, DOI 10.1128/JVI.66.6.3941-3945.1992; Bartholomew JS, 1997, CANCER RES, V57, P937; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Boyer SN, 1996, CANCER RES, V56, P4620; BUTZ K, 1995, ONCOGENE, V10, P927; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; CAMPO MS, 1992, CANCER RES, V52, P6898; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1996, PAPILLOMAVIRUS REV C, P55; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU TH, 1995, INT J ONCOL, V6, P167; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Hwang ES, 1996, ONCOGENE, V12, P795; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; SanchezPerez AM, 1997, J GEN VIROL, V78, P3009, DOI 10.1099/0022-1317-78-11-3009; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; THIERRY F, 1996, PAPILLOMAVIRUS REV C, P21; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	43	111	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					87	94		10.1074/jbc.275.1.87	http://dx.doi.org/10.1074/jbc.275.1.87			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617590	hybrid			2022-12-25	WOS:000085951600014
J	Drexler, HCA; Risau, W; Konerding, MA				Drexler, HCA; Risau, W; Konerding, MA			Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; proteolysis; cell cycle; p27(Kip1)	NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; TUMOR ANGIOGENESIS FACTOR; C-MYC PROTEIN; BREAST-CANCER; GROWTH-FACTOR; THYMOCYTE APOPTOSIS; U937 CELLS; IN-VIVO	Proteolysis mediated by the ubiquitin-proteasome system has been implicated in the regulation of programmed cell death. Here we investigated the differential effects of proteasomal inhibitors on the viability of proliferating and quiescent primary endothelial cells in vitro and in vivo. Subconfluent, proliferating cells underwent carbobenzoxy-L-isoleucyl-gamma-t-butyl-L-glutamyl-L-alanyl-L-leucinal (PSI)-induces apoptosis at low concentrations (EC50 = 24 nM), whereas at least 340-fold higher concentrations of PSI were necessary to obtain the same effect in confluent, contact-inhibited cells. PSI-mediated cell death could be blocked by a caspase-3 inhibitor (Ac-DEVD-H), but not by a caspase-1 inhibitor (Ac-YVAD-H), suggesting that a caspase-3-like enzyme is activated during PSI-induced apoptosis. When applied to the embryonic chick chorioallantoic membrane, a rapidly expanding tissue, PSI induced massive apoptosis also in vivo. PSI treatment of the CAM led to the formation of areas devoid of blood flow due to the induction of apoptosis in endothelial and other cells and to the collapse of capillaries and first order vessels. Our results demonstrate that proteasomal inhibitors inhibitors such as PSI may prove effective as novel anti-angiogenic and anti-neoplastic substances.	Max Planck Inst Physiol & Klin Forsch, Abt Mol Zellbiol, D-61231 Bad Nauheim, Germany; Univ Mainz, Inst Anat, D-55099 Mainz, Germany	Max Planck Society; Johannes Gutenberg University of Mainz	Drexler, HCA (corresponding author), Max Planck Inst Physiol & Klin Forsch, Abt Mol Zellbiol, Parkstr 1, D-61231 Bad Nauheim, Germany.		Drexler, Hannes/AAI-3449-2020					Adams J, 1999, CANCER RES, V59, P2615; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brown JP, 1997, BBA-REV CANCER, V1332, pO1, DOI 10.1016/S0304-419X(96)00048-0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; Dimitropoulou C, 1998, Angiogenesis, V2, P255, DOI 10.1023/A:1009210918738; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DREXLER HCA, 1988, APOPTOSIS, V3, P1; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1974, CANCER RES, V34, P2109; Fujita E, 1996, BIOCHEM BIOPH RES CO, V224, P74, DOI 10.1006/bbrc.1996.0986; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lockyer JM, 1998, CIRC RES, V82, P314, DOI 10.1161/01.RES.82.3.314; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mitchell CA, 1998, DEV DYNAM, V213, P322, DOI 10.1002/(SICI)1097-0177(199811)213:3<322::AID-AJA8>3.0.CO;2-E; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oikawa T, 1998, BIOCHEM BIOPH RES CO, V246, P243, DOI 10.1006/bbrc.1998.8604; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Orlowski RZ, 1998, CANCER RES, V58, P4342; Ostrowska H, 1997, BIOCHEM BIOPH RES CO, V234, P729, DOI 10.1006/bbrc.1997.6434; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RICHARDSON KC, 1960, STAIN TECHNOL, V35, P313, DOI 10.3109/10520296009114754; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tanimoto Y, 1997, J BIOCHEM-TOKYO, V121, P542; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450	61	134	138	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					65	77		10.1096/fasebj.14.1.65	http://dx.doi.org/10.1096/fasebj.14.1.65			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627281				2022-12-25	WOS:000084784700009
J	Singbartl, K; Green, SA; Ley, K				Singbartl, K; Green, SA; Ley, K			Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure	FASEB JOURNAL			English	Article						neutrophils; adhesion molecules; renal function; gene targeting; antibodies	ISCHEMIC-REPERFUSION INJURY; GRANULE MEMBRANE-PROTEIN; RAT-KIDNEY; ENDOTHELIAL-CELLS; IN-VIVO; NEUTROPHIL; ADHESION; ANTIBODY; ICAM-1; MICE		Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Munster, Klin & Poliklin Anasthesiol, Munster, Germany	University of Virginia; University of Virginia; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster	Ley, K (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Box 377, Charlottesville, VA 22908 USA.	kf13f@virginia.edu			NHLBI NIH HHS [HL-54136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Diacovo TG, 1996, BLOOD, V88, P146; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Goussev AV, 1998, J NEUROL SCI, V161, P16, DOI 10.1016/S0022-510X(98)00262-7; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; Haller H, 1996, KIDNEY INT, V50, P473, DOI 10.1038/ki.1996.338; HELLBERG POA, 1989, KIDNEY INT, V36, P555, DOI 10.1038/ki.1989.230; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; JONSON JP, 1995, ACUTE RENAL FAILURE, P28; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794; Koo DDH, 1998, AM J PATHOL, V153, P557, DOI 10.1016/S0002-9440(10)65598-8; Lefer DJ, 1996, AM J PHYSIOL-HEART C, V270, pH88, DOI 10.1152/ajpheart.1996.270.1.H88; Linas S, 1997, AM J PHYSIOL-RENAL, V272, pF48, DOI 10.1152/ajprenal.1997.272.1.F48; LINAS SL, 1995, KIDNEY INT, V48, P1584, DOI 10.1038/ki.1995.451; MASON J, 1989, MINER ELECTROL METAB, V15, P114; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MENGER MD, 1994, MICROSURG, V15, P383, DOI 10.1002/micr.1920150605; Muller JM, 1997, J SURG RES, V71, P1, DOI 10.1006/jsre.1997.5132; Ohnishi M, 1999, EUR J PHARMACOL, V366, P271, DOI 10.1016/S0014-2999(98)00923-6; OLOF P, 1990, AM J PHYSIOL, V258, pF1018, DOI 10.1152/ajprenal.1990.258.4.F1018; PALLER MS, 1989, J LAB CLIN MED, V113, P379; RABB H, 1994, AM J PHYSIOL-RENAL, V267, pF1052, DOI 10.1152/ajprenal.1994.267.6.F1052; Rabb H, 1996, AM J PHYSIOL-RENAL, V271, pF408, DOI 10.1152/ajprenal.1996.271.2.F408; RABB H, 1995, BIOCHEM BIOPH RES CO, V211, P67, DOI 10.1006/bbrc.1995.1779; Rabb H, 1998, CLIN EXP PHARMACOL P, V25, P286, DOI 10.1111/j.1440-1681.1998.t01-1-.x; RACUSEN LC, 1995, ACUTE RENAL FAILURE, P1; SANDERS WE, 1992, BLOOD, V80, P795; Singh I, 1998, TRANSPLANT P, V30, P2324, DOI 10.1016/S0041-1345(98)00640-X; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; TETTA C, 1995, ACUTE RENAL FAILURE, P64; THORNTON MA, 1989, AM J PATHOL, V135, P509; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Zizzi HC, 1997, J PEDIATR SURG, V32, P1010, DOI 10.1016/S0022-3468(97)90388-2	45	159	170	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					48	54		10.1096/fasebj.14.1.48	http://dx.doi.org/10.1096/fasebj.14.1.48			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627279				2022-12-25	WOS:000084784700007
J	Lim, SE; Longley, MJ; Copeland, WC				Lim, SE; Longley, MJ; Copeland, WC			The mitochondrial p55 accessory subunit of human DNA polymerase gamma enhances DNA binding, promotes processive DNA synthesis, and confers N-ethylmaleimide resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; DROSOPHILA EMBRYOS; CATALYTIC SUBUNIT; IDENTIFICATION; PURIFICATION; REPLICATION; BACTERIOPHAGE-T7; EXONUCLEASE; PROTEIN; EXCISION	Human DNA polymerase gamma is composed of a 140-kDa catalytic subunit and a smaller accessory protein variously reported to be 43-54 kDa. Immunoblot analysis of the purified, heterodimeric native human polymerase gamma complex identified the accessory subunit as 55 kDa, We isolated the full-length cDNA encoding a 55-kDa polypeptide, expressed the cDNA in Escherichia coli and purified the 55-kDa protein to homogeneity, Recombinant Hp55 forms a high affinity, salt-stable complex with Hp140 during protein affinity chromatography. Immunoprecipitation, gel filtration, and sedimentation analyses revealed a 190-kDa complex indicative of a native heterodimer, Reconstitution of Hp140 Hp55 raises the salt optimum of Hp140, stimulates the polymerase and exonuclease activities, and increases the processivity of the enzyme by several 100-fold. Similar to Hp140, isolated Hp55 binds DNA with moderate strength and was a specificity for double-stranded primer-template DNA. However, Hp140 Hp55 has a surprisingly high affinity for DNA, and kinetic analyses indicate Hp55 enhances the affinity of Hp140 for primer termini by 2 orders of magnitude. Thus the enhanced DNA binding caused by Hp55 is the basis for the salt tolerance and high processivity characteristic of DNA polymerase gamma, Observation of native DNA polymerase gamma both as an Hp140 monomer and as a heterodimer with Hp55 supports the notion that the two forms act in mitochondrial DNA repair and replication. Additionally, association of Hp55 with Hp140 protects the polymerase from inhibition by N-ethylmaleimide.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953				BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; GRAY H, 1992, J BIOL CHEM, V267, P5835; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KORNBERG A, 1992, DNA REPLICATION, P209; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MOSBAUGH DW, 1988, NUCLEIC ACIDS RES, V16, P5645, DOI 10.1093/nar/16.12.5645; OLSON MW, 1992, J BIOL CHEM, V267, P23136; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; ROPP PA, 1995, GENE, V165, P103, DOI 10.1016/0378-1119(95)00412-Y; Sambrook J., 2002, MOL CLONING LAB MANU; SHOFFNER JM, 1994, ANNU REV NUTR, V14, P535, DOI 10.1146/annurev.nu.14.070194.002535; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TABOR S, 1987, J BIOL CHEM, V262, P16212; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WYMAN C, 1995, CURR BIOL, V5, P334, DOI 10.1016/S0960-9822(95)00065-0	31	174	180	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38197	38203		10.1074/jbc.274.53.38197	http://dx.doi.org/10.1074/jbc.274.53.38197			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608893	hybrid			2022-12-25	WOS:000084528000093
J	McKiernan, CJ; Friedlander, M				McKiernan, CJ; Friedlander, M			The retinal rod Na+/Ca2+,K+ exchanger contains a noncleaved signal sequence required for translocation of the N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-CA2+ EXCHANGER; TRANSMEMBRANE GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; PROTEIN TRANSLOCATION; MEMBRANE INTEGRATION; SECRETORY PROTEINS; PRECURSOR; CHAPERONE; RECEPTOR	The retinal rod Na+/Ca2+,K+ exchanger (RodX) is a polytopic membrane protein found in photoreceptor outer segments where it is the principal extruder of Ca2+ ions during light adaptation. We have examined the role of the N-terminal 65 amino acids in targeting, translocation, and integration of the RodX using an in vitro translation/translocation system, cDNAs encoding human RodX and bovine RodX through the first transmembrane domain were correctly targeted and integrated into microsomal membranes; deletion of the N-terminal 65 amino acids (aa) resulted in a translation product that was not targeted or integrated. Deletion of the first 65 aa had no effect on membrane targeting of full-length RodX, but the N-terminal hydrophilic domain no longer translocated. Chimeric constructs encoding the first 65 aa of bovine RodX fused to globin were translocated across microsomal membranes, demonstrating that the sequence could function heterologously. Studies of fresh bovine retinal extracts demonstrated that the first 65 aa are present in the native protein. These data demonstrate that the first 65 aa of RodX constitute an uncleaved signal sequence required for the efficient membrane targeting and proper membrane integration of RodX.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Friedlander, M (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,MB-28, La Jolla, CA 92037 USA.				NEI NIH HHS [5F32 EY06820] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006820] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMOWSKI D, 1995, J NEUROCHEM, V65, P782; ANDERSON DJ, 1982, J CELL BIOL, V93, P501, DOI 10.1083/jcb.93.2.501; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; Cooper CB, 1999, BIOCHEMISTRY-US, V38, P6276, DOI 10.1021/bi983068o; DOBNER PR, 1987, P NATL ACAD SCI USA, V84, P3516, DOI 10.1073/pnas.84.10.3516; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FURMAN I, 1995, J BIOL CHEM, V270, P19120, DOI 10.1074/jbc.270.32.19120; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; Hajek P, 1997, MOL CELL BIOL, V17, P7169, DOI 10.1128/MCB.17.12.7169; Haynes RL, 1997, J BIOL CHEM, V272, P17126, DOI 10.1074/jbc.272.27.17126; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; KABACK HR, 1992, MOL BIOL RECEPTORS T, P98; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGAPPA VR, 1978, J BIOL CHEM, V253, P8667; LOO TW, 1995, J BIOL CHEM, V270, P19345, DOI 10.1074/jbc.270.33.19345; McClellan AJ, 1998, MOL BIOL CELL, V9, P3533, DOI 10.1091/mbc.9.12.3533; NICOLL DA, 1989, J BIOL CHEM, V264, P16207; PHILIPSON K D, 1992, Current Opinion in Cell Biology, V4, P678, DOI 10.1016/0955-0674(92)90089-U; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SAHINTOTH M, 1995, BIOCHEM BIOPH RES CO, V212, P968, DOI 10.1006/bbrc.1995.2064; Tucker JE, 1998, INVEST OPHTH VIS SCI, V39, P435; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	26	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38177	38182		10.1074/jbc.274.53.38177	http://dx.doi.org/10.1074/jbc.274.53.38177			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608890	hybrid			2022-12-25	WOS:000084528000090
J	Murata, S; Kawahara, H; Tohma, S; Yamamoto, K; Kasahara, M; Nabeshima, Y; Tanaka, K; Chiba, T				Murata, S; Kawahara, H; Tohma, S; Yamamoto, K; Kasahara, M; Nabeshima, Y; Tanaka, K; Chiba, T			Growth retardation in mice lacking the proteasome activator PA28 gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20S PROTEASOME; PROTEIN ACTIVATOR; PA28 SUBUNITS; ALPHA-SUBUNIT; BETA-SUBUNIT; GAMMA; REGULATOR; PURIFICATION; LOCALIZATION; LIGANDS	The proteasome activator PA28 binds to both ends of the central catalytic machine, known as the 20 S proteasome, in opposite orientations to form the enzymatically active proteasome. The PA28 family is composed of three members designated alpha, beta, and gamma; PA28 alpha and PA28 beta form the heteropolymer mainly located in the cytoplasm, whereas PA28 gamma forms a homopolymer that predominantly occurs in the nucleus. Available evidence indicates that the heteropolymer of PA28 alpha and PA28 beta is involved in the processing of intracellular antigens, but the function of PA28 gamma remains elusive. To investigate the role of PA28 gamma in vivo, we generated mice deficient in the PA28 gamma gene. The PA28 gamma-deficient mice were born without appreciable abnormalities in all tissues examined, but their growth after birth was retarded compared with that of PA28 gamma(+/-) or PA28 gamma(+/+) mice. We also investigated the effects of the PA28 gamma deficiency using cultured embryonic fibroblasts; cells lacking PA28 gamma were larger and displayed a lower saturation density than their wild-type counterparts. Neither the expression of PA28 alpha/beta nor the subcellular localization of PA28 alpha was affected in PA28 gamma(-/-) cells. These results indicate that PA28 gamma functions as a regulator of cell proliferation and body growth in mice and suggest that neither PA28 alpha: nor PA28 beta compensates for the PA28 gamma deficiency.	Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Inst Mol & Cellular Sci, Bunkyo Ku, Tokyo 1138655, Japan; Grad Univ Adv Studies, Sch Adv Sci, Dept Biosyst Sci, Hayama 2400193, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol, Sakyo Ku, Kyoto 6190237, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; University of Tokyo; Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST); Kyoto University	Chiba, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Kasahara, Masanori/G-7651-2011; Murata, Shigeo/A-1426-2010; Yamamoto, Kazuhiko/N-5096-2015	Murata, Shigeo/0000-0002-3177-3503; 				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kandil E, 1997, IMMUNOGENETICS, V46, P337, DOI 10.1007/s002510050281; Kohda K, 1998, J IMMUNOL, V160, P4923; MA CP, 1992, J BIOL CHEM, V267, P10515; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimbara N, 1998, J BIOL CHEM, V273, P23062, DOI 10.1074/jbc.273.36.23062; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; Soza A, 1997, FEBS LETT, V413, P27, DOI 10.1016/S0014-5793(97)00864-8; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; Tanaka K, 1998, BIOCHEM BIOPH RES CO, V247, P537, DOI 10.1006/bbrc.1998.8617; Tanaka K, 1998, IMMUNOL REV, V163, P161; Wojcik C, 1998, EUR J CELL BIOL, V77, P151, DOI 10.1016/S0171-9335(98)80083-6; Zhang ZG, 1999, BIOCHEMISTRY-US, V38, P5651, DOI 10.1021/bi990056+	29	144	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38211	38215		10.1074/jbc.274.53.38211	http://dx.doi.org/10.1074/jbc.274.53.38211			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608895	hybrid			2022-12-25	WOS:000084528000095
J	Pical, C; Westergren, T; Dove, SK; Larsson, C; Sommarin, M				Pical, C; Westergren, T; Dove, SK; Larsson, C; Sommarin, M			Salinity and hyperosmotic stress induce rapid increases in phosphatidylinositol 4,5-bisphosphate, diacylglycerol pyrophosphate, and phosphatidylcholine in Arabidopsis thaliana cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA; SPIRODELA-POLYRHIZA L; STOMATAL GUARD-CELLS; 4,5-PHOSPHORYLATED PHOSPHATIDYLINOSITOLS; INOSITOL 1,4,5-TRISPHOSPHATE; OSMOTIC-STRESS; MEMBRANE; CALCIUM; PROTEIN; PLANTS	In animal cells, phosphoinositides are key components of the inositol 1,4,5-trisphosphate/diacylglycerol-based signaling pathway, but also have many other cellular functions. These lipids are also believed to fulfill similar functions in plant cells, although many details concerning the components of a plant phosphoinositide system, and their regulation are still missing. Only recently have the different phosphoinositide isomers been unambiguously identified in plant cells. Another problem that hinders the study of the function of phosphoinositides and their derivatives, as well as the regulation of their metabolism, in plant cells is the need for a homogenous, easily obtainable material, from which the extraction and purification of phospholipids is relatively easy and quantitatively reproducible. We present here a thorough characterization of the phospholipids purified from [P-32]orthophosphate- and myo-[2-H-3]inositol-radiolabded Arabidopsis thaliana suspension-cultured cells. We then show that NaCl treatment induces dramatic increases in the levels of phosphatidylinositol 4,5-bisphosphate and diacylglycerol pyrophosphate and also affects the turnover of phosphatidylcholine. The increase in phosphatidylinositol 4,5-bisphosphate was also observed with a non-ionic hyperosmotic shock. In contrast, the increase in diacylglycerol pyrophosphate and the turnover of phosphatidylcholine mere relatively specific to salt treatments as only minor changes in the metabolism of these two phospholipids were detected when the cells were treated with sorbitol instead of NaCl.	Univ Lund, Dept Plant Biochem, SE-22100 Lund, Sweden; Univ Birmingham, Ctr Clin Res Immunol & Signalling, Birmingham B15 2TT, W Midlands, England	Lund University; University of Birmingham	Pical, C (corresponding author), Univ Lund, Dept Plant Biochem, POB 117, SE-22100 Lund, Sweden.							ALEXANDRE J, 1990, NATURE, V343, P567, DOI 10.1038/343567a0; Ashcroft FM, 1998, SCIENCE, V282, P1059, DOI 10.1126/science.282.5391.1059; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLATT MR, 1990, NATURE, V346, P766, DOI 10.1038/346766a0; BREARLEY CA, 1993, BIOCHEM J, V290, P145, DOI 10.1042/bj2900145; Brearley CA, 1997, BIOCHEM J, V324, P123, DOI 10.1042/bj3240123; BREARLEY CA, 1992, BIOCHEM J, V283, P255, DOI 10.1042/bj2830255; BREARLEY CA, 1995, BIOCHEM J, V311, P1001, DOI 10.1042/bj3111001; BREARLEY CA, 1997, SIGNALLING INOSITIDE, P1; CHO MH, 1993, PLANT PHYSIOL, V103, P637, DOI 10.1104/pp.103.2.637; COTE GG, 1989, PLANT PHYSIOL, V90, P1422, DOI 10.1104/pp.90.4.1422; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DOVE SK, 1999, SIGNAL TRANSDUCTION, P255; DROBAK BK, 1994, PLANT J, V6, P389, DOI 10.1046/j.1365-313X.1994.06030389.x; DROBAK BK, 1988, PLANT PHYSIOL, V87, P217, DOI 10.1104/pp.87.1.217; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; EINSPAHR KJ, 1988, J BIOL CHEM, V263, P5775; EPSTEIN E, 1980, SCIENCE, V210, P399, DOI 10.1126/science.210.4468.399; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; HANSON AD, 1983, PLANT PHYSIOL, V71, P692, DOI 10.1104/pp.71.3.692; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; IRVINE RF, 1989, PLANT PHYSIOL, V89, P888, DOI 10.1104/pp.89.3.888; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; Kopka J, 1998, PLANT PHYSIOL, V116, P239, DOI 10.1104/pp.116.1.239; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LESTER RL, 1978, INOSITOL METABOLISM, P83; LIU B, 1994, PLANT CELL, V6, P303, DOI 10.1105/tpc.6.2.303; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; LYNCH J, 1989, PLANT PHYSIOL, V90, P1271, DOI 10.1104/pp.90.4.1271; Meijer HJG, 1999, PLANTA, V208, P294; Mikami K, 1998, PLANT J, V15, P563, DOI 10.1046/j.1365-313X.1998.00227.x; MUNNIK T, 1994, BIOCHEM J, V298, P269, DOI 10.1042/bj2980269; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; MUNNIK T, 1994, PLANTA, V193, P89, DOI 10.1007/BF00191611; NIU XM, 1995, PLANT PHYSIOL, V109, P735, DOI 10.1104/pp.109.3.735; Nuccio ML, 1998, PLANT J, V16, P487, DOI 10.1046/j.1365-313x.1998.00316.x; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; PARMAR PN, 1993, PLANT J, V4, P255, DOI 10.1046/j.1365-313X.1993.04020255.x; PICAL C, 1997, PLANT PHYSIOL, V114, P747; Rhodes D., 1994, CELLULAR MOL PHYSL C, P347; SHI JR, 1995, PLANT J, V8, P381, DOI 10.1046/j.1365-313X.1995.08030381.x; WELTERS P, 1994, P NATL ACAD SCI USA, V91, P11398, DOI 10.1073/pnas.91.24.11398; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xue HW, 1999, J BIOL CHEM, V274, P5738, DOI 10.1074/jbc.274.9.5738; YANG WN, 1993, J BIOL CHEM, V268, P392; Zhu JK, 1997, CRIT REV PLANT SCI, V16, P253, DOI 10.1080/713608147	52	143	149	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38232	38240		10.1074/jbc.274.53.38232	http://dx.doi.org/10.1074/jbc.274.53.38232			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608898	hybrid			2022-12-25	WOS:000084528000098
J	Yeo, EJ; Briggs, WT; Wagner, C				Yeo, EJ; Briggs, WT; Wagner, C			Inhibition of glycine N-methyltransferase by 5-methyltetrahydrofolate pentaglutamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-GROUP METABOLISM; FOLATE BINDING-PROTEIN; RAT-LIVER CYTOSOL; PURIFICATION; FOLYLPOLYGLUTAMATES; DEOXYHEMOGLOBIN; IDENTIFICATION; DERIVATIVES	Glycine N-methyltransferase (EC 2.1.1.20) catalyzes the methylation of glycine by S-adenosylmethionine to form sarcosine and S-adenosylhomocysteine. The enzyme was previously shown to be abundant in both the liver and pancreas of the rat, to consist of four identical monomers, and to contain tightly bound folate polyglutamates in vivo. We now report that the inhibition of glycine N-methyltransferase by (GS)-5-CH3-H(4)PteGlu(5) is noncompetitive with regard to both S-adenosylmethionine and glycine, The enzyme exhibits strong positive cooperativity with respect to S-adenosylmethionine. Cooperativity increases with increasing concentrations of 5-CH3-H(4)PteGlu(5) and is greater at physiological pH than at pH 9.0, the pH optimum. Under the same conditions, cooperativity is much greater for the pancreatic form of the enzyme. The V-max for the liver form of the enzyme is approximately twice that of the pancreatic enzyme, while K-m values for each substrate are similar in the liver and pancreatic enzymes. For the liver enzyme, at pH 7.0 half-maximal inhibition is seen at a concentration of about 0.2 mu M (6S)-5-CH3-H(4)PteGl(5), while at pH 9.0 this value is increased to about 1 mu M. For the liver form of the enzyme, 50% inhibition with respect to S-adenosylmethionine at pH 7.4 occurs at about 0.27 mu M. The dissociation constant, K-s obtained from binding data at pH 7.4 is 0.095, About 1 mol of (6S)-5-CH3-H(4)PteGlu(5) was bound per tetramer at pH 7.0, and 1.6 mol were bound at pH 9.0, The degree of binding and inhibition were closely parallel at each pH, At equal concentrations of (6R,6S)- and (6S)-5-CH3-H(4)PteGlu(5), the natural (6S) form was about twice as inhibitory. These studies indicate that glycine N-methyltransferase is a highly allosteric enzyme, which is consistent with its role as a regulator of methyl group metabolism in both the liver and the pancreas.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wagner, C (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 620 Light Hall, Nashville, TN 37232 USA.							ARNONE A, 1986, J BIOL CHEM, V261, P5853; BALAGHI M, 1992, J NUTR, V122, P1391, DOI 10.1093/jn/122.7.1391; BENESCH RE, 1985, J BIOL CHEM, V260, P4653; BENESCH RE, 1983, P NATL ACAD SCI-BIOL, V80, P6202, DOI 10.1073/pnas.80.20.6202; BLUMENSTEIN J, 1960, BIOCHEM BIOPH RES CO, V3, P259, DOI 10.1016/0006-291X(60)90235-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTONI GL, 1978, TRANSMETHYLATION, P155; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; Dahlquist F W, 1978, Methods Enzymol, V48, P270; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; GIULIDORI P, 1981, CLIN CHEM, V27, P2041; HEADY JE, 1973, J BIOL CHEM, V248, P69; HORNE D W, 1989, Biofactors, V2, P65; Horne D W, 1980, Methods Enzymol, V66, P545; KERR SJ, 1972, J BIOL CHEM, V247, P4248; KONISHI K, 1987, BIOCHEMISTRY-US, V26, P8496, DOI 10.1021/bi00399a069; KONISHI K, 1988, J BIOL CHEM, V263, P13381; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; OGAWA H, 1982, J BIOL CHEM, V257, P3447; Ogawa H, 1997, BIOCHEM J, V327, P407, DOI 10.1042/bj3270407; OGAWA H, 1984, BIOCHEM BIOPH RES CO, V124, P44, DOI 10.1016/0006-291X(84)90913-6; SEGEL IH, 1993, ENZYME KINETICS WILE, P15; SUZUKI N, 1980, ARCH BIOCHEM BIOPHYS, V199, P236, DOI 10.1016/0003-9861(80)90277-5; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; WILSON SD, 1986, METHOD ENZYMOL, V122, P269, DOI 10.1016/0076-6879(86)22181-3; YEO EJ, 1992, J BIOL CHEM, V267, P24669; ZAMIEROWSKI MM, 1977, J BIOL CHEM, V252, P933; ZAPPIA V, 1983, METHOD ENZYMOL, V94, P57	28	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37559	37564		10.1074/jbc.274.53.37559	http://dx.doi.org/10.1074/jbc.274.53.37559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608809	hybrid			2022-12-25	WOS:000084528000009
J	Yousef, GM; Diamandis, EP				Yousef, GM; Diamandis, EP			The new kallikrein-like gene, KLK-L2 - Molecular characterization, mapping, tissue expression, and hormonal regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; HUMAN GLANDULAR KALLIKREIN; SEQUENCE-ANALYSIS; SERINE-PROTEASE; POSITIONAL CLONING; CDNA; LOCUS; IDENTIFICATION; TRYPSIN; BREAST	Since in rodents the kallikreins are represented by a large multi-gene family, the restriction of this family in humans to three genes is somewhat surprising. In an effort to identify new human kallikrein genes, we examined a genomic area of about 300 kilobases on chromosome 19q13.3-q13.4, a region that contains most of the currently known kallikreins. By using the positional candidate approach, we were able to identify a new gene named KLK-L2 (for kallikrein-like gene 2). Screening of human EST libraries allowed us to delineate the full genomic and cDNA structure of the new gene. KLK-L2 consists of 5 coding exons and 4 introns and has significant similarities to other members of the kallikrein multi-gene family. Homology studies suggest that the protein is likely secreted. KLK-L2 is expressed mainly in breast, brain, and testis and to a lesser extent in many other tissues. KLK-L2 is up-regulated by estrogens and progestins in the breast cancer cell line BT-474.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.			Diamandis, Eleftherios/0000-0002-1589-820X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4520, DOI 10.1021/bi00338a006; BAKER AR, 1985, DNA-J MOLEC CELL BIO, V4, P445, DOI 10.1089/dna.1985.4.445; Boehm T, 1998, METHODS, V14, P152, DOI 10.1006/meth.1997.0574; CLEMENTS J, 1997, KININ SYSTEM, P71; Clements JA, 1996, CLIN ENDOCRINOL, V44, P223, DOI 10.1046/j.1365-2265.1996.661481.x; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAYHOFF MO, 1976, FED PROC, V35, P2132; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; EVANS BA, 1988, BIOCHEMISTRY-US, V27, P3124, DOI 10.1021/bi00409a003; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FUKUSHIMA D, 1985, BIOCHEMISTRY-US, V24, P8037, DOI 10.1021/bi00348a030; Goyal J, 1998, CANCER RES, V58, P4782; IIDA Y, 1990, J THEOR BIOL, V145, P523, DOI 10.1016/S0022-5193(05)80486-2; IRWIN DM, 1988, J MOL BIOL, V200, P31, DOI 10.1016/0022-2836(88)90331-2; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIN FK, 1993, BIOCHIM BIOPHYS ACTA, V1173, P325, DOI 10.1016/0167-4781(93)90131-V; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Liu XL, 1996, CANCER RES, V56, P3371; MIYATA T, 1979, J MOL EVOL, V12, P219, DOI 10.1007/BF01732340; MURRAY SR, 1990, J CADIOVASC PHARM S6, V15, P7; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; RICHARDS RI, 1991, GENOMICS, V11, P77, DOI 10.1016/0888-7543(91)90103-L; RIEGMAN PHJ, 1989, FEBS LETT, V247, P123, DOI 10.1016/0014-5793(89)81253-0; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; SAUNDERS AM, 1990, GENOMICS, V8, P525, DOI 10.1016/0888-7543(90)90040-2; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; Simmer JP, 1998, J DENT RES, V77, P377, DOI 10.1177/00220345980770020601; Stenman UH, 1999, CLIN CHEM, V45, P753; Takayama TK, 1997, J BIOL CHEM, V272, P21582, DOI 10.1074/jbc.272.34.21582; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Yoshida S, 1998, GENE, V213, P9, DOI 10.1016/S0378-1119(98)00232-7	37	90	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37511	37516		10.1074/jbc.274.53.37511	http://dx.doi.org/10.1074/jbc.274.53.37511			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608802	hybrid			2022-12-25	WOS:000084528000002
J	Panagopoulos, I; Mencinger, M; Dietrich, CU; Bjerkehagen, B; Saeter, G; Mertens, F; Mandahl, N; Heim, S				Panagopoulos, I; Mencinger, M; Dietrich, CU; Bjerkehagen, B; Saeter, G; Mertens, F; Mandahl, N; Heim, S			Fusion of the RBP56 and CHN genes in extraskeletal myxoid chondrosarcomas with translocation t(9;17)(q22;q11)	ONCOGENE			English	Article						chondrosarcoma; gene fusion; translocation genetics; karyotyping	RNA-BINDING PROTEIN; EWINGS-SARCOMA TRANSLOCATION; ORPHAN NUCLEAR RECEPTOR; CHROMOSOME-TRANSLOCATION; EWS GENE; MYELOID-LEUKEMIA; FAMILY; TUMORS; CHOP; ERG	Although most extraskeletal myxoid chondrosarcomas (EMC) are cytogenetically characterized by the translocation t(9;22)(q22;q12), another subset has recently been identified carrying a t(9;17)(q22;q11). Whereas the t(9;22) is known to result in fusion of the CHN (TEC) gene from 9q22 with the EWS gene from 22q12, creating a chimeric EWS/CHN, the genes involved in the t(9;17) of EMC are unknown. We examined two EMC with t(9;17)(q22;q11) and found that the CHN gene was recombined with the RBP56 gene from 17q11 to generate a chimeric RBP56/CHN, RBP56 has not previously been shown to be involved in tumorigenesis but it encodes a putative RNA-binding protein similar to the EWS and FUS (TLS) proteins known to play a pathogenetic role in several sarcomas, The presence of the RBP56/CHN chimeric gene in EMC with t(9;17)(q22;q11) shows that the N-terminal parts of EWS and RBP56 have similar oncogenic potential making them pathogenetically equivalent in oncoproteins arising from fusions with certain transcription factors.	Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Genet, N-0310 Oslo, Norway; Inst Canc Res, N-0310 Oslo, Norway	Lund University; Skane University Hospital; University of Oslo; University of Oslo; University of Oslo	Panagopoulos, I (corresponding author), Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.		Mencinger, Marina/AAC-9468-2022	Mencinger, Marina/0000-0002-4349-1511; Mertens, Fredrik/0000-0002-6278-5232; Panagopoulos, Ioannis/0000-0003-2159-5341				Antonescu CR, 1998, CANCER, V83, P1504, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1504::AID-CNCR5>3.0.CO;2-B; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BJERKEHAGEN B, 1999, IN PRESS VIRCHOWS AR; Brody RI, 1997, AM J PATHOL, V150, P1049; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ELIZALDE JM, 1993, TUMORI, V79, P283, DOI 10.1177/030089169307900413; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KLIJANIENKO J, 1990, HISTOPATHOLOGY, V16, P196; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LIUSHINDO M, 1989, OTOLARYNG HEAD NECK, V101, P485, DOI 10.1177/019459988910100414; MITELMAN F, 1998, CATALOG CHROMOSOME A; Morohoshi F, 1996, GENOMICS, V38, P51, DOI 10.1006/geno.1996.0591; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STEFFEN CM, 1992, J SURG ONCOL, V50, P58, DOI 10.1002/jso.2930500116; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	30	60	62	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7594	7598		10.1038/sj.onc.1203155	http://dx.doi.org/10.1038/sj.onc.1203155			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602519				2022-12-25	WOS:000084119600021
J	Kang, SH; Bang, YJ; Im, YH; Yang, HK; Lee, DA; Lee, HY; Lee, HS; Kim, NK; Kim, SJ				Kang, SH; Bang, YJ; Im, YH; Yang, HK; Lee, DA; Lee, HY; Lee, HS; Kim, NK; Kim, SJ			Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer	ONCOGENE			English	Article						transforming growth factor-beta; CpG methylation; cancer; receptor	TUMOR-SUPPRESSOR GENE; COLON-CARCINOMA CELLS; MICROSATELLITE INSTABILITY; CPG ISLAND; COLORECTAL-CANCER; MISMATCH REPAIR; EXPRESSION; ACTIVATION; MALIGNANCY; PROMOTER	The transforming growth factor-beta (TGF-beta) signaling pathway subserves an essential tumor suppressor function in various cell types. A heteromeric complex composed of TGF-beta type I (RI) and type II (RII) receptors is required for TGF-beta signaling. We have identified a subset of human gastric cancer cell lines which are insensitive to TGF-beta and which express a low level of TGF-beta type I receptor mRNA relative to a gastric cancer cell line which is highly responsive to TGF-beta. Using these cells, we show that hypermethylation of a CpG island in the 5' region of the TGF-beta RI gene provides another potentially important mechanism of escape from negative growth control by TGF-beta, This hypermethylation was found in four of five human gastric cancer cell lines and five out of 40 (12.5%) primary tumors examined, In human gastric cancer cell lines, treatment with the demethylating agent, 5-aza-2'-deoxycytidine, resulted in increased expression of the TGF-beta RI gene, but not the RII gene, Transient transfection of an RI expression vector into the TGF-beta resistant SNU-601 cell line restores TGF-beta responsiveness. These findings suggest that one of the mechanisms of escape from autocrine or paracrine growth control by TGF-beta during carcinogenesis could involve aberrant methylation of CpG islands in the 5' region of the TGF-beta RI gene.	Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kim, SJ (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea.		Bang, Yung Jue/J-2759-2012; Yang, Han-Kwang/J-2767-2012	Bang, Yung Jue/0000-0001-6000-4597; 				BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; Chang J, 1997, CANCER RES, V57, P2856; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3892; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jones PA, 1996, CANCER RES, V56, P2463; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK K, 1994, P NATL ACAD SCI USA, V81, P8772; PARSONS R, 1995, CANCER RES, V55, P5548; Reiss M, 1997, ONCOL RES, V9, P447; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SAKAI T, 1991, AM J HUM GENET, V48, P880; SUARDET L, 1992, CANCER RES, V52, P3705; SUN LZ, 1994, J BIOL CHEM, V269, P26449; WAKEFIELD LM, 1991, TUMOR SUPPRESSOR GEN, P217; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	41	103	114	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7280	7286		10.1038/sj.onc.1203146	http://dx.doi.org/10.1038/sj.onc.1203146			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602482				2022-12-25	WOS:000084119400012
J	Lopez, P; Vidal, F; Rassoulzadegan, M; Cuzin, F				Lopez, P; Vidal, F; Rassoulzadegan, M; Cuzin, F			A role of inhibin as a tumor suppressor in Sertoli cells: down-regulation upon aging and repression by a viral oncogene	ONCOGENE			English	Article						testis; gonadal tumor; inhibin-activin; polyoma virus; T antigen; gene regulation	LARGE T-ANTIGEN; RECOMBINANT HUMAN INHIBIN; ALPHA-INHIBIN; BINDING-SITE; PROTEIN; GENE; MICE; DNA; EXPRESSION; ACTIVIN	Inhibin, a member of the TGF-beta superfamily, is synthesized in the testis by Sertoli cells and exerts an endocrine regulatory function on pituitary hormone synthesis, A distinct local function has been proposed, negatively controlling cellular growth in the testis (tumor suppressor activity). A critical test for the identification of a tumor suppressor is the reversal of transformed growth properties upon re-expression of the gene in tumor-derived cell lines. Sertoli cell-derived tumoral lines were previously established from tumors that develop in elderly transgenic males which express in the testis the large T antigen of polyoma virus. Both the tumors and the cells in culture exhibited reduced levels of the inhibin alpha subunit mRNA, Stable transfectants were generated, in which this subunit was expressed from a heterologous promoter. All of them exhibited a strict inhibition of growth at confluency, On the other hand, in addition to an aging-related decrease in inhibin synthesis, the alpha subunit gene was down regulated in vivo in cells expressing the viral protein. The conjunction of these two factors accounts for the age-related occurrence of testicular cancers in the transgenic model, again pointing to inhibin as a potent cell growth regulator in the seminiferous epithelium.	Univ Nice, INSERM, U470, F-06108 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Cuzin, F (corresponding author), Univ Nice, INSERM, U470, F-06108 Nice, France.		Rassoulzadegan, Minoo/O-7939-2016	Lopez, Pascal/0000-0002-3936-3058				BARUT B, 1993, J CLIN INVEST, V92, P2346, DOI 10.1172/JCI116839; BOITANI C, 1995, ENDOCRINOLOGY, V136, P5438, DOI 10.1210/en.136.12.5438; CHEN CLC, 1993, ENDOCRINOLOGY, V132, P4, DOI 10.1210/en.132.1.4; CHEN CLC, 1992, MOL BIOL REPROD SERO, P97; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWIE A, 1984, J VIROL, V52, P750, DOI 10.1128/JVI.52.3.750-760.1984; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GAUDRAY P, 1981, NUCLEIC ACIDS RES, V9, P5697, DOI 10.1093/nar/9.21.5697; Grandjean V, 1997, BIOL REPROD, V57, P1115, DOI 10.1095/biolreprod57.5.1115; Grimaldi P, 1996, MOL CELL ENDOCRINOL, V117, P167, DOI 10.1016/0303-7207(95)03744-6; GUERRAGARCIA R, 1989, ARCH ANDROLOGY, V22, P35, DOI 10.3109/01485018908986748; HAKOVIRTA H, 1993, ENDOCRINOLOGY, V133, P1664, DOI 10.1210/en.133.4.1664; HANGOC G, 1992, EXP HEMATOL, V20, P1243; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JAKUBOWIAK A, 1991, MOL CELL ENDOCRINOL, V82, P265, DOI 10.1016/0303-7207(91)90040-Y; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; PAL D, 1991, BIOL REPROD, V45, P869, DOI 10.1095/biolreprod45.6.869; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; PECH N, 1993, BLOOD, V82, P1502; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; RASSOULZADEGAN M, 1981, VIROLOGY, V114, P489, DOI 10.1016/0042-6822(81)90228-2; RICH KA, 1983, ENDOCRINOLOGY, V113, P2284, DOI 10.1210/endo-113-6-2284; SKINNER MK, 1993, SERTOLI CELL, P237; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; VANDISSELEMILIANI FMF, 1989, ENDOCRINOLOGY, V125, P1899, DOI 10.1210/endo-125-4-1898; Vincent S, 1998, DEVELOPMENT, V125, P4585; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	33	11	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7303	7309		10.1038/sj.onc.1203143	http://dx.doi.org/10.1038/sj.onc.1203143			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602485				2022-12-25	WOS:000084119400015
J	Garate, MA; Nunez, MT				Garate, MA; Nunez, MT			Overexpression of the ferritin iron-responsive element decreases the labile iron pool and abolishes the regulation of iron absorption by intestinal epithelial (Caco-2) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; RNA-BINDING; MAMMALIAN-CELLS; MESSENGER-RNA; TRANSFERRIN; HEMOCHROMATOSIS; TRANSPORTER; DEGRADATION; EXPRESSION; ACONITASE	Mammalian cells regulate iron levels tightly through the activity of iron-regulatory proteins (IRPs) that bind to RNA motifs called iron-responsive elements (IREs), When cells become iron-depleted, IRPs bind to IREs present in the mRNAs of ferritin and the transferrin receptor, resulting in diminished translation of the ferritin mRNA and increased translation of the transferrin receptor mRNA. Likewise, intestinal epithelial cells regulate iron absorption by a process that also depends on the intracellular levels of iron. Although intestinal epithelial cells have an active IRE/IRP system, it has not been proven that this system is involved in the regulation of iron absorption in these cells. In this study, we characterized the effect of overexpression of the ferritin IRE on iron absorption by Caco-2 cells, a model of intestinal epithelial cells. Cells overexpressing ferritin IRE had increased levels of ferritin, whereas the levels of the transferrin receptor were decreased. Iron absorption in IRE-transfected cells was deregulated: iron uptake from the apical medium was increased, but the capacity to retain this newly incorporated iron diminished. Cells overexpressing IRE were not able to control iron absorption as a function of intracellular iron, because both iron-deficient cells as well as iron-loaded cells absorbed similarly high levels of iron. The labile iron pool of IRE-transfected cell was extremely low. Likewise, the reduction of the labile iron pool in control cells resulted in cells having increased iron absorption. These results indicate that cells overexpressing IRE do not regulate iron absorption, an effect associated with decreased levels of the regulatory iron pool.	Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile; Millennium Inst Advances Studies Cell Biol & Biot, Santiago, Chile	Universidad de Chile	Nunez, MT (corresponding author), Univ Chile, Fac Ciencias, Dept Biol, Casilla 653, Santiago, Chile.	mnunez@abello.dic.uchile.cl	Nunez, Marco/H-6348-2014	Nunez, Marco/0000-0002-1967-8570				ALVAREZHERNANDEZ X, 1994, BBA-BIOMEMBRANES, V1192, P215, DOI 10.1016/0005-2736(94)90121-X; Arredondo M, 1997, AM J PHYSIOL-GASTR L, V273, pG275, DOI 10.1152/ajpgi.1997.273.2.G275; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BOYD D, 1985, J BIOL CHEM, V260, P1755; Cairo G, 1997, BLOOD, V89, P2546, DOI 10.1182/blood.V89.7.2546; DERUSSO PA, 1995, J BIOL CHEM, V270, P15451, DOI 10.1074/jbc.270.26.15451; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; FLANAGAN PR, 1995, HEPATOLOGY, V22, P828, DOI 10.1002/hep.1840220321; FLANAGAN PR, 1990, ACTA PEDIAT SCAND S, V361, P21; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; GAVIN MW, 1994, AM J CLIN NUTR, V59, P1376, DOI 10.1093/ajcn/59.6.1376; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; GUO B, 1994, J BIOL CHEM, V269, P24252; Gutierrez JA, 1997, J CELL BIOL, V139, P895, DOI 10.1083/jcb.139.4.895; HAN O, 1995, J NUTR, V125, P1291; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; HILLGREN KM, 1995, MED RES REV, V15, P83, DOI 10.1002/med.2610150202; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NUNEZ MT, 1994, AM J PHYSIOL-CELL PH, V267, pC1582, DOI 10.1152/ajpcell.1994.267.6.C1582; Nunez MT, 1996, J NUTR, V126, P2151, DOI 10.1093/jn/126.9.2151; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Tapia V, 1996, AM J PHYSIOL-GASTR L, V271, pG443, DOI 10.1152/ajpgi.1996.271.3.G443; TOPHAM RW, 1992, BIOCHEM J, V284, P877, DOI 10.1042/bj2840877	31	20	20	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1651	1655		10.1074/jbc.275.3.1651	http://dx.doi.org/10.1074/jbc.275.3.1651			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636858	hybrid			2022-12-25	WOS:000084940000021
J	Kuner, P; Bohrmann, B; Tjernberg, LO; Naslund, J; Huber, G; Celenk, S; Gruninger-Leitch, F; Richards, JG; Jakob-Roetne, R; Kemp, JA; Nordstedt, C				Kuner, P; Bohrmann, B; Tjernberg, LO; Naslund, J; Huber, G; Celenk, S; Gruninger-Leitch, F; Richards, JG; Jakob-Roetne, R; Kemp, JA; Nordstedt, C			Controlling polymerization of beta-amyloid and prion-derived peptides with synthetic small molecule ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; ALZHEIMER-DISEASE; APOLIPOPROTEIN-E; CONGO RED; FIBRIL FORMATION; CYCLOSPORINE-A; PROTEIN; BINDING; COMPLEX; ACCELERATION	The Alzheimer beta-amyloid peptide (A beta) and a fragment of the prion protein have the capacity of forming amyloid-like fibrils when incubated under physiological conditions in vitro, Here we show that a small amyloid ligand, RO-47-1816/001, enhances this process severalfold by binding to amyloid molecules and apparently promote formation of the peptide-to-peptide bonds that join the monomers of the amyloid fibrils. This effect could be antagonized by other ligands, including analogues of RO-47-1816/001, as well as the structurally unrelated ligand Congo red. Analogues of RO-47-1816/001 with low affinity for amyloid did not display any antagonistic effect. In conclusion, these data suggest that synthetic molecules, and possibly also small natural substances present in the brain, may act in a chaperone-like fashion, promoting A beta polymerization and growth of amyloid fibrils in vitro and possibly also in vivo, Furthermore, we demonstrate that small organic molecules can be used to inhibit the action of amyloid-enhancing compounds.	F Hoffmann La Roche & Co Ltd, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland; Karolinska Hosp, Dept Clin Neurosci, Sect Drug Dependence Res, Lab Biochem & Mol Pharmacol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Clin Neurosci Occupat Therapy & Elderly Care, KFC Novum Plan 4, S-14186 Huddinge, Sweden	Roche Holding; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Nordstedt, C (corresponding author), F Hoffmann La Roche & Co Ltd, Div Pharma, Preclin Res, CH-4070 Basel, Switzerland.			Kuner, Pascal/0000-0001-6513-5414				Bohrmann B, 1999, J BIOL CHEM, V274, P15990, DOI 10.1074/jbc.274.23.15990; Briesewitz R, 1999, P NATL ACAD SCI USA, V96, P1953, DOI 10.1073/pnas.96.5.1953; Brown DR, 1997, EUR J NEUROSCI, V9, P1162, DOI 10.1111/j.1460-9568.1997.tb01470.x; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Forloni G, 1996, MOL CHEM NEUROPATHOL, V28, P163, DOI 10.1007/BF02815218; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Hardman J. G., 1996, GOODMAN GILMANS PHAR; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Hughes SR, 1996, P NATL ACAD SCI USA, V93, P2065, DOI 10.1073/pnas.93.5.2065; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; Klunk WE, 1998, LIFE SCI, V63, P1807, DOI 10.1016/S0024-3205(98)00454-8; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; SOTO C, 1995, FEBS LETT, V371, P110, DOI 10.1016/0014-5793(95)00863-5; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; TAYLOR DL, 1974, J HISTOCHEM CYTOCHEM, V22, P1105, DOI 10.1177/22.12.1105; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Tjernberg LO, 1997, J BIOL CHEM, V272, P12601, DOI 10.1074/jbc.272.19.12601; TURNELL WG, 1992, J MOL BIOL, V227, P1205, DOI 10.1016/0022-2836(92)90532-O; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Wood SJ, 1996, CHEM BIOL, V3, P949, DOI 10.1016/S1074-5521(96)90183-0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	42	72	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1673	1678		10.1074/jbc.275.3.1673	http://dx.doi.org/10.1074/jbc.275.3.1673			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636861	hybrid			2022-12-25	WOS:000084940000024
J	Mense, M; Dunbar, LA; Blostein, R; Caplan, MJ				Mense, M; Dunbar, LA; Blostein, R; Caplan, MJ			Residues of the fourth transmembrane segments of the Na,K-ATPase and the gastric H,H-ATPase contribute to cation selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; RAT-KIDNEY NA+,K+-ATPASE; ALPHA-SUBUNIT; FUNCTIONAL CONSEQUENCES; DIRECTED MUTAGENESIS; VANADATE; SITE; DOMAIN; STATE; PUMPS	We have generated protein chimeras to investigate the role of the fourth transmembrane segments (TM4) of the Na,K- and gastric H,K-ATPases in determining the distinct cation selectivities of these two pumps, Based on a helical wheel analysis, three residues of TM4 of the Na,K-ATPase were changed to their H,K-counterparts. A construct carrying three mutations in TM4 (L319F, N326Y, and T340S) and two control constructs were heterologously expressed in Xenopus laevis oocytes and in the pig kidney epithelial cell line LLC-PK1, Biochemical ATPase assays demonstrated a large sodium-independent ATPase activity at pH 6.0 for the pump carrying the TM4 substitutions, whereas the control constructs exhibited little or no activity in the absence of sodium, Furthermore, at pH 6.0 the K-1/2(Na+) shifted to 1.5 mM for the TM4 construct compared with 9.4 and 5.9 mM for the controls. In contrast, at pH 7.5 all three constructs had characteristics similar to wild type Na,K-ATPase, Large increases in K-1/2(K+) were observed for the TM4 construct compared with the control constructs both in two electrode voltage clamp experiments in Xenopus oocytes and in ATPase assays. ATPase assays also revealed a 10-fold shift in vanadate sensitivity for the TM4 construct. Based on these findings, it appears that the three identified TM4 residues play an important role in determining both the specific cation selectivities and the E-1/E-2 conformational equilibria of the Na,K- and H,K-ATPase.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada	Yale University; McGill University; McGill University	Mense, M (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	Martin.Mense@yale.edu		Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42136] Funding Source: Medline; PHS HHS [DR17433] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ANNER BM, 1994, MOL MEMBR BIOL, V11, P237, DOI 10.3109/09687689409160433; Blostein R, 1999, J BIOL CHEM, V274, P18374, DOI 10.1074/jbc.274.26.18374; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; DALY SE, 1994, J BIOL CHEM, V269, P23944; Doucet A, 1997, EXP NEPHROL, V5, P271; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; Friedrich T, 1996, BIOPHYS J, V71, P2486, DOI 10.1016/S0006-3495(96)79442-0; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V705, P38, DOI 10.1016/0167-4838(82)90333-8; KRIEG PA, 1987, P NATL ACAD SCI USA, V84, P2331, DOI 10.1073/pnas.84.8.2331; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; RAO R, 1993, J BIOL CHEM, V268, P6708; SACHS JR, 1987, J GEN PHYSIOL, V90, P291, DOI 10.1085/jgp.90.2.291; Schneeberger A, 1999, J MEMBRANE BIOL, V168, P221, DOI 10.1007/s002329900511; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SMITH RL, 1980, J BIOL CHEM, V255, P9852; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q	28	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1749	1756		10.1074/jbc.275.3.1749	http://dx.doi.org/10.1074/jbc.275.3.1749			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636871	hybrid			2022-12-25	WOS:000084940000034
J	Cvetkovic, B; Yang, B; Williamson, RA; Sigmund, CD				Cvetkovic, B; Yang, B; Williamson, RA; Sigmund, CD			Appropriate tissue- and cell-specific expression of a single copy human angiotensinogen transgene specifically targeted upstream of the HPRT locus by homologous recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; ESSENTIAL-HYPERTENSION; AFRICAN-AMERICANS; BLOOD-PRESSURE; HUMAN RENIN; GENE; MICE; VARIANT; ASSOCIATION; POPULATION	Development of experimental models by genetic manipulation in mice has proven to be very useful in determining the significance of particular genes in the development of or susceptibility to hypertension. Advances in molecular genetics, transgenic mouse technology, and physiological measurements in mice provided an opportunity to go a step further and develop models to analyze the physiological significance of specific gene variants potentially causing hypertension. In this report, we describe the development of a human angiotensinogen transgenic mouse model generated by targeting the human angiotensinogen gene upstream of the mouse HPRT locus by homologous recombination. The main benefit of this transgenic mouse model is that the human angiotensinogen gene is inserted into the mouse genome as a single copy at a predefined locus and in a specific orientation-a process that can be repeated utilizing other variants of this gene. We establish the validity of this approach by showing that the hAGT(hprt) mice have normal tissue- and cell-specific expression of the human angiotensinogen gene and normally produce and process the hAGT protein at physiological levels.	Univ Iowa, Coll Med, Dept Internal Med & Physiol & Biophys, Mol Biol Interdisciplinary Program,Med Lab 2191, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Obstet & Gynecol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Sigmund, CD (corresponding author), Univ Iowa, Coll Med, Dept Internal Med & Physiol & Biophys, Mol Biol Interdisciplinary Program,Med Lab 2191, Iowa City, IA 52242 USA.		Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048058, R37HL048058, P50HL055006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55006, HL48058] Funding Source: Medline; NIDDK NIH HHS [DK52617] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT CL, 1993, BIOCHEM BIOPH RES CO, V197, P833, DOI 10.1006/bbrc.1993.2554; BLOEM LJ, 1995, J CLIN INVEST, V95, P948, DOI 10.1172/JCI117803; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; Corvol P, 1999, HYPERTENSION, V33, P1324, DOI 10.1161/01.HYP.33.6.1324; CVETKOVIC B, 2000, IN PRESS KIDNEY INT; Davisson RL, 1997, J CLIN INVEST, V99, P1258, DOI 10.1172/JCI119283; Davisson RL, 1998, CIRC RES, V83, P1047, DOI 10.1161/01.RES.83.10.1047; ELLISON KE, 1989, J CLIN INVEST, V83, P1941, DOI 10.1172/JCI114102; FORNAGE M, 1995, HUM GENET, V96, P295; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; Hatada S, 1999, J BIOL CHEM, V274, P948, DOI 10.1074/jbc.274.2.948; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; Hingorani AD, 1996, HYPERTENSION, V28, P907, DOI 10.1161/01.HYP.28.5.907; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; ISHIGAMI T, 1995, CIRCULATION, V91, P951, DOI 10.1161/01.CIR.91.4.951; IWAI N, 1995, HYPERTENSION, V25, P688, DOI 10.1161/01.HYP.25.4.688; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Jeunemaitre X, 1999, Curr Hypertens Rep, V1, P31, DOI 10.1007/s11906-999-0071-0; Jeunemaitre X, 1993, J HYPERTENS, V11, P80; KATSUYA T, 1995, LANCET, V345, P1600, DOI 10.1016/S0140-6736(95)90115-9; LIFTON RP, 1993, J HYPERTENS, V11, P231, DOI 10.1097/00004872-199303000-00002; Morgan T, 1997, J CLIN INVEST, V100, P1406, DOI 10.1172/JCI119661; ROTIMI C, 1994, HYPERTENSION, V24, P591, DOI 10.1161/01.HYP.24.5.591; RUTLEDGE DR, 1994, BIOCHEM MOL BIOL INT, V34, P1271; SHAWWHITE JR, 1993, TRANSGENIC RES, V2, P1, DOI 10.1007/BF01977675; Sinn PL, 1999, AM J PHYSIOL-RENAL, V277, pF634, DOI 10.1152/ajprenal.1999.277.4.F634; Stec DE, 1999, J BIOL CHEM, V274, P21285, DOI 10.1074/jbc.274.30.21285; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Yang GY, 1998, HYPERTENSION, V31, P734, DOI 10.1161/01.HYP.31.3.734; YANG GY, 1994, J BIOL CHEM, V269, P32497	31	39	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1073	1078		10.1074/jbc.275.2.1073	http://dx.doi.org/10.1074/jbc.275.2.1073			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625648	hybrid			2022-12-25	WOS:000084836600052
J	Kimura, A; Singh, D; Wawrousek, EF; Kikuchi, M; Nakamura, M; Shinohara, T				Kimura, A; Singh, D; Wawrousek, EF; Kikuchi, M; Nakamura, M; Shinohara, T			Both PCE-1/RX and OTX/CRX interactions are necessary for photoreceptor-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; HOMEOBOX GENE; HOMEODOMAIN PROTEINS; BOX GENE; PROMOTER; RETINA; SITE; TRANSCRIPTION; DROSOPHILA; MUTATIONS	RX, a homeodomain-containing protein essential for proper eye development (Mathers, P. H. Grinberg, A., Mahon, K. A., and Jamrich, M. (1997) Nature 387, 603-607), binds to the photoreceptor conserved element-1 (PCE-1/Ret 1) in the photoreceptor cell-specific arrestin promoter and stimulates gene expression. RX is found in many retinal cell types including photoreceptor cells. Another homeodomain-containing protein, CRX, which binds to the OTX element to stimulate promoter activity, is found exclusively in photoreceptor cells (Chen, S., Wang, Q. L., Nie, Z., Sun, H., Lennon, G., Copeland, N. G., Gillbert, D. J. Jenkins, N. A., and Zack, D. J. (1997) Neuron 19, 1017-1030; Furukawa, T., Morrow, E. M., and Cepko, C. L. (1997) Cell 91, 531-541). Binding assay and cell culture studies indicate that both PCE-1 and OTX elements and at least two different regulatory factors RX and CRX are necessary for high level, photoreceptor cell-restricted gene expression. Thus, photoreceptor specificity can be achieved by multiple promoter elements interacting with a combination of both photoreceptor-specific regulatory factors and factors present in closely related cell lineages.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Ophthalmol,Ctr Ophthalm Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Ophthalmol,Cerebrovasc & NeuroSci Res Inst, Boston, MA 02115 USA; NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Shinohara, T (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Ophthalmol,Ctr Ophthalm Res, Boston, MA 02115 USA.		Wawrousek, Eric/A-4547-2008	Shinohara, Toshimichi/0000-0002-7197-9039	NATIONAL EYE INSTITUTE [Z01EY000285] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Boatright JH, 1997, EXP EYE RES, V64, P269, DOI 10.1006/exer.1996.0222; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; DEJONG R, 1993, NUCLEIC ACIDS RES, V21, P4711, DOI 10.1093/nar/21.20.4711; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Innis MA, 1990, PCR PROTOCOLS GUIDE; Kennedy BN, 1998, J BIOL CHEM, V273, P5591, DOI 10.1074/jbc.273.10.5591; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LEGENDRE N, 1990, Biotechniques, V9, P788; Martinez JA, 1998, BIOCHEM BIOPH RES CO, V250, P175, DOI 10.1006/bbrc.1998.9261; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; OPSTELTEN DJE, 1991, MECH DEVELOP, V34, P29, DOI 10.1016/0925-4773(91)90089-O; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, CELL, V59, P553; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Yu X, 1996, J NEUROCHEM, V67, P2494	29	113	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1152	1160		10.1074/jbc.275.2.1152	http://dx.doi.org/10.1074/jbc.275.2.1152			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625658	hybrid			2022-12-25	WOS:000084836600062
J	Miller, SP; Chen, RD; Karschnia, EJ; Romfo, C; Dean, A; LaPorte, DC				Miller, SP; Chen, RD; Karschnia, EJ; Romfo, C; Dean, A; LaPorte, DC			Locations of the regulatory sites for isocitrate dehydrogenase kinase/phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ML308; ATP-BINDING-SITE; KINASE PHOSPHATASE; ACTIVE-SITE; PHOSPHORYLATION; INACTIVATION; SENSITIVITY; PROTEINS; CYCLE	Isocitrate dehydrogenase (IDH)(1) of Escherichia coli is regulated by a bifunctional protein, IDH kinase/phosphatase, In this paper, we demonstrate that the effecters controlling these activities belong to two distinct classes that differ in mechanism and in the locations of their binding sites. NADPH and isocitrate are representative members of one of these effector classes. NADPH inhibits both IDH kinase and IDH phosphatase, whereas isocitrate inhibits only IDH kinase, Isocitrate can "activate" IDH phosphatase by reversing product inhibition by dephospho-IDH. Mutations in icd, which encodes IDH, had parallel effects on the binding of these ligands to the IDH active site and on their effects on IDH kinase and phosphatase, indicating that these ligands regulate IDH kinase/phosphatase through the IDH active site. Kinetic analyses suggested that isocitrate and NADPH prevent formation of the complex between IDH kinase/phosphatase and its protein substrate. AMP, 3-phosphoglycerate, and pyruvate represent a class of regulatory ligands that is distinct from that which includes isocitrate and NADPH. These ligands bind directly to IDH kinase/phosphatase, a conclusion which is supported by the observation that they inhibit the IDH-independent ATPase activity of this enzyme. These effector classes can also be distinguished by the observation that mutant derivatives of IDH kinase/phosphatase expressed from aceK3 and aceK4 exhibited dramatic changes in their responses to AMP, 3-phosphoglycerate, and pyruvate but not to NADPH and isocitrate.	Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	LaPorte, DC (corresponding author), Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA.	DAVID-L@LENTI.MED.UMN.EDU			NIDDK NIH HHS [DK40486] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040486] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELSON JT, 1981, ANAL BIOCHEM, V116, P357, DOI 10.1016/0003-2697(81)90371-7; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BENNETT PM, 1975, J GEN MICROBIOL, V87, P37, DOI 10.1099/00221287-87-1-37; BORTHWICK AC, 1984, BIOCHEM J, V222, P797, DOI 10.1042/bj2220797; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; Chen RD, 1996, PROTEIN SCI, V5, P287; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DEAN AM, 1989, J BIOL CHEM, V264, P20482; FinerMoore J, 1997, BIOCHEMISTRY-US, V36, P13890, DOI 10.1021/bi9711691; GARNAK M, 1979, SCIENCE, V203, P1111, DOI 10.1126/science.34215; GARNAK M, 1979, J BIOL CHEM, V254, P7915; Graves D J, 1980, Methods Enzymol, V64, P325; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; IKEDA T, 1991, J BACTERIOL, V173, P1801, DOI 10.1128/jb.173.5.1801-1806.1991; IKEDA TP, 1992, J BACTERIOL, V174, P1414, DOI 10.1128/jb.174.4.1414-1416.1992; KORNBERG HL, 1957, BIOCHIM BIOPHYS ACTA, V24, P651, DOI 10.1016/0006-3002(57)90268-8; KORNBERG HL, 1966, BIOCHEM J, V99, P1; KOSHLAND DE, 1985, CURR TOP CELL REGUL, V27, P13; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE DC, 1983, NATURE, V305, P286, DOI 10.1038/305286a0; LAPORTE DC, 1984, J BIOL CHEM, V259, P4068; LAPORTE DC, 1993, J CELL BIOCHEM, V51, P14, DOI 10.1002/jcb.240510104; LAPORTE DC, 1985, J BIOL CHEM, V260, P563; LAPORTE DC, 1985, J BIOL CHEM, V260, P5291; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miller SP, 1996, J BIOL CHEM, V271, P19124, DOI 10.1074/jbc.271.32.19124; NIMMO GA, 1984, EUR J BIOCHEM, V141, P409, DOI 10.1111/j.1432-1033.1984.tb08206.x; STUELAND CS, 1987, J BIOL CHEM, V262, P16095; STUELAND CS, 1989, J BIOL CHEM, V264, P13775; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; VARELA I, 1988, FEBS LETT, V231, P361, DOI 10.1016/0014-5793(88)80850-0	32	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					833	839		10.1074/jbc.275.2.833	http://dx.doi.org/10.1074/jbc.275.2.833			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625615	hybrid			2022-12-25	WOS:000084836600019
J	Huang, C; Morales, G; Vagi, A; Chanasyk, K; Ferrazzi, M; Burklow, C; Qiu, WT; Feyfant, E; Sali, A; Stevens, RL				Huang, C; Morales, G; Vagi, A; Chanasyk, K; Ferrazzi, M; Burklow, C; Qiu, WT; Feyfant, E; Sali, A; Stevens, RL			Formation of enzymatically active, homotypic, and heterotypic tetramers of mouse mast cell tryptases - Dependence on a conserved Trp-rich domain on the surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG TRYPTASE; HUMAN-SKIN TRYPTASE; MOLECULAR-CLONING; SERINE PROTEASES; SPONTANEOUS INACTIVATION; COMPLEMENTARY-DNA; PURIFICATION; EXPRESSION; CDNA; GENE	Mouse mast cell protease (mMCP) 6 and mMCP-7 are homologous tryptases stored in granules as macromolecular complexes with heparin and/or chondroitin sulfate E containing serglycin proteoglycans, When pro-mMCP-7 and pseudozymogen forms of this tryptase and mMCP-6 were separately expressed in insect cells, all three recombinant proteins were secreted into the conditioned medium as properly folded, enzymatically inactive 33-kDa monomers, However, when their propeptides were removed, mMCP 6 and mMCP-7 became enzymatically active and spontaneously assumed an similar to 150-kDa tetramer structure. Heparin was not required for this structural change. When incubated at 37 degrees C, recombinant mMCP-7 progressively lost its enzymatic activity in a time-dependent manner. Its N-linked glycans helped regulate the thermal stability of mMCP-7. However, the ability of this tryptase to form the enzymatically active tetramer was more dependent on a highly conserved Trp-rich domain on its surface. Although recombinant mMCP-6 and mMCP-7 preferred to form homotypic tetramers, these tryptases readily formed heterotypic tetramers in vitro. This latter finding indicates that the tetramer structural unit is a novel way the mast cell uses to assemble varied combinations of tryptases.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Rockefeller Univ, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Rockefeller University	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,75 Francis St, Boston, MA 02115 USA.	rstevens@rics.bwh.harvard.edu			NHLBI NIH HHS [HL-36110, HL-63284] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063284, P01HL036110] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Addington AK, 1996, BIOCHEMISTRY-US, V35, P13511, DOI 10.1021/bi960042t; BRAGANZA VJ, 1991, BIOCHEMISTRY-US, V30, P4997, DOI 10.1021/bi00234a023; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHU W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P83, DOI 10.1016/0167-4838(92)90340-J; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; Erba F, 1998, PEPTIDES, V19, P437, DOI 10.1016/S0196-9781(97)00423-3; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; Friend DS, 1998, J IMMUNOL, V160, P5537; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HARVIMA IT, 1988, BIOCHIM BIOPHYS ACTA, V957, P71, DOI 10.1016/0167-4838(88)90158-6; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Hunt JE, 1997, J BIOL CHEM, V272, P29158, DOI 10.1074/jbc.272.46.29158; IDE H, 1995, J BIOCHEM-TOKYO, V118, P210, DOI 10.1093/oxfordjournals.jbchem.a124880; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MURAKUMO Y, 1995, BIOCHEM J, V309, P921, DOI 10.1042/bj3090921; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; SCHECHTER NM, 1995, BIOCHEMISTRY-US, V34, P10628, DOI 10.1021/bi00033a038; SCHECHTER NM, 1993, BIOCHEMISTRY-US, V32, P2617, DOI 10.1021/bi00061a020; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1990, J IMMUNOL, V144, P2304; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; Svendsen L., 1972, THROMB RES, V1, P267, DOI 10.1016/0049-3848(72)90023-0; TRONG HL, 1989, BIOCHEMISTRY-US, V28, P391; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784	49	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					351	358		10.1074/jbc.275.1.351	http://dx.doi.org/10.1074/jbc.275.1.351			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617625	hybrid			2022-12-25	WOS:000085951600049
J	Naltner, A; Ghaffari, M; Whitsett, JA; Yan, C				Naltner, A; Ghaffari, M; Whitsett, JA; Yan, C			Retinoic acid stimulation of the human surfactant protein B promoter is thyroid transcription factor 1 site-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; NUCLEAR RECEPTORS; RESPONSE ELEMENT; BINDING PROTEIN; VITAMIN-A; BRONCHOPULMONARY DYSPLASIA; HISTONE ACETYLTRANSFERASE; TUBULAR MYELIN; DIRECT REPEATS; CO-REPRESSOR	Surfactant B (SP-B) is a 79-amino acid peptide critical to postnatal respiratory adaptation. Expression of SP-B by respiratory epithelial cells is regulated by developmental and hormonal influences at the level of gene transcription. Previous studies supported the role of retinoic acids (RA) and their receptors (RARs) in SP-B gene transcription. In the present study, RAR alpha was detected in mouse alveolar type II epithelial cells where SP-B is synthesized and processed. Deletion and site-specific mutagenesis analysis identified clustered retinoic acid-responsive element sites in the 5'-flanking enhancer region of the hSP-B gene that bound RAR alpha proteins. RAR coactivators ACTR, SRC-1, and transcriptional intermediary factor 2 (TIF2) stimulated human (h) SP-B promoter activity in a dose-dependent fashion in pulmonary adenocarcinoma H441 cells. In addition, an RAR-associated protein, CREB-binding protein (CBP), potentiated the effects of RAR on hSP-B promoter activity in H441 cells. Importantly, RA stimulation of the hSP-B promoter depends on tissue-specific thyroid transcription factor (TTF-1) DNA-binding sites. TTF-1 protein synergistically stimulated the hSP-B promoter with RAR alpha, CBP, and nuclear receptor coactivators in H441 cells. In addition, TTF-1 interacted directly with RAR alpha and TIF2 in the mammalian two-hybrid system. These findings support a model in which RAR/retinoid X receptor, TTF-1, coactivators, and CBP form a transcription activation complex in the upstream enhancer region of the hSP-B gene.	Childrens Hosp, Med Ctr, Div Pulm Biol, TCHRF, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Yan, C (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, TCHRF, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NHLBI NIH HHS [HL-61803, HL-56387, HL38859, R01 HL061803] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061803, R01HL038859, R37HL038859, P01HL056387, P50HL056387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballard PL, 1996, AM J RESP CELL MOL, V14, P599, DOI 10.1165/ajrcmb.14.6.8652188; BAMMISTER AJ, 1996, NATURE, V384, P641; Bogue CW, 1996, AM J PHYSIOL-LUNG C, V271, pL862, DOI 10.1152/ajplung.1996.271.5.L862; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; George TN, 1998, AM J PHYSIOL-LUNG C, V274, pL560, DOI 10.1152/ajplung.1998.274.4.L560; GEORGE TN, 1997, PEDIATR RES, V41, P693; Ghaffari M, 1999, AM J PHYSIOL-LUNG C, V276, pL398, DOI 10.1152/ajplung.1999.276.3.L398; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JACOBS KA, 1987, J BIOL CHEM, V262, P9808; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Massaro GD, 1997, NAT MED, V3, P675, DOI 10.1038/nm0697-675; Massaro GD, 1996, AM J PHYSIOL-LUNG C, V270, pL305, DOI 10.1152/ajplung.1996.270.2.L305; MASUYAMA H, 1995, BIOL NEONATE, V67, P264, DOI 10.1159/000244174; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; METZLER MD, 1993, ENDOCRINOLOGY, V133, P1990, DOI 10.1210/en.133.5.1990; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; OREILLY MA, 1991, AM J PHYSIOL, V260, pL37, DOI 10.1152/ajplung.1991.260.2.L37; Panariello L, 1996, J BIOL CHEM, V271, P25524, DOI 10.1074/jbc.271.41.25524; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; POULAIN FR, 1992, AM J PHYSIOL, V262, pL730, DOI 10.1152/ajplung.1992.262.6.L730; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; SHENAI JP, 1981, J PEDIATR-US, V99, P302, DOI 10.1016/S0022-3476(81)80484-2; SHENAI JP, 1985, PEDIATR RES, V19, P185, DOI 10.1203/00006450-198502000-00007; SHENAI JP, 1987, J PEDIATR-US, V111, P269, DOI 10.1016/S0022-3476(87)80086-0; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; WILLIAMS MC, 1991, AM J RESP CELL MOL, V5, P41, DOI 10.1165/ajrcmb/5.1.41; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Yan C, 1998, AM J PHYSIOL-LUNG C, V275, pL239, DOI 10.1152/ajplung.1998.275.2.L239; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; YAN C, 1992, P NATL ACAD SCI USA, V89, P8859, DOI 10.1073/pnas.89.19.8859; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	64	53	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					56	62		10.1074/jbc.275.1.56	http://dx.doi.org/10.1074/jbc.275.1.56			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617585	hybrid			2022-12-25	WOS:000085951600009
J	Onodera, S; Kaneda, K; Mizue, Y; Koyama, Y; Fujinaga, M; Nishihira, J				Onodera, S; Kaneda, K; Mizue, Y; Koyama, Y; Fujinaga, M; Nishihira, J			Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; COLLAGENASE GENE-EXPRESSION; EPIDERMAL GROWTH-FACTOR; HUMAN SKIN FIBROBLASTS; TISSUE INHIBITOR; FACTOR MIF; TRANSCRIPTIONAL ACTIVATION; INTERSTITIAL COLLAGENASE; TRANSDUCTION PATHWAYS; STROMELYSIN PROMOTER	Neutral matrix metalloproteinases (MMPs) are responsible for the pathological features of rheumatoid arthritis (RA) such as degradation of cartilage. We herein show the up-regulation of MMP-1 (interstitial collagenase) and MMP-3 (stromelysin) mRNAs of cultured synovial fibroblasts retrieved from rheumatoid arthritis (RA) patients in response to macrophage migration inhibitory factor (MIF). The elevation of MMP-1 and MMP-3 mRNA was dose-dependent and started at 6 h post-stimulation by MIF, reached the maximum level at 24 h, and was sustained at least up to 36 h. Interleukin (IL)-1 beta mRNA was also up-regulated by MIF. These events were preceded by up-regulation of c-jun and c-fos mRNA. Tissue inhibitor of metalloproteinase (TIMP)-1, a common inhibitor of these proteases, was slightly upregulated by MIF, Similarly, mRNA up-regulation of MMP-1 and MMP-3 was observed in the synovial fibroblasts of patients with osteoarthritis. However, their expression levels were much lower than those of RA synovial fibroblasts. The mRNA up-regulation by MIF was inhibited by the tyrosine kinase inhibitors genestein and herbimycin A, as well as the protein kinase C inhibitors staurosporine and H-7. On the other hand, the inhibition was not seen after the addition of the cyclic AMP dependent kinase inhibitor, H-8. The mRNA upregulation of MMPs was also inhibited by curcumin, an inhibitor of transcription factor AP-1, whereas interleukin-1 receptor antagonist, an IL-1 receptor antagonist, failed to inhibit the mRNA up-regulation, Considering these results, it is suggested that 1) MTF plays an important role in the tissue destruction of rheumatoid joints via induction of the proteinases, and 2) MIF up-regulates MMP-1 and MMP-3 via tyrosine kinase-, protein kinase C-, and AP-1- dependent pathways, bypassing IL-1 beta signal transduction.	Hokkaido Univ, Sch Med, Cent Res Inst, Sapporo, Hokkaido 060, Japan; Hokkaido Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 060, Japan; Hokkaido Univ, Sch Med, Dept Orthopaed, Sapporo, Hokkaido 060, Japan; Sapporo Immunodiagnost Labs, Sapporo, Hokkaido 001, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Nishihira, J (corresponding author), Hokkaido Univ, Sch Med, Cent Res Inst, Sapporo, Hokkaido 060, Japan.	j_nisihi@med.hokudai.ac.jp		Mizue, Yuka/0000-0002-2208-0772				ALVAROGRACIA JM, 1990, J CLIN INVEST, V86, P1790, DOI 10.1172/JCI114908; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Bendrat K, 1997, BIOCHEMISTRY-US, V36, P15356, DOI 10.1021/bi971153a; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Callaghan MM, 1996, J LEUKOCYTE BIOL, V59, P125, DOI 10.1002/jlb.59.1.125; CASE JP, 1990, J IMMUNOL, V145, P3755; Cawston T.E., 1986, PROTEINASE INHIBITOR, P589; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; DAYER JM, 1977, SCIENCE, V195, P181, DOI 10.1126/science.188134; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; EVANSON JM, 1968, J CLIN INVEST, V47, P2639, DOI 10.1172/JCI105947; EVERSON JM, 1967, SCIENCE, V158, P499, DOI 10.1126/science.158.3800.499; FINI ME, 1994, J BIOL CHEM, V269, P11291; FIRESTEIN GS, 1991, ARTHRITIS RHEUM, V34, P1094, DOI 10.1002/art.1780340905; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GAY S, 1993, ANN RHEUM DIS, V52, pS39, DOI 10.1136/ard.52.Suppl_1.S39; GAY S, 1989, RHEUMATOL INT, V9, P105; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRAVALLESE EM, 1991, ARTHRITIS RHEUM-US, V34, P1076, DOI 10.1002/art.1780340903; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; IWAKURA Y, 1995, J IMMUNOL, V155, P1588; Jumblatt MM, 1997, CURR EYE RES, V16, P428, DOI 10.1076/ceyr.16.5.428.7048; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Keyszer G, 1998, ARTHRITIS RHEUM, V41, P1378, DOI 10.1002/1529-0131(199808)41:8<1378::AID-ART6>3.0.CO;2-J; Kishima Koji, 1994, Medical Journal of Kinki University, V19, P47; KLARESKOG L, 1982, SCAND J IMMUNOL, V15, P501, DOI 10.1111/j.1365-3083.1982.tb00676.x; KRANE SM, 1986, MED CLIN N AM, V70, P263, DOI 10.1016/S0025-7125(16)30953-1; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; Lambert CA, 1998, J BIOL CHEM, V273, P23143, DOI 10.1074/jbc.273.36.23143; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MACKAY AR, 1992, INVAS METAST, V12, P168; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; Mikulowska A, 1997, J IMMUNOL, V158, P5514; Muller-Ladner U, 1996, Curr Opin Rheumatol, V8, P210; MUNOZ E, 1990, J IMMUNOL, V144, P964; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Nishihira J, 1998, BIOCHEM BIOPH RES CO, V243, P538, DOI 10.1006/bbrc.1998.8123; NISHIHIRA J, 1995, BBA-PROTEIN STRUCT M, V1247, P159, DOI 10.1016/0167-4838(94)00215-3; NISHINO T, 1995, MOL MED, V1, P781, DOI 10.1007/BF03401892; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1986, J BIOL CHEM, V261, P14245; Onodera S, 1999, CYTOKINE, V11, P163, DOI 10.1006/cyto.1998.0402; REITAMO S, 1994, J CLIN INVEST, V94, P2489, DOI 10.1172/JCI117618; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SUBDECK BD, 1994, J BIOL CHEM, V269, P30022; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Swope M, 1998, EMBO J, V17, P3534, DOI 10.1093/emboj/17.13.3534; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; Vincenti MP, 1996, ARTHRITIS RHEUM-US, V39, P574, DOI 10.1002/art.1780390406; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Watkins DN, 1997, AM J RESP CELL MOL, V16, P629, DOI 10.1165/ajrcmb.16.6.9191464; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WU JJ, 1991, J BIOL CHEM, V266, P5625; YOUNG CL, 1984, ARTHRITIS RHEUM, V27, P32, DOI 10.1002/art.1780270106	71	211	237	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					444	450		10.1074/jbc.275.1.444	http://dx.doi.org/10.1074/jbc.275.1.444			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617637	hybrid			2022-12-25	WOS:000085951600061
J	Sajid, M; Withers-Martinez, C; Blackman, MJ				Sajid, M; Withers-Martinez, C; Blackman, MJ			Maturation and specificity of Plasmodium falciparum subtilisin-like protease-1, a malaria merozoite subtilisin-like serine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE PROTEIN-1; INTRAERYTHROCYTIC STAGE; SECRETORY PATHWAY; PROPEPTIDE; LOCALIZATION; INVASION; GLYCOSYLATION; TRANSLOCATION; ENDOPROTEASE; REQUIREMENTS	Plasmodium falciparum subtilisin-like protease-1 (Pf-SUB-1) is a protein belonging to the subtilisin-like superfamily of serine proteases (subtilases), PfSUB-1 undergoes extensive posttranslational proteolytic processing. The primary translation product is converted in the parasite endoplasmic reticulum to p54. This is further processed to p47, which accumulates in secretory organelles within the merozoite, Here, we present a detailed study of this processing. In vitro translated PfSUB-1 showed no capacity to undergo autocatalytic processing. However, parasite extracts contain a protease that cleaves the in vitro translated pro-protein between Asp(219) and Asn(220) to form two products of 31 (p31) and 54 kDa; the latter was indistinguishable from authentic p54 and remained complexed with p31 in a noncovalent interaction characteristic of that between a subtilase prodomain and its cognate catalytic domain. Cross-linking studies showed that this complex also exists in the parasite. Expression of PfSUB-1 in recombinant baculovirus also resulted in processing to p54, Mutation of the predicted active site serine abolished processing. Recombinant p54 was secreted in a complex with p31, and could be further converted to p47 in vitro. Conversion required calcium, was an intramolecular autocatalytic process, and involved a second cleavage between Asp(251) and Ala(252). A decapeptide based on sequence flanking Asp(219) was efficiently cleaved by recombinant PfSUB-1. We conclude that Pf-SUB-1. is a subtilase with an unusual substrate specificity and that it is activated by two autocatalytic processing steps.	Natl Inst Med Res, Div Parasitol, London NW7 1AA, England	MRC National Institute for Medical Research	Blackman, MJ (corresponding author), Natl Inst Med Res, Div Parasitol, Mill Hill, London NW7 1AA, England.							Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Barale JC, 1999, P NATL ACAD SCI USA, V96, P6445, DOI 10.1073/pnas.96.11.6445; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P29, DOI 10.1016/0166-6851(91)90127-R; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; BLACKMAN MJ, 1993, MOL BIOCHEM PARASIT, V62, P103, DOI 10.1016/0166-6851(93)90182-W; BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; BRAUNBRETON C, 1992, P NATIONAL ACADEMY S, V89, P9647; Cheng D, 1999, J BIOL CHEM, V274, P22805, DOI 10.1074/jbc.274.32.22805; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DIECKMANNSCHUPPERT A, 1992, EUR J BIOCHEM, V205, P815, DOI 10.1111/j.1432-1033.1992.tb16846.x; DLUZEWSKI AR, 1986, EXP PARASITOL, V62, P416, DOI 10.1016/0014-4894(86)90050-0; Gowda DC, 1997, J BIOL CHEM, V272, P6428, DOI 10.1074/jbc.272.10.6428; Hackett F, 1999, MOL BIOCHEM PARASIT, V103, P183, DOI 10.1016/S0166-6851(99)00122-X; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRTZLIN J, 1995, EUR J BIOCHEM, V232, P765, DOI 10.1111/j.1432-1033.1995.tb20871.x; Howard RF, 1998, MOL BIOCHEM PARASIT, V92, P111, DOI 10.1016/S0166-6851(97)00238-7; JACOBS M, 1993, MOL MICROBIOL, V8, P957, DOI 10.1111/j.1365-2958.1993.tb01640.x; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; KIMARA EA, 1996, J BIOL CHEM, V271, P14452; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; LAU JTY, 1983, J BIOL CHEM, V258, P5255; Li YY, 1996, J MOL BIOL, V262, P591, DOI 10.1006/jmbi.1996.0537; Marshall VM, 1997, INFECT IMMUN, V65, P4460, DOI 10.1128/IAI.65.11.4460-4467.1997; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MCCOLL DJ, 1994, MOL BIOCHEM PARASIT, V68, P53, DOI 10.1016/0166-6851(94)00149-9; MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.mi.47.100193.004133; MCPHERSON RA, 1993, MOL BIOCHEM PARASIT, V62, P233, DOI 10.1016/0166-6851(93)90112-B; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; RAGGE K, 1990, MOL BIOCHEM PARASIT, V42, P93, DOI 10.1016/0166-6851(90)90116-4; Rosenthal PJ, 1999, ADV PARASIT, V43, P105, DOI 10.1016/S0065-308X(08)60242-0; Scougall K, 1998, BIOCHEM J, V334, P531, DOI 10.1042/bj3340531; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; Shinde U., 1995, INTRAMOLECULAR CHAPE, P1; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; STAFFORD WHL, 1994, MOL BIOCHEM PARASIT, V66, P157, DOI 10.1016/0166-6851(94)90048-5; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; TILNEY LG, 1993, MOL BIOL, V4, P323; Volkov A, 1996, J MOL BIOL, V262, P595, DOI 10.1006/jmbi.1996.0538; Ward GE, 1997, PARASITOL TODAY, V13, P57, DOI 10.1016/S0169-4758(96)10080-6; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; WITHERSMARTINEZ C, 1999, IN PRESS PROTEIN ENG	50	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					631	641		10.1074/jbc.275.1.631	http://dx.doi.org/10.1074/jbc.275.1.631			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617661	hybrid			2022-12-25	WOS:000085951600085
J	Torres, L; Avila, MA; Carretero, MV; Latasa, MU; Caballeria, J; Lopez-Rodas, G; Boukaba, A; Lu, SC; Franco, L; Mato, JM				Torres, L; Avila, MA; Carretero, MV; Latasa, MU; Caballeria, J; Lopez-Rodas, G; Boukaba, A; Lu, SC; Franco, L; Mato, JM			Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation: implications for MAT1A silencing during transformation	FASEB JOURNAL			English	Article						S-adenosylmethionine synthesis; DNA methylation; tissue-specific expression; liver cirrhosis; hepatocarcinoma	S-ADENOSYLMETHIONINE SYNTHETASE; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; MESSENGER-RNA; HEPATOCYTES; DEACETYLASE; INHIBITION; GROWTH; INJURY; MECP2	Methionine adenoyltransferase (MAT) is the enzyme that catalyses the synthesis of S-adenosylmethionine (AdoMet), the main donor of methyl groups in the cell. In mammals MAT is the product of two genes, MAT1A and MAT2A. MAT1A is expressed only in the mature liver whereas fetal hepatocytes, extrahepatic tissues and liver cancer cells express MAT2A. The mechanisms behind the tissue and differentiation state specific MAT1A expression are no known. In present work we examined MAT1A promoter methylation status by means of methylation sensitive restriction enzyme analysis. Our data indicate that MAT1A promoter is hypomethylated in liver and hypomethylated in kidney and fetal rat hepatocytes indicating that this modification is tissue specific and developmentally regulated. Immunoprecipitation of mononucleosomes from liver and kidney tissues with antibodies mainly specific to acetylated histone H4 and subsequent Southern blot analysis with MAT1A promoter probe demonstrated that MAT1A expression is linked to elevated levels of chromatin acetylation. Early changes in MAT1A methylation are already observed in the precancerous cirrhotic livers from rats, which slow reduced MAT1A expression. Human hepatoma cell lines which MAT1A is not expressed were also hypermethylated at this locus. Finally we demonstrate that MAT1A expression is reactivated in the human hepatoma cell line hepG2 treated with 5-aza-2'-deoxycytidine or the histone deacetylase inhibitor trichostatin, suggesting a role for DNA hypermethylation and histone deaceytylation in MAT1A silencing.-Torres, L., Avila, M. A, Carretero, M. V., Latasa, M. U., Caballeria, J., Lopez-Rodas, G., Boukaba, A., Lu, S. C., Franco, I., Mato J.M. Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation; im plications for MAT1A silencing during transformation.	Univ Navarra, Fac Med, Dept Med Interna, Div Hepatol & Terapia Gen, Navarra 31008, Spain; Hosp Clin Barcelona, Serv Hepatol, Barcelona 08036, Spain; Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain; Univ So Calif, Sch Med, Dept Med, Ctr Liver Dis Res, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Med, Div Gastrointestinal Liver Dis, Los Angeles, CA 90033 USA	University of Navarra; University of Barcelona; Hospital Clinic de Barcelona; University of Valencia; University of Southern California; University of Southern California	Mato, JM (corresponding author), Univ Navarra, Fac Med, Dept Med Interna, Div Hepatol & Terapia Gen, Navarra 31008, Spain.	jmmato@unav.es	MATO, JOSE/A-5187-2011; Torres, Luis/AAB-2403-2019; Avila, Matias A/Y-6342-2019; LOPEZ-RODAS, GERARDO/I-1349-2015	MATO, JOSE/0000-0003-1264-3153; Avila, Matias A/0000-0001-6570-3557; Franco, Luis/0000-0001-9610-6448; LOPEZ-RODAS, GERARDO/0000-0001-8367-653X; Latasa, Maria Ujue/0000-0002-0878-1337	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051719] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51719] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez L, 1997, J BIOL CHEM, V272, P22875, DOI 10.1074/jbc.272.36.22875; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; Bender CM, 1998, CANCER RES, V58, P95; Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; Carretero MV, 1998, FEBS LETT, V439, P55, DOI 10.1016/S0014-5793(98)01335-0; CLAYTON AL, 1993, FEBS LETT, V336, P23, DOI 10.1016/0014-5793(93)81601-U; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; Counts JL, 1997, MOL CARCINOGEN, V18, P97, DOI 10.1002/(SICI)1098-2744(199702)18:2<97::AID-MC5>3.0.CO;2-N; CraneRobinson C, 1997, METHODS, V12, P48, DOI 10.1006/meth.1997.0446; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Gil B, 1996, HEPATOLOGY, V24, P876; HOFFMAN RM, 1983, BIOCHIM BIOPHYS ACTA, V738, P49, DOI 10.1016/0304-419X(84)90019-2; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MUDD SH, 1958, J BIOL CHEM, V231, P481; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Sun L, 1997, JPN J CANCER RES, V88, P1165, DOI 10.1111/j.1349-7006.1997.tb00345.x; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; TSAO JL, 1991, ANAL BIOCHEM, V197, P137, DOI 10.1016/0003-2697(91)90369-5; TSUDA H, 1988, GASTROENTEROLOGY, V95, P1664, DOI 10.1016/S0016-5085(88)80093-3; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; VARELAMOREIRAS G, 1995, HEPATOLOGY, V22, P1310, DOI 10.1016/0270-9139(95)90644-4; VELASCO JA, 1994, ONCOGENE, V9, P2065; YASUI H, 1992, CANCER RES, V52, P6810; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	35	69	70	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					95	102		10.1096/fasebj.14.1.95	http://dx.doi.org/10.1096/fasebj.14.1.95			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627284				2022-12-25	WOS:000084784700012
J	Beraud-Dufour, S; Paris, S; Chabre, M; Antonny, B				Beraud-Dufour, S; Paris, S; Chabre, M; Antonny, B			Dual interaction of ADP ribosylation factor 1 with Sec7 domain and with lipid membranes during catalysis of guanine nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR ARNO; PHOSPHOLIPASE-D; ARF GTPASE; PROTEIN; GDP; MYRISTOYLATION; ACTIVATION; BINDING; CYTOHESIN-1; COATOMER	Sec7 domains catalyze the replacement of GDP by GTP on the G protein ADP-ribosylation factor 1 (myrARF1) by interacting with its switch I and II regions and by destabilizing, through a glutamic finger, the P-phosphate of the bound G;DP, The myristoylated N-terminal helix that allows myrARF1 to interact with membrane lipids in a GTP-dependent manner is located some distance from the Sec7 domain-binding region. However, these two regions are connected. Measuring the binding to liposomes of functional or abortive complexes between myrARF1 and the Sec7 domain of ARNO demonstrates that myrARF1, in complex with the Sec7 domain, adopts a high affinity state for membrane lipids, similar to that of the free G;TP-bound form. This tight membrane attachment does not depend on the release of GDP induced by the Sec7 domain but is partially inhibited by the uncompetitive inhibitor brefeldin A. These results suggest that the conformational switch of the N-terminal helix of myrARF1 to the membrane-bound form is an early event in the nucleotide exchange pathway and is a prerequisite for a structural rearrangement at the myrARF1-GDP/Sec7 domain interface that allows the glutamic finger to expel GDP from myrARF1.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Antonny, B (corresponding author), Univ Calif Berkeley, Dept Mol & Cellular Biol, 401 Barker Hall, Berkeley, CA 94720 USA.		Antonny, Bruno/ABH-7434-2020; BERAUD-DUFOUR, Sophie/M-4641-2016	Antonny, Bruno/0000-0002-9166-8668; BERAUD-DUFOUR, Sophie/0000-0002-0062-6842				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Jones DH, 1999, BIOCHEM J, V341, P185, DOI 10.1042/0264-6021:3410185; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Losonczi JA, 1998, BIOCHEMISTRY-US, V37, P706, DOI 10.1021/bi9717791; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Pacheco-Rodriguez G, 1999, J BIOL CHEM, V274, P12438, DOI 10.1074/jbc.274.18.12438; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sata M, 1999, P NATL ACAD SCI USA, V96, P2752, DOI 10.1073/pnas.96.6.2752; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	34	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37629	37636		10.1074/jbc.274.53.37629	http://dx.doi.org/10.1074/jbc.274.53.37629			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608818	hybrid			2022-12-25	WOS:000084528000018
J	de Rooij, J; Boenink, NM; van Triest, M; Cool, RH; Wittinghofer, A; Bos, JL				de Rooij, J; Boenink, NM; van Triest, M; Cool, RH; Wittinghofer, A; Bos, JL			PDZ-GEF1, a guanine nucleotide exchange factor specific for Rap1 and Rap2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MOUSE LYMPHOMA-CELLS; SMALL GTPASE RAP1; BINDING SITE-A; CYCLIC-AMP; REGULATORY SUBUNIT; RAT-1 FIBROBLASTS; STRUCTURAL BASIS; PDZ DOMAINS; H-RAS	The small GTPase Rap1 has been implicated in a variety of cellular processes including the control of cell morphology, proliferation, and differentiation. Stimulation of a large variety of cell surface receptors results in the rapid activation of Rap1, i.e. an increase in the GTP-bound form. This activation is mediated by second messengers like calcium, cAMP, and diacylglycerol, but additional pathways may exist as well. Here we describe a ubiquitously expressed guanine nucleotide exchange factor of 200 kDa that activates Rap1 both in vivo and in vitro. This exchange factor has two putative regulatory domains: a domain with an amino acid sequence related to cAMP-binding domains and a PDZ domain. Therefore, we named it PDZ-GEF1. PDZ-GEFs are closely related to Epacs, Rap-specific exchange factors with a genuine cAMP binding site, that are directly regulated by cAMP. The domain related to cAMP-binding domains, like the cAMP binding site in Epac, serves as a negative regulatory domain. However, PDZ-GEF1 does not interact with cAMP or cGMP. Interestingly, PDZ-GEF1 also activates Rap2, a close relative of Rap1. This is the first example of an exchange factor acting on Rap2. We conclude that PDZ-GEF1 is a guanine nucleotide exchange factor, specific for Rap1 and Rap2, that is controlled by a negative regulatory domain.	Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Utrecht University; Utrecht University; Max Planck Society	Bos, JL (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	j.l.bos@med.uu.nl	de rooij, johan/C-1325-2019	Cool, Robbert/0000-0002-9845-2202				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P301, DOI 10.1007/BF02254719; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Ishiki M, 1997, ENDOCRINOLOGY, V138, P4950, DOI 10.1210/en.138.11.4950; Janoueix-Lerosey I, 1998, EUR J BIOCHEM, V252, P290, DOI 10.1046/j.1432-1327.1998.2520290.x; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kedra D, 1997, HUM GENET, V100, P611, DOI 10.1007/s004390050562; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; OGREID D, 1988, J BIOL CHEM, V263, P17397; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	49	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38125	38130		10.1074/jbc.274.53.38125	http://dx.doi.org/10.1074/jbc.274.53.38125			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608883	hybrid, Green Published			2022-12-25	WOS:000084528000083
J	Jacob-Dubuisson, F; El-Hamel, C; Saint, N; Guedin, S; Willery, E; Molle, G; Locht, C				Jacob-Dubuisson, F; El-Hamel, C; Saint, N; Guedin, S; Willery, E; Molle, G; Locht, C			Channel formation by FhaC, the outer membrane protein involved in the secretion of the Bordetella pertussis filamentous hemagglutinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; SEQUENCE SIMILARITIES; ACCESSORY GENES; HEMOLYSIN; PURIFICATION; PORINS; IDENTIFICATION; TRANSPORT	Many virulence factors of pathogenic microorganisms are presented at the cell surface, However, protein secretion across the outer membrane of Gram-negative bacteria remains poorly understood. Here we used the extremely efficient secretion of the Bordetella pertussis filamentous hemagglutinin (FHA) to decipher this process. FHA secretion requires a single specific accessory protein, FhaC, the prototype of a family of proteins necessary for the extracellular localization of various virulence proteins in Gram-negative bacteria. We show that FhaC is heat-modifiable and localized in the outer membrane. Circular dichroism spectra indicated that FhaC is rich in beta-strands, in agreement with structural predictions for this protein. We further demonstrated that FhaC forms pores in artificial membranes, as evidenced by single-channel conductance measurements through planar lipid bilayers, as well as by liposome swelling assays and patch-clamp experiments using proteoliposomes, Single-channel conductance appeared to fluctuate very fast, suggesting that the FhaC channels frequently assume a closed conformation. We thus propose that FhaC forms a specific beta-barrel channel in the outer membrane for the outward translocation of FHA.	Inst Pasteur, Inst Biol Lille, INSERM, U447, F-59019 Lille, France; Fac Sci Rouen, Inst Rech Multidisciplinaire Peptides 23, CNRS, Unite Mixte Rech 6522, F-76821 Mt St Aignan, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS)	Jacob-Dubuisson, F (corresponding author), Inst Pasteur, Inst Biol Lille, INSERM, U447, 1 Rue Calmette, F-59019 Lille, France.		Locht, Camille/L-3516-2018; Saint, Nathalie/S-5286-2016; Jacob-Dubuisson, Françoise/F-1610-2018	Saint, Nathalie/0000-0001-5219-9486; Jacob-Dubuisson, Françoise/0000-0002-5102-1704				BARENKAMP SJ, 1994, INFECT IMMUN, V62, P3320, DOI 10.1128/IAI.62.8.3320-3328.1994; BENZ R, 1993, ZBL BAKT-INT J MED M, V278, P187, DOI 10.1016/S0934-8840(11)80836-4; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; Bitter W, 1998, MOL MICROBIOL, V27, P209, DOI 10.1046/j.1365-2958.1998.00677.x; Bitter W, 1999, TRENDS MICROBIOL, V7, P4, DOI 10.1016/S0966-842X(98)01398-5; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; BUEHLER LK, 1991, J BIOL CHEM, V266, P24446; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; FREUDL R, 1987, J BACTERIOL, V169, P66, DOI 10.1128/jb.169.1.66-71.1987; Guedin S, 1998, MOL MICROBIOL, V29, P763, DOI 10.1046/j.1365-2958.1998.00970.x; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Hirono I, 1997, MOL MICROBIOL, V24, P851, DOI 10.1046/j.1365-2958.1997.3971760.x; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; JacobDubuisson F, 1996, MOL MICROBIOL, V19, P65, DOI 10.1046/j.1365-2958.1996.349883.x; JacobDubuisson F, 1997, J BACTERIOL, V179, P775, DOI 10.1128/jb.179.3.775-783.1997; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; Konninger UW, 1999, MOL MICROBIOL, V32, P1212, DOI 10.1046/j.1365-2958.1999.01433.x; Koronakis V, 1997, MOL MICROBIOL, V23, P617, DOI 10.1046/j.1365-2958.1997.d01-1880.x; Lambert-Buisine C, 1998, MOL MICROBIOL, V28, P1283, DOI 10.1046/j.1365-2958.1998.00892.x; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; LOCHT C, 1992, EMBO J, V11, P3175, DOI 10.1002/j.1460-2075.1992.tb05394.x; LOCHT C, 1993, MOL MICROBIOL, V9, P653, DOI 10.1111/j.1365-2958.1993.tb01725.x; Marciano DK, 1999, SCIENCE, V284, P1516, DOI 10.1126/science.284.5419.1516; MENOZZI FD, 1994, INFECT IMMUN, V62, P769, DOI 10.1128/IAI.62.3.769-778.1994; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; Palmer KL, 1995, MOL MICROBIOL, V18, P821, DOI 10.1111/j.1365-2958.1995.18050821.x; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1111/j.1574-6968.1998.tb13027.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rappuoli R, 1994, Curr Top Microbiol Immunol, V192, P319; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; Taylor R, 1998, J BIOL CHEM, V273, P31113, DOI 10.1074/jbc.273.47.31113; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; WILLEMS RJL, 1994, MOL MICROBIOL, V11, P337, DOI 10.1111/j.1365-2958.1994.tb00314.x; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308	39	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37731	37735		10.1074/jbc.274.53.37731	http://dx.doi.org/10.1074/jbc.274.53.37731			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608832	hybrid			2022-12-25	WOS:000084528000032
J	Lebel, M; Spillare, EA; Harris, CC; Leder, P				Lebel, M; Spillare, EA; Harris, CC; Leder, P			The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; POLY(ADP-RIBOSE) POLYMERASE; SYNDROME PROTEIN; HELICASE; HOMOLOG; SGS1; RECQ; HYBRIDIZATION; CLONING	Werner syndrome (WS) is a recessive disorder characterized by genomic instability and by the premature onset of a number of age-related diseases. To understand the molecular basis of this disease, we deleted a segment of the murine Wrn gene and created Wrn-deficient embryonic stem (ES) cells. At the molecular level, wild type-but not mutant-WS protein co-purifies through a series of centrifugation, chromatography, and sucrose gradient steps with the well characterized 17 S multiprotein DNA replication complex. Furthermore, wild type WS protein co-immunoprecipitates with a prominent component of the multiprotein replication complex, proliferating cell nuclear antigen (PCNA), In vitro studies also indicate that PCNA binds to a region in the N terminus portion of the WS protein containing a potential 3'-5' exonuclease domain. Finally, human WS protein also co-immunoprecipitates with both PCNA and topoisomerase I. These results suggest that the WS protein interacts with several components of the DNA replication fork.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; Elli R, 1996, CANCER GENET CYTOGEN, V87, P112, DOI 10.1016/0165-4608(95)00294-4; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Imamura O, 1997, GENOMICS, V41, P298, DOI 10.1006/geno.1997.4661; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Okada M, 1998, BIOL PHARM BULL, V21, P235; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; SAITOH A, 1995, NUCLEIC ACIDS RES, V23, P2014, DOI 10.1093/nar/23.11.2014; SALK D, 1981, HUM GENET, V58, P310, DOI 10.1007/BF00294930; SATO K, 1988, GERONTOLOGY, V34, P212, DOI 10.1159/000212956; SCAPPATICCI S, 1990, ANN GENET-PARIS, V33, P5; SCHONBERG S, 1984, AM J HUM GENET, V36, P387; Schulz VP, 1996, HUM GENET, V97, P750; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Walther AP, 1999, NUCLEIC ACIDS RES, V27, P656, DOI 10.1093/nar/27.2.656; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WU Y, 1994, J CELL BIOCHEM, V54, P32, DOI 10.1002/jcb.240540105; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	37	195	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37795	37799		10.1074/jbc.274.53.37795	http://dx.doi.org/10.1074/jbc.274.53.37795			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608841	hybrid			2022-12-25	WOS:000084528000041
J	Tamrakar, S; Mittnacht, S; Ludlow, JW				Tamrakar, S; Mittnacht, S; Ludlow, JW			Binding of select forms of pRB to protein phosphatase type 1 independent of catalytic activity	ONCOGENE			English	Article						retinoblastoma protein; protein phosphatase type 1; pRB dephosphorylation; PPI activity; phosphatase inhibitors	RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; OKADAIC ACID; SUSCEPTIBILITY GENE; SPONGE TOXIN; PHOSPHORYLATION; SUBUNIT; DEPHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION	The product of the retinoblastoma susceptibility gene, pRB, is a demonstrated substrate for the type 1 serine/threonine protein phosphatases (PPI). Curiously, there has been a paucity of data supporting the idea that phosphorylated pRB can be found in a complex with PP1. To more fully characterize the association between these two proteins, we utilized a PP1-affinity chromatography approach to increase our ability to capture from mammalian cell lysate populations of pRB capable of binding to PPI. Western blot analysis of the bound proteins indicates that both faster migrating, hypophosphorylated pRB, as web as slower migrating, hyperphosphorylated pRB can bind. Phosphorylated pRB binding was confirmed by immunoprecipitation of eluted P-32-labeled pRB. In addition, Western blotting of eluted proteins with pRB phosphorylated-site-specific antibodies revealed select phosphorylated forms of pRB binding to PP1. Similar binding studies performed with toxin-inhibited PP1 indicate that catalytic activity of PPI is not required for pRB binding. The significance of this finding with respect to the functional importance of this interaction is discussed.	Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Inst Canc Res, Dept Cell & Mol Biol, London SW3 6JB, England	University of Rochester; University of Rochester; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ludlow, JW (corresponding author), Univ Rochester, Ctr Canc, Box 704,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; Ludlow JW, 1996, J VIROL METHODS, V59, P105, DOI 10.1016/0166-0934(96)02027-7; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUSSOW AR, 1991, EUR J IMMUNOL, V21, P2297, DOI 10.1002/eji.1830211002; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Siegert JL, 1999, MOL CELL BIOL, V19, P846; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Tognarini M, 1998, METH MOL B, V93, P169; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang LF, 1996, BIOCHEMISTRY-US, V35, P1606, DOI 10.1021/bi9521396	41	19	19	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7803	7809		10.1038/sj.onc.1203211	http://dx.doi.org/10.1038/sj.onc.1203211			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618721				2022-12-25	WOS:000084256900010
J	Feldkamp, MM; Lau, N; Guha, A				Feldkamp, MM; Lau, N; Guha, A			Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects	ONCOGENE			English	Article						farnesyl transferase inhibitor, FTI; L-744,832; astrocytoma; glioma; Ras	RAS-TRANSFORMED-CELLS; HUMAN-BRAIN-TUMORS; NIH 3T3 CELLS; FARNESYLTRANSFERASE INHIBITORS; FACTOR RECEPTOR; PROTEIN TRANSFERASE; ACTIN CYTOSKELETON; TRANSGENIC MICE; KINASE-KINASE; ONCOGENIC RAS	While 25% of human cancers harbor oncogenic Ras mutations, such mutations are not found in astrocytomas. We have previously demonstrated that the activation of receptor tyrosine kinases expressed by malignant human astrocytoma cells and specimens results in functional upregulation of the Ras signalling pathway and increased levels of activated Ras GTP. Farnesyl transferase inhibitors (FTIs) are promising anti-cancer agents in early clinical trials, which may exert their effect through pharmacological inhibition of the Ras signalling pathway, In this study we establish the anti-tumorigenic properties of the FTI L-744,832 against a panel of malignant human astrocytoma cell Lines. Furthermore, we demonstrate the multiple mechanisms by which L744,832 exerts its effect. L-744,832 demonstrates both cytostatic and cytotoxic effects on astrocytoma cells, and cells expressing a truncated constitutively phosphorylated Epidermal Growth Factor Receptor common in high-grade astrocytomas (EGFRvIII/p140(EGF-R)) demonstrate increased sensitivity to the agent. L-744,832 is capable of inducing apoptosis in astrocytoma cells under anchorage-dependent conditions; this process occurs in a p53-independent manner and is associated with increased expression of Bax and Bak, L-744,832 also induces cell cycle arrest at both the G(1)/M and G(2)/S checkpoints; this process is also independent of p53 mutational status. Cell cycle arrest in drug-treated cells can be accompanied by induction of p21(WAF1/CIP1), but this induction is not necessary for the cell cycle inhibitory effects, nor is it dependent on functional p53, Finally, angiogenesis in astrocytomas has been shown to be dependent on secretion of Vascular Endothelial Growth Factor (VEGF) by tumour cells, particularly under hypoxic conditions, L-744,832 potently inhibits the secretion of VEGF under hypoxic conditions. These combinations of mechanisms suggest that these tumours, despite the absence of oncogenic Ras mutations, will be amenable to growth inhibition by FTIs, through a combination of anti-proliferative, pro-apoptotic, and anti-angiogenic effects.	Toronto Western Hosp, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON, Canada; Princess Margaret Hosp, Ontario Canc Inst, Dept Surg Oncol, Toronto, ON M4X 1K9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Guha, A (corresponding author), Toronto Western Hosp, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada.							ASANO M, 1995, CANCER RES, V55, P5296; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BOS JL, 1989, CANCER RES, V49, P4682; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; Du W, 1999, MOL CELL BIOL, V19, P1831; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.3.CO;2-X; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FLEMING TP, 1992, CANCER RES, V52, P4550; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GomezManzano C, 1996, CANCER RES, V56, P694; GOODWIN CJ, 1995, J IMMUNOL METHODS, V179, P95, DOI 10.1016/0022-1759(94)00277-4; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; GUHA A, 1995, J NEUROL NEUROSUR PS, V58, P711, DOI 10.1136/jnnp.58.6.711; Gutmann DH, 1996, ONCOGENE, V12, P2121; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Izawa I, 1996, FEBS LETT, V382, P53, DOI 10.1016/0014-5793(96)00137-8; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Law BK, 1999, J BIOL CHEM, V274, P4743, DOI 10.1074/jbc.274.8.4743; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LIBERMANN TA, 1984, CANCER RES, V44, P753; MANNE V, 1995, ONCOGENE, V10, P1763; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Melnyk O, 1996, CANCER RES, V56, P921; Millauer B, 1996, CANCER RES, V56, P1615; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; NAGASU T, 1995, CANCER RES, V55, P5310; NISTER M, 1988, CANCER RES, V48, P3910; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RAK J, 1995, CANCER RES, V55, P4575; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Saleh M, 1996, CANCER RES, V56, P393; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Sepp-Lorenzino L, 1998, J BIOL CHEM, V273, P20243, DOI 10.1074/jbc.273.32.20243; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TUZI NL, 1991, BRIT J CANCER, V63, P227, DOI 10.1038/bjc.1991.54; Vogt A, 1996, ONCOGENE, V13, P1991; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Zhang FL, 1997, J BIOL CHEM, V272, P10232; ZIMMERMA.HM, 1969, ANN NY ACAD SCI, V159, P337, DOI 10.1111/j.1749-6632.1969.tb48290.x	71	98	98	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7514	7526		10.1038/sj.onc.1203105	http://dx.doi.org/10.1038/sj.onc.1203105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602510				2022-12-25	WOS:000084119600012
J	Van Keymeulen, A; Bartek, J; Dumont, JE; Roger, PP				Van Keymeulen, A; Bartek, J; Dumont, JE; Roger, PP			Cyclin D3 accumulation and activity integrate and rank the comitogenic pathways of thyrotropin and insulin in thyrocytes in primary culture	ONCOGENE			English	Article						cell cycle; cyclins D; p27(kipl); cAMP; thyroid; synergy	THYROID EPITHELIAL-CELLS; GROWTH-FACTOR-I; CDK-ACTIVATING KINASE; G1 PHASE PROGRESSION; RETINOBLASTOMA PROTEIN; DEPENDENT KINASE; SUBCELLULAR-LOCALIZATION; INHIBITOR P27(KIP1); MITOGENIC PATHWAYS; SIGNALING CASCADES	The proliferation of most normal cells depends on the synergistic interaction of several growth factors and hormones, but the cell cycle basis for this combined requirement remains largely uncharacterized, We have addressed the question of the requirement for insulin/IGF-1 also observed in many cell culture systems in the physiologically relevant system of primary cultures of dog thyroid epithelial cells stimulated by TSH, which exerts its mitogenic activity only via cAMP, The induction of cyclin A and cdc2, the phosphorylation of cdk2, the nuclear translocation of cdk4 and the assembly of cyclin D3-cdk4 complexes required the synergy of TSH and insulin. Cyclin D3 (the most abundant cyclin D) was necessary for the proliferation stimulated by TSH in the presence of insulin as shown by microinjection of a neutralizing antibody, Cyclin D3 accumulation and activity mere differentially regulated by insulin and TSH, which points out this cyclin as an integrator that ranks these comitogenic pathways as supportive and activatory, respectively. Paradoxically TSH alone strongly repressed cyclin D3 accumulation. This inhibition was overridden by insulin, which markedly stimulated cyclin D3 mRNA and protein accumulation, but failed to assemble cyclin D3-cdk4 complexes in the absence of TSH. TSH unmasked the DCS-22 epitope of cyclin D3 and assembled cyclin D3-cdk4 in the presence of insulin. These data demonstrate that cyclin D synthesis and cyclin D-cdk assembly can be dissociated and complementarily regulated by different agents and signalling pathways.	Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Danish Canc Soc, Div Canc Biol, DK-2100 Copenhagen, Denmark	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Danish Cancer Society	Roger, PP (corresponding author), Free Univ Brussels, Inst Interdisciplinary Res, 808 Route Lennik,Campus Erasme, B-1070 Brussels, Belgium.		Bartek, Jiri/G-5870-2014	Roger, Pierre/0000-0002-5812-1783				Baptist M, 1996, J CELL PHYSIOL, V166, P256; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Burikhanov R, 1996, J BIOL CHEM, V271, P29400, DOI 10.1074/jbc.271.46.29400; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheung NW, 1996, J CLIN ENDOCR METAB, V81, P1179, DOI 10.1210/jc.81.3.1179; Coppee F, 1998, ONCOGENE, V17, P631, DOI 10.1038/sj.onc.1201966; Coulonval K, 1997, EXP CELL RES, V233, P395, DOI 10.1006/excr.1997.3582; de Asua L J, 1977, Proc Natl Acad Sci U S A, V74, P3845; Deleu S, 1999, MOL CELL ENDOCRINOL, V149, P41, DOI 10.1016/S0303-7207(99)00005-2; DELEU S, 1999, IN PRESS J CELL PHYS; Depoortere F, 1996, J CELL SCI, V109, P1759; Depoortere F, 1998, J CELL BIOL, V140, P1427, DOI 10.1083/jcb.140.6.1427; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAMY F, 1989, J CELL PHYSIOL, V138, P568, DOI 10.1002/jcp.1041380318; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; REUSE S, 1991, EXP CELL RES, V196, P210, DOI 10.1016/0014-4827(91)90253-Q; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROGER P, 1988, J CLIN ENDOCR METAB, V66, P1158, DOI 10.1210/jcem-66-6-1158; Roger PP, 1997, EUR J ENDOCRINOL, V137, P579, DOI 10.1530/eje.0.1370579; ROGER PP, 1987, EXP CELL RES, V172, P282, DOI 10.1016/0014-4827(87)90387-9; ROGER PP, 1987, J CELL PHYSIOL, V130, P58, DOI 10.1002/jcp.1041300110; ROGER PP, 1992, J CELL BIOL, V117, P383, DOI 10.1083/jcb.117.2.383; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TAKAHASHI SI, 1991, J BIOL CHEM, V266, P7834; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMAS GA, 1994, J PATHOL, V173, P355, DOI 10.1002/path.1711730411; TOMINAGA T, 1994, ENDOCRINOLOGY, V135, P1212, DOI 10.1210/en.135.3.1212; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; Ward AC, 1996, BIOCHEM BIOPH RES CO, V224, P10, DOI 10.1006/bbrc.1996.0976; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1998, CANCER RES, V58, P5053; WERNER H, 1994, VITAM HORM, V48, P1, DOI 10.1016/S0083-6729(08)60495-1; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	58	28	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7351	7359		10.1038/sj.onc.1203164	http://dx.doi.org/10.1038/sj.onc.1203164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602491				2022-12-25	WOS:000084119400021
J	Abe, JI; Okuda, M; Huang, QH; Yoshizumi, M; Berk, BC				Abe, JI; Okuda, M; Huang, QH; Yoshizumi, M; Berk, BC			Reactive oxygen species activate p90 ribosomal S6 kinase via Fyn and Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; H+ EXCHANGER KINASE; PROTEIN-KINASE; HYDROGEN-PEROXIDE; SIGNAL-TRANSDUCTION; ANGIOTENSIN-II; SRC FAMILY; PROTEIN-KINASE-1 BMK1; MEDIATED ACTIVATION; ENDOTHELIAL-CELLS	Reactive oxygen species and growth factors stimulate similar intracellular signal transduction events including activation of Src kinase family members and extracellular signal-regulated kinases (ERK1/2), A potentially important downstream effector of Src and ERK1/2 is p90 ribosomal S6 kinase (p90RSK), which plays an important role in cell growth by activating several transcription factors as well as the Na+/H+ exchanger. In the present study, we determined whether H2O2 activates p90RSK to gain insight into signal transduction mechanisms activated by reactive oxygen species. H2O2 (200 mu M) Stimulated ERK1/2 and p90RSK activity in lymphocytes, endothelial cells, and fibroblasts. The MEK-1 inhibitor, PD98059 (30 mu M), inhibited H2O2-mediated activation of ERK1/2 but not of p90RSK, An essential role for Fyn and Ras in p90RSK activation was suggested by five findings. 1) The tyrosine kinase inhibitor, herbimycin A and the specific Src kinase family inhibitor, PP1, blocked p90RSK activation by H2O2 in a concentration-dependent manner. 2) p90RSK activation by H2O2 was significantly reduced in fibroblasts derived from transgenic mice deficient in Fyn, but not c-Src. 3) H2O2 rapidly activated Ras (peak at 2-5 min), which preceded p90RSK activation (peak at 20 min). 4) Dominant negative Res completely blocked H2O2-induced activation of p90RSK. 5) In Fyn-/- fibroblasts, activation of Ras by H2O2 was significantly attenuated. These results show essential roles for Fyn and Ras in H2O2-mediated activation of p90RSK and establish redox-sensitive regulation of Ras and p90RSK as a new function for Fyn.	Univ Rochester, Sch Med & Dent, Cardiol Unit, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Kobe Univ, Sch Med, Dept Internal Med, Div 1, Kobe, Hyogo 6500017, Japan	University of Rochester; Kobe University	Berk, BC (corresponding author), Univ Rochester, Sch Med & Dent, Cardiol Unit, Cardiovasc Res Ctr, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HL49192, HL44721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192, R01HL044721] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; AUCHSCHWELK W, 1992, J CARDIOVASC PHARM, V20, pS62, DOI 10.1097/00005344-199200209-00012; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BERK BC, 1987, J BIOL CHEM, V262, P5065; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOYER CS, 1995, BIOCHEM PHARMACOL, V50, P753, DOI 10.1016/0006-2952(95)00195-6; BOYUM A, 1991, SCAND J IMMUNOL, V34, P697, DOI 10.1111/j.1365-3083.1991.tb01594.x; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOAN TN, 1994, BIOCHEM J, V297, P209, DOI 10.1042/bj2970209; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Fukuta Y, 1998, BIOCHEM PHARMACOL, V55, P481, DOI 10.1016/S0006-2952(97)00496-6; GERRITY RG, 1979, AM J PATHOL, V95, P775; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Griffith CE, 1998, J BIOL CHEM, V273, P10771, DOI 10.1074/jbc.273.17.10771; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HOMANMULLER JWT, 1975, J LAB CLIN MED, V85, P198; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Li HL, 1997, J BIOL CHEM, V272, P18200, DOI 10.1074/jbc.272.29.18200; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LIBBY P, 1991, LAB INVEST, V64, P5; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NEGRI M, 1991, CLIN CHIM ACTA, V199, P305, DOI 10.1016/0009-8981(91)90124-U; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Okuda M, 1996, AM J PHYSIOL-HEART C, V271, pH595, DOI 10.1152/ajpheart.1996.271.2.H595; Pende M, 1997, J NEUROSCI, V17, P1291; Phan VN, 1997, HYPERTENSION, V29, P1265, DOI 10.1161/01.HYP.29.6.1265; Puceat M, 1998, J CELL BIOL, V141, P1637, DOI 10.1083/jcb.141.7.1637; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sabri A, 1998, CIRC RES, V82, P1053, DOI 10.1161/01.RES.82.10.1053; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Takahashi E, 1997, CIRC RES, V81, P268, DOI 10.1161/01.RES.81.2.268; TARDIF JC, 1996, CIRCULATION S1, V94, P91; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	65	122	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1739	1748		10.1074/jbc.275.3.1739	http://dx.doi.org/10.1074/jbc.275.3.1739			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636870	hybrid			2022-12-25	WOS:000084940000033
J	Cheng, AY; Dean, NM; Honkanen, RE				Cheng, AY; Dean, NM; Honkanen, RE			Serine/threonine protein phosphatase type 1 gamma 1 is required for the completion of cytokinesis in human A549 lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGONUCLEOTIDES; CATALYTIC SUBUNIT; MOLECULAR-CLONING; GROWTH ARREST; OKADAIC ACID; CDNA CLONE; GENE; SEQUENCE; ANAPHASE; MITOSIS	In lower eukaryotic organisms, the loss of serine/threonine protein phosphatase type 1 (PP1) results in growth arrest after the onset of mitosis. In humans, four highly homologous isoforms of PP1 (PP1 alpha, PP1 delta, PP1 gamma 1, and PP1 gamma 2) have been identified. Determining the roles of these phosphatases, however, has proven difficult due to the lack of subtype-specific inhibitors. In this study, we developed chimeric antisense 2'-O-(2-methoxy)ethylphosphothioate oligonucleotides targeting human PP1 gamma 1 that specifically inhibit PP1 gamma 1 gene expression. Two potent antisense oligonucleotides (ISIS 14435 and 14439; IC50 similar to 50 nM) were then employed to elucidate the cellular functions of PP1 gamma 1 during cell cycle progression. In A549 cells, the inhibition of PP1 gamma 1 expression resulted in a dose-dependent inhibition of cellular proliferation, with growth arrest occurring after similar to 36-48 h, when PP1 gamma 1 mRNA expression was inhibited by >85%. Fluorescence-activated cell sorter analysis revealed that ISIS 14435/14439-induced growth arrest was associated with an increase in the number of cells containing 4N DNA. Immunostaining of treated cells revealed that the inhibition of PP1 gamma 1 expression had no apparent effect on the formation of mitotic spindles. However, decreased expression was associated with the failure of cell division in a late stage of cytokinesis and the formation of dikaryons.	Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36688 USA; ISIS Pharmaceut, Dept Pharmacol, Carlsbad, CA 92008 USA	University of South Alabama; Isis Pharmaceuticals Inc	Honkanen, RE (corresponding author), Univ S Alabama, Dept Biochem & Mol Biol, MSB 2198, Mobile, AL 36688 USA.	honkanen@sungcg.usouthal.edu						ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BALCZON RD, 1987, J CELL BIOL, V105, P855, DOI 10.1083/jcb.105.2.855; BARKER HM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P228, DOI 10.1016/0167-4889(93)90014-G; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; Bastians H, 1996, J CELL SCI, V109, P2865; BECKER W, 1994, J BIOL CHEM, V269, P22586; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Cheng AY, 1998, CANCER RES, V58, P3611; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GUERINI D, 1989, DNA-J MOLEC CELL BIO, V8, P675, DOI 10.1089/dna.1.1989.8.675; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; Huang XZ, 1997, GENOMICS, V44, P336, DOI 10.1006/geno.1997.4891; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Montini E, 1997, HUM MOL GENET, V6, P1137, DOI 10.1093/hmg/6.7.1137; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILVA EFDE, 1991, BIOCHIM BIOPHYS ACTA, V1089, P269, DOI 10.1016/0167-4781(91)90023-F; SONG Q, 1993, GENE, V129, P291, DOI 10.1016/0378-1119(93)90282-8; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; Sugiyama H, 1997, ONCOGENE, V15, P443, DOI 10.1038/sj.onc.1201207; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VANDOLAH FM, 1992, J CELL PHYSIOL, V152, P190, DOI 10.1002/jcp.1041520124; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	47	52	53	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1846	1854		10.1074/jbc.275.3.1846	http://dx.doi.org/10.1074/jbc.275.3.1846			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636884	hybrid			2022-12-25	WOS:000084940000047
J	Freire, E; Coelho-Sampaio, T				Freire, E; Coelho-Sampaio, T			Self-assembly of laminin induced by acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANES; BINDING DOMAIN; ATTACHMENT; GLYCOPROTEIN; PROTEINS; CELLS; POLYMERIZATION; DYSTROGLYCAN; CYTOSKELETON	The supramolecular architecture of the basement membrane is provided by two enmeshed networks of collagen IV and laminin, The laminin network is maintained exclusively by interactions among individual laminin molecules and does not depend on the presence of other extracellular matrix components. Laminin polymers can be obtained in vitro either in solution or in association with the surface of bilayers containing acidic lipids, In this work, we have tested the hypothesis that the negative charges present on acidic lipids establish an acid microenvironment that is directly responsible for inducing laminin aggregation. Using light-scattering measurements, we show that laminin does not aggregate on vesicles of neutral lipids, whereas instantaneous aggregation occurs to progressively greater extents as the proportion of acidic phospholipids in the vesicles is increased. Aggregation of laminin induced by vesicles containing acidic phospholipids occurs very rapidly, so that maximal aggregation for each condition is reached within 1 min after laminin dilution. Aggregation depends on the presence of Ca2+ ions, is reversed by increasing ionic strength, and can be detected at laminin concentrations as low as 6 nM. In addition, we show that, in the absence of vesicles, acidification of the bulk solution can also induce laminin self-polymerization through a process that exhibits the same properties as lipid-induced polymerization. The fact that there is a correspondence between the processes of self-polymerization of laminin in acidic medium and in neutral medium but in the presence of vesicles containing negatively charged lipids leads us to propose that the microenvironment of an acidic surface may trigger the assembly of laminin networks. In vivo, such an acidic microenvironment would be provided by negatively charged sialic acid and sulfate groups present in the glycocalyx surrounding the cells.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Coelho-Sampaio, T (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941 Rio De Janeiro, Brazil.							Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Aumailley M, 1996, J INVEST DERMATOL, V106, P209, DOI 10.1111/1523-1747.ep12340471; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P832; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; COOPER AR, 1983, DEV BIOL, V96, P467, DOI 10.1016/0012-1606(83)90183-5; DZIADEK M, 1985, EMBO J, V4, P2513, DOI 10.1002/j.1460-2075.1985.tb03964.x; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P700, DOI 10.1016/S0955-0674(96)80112-8; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; GEE SH, 1993, J BIOL CHEM, V268, P14972; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; KALB E, 1991, J BIOL CHEM, V266, P19047; KLEINMAN HK, 1993, VITAM HORM, V47, P161, DOI 10.1016/S0083-6729(08)60446-X; LAITINEN J, 1987, FEBS LETT, V217, P94, DOI 10.1016/0014-5793(87)81250-4; Malinda KM, 1996, INT J BIOCHEM CELL B, V28, P957, DOI 10.1016/1357-2725(96)00042-8; MARTINEZHERNAND.A, 1983, LAB INVEST, V48, P657; MCCARTHY JB, 1983, J CELL BIOL, V97, P772, DOI 10.1083/jcb.97.3.772; NURCOMBE V, 1992, PHARMACOL THERAPEUT, V56, P247, DOI 10.1016/0163-7258(92)90019-V; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PAULSSON M, 1988, EUR J BIOCHEM, V177, P477, DOI 10.1111/j.1432-1033.1988.tb14397.x; RAMSDEN JJ, 1993, BIOPOLYMERS, V33, P475, DOI 10.1002/bip.360330313; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; SUGRUE SP, 1981, J CELL BIOL, V91, P45, DOI 10.1083/jcb.91.1.45; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; TERRANOVA VP, 1986, J CELL PHYSIOL, V127, P473, DOI 10.1002/jcp.1041270318; TERRANOVA VP, 1980, CELL, V22, P719, DOI 10.1016/0092-8674(80)90548-6; TERRANOVA VP, 1982, CANCER RES, V42, P2265; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; UTANI A, 1994, J BIOL CHEM, V269, P19167; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Wettreich A, 1999, J BIOL CHEM, V274, P31468, DOI 10.1074/jbc.274.44.31468; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	42	40	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					817	822		10.1074/jbc.275.2.817	http://dx.doi.org/10.1074/jbc.275.2.817			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625612	hybrid			2022-12-25	WOS:000084836600016
J	Griffioen, G; Anghileri, P; Imre, E; Baroni, MD; Ruis, H				Griffioen, G; Anghileri, P; Imre, E; Baroni, MD; Ruis, H			Nutritional control of nucleocytoplasmic localization of cAMP-dependent protein kinase catalytic and regulatory subunits in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; RESPONSE ELEMENT STRE; ADENYLATE-CYCLASE; FRUCTOSE 2,6-BISPHOSPHATE; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; GENES; TRANSCRIPTION; EXPRESSION	In budding yeast, cAMP-dependent protein kinase (PKA) plays a central role in the nutritional control of metabolism, cell cycle, and transcription. This study shows that both the regulatory subunit Bcy1p and the catalytic subunit Tpk1p associated with it are predominantly localized in the nucleus of rapidly growing cells. Activation of nuclear PKA by cAMP leads to fast entry of a significant part of Tpk1p into the cytoplasm, while the regulatory subunit remains nuclear, In contrast to rapidly proliferating cells, both Bcy1p and Tpk1p are distributed over nucleus and cytoplasm in cells growing on a nonfermentable carbon source or in stationary phase cells. These results demonstrate that at least two different mechanisms determine the subcellular localization of PKA; cAMP controls the localization of Tpk1p, and the carbon source determines that of Bcy1p, The N-terminal domain of Bcy1p serves to target it properly during logarithmic and stationary phase. Studies with Bcy1p mutant versions unable to concentrate in the nucleus revealed that cells producing them are less viable in stationary phase than wild type cells, display delayed reproliferation following transfer to fresh growth medium, and, as diploids, exhibit reduced efficiency of sporulation.	Univ Vienna, Inst Biochem & Mol Zellbiol, Vienna Bioctr, A-1030 Vienna, Austria; Ludwig Boltzmann Forschungstelle Biochem, A-1030 Vienna, Austria; Univ Milan, Dipartimento Fisiol & Biochim Gen, Sez Biochim Comparata, I-20133 Milan, Italy	University of Vienna; Vienna Biocenter (VBC); Ludwig Boltzmann Institute; University of Milan	Ruis, H (corresponding author), Univ Vienna, Inst Biochem & Mol Zellbiol, Vienna Bioctr, Waehringer Guertel 18, A-1030 Vienna, Austria.		Baroni, Maurizio David/AAL-8064-2021	Baroni, Maurizio David/0000-0001-6355-9950				BOORSTEIN WR, 1990, EMBO J, V9, P2543, DOI 10.1002/j.1460-2075.1990.tb07435.x; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Eide T, 1998, EXP CELL RES, V238, P305, DOI 10.1006/excr.1997.3855; ELION A, 1995, TRENDS CELL BIOL, V5, P322; FRANCOIS J, 1984, EUR J BIOCHEM, V145, P187, DOI 10.1111/j.1432-1033.1984.tb08539.x; FRANCOIS J, 1987, EUR J BIOCHEM, V164, P369, DOI 10.1111/j.1432-1033.1987.tb11067.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GRIFFIOEN G, 1994, FEMS MICROBIOL LETT, V123, P137, DOI 10.1111/j.1574-6968.1994.tb07213.x; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Jiang Y, 1998, EMBO J, V17, P6942, DOI 10.1093/emboj/17.23.6942; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rose MD., 1990, METHODS YEAST GENETI; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SIKORSKI RS, 1989, GENETICS, V122, P19; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; THEVELEIN JM, 1992, ANTON LEEUW INT J G, V62, P109, DOI 10.1007/BF00584466; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; TORNOW J, 1990, GENE, V90, P79, DOI 10.1016/0378-1119(90)90441-S; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WERNERWASHBURNE M, 1991, J BIOL CHEM, V266, P19704	40	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1449	1456		10.1074/jbc.275.2.1449	http://dx.doi.org/10.1074/jbc.275.2.1449			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625697	hybrid			2022-12-25	WOS:000084836600101
J	Jisaka, M; Kim, RB; Boeglin, WE; Brash, AR				Jisaka, M; Kim, RB; Boeglin, WE; Brash, AR			Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ACTIVE-SITE; LIPOXYGENASE; EXPRESSION; SKIN; 15-LIPOXYGENASE; MUTAGENESIS; ALIGNMENT	Phorbol ester-inducible mouse 8S-lipoxygenase (8-LOX) and its human homologue, 15S-lipoxygenase-2 (15-LOX-2), share 78% identity in amino acid sequences, yet there is no overlap in their positional specificities. In this study, we investigated the determinants of positional specificity using a random chimeragenesis approach in combination with site-directed mutagenesis, Exchange of the C-terminal one-third of the 8-LOX with the corresponding portion of 15-LOX-2 yielded a chimeric enzyme with exclusively 15S-lipoxygenase activity. The critical region was narrowed down to a cluster of five amino acids by expression of multiple cDNAs obtained by in situ chimeragenesis in Escherichia coli, Finally, a pair of amino acids, Tyr(603) and His(604), was identified as the positional determinant by site-directed mutagenesis, Mutation of both of these amino acids to the corresponding amino acids in 15-LOX-2 (Asp and Val, respectively) converted the positional specificity from 8S to 90% 15S without yielding any other by-products. Mutation of the corresponding residues in 15-LOX-2 to the 8-LOX sequence changed specificity to 50% oxygenation at C-8 for one amino acid substitution and 70% at C-8 for the double mutant. Based on the crystal structure of the reticulocyte 15-LOX, these two amino acids lie opposite the open coordination position of the catalytic iron in a likely site for substrate binding, The change from 8 to 15 specificity entails a switch in the head to tail binding of substrate. Enzymes that react with substrate "head first" (5-LOX and 8-LOX) have a bulky aromatic amino acid and a histidine in these positions, whereas lipoxygenases that accept substrates "tail first" (12-LOX and 15-LOX) have an aliphatic residue with a glutamine or aspartate. Thus, this positional determinant of the 8-LOX and 15-LOX-2 may have significance for other lipoxygenases.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN 37232 USA; Shimane Univ, Dept Life Sci & Biotechnol, Matsue, Shimane 6908504, Japan	Vanderbilt University; Shimane University	Brash, AR (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Clin Pharmacol, 23rd Ave Pierce, Nashville, TN 37232 USA.	jisaka@life.shimane-u.ac.jp; alan.brash@mcmail.vanderbilt.edu	Kim, Richard/D-6971-2011	Kim, Richard/0000-0001-8148-1632	NIGMS NIH HHS [GM-53638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boeglin WE, 1998, P NATL ACAD SCI USA, V95, P6744, DOI 10.1073/pnas.95.12.6744; Borngraber S, 1996, J MOL BIOL, V264, P1145, DOI 10.1006/jmbi.1996.0702; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; EGMOND MR, 1972, BIOCHEM BIOPH RES CO, V48, P1055, DOI 10.1016/0006-291X(72)90815-7; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; Hornung E, 1999, P NATL ACAD SCI USA, V96, P4192, DOI 10.1073/pnas.96.7.4192; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; Kinzig A, 1999, GENOMICS, V58, P158, DOI 10.1006/geno.1999.5816; Krieg P, 1998, BBA-LIPID LIPID MET, V1391, P7, DOI 10.1016/S0005-2760(97)00214-2; KUHN H, 1990, J BIOL CHEM, V265, P16300; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MOORE KR, 1994, BIOTECHNIQUES, V17, P130; Prigge ST, 1996, PROTEINS, V24, P275; Schwarz K, 1998, BIOCHEMISTRY-US, V37, P15327, DOI 10.1021/bi9816204; SkrzypczakJankun E, 1997, PROTEINS, V29, P15, DOI [10.1002/(SICI)1097-0134(199709)29:1&lt;15::AID-PROT2&gt;3.0.CO;2-E, 10.1002/(SICI)1097-0134(199709)29:1<15::AID-PROT2>3.3.CO;2-F]; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; Sun DX, 1998, J BIOL CHEM, V273, P33540, DOI 10.1074/jbc.273.50.33540	24	89	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1287	1293		10.1074/jbc.275.2.1287	http://dx.doi.org/10.1074/jbc.275.2.1287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625675	hybrid			2022-12-25	WOS:000084836600079
J	Suter, M; von Ballmoos, P; Kopriva, S; den Camp, RO; Schaller, J; Kuhlemeier, C; Schurmann, P; Brunold, C				Suter, M; von Ballmoos, P; Kopriva, S; den Camp, RO; Schaller, J; Kuhlemeier, C; Schurmann, P; Brunold, C			Adenosine 5 '-phosphosulfate sulfotransferase and adenosine 5 '-phosphosulfate reductase are identical enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERREDOXIN-SULFITE REDUCTASE; LEMNA-MINOR-L; SULFATE ASSIMILATION; PAPS-REDUCTASE; HIGHER-PLANTS; 5'-ADENYLYLSULFATE REDUCTASE; ARABIDOPSIS-THALIANA; APS-SULFOTRANSFERASE; ESCHERICHIA-COLI; SPINACH	Adenosine 5'-phosphosulfate (APS) sulfotransferase and APS reductase have been described as key enzymes of assimilatory sulfate reduction of plants catalyzing the reduction of APS to bound and free sulfite, respectively. APS sulfotransferase was purified to homogeneity from Lemna minor and compared with APS reductase previously obtained by functional complementation of a mutant strain of Escherichia coli with an Arabidopsis thaliana cDNA library. APS sulfotransferase was a homodimer with a monomer M-r of 43,000, Its amino acid sequence was 73% identical with APS reductase. APS sulfotransferase purified from Lemna as well as the recombinant enzyme were yellow proteins, indicating the presence of a cofactor. Like recombinant APS reductase, recombinant APS sulfotransferase used APS (K-m = 6.5 mu M) and not adenosine 3'-phosphate 5'-phosphosulfate as sulfonyl donor. The V-max of recombinant Lemna APS sulfotransferase (40 mu mol min(-1) mg protein(-1)) was about 10 times higher than the previously published V-max of APS reductase. The product of APS sulfotransferase from APS and GSH was almost exclusively SO32-. Bound sulfite in the form of S-sulfoglutathione was only appreciably formed when oxidized glutathione was added to the incubation mixture. Because SO32- was the first reaction product of APS sulfotransferase, this enzyme should be renamed APS reductase.	Univ Bern, Inst Plant Physiol, CH-3013 Bern, Switzerland; Univ Neuchatel, Biochim Lab, CH-2000 Neuchatel, Switzerland; Univ Bern, Dept Biochem & Chem, CH-3012 Bern, Switzerland	University of Bern; University of Neuchatel; University of Bern	Brunold, C (corresponding author), Univ Bern, Inst Plant Physiol, Altenbergrain 21, CH-3013 Bern, Switzerland.	christian.brunold@pfp.unibe.ch	Kopriva, Stanislav/C-7401-2013; von Ballmoos, Peter/B-4123-2008	Kopriva, Stanislav/0000-0002-7416-6551; von Ballmoos, Peter/0000-0001-9649-2289				ABRAMS WR, 1973, ARCH MIKROBIOL, V94, P1, DOI 10.1007/BF00414074; AKETAGAWA J, 1980, AGR BIOL CHEM TOKYO, V44, P2371, DOI 10.1080/00021369.1980.10864341; ARA T, 1996, SULPHUR METABOLISM H, P177; Bick JA, 1998, P NATL ACAD SCI USA, V95, P8404, DOI 10.1073/pnas.95.14.8404; BRUNOLD C, 1984, PLANT PHYSIOL, V76, P579, DOI 10.1104/pp.76.3.579; BRUNOLD C, 1989, PLANTA, V179, P228, DOI 10.1007/BF00393693; BRUNOLD C, 1987, PHYSIOL PLANTARUM, V70, P168, DOI 10.1111/j.1399-3054.1987.tb06127.x; BRUNOLD C, 1993, SULFUR NUTRITION AND ASSIMILATION IN HIGHER PLANTS, P61; Brunold C., 1990, METHODS PLANT BIOCH, P339; FANKHAUSER H, 1978, PLANTA, V143, P285, DOI 10.1007/BF00392000; FANKHAUSER H, 1978, EXPERIENTIA, V34, P939; GALLI U, 1993, NEW PHYTOL, V125, P837, DOI 10.1111/j.1469-8137.1993.tb03932.x; GutierrezMarcos JF, 1996, P NATL ACAD SCI USA, V93, P13377, DOI 10.1073/pnas.93.23.13377; Kanno N, 1996, PLANTA, V198, P440, DOI 10.1007/BF00620061; KOPRIVA S, 1999, SULFUR NUTR SULFUR A, P138; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P419; KRUEGER RJ, 1982, BIOCHEMISTRY-US, V21, P2892, DOI 10.1021/bi00541a014; Leustek T, 1996, PHYSIOL PLANTARUM, V97, P411, DOI 10.1034/j.1399-3054.1996.970228.x; LI JY, 1991, BIOCHEM J, V274, P355, DOI 10.1042/bj2740355; MANNERVIK B, 1978, FUNCTIONS GLUTATHION, P148; NEUENSCHWANDER U, 1991, PLANT PHYSIOL, V97, P253, DOI 10.1104/pp.97.1.253; Noctor G, 1998, J EXP BOT, V49, P623, DOI 10.1093/jexbot/49.321.623; Prior A, 1999, BBA-PROTEIN STRUCT M, V1430, P25, DOI 10.1016/S0167-4838(98)00266-0; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; Savage H, 1997, STRUCTURE, V5, P895, DOI 10.1016/S0969-2126(97)00244-X; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SCHMIDT A, 1972, Z NATURFORSCH PT B, VB 27, P183; SCHMIDT A, 1973, ARCH MIKROBIOL, V93, P29, DOI 10.1007/BF00666079; SCHMIDT A, 1976, PLANTA, V130, P257, DOI 10.1007/BF00387830; SCHMIDT A, 1972, ARCH MIKROBIOL, V84, P77, DOI 10.1007/BF00408084; SCHWENN JD, 1987, Z NATURFORSCH C, V42, P93; SCHWENN JD, 1989, Z NATURFORSCH C, V44, P504; Setya A, 1996, P NATL ACAD SCI USA, V93, P13383, DOI 10.1073/pnas.93.23.13383; Siegel L.M., 1975, METABOLISM SULFUR CO, P217; Sohndel S, 1996, BIOCHEMISTRY-US, V35, P2357, DOI 10.1021/bi9520949; Takahashi H, 1997, P NATL ACAD SCI USA, V94, P11102, DOI 10.1073/pnas.94.20.11102; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; TSANG MLS, 1971, PLANT PHYSIOL, V47, P20; TSANG MLS, 1976, PLANT CELL PHYSIOL, V17, P1209; VANDEPEER Y, 1993, COMPUT APPL BIOSCI, V9, P177; WALEY SG, 1995, BIOCHEM J, V71, P132; Wray JL, 1998, CHEM-BIOL INTERACT, V109, P153, DOI 10.1016/S0009-2797(97)00130-0	44	72	83	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					930	936		10.1074/jbc.275.2.930	http://dx.doi.org/10.1074/jbc.275.2.930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625629	Green Submitted, hybrid			2022-12-25	WOS:000084836600033
J	Tucker, WC; Du, ZY; Hein, R; Richter, ML; Gromet-Elhanan, Z				Tucker, WC; Du, ZY; Hein, R; Richter, ML; Gromet-Elhanan, Z			Hybrid Rhodospirillum rubrum F0F1 ATP synthases containing spinach chloroplast F-1 beta or alpha and beta subunits reveal the essential role of the alpha subunit in ATP synthesis and tentoxin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI F1-ATPASE; CROSS-LINKING; DELTA-SUBUNITS; 2ND STALK; ROTATION; COMPLEX; BINDING; RECONSTITUTION; PURIFICATION	Trace amounts (similar to 55%) of the chloroplast or subunit were found to be absolutely required for effective restoration of catalytic function to LiCl-treated chromatophores of Rhodospirillum rubrum with the chloroplast beta subunit (Avital, S., and Gromet-Elhanan, Z. (1991) J. Biol. Chem. 266, 7067-7072). To clarify the role of the Lu subunit in the rebinding of beta, restoration of catalytic function, and conferral of sensitivity to the chloroplast-specific inhibitor tentoxin, LiCl-treated chromatophores were analyzed by immunoblotting before and after reconstitution with mixtures of R. rubrum and chloroplast alpha and beta subunits. The treated chromatophores were found to have lost, in addition to most of their beta subunits, approximately a third of the alpha subunits, and restoration of catalytic activity required rebinding of both subunits. The hybrid reconstituted with the R. rubrum alpha and chloroplast beta subunits was active in ATP synthesis as well as hydrolysis, and both activities were completely resistant to tentoxin. In contrast, a hybrid reconstituted with both chloroplast or and beta subunits restored only a MgATPase activity, which was fully inhibited by tentoxin, These results indicate that all three copies of the R. rubrum alpha subunit are required for proton-coupled ATP synthesis, whereas for conferral of tentoxin sensitivity at least one copy of the chloroplast alpha subunit is required together with the chloroplast beta subunit. The hybrid system was further used to examine the effects of amino acid substitution at position 83 of the beta subunit on sensitivity to tentoxin.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	Weizmann Institute of Science; University of Kansas	Gromet-Elhanan, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	z.gromet-elhanan@weizmann.ac.il			NIGMS NIH HHS [GM08545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANDRALOJC PJ, 1992, FEBS LETT, V310, P187, DOI 10.1016/0014-5793(92)81326-H; Averboukh L, 1996, BIOTECHNIQUES, V20, P918; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVNI A, 1991, J BIOL CHEM, V266, P7317; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAGG PD, 1986, ARCH BIOCHEM BIOPHYS, V244, P361, DOI 10.1016/0003-9861(86)90125-6; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; CHEN ZG, 1995, J BIOL CHEM, V270, P17124, DOI 10.1074/jbc.270.29.17124; CHEN ZG, 1992, FEBS LETT, V298, P69, DOI 10.1016/0014-5793(92)80024-B; Clayton R. K., 1963, BACTERIAL PHOTOSYNTH, P495; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DU Z, 1995, PHOTOSYNTHESIS LIGHT, V3, P27; Du ZY, 1999, EUR J BIOCHEM, V263, P430, DOI 10.1046/j.1432-1327.1999.00512.x; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; GAO F, 1995, J BIOL CHEM, V270, P9763, DOI 10.1074/jbc.270.17.9763; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; Gromet-Elhanan Z., 1995, ANOXYGENIC PHOTOSYNT, P807; GROMETELHANAN Z, 1989, BIOCHEMISTRY-US, V28, P3645, DOI 10.1021/bi00435a004; GrometElhanan Z, 1995, PHOTOSYNTH RES, V46, P79, DOI 10.1007/BF00020418; GROMETELHANAN Z, 1992, BIOCHIM BIOPHYS ACTA, V1102, P379, DOI 10.1016/0167-4838(92)90525-I; GROMETELHANAN Z, 1986, METHOD ENZYMOL, V126, P528; Hu DL, 1997, J BIOL CHEM, V272, P5457, DOI 10.1074/jbc.272.9.5457; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTY RE, 1996, OXYGENIC PHOTOSYNTHE, P807; Nathanson L, 2000, J BIOL CHEM, V275, P901, DOI 10.1074/jbc.275.2.901; Nathanson L, 1998, J BIOL CHEM, V273, P10933, DOI 10.1074/jbc.273.18.10933; NATHANSON L, 1995, PHOTOSYNTHESIS LIGHT, V3, P51; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; PHILOSOPH S, 1977, J BIOL CHEM, V252, P8747; PHILOSOPH S, 1981, EUR J BIOCHEM, V119, P107, DOI 10.1111/j.1432-1033.1981.tb05583.x; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; RICHTER ML, 1996, OXYGENIC PHOTOSYNTHE, P453; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SONE N, 1986, BIOCHEM CELL BIOL, V64, P229, DOI 10.1139/o86-033; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; Strotmann H., 1998, MOL BIOL CHLOROPLAST, P477; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; WEBSTER GD, 1977, FEBS LETT, V76, P29, DOI 10.1016/0014-5793(77)80114-2; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	51	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					906	912		10.1074/jbc.275.2.906	http://dx.doi.org/10.1074/jbc.275.2.906			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625626	hybrid			2022-12-25	WOS:000084836600030
J	Watson, RT; Pessin, JE				Watson, RT; Pessin, JE			Functional cooperation of two independent targeting domains in syntaxin 6 is required for its efficient localization in the trans-Golgi network of 3T3L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC PROTEIN-TRANSPORT; STIMULATED GLUT4 TRANSLOCATION; CYTOPLASMIC DOMAIN; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; CELL-SURFACE; SYNAPTIC VESICLES; CYTOSOLIC DOMAIN; SNARE PROTEINS; MDCK CELLS	To identify the targeting domains of syntaxin 6 responsible for its localization to the trans-Golgi network (TGN), we examined the subcellular distribution of enhanced green fluorescent protein (EGFP) epitope-tagged syntaxin 6/syntaxin 4 chimerae and syntaxin 6 truncation/deletion mutants in 3T3L1 adipocytes, Expression of EGFP-syntaxin 6 resulted in a perinuclear distribution identical to endogenous syntaxin 6 as determined both by confocal fluorescence microscopy and subcellular fractionation, Furthermore, both the endogenous and the expressed EGFP-syntaxin 6 fusion protein were localized to a brefeldin A-insensitive but okadaic acid-sensitive compartment characteristic of the TGN, In contrast, EGFP-syntaxin 6 constructs lacking the H2 domain were excluded from the TGN and were instead primarily localized to the plasma membrane. Although syntaxin 4 was localized to the plasma membrane, syntaxin 6/syntaxin 4 chimerae and syntaxin 6 truncations containing the H2 domain of syntaxin 6 were predominantly directed to the TGN. Importantly, the syntaxin 6 H2 domain fused to the transmembrane domain of syntaxin 4 was also localized to the TGN, demonstrating that the H2 domain was sufficient to confer TGN localization. In addition to the H2 domain, a tyrosine-based plasma membrane internalization signal (YGRL) was identified between the H1 and H2 domains of syntaxin 6, Deletion of this sequence resulted in the accumulation of the EGFP-syntaxin 6 reporter construct at the plasma membrane. Together, these data demonstrate that syntaxin 6 utilizes two distinct domains to drive its specific subcellular localization to the TGN.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	jeffrey-pessin@uiowa.edu			NIDDK NIH HHS [DK25925, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Banting G, 1997, BBA-MOL CELL RES, V1355, P209, DOI 10.1016/S0167-4889(96)00146-2; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Bryant NJ, 1997, J CELL BIOL, V136, P287, DOI 10.1083/jcb.136.2.287; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Gotte M, 1997, FEBS LETT, V411, P48, DOI 10.1016/S0014-5793(97)00575-9; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HORN M, 1994, BIOCHEM J, V301, P69, DOI 10.1042/bj3010069; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Keller P, 1997, J CELL SCI, V110, P3001; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stanley KK, 1996, MOL MEMBR BIOL, V13, P19, DOI 10.3109/09687689609160570; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Tang BL, 1998, BIOCHEM BIOPH RES CO, V242, P345, DOI 10.1006/bbrc.1997.7966; Tang BL, 1998, BIOCHEM BIOPH RES CO, V242, P673, DOI 10.1006/bbrc.1997.8029; Tang BL, 1998, J BIOL CHEM, V273, P6944, DOI 10.1074/jbc.273.12.6944; Tellam JT, 1997, J BIOL CHEM, V272, P6187, DOI 10.1074/jbc.272.10.6187; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; Valdez AC, 1999, J CELL SCI, V112, P845; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WONG SH, 1993, J BIOL CHEM, V268, P22853; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	65	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1261	1268		10.1074/jbc.275.2.1261	http://dx.doi.org/10.1074/jbc.275.2.1261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625671	hybrid			2022-12-25	WOS:000084836600075
J	Bearne, SL; Blouin, C				Bearne, SL; Blouin, C			Inhibition of Escherichia coli glucosamine-6 phosphate synthase by reactive intermediate analogues - The role of the 2-amino function in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; FRUCTOSE 6-PHOSPHATE; ENZYME CATALYSIS; PHOSPHOGLUCOSE ISOMERASE; BINDING-SITE; MECHANISM; SYNTHETASE; AMIDOTRANSFERASES; DERIVATIVES; SUBSTRATE	Glucosamine-6-phosphate synthase (GlmS) catalyzes the formation of D-glucosamine 6-phosphate from D-fructose 6-phosphate using L-glutamine as the ammonia source. Because N-acetylglucosamine is an essential building block of both bacterial cell walls and fungal cell wall chitin, the enzyme is a potential target for antibacterial and antifungal agents. The most potent carbohydrate-based inhibitor of GlmS reported to date is 2-amino-2-deoxy-D-glucitol 6-phosphate, an analogue of the putative cis-enolamine intermediate formed during catalysis. The interaction of a series of structurally related cis-enolamine intermediate analogues with GlmS is described. Although arabinose oxime 6-phosphate is identified as a good competitive inhibitor of GlmS with an inhibition constant equal to 1.2 (+/-0.3) mM, the presence of the amino function at the 2-position is shown to be important for potent inhibition. Comparison of the binding affinities of 2-deoxy-D-glucitol 6-phosphate and 2-amino-2-deoxy-D-glucitol 6-phosphate indicates that the amino function contributes -4.1 (+/-0.1) kcal/mol to the free energy of inhibitor binding. Similarly, comparison of the binding affinities of 2-deoxy-D-glucose 6-phosphate and D-glucosamine 6-phosphate indicates that the amino function contributes -3.0 (+/-0.1) kcal/mol to the free energy of product binding. Interactions between GlmS and the 2-amino function of its ligands contribute to the uniform binding of the product and the cis-enolamine intermediate as evidenced by the similar contribution of the amino group to the free energy of binding of D-glucosamine 6-phosphate and 2-amino-2-deoxy-D-glucitol 6-phosphate, respectively.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Bearne, SL (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.		Bearne, Stephen/ABF-8338-2021	Blouin, Christian/0000-0002-4434-4142				ALBERY WJ, 1977, ANGEW CHEM INT EDIT, V16, P285, DOI 10.1002/anie.197702851; ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; ANDRUSZKIEWICZ R, 1986, INT J PEPT PROT RES, V27, P449; AUVIN S, 1991, BIOORG CHEM, V19, P143, DOI 10.1016/0045-2068(91)90030-S; BADET B, 1988, BIOCHEMISTRY-US, V27, P2282, DOI 10.1021/bi00407a006; BADETDENISOT MA, 1995, BIOORG MED CHEM LETT, V5, P815, DOI 10.1016/0960-894X(95)00119-E; BADETDENISOT MA, 1993, B SOC CHIM FR, V130, P249; Bearne SL, 1996, J BIOL CHEM, V271, P3052; BEARNE SL, 1995, BIOCHEMISTRY-US, V34, P11515, DOI 10.1021/bi00036a026; BIGHAM EC, 1984, J MED CHEM, V27, P717, DOI 10.1021/jm00372a003; BUCHANAN JM, 1973, ADV ENZYMOL RAMB, V39, P91; CHIRGWIN JM, 1975, J BIOL CHEM, V250, P7272; CHMARA H, 1986, BIOCHIM BIOPHYS ACTA, V870, P357, DOI 10.1016/0167-4838(86)90240-2; CLARKE J, 1977, CLIN EXP DERMATOL, V2, P167, DOI 10.1111/j.1365-2230.1977.tb01561.x; COLLINS KD, 1974, J BIOL CHEM, V249, P136; CORIZZI V, 1992, J CHEM SOC CHEM COMM, P189, DOI 10.1039/c39920000189; DENISOT MA, 1991, ARCH BIOCHEM BIOPHYS, V288, P225, DOI 10.1016/0003-9861(91)90188-O; DYSON JED, 1968, J BIOL CHEM, V243, P1401; FARBER GK, 1989, BIOCHEMISTRY-US, V28, P7289, DOI 10.1021/bi00444a022; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Fersht AR, 1999, STRUCTURE MECHANISM, P340; FINCH P, 1975, J CHEM SOC PERK T 1, P1682, DOI 10.1039/p19750001682; FINCH P, 1979, CARBOHYD RES, V76, P225, DOI 10.1016/0008-6215(79)80021-X; GHOSH S, 1960, J BIOL CHEM, V235, P1265; GOLINELLIPIMPANEAU B, 1989, J AM CHEM SOC, V111, P3029, DOI 10.1021/ja00190a042; GRACY RW, 1968, J BIOL CHEM, V243, P5410; Hockett RC, 1935, J AM CHEM SOC, V57, P2265, DOI 10.1021/ja01314a067; HOCKETT RC, 1939, J AM CHEM SOC, V61, P2111; HOLLER E, 1973, BIOCHEMISTRY-US, V12, P1150, DOI 10.1021/bi00730a021; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KATI WM, 1989, SCIENCE, V243, P1591, DOI 10.1126/science.2928795; Kort M.J., 1970, ADV CARBOHYD CHEM BI, VVolume 25, P311, DOI DOI 10.1016/S0065-2318(08)60431-X; KUCHARCZYK N, 1990, BIOCHEMISTRY-US, V29, P3668, DOI 10.1021/bi00467a012; LELOIR LF, 1957, METHOD ENZYMOL, V3, P840, DOI 10.1016/S0076-6879(57)03459-X; Leriche C, 1997, EUR J BIOCHEM, V245, P418, DOI 10.1111/j.1432-1033.1997.00418.x; Leriche C, 1996, J AM CHEM SOC, V118, P1797, DOI 10.1021/ja953614q; LOLIS E, 1990, ANNU REV BIOCHEM, V59, P597, DOI 10.1146/annurev.bi.59.070190.003121; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; MEI BG, 1990, J BACTERIOL, V172, P3512, DOI 10.1128/jb.172.6.3512-3514.1990; MIDELFORT CF, 1977, BIOCHEMISTRY-US, V16, P1590, DOI 10.1021/bi00627a010; MILEWSKI S, 1992, BIOCHIM BIOPHYS ACTA, V1115, P225, DOI 10.1016/0304-4165(92)90058-3; MULIVOR R, 1973, J MOL BIOL, V76, P123, DOI 10.1016/0022-2836(73)90084-3; NOLTMANN EA, 1972, ENZYMES, V6, P271; Oliva G, 1995, STRUCTURE, V3, P1323, DOI 10.1016/S0969-2126(01)00270-2; PIERCE J, 1985, J AM CHEM SOC, V107, P2448, DOI 10.1021/ja00294a041; ROESTAMADJI J, 1995, J AM CHEM SOC, V117, P11060, DOI 10.1021/ja00150a004; ROSE IA, 1981, PHILOS T ROY SOC B, V293, P131, DOI 10.1098/rstb.1981.0067; ROSE IA, 1975, ADV ENZYMOL RAMB, V43, P491; SALAS M, 1965, J BIOL CHEM, V240, P561; SANTI DV, 1971, BIOCHEMISTRY-US, V10, P4813, DOI 10.1021/bi00801a032; SCHRAY KJ, 1973, J BIOL CHEM, V248, P2219; STREET IP, 1986, BIOCHEMISTRY-US, V25, P6021, DOI 10.1021/bi00368a028; Teplyakov A, 1998, STRUCTURE, V6, P1047, DOI 10.1016/S0969-2126(98)00105-1; Teplyakov A, 1999, PROTEIN SCI, V8, P596; WOLFENDEN R, 1972, ACCOUNTS CHEM RES, V5, P10, DOI 10.1021/ar50049a002; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415; WOLFENDEN R, 1974, MOL CELL BIOCHEM, V3, P207, DOI 10.1007/BF01686645; WOLFENDEN R, 1970, BIOCHEMISTRY-US, V9, P3404, DOI 10.1021/bi00819a018; WOLFENDEN R, 1987, ENZYME MECHANISMS, P97; WOODRUFF WW, 1979, J BIOL CHEM, V254, P5866; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	61	42	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					135	140		10.1074/jbc.275.1.135	http://dx.doi.org/10.1074/jbc.275.1.135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617596	hybrid, Green Submitted			2022-12-25	WOS:000085951600020
J	Araga, S; Xu, LK; Nakashima, K; Villain, M; Blalock, JE				Araga, S; Xu, LK; Nakashima, K; Villain, M; Blalock, JE			A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help	FASEB JOURNAL			English	Article						complementary peptide; T cell receptor; anticlonotypic antibody; autoimmunity; acetylcholine receptor	MYELIN BASIC-PROTEIN; ANTI-IDIOTYPIC ANTIBODIES; MAIN IMMUNOGENIC REGION; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MONOCLONAL ANTIIDIOTYPIC ANTIBODIES; CALIFORNICA ACETYLCHOLINE-RECEPTOR; COMPLEMENTARY PEPTIDES; ALPHA-SUBUNIT; MESSENGER-RNA; AMINO-ACIDS	Myasthenia gravis (MG) and its animal model, experimental autoimmune (EA) MG, are caused by T cell-dependent autoantibodies that react with the nicotinic acetylcholine receptor (AChR) on muscle and interfere with neuromuscular transmission. Thus, selective inactivation of CD4(+) AChR-specific T helper cells should lower AChR Ab levels and ameliorate disease. In the Lewis rat model of EAMG, alpha chain residues 100-116 of the AChR represent the dominant T cell epitope, which is important in helping Ab responses to this autoantigen, In the present report, we have applied a new design technique that requires no knowledge of Ag receptor sequences on errant T cells in order to develop a synthetic peptide vaccine against T cells reactive with the aforementioned T cell epitope, Immunization with the peptide 1) induced polyclonal and monoclonal Ab, which inhibited AChR 100-116 stimulation of AChR-sensitized lymphocytes and recognized V beta 15 containing T cell receptors on AChR 100-116-specific T cell lines and clones; 2) lowered AChR Ab levels; 3) reduced the loss of muscle AChR; and 4) lessened the incidence and severity of EAMG, These findings suggest a new strategy for the functional abrogation of epitope-specific T cells that could have potential application to human autoimmune diseases.	Univ Alabama Birmingham, Dept Phys & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Neuroimmunol, Birmingham, AL 35294 USA; Tottori Univ, Fac Med, Inst Neurol Sci, Div Neurol, Yonago, Tottori 683, Japan	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Tottori University	Blalock, JE (corresponding author), Univ Alabama Birmingham, Dept Phys & Biophys, 1918 Univ Blvd,MCLM 896, Birmingham, AL 35294 USA.	Blalock@uab.edu		Blalock, J. Edwin/0000-0001-5303-8123	NIAID NIH HHS [AI37670] Funding Source: Medline; NIMH NIH HHS [MH52527] Funding Source: Medline; NINDS NIH HHS [NS29719] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037670, R21AI037670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029719] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araga S, 1999, J IMMUNOL, V163, P476; ARAGA S, 1993, P NATL ACAD SCI USA, V90, P8747, DOI 10.1073/pnas.90.18.8747; Araga S, 1994, Immunomethods, V5, P130, DOI 10.1006/immu.1994.1047; Araga S, 1996, J IMMUNOL, V157, P386; BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; BARKAS T, 1988, J BIOL CHEM, V263, P5916; BLALOCK JE, 1990, TRENDS BIOTECHNOL, V8, P140, DOI 10.1016/0167-7799(90)90159-U; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BLALOCK JE, 1995, NAT MED, V1, P876, DOI 10.1038/nm0995-876; BLALOCK JE, 1989, METHOD ENZYMOL, V178, P63; BLALOCK JE, 1986, BIOCHEM J, V234, P679, DOI 10.1042/bj2340679; Blalock JE, 1999, CELL MOL LIFE SCI, V55, P513, DOI 10.1007/s000180050309; BOQUET D, 1995, MOL IMMUNOL, V32, P303, DOI 10.1016/0161-5890(95)00012-4; BOROVSKY D, 1994, FASEB J, V8, P350, DOI 10.1096/fasebj.8.3.7908271; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; CHRISTADOSS P, 1986, J IMMUNOL, V136, P2437; CLARKE BL, 1990, P NATL ACAD SCI USA, V87, P9708, DOI 10.1073/pnas.87.24.9708; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DAVIES AA, 1987, LYMPHOCYTES PRACTICA, P229; Dery O, 1997, J NEUROIMMUNOL, V76, P1, DOI 10.1016/S0165-5728(97)00026-X; DILL KA, 1995, PROTEIN SCI, V4, P561; DILLON J, 1991, P NATL ACAD SCI USA, V88, P9726, DOI 10.1073/pnas.88.21.9726; DRACHMAN DB, 1982, NEW ENGL J MED, V307, P769, DOI 10.1056/NEJM198209233071301; ENGEL AG, 1981, ANN NY ACAD SCI, V377, P158, DOI 10.1111/j.1749-6632.1981.tb33730.x; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FROEHNER SC, 1979, BIOCHEMISTRY-US, V18, P301, DOI 10.1021/bi00569a011; FUJII Y, 1988, J IMMUNOL, V140, P1830; GHISO J, 1990, P NATL ACAD SCI USA, V87, P1288, DOI 10.1073/pnas.87.4.1288; HOHLFELD R, 1983, MUSCLE NERVE, V6, P160, DOI 10.1002/mus.880060213; JARPE MA, 1994, PEPTIDES DESIGN SYNT, P165; Johnson H M, 1994, Immunomethods, V5, P167, DOI 10.1006/immu.1994.1051; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KINEBUCHI M, 1995, TRANSPLANT P, V27, P1511; Kinebuchi M, 1997, J IMMUNOL, V159, P748; LENNON VA, 1975, J EXP MED, V141, P1365, DOI 10.1084/jem.141.6.1365; LINDDELL JE, 1991, PRACTICAL GUIDE MONO, P85; LINDSTROM J, 1985, ANNU REV IMMUNOL, V3, P109; LINDSTROM JM, 1976, NEUROLOGY, V26, P1054, DOI 10.1212/WNL.26.11.1054; Maier C C, 1994, Immunomethods, V5, P107, DOI 10.1006/immu.1994.1044; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; McGuigan J E, 1994, Immunomethods, V5, P158, DOI 10.1006/immu.1994.1050; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; OMICHINSKI JG, 1988, DESIGN ANTISENSE PEP, V58, pS321; PALLA E, 1993, J BIOL CHEM, V268, P13486; PASCUAL D W, 1989, Peptide Research, V2, P207; PATRICK J, 1973, SCIENCE, V180, P871, DOI 10.1126/science.180.4088.871; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Ruiz-Opazo N, 1998, MOL MED, V4, P96, DOI 10.1007/BF03401733; RUIZOPAZO N, 1995, NAT MED, V1, P1074, DOI 10.1038/nm1095-1074; Saoudi A, 1999, J IMMUNOL, V162, P7189; SMITH LR, 1991, J IMMUNOL, V147, P375; SMITH LR, 1994, J IMMUNOL, V152, P2596; SMITH LR, 1987, J IMMUNOL, V138, P7; TAYLOR PM, 1987, LYMPHOCYTES PRACTICA, P133; TORRES BA, 1990, J NEUROIMMUNOL, V27, P191, DOI 10.1016/0165-5728(90)90069-Y; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899; WALDOR MK, 1983, P NATL ACAD SCI-BIOL, V80, P2713, DOI 10.1073/pnas.80.9.2713; Weigent D A, 1994, Immunomethods, V5, P91, DOI 10.1006/immu.1994.1042; WHITAKER JN, 1989, J NEUROIMMUNOL, V22, P157, DOI 10.1016/0165-5728(89)90047-7; WOFSY L, 1969, J IMMUNOL, V103, P380; YEH TM, 1990, J IMMUNOL, V144, P1654; Zhou S R, 1994, Immunomethods, V5, P136, DOI 10.1006/immu.1994.1048; ZHOU SR, 1994, J IMMUNOL, V153, P2340; ZHOU SR, 1990, J IMMUNOL, V145, P2554; ZHOU SR, 1993, J IMMUNOL, V150, P1629; Zhou SR, 1996, J NEUROSCI RES, V45, P439, DOI 10.1002/(SICI)1097-4547(19960815)45:4<439::AID-JNR13>3.0.CO;2-W; ZHOU SR, 1992, CLIN IMMUNOL IMMUNOP, V63, P74, DOI 10.1016/0090-1229(92)90096-7; ZHOU SR, 1994, CLIN IMMUNOL IMMUNOP, V70, P251, DOI 10.1006/clin.1994.1037	68	27	31	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					185	196		10.1096/fasebj.14.1.185	http://dx.doi.org/10.1096/fasebj.14.1.185			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627293				2022-12-25	WOS:000084784700021
J	Fivaz, M; Velluz, MC; van der Goot, FG				Fivaz, M; Velluz, MC; van der Goot, FG			Dimer dissociation of the pore-forming toxin aerolysin precedes receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-CHANNEL; ANCHORED PROTEIN; PROAEROLYSIN; ACTIVATION; INSERTION	The pore-forming toxin aerolysin is secreted by Aeromonas hydrophila as an inactive precursor. Based on chemical cross-linking and gel filtration, we show here that proaerolysin exists as a monomer at low concentrations but is dimeric above 0.1 mg/ml. At intermediate concentrations, monomers and dimers appeared to be in rapid equilibrium, All together our data indicate that, at low concentrations, the toxin is a monomer and that this species is competent for receptor binding. In contrast, a mutant toxin that forms a covalent dimer was unable to bind to target cells.	Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland	University of Geneva	van der Goot, FG (corresponding author), Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland.		van der Goot, Gisou G/B-2279-2012	van der Goot, Gisou G/0000-0002-8522-274X; Fivaz, Marc/0000-0003-1003-7934				Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Abrami L, 1999, J CELL BIOL, V147, P175, DOI 10.1083/jcb.147.1.175; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; Cabiaux V, 1997, BIOCHEMISTRY-US, V36, P15224, DOI 10.1021/bi971216p; Cowell S, 1997, MOL MICROBIOL, V25, P343, DOI 10.1046/j.1365-2958.1997.4691828.x; HARDIE KR, 1995, MOL MICROBIOL, V17, P1035, DOI 10.1111/j.1365-2958.1995.mmi_17061035.x; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; Krause KH, 1998, J BIOL CHEM, V273, P18122, DOI 10.1074/jbc.273.29.18122; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; Nelson KL, 1999, CELL MICROBIOL, V1, P69, DOI 10.1046/j.1462-5822.1999.00009.x; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; Rossjohn J, 1998, J STRUCT BIOL, V121, P92, DOI 10.1006/jsbi.1997.3947; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x	21	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37705	37708		10.1074/jbc.274.53.37705	http://dx.doi.org/10.1074/jbc.274.53.37705			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608828	hybrid			2022-12-25	WOS:000084528000028
J	Schulz, S; Huber, A; Schwab, K; Paulsen, R				Schulz, S; Huber, A; Schwab, K; Paulsen, R			A novel G gamma isolated from Drosophila constitutes a visual G protein gamma subunit of the fly compound eye	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ-DOMAIN PROTEIN; PHOTORECEPTOR-MEMBRANES; GENE; NORPA; INAD; PHOTOTRANSDUCTION; MELANOGASTER; RHODOPSIN; PHOSPHORYLATION; LOCALIZATION	Visual transduction in the compound eye of flies is a well established model system for the study of G protein-coupled transduction pathways. To characterize key components of the phototransduction cascade we performed substractive hybridization screening. We cloned the cDNA coding for the visual G gamma (G gamma(e)) subunit from Drosophila which had so far eluded identification at,the molecular level. Northern blot analysis revealed the presence of a major, 1.4-kilobase(kb) G gamma(e) transcript and two minor transcripts of 1.8 and 6 kb in size. The major 1.4-kb mRNA is expressed preferentially in the eye. The spatial expression pattern determined for G gamma(e) as well as co-immunoprecipitation experiments demonstrated that G gamma(e) dimerizes with G beta(e) to form the heterodimeric G beta gamma subunit which functions in visual transduction in the Drosophila compound eye. G gamma(e) shares common characteristics with the visual G gamma subunits of human rod and cone photoreceptors although different classes of G alpha subunits are employed in vertebrate and invertebrate phototransduction. By the molecular cloning and characterization of the visual gamma subunit of Drosophila one of the few missing links in the well studied Drosophila phototransduction cascade has been characterized to complete our knowledge about the Drosophila visual transduction pathway.	Univ Karlsruhe, Inst Zool, Dept Cell & Neurobiol, D-76128 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Huber, A (corresponding author), Univ Karlsruhe, Inst Zool, Dept Cell & Neurobiol, Kornblumenstr 13, D-76128 Karlsruhe, Germany.	DC05@rz.unl-karlsruhe.de		Huber, Armin/0000-0003-3977-089X				Bentrop J, 1997, EMBO J, V16, P1600, DOI 10.1093/emboj/16.7.1600; BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Chou WH, 1999, DEVELOPMENT, V126, P607; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DOLPH PJ, 1994, NATURE, V370, P59, DOI 10.1038/370059a0; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; HUBER A, 1994, EUR J CELL BIOL, V63, P219; HUBER A, 1990, J BIOL CHEM, V265, P17906; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEE YJ, 1994, NEURON, V13, P1143, DOI 10.1016/0896-6273(94)90052-3; LOTT JS, 1992, FEBS LETT, V312, P241, DOI 10.1016/0014-5793(92)80943-B; MCKAY RR, 1995, J BIOL CHEM, V270, P13271, DOI 10.1074/jbc.270.22.13271; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PAULSEN R, 1984, J COMP PHYSIOL, V155, P47, DOI 10.1007/BF00610930; Pearn MT, 1996, J BIOL CHEM, V271, P4937; PLANGGER A, 1994, J BIOL CHEM, V269, P26969; RAY K, 1992, J BIOL CHEM, V267, P6086; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEUWLY S, 1991, J BIOL CHEM, V266, P24314; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Selinger Z., 1987, Progress in Clinical and Biological Research, V249, P169; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Ueda H, 1998, J BIOCHEM-TOKYO, V124, P1033, DOI 10.1093/oxfordjournals.jbchem.a022196; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B	45	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37605	37610		10.1074/jbc.274.53.37605	http://dx.doi.org/10.1074/jbc.274.53.37605			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608815	hybrid			2022-12-25	WOS:000084528000015
J	Doitsh, G; Shaul, Y				Doitsh, G; Shaul, Y			HBV transcription repression in response to genotoxic stress is p53-dependent and abrogated by pX	ONCOGENE			English	Article						HBV transcription; DNA-damage; cisplatin; HCC; pX and p53; HBV RNA half life	HEPATITIS-B-VIRUS; SUPPRESSOR GENE-PRODUCT; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; C-ABL; ENCODED COACTIVATOR; ENHANCER ELEMENT; BINDING PROTEIN; TRANSGENIC MICE; P53	Transcription of hepatitis B Virus (HBV), an important risk factor of hepatocellular carcinoma (HCC), is controlled by cellular transcription activators including some of the cellular signaling targets, Consequently, HBV transcription rate changes in response to the cellular physiological conditions. In this report we investigated HBV gene expression and the role of physiological levels of the viral X protein (pX) under cisplatin induced genotoxic stress. We show that under these conditions the RNA level of an HBV mutant which does not express pX is sharply reduced. Studies revealed that transcription repression is responsible for the observed reduction in HBV RNA level. Repression of HBV transcription was obtained only in the p53 proficient cells. Furthermore, HBV transcription rate is recovered by the cotransfected p53 dominant negative plasmid, indicating that p53 is directly responsible for HBV transcription repression. Unexpectedly, p73, the recent p53 homologue, does not repress but rather activates HBV transcription. Interestingly, pX produced either by the HBV genome or by a cotransfected plasmid, relieves the p53 mediated repression. Collectively, these results attribute a physiological role to p53-inactivation by pX, and explain how pX may support HCC development.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.							Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; CHEONG JH, 1995, EMBO J, V14, P142; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Haviv I, 1998, GENE DEV, V12, P1217, DOI 10.1101/gad.12.8.1217; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; HOSONO S, 1991, ONCOGENE, V6, P237; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Lin Y, 1997, CANCER RES, V57, P5137; LIU X, 1995, MOL CELL BIOL, V15, P6474; LUBER B, 1993, RES VIROLOGY, V144, P311, DOI 10.1016/S0923-2516(06)80047-6; NATOLI G, 1994, ONCOGENE, V9, P2837; Ohno H, 1997, J MED VIROL, V52, P413, DOI 10.1002/(SICI)1096-9071(199708)52:4<413::AID-JMV12>3.0.CO;2-H; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Raney AK, 1997, J VIROL, V71, P1058, DOI 10.1128/JVI.71.2.1058-1071.1997; ROBERTS JJ, 1981, BIOCHIM BIOPHYS ACTA, V655, P146, DOI 10.1016/0005-2787(81)90004-6; Sambrook J., 2002, MOL CLONING LAB MANU; Schaefer S, 1998, J GEN VIROL, V79, P767, DOI 10.1099/0022-1317-79-4-767; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHAUL Y, 1981, EUR J BIOCHEM, V116, P461, DOI 10.1111/j.1432-1033.1981.tb05358.x; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SHAULIAN E, 1995, ONCOGENE, V10, P671; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Takada S, 1996, VIROLOGY, V216, P80, DOI 10.1006/viro.1996.0036; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Zhu JH, 1998, CANCER RES, V58, P5061	57	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7506	7513		10.1038/sj.onc.1203209	http://dx.doi.org/10.1038/sj.onc.1203209			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602509				2022-12-25	WOS:000084119600011
J	del Peso, L; Gonzalez, VM; Hernandez, R; Barr, FG; Nunez, G				del Peso, L; Gonzalez, VM; Hernandez, R; Barr, FG; Nunez, G			Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt	ONCOGENE			English	Article						Akt; FKHR; PAX3-FKHR; transcription	TUMOR ALVEOLAR RHABDOMYOSARCOMA; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN; PAX3; PHOSPHORYLATION; SIGNALS; DAF-16; GENE; TRANSLOCATION	Akt, a proto-oncogene that encodes a cytosolic serine/threonine kinase, can phosphorylate and modulate the activity of several proteins involved in cellular metabolism and survival. Recently, two mammalian highly related forkhead transcription factors FKHRL1 and AFX and their nematode homologue Daf-16 have been found to be targets of this kinase, Here we show that Akt, but not inactive Akt, represses the transcriptional activity of FKHR, another member of the forkhead family. FKHR mutants with alanine substitutions at three Akt phosphorylation consensus sites (T24, S256 and S319) were inhibited by Akt, but mutation of all three sites rendered FKHR resistant to suppression. By contrast, the transcriptional activity of the oncogenic PAX3-FKHR fusion protein, containing two consensus phosphorylation sites, was not inhibited by Akt, Importantly, Akt inhibited the translocation of FKHR to the nucleus, providing a mechanism by which Akt might regulate the transcriptional activity of FKHR, Consistent with this model, the localization of the PAX3-FKHR fusion protein was nuclear and was not altered by Akt, These results provide evidence that Akt inhibits the transcriptional activity of FKHR by controlling its trafficking into the nucleus and that oncogenic PAX3-FKHR can escape this negative regulation by Akt.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		del Peso, Luis/K-9391-2014; Gonzalez, Victor M/F-7396-2010; Nuñez, Gabriel/A-7160-2014	del Peso, Luis/0000-0003-4014-5688; Gonzalez, Victor M/0000-0001-7538-0552; 	NATIONAL CANCER INSTITUTE [P01CA075136, K04CA064421, R01CA064202] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64202, P01-CA75136-01A1, CA-64421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SUBLETT JE, 1995, ONCOGENE, V11, P545; Wang W, 1998, CANCER RES, V58, P4426	24	107	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7328	7333		10.1038/sj.onc.1203159	http://dx.doi.org/10.1038/sj.onc.1203159			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602488				2022-12-25	WOS:000084119400018
J	Powell, AJ; Darmon, AJ; Gonos, ES; Lam, EWF; Peden, KWC; Jat, PS				Powell, AJ; Darmon, AJ; Gonos, ES; Lam, EWF; Peden, KWC; Jat, PS			Different functions are required for initiation and maintenance of immortalization of rat embryo fibroblasts by SV40 large T antigen	ONCOGENE			English	Article						SV40 T antigen; immortalization; REFs	VIRUS-40 LARGE-T; SIMIAN-VIRUS-40 LARGE-T; LARGE TUMOR-ANTIGEN; SIMIAN VIRUS-40; ADENOVIRUS E1A; J-DOMAIN; TRANSFORMING FUNCTION; CELLULAR PROTEIN-P53; HYDROPHOBIC REGION; P53 BINDING	We have used two different, but complementary assays to characterize functions of SV40 T antigen that are necessary for its ability to immortalize rat embryo fibroblasts. In accordance with previous work, we found that several functions were required. These include activities that map to the p53 binding domain and the amino terminal 176 amino acids which contain the J domain as well as the CR1 and CR2 domain required for binding and sequestering the RE family of pocket proteins. Moreover, we found that even though activities dependent only upon the amino terminus were sufficient for immortalization they were unable to maintain it. This suggests that immortalization by these amino terminal functions requires either additional events or immortalization of a subset of cells within the heterogeneous rat embryo fibroblast population, We further found that an activity dependent upon amino acids 17-27 which remove a portion of the CR1 domain and the predicted alpha-1 helix of the J domain was not necessary to maintain growth but was required for direct immortalization suggesting that at least one of the functions required initially was not required to maintain the immortal state. This represents the first demonstration that some of the functions required for maintenance of the immortal state differ from those required for initiation of immortalization.	Royal Free & Univ Coll Med Sch, Sch Med, Ludwig Inst Canc Res, London W1P 8BT, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Cell Biol & Virol, London W2 1PG, England; US FDA, Ctr Biol Evaluat & Res, Lab Retrovirus Res, Bethesda, MD 20892 USA; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; US Food & Drug Administration (FDA); University of London; University College London	Jat, PS (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.		Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Powell, Andrew/0000-0003-1540-537X				Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; CAVENDER JF, 1995, J VIROL, V69, P923, DOI 10.1128/JVI.69.2.923-934.1995; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; Conzen SD, 1995, ONCOGENE, V11, P2295; CONZEN SD, 1994, SEMIN VIROL, V5, P349, DOI 10.1006/smvy.1994.1039; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1989, ONCOGENE, V4, P1103; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1992, ONCOGENE, V7, P1885; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; Peden KWC, 1998, VIRUS GENES, V16, P153, DOI 10.1023/A:1007941622680; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; Porras A, 1996, J VIROL, V70, P6902; Powell AJ, 1998, EXP CELL RES, V240, P252, DOI 10.1006/excr.1998.3937; RILEY TEW, 1990, MOL CELL BIOL, V10, P6664, DOI 10.1128/MCB.10.12.6664; Salminen A, 1997, BIOCHEM BIOPH RES CO, V238, P712, DOI 10.1006/bbrc.1997.7371; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOULE HR, 1979, J VIROL, V30, P523, DOI 10.1128/JVI.30.2.523-532.1979; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; Tevethia MJ, 1998, VIROLOGY, V243, P303, DOI 10.1006/viro.1998.9056; TEVETHIA MJ, 1988, VIROLOGY, V162, P79; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VOUSDEN KH, 1989, ONCOGENE, V4, P153; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	56	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7343	7350		10.1038/sj.onc.1203154	http://dx.doi.org/10.1038/sj.onc.1203154			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602490				2022-12-25	WOS:000084119400020
J	Arora, A; Rinehart, D; Szabo, G; Tamm, LK				Arora, A; Rinehart, D; Szabo, G; Tamm, LK			Refolded outer membrane protein A of Escherichia coli forms ion channels with two conductance states in planar lipid bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; OMPA PROTEIN; OPRF; LIPOPOLYSACCHARIDE; PERMEATION; MALTOPORIN; RESOLUTION; INSERTION; PORINS; GROWTH	Outer membrane protein A (OmpA), a major structural protein of the outer membrane of Escherichia coli, consists of an N-terminal 8-stranded beta-barrel transmembrane domain and a C-terminal periplasmic domain. OmpA has served as an excellent model for studying the mechanism of insertion, folding, and assembly of constitutive integral membrane proteins in vivo and in vitro. The function of OmpA is currently not well understood. Particularly, the question whether or not OmpA forms an ion channel and/or nonspecific pore for uncharged larger solutes, as some other porins do, has been controversial. We have incorporated detergent-purified OmpA into planar lipid bilayers and studied its permeability to ions by single channel conductance measurements. In 1 M KCI, OmpA formed small (50-80 pS) and large (260-320 pS) channels. These two conductance states were interconvertible, presumably corresponding to two different conformations of OmpA in the membrane. The smaller channels are associated with the N-terminal transmembrane domain, whereas both domains are required to form the larger channels. The two channel activities provide a new functional assay for the refolding in vitro of the two respective domains of OmpA Wild-type and five single tryptophan mutants of urea-denatured OmpA are shown to refold into functional channels in lipid bilayers.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Struct Biol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Tamm, LK (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.	lkt2e@virginia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037127, R37HL037127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051329] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37127] Funding Source: Medline; NIGMS NIH HHS [GM51329, R01 GM051329] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Busath D, 1981, NATURE, V294, P371, DOI 10.1038/294371a0; Busath DD, 1998, BIOPHYS J, V75, P2830, DOI 10.1016/S0006-3495(98)77726-4; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DARGENT B, 1987, FEBS LETT, V220, P136, DOI 10.1016/0014-5793(87)80891-8; De E, 1997, MICROBIOL-UK, V143, P1029, DOI 10.1099/00221287-143-3-1029; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; KENNELL WL, 1992, INFECT IMMUN, V60, P380, DOI 10.1128/IAI.60.2.380-384.1992; Ketchem RR, 1997, STRUCTURE, V5, P1655, DOI 10.1016/S0969-2126(97)00312-2; Kleinschmidt JH, 1999, PROTEIN SCI, V8, P2065, DOI 10.1110/ps.8.10.2065; Kleinschmidt JH, 1999, BIOCHEMISTRY-US, V38, P4996, DOI 10.1021/bi9824644; Kleinschmidt JH, 1999, BIOCHEMISTRY-US, V38, P5006, DOI 10.1021/bi982465w; Kleinschmidt JH, 1996, BIOCHEMISTRY-US, V35, P12993, DOI 10.1021/bi961478b; KOEBNIK R, 1995, MOL MICROBIOL, V16, P1269, DOI 10.1111/j.1365-2958.1995.tb02348.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUELLER P, 1962, CIRCULATION, V26, P1167, DOI 10.1161/01.CIR.26.5.1167; Pautsch A, 1999, PROTEINS, V34, P167, DOI 10.1002/(SICI)1097-0134(19990201)34:2<167::AID-PROT2>3.3.CO;2-8; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; Phale PS, 1997, P NATL ACAD SCI USA, V94, P6741, DOI 10.1073/pnas.94.13.6741; Rawling EG, 1998, J BACTERIOL, V180, P3556, DOI 10.1128/JB.180.14.3556-3562.1998; REID G, 1994, MOL GEN GENET, V243, P127; SAINT N, 1993, BIOCHIM BIOPHYS ACTA, V1145, P119, DOI 10.1016/0005-2736(93)90388-G; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Schmid B, 1998, PROTEIN SCI, V7, P1603, DOI 10.1002/pro.5560070714; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; Sugawara E., 1997, Biophysical Journal, V72, pA138; SUGAWARA E, 1994, J BIOL CHEM, V269, P17981; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; Sugawara E, 1996, J BACTERIOL, V178, P6067, DOI 10.1128/jb.178.20.6067-6069.1996; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; ULLSTROM CA, 1991, J BACTERIOL, V173, P768, DOI 10.1128/jb.173.2.768-775.1991; WOODRUFF WA, 1986, J BACTERIOL, V167, P473, DOI 10.1128/jb.167.2.473-479.1986	33	132	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1594	1600		10.1074/jbc.275.3.1594	http://dx.doi.org/10.1074/jbc.275.3.1594			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636850	hybrid			2022-12-25	WOS:000084940000013
J	Kim, YS; Wall, JS; Meyer, J; Murphy, C; Randolph, TW; Manning, MC; Solomon, A; Carpenter, JF				Kim, YS; Wall, JS; Meyer, J; Murphy, C; Randolph, TW; Manning, MC; Solomon, A; Carpenter, JF			Thermodynamic modulation of light chain amyloid fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; HUMAN INTERFERON-GAMMA; NATIVE-STATE; PROTEIN AGGREGATION; HYDROGEN-EXCHANGE; DEPOSITION; STABILIZATION; STABILITY; PATHOGENESIS; VARIANTS	To obtain further insight into the pathogenesis of amyloidosis and develop therapeutic strategies to inhibit fibril formation we investigated: 1) the relationship between intrinsic physical properties (thermodynamic stability and hydrogen-deuterium (H-D) exchange rates) and the propensity of human immunoglobulin light chains to form amyloid fibrils in vitro; and 2) the effects of extrinsically modulating these properties on fibril formation. An amyloid-associated protein readily formed amyloid fibrils in vitro and had a lower free energy of unfolding than a homologous nonpathological protein, which did not form fibrils in vitro. H-D exchange was much faster for the pathological protein, suggesting it had a greater fraction of partially folded molecules. The thermodynamic stabilizer sucrose completely inhibited fibril formation by the pathological protein and shifted the values for its physical parameters to those measured for the nonpathological protein in buffer alone. Conversely, urea sufficiently destabilized the nonpathological protein such that its measured physical properties were equivalent to those of the pathological protein in buffer, and it formed fibrils. Thus, fibril formation by light chains is predominantly controlled by thermodynamic stability; and a rational strategy to inhibit amyloidosis is to design high affinity ligands that specifically increase the stability of the native protein.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Tennessee, Grad Sch Med, Human Immunol & Canc Program, Knoxville, TN 37920 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Tennessee System; University of Tennessee Health Science Center; University of Colorado System; University of Colorado Boulder	Carpenter, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Box C238,4200 E 9th Ave, Denver, CO 80262 USA.	john.carpenter@uchsc.edu		Kim, Yong-Sung/0000-0003-2673-1509; Wall, Jonathan/0000-0002-5516-8578	NATIONAL CANCER INSTITUTE [R01CA010056] Funding Source: NIH RePORTER; NCI NIH HHS [CA10056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Chang BS, 1996, BIOPHYS J, V71, P3399, DOI 10.1016/S0006-3495(96)79534-6; Dhodapkar MV, 1997, HEMATOL ONCOL CLIN N, V11, P89, DOI 10.1016/S0889-8588(05)70417-2; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Freire E, 1998, ADV PROTEIN CHEM, V51, P255; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Gillmore JD, 1997, BRIT J HAEMATOL, V99, P245, DOI 10.1046/j.1365-2141.1997.303194.x; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Helms LR, 1996, J MOL BIOL, V257, P77, DOI 10.1006/jmbi.1996.0148; HIETER PA, 1982, J BIOL CHEM, V257, P1516; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kendrick BS, 1998, P NATL ACAD SCI USA, V95, P14142, DOI 10.1073/pnas.95.24.14142; Kendrick BS, 1997, P NATL ACAD SCI USA, V94, P11917, DOI 10.1073/pnas.94.22.11917; Kendrick BS, 1998, J PHARM SCI, V87, P1069, DOI 10.1021/js9801384; Kreilgaard L, 1998, ARCH BIOCHEM BIOPHYS, V360, P121, DOI 10.1006/abbi.1998.0948; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LEE JC, 1981, J BIOL CHEM, V256, P7193; LIU YF, 1995, BIOCHEMISTRY-US, V34, P12884, DOI 10.1021/bi00039a051; Luque I, 1998, METHOD ENZYMOL, V295, P100; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; MYATT EA, 1994, P NATL ACAD SCI USA, V91, P3034, DOI 10.1073/pnas.91.8.3034; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; Raffen R, 1999, PROTEIN SCI, V8, P509; SCHELLMAN JA, 1990, BIOPOLYMERS, V29, P215, DOI 10.1002/bip.360290126; Solomon A, 1998, P NATL ACAD SCI USA, V95, P9547, DOI 10.1073/pnas.95.16.9547; Solomon A, 1995, AMYLOID, V2, P269, DOI 10.3109/13506129508999010; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; Wall J, 1999, BIOCHEMISTRY-US, V38, P14101, DOI 10.1021/bi991131j; Westermark P, 1998, AM J PATHOL, V152, P1125; Wetzel R, 1997, ADV PROTEIN CHEM, V50, P183, DOI 10.1016/S0065-3233(08)60322-8; Wetzel R, 1996, CELL, V86, P699, DOI 10.1016/S0092-8674(00)80143-9	39	114	120	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1570	1574		10.1074/jbc.275.3.1570	http://dx.doi.org/10.1074/jbc.275.3.1570			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636846	hybrid			2022-12-25	WOS:000084940000009
J	Octave, JN; Essalmani, R; Tasiaux, B; Menager, J; Czech, C; Mercken, L				Octave, JN; Essalmani, R; Tasiaux, B; Menager, J; Czech, C; Mercken, L			The role of presenilin-1 in the gamma-secretase cleavage of the amyloid precursor protein of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; PEPTIDE; CELLS; EXPRESSION; LOCALIZATION; MEMBRANES; FRAGMENT	Presenilin-1 (PS1) is required for the release of the intracellular domain of Notch from the plasma membrane as well as for the cleavage of the amyloid precursor protein (APP) at the gamma-secretase cleavage site. It remains to be demonstrated whether PS1 acts by facilitating the activity of the protease concerned or is the protease itself. PS1 could have a gamma-secretase activity by itself or could traffic APP and Notch to the appropriate cellular compartment for processing. Human APP 695 and PS1 were coexpressed in Sf9 insect cells, in which endogenous gamma-secretase activity is not detected. In baculovirus-infected Sf9 cells, PS1 undergoes endoproteolysis and interacts with APP. However, PSI does not cleave APP in Sf9 cells. In CHO cells, endocytosis of APP is required for A beta secretion. Deletion of the cytoplasmic sequence of APP (APP Delta C) inhibits both APP endocytosis and A beta production. When APP Delta C and PS1 are coexpressed in CHO cells, A beta is secreted without endocytosis of APP. Taken together, these results conclusively show that, although PS1 does not cleave APP in Sf9 cells, PS1 allows the secretion of A beta without endocytosis of APP by CHO cells.	Catholic Univ Louvain, Lab Pharmacol Expt, B-1200 Brussels, Belgium; Rhone Poulenc Rorer, F-94400 Vitry Sur Seine, France	Universite Catholique Louvain; Sanofi-Aventis	Octave, JN (corresponding author), Catholic Univ Louvain, Lab Pharmacol Expt, FARL 5410,Ave Hippocrate 54, B-1200 Brussels, Belgium.	octave@nchm.ucl.ac.be		Czech, Christian/0000-0001-7746-0134				Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; CURRIE JR, 1991, J NEUROSCI RES, V30, P687, DOI 10.1002/jnr.490300413; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Essalmani R, 1996, FEBS LETT, V389, P157, DOI 10.1016/0014-5793(96)00561-3; Essalmani R, 1996, BIOCHEM BIOPH RES CO, V218, P89, DOI 10.1006/bbrc.1996.0017; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 1999, NATURE, V398, P466, DOI 10.1038/18979; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Macq AF, 1998, J BIOL CHEM, V273, P28931, DOI 10.1074/jbc.273.44.28931; Octave JN, 1995, REV NEUROSCIENCE, V6, P287; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	29	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1525	1528		10.1074/jbc.275.3.1525	http://dx.doi.org/10.1074/jbc.275.3.1525			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636839	hybrid			2022-12-25	WOS:000084940000002
J	Scragg, IG; Kwiatkowski, D; Vidal, V; Reason, A; Paxton, T; Panico, M; Dell, A; Morris, H				Scragg, IG; Kwiatkowski, D; Vidal, V; Reason, A; Paxton, T; Panico, M; Dell, A; Morris, H			Structural characterization of the inflammatory moiety of a variable major lipoprotein of Borrelia recurrentis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SURFACE PROTEIN-A; FACTOR-KAPPA-B; TREPONEMA-PALLIDUM; BURGDORFERI LIPOPROTEINS; MASS-SPECTROMETRY; ENDOTHELIAL-CELLS; OUTER-MEMBRANE; LIPID MODIFICATION; FACTOR-ALPHA	Louse-borne relapsing fever, caused by Borrelia recurrentis, provides one of the best documented examples of the causative role of tumor necrosis factor (TNF) in the pathology of severe infection in humans, We have identified the principal TNF-inducing factor of B. recurrentis as a variable major lipoprotein (Vmp), Here we report the complete gene sequence of Vmp, including its lipoprotein leader sequence. Using metabolically labeled forms of the native Vmp we confirm that the TNF inducing properties are associated with the lipid portion of the molecule. Quadrupole orthogonal time of flight mass spectrometry unequivocally locates the lipidic moiety at the NH2-terminal cysteine of the native polypeptide, and indicates the existence of three forms which are consistent with the structures C16:0, C16:0, C16:0 glyceryl cysteine; C18:1, C16:0, C16:0 glyceryl cysteine; and C18:0, C16:0, C16:0 glyceryl cysteine, These data provide the first direct evidence that the TNF inducing lipid modification of native Borrelia lipoproteins is a structural homologue of the murein lipoprotein of Escherichia coli.	Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England	University of Oxford	Kwiatkowski, D (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.			Kwiatkowski, Dominic/0000-0002-5023-0176				AKINS DR, 1993, INFECT IMMUN, V61, P1202, DOI 10.1128/IAI.61.4.1202-1210.1993; ALLAN RJ, 1993, INFECT IMMUN, V61, P4772, DOI 10.1128/IAI.61.11.4772-4776.1993; BARBOUR AG, 1987, SCIENCE, V237, P409, DOI 10.1126/science.3603026; BELISLE JT, 1994, J BACTERIOL, V176, P2151, DOI 10.1128/JB.176.8.2151-2157.1994; BESSLER WG, 1985, J IMMUNOL, V135, P1900; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Bouchon B, 1997, ANAL BIOCHEM, V246, P52, DOI 10.1006/abio.1996.9982; BRANDT ME, 1990, INFECT IMMUN, V58, P983, DOI 10.1128/IAI.58.4.983-991.1990; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Burns MJ, 1997, INFECT IMMUN, V65, P1217, DOI 10.1128/IAI.65.4.1217-1222.1997; Ebnet K, 1997, J IMMUNOL, V158, P3285; Fekade D, 1996, NEW ENGL J MED, V335, P311, DOI 10.1056/NEJM199608013350503; Giambartolomei GH, 1999, INFECT IMMUN, V67, P140, DOI 10.1128/IAI.67.1.140-147.1999; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; LEX A, 1986, J IMMUNOL, V137, P2676; MA Y, 1993, INFECT IMMUN, V61, P3843, DOI 10.1128/IAI.61.9.3843-3853.1993; MA Y, 1994, INFECT IMMUN, V62, P3663, DOI 10.1128/IAI.62.9.3663-3671.1994; Marietta EV, 1997, J IMMUNOL, V159, P2840; Metzger J W, 1995, J Pept Sci, V1, P184, DOI 10.1002/psc.310010305; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; MORRIS HR, 1998, MASS SPECTROMETRY BI; Morrison TB, 1997, J IMMUNOL, V158, P4838; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Muhlradt PF, 1998, INFECT IMMUN, V66, P4804; NEGUSSIE Y, 1992, J EXP MED, V175, P1207, DOI 10.1084/jem.175.5.1207; PITTENAUER E, 1995, J AM SOC MASS SPECTR, V6, P892, DOI 10.1016/1044-0305(95)00481-R; RADOLF JD, 1991, J IMMUNOL, V147, P1968; RADOLF JD, 1995, J IMMUNOL, V154, P2866; Sellati TJ, 1996, INFECT IMMUN, V64, P3180, DOI 10.1128/IAI.64.8.3180-3187.1996; Sellati TJ, 1998, J IMMUNOL, V160, P5455; TAI KF, 1994, INFECT IMMUN, V62, P520, DOI 10.1128/IAI.62.2.520-528.1994; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; WEYER KA, 1987, BIOCHEMISTRY-US, V26, P2909, DOI 10.1021/bi00384a036; Wooten RM, 1996, J IMMUNOL, V157, P4584; Wooten RM, 1998, J IMMUNOL, V160, P5485; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	37	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					937	941		10.1074/jbc.275.2.937	http://dx.doi.org/10.1074/jbc.275.2.937			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625630	hybrid			2022-12-25	WOS:000084836600034
J	Peng, HF; Jackson, V				Peng, HF; Jackson, V			In vitro studies on the maintenance of transcription-induced stress by histones and polyamines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME-ASSEMBLY PROTEIN; CLOSED CIRCULAR DNA; SINGLE-STRANDED-DNA; R-LOOP FORMATION; ESCHERICHIA-COLI; TOPOISOMERASE-I; RNA-POLYMERASE; OMEGA-PROTEIN; PLASMID DNA; COILED DNA	Several factors were evaluated to determine their role in facilitating the presence of transcription-induced stresses in a circular. DNA, Transcription was done with T7 RNA polymerase in the presence of E. coli topoisomerase I and closed circular DNA Positive stress was observed in hypotonic conditions or when one of the polyamines, spermidine or spermine, were present. Polycations such as polylysine, polyarginine, histone H1, histones H2A-H2B, and protamine were observed to induce minimal positive stress. It is known that polyamines influence DNA structure by causing both self-association and sequence-specific structural alterations (polyamine-induced localized bending). Experimental evidence indicates that the likely cause of the positive stress is the induced bending. In order to evaluate protein-mediated bending, transcription was done on nucleosomes, A minimum of three nucleosomes on a DNA of 6055 bp was sufficient to generate very high levels of positive stress. Histones H3-H4 in the absence of H2A-H2B were responsible for this effect. Since these histones by themselves are able to maintain negative coils on DNA, it is concluded that protein-mediated bending is yet another mechanism for placing rotational restriction on DNA, The bending of DNA by either polyamines or histones is an effective mechanism for promoting transcription-induced stresses at physiological ionic strength.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Jackson, V (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.							ANDERSON P, 1978, BIOCHEMISTRY-US, V17, P594, DOI 10.1021/bi00597a006; Basu HS, 1997, EUR J BIOCHEM, V243, P247, DOI 10.1111/j.1432-1033.1997.0247a.x; BASU HS, 1987, NUCLEIC ACIDS RES, V15, P5873, DOI 10.1093/nar/15.14.5873; Baumann CG, 1997, P NATL ACAD SCI USA, V94, P6185, DOI 10.1073/pnas.94.12.6185; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; BROOKS W, 1994, J BIOL CHEM, V269, P18155; CHRISTIANSEN C, 1977, J MOL BIOL, V115, P441, DOI 10.1016/0022-2836(77)90164-4; COOK DN, 1992, P NATL ACAD SCI USA, V88, P9675; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; DROLET M, 1994, J BIOL CHEM, V269, P2068; FEURSTEIN BG, 1990, NUCLEIC ACIDS RES, V18, P1271; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GARTENBERG MR, 1993, P NATL ACAD SCI USA, V90, P10514, DOI 10.1073/pnas.90.22.10514; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Howell ML, 1996, BIOCHEMISTRY-US, V35, P15373, DOI 10.1021/bi961881i; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; ISHMI Y, 1991, J BIOL CHEM, V266, P7025; JACKSON S, 1994, BIOCHEMISTRY-US, V33, P5392, DOI 10.1021/bi00184a006; JACKSON V, 1995, BIOCHEMISTRY-US, V34, P10607, DOI 10.1021/bi00033a036; JACKSON V, 1993, BIOCHEMISTRY-US, V32, P5901, DOI 10.1021/bi00073a024; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KOO HS, 1990, J BIOL CHEM, V265, P12300; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KUNG VT, 1977, J BIOL CHEM, V252, P5398; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LEE MS, 1991, P NATL ACAD SCI USA, V89, P11461; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1976, J MOL BIOL, V106, P439, DOI 10.1016/0022-2836(76)90095-4; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; LODGE JK, 1989, J BACTERIOL, V171, P2181, DOI 10.1128/jb.171.4.2181-2187.1989; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; MANNING GS, 1985, CELL BIOPHYS, V7, P57, DOI 10.1007/BF02788639; MARQUET R, 1988, J BIOMOL STRUCT DYN, V6, P235, DOI 10.1080/07391102.1988.10507710; MARQUET R, 1987, BIOCHIM BIOPHYS ACTA, V909, P165, DOI 10.1016/0167-4781(87)90074-1; Masse E, 1997, J BIOL CHEM, V272, P12816, DOI 10.1074/jbc.272.19.12816; MORGAN JE, 1986, ARCH BIOCHEM BIOPHYS, V246, P225, DOI 10.1016/0003-9861(86)90467-4; MURPHY LD, 1995, BIOPHYS CHEM, V57, P71, DOI 10.1016/0301-4622(95)00047-2; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; Pelta J, 1996, J BIOL CHEM, V271, P5656, DOI 10.1074/jbc.271.10.5656; Pelta J, 1996, BIOPHYS J, V71, P48, DOI 10.1016/S0006-3495(96)79232-9; Peng HF, 1997, BIOCHEMISTRY-US, V36, P12371, DOI 10.1021/bi971046g; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; PFAFFLE P, 1990, J BIOL CHEM, V265, P16821; Phoenix P, 1997, J BIOL CHEM, V272, P1473, DOI 10.1074/jbc.272.3.1473; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; Raspaud E, 1998, BIOPHYS J, V74, P381, DOI 10.1016/S0006-3495(98)77795-1; Rybenkov VV, 1997, NUCLEIC ACIDS RES, V25, P1412, DOI 10.1093/nar/25.7.1412; SARHAN S, 1989, BIOL CHEM H-S, V370, P1279, DOI 10.1515/bchm3.1989.370.2.1279; SCHMID N, 1991, BIOCHEMISTRY-US, V30, P4357, DOI 10.1021/bi00231a035; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SRIVENUGOPAL KS, 1985, BIOCHEMISTRY-US, V24, P4766, DOI 10.1021/bi00339a009; SRIVENUGOPAL KS, 1987, NUCLEIC ACIDS RES, V15, P2563, DOI 10.1093/nar/15.6.2563; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; van Holde KE., 1989, SPRINGER SERIES MOL; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; XIAO L, 1991, NUCLEIC ACIDS RES, V19, P3701, DOI 10.1093/nar/19.13.3701; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	75	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					657	668		10.1074/jbc.275.1.657	http://dx.doi.org/10.1074/jbc.275.1.657			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617664	hybrid			2022-12-25	WOS:000085951600088
J	Forlino, A; Porter, FD; Lee, EJ; Westphal, H; Marini, JC				Forlino, A; Porter, FD; Lee, EJ; Westphal, H; Marini, JC			Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha 1(I) G349C substitution - Variability in phenotype in BrtlIV mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(I) COLLAGEN GENE; TRIPLE-HELICAL DOMAIN; GLYCINE SUBSTITUTIONS; PATERNAL MOSAICISM; TRANSGENIC MICE; CRE RECOMBINASE; MUTATIONS; COL1A1; PROCOLLAGEN; SERINE	We utilized the Cre/lox recombination system to develop the first knock-in murine model for osteogenesis imperfecta (OI). The moderately severe OI phenotype was obtained from an alpha 1(I) Gly(349) --> CyS substitution in type I collagen, reproducing the mutation in a type IV OI child. We introduced four single nucleotide (nt) changes into murine collal exon 23: the disease causing G --> T transversion (nt 1546), an adjacent G --> T change (nt 1551) to generate a GUC ribozyme cleavage site, and two transversions (nt 1567 C --> A and nt 1569 C --> G;) to cause a Leu --> Met substitution, We also introduced a 3.2-kilobase pair transcription/translation stop cassette in intron 22, flanked by directly repeating lox recombination sites. After homologous recombination in ES cells, two male chimeras were obtained, Chimeras were mated with transgenic females expressing Cre recombinase to remove the stop cassette from a portion of the progeny's cells. To generate mice with full expression of the Gly(349) --> CYS mutation, these offspring were then mated with wild-type females. Skeletal staining and bone histology of the F2 revealed a classical OI phenotype with deformity, fragility, osteoporosis and disorganized trabecular structure. We designate these mice Brt1IV (Brittle IV). Brt1IV mice have phenotypic variability ranging from perinatal lethality to long term survival with reproductive success. The phenotypic variability is not associated with differences in expression levels of the mutant allele in total RNA derived from tissue extracts. Expression of the mutant protein is also equivalent in different phenotypes. Thus, these mice are an excellent model for delineation of the modifying factors postulated to affect human OI phenotypes. In addition, we generated knock-in mice carrying an "intronic" inclusion by mating chimeras with wild-type females. Alternative splicing involving the stop cassette results in retention of non-collagenous sequences. These mice reproduce the lethal phenotype of similar human mutations and are designated BrtIII.	NICHD, SCTD, HDB, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mammalian genet & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Marini, JC (corresponding author), NICHD, SCTD, HDB, NIH, Bldg 10,Rm 9S241,10 Ctr Dr,MSC-1830, Bethesda, MD 20892 USA.		Forlino, Antonella/H-5385-2015	Forlino, Antonella/0000-0002-6385-1182	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000408] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000408] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BATEMAN JF, 1992, BIOCHEM J, V288, P131, DOI 10.1042/bj2880131; Byers Peter H., 1993, P317; CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; GENOVESE C, 1989, J BIOL CHEM, V264, P9632; GRANGE DK, 1990, NUCLEIC ACIDS RES, V18, P4227, DOI 10.1093/nar/18.14.4227; Grassi G, 1997, NUCLEIC ACIDS RES, V25, P3451, DOI 10.1093/nar/25.17.3451; HOESS RH, 1990, NUCLEIC ACIDS MOL BI, V4, P99; Hormuzdi SG, 1998, MOL CELL BIOL, V18, P3368, DOI 10.1128/MCB.18.6.3368; INOUYE M, 1976, Congenital Anomalies, V16, P171; KHILLAN JS, 1991, J BIOL CHEM, V266, P23373; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lund AM, 1997, HUM MUTAT, V9, P378, DOI 10.1002/(SICI)1098-1004(1997)9:4<378::AID-HUMU16>3.3.CO;2-5; MACKAY K, 1993, HUM MOL GENET, V2, P1155, DOI 10.1093/hmg/2.8.1155; Marini J C, 1988, Adv Pediatr, V35, P391; MARINI JC, 1993, AM J HUM GENET, V53, P1199; MARINI JC, 1993, J BIOL CHEM, V268, P2667; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOTTES M, 1993, HUM MUTAT, V2, P196, DOI 10.1002/humu.1380020308; NAMIKAWA C, 1995, HUM GENET, V95, P666; Nuytinck L, 1997, EUR J HUM GENET, V5, P161; PETERKOFSKY B, 1986, J BIOL CHEM, V261, P6818; ROSE NJ, 1994, HUM MUTAT, V3, P391, DOI 10.1002/humu.1380030411; Sarafova AP, 1998, HUM MUTAT, V11, P395, DOI 10.1002/(SICI)1098-1004(1998)11:5<395::AID-HUMU7>3.3.CO;2-W; SAUER B, 1993, METHOD ENZYMOL, V225, P890; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; STERNBERG N, 1986, J MOL BIOL, V187, P197, DOI 10.1016/0022-2836(86)90228-7; SUPERTIFURGA A, 1989, J MED GENET, V26, P358, DOI 10.1136/jmg.26.6.358; VALLI M, 1991, J BIOL CHEM, V266, P1872; VIRDI AS, 1994, HUM GENET, V93, P287, DOI 10.1007/BF00212024; WILLING MC, 1992, AM J HUM GENET, V51, P508; Zhuang JP, 1996, HUM MUTAT, V7, P89, DOI 10.1002/(SICI)1098-1004(1996)7:2<89::AID-HUMU1>3.3.CO;2-#	36	100	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37923	37931		10.1074/jbc.274.53.37923	http://dx.doi.org/10.1074/jbc.274.53.37923			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608859	hybrid			2022-12-25	WOS:000084528000059
J	Giesemann, T; Rathke-Hartlieb, S; Rothkegel, M; Bartsch, JW; Buchmeier, S; Jockusch, BM; Jockusch, H				Giesemann, T; Rathke-Hartlieb, S; Rothkegel, M; Bartsch, JW; Buchmeier, S; Jockusch, BM; Jockusch, H			A role for polyproline motifs in the spinal muscular atrophy protein SMN - Profilins bind to and colocalize with SMN in nuclear gems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NEURON GENE; TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; SURVIVAL; ACTIN; COMPLEX; CELLS; VASP; LOCALIZATION; PLAKOGLOBIN	Spinal muscular atrophy (SMA) is an autosomal, recessive disorder characterized by the loss of a-motoneurons in the spinal cord followed by atrophy of skeletal muscles. SMA-determining candidate genes, SMN1 and SMN2, have been identified on human chromosome 5q. The corresponding SMN protein is expressed ubiquitously. It is coded by seven exons and contains conspicuous proline-rich motifs in its COOH-terminal third (exons 4, 5, and 6). Such motifs are known to bind to profilins (PFNs), small proteins engaged in the control of actin dynamics. We tested whether profilins interact with SMN via its polyproline stretches. Using the yeast two-hybrid system we show that profilins bind to SMN and that this binding depends on its proline-rich motifs, These results were confirmed by coimmunoprecipitation and by in vitro binding studies. Two PFN isoforms, I and II, are known, of which II is characteristic for central nervous system tissue. me show by in situ hybridization that both PFNs are highly expressed in mouse spinal cord and that PFN II is expressed predominantly in neurons. In motoneurons, the primary target of neurodegeneration in SMA, profilins are highly concentrated and colocalize with SMN in the cytoplasm of the cell body and in nuclear gems. Likewise, SMN and PFN I colocalize in gems of HeLa cells. Although SMN interacts with both profilin isoforms, binding of PFN II was stronger than of PFN I in all assays employed. Because the SMN genes are expressed ubiquitously, our findings suggest that the interaction of PFN II with SMN may be involved in neuron-specific effects of SMN mutations.	Univ Bielefeld, Dept Dev Biol & Mol Pathol, D-33501 Bielefeld, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Dept Cell Biol, Inst Zool, D-38092 Braunschweig, Germany	University of Bielefeld; Braunschweig University of Technology	Jockusch, H (corresponding author), Univ Bielefeld, Dept Dev Biol & Mol Pathol, W7, D-33501 Bielefeld, Germany.	h.jockusch@biologie.uni-bielefeld.de	Bartsch, Joerg Walter/AAB-2951-2020	Bartsch, Prof. Joerg Walter/0000-0002-2773-3357; , Martin/0000-0001-5041-4429				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; DiDonato CJ, 1997, GENOME RES, V7, P339, DOI 10.1101/gr.7.4.339; Domke T, 1997, FEBS LETT, V411, P291, DOI 10.1016/S0014-5793(97)00719-9; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Francis JW, 1998, P NATL ACAD SCI USA, V95, P6492, DOI 10.1073/pnas.95.11.6492; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; Giesemann T., 1999, European Journal of Cell Biology, V78, P88; Gonsior SM, 1999, J CELL SCI, V112, P797; Hahnen E, 1997, HUM MOL GENET, V6, P821, DOI 10.1093/hmg/6.5.821; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; JOCKUSCH H, 1997, MOL BIOL NEURON, P21; LAMBRECHTS A, 1995, EUR J BIOCHEM, V230, P281, DOI 10.1111/j.1432-1033.1995.0281i.x; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Mattaj IW, 1998, CURR BIOL, V8, pR93, DOI 10.1016/S0960-9822(98)70055-7; Mayboroda O, 1997, CELL MOTIL CYTOSKEL, V37, P166, DOI 10.1002/(SICI)1097-0169(1997)37:2<166::AID-CM9>3.0.CO;2-6; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; Parsons DW, 1996, HUM MOL GENET, V5, P1727, DOI 10.1093/hmg/5.11.1727; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rudiger M, 1997, BIOTECHNIQUES, V23, P96, DOI 10.2144/97231bm20; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497; vanderSteege G, 1996, AM J HUM GENET, V59, P834; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wiedemann P, 1996, J BIOL CHEM, V271, P29915, DOI 10.1074/jbc.271.47.29915; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; WITKE W, 1993, MOL BIOL CELL, V4, P149	43	166	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37908	37914		10.1074/jbc.274.53.37908	http://dx.doi.org/10.1074/jbc.274.53.37908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608857	hybrid			2022-12-25	WOS:000084528000057
J	Kannt, A; Pfitzner, U; Ruitenberg, M; Hellwig, P; Ludwig, B; Mantele, W; Fendler, K; Michel, H				Kannt, A; Pfitzner, U; Ruitenberg, M; Hellwig, P; Ludwig, B; Mantele, W; Fendler, K; Michel, H			Mutation of Arg-54 strongly influences heme composition and rate and directionality of electron transfer in Paracoccus denitrificans cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTON PUMP; SITE; PROTEIN; REDUCTION; OXYGEN; TRANSLOCATION; SPECTROSCOPY; PURIFICATION; SPHAEROIDES	The effect of a single site mutation of Arg-54 to methionine in Paracoccus denitrificans cytochrome c oxidase was studied using a combination of optical spectroscopy, electrochemical and rapid kinetics techniques, and time-resolved measurements of electrical membrane potential. The mutation resulted in a blue-shift of the heme a alpha-band by 15 nm and partial occupation of the low-spin heme site by heme O. Additionally, there was a marked decrease in the midpoint potential of the low-spin heme, resulting in slow reduction of this heme species. A stopped-flow investigation of the reaction with ferrocytochrome c yielded a kinetic difference spectrum resembling that of heme a(3). This observation, and the absence of transient absorbance changes at the corresponding wavelength of the low-spin heme, suggests that, in the mutant enzyme, electron transfer from Cu-A to the binuclear center may not occur via heme a but that instead direct electron transfer to the high-spin heme is the dominating process. This was supported by charge translocation measurements where Delta psi generation was completely inhibited in the presence of HCN. Our results thus provide an example for how the interplay between protein and cofactors can modulate the functional properties of the enzyme complex.	Max Planck Inst Biophys, Abt Mol Membranbiol, D-60528 Frankfurt, Germany; Univ Frankfurt, Inst Biochem, D-60439 Frankfurt, Germany; Univ Frankfurt, Inst Biophys, D-60590 Frankfurt, Germany; Max Planck Inst Biophys, Biophys Chem Abt, D-60596 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt; Goethe University Frankfurt; Max Planck Society	Michel, H (corresponding author), Max Planck Inst Biophys, Abt Mol Membranbiol, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.		Kannt, Aimo/AAZ-6898-2020	hellwig, petra/0000-0001-6294-5163; Fendler, Klaus/0000-0002-5699-7060; Kannt, Aimo/0000-0002-5197-2286				ADELROTH P, 1995, BIOCHEMISTRY-US, V34, P2844; Adelroth P, 1998, BBA-BIOENERGETICS, V1367, P107, DOI 10.1016/S0005-2728(98)00142-X; ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; BABCOCK GT, 1983, BIOCHEMISTRY-US, V22, P2314, DOI 10.1021/bi00279a002; BAMBERG E, 1979, BIOPHYS STRUCT MECH, V5, P277, DOI 10.1007/BF02426663; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Brzezinski P, 1996, BIOCHEMISTRY-US, V35, P5611, DOI 10.1021/bi960260m; CALLAHAN PM, 1983, BIOCHEMISTRY-US, V22, P452, DOI 10.1021/bi00271a031; CAUGHEY WS, 1975, J BIOL CHEM, V250, P7602; GEREN LM, 1995, J BIOL CHEM, V270, P2466, DOI 10.1074/jbc.270.6.2466; GERHUS E, 1990, J BACTERIOL, V172, P2392, DOI 10.1128/jb.172.5.2392-2400.1990; Gropp T, 1998, BBA-BIOMEMBRANES, V1368, P184, DOI 10.1016/S0005-2736(97)00162-4; Hartung K, 1997, BIOPHYS J, V72, P2503, DOI 10.1016/S0006-3495(97)78895-7; HARTZELL CR, 1976, BIOCHIM BIOPHYS ACTA, V423, P323, DOI 10.1016/0005-2728(76)90189-4; HAZZARD JT, 1991, BIOCHEMISTRY-US, V30, P213, DOI 10.1021/bi00215a031; Hellwig P, 1999, BIOCHEMISTRY-US, V38, P1685, DOI 10.1021/bi982282+; HILL BC, 1994, J BIOL CHEM, V269, P2419; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kannt A, 1998, J BIOENERG BIOMEMBR, V30, P81, DOI 10.1023/A:1020563629032; Kannt A, 1998, BIOPHYS J, V74, P708, DOI 10.1016/S0006-3495(98)73996-7; KLEYMANN G, 1995, BIO-TECHNOL, V13, P155, DOI 10.1038/nbt0295-155; LARSSON S, 1995, P NATL ACAD SCI USA, V92, P7167, DOI 10.1073/pnas.92.16.7167; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; MATSUSHITA K, 1992, J BIOL CHEM, V267, P24748; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; MOODY AJ, 1991, FEBS LETT, V293, P101, DOI 10.1016/0014-5793(91)81161-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILSSON T, 1992, P NATL ACAD SCI USA, V89, P6497, DOI 10.1073/pnas.89.14.6497; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Papa S, 1998, FEBS LETT, V439, P1, DOI 10.1016/S0014-5793(98)01305-2; Pfitzner U, 1998, J BIOENERG BIOMEMBR, V30, P89, DOI 10.1023/A:1020515713103; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; Ramirez BE, 1995, P NATL ACAD SCI USA, V92, P11949, DOI 10.1073/pnas.92.26.11949; Regan JJ, 1998, J BIOENERG BIOMEMBR, V30, P35, DOI 10.1023/A:1020551326307; Schroter T, 1998, FEBS LETT, V432, P109, DOI 10.1016/S0014-5793(98)00839-4; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; TSUDZUKI T, 1971, ARCH BIOCHEM BIOPHYS, V145, P149, DOI 10.1016/0003-9861(71)90021-X; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; VERKHOVSKY MI, 1995, BIOCHEMISTRY-US, V34, P7483, DOI 10.1021/bi00022a023; Voss S, 1997, PROTEIN ENG, V10, P975, DOI 10.1093/protein/10.8.975; WEINSTEIN JD, 1983, J BIOL CHEM, V258, P6799; WIKSTROM MKF, 1981, CYTOCHROME OXIDASE S, P88; WILSON DF, 1972, BIOCHIM BIOPHYS ACTA, V256, P277, DOI 10.1016/0005-2728(72)90058-8; WINKLER JR, 1995, BIOPHYS CHEM, V54, P199, DOI 10.1016/0301-4622(94)00156-E; Witt H, 1998, EUR J BIOCHEM, V251, P367, DOI 10.1046/j.1432-1327.1998.2510367.x; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	53	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37974	37981		10.1074/jbc.274.53.37974	http://dx.doi.org/10.1074/jbc.274.53.37974			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608865	hybrid			2022-12-25	WOS:000084528000065
J	Papoff, G; Hausler, P; Eramo, A; Pagano, MG; Di Leve, G; Signore, A; Ruberti, G				Papoff, G; Hausler, P; Eramo, A; Pagano, MG; Di Leve, G; Signore, A; Ruberti, G			Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; NECROSIS-FACTOR RECEPTOR; FAS-MEDIATED APOPTOSIS; SIGNALING COMPLEX DISC; TNF RECEPTOR; SOLUBLE FAS; CELL-DEATH; FAS/APO-1 CD95; HEART-FAILURE; SERUM LEVELS	The CD95 death receptor plays an important role in several physiological and pathological apoptotic processes involving in particular the immune system. CD95 ligation leads to clustering of the receptor cytoplasmic "death domains" and recruitment of the zymogen form of caspase-8 to the cell surface. Activation of this protease through self-cleavage, followed by activation of downstream effector caspases, culminates in cleavage of a set of cellular proteins resulting in apoptosis with disassembly of the cell. It is very well known that the extracellular region of the CD95 receptor is required for CD95L interaction and that the death domain is necessary for the induction of the apoptotic signaling. Here, we identified and characterized a novel CD95 ligand- and death domain-independent oligomerization domain mapping to the NH2-terminal extracellular region of the CD95 receptor. In vitro and in vivo studies indicated that this domain, conserved among all soluble CD95 variants, mediates homo-oligomerization of the CD95 receptor and of the soluble CD95 proteins, as well as hetero-oligomerization of the receptor with the soluble variants. These results offer new insight into the mechanism of apoptosis inhibition mediated by the soluble CD95 proteins and suggest a role of the extracellular oligomerization domain in the regulation of the non-signaling state of the CD95 receptor.	CNR, Inst Cell Biol, I-00016 Monterotondo, Rome, Italy; Univ Roma La Sapienza, Med Clin 2, NuMED Grp, I-00161 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Ruberti, G (corresponding author), CNR, Inst Cell Biol, Campus Adriano Buzzati Traverso,Via E Ramarini 32, I-00016 Monterotondo, Rome, Italy.	gruberti@ibc.rm.cnr.it	PAPOFF, GIULIANA/AAX-9520-2020; Signore, Alberto/E-5812-2010; Eramo, Adriana/K-6694-2016	PAPOFF, GIULIANA/0000-0003-2251-8794; Signore, Alberto/0000-0001-8923-648X; Eramo, Adriana/0000-0002-0814-6683; RUBERTI, Giovina/0000-0003-2367-9709				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cascino I, 1996, J IMMUNOL, V156, P13; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Fadeel B, 1995, INT IMMUNOL, V7, P1967, DOI 10.1093/intimm/7.12.1967; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Goel N, 1995, ARTHRITIS RHEUM, V38, P1738, DOI 10.1002/art.1780381206; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jodo S, 1997, CLIN EXP IMMUNOL, V107, P89, DOI 10.1046/j.1365-2249.1997.d01-901.x; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Knipping E, 1995, ARTHRITIS RHEUM, V38, P1735, DOI 10.1002/art.1780381205; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LIU CD, 1995, BIOCHEM J, V310, P957, DOI 10.1042/bj3100957; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Midis GP, 1996, CANCER RES, V56, P3870; MITA E, 1994, BIOCHEM BIOPH RES CO, V204, P468, DOI 10.1006/bbrc.1994.2483; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nozawa K, 1997, ARTHRITIS RHEUM, V40, P1126, DOI 10.1002/art.1780400617; Okuyama M, 1997, AM J CARDIOL, V79, P1698, DOI 10.1016/S0002-9149(97)00228-2; Orlinick JR, 1997, J BIOL CHEM, V272, P28889, DOI 10.1074/jbc.272.46.28889; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Papoff G, 1996, J IMMUNOL, V156, P4622; PETER ME, 1995, CELL DEATH DIFFER, V2, P163; Prasad NKA, 1998, J IMMUNOL, V161, P3781; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RODSETH LE, 1994, J MOL BIOL, V239, P332, DOI 10.1006/jmbi.1994.1371; Ruberti G, 1996, ADV EXP MED BIOL, V406, P125; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827; SESSA G, 1993, EMBO J, V12, P3507, DOI 10.1002/j.1460-2075.1993.tb06025.x; SIGNORE A, 1992, NUCL MED COMMUN, V13, P713, DOI 10.1097/00006231-199213100-00003; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Starling GC, 1997, J EXP MED, V185, P1487, DOI 10.1084/jem.185.8.1487; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toyozaki T, 1998, AM J CARDIOL, V81, P798, DOI 10.1016/S0002-9149(97)01032-1; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Walker PR, 1998, CURR OPIN IMMUNOL, V10, P564, DOI 10.1016/S0952-7915(98)80225-2; Yufu Y, 1998, AM J HEMATOL, V58, P334, DOI 10.1002/(SICI)1096-8652(199808)58:4<334::AID-AJH15>3.0.CO;2-7	55	122	125	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38241	38250		10.1074/jbc.274.53.38241	http://dx.doi.org/10.1074/jbc.274.53.38241			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608899	hybrid			2022-12-25	WOS:000084528000099
J	Cong, F; Zou, XM; Hinrichs, K; Calame, K; Goff, SP				Cong, F; Zou, XM; Hinrichs, K; Calame, K; Goff, SP			Inhibition of v-Abl transformation by p53 and p19ARF	ONCOGENE			English	Article						v-Abl; p53; p19ARF; transformation	MURINE LEUKEMIA-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; ARF TUMOR-SUPPRESSOR; TYROSINE KINASE; P53-DEPENDENT APOPTOSIS; GENE-PRODUCT; CELLS; P19(ARF); DNA; SENESCENCE	Tumorigenesis is a multistep process that involves the activation of oncogenes and the inactivation of tumor suppressor genes. The transforming activity of the v-Abl oncogene of Abelson murine leukemia virus (A-MuLV) in immortal cell lines has been well studied, while the effects of v-Abl in primary fibroblasts are less clear. Here we show that v-Abl causes cell cycle arrest in primary mouse embryonic fibroblasts (MEFs) and elevated levels of both p53 and the cyclin-dependent kinase inhibitor p21(Cip). p53(-/-) or p19ARF(-/-) MEFs were resistant to v-Abl-induced cell cycle arrest. Although wild-type MEFs were resistant to v-Abl transforming activity, p53(-/-) or p19ARF(-/-) MEFs were susceptible. The results indicate that loss of p19ARF and p53 function plays an important role during the transformation of primary cells by v-Abl. We suggest that although v-Abl is a potent oncogene, its full potential transforming activity cannot be realized until the ARF-, and p53-dependent growth inhibitory pathway is disabled. We also show that p53 is not the mediator of v-Abl toxicity in immortal fibroblasts and does not determine the susceptibility of immortal fibroblasts to v-Abl transformation.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Biol Sci, New York, NY 10025 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Goff, SP (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, Room 1127 HHSC,701 W 168th St, New York, NY 10032 USA.		Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NATIONAL CANCER INSTITUTE [P01CA075399] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Chen Y, 1996, J BIOL CHEM, V271, P19637, DOI 10.1074/jbc.271.33.19637; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, ONCOGENE, V11, P791; GREEN PL, 1989, J VIROL, V63, P1989, DOI 10.1128/JVI.63.5.1989-1994.1989; GREEN PL, 1987, J VIROL, V61, P2192, DOI 10.1128/JVI.61.7.2192-2197.1987; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Huang TS, 1996, ONCOGENE, V13, P625; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PRATT DM, 1977, CELL, V12, P683, DOI 10.1016/0092-8674(77)90268-9; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; PROKOCIMER M, 1994, BLOOD, V84, P2391; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Thome KC, 1997, J VIROL, V71, P8149, DOI 10.1128/JVI.71.11.8149-8156.1997; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Unnikrishnan I, 1999, MOL CELL BIOL, V19, P4825, DOI 10.1128/mcb.19.7.4825; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	51	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7731	7739		10.1038/sj.onc.1203290	http://dx.doi.org/10.1038/sj.onc.1203290			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618713	Bronze			2022-12-25	WOS:000084256900002
J	Page, G; Kogel, D; Rangnekar, V; Scheidtmann, KH				Page, G; Kogel, D; Rangnekar, V; Scheidtmann, KH			Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis	ONCOGENE			English	Article						Dlk/ZIP kinase; two hybrid interaction screen; leucine zipper; Par-4; actin filaments; apoptosis	ATAXIA-TELANGIECTASIA GENE; SERINE THREONINE KINASE; ZIPPER PROTEIN PAR-4; LEUCINE-ZIPPER; SERINE/THREONINE KINASE; MOLECULAR-CLONING; CATALYTIC DOMAIN; DNA-BINDING; HUMAN BRAIN; CELL-DEATH	Dlk/ZIP kinase is a newly discovered serine/threonine kinase which, due to its homology to DAP kinase, was named DAP like kinase, Dlk. This kinase is tightly associated with nuclear structures, it undergoes extensive autophosphorylation and phosphorylates myosin light chain and core histones H3, H2A and H4 in vitro. Moreover, it possesses a leucine zipper which mediates interaction with transcription factor ATF-4, therefore it was called ZIP kinase. We employed the yeast two-hybrid system to identify interaction partners of Dlk that might serve as regulators or targets. Besides ATF-4 and others we found Par-4, a modulator of transcription factor WT1 and mediator of apoptosis. Complex formation between Dlk and Par-4 was confirmed by GST pull-down experiments and kinase reactions in vitro and coexpression experiments in vivo. The interaction domain within Dlk was mapped to an arginine-rich region between residues 338-417, rather than to the leucine zipper. Strikingly, coexpression of Dlk and Par-4 lead to relocation of Dlk from the nucleus to the cytoplasm, particularly to actin filaments. These interactions provoked a dramatic reorganization of the cytoskeleton and morphological symptoms of apoptosis, thus suggesting a functional relationship between Dlk and Par-4 in the control of apoptosis.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany; Univ Kentucky, Lexington, KY 40536 USA	University of Bonn; University of Kentucky	Scheidtmann, KH (corresponding author), Univ Bonn, Inst Genet, Roemerstr 164, D-53117 Bonn, Germany.			Kogel, Donat/0000-0003-1209-0210				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blouin R, 1996, DNA CELL BIOL, V15, P631, DOI 10.1089/dna.1996.15.631; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hunter Tony, 1994, Seminars in Cell Biology, V5, P367, DOI 10.1006/scel.1994.1044; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MULLER E, 1995, ONCOGENE, V10, P1175; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Sambrook J., 2002, MOL CLONING LAB MANU; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854	48	92	99	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7265	7273		10.1038/sj.onc.1203170	http://dx.doi.org/10.1038/sj.onc.1203170			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602480				2022-12-25	WOS:000084119400010
J	Pritchard, DM; Potten, CS; Korsmeyer, SJ; Roberts, S; Hickman, JA				Pritchard, DM; Potten, CS; Korsmeyer, SJ; Roberts, S; Hickman, JA			Damage-induced apoptosis in intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo	ONCOGENE			English	Article						apoptosis; bcl-2; bax; 5-fluorouracil; gamma-irradiation; intestinal epithelia	RADIATION-INDUCED APOPTOSIS; HUMAN COLORECTAL ADENOMAS; MURINE SMALL-INTESTINE; CELL-DEATH; GAMMA-IRRADIATION; P53-DEPENDENT APOPTOSIS; GASTROINTESTINAL-TRACT; HIERARCHICAL STATUS; CRYPT CELLS; P53	The influence of bcl-2 and bax expression on apoptotic cell death in mouse intestinal epithelia was assessed using homozygously null mice. Apoptosis was induced in vivo by the enterotoxin 5-fluorouracil (5FU) or by gamma-irradiation and its cell positional incidence was assessed. 5FU and gamma-radiation treated bax-null mice surprisingly showed no reductions in apoptotic yield in the small intestine or midcolon at 4.5 h at cell positions in which both agents had previously been shown to strongly induce p53 protein expression. The colonic epithelia of 5FU treated bcl-2-null mice showed elevated levels of apoptosis at 4.5 h: from 48 apoptotic events in wild-type mice to 273 in the nulls, scoring 200 half crypts. The increase occurred specifically in the cell positions considered to harbour colonic stem cells, at the base of crypts, where there is selective expression of bcl-2. There was a modest but significant increase in apoptosis in the small intestine of the bcl-2-null mice although the epithelia of wild-type mice here are not immunohistochemically positive for bcl-2 protein. These findings show that bcl-2 plays a key role in determining the sensitivity of colonic stem cells to damage-induced death but that bax is not responsible for the p53-dependent induction of apoptosis in this context.	Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England; Christie Hosp NHS Trust, Paterson Inst, Dept Epithelial Biol, CRC, Manchester M20 9BX, Lancs, England; Dana Farber Canc Inst, Boston, MA 02115 USA; Christie Hosp NHS Trust, Paterson Inst, CRC, Biomath & Comp Unit, Manchester M20 9BX, Lancs, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Harvard University; Dana-Farber Cancer Institute; Christie NHS Foundation Trust; Christie Hospital	Hickman, JA (corresponding author), Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Stopford Bldg G38, Manchester M13 9PT, Lancs, England.			Pritchard, David Mark/0000-0001-7971-3561				CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chresta CM, 1996, CANCER RES, V56, P1834; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; HAGUE A, 1994, ONCOGENE, V9, P3367; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IJIRI K, 1983, BRIT J CANCER, V47, P175, DOI 10.1038/bjc.1983.25; IJIRI K, 1987, BRIT J CANCER, V55, P113, DOI 10.1038/bjc.1987.25; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Lamb JR, 1997, NAT MED, V3, P962, DOI 10.1038/nm0997-962; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MERRITT AJ, 1995, J CELL SCI, V108, P2261; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; Merritt Anita J., 1996, P269; MIYASHITA T, 1995, CELL, V80, P293; NAKAMURA H, 1994, DEV HYDROB, V91, P3; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; POTTEN CS, 1990, INT J RADIAT BIOL, V57, P185, DOI 10.1080/09553009014550431; Potten CS, 1996, BRIT J CANCER, V74, P1743, DOI 10.1038/bjc.1996.624; Potten CS, 1998, BRIT J CANCER, V78, P993, DOI 10.1038/bjc.1998.618; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Pritchard DM, 1998, CANCER RES, V58, P5453; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 1999, CANC DRUG DISC DEV, V5, P99; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Simms LA, 1998, ONCOGENE, V17, P2003, DOI 10.1038/sj.onc.1202109; Watson AJM, 1996, BRIT J CANCER, V73, P889, DOI 10.1038/bjc.1996.178; WILSON JW, 1996, APOPTOSIS, V1, P183; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	38	87	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7287	7293		10.1038/sj.onc.1203150	http://dx.doi.org/10.1038/sj.onc.1203150			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602483				2022-12-25	WOS:000084119400013
J	Suhasini, M; Pilz, RB				Suhasini, M; Pilz, RB			Transcriptional elongation of c-myb is regulated by NF-kappa B (p50/RelB)	ONCOGENE			English	Article						c-myb; NF-kappa B; transcriptional regulation; erythroid differentiation; murine erythroleukemia cells	ERYTHROLEUKEMIA CELL-DIFFERENTIATION; MESSENGER-RNA; UP-REGULATION; EXPRESSION; PROMOTER; BINDING; FAMILY; GENE; IDENTIFICATION; ONCOGENE	High levels of c-myb expression are necessary for the proliferation of hematopoietic precursor cells whereas do,vn-regulation of c-myb is required for terminal differentiation; this down-regulation occurs through a conditional block to transcriptional elongation in intron I, We previously observed that cAMP analogs prevented the late down-regulation of c-myb during hexamethylene bisacetamide (HMBA)-induced differentiation of murine erythroleukemia (MEL) cells and blocked differentiation; this correlated with the induction of NF-kappa B (p50/RelB) complexes which were shown to bind to NF-kappa B recognition sites flanking the transcriptional pause site of c-myb. We now selected stably-transfected MEL cells which overexpressed p50, RelB or both at levels similar to those induced by cAMP to determine whether these NF-kappa B proteins regulate c-myb expression in intact cells, We demonstrate that transcriptionally active NF-kappa B (p50/RelB) complexes, but not p50 or RelB alone, prevented the early and late down-regulation of c-myb mRNA and increased c-myb transcriptional elongation in HMBA-induced MEL cells. The increase in c-myb expression was sufficient to block erythroid differentiation and allow continuous proliferation of cells in the presence of HMBA, Steady-state c-myb mRNA levels in untreated cells were not affected by overexpression of NF-kappa B, suggesting that p50/RelB specifically modulated the efficiency of transcriptional attenuation during MEL cell differentiation.	Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM55586] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIL OL, 1993, EMBO J, V12, P5043; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; DANISH R, 1992, ONCOGENE, V7, P901; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dooley S, 1996, LEUKEMIA RES, V20, P429, DOI 10.1016/0145-2126(96)00012-4; Gonda TJ, 1998, INT J BIOCHEM CELL B, V30, P547, DOI 10.1016/S1357-2725(98)00003-X; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; JACOBS SM, 1994, ONCOGENE, V9, P227; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOUNTZ JD, 1993, MOL IMMUNOL, V30, P787, DOI 10.1016/0161-5890(93)90001-R; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Phan SC, 1996, MOL CELL BIOL, V16, P2387; PILZ RB, 1992, J BIOL CHEM, V267, P16161; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Shain KH, 1999, J CELL BIOCHEM, V73, P237, DOI 10.1002/(SICI)1097-4644(19990501)73:2<237::AID-JCB10>3.0.CO;2-H; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; VALTIERI M, 1991, BLOOD, V77, P1181; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; Wang ZB, 1999, EMBO J, V18, P2218, DOI 10.1093/emboj/18.8.2218; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144	41	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7360	7369		10.1038/sj.onc.1203158	http://dx.doi.org/10.1038/sj.onc.1203158			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602492				2022-12-25	WOS:000084119400022
J	Fujiyoshi, Y				Fujiyoshi, Y			Molecular structure of proton primp revealed with electron crystallography	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		PURPLE MEMBRANE; HALOBACTERIUM-HALOBIUM; BACTERIORHODOPSIN; RESOLUTION; MICROSCOPY; MODEL		Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Fujiyoshi, Y (corresponding author), Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		Fujiyoshi, Yoshinori/E-5989-2012	Fujiyoshi, Yoshinori/0000-0002-8070-1493				BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; Fujiyoshi Y, 1998, ADV BIOPHYS, V35, P25, DOI 10.1016/S0065-227X(98)90004-1; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; KRIVANEK OL, 1993, ULTRAMICROSCOPY, V49, P95, DOI 10.1016/0304-3991(93)90216-K; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0	11	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S191	S194		10.1096/fasebj.13.9002.S191	http://dx.doi.org/10.1096/fasebj.13.9002.S191			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619126				2022-12-25	WOS:000084390200004
J	Hirschberg, K; Lippincott-Schwartz, J				Hirschberg, K; Lippincott-Schwartz, J			Secretory pathway kinetics and in vivo analysis of protein traffic from the Golgi complex to the cell surface	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MA	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		GREEN FLUORESCENT PROTEIN; PLASMA-MEMBRANE PROTEINS; ENDOPLASMIC-RETICULUM; LIVING CELLS; TRANSPORT VESICLES; VISUALIZATION; EXPRESSION; MICROSCOPY; APPARATUS; DYNAMICS		NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hirschberg, K (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Room 101,18 Lib Dr, Bethesda, MD 20892 USA.	jlippin@helix.nih.gov	Hirschberg, Koret/AAF-4566-2019					Alberts B., 1994, MOL BIOL CELL; ARNHEITER H, 1984, CELL, V39, P99, DOI 10.1016/0092-8674(84)90195-8; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; Bergmann JE, 1989, METHOD CELL BIOL, V32, P85; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; Lafont F, 1995, COLD SPRING HARB SYM, V60, P753, DOI 10.1101/SQB.1995.060.01.081; LIPPINCOTTSCHWA.J, 1998, METHODS CELL BIOL GF; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PISTON D, 1998, METHODS CELL BIOL GF; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHEELE G, 1985, J BIOL CHEM, V260, P926; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Wacker I, 1997, J CELL SCI, V110, P1453; WEHLAND J, 1982, CELL, V28, P831, DOI 10.1016/0092-8674(82)90062-9	33	34	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13			2			S251	S256		10.1096/fasebj.13.9002.S251	http://dx.doi.org/10.1096/fasebj.13.9002.S251			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619138				2022-12-25	WOS:000084390200016
J	Drewett, V; Muller, S; Goodall, J; Shaw, PE				Drewett, V; Muller, S; Goodall, J; Shaw, PE			Dimer formation by ternary complex factor ELK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; SERUM RESPONSE ELEMENT; C-FOS EXPRESSION; ETS-DOMAIN; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; BINDING MOTIF; DNA-BINDING; MAP KINASES; IN-VIVO	Ternary complex factors (TCFs), a subgroup of the ets protein family, bind with a dimer of serum response factor to the c-fos serum response element. Both DNA binding and transcriptional activation by TCFs are regulated by mitogen-activated protein kinases. When activated, mitogen-activated protein kinases form homodimers that translocate to the nucleus, where they interact with TCFs via specific docking sites. Here we show by three different criteria that Elk-l is capable of forming dimers in eukaryotic cells through two distinct interaction domains. These observations are consistent with a dynamic model of TCF-promoter interactions.	Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.			SHAW, Peter/0000-0002-2598-4283				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gille H, 1996, MOL CELL BIOL, V16, P1094; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; PINGOUD V, 1994, J BIOL CHEM, V269, P23310; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WULFING C, 1994, J BIOL CHEM, V269, P2895; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	37	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1757	1762		10.1074/jbc.275.3.1757	http://dx.doi.org/10.1074/jbc.275.3.1757			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636872	hybrid			2022-12-25	WOS:000084940000035
J	Ganapathy, ME; Huang, W; Rajan, DP; Carter, AL; Sugawara, M; Iseki, K; Leibach, FH; Ganapathy, V				Ganapathy, ME; Huang, W; Rajan, DP; Carter, AL; Sugawara, M; Iseki, K; Leibach, FH; Ganapathy, V			beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER-MEMBRANE; RENAL PEPTIDE TRANSPORTERS; CARNITINE TRANSPORT; CEPHALORIDINE; AFFINITY; KIDNEY; PEPT-2; METABOLISM; VESICLES; CELLS	Therapeutic use of cephaloridine, a beta-lactam antibiotic, in humans is associated with carnitine deficiency. A potential mechanism for the development of carnitine deficiency is competition between cephaloridine and carnitine for the renal reabsorptive process. OCTN2 is an organic cation/carnitine transporter that is responsible for Na+-coupled transport of carnitine in the kidney and other tissues. We investigated the interaction of several beta-lactam antibiotics with OCTN2 using human cell lines that express the transporter constitutively as well as using cloned human and rat OCTN2s expressed heterologously in human cell lines. The beta-lactam antibiotics cephaloridine, cefoselis, cefepime, and cefluprenam were found to inhibit OCTN2-mediated carnitine transport, These antibiotics possess a quaternary nitrogen as does carnitine, Several other beta-lactam antibiotics that do not possess this structural feature did not interact with OCTN2, The interaction of cephaloridine with OCTN2 is competitive with respect to carnitine, Interestingly, many of the beta-lactam antibiotics that were not recognized by OCTN2 were good substrates for the H+-coupled peptide transporters PEPT1 and PEPT2, In contrast, cephaloridine, cefoselis, cefepime, and cefluprenam, which were recognized by OCTN2, did not interact with PEPT1 and PEPT2, The interaction of cephaloridine with OCTN2 was Na+-dependent, whereas the interaction of cefoselis and cefepime with OCTN2 was largely Na+-independent, Furthermore, the Na+-dependent, OCTN2-mediated cellular uptake of cephaloridine could be demonstrated by direct uptake measurements, These studies show that OCTN2 plays a crucial role in the pharmacokinetics and therapeutic efficacy of certain beta-lactam antibiotics such as cephaloridine and that cephaloridine-induced carnitine deficiency is likely to be due to inhibition of carnitine reabsorption in the kidney.	Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Hokkaido Univ Hosp, Dept Pharm, Sapporo, Hokkaido 0608648, Japan	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Hokkaido University	Ganapathy, ME (corresponding author), Med Coll Georgia, Dept Med, Augusta, GA 30912 USA.	mganapat@mail.mcg.edu	Sugawara, Mitsuru/A-5274-2012	Sugawara, Mitsuru/0000-0001-5350-2950	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054412] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54412] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bretschneider B, 1999, PHARMACEUT RES, V16, P55, DOI 10.1023/A:1018814627484; Burwinkel B, 1999, BIOCHEM BIOPH RES CO, V261, P484, DOI 10.1006/bbrc.1999.1060; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DANIEL H, 1993, J CLIN INVEST, V92, P2215, DOI 10.1172/JCI116824; Ganapathy ME, 1997, BBA-BIOMEMBRANES, V1324, P296, DOI 10.1016/S0005-2736(96)00234-9; GANAPATHY ME, 1995, J BIOL CHEM, V270, P25672, DOI 10.1074/jbc.270.43.25672; Huang W, 1999, BIOCHEM PHARMACOL, V58, P1361, DOI 10.1016/S0006-2952(99)00219-1; Jariyawat S, 1999, J PHARMACOL EXP THER, V290, P672; Kerner J, 1998, ANNU REV NUTR, V18, P179, DOI 10.1146/annurev.nutr.18.1.179; Koepsell H, 1999, J MEMBRANE BIOL, V167, P103, DOI 10.1007/s002329900475; Lamhonwah AM, 1998, BIOCHEM BIOPH RES CO, V252, P396, DOI 10.1006/bbrc.1998.9679; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030; Prasad PD, 1996, BBA-BIOMEMBRANES, V1284, P109, DOI 10.1016/0005-2736(96)00126-5; RAMAMOORTHY S, 1995, BBA-BIOMEMBRANES, V1240, P1, DOI 10.1016/0005-2736(95)00178-7; REBOUCHE CJ, 1984, ARCH BIOCHEM BIOPHYS, V235, P393, DOI 10.1016/0003-9861(84)90212-1; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Roque AS, 1996, BBA-BIOMEMBRANES, V1282, P274, DOI 10.1016/0005-2736(96)00068-5; Stanley C A, 1995, Adv Pediatr, V42, P209; STIEGER B, 1995, BIOCHEM J, V309, P643, DOI 10.1042/bj3090643; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Tang NLS, 1999, HUM MOL GENET, V8, P655, DOI 10.1093/hmg/8.4.655; TSUJI A, 1993, J PHARM PHARMACOL, V45, P996, DOI 10.1111/j.2042-7158.1993.tb05645.x; TUNE BM, 1980, KIDNEY INT, V18, P591, DOI 10.1038/ki.1980.177; TUNE BM, 1994, J PHARMACOL EXP THER, V270, P873; TUNE BM, 1995, BIOCHEM PHARMACOL, V50, P562, DOI 10.1016/0006-2952(95)00169-Z; Tune Bruce M., 1993, P257; Wang YH, 1999, P NATL ACAD SCI USA, V96, P2356, DOI 10.1073/pnas.96.5.2356; Wenzel U, 1996, J PHARMACOL EXP THER, V277, P831; WOLD JS, 1977, J CHROMATOGR, V136, P170; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	32	128	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1699	1707		10.1074/jbc.275.3.1699	http://dx.doi.org/10.1074/jbc.275.3.1699			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636865	hybrid			2022-12-25	WOS:000084940000028
J	Ravier, MA; Eto, K; Jonkers, FC; Nenquin, M; Kadowaki, T; Henquin, JC				Ravier, MA; Eto, K; Jonkers, FC; Nenquin, M; Kadowaki, T; Henquin, JC			The oscillatory behavior of pancreatic islets from mice with mitochondrial glycerol-3-phosphate dehydrogenase knockout	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL-PHOSPHATE DEHYDROGENASE; STIMULATED INSULIN-SECRETION; MALATE-ASPARTATE SHUTTLE; SENSITIVE K+ CHANNELS; MOUSE B-CELLS; BETA-CELLS; CYTOPLASMIC CA2+; GLYCEROPHOSPHATE DEHYDROGENASE; ADENINE-NUCLEOTIDES; ENERGY-STATE	Glucose stimulation of pancreatic beta cells induces oscillations of the membrane potential, cytosolic Ca2+ ([Ca2+](i)), and insulin secretion. Each of these events depends on glucose metabolism. Both intrinsic oscillations of metabolism and repetitive activation of mitochondrial dehydrogenases by Ca2+ have been suggested to be decisive for this oscillatory behavior. Among these dehydrogenases, mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH), the key enzyme of the glycerol phosphate NADH shuttle, is activated by cytosolic [Ca2+](i),, In the present study, we compared different types of oscillations in beta cells from wild-type and mGPDH(-/-) mice. In clusters of 5-30 islet cells and in intact islets, 15 mM glucose induced an initial drop of [Ca2+](i), followed by am increase in three phases: a marked initial rise, a partial decrease with rapid oscillations and eventually large and slow oscillations. These changes, in particular the frequency of the oscillations and the magnitude of the [Ca2+] rise, were similar in wild-type and mGPDH(-/-) mice. Glucose-induced electrical activity (oscillations of the membrane potential with bursts of action potentials) was not altered in mGPDH(-/-) beta cells. In single islets from either type of mouse, insulin secretion strictly followed the changes in [Ca2+](i) during imposed oscillations induced by pulses of high K+ or glucose and during the biphasic elevation induced by sustained stimulation with glucose. An imposed and controlled rise of [Ca2+](i) in beta cells similarly increased NAD(P)B fluorescence in control and mGDPH(-/-) islets. Inhibition of the malate-aspartate NADH shuttle with aminooxyacetate only had minor effects in control islets but abolished the electrical, [Ca2+](i) and secretory responses in mGPDH(-/-) islets, The results show that the two distinct NADH shuttles play an important but at least partially redundant role in glucose-induced insulin secretion. The oscillatory behavior of beta cells does not depend on the functioning of mGPDH and on metabolic oscillations that would be generated by cyclic activation of this enzyme by Ca2+.	Univ Catholique Louvain, Fac Med, Unite Endocrinol & Metab, B-1200 Brussels, Belgium; Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan	Universite Catholique Louvain; University of Tokyo	Henquin, JC (corresponding author), Univ Catholique Louvain, Fac Med, Unite Endocrinol & Metab, 55-30 Ave Hippocrate 55, B-1200 Brussels, Belgium.		Ravier, Magalie/K-9911-2019; Ravier, Magalie A/N-6934-2017	Ravier, Magalie/0000-0001-6607-6559; Ravier, Magalie A/0000-0001-6607-6559				ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; Barbosa RM, 1998, J PHYSIOL-LONDON, V510, P135, DOI 10.1111/j.1469-7793.1998.135bz.x; Barron JT, 1998, J MOL CELL CARDIOL, V30, P1571, DOI 10.1006/jmcc.1998.0722; BERGLUND O, 1980, ACTA ENDOCRINOL-COP, V93, P54, DOI 10.1530/acta.0.0930054; BERGSTEN P, 1994, J BIOL CHEM, V269, P8749; BERRY MN, 1994, EUR J BIOCHEM, V225, P557, DOI 10.1111/j.1432-1033.1994.00557.x; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; Cunningham BA, 1996, AM J PHYSIOL-ENDOC M, V271, pE702, DOI 10.1152/ajpendo.1996.271.4.E702; DETIMARY P, 1994, BIOCHEM J, V297, P455, DOI 10.1042/bj2970455; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; DUKES ID, 1994, J BIOL CHEM, V269, P10979; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Eto K, 1999, J BIOL CHEM, V274, P25386, DOI 10.1074/jbc.274.36.25386; GARDNER RS, 1974, ANAL BIOCHEM, V59, P272, DOI 10.1016/0003-2697(74)90033-5; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GILON P, 1993, J BIOL CHEM, V268, P22265; GILON P, 1992, J BIOL CHEM, V267, P20713; HENQUIN JC, 1982, BIOCHEM PHARMACOL, V31, P1407, DOI 10.1016/0006-2952(82)90036-3; IDAHL LA, 1995, BIOCHEM J, V312, P287, DOI 10.1042/bj3120287; Jonas JC, 1998, DIABETES, V47, P1266, DOI 10.2337/diabetes.47.8.1266; Jonkers FC, 1999, J PHYSIOL-LONDON, V520, P839, DOI 10.1111/j.1469-7793.1999.00839.x; Kennedy ED, 1998, DIABETES METAB, V24, P15; LENZEN S, 1979, AM J PHYSIOL, V236, pE391, DOI 10.1152/ajpendo.1979.236.4.E391; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MacDonald MJ, 1997, DIABETES, V46, P1996, DOI 10.2337/diabetes.46.12.1996; MacDonald MJ, 1996, DIABETES, V45, P886, DOI 10.2337/diabetes.45.7.886; Malaisse W., 1996, DIABETES REV, P145; MALAISSE WJ, 1982, ENDOCRINOLOGY, V111, P392, DOI 10.1210/endo-111-2-392; MATSCHINSKY FM, 1996, DIABETES REV, V4, P130; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MEISSNER HP, 1990, METHOD ENZYMOL, V192, P235; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RASSCHAERT J, 1991, BIOCHEM J, V278, P335, DOI 10.1042/bj2780335; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SEKINE N, 1994, J BIOL CHEM, V269, P4895; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; Ueda K, 1998, DIABETOLOGIA, V41, P649, DOI 10.1007/s001250050963; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	45	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	2000	275	3					1587	1593		10.1074/jbc.275.3.1587	http://dx.doi.org/10.1074/jbc.275.3.1587			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277NQ	10636849	hybrid			2022-12-25	WOS:000084940000012
J	Chin, LS; Nugent, RD; Raynor, MC; Vavalle, JP; Li, L				Chin, LS; Nugent, RD; Raynor, MC; Vavalle, JP; Li, L			SNIP, a novel SNAP-25-interacting protein implicated in regulated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; MEMBRANE-FUSION COMPLEX; HUMAN GROWTH-HORMONE; PC12 CELLS; SYNAPTIC VESICLES; IN-VITRO; T-SNARE; CA2+-DEPENDENT EXOCYTOSIS; NEUROTRANSMITTER RELEASE; CLOSTRIDIAL NEUROTOXINS	Synaptosome-associated protein of 25 kDa (SNAP-25) is a presynaptic membrane protein that has been clearly implicated in membrane fusion in both developing and mature neurons, although its mechanisms of action are unclear. We have now identified a novel SNAP-BB-interacting protein named SNIP, SNIP is a hydrophilic, 145-kDa protein that comprises two predicted coiled-coil domains, two highly charged regions, and two proline-rich domains with multiple PPXY and PXXP motifs, SNIP is selectively expressed in brain where it codistributes with SNAP-25 in most brain regions. Biochemical studies have revealed that SNIP is tightly associated with the brain cytoskeleton. Subcellular fractionation and immunofluorescence localization studies have demonstrated that SNIP co-localizes with SNAP-25 as well as the cortical actin cytoskeleton, suggesting that SMP serves as a linker protein connecting SNAP-25 to the submembranous cytoskeleton. By using deletion analysis, we have mapped the binding domains of SNIP and SNAP-25, and we have demonstrated that the SNIP-SNAP-25 association is mediated via coiled-coil interactions. Moreover, we have shown that overexpression of SNIP or its SNAP-25-interacting domain inhibits Ca2+-dependent exocytosis from PC12 cells. These results indicate that SNIP is involved in regulation of neurosecretion, perhaps via its interaction with SNAP-25 and the cytoskeleton.	Univ N Carolina, Dept Pharmacol, Sch Med, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Physiol, Sch Med, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Li, L (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, Bowles Ctr Alcohol Studies, Rm 1025A Thurston Bowles, Chapel Hill, NC 27599 USA.			Li, Lian/0000-0003-4700-1134; Chin, Lih-Shen/0000-0002-0817-0368	NINDS NIH HHS [NS37939] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037939] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; Bennett MK, 1997, CURR OPIN NEUROBIOL, V7, P316, DOI 10.1016/S0959-4388(97)80058-X; BINZ T, 1994, J BIOL CHEM, V269, P1617; Bretscher A, 1997, J CELL SCI, V110, P3011; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Deitcher D. L., 1997, Society for Neuroscience Abstracts, V23, P1170; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Foster LJ, 1999, AM J PHYSIOL-CELL PH, V276, pC1108, DOI 10.1152/ajpcell.1999.276.5.C1108; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; GALLI T, 1995, NEUROPHARMACOLOGY, V34, P1351, DOI 10.1016/0028-3908(95)00113-K; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hess EJ, 1996, J NEUROSCI, V16, P3104, DOI 10.1523/jneurosci.16-09-03104.1996; HESS EJ, 1992, J NEUROSCI, V12, P2865; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mains RE, 1999, J BIOL CHEM, V274, P2929, DOI 10.1074/jbc.274.5.2929; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Mehta PP, 1996, P NATL ACAD SCI USA, V93, P10471, DOI 10.1073/pnas.93.19.10471; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OsenSand A, 1996, J COMP NEUROL, V367, P222, DOI 10.1002/(SICI)1096-9861(19960401)367:2<222::AID-CNE5>3.0.CO;2-7; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; PFENNINGER KH, 1993, DEV BRAIN RES, V71, P181, DOI 10.1016/0165-3806(93)90170-F; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Raber J, 1997, J NEUROCHEM, V68, P176; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Steffensen SC, 1996, SYNAPSE, V22, P281, DOI 10.1002/(SICI)1098-2396(199603)22:3<281::AID-SYN11>3.3.CO;2-7; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tahara M, 1998, J BIOL CHEM, V273, P33667, DOI 10.1074/jbc.273.50.33667; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Wang GY, 1997, J CELL SCI, V110, P505; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; WICK PF, 1993, J BIOL CHEM, V268, P10983; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; Wilson MC, 1996, BIOCHEM SOC T, V24, P670, DOI 10.1042/bst0240670; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	83	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1191	1200		10.1074/jbc.275.2.1191	http://dx.doi.org/10.1074/jbc.275.2.1191			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625663	Green Published, hybrid			2022-12-25	WOS:000084836600067
J	Garcia-Ocana, A; Takane, KK; Syed, MA; Philbrick, WM; Vasavada, RC; Stewart, AF				Garcia-Ocana, A; Takane, KK; Syed, MA; Philbrick, WM; Vasavada, RC; Stewart, AF			Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PROTEIN; FETAL PANCREATIC-CELLS; FACTOR SCATTER FACTOR; MOLECULAR-CLONING; EPITHELIAL-CELLS; RAT PANCREAS; EXPRESSION; RECEPTOR; REPLICATION; ACTIVATION	Hepatocyte growth factor (HGF) is produced in pancreatic mesenchyme-derived cells and in islet cells. In vitro, HGF increases the insulin content and proliferation of islets. To study the role of HGF in the islet in vivo, we have developed three lines of transgenic mice overexpressing mHGF using the rat insulin II promoter (RIP). Each RIP-HGF transgenic line displays clear expression of HGF mRNA and protein in the islet. RIP-mHGF mice are relatively hypoglycemic in post-prandial and fasting states compared with their normal littermates. They display inappropriate insulin production, striking overexpression of insulin mRNA in the islet, and a a-fold increase in the insulin content in islet extracts. Importantly, beta cell replication rates in vivo are two to three times higher in RIP-HGF mice. This increase in proliferation results in a 2-3-fold increase in islet mass. Moreover, the islet number per pancreatic area was also increased by approximately 50%. Finally, RIP-mHGF mice show a dramatically attenuated response to the diabetogenic effects of streptozotocin. We conclude that the overexpression of HGF in the islet increases beta cell proliferation, islet number, beta cell mass, and total insulin production in vivo. These combined effects result in mild hypoglycemia and resistance to the diabetogenic effects of streptozotocin.	Univ Pittsburgh, Sch Med, Div Endocrinol, Pittsburgh, PA 15213 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University	Garcia-Ocana, A (corresponding author), Univ Pittsburgh, Sch Med, Div Endocrinol, BST E-1140,3550 Terrace St, Pittsburgh, PA 15213 USA.				NIDCR NIH HHS [DE 12616] Funding Source: Medline; NIDDK NIH HHS [DK 47168, DK 55023] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055023, R01DK047168] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRELJE TC, 1993, ENDOCRINOLOGY, V132, P879, DOI 10.1210/en.132.2.879; Calvo EL, 1996, BIOCHEM BIOPH RES CO, V229, P257, DOI 10.1006/bbrc.1996.1789; DAVALLI AM, 1995, DIABETES, V44, P104, DOI 10.2337/diabetes.44.1.104; Efrat S, 1996, DIABETES REV, V4, P224; EIZIRIK DL, 1991, BIOCHEM PHARMACOL, V42, P2275, DOI 10.1016/0006-2952(91)90230-3; FURUKAWA T, 1995, AM J PATHOL, V147, P889; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; HAYEK A, 1995, DIABETES, V44, P1458, DOI 10.2337/diabetes.44.12.1458; HOGG J, 1993, J ENDOCRINOL, V138, P401, DOI 10.1677/joe.0.1380401; KORC M, 1993, J CLIN INVEST, V92, P1113, DOI 10.1172/JCI116677; Kosai K, 1998, BIOCHEM BIOPH RES CO, V244, P683, DOI 10.1006/bbrc.1998.8293; Lefebvre VH, 1998, DIABETES, V47, P134, DOI 10.2337/diabetes.47.1.134; Liu YH, 1998, BIOCHEM BIOPH RES CO, V246, P821, DOI 10.1006/bbrc.1998.8676; MARS WM, 1993, AM J PATHOL, V143, P949; Mashima H, 1996, ENDOCRINOLOGY, V137, P3969, DOI 10.1210/en.137.9.3969; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MIYAURA C, 1991, MOL ENDOCRINOL, V5, P226, DOI 10.1210/mend-5-2-226; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MONTANA E, 1994, J CLIN INVEST, V93, P1577, DOI 10.1172/JCI117137; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; OTONKOSKI T, 1994, DIABETES, V43, P1164, DOI 10.2337/diabetes.43.9.1164; Otonkoski T, 1996, ENDOCRINOLOGY, V137, P3131, DOI 10.1210/en.137.7.3131; OTONKOSKI T, 1994, DIABETES, V43, P947, DOI 10.2337/diabetes.43.7.947; Porter SE, 1998, ENDOCRINOLOGY, V139, P3743, DOI 10.1210/en.139.9.3743; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Rafaeloff R, 1997, J CLIN INVEST, V99, P2100, DOI 10.1172/JCI119383; SCAGLIA L, 1995, ENDOCRINOLOGY, V136, P5461, DOI 10.1210/en.136.12.5461; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SOIFER NE, 1993, J CLIN INVEST, V92, P2850, DOI 10.1172/JCI116905; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STEWART AF, 1982, J CLIN ENDOCR METAB, V55, P219, DOI 10.1210/jcem-55-2-219; SWENNE I, 1985, DIABETES, V34, P803, DOI 10.2337/diabetes.34.8.803; TSUDA H, 1992, JPN J CANCER RES, V83, P1262, DOI 10.1111/j.1349-7006.1992.tb02756.x; TURK J, 1993, BIOCHEM BIOPH RES CO, V197, P1458, DOI 10.1006/bbrc.1993.2641; Vasavada RC, 1996, J BIOL CHEM, V271, P1200, DOI 10.1074/jbc.271.2.1200; WANG TC, 1993, J CLIN INVEST, V92, P1349, DOI 10.1172/JCI116708; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	47	185	194	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					1226	1232		10.1074/jbc.275.2.1226	http://dx.doi.org/10.1074/jbc.275.2.1226			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625667	hybrid			2022-12-25	WOS:000084836600071
J	Hanley, JG; Jones, EMC; Moss, SJ				Hanley, JG; Jones, EMC; Moss, SJ			GABA receptor rho 1 subunit interacts with a novel splice variant of the glycine transporter, GLYT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGER SALAMANDER RETINA; XENOPUS OOCYTES; AMACRINE CELLS; BIPOLAR CELLS; RAT RETINA; C-RECEPTOR; CLONING; LOCALIZATION; EXPRESSION; BRAIN	Ionotropic gamma-aminobutyric acid (GABA(A) and GABA(C)) receptors mediate fast synaptic inhibition in the central nervous system. GABA(C) receptors are expressed predominantly in the retina on bipolar cell axon terminals, and are thought to mediate feedback inhibition from GABAergic amacrine cells. Utilizing the yeast two-hybrid system, we previously identified MAP1B as a binding partner of the GABA(C) receptor rho 1 subunit, Here we describe the isolation of an additional rho 1 interacting protein: a novel C-terminal variant of the glycine transporter GLYT-1. We show that GLYT-1 exists as four alternatively spliced mRNAs which encode proteins expressing one of two possible intracellullar N- and C-terminal domains. Variants containing the novel C terminus efficiently transport glycine when expressed in COS cells, but with unusual kinetics. We have confirmed the interaction between the novel C terminus and rho 1 subunit and demonstrated binding in heterologous cells. This interaction may be crucial for the integration of GABAergic and glycinergic neurotransmission in the retina.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Univ Chicago, Comm Neurobiol, Chicago, IL USA	University of London; University College London; University of London; University College London; University of Chicago	Moss, SJ (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	steve.moss@ucl.ac.uk		Hanley, Jonathan/0000-0003-1704-4707				ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Bergeron R, 1998, P NATL ACAD SCI USA, V95, P15730, DOI 10.1073/pnas.95.26.15730; BLONDEL O, 1994, J BIOL CHEM, V269, P27167; Borowsky B, 1998, J BIOL CHEM, V273, P29077, DOI 10.1074/jbc.273.44.29077; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; CALVO DJ, 1995, NEUROREPORT, V6, P1118, DOI 10.1097/00001756-199505300-00011; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; Dong CJ, 1998, J NEUROPHYSIOL, V79, P2171, DOI 10.1152/jn.1998.79.4.2171; Enz R, 1996, J NEUROSCI, V16, P4479; Enz R, 1998, VISION RES, V38, P1431, DOI 10.1016/S0042-6989(97)00277-0; ENZ R, 1995, EUR J NEUROSCI, V7, P1495, DOI 10.1111/j.1460-9568.1995.tb01144.x; FEIGENSPAN A, 1993, NATURE, V361, P159, DOI 10.1038/361159a0; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; Hackam AS, 1997, J BIOL CHEM, V272, P13750, DOI 10.1074/jbc.272.21.13750; Hanley JG, 1999, NATURE, V397, P66, DOI 10.1038/16258; Innis MA, 1990, PCR PROTOCOLS GUIDE; KANNER BI, 1994, J EXP BIOL, V196, P237; Kim JH, 1999, CURR OPIN CELL BIOL, V11, P248, DOI 10.1016/S0955-0674(99)80033-7; KIM KM, 1994, MOL PHARMACOL, V45, P608; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; Lukasiewicz PD, 1996, MOL NEUROBIOL, V12, P181, DOI 10.1007/BF02755587; LUKASIEWICZ PD, 1994, J NEUROSCI, V14, P1213, DOI 10.1523/JNEUROSCI.14-03-01213.1994; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; OGURUSU T, 1995, J NEUROCHEM, V65, P964; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; PAN ZH, 1995, J NEUROSCI, V15, P2668; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; TACHIBANA M, 1987, P NATL ACAD SCI USA, V84, P3501, DOI 10.1073/pnas.84.10.3501; THOMSON AM, 1989, TRENDS NEUROSCI, V12, P349, DOI 10.1016/0166-2236(89)90042-8; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823; WAESSLE H, 1991, Physiological Reviews, V71, P447; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WANG TL, 1994, J NEUROSCI, V14, P6524; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	40	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					840	846		10.1074/jbc.275.2.840	http://dx.doi.org/10.1074/jbc.275.2.840			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625616	hybrid			2022-12-25	WOS:000084836600020
J	Zingone, A; Hiraiwa, H; Pan, CJ; Lin, BC; Chen, HW; Ward, JM; Chou, JY				Zingone, A; Hiraiwa, H; Pan, CJ; Lin, BC; Chen, HW; Ward, JM; Chou, JY			Correction of glycogen storage disease type 1a in a mouse model by gene therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT ADENOVIRUSES IMPROVES; GLUCOSE-6-PHOSPHATASE SYSTEM; MURINE GLUCOSE-6-PHOSPHATASE; LIVER; TRANSPLANTATION; TRANSPORT; GLUCOSE; CLONING; VECTORS; E2A	Glycogen storage disease type 1a (GSD-1a), characterized by hypoglycemia, liver and kidney enlargement, growth retardation, hyperlipidemia, and hyperuricemia, is caused by a deficiency in glucose-6-phosphatase (G6Pase), a key enzyme in glucose homeostasis. To evaluate the feasibility of gene replacement therapy for GSD-1a, we have infused adenoviral vector containing the murine G6Pase gene (Ad-mG6Pase) into G6Pase-deficient (G6Pase(-/-)) mice that manifest symptoms characteristic of human GSD-1a. Whereas < 15% of G6Pase(-/-) mice under glucose therapy survived weaning, a 100% survival rate was achieved when G6Pase(-/-) mice were infused with Ad-mG6Pase, 90% of which lived to 3 months of age. Hepatic G6Pase activity in Ad-mG6Pase-infused mice was restored to 19% of that in G6Pase(+/+) mice at 7-14 days post-infusion; the activity persisted for at least 70 days. Ad-mG6Pase infusion also greatly improved growth of G6Pase(-/-) mice and normalized plasma glucose, cholesterol, triglyceride, and uric acid profiles. Furthermore, liver and kidney enlargement was less pronounced with near-normal levels of glycogen depositions in both organs. Our data demonstrate that a single administration of a recombinant adenoviral vector can alleviate the pathological manifestations of GSD-1a in mice, suggesting that this disorder in humans can potentially be corrected by gene therapy.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Acad Sinica, Inst Biol Chem, Taipei, Taiwan; NCI, Frederick Canc Res & Dev Ctr, Vet & Tumor Pathol Sect,Off Lab Anim Sci, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Academia Sinica - Taiwan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.		Lin, Baochuan/A-8390-2009	Lin, Baochuan/0000-0002-9484-0785	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ARION WJ, 1980, J BIOL CHEM, V255, P396; Chen Y-T, 1995, METABOLIC MOL BASES, P935; CHEN YT, 1991, J INHERIT METAB DIS, V14, P80, DOI 10.1007/BF01804394; CHEN YT, 1984, NEW ENGL J MED, V310, P171, DOI 10.1056/NEJM198401193100306; EMMETT M, 1978, JAMA-J AM MED ASSOC, V239, P1642, DOI 10.1001/jama.239.16.1642; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; KIRSCHNER BS, 1991, GASTROENTEROLOGY, V101, P238, DOI 10.1016/0016-5085(91)90483-2; KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; MITTEREDER N, 1994, HUM GENE THER, V5, P719; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pan CJ, 1998, ARCH BIOCHEM BIOPHYS, V358, P17, DOI 10.1006/abbi.1998.0849; SELBY R, 1993, EUR J PEDIATR, V152, pS71; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; STRATFORDPERRIC.LD, 1991, GENE THERAPEUTICS ME, P345; TEUTSCH HF, 1981, PROGR HISTOCHEMISTRY, V14; TRAPNELL BC, 1993, ADV DRUG DELIVER REV, V12, P185, DOI 10.1016/0169-409X(93)90059-D; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362	23	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	2000	275	2					828	832		10.1074/jbc.275.2.828	http://dx.doi.org/10.1074/jbc.275.2.828			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	275TQ	10625614	hybrid			2022-12-25	WOS:000084836600018
J	Okochi, M; Walter, J; Koyama, A; Nakajo, S; Baba, M; Iwatsubo, T; Meijer, L; Kahle, PJ; Haass, C				Okochi, M; Walter, J; Koyama, A; Nakajo, S; Baba, M; Iwatsubo, T; Meijer, L; Kahle, PJ; Haass, C			Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-SYSTEM ATROPHY; CASEIN KINASE-II; A-BETA COMPONENT; CAMP-REGULATED PHOSPHOPROTEIN; GLIAL CYTOPLASMIC INCLUSIONS; CENTRAL-NERVOUS-SYSTEM; LEWY BODY DISEASE; ALZHEIMERS-DISEASE; NACP/ALPHA-SYNUCLEIN; PRECURSOR PROTEIN	alpha-Synuclein has been implicated in the pathogenesis of Parkinson's disease, since rare autosomal dominant mutations are associated with early onset of the disease and alpha-synuclein was found to be a major constituent of Lewy bodies. We have analyzed alpha-synuclein expression in transfected cell lines. In pulse-chase experiments alpha-synuclein appeared to be stable over long periods (t(1/2) 54 h) and no endoproteolytic processing was observed. alpha-Synuclein was constitutively phosphorylated in human kidney 293 cells as well as in rat pheochromocytoma PC12 cells. In both cell lines phosphorylation was highly sensitive to phosphatases, since okadaic acid markedly stabilized phosphate incorporation. Phosphoamino acid analysis revealed that phosphorylation occurred predominantly on serine. Using site-directed mutagenesis we have identified a major phosphorylation site at serine 129 within the C-terminal domain of alpha-synuclein. An additional site, which was phosphorylated less efficiently, was mapped to serine 87. The major phosphorylation site was located within a consensus recognition sequence of casein kinase 1 (CK-1). In vitro experiments and two-dimensional phosphopeptide mapping provided further evidence that serine 129 was phosphorylated by CK-1 and CK-2. Moreover, phosphorylation of serine 129 was reduced in vivo upon inhibition of CK-1 or CK-2. These data demonstrate that alpha-synuclein is constitutively phosphorylated within its C terminus and may indicate that the function of alpha-synuclein is regulated by phosphorylation/dephosphorylation.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, D-80336 Munich, Germany; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Tokyo 1130033, Japan; Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Tokyo, Japan; CNRS, Biol Stn, F-29682 Roscoff, France	University of Munich; University of Tokyo; Showa University; Centre National de la Recherche Scientifique (CNRS)	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Schillerst 44, D-80336 Munich, Germany.	chaass@pbm.med.uni-muenchen.de	Wang, Caihong/T-5837-2019; MEIJER, Laurent/ABE-7465-2021; Walter, Jochen/B-3677-2014	Wang, Caihong/0000-0002-6808-3709; Okochi, Masayasu/0000-0002-2318-7651; Walter, Jochen/0000-0002-4678-2912; , laurent/0000-0003-3511-4916				AHMED K, 1994, CELL MOL BIOL RES, V40, P1; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Baba M, 1998, AM J PATHOL, V152, P879; BENNETT MK, 1993, J NEUROSCI, V13, P1701; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; DIAZNIDO J, 1988, J CELL BIOL, V106, P2057, DOI 10.1083/jcb.106.6.2057; Farrer M, 1998, ANN NEUROL, V43, P394, DOI 10.1002/ana.410430320; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GROSS SD, 1995, J CELL BIOL, V130, P711, DOI 10.1083/jcb.130.3.711; Grunberg J, 1998, BIOCHEMISTRY-US, V37, P2263, DOI 10.1021/bi972106l; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hollander BA, 1999, CELL MOTIL CYTOSKEL, V43, P114, DOI 10.1002/(SICI)1097-0169(1999)43:2<114::AID-CM3>3.3.CO;2-D; HUANG FL, 1991, METHODS ENZYMOL, V200, P454; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; NAKAJO S, 1990, J NEUROCHEM, V55, P2031, DOI 10.1111/j.1471-4159.1990.tb05792.x; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nussbaum RL, 1997, HUM MOL GENET, V6, P1687, DOI 10.1093/hmg/6.10.1687; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Takeda A, 1998, AM J PATHOL, V152, P367; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Tomita T, 1998, NEUROREPORT, V9, P911, DOI 10.1097/00001756-199803300-00027; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; UEDA K, 1994, BIOCHEM BIOPH RES CO, V205, P1366, DOI 10.1006/bbrc.1994.2816; VANCURA A, 1994, J BIOL CHEM, V269, P19271; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	66	406	422	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2000	275	1					390	397		10.1074/jbc.275.1.390	http://dx.doi.org/10.1074/jbc.275.1.390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	295DN	10617630	hybrid			2022-12-25	WOS:000085951600054
J	Kroncke, KD; Carlberg, C				Kroncke, KD; Carlberg, C			Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide	FASEB JOURNAL			English	Article						protein-DNA interaction; transcriptional regulation/1 alpha; 25(OH)(2)D-3 receptor 1 alpha,25(OH)(2)D-3 signaling	NUCLEAR RECEPTOR SUPERFAMILY; RETINOID-X-RECEPTOR; NF-KAPPA-B; FUNCTIONAL-CHARACTERIZATION; D-3 RECEPTOR; DNA-BINDING; VITAMIN-D; IN-VITRO; SYNTHASE; INHIBITION	Nitric oxide (NO) is known to induce Zn2+ release from the zinc-storing protein metallothionein and to induce Zn2+ release within the nuclei and cytoplasm of cells. This suggests that zinc finger proteins may be primary targets of NO-induced stress. Zn this study, the specific interaction of the heterodimeric complex of two zinc finger transcription factors, 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) receptor (VDR) and retinoid X receptor (RXR) with 1 alpha,25(OH)(2)D-3 response elements (VDREs), was used as a model system, NO was applied to this system via the NO donors SNOC and MAMA/NO and caused a dose-dependent inhibition of VDR-RXR-VDRE complex formation (IC50 values 0.5-0.8 mM), Ligand-bound or preformed complexes displayed less sensitivity to NO-induced stress. These in vitro effects of NO were found to be reversible, Functional assays in transiently transfected cells indicated that NO can also act in vivo as a repressor of 1 alpha,25(OH)(2)D-3 signaling (IC50 value of the slow NO donor DETA/NO, 0.5 mM), These findings suggest that NO has a modulatory role on transcription factors depending on their sensitivity to NO-induced stress, thus providing a mechanism for a gene regulatory function of NO.-Kroncke, K. D., Carlberg, C. Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide.	Univ Dusseldorf, Forschungsgruppe Immunbiol, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Inst Physiol Chem 1, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Kroncke, KD (corresponding author), Univ Dusseldorf, Forschungsgruppe Immunbiol, 14-80,Posfach 10 10 07, D-40001 Dusseldorf, Germany.	kroencke@uni-duesseldorf.de	Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carlberg C, 1996, ENDOCRINE, V4, P91, DOI 10.1007/BF02782754; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Carlberg C, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P10; Forstermann U, 1998, FASEB J, V12, P773; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; Kahlen JP, 1997, NUCLEIC ACIDS RES, V25, P4307, DOI 10.1093/nar/25.21.4307; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Kroncke KD, 1996, METHOD ENZYMOL, V269, P279; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Laurent M, 1996, BIOCHEM J, V314, P109, DOI 10.1042/bj3140109; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Moormann AM, 1996, REDOX REP, V2, P249, DOI 10.1080/13510002.1996.11747057; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; Powis G, 1997, Adv Pharmacol, V38, P329; Quack M, 1998, NUCLEIC ACIDS RES, V26, P5372, DOI 10.1093/nar/26.23.5372; Schrader M, 1997, BIOCHEM BIOPH RES CO, V230, P646, DOI 10.1006/bbrc.1996.6025; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6	29	99	100	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					166	173						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627291				2022-12-25	WOS:000084784700019
J	Fernandez, MR; Biosca, JA; Torres, D; Crosas, B; Pares, X				Fernandez, MR; Biosca, JA; Torres, D; Crosas, B; Pares, X			A double residue substitution in the coenzyme-binding site accounts for the different kinetic properties between yeast and human formaldehyde dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-III ALCOHOL; HUMAN-LIVER; SACCHAROMYCES-CEREVISIAE; ENZYMATIC-PROPERTIES; GENE DISRUPTION; RAT-LIVER; CLASS-P; CLASS-I; GLUTATHIONE; PURIFICATION	Glutathione-dependent formaldehyde dehydrogenase (FALDH) is the main enzymatic system for formaldehyde detoxification in all eukaryotic and many prokaryotic organisms. The enzyme of yeasts and some bacteria exhibits about 10-fold higher k(cat) and K-m values than those of the enzyme from animals and plants. Typically Thr-269 and Glu-267 are found in the coenzyme-binding site of yeast FALDH, but Ile-269 and Asp-267 are present in the FALDH of animals. By site-directed mutagenesis we have prepared the T269I and the D267E mutants and the D267E/T269I double mutant of Saccharomyces cerevisiae FALDH with the aim of investigating the role of these residues in the kinetics. The T269I and the D267E mutants have identical kinetic properties as compared with the wild-type enzyme, although T269I is highly unstable. In contrast, the D267E/T269I double mutant is stable and shows low K-m, (2.5 mu M) and low k(cat) (285 min(-1)) values with S-hydroxymethylglutathione, similar to those of the human enzyme. Therefore, the simultaneous exchange at both residues is the structural basis of the two distinct FALDH kinetic types. The local structural perturbations imposed by the substitutions are suggested by molecular modeling studies. Finally, we have studied the effect of FALDH deletion and overexpression on the growth of S. cerevisiae, It is concluded that the FALDH gene is not essential but enhances the resistance against formaldehyde (0.3-1 mM), Moreover, the wild-type enzyme (with high k(cat) and K-m) provides more resistance than the double mutant (with low k(cat) and K-m).	Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Fac Sci, E-08193 Barcelona, Spain	Autonomous University of Barcelona	Pares, X (corresponding author), Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Fac Sci, E-08193 Barcelona, Spain.		Fernandez, Maria Rosario R/F-4015-2016; Biosca, Josep/G-3137-2013; Pares, Xavier/K-8228-2017	Fernandez, Maria Rosario R/0000-0002-1750-7786; Biosca, Josep/0000-0003-2794-3124; Torres Navarro, Damaso/0000-0003-3272-6079; Pares, Xavier/0000-0002-5071-9465				ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; ALLAIS JJ, 1983, AGR BIOL CHEM TOKYO, V47, P1509, DOI 10.1080/00021369.1983.10865804; Barber RD, 1996, J BACTERIOL, V178, P1386, DOI 10.1128/jb.178.5.1386-1393.1996; BECKER DM, 1994, CURRENT PROTOCOLS MO, V2; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown T., 1993, CURRENT PROTOCOLS MO, V1; CLELAND WW, 1979, METHOD ENZYMOL, V189, P436; CORMACK B, 1997, CURRENT PROTOCOLS MO, V2; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; FAN F, 1995, BIOCHEMISTRY-US, V34, P4709, DOI 10.1021/bi00014a027; FERNANDEZ MR, 1995, FEBS LETT, V370, P23; FERNANDEZ MR, 1993, FEBS LETT, V328, P235, DOI 10.1016/0014-5793(93)80934-M; Fersht A, 1999, STRUCTURE MECH PROTE, P362; FUJIWARA K, 1984, J BIOL CHEM, V259, P664; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIRI PR, 1989, BRAIN RES, V481, P131; GULTHEIL WG, 1992, BIOCHEMISTRY-US, V31, P475; HALLIER E, 1994, ARCH TOXICOL, V68, P423, DOI 10.1007/s002040050092; HOLMQUIST B, 1991, BIOCHEM BIOPH RES CO, V178, P1371, DOI 10.1016/0006-291X(91)91045-E; Jensen DE, 1998, BIOCHEM J, V331, P659, DOI 10.1042/bj3310659; Jornvall H, 1997, ADV EXP MED BIOL, V414, P281; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACK M, 1988, MOL GEN GENET, V211, P260, DOI 10.1007/BF00330602; Martinez MC, 1996, EUR J BIOCHEM, V241, P849, DOI 10.1111/j.1432-1033.1996.00849.x; MOULIS JM, 1991, BIOCHEMISTRY-US, V30, P5743, DOI 10.1021/bi00237a016; PARES X, 1981, BIOCHEM BIOPH RES CO, V98, P122, DOI 10.1016/0006-291X(81)91878-7; PORTER DH, 1985, ARCH BIOCHEM BIOPHYS, V243, P396, DOI 10.1016/0003-9861(85)90516-8; POURMOTABBED T, 1989, J BIOL CHEM, V264, P17384; RAS J, 1995, J BACTERIOL, V177, P247, DOI 10.1128/jb.177.1.247-251.1995; ROSE ZB, 1962, J BIOL CHEM, V237, P3279; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SASNAUSKAS K, 1992, GENE, V122, P207, DOI 10.1016/0378-1119(92)90052-Q; Shafqat J, 1996, P NATL ACAD SCI USA, V93, P5595, DOI 10.1073/pnas.93.11.5595; SHARA MA, 1992, J CHROMATOGR-BIOMED, V576, P221, DOI 10.1016/0378-4347(92)80196-W; UOTILA L, 1974, J BIOL CHEM, V249, P7653; UOTILA L, 1979, BIOCHEM J, V177, P869, DOI 10.1042/bj1770869; UOTILA L, 1980, BIOCHIM BIOPHYS ACTA, V616, P153, DOI 10.1016/0005-2744(80)90133-3; Uotila L., 1989, COENZYMES COFACTOR A, P517; WAGNER FW, 1984, BIOCHEMISTRY-US, V23, P2193, DOI 10.1021/bi00305a014; WAYDHAS C, 1978, EUR J BIOCHEM, V89, P143, DOI 10.1111/j.1432-1033.1978.tb20906.x; WEHNER EP, 1993, MOL GEN GENET, V237, P351, DOI 10.1007/BF00279438; Yang ZN, 1997, J MOL BIOL, V265, P330, DOI 10.1006/jmbi.1996.0731; Yu PH, 1997, NEUROCHEM RES, V22, P615, DOI 10.1023/A:1022478221421	46	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37869	37875		10.1074/jbc.274.53.37869	http://dx.doi.org/10.1074/jbc.274.53.37869			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608852	hybrid			2022-12-25	WOS:000084528000052
J	Huang, LW; Sankar, S; Lin, C; Kontos, CD; Schroff, AD; Cha, EH; Feng, SM; Li, SF; Yu, ZM; Van Etten, RL; Blanar, MA; Peters, KG				Huang, LW; Sankar, S; Lin, C; Kontos, CD; Schroff, AD; Cha, EH; Feng, SM; Li, SF; Yu, ZM; Van Etten, RL; Blanar, MA; Peters, KG			HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-INDUCED ANGIOGENESIS; NITRIC-OXIDE SYNTHASE; RAT AORTA; IN-VIVO; INHIBITION; KINASE; EXPRESSION; PERMEABILITY; DOWNSTREAM; CELLS	Angiogenesis is a tightly controlled process in which signaling by the receptors for vascular endothelial growth factor (VEGF) plays a key role. In order to define signaling pathways downstream of VEGF receptors (VEGFR), the kinase domain of VEGFRS (Flk-1) was used as a bait to screen a human fetal heart library in the yeast two-hybrid system. One of the signaling molecules identified in this effort was HCPTPA, a low molecular weight, cytoplasmic protein tyrosine phosphatase. Although HCPTPA possesses no identifiable phosphotyrosine binding domains (i.e. SH2 or phosphotyrosine binding domains), it bound specifically to active, autophosphorylated VEGFR2 but not to a mutated, kinase-inactive VEGFR2. Recombinant VEGFR2 and endogenous VEGFR2 were substrates for recombinant HCPTPA, and HCPTPA was co-expressed with VEGFR2 in endothelial cell. Lines, suggesting that HCPTPA may be It negative regulator of VEGFR2 signal transduction. To pursue this possibility, an adenovirus directing the expression of HCPTPA was constructed. When used to infect cultured endothelial cells, this adenovirus directed high level expression of HCPTPA that resulted in impairment of VEGF-mediated VEGFR2 autophosphorylation and mitogen-activated protein kinase activation. Adenovirus-mediated overexpression of HCPTPA also inhibited VEGF-induced cellular responses (endothelial cell migration and proliferation) and inhibited angiogenesis in the rat aortic ring assay. Taken together, these findings indicate that HCPTPA may be an important regulator of VEGF mediated signaling and biological activity. Potential interactions with other signaling pathways and possible therapeutic implications are discussed.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Cardiovasc Drug Discovery, Princeton, NJ 08543 USA	Duke University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Bristol-Myers Squibb	Peters, KG (corresponding author), Procter & Gamble Co, Hlth Care Res Ctr, POB 8006, Mason, OH 45040 USA.			Kontos, Christopher/0000-0002-8056-3115				BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; Bucciantini M, 1998, FEBS LETT, V422, P213, DOI 10.1016/S0014-5793(98)00009-X; CASELLI A, 1995, FEBS LETT, V374, P249, DOI 10.1016/0014-5793(95)01120-4; CASELLI A, 1994, J BIOL CHEM, V269, P24878; Channon KM, 1996, CARDIOVASC RES, V32, P962; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Chiarugi P, 1996, BIOCHEM BIOPH RES CO, V219, P21, DOI 10.1006/bbrc.1996.0174; CLYMAN RI, 1994, CELL ADHES COMMUN, V1, P333, DOI 10.3109/15419069409097264; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5850; FANTL WJ, 1996, GROW FACT CYTOK  A&B, V1, P179; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hariawala MD, 1996, J SURG RES, V63, P77, DOI 10.1006/jsre.1996.0226; HUANG LW, 1995, ONCOGENE, V11, P2097; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; NICOSIA RF, 1990, LAB INVEST, V63, P115; Nicosia RF, 1997, AM J PATHOL, V151, P1379; NICOSIA RF, 1994, IN VITRO CELL DEV-AN, V30A, P394, DOI 10.1007/BF02634360; NICOSIA RF, 1992, ATHEROSCLEROSIS, V95, P191, DOI 10.1016/0021-9150(92)90022-9; NICOSIA RF, 1995, LAB INVEST, V73, P658; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sellke FW, 1996, AM J PHYSIOL-HEART C, V271, pH713, DOI 10.1152/ajpheart.1996.271.2.H713; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; vanderZee R, 1997, CIRCULATION, V95, P1030; WO YYP, 1992, J BIOL CHEM, V267, P10856; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	48	72	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38183	38188		10.1074/jbc.274.53.38183	http://dx.doi.org/10.1074/jbc.274.53.38183			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608891	hybrid			2022-12-25	WOS:000084528000091
J	Leng, J; Klemke, RL; Reddy, AC; Cheresh, DA				Leng, J; Klemke, RL; Reddy, AC; Cheresh, DA			Potentiation of cell migration by adhesion-dependent cooperative signals from the GTPase Rac and Raf kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACTIN STRESS FIBERS; GROWTH-FACTOR; INTEGRIN ALPHA(V)BETA(3); EPITHELIAL-CELLS; FOCAL ADHESIONS; RHO-GTPASES; MYOSIN-II; CDC42; BINDING	The small GTPase Rac is thought to regulate cell movement by influencing actin cytoskeletal organization and membrane ruffling. However, cell migration also depends on the activation of mitogen-activated protein kinase (MAPK), which can regulate myosin motor function, an event critical for cell contraction. Evidence is provided that, during active cell adhesion to the extracellular matrix, Rac potentiates the MAPK pathway and influences cell migration by selectively synergizing with Raf kinase but not with Ras or MAPK kinase. In fact, the synergy between Rac and Raf kinase increases the chemotactic sensitivity of cells to epidermal growth factor by 1000-fold. Therefore, the role of Rac in cell migration not only depends on its ability to regulate actin cytoskeletal organization but also on its capacity to potentiate chemokine activation of MAPK in a manner that depends on active cell adhesion to the extracellular matrix.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol, IMM24,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA45728, CA50286] Funding Source: Medline; NHLBI NIH HHS [HL54444] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050286, R37CA050286] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Cary LA, 1996, J CELL SCI, V109, P1787; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Clark RAF, 1996, AM J PATHOL, V148, P1407; CONRAD PA, 1993, J CELL BIOL, V120, P1381, DOI 10.1083/jcb.120.6.1381; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; Guillemot JC, 1997, J CELL SCI, V110, P2215; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KOLEGA J, 1993, MOL BIOL CELL, V4, P819, DOI 10.1091/mbc.4.8.819; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Xie H, 1998, J CELL SCI, V111, P615	47	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					37855	37861		10.1074/jbc.274.53.37855	http://dx.doi.org/10.1074/jbc.274.53.37855			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608850	hybrid			2022-12-25	WOS:000084528000050
J	Mueller, C; Corazza, N; Trachsel-Loseth, S; Eugster, HP; Buhler-Jungo, M; Brunner, T; Imboden, MA				Mueller, C; Corazza, N; Trachsel-Loseth, S; Eugster, HP; Buhler-Jungo, M; Brunner, T; Imboden, MA			Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNF alpha) mediates effects distinct from those of wild-type TNF alpha in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT MICE; METALLOPROTEINASE INHIBITOR; INTERLEUKIN-12 PRODUCTION; EXPERIMENTAL HEPATITIS; MONOCLONAL-ANTIBODY; INTERFERON-GAMMA; RECEPTOR; EXPRESSION; CELLS; RESPONSES	Tumor necrosis factor-alpha (TNF alpha) exists in two biologically active forms, a 26-kDa transmembrane form and a proteolytically cleaved and secreted form. We sequentially inactivated all three known cleavage sites of mouse TNF alpha by mutating the corresponding DNA sequences. A murine T cell hybridoma transfected with the nonsecretable mutant TNF alpha efficiently lysed L929 target cells in a cell contact-dependent manner and induced expression of vascular cell adhesion molecule-1 on mouse endothelioma cells. A genomic mouse TNF alpha clone encoding this mutant was subsequently introduced as a transgene into TNF alpha(-/-) lymphotoxin-alpha(-/-) mice. The 3' AU-rich regulatory elements of the TNF locus were maintained in the transgene to assure adequate gene regulation. Transmembrane TNF alpha transgenic mice were fully protected from endotoxic shock, and no TNF alpha bioactivity was detectable in the serum after stimulation with lipopolysaccharide. Activated CD4 T cells from these animals, however, lysed L929 cells in a cell contact-dependent way. After administration of Lipopolysaccharide, transmembrane TNF alpha transgenic mice produced significantly higher levels of interleukin-12 than wild-type mice or TNF-deficient mice. This indicates that transmembrane TNF alpha may greatly affect the course of a cellular immune responses in vivo and exerts quantitatively and qualitatively distinct functions from secreted TNF alpha in vitro and in vivo.	Univ Bern, Dept Pathol, Div Immunopathol, CH-3010 Bern, Switzerland; Univ Zurich, Dept Clin Immunol, CH-8044 Zurich, Switzerland; ZLB Cent Lab, CH-3000 Bern, Switzerland	University of Bern; University of Zurich	Mueller, C (corresponding author), Univ Bern, Dept Pathol, Div Immunopathol, Murtenstr 31, CH-3010 Bern, Switzerland.	christoph.mueller@pathology.unibe.ch	Mueller, Christoph/F-2233-2014	Mueller, Christoph/0000-0002-3921-8678				Alexopoulou L, 1997, EUR J IMMUNOL, V27, P2588, DOI 10.1002/eji.1830271018; Bean AGD, 1999, J IMMUNOL, V162, P3504; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Cope AP, 1997, J EXP MED, V185, P1573, DOI 10.1084/jem.185.9.1573; CSEH K, 1989, J BIOL CHEM, V264, P16256; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Douni E, 1996, J INFLAMM, V47, P27; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; ENGLARD S, 1990, METHOD ENZYMOL, V182, P285; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; ESPEVIK T, 1987, IMMUNOLOGY, V61, P443; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; FLESCH IEA, 1995, J EXP MED, V181, P1615, DOI 10.1084/jem.181.5.1615; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Haraldsen G, 1996, J IMMUNOL, V156, P2558; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodge-Dufour J, 1998, P NATL ACAD SCI USA, V95, P13806, DOI 10.1073/pnas.95.23.13806; Hunger RE, 1996, J CLIN INVEST, V98, P954, DOI 10.1172/JCI118879; Kagi D, 1999, J IMMUNOL, V162, P4598; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Kusters S, 1997, EUR J IMMUNOL, V27, P2870, DOI 10.1002/eji.1830271119; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; Pakala SV, 1999, J EXP MED, V189, P1053, DOI 10.1084/jem.189.7.1053; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PECK R, 1989, CELL IMMUNOL, V122, P1, DOI 10.1016/0008-8749(89)90143-3; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; Peschon JJ, 1998, J IMMUNOL, V160, P943; RobacheGallea S, 1997, EUR J IMMUNOL, V27, P1275, DOI 10.1002/eji.1830270532; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SEMON D, 1987, NUCLEIC ACIDS RES, V15, P9083, DOI 10.1093/nar/15.21.9083; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIKORSKI EE, 1993, J IMMUNOL, V151, P5239; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; Solorzano CC, 1997, J IMMUNOL, V158, P414; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Trinchieri G, 1998, IMMUNOL RES, V17, P269, DOI 10.1007/BF02786451; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WAHL SM, 1993, CURRENT PROTOCOLS IM, V1; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	47	66	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38112	38118		10.1074/jbc.274.53.38112	http://dx.doi.org/10.1074/jbc.274.53.38112			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608881	hybrid, Green Published			2022-12-25	WOS:000084528000081
J	Saam, JR; Gordon, JI				Saam, JR; Gordon, JI			Inducible gene knockouts in the small intestinal and colonic epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; SITE-SPECIFIC RECOMBINATION; TETRACYCLINE-RESPONSIVE PROMOTER; STEM-CELL DIFFERENTIATION; RABBIT URINARY-BLADDER; BINDING PROTEIN GENE; TRANSGENIC MICE; CRE RECOMBINASE; MAMMALIAN-CELLS; STOCHASTIC-THEORY	We have developed two systems for performing Cre-mediated recombination of target genes in the rapidly self-renewing mouse small intestinal and colonic epithelium, When expression of Cre recombinase is placed directly under the control of transcriptional regulatory elements from a fatty acid-binding protein gene (Fabp), deletion of loxP flanked (floxed) DNA sequences is initiated as early as embryonic day 13.5, well before completion of intestinal morphogenesis. By embryonic day 16.5, Fabp-Cre also directs recombination in all cell layers of the transitional epithelium that lines the renal calyces and pelvis, meters, and bladder, Fabp-Cre expression and recombination are maintained in both epithelia throughout adulthood. The second system allows recombination to be induced only in the gut and at any period during adulthood. This system uses Fabp regulatory elements to direct expression of a reverse tetracycline-regulated transactivator (rtTA), Another transgene encodes Cre under the control of tet operator sequences and a minimal promoter from human cytomegalovirus (tetO-P-hCMV-Cre). In the absence of a doxycycline inducer, no basal recombination is detectable in the gut of adult tri-transgenic mice containing Fabp-rtTA, tetO-P-hCMV-Cre, plus a floxed reporter gene. After 4 days of oral administration of doxycycline, recombination of the reporter is apparent in the small intestinal, cecal, and colonic epithelium, After doxycycline is withdrawn, the recombined locus persists for at least 60 days, indicating that recombination has occurred in epithelial cell progenitors that have long residency times in the proliferative units of the intestine (crypts of Lieberkuhn), This inducible system should have a number of applications for examining gene function at selected times in postnatal life, under selected physiologic or pathophysiologic conditions.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009724, R01DK030292, R37DK030292] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09724, DK30292, DK39760] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; AYRES PH, 1985, J UROLOGY, V133, P506, DOI 10.1016/S0022-5347(17)49042-2; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; BJERKNES M, 1986, BIOPHYS J, V49, P1223, DOI 10.1016/S0006-3495(86)83751-1; BJERKNES M, 1994, J THEOR BIOL, V168, P349, DOI 10.1006/jtbi.1994.1115; Brocard J, 1998, NUCLEIC ACIDS RES, V26, P4086, DOI 10.1093/nar/26.17.4086; CALVERT R, 1990, ANAT REC, V227, P199, DOI 10.1002/ar.1092270208; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; FARSUND T, 1978, VIRCHOWS ARCH B, V26, P215; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Jezernik K, 1997, CELL BIOL INT, V21, P1, DOI 10.1006/cbir.1996.0109; JOST SP, 1986, CELL TISSUE KINET, V19, P155, DOI 10.1111/j.1365-2184.1986.tb00725.x; Kerr DE, 1998, NAT BIOTECHNOL, V16, P75, DOI 10.1038/nbt0198-75; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; LEWIS SA, 1976, J MEMBRANE BIOL, V28, P1, DOI 10.1007/BF01869689; LEWIS SA, 1976, J MEMBRANE BIOL, V28, P41, DOI 10.1007/BF01869690; LI YQ, 1994, J CELL SCI, V107, P3271; LIN JH, 1995, P NATL ACAD SCI USA, V92, P679, DOI 10.1073/pnas.92.3.679; LOPEZ MJ, 1995, J BIOL CHEM, V270, P885, DOI 10.1074/jbc.270.25.14989; METZGER D, 1995, P NATL ACAD SCI USA, V92, P6991, DOI 10.1073/pnas.92.15.6991; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SENECOFF JF, 1986, J BIOL CHEM, V261, P7380; Simon TC, 1997, J BIOL CHEM, V272, P10652; STEWART FA, 1980, CELL TISSUE KINET, V13, P75, DOI 10.1111/j.1365-2184.1980.tb00451.x; StOnge L, 1996, NUCLEIC ACIDS RES, V24, P3875, DOI 10.1093/nar/24.19.3875; Truschel ST, 1999, J BIOL CHEM, V274, P15020, DOI 10.1074/jbc.274.21.15020; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; WEISER MM, 1973, J BIOL CHEM, V248, P2536; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; Zhang ZT, 1999, CANCER RES, V59, P3512	45	161	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 31	1999	274	53					38071	38082		10.1074/jbc.274.53.38071	http://dx.doi.org/10.1074/jbc.274.53.38071			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	270GW	10608876	hybrid			2022-12-25	WOS:000084528000076
J	Mattingly, RR				Mattingly, RR			Phosphorylation of serine 916 of Ras-GRF1 contributes to the activation of exchange factor activity by muscarinic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RAS-GRF; PROTEIN-MEDIATED SIGNALS; FACTOR CDC25(MM); TYROSINE KINASE; CYCLIC-AMP; CALCIUM; DOMAIN; CLONING; BRAIN	The Ras-GRF1 exchange factor is strongly implicated in the control of neuronal Ras. The activity of Ras-GRF1 is regulated by increases in intracellular calcium and the release of G beta gamma subunits from heterotrimeric G-proteins, Increases in Ras-GRF1 activity toward has that are stimulated by receptors coupled to G-proteins are associated with enhanced phosphorylation of Ras-GRF1 on one or more serine residues. Co-expression of Ras-GRF1 with subtype 1 human muscarinic receptors in COS-7 cells allowed mapping of a carbachol-stimulated phosphorylation site to a region composed of residues 916-976, Site-directed mutagenesis replaced each of the serine residues within this region with alanine and demonstrated that serine 916 is a major site of in vivo phosphorylation of Ras-GRF1 in both COS-7 cells and NIH-3T3 fibroblasts. Serine 916 was a substrate for protein kinase A both in vivo and in vitro, suggesting a novel link between the cAMP and Ras signaling systems. Carbachol-dependent phosphorylation of serine 916 occurred through a protein kinase A-independent pathway, however. Full-length Ras-GRF1 that contains an alanine 916 mutation was only partially activated by carbachol, suggesting that phosphorylation at residue 916 is necessary for full activation. Phosphorylation of serine 916 in response to forskolin treatment did not, however, increase the activity of Ras-GRF1, indicating that it is not sufficient for activation.	Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA; Barbara Ann Karmanos Canc Inst, Program Mol Biol & Genet, Detroit, MI 48201 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute	Mattingly, RR (corresponding author), Wayne State Univ, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.	r.mattingly@wayne.edu			NCI NIH HHS [CA-38888] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038888] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHENG HC, 1986, J BIOL CHEM, V261, P989; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; CONNELLY PA, 1987, J BIOL CHEM, V262, P4324; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; Finkbeiner S, 1998, BIOESSAYS, V20, P691, DOI 10.1002/(SICI)1521-1878(199809)20:9<691::AID-BIES1>3.3.CO;2-H; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Freshney NW, 1997, FEBS LETT, V407, P111, DOI 10.1016/S0014-5793(97)00309-8; Giglione C, 1998, J BIOL CHEM, V273, P34737, DOI 10.1074/jbc.273.52.34737; Guerrero C, 1996, ONCOGENE, V12, P1097; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Itier JM, 1998, NATURE, V393, P125, DOI 10.1038/30120; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Mattingly RR, 1999, CELL SIGNAL, V11, P603, DOI 10.1016/S0898-6568(99)00034-0; Mattingly RR, 1998, IN VITRO MOL TOXICOL, V11, P57; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; TAKAHASHI M, 1991, EUR J PHARMACOL, V200, P293; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; Wulczyn FG, 1998, NUCLEIC ACIDS RES, V26, P1724, DOI 10.1093/nar/26.7.1724; Zippel R, 1997, MOL BRAIN RES, V48, P140; Zippel R, 1996, ONCOGENE, V12, P2697	52	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37379	37384		10.1074/jbc.274.52.37379	http://dx.doi.org/10.1074/jbc.274.52.37379			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601308	hybrid			2022-12-25	WOS:000084382700079
J	Yuasa, K; Michibata, H; Omori, K; Yanaka, N				Yuasa, K; Michibata, H; Omori, K; Yanaka, N			A novel interaction of cGMP-dependent protein kinase I with troponin T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; CARDIAC TROPONIN; ANCHORING PROTEINS; MOLECULAR-CLONING; SKELETAL-MUSCLE; SMOOTH-MUSCLE; CA2+ CURRENT; EXPRESSION; BINDING; PHOSPHORYLATION	cGMP-dependent protein kinase (cGK) is a major intracellular receptor of cGMP and is implicated in several signal transduction pathways. To identify proteins that participate in the cGMP/cGK signaling pathway, we employed the yeast two-hybrid system with cGK I alpha as bait. cDNAs encoding slow skeletal troponin T (skTnT) were isolated from both mouse embryo and human skeletal muscle cDNA libraries, The skTnT protein interacted with cGK I beta but not with cGK II nor cAMP-dependent protein kinase, The yeast two-hybrid and in vitro binding assays revealed that the N-terminal region of cGK I alpha, containing the leucine zipper motif, is sufficient for the association with skTnT, In vivo analysis, mutations in cGK I alpha, which disrupted the leucine zipper motif, were shown to completely abolish the binding to skTnT. Furthermore, cGK I also interacted with cardiac TnT (CTnT) but not with cardiac troponin I (cTnI), Together with the observations that cTnI is a good substrate for cGK I and is effectively phosphorylated in the presence of cTnT in vitro, these findings suggest that TnT functions as an anchoring protein for cGK I and that cGK I may participate in the regulation of muscle contraction through phosphorylation of TnI.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation	Yanaka, N (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, 16-89 Kashima 3 Chome, Osaka 5328505, Japan.		Yanaka, Noriyuki/P-9096-2016					ALHILLAWI E, 1994, EUR J BIOCHEM, V225, P1195, DOI 10.1111/j.1432-1033.1994.1195b.x; BLUMENTHAL DK, 1978, J BIOL CHEM, V253, P334; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FUJII M, 1995, FEBS LETT, V375, P263, DOI 10.1016/0014-5793(95)01223-2; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HUGGINS JP, 1989, BIOCHEM J, V260, P829, DOI 10.1042/bj2600829; Jideama NM, 1996, J BIOL CHEM, V271, P23277, DOI 10.1074/jbc.271.38.23277; Jin JP, 1998, GENE, V214, P121, DOI 10.1016/S0378-1119(98)00214-5; Kaumann A, 1999, CIRCULATION, V99, P65, DOI 10.1161/01.CIR.99.1.65; LINCOLN TM, 1976, P NATL ACAD SCI USA, V73, P2559, DOI 10.1073/pnas.73.8.2559; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LINCOLN TM, 1978, J BIOL CHEM, V253, P337; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MESNARD L, 1993, FEBS LETT, V328, P139, DOI 10.1016/0014-5793(93)80981-Y; MITTMANN K, 1990, FEBS LETT, V273, P41, DOI 10.1016/0014-5793(90)81046-Q; MITTMANN K, 1992, FEBS LETT, V302, P133, DOI 10.1016/0014-5793(92)80423-E; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; PFITZER G, 1982, FEBS LETT, V149, P171, DOI 10.1016/0014-5793(82)81095-8; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; Stefancsik R, 1998, P NATL ACAD SCI USA, V95, P957, DOI 10.1073/pnas.95.3.957; SUMII K, 1995, CIRC RES, V77, P803, DOI 10.1161/01.RES.77.4.803; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; WAHLER GM, 1995, AM J PHYSIOL-CELL PH, V268, pC45, DOI 10.1152/ajpcell.1995.268.1.C45; Wang X, 1997, J NEUROCHEM, V68, P443; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	47	64	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 24	1999	274	52					37429	37434		10.1074/jbc.274.52.37429	http://dx.doi.org/10.1074/jbc.274.52.37429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	267WR	10601315	hybrid			2022-12-25	WOS:000084382700086
J	Attwooll, C; Tariq, M; Harris, M; Coyne, JD; Telford, N; Varley, JM				Attwooll, C; Tariq, M; Harris, M; Coyne, JD; Telford, N; Varley, JM			Identification of a novel fusion gene involving hTAF(II)68 and CHN from a t(9;17)(q22;q11.2) translocation in an extraskeletal myxoid chondrosarcoma	ONCOGENE			English	Article						t(9;17)(q22;q11.2); RBP56/hTAF(II)68; CHN; extraskeletal myxoid chrondrosarcoma	RNA-BINDING PROTEIN; ORPHAN NUCLEAR RECEPTOR; POLYMERASE-II; EWS; LIPOSARCOMA; CHOP; TLS/FUS; FUS/TLS; FAMILY; MEMBER	A proportion of extraskeletal myxoid chondrosarcomas (EMC) have been shown to have a characteristic translocation t(9;22)(q22;q12) involving the EWS gene at 22q12 and the CHN orphan nuclear receptor gene at 9q22, This translocation appears to be largely specific for EMC, but has not been detected in all such tumours. We report here a case of EMC with a t(9;17)(q22;q11.2) as the sole chromosome abnormality. We have determined that the translocation results in the fusion of the entire coding region of CHN to the N-terminal transactivation domain of RBP56/hTAF(II)68. This is the first report of a translocation involving RBP56/hTAF(II) 68, a protein with sequence homology to both EWS and TLS/FUS, The involvement of RBP56/hTAF(II)68 may explain some unusual features of the tumour.	Withington Hosp, Dept Histopathol, Manchester M20 8LR, Lancs, England; Paterson Inst Canc Res, CRC, Dept Canc Genet, Manchester M20 9BX, Lancs, England; Christie Hosp, Dept Oncol Cytogenet, Manchester, Lancs, England; Christie Hosp, Dept Histopathol, Manchester, Lancs, England	Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital	Varley, JM (corresponding author), Withington Hosp, Dept Histopathol, Manchester M20 8LR, Lancs, England.							Antonescu CR, 1998, CANCER, V83, P1504, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1504::AID-CNCR5>3.0.CO;2-B; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Brody RI, 1997, AM J PATHOL, V150, P1049; Chhieng DC, 1998, MODERN PATHOL, V11, p8A; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; ICHIKAWA H, 1994, CANCER RES, V54, P2865; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; MARKVENDEL E, 1991, CANCER GENET CYTOGEN, V52, P267; Morohoshi F, 1996, GENOMICS, V38, P51, DOI 10.1006/geno.1996.0591; Morohoshi F, 1998, GENE, V221, P191, DOI 10.1016/S0378-1119(98)00463-6; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; Panagopoulos I, 1996, ONCOGENE, V12, P489; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SCOTT JE, 1965, HISTOCHEMISTRY, V5, P221, DOI 10.1007/BF00306130	17	75	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7599	7601		10.1038/sj.onc.1203156	http://dx.doi.org/10.1038/sj.onc.1203156			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602520				2022-12-25	WOS:000084119600022
J	Koike, M; Ikuta, T; Miyasaka, T; Shiomi, T				Koike, M; Ikuta, T; Miyasaka, T; Shiomi, T			Ku80 can translocate to the nucleus independent of the translocation of Ku70 using its own nuclear localization signal	ONCOGENE			English	Article						cell cycle; GFP; Ku; NLS; PTAC58/PTAC97	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; SV40-TRANSFORMED HUMAN KERATINOCYTES; SEVERE COMBINED IMMUNODEFICIENCY; PORE-TARGETING COMPLEX; DNA-BINDING PROTEINS; V(D)J RECOMBINATION; IN-VIVO; MONOCLONAL-ANTIBODIES; INTERACTION REGIONS	Ku antigen is a complex of Ku70 and Ku80 subunits and plays an important role in not only DNA double-strand breaks (DSB) repair and V(D)J recombination, but also in growth regulation, Ku is generally believed to always form and function as heterodimers on the basis of in vitro observations. Here we demonstrate that the localization of Ku80 does not completely coincide with that of Ku70, Ku70 and Ku80 were colocalized in the nucleus in the interphase but not in the late telophase/early G1 phase of the cell cycle, Since the in vivo function of Ku might be partially regulated by the control of its transport, we attempted to investigate the molecular mechanisms underlying the nuclear translocation of Ku. The nuclear translocation of Ku80 started during the late telophase/early G1 phase after the nuclear envelope was formed and this was preceded by the nuclear translocation of Ku70, Furthermore, we found that the Ku80 protein was transported to the nucleus without heterodimerization with Ku70, To understand in detail the mechanism of transport of Ku80, we attempted to identify the nuclear localization signal (NLS) of Ku80 and defined to a region spanning nine amino acid residues (positions 561-569), The Ku80 NLS was demonstrated to be mediated to the nuclear rim by two components of PTAC58 and PTAC97. All these findings support the idea that Ku80 can translocate to the nucleus using its own NLS independent of the translocation of Ku70.	Natl Inst Radiol Sci, Genome Res Grp, Inage Ku, Chiba 2638555, Japan; Saitama Canc Ctr, Res Ctr, Ina, Saitama 3620806, Japan	National Institutes for Quantum Science & Technology	Koike, M (corresponding author), Natl Inst Radiol Sci, Genome Res Grp, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.		Koike, Manabu/AAP-3107-2021					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; Cary RB, 1998, NUCLEIC ACIDS RES, V26, P974, DOI 10.1093/nar/26.4.974; DANZIEL RG, 1992, AUTOIMMUNITY, V13, P265; Errami A, 1996, MOL CELL BIOL, V16, P1519; Fewell JW, 1996, J CELL SCI, V109, P1937; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1996, EUR J BIOCHEM, V241, P931, DOI 10.1111/j.1432-1033.1996.00931.x; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Koike M, 1998, BIOCHEM BIOPH RES CO, V252, P679, DOI 10.1006/bbrc.1998.9368; Koike M, 1999, EXP CELL RES, V250, P401, DOI 10.1006/excr.1999.4507; KOIKE M, 1995, ONCOGENE, V10, P117; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; KOIKE M, 1993, MOL CARCINOGEN, V8, P105, DOI 10.1002/mc.2940080207; Koike M, 1996, GENOMICS, V38, P38, DOI 10.1006/geno.1996.0589; Koike M, 1996, CANCER LETT, V108, P185, DOI 10.1016/S0304-3835(96)04408-4; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Osipovich O, 1997, J BIOL CHEM, V272, P27259, DOI 10.1074/jbc.272.43.27259; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; REEVES WH, 1994, RHEUM DIS CLIN N AM, V20, P1; Reeves WH, 1997, ANTIBODIES, P33; SATOH M, 1995, EUR J CELL BIOL, V66, P127; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tovari J, 1998, CELL SIGNAL, V10, P277, DOI 10.1016/S0898-6568(97)00128-9; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; Yoneda Y, 1997, J BIOCHEM, V121, P811; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	55	61	63	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7495	7505		10.1038/sj.onc.1203247	http://dx.doi.org/10.1038/sj.onc.1203247			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602508				2022-12-25	WOS:000084119600010
